FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Mendonca, LO
   Grossi, A
   Caroli, F
   de Oliveira, RA
   Kalil, J
   Castro, FFM
   Pontillo, A
   Ceccherini, I
   Barros, MAMT
   Gattorno, M
AF Mendonca, Leonardo Oliveira
   Grossi, Alice
   Caroli, Francesco
   de Oliveira, Robson Aguiar
   Kalil, Jorge
   Castro, Fabio Fernandes Morato
   Pontillo, Alessandra
   Ceccherini, Isabella
   Barros, Myrthes Anna Maragna Toledo
   Gattorno, Marco
TI A case report of a novel compound heterozygous mutation in a Brazilian
   patient with deficiency of Interleukin-1 receptor antagonist (DIRA)
SO PEDIATRIC RHEUMATOLOGY
LA English
DT Review
DE DIRA; Deficiency of interleukin-1 receptor antagonist; IL1RN
AB Background Deficiency of the natural antagonist of interleukin-1 was first described in 2009 and so far 20 patients has been reported. In Brazil just two cases have been reported both carrying the same homozygous 15 bp deletion. Blocking interleukin-1 has changed rate survival for DIRA patients. The use of anakinra and rilonacept has been reported safe and efficient, whereas the selective blockade of interleukin-1 beta, using the monoclonal antibody canakinumab has been reported in a single case only. Case presentation Here we report a case of a 7 years old Brazilian boy that presented with recurrent episodes of systemic inflammation with severe disabling osteomyelitis with mild pustular skin rash. A Next Generation Sequencing gene panel allowed to detect two pathogenic mutations in the IL1RN gene, described in compound heterozygosity. Corticosteroids was effective in controlling inflammation and anti-IL1 beta blocker triggered disease flare. Complete clinical control could be achieved using IL-1 receptor antagonist. Conclusions DIRA is a severe, life threatening autoinflammatory condition with low numbers of patients described all over the world. The mutation p.Asp72_Ile76del in IL1RN is presented in all Brazilian DIRA patients already described and p.Q45* (rs1019766125) is a new mutation affecting the IL1RN gene. Following the pathogenesis of DIRA, blocking both subunits of interleukin one as well as antagonizing the receptor using anakinra or rilonacept seems to be effective. There is just one report using canakinumab for the treatment of DIRA and this is the first report of disease flare using this drug.
C1 [Mendonca, Leonardo Oliveira; de Oliveira, Robson Aguiar; Kalil, Jorge; Castro, Fabio Fernandes Morato; Barros, Myrthes Anna Maragna Toledo] Univ Sao Paulo, Sch Med, Autoimmune & Autoinflammatory Unit, Rua Dr Eneas Carvalho Aguiar,255-8 Andar, Sao Paulo, Brazil.
   [Mendonca, Leonardo Oliveira; de Oliveira, Robson Aguiar; Kalil, Jorge; Castro, Fabio Fernandes Morato; Barros, Myrthes Anna Maragna Toledo] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Dept, Rua Dr Eneas Carvalho Aguiar,255-8 Andar, Sao Paulo, Brazil.
   [Mendonca, Leonardo Oliveira; Grossi, Alice; Caroli, Francesco; Ceccherini, Isabella] Ist Giannina Gaslini, UOSD Genet & Genom Rare Dis, Genoa, Italy.
   [Mendonca, Leonardo Oliveira; Pontillo, Alessandra] Univ Sao Paulo, Dept Immunol, Immunogenet Lab, Biomed Sci Inst, Sao Paulo, Brazil.
   [Mendonca, Leonardo Oliveira; Gattorno, Marco] IRCCS Giannina Gaslini, Ctr Autoinflammatory Dis & Immunodeficiencies, Genoa, Italy.
RP Mendonca, LO (corresponding author), Univ Sao Paulo, Sch Med, Autoimmune & Autoinflammatory Unit, Rua Dr Eneas Carvalho Aguiar,255-8 Andar, Sao Paulo, Brazil.; Mendonca, LO (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Dept, Rua Dr Eneas Carvalho Aguiar,255-8 Andar, Sao Paulo, Brazil.; Mendonca, LO (corresponding author), Ist Giannina Gaslini, UOSD Genet & Genom Rare Dis, Genoa, Italy.
EM leonardo.oliveira.mendonca@gmail.com
RI Pontillo, Alessandra/ABC-6266-2020
OI Pontillo, Alessandra/0000-0002-7883-0640; Gattorno,
   Marco/0000-0003-0704-1916
FU European Society for Immunodeficiencies for Fellowship in
   Autoinflammatory Diseases at Giannina Gaslini Institute
FX Leonardo Oliveira Mendonca received grant of the European Society for
   Immunodeficiencies for Fellowship in Autoinflammatory Diseases at
   Giannina Gaslini Institute.
CR Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865
   Bernot A, 1997, NAT GENET, V17, P25
   Garg M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94838
   Jesus AA, 2011, ARTHRITIS RHEUM-US, V63, P4007, DOI 10.1002/art.30588
   Kuemmerle-Deschner J.B., 2019, PEDIAT RHEUMATOL S1, V17, pP1041
   Kutukculer N, 2019, CASE REP IMMUNOL, V2019, DOI 10.1155/2019/1902817
   Mendonca LO, 2017, J CLIN IMMUNOL, V37, P445, DOI 10.1007/s10875-017-0399-1
   Rusmini M, 2016, ANN RHEUM DIS, V75, P1550, DOI 10.1136/annrheumdis-2015-207701
   Stenerson M, 2011, ARTHRITIS RHEUM-US, V63, P4018, DOI 10.1002/art.30565
   Stern SM, 2013, RHEUM DIS CLIN N AM, V39, P735, DOI 10.1016/j.rdc.2013.05.002
   Ulusoy Ezgi, 2015, J Med Case Rep, V9, P145, DOI 10.1186/s13256-015-0618-4
NR 11
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1546-0096
J9 PEDIATR RHEUMATOL
JI Pediatr. Rheumatol.
PD AUG 20
PY 2020
VL 18
IS 1
AR 67
DI 10.1186/s12969-020-00454-5
PG 5
WC Pediatrics; Rheumatology
SC Pediatrics; Rheumatology
GA NJ7MZ
UT WOS:000566228600001
PM 32819369
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Amaral, MS
   Goulart, E
   Caires, LC
   Morales-Vicente, DA
   Soares-Schanoski, A
   Gomes, RP
   Olberg, GGD
   Astray, RM
   Kalil, JE
   Zatz, M
   Verjovski-Almeida, S
AF Amaral, Murilo Sena
   Goulart, Ernesto
   Caires-Junior, Luiz Carlos
   Morales-Vicente, David Abraham
   Soares-Schanoski, Alessandra
   Gomes, Roselane Paiva
   Olberg, Giovanna Goncalves de Oliveira
   Astray, Renato Mancini
   Kalil, Jorge E.
   Zatz, Mayana
   Verjovski-Almeida, Sergio
TI Differential gene expression elicited by ZIKV infection in trophoblasts
   from congenital Zika syndrome discordant twins
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID EMBRYONIC STEM-CELLS; VIRUS-INFECTION; EXTRAVILLOUS TROPHOBLAST;
   VERTICAL TRANSMISSION; BRAZIL; PATHOPHYSIOLOGY; INTERFERONS; CONVERSION;
   PREGNANCY; CYTOKINES
AB Zika virus (ZIKV) causes congenital Zika syndrome (CZS), which is characterized by fetal demise, microcephaly and other abnormalities. ZIKV in the pregnant woman circulation must cross the placental barrier that includes fetal endothelial cells and trophoblasts, in order to reach the fetus. CZS occurs in similar to 1-40% of cases of pregnant women infected by ZIKV, suggesting that mothers' infection by ZIKV during pregnancy is not deterministic for CZS phenotype in the fetus. Therefore, other susceptibility factors might be involved, including the host genetic background. We have previously shown that in three pairs of dizygotic twins discordant for CZS, neural progenitor cells (NPCs) from the CZS-affected twins presented differentialin vitroZIKV susceptibility compared with NPCs from the non-affected. Here, we analyzed human-induced-pluripotent-stem-cell-derived (hiPSC-derived) trophoblasts from these twins and compared by RNA-Seq the trophoblasts from CZS-affected and non-affected twins. Followingin vitroexposure to a Brazilian ZIKV strain (ZIKV(BR)), trophoblasts from CZS-affected twins were significantly more susceptible to ZIKV(BR) infection when compared with trophoblasts from the non-affected. Transcriptome profiling revealed no differences in gene expression levels of ZIKV candidate attachment factors, IFN receptors and IFN in the trophoblasts, either before or after ZIKV(BR) infection. Most importantly, ZIKV(BR) infection caused, only in the trophoblasts from CZS-affected twins, the downregulation of genes related to extracellular matrix organization and to leukocyte activation, which are important for trophoblast adhesion and immune response activation. In addition, only trophoblasts from non-affected twins secreted significantly increased amounts of chemokines RANTES/CCL5 and IP10 after infection with ZIKV(BR). Overall, our results showed that trophoblasts from non-affected twins have the ability to more efficiently activate genes that are known to play important roles in cell adhesion and in triggering the immune response to ZIKV infection in the placenta, and this may contribute to predict protection from ZIKV dissemination into fetuses' tissues.
   Author summary The Zika virus (ZIKV) infection in adults is usually characterized by mild flu-like symptoms, with most cases remaining asymptomatic. However, in the last years, widespread ZIKV infection was shown for the first time to be associated with congenital Zika syndrome (CZS) and death of neonates. It is estimated that CZS occurs in similar to 1-40% of cases of pregnant women infected by ZIKV, which suggests that different susceptibility factors might be involved, including the host genetic background. Here, by analyzing trophoblast cells that recapitulate the placenta from three pairs of dizygotic twins discordant for CZS, we were able to show that trophoblasts from CZS-affected twins were significantly more susceptible to ZIKV infection when compared with trophoblasts from the non-affected twins. We also provide a detailed picture of genes differentially expressed by trophoblasts from the discordant twins after infection with ZIKV. These genes can be further investigated as possible therapeutic targets to avoid viral dissemination into developing fetus' tissues. Our results suggest that CZS might be caused, among other factors, by a decreased ability of the placenta to respond to ZIKV infection in CZS-affected neonates, concomitant with a previously known deregulation of neural development genes in ZIKV-infected neuroprogenitor cells of these CZS-affected babies.
C1 [Amaral, Murilo Sena; Morales-Vicente, David Abraham; Olberg, Giovanna Goncalves de Oliveira; Verjovski-Almeida, Sergio] Inst Butantan, Lab Parasitol, Sao Paulo, Brazil.
   [Goulart, Ernesto; Caires-Junior, Luiz Carlos; Zatz, Mayana] Univ Sao Paulo, Inst Biociencias, Ctr Pesquisas Genoma Humano & Celulas Tronco, Dept Genet & Biol Evolut, Sao Paulo, Brazil.
   [Morales-Vicente, David Abraham; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil.
   [Soares-Schanoski, Alessandra] Inst Butantan, Lab Bacteriol, Sao Paulo, Brazil.
   [Gomes, Roselane Paiva; Astray, Renato Mancini] Inst Butantan, Lab Imunol Viral, Sao Paulo, Brazil.
   [Kalil, Jorge E.] Univ Sao Paulo, Fac Med, Lab Imunol, Sao Paulo, Brazil.
   [Kalil, Jorge E.] Univ Sao Paulo, Inst Coracao, Sao Paulo, Brazil.
RP Verjovski-Almeida, S (corresponding author), Inst Butantan, Lab Parasitol, Sao Paulo, Brazil.; Verjovski-Almeida, S (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil.
EM verjo@iq.usp.br
RI Soares Schanoski, Alessandra/H-8144-2014; Verjovski-Almeida,
   Sergio/E-4082-2012
OI Soares Schanoski, Alessandra/0000-0002-6514-8458; de Caires Junior, Luiz
   Carlos/0000-0002-1735-2008; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/03620-2,
   2018/23693-5]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) INCTNational Council for Scientific and Technological
   Development (CNPq) [465355/2014-5]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), BrazilCAPES [001]; Fundacao Butantan;
   CNPq, BrazilNational Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) (CEPID)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/08028-1]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) (INCT)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [14/50931-3]
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) (Thematic grant number 2014/03620-2 and
   2018/23693-5 to SVA and CEPID number 2013/08028-1 and INCT number
   14/50931-3 to MZ) and from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) INCT number 465355/2014-5 to MZ. DAMV
   received a fellowship from Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Brazil - Finance Code 001; LCCJ is a fellow of
   FAPESP (2017/16283-2); EG is a fellow of FAPESP (2019/18469-1); SVA
   laboratory was also supported by institutional funds from Fundacao
   Butantan; SVA received an established investigator fellowship award from
   CNPq, Brazil. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Aagaard KM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41389
   Amita M, 2013, P NATL ACAD SCI USA, V110, pE1212, DOI 10.1073/pnas.1303094110
   Ander SE, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat6114
   Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3
   Arima K, 2000, MOL HUM REPROD, V6, P246, DOI 10.1093/molehr/6.3.246
   Arora N, 2017, CELL HOST MICROBE, V21, P561, DOI 10.1016/j.chom.2017.04.007
   Barbier A, 2013, PEDIATRICS, V131, pE1158, DOI 10.1542/peds.2011-3846
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bojic-Trbojevic Z, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38374-w
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Caine EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07993-2
   CAIRESJUNIOR LC, 2018, NAT COMM, V0009
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao B, 2017, J INTERF CYTOK RES, V37, P287, DOI 10.1089/jir.2017.0011
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chen JL, 2017, CELL REP, V21, P1588, DOI 10.1016/j.celrep.2017.10.059
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Christian KM, 2019, ANNU REV NEUROSCI, V42, P249, DOI 10.1146/annurev-neuro-080317-062231
   Counotte MJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002611
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dominguez F, 2008, MOL HUM REPROD, V14, P423, DOI 10.1093/molehr/gan032
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fazleabas AT, 1997, BIOL REPROD, V56, P348, DOI 10.1095/biolreprod56.2.348
   Ferraris P, 2019, MICROBES INFECT
   Figueiredo CP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11866-7
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Fujiwara H, 2005, BBA-PROTEINS PROTEOM, V1751, P26, DOI 10.1016/j.bbapap.2005.04.007
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   He P, 2015, J OBSTET GYNAECOL, V35, P578, DOI 10.3109/01443615.2014.990430
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Hou PS, 2013, NUCLEIC ACIDS RES, V41, P7753, DOI 10.1093/nar/gkt567
   Hutter S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040523
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Kayisli UA, 2002, AM J REPROD IMMUNOL, V47, P213, DOI 10.1034/j.1600-0897.2002.01075.x
   Khaiboullina SF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01465
   Kim JA, 2019, J INVEST DERMATOL, V139, P391, DOI 10.1016/j.jid.2018.07.038
   Kim MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156038
   Kolundzic N, 2011, PLACENTA, V32, P909, DOI 10.1016/j.placenta.2011.07.087
   Kolundzic N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028514
   Kumamoto T, 2017, DEV GROWTH DIFFER, V59, P258, DOI 10.1111/dgd.12367
   Lee CQE, 2016, STEM CELL REP, V6, P257, DOI 10.1016/j.stemcr.2016.01.006
   Lee I, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050233
   Lee JK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051101
   Levy JA, 2009, J IMMUNOL, V182, P3945, DOI 10.4049/jimmunol.0990015
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li HD, 2016, NEURON, V92, P949, DOI 10.1016/j.neuron.2016.11.031
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   McGrath EL, 2017, STEM CELL REP, V8, P715, DOI 10.1016/j.stemcr.2017.01.008
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Morris G, 2018, MOL NEUROBIOL, V55, P4160, DOI 10.1007/s12035-017-0635-y
   Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012
   Ojha CR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208543
   Pagani I, 2017, SCI REP-UK, V7, DOI 10.1038/srep44286
   Pardy RD, 2019, CYTOKINE, V119, P7, DOI 10.1016/j.cyto.2019.02.009
   Perera-Lecoin Manuel, 2013, Viruses, V6, P69, DOI 10.3390/v6010069
   Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991
   Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114
   Roberts RM, 2011, BIOL REPROD, V84, P412, DOI 10.1095/biolreprod.110.088724
   Rossi SL, 2018, TRENDS MICROBIOL, V26, P877, DOI 10.1016/j.tim.2018.05.007
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114
   Sobhani NC, 2019, J INFECT DIS, DOI [10.1093/infdis/jiz1629, DOI 10.1093/INFDIS/JIZ1629]
   STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0
   Strange DP, 2019, MBIO, V10, DOI 10.1128/mBio.01372-19
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Tan L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12063-2
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tiwari SK, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.9
   Triunfol M, 2016, LANCET INFECT DIS, V16, P527, DOI 10.1016/S1473-3099(16)30015-9
   Vambergue A, 2011, WORLD J DIABETES, V2, P196, DOI 10.4239/wjd.v2.i11.196
   Vazirinejad R, 2014, NEUROIMMUNOMODULAT, V21, P322, DOI 10.1159/000357780
   Weisblum Y, 2017, J VIROL, V91, DOI [10.1128/jvi.01905-16, 10.1128/JVI.01905-16]
   Wells AI, 2018, TRENDS IMMUNOL, V39, P848, DOI 10.1016/j.it.2018.08.008
   Wen ZX, 2017, GENE DEV, V31, P849, DOI 10.1101/gad.298216.117
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   Yockey LJ, 2018, IMMUNITY, V49, P397, DOI 10.1016/j.immuni.2018.07.017
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111
   ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316
NR 95
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2020
VL 14
IS 8
AR e0008424
DI 10.1371/journal.pntd.0008424
PG 24
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA NA7OG
UT WOS:000560005600002
PM 32745093
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Marin, MLC
   Coelho, VN
   Visentainer, JEL
   Alves, HV
   Kohler, KF
   Rached, MR
   Abrao, MS
   Kalil, J
AF Marin, Maria Lucia Carnevale
   Coelho, Veronica
   Visentainer, Jeane Eliete Laguila
   Alves, Hugo Vicentin
   Kohler, Karen Francine
   Rached, Marici Rached
   Abrao, Mauricio Simoes
   Kalil, Jorge
TI InhibitoryKIR2DL2Gene: Risk for Deep Endometriosis in Euro-descendants
SO REPRODUCTIVE SCIENCES
LA English
DT Article; Early Access
DE Endometriosis; NK cells; Killer cell immunoglobulin-like receptors;
   KIR-HLA ligand combinations
ID IMMUNOGLOBULIN-LIKE RECEPTORS; NATURAL-KILLER ACTIVITY; HLA-C; MATERNAL
   KIR; CELL; WOMEN; POLYMORPHISM; DIVERSITY; BINDING; SUSCEPTIBILITY
AB Endometriosis (EDT) is an inflammatory disease characterized by implantation/growth of endometrial tissue, glands, and/or stroma, outside the uterus. Reduced NK cell cytotoxic activity has been implicated in its pathogenesis, together with other immunologic alterations. We investigated the influence ofKIRgene polymorphisms and their HLA ligand combinations in deep endometriosis (DE) susceptibility. One hundred sixty women with a histological diagnosis of DE and 202 control women without the disease, who underwent laparoscopy, were enrolled. The DE group was subdivided into initial (I/II;n = 60) and advanced stages (III/IV,n = 100).KIRand HLA class I gene polymorphisms were typed by PCR-SSP and sequence-based-typing (SBT), respectively. We observed a significant association ofKIR2DL2, an inhibitory gene of B haplotype, conferring risk for DE in Euro-descendants. Positive associations of Bx haplotype and centromeric AB segments were also found. However, no association with KIR-HLA ligand combination was observed. Our data suggestKIR2DL2gene to be a relevant factor favoring NK inhibition in DE in Euro-descendants, contributing to the defective NK cytotoxic activity and impaired clearance of ectopic endometrial cells in the disease.
C1 [Marin, Maria Lucia Carnevale; Coelho, Veronica; Kohler, Karen Francine; Rached, Marici Rached; Kalil, Jorge] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Immunol,Heart Inst InCor, Sao Paulo, SP, Brazil.
   [Marin, Maria Lucia Carnevale; Coelho, Veronica; Kalil, Jorge] Univ Sao Paulo, Hosp Clin HCFMUSP, Histocompatibil & Cellular Immunol Lab, LIM 19,Fac Med, Sao Paulo, SP, Brazil.
   [Coelho, Veronica; Kalil, Jorge] Natl Inst Sci & Technol iii INCT, Inst Invest Immunol, Sao Paulo, SP, Brazil.
   [Coelho, Veronica; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, Fac Med, Sao Paulo, SP, Brazil.
   [Visentainer, Jeane Eliete Laguila; Alves, Hugo Vicentin] Univ Estadual Maringa, Dept Basic Hlth Sci, Lab Immunogenet, Maringa, PR, Brazil.
   [Abrao, Mauricio Simoes] Univ Sao Paulo, Obstet & Gynecol Dept, Fac Med, Sao Paulo, SP, Brazil.
   [Abrao, Mauricio Simoes] BP, Gynecol Div, Sao Paulo, SP, Brazil.
   [Abrao, Mauricio Simoes] Rua Sao Sebastiao 550, BR-04708001 Sao Paulo, Brazil.
RP Abrao, MS (corresponding author), Univ Sao Paulo, Obstet & Gynecol Dept, Fac Med, Sao Paulo, SP, Brazil.; Abrao, MS (corresponding author), BP, Gynecol Div, Sao Paulo, SP, Brazil.; Abrao, MS (corresponding author), Rua Sao Sebastiao 550, BR-04708001 Sao Paulo, Brazil.
EM msabrao@mac.com
RI Alves, Hugo/L-9802-2016; KALIL, JORGE/C-8029-2012; visentainer,
   jeane/B-3510-2009
OI Alves, Hugo/0000-0002-3106-8820; KALIL, JORGE/0000-0001-8415-4274;
   visentainer, jeane/0000-0002-5815-7903
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/10338-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) (grant number: 2010/10338-0).
CR Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131
   ARUMUGAM K, 1992, AUST NZ J OBSTET GYN, V32, P164, DOI 10.1111/j.1479-828X.1992.tb01932.x
   Augusto DG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00121
   Burney RO, 2012, FERTIL STERIL, V98, P511, DOI 10.1016/j.fertnstert.2012.06.029
   Canis M, 1997, FERTIL STERIL, V67, P817
   Charron D, 1996, HUM IMMUNOL, V47, P1, DOI 10.1016/S0198-8859(96)85602-3
   Chou YC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61702-y
   COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000
   Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051
   CORNILLIE FJ, 1990, FERTIL STERIL, V53, P978
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Fauconnier A, 2005, HUM REPROD UPDATE, V11, P595, DOI 10.1093/humupd/dmi029
   Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208
   Feyaerts D, 2018, HUM REPROD, V33, P441, DOI 10.1093/humrep/dey001
   GARZETTI GG, 1993, OBSTET GYNECOL, V81, P665
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Gonzalez-Foruria I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119961
   Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214
   Hiby SE, 2014, J IMMUNOL, V192, P5069, DOI 10.4049/jimmunol.1400577
   HO HN, 1995, HUM REPROD, V10, P2671, DOI 10.1093/oxfordjournals.humrep.a135765
   Hsu KC, 2002, J IMMUNOL, V169, P5118, DOI 10.4049/jimmunol.169.9.5118
   Ivarsson MA, 2017, MUCOSAL IMMUNOL, V10, P322, DOI 10.1038/mi.2016.50
   Jh M, 2014, HDB BIOL STAT
   Jonsson AH, 2010, J IMMUNOL, V184, P3424, DOI 10.4049/jimmunol.0904057
   KIRSHON B, 1989, J REPROD MED, V34, P215
   Kitawaki J, 2007, AM J REPROD IMMUNOL, V58, P481, DOI 10.1111/j.1600-0897.2007.00533.x
   Lavender KJ, 2007, J IMMUNOL, V179, P6856, DOI 10.4049/jimmunol.179.10.6856
   LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S
   Lowe DP, 2009, RHEUMATOLOGY, V48, P359, DOI 10.1093/rheumatology/ken503
   Marsh SGE, 2003, TISSUE ANTIGENS, V62, P79, DOI 10.1034/j.1399-0039.2003.00072.x
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Matalliotakis IM, 2008, ARCH GYNECOL OBSTET, V277, P389, DOI 10.1007/s00404-007-0479-1
   Middleton D, 2010, IMMUNOLOGY, V129, P8, DOI 10.1111/j.1365-2567.2009.03208.x
   Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275
   Moesta AK, 2008, J IMMUNOL, V180, P3969, DOI 10.4049/jimmunol.180.6.3969
   Moesta AK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00336
   Montaldo E, 2013, CYTOM PART A, V83A, P702, DOI 10.1002/cyto.a.22302
   Naumova E, 2005, CANCER IMMUNOL IMMUN, V54, P172, DOI 10.1007/s00262-004-0575-z
   Nisolle M, 1997, FERTIL STERIL, V68, P585, DOI 10.1016/S0015-0282(97)00191-X
   Nowak I, 2015, IMMUNOGENETICS, V67, P203, DOI 10.1007/s00251-015-0828-3
   OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45
   OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Pyo CW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015115
   Rached MR, 2019, EUR J OBSTET GYN R B, V235, P36, DOI 10.1016/j.ejogrb.2019.01.030
   Ranstam J, 2016, OSTEOARTHR CARTILAGE, V24, P763, DOI 10.1016/j.joca.2016.01.008
   Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320
   Suzuki Y, 2004, J INVEST DERMATOL, V122, P1133, DOI 10.1111/j.0022-202X.2004.22517.x
   Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5
   Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3
   Verheyden S, 2004, LEUKEMIA, V18, P2002, DOI 10.1038/sj.leu.2403525
   Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942
   Winter CC, 1997, J IMMUNOL, V158, P4026
   Winter CC, 1998, J IMMUNOL, V161, P571
NR 54
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
DI 10.1007/s43032-020-00255-x
EA JUL 2020
PG 14
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA MJ4SB
UT WOS:000548080900001
PM 32661880
DA 2020-11-26
ER

PT J
AU Frade-Barros, AF
   Ianni, BM
   Cabantous, S
   Pissetti, CW
   Saba, B
   Lin-Wang, HT
   Buck, P
   Marin-Neto, JA
   Schmidt, A
   Dias, F
   Hirata, MH
   Sampaio, M
   Fragata, A
   Pereira, AC
   Donadi, E
   Rodrigues, V
   Kalil, J
   Chevillard, C
   Cunha-Neto, E
AF Frade-Barros, Amanda Farage
   Ianni, Barbara Maria
   Cabantous, Sandrine
   Pissetti, Cristina Wide
   Saba, Bruno
   Lin-Wang, Hui Tzu
   Buck, Paula
   Marin-Neto, Jose Antonio
   Schmidt, Andre
   Dias, Fabricio
   Hirata, Mario Hiroyuki
   Sampaio, Marcelo
   Fragata, Abilio
   Pereira, Alexandre Costa
   Donadi, Eduardo
   Rodrigues, Virmondes
   Kalil, Jorge
   Chevillard, Christophe
   Cunha-Neto, Edecio
TI Polymorphisms in Genes Affecting Interferon-gamma Production and Th1 T
   Cell Differentiation Are Associated With Progression to Chagas Disease
   Cardiomyopathy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Chagas disease; cardiomyopathy; susceptibility; IL12; IL 10; IFN; IL4
ID CHEMOKINE RECEPTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; HEART-DISEASE;
   MYOCARDITIS; MORBIDITY; INFECTION; CYTOKINES; IL-10
AB Background:Chagas disease, caused by the protozoanTrypanosoma cruzi, is endemic in Latin America. Thirty percent of infected individuals develop chronic Chagas cardiomyopathy (CCC), an inflammatory dilated cardiomyopathy that is the most important clinical consequence ofT. cruziinfection, while the others remain asymptomatic (ASY). IFN-gamma and IFN-gamma-producing Th1-type T cells are increased in peripheral blood and CCC myocardium as compared to ASY patients, while the Th1-antagonizing cytokine IL-10 is more expressed in ASY patients. Importantly IFN-gamma-producing Th1-type T cells are the most frequent cytokine-producing T cell subset in CCC myocardium, while expression of Th1-antagonizing cytokines IL-10 and IL-4 is unaltered. The control of IFN-gamma production by Th1-type T cells may be a key event for progression toward CCC. A genetic component to disease progression was suggested by the familial aggregation of cases and the association of gene polymorphisms with CCC development. We here investigate the role of gene polymorphisms (SNPs) in several genes involved in the control of IFN-gamma production and Th1 T cell differentiation in CCC development. Methods:We studied a Brazilian population including 315 CCC cases and 118 ASY subjects. We assessed 35 Tag SNPs designed to represent all the genetic information contained in theIL12B, IL10, IFNG, andIL4genes. Results:We found 2IL12SNPs (rs2546893, rs919766) and a trend of association for aIL10SNP (rs3024496) to be significantly associated with the ASY group. these associations were confirmed by multivariate analysis and allele tests. The rs919766C, 12rs2546893G, and rs3024496C alleles were associated to an increase risk to CCC development. Conclusions:Our data show that novel polymorphisms affectingIL12BandIL10, but notIFNGorIL4genes play a role in genetic susceptibility to CCC development. This might indicate that the increased Th1 differentiation and IFN-gamma production associated with CCC is genetically controlled.
C1 [Frade-Barros, Amanda Farage; Ianni, Barbara Maria; Buck, Paula; Pereira, Alexandre Costa; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med FMUSP, Heart Inst InCor, Sao Paulo, Brazil.
   [Frade-Barros, Amanda Farage; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol 3, Sao Paulo, Brazil.
   [Frade-Barros, Amanda Farage; Cabantous, Sandrine] Aix Marseille Univ, INSERM, GIMP, UMR S906, Marseille, France.
   [Frade-Barros, Amanda Farage; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Frade-Barros, Amanda Farage; Kalil, Jorge] Univ Brasil, Inst Tecnol, Bioengn Program, Sao Paulo, Brazil.
   [Pissetti, Cristina Wide; Rodrigues, Virmondes] Univ Fed Triangulo Mineiro UFTM, Lab Immunol, Uberaba, Brazil.
   [Saba, Bruno; Lin-Wang, Hui Tzu; Sampaio, Marcelo; Fragata, Abilio] Inst Cardiol Dante Pazzanese IDPC, Lab Invest Mol Cardiol, Sao Paulo, Brazil.
   [Marin-Neto, Jose Antonio; Schmidt, Andre; Dias, Fabricio; Donadi, Eduardo] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Ribeirao Preto, Brazil.
   [Hirata, Mario Hiroyuki] Univ Sao Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, Sao Paulo, Brazil.
   [Chevillard, Christophe] Aix Marseille Univ, INSERM, TAGC, Theories & Approaches Genom Complex,UMR 1090, Marseille, France.
RP Frade-Barros, AF (corresponding author), Univ Sao Paulo, Sch Med FMUSP, Heart Inst InCor, Sao Paulo, Brazil.; Frade-Barros, AF (corresponding author), INCT, Inst Invest Immunol 3, Sao Paulo, Brazil.; Frade-Barros, AF (corresponding author), Aix Marseille Univ, INSERM, GIMP, UMR S906, Marseille, France.; Frade-Barros, AF (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM amanda.frade@universidadebrasil.edu.br
FU Institut National de la Sante et de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille University (Direction des Relations
   Internationales); ARCUS II PACA Bresil program; CNPq (the Brazilian
   National Research Council)National Council for Scientific and
   Technological Development (CNPq); FAPESP (Sao Paulo State Research
   Funding Agency-Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); French ANRFrench National Research Agency (ANR);
   Brazilian FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Sao Paulo State Research Funding Agency, FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Council for
   Scientific and Technological Development-CNPqNational Council for
   Scientific and Technological Development (CNPq); French consulate in
   Brazil; University of Sao Paulo (USP)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM), Aix-Marseille University (Direction des
   Relations Internationales), the ARCUS II PACA Bresil program, CNPq (the
   Brazilian National Research Council), and FAPESP (Sao Paulo State
   Research Funding Agency-Brazil). EC-N and CC were recipient for an
   international program funded either by the French ANR and the Brazilian
   FAPESP agencies (Br-Fr-chagas). AF-B hold fellowships from the Sao Paulo
   State Research Funding Agency, FAPESP. EC-N and JK have received a
   Council for Scientific and Technological Development-CNPq productivity
   award. CC was a recipient of a temporary professor position supported by
   the French consulate in Brazil and the University of Sao Paulo (USP).
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Acosta-Herrera M, 2019, ACTA TROP, V197, DOI 10.1016/j.actatropica.2019.105062
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Arnez LEA, 2011, J ALLERGY CLIN IMMUN, V127, P279, DOI 10.1016/j.jaci.2010.10.026
   Barbosa AP, 2011, ARQ BRAS CARDIOL, V97, P517, DOI 10.1590/S0066-782X2011005000112
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bocchi EA, 2017, J AM COLL CARDIOL, V70, P1510, DOI 10.1016/j.jacc.2017.08.004
   Chevillard C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02791
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Coura JR, 2012, REV SOC BRAS MED TRO, V45, P286, DOI 10.1590/S0037-86822012000300002
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   De Alba-Alvarado M, 2018, ACTA TROP, V178, P134, DOI 10.1016/j.actatropica.2017.11.009
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Florez O, 2011, PARASITE IMMUNOL, V33, P506, DOI 10.1111/j.1365-3024.2011.01314.x
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HOLM S, 1979, SCAND J STAT, V6, P65
   Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000
   Januzzi JL, 2013, J AM COLL CARDIOL, V61, P1507, DOI 10.1016/j.jacc.2013.01.039
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Medina TS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01213
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346
   Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Rodrigues DBR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/361730
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Soares MP, 2014, TRENDS IMMUNOL, V35, P483, DOI 10.1016/j.it.2014.08.001
   Sousa GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087082
   Strauss M, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007859
   Talvani A, 2004, J INFECT DIS, V189, P214, DOI 10.1086/380803
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   van Veldhuisen DJ, 2013, J AM COLL CARDIOL, V61, P1498, DOI 10.1016/j.jacc.2012.12.044
   Zafra G, 2007, MICROBES INFECT, V9, P1049, DOI 10.1016/j.micinf.2007.04.010
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 41
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 7
PY 2020
VL 11
AR 1386
DI 10.3389/fimmu.2020.01386
PG 12
WC Immunology
SC Immunology
GA MR2GP
UT WOS:000553408400001
PM 32733459
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Precioso, AR
   Palacios, R
   Thome, B
   Braga, PE
   Vanni, T
   Campos, LMA
   Ferrari, L
   Mondini, G
   Salomao, MD
   da Silva, A
   Espinola, HM
   Santos, JD
   Santos, CLS
   Timenetsky, MDST
   Miraglia, JL
   Gallina, NMF
   Weiskopf, D
   Sette, A
   Goulart, R
   Salles, RT
   Maestri, A
   Sallum, AME
   Farhat, SCL
   Sakita, NK
   Ferreira, JCOA
   Silveira, CGT
   Costa, PR
   Raw, I
   Whitehead, SS
   Durbin, AP
   Kalil, J
AF Kallas, Esper G.
   Precioso, Alexander Roberto
   Palacios, Ricardo
   Thome, Beatriz
   Braga, Patricia Emilia
   Vanni, Tazio
   Campos, Lucia M. A.
   Ferrari, Lilian
   Mondini, Gabriella
   Salomao, Maria da Graca
   da Silva, Anderson
   Espinola, Heloisa M.
   Santos, Joane do Prado
   Santos, Cecilia L. S.
   Timenetsky, Maria do Carmo S. T.
   Miraglia, Joao Luiz
   Gallina, Neuza M. F.
   Weiskopf, Daniela
   Sette, Alessandro
   Goulart, Raphaella
   Salles, Rafael Tavares
   Maestri, Alvino
   Sallum, Adriana Maluf Elias
   Farhat, Sylvia Costa Lima
   Sakita, Neusa K.
   Ferreira, Juliana C. O. A.
   Silveira, Cassia G. T.
   Costa, Priscilla R.
   Raw, Isaias
   Whitehead, Stephen S.
   Durbin, Anna P.
   Kalil, Jorge
TI Safety and immunogenicity of the tetravalent, live-attenuated dengue
   vaccine Butantan-DV in adults in Brazil: a two-step, double-blind,
   randomised placebo-controlled phase 2 trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID T-CELL RESPONSES; VIRUS SEROTYPES; CANDIDATE; NAIVE; CHILDREN; HEALTHY
AB Background The Butantan Institute has manufactured a lyophilised tetravalent live-attenuated dengue vaccine Butantan-DV, which is analogous to the US National Institutes of Health (NIH) TV003 admixture. We aimed to assess the safety and immunogenicity of Butantan-DV.
   Methods We did a two-step, double-blind, randomised placebo-controlled phase 2 trial at two clinical sites in Sao Paulo, Brazil. We recruited healthy volunteers aged 18-59 years; pregnant women, individuals with a history of neurological, heart, lung, liver or kidney disease, diabetes, cancer, or autoimmune diseases, and individuals with HIV or hepatitis C were excluded. Step A was designed as a small bridge-study between Butantan-DV and TV003 in DENV-naive participants. In step A, we planned to randomly assign 50 dengue virus (DENV)-naive individuals to receive two doses of Butantan-DV, TV003, or placebo, given 6 months apart. In step B, we planned to randomly assign 250 participants (DENV-naive and DENV-exposed) to receive one dose of Butantan-DV or placebo. Participants were randomly assigned, by computer-generated block randomisation (block sizes of five); participants in step A were randomly assigned (2:2:1) to receive Butantan-DV, TV003, or placebo and participants in step B were randomly assigned (4:1) to receive Butantan-DV or placebo. Participants and study staff were unaware of treatment allocation. The primary safety outcome was the frequency of solicited and unsolicited local and systemic adverse reactions within 21 days of the first vaccination, analysed by intention to treat. The primary immunogenicity outcome was seroconversion rates of the DENV-1-4 serotypes measured 91 days after the first vaccination, analysed in the per-protocol population, which included all participants in step A, and all participants included in step B who completed all study visits with serology sample collection. This trial is registered with ClinicalTrials. gov, NCT01696422.
   Findings Between Nov 5, 2013, and Sept 21, 2015, 300 individuals were enrolled and randomly assigned: 155 (52%) DENV-naive participants and 145 (48%) DENV-exposed participants. Of the 155 DENV-naive participants, 97 (63%) received Butantan-DV, 17 (11%) received TV003, and 41 (27%) received placebo. Of the 145 DENV-exposed participants, 113 (78%) received Butantan-DV, three (2%) received TV003, and 29 (20%) received placebo. Butantan-DV and TV003 were both immunogenic, well-tolerated, and no serious adverse reactions were observed. In step A, rash was the most frequent adverse event (16 [845] of 19 participants in the Butantan-DV group and 13 [76%] of 17 participants in the TV003 group). Viraemia was similar between the Butantan-DV and TV003 groups. Of the 85 DENV-naive participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis and thus were included in the per-protocol analysis population, 74 (87%) achieved seroconversion to DENV-1, 78 (92%) to DENV-2, 65 (76%) to DENV-3, and 76 (89%) to DENV-4. Of the 101 DENV-exposed participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis, 82 (81%) achieved seroconversion to DENV-1, 79 (78%) to DENV-2, 83 (82%) to DENV-3, and 78 (77%) to DENV-4.
   Interpretation Butantan-DV and TV003 were safe and induced robust, balanced neutralising antibody responses against the four DENV serotypes. Efficacy evaluation of the Butantan-DV vaccine is ongoing. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Precioso, Alexander Roberto; Campos, Lucia M. A.; Sallum, Adriana Maluf Elias; Farhat, Sylvia Costa Lima; Sakita, Neusa K.; Ferreira, Juliana C. O. A.] Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Ferrari, Lilian; Goulart, Raphaella; Salles, Rafael Tavares; Maestri, Alvino; Silveira, Cassia G. T.; Costa, Priscilla R.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Precioso, Alexander Roberto; Palacios, Ricardo; Braga, Patricia Emilia; Vanni, Tazio; Mondini, Gabriella; Salomao, Maria da Graca; da Silva, Anderson; Espinola, Heloisa M.; Santos, Joane do Prado; Miraglia, Joao Luiz; Gallina, Neuza M. F.; Raw, Isaias] Inst Butantan, Div Clin Trials & Pharmacovigilance, BR-05503900 Sao Paulo, Brazil.
   [Thome, Beatriz] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil.
   [Santos, Cecilia L. S.; Timenetsky, Maria do Carmo S. T.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, San Diego, CA USA.
   [Whitehead, Stephen S.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Durbin, Anna P.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA.
RP Precioso, AR (corresponding author), Inst Butantan, Div Clin Trials & Pharmacovigilance, BR-05503900 Sao Paulo, Brazil.
EM alexander.precioso@butantan.gov.br
RI thome, beatriz/B-7337-2018; Precioso, Alexander/A-9712-2013; Palacios,
   Ricardo/B-7248-2018; Salomao, Maria da Graca/L-1349-2014
OI thome, beatriz/0000-0002-3941-3756; Caires de Oliveira Achili Ferreira,
   Juliana/0000-0002-9249-2318; Precioso, Alexander/0000-0001-8657-9292;
   Palacios, Ricardo/0000-0002-1410-8579; Miraglia, Joao
   Luiz/0000-0002-4788-6254; Salomao, Maria da Graca/0000-0001-8066-6774
FU Intramural Research Program US NIH National Institute of Allergy and
   Infectious Diseases; Brazilian National Bank for Economic and Social
   Development; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Fundacao Butantan
FX Intramural Research Program US NIH National Institute of Allergy and
   Infectious Diseases, Brazilian National Bank for Economic and Social
   Development, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, and
   Fundacao Butantan.
CR Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179
   Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10
   Buddhari D, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003230
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Durbin Anna P, 2016, J Infect Dis, V214, P832, DOI 10.1093/infdis/jiw067
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   European Medicines Agency, 1995, ICH TOP E2A CLIN SAF
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   Halstead SB, 2009, ANN NY ACAD SCI, V1171, pE48, DOI 10.1111/j.1749-6632.2009.05052.x
   Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Mahoney RT, 2012, VACCINE, V30, P4892, DOI 10.1016/j.vaccine.2012.02.064
   Nivarthi UK, 2017, J VIROL, V91, DOI 10.1128/JVI.02041-16
   Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328
   Precioso AR, 2015, VACCINE, V33, P7121, DOI 10.1016/j.vaccine.2015.09.105
   Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8
   Sirivichayakul C, 2016, J INFECT DIS, V213, P1562, DOI 10.1093/infdis/jiv762
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   The Uppsala Monitoring Centre, US WHO UMC SYST STAN
   U.S. Department of Health and Human Services, COMMON TERMINOLOGY C
   U.S. Department of Health and Human Services. Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND TOX GRAD SC
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whitehead SS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005584
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
NR 33
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2020
VL 20
IS 7
BP 839
EP 850
DI 10.1016/S1473-3099(20)30023-2
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA ME3PZ
UT WOS:000544572300041
PM 32220283
DA 2020-11-26
ER

PT J
AU Ferreira, LRP
   Ferreira, FM
   Nakaya, HI
   Deng, XT
   Candido, DD
   de Oliveira, LC
   Billaud, JN
   Lanteri, MC
   Rigaud, VOC
   Seielstad, M
   Kalil, J
   Fernandes, F
   Ribeiro, ALP
   Sabino, EC
   Cunha-Neto, E
AF Pinto Ferreira, Ludmila Rodrigues
   Ferreira, Frederico Moraes
   Nakaya, Helder Imoto
   Deng, Xutao
   Candido, Darlan da Silva
   de Oliveira, Lea Campos
   Billaud, Jean-Noel
   Lanteri, Marion C.
   Rigaud, Vagner Oliveira-Carvalho
   Seielstad, Mark
   Kalil, Jorge
   Fernandes, Fabio
   Pinho Ribeiro, Antonio Luiz
   Sabino, Ester Cerdeira
   Cunha-Neto, Edecio
TI Blood Gene Signatures of Chagas Cardiomyopathy With or Without
   Ventricular Dysfunction (vol 215, pg 387, 2017)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Correction
C1 [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Lab Immunol, Sao Paulo, Brazil.
   [Fernandes, Fabio] Univ Sao Paulo, Cardiomyopathy Unit, Heart Inst, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nakaya, Helder Imoto] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Pathophysiol & Toxicol, Sao Paulo, Brazil.
   [de Oliveira, Lea Campos; Sabino, Ester Cerdeira] Univ Sao Paulo, Dept Infect Dis, Inst Trop Med, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes] Univ Santo Amaro, Sao Paulo, Brazil.
   [Pinho Ribeiro, Antonio Luiz] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil.
   [Pinho Ribeiro, Antonio Luiz] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil.
   [Nakaya, Helder Imoto] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Deng, Xutao; Lanteri, Marion C.; Seielstad, Mark] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA.
   [Deng, Xutao] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA.
   [Lanteri, Marion C.; Seielstad, Mark] Univ Calif San Francisco, Dept Lab Med, Inst Human Genet, San Francisco, CA USA.
   [Billaud, Jean-Noel] Qiagen, Dept Bioinformat, Redwood City, CA USA.
RP Ferreira, LRP (corresponding author), Univ Sao Paulo, Lab Immunol, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Univ Santo Amaro, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009
OI Cunha-Neto, Edecio/0000-0002-3699-3345
FU Science Technology Demonstration Project for Emerging Infectious
   Diseases Control and Prevention [BE2015714, BE2017749]
FX In "Interventions in Live Poultry Markets for the Control of Avian
   Influenza: A Systematic Review and Meta-analysis" by Shi et al [J Infect
   Dis 2019; https://doi.org/10.1093/infdis/jiz372], there was an error in
   a grant number. In the financial support section, this grant should read
   "Science Technology Demonstration Project for Emerging Infectious
   Diseases Control and Prevention (grant numbers BE2015714, BE2017749)."
CR Ferreira LRP, 2017, J INFECT DIS, V215, P387, DOI 10.1093/infdis/jiw540
NR 1
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2020
VL 221
IS 9
BP 1564
EP 1564
DI 10.1093/infdis/jiz661
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LS6SN
UT WOS:000536512000022
PM 31884515
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Tenore, SD
   Avelino-Silva, VI
   Costa, PR
   Franco, LM
   Sabino, EC
   Kalil, J
   Cerqueira, NB
   Nakagawa, Z
   Kallas, EG
AF Tenore, Simone de Barros
   Avelino-Silva, Vivian Iida
   Costa, Priscilla Ramos
   Franco, Lucas M.
   Sabino, Ester Cerdeira
   Kalil, Jorge
   Cerqueira, Natalia Barros
   Nakagawa, Zelinda
   Kallas, Esper Georges
TI Immune effects ofLactobacillus caseiShirota in treated HIV-infected
   patients with poor CD4+T-cell recovery
SO AIDS
LA English
DT Article
DE Lactobacillus caseiShirota; CD4+; HIV; immune discordant;
   Lactobacillusspp; probiotic; recovery
ID ACTIVE ANTIRETROVIRAL THERAPY; MICROBIAL TRANSLOCATION; DOUBLE-BLIND;
   PROBIOTIC YOGURT; CELL RECOVERY; INDIVIDUALS; ACTIVATION; MICRONUTRIENT;
   RESTORATION; SUPPRESSION
AB Background: HIV infection leads to depletion of intestinal CD4+ T cells, mucosal barrier dysfunction, increased gut permeability and microbial translocation even among patients on suppressive ART. Previous studies suggest probiotics may help restore intestinal function. Methods: In this double-blind, placebo-controlled pilot study, we enrolled HIV-infected patients on suppressive ART with poor CD4+ recovery to address the effect of daily oral use ofLactobacillus caseiShirota (LcS) on CD4+ T-cell count and CD4+/CD8+ ratio at 6 and 12 weeks after treatment initiation; immune activation and intestinal microbiome composition were addressed as secondary outcomes. Results: From January 2015 to July 2016, 48 patients were randomized (1 : 1) to active intervention or placebo. Groups had comparable demographic and clinical characteristics; only CD4+ T-cell nadir was statistically different between groups. All participants were virologically suppressed under ART. At week 6, the increment in CD4+ T-cell count was 17 cells/mu l [interquartile range (IQR) -33 to 74] in the active intervention arm and 4 cells/mu l (IQR -43 to 51) in the placebo arm (P = 0.291); at week 12, the change in CD4+ T-cell count was 8 cells//mu l (IQR -30 to 70) in the active arm and 10 cells//mu l (IQR -50 to 33) among participants allocated to placebo (P = 0.495). Median change in CD4+/CD8+ ratio at week 6 compared with baseline was 0 (IQR -0.04 to 0.05) in the active intervention arm and -0.01 in the placebo arm (IQR -0.06 to 0.03;P = 0.671). At week 12, the change in CD4+/CD8+ ratio was higher in the active product group compared with placebo (respectively 0.07 and 0.01), but this difference failed to reach statistical significance (P = 0.171). We found no significant effects of LcS on immune activation markers, CD4+ and CD8+ subpopulations, sCD14 levels or NK cells at week 12. Finally, we found no statistically significant differences between groups in the change of enteric microbiome at week 12. Conclusion: In this pilot study, we found no statistically significant effect of LcS probiotic on CD4+ T-cell counts, CD4+/CD8+ ratio, immune activation or intestinal microbiome among HIV-infected patients on suppressive ART with poor CD4+ recovery.
C1 [Tenore, Simone de Barros; Avelino-Silva, Vivian Iida; Sabino, Ester Cerdeira; Kallas, Esper Georges] Univ Sao Paulo, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Costa, Priscilla Ramos; Kalil, Jorge; Cerqueira, Natalia Barros; Nakagawa, Zelinda; Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Franco, Lucas M.; Sabino, Ester Cerdeira] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Sao Paulo, SP, Brazil.
EM esper.kallas@usp.br
RI Avelino-Silva, Vivian/L-2640-2013
OI Avelino-Silva, Vivian/0000-0002-6660-3088
CR Avelino-Silva VI, 2016, JAIDS-J ACQ IMM DEF, V71, P189, DOI 10.1097/QAI.0000000000000845
   Avelino-Silva VI, 2011, AGEING RES REV, V10, P163, DOI 10.1016/j.arr.2010.10.004
   Bandera A, 2018, CURR OPIN HIV AIDS, V13, P73, DOI [10.1097/coh.0000000000000429, 10.1097/COH.0000000000000429]
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   d'Ettorre G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137200
   Falster K, 2009, JAIDS-J ACQ IMM DEF, V50, P307, DOI 10.1097/QAI.0b013e3181945ed4
   Gootenberg DB, 2017, CURR OPIN INFECT DIS, V30, P31, DOI 10.1097/QCO.0000000000000341
   Heiser Carla R, 2004, J Int Assoc Physicians AIDS Care (Chic), V3, P121, DOI 10.1177/154510970400300403
   Hemsworth JC, 2012, GUT MICROBES, V3, P414, DOI 10.4161/gmic.21248
   Hummelen R, 2011, NUTRIENTS, V3, P897, DOI 10.3390/nu3100897
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Irvine SL, 2010, J CLIN GASTROENTEROL, V44, pE201, DOI 10.1097/MCG.0b013e3181d8fba8
   Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476
   Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484
   Kim CJ, 2014, JAIDS-J ACQ IMM DEF, V67, P514, DOI 10.1097/QAI.0000000000000359
   Lozupone CA, 2014, GUT MICROBES, V5, P562, DOI 10.4161/gmic.32132
   Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746
   Muller GC, 2015, CELL IMMUNOL, V296, P149, DOI 10.1016/j.cellimm.2015.05.006
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pontes Rose Meire Albuquerque, 2004, Arq. Gastroenterol., V41, P137, DOI 10.1590/S0004-28032004000200014
   Ribeiro ABDTM, 2017, EUR J MICROBIOL IMMU, V7, P158, DOI 10.1556/1886.2017.00016
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075
   Stiksrud B, 2015, JAIDS-J ACQ IMM DEF, V70, P329, DOI 10.1097/QAI.0000000000000784
   Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002
   Trois L, 2008, J TROP PEDIATRICS, V54, P19, DOI 10.1093/tropej/fmm066
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Villar-Garcia J, 2015, JAIDS-J ACQ IMM DEF, V68, P256, DOI 10.1097/QAI.0000000000000468
   Yang OO, 2014, AIDS RES HUM RETROV, V30, P988, DOI [10.1089/aid.2014.0181, 10.1089/AID.2014.0181]
   Zevin AS, 2016, CURR OPIN HIV AIDS, V11, P182, DOI 10.1097/COH.0000000000000234
NR 31
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 1
PY 2020
VL 34
IS 3
BP 381
EP 389
DI 10.1097/QAD.0000000000002420
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ME8JF
UT WOS:000544898400005
PM 31714353
DA 2020-11-26
ER

PT J
AU Cunha, LI
   Dias, G
   Giavina-Bianchi, P
   Kalil, J
   Agondi, R
AF Cunha, La Is
   Dias, Gabriella
   Giavina-Bianchi, Pedro
   Kalil, Jorge
   Agondi, Rosana
TI Eosinophilia in asthmatic patients and its relationship with
   Aspirin-Exacerbated Respiratory Disease
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 13-16, 2020
CL Philadelphia, PA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Cunha, La Is; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Dias, Gabriella; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sao Paulo, Brazil.
   [Agondi, Rosana] Clin Immunol & Allergy Div, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2020
VL 145
IS 2
SU S
MA 372
BP AB118
EP AB118
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA KQ7IJ
UT WOS:000517092700371
DA 2020-11-26
ER

PT J
AU Aun, MV
   de Almeida, FM
   Saraiva-Romanholo, BM
   Martins, MD
   Kalil, J
   Arantes-Costa, FM
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   de Almeida, Francine Maria
   Saraiva-Romanholo, Beatriz Mangueira
   Martins, Milton de Arruda
   Kalil, Jorge
   Arantes-Costa, Fernanda Magalhaes
   Giavina-Bianchi, Pedro
TI Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation
   and remodelling in an animal model of mite-induced respiratory allergy
SO VACCINE
LA English
DT Article
DE Asthma; Animal model; IgE; Remodelling; Vaccine; Bordetella pertussis
ID HOUSE-DUST MITE; GROWTH-FACTOR-BETA; BORDETELLA-PERTUSSIS; AIRWAY
   INFLAMMATION; INFECTION; ASTHMA; IMMUNOTHERAPY; SENSITIZATION;
   EXACERBATION; IMMUNIZATION
AB Background: Adjuvants, such as bacterial lipopolysaccharides, have been studied to improve the efficacy of allergen-specific immunotherapy. The Bordetella pertussis (Pw) vaccine has been shown to have a protective role in ovalbumin-induced asthma models. However, its role in allergy to mites is unknown. We evaluated the effects of the diphtheria-tetanus-pertussis (DTPw) vaccine on a murine model of respiratory allergy induced by Dermatophagoides pteronyssinus (Derp).
   Methods: In a 30-day protocol, BALB/c mice were immunized subcutaneously with saline or Derp, alone or in combination with diphtheria-tetanus (DT) or DTPw vaccines (days 0, 7 and 14). Subsequently, they underwent a daily intranasal challenge with saline or Derp (days 22-28) and were then sacrificed (day 29). We evaluated serum-specific immunoglobulins, bronchoalveolar lavage (BAL) cellularity, remodelling of the lower airways, density of polymorphonuclear leukocytes (PMNs) and acidic nasal mucus content.
   Results: The animals sensitized with Derp produced high levels of specific immunoglobulins, increased density of PMNs and nasal mucus content, and elevated BAL cellularity and remodelling. Vaccines led to a reduction in IgE levels, with the Derp-DTPw group being similar to the saline groups. The vaccinated groups had reductions of BAL cellularity and remodelling, with more expressive results in the Derp-DTPw group compared to the Derp-DT group. The DT and DTPw vaccines inhibited the nasal PMN infiltrate, and DTPw modulated the production of acidic nasal mucus.
   Conclusions: The DTPw vaccine reduced serum specific IgE, nasal and pulmonary inflammation and remodelling of the lower airways. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Aun, Marcelo Vivolo; de Almeida, Francine Maria; Saraiva-Romanholo, Beatriz Mangueira; Martins, Milton de Arruda; Arantes-Costa, Fernanda Magalhaes] Univ Sao Paulo, Dept Internal Med, Lab Expt Therapeut LIM20, Sao Paulo, SP, Brazil.
RP Aun, MV (corresponding author), Ave Brigadeiro Luis Antonio 4267, BR-01401002 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
FU National Institute of Science and Technology (INCT); Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX This work was supported by National Institute of Science and Technology
   (INCT) and Sa similar to o Paulo Research Foundation (FAPESP).
CR Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022
   Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088
   Aun MV, 2015, EINSTEIN-SAO PAULO, V13, P560, DOI 10.1590/S1679-45082015AO3389
   Barnard A, 1996, IMMUNOLOGY, V87, P372, DOI 10.1046/j.1365-2567.1996.497560.x
   Blanco-Quiros A, 2005, PEDIAT ALLERG IMM-UK, V16, P637, DOI 10.1111/j.1399-3038.2005.00331.x
   Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x
   Capili CR, 2012, J ALLERGY CLIN IMMUN, V129, P957, DOI 10.1016/j.jaci.2011.11.020
   Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007
   Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034
   Cui YB, 2013, MOL BIOL REP, V40, P681, DOI 10.1007/s11033-012-2108-8
   Dong W, 2003, TOXICOL SCI, V72, P113, DOI 10.1093/toxsci/kfg015
   Drachenberg K J, 2003, Allergol Immunopathol (Madr), V31, P270
   Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x
   Ennis DP, 2005, CLIN DIAGN LAB IMMUN, V12, P409, DOI 10.1128/CDLI.12.3.409-417.2005
   Ennis DP, 2005, IMMUNOL LETT, V97, P91, DOI 10.1016/j.imlet.2004.10.011
   Ennis DP, 2004, CLIN EXP ALLERGY, V34, P1488, DOI 10.1111/j.1365-2222.2004.02042.x
   Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219
   Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC
   Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064
   Gandhi VD, 2013, CURR ALLERGY ASTHM R, V13, P262, DOI 10.1007/s11882-013-0349-9
   Giavina-Bianchi P, 2016, J ASTHMA ALLERGY, V9, P93, DOI 10.2147/JAA.S81541
   Gruber C, 2006, ALLERGY, V61, P820, DOI 10.1111/j.1398-9995.2006.01093.x
   Hagner S, 2016, INT ARCH ALLERGY IMM, V170, P22, DOI 10.1159/000446155
   Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR
   Hizume DC, 2012, RESP PHYSIOL NEUROBI, V181, P167, DOI 10.1016/j.resp.2012.03.005
   Jacobsen EA, 2014, CLIN EXP ALLERGY, V44, P1119, DOI 10.1111/cea.12358
   Johnson JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016175
   Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC
   Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047
   Kendirli SG, 2009, ALLERGOL IMMUNOPATH, V37, P21, DOI 10.1016/S0301-0546(09)70247-2
   Kim YS, 2004, IMMUNOLOGY, V112, P624, DOI 10.1111/j.1365-2567.2004.01880.x
   Lambert AL, 1998, AM J RESP CRIT CARE, V157, P1991, DOI 10.1164/ajrccm.157.6.9704057
   Lee YG, 2015, AM J RESP CELL MOL, V52, P772, DOI 10.1165/rcmb.2014-0255OC
   Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879
   Nagatal Makoto, 2010, Allergology International, V59, P15, DOI 10.2332/allergolint.09-RAI-0150
   PAUWELS R, 1983, ALLERGY, V38, P239, DOI 10.1111/j.1398-9995.1983.tb01617.x
   Prado CM, 2019, PULM MED, V2019, DOI 10.1155/2019/4781528
   Quintilio W, 2009, VACCINE, V27, P4219, DOI 10.1016/j.vaccine.2009.04.047
   REDHEAD K, 1993, INFECT IMMUN, V61, P3190, DOI 10.1128/IAI.61.8.3190-3198.1993
   Ryan M, 1997, DEV BIOLOGICALS, V89, P297
   Siddiqui S, 2008, CLIN EXP ALLERGY, V38, P1381, DOI 10.1111/j.1365-2222.2008.03009.x
   Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001
   Wheeler AW, 2001, INT ARCH ALLERGY IMM, V126, P135, DOI 10.1159/000049504
   WJST M, 1994, ANN ALLERGY, V73, P450
   Yang Y, 2014, ALLERGY, V69, P699, DOI 10.1111/all.12403
   Yoshizaki K, 2014, EFFECTS PARTICIPATIO
NR 46
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 70
EP 78
DI 10.1016/j.vaccine.2019.09.095
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400010
PM 31630941
DA 2020-11-26
ER

PT J
AU Pereira, ARF
   Motta, AA
   Kalil, J
   Agondi, RC
AF Firmino Pereira, Amanda Rocha
   Motta, Antonio Abilio
   Kalil, Jorge
   Agondi, Rosana Camara
TI Chronic inducible urticaria: confirmation through challenge tests and
   response to treatment
SO EINSTEIN-SAO PAULO
LA English
DT Article
DE Urticaria; Angioedema; Diagnosis; Drug therapy; Dose-response
   relationship; drug
ID PHYSICAL URTICARIAS; COLD URTICARIA; IMPACT; CLASSIFICATION; PREVALENCE;
   GUIDELINES; MANAGEMENT; TOLERANCE
AB Objective: To evaluate the positivity of challenge tests of patients suspected of chronic inducible urticaria and the response to treatment. Methods: A retrospective study of electronic medical records of patients suspected of chronic inducible urticaria. All patients were submitted to challenge tests with triggering stimuli, according to the clinical history and, subsequently, the response to drug treatment was evaluated. Results: A total of 191 patients with suspected chronic inducible urticaria were included. It was confirmed in 118 patients and 122 positive tests (4 patients with 2 different positive tests). Most had dermographic urticaria (70.3%), followed by cholinergic urticaria (17.8%). Regarding treatment, 28% responded to antihistamine in licensed doses, 34.7% with increased doses, 9.3% responded to the addition of another medication. The concomitance of chronic inducible urticaria and chronic spontaneous urticaria was found in 35.3% of patients, being more frequent in females, with longer time to control symptoms and higher frequency of cholinergic urticaria. Conclusion: The confirmation of chronic inducible urticaria in patients with this suspicion, after challenge tests, was high. There was a good response to antihistamine. In the concomitance of chronic spontaneous urticaria, longer time to control symptoms and higher frequency of cholinergic urticaria were observed.
C1 [Firmino Pereira, Amanda Rocha; Agondi, Rosana Camara] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
   [Motta, Antonio Abilio; Kalil, Jorge] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
RP Pereira, ARF (corresponding author), Ambulatorio Imunol Clin & Alergia, Ave Dr Eneas Carvalho Aguiar 155,5 Floor,Bldg 4B, BR-05401050 Sao Paulo, SP, Brazil.
EM amandafirpe@yahoo.com.br
RI ; KALIL, JORGE/C-8029-2012
OI Agondi, Rosana Camara/0000-0002-0503-5179; KALIL,
   JORGE/0000-0001-8415-4274
CR Abajian M, 2014, IMMUNOL ALLERGY CLIN, V34, P73, DOI 10.1016/j.iac.2013.09.010
   Balp MM, 2017, DERMATOLOGY THER, V7, P547, DOI 10.1007/s13555-017-0200-7
   BLACK AK, 1979, LANCET, V2, P964
   Black AK, 1996, CLIN EXP DERMATOL, V21, P424, DOI 10.1111/j.1365-2230.1996.tb00146.x
   Dias GAC, 2016, AN BRAS DERMATOL, V91, P754, DOI 10.1590/abd1806-4841.20165071
   Curto-Barredo L, 2018, ACTA DERM-VENEREOL, V98, P641, DOI 10.2340/00015555-2941
   Dressler C, 2018, J ALLERGY CLIN IMMUN, V141, P1726, DOI 10.1016/j.jaci.2018.01.031
   Duarte RA, 2018, ARQ ASMA ALERG IMUNO, V2, P434
   Geller M, 2007, EINSTEIN-SAO PAULO, V5, P273
   Grob JJ, 2005, BRIT J DERMATOL, V152, P289, DOI 10.1111/j.1365-2133.2005.06385.x
   Guillen-Aguinaga S, 2016, BRIT J DERMATOL, V175, P1153, DOI 10.1111/bjd.14768
   Kocaturk E, 2017, J DERMATOL SCI, V87, P60, DOI 10.1016/j.jdermsci.2017.02.283
   KontouFili K, 1997, ALLERGY, V52, P504, DOI 10.1111/j.1398-9995.1997.tb02593.x
   LEIGH IM, 1974, T ST JOHNS HOSP DERM, V60, P40
   LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x
   Lima SO, 2008, REV BRAS ALERG IMUNO, V31, P220
   Magerl M, 2016, ALLERGY, V71, P780, DOI 10.1111/all.12884
   Maurer M, 2018, J ALLER CL IMM-PRACT, V6, P1119, DOI 10.1016/j.jaip.2018.03.007
   Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P638, DOI 10.1016/j.jaci.2017.06.032
   Metz M, 2011, INT ARCH ALLERGY IMM, V154, P177, DOI 10.1159/000320233
   ODonnell BF, 1997, BRIT J DERMATOL, V136, P197
   RAMSAY CA, 1977, ARCH DERMATOL, V113, P1222, DOI 10.1001/archderm.113.9.1222
   Sanchez J, 2017, J ALLER CL IMM-PRACT, V5, P464, DOI 10.1016/j.jaip.2016.09.029
   Schoepke N, 2015, J EUR ACAD DERMATOL, V29, P708, DOI 10.1111/jdv.12661
   Silpa-archa N, 2011, J EUR ACAD DERMATOL, V25, P1194, DOI 10.1111/j.1468-3083.2010.03951.x
   Trevisonno J, 2015, POSTGRAD MED, V127, P565, DOI 10.1080/00325481.2015.1045817
   WARIN RP, 1987, BRIT J DERMATOL, V116, P742, DOI 10.1111/j.1365-2133.1987.tb05913.x
   Zuberbier H C Torsten, 2014, IMMUNOL ALLERGY CLIN, V34, pxix
   Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397
NR 29
TC 0
Z9 0
U1 1
U2 1
PU INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
PI SAO PAULO SP
PA AVENIDA ALBERT EINSTEIN, 627 701, SAO PAULO SP, 05651-901, BRAZIL
SN 1679-4508
EI 2317-6385
J9 EINSTEIN-SAO PAULO
JI Einstein
PY 2020
VL 18
AR eAO5175
DI 10.31744/einstein_journal/2020AO5175
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MW9TB
UT WOS:000557372400001
PM 32667419
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Pereira, ARF
   Aun, MV
   Kelmann, NCP
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
AF Firmino Pereira, Amanda Rocha
   Aun, Marcelo Vivolo
   Portilho Kelmann, Nathalia Coelho
   Motta, Antonio Abilio
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Loss of tolerance 5 days after discontinuing sulphonamide introduced via
   desensitization in delayed reaction
SO EINSTEIN-SAO PAULO
LA English
DT Article
DE Drug hypersensitivity; Trimethoprim; sulfamethoxazole drug combination;
   Drug eruptions; Desensitization; immunologic; Drug tolerance
ID FIXED DRUG ERUPTION; TRIMETHOPRIM-SULFAMETHOXAZOLE
AB The fixed drug eruption is a non-immediate hypersensitivity reaction to drug, characterized by recurrent erythematous or violaceous, rounded, well-defined border plaques, which always appear in the same location every time the culprit drug is administered. The usual practice is to avoid the drug involved and to use a structurally different drug. However, there are situations in which there is no safe and effective therapy. In such situations, desensitization is the only option. We describe the case of a patient who presented fixed eruption due to sulfamethoxazole-trimethoprim, who underwent successful desensitization, but required a repeat procedure twice due to relapse after inadvertent full-dose reintroduction. In non-immediate hypersensitivity reaction to drug, the indication is controversial and there is no technical standardization. Furthermore, the time at which such tolerance is lost after discontinuing the drug involved is unknown. In severe non-immediate reactions of types II and III, desensitization is contraindicated. The patient underwent desensitisation to sulfamethoxazole-trimethoprim three times - the first with recurrence of lesions and the second and third without manifestations, all concluded successfully and with no premedication.
C1 [Firmino Pereira, Amanda Rocha] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
   [Aun, Marcelo Vivolo] Fac Israelita Ciencias Saude Albert Einstein, Sao Paulo, SP, Brazil.
   [Portilho Kelmann, Nathalia Coelho; Motta, Antonio Abilio; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
RP Pereira, ARF (corresponding author), Ambulatorio Imunol Clin & Alergia, Ave Dr Eneas Carvalho Aguiar 155,5 Floor,Bldg 4B, BR-05403000 Sao Paulo, SP, Brazil.
EM amandafirpe@yahoo.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Rocha Firmino Pereira,
   Amanda/0000-0003-1536-5291; Giavina-Bianchi, Pedro/0000-0002-1034-7580;
   Reis, AlessanRSS/0000-0001-8486-7469
CR ABSAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001, DOI 10.1016/S0091-6749(94)70048-6
   Audiacana M, 1990, CLIN EXP ALLERGY, P121
   BORISH L, 1987, J ALLERGY CLIN IMMUN, V80, P314, DOI 10.1016/0091-6749(87)90037-6
   Brockow K, 2019, ALLERGY, V74, P14, DOI 10.1111/all.13562
   Can C, 2014, PEDIAT ALLERG IMM-UK, V25, P413, DOI 10.1111/pai.12204
   Emre S, 2017, CUTAN OCUL TOXICOL, V36, P294, DOI 10.1080/15569527.2016.1249796
   FEGUEUX S, 1991, AIDS, V5, P1275, DOI 10.1097/00002030-199110000-00028
   Garces M, 1995, ALLERGY S, V50, P213
   Rodriguez RG, 2011, J INVEST ALLERG CLIN, V21, P76
   Jung JW, 2014, ALLERGY ASTHMA IMMUN, V6, P415, DOI 10.4168/aair.2014.6.5.415
   Kavoussi H, 2015, DERMAT RES PRACT, DOI 10.1155/2015/236703
   Kelso JM, 1996, J ALLERGY CLIN IMMUN, V97, P1171, DOI 10.1016/S0091-6749(96)70275-0
   Kouotou EA, 2017, BMC DERMATOL, V17, DOI 10.1186/s12895-017-0053-x
   Leoung GS, 2001, J INFECT DIS, V184, P992, DOI 10.1086/323353
   Lipowicz S, 2013, BRIT J DERMATOL, V168, P726, DOI 10.1111/bjd.12133
   Patriarea G, 2008, J INVEST ALLERG CLIN, V18, P309
   Scherer K, 2013, ALLERGY, V68, P844, DOI 10.1111/all.12161
   Teraki Y, 2004, DERMATOLOGY, V209, P29, DOI 10.1159/000078583
   Umpierrez A, 1998, J ALLERGY CLIN IMMUN, V101, P286, DOI 10.1016/S0091-6749(98)70396-3
   Zaouak A, 2019, THERAPIE, V74, P527, DOI 10.1016/j.therap.2019.01.009
NR 20
TC 0
Z9 0
U1 0
U2 0
PU INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
PI SAO PAULO SP
PA AVENIDA ALBERT EINSTEIN, 627 701, SAO PAULO SP, 05651-901, BRAZIL
SN 1679-4508
EI 2317-6385
J9 EINSTEIN-SAO PAULO
JI Einstein
PY 2020
VL 18
AR eRC5002
DI 10.31744/einstein_journal/2020RC5002
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX0AC
UT WOS:000557390700001
PM 31778467
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Carmona, P
   Medina-Armenteros, Y
   Cabral, A
   Monteiro, SM
   Fonseca, SG
   Faria, AC
   Lemos, F
   Saitovitch, D
   Noronha, IL
   Kalil, J
   Coelho, V
AF Carmona, Priscila
   Medina-Armenteros, Yordanka
   Cabral, Amanda
   Monteiro, Sandra Maria
   Fonseca, Simone Goncalves
   Faria, Ana Caetano
   Lemos, Francine
   Saitovitch, David
   Noronha, Irene L.
   Kalil, Jorge
   Coelho, Veronica
TI Regulatory/inflammatory cellular response discrimination in operational
   tolerance
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE antigen-specific cellular response; HLA-DR peptide; immunoregulation;
   operational tolerance; renal transplantation
ID HEAT-SHOCK PROTEINS; MEMORY T-CELLS; KIDNEY-TRANSPLANTATION; REGULATORY
   FUNCTIONS; CROSS-REACTIVITY; TH2 CLONES; AUTOIMMUNITY; EXPRESSION;
   BIOMARKERS; SIGNATURE
AB Background. Antigen-specific cellular response is essential in immune tolerance. We tested whether antigen-specific cellular response is differentially modulated in operational tolerance (OT) in renal transplantation with respect to critical antigenic challenges in allotransplantation-donor antigens, pathogenic antigens and self-antigens.
   Methods. We analysed the profile of immunoregulatory (REG) and pro-inflammatory (INFLAMMA) cytokines for the antigen-specific response directed to these three antigen groups, by Luminex.
   Results. We showed that, in contrast to chronic rejection and healthy individuals, OT gives rise to an immunoregulatory deviation in the cellular response to donor human leucocyte antigen DR isotype peptides, while preserving the pro-inflammatory response to pathogenic peptides. Cellular autoreactivity to the N6 heat shock protein 60 (Hsp60) peptide also showed a REG profile in OT, increasing IL4, IL-5, IL-10 and IL-13.
   Conclusions. The REG shift of donor indirect alloreactivity in OT, with inhibition of interleukin (IL)-1B, IL-8, IL-12, IL-17, granulocyte colony-stimulating factor, Interferon-gamma and monocyte chemoattractant protein-1, indicates that this may be an important mechanism in OT. In addition, the differential REG profile of cellular response to the Hsp60 peptide in OT suggests that REG autoimmunity may also play a role in human transplantation tolerance. Despite cross-reactivity of antigen-specific T cell responses, a systemic functional antigen-specific discrimination takes place in OT.
C1 [Carmona, Priscila; Medina-Armenteros, Yordanka; Cabral, Amanda; Monteiro, Sandra Maria; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Lab Imunol, Inst Coracao InCor, Fac Med, Sao Paulo, SP, Brazil.
   [Carmona, Priscila; Medina-Armenteros, Yordanka; Cabral, Amanda; Monteiro, Sandra Maria; Fonseca, Simone Goncalves; Faria, Ana Caetano; Noronha, Irene L.; Kalil, Jorge; Coelho, Veronica] Inst Nacl Ciencias & Tecnol III INCT, Inst Invest Imunol, Rio De Janeiro, Brazil.
   [Fonseca, Simone Goncalves] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Faria, Ana Caetano] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Serv Transplante Renal, Fac Med, Sao Paulo, SP, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Div Nefrol, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [Saitovitch, David] Hosp Moinhos de Vento, Serv Nefrol, Grp Transplante Renal, Porto Alegre, RS, Brazil.
   [Noronha, Irene L.] Univ Sao Paulo, Lab Nefrol Celular & Mol, Div Nefrol, Fac Med, Sao Paulo, SP, Brazil.
RP Coelho, VN (corresponding author), Univ Sao Paulo, Lab Imunol, Inst Coracao InCor, Fac Med, Sao Paulo, SP, Brazil.; Coelho, VN (corresponding author), Inst Nacl Ciencias & Tecnol III INCT, Inst Invest Imunol, Rio De Janeiro, Brazil.
EM vecoelho@usp.br
OI Coelho, Veronica/0000-0002-0989-2581; Faria, Ana
   Maria/0000-0002-0604-8510
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - (CNPq-FAPESP) [465434/2014-2]
FX The authors thank the Brazilian Multicenter Study on Operational
   Tolerance group, Fabiana Agena for collecting samples and clinical data
   and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   (CNPq-FAPESP-Process no 465434/2014-2) for financial support.
CR Amirzargar A, 2005, TRANSPL P, V37, P2985, DOI 10.1016/j.transproceed.2005.08.004
   BANDEIRA A, 1989, P NATL ACAD SCI USA, V86, P272, DOI 10.1073/pnas.86.1.272
   Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159
   Brouard S, 2012, AM J TRANSPLANT, V12, P3296, DOI 10.1111/j.1600-6143.2012.04249.x
   Chen X, 2012, BONE MARROW TRANSPL, V47, P967, DOI 10.1038/bmt.2011.203
   Cohen I. R., 2000, TENDING ADAMS GARDEN
   Cohn M, 2005, MOL IMMUNOL, V42, P651, DOI 10.1016/j.molimm.2004.09.010
   Costa C, 2014, J CLIN VIROL, V61, P523, DOI 10.1016/j.jcv.2014.09.015
   COUTINHO GC, 1994, EUR J IMMUNOL, V24, P1858, DOI 10.1002/eji.1830240821
   Curci C, 2016, NEPHROL DIAL TRANSPL, V31, P2131, DOI 10.1093/ndt/gfw245
   Dhaouadi T, 2013, TRANSPL P, V45, P2152, DOI 10.1016/j.transproceed.2012.12.006
   Dragun D, 2005, NEW ENGL J MED, V352, P558, DOI 10.1056/NEJMoa035717
   Dugast E, 2014, IMMUNOL REV, V258, P208, DOI 10.1111/imr.12156
   Eberl G, 2016, NAT REV IMMUNOL, V16, P524, DOI 10.1038/nri.2016.75
   Espinosa JR, 2016, NAT REV NEPHROL, V12, P339, DOI 10.1038/nrneph.2016.9
   Faria AMC, 2006, CLIN DEV IMMUNOL, V13, P143, DOI 10.1080/17402520600876804
   Gorbacheva V, 2016, J AM SOC NEPHROL, V27, P3299, DOI 10.1681/ASN.2015080848
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   Gronski MA, 2004, NAT MED, V10, P1234, DOI 10.1038/nm1114
   Hernandez-Fuentes MP, 2010, NAT REV NEPHROL, V6, P606, DOI 10.1038/nrneph.2010.112
   Hill GR, 2010, AM J TRANSPLANT, V10, P173, DOI 10.1111/j.1600-6143.2009.02872.x
   Iwata T, 2008, J IMMUNOL, V181, P5738, DOI 10.4049/jimmunol.181.8.5738
   Karczewski J, 2008, TRANSPL P, V40, P3390, DOI 10.1016/j.transproceed.2008.07.125
   Kim JY, 2016, STROKE, V47, P2103, DOI 10.1161/STROKEAHA.116.012763
   Kist-van Holthe JE, 2002, KIDNEY INT, V62, P627
   Luna E, 2007, CELL STRESS CHAPERON, V12, P112, DOI 10.1379/CSC-209R.1
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Moraes-Vieira PMM, 2012, CLIN IMMUNOL, V142, P117, DOI 10.1016/j.clim.2011.08.015
   Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933
   Pallier A, 2010, KIDNEY INT, V78, P503, DOI 10.1038/ki.2010.162
   Pockley AG, 2005, CONTRIB NEPHROL, V148, P122, DOI 10.1159/000086057
   Portugal K, 2001, INT IMMUNOL, V13, P747, DOI 10.1093/intimm/13.6.747
   Rebollo-Mesa I, 2016, AM J TRANSPLANT, V16, P3443, DOI 10.1111/ajt.13932
   Ruiz P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00596
   Saito T, 2013, AM J TRANSPLANT, V13, P3192, DOI 10.1111/ajt.12492
   SALAUN J, 1990, SCIENCE, V247, P1471, DOI 10.1126/science.2321009
   Schmaler M, 2015, P NATL ACAD SCI USA, V112, P13330, DOI 10.1073/pnas.1510045112
   Shiu KY, 2015, KIDNEY INT, V88, P560, DOI 10.1038/ki.2015.100
   Silva HM, 2012, MOL MED, V18, P733, DOI 10.2119/molmed.2011.00281
   Simonetta F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113314
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   Spadafora-Ferreira M, 2007, SCAND J IMMUNOL, V66, P352, DOI 10.1111/j.1365-3083.2007.01976.x
   Van Eden W, 2007, ANN NY ACAD SCI, V1113, P217, DOI 10.1196/annals.1391.020
   van Heemst J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7681
   vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553
   Waaga AM, 2001, J CLIN INVEST, V107, P909, DOI 10.1172/JCI11427
   Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008
   Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227
   Zhao Y, 2010, CELL MOL IMMUNOL, V7, P20, DOI 10.1038/cmi.2009.101
   Zuo DM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00075
NR 50
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD DEC
PY 2019
VL 34
IS 12
BP 2143
EP 2154
DI 10.1093/ndt/gfz114
PG 13
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA KF8RQ
UT WOS:000509504600022
PM 31280312
DA 2020-11-26
ER

PT J
AU de Campos, L
   Galvao, CES
   Mairena, EC
   Voegels, R
   Kalil, J
   Castro, FM
   Cunha-Neto, E
AF de Campos, Lucila
   Santos Galvao, Clovis Eduardo
   Mairena, Eliane Conti
   Voegels, Richard
   Kalil, Jorge
   Castro, Fabio Morato
   Cunha-Neto, Edecio
TI Increased gene expression of inflammatory markers in nasal turbinate of
   patients with persistent allergic rhinitis and chronic obstruction
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Article
DE Allergic rhinitis; Gene expression; Nasal mucosa; Cytokines; IL-4;
   Remodeling
AB Purpose The pathogenesis of persistent allergic rhinitis with chronic and refractory nasal obstruction is still unknown. Inflammation and tissue remodeling are known to play a role, but this has not been studied thoroughly. The purpose of this study is to identify the profile of gene expression of inflammatory and remodeling markers in nasal mucosa of patients with PAR and chronic obstruction. Methods After informed consent, we obtained nasal mucosa tissue from five aeroallergen-sensitized PAR patients undergoing anterior turbinectomy, and control non-sensitized individuals undergoing cerebrospinal fluid fistula repair or rhinoplasty. We assessed the expression of 34 genes related to inflammation and tissue remodeling using the real-time polymerase chain reaction (qPCR) to quantify each mRNA. Results IL-4 mRNA was upregulated in nasal mucosa of all five patients; CCR3, CCR8 and Eotaxin-2 were upregulated in four out of five patient samples; while IL-5 and IL-13 were upregulated in two of them. TGF-beta 1 was not upregulated in PAR samples. mRNA from metalloproteinases MMP-7, MMP13 and MMP15 were upregulated in three out of five samples. Our results indicate a typical mRNA expression profile of the infiltrating inflammatory Th2 cells and eosinophils, combined with altered gene expression of remodeling-related proteins in stromal cells from the mucosa. Conclusion Prolonged allergen challenge can lead to persistent upregulation of genes for inflammatory mediators such as IL-4 Th2/eosinophil cytokines, chemokines and receptors, which may play an important role in maintaining PAR with chronic nasal obstruction. Our findings may have therapeutic implications, including the use of anti-IL4, -CCR3 or -MMP therapy to ameliorate the condition.
C1 [de Campos, Lucila; Santos Galvao, Clovis Eduardo; Kalil, Jorge; Castro, Fabio Morato; Cunha-Neto, Edecio] Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Med, Fac Med FMUSP, Ave Dr Arnaldo,455 S 3207, BR-01246000 Sao Paulo, SP, Brazil.
   [Mairena, Eliane Conti; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Inst Coracao Incor Hosp Clin HCFMUSP, Lab Immunol, Fac Med, Sao Paulo, SP, Brazil.
   [Voegels, Richard] Univ Sao Paulo, Div Otorhinolaryngol, Fac Med FMUSP, Sao Paulo, SP, Brazil.
   [Kalil, Jorge; Castro, Fabio Morato; Cunha-Neto, Edecio] INCT, Inst Invest Immunol Iii, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Med, Fac Med FMUSP, Ave Dr Arnaldo,455 S 3207, BR-01246000 Sao Paulo, SP, Brazil.; Cunha-Neto, E (corresponding author), Univ Sao Paulo, Inst Coracao Incor Hosp Clin HCFMUSP, Lab Immunol, Fac Med, Sao Paulo, SP, Brazil.; Cunha-Neto, E (corresponding author), INCT, Inst Invest Immunol Iii, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Castro, Fabio/AAP-5433-2020; Cunha-Neto, Edecio/B-4157-2009
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Voegels,
   Richard/0000-0003-0192-3387
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/08488-3]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil)
   Grant number 04/08488-3.
CR Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x
   Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102
   Eloy P, 2011, CURR ALLERGY ASTHM R, V11, P146, DOI 10.1007/s11882-011-0180-0
   Francis JN, 2007, ALLERGY, V62, P59, DOI 10.1111/j.1398-9995.2006.01253.x
   Lei F, 2010, AM J RHINOL ALLERGY, V24, pE23, DOI 10.2500/ajra.2010.24.3414
   Montero Mora Patricia, 2003, Rev Alerg Mex, V50, P79
   PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776
   Richards TJ, 2012, AM J PHYSIOL-LUNG C, V302, pL746, DOI 10.1152/ajplung.00319.2011
   Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
NR 10
TC 0
Z9 0
U1 6
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
PD NOV
PY 2019
VL 276
IS 11
BP 3247
EP 3249
DI 10.1007/s00405-019-05581-8
PG 3
WC Otorhinolaryngology
SC Otorhinolaryngology
GA JG4IM
UT WOS:000492037800037
PM 31363902
DA 2020-11-26
ER

PT J
AU De Amicis, K
   Costa, PR
   Figo, DD
   De Lima, CMF
   Castro, FFM
   Kalil, J
   Santos, KS
   Galvao, CES
AF De Amicis, Karine
   Costa, Priscilla Ramos
   Figo, Daniele Danella
   Fonsecade De Lima, Cynthia Mafra
   Morato Castro, Fabio Fernandes
   Kalil, Jorge
   Santos, Keity Souza
   Santos Galvao, Clovis Eduardo
TI Immunophenotypical Characterization of a Brazilian POIS (Post-Orgasmic
   Illness Syndrome) Patient: Adding More Pieces to Puzzle
SO JOURNAL OF SEX & MARITAL THERAPY
LA English
DT Article
ID NATURAL-KILLER-CELL; DEPRESSION; ALLERGY
AB Post-orgasmic illness syndrome (POIS) is a rare condition characterized by post-ejaculatory symptoms. Here is reported the first Brazilian POIS patient. Immunological investigation did not confirm the previous hypothesis of a hypersensitivity reaction. Cell immunophenotyping comparing healthy individuals produced evidence of abnormalities not associated to clinical manifestations. The patient was submitted to specific immunotherapy with transient clinical response and was referred to a psychologist but did not demonstrate clinical improvement of symptoms. Therefore, etiology of POIS remains unclear.
C1 [De Amicis, Karine; Costa, Priscilla Ramos; Figo, Daniele Danella; Fonsecade De Lima, Cynthia Mafra; Morato Castro, Fabio Fernandes; Kalil, Jorge; Santos, Keity Souza] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Morato Castro, Fabio Fernandes; Santos Galvao, Clovis Eduardo] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Serv Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Kalil, Jorge; Santos, Keity Souza] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Sao Paulo, Brazil.
   [Morato Castro, Fabio Fernandes; Kalil, Jorge; Santos, Keity Souza] INCT, III, Sao Paulo, Brazil.
RP Santos, KS; Galvao, CES (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
EM keitysouzasantos@gmail.com; clovis.galvao@hc.fm.usp.br
RI Castro, Fabio/AAP-5433-2020; De Amicis Lima, Karine/D-3890-2013
OI De Amicis Lima, Karine/0000-0002-9936-2436; Mafra,
   Cynthia/0000-0002-3219-7253; Santos, Keity/0000-0001-5271-4011
FU Fundacao de Amparo a Pesquisa de Sao Paulo (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2012/14019-2]; FAPESPFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao
   Faculdade de Medicina (FFMUSP)
FX This research was funded by Fundacao de Amparo a Pesquisa de Sao Paulo
   (FAPESP) (grant#2012/14019-2). K.D.A. was funded by FAPESP, P.R.C and
   D.D.F. was funded by Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES), K.S.S. was funded by Fundacao Faculdade de Medicina
   (FFMUSP).
CR Ashby J, 2010, J SEX MED, V7, P1976, DOI 10.1111/j.1743-6109.2010.01707.x
   Denys D, 2004, PSYCHONEUROENDOCRINO, V29, P945, DOI 10.1016/j.psyneuen.2003.08.008
   Depreux N, 2018, REV INT ANDROL, V16, P42, DOI 10.1016/j.androl.2017.06.002
   Enstrom AM, 2009, BRAIN BEHAV IMMUN, V23, P124, DOI 10.1016/j.bbi.2008.08.001
   EVANS DL, 1992, ARCH GEN PSYCHIAT, V49, P388
   Farnam A, 2016, IRAN J IMMUNOL, V13, P37, DOI IJIv13i1A5
   Nguyen HMT, 2018, SEX MED REV, V6, P11, DOI 10.1016/j.sxmr.2017.08.006
   IRWIN M, 1992, PSYCHOL MED, V22, P1045, DOI 10.1017/S0033291700038617
   Jiang NN, 2015, J SEX MED, V12, P840, DOI 10.1111/jsm.12813
   Kim TB, 2018, SEX MED-UK, V6, P174, DOI 10.1016/j.esxm.2017.12.004
   Morimoto K, 2001, SCI TOTAL ENVIRON, V270, P3, DOI 10.1016/S0048-9697(00)00782-8
   Nguyen T, 2011, ANN ALLERG ASTHMA IM, V107, pA48
   PEPYS J, 1984, BRIT J HOSP MED, V32, P120
   Serefoglu EC, 2017, J SEX MED, V14, P641, DOI 10.1016/j.jsxm.2017.03.250
   Waldinger MD, 2011, J SEX MED, V8, P1164, DOI 10.1111/j.1743-6109.2010.02166.x
   Waldinger MD, 2011, J SEX MED, V8, P1171, DOI 10.1111/j.1743-6109.2010.02167.x
   Waldinger MD, 2002, J SEX MARITAL THER, V28, P251, DOI 10.1080/009262302760328280
   Watanabe AS, 2010, SAO PAULO MED J, V128, P30, DOI 10.1590/S1516-31802010000100007
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0092-623X
EI 1521-0715
J9 J SEX MARITAL THER
JI J. Sex Marital Ther.
PD APR 2
PY 2020
VL 46
IS 3
BP 227
EP 233
DI 10.1080/0092623X.2019.1677835
EA OCT 2019
PG 7
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA KW6XE
UT WOS:000492487700001
PM 31612795
DA 2020-11-26
ER

PT J
AU Neto, EC
   Marquet, S
   Frade, AF
   Ferreira, AM
   Ouarhache, M
   Ianni, B
   Ferreira, LRP
   Rigaud, VOC
   Almeida, RR
   Candido, D
   Torres, M
   Gallardo, F
   Fernandes, R
   Mady, C
   Buck, P
   Cardoso, C
   Santos, OR
   Oliveira, LC
   Oliveira, CDL
   Nunes, MD
   Abel, L
   Kalil, J
   Ribeiro, ALP
   Sabino, EC
   Chevillard, C
AF Cunha-Neto, E.
   Marquet, S.
   Farage Frade, A.
   Mota Ferreira, A.
   Ouarhache, M.
   Ianni, B.
   Rodrigues Pinto Ferreira, L.
   Oliveira-Carvalho Rigaud, V.
   Ribeiro Almeida, R.
   Candido, D.
   Torres, M.
   Gallardo, F.
   Fernandes, R.
   Mady, C.
   Buck, P.
   Cardoso, C.
   Santos-Junior, O. R.
   Oliveira, L. C.
   Oliveira, C. D. L.
   do Carmo Nunes, M.
   Abel, L.
   Kalil, J.
   Ribeiro, A. L. P.
   Sabino, E. C.
   Chevillard, C.
TI Whole exome sequencing of Chagas disease cardiomyopathy families reveals
   accumulation of rare variants in mitochondrial and
   inflammation-associated genes
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 17th International Congress of Immunology of the
   International-Union-of-Immunological-Societies (IUIS)
CY OCT 19-23, 2019
CL Beijing, PEOPLES R CHINA
SP Int Union Immunol Soc
C1 [Cunha-Neto, E.; Farage Frade, A.; Ribeiro Almeida, R.] Univ Sao Paulo, Div Clin Immunol & Allergy, Heart Inst InCor, Sao Paulo, Brazil.
   [Marquet, S.] Aix Marseille Univ, Labex ParaFrap, INSERM, GIMP,UMR906, Marseille, France.
   [Mota Ferreira, A.] Univ Estadual Montes Claros, Hlth Sci Programme, Montes Claros, Brazil.
   [Ouarhache, M.] Aix Marseille Univ, URMITE, IHU Mediterranee Infect, UM63,CNRS 7278,IRD 198,INSERM 1095, Marseille, France.
   [Ianni, B.; Mady, C.; Buck, P.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Myocardiopathies Unit, Sao Paulo, Brazil.
   [Rodrigues Pinto Ferreira, L.; Oliveira-Carvalho Rigaud, V.; Candido, D.; Fernandes, R.; Kalil, J.] Univ Sao Paulo, Inst Invest Immunol, Inst Nacl Ciencia & Tecnol, Lab Immunol,Heart Inst InCor,Div Clin Immunol &, Sao Paulo, Brazil.
   [Torres, M.] Aix Marseille Univ, INSERM, UMR 1090, Marseille, France.
   [Gallardo, F.] Aix Marseille Univ, INSERM, TAGC UMR S1090, Marseille, France.
   [Cardoso, C.] Univ Fed Sao Joao del Rei, Sch Med, Divinopolis, Brazil.
   [Santos-Junior, O. R.; do Carmo Nunes, M.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Oliveira, L. C.] Univ Sao Paulo, Sch Med, Gen Hosp, Lab Med Laboratorial LIM03, Sao Paulo, Brazil.
   [Oliveira, C. D. L.] Univ Fed Sao Joao del Rei, Sch Med, Divinopolis, Brazil.
   [Abel, L.] Paris Descartes Univ, Sorbonne Paris Cite, Lab Human Genet Infect Dis, Necker Branch,INSERM,U1163, Paris, France.
   [Ribeiro, A. L. P.] Univ Fed Minas Gerais, Dept Internal Med, Belo Horizonte, MG, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Chevillard, C.] Aix Marseille Univ, INSERM, GIMP UMR S906, Marseille, France.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD OCT
PY 2019
VL 49
SU 3
SI SI
MA O092
BP 1171
EP 1172
PG 2
WC Immunology
SC Immunology
GA JD5MK
UT WOS:000490026903505
DA 2020-11-26
ER

PT J
AU Pandey, RP
   Nascimento, S
   Barrios, L
   Gibaldi, D
   Lannes-Vieira, J
   Kalil, J
   Cunha-Neto, E
AF Pandey, R. P.
   Savoia Nascimento, M.
   Barrios, L.
   Gibaldi, D.
   Lannes-Vieira, J.
   Kalil, J.
   Cunha-Neto, E.
TI Repurposed drugs acting on host mechanisms of T. cruzi invasion
   synergize with Benznidazole: New therapies for Chagas disease
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 17th International Congress of Immunology of the
   International-Union-of-Immunological-Societies (IUIS)
CY OCT 19-23, 2019
CL Beijing, PEOPLES R CHINA
SP Int Union Immunol Soc
C1 [Pandey, R. P.] SRM Univ, Delhi NCR, Sonepat, India.
   [Pandey, R. P.; Savoia Nascimento, M.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Barrios, L.; Gibaldi, D.; Lannes-Vieira, J.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD OCT
PY 2019
VL 49
SU 3
SI SI
MA P2131
BP 1208
EP 1209
PG 2
WC Immunology
SC Immunology
GA JD5MK
UT WOS:000490026904008
DA 2020-11-26
ER

PT J
AU Bellelis, P
   Barbeiro, DF
   Gueuvoghlanian-Silva, BY
   Kalil, J
   Abrao, MS
   Podgaec, S
AF Bellelis, Patrick
   Barbeiro, Denise Frediani
   Gueuvoghlanian-Silva, Barbara Yasmin
   Kalil, Jorge
   Abrao, Mauricio Simoes
   Podgaec, Sergio
TI Interleukin-15 and Interleukin-7 are the Major Cytokines to Maintain
   Endometriosis
SO GYNECOLOGIC AND OBSTETRIC INVESTIGATION
LA English
DT Article
DE Endometriosis; Natural killer cells; T-Regulatory cells; Cytokines;
   Endometrium
ID NATURAL-KILLER; IL-15; CELLS; IMMUNOLOGY; EXPRESSION; LESIONS; WOMEN
AB Objective: The objective of this study was to evaluate cytokines related to natural killer and T-regulatory cells in endometriotic lesions, peritoneal fluid (PF) and the peripheral blood (PB) of patients with deep infiltrative endometriosis. Study Design: A case-control study was conducted in a tertiary referral hospital. Sixty-four consecutive patients after laparoscopy were divided into 2 groups: with endometriosis (Group A - n = 32) and without endometriosis (Group B - n = 32). Main Outcome Measures: Interleukin (IL)-2, IL-4, IL-7, IL-10, IL-12, IL-15, transforming growth factor beta 1, and IFN gamma concentration was measured using a Luminex(TM) multiplex suspension bead array. Tissues from endometriotic lesions of patients with endometriosis and from eutopic endometrium were evaluated, as well as PF and PB of all patients. Results: Compared to the other analyzed groups, IL-15 concentration was significantly higher in the ectopic endometrium and IL-7 in the eutopic endometrium of the endometriosis group (p < 0.05). Compared to endometriosis group, IFN gamma, IL-7, and IL-15 were observed to be significantly higher in the PF of the control group, and IL-10 was lower in the control group (p < 0.05). In PB, compared to endometriosis group, IL-4, IL-10, IL-12, IL-15, and IFN gamma concentrations were significantly higher in the control group (p < 0.05). Conclusions: Our hypothesis is that deep endometriosis is a disease out of control. This disease's nature is of progression and invasion of adjacent structures, and proof of this disease state is the disorganized secretion of cytokine regulation and inflammation, which seem to be among the factors responsible for the maintenance of the disease.
C1 [Bellelis, Patrick; Abrao, Mauricio Simoes; Podgaec, Sergio] Univ Sao Paulo, Dept Obstet & Gynecol, Med Sch, Rua Dr Homem de Mello 1020, BR-05007002 Sao Paulo, SP, Brazil.
   [Barbeiro, Denise Frediani] Univ Sao Paulo, Med Invest Lab LIM 51, Med Sch, Sao Paulo, Brazil.
   [Gueuvoghlanian-Silva, Barbara Yasmin; Podgaec, Sergio] Albert Einstein Hosp, Jewish Teaching & Res Inst, Sao Paulo, Brazil.
   [Kalil, Jorge] Discipline Allergy & Immunol HC Incor FMUSP, INCT, Sao Paulo, Brazil.
   [Abrao, Mauricio Simoes] BP A Beneficencia Portuguesa Sao Paulo, Gynecol Div, Sao Paulo, Brazil.
RP Bellelis, P (corresponding author), Univ Sao Paulo, Dept Obstet & Gynecol, Med Sch, Rua Dr Homem de Mello 1020, BR-05007002 Sao Paulo, SP, Brazil.
EM pbellelis@gmail.com
RI Abrao, Mauricio S/L-3387-2017
OI Abrao, Mauricio S/0000-0003-1320-3010
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/10338-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP#2010/10338-0).
CR Abbas A, 2011, IMUNOLOGIA CELULAR M, P55
   Acien Pedro, 2013, ISRN Obstet Gynecol, V2013, P242149, DOI 10.1155/2013/242149
   Bellelis P, 2013, FERTIL STERIL, V99, P1987, DOI 10.1016/j.fertnstert.2013.02.038
   Bellelis P, 2010, REV ASSOC MED BRAS, V56, P467, DOI 10.1590/S0104-42302010000400022
   Berbic M, 2013, WOMENS HEALTH, V9, P387, DOI [10.2217/WHE.13.32, 10.2217/whe.13.32]
   Berkkanoglu M, 2003, AM J REPROD IMMUNOL, V50, P48, DOI 10.1034/j.1600-0897.2003.00042.x
   Dias JA, 2012, J MINIM INVAS GYN, V19, P317, DOI 10.1016/j.jmig.2011.12.021
   Fairbanks F, 2009, FERTIL STERIL, V91, P320, DOI 10.1016/j.fertnstert.2007.11.060
   Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14
   Gao X, 2006, CURR MED RES OPIN, V22, P1787, DOI 10.1185/030079906X121084
   Gueuvoghlanian-Silva BY, 2018, J REPROD IMMUNOL, V126, P32, DOI 10.1016/j.jri.2018.02.003
   Guo Saiqun, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P1322
   Harada T, 2001, FERTIL STERIL, V76, P1, DOI 10.1016/S0015-0282(01)01816-7
   King A, 1996, NAT IMMUN, V15, P41
   Li MQ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.414
   Lin SJ, 2014, METHODS MOL BIOL, V1139, P223, DOI 10.1007/978-1-4939-0345-0_19
   Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727
   Meyer R, 1919, ZBL GYNAKOL, V36, P745
   Mier-Cabrera J, 2011, BJOG-INT J OBSTET GY, V118, P6, DOI 10.1111/j.1471-0528.2010.02777.x
   Monsanto SP, 2016, FERTIL STERIL, V105, P968, DOI 10.1016/j.fertnstert.2015.11.047
   Othman EEDR, 2008, EUR J OBSTET GYN R B, V137, P240, DOI 10.1016/j.ejogrb.2007.05.001
   Pagliari D, 2013, CYTOKINE GROWTH F R, V24, P455, DOI 10.1016/j.cytogfr.2013.05.004
   Podgaec S, 2007, HUM REPROD, V22, P1373, DOI 10.1093/humrep/del516
   Podgaec S, 2014, J REPROD IMMUNOL, V104, P96, DOI 10.1016/j.jri.2014.05.002
   Podgaec S, 2012, AM J REPROD IMMUNOL, V68, P301, DOI 10.1111/j.1600-0897.2012.01173.x
   Read KA, 2016, EXP HEMATOL, V44, P799, DOI 10.1016/j.exphem.2016.06.003
   Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X
   Tosti C, 2015, REPROD SCI, V22, P1053, DOI 10.1177/1933719115592713
   Yu JJ, 2016, REPRODUCTION, V152, P151, DOI 10.1530/REP-16-0089
NR 29
TC 5
Z9 5
U1 3
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-7346
EI 1423-002X
J9 GYNECOL OBSTET INVES
JI Gynecol.Obstet.Invest.
PD SEP
PY 2019
VL 84
IS 5
BP 435
EP 444
DI 10.1159/000496607
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA IZ4BO
UT WOS:000487029500002
PM 30712043
DA 2020-11-26
ER

PT J
AU Barros, MT
   De Melo, DB
   Pereira, RMR
   Sini, B
   Coutinho, EM
   Takayama, L
   Kokron, CM
   Marinho, AK
   Grecco, O
   Kalil, J
   Antila, HG
AF Toledo Barros, M.
   Barreto De Melo, D.
   Rodrigues Pereira, R. M.
   Sini, B.
   Coutinho, E. M.
   Takayama, L.
   Kokron, C. M.
   Marinho, A. K.
   Grecco, O.
   Kalil, J.
   Antila, H. G.
TI Low bone mineral density and muscle mass in common variable
   immunodeficiency patients: Association with CD4+T cells and B cells
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Toledo Barros, M.; Barreto De Melo, D.; Sini, B.; Coutinho, E. M.; Kokron, C. M.; Marinho, A. K.; Grecco, O.; Kalil, J.; Antila, H. G.] Univ Sao Paulo, Clin Immunol & Allergy Div, Fac Med, Sao Paulo, Brazil.
   [Rodrigues Pereira, R. M.; Takayama, L.] Univ Sao Paulo, Div Rheumatol, Fac Med, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA PD0432
BP 242
EP 242
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254002019
DA 2020-11-26
ER

PT J
AU Mamede, LDQ
   Gomes, LS
   Pereira, GDF
   Maia, LP
   Kalil, J
   Motta, AA
   Agondi, RC
AF Mamede, L. D. Q.
   Gomes, L. S.
   Pereira, G. D. F.
   Maia, L. P.
   Kalil, J.
   Motta, A. A.
   Agondi, R. C.
TI Frequency of helicobacter pylori and response to its treatment in the
   clinical evolution of patients with chronic urticaria
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Mamede, L. D. Q.; Gomes, L. S.; Pereira, G. D. F.; Maia, L. P.; Kalil, J.; Motta, A. A.; Agondi, R. C.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA PD0516
BP 282
EP 282
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254002098
DA 2020-11-26
ER

PT J
AU Aliaga, GLC
   Brolio, A
   Gomes, L
   Anagusko, CLY
   Grecco, O
   Marinho, AKB
   Kalil, J
   Kokron, CM
   Barros, MT
AF Cortez Aliaga, G. L.
   Brolio, A.
   Gomes, L.
   Anagusko, C. L. Y.
   Grecco, O.
   Marinho, A. K. B.
   Kalil, J.
   Kokron, C. M.
   Barros, M. T.
TI Intravenous human immunoglobulin infusion adverse effects in patients
   with immunodeficiency
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Cortez Aliaga, G. L.; Brolio, A.; Gomes, L.; Anagusko, C. L. Y.; Grecco, O.; Marinho, A. K. B.; Kalil, J.; Kokron, C. M.; Barros, M. T.] Hosp Clin Sao Paulo, Dept Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA LBPD1753
BP 349
EP 349
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254002225
DA 2020-11-26
ER

PT J
AU Gomes, LS
   Pereira, GDF
   Mamede, LDQ
   Maia, LP
   Kalil, J
   Motta, AA
   Agondi, RC
   Barros, MT
AF Gomes, L. S.
   Pereira, G. D. F.
   Mamede, L. D. Q.
   Maia, L. P.
   Kalil, J.
   Motta, A. A.
   Agondi, R. C.
   Barros, M. T.
TI Evaluate the frequency of autologous serum skin test in patients with
   autoimmune diseases
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Gomes, L. S.; Pereira, G. D. F.; Mamede, L. D. Q.; Maia, L. P.; Kalil, J.; Motta, A. A.; Agondi, R. C.; Barros, M. T.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP0619
BP 377
EP 377
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254003004
DA 2020-11-26
ER

PT J
AU Dias, GMFS
   Assis, JP
   Kalil, J
   Giavina-Bianchi, PF
   Agondi, RC
AF Dias, G. M. F. S.
   Assis, J. P.
   Kalil, J.
   Giavina-Bianchi, P. F.
   Agondi, R. C.
TI Clinical characteristics of patients with AERD and eligibility for
   therapy with monoclonal antibody in a Brazilian cohort
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Dias, G. M. F. S.; Assis, J. P.; Kalil, J.; Giavina-Bianchi, P. F.; Agondi, R. C.] HC FMUSP, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP0800
BP 453
EP 454
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254003161
DA 2020-11-26
ER

PT J
AU Assis, JPD
   Takejima, P
   Penido, APC
   Dias, GMFS
   Kalil, J
   Giavina-Bianchi, P
   Agondi, RC
AF Assis, J. P. D.
   Takejima, P.
   Penido, A. P. C.
   Dias, G. M. F. S.
   Kalil, J.
   Giavina-Bianchi, P.
   Agondi, R. C.
TI Adverse events of high dose of inhaled corticosteroid for patients with
   severe asthma
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Assis, J. P. D.; Takejima, P.; Penido, A. P. C.; Dias, G. M. F. S.; Kalil, J.; Giavina-Bianchi, P.; Agondi, R. C.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP0804
BP 456
EP 456
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254003165
DA 2020-11-26
ER

PT J
AU Fonseca, LG
   Antila, HG
   Souza, AB
   Kalil, J
   Motta, AA
   Agondi, RC
AF Fonseca, L. G.
   Antila, H. G.
   Souza, A. B.
   Kalil, J.
   Motta, A. A.
   Agondi, R. C.
TI Questionnaire to evaluate the first-generation antihistamine side
   effects in patients with chronic spontaneous urticaria
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Fonseca, L. G.; Antila, H. G.; Souza, A. B.; Kalil, J.; Motta, A. A.; Agondi, R. C.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP0866
BP 482
EP 482
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254003220
DA 2020-11-26
ER

PT J
AU Pereira, GDF
   Mamede, LDQ
   Gomes, LS
   Maia, LP
   Kalil, J
   Motta, AA
   Barros, MT
   Agondi, RC
AF Pereira, G. D. F.
   Mamede, L. D. Q.
   Gomes, L. S.
   Maia, L. P.
   Kalil, J.
   Motta, A. A.
   Barros, M. T.
   Agondi, R. C.
TI Evaluation of autologous serum skin test positivity and autoantibodies
   status in patients with chronic spontaneous urticaria (CSU)
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Pereira, G. D. F.; Mamede, L. D. Q.; Gomes, L. S.; Maia, L. P.; Kalil, J.; Motta, A. A.; Barros, M. T.; Agondi, R. C.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP1217
BP 644
EP 644
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254004092
DA 2020-11-26
ER

PT J
AU Castro, RB
   Dias, GM
   Zanandreia, A
   Kalil, J
   Giavina-Bianchi, P
   Agondi, R
AF Castro, R. B.
   Dias, G. M.
   Zanandreia, A.
   Kalil, J.
   Giavina-Bianchi, P.
   Agondi, R.
TI Severity of allergic asthma associated with sensitization to food
   allergens
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Castro, R. B.; Dias, G. M.; Zanandreia, A.; Kalil, J.; Giavina-Bianchi, P.; Agondi, R.] Hosp Clin Sao Paulo, Fac Med Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP1506
BP 776
EP 776
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254004358
DA 2020-11-26
ER

PT J
AU Grecco, O
   Barbuti, RC
   Kokron, CM
   Marinho, AKB
   Sini, BC
   Figueira, RCL
   Kalil, J
   Barros, MT
AF Grecco, O.
   Barbuti, R. C.
   Kokron, C. M.
   Marinho, A. K. B.
   Sini, B. C.
   Figueira, R. C. L.
   Kalil, J.
   Barros, M. T.
TI Is the incidence of gastric tumor increasing in variable common
   immunodeficiency patients?
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 01-05, 2019
CL Lisbon, PORTUGAL
SP European Acad Allergy & Clin Immunol
C1 [Grecco, O.; Kokron, C. M.; Marinho, A. K. B.; Sini, B. C.; Kalil, J.; Barros, M. T.] HC FMUSP SP, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Barbuti, R. C.] HC FMUSP SP, Div Gastroenterol, Sao Paulo, Brazil.
   [Figueira, R. C. L.] Univ Sao Paulo, Inst Oceanog, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; Barbuti, Ricardo/AAK-5495-2020
OI Kokron, Cristina M/0000-0002-9080-0305; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2019
VL 74
SU 106
SI SI
MA TP1626
BP 824
EP 825
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA IP7UR
UT WOS:000480254004464
DA 2020-11-26
ER

PT J
AU Postol, E
   Sa-Rocha, LC
   Sampaio, RO
   Dernarchi, LMMF
   Alencar, RE
   Abduch, MCD
   Kalil, J
   Guilherme, L
AF Postol, Edilberto
   Sa-Rocha, Luiz C.
   Sampaio, Roney O.
   Dernarchi, Lea M. M. F.
   Alencar, Raquel E.
   Abduch, Maria C. D.
   Kalil, Jorge
   Guilherme, Luiza
TI Group A Streptococcus Adsorbed Vaccine: Repeated Intramuscular Dose
   Toxicity Test in Minipigs
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RHEUMATIC HEART-DISEASE; REFERENCE INTERVALS; ASSOCIATION; ANTIGENS;
   STREPTINCOR; BIOLOGY; SAFETY; FEVER; MODEL
AB Streptococcus pyogenes infection continues to be a worldwide public health problem causing various diseases in humans and plays an important role in the pathogenesis of rheumatic fever and rheumatic heart disease. We developed a vaccine candidate to prevent S. pyogenes infections, identified as StreptInCor, that presented promising results in mouse models. A certified and independent laboratory conducted two repeated intramuscular dose toxicity tests (28 days, four weekly injections). The first test, composed of four experimental groups treated with 0 (vehicle), 50, 100 or 200 mu g/500 mu L StreptInCor, did not show significant alterations in clinical, hematological, biochemical or anatomopathologica I parameters related to the administration of StreptInCor. In addition to the parameters mentioned above, we evaluated the cardiac function and valves of animals by echocardiography before and after administration of 200 mu g/500 mu L StreptInCor versus placebo. We did not observe any changes related to StreptInCor administration, including changes in cardiac function and valves in animals, after receiving the highest dose of this vaccine candidate. The results obtained in the two repeated intramuscular dose toxicity tests showed that this vaccine formulation did not induce harmful effects to the tissues and organs studied, indicating that the candidate vaccine is well tolerated in minipigs.
C1 [Postol, Edilberto; Sampaio, Roney O.; Dernarchi, Lea M. M. F.; Alencar, Raquel E.; Abduch, Maria C. D.; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Sa-Rocha, Luiz C.] Univ Sao Paulo, Neuroimmunol Lab, Sch Vet Med & Anim Sci, Sao Paulo, Brazil.
   [Postol, Edilberto; Sa-Rocha, Luiz C.; Alencar, Raquel E.; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Immunol Invest Inst, Natl Inst Sci & Technol, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.; Guilherme, L (corresponding author), Univ Sao Paulo, Immunol Invest Inst, Natl Inst Sci & Technol, Sao Paulo, Brazil.
EM luizagui@usp.br
RI SAMPAIO, RONEY O/L-1643-2016
OI SAMPAIO, RONEY O/0000-0001-6524-9614
FU "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico"
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [467153/2014-0]; "Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo" (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2017/16853-3]; "Banco Nacional de Desenvolvimento Economico e
   Social" (BNDES) [14.2.1159.1]
FX This work was supported by the "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico" (CNPq, Grant Number 467153/2014-0), "Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo" (FAPESP, Grant Number
   2017/16853-3) and "Banco Nacional de Desenvolvimento Economico e Social"
   (BNDES, Grant Number 14.2.1159.1).
CR AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Bessen DE, 2009, INFECT GENET EVOL, V9, P581, DOI 10.1016/j.meegid.2009.03.002
   Bisno AL, 2005, CLIN INFECT DIS, V41, P1150, DOI 10.1086/444505
   Bode G, 2010, J PHARMACOL TOX MET, V62, P196, DOI 10.1016/j.vascn.2010.05.009
   Carapetis JR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.84
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Colleton C, 2016, TOXICOL PATHOL, V44, P458, DOI 10.1177/0192623315617562
   Cooper CA, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-5
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   De Amicis KM, 2014, VACCINE, V32, P4104, DOI 10.1016/j.vaccine.2013.08.043
   Evans G. O, 2009, ANIMAL CLIN CHEM PRA, P328
   Evans G. O, 2008, ANIMAL HEMATOTOXICOL, P183
   Fae KC, 2005, J AUTOIMMUN, V24, P101, DOI 10.1016/j.jaut.2005.01.007
   Faustini M, 2003, J VET MED A, V50, P466, DOI 10.1046/j.1439-0442.2003.00581.x
   Ganderup NC, 2012, INT J TOXICOL, V31, P507, DOI 10.1177/1091581812462039
   Gerber MA, 2009, CIRCULATION, V119, P1541, DOI 10.1161/CIRCULATIONAHA.109.191959
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2018, CURR PROTEIN PEPT SC, V19, P900, DOI 10.2174/1389203718666170725115855
   Hanly W. Carey, 1995, ILAR J, V37, P93
   He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026
   Helke KL, 2016, TOXICOL PATHOL, V44, P325, DOI 10.1177/0192623315611762
   Institute for Laboratory Animal Research, 2011, GUIDE CARE USE LAB A
   Karthikeyan G, 2018, LANCET, V392, P820
   Kawaguchi H, 2012, J VET MED SCI, V74, P933, DOI 10.1292/jvms.11-0571
   Klem TB, 2010, VET CLIN PATH, V39, P221, DOI 10.1111/j.1939-165X.2009.00199.x
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   LANCEFIELD RC, 1962, J IMMUNOL, V89, P307
   Leenaars M, 2005, ILAR J, V46, P269, DOI 10.1093/ilar.46.3.269
   Lu FJ, 2013, VACCINE, V31, P3979, DOI 10.1016/j.vaccine.2013.05.107
   Marijon E, 2012, LANCET, V379, P953, DOI 10.1016/S0140-6736(11)61171-9
   McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   OECD Environmental Health and Safety Publications, 1998, SER PRINC GOOD LAB P, V1
   Perri AM, 2017, CAN VET J, V58, P371
   Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
   Schomberg DT, 2016, TOXICOL PATHOL, V44, P299, DOI 10.1177/0192623315618292
   Sekuloski S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198658
   Sikder S, 2018, J INFECT DIS, V218, P324, DOI 10.1093/infdis/jix637
   Smeesters PR, 2010, TRENDS MICROBIOL, V18, P275, DOI 10.1016/j.tim.2010.02.007
   Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103
   Steer AC, 2016, VACCINE, V34, P2953, DOI 10.1016/j.vaccine.2016.03.073
   Wang HB, 2008, J LEUKOCYTE BIOL, V83, P817, DOI 10.1189/jlb.0607392
   WHO, 2005, WHO TECHN REP SER, V894
   YEOM S, 2010, J AM ASSOC LAB ANIM, V49, P733
NR 46
TC 3
Z9 3
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 5
PY 2019
VL 9
AR 9733
DI 10.1038/s41598-019-46244-2
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IH1DG
UT WOS:000474230900013
PM 31278336
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Kalil, J
AF Giavina-Bianchi, Pedro
   Kalil, Jorge
TI Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Editorial Material
C1 [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 Ap 211A, BR-01454010 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
CR Chen CB, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6431694
   Giavina-Bianchi P, 2018, CURR OPIN ALLERGY CL, V18, P59, DOI 10.1097/ACI.0000000000000411
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Kennard L, 2018, J ALLER CL IMM-PRACT, V6, P2173, DOI 10.1016/j.jaip.2018.08.033
   Ribeiro MR, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e185
   Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003
   Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760
   Wenande EC, 2013, J ALLERGY CLIN IMMUN, V131, P1425, DOI 10.1016/j.jaci.2012.09.037
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2019
VL 7
IS 6
BP 1874
EP 1875
DI 10.1016/j.jaip.2019.05.001
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA IG4ML
UT WOS:000473777600024
PM 31279466
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Goncalves, DG
   Zanandrea, A
   de Castro, RB
   Garro, LS
   Kalil, J
   Castells, M
AF Giavina-Bianchi, Pedro
   Goncalves, Danilo Gois
   Zanandrea, Andressa
   de Castro, Raisa Borges
   Garro, Laila Sabino
   Kalil, Jorge
   Castells, Mariana
TI Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
C1 [Giavina-Bianchi, Pedro; Goncalves, Danilo Gois; Zanandrea, Andressa; de Castro, Raisa Borges; Garro, Laila Sabino; Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin & Immunol Div, Sao Paulo, Brazil.
   [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178,Ap 211a Jd Amer, Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
CR Babina M, 2018, ALLERGY, V73, P256, DOI 10.1111/all.13301
   Bonadonna P, 2018, IMMUNOL ALLERGY CLIN, V38, P455, DOI 10.1016/j.iac.2018.04.010
   Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4
   Giavina-Bianchi P, 2018, CURR OPIN ALLERGY CL, V18, P59, DOI 10.1097/ACI.0000000000000411
   Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034
   McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022
   Niedoszytko M, 2014, IMMUNOL ALLERGY CLIN, V34, P365, DOI 10.1016/j.iac.2014.02.004
   Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051
   Valent P, 2017, CANCER RES, V77, P1261, DOI 10.1158/0008-5472.CAN-16-2234
NR 9
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2019
VL 7
IS 6
BP 2089
EP 2090
DI 10.1016/j.jaip.2019.01.059
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA IG4ML
UT WOS:000473777600065
PM 30797080
DA 2020-11-26
ER

PT J
AU Santos, A
   Chevillard, C
   Gonfinetti, N
   Bertonha, F
   Moreira, C
   Kalil, J
   Cunha-Neto, E
   Silva, ME
AF Santos, Aritania
   Chevillard, Christophe
   Gonfinetti, Nelson
   Bertonha, Fernanda
   Moreira-Filho, Carlos
   Kalil, Jorge
   Cunha-Neto, Edecio
   Silva, Maria Elizabeth
TI PBMC of Recent-Onset Patients with Type 1 Diabetes Present a
   Differential Gene Expression Profile
SO DIABETES
LA English
DT Meeting Abstract
CT 79th Scientific Sessions of the American-Diabetes-Association (ADA)
CY JUN 07-11, 2019
CL San Francisco, CA
SP Amer Diabet Assoc
RI Santos, Aritania/AAD-3548-2020
FU European Foundation for the Study of Diabetes; Sao Paulo Research
   FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX European Foundation for the Study of Diabetes; Sao Paulo Research
   Foundation
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD JUN 1
PY 2019
VL 68
SU 1
MA 1696-P
DI 10.2337/db19-1696-P
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA JU0JU
UT WOS:000501366904100
DA 2020-11-26
ER

PT J
AU Soares-Schanoski, A
   Baptista Cruz, N
   de Castro-Jorge, LA
   de Carvalho, RVH
   dos Santos, CA
   da Ros, N
   Oliveira, U
   Costa, DD
   dos Santos, CLS
   Cunha, MD
   Oliveira, MLS
   Alves, JC
   Ocea, RADC
   Ribeiro, DR
   Goncalves, ANA
   Gonzalez-Dias, P
   Suhrbier, A
   Zanotto, PMD
   de Azevedo, IJ
   Zamboni, DS
   Almeida, RP
   Ho, PL
   Kalil, J
   Nishiyama, MY
   Nakaya, HI
AF Soares-Schanoski, Alessandra
   Baptista Cruz, Natalia
   de Castro-Jorge, Luiza Antunes
   Homem de Carvalho, Renan Villanova
   dos Santos, Cliomar Alves
   da Ros, Nancy
   Oliveira, Ursula
   Costa, Danuza Duarte
   Simoes dos Santos, Cecilia Luiza
   Cunha, Marielton dos Passos
   Sarno Oliveira, Maria Leonor
   Alves, Juliana Cardoso
   de Lucena Couto Ocea, Regina Adalva
   Ribeiro, Danielle Rodrigues
   Aquime Goncalves, Andre Nicolau
   Gonzalez-Dias, Patricia
   Suhrbier, Andreas
   de Andrade Zanotto, Paolo Marinho
   de Azevedo, Inacio Junqueira
   Zamboni, Dario S.
   Almeida, Roque Pacheco
   Ho, Paulo Lee
   Kalil, Jorge
   Nishiyama, Milton Yutaka
   Nakaya, Helder I.
TI Systems analysis of subjects acutely infected with the Chikungunya virus
SO PLOS PATHOGENS
LA English
DT Article
ID DISEASE; NEUTROPHILS; POPULATION; EVOLUTION; MONOCYTES; ARTHRITIS;
   REVEALS; BIOLOGY
AB The largest ever recorded epidemic of the Chikungunya virus (CHIKV) broke out in 2004 and affected four continents. Acute symptomatic infections are typically associated with the onset of fever and often debilitating polyarthralgia/polyarthritis. In this study, a systems biology approach was adopted to analyze the blood transcriptomes of adults acutely infected with the CHIKV. Gene signatures that were associated with viral RNA levels and the onset of symptoms were identified. Among these genes, the putative role of the Eukaryotic Initiation Factor (eIF) family genes and apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC3A) in the CHIKV replication process were displayed. We further compared these signatures with signatures induced by the Dengue virus infection and rheumatoid arthritis. Finally, we demonstrated that the CHIKV in vitro infection of murine bone marrow-derived macrophages induced IL-1 beta production in a mechanism that is significantly dependent on the inflammasome NLRP3 activation. The observations provided valuable insights into virus-host interactions during the acute phase and can be instrumental in the investigation of new and effective therapeutic interventions.
   Author summary The Chikungunya virus (CHIKV) has infected millions of people worldwide and presents a serious public health issue. Acute symptomatic infections caused by contracting this mosquito-transmitted arbovirus are typically associated with an abrupt onset of fever and often debilitating polyarthralgia/ polyarthritis, as well as prolonged periods of disability in some patients. These dramatic effects call for a careful evaluation of the molecular mechanisms involved in this puzzling infection. By analyzing the blood transcriptome of adults acutely infected with CHIKV, we were able to provide a detailed picture of the early molecular events induced by the infection. Additionally, the systems biology approach revealed genes that can be investigated extensively as probable therapeutic targets for the disease.
C1 [Soares-Schanoski, Alessandra; Sarno Oliveira, Maria Leonor] Butantan Inst, Bacteriol Lab, Sao Paulo, Brazil.
   [Baptista Cruz, Natalia; Aquime Goncalves, Andre Nicolau; Gonzalez-Dias, Patricia; Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [de Castro-Jorge, Luiza Antunes; Homem de Carvalho, Renan Villanova; Zamboni, Dario S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular Mol & Bioagentes Patogen, Ribeirao Preto, Brazil.
   [dos Santos, Cliomar Alves; Costa, Danuza Duarte] State Secretary Hlth, Cent Lab Publ Hlth LACEN SE, Hlth Fdn Parreiras Horta, Sergipe, Brazil.
   [da Ros, Nancy; Oliveira, Ursula; Nishiyama, Milton Yutaka] Butantan Inst, Special Lab Appl Toxinol, Sao Paulo, Brazil.
   [Simoes dos Santos, Cecilia Luiza] Adolfo Lutz Inst, Virol Ctr, Resp Dis Div, Sao Paulo, Brazil.
   [Cunha, Marielton dos Passos; de Andrade Zanotto, Paolo Marinho] Univ Sao Paulo, Biomed Sci Inst, Dept Microbiol, Lab Mol Evolut & Bioinformat, Sao Paulo, Brazil.
   [Alves, Juliana Cardoso; de Lucena Couto Ocea, Regina Adalva; Ribeiro, Danielle Rodrigues] Univ Fed Sergipe, Univ Hosp EBSERH, Div Immunol & Mol Biol Lab, Sergipe, Brazil.
   [Suhrbier, Andreas] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [Ho, Paulo Lee] Butantan Inst, Bioind Div, Bacteriol Serv, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Fac Med, Heart Inst, Sao Paulo, Brazil.
RP Nakaya, HI (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
EM hnakaya@usp.br
RI Zamboni, Dario S/D-3024-2012; Oliveira, Maria Leonor S/F-4988-2012;
   Nakaya, Helder/AAF-1738-2020; Junqueira-de-Azevedo, Inacio L.
   M./H-5239-2011; de A. Zanotto, Paolo M./B-9286-2019; Center of Toxins,
   Immune-response/J-5731-2015; Nakaya, Helder I/A-1397-2010; de Carvalho,
   Renan V. H./AAC-7673-2019; Junior, Milton Y Nishiyama/H-4002-2013;
   Soares Schanoski, Alessandra/H-8144-2014
OI Zamboni, Dario S/0000-0002-7856-7512; Nakaya,
   Helder/0000-0001-5297-9108; Junqueira-de-Azevedo, Inacio L.
   M./0000-0003-4491-0180; de A. Zanotto, Paolo M./0000-0002-8167-0625;
   Nakaya, Helder I/0000-0001-5297-9108; de Carvalho, Renan V.
   H./0000-0001-5740-0652; Junior, Milton Y Nishiyama/0000-0002-2410-0562;
   Gonzalez-Dias, Patricia/0000-0002-6434-3841; Baptista-Cruz,
   Natalia/0000-0002-8864-4139; Soares Schanoski,
   Alessandra/0000-0002-6514-8458
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/50137-3, 2012/19278-6, 2013/08216-2,
   CEPID 2013/07467-1]; Butantan Foundation; CNPqNational Council for
   Scientific and Technological Development (CNPq) [443371/2016-4,
   306992/2014-0]; Brazilian Health Ministry; FINEPCiencia Tecnologia e
   Inovacao (FINEP) [0116005600]; CAPESCAPES [001]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/25055-8]; 
   [FAPESP -2016/08204-2]
FX H.I.N. is supported by the Sao Paulo Research Foundation (FAPESP; grants
   2017/50137-3, 2012/19278-6, and 2013/08216-2). A.S.S. is supported by
   Butantan Foundation, CNPq (Grant 443371/2016-4) and Brazilian Health
   Ministry. R. A. is supported by FINEP Grant 0116005600. D. R. R. has a
   postdoctoral fellowship from CNPq. J.C.A. has a postdoctoral fellowship
   from CAPES - Finance Code 001. M.P.C. has a PhD fellowship from FAPESP
   -2016/08204-2. I.J.A is supported by Sao Paulo Research Foundation
   (FAPESP; grant: CEPID 2013/07467-1). P.L.H is supported by Butantan
   Foundation, CNPq 306992/2014-0 and Fapesp 2015/25055-8. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bastos MLA, 2018, BRAZ J INFECT DIS, V22, P248, DOI 10.1016/j.bjid.2018.05.002
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Burt FJ, 2017, LANCET INFECT DIS, V17, pE107, DOI 10.1016/S1473-3099(16)30385-1
   Carrasco L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020070
   Chang AY, 2018, ARTHRITIS RHEUMATOL, V70, P585, DOI 10.1002/art.40383
   Chang AY, 2018, ARTHRITIS RHEUMATOL, V70, P578, DOI 10.1002/art.40384
   Chen WQ, 2017, NAT MICROBIOL, V2, P1435, DOI 10.1038/s41564-017-0015-4
   Chirathaworn C, 2013, ASIAN PAC J TROP MED, V6, P631, DOI 10.1016/S1995-7645(13)60108-X
   Chopra A, 2008, ARTHRITIS RHEUM, V58, P2921, DOI 10.1002/art.23753
   Cunha MD, 2017, J CLIN VIROL, V97, P44, DOI 10.1016/j.jcv.2017.10.015
   David RYS, 2016, ELIFE, V5, DOI 10.7554/eLife.11275
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Gabriel C, 2013, DNA CELL BIOL, V32, P665, DOI 10.1089/dna.2013.2211
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603-09
   Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018
   Guaraldo L, 2018, EXPERT REV ANTI-INFE, V16, P333, DOI 10.1080/14787210.2018.1450629
   Gunn BM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002586
   Her ZS, 2010, J IMMUNOL, V184, P5903, DOI 10.4049/jimmunol.0904181
   Hochedez P, 2006, EMERG INFECT DIS, V12, P1565, DOI 10.3201/eid1210.060495
   Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004
   Hossain MS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006561
   Jaffar-Bandjee MC, 2010, EXPERT REV ANTI-INFE, V8, P987, DOI [10.1586/eri.10.92, 10.1586/ERI.10.92]
   Jakobs C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131702
   Jianying Li PRB, 2009, PRINCIPAL VARIANCE C
   Joubert PE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005091
   Karasu E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00543
   Khadivjam B, 2017, J VIROL, V91, DOI 10.1128/JVI.02411-16
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kirschfink M, 1999, MOL IMMUNOL, V36, P225, DOI 10.1016/S0161-5890(99)00048-6
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lewthwaite P, 2009, EMERG INFECT DIS, V15, P329, DOI 10.3201/eid1502.080902
   Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789
   Lian JQ, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.18892
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   Michlmayr D, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20177862
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Figueiredo LTM, 2017, REV SOC BRAS MED TRO, V50, P583, DOI 10.1590/0037-8682-0397-2017
   Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113
   Nakaya HI, 2012, ARTHRITIS RHEUM-US, V64, P3553, DOI 10.1002/art.34631
   Nanjappa SG, 2011, BLOOD, V117, P5123, DOI 10.1182/blood-2010-12-323154
   Naumenko V, 2018, CELL TISSUE RES, V371, P505, DOI 10.1007/s00441-017-2763-0
   Ng LC, 2010, INFECT GENET EVOL, V10, P876, DOI 10.1016/j.meegid.2010.07.012
   Patkar C, 2013, AM J TROP MED HYG, V88, P89, DOI 10.4269/ajtmh.2012.12-0474
   Poo YS, 2014, J VIROL, V88, P6862, DOI 10.1128/JVI.03364-13
   Prow NA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006788
   Rayamajhi Manira, 2013, Methods Mol Biol, V1040, P85, DOI 10.1007/978-1-62703-523-1_7
   Rolle A, 2016, EMERG INFECT DIS, V22, P891, DOI 10.3201/eid2205.151449
   Rudd PA, 2012, J VIROL, V86, P9888, DOI 10.1128/JVI.00956-12
   Russo PST, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2053-1
   Sanfilippo C, 2017, INFLAMM RES, V66, P1107, DOI 10.1007/s00011-017-1091-x
   Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368
   Silva LA, 2017, J CLIN INVEST, V127, P737, DOI 10.1172/JCI84417
   Simarmata D, 2016, SCI REP-UK, V6, DOI 10.1038/srep26097
   Spalinger MR, 2017, AUTOPHAGY, V13, P1590, DOI 10.1080/15548627.2017.1341453
   SVS-MS, 2018, MON CAS DENG FEBR CH
   Swanson KV, 2019, NAT REV IMMUNOL, DOI [10.1038/s41577-019-0165-031036962, DOI 10.1038/S41577-019-0165-031036962]
   Tan Y, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006670
   Tsetsarkin KA, 2011, CURR OPIN VIROL, V1, P310, DOI 10.1016/j.coviro.2011.07.004
   Volk SM, 2010, J VIROL, V84, P6497, DOI 10.1128/JVI.01603-09
   Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155
NR 67
TC 6
Z9 6
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2019
VL 15
IS 6
AR e1007880
DI 10.1371/journal.ppat.1007880
PG 23
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA IO1PP
UT WOS:000479154700054
PM 31211814
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Figo, DD
   De Amicis, K
   de Aquino, DNS
   Pomiecinski, F
   Gadermaier, G
   Briza, P
   Galvao, CES
   do Amaral, JB
   Martins, CD
   Castro, FFM
   Kalil, J
   Santos, KS
AF Figo, Daniele Danella
   De Amicis, Karine
   Santos de Aquino, Denise Neiva
   Pomiecinski, Fabiane
   Gadermaier, Gabriele
   Briza, Peter
   Santos Galvao, Clovis Eduardo
   do Amaral, Jonatas Bussador
   Martins, Carlo de Oliveira
   Morato Castro, Fabio Fernandes
   Kalil, Jorge
   Santos, Keity Souza
TI Cashew Tree Pollen: An Unknown Source of IgE-Reactive Molecules
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE novel allergens; Brazil; pollinosis; proteome; shotgun analysis;
   aeroallergens
ID BIRCH POLLEN; IMAGE-ANALYSIS; ALLERGENS; PROTEIN; CLASSIFICATION;
   EXTRACTS; CLONING
AB Pollinosis is sub-diagnosed and rarely studied in tropical countries. Cashew tree pollen has been reported as an allergen source although the knowledge of its immunoglobulin E (IgE)-reactive molecules is lacking. Therefore, this work aimed to identify IgE-reactive molecules and provide a proteomic profile of this pollen. From the 830 proteins identified by shotgun analysis, 163 were annotated to gene ontology, and a list of 39 proteins filtered for high confidence was submitted to the Allfam database where nine were assigned to allergenic families. Thus, 12 patients from the northeast of Brazil with persistent allergic rhinitis and aggravation of symptoms during cashew flowering season were selected. Using a 2D-based approach, we identified 20 IgE-reactive proteins, four already recognized as allergens, including a homolog of the birch isoflavone-reductase (Bet v 6). IgE-reactivity against the extract in native form was confirmed for five patients in ELISA, with three being positive for Bet v 6. Herein, we present a group of patients with rhinitis exposed to cashew tree pollen with the first description of IgE-binding proteins and a proteomic profile of the whole pollen. Cashew tree pollen is considered an important trigger of rhinitis symptoms in clinical practice in the northeast of Brazil, and the elucidation of its allergenic molecules can improve the diagnostics and treatment for allergic patients.
C1 [Figo, Daniele Danella; De Amicis, Karine; Morato Castro, Fabio Fernandes; Kalil, Jorge; Santos, Keity Souza] Univ Sao Paulo, Disciplina Imunol Clin & Alergia, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [Santos de Aquino, Denise Neiva; Pomiecinski, Fabiane] Univ Fortaleza, UNIFOR, BR-60811905 Fortaleza, Ceara, Brazil.
   [Gadermaier, Gabriele; Briza, Peter] Paris Lodron Univ Salzburg, Dept Biosci, A-5020 Salzburg, Austria.
   [Santos Galvao, Clovis Eduardo] Univ Sao Paulo, Serv Imunol Clin & Alergia, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [do Amaral, Jonatas Bussador] Univ Fed Sao Paulo, ENT Res Lab, Dept Otorhinolaryngol Head & Neck Surg, BR-04021001 Sao Paulo, Brazil.
   [Martins, Carlo de Oliveira] John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.
   [Morato Castro, Fabio Fernandes] Univ Sao Paulo, Disciplina Imunol Clin & Alergia, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [Kalil, Jorge; Santos, Keity Souza] Univ Sao Paulo, Lab Imunol, Inst Coracao, Hosp Clin,Fac Med, BR-01246903 Sao Paulo, Brazil.
   [Kalil, Jorge; Santos, Keity Souza] INCT, Inst Invest Immunol, BR-01246903 Sao Paulo, Brazil.
RP Santos, KS (corresponding author), Univ Sao Paulo, Disciplina Imunol Clin & Alergia, Fac Med, BR-01246903 Sao Paulo, Brazil.; Santos, KS (corresponding author), Univ Sao Paulo, Lab Imunol, Inst Coracao, Hosp Clin,Fac Med, BR-01246903 Sao Paulo, Brazil.; Santos, KS (corresponding author), INCT, Inst Invest Immunol, BR-01246903 Sao Paulo, Brazil.
EM danidanella@hotmail.com; karineamicis@gmail.com; deniseneiva@gmail.com;
   fabiane.alergia@hotmail.com; Gabriele.Gadermaier@sbg.ac.at;
   Peter.Briza@sbg.ac.at; clovis.galvao@hc.fm.usp.br; amaraljb@gmail.com;
   carloleia@gmail.com; fabio.castro@imabrasil.com.br; jkalil@usp.br;
   keity.santos@fm.usp.br
RI Briza, Peter/D-7309-2012; Castro, Fabio/AAP-5433-2020; De Amicis Lima,
   Karine/D-3890-2013; Gadermaier, Gabriele/L-5997-2015; KALIL,
   JORGE/C-8029-2012
OI Briza, Peter/0000-0002-4941-6782; De Amicis Lima,
   Karine/0000-0002-9936-2436; Gadermaier, Gabriele/0000-0002-4886-417X;
   Santos, Keity/0000-0001-5271-4011; de Oliveira Martins,
   Carlo/0000-0003-1287-8884; KALIL, JORGE/0000-0001-8415-4274
FU Young Research Award of FAPESP [2012/14019-2]; Fundacao Faculdade de
   Medicina (FFM) - Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES
FX This research was funded by a Young Research Award of FAPESP (Project
   2012/14019-2). K.S.S. was funded by Fundacao Faculdade de Medicina
   (FFM), and D.D.F. was funded by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES).
CR ACR Institute for Tropical and Subtropical Crops SA, 2015, CULT CASH NUTS
   Aronne G, 2001, BIOTECH HISTOCHEM, V76, P35, DOI 10.1080/714028122
   ASBAI, 2009, ASS BRAS AL IM INF P
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Buters JTM, 2012, ATMOS ENVIRON, V55, P496, DOI 10.1016/j.atmosenv.2012.01.054
   Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844
   Carini A., 1908, REV MED SAO PAULO, V11, P23
   Carpentier SC, 2005, PROTEOMICS, V5, P2497, DOI 10.1002/pmic.200401222
   CashewInfo. com, 2018, CASHEWINFO
   Comstock SS, 2006, J ALLERGY CLIN IMMUN, V117, pS49, DOI 10.1016/j.jaci.2005.12.202
   D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x
   DRIESSEN MNBM, 1991, EUR RESPIR J, V4, P359
   Dutra B.M.R.S., 2001, REV BRAS ALERG IMUNO, V24, P89
   EAACI, 2016, MOL ALL US GUID
   Embrapa, CULT CAJ 2003
   FERNANDES L, 1995, J ALLERGY CLIN IMMUN, V95, P501, DOI 10.1016/S0091-6749(95)70311-X
   Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145
   Fonseca AE, 2002, CROP SCI, V42, P2201, DOI 10.2135/cropsci2002.2201
   Galan C, 2013, ALLERGY, V68, P809, DOI 10.1111/all.12144
   Gruehn S, 2003, INT ARCH ALLERGY IMM, V131, P91, DOI 10.1159/000070924
   Huecas S, 2001, J BIOL CHEM, V276, P27959, DOI 10.1074/jbc.M103041200
   Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047
   Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1
   Matricardi PM, 2019, J ALLERGY CLIN IMMUN, V143, P831, DOI 10.1016/j.jaci.2018.12.1021
   McCrone W.C., 1973, PARTICLE ATLAS
   Menezes EA, 2002, J INVEST ALLERG CLIN, V12, P25
   Mitsumoto K, 2009, J BIOSCI BIOENG, V107, P90, DOI 10.1016/j.jbiosc.2008.10.001
   Pablos I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06213-z
   PINNICK RG, 1995, AEROSOL SCI TECH, V23, P653, DOI 10.1080/02786829508965345
   Postigo I, 2009, J INVEST ALLERG CLIN, V19, P504
   Quiralte J, 2007, J INVEST ALLERG CLIN, V17, P24
   Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025
   Radev Z., 2018, AM J ENTOMOL, V2, P23, DOI [10.11648/j.aje.20180203.11, DOI 10.11648/J.AJE.20180203.11]
   Reitsma M, 2016, J AGR FOOD CHEM, V64, P1191, DOI 10.1021/acs.jafc.5b04401
   Roberts G, 2013, ALLERGY, V68, P1102, DOI 10.1111/all.12235
   Ronneberger Olaf, 2002, Aerobiologia, V18, P107, DOI 10.1023/A:1020623724584
   Rosario Filho N.A., 1987, REV BRAS ALERGIA IMU, V10, P25
   Saha B, 2017, J PROTEOMICS, V165, P1, DOI 10.1016/j.jprot.2017.05.021
   Taketomi Ernesto Akio, 2006, Rev. Bras. Otorrinolaringol., V72, P562, DOI 10.1590/S0034-72992006000400020
   Valenta R, 2011, ALLERGY, V66, P775, DOI 10.1111/j.1398-9995.2011.02565.x
   Vejvar E., 2011, NOVEL ALLERGEN UNPUB
   Vieths S, 1998, SCAND J IMMUNOL, V47, P263
NR 42
TC 0
Z9 0
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY 2
PY 2019
VL 20
IS 10
AR 2397
DI 10.3390/ijms20102397
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA IC5IP
UT WOS:000471001400028
PM 31096561
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Mendonca, LO
   de Lima, CMF
   Macedo, PRC
   Santo Cunha, VD
   Hahnstadt, RL
   Kalil, J
   Galvao, CES
AF Mendonca, Leonardo Oliveira
   Fonseca de Lima, Cynthia Mafra
   Cordeiro Macedo, Priscilla Rios
   Santo Cunha, Victor do Espirito
   Hahnstadt, Ruppert Ludwig
   Kalil, Jorge
   Santos Galvao, Clovis Eduardo
TI Anaphylaxis triggered by prick test with latex extract: a case report
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE Latex hypersensitivity; Diagnostic test, routine; Anaphylaxis
ID IMMUNOTHERAPY; FATALITIES
AB CONTEXT: Adverse reactions associated with prick tests are rare but may be present as serious systemic reactions.
   CASE REPORT: A 38-year-old female nursing technician complained of three episodes of anaphylaxis in one year, all in the workplace. To investigate latex allergy, the patient underwent the prick test with latex, and immediately developed a rash, itchy skin, hoarseness, dyspnea and dry cough. Her condition improved promptly after appropriate measures were established for controlling her anaphylaxis.
   CONCLUSION:The skin test must be performed under medical supervision, since complications that can lead to life-threatening reactions, if support measures are not readily implemented, have been attributed to this test.
C1 [Mendonca, Leonardo Oliveira; Fonseca de Lima, Cynthia Mafra; Cordeiro Macedo, Priscilla Rios; Santo Cunha, Victor do Espirito; Hahnstadt, Ruppert Ludwig; Kalil, Jorge; Santos Galvao, Clovis Eduardo] Univ Sao Paulo FMUSP, Hosp Clin, Clin Immunol & Allergy Div, Outpatient Unit,Fac Med, Sao Paulo, SP, Brazil.
   [Mendonca, Leonardo Oliveira; Fonseca de Lima, Cynthia Mafra; Cordeiro Macedo, Priscilla Rios] Univ Sao Paulo FMUSP, Fac Med, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Santo Cunha, Victor do Espirito; Hahnstadt, Ruppert Ludwig] FDA Allergen, Immunotech Labs, Rio De Janeiro, RJ, Brazil.
   [Kalil, Jorge; Santos Galvao, Clovis Eduardo] Univ Sao Paulo FMUSP, Fac Med, Hosp Clin, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
RP Galvao, CES (corresponding author), Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Divisao Imunol Clin & Alergia, Av Dr Eneas de Carvalho Aguiar,155-8 Andar, Sao Paulo, SP, Brazil.
EM clovis.galvao@hc.fm.usp.br
RI ; KALIL, JORGE/C-8029-2012
OI Hanstadt, Ruppert/0000-0002-7440-8549; Galvao,
   Clovis/0000-0002-0824-8671; KALIL, JORGE/0000-0001-8415-4274
CR Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006
   Kahn SL, 2016, DM-DIS MON, V62, P5, DOI 10.1016/j.disamonth.2015.11.002
   Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126
   LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1
   REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J
   Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD MAY-JUN
PY 2019
VL 137
IS 3
BP 295
EP 297
DI 10.1590/1516-3180.2017.0295031217
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA IV0HI
UT WOS:000483959700013
PM 29898012
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Cabral, A
   Candido, DD
   Monteiro, SM
   Lemos, F
   Saitovitch, D
   Noronha, IL
   Alves, LF
   Geraido, MV
   Kalil, J
   Cunha-Neto, E
   Ferreira, LRP
   Coeiho, V
AF Cabral, Amanda
   Candido, Daran da Silva
   Monteiro, Sandra Maria
   Lemos, Francine
   Saitovitch, David
   Noronha, Irene L.
   Alves, Leticia Ferreira
   Geraido, Murilo Vieira
   Kalil, Jorge
   Cunha-Neto, Edecio
   Pinto Ferreira, Ludmila Rodrigues
   Coeiho, Veronica
TI Differential microRNA Profile in Operational Tolerance: A Potential Role
   in Favoring Cell Survival
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE kidney transplantation; operational tolerance; immunoregulation; chronic
   rejection; microRNAs; cell death; epigenetics
ID RENAL-TRANSPLANT TOLERANCE; NF-KAPPA-B; CIRCULATING MICRORNAS; T-CELLS;
   BIOMARKERS; IDENTIFICATION; BIOGENESIS; ACTIVATION; REGULATORS;
   SIGNATURE
AB Background: Operational tolerance (OT) is a state of graft functional stability that occurs after at least 1 year of immunosuppressant withdrawal. MicroRNAs (microRNA) are small non-coding RNAs that downregulate messenger RNA/protein expression of innumerous molecules and are critical for homeostasis. We investigated whether OT in kidney transplantation displays a differential microRNA profile, which would suggest that microRNAs participate in Operational Tolerance mechanisms, and may reveal potential molecular pathways.
   Methods: We first compared serum microRNA in OT (n = 8) with chronic rejection (CR) (n = 5) and healthy individuals (HI) (n = 5), using a 768-microRNA qPCR-panel. We used the Thermo Fisher Cloud computing platform to compare the levels of microRNAs in the OT group in relation to the other study groups. We performed validation experiments for miR-885-5p, by q-PCR, in a larger number of study subjects (OT = 8, CR = 12, HI = 12), as individual samples.
   Results: We detected a differential microRNA profile in OT vs. its opposing clinical outcome-CR-suggesting that microRNAs may integrate transplantation tolerance mechanisms. Some miRNAs were detected at higher levels in OT: miR-885-5p, miR-331-3p, miR-27a-5p vs. CR; others, we found at lower levels: miR-1233-3p, miR-572, miR-638, miR-1260a. Considering highly predicted/experimentally demonstrated targets of these miRNAs, bioinformatics analysis revealed that the granzyme B, and death receptor pathways are dominant, suggesting that cell death regulation integrates transplantation tolerance mechanisms. We confirmed higher miR-885-5p levels in OT vs. CR, and vs. HI, in a larger number of subjects.
   Conclusions: We propose that epigenetics mechanisms involving microRNAs may integrate human transplantation tolerance mechanisms, and regulate key members of the cell death/survival signaling. miR-885-5p could favor cell survival in OT by diminishing the levels of CRADD/RAIDD and CASP3. Nonetheless, given the nature of any complex phenomenon in humans, only cumulative data will help to determine whether this microRNA differential profile may be related to the cause or consequence of operational tolerance.
C1 [Cabral, Amanda; Candido, Daran da Silva; Monteiro, Sandra Maria; Kalil, Jorge; Cunha-Neto, Edecio; Pinto Ferreira, Ludmila Rodrigues; Coeiho, Veronica] Univ Sao Paulo, Fac Med, Inst Coracao InCor, Lab Imunol, Sao Paulo, Brazil.
   [Cabral, Amanda; Candido, Daran da Silva; Monteiro, Sandra Maria; Noronha, Irene L.; Kalil, Jorge; Cunha-Neto, Edecio; Coeiho, Veronica] INCT, III, Sao Paulo, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Serv Transplante Renal, Fac Med, Sao Paulo, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Div Nefrol, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [Noronha, Irene L.] Univ Sao Paulo, Lab Nefrol Celular Genet & Mol, Disciplina Nefrol, Fac Med, Porto Alegre, Brazil.
   [Alves, Leticia Ferreira; Geraido, Murilo Vieira] Univ Estadual Campinas, Inst Biol, Dept Biol Estrutural & Funcional, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio; Coeiho, Veronica] Univ Sao Paulo, Fac Med, LIM 19, Lab Histocompatibilidade & Imunol Celular, Sao Paulo, Brazil.
   [Saitovitch, David] Hosp Moinhos Vento, Serv Nefrol, Porto Alegre, RS, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues] Univ Fed Minas Gerais, ICB, Dept Morfol, Belo Horizonte, MG, Brazil.
   [Candido, Daran da Silva] Univ Oxford, Dept Zool, Oxford, England.
RP Coeiho, V (corresponding author), Univ Sao Paulo, Fac Med, Inst Coracao InCor, Lab Imunol, Sao Paulo, Brazil.; Coeiho, V (corresponding author), INCT, III, Sao Paulo, Brazil.; Coeiho, V (corresponding author), Univ Sao Paulo, Fac Med, LIM 19, Lab Histocompatibilidade & Imunol Celular, Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Cunha-Neto, Edecio/B-4157-2009
OI Cunha-Neto, Edecio/0000-0002-3699-3345; da Silva Candido,
   Darlan/0000-0002-5080-3130; Rodrigues Pinto Ferreira,
   Ludmila/0000-0001-9944-6691; Coelho, Veronica/0000-0002-0989-2581
FU CAPES-Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES
   [CAPES-PROEX-33002010061P9]; iii-INCT-Institute for Investigation in
   Immunology-National Institute of Science and Technology; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico-(CNPq-FAPESP)
   [465434/2014-2]
FX The authors thank the Brazilian Multicenter Study on Operational
   Tolerance group, Fabiana Agena for collecting samples and clinical data.
   We also thank CAPES-Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES-PROEX-33002010061P9) for providing AC's fellowship; the
   iii-INCT-Institute for Investigation in Immunology-National Institute of
   Science and Technology and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico-(CNPq-FAPESP-Process n. 465434/2014-2) for
   financial support.
CR Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Braudeau C, 2007, TRANSPL INT, V20, P845, DOI 10.1111/j.1432-2277.2007.00537.x
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chesneau M, 2014, AM J TRANSPLANT, V14, P144, DOI 10.1111/ajt.12508
   Danger R, 2012, J AM SOC NEPHROL, V23, P597, DOI 10.1681/ASN.2011060543
   Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0
   Farid WRR, 2012, LIVER TRANSPLANT, V18, P290, DOI 10.1002/lt.22438
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Gao W, 2007, AM J TRANSPLANT, V7, P1722, DOI 10.1111/j.1600-6143.2007.01842.x
   Garofalo M, 2010, CELL DEATH DIFFER, V17, P200, DOI 10.1038/cdd.2009.105
   Guan XX, 2013, FASEB J, V27, P1404, DOI 10.1096/fj.12-223420
   Guay C, 2013, NAT REV ENDOCRINOL, V9, P513, DOI 10.1038/nrendo.2013.86
   Hattori K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-9
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Kroesen BJ, 2015, IMMUNOLOGY, V144, P1, DOI 10.1111/imm.12367
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lindsay MA, 2008, TRENDS IMMUNOL, V29, P343, DOI 10.1016/j.it.2008.04.004
   Liu G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075251
   Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X
   Lozano JJ, 2011, AM J TRANSPLANT, V11, P1916, DOI 10.1111/j.1600-6143.2011.03638.x
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004
   Moraes-Vieira PMM, 2010, HUM IMMUNOL, V71, P442, DOI 10.1016/j.humimm.2010.01.022
   Morita M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06649
   Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933
   Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Revilla-Nuin B, 2017, LIVER TRANSPLANT, V23, P933, DOI 10.1002/lt.24691
   Sagoo P, 2010, J CLIN INVEST, V120, P1848, DOI 10.1172/JCI39922
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Silva HM, 2012, MOL MED, V18, P733, DOI 10.2119/molmed.2011.00281
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wong CH, 2006, PLAST RECONSTR SURG, V117, P1206, DOI 10.1097/01.prs.0000200070.66604.1e
   Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9
   Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382
   1997, CELL, V91, P479, DOI DOI 10.1016/S0092-8674(00)80434-1
NR 39
TC 0
Z9 0
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 25
PY 2019
VL 10
AR 740
DI 10.3389/fimmu.2019.00740
PG 13
WC Immunology
SC Immunology
GA HV1ES
UT WOS:000465734500001
PM 31073299
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rached, MR
   Coelho, V
   Marin, MLC
   Pincerato, K
   Fujita, A
   Kalil, JE
   Abrao, MS
AF Rached, Marici R.
   Coelho, Veronica
   Marin, Maria Lucia C.
   Pincerato, Kstja
   Fujita, Andre
   Kalil, Jorge E.
   Abrao, Mauricio S.
TI HLA-G is upregulated in advanced endometriosis
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Endometriosis; HLA-G antigens; Immunosuppression; Immunomodulation
ID LEUKOCYTE ANTIGEN-G; NATURAL-KILLER ACTIVITY; PERITONEAL-FLUID; G
   MOLECULES; INFILTRATING ENDOMETRIOSIS; INFLAMMATORY STATUS; CELL
   ACTIVITY; G EXPRESSION; WOMEN; CYTOKINES
AB Objective: To assess whether the HLA-G immunomodulatory protein is potentially involved in the pathophysiology of endometriosis or disease progression.
   Study design: Cross-sectional observational study of 227 women who underwent laparoscopy, being 146 for endometriosis excision and 81 for elective tubal ligation (control group). Soluble HLA-G (sHLA-G) levels in the serum and peritoneal fluid (PF), as well as the HLA-G protein expression in matched eutopic and ectopic endometrium of women with and without endometriosis were evaluated by ELISA and immunohistochemistry assays, respectively. Women with endometriosis were separated into groups according to the initial (I/II, n=60) and advanced (III/IV, n=86) stages of disease. sHLA-G measurement was performed only in women with matched serum and PF samples in both the control (CTRL; n=77) and endometriosis (EDT; I-II, n=60; n=83) groups. HLA-G protein expression was evaluated in 26 women with deep endometriosis (I-II, n=12; III-IV, n=14) and 22 controls.
   Results: Higher concentrations of sHLA-G (P=0.013) in the serum but not in the PF were observed in women with advanced endometriosis compared to the control group. In situ expression of HLA-G protein was also higher in ectopic (P=0.018) but not in eutopic endometrium of women with advanced endometriosis compared to control group.
   Conclusion: Our findings suggest that HLA-G upregulation in advanced stages may contribute to the state of immunosuppression in endometriosis as disease progresses. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Rached, Marici R.; Kalil, Jorge E.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Coelho, Veronica; Marin, Maria Lucia C.; Kalil, Jorge E.] Univ Sao Paulo, Heart Inst InCor, Sch Med, Sao Paulo, Brazil.
   [Coelho, Veronica; Marin, Maria Lucia C.; Kalil, Jorge E.] Univ Sao Paulo, Sch Med, Histocompatibil & Cellular Immunol Lab, LIM 19, Sao Paulo, SP, Brazil.
   [Coelho, Veronica; Kalil, Jorge E.] Univ Sao Paulo, Inst Invest Immunol, Natl Inst Sci & Technol Iii INCT, Sao Paulo, SP, Brazil.
   [Pincerato, Kstja] Univ Sao Paulo, Pathol Div, Sch Med, Clin Hosp, Sao Paulo, SP, Brazil.
   [Fujita, Andre] Univ Paulo, Inst Math & Stat, Sao Paulo, SP, Brazil.
   [Abrao, Mauricio S.] Univ Sao Paulo, Hosp Clin HCFMUSP, Gynecol Div, Endometriosis Sect,Fac Med, Sao Paulo, SP, Brazil.
   [Abrao, Mauricio S.] BP, Gynecol Div, Sao Paulo, SP, Brazil.
RP Abrao, MS (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Gynecol Div, Endometriosis Sect,Fac Med, Sao Paulo, SP, Brazil.
EM msabrao@mac.com
RI Abrao, Mauricio S/L-3387-2017
OI Abrao, Mauricio S/0000-0003-1320-3010; Coelho,
   Veronica/0000-0002-0989-2581
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/10338-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (Brazil). Grant no. 2010/10338-0.
CR Abrao MS, 2006, FERTIL STERIL, V86, P543, DOI 10.1016/j.fertnstert.2006.02.102
   Agaugue S, 2011, BLOOD, V117, P7021, DOI 10.1182/blood-2010-07-294389
   Antsiferova YS, 2005, FERTIL STERIL, V84, P1705, DOI 10.1016/j.fertnstert.2005.05.066
   Barrier BF, 2006, HUM REPROD, V21, P864, DOI 10.1093/humrep/dei408
   Barrier BF, 2006, GYNECOL ONCOL, V103, P25, DOI 10.1016/j.ygyno.2006.01.045
   Borrelli GM, 2016, MOL HUM REPROD, V22, P329, DOI 10.1093/molehr/gaw009
   BRAUN DP, 1992, FERTIL STERIL, V57, P1203
   Canis M, 1997, FERTIL STERIL, V67, P817
   Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015
   Eidukaite A, 2008, FERTIL STERIL, V89, P465, DOI 10.1016/j.fertnstert.2007.02.036
   HALME J, 1984, OBSTET GYNECOL, V64, P151
   Ibrahim EC, 2000, CELL STRESS CHAPERON, V5, P207, DOI 10.1379/1466-1268(2000)005<0207:HSAAIE>2.0.CO;2
   KANZAKI H, 1992, AM J OBSTET GYNECOL, V167, P257, DOI 10.1016/S0002-9378(11)91670-6
   Kawashima M, 2009, FERTIL STERIL, V91, P343, DOI 10.1016/j.fertnstert.2007.12.005
   Leyendecker G, 2002, HUM REPROD, V17, P2725, DOI 10.1093/humrep/17.10.2725
   Leyendecker G, 2009, ARCH GYNECOL OBSTET, V280, P529, DOI 10.1007/s00404-009-1191-0
   Mach P, 2010, AM J REPROD IMMUNOL, V63, P387, DOI 10.1111/j.1600-0897.2009.00806.x
   Maeda Nagamasa, 2012, Front Biosci (Schol Ed), V4, P1568
   Malutan AM, 2015, CENT EUR J IMMUNOL, V40, P96, DOI 10.5114/ceji.2015.50840
   Malutan AM, 2015, J RES MED SCI, V20, P668, DOI 10.4103/1735-1995.166215
   Matarese G, 2003, TRENDS MOL MED, V9, P223, DOI 10.1016/S1471-4914(03)00051-0
   Menier C, 2003, HUM IMMUNOL, V64, P315, DOI 10.1016/S0198-8859(02)00821-2
   Monsanto SP, 2016, FERTIL STERIL, V105, P968, DOI 10.1016/j.fertnstert.2015.11.047
   Morandi F, 2007, CANCER RES, V67, P6433, DOI 10.1158/0008-5472.CAN-06-4588
   Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803
   OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45
   OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290
   OOSTERLYNCK DJ, 1993, OBSTET GYNECOL, V82, P206
   OOSTERLYNCK DJ, 1994, AM J REPROD IMMUNOL, V31, P25, DOI 10.1111/j.1600-0897.1994.tb00843.x
   Osuga Y, 2011, AM J REPROD IMMUNOL, V65, P1, DOI 10.1111/j.1600-0897.2010.00887.x
   Podgaec S, 2007, HUM REPROD, V22, P1373, DOI 10.1093/humrep/del516
   Podgaec S, 2012, AM J REPROD IMMUNOL, V68, P301, DOI 10.1111/j.1600-0897.2012.01173.x
   Puppo Francesco, 2002, ScientificWorldJournal, V2, P421
   Rebmann V, 2003, HUM IMMUNOL, V64, P1017, DOI 10.1016/j.humimm.2003.08.354
   Rouas-Freiss N, 2007, SEMIN CANCER BIOL, V17, P413, DOI 10.1016/j.semcancer.2007.07.003
   Rutten MJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/274584
   Sampson JA, 1927, AM J PATHOL, V3, P93
   Sebti Y, 2007, BRIT J HAEMATOL, V138, P202, DOI 10.1111/j.1365-2141.2007.06647.x
   Suen JL, 2014, AM J PATHOL, V184, P464, DOI 10.1016/j.ajpath.2013.10.023
   Tabibzadeh S, 2003, FRONT BIOSCI-LANDMRK, V8, pA70, DOI 10.2741/1045
   Wang F, 2008, FERTIL STERIL, V90, P1599, DOI 10.1016/j.fertnstert.2007.06.073
   Yang YP, 1996, J IMMUNOL, V156, P4224
NR 42
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD APR
PY 2019
VL 235
BP 36
EP 41
DI 10.1016/j.ejogrb.2019.01.030
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA HS7ZD
UT WOS:000464086900007
PM 30784825
DA 2020-11-26
ER

PT J
AU Kalil, JA
   Poirier, J
   Becker, B
   Van Dam, R
   Keutgen, X
   Schadde, E
AF Kalil, Jennifer A.
   Poirier, Jennifer
   Becker, Bjoern
   Van Dam, Robert
   Keutgen, Xavier
   Schadde, Erik
TI Laparoscopic Parenchymal-Sparing Hepatectomy: the New Maximally Minimal
   Invasive Surgery of the Livera Systematic Review and Meta-Analysis
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Laparoscopic parenchymal-sparing hepatectomy; Parenchymal-sparing liver
   surgery; Colorectal liver metastasis
ID HEPATIC RESECTION; POSTEROSUPERIOR SEGMENTS; ANATOMIC RESECTION;
   CLINICAL-OUTCOMES; METASTASES; SURVIVAL; POSITION; IMPROVES; LESIONS;
   MARGIN
AB BackgroundParenchymal-sparing hepatectomies (PSH) are liver resections with preservation of as much liver parenchyma as possible. PSH can be performed laparoscopically (LPSH), but access to the posterosuperior segments is difficult and they are challengingwhen there are multiple bilobar lesions; the procedure may require repositioning and may be long and cumbersome. The objective of this systematic review is to analyze the feasibility and limitations of laparoscopic PSH in the literature.MethodsA systematic review of the literature was performed by searching Medline/PubMed, Scopus, and Cochrane databases. Resections were categorized by segment(s), and data regarding operative time, blood loss, length of hospital stay, complications, and R0 resection were analyzed.ResultsOf 351 studies screened for relevance, 48 studies were reviewed. Ten publications fulfilled inclusion criteria, reporting data from 579 patients undergoing LPSH. The most common indication was CRLM (58%) followed by hepatocellular carcinoma (16%). Only 92 patients were reported to have resections of more than one tumor; the maximum number of lesions resected was seven. Of resected lesions, 21.5% were located in the cranial segments. Mean operating time was 335.2min, estimated blood loss was 462cc, and hospital stay was 7.6days. Conversion rate was 9.7%, and complications occurred in 19.4% of cases. No perioperative mortality was reported. R0 resections were achieved in 87.7% of cases.ConclusionLaparoscopic PSH is performed and reported, but the data quality is low so far. The main limitation of LPSH is the low number of lesions resected, especially for bilobar, metastatic disease. Prospective reports with tumor-specific oncological data are desirable.
C1 [Kalil, Jennifer A.; Poirier, Jennifer; Keutgen, Xavier; Schadde, Erik] Rush Univ, Med Ctr, Dept Surg Transplant Surg, 1653 W Congress Pkwy,Jelke Bldg 7th Floor, Chicago, IL 60612 USA.
   [Becker, Bjoern] Cantonal Hosp Winterthur, Dept Gastroenterol, Brauerstr 15, CH-8401 Winterthur, Switzerland.
   [Van Dam, Robert] Maastricht Univ, Med Ctr, Dept Surg, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands.
   [Schadde, Erik] Cantonal Hosp Winterthur, Dept Surg, Brauerstr 15, CH-8401 Winterthur, Switzerland.
RP Schadde, E (corresponding author), Rush Univ, Med Ctr, Dept Surg Transplant Surg, 1653 W Congress Pkwy,Jelke Bldg 7th Floor, Chicago, IL 60612 USA.; Schadde, E (corresponding author), Cantonal Hosp Winterthur, Dept Surg, Brauerstr 15, CH-8401 Winterthur, Switzerland.
EM erik.schadde@uzh.ch
OI Kalil, Jennifer/0000-0001-6304-4690
CR Alvarez FA, 2016, WORLD J GASTRO SURG, V8, P407, DOI 10.4240/wjgs.v8.i6.407
   Billingsley KG, 1998, J AM COLL SURGEONS, V187, P471, DOI 10.1016/S1072-7515(98)00231-2
   Buell JF, 2009, ANN SURG, V250, P825, DOI 10.1097/SLA.0b013e3181b3b2d8
   Chen YX, 2016, CHINESE MED J-PEKING, V129, P39, DOI 10.4103/0366-6999.172567
   Cho JY, 2008, SURGERY, V144, P32, DOI 10.1016/j.surg.2008.03.020
   Cipriani F, 2015, J AM COLL SURGEONS, V221, P265, DOI 10.1016/j.jamcollsurg.2015.03.029
   Conrad C, 2015, SURG ENDOSC, V29, P2410, DOI 10.1007/s00464-014-3924-9
   D'Hondt M, 2016, LANGENBECK ARCH SURG, V401, P255, DOI 10.1007/s00423-016-1375-6
   De'Angelis N, 2015, J LAPAROENDOSC ADV S, V25, P12, DOI 10.1089/lap.2014.0477
   Di Fabio F, 2014, WORLD J SURG, V38, P3169, DOI 10.1007/s00268-014-2724-7
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Gold JS, 2008, ANN SURG, V247, P109, DOI 10.1097/SLA.0b013e3181557e47
   Hasegawa K, 2005, ANN SURG, V242, P252, DOI 10.1097/01.sla.0000171307.37401.db
   Ishizawa T, 2012, ANN SURG, V256, P959, DOI 10.1097/SLA.0b013e31825ffed3
   Kaibori M, 2017, J HEPATO-BIL-PAN SCI, V24, P616, DOI 10.1002/jhbp.502
   Kazaryan AM, 2011, SURG ENDOSC, V25, P3881, DOI 10.1007/s00464-011-1815-x
   Nguyen KT, 2011, ARCH SURG-CHICAGO, V146, P348, DOI 10.1001/archsurg.2010.248
   Lee KF, 2010, HPB, V12, P649, DOI 10.1111/j.1477-2574.2010.00221.x
   Marvin Michael R, 2009, Adv Surg, V43, P159
   Matsuki R, 2016, SURGERY, V160, P1256, DOI 10.1016/j.surg.2016.06.041
   Mise Y, 2016, ANN SURG, V263, P146, DOI 10.1097/SLA.0000000000001194
   Montalti R, 2014, EJSO-EUR J SURG ONC, V40, P536, DOI 10.1016/j.ejso.2014.01.005
   Montalti R, 2016, SURG ENDOSC, V30, P1004, DOI 10.1007/s00464-015-4284-9
   Montalti R, 2015, SURG ENDOSC, V29, P2736, DOI 10.1007/s00464-014-3999-3
   Moris D, 2017, ANTICANCER RES, V37, P9, DOI 10.21873/anticanres.11283
   Moris D, 2017, J GASTROINTEST SURG, V21, P1076, DOI 10.1007/s11605-017-3397-y
   Ogiso S, 2015, ANN SURG, V262, P358, DOI 10.1097/SLA.0000000000001015
   Pawlik TM, 2005, ANN SURG, V241, P715, DOI 10.1097/01.sla.0000160703.75808.7d
   Regimbeau JM, 2002, SURGERY, V131, P311, DOI 10.1067/msy.2002.121892
   Strasberg SM, 2009, ANN SURG, V250, P177, DOI 10.1097/SLA.0b013e3181afde41
   Vauthey JN, 2000, SURGERY, V127, P512, DOI 10.1067/msy.2000.105294
   Weber SM, 2000, ANN SURG ONCOL, V7, P643, DOI 10.1007/s10434-000-0643-3
NR 32
TC 2
Z9 2
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
EI 1873-4626
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD APR
PY 2019
VL 23
IS 4
BP 860
EP 869
DI 10.1007/s11605-019-04128-w
PG 10
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA HQ5TS
UT WOS:000462476100028
PM 30756316
DA 2020-11-26
ER

PT J
AU Campos, L
   Galvao, VR
   Kalil, J
   Castells, M
   Giavina-Bianchi, P
AF Campos, Lucila
   Galvao, Violeta Regnier
   Kalil, Jorge
   Castells, Mariana
   Giavina-Bianchi, Pedro
TI BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily
   Practice?
SO CURRENT ALLERGY AND ASTHMA REPORTS
LA English
DT Review
DE Basophil activation test; BAT; Hypersensitivity reactions; Drug allergy
ID BASOPHIL ACTIVATION TEST; IN-VITRO DIAGNOSIS; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; HYPERSENSITIVITY REACTIONS; CD63 EXPRESSION;
   SULFIDOLEUKOTRIENE PRODUCTION; MEDIATED HYPERSENSITIVITY; INTERNATIONAL
   CONSENSUS; CROSS-REACTIVITY; IMMEDIATE
AB Purpose of ReviewThe aim of this study is to critically review the relevant literature published on basophil activation test, presenting the current knowledge and future perspectives.Recent FindingsBasophil activation test (BAT) results varied accordingly to the class of the drug studied, and have promising results in immediate hypersensitivity reactions to pyrazolone (selective reactors), neuromuscular blockers, beta-lactams, and platinum compounds, all examples of classical IgE-mediated hypersensitivity drug reactions.SummaryCurrently, BAT is applied in research settings, but based in the results of our review, the test can be considered as a diagnostic tool for daily practice for selected patients and selected drugs, when the test is available, particularly for patients who experienced severe reactions and when diagnosis cannot be stablished by serum-specific IgE and skin testing, in order to avoid unnecessary drug provocations tests.
C1 [Campos, Lucila; Galvao, Violeta Regnier; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
   [Castells, Mariana] Harvard Med Sch, Boston, MA 02115 USA.
   [Castells, Mariana] Brigham & Womens Hosp, Adverse Drug React & Desesitizat Program, Jimmy Fund Way,Smith Bldg, Boston, MA USA.
   [Castells, Mariana] Brigham & Womens Hosp, Dept Med, Allergy & Immunol Training Program, 75 Francis St, Boston, MA 02115 USA.
   [Castells, Mariana] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.
RP Campos, L (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
EM lucila.campos@uol.com.br; pbianchi@usp.br
CR Abuaf N, 2008, CLIN EXP ALLERGY, V38, P921, DOI 10.1111/j.1365-2222.2008.02960.x
   Abuaf N, 2012, J Allergy (Cairo), V2012, P580873, DOI 10.1155/2012/580873
   Abuaf N, 1999, J ALLERGY CLIN IMMUN, V104, P411, DOI 10.1016/S0091-6749(99)70386-6
   Aranda A, 2011, ALLERGY, V66, P247, DOI 10.1111/j.1398-9995.2010.02460.x
   Ariza A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23845
   Aun MV, 2017, IMMUNOL ALLERGY CLIN, V37, P629, DOI 10.1016/j.iac.2017.06.002
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Barni S, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0360-1
   Bavbek S, 2009, INT ARCH ALLERGY IMM, V150, P261, DOI 10.1159/000222678
   Ben Said B, 2010, ALLERGY, V65, P535, DOI 10.1111/j.1398-9995.2009.02213.x
   Blanca-Lopez N, 2013, CLIN EXP ALLERGY, V43, P560, DOI 10.1111/cea.12099
   Blanca-Lopez N, 2016, INT ARCH ALLERGY IMM, V169, P223, DOI 10.1159/000444798
   Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142
   Celik GE, 2009, CLIN EXP ALLERGY, V39, P1522, DOI 10.1111/j.1365-2222.2009.03277.x
   Chinuki Y, 2012, J ALLERGY CLIN IMMUN, V129, P1404, DOI 10.1016/j.jaci.2012.02.049
   Martinez RD, 2017, ALLERGOL INT, V66, P357, DOI 10.1016/j.alit.2016.09.002
   De Weck AL, 2010, J INVEST ALLERG CLIN, V20, P39
   De Weck AL, 2009, J INVEST ALLERG CLIN, V19, P91
   Decuyper II, 2017, DRUGS R&D, V17, P265, DOI 10.1007/s40268-017-0176-x
   Decuyper II, 2016, CLIN CHIM ACTA, V460, P184, DOI 10.1016/j.cca.2016.06.043
   Demir S, 2017, ALLERGY ASTHMA IMMUN, V9, P347, DOI 10.4168/aair.2017.9.4.347
   Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350
   Dewachter P, 2018, J ALLER CL IMM-PRACT, V6, P1681, DOI 10.1016/j.jaip.2017.12.037
   Dona I, 2017, ALLERGY, V72, P1346, DOI 10.1111/all.13147
   Dona I, 2012, J INVEST ALLERG CLIN, V22, P363
   Dona I, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0725-y
   Dona I, 2017, ALLERGY ASTHMA IMMUN, V9, P288, DOI 10.4168/aair.2017.9.4.288
   Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P205
   Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P135
   Eberlein B, 2010, CLIN EXP ALLERGY, V40, P411, DOI 10.1111/j.1365-2222.2009.03426.x
   Ebo DG, 2006, ALLERGY, V61, P935, DOI 10.1111/j.1398-9995.2006.01094.x
   Ebo DG, 2018, J ALLER CL IMM-PRACT, V6, P1176, DOI 10.1016/j.jaip.2018.01.004
   Fernandez TD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003679
   Gamboa P, 2004, CLIN EXP ALLERGY, V34, P1448, DOI 10.1111/j.1365-2222.2004.02050.x
   Gamboa PM, 2004, J INVEST ALLERG CLIN, V14, P278
   Gamboa PM, 2003, ALLERGY, V58, P312, DOI 10.1034/j.1398-9995.2003.00096.x
   Garcia-Ortega P, 2010, ALLERGY, V65, P1204, DOI 10.1111/j.1398-9995.2010.02333.x
   Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006
   Gomes ER, 2005, CURR OPIN ALLERGY CL, V5, P309, DOI 10.1097/01.all.0000173785.81024.33
   Gomez E, 2009, CLIN EXP ALLERGY, V39, P1217, DOI 10.1111/j.1365-2222.2009.03237.x
   Gonzalez-de-Olano D, 2016, J ALLER CL IMM-PRACT, V4, P338, DOI 10.1016/j.jaip.2015.10.007
   Hagau N, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-42
   Hagau N, 2013, ALLERGY ASTHMA IMMUN, V5, P383, DOI 10.4168/aair.2013.5.6.383
   Harrer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013707
   Hunziker T, 2002, PHARMACOEPIDEM DR S, V11, P159, DOI 10.1002/pds.669
   Iwamoto T, 2014, CANCER SCI, V105, P1472, DOI 10.1111/cas.12538
   Iwamoto T, 2012, BIOL PHARM BULL, V35, P1487, DOI 10.1248/bpb.b12-00150
   Kim MS, 2012, ALLERGY ASTHMA IMMUN, V4, P137, DOI 10.4168/aair.2012.4.3.137
   Korosec P, 2011, INT ARCH ALLERGY IMM, V155, P257, DOI 10.1159/000319846
   Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x
   Kvedariene V, 2006, ALLERGY, V61, P311, DOI 10.1111/j.1398-9995.2006.00978.x
   Leysen J, 2014, CLIN EXP ALLERGY, V44, P1069, DOI 10.1111/cea.12344
   Lobera T, 2010, J INVEST ALLERG CLIN, V20, P607
   Malbran A, 2007, CLIN EXP IMMUNOL, V147, P99, DOI 10.1111/j.1365-2249.2006.03265.x
   Mangodt EA, 2015, INT ARCH ALLERGY IMM, V168, P3, DOI 10.1159/000440663
   Mayorga C, 2013, INT ARCH ALLERGY IMM, V160, P377, DOI 10.1159/000343023
   McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022
   Monneret G, 2002, CLIN IMMUNOL, V102, P192, DOI 10.1006/clim.2001.5156
   Piva E, 2012, AM J HEMATOL, V87, pE130, DOI 10.1002/ajh.23329
   Rodriguez-Trabado A, 2008, ALLERGY ASTHMA PROC, V29, P241, DOI 10.2500/aap.2008.29.3114
   Rouzaire P, 2012, INT ARCH ALLERGY IMM, V157, P299, DOI 10.1159/000328211
   Salas M, 2018, J ALLER CL IMM-PRACT, V6, P1010, DOI 10.1016/j.jaip.2017.08.009
   Sanz ML, 2005, INT ARCH ALLERGY IMM, V136, P58, DOI 10.1159/000082586
   Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x
   Seitz CS, 2009, CLIN EXP ALLERGY, V39, P1738, DOI 10.1111/j.1365-2222.2009.03338.x
   Stein ML, 2012, J COMPUT GRAPH STAT, V21, P155, DOI 10.1198/jcgs.2010.10069
   Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x
   Thinnes A, 2018, CUTAN OCUL TOXICOL, V37, P309, DOI 10.1080/15569527.2018.1448990
   Torres MJ, 2011, CLIN EXP ALLERGY, V41, P1595, DOI 10.1111/j.1365-2222.2011.03834.x
   Torres MJ, 2010, ALLERGY, V65, P590, DOI 10.1111/j.1398-9995.2009.02245.x
   Torres MJ, 2004, CLIN EXP ALLERGY, V34, P1768, DOI 10.1111/j.1365-2222.2004.02110.x
   Uyttebroek AP, 2014, ALLERGY, V69, P1324, DOI 10.1111/all.12468
   Viardot-Helmer A, 2008, HAUTARZT, V59, P883, DOI 10.1007/s00105-008-1653-5
   Wise SK, 2018, INT FORUM ALLERGY RH, V8, P108, DOI 10.1002/alr.22073
NR 74
TC 1
Z9 1
U1 0
U2 2
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1529-7322
EI 1534-6315
J9 CURR ALLERGY ASTHM R
JI Curr. Allergy Asthma Rep.
PD APR
PY 2019
VL 19
IS 4
AR 20
DI 10.1007/s11882-019-0852-8
PG 13
WC Allergy; Immunology
SC Allergy; Immunology
GA HO4TG
UT WOS:000460914900001
PM 30859323
DA 2020-11-26
ER

PT J
AU Schadde, E
   Guiu, B
   Deal, R
   Kalil, J
   Arslan, B
   Tasse, J
   Olthof, PB
   Heil, J
   Schnitzbauer, AA
   Jakate, S
   Breitenstein, S
   Schlapfer, M
   Schimmer, BB
   Hertl, M
AF Schadde, Erik
   Guiu, Boris
   Deal, Rebecca
   Kalil, Jennifer
   Arslan, Bulent
   Tasse, Jordan
   Olthof, Pim B.
   Heil, Jan
   Schnitzbauer, Andreas A.
   Jakate, Shriram
   Breitenstein, Stefan
   Schlapfer, Martin
   Schimmer, Beatrice Beck
   Hertl, Martin
TI Simultaneous hepatic and portal vein ligation induces rapid liver
   hypertrophy: A study in pigs
SO SURGERY
LA English
DT Article
ID STAGED HEPATECTOMY; VENOUS DEPRIVATION; MAJOR HEPATECTOMY; LOBE
   HYPERTROPHY; ALPPS; EMBOLIZATION; PARTITION; REGENERATION; MORTALITY;
   OCCLUSION
AB Background: Liver hypertrophy induced by partial portal vein occlusion (PVL) is accelerated by adding simultaneous parenchymal transection ("ALPPS procedure"). This preclinical experimental study in pigs tests the hypothesis that simultaneous ligation of portal and hepatic veins of the liver also accelerates regeneration by abrogation of porto-portal collaterals without need for operative transection.
   Methods: A pig model of portal vein occlusion was compared with the novel model of simultaneous portal and hepatic vein occlusion, where major hepatic veins draining the portal vein-deprived lobe were identified with intraoperative ultrasonography and ligated using pledgeted transparenchymal sutures. Kinetic growth was compared, and the portal vein system was then studied after 7 days using epoxy casts of the portal circulation. Portal vein flow and portal pressure were measured, and Ki-67 staining was used to evaluate the proliferative response.
   Results: Pigs were randomly assigned to portal vein occlusion (n = 8) or simultaneous portal and hepatic vein occlusion (n = 6). Simultaneous portal and hepatic vein occlusion was well tolerated and led to mild cytolysis, with no necrosis in the outflow vein-deprived liver sectors. The portal vein-supplied sector increased by 90 +/- 22% (mean +/- standard deviation) after simultaneous portal and hepatic vein occlusion compared with 29 +/- 18% after PVL (P < .001). Collaterals to the deportalized liver developed after 7 days in both procedures but were markedly reduced in simultaneous portal and hepatic vein occlusion. Ki-67 staining at 7 days was comparable.
   Conclusion: This study in pigs found that simultaneous portal and hepatic vein occlusion led to rapid hypertrophy without necrosis of the deportalized liver. The findings suggest that the use of simultaneous portal and hepatic vein occlusion accelerates liver hypertrophy for extended liver resections and should be evaluated further. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Schadde, Erik; Deal, Rebecca; Kalil, Jennifer; Hertl, Martin] Rush Univ, Med Ctr, Dept Surg, Chicago, IL 60612 USA.
   [Schadde, Erik; Breitenstein, Stefan] Cantonal Hosp Winterthur, Dept Surg, Zurich, Switzerland.
   [Schadde, Erik; Schlapfer, Martin; Schimmer, Beatrice Beck] Univ Zurich, Ctr Integrat Human Physiol, Inst Physiol, Zurich, Switzerland.
   [Guiu, Boris] St Eloi Univ Hosp, Dept Radiol, Montpellier, France.
   [Arslan, Bulent; Tasse, Jordan] Rush Univ, Med Ctr, Dept Radiol, Intervent Radiol, Chicago, IL 60612 USA.
   [Olthof, Pim B.] Acad Med Ctr, Dept Expt Surg, Amsterdam, Netherlands.
   [Heil, Jan; Schnitzbauer, Andreas A.] Goethe Univ Frankfurt, Med Ctr, Dept Surg, Frankfurt, Germany.
   [Jakate, Shriram] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA.
RP Schadde, E (corresponding author), Rush Univ, Med Ctr, Dept Surg, Div Transplant Surg,Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.
EM erik.schadde@uzh.ch
RI ; Guiu, Boris/L-5377-2017
OI Kalil, Jennifer/0000-0001-6304-4690; Guiu, Boris/0000-0003-1277-3054
CR Abdalla EK, 2004, SURG CLIN N AM, V84, P563, DOI 10.1016/S0039-6109(03)00231-7
   Aloia TA, 2012, ANN SURG, V256, pE9, DOI 10.1097/SLA.0b013e318265fd3e
   Ardiles V, 2014, ANN SURG, V260, pE4, DOI 10.1097/SLA.0000000000000735
   Belghiti J, 2016, SURGERY, V159, P1287, DOI 10.1016/j.surg.2015.12.027
   de Santibanes E, 2012, ANN SURG, V255, P415, DOI 10.1097/SLA.0b013e318248577d
   Deal RA, 2017, J GASTROINTEST SURG
   Deal R, 2018, J GASTROINTEST SURG, V22, P203, DOI 10.1007/s11605-017-3512-0
   Denys AL, 1999, AM J ROENTGENOL, V173, P633, DOI 10.2214/ajr.173.3.10470893
   Dokmak S, 2012, ANN SURG, V256, pE6, DOI 10.1097/SLA.0b013e318265fd64
   FRANCAVILLA A, 1992, HEPATOLOGY, V16, P1267, DOI 10.1002/hep.1840160524
   Guiu B, 2017, EUR RADIOL, V27, P3343, DOI 10.1007/s00330-017-4744-9
   Guiu B, 2016, EUR RADIOL, V26, P4259, DOI 10.1007/s00330-016-4291-9
   Huisman F, 2014, J SURG RES, V191, P179, DOI 10.1016/j.jss.2014.05.089
   Hwang S, 2015, WORLD J SURG, V39, P2990, DOI 10.1007/s00268-015-3194-2
   Hwang S, 2009, ANN SURG, V249, P608, DOI 10.1097/SLA.0b013e31819ecc5c
   Kianmanesh R, 2003, J AM COLL SURGEONS, V197, P164, DOI 10.1016/S1072-7515(03)00334-X
   Kilkenny C, 2010, LAB ANIM-UK, V44, P377, DOI 10.1258/la.2010.0010021
   Linecker M, 2017, ANN SURG, V266, P779, DOI 10.1097/SLA.0000000000002446
   Matsuo K, 2017, ANN SURG ONCOL, V24, P2456, DOI 10.1245/s10434-017-5922-3
   Matsuo K, 2016, SURGERY, V159, P1289, DOI 10.1016/j.surg.2015.12.004
   Olthof PB, 2017, SURGERY, V162, P775, DOI 10.1016/j.surg.2017.05.022
   Olthof PB, 2017, SURGERY, V162, P732, DOI 10.1016/j.surg.2016.12.014
   Rous P, 1920, J EXP MED, V31, P609, DOI 10.1084/jem.31.5.609
   Sandstrom P, 2018, ANN SURG, V267, P833, DOI 10.1097/SLA.0000000000002511
   Schadde E, 2017, SURGERY, V161, P666, DOI 10.1016/j.surg.2016.05.018
   Schadde E, 2015, ANN SURG, V262, P780, DOI 10.1097/SLA.0000000000001450
   Schadde E, 2015, SURGERY, V157, P676, DOI 10.1016/j.surg.2014.11.015
   Schadde E, 2014, ANN SURG, V260, P829, DOI 10.1097/SLA.0000000000000947
   Schnitzbauer AA, 2012, ANN SURG, V255, P405, DOI 10.1097/SLA.0b013e31824856f5
   Truant S, 2016, ANN SURG, V263, pe33, DOI 10.1097/SLA.0000000000001603
   van Lienden KP, 2013, CARDIOVASC INTER RAD, V36, P1572, DOI 10.1007/s00270-013-0591-5
   van Lienden KP, 2012, J VASC INTERV RADIOL, V23, P962, DOI 10.1016/j.jvir.2012.03.011
   Vauthey JN, 2017, ANN SURG ONCOL, V24, P1456, DOI 10.1245/s10434-017-5801-y
NR 33
TC 6
Z9 7
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD MAR
PY 2019
VL 165
IS 3
BP 525
EP 533
DI 10.1016/j.surg.2018.09.001
PG 9
WC Surgery
SC Surgery
GA HO3TI
UT WOS:000460845400005
PM 30482517
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Castro, RB
   Dias, GMFS
   de Assis, JP
   Brugnolli, RM
   Kalil, J
   Giavina-Bianchi, P
   Agondi, RC
AF Castro, Raisa Borges
   Dias, Gabriella M. F. S.
   de Assis, Joao Paulo
   Brugnolli, Rebeca M.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Agondi, Rosana C.
TI Sensitization to food allergens in allergic asthmatic patients:
   association between cockroach and shrimp sensitization
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 22-25, 2019
CL San Francisco, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Castro, Raisa Borges; Dias, Gabriella M. F. S.; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sao Paulo, Brazil.
   [de Assis, Joao Paulo] Univ Sao Paulo, Sao Paulo, Brazil.
   [Brugnolli, Rebeca M.; Giavina-Bianchi, Pedro; Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Fac Med FMUSP, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2019
VL 143
IS 2
SU S
MA 326
BP AB108
EP AB108
DI 10.1016/j.jaci.2018.12.329
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA HK2VO
UT WOS:000457771200322
OA Bronze
DA 2020-11-26
ER

PT J
AU Dias, GMFS
   de Assis, JP
   Castro, RB
   Kalil, J
   Giavina-Bianchi, P
   Agondi, RC
AF Dias, Gabriella M. F. S.
   de Assis, Joao Paulo
   Castro, Raisa Borges
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Agondi, Rosana C.
TI AERD: PERSPECTIVE OF THE USE OF LICENSED MONOCLONALS FOR TREATMENT BASED
   ON THEIR PHENOTYPES
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 22-25, 2019
CL San Francisco, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Dias, Gabriella M. F. S.; de Assis, Joao Paulo; Castro, Raisa Borges; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Agondi, Rosana C.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2019
VL 143
IS 2
SU S
MA 302
BP AB100
EP AB100
DI 10.1016/j.jaci.2018.12.305
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA HK2VO
UT WOS:000457771200299
OA Bronze
DA 2020-11-26
ER

PT J
AU de Lima, CMF
   Hernandes, GHY
   Algranti, E
   Macaira, ED
   Kalil, J
   Castro, FM
   Galvo, CES
AF Fonseca de Lima, Cynthia Mafra
   Hernandes y Hernandes, Giovanna
   Algranti, Eduardo
   Macaira, Elayne de Fatima
   Kalil, Jorge
   Castro, Fabio M.
   Galvo, Clovis E. S.
TI Comparative Evaluation Of Pulmonary Function Tests In Professional
   Cleaners While Exposed To The Occupational Workplace And After The
   Vacation Period
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 22-25, 2019
CL San Francisco, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Fonseca de Lima, Cynthia Mafra; Castro, Fabio M.; Galvo, Clovis E. S.] Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Div, Hosp Clin, Sao Paulo, Brazil.
   [Hernandes y Hernandes, Giovanna] Univ Anhembi Morumbi, Escola Ciencias Med, Anhembi Morumbi Med Sch, Sao Paulo, Brazil.
   [Algranti, Eduardo; Macaira, Elayne de Fatima] FUNDACEN TRO, Dept Med, Sao Paulo, SP, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI algranti, eduardo/Y-7575-2019; Castro, Fabio/AAP-5433-2020
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2019
VL 143
IS 2
SU S
MA 70
BP AB24
EP AB24
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA HK2VO
UT WOS:000457771200070
DA 2020-11-26
ER

PT J
AU Penido, A
   de Assis, JP
   Grecco, O
   Barros, MT
   Kalil, J
   Kokron, CM
   Marinho, AKBB
AF Penido, Antonio
   de Assis, Joao Paulo
   Grecco, Octavio
   Barros, Myrthes T.
   Kalil, Jorge
   Kokron, Cristina M.
   Marinho, Ana Karolina B. B.
TI Vaccination against yellow fever in patients with IgA deficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 22-25, 2019
CL San Francisco, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Penido, Antonio; de Assis, Joao Paulo; Grecco, Octavio; Barros, Myrthes T.; Kokron, Cristina M.; Marinho, Ana Karolina B. B.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2019
VL 143
IS 2
SU S
MA 686
BP AB226
EP AB226
DI 10.1016/j.jaci.2018.12.690
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA HK2VO
UT WOS:000457771200680
OA Bronze
DA 2020-11-26
ER

PT J
AU Garcia, JFB
   Takejima, P
   Veronez, CL
   Aun, MV
   Motta, AA
   Kalil, J
   Pesquero, JB
   Giavina-Bianchi, P
AF Garcia, Juliana F. B.
   Takejima, Priscila
   Veronez, Camila Lopes
   Aun, Marcelo V.
   Motta, Antonio A.
   Kalil, Jorge
   Pesquero, Joao Bosco
   Giavina-Bianchi, Pedro
TI C1-INH concentrate for prophylaxis during pregnancy in hereditary
   angioedema with normal C1-INH Reply
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
C1 [Garcia, Juliana F. B.; Takejima, Priscila; Aun, Marcelo V.; Motta, Antonio A.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178,Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
   [Veronez, Camila Lopes; Pesquero, Joao Bosco] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178,Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI Veronez, Camila Lopes/O-6134-2015; Aun, Marcelo V/E-6775-2014
OI Veronez, Camila Lopes/0000-0001-9565-1911; Aun, Marcelo
   V/0000-0001-9882-5200
CR CITARELLA F, 1993, BIOCHIM BIOPHYS ACTA, V1172, P197, DOI 10.1016/0167-4781(93)90294-N
   Garcia JFB, 2018, J ALLER CL IMM-PRACT, V6, P1406, DOI 10.1016/j.jaip.2017.12.022
   Giavina-Bianchi P, 2017, ARQ ASMA ALERG IMUNO, V1, P23, DOI DOI 10.5935/2526-5393.20170005
   Giavina-Bianchi P, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e310
   Gibbons KR, 2017, ANN ALLERG ASTHMA IM, V119, P558, DOI 10.1016/j.anai.2017.08.015
   Joseph K, 2017, J ALLERGY CLIN IMMUN, V140, P170, DOI 10.1016/j.jaci.2016.09.032
   Valencia RM, 2019, J ALLER CL IMM-PRACT, V7, P754, DOI 10.1016/j.jaip.2018.10.056
NR 7
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD FEB
PY 2019
VL 7
IS 2
BP 754
EP 755
DI 10.1016/j.jaip.2018.11.022
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA HK1CG
UT WOS:000457641700079
PM 30717878
DA 2020-11-26
ER

PT J
AU Chevillard, C
   Nunes, JPS
   Frade, AF
   Almeida, RR
   Pandey, RP
   Nascimento, MS
   Kalil, J
   Cunha-Neto, E
AF Chevillard, Christophe
   Nunes, Joao Paulo Silva
   Frade, Amanda Farage
   Almeida, Rafael Ribeiro
   Pandey, Ramendra Pati
   Nascimento, Marilda Savoia
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma
   cruzi Persistence and Differential Progression to Chagas Disease
   Cardiomyopathy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE disease tolerance gene; pathogen resistance genes; Tripanosoma cruzi;
   chagas cardiomyopathy; interferon gamma
ID NECROSIS-FACTOR-ALPHA; DISCRETE TYPING UNITS; NITRIC-OXIDE SYNTHASE;
   IFN-GAMMA PRODUCTION; T-CELL-ACTIVATION; C-C-CHEMOKINES;
   INTERFERON-GAMMA; HOST-RESISTANCE; PARASITE REPLICATION; MICE DEFICIENT
AB Chagas disease is caused by infection with the protozoan Trypanosoma cruzi and affects over 8 million people worldwide. In spite of a powerful innate and adaptive immune response in acute infection, the parasite evades eradication, leading to a chronic persistent infection with low parasitism. Chronically infected subjects display differential patterns of disease progression. While 30% develop chronic Chagas disease cardiomyopathy (CCC)-a severe inflammatory dilated cardiomyopathy-decades after infection, 60% of the patients remain disease-free, in the asymptomatic/indeterminate (ASY) form, and 10% develop gastrointestinal disease. Infection of genetically deficient mice provided a map of genes relevant for resistance to T. cruzi infection, leading to the identification of multiple genes linked to survival to infection. These include pathogen resistance genes (PRG) needed for intracellular parasite destruction, and genes involved in disease tolerance (protection against tissue damage and acute phase death-DTG). All identified DTGs were found to directly or indirectly inhibit IFN-gamma production or Th1 differentiation. We hypothesize that the absolute need for DTG to control potentially lethal IFN-gamma PRG activity leads to T. cruzi persistence and establishment of chronic infection. IFN-gamma production is higher in CCC than ASY patients, and is the most highly expressed cytokine in CCC hearts. Key DTGs that downmodulate IFN-gamma, like IL-10, and Ebi3/IL27p28, are higher in ASY patients. Polymorphisms in PRG and DTG are associated with differential disease progression. We thus hypothesize that ASY patients are disease tolerant, while an imbalance of DTG and IFN-gamma PRG activity leads to the inflammatory heart damage of CCC.
C1 [Chevillard, Christophe] Aix Marseille Univ, INSERM UMR 1090, TAGC, Marseille, France.
   [Nunes, Joao Paulo Silva; Frade, Amanda Farage; Almeida, Rafael Ribeiro; Pandey, Ramendra Pati; Nascimento, Marilda Savoia; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Sao Paulo, Brazil.
   [Nunes, Joao Paulo Silva; Almeida, Rafael Ribeiro; Pandey, Ramendra Pati; Nascimento, Marilda Savoia; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Nunes, Joao Paulo Silva; Frade, Amanda Farage; Almeida, Rafael Ribeiro; Pandey, Ramendra Pati; Nascimento, Marilda Savoia; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol III, Sao Paulo, Brazil.
   [Frade, Amanda Farage] Brazil Univ, Dept Bioengn, Sao Paulo, Brazil.
RP Chevillard, C (corresponding author), Aix Marseille Univ, INSERM UMR 1090, TAGC, Marseille, France.; Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Sao Paulo, Brazil.; Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.; Cunha-Neto, E (corresponding author), INCT, Inst Invest Immunol III, Sao Paulo, Brazil.
EM christophe.chevillard@univ-amu.fr; edecunha@gmail.com
RI chevillard, christophe/A-7087-2015; Almeida, Rafael/F-8014-2014;
   Cunha-Neto, Edecio/B-4157-2009; Nunes, Joao Paulo Silva/Z-6015-2019;
   Frade, Amanda F/O-3322-2017
OI chevillard, christophe/0000-0002-5269-8813; Almeida,
   Rafael/0000-0003-3984-7527; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Frade, Amanda F/0000-0002-9004-8811
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2014/50890-5, 2016/15209-0, 2013/50302-3]; Agence Nationale de
   Recherche (ANR France Br-Fr-Chagas); Institut National de la Sante et de
   la Recherche Medicale (INSERM)Institut National de la Sante et de la
   Recherche Medicale (Inserm); Aix-Marseille Universite; USP-COFECUB;
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES)CAPES [001]; NIAID/NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [2U19AI098461-06];
   ARCUS/Institut de Recherche pour le Developpement; 
   [ParaFrap-ANR-11-LABX-0024]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461, U19AI098461,
   U19AI098461] Funding Source: NIH RePORTER
FX This work was funded by the following research support agencies:
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil)
   2014/50890-5; 2016/15209-0, 2013/50302-3. Co-funded by Agence Nationale
   de Recherche (ANR France Br-Fr-Chagas), Institut National de la Sante et
   de la Recherche Medicale (INSERM), Aix-Marseille Universite,
   ARCUS/Institut de Recherche pour le Developpement, USP-COFECUB and from
   ParaFrap-ANR-11-LABX-0024, France; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior-Brasil (CAPES)-Finance Code 001; and NIAID/NIH
   grant 2U19AI098461-06. EC-N and JK are recipients of CNPq productivity
   awards.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Machuca MA, 2014, HUM IMMUNOL, V75, P1210, DOI 10.1016/j.humimm.2014.09.023
   Antonio CSE, 2008, MOL IMMUNOL, V45, P3580, DOI 10.1016/j.molimm.2008.05.004
   Arantes RME, 2004, AM J PATHOL, V164, P1361, DOI 10.1016/S0002-9440(10)63222-1
   Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Benatar AF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004148
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bohme J, 2016, IMMUNOLOGY, V147, P338, DOI 10.1111/imm.12565
   Bombeiro AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049022
   Brown DA, 2017, NAT REV CARDIOL, V14, P238, DOI 10.1038/nrcardio.2016.203
   Caetano BC, 2011, J IMMUNOL, V187, P1903, DOI 10.4049/jimmunol.1003911
   Cai CW, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005902
   Calzada JE, 2001, TISSUE ANTIGENS, V58, P154, DOI 10.1034/j.1399-0039.2001.580302.x
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Cardoso MS, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00659
   Caruso R, 2014, MUCOSAL IMMUNOL, V7, P1467, DOI 10.1038/mi.2014.35
   Chae HJ, 2006, NITRIC OXIDE-BIOL CH, V14, P189, DOI 10.1016/j.niox.2005.11.008
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
   Criado L, 2012, CYTOKINE, V57, P398, DOI 10.1016/j.cyto.2011.12.007
   Cummings KL, 2004, INFECT IMMUN, V72, P4081, DOI 10.1128/IAI.72.7.4081-4089.2004
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cura CI, 2012, PARASITOLOGY, V139, P516, DOI 10.1017/S0031182011002186
   Guedes PMD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000604
   Dai B, 2013, CELL PHYSIOL BIOCHEM, V32, P960, DOI 10.1159/000354499
   De Alba-Alvarado M, 2018, ACTA TROP, V178, P134, DOI 10.1016/j.actatropica.2017.11.009
   de Oliveira AP, 2016, INFECT GENET EVOL, V45, P132, DOI 10.1016/j.meegid.2016.08.012
   de Oliveira AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141847
   Dhiman M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004516
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Dinkova-Kostova AT, 2015, FREE RADIC BIOL ME B, V88, P179, DOI DOI 10.1016/J.FREERADBI0MED.2015.04.036
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Durand JL, 2009, AM J TROP MED HYG, V80, P782, DOI 10.4269/ajtmh.2009.80.782
   Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123
   Erdmann H, 2013, IMMUNOBIOLOGY, V218, P910, DOI 10.1016/j.imbio.2012.10.005
   Fernandes MC, 2012, FEMS MICROBIOL REV, V36, P734, DOI 10.1111/j.1574-6976.2012.00333.x
   Fernandez-Mestre MT, 2004, HUM IMMUNOL, V65, P725, DOI 10.1016/j.humimm.2004.05.002
   Florez O, 2011, PARASITE IMMUNOL, V33, P506, DOI 10.1111/j.1365-3024.2011.01314.x
   Florez O, 2012, HUM IMMUNOL, V73, P852, DOI 10.1016/j.humimm.2012.04.005
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Frade AF, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-587
   Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707
   Gao WD, 2002, INT J PARASITOL, V32, P167, DOI 10.1016/S0020-7519(01)00322-8
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022
   Hamano S, 2003, IMMUNITY, V19, P657, DOI 10.1016/S1074-7613(03)00298-X
   Hardison JL, 2006, INFECT IMMUN, V74, P135, DOI 10.1128/IAI.74.1.135-143.2006
   Harris LD, 2010, BLOOD, V116, P4148, DOI 10.1182/blood-2010-05-283549
   Harris LD, 2010, J VIROL, V84, P7886, DOI 10.1128/JVI.02612-09
   He XB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003569
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Holscher C, 1998, INFECT IMMUN, V66, P1208
   Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000
   Hunter CA, 1997, J IMMUNOL, V158, P3311
   Jansen AM, 2015, ACTA TROP, V151, P1, DOI 10.1016/j.actatropica.2015.07.018
   KALOVIDOURIS AE, 1993, J RHEUMATOL, V20, P1718
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Koga R, 2006, J IMMUNOL, V177, P7059, DOI 10.4049/jimmunol.177.10.7059
   Koo SJ, 2016, INFECT IMMUN, V84, P3527, DOI 10.1128/IAI.00809-16
   Kovac S, 2015, BBA-GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021
   Krause CD, 2006, CELL RES, V16, P113, DOI 10.1038/sj.cr.7310015
   Kulkarni MM, 2015, IMMUNOLOGY, V145, P225, DOI 10.1111/imm.12438
   Lee HJ, 2007, J MOL BIOL, V369, P967, DOI 10.1016/j.jmb.2007.03.072
   Levick S, 2014, HEART FAIL REV, V19, P227, DOI 10.1007/s10741-013-9393-8
   Meza SKL, 2014, EXP PARASITOL, V146, P34, DOI 10.1016/j.exppara.2014.08.014
   LUSS H, 1995, J MOL CELL CARDIOL, V27, P2015, DOI 10.1016/0022-2828(95)90023-3
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Machado FS, 2005, J INFECT DIS, V191, P627, DOI 10.1086/427515
   MacMurray J, 2014, BRAIN BEHAV IMMUN, V35, P169, DOI 10.1016/j.bbi.2013.09.012
   Magalhaes LMD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003816
   Marinho CRF, 2007, SCAND J IMMUNOL, V66, P297, DOI 10.1111/j.1365-3083.2007.01958.x
   Martins GA, 2004, MICROBES INFECT, V6, P1133, DOI 10.1016/j.micinf.2004.07.002
   Martins GA, 1999, INFECT IMMUN, V67, P3864, DOI 10.1128/IAI.67.8.3864-3871.1999
   Medina TS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01213
   Michailowsky V, 2004, J IMMUNOL, V173, P463, DOI 10.4049/jimmunol.173.1.463
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Miyazaki Y, 2010, J IMMUNOL, V185, P1150, DOI 10.4049/jimmunol.0900047
   Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346
   Munoz-San Martin C, 2018, ACTA TROP, V185, P280, DOI 10.1016/j.actatropica.2018.05.004
   Alvarez MN, 2011, J BIOL CHEM, V286, P6627, DOI 10.1074/jbc.M110.167247
   Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Oliveira AC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000870
   Paiva CN, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006928
   Paiva CN, 2009, J LEUKOCYTE BIOL, V86, P1239, DOI 10.1189/jlb.0309187
   Pall ML, 2013, INT J MOL SCI, V14, P22274, DOI 10.3390/ijms141122274
   Parissis JT, 2002, J INTERF CYTOK RES, V22, P223, DOI 10.1089/107999002753536194
   Patten M, 2001, PFLUG ARCH EUR J PHY, V442, P920
   Perez AR, 2007, BRAIN BEHAV IMMUN, V21, P890, DOI 10.1016/j.bbi.2007.02.004
   Ferreira LRP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18080-9
   Ferreira LRP, 2014, WORLD J CARDIOL, V6, P782, DOI 10.4330/wjc.v6.i8.782
   Pissetti CW, 2013, J INTERF CYTOK RES, V33, P130, DOI 10.1089/jir.2012.0024
   Pissetti CW, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000976
   Poncini CV, 2015, J IMMUNOL, V195, P3311, DOI 10.4049/jimmunol.1403019
   Rakshit S, 2014, BBA-MOL CELL RES, V1843, P2645, DOI 10.1016/j.bbamcr.2014.06.014
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2009, J INFECT DIS, V199, P1838, DOI 10.1086/599212
   Reifenberg K, 2007, AM J PATHOL, V171, P463, DOI 10.2353/ajpath.2007.060906
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Risso MG, 2011, AM J TROP MED HYG, V84, P78, DOI 10.4269/ajtmh.2011.10-0177
   Rodrigues DBR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/361730
   Rodrigues Mauricio M., 2012, Journal of Parasitology Research, P507874, DOI 10.1155/2012/507874
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Roy BA, 2000, EVOLUTION, V54, P51, DOI 10.1111/j.0014-3820.2000.tb00007.x
   Sales-Campos H, 2015, ACTA PARASITOL, V60, P435, DOI 10.1515/ap-2015-0060
   Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165
   Savan R, 2009, CYTOKINE GROWTH F R, V20, P115, DOI 10.1016/j.cytogfr.2009.02.006
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Schroder K, 2007, J LEUKOCYTE BIOL, V81, P1577, DOI 10.1189/jlb.0107036
   Sharma J, 2013, INFECT IMMUN, V81, P2278, DOI 10.1128/IAI.00497-12
   Sieve AN, 2010, EUR J IMMUNOL, V40, P2236, DOI 10.1002/eji.200939759
   Silva GK, 2013, J IMMUNOL, V191, P3373, DOI 10.4049/jimmunol.1203293
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995
   Silva MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03986-3
   Silva RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118600
   Soares MP, 2014, TRENDS IMMUNOL, V35, P483, DOI 10.1016/j.it.2014.08.001
   Sousa GR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172833
   Stahl P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110512
   STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Talvani A, 2003, MICROBES INFECT, V5, P789, DOI 10.1016/S1286-4579(03)00146-1
   Tarleton RL, 2000, J IMMUNOL, V165, P1520, DOI 10.4049/jimmunol.165.3.1520
   Teixeira MMG, 2006, TROP MED INT HEALTH, V11, P294, DOI 10.1111/j.1365-3156.2006.01575.x
   Teixeira PC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001205
   Torres OA, 2010, INFECT GENET EVOL, V10, P682, DOI 10.1016/j.meegid.2010.03.009
   Torzewski M, 2012, AM J PATHOL, V180, P73, DOI 10.1016/j.ajpath.2011.09.006
   Boari JT, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002658
   Van Linthout Sophie, 2017, Curr Heart Fail Rep, V14, P251, DOI 10.1007/s11897-017-0337-9
   VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994
   Vila-del Sol V, 2008, J IMMUNOL, V181, P4461, DOI 10.4049/jimmunol.181.7.4461
   Vilar-Pereira G, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005947
   Wan XX, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005954
   Wan XX, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003855
   Wang DC, 1996, LAB INVEST, V75, P809
   Wang ZY, 2002, BIOCHEM PHARMACOL, V63, P1197, DOI 10.1016/S0006-2952(02)00853-5
   Weitzel T, 2012, AM J TROP MED HYG, V86, P229, DOI 10.4269/ajtmh.2012.11-0539
   Wen JJ, 2017, ANTIOXID REDOX SIGN, V27, P550, DOI 10.1089/ars.2016.6831
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Wu AJ, 1997, J CELL PHYSIOL, V171, P117, DOI 10.1002/(SICI)1097-4652(199705)171:2<117::AID-JCP1>3.0.CO;2-R
   Wu YZ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.191031
   Zafra G, 2007, MICROBES INFECT, V9, P1049, DOI 10.1016/j.micinf.2007.04.010
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
   Zorova LD, 2018, ANAL BIOCHEM, V552, P50, DOI 10.1016/j.ab.2017.07.009
NR 150
TC 10
Z9 10
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 3
PY 2018
VL 9
AR 2791
DI 10.3389/fimmu.2018.02791
PG 14
WC Immunology
SC Immunology
GA HC6YC
UT WOS:000451946600001
PM 30559742
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo V.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Adults and children with anaphylaxis in the emergency room: why it is
   not recognized?
SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Review
DE anaphylaxis; emergency department; epinephrine; underdiagnosis;
   undertreatment
ID DRUG-INDUCED ANAPHYLAXIS; INTERNATIONAL CLASSIFICATION; EPINEPHRINE;
   MANAGEMENT; UNDERNOTIFICATION; DIAGNOSIS; DISEASES; DEATHS; BRAZIL
AB Purpose of review
   Despite many international guidelines have been published in the last 10 years, anaphylaxis continues to be underdiagnosed, undernotified, and undertreated. Anaphylactic reactions in adults and children in emergency departments are frequently not recognized, leading to underutilization of epinephrine, and a higher risk of death.
   Recent findings
   A few studies have been recently published showing that educational intervention for both physicians and other healthcare professionals improve diagnosis and treatment of anaphylaxis. Moreover, the new International Classification of Diseases, 11th edition improved classification of anaphylaxis, making it easier to be notified.
   Summary
   Anaphylaxis is a life-threatening hypersensitivity reaction that is most frequently seen by emergency physicians and nurses than allergists or immunologists. Education seems to be best strategy to improve management of this severe condition.
C1 [Aun, Marcelo V.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Aun, Marcelo V.] Albert Einstein Coll Med, Fac Israelita Ciencias Saude, Div Host & Def, Sao Paulo, Brazil.
RP Aun, MV (corresponding author), Fac Israelita Ciencias Saude FICS Albert Einstein, Ave Brigadeiro Luis Antonio 4267, BR-01401002 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI Aun, Marcelo V/E-6775-2014
OI Aun, Marcelo V/0000-0001-9882-5200
CR Arroabarren E, 2018, J INVEST ALLERG CLIN, V28, P401, DOI 10.18176/jiaci.0271
   Aun MV, 2017, IMMUNOL ALLERGY CLIN, V37, P629, DOI 10.1016/j.iac.2017.06.002
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Aun MV, 2017, CURR TREAT OPTIONS A, V4, P320
   Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P46, DOI 10.1016/j.jaip.2013.08.012
   Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P76, DOI 10.1016/j.jaip.2014.06.007
   Demoly P, 2014, ALLERGY, V69, P559, DOI 10.1111/all.12386
   Dhami S, 2014, ALLERGY, V69, P168, DOI 10.1111/all.12318
   Giavina-Bianchi P, 2018, CURR OPIN ALLERGY CL, V18, P59, DOI 10.1097/ACI.0000000000000411
   Hitti EA, 2015, EUR J EMERG MED, V22, P253, DOI 10.1097/MEJ.0000000000000155
   Jongco AM, 2016, J ALLERGY CAIRO, V2016
   Ribeiro MLKK, 2017, EINSTEIN-SAO PAULO, V15, P500, DOI [10.1590/S1679-45082017RW4089, 10.1590/s1679-45082017rw4089]
   Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126
   Lieberman PL, 2014, AM J MED, V127, pS6, DOI 10.1016/j.amjmed.2013.09.008
   Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437
   Rueter K, 2018, J ALLERGY CLIN IMMUN
   Saff RR, 2016, J ALLER CL IMM-PRACT, V4, P114, DOI 10.1016/j.jaip.2015.07.013
   Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303
   Sclar DA, 2014, AM J MED, V127, pS1, DOI 10.1016/j.amjmed.2013.09.007
   Sicherer SH, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4006
   Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1097/WOX.0b013e318211496c
   Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1
   Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9
   Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3
   Tanno LK, 2017, ALLERGY, V72, P120, DOI 10.1111/all.13006
   Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x
   Tanno LK, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0234-0
   Tanno LK, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0607-3
   Tanno LK, 2016, ASIA PAC ALLERGY, V6, P149, DOI 10.5415/apallergy.2016.6.3.149
   Thomson H, 2017, J PAEDIATR CHILD H, V53, P698, DOI 10.1111/jpc.13483
   Wang TS, 2017, INT ARCH ALLERGY IMM, V173, P51, DOI 10.1159/000475498
   World Health Organization, 2018, INT CLASS DIS
NR 32
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-4050
EI 1473-6322
J9 CURR OPIN ALLERGY CL
JI Curr. Opin. Allergy Clin. Immunol.
PD OCT
PY 2018
VL 18
IS 5
BP 377
EP 381
DI 10.1097/ACI.0000000000000469
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA HI2ZB
UT WOS:000456314700004
PM 30020259
DA 2020-11-26
ER

PT J
AU Santos, AS
   Chevillard, C
   Gonfinetti, NV
   Kalil, J
   Cunha, E
   Silva, MR
AF Santos, A. S.
   Chevillard, C.
   Gonfinetti, N. V.
   Kalil, J.
   Cunha-Neto, E.
   Silva, M. R.
TI Gene expression profile of peripheral blood mononuclear cells of
   recent-onset type 1 diabetes
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 54th Annual Meeting of the
   European-Association-for-the-Study-of-Diabetes (EASD)
CY OCT 01-05, 2018
CL Berlin, GERMANY
SP European Assoc Study Diabetes
C1 [Santos, A. S.; Silva, M. R.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Endocrinol Lab Carboidratos & Radioimunoensios LI, Sao Paulo, SP, Brazil.
   [Chevillard, C.] Aix Marseille Univ, INSERM, AMU UMR 1090, Marselha, France.
   [Gonfinetti, N. V.] Inst Castro Med, Endocrinol, Sao Paulo, Brazil.
   [Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Imunol, Disciplina Imunol & Alergia LIM 60, Sao Paulo, Brazil.
   [Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Inst Coracao, FMUSP, Lab Imunol, Sao Paulo, Brazil.
RI Santos, Aritania/AAD-3548-2020
FU EFSD
FX Supported by: EFSD
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD OCT
PY 2018
VL 61
SU 1
MA 304
BP S153
EP S154
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA GS3WE
UT WOS:000443556002100
DA 2020-11-26
ER

PT J
AU da Rocha, LKA
   de Barros, SF
   Bandeira, F
   Bollini, A
   Testa, LHD
   Simione, AJ
   Souza, MDE
   Zanetti, LP
   de Oliveira, LCS
   dos Santos, ACF
   de Souza, MP
   Colturado, VAR
   Kalil, J
   Machado, CM
   Guilherme, L
AF da Rocha, Luis Klaus A.
   de Barros, Samar Freschi
   Bandeira, Francine
   Bollini, Alexia
   Testa, Lucia Helena de A.
   Simione, Anderson Joao
   Souza, Marina de O. e
   Zanetti, Lilian P.
   de Oliveira, Leila Cibele S.
   dos Santos, Ana Claudia F.
   de Souza, Mair Pedro
   Colturado, Vergilio Antonio R.
   Kalil, Jorge
   Machado, Clarisse M.
   Guilherme, Luiza
TI Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE T-cell receptor excision circles; T-cell receptor gene; autologous
   hematopoietic stem cell transplantation; allogeneic hematopoietic stem
   cell transplantation; malignant hematological diseases; immune
   reconstitution; thymopoiesis; adaptive immune system
ID RECEPTOR EXCISION CIRCLES; POLYMERASE-CHAIN-REACTION; RECENT THYMIC
   EMIGRANTS; AGE ESTIMATION; BLOOD; TRECS; QUANTIFICATION; ADULT
AB Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function is needed to support the immune system. One way to measure thymic function is through T-cell receptor excision circle (TREC) quantification. TRECs are generated by T-cell receptor gene rearrangements during T-cell maturation in the thymus and represent a reliable marker for thymic output. In this study, we aimed to assess aging and malignant hematological diseases as two important factors that may influence thymic output before HSCT. We observed that patients before HSCT presented signal joint TREC (sjTREC) numbers lower than 606.55 copies/mu g DNA (low values) compared with healthy individuals, with an odds ratio (OR) of 12.88 [95% confidence interval (CI): 5.26-31.53; p < 0.001]. Our results showed that a group of older individuals (>= 50 years old), comprising both healthy individuals and patients, had an OR of 10.07 (95% CI: 2.80-36.20) for low sjTREC values compared with younger individuals (<= 24 years old; p < 0.001). Multiple logistic regression analysis confirmed that both older age (>= 50 years old) and malignant hematological diseases and their treatments were important and independent risk factors related to thymic function impairment (p < 0.001). The median sjTREC value for patients of all ages was significantly lower than the sjTREC median for the subgroup of older healthy individuals (>= 50 years old; p < 0.001). These data suggested that patients before HSCT and healthy individuals exhibited age-dependent thymic impairment, and that prior treatment for hematological diseases may exacerbate aging-related deterioration of natural thymic function. Furthermore, we analyzed these patients 9 months post-HSCT and compared patients who underwent autologous HSCT with those who underwent allogeneic HSCT. Both groups of patients achieved sjTREC copy numbers similar to those of healthy individuals. We did not find a close relationship between impaired thymic function prior to HSCT and worse thymic recovery after HSCT.
C1 [da Rocha, Luis Klaus A.; de Barros, Samar Freschi; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Heart Inst InCor, Clin Hosp, Lab Immunol, Sao Paulo, Brazil.
   [Bandeira, Francine; Bollini, Alexia; Testa, Lucia Helena de A.; Simione, Anderson Joao; Souza, Marina de O. e; Zanetti, Lilian P.; de Oliveira, Leila Cibele S.; dos Santos, Ana Claudia F.; de Souza, Mair Pedro; Colturado, Vergilio Antonio R.] Amaral Carvalho Hosp, Hematopoiet Stem Cell Transplantat Sect, Jau, Brazil.
   [Machado, Clarisse M.] Univ Sao Paulo, Trop Med Inst IMT, Lab Virol, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Heart Inst InCor, Clin Hosp, Lab Immunol, Sao Paulo, Brazil.
EM luizagui@usp.br
RI de Barros, Samar Freschi/Q-4970-2018
OI Simione, Anderson/0000-0002-6939-906X; Alves da Rocha, Luis
   Klaus/0000-0003-1903-1985
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/02879-2]
FX We thank the medical, nursing, laboratory, and administrative staff of
   Amaral Carvalho Hospital, Jau, the medical and nursing staff of the
   blood transfusion service COLSAN (Beneficial Blood Collection
   Association), Sao Paulo, and the Laboratory of Immunology of Heart
   Institute (InCor), Sao Paulo, Brazil. This study was supported by grants
   (2014/02879-2) from the Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP).
CR Al-Harthi L, 2000, J IMMUNOL METHODS, V237, P187, DOI 10.1016/S0022-1759(00)00136-8
   Atschekzei F, 2016, INT ARCH ALLERGY IMM, V171, P136, DOI 10.1159/000450950
   Benjamin CL, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88787
   Cho S, 2017, INT J LEGAL MED, V131, P1061, DOI 10.1007/s00414-017-1540-7
   Cho S, 2014, LEGAL MED-TOKYO, V16, P135, DOI 10.1016/j.legalmed.2014.01.009
   Clave E, 2005, BLOOD, V105, P2608, DOI 10.1182/blood-2004-04-1667
   Clave E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00054
   CLOT J, 1978, CLIN EXP IMMUNOL, V32, P346
   Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374
   Douek DC, 2000, VACCINE, V18, P1638, DOI 10.1016/S0264-410X(99)00499-5
   Dworacki G, 2015, IMMUNOLOGY, V146, P456, DOI 10.1111/imm.12522
   ELLIOTT JF, 1988, NATURE, V331, P627
   Gaballa A, 2018, BONE MARROW TRANSPL, V53, P69, DOI 10.1038/bmt.2017.216
   Gaballa A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101705
   Geenen V, 2003, J ENDOCRINOL, V176, P305, DOI 10.1677/joe.0.1760305
   Haining WN, 2005, BLOOD, V106, P1749, DOI 10.1182/blood-2005-03-1082
   Hisazumi R, 2016, VET IMMUNOL IMMUNOP, V169, P74, DOI 10.1016/j.vetimm.2015.12.009
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   HULSTAERT F, 1994, CLIN IMMUNOL IMMUNOP, V70, P152, DOI 10.1006/clin.1994.1023
   Ibrahim SF, 2016, J FORENSIC SCI, V61, P1107, DOI 10.1111/1556-4029.12988
   Ito G, 2015, VET IMMUNOL IMMUNOP, V166, P1, DOI 10.1016/j.vetimm.2015.05.003
   Kirkwood BR, 2006, ESSENTIAL MED STAT
   Li YQ, 2009, CANCER IMMUNOL IMMUN, V58, P1047, DOI 10.1007/s00262-008-0621-3
   Morgun A, 2004, J CLIN IMMUNOL, V24, P612, DOI 10.1007/s10875-004-6246-1
   MyTRECKit, 2017, MYTREC REAL TIM QPCR
   Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446
   Palmer DB, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00316
   Poulin JF, 2003, BLOOD, V102, P4600, DOI 10.1182/blood-2003-05-1428
   QIAamp, 2012, QIAMP DNA MIN BLOOD
   Ringhoffer S, 2013, HAEMATOLOGICA, V98, P1600, DOI 10.3324/haematol.2012.072264
   Serana F, 2011, J CLIN IMMUNOL, V31, P540, DOI 10.1007/s10875-011-9526-6
   Steffens CM, 2000, CLIN IMMUNOL, V97, P95, DOI 10.1006/clim.2000.4938
   Sun DP, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00654
   Svaldi M, 2003, BRIT J HAEMATOL, V122, P795, DOI 10.1046/j.1365-2141.2003.04482.x
   Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x
   Wilson K, 2018, HUM VACC IMMUNOTHER, V14, P1378, DOI 10.1080/21645515.2018.1433971
   Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725
   Zhang SL, 2012, IMMUNITY, V36, P163, DOI 10.1016/j.immuni.2012.02.005
NR 38
TC 4
Z9 4
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 7
PY 2018
VL 9
AR 1889
DI 10.3389/fimmu.2018.01889
PG 13
WC Immunology
SC Immunology
GA GS9OM
UT WOS:000444050000001
PM 30245685
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rodrigues, AT
   Ramanholo, BS
   Brugnolli, RM
   Neto, EC
   Kalil, J
   Galvao, CE
AF Rodrigues, A. T.
   Ramanholo, B. S.
   Brugnolli, R. M.
   Neto, E. C.
   Kalil, J.
   Galvao, C. E.
TI Inflammatory mediators in the nasal lavage of patients with allergic
   rhinitis before and after specific immunotherapy with Dermatophagoides
   pteronyssinus extract after specific nasal challenge
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Rodrigues, A. T.; Ramanholo, B. S.; Brugnolli, R. M.; Neto, E. C.; Kalil, J.; Galvao, C. E.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 0904
BP 488
EP 489
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690403036
DA 2020-11-26
ER

PT J
AU Duarte, RA
   Brugnolli, RM
   De Castro, RB
   Almonfrey, FB
   Kalil, J
   Motta, AA
   Agondi, RC
AF Duarte, R. A.
   Brugnolli, R. M.
   De Castro, R. B.
   Almonfrey, F. B.
   Kalil, J.
   Motta, A. A.
   Agondi, R. C.
TI Clinical features and autoimmunity in patients with dermographic
   urticaria
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Duarte, R. A.; Brugnolli, R. M.; De Castro, R. B.; Almonfrey, F. B.; Kalil, J.; Motta, A. A.; Agondi, R. C.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 1056
BP 553
EP 553
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690403166
DA 2020-11-26
ER

PT J
AU Mouco, CC
   Zanadrea, A
   Kalil, J
   Motta, AA
   Agondi, RC
   Brugnolli, RM
AF Mouco, C. C.
   Zanadrea, A.
   Kalil, J.
   Motta, A. A.
   Agondi, R. C.
   Brugnolli, R. M.
TI Chronic spontaneous urticaria and thyroid autoimmune disease: A follow
   up study of patients with chronic urticaria for 17 years
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Mouco, C. C.; Zanadrea, A.; Kalil, J.; Motta, A. A.; Agondi, R. C.; Brugnolli, R. M.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 1058
BP 554
EP 554
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690403168
DA 2020-11-26
ER

PT J
AU Brugnolli, RM
   Pereira, ARF
   Kalil, J
   Motta, AA
   Aun, MV
   Giavina-Bianchi, P
AF Brugnolli, R. M.
   Pereira, A. R. F.
   Kalil, J.
   Motta, A. A.
   Aun, M., V
   Giavina-Bianchi, P.
TI Case report of severe anaphylaxis induced by morphine and tramadol
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Brugnolli, R. M.; Pereira, A. R. F.; Kalil, J.; Motta, A. A.; Aun, M., V; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014
OI Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 1139
BP 592
EP 592
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690404039
DA 2020-11-26
ER

PT J
AU Brugnolli, RM
   Marques, PQ
   Penido, AP
   Salles, PD
   Barreto, AK
   Grecco, O
   Kalil, J
   Kokron, C
   Barros, MT
AF Brugnolli, R. M.
   Marques, P. Q.
   Penido, A. P.
   Salles, P. D.
   Barreto, A. K.
   Grecco, O.
   Kalil, J.
   Kokron, C.
   Barros, M. T.
TI Reversible secondary hypogammaglobulinemia related to anticonvulsant
   therapy in adult patients: A report of three cases
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Brugnolli, R. M.; Marques, P. Q.; Penido, A. P.; Salles, P. D.; Barreto, A. K.; Grecco, O.; Kalil, J.; Kokron, C.; Barros, M. T.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 1529
BP 766
EP 766
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690405191
DA 2020-11-26
ER

PT J
AU Mouco, CC
   Brugnolli, RM
   De Assis, JP
   Cau, LP
   Grecco, O
   Kalil, J
   Kokron, C
   Barros, MT
   Barreto, AK
AF Mouco, C. C.
   Brugnolli, R. M.
   De Assis, J. P.
   Cau, L. P.
   Grecco, O.
   Kalil, J.
   Kokron, C.
   Barros, M. T.
   Barreto, A. K.
TI Evolution of patients with hypogammaglobulinemia secondary to the use of
   Rituximab accompanied in a tertiary outpatient clinic
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY MAY 26-30, 2018
CL Munich, GERMANY
SP European Acad Allergy & Clin Immunol
C1 [Mouco, C. C.; Brugnolli, R. M.; De Assis, J. P.; Cau, L. P.; Grecco, O.; Kalil, J.; Kokron, C.; Barros, M. T.; Barreto, A. K.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2018
VL 73
SU 105
SI SI
MA 1530
BP 766
EP 766
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GQ5BD
UT WOS:000441690405192
DA 2020-11-26
ER

PT J
AU Garcia, JFB
   Takejima, P
   Veronez, CL
   Aun, MV
   Motta, AA
   Kalil, J
   Pesquero, JB
   Giavina-Bianchi, P
AF Garcia, Juliana F. B.
   Takejima, Priscila
   Veronez, Camila Lopes
   Aun, Marcelo V.
   Motta, Antonio A.
   Kalil, Jorge
   Pesquero, Joao Bosco
   Giavina-Bianchi, Pedro
TI Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy
   in hereditary angioedema with normal C1-INH
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID MANAGEMENT
C1 [Garcia, Juliana F. B.; Takejima, Priscila; Aun, Marcelo V.; Motta, Antonio A.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178 Ap 211A, BR-01454010 Sao Paulo, SP, Brazil.
   [Veronez, Camila Lopes; Pesquero, Joao Bosco] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, SP, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178 Ap 211A, BR-01454010 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI Aun, Marcelo V/E-6775-2014; Veronez, Camila Lopes/O-6134-2015;
   Giavina-Bianchi, Pedro/I-3112-2014
OI Aun, Marcelo V/0000-0001-9882-5200; Veronez, Camila
   Lopes/0000-0001-9565-1911; Giavina-Bianchi, Pedro/0000-0002-1034-7580
FU Shire; CSL Behring
FX J. F. B. Garcia and P. Takejima declare that they have received
   financial support from Shire. P. Giavina-Bianchi and M. V. Aun declare
   that they have received financial support from CSL Behring and Shire.
   The rest of the authors declare that they have no relevant conflicts of
   interest.
CR Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1
   Bork K, 2017, ALLERGY, V72, P320, DOI 10.1111/all.13076
   Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648
   Bouillet L, 2017, EUR J DERMATOL, V27, P155, DOI 10.1684/ejd.2016.2948
   Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380
   Craig T, 2012, WORLD ALLERGY ORGAN, V5, P182, DOI 10.1097/WOX.0b013e318279affa
   Fox J, 2017, ALLERGY ASTHMA PROC, V38, P216, DOI 10.2500/aap.2017.38.4038
   Giavina-Bianchi P, BRAZILIAN GUIDELINES
   Gonzalez-Quevedo T, 2016, J INVEST ALLERG CLIN, V26, P161, DOI 10.18176/jiaci.0037
   Picone O, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/957507
NR 10
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2018
VL 6
IS 4
BP 1406
EP 1408
DI 10.1016/j.jaip.2017.12.022
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA GM1ON
UT WOS:000437838800050
PM 29439936
DA 2020-11-26
ER

PT J
AU Poland, GA
   Kennedy, RB
   Ovsyannikova, IG
   Palacios, R
   Ho, PL
   Kalil, J
AF Poland, Gregory A.
   Kennedy, Richard B.
   Ovsyannikova, Inna G.
   Palacios, Ricardo
   Ho, Paulo Lee
   Kalil, Jorge
TI Development of vaccines against Zika virus
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID ORIGINAL ANTIGENIC SIN; YELLOW-FEVER; WESTERN-HEMISPHERE;
   INFLUENZA-VIRUSES; DENGUE VIRUS; GLIAL-CELLS; INFECTION; TRANSMISSION;
   VACCINATION; ANTIBODIES
AB Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barre syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
C1 [Poland, Gregory A.; Kennedy, Richard B.; Ovsyannikova, Inna G.] Mayo Clin, Vaccine Res Grp, Rochester, MN USA.
   [Palacios, Ricardo; Ho, Paulo Lee] Inst Butantan, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
RP Poland, GA (corresponding author), Mayo Clin, Mayo Vaccine Res Grp, Rochester, MN 55905 USA.
EM poland.gregory@mayo.edu
RI amsalu, ribka/G-8780-2019; Palacios, Ricardo/AAN-7606-2020
OI Palacios, Ricardo/0000-0002-1410-8579
CR ABBASI J, 2016, JAMA J AM MED ASSOC, V316, P1249
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005168
   [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P2588, DOI [10.1001/jama.2016.19328, 10.1001/jama.2016.18655]
   Atkinson B, 2017, EMERG INFECT DIS, V23, P611, DOI 10.3201/eid2304.161692
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Barba-Spaeth G, NW16, V536, P48
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   BRES P, 1970, B WORLD HEALTH ORGAN, V43, P223
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   DARWISH MA, 1983, T ROY SOC TROP MED H, V77, P442, DOI 10.1016/0035-9203(83)90106-2
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2016, SEMIN REPROD MED, V34, P299, DOI 10.1055/s-0036-1592070
   Dyer O, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3588
   Favoretto S, 2016, BIORXIV
   Fernandez E, 2017, CURR OPIN VIROL, V23, P59, DOI 10.1016/j.coviro.2017.03.006
   FILIPE AR, 1973, ARCH GES VIRUSFORSCH, V43, P315, DOI 10.1007/BF01556147
   Fulton TR, 2015, VACCINE, V33, P6453, DOI 10.1016/j.vaccine.2015.08.043
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Gulati U, 2005, VACCINE, V23, P1414, DOI 10.1016/j.vaccine.2004.08.053
   Gulich GA, 2016, J INFECT DIS THER, V4, P278
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Kim E, 2016, EBIOMEDICINE, V13, P315, DOI 10.1016/j.ebiom.2016.09.028
   Kim JH, 2012, P NATL ACAD SCI USA, V109, P13751, DOI 10.1073/pnas.0912458109
   Kim JH, 2009, J IMMUNOL, V183, P3294, DOI 10.4049/jimmunol.0900398
   Kim SY, 2017, BIOCHEMISTRY-US, V56, P1151, DOI 10.1021/acs.biochem.6b01056
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   National Institute of Allergy and Infectious Diseases, 2016, NIH BEG TEST INV ZIK
   OLSON JG, 1983, ANN TROP MED PARASIT, V77, P131, DOI 10.1080/00034983.1983.11811687
   Omer SB, 2016, JAMA-J AM MED ASSOC, V315, P1227, DOI 10.1001/jama.2016.2237
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Palacios R, 2016, VACCINE, V34, P2291, DOI 10.1016/j.vaccine.2016.03.059
   Panchaud A, 2016, CLIN MICROBIOL REV, V29, P659, DOI 10.1128/CMR.00014-16
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Plotkin SA, 2015, NEW ENGL J MED, V373, P297, DOI 10.1056/NEJMp1506820
   Prasad VM, 2017, NAT STRUCT MOL BIOL, V24, P184, DOI 10.1038/nsmb.3352
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rodriguez-Morales AJ, 2016, TRAVEL MED INFECT DI, V14, P177, DOI 10.1016/j.tmaid.2016.05.004
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Roze B, 2016, EUROSURVEILLANCE, P21, DOI DOI 10.28707/1560-7917.ES.2016.21.9.30154
   SALUZZO JF, 1982, B SOC PATHOL EXOT, V75, P262
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Shuaib W, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.02.027
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Tripp RA, 2016, EXPERT REV VACCINES, V15, P1083, DOI 10.1080/14760584.2016.1192474
   Vannice KS, 2019, VACCINE, V37, P7443, DOI 10.1016/j.vaccine.2016.10.034
   Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014
   White MK, 2016, ANN NEUROL, V80, P479, DOI 10.1002/ana.24748
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   World Health Organization, 2017, ZIK SIT REP ZIK VIR
   World Health Organization, 2016, CURR ZIK PROD PIP
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   Yi GH, 2017, EBIOMEDICINE, V25, P87, DOI 10.1016/j.ebiom.2017.10.006
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 81
TC 52
Z9 52
U1 0
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2018
VL 18
IS 7
BP E211
EP E219
DI 10.1016/S1473-3099(18)30063-X
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA GL0QI
UT WOS:000436794600003
PM 29396004
OA Bronze
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Andrade, MC
   Takejima, P
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana Camara
   Andrade, Mayra Coutinho
   Takejima, Priscila
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Atopy Is Associated with Age at Asthma Onset in Elderly Patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Asthma; Allergic asthma; Elderly; Aeroallergens; Atopy; IgE; Asthma-COPD
   overlap syndrome (ACOS); Age of asthma onset
ID GASTROESOPHAGEAL-REFLUX DISEASE; COPD OVERLAP SYNDROME; ADULTS; OLDER;
   SENSITIZATION; DEFINITION; PREVALENCE; MANAGEMENT; DIAGNOSIS; ALLERGENS
AB BACKGROUND: Asthma in the elderly population (60 years of age and older) is frequently underdiagnosed, as well as atopy. Atopy, although more prevalent in younger patients, can be a major cause of asthma in the elderly. Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are common differential diagnoses, especially in elderly smokers.
   OBJECTIVE: The objective of this study was to assess atopy and comorbidities in elderly patients with asthma.
   METHODS: This was an observational and retrospective study involving elderly asthmatic patients followed up at a tertiary center. Patients were assessed for severity of asthma, frequency of atopy, and frequency of comorbidities concomitant with asthma. Then, they were classified according to their age at asthma onset and the groups compared with each other for atopy, spirometric parameters, and comorbidities.
   RESULTS: This study included 243 elderly asthmatic patients, 71.8% of them presenting severe disease and 82.3% forced expiratory volume in 1 second (FENT]) < 80%. Gastroesophageal reflux disease, obesity, and asthma-COPD overlap syndrome were observed, respectively, in 64%, 37%, and 13% of these patients. Atopy was observed in 63%, mainly in those with early onset disease, and its frequency decreased as the age of asthma onset increased (P <.05). Total serum IgE was higher for allergic patients and FEVI values were lower for patients with long-term asthma. Aspirin-exacerbated respiratory disease was more frequent in patients with nonallergic asthma.
   CONCLUSIONS: Most elderly asthmatic patients followed up in our tertiary center were atopic and higher values of total serum IgE suggest atopy. Atopy was inversely correlated with age of asthma onset. The diagnosis of allergic asthma in the elderly population is essential to treat patients more properly, improving their quality of life and decreasing asthma morbidity and mortality. (C) 2017 American Academy of Allergy, Asthma & Immunology
C1 [Agondi, Rosana Camara; Kalil, Jorge] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol LIM19, Sao Paulo, Brazil.
   [Agondi, Rosana Camara; Andrade, Mayra Coutinho; Takejima, Priscila; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Rua Bage 100,Apto 152, BR-04012140 Sao Paulo, Brazil.
RP Agondi, RC (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Rua Bage 100,Apto 152, BR-04012140 Sao Paulo, Brazil.
EM ragondi@gmail.com
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   Agondi, Rosana Camara/0000-0002-0503-5179
CR Agondi RC, 2012, CLIN EXP ALLERGY, V42, P1183, DOI 10.1111/j.1365-2222.2011.03951.x
   Al-Alawi M, 2014, AM J MED, V127, P370, DOI 10.1016/j.amjmed.2013.12.013
   Battaglia S, 2016, BREATHE, V12, P19, DOI 10.1183/20734735.002816
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   Bondy SJ, 2013, NICOTINE TOB RES, V15, P1201, DOI 10.1093/ntr/nts259
   Bonten TN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02008-2016
   Bozek A, 2015, ANN ALLERG ASTHMA IM, V114, P199, DOI 10.1016/j.anai.2014.12.013
   Brar T, 2012, CURR OPIN PULM MED, V18, P14, DOI 10.1097/MCP.0b013e32834dccc0
   BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935
   BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H
   Busse PJ, 2013, ANN ALLERG ASTHMA IM, V110, P247, DOI 10.1016/j.anai.2013.01.016
   Busse PJ, 2010, J ALLERGY CLIN IMMUN, V126, P690, DOI 10.1016/j.jaci.2010.08.011
   Diaz-Guzman E, 2010, J ALLERGY CLIN IMMUN, V126, P702, DOI 10.1016/j.jaci.2010.08.022
   Ding B, 2016, EXPERT REV RESP MED, V10, P363, DOI 10.1586/17476348.2016.1144476
   Forno E, 2015, THORAX, V70, P898, DOI 10.1136/thoraxjnl-2015-207199
   Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204
   Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN
   Haahtela T, 2014, CLIN EXP ALLERGY, V44, P407, DOI 10.1111/cea.12240
   Hanania NA, 2011, J ALLERGY CLIN IMMUN, V128, pS4, DOI 10.1016/j.jaci.2011.06.048
   Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x
   Hirose K, 2017, IMMUNOL REV, V278, P145, DOI 10.1111/imr.12540
   Holgate ST, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.25
   IBGE, EST PROJ POP
   Soler-Cataluna JJ, 2012, ARCH BRONCONEUMOL, V48, P331, DOI 10.1016/j.arbres.2011.12.009
   Kankaanranta H, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3690628
   Kumbhare S, 2016, ANN AM THORAC SOC, V13, P803, DOI 10.1513/AnnalsATS.201508-554OC
   MALLING HJ, 1984, ALLERGY, V39, P596, DOI 10.1111/j.1398-9995.1984.tb01979.x
   Mathur SK, 2010, SEMIN RESP CRIT CARE, V31, P587, DOI 10.1055/s-0030-1265899
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041
   de Oca MM, 2017, RESP CARE, V62, P1058, DOI 10.4187/respcare.05440
   Nielsen M, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S85363
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Platts-Mills T, 2007, AM FAM PHYSICIAN, V76, P675
   Postma DS, 2014, CLIN CHEST MED, V35, P143, DOI 10.1016/j.ccm.2013.09.010
   Salvi S, 2014, CLIN CHEST MED, V35, P17, DOI 10.1016/j.ccm.2013.09.011
   Scichilone N, 2014, EUR J INTERN MED, V25, P336, DOI 10.1016/j.ejim.2014.01.004
   Scichilone N, 2011, RESP MED, V105, P651, DOI 10.1016/j.rmed.2010.12.014
   Sin DD, 2016, EUR RESPIR J, V48, P664, DOI 10.1183/13993003.00436-2016
   Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x
   van Boven JFM, 2016, CHEST, V149, P1011, DOI 10.1016/j.chest.2015.12.002
   Yanez A, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-8
   Zeki Amir A, 2011, J Allergy (Cairo), V2011, P861926, DOI 10.1155/2011/861926
NR 44
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAY-JUN
PY 2018
VL 6
IS 3
BP 865
EP 871
DI 10.1016/j.jaip.2017.10.028
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA GG1QN
UT WOS:000432461800024
PM 29175370
DA 2020-11-26
ER

PT J
AU Caires, LC
   Goulart, E
   Melo, US
   Araujo, BHS
   Alvizi, L
   Soares-Schanoski, A
   de Oliveira, DF
   Kobayashi, GS
   Griesi-Oliveira, K
   Musso, CM
   Amaral, MS
   daSilva, LF
   Astray, RM
   Suarez-Patino, SF
   Ventini, DC
   da Silva, SG
   Yamamoto, GL
   Ezquina, S
   Naslavsky, MS
   Telles-Silva, KA
   Weinmann, K
   van der Linden, V
   van der Linden, H
   de Oliveira, JRM
   Arrais, NMR
   Melo, A
   Figueiredo, T
   Santos, S
   Meira, JGC
   Passos, SD
   de Almeida, RP
   Bispo, AJB
   Cavalheiro, EA
   Kalil, J
   Cunha-Neto, E
   Nakaya, H
   Andreata-Santos, R
   Ferreira, LCD
   Verjovski-Almeida, S
   Ho, PL
   Passos-Bueno, MR
   Zatz, M
AF Caires-Junior, Luiz Carlos
   Goulart, Ernesto
   Melo, Uira Souto
   Silva Araujo, Bruno Henrique
   Alvizi, Lucas
   Soares-Schanoski, Alessandra
   de Oliveira, Danyllo Felipe
   Kobayashi, Gerson Shigeru
   Griesi-Oliveira, Karina
   Musso, Camila Manso
   Amaral, Murilo Sena
   daSilva, Lucas Ferreira
   Astray, Renato Mancini
   Suarez-Patino, Sandra Fernanda
   Ventini, Daniella Cristina
   da Silva, Sergio Gomes
   Yamamoto, Guilherme Lopes
   Ezquina, Suzana
   Naslavsky, Michel Satya
   Telles-Silva, Kayque Alves
   Weinmann, Karina
   van der Linden, Vanessa
   van der Linden, Helio
   Mendes de Oliveira, Joao Ricardo
   Rodrigues Arrais, Nivia Maria
   Melo, Adriana
   Figueiredo, Thalita
   Santos, Silvana
   Castro Meira, Joanna Goes
   Passos, Saulo Duarte
   de Almeida, Roque Pacheco
   Barreto Bispo, Ana Jovina
   Cavalheiro, Esper Abrao
   Kalil, Jorge
   Cunha-Neto, Edecio
   Nakaya, Helder
   Andreata-Santos, Robert
   de Souza Ferreira, Luis Carlos
   Verjovski-Almeida, Sergio
   Ho, Paulo Lee
   Passos-Bueno, Maria Rita
   Zatz, Mayana
TI Discordant congenital Zika syndrome twins show differential in vitro
   viral susceptibility of neural progenitor cells (vol 9, 2018)
SO NATURE COMMUNICATIONS
LA English
DT Correction
C1 [Caires-Junior, Luiz Carlos; Goulart, Ernesto; Melo, Uira Souto; Alvizi, Lucas; de Oliveira, Danyllo Felipe; Kobayashi, Gerson Shigeru; Griesi-Oliveira, Karina; Musso, Camila Manso; Yamamoto, Guilherme Lopes; Ezquina, Suzana; Naslavsky, Michel Satya; Telles-Silva, Kayque Alves; Weinmann, Karina; Figueiredo, Thalita; Passos-Bueno, Maria Rita; Zatz, Mayana] Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
   [Silva Araujo, Bruno Henrique] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.
   [Silva Araujo, Bruno Henrique; Cavalheiro, Esper Abrao] Fed Univ Sao Paulo UNIFESP, EPM, Dept Neurol & Neurosurg, Neurosci Lab, BR-04039002 Sao Paulo, SP, Brazil.
   [Soares-Schanoski, Alessandra; Amaral, Murilo Sena; Astray, Renato Mancini; Suarez-Patino, Sandra Fernanda; Ventini, Daniella Cristina; Kalil, Jorge; Verjovski-Almeida, Sergio; Ho, Paulo Lee] Butantan Inst, BR-05503900 Sao Paulo, SP, Brazil.
   [Griesi-Oliveira, Karina; da Silva, Sergio Gomes] Albert Einstein Hosp, BR-05652900 Sao Paulo, SP, Brazil.
   [daSilva, Lucas Ferreira; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, SP, Brazil.
   [da Silva, Sergio Gomes] Univ Mogi das Cruzes, BR-08780911 Mogi Das Cruzes, SP, Brazil.
   [van der Linden, Vanessa] AACD, BR-50080810 Recife, PE, Brazil.
   [van der Linden, Helio] Rehabil Ctr Dr Henrique Santillo, BR-74653230 Goiania, Go, Brazil.
   [Mendes de Oliveira, Joao Ricardo] Fed Univ Pernambuco UFPE, Neuropsychiat Dept, BR-50670901 Recife, PE, Brazil.
   [Mendes de Oliveira, Joao Ricardo] Fed Univ Pernambuco UFPE, KeizoAsami Lab, BR-50670901 Recife, PE, Brazil.
   [Rodrigues Arrais, Nivia Maria] Fed Univ Rio Grande do Norte UFRN, Dept Pediat, BR-59010180 Natal, RN, Brazil.
   [Melo, Adriana] ISEA, BR-58400220 Campina Grande, PB, Brazil.
   [Santos, Silvana] Paraiba State Univ UEPB, Dept Biol, BR-58429500 Campina Grande, PB, Brazil.
   [Castro Meira, Joanna Goes] Fed Univ Bahia UFBA, BR-40170115 Salvador, BA, Brazil.
   [Passos, Saulo Duarte] Med Sch Jundiai, Infect Pediat Lab, BR-40170115 Jundiai, SP, Brazil.
   [de Almeida, Roque Pacheco; Barreto Bispo, Ana Jovina] Fed Univ Sergipe UFS, Div Immunol, BR-49100000 Aracaju, SP, Brazil.
   [de Almeida, Roque Pacheco; Barreto Bispo, Ana Jovina] Fed Univ Sergipe UFS, Mol Biol Lab, BR-49100000 Aracaju, SP, Brazil.
   [Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Heart Inst, BR-05403900 Sao Paulo, SP, Brazil.
   [Nakaya, Helder] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508900 Sao Paulo, SP, Brazil.
   [Andreata-Santos, Robert; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Vaccine Dev Lab, BR-05508900 Sao Paulo, SP, Brazil.
RP Zatz, M (corresponding author), Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
EM mayazatz@usp.br
RI Zatz, Mayana/M-5338-2015; Amaral, Murilo S/G-5769-2013; Melo, Adriana S
   O/H-5650-2016; Kobayashi, Gerson Shigeru/AAB-9113-2019; Goulart,
   Ernesto/AAC-3713-2020; Kobayashi, Gerson/H-4017-2013; KALIL,
   JORGE/C-8029-2012; Verjovski-Almeida, Sergio/E-4082-2012; Passos-Bueno,
   Maria Rita/I-6796-2016; Nakaya, Helder/AAF-1738-2020; Cunha-Neto,
   Edecio/B-4157-2009; Schanoski, Alessandra/H-8144-2014; Cavalheiro,
   Esper/I-3084-2016; Naslavsky, Michel/L-1772-2015
OI Zatz, Mayana/0000-0003-3970-8025; Kobayashi, Gerson
   Shigeru/0000-0002-6520-5774; Kobayashi, Gerson/0000-0002-6520-5774;
   KALIL, JORGE/0000-0001-8415-4274; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Passos-Bueno, Maria
   Rita/0000-0002-9248-3008; Nakaya, Helder/0000-0001-5297-9108;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Schanoski,
   Alessandra/0000-0002-6514-8458; Cavalheiro, Esper/0000-0002-0854-3582;
   Goulart, Ernesto/0000-0001-9526-8701; Naslavsky,
   Michel/0000-0002-9068-1713; Santos, Silvana/0000-0002-5252-0206
FU CAPESCAPES; DECIT-MS
FX Financial support from CAPES and DECIT-MS
CR CAIRESJUNIOR LC, 2018, NAT COMM, V0009
NR 1
TC 5
Z9 5
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 13
PY 2018
VL 9
AR 1114
DI 10.1038/s41467-018-03497-1
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ0HK
UT WOS:000427248800003
PM 29535311
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Barbosa, AC
   Castro, FM
   Meireles, PR
   Arruda, LK
   Cardoso, SR
   Kalil, J
   Yang, AC
AF Barbosa, Adriana C.
   Castro, Fabio Morato
   Meireles, Paula Rezende
   Karla Arruda, L.
   Cardoso, Silvia Regina
   Kalil, Jorge
   Yang, Ariana C.
TI Eosinophilic Esophagitis: Latent Disease in Patients with Anaphylactic
   Reaction to Cow's Milk
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Anaphylaxis; Milk hypersensitivity; Food hypersensitivity; Eosinophilia;
   Eosinophils; Eosinophilic esophagitis; Esophagus
ID ORAL IMMUNOTHERAPY; FOOD ALLERGY; DIAGNOSIS; PREVALENCE; DYSPHAGIA;
   CHILDREN; DELAY; RISK
AB BACKGROUND: Food allergy and eosinophilic esophagitis are a substantial and evolving public health issue. Clinicians should know the relationship between these diseases and how one may predispose to the other. This can help minimize misdiagnosis.
   OBJECTIVE: The objective of this study was to assess esophageal eosinophilia and eosinophilic esophagitis frequency in patients with persistent cow's milk allergy and anaphylaxis manifestations.
   METHODS: Patients with persistent cow's milk allergy with anaphylaxis manifestations were enrolled from 2012 through 2016 at the Sao Paulo University Hospital, Brazil. All of them were submitted to endoscopy despite the presence or absence of gastrointestinal symptoms. Demographics data, atopic comorbidities, medication use, endoscopic findings, and esophageal eosinophilia frequency were evaluated.
   RESULTS: Eighty-nine patients were selected. The median age was 8 years. It was observed that 34 of 89 patients (38.2%; 95% confidence interval [CI]: 28.14%-49.16%) presented with esophageal eosinophilia. Five patients (7.1%) presented proton pump inhibitor-responsive esophageal eosinophilia, and 10 patients (14.2%) presented eosinophilic esophagitis. We found that 29.4% were asymptomatic patients, 23.5% had nonspecific symptoms, 23.5% had persistent typical symptoms, and 23.5% had intermittent typical symptoms. There was an association with inflammatory endoscopy findings in 21 patients (61.7%).
   CONCLUSIONS: This description demands scientific attention because it is the highest frequency of esophageal eosinophilia yet described in a group of patients with cow's milk allergy presenting with anaphylaxis. Eosinophilic esophagitis is a condition that can coexist "silently" with an IgE-mediated food allergy and is most often underestimated and under-diagnosed. (C) 2017 American Academy of Allergy, Asthma & Immunology
C1 [Barbosa, Adriana C.; Castro, Fabio Morato; Meireles, Paula Rezende; Kalil, Jorge; Yang, Ariana C.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Rua Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, Brazil.
   [Karla Arruda, L.] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil.
   [Cardoso, Silvia Regina] Univ Sao Paulo, Div Endoscopy, Sao Paulo, Brazil.
RP Barbosa, AC (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Rua Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, Brazil.
EM adriana.marcia.barbosa@gmail.com
RI Arruda, L. Karla/D-5845-2013; Castro, Fabio/AAP-5433-2020; KALIL,
   JORGE/C-8029-2012
OI Arruda, L. Karla/0000-0002-7505-210X; KALIL, JORGE/0000-0001-8415-4274
FU Sao Paulo State Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)
FX J. Kalil and F. M. Castro are supported by a research grant to the
   Institute of Immunology Research (III-Instituto de Investigacao em
   Imunologia) from the Sao Paulo State Research Foundation (FAPESP).
CR Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044
   ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781
   De la Cruz-Patino E, 2015, DIS ESOPHAGUS, V28, P524, DOI 10.1111/dote.12238
   Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71
   Dellon ES, 2012, CLIN GASTROENTEROL H, V10, P1066, DOI 10.1016/j.cgh.2012.06.003
   Hill DA, 2016, J ALLERGY CLIN IMMUN, V5, P369
   Hill DA, 2015, J ALLER CL IMM-PRACT, V3, P123, DOI 10.1016/j.jaip.2014.08.005
   Hochwallner H, 2014, METHODS, V66, P22, DOI 10.1016/j.ymeth.2013.08.005
   Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2
   Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040
   Lipka S, 2016, J CLIN GASTROENTEROL, V50, P134, DOI 10.1097/MCG.0000000000000297
   Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004
   Maggadottir SM, 2014, J ALLERGY CLIN IMMUN, V133, P1487, DOI 10.1016/j.jaci.2014.02.004
   Merves J, 2014, ANN ALLERG ASTHMA IM, V112, P397, DOI 10.1016/j.anai.2014.01.023
   Molina-Infante J, 2014, ALIMENT PHARM THER, V40, P955, DOI 10.1111/apt.12914
   Muller S, 2007, ENDOSCOPY, V39, P339, DOI 10.1055/s-2007-966216
   Prasad GA, 2007, AM J GASTROENTEROL, V102, P2627, DOI 10.1111/j.1572-0241.2007.01512.x
   Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010
   Rocha R, 2011, EUR J PEDIATR, V170, P1471, DOI 10.1007/s00431-011-1540-4
   Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002
   Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042
   Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015
   Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037
   Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846
   Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282
   Sugnanam KKN, 2007, ALLERGY, V62, P1257, DOI 10.1111/j.1398-9995.2007.01454.x
   Veerappan GR, 2009, CLIN GASTROENTEROL H, V7, P420, DOI 10.1016/j.cgh.2008.10.009
   Warners MJ, 2015, EUR J GASTROEN HEPAT, V27, P506, DOI 10.1097/MEG.0000000000000331
   Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043
NR 29
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAR-APR
PY 2018
VL 6
IS 2
BP 451
EP +
DI 10.1016/j.jaip.2017.04.037
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA FZ4NF
UT WOS:000427568200016
PM 28566137
DA 2020-11-26
ER

PT J
AU de Caires, LC
   Goulart, E
   Melo, U
   Araujo, BSH
   Alvizi, L
   Schanoski, AS
   de Oliveira, DF
   Kobayashi, GS
   Griesi-Oliveira, K
   Musso, CM
   Amaral, M
   dasilva, LF
   Astray, RM
   Suarez-Patino, SF
   Ventini, DC
   da Silva, SG
   Yamamoto, GL
   Ezquina, S
   Naslavsky, MS
   Silva, KTA
   Weinmann, K
   Van der Linden, V
   Van der Linden, H
   de Oliveira, JMR
   Arrais, NRM
   Melo, A
   Figueiredo, T
   Santos, S
   Meira, JCG
   Passos, SD
   de Almeida, RP
   Bispo, AJ
   Cavalheiro, E
   Kalil, J
   Cunha-Neto, E
   Nakaya, H
   Santos, RA
   Ferreira, LCD
   Verjovski-Almeida, S
   Ho, PL
   Passos-Bueno, MR
   Zatz, M
AF de Caires, Luiz Carlos, Jr.
   Goulart, Ernesto
   Melo, UiraSouto
   Henrique Araujo, Bruno Silva
   Alvizi, Lucas
   Schanoski, Alessandra Soares
   de Oliveira, Danyllo Felipe
   Kobayashi, Gerson Shigeru
   Griesi-Oliveira, Karina
   Musso, Camila Manso
   Amaral, MuriloSena
   dasilva, Lucas Ferreira
   Astray, Renato Mancini
   Suarez-Patino, Sandra Fernanda
   Ventini, Daniella Cristina
   da Silva, Sergio Gomes
   Yamamoto, Guilherme Lopes
   Ezquina, Suzana
   Naslavsky, Michel Satya
   Alves Silva, Kayque Telles
   Weinmann, Karina
   Van der Linden, Vanessa
   Van der Linden, Helio
   Ricardo de Oliveira, Joao Mendes
   Maria Arrais, Nivia Rodrigues
   Melo, Adriana
   Figueiredo, Thalita
   Santos, Silvana
   Goes Meira, Joanna Castro
   Passos, Saulo Duarte
   de Almeida, Roque Pacheco
   Bispo, Ana JovinaBarreto
   Cavalheiro, EsperAbrao
   Kalil, Jorge
   Cunha-Neto, Edecio
   Nakaya, Helder
   Santos, Robert Andreata
   de Souza Ferreira, Luis Carlos
   Verjovski-Almeida, Sergio
   Ho, Paulo Lee
   Passos-Bueno, Maria Rita
   Zatz, Mayana
TI Discordant congenital Zika syndrome twins show differential in vitro
   viral susceptibility of neural progenitor cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID VIRUS-INFECTION; STEM-CELLS; MENTAL-RETARDATION; GENETIC-VARIANTS;
   SEQUENCING DATA; ASSOCIATION; IDENTIFICATION; FLAVIVIRUSES; INTEGRATION;
   EXPRESSION
AB Congenital Zika syndrome (CZS) causes early brain development impairment by affecting neural progenitor cells (NPCs). Here, we analyze NPCs from three pairs of dizygotic twins discordant for CZS. We compare by RNA-Seq the NPCs derived from CZS-affected and CZS-unaffected twins. Prior to Zika virus (ZIKV) infection the NPCs from CZS babies show a significantly different gene expression signature of mTOR and Wnt pathway regulators, key to a neurodevelopmental program. Following ZIKV in vitro infection, cells from affected individuals have significantly higher ZIKV replication and reduced cell growth. Whole-exome analysis in 18 affected CZS babies as compared to 5 unaffected twins and 609 controls excludes a monogenic model to explain resistance or increased susceptibility to CZS development. Overall, our results indicate that CZS is not a stochastic event and depends on NPC intrinsic susceptibility, possibly related to oligogenic and/or epigenetic mechanisms.
C1 [de Caires, Luiz Carlos, Jr.; Goulart, Ernesto; Melo, UiraSouto; Alvizi, Lucas; de Oliveira, Danyllo Felipe; Kobayashi, Gerson Shigeru; Griesi-Oliveira, Karina; Musso, Camila Manso; Yamamoto, Guilherme Lopes; Ezquina, Suzana; Naslavsky, Michel Satya; Alves Silva, Kayque Telles; Weinmann, Karina; Figueiredo, Thalita; Passos-Bueno, Maria Rita; Zatz, Mayana] Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
   [Henrique Araujo, Bruno Silva] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.
   [Henrique Araujo, Bruno Silva; Cavalheiro, EsperAbrao] Fed Univ Sao Paulo Univ UNIFESP EPM, Dept Neurol & Neurosurg, Neurosci Lab, BR-04039002 Sao Paulo, SP, Brazil.
   [Schanoski, Alessandra Soares; Amaral, MuriloSena; Astray, Renato Mancini; Suarez-Patino, Sandra Fernanda; Ventini, Daniella Cristina; Kalil, Jorge; Verjovski-Almeida, Sergio; Ho, Paulo Lee] Butantan Inst, BR-05503900 Sao Paulo, SP, Brazil.
   [Griesi-Oliveira, Karina; da Silva, Sergio Gomes] Albert Einstein Hosp, BR-05652900 Sao Paulo, SP, Brazil.
   [dasilva, Lucas Ferreira; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, SP, Brazil.
   [da Silva, Sergio Gomes] Univ Mogi das Cruzes, BR-08780911 Mogi Das Cruzes, SP, Brazil.
   [Van der Linden, Vanessa] AACD, BR-50080810 Recife, PE, Brazil.
   [Van der Linden, Helio] Rehabil Ctr Dr Henrique Santillo, BR-74653230 Goiania, Go, Brazil.
   [Ricardo de Oliveira, Joao Mendes] Fed Univ Pernambuco UFPE, Neuropsychiat Dept, BR-50670901 Recife, PE, Brazil.
   [Ricardo de Oliveira, Joao Mendes] Fed Univ Pernambuco UFPE, KeizoAsami Lab, BR-50670901 Recife, PE, Brazil.
   [Maria Arrais, Nivia Rodrigues] Fed Univ Rio Grande Norte UFRN, Dept Pediat, BR-59010180 Natal, RN, Brazil.
   [Melo, Adriana] ISEA, BR-58400220 Campina Grande, PB, Brazil.
   [Figueiredo, Thalita] Paraiba State Univ UEPB, Dept Biol, BR-58429500 Campina Grande, PB, Brazil.
   [Goes Meira, Joanna Castro] Fed Univ Bahia UFBA, BR-40170115 Salvador, BA, Brazil.
   [Passos, Saulo Duarte] Med Sch Jundiai, Infect Pediat Lab, BR-13202550 Jundiai, SP, Brazil.
   [de Almeida, Roque Pacheco; Bispo, Ana JovinaBarreto] Fed Univ Sergipe UFS, Div Immunol, BR-49100000 Aracaju, SP, Brazil.
   [de Almeida, Roque Pacheco; Bispo, Ana JovinaBarreto] Fed Univ Sergipe UFS, Mol Biol Lab, BR-49100000 Aracaju, SP, Brazil.
   [Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Heart Inst, BR-05403900 Sao Paulo, SP, Brazil.
   [Nakaya, Helder] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508900 Sao Paulo, SP, Brazil.
   [Santos, Robert Andreata; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Vaccine Dev Lab, BR-05508900 Sao Paulo, SP, Brazil.
RP Zatz, M (corresponding author), Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
EM mayazatz@usp.br
RI Araujo, Bruno/P-9975-2019; Schanoski, Alessandra/H-8144-2014; Melo,
   Adriana S O/H-5650-2016; Goulart, Ernesto/AAC-3713-2020; Kobayashi,
   Gerson/H-4017-2013; Cunha-Neto, Edecio/B-4157-2009; Naslavsky,
   Michel/U-6595-2019; Astray, Renato Mancini/N-6627-2013;
   Verjovski-Almeida, Sergio/AAI-2728-2020; Kobayashi, Gerson
   Shigeru/AAB-9113-2019; KALIL, JORGE/C-8029-2012; Nakaya,
   Helder/AAF-1738-2020; Amaral, Murilo S/G-5769-2013; da Silva, Sergio
   Gomes/F-1847-2013; Cavalheiro, Esper A/I-3084-2016; Naslavsky,
   Michel/L-1772-2015; Nakaya, Helder I/A-1397-2010; Zatz,
   Mayana/M-5338-2015; Verjovski-Almeida, Sergio/E-4082-2012; Passos-Bueno,
   Maria Rita/I-6796-2016; Araujo, Bruno/B-8741-2013; Passos,
   Saulo/C-5166-2012
OI Araujo, Bruno/0000-0003-0012-4217; Schanoski,
   Alessandra/0000-0002-6514-8458; Kobayashi, Gerson/0000-0002-6520-5774;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Astray, Renato
   Mancini/0000-0002-6983-5298; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Kobayashi, Gerson
   Shigeru/0000-0002-6520-5774; KALIL, JORGE/0000-0001-8415-4274; Nakaya,
   Helder/0000-0001-5297-9108; da Silva, Sergio Gomes/0000-0002-9650-809X;
   Cavalheiro, Esper A/0000-0002-0854-3582; Naslavsky,
   Michel/0000-0002-9068-1713; Nakaya, Helder I/0000-0001-5297-9108; Zatz,
   Mayana/0000-0003-3970-8025; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Passos-Bueno, Maria
   Rita/0000-0002-9248-3008; Araujo, Bruno/0000-0003-0012-4217; Alves
   Telles Silva, Kayque/0000-0002-2994-609X; Alexandrasmello@gmail.com,
   Alexandra/0000-0002-7996-873X; VAN DER LINDEN JUNIOR,
   HELIO/0000-0002-3123-2264; Goulart, Ernesto/0000-0001-9526-8701; Passos,
   Saulo/0000-0002-0908-2677; Santos, Silvana/0000-0002-5252-0206
FU FAPESP (CEPID)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/08028-1]; FAPESP (INCT) [14/50931-3]; FAPESP (Thematic
   grant) [2014/03620-2]; CNPq (INCT)National Council for Scientific and
   Technological Development (CNPq) [465355/2014-5]; AACD (Recife-PE);
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [440770/2016-5]
FX This study was supported by grants from FAPESP (CEPID number
   2013/08028-1 and INCT number 14/50931-3 to M.Z. and Thematic grant
   number 2014/03620-2 to S.V.-A.) and CNPq (INCT number 465355/2014-5 to
   M.Z.); Luiz Carlos de Caires Junior is a fellow of FAPESP
   (2017/16283-2); Ernesto Goulart is a fellow of FAPESP (2015/14821-1);
   Bruno Araujo is a fellow of FAPESP (2014/08049-1); Vanessa van der
   Linden Mota is supported by AACD (Recife-PE); Joao Ricardo de Oliveira
   is supported by CNPq (440770/2016-5). We are extremely grateful to Dr.
   S. Raia, D. Bertola, M. Vibranoski, P. Cunha, E.L. Durigon, W. Cumpady,
   P. Zanotto, C.R.S. Maia, A.N. Melo, M.T.A.L. Bezerra, D.A.M. de Araujo,
   A. Tanuri, R.S. de Aguiar, and T.R. Gollop for scientific discussions
   and sample collections. L. Suzuki and E. Amaro-Junior for helping with
   CT analysis. N. Lourenco, and M. Aguena for technical support in exome
   sequencing and MLPA assay.
CR Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Araujo B. H. S., 2017, MOL NEUROBIOL
   Barbier A, 2013, PEDIATRICS, V131, pE1158, DOI 10.1542/peds.2011-3846
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109
   Cloetta D, 2013, J NEUROSCI, V33, P7799, DOI 10.1523/JNEUROSCI.3294-12.2013
   Datan E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.409
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Alves RPD, 2016, CLIN VACCINE IMMUNOL, V23, P460, DOI 10.1128/CVI.00081-16
   Edgil D, 2006, J VIROL, V80, P2976, DOI 10.1128/JVI.80.6.2976-2986.2006
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Homem CCF, 2015, NAT REV NEUROSCI, V16, P647, DOI 10.1038/nrn4021
   Hou PS, 2013, NUCLEIC ACIDS RES, V41, P7753, DOI 10.1093/nar/gkt567
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jehee FS, 2011, EUR J MED GENET, V54, pE425, DOI 10.1016/j.ejmg.2011.03.007
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Joubert PE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005091
   Kassai H, 2014, CELL REP, V7, P1626, DOI 10.1016/j.celrep.2014.04.048
   Kortum F, 2011, J MED GENET, V48, P396, DOI 10.1136/jmg.2010.087528
   Kumamoto T, 2017, DEV GROWTH DIFFER, V59, P258, DOI 10.1111/dgd.12367
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Marceau CD, 2016, NATURE, V535, P159, DOI 10.1038/nature18631
   McGrath EL, 2017, STEM CELL REP, V8, P715, DOI 10.1016/j.stemcr.2017.01.008
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Naslavsky MS, 2017, HUM MUTAT, V38, P751, DOI 10.1002/humu.23220
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Savidis G, 2016, CELL REP, V16, P232, DOI 10.1016/j.celrep.2016.06.028
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sham PC, 2000, AM J HUM GENET, V66, P1616, DOI 10.1086/302891
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Werner H, 2016, PRENATAL DIAG, V36, P785, DOI 10.1002/pd.4860
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
   Zhang R, 2016, NATURE, V535, P164, DOI 10.1038/nature18625
NR 45
TC 11
Z9 12
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 2
PY 2018
VL 9
AR 475
DI 10.1038/s41467-017-02790-9
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU7VL
UT WOS:000424060700001
PM 29396410
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Brugnolli, RM
   Salles, PD
   Cau, LP
   Castro, RB
   Kalil, JE
   Motta, AA
   Agondi, RC
AF Brugnolli, Rebeca M.
   Salles, Pamella Diogo
   Cau, Larissa P.
   Castro, Raisa B.
   Kalil Filho, Jorge Elias
   Motta, Antonio Abilio
   Agondi, Rosana C.
TI Cold contact urticaria: association of positive ice cube test and
   autoimmunity
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Brugnolli, Rebeca M.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Salles, Pamella Diogo; Cau, Larissa P.; Castro, Raisa B.; Kalil Filho, Jorge Elias; Motta, Antonio Abilio] Univ Sao Paulo, Clin Imunoll & Allergy Div, Sao Paulo, Brazil.
   [Cau, Larissa P.] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 189
BP AB59
EP AB59
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700189
DA 2020-11-26
ER

PT J
AU Chagury, AA
   Sennes, LU
   Gil, JM
   Kalil, J
   Rodrigues, H
   Rosales, CB
   Miziara, ID
AF Chagury, Azis Arruda
   Sennes, Luiz Ubirajara
   Gil, Julio Miranda
   Kalil, Jorge
   Rodrigues, Helcio
   Rosales, Claudia B.
   Miziara, Ivan Dieb
TI HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 Alleles Associated to
   Bullous Pemphigoid in Brazilian Population
SO ANNALS OF DERMATOLOGY
LA English
DT Article
DE Genes; MHC class I; Genes; MHC class II; HLA antigens; Pemphigoid;
   bullous; Polymerase chain reaction
ID AUTOANTIBODIES; DIAGNOSIS; VULGARIS
AB Background: Bullous pemphigoid (BP) is an autoimmune disease with bullous vesicles and an incidence of 0.2 to 1.4 per 100,000 inhabitants. Many studies have been published demonstrating the association of pemphigoid with HLA class II system alleles in different populations, however there are no data on the BP, one of the most heterogeneous in the world. Objective: To typify HLA alleles in Brazilians with Bullous pemphigoid. Methods: The study group included 17 Brazilian patients with a confirmed diagnosis of BP from a hospital in Sao Paulo city, southeast Brazil. DNA was extracted from peripheral blood using Qiagen kits and HLA A, B, C, DR and DQ typing was performed using polymerase chain reaction. The control group was composed of a database of 297 deceased donors from the city of Sao Paulo. The statistical significance level was adjusted using the Bonferroni correction depending on the phenotypic frequencies evaluated for HLA class I (A, B and C) and class II (DRB1, DQB1 and DQA1). Results: Our findings show that alleles HLA C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 are associated with the onset of the disease in the Brazilian population, with relative risks of 8.31 (2.46 to 28.16), 3.76 (1.81 to 7.79), 3.57 (1.53 to 8.33), and 4.02 (1.87 to 8.64), respectively (p<0.005). Conclusion: Our data indicate that Brazilian patients with BP present the same genetic predisposition linked to HLA-DQB1 *03:01 previously reported in Caucasian and Iranian individuals and our study introduces three new alleles (C*17, DQA1*01:03 and DQA1*05:05) involved in the pathophysiology of BP.
C1 [Chagury, Azis Arruda; Sennes, Luiz Ubirajara; Gil, Julio Miranda; Miziara, Ivan Dieb] Univ Sao Paulo, Sch Med, ENT Dept Otorhinolaryngol, Sao Paulo, Brazil.
   [Kalil, Jorge; Rodrigues, Helcio; Rosales, Claudia B.] Univ Sao Paulo, Sch Med, Transplant Immunol & Immunogenet Lab, Heart Inst INCOR, Sao Paulo, Brazil.
RP Chagury, AA (corresponding author), Univ Sao Paulo, Clin Hosp, FMUSP Cent Inst, Dept Otolaryngol, R Dr Ovidio Pires de Campos 255, BR-05403000 Sao Paulo, Brazil.
EM azischagury@gmail.com
RI Sennes, Luiz U/E-6815-2012; KALIL, JORGE/C-8029-2012; Sennes,
   Luiz/AAN-2955-2020; Miziara, Ivan D/L-8422-2013
OI Sennes, Luiz U/0000-0002-7378-9490; KALIL, JORGE/0000-0001-8415-4274;
   Sennes, Luiz/0000-0002-7378-9490; 
CR BERNARD P, 1995, ARCH DERMATOL, V131, P48, DOI 10.1001/archderm.131.1.48
   Budinger L, 1998, J CLIN INVEST, V102, P2082, DOI 10.1172/JCI3335
   DABELSTEEN E, 1974, ACTA DERM-VENEREOL, V54, P189
   Delgado JC, 1996, P NATL ACAD SCI USA, V93, P8569, DOI 10.1073/pnas.93.16.8569
   Esmaili N, 2013, IRAN J IMMUNOL, V10, P1, DOI IJIv10i1A1
   Gao XH, 2002, CLIN EXP DERMATOL, V27, P319, DOI 10.1046/j.1365-2230.2002.01037.x
   Gudi VS, 2005, BRIT J DERMATOL, V153, P424, DOI 10.1111/j.1365-2133.2005.06662.x
   Kasperkiewicz M, 2007, CLIN REV ALLERG IMMU, V33, P67, DOI 10.1007/s12016-007-0030-y
   LABIB RS, 1986, J IMMUNOL, V136, P1231
   Langan SM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a180
   Lin MS, 2000, J INVEST DERMATOL, V115, P955, DOI 10.1046/j.1523-1747.2000.00153.x
   Okazaki A, 2000, J Dermatol, V27, P149
   ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199
   Sami N, 2001, CLIN IMMUNOL, V100, P219, DOI 10.1006/clim.2001.5065
   Sami N, 2001, DERMATOLOGY, V202, P293, DOI 10.1159/000051661
   Schmidt E, 2010, AUTOIMMUN REV, V10, P84, DOI 10.1016/j.autrev.2010.08.007
   STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X
   Walsh SRA, 2005, DRUGS, V65, P905, DOI 10.2165/00003495-200565070-00002
   Weber R, 2011, TISSUE ANTIGENS, V78, P92, DOI 10.1111/j.1399-0039.2011.01705.x
NR 19
TC 4
Z9 4
U1 0
U2 4
PU KOREAN DERMATOLOGICAL ASSOC
PI SEOUL
PA 305 SEOCHO NASAN, SUITE OFFICE 1330-16, SEOCHO-2-DONG, SEOCHO-GU, SEOUL,
   137-858, SOUTH KOREA
SN 1013-9087
EI 2005-3894
J9 ANN DERMATOL
JI Ann. Dermatol.
PD FEB
PY 2018
VL 30
IS 1
BP 8
EP 12
DI 10.5021/ad.2018.30.1.8
PG 5
WC Dermatology
SC Dermatology
GA GH9LV
UT WOS:000433991800002
PM 29386826
OA Green Published
DA 2020-11-26
ER

PT J
AU Andrade, MC
   Pacheco, RD
   Almeida, M
   Takejima, P
   Kalil, JE
   Giavina-Bianchi, P
   Agondi, RC
AF Andrade, Mayra Coutinho
   Pacheco, Rosilane dos Reis
   Almeida, Mila
   Takejima, Priscila
   Kalil Filho, Jorge Elias
   Giavina-Bianchi, Pedro
   Agondi, Rosana C.
TI Frequency Of Anti-inflammatory Related Cutaneous Manifestation In
   Patients With Aspirin-exacerbated Respiratory Disease (AERD)
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Andrade, Mayra Coutinho; Pacheco, Rosilane dos Reis; Almeida, Mila; Takejima, Priscila; Kalil Filho, Jorge Elias; Giavina-Bianchi, Pedro; Agondi, Rosana C.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 307
BP AB97
EP AB97
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700307
DA 2020-11-26
ER

PT J
AU Castro, RB
   Duarte, RAG
   Zanandrea, A
   Mouco, CC
   de Assis, JP
   Dias, GMFS
   Almonfrey, F
   Brugnolli, RM
   Kalil, J
   Agondi, RC
AF Castro, Raisa Borges
   Gaia Duarte, Rafaella Amorim
   Zanandrea, Andressa
   Mouco, Claudia Castilho
   de Assis, Joao Paulo
   Fontes Silva Dias, Gabriella Melo
   Almonfrey, Franciane
   Brugnolli, Rebeca M.
   Kalil, Jorge
   Agondi, Rosana C.
TI Clinical evolution of patients with chronic spontaneous urticaria
   steroid-dependent
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Castro, Raisa Borges; Gaia Duarte, Rafaella Amorim; Zanandrea, Andressa; Mouco, Claudia Castilho; de Assis, Joao Paulo; Fontes Silva Dias, Gabriella Melo; Almonfrey, Franciane; Brugnolli, Rebeca M.; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 175
BP AB55
EP AB55
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700175
DA 2020-11-26
ER

PT J
AU D'Onofrio, AC
   Boralli, CF
   Portilho, NC
   Garro, LS
   Ribeiro, MR
   De Magalhaes, MC
   Campos, L
   Motta, AA
   Kalil, JE
   Giavina-Bianchi, P
   Aun, MV
AF D'Onofrio, Ana Carolina
   Boralli, Cristiane Fernandes
   Portilho, Nathalia Coelho
   Garro, Laila Sabino
   Ribeiro, Marisa Rosimeire
   De Magalhaes, Manoela Crespo
   Campos, Lucila
   Motta, Antonio Abilio
   Kalil Filho, Jorge Elias
   Giavina-Bianchi, Pedro
   Aun, Marcelo V.
TI Midazolam is a major cause of intraoperative immediate hypersensitivity
   reactions
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [D'Onofrio, Ana Carolina; Boralli, Cristiane Fernandes; Portilho, Nathalia Coelho; Ribeiro, Marisa Rosimeire; De Magalhaes, Manoela Crespo; Campos, Lucila] Univ Sao Paulo, Sao Paulo, Brazil.
   [Garro, Laila Sabino; Motta, Antonio Abilio; Aun, Marcelo V.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kalil Filho, Jorge Elias; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 121
BP AB38
EP AB38
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700121
DA 2020-11-26
ER

PT J
AU de Assis, JP
   Dias, GMFS
   Mouco, CC
   Zanandrea, A
   Castro, RB
   Kalil, J
   Motta, AA
   Agondi, RC
AF de Assis, Joao Paulo
   Fontes Silva Dias, Gabriella Melo
   Mouco, Claudia Castilho
   Zanandrea, Andressa
   Castro, Raisa Borges
   Kalil, Jorge
   Motta, Antonio Abilio
   Agondi, Rosana C.
TI Angioedema in patients with chronic spontaneous urticaria: assessment of
   disease severity and response to treatment
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [de Assis, Joao Paulo; Fontes Silva Dias, Gabriella Melo; Mouco, Claudia Castilho; Castro, Raisa Borges] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Zanandrea, Andressa] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kalil, Jorge; Motta, Antonio Abilio] Univ Sao Paulo, Clin Imunoll & Allergy Div, Sao Paulo, Brazil.
   [Motta, Antonio Abilio; Agondi, Rosana C.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 166
BP AB52
EP AB52
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700166
DA 2020-11-26
ER

PT J
AU Dias, GMFS
   de Assis, JP
   Andrade, MC
   Castro, RB
   Mouco, CC
   Zanandrea, A
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
   Agondi, RC
AF Fontes Silva Dias, Gabriella Melo
   de Assis, Joao Paulo
   Andrade, Mayra Coutinho
   Castro, Raisa Borges
   Mouco, Claudia Castilho
   Zanandrea, Andressa
   Aun, Marcelo V.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Agondi, Rosana C.
TI Diagnosis and treatment of AERD: clinical practice realities
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Fontes Silva Dias, Gabriella Melo; de Assis, Joao Paulo; Castro, Raisa Borges; Mouco, Claudia Castilho; Zanandrea, Andressa; Aun, Marcelo V.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Andrade, Mayra Coutinho; Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 316
BP AB100
EP AB100
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700316
DA 2020-11-26
ER

PT J
AU Lopes, M
   Diogo-Salles, P
   Kalil, J
   Motta, AA
   Agondi, RC
AF Lopes, Mariele
   Diogo-Salles, Pamella
   Kalil, Jorge
   Motta, Antonio Abilio
   Agondi, Rosana C.
TI Acute Respiratory Reactions Triggered by NSAIDs in Patients With Chronic
   Spontaneous Urticaria Exacerbated by NSAIDs
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Lopes, Mariele; Diogo-Salles, Pamella; Kalil, Jorge; Motta, Antonio Abilio; Agondi, Rosana C.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 177
BP AB56
EP AB56
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700177
DA 2020-11-26
ER

PT J
AU Mouco, CC
   Zanandrea, A
   de Assis, JP
   Castro, RB
   Dias, GMFS
   Kalil, J
   Motta, AA
   Agondi, RC
AF Mouco, Claudia Castilho
   Zanandrea, Andressa
   de Assis, Joao Paulo
   Castro, Raisa Borges
   Fontes Silva Dias, Gabriella Melo
   Kalil, Jorge
   Motta, Antonio Abilio
   Agondi, Rosana C.
TI Chronic spontaneous urticaria and autoimmunity: a follow up study of
   patients with chronic urticaria for 16 years
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Mouco, Claudia Castilho; Zanandrea, Andressa; de Assis, Joao Paulo; Castro, Raisa Borges; Fontes Silva Dias, Gabriella Melo] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kalil, Jorge; Motta, Antonio Abilio] Univ Sao Paulo, Clin Imunoll & Allergy Div, Sao Paulo, Brazil.
   [Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 186
BP AB58
EP AB58
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700186
DA 2020-11-26
ER

PT J
AU Pacheco, RD
   Andrade, MC
   Pedroso, NF
   Takejima, P
   Aun, MV
   Kalil, JE
   Giavina-Bianchi, P
   Agondi, RC
AF Pacheco, Rosilane dos Reis
   Andrade, Mayra Coutinho
   Pedroso, Natalia Falci
   Takejima, Priscila
   Aun, Marcelo V.
   Kalil Filho, Jorge Elias
   Giavina-Bianchi, Pedro
   Agondi, Rosana C.
TI Inhaled corticoids in asthmatic patients: effect on body mass index and
   spirometry
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Pacheco, Rosilane dos Reis; Andrade, Mayra Coutinho; Pedroso, Natalia Falci; Takejima, Priscila; Kalil Filho, Jorge Elias; Giavina-Bianchi, Pedro; Agondi, Rosana C.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Aun, Marcelo V.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 659
BP AB210
EP AB210
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700658
DA 2020-11-26
ER

PT J
AU Zanandrea, A
   Mouco, CC
   de Assis, JP
   Dias, GMFS
   Castro, RB
   Brugnolli, RM
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
   Aun, MV
AF Zanandrea, Andressa
   Mouco, Claudia Castilho
   de Assis, Joao Paulo
   Fontes Silva Dias, Gabriella Melo
   Castro, Raisa Borges
   Brugnolli, Rebeca M.
   Kalil, Jorge
   Motta, Antonio Abilio
   Giavina-Bianchi, Pedro
   Aun, Marcelo V.
TI Hypersensitivity to paracetamol: placebo effect or overdiagnosis?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology /
   World-Allergy-Organization Joint Congress
CY MAR 02-08, 2018
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol, World Allergy Org
C1 [Zanandrea, Andressa; Mouco, Claudia Castilho; de Assis, Joao Paulo; Fontes Silva Dias, Gabriella Melo; Castro, Raisa Borges; Brugnolli, Rebeca M.; Kalil, Jorge; Motta, Antonio Abilio; Aun, Marcelo V.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 141
IS 2
SU S
MA 138
BP AB43
EP AB43
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA GB8DX
UT WOS:000429306700138
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Kalil, J
AF Giavina-Bianchi, Pedro
   Aun, Marcelo V.
   Kalil, Jorge
TI Drug-induced anaphylaxis: is it an epidemic?
SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Review
DE anaphylaxis; drugs; epidemic; hypersensitivity reactions; mortality
ID WORLD-ALLERGY-ORGANIZATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   IMMEDIATE HYPERSENSITIVITY REACTION; CONTRAST-MEDIA; RISK
   STRATIFICATION; FATAL ANAPHYLAXIS; ADVERSE-REACTIONS; UNITED-STATES;
   MANAGEMENT; GADOLINIUM
AB Purpose of reviewThe present review addresses the epidemiology, analyzes the current data and promotes global awareness of drug-induced anaphylaxis.Recent findingsAnaphylaxis is a medical emergency that may cause death! In the last decade, studies have shown an increasing incidence and prevalence of anaphylaxis.SummaryDrug-induced anaphylaxis fatalities have increased, and this syndrome remains underdiagnosed and undertreated.
C1 [Giavina-Bianchi, Pedro; Aun, Marcelo V.; Kalil, Jorge] Univ Sao Paulo, Dept Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
CR Abrams EM, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0165-6
   Aran S, 2015, CLIN RADIOL, V70, P466, DOI 10.1016/j.crad.2014.12.011
   Aranda A, 2011, ALLERGY, V66, P247, DOI 10.1111/j.1398-9995.2010.02460.x
   Ariza A, 2015, J INVEST ALLERG CLIN, V25, P12
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Ball P, 2003, J ANTIMICROB CHEMOTH, V51, P21, DOI 10.1093/jac/dkg209
   Blanca-Lopez N, 2013, CLIN EXP ALLERGY, V43, P560, DOI 10.1111/cea.12099
   Blanca-Lopez N, 2011, CURR OPIN ALLERGY CL, V11, P285, DOI 10.1097/ACI.0b013e3283489bc3
   Bohm I, 2017, POSTGRAD MED, V129, P259, DOI 10.1080/00325481.2017.1282296
   Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x
   Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142
   Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x
   Calapai G, 2016, PEDIATR EMERG CARE, V32, P32, DOI 10.1097/PEC.0000000000000311
   Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012
   Costello James R, 2016, Top Magn Reson Imaging, V25, P257
   Decuyper II, 2017, DRUGS R&D, V17, P265, DOI 10.1007/s40268-017-0176-x
   Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350
   Ensina LF, 2014, J ALLER CL IMM-PRACT, V2, P825, DOI 10.1016/j.jaip.2014.08.016
   Faria E, 2014, J INVEST ALLERG CLIN, V24, P40
   Fernandez TD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003679
   Fok JS, 2017, CURR OPIN ALLERGY CL, V17, P241, DOI 10.1097/ACI.0000000000000371
   Galvao VR, 2017, J ALLER CL IMM-PRACT, V5, P816, DOI 10.1016/j.jaip.2016.08.012
   Galvao VR, 2015, J ALLER CL IMM-PRACT, V3, P175, DOI 10.1016/j.jaip.2014.12.006
   Galvao VR, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0452-6
   Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006
   Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P593, DOI 10.1016/j.jaip.2017.03.015
   Giavina-Bianchi P, 2016, CURR OPIN ALLERGY CL, V16, P323, DOI 10.1097/ACI.0000000000000292
   Gomes E, 2004, CLIN EXP ALLERGY, V34, P1597, DOI 10.1111/j.1365-2222.2004.02070.x
   GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P540, DOI 10.1016/0091-6749(84)90391-9
   GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P600, DOI 10.1016/0091-6749(84)90113-1
   Hesterberg PE, 2009, J ALLERGY CLIN IMMUN, V123, P1262, DOI 10.1016/j.jaci.2009.02.042
   IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159
   Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Jares EJ, 2015, J ALLER CL IMM-PRACT, V3, P780, DOI 10.1016/j.jaip.2015.05.012
   Jung JW, 2012, RADIOLOGY, V264, P414, DOI 10.1148/radiol.12112025
   Karakaya G, 2013, RESP MED, V107, P967, DOI 10.1016/j.rmed.2013.03.014
   Kim SR, 2017, CLIN EXP ALLERGY, V47, P106, DOI 10.1111/cea.12803
   Kim YJ, 2014, ALLERGY ASTHMA IMMUN, V6, P156, DOI 10.4168/aair.2014.6.2.156
   Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x
   Laporte JR, 2003, PHARMACOEPIDEM DR S, V12, P195, DOI 10.1002/pds.822
   Leone R, 2005, DRUG SAFETY, V28, P547, DOI 10.2165/00002018-200528060-00006
   Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049
   Macy E, 2015, J ALLERGY CLIN IMMUN, V135, P745, DOI 10.1016/j.jaci.2014.07.062
   Manfredi M, 2004, J ALLERGY CLIN IMMUN, V113, P155, DOI 10.1016/j.jaci.2003.09.035
   Markman M, 1999, J CLIN ONCOL, V17, P1141, DOI 10.1200/JCO.1999.17.4.1141
   McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022
   Mirakian R, 2015, CLIN EXP ALLERGY, V45, P300, DOI 10.1111/cea.12468
   Mota I, 2016, EUR ANN ALLERGY CLIN, V48, P212
   Napoli Diane C., 2000, Pediatric Asthma Allergy and Immunology, V14, P329, DOI 10.1089/088318700750070439
   Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15
   Picard M, 2017, J ALLER CL IMM-PRACT, V5, P600, DOI 10.1016/j.jaip.2016.12.001
   Picard M, 2016, J ALLERGY CLIN IMMUN, V137, P1154, DOI 10.1016/j.jaci.2015.10.039
   Pinnobphun P, 2011, ANN ALLERG ASTHMA IM, V106, P387, DOI 10.1016/j.anai.2010.12.020
   Prieto-Garcia A, 2017, J ALLER CL IMM-PRACT, V5, P1433, DOI 10.1016/j.jaip.2017.05.008
   Prince MR, 2011, AM J ROENTGENOL, V196, pW138, DOI 10.2214/AJR.10.4885
   Raisch DW, 2014, EXPERT OPIN DRUG SAF, V13, P15, DOI 10.1517/14740338.2013.832752
   Renaudin JM, 2013, ALLERGY, V68, P929, DOI 10.1111/all.12168
   Ribeiro MRMA, 2018, CLINICS SAO PAULO IN, P73
   Ribeiro-Vaz I, 2013, EUR J CLIN PHARMACOL, V69, P673, DOI 10.1007/s00228-012-1376-5
   Riezzo I, 2010, ALLERGY, V65, P130, DOI 10.1111/j.1398-9995.2009.02088.x
   Ingelmo AR, 2016, J INVEST ALLERG CLIN, V26, P144, DOI 10.18176/jiaci.0058
   Rosado Ingelmo A, 2016, J INVESTIG ALLERGOL, V26, pquiz
   Sachs B, 2006, DRUG SAFETY, V29, P1087, DOI 10.2165/00002018-200629110-00008
   Salas M, 2013, ALLERGY, V68, P1203, DOI 10.1111/all.12214
   Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303
   Seitz CS, 2009, CLIN EXP ALLERGY, V39, P1738, DOI 10.1111/j.1365-2222.2009.03338.x
   Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1097/WOX.0b013e318211496c
   Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1
   Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019
   Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002
   Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947
   STEVENSON DD, 1993, ANN ALLERGY, V71, P417
   Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051
   Torres MJ, 2010, MED CLIN N AM, V94, P805, DOI 10.1016/j.mcna.2010.04.006
   VanDerKlauw MM, 1996, CLIN EXP ALLERGY, V26, P1355, DOI 10.1046/j.1365-2222.1996.d01-300.x
   Wang DY, 1998, PHARMACOEPIDEM DR S, V7, P269, DOI 10.1002/(SICI)1099-1557(199807/08)7:4<269::AID-PDS366>3.0.CO;2-3
   Wong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011
NR 78
TC 6
Z9 6
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-4050
EI 1473-6322
J9 CURR OPIN ALLERGY CL
JI Curr. Opin. Allergy Clin. Immunol.
PD FEB
PY 2018
VL 18
IS 1
BP 59
EP 65
DI 10.1097/ACI.0000000000000411
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA FR1XM
UT WOS:000418861100009
PM 29135486
DA 2020-11-26
ER

PT J
AU Garro, LS
   Aun, MV
   Soares, ISC
   Ribeiro, MR
   Motta, AA
   Kalil, J
   Castells, MC
   Carmona, MJC
   Giavina-Bianchi, P
AF Garro, Laila S.
   Aun, Marcelo, V
   Soares, Iracy Silvia C.
   Ribeiro, Marisa R.
   Motta, Antonio A.
   Kalil, Jorge
   Castells, Mariana C.
   Carmona, Maria Jose C.
   Giavina-Bianchi, Pedro
TI Specific questionnaire detects a high incidence of intra-operative
   hypersensitivity reactions
SO CLINICS
LA English
DT Article
DE Anaphylaxis; Anesthesia; Drug Allergy; Intraoperative; Questionnaire
ID PERIOPERATIVE ANAPHYLAXIS; CLINICAL-PRACTICE; ANESTHESIA; GUIDELINES;
   ALLERGY; FRANCE; RISK
AB OBJECTIVE: To assess the incidence of intra-operative immediate hypersensitivity reactions and anaphylaxis.
   METHODS: A cross-sectional observational study was conducted at the Department of Anesthesiology, University of Sao Paulo School of Medicine, Hospital das Clinicas, Sao Paulo, Brazil, from January to December 2010. We developed a specific questionnaire to be completed by anesthesiologists. This tool included questions about hypersensitivity reactions during anesthesia and provided treatments. We included patients with clinical signs compatible with immediate hypersensitivity reactions. Hhypersensitivity reactions were categorized according to severity (grades I-V). American Society of Anesthesiologists physical status classification (ASA 1-6) was analyzed and associated with the severity of hypersensitivity reactions.
   RESULTS: In 2010, 21,464 surgeries were performed under general anesthesia. Anesthesiologists answered questionnaires on 5,414 procedures (25.2%). Sixty cases of intra-operative hypersensitivity reactions were reported. The majority patients (45, 75%) had hypersensitivity reactions grade I reactions (incidence of 27.9:10,000). Fifteen patients (25%) had grade II, III or IV reactions (intra-operative anaphylaxis) (incidence of 7:10,000). No patients had grade V reactions. Thirty patients (50%) were classified as ASA 1. The frequency of cardiovascular shock was higher in patients classified as ASA 3 than in patients classified as ASA 1 or ASA 2. Epinephrine was administered in 20% of patients with grade III hypersensitivity reactions and in 50% of patients with grade II hypersensitivity reactions.
   CONCLUSIONS: The majority of patients had hypersensitivity reactions grade I reactions; however, the incidence of intra-operative anaphylaxis was higher than that previously reported in the literature. Patients with ASA 3 had more severe anaphylaxis; however, the use of epinephrine was not prescribed in all of these cases. Allergists and anesthesiologists should implement preventive measures to reduce the occurrence of anaphylaxis.
C1 [Garro, Laila S.; Aun, Marcelo, V; Ribeiro, Marisa R.; Motta, Antonio A.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med FMUSP, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
   [Soares, Iracy Silvia C.; Carmona, Maria Jose C.] Univ Sao Paulo, Fac Med FMUSP, Dept Anestesiol, Sao Paulo, SP, Brazil.
   [Castells, Mariana C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA.
RP Aun, MV (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012; CARMONA, MARIA
   JOSE CARVALHO/G-3653-2014
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   CARMONA, MARIA JOSE CARVALHO/0000-0002-3031-2924
CR Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350
   Dewachter P., 2007, DRUG HYPERSENSITIVIT, P2004
   Faria E, 2008, REV PORT IMUNOALERG, V16, P73
   Galvao VR, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0452-6
   Harper NJN, 2009, ANAESTHESIA, V64, P199, DOI 10.1111/j.1365-2044.2008.05733.x
   Laxenaire MC, 1999, ANN FR ANESTH, V18, P796, DOI 10.1016/S0750-7658(00)88460-9
   Levy JH, 2011, ANESTH ANALG, V113, P979, DOI 10.1213/ANE.0b013e31822d68a5
   Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049
   Mertes PM, 2011, J INVEST ALLERG CLIN, V21, P442
   Mertes PM, 2009, IMMUNOL ALLERGY CLIN, V29, P429, DOI 10.1016/j.iac.2009.04.004
   Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003
   Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91
   Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007
   Morais-Almeida M, 2007, REV PORT IMUNOALERG, V15, P19
   Saager L, 2015, ANESTHESIOLOGY, V122, P551, DOI 10.1097/ALN.0000000000000529
   Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9
   Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038
NR 18
TC 1
Z9 1
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2018
VL 73
DI 10.6061/clinics/2018/e287
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA GG8OO
UT WOS:000432957400001
PM 29791521
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Kalil, J
AF Giavina-Bianchi, Pedro
   Kalil, Jorge
TI Improving the Management of Hereditary Angioedema
SO CLINICS
LA English
DT Editorial Material
C1 [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Fac Med FMUSP, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Giavina-Bianchi P, 2017, ARQ ASMA ALERG IMUNO, V1, P23, DOI DOI 10.5935/2526-5393.20170005
   Giavina-Bianchi P, 2010, REV BRAS ALERG IMUNO, V33, P241
   Giavina-Bianchi P, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e310
   Giavina-Bianchi P, 2011, CLINICS, V66, P1627, DOI 10.1590/S1807-59322011000900021
NR 4
TC 2
Z9 2
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2018
VL 73
AR e354
DI 10.6061/clinics/2018/e354
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA GG8NU
UT WOS:000432955200001
PM 29791522
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ribeiro, MR
   Motta, AA
   Marcondes-Fonseca, LA
   Kalil-Filho, J
   Giavina-Bianchi, P
AF Ribeiro, Marisa Rosimeire
   Motta, Antonio Abilio
   Marcondes-Fonseca, Luiz Augusto
   Kalil-Filho, Jorge
   Giavina-Bianchi, Pedro
TI Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug
   Administered in Hospitalized Patients
SO CLINICS
LA English
DT Article
DE Adverse Drug Reactions; Hypersensitivity Reactions; In-patients;
   Incidence; Risk factors
ID INTERNAL-MEDICINE; EPIDEMIOLOGY; PHARMACOVIGILANCE; IMPACT;
   HYPERSENSITIVITY; ADMISSION; SEVERITY; ASTHMA; COST
AB OBJECTIVE: To assess the risk factors, incidence and severity of adverse drug reactions in in-patients.
   METHODS: This prospective study evaluated 472 patients treated at a teaching hospital in Brazil between 2010 and 2013 by five medical specialties: Internal Medicine, General Surgery, Geriatrics, Neurology, and Clinical Immunology and Allergy. The following variables were assessed: patient age, gender, comorbidities, family history of hypersensitivity, personal and family history of atopy, number of prescribed drugs before and during hospitalization, hospital diagnoses, days of hospitalization. The patients were visited every other day, and medical records were reviewed by the investigators to detect adverse drug reactions.
   RESULTS: There were a total of 94 adverse drug reactions in 75 patients. Most reactions were predictable and of moderate severity. The incidence of adverse drug reactions was 16.2%, and the incidence varied, according to the medical specialty; it was higher in Internal Medicine (30%). Antibiotics were the most commonly involved medication. Chronic renal failure, longer hospital stay, greater number of diagnoses and greater number of medications upon admission were risk factors. For each medication introduced during hospitalization, there was a 10% increase in the rate of adverse drug reaction. In the present study, the probability of observing an adverse drug reaction was 1 in 104 patients per day.
   CONCLUSIONS: Adverse drug reactions are frequent and potentially serious and should be better monitored in patients with chronic renal failure or prolonged hospitalization and especially in those on 'polypharmacy' regimens. The rational use of medications plays an important role in preventing adverse drug reactions.
C1 [Ribeiro, Marisa Rosimeire; Motta, Antonio Abilio; Marcondes-Fonseca, Luiz Augusto; Kalil-Filho, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Serv Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
   [Kalil-Filho, Jorge; Giavina-Bianchi, Pedro] INCT, Invest Imunol, Sao Paulo, SP, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Serv Imunol Clin & Alergia, Sao Paulo, SP, Brazil.; Giavina-Bianchi, P (corresponding author), INCT, Invest Imunol, Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Agondi RC, 2010, ALLERGY, V65, P510, DOI 10.1111/j.1398-9995.2009.02211.x
   Lobo MGAD, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-5
   [Anonymous], 2012, GLOB STRAT ASTHM MAN
   Arulmani R, 2008, BRIT J CLIN PHARMACO, V65, P210, DOI 10.1111/j.1365-2125.2007.02993.x
   Asher I, 2008, NEW ZEAL MED J, V121, P117
   Noblat ACB, 2011, REV ASSOC MED BRAS, V57, P42, DOI 10.1590/S0104-42302011000100014
   Davies EC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004439
   Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x
   Demoly P, 2001, REV PORT IMUNOALERG, V8, P231
   Fattinger K, 2000, BRIT J CLIN PHARMACO, V49, P158, DOI 10.1046/j.1365-2125.2000.00132.x
   Gomes ER, 2005, CURR OPIN ALLERGY CL, V5, P309, DOI 10.1097/01.all.0000173785.81024.33
   HARTWIG SC, 1992, AM J HOSP PHARM, V49, P2229, DOI 10.1093/ajhp/49.9.2229
   Hernandez-Salazar A, 2006, ARCH MED RES, V37, P899, DOI 10.1016/j.arcmed.2006.03.010
   Hosmer DW, 2000, APPL LOGISTIC REGRES, P320
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Kane-Gill SL, 2012, DRUG SAFETY, V35, P645, DOI 10.2165/11599730-000000000-00000
   Khan LM, 2012, SAUDI MED J, V33, P863
   Khan LM, 2013, EUR J CLIN PHARMACOL, V69, P1985, DOI 10.1007/s00228-013-1563-z
   Kirkwood BR, 2006, ESSENTIAL MED STAT
   Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379
   Kvasz M, 2000, MedGenMed, V2, pE3
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Neter J., 1996, APPL LINEAR STAT MOD
   Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15
   Pourseyed S, 2009, PHARMACOEPIDEM DR S, V18, P104, DOI 10.1002/pds.1663
   Ramesh M, 2003, PHARMACOEPIDEM DR S, V12, P687, DOI 10.1002/pds.871
   Rawlins M, 1977, TXB ADVERSE DRUG REA, P10
   Munoz-Torrero JFS, 2010, EUR J CLIN PHARMACOL, V66, P1257, DOI 10.1007/s00228-010-0866-6
   Suh DC, 2000, ANN PHARMACOTHER, V34, P1373, DOI 10.1345/aph.10094
   WHO, 1972, 498 WHO
NR 31
TC 5
Z9 5
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2018
VL 73
AR e185
DI 10.6061/clinics/2018/e185
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA FW5JS
UT WOS:000425353500001
PM 29451619
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Felix, SN
   Agondi, RC
   Aun, MV
   Kurkejak, A
   Avona, MD
   Amorim, TS
   Lopes, MR
   Almeida, FM
   Genaro, IS
   Bezerra, SK
   Giavina-Bianchi, P
   Kalil, J
   Tiberio, ID
   Martins, MD
   Saraiva-Romanholo, BM
AF Felix, S. N.
   Agondi, R. C.
   Aun, M. V.
   Kurkejak, A.
   Avona, M. D.
   Amorim, T. S.
   Lopes, M. R.
   Almeida, F. M.
   Genaro, I. S.
   Bezerra, S. K.
   Giavina-Bianchi, P.
   Kalil, J.
   Tiberio, I. D.
   Martins, M. D.
   Saraiva-Romanholo, B. M.
TI Clinical, Functional and Inflammatory Evaluation in Asthmatic Patients
   After a Simple Short-Term Educational Program
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT International Conference of the American-Thoracic-Society
CY MAY 18-23, 2018
CL San Diego, CA
SP Amer Thoracic Soc
C1 [Felix, S. N.; Genaro, I. S.; Bezerra, S. K.] IAMSPE Hosp Publ Employee Sao Paulo, Sao Paulo, Brazil.
   [Agondi, R. C.; Aun, M. V.; Almeida, F. M.; Giavina-Bianchi, P.; Kalil, J.] Univ Sao Paulo, Dept Med, Sao Paulo, Brazil.
   [Kurkejak, A.; Avona, M. D.; Amorim, T. S.; Lopes, M. R.] Univ City Sao Paulo UNICID, Sao Paulo, Brazil.
   [Martins, M. D.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Saraiva-Romanholo, B. M.] FMUSP, UNICID, IAMSPE, Sao Paulo, Brazil.
EM soraia.ank@gmail.com
RI Martins, Manoela Domingues/G-8209-2012; Almeida, Francine
   Maria/H-3733-2013; Martins, Milton A/L-7541-2017; de Almeida, Francine
   Maria/S-2314-2019; Aun, Marcelo V/E-6775-2014; Tiberio, Iolanda
   FLC/C-6461-2012
OI Martins, Manoela Domingues/0000-0001-8662-5965; Almeida, Francine
   Maria/0000-0001-9755-5034; de Almeida, Francine
   Maria/0000-0001-9755-5034; Aun, Marcelo V/0000-0001-9882-5200; Tiberio,
   Iolanda FLC/0000-0002-5662-7895
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2018
VL 197
MA A3637
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA HA1NA
UT WOS:000449978904291
DA 2020-11-26
ER

PT J
AU Guilherme, L
   de Barros, SF
   Kohler, KF
   Santos, SR
   Ferreira, FM
   Silva, WR
   Alencar, R
   Postol, E
   Kalil, J
AF Guilherme, L.
   Freschi de Barros, S.
   Kohler, K. F.
   Santos, S. R.
   Morais Ferreira, F.
   Silva, W. R.
   Alencar, R.
   Postol, E.
   Kalil, J.
TI Rheumatic Heart Disease: Pathogenesis and Vaccine
SO CURRENT PROTEIN & PEPTIDE SCIENCE
LA English
DT Review
DE Rheumatic fever; rheumatic heart disease; M protein; genes; cytokines; T
   and B lymphocytes; heart-tissue proteins; anti-S. pyogenes vaccine
ID GROUP-A STREPTOCOCCUS; T-CELL-CLONES; HLA CLASS-I; GROWTH-FACTOR-BETA-1
   GENE C-509T; CLINICALLY HOMOGENEOUS PATIENTS; EMM TYPE DISTRIBUTION;
   MOLECULAR EPIDEMIOLOGY; ANTIMICROBIAL SUSCEPTIBILITY; BRAZILIAN
   POPULATION; T869C POLYMORPHISMS
AB Rheumatic fever (RF) and rheumatic heart disease (RHD) follow untreated S. pyogenes throat infections in children who present susceptible genes that favor the development of autoimmune reactions. In this review, we focus on the genes that confer susceptibility and on the autoimmune reactions that occur due to molecular mimicry between human-tissue proteins and streptococcal M protein. Polyarthritis is the initial manifestation, which can evolve to carditis and severe valve damage; these culminate in rheumatic heart disease (RHD) or Sydenham's chorea, which affects the central nervous system. A perspective on vaccine development to prevent the disease is also discussed.
C1 [Guilherme, L.; Freschi de Barros, S.; Kohler, K. F.; Santos, S. R.; Morais Ferreira, F.; Silva, W. R.; Alencar, R.; Postol, E.; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Guilherme, L.; Freschi de Barros, S.; Kohler, K. F.; Santos, S. R.; Morais Ferreira, F.; Silva, W. R.; Alencar, R.; Postol, E.; Kalil, J.] Univ Sao Paulo, Sch Med, Inst Invest Immunol, Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy, Dept Clin Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44, BR-05403903 Sao Paulo, SP, Brazil.
EM luizagui@usp.br
RI de Barros, Samar Freschi/Q-4970-2018; Ferreira, Frederico
   Moraes/A-4622-2013
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   Areas GP, 2014, MEM I OSWALDO CRUZ, V109, P935, DOI 10.1590/0074-0276140231
   Arya DK, 2014, J INFECT DEV COUNTR, V8, P271, DOI 10.3855/jidc.2874
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Azevedo PM, 2010, CYTOKINE, V49, P109, DOI 10.1016/j.cyto.2009.09.003
   Baroux N, 2014, CLIN INFECT DIS, V59, pE84, DOI 10.1093/cid/ciu490
   Bas HD, 2014, J INVEST MED, V62, P78, DOI 10.2310/JIM.0000000000000023
   Batzloff MR, 2003, J INFECT DIS, V187, P1598, DOI 10.1086/374800
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   Berdeli A, 2004, CLIN BIOCHEM, V37, P925, DOI 10.1016/j.clinbiochem.2004.06.007
   Bessen DE, 2009, INFECT GENET EVOL, V9, P581, DOI 10.1016/j.meegid.2009.03.002
   Boyd R, 2016, EPIDEMIOL INFECT, V144, P1018, DOI 10.1017/S0950268815002010
   CAVELTI PA, 1945, P SOC EXP BIOL MED, V60, P379
   Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   DALE JB, 1995, J INFECT DIS, V171, P1038, DOI 10.1093/infdis/171.4.1038
   De Amicis KM, 2014, VACCINE, V32, P4104, DOI 10.1016/j.vaccine.2013.08.043
   de Barros SF, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1052-3
   Donadi EA, 2000, J NEUROL, V247, P122, DOI 10.1007/s004150070191
   Dundar D, 2010, MICROB DRUG RESIST, V16, P279, DOI 10.1089/mdr.2010.0021
   Duzgun N, 2009, TISSUE ANTIGENS, V74, P539, DOI 10.1111/j.1399-0039.2009.01347.x
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Engel ME, 2014, PEDIATR INFECT DIS J, V33, P208, DOI 10.1097/INF.0b013e3182a5c32a
   Espinosa LE, 2003, J CLIN MICROBIOL, V41, P373, DOI 10.1128/JCM.41.1.373-378.2003
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Fae KC, 2013, INFLAMMATION, V36, P800, DOI 10.1007/s10753-013-9606-2
   FISCHETTI VA, 1988, J IMMUNOL, V141, P3592
   Friaes A, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-280
   Gu J, 1997, Zhonghua Nei Ke Za Zhi, V36, P308
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Haydardedeoglu FE, 2006, TISSUE ANTIGENS, V68, P293, DOI 10.1111/j.1399-0039.2006.00678.x
   Hernandez-Pacheco G, 2003, INT J CARDIOL, V92, P49, DOI 10.1016/S0167-5273(03)00040-8
   Hraoui M, 2011, MICROB DRUG RESIST, V17, P377, DOI 10.1089/mdr.2010.0160
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   Imohl M, 2010, FEMS IMMUNOL MED MIC, V58, P389, DOI 10.1111/j.1574-695X.2010.00652.x
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   Kamal H, 2010, ACTA CARDIOL, V65, P177, DOI 10.2143/AC.65.2.2047051
   Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892
   Kirvan CA, 2007, J IMMUNOL, V178, P7412, DOI 10.4049/jimmunol.178.11.7412
   Koutouzi F, 2015, J CLIN MICROBIOL, V53, P2015, DOI 10.1128/JCM.00301-15
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   Lopardo HA, 2005, J CLIN MICROBIOL, V43, P802, DOI 10.1128/JCM.43.2.802-807.2005
   Luca-Harari B, 2008, J CLIN MICROBIOL, V46, P79, DOI 10.1128/JCM.01626-07
   Ma Y, 2009, EPIDEMIOL INFECT, V137, P1414, DOI 10.1017/S0950268809002118
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   Martins CDO, 2014, CLIN MED INSIGHTS-CA, V8, P79, DOI 10.4137/CMC.S17622
   McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
   Meisal R, 2010, J CLIN MICROBIOL, V48, P842, DOI 10.1128/JCM.01312-09
   Messias-Reason IJ, 2009, CLIN EXP IMMUNOL, V157, P395, DOI 10.1111/j.1365-2249.2009.03975.x
   MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x
   Mukhopadhyay S, 2013, J HEART VALVE DIS, V22, P118
   Murray CJL, 2013, LANCET, V382, P491, DOI 10.1016/S0140-6736(13)61692-X
   O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409
   O'Grady KAF, 2007, MED J AUSTRALIA, V186, P565, DOI 10.5694/j.1326-5377.2007.tb01054.x
   OLMEZ U, 1993, SCAND J RHEUMATOL, V22, P49
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Ramasawmy R, 2008, CLIN VACCINE IMMUNOL, V15, P932, DOI 10.1128/CVI.00324-07
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Rehman S, 2009, IMMUNOL INVEST, V38, P812, DOI 10.3109/08820130903271415
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Rogers S, 2007, J INFECT DIS, V195, P1625, DOI 10.1086/513875
   Sanderson-Smith M, 2014, J INFECT DIS, V210, P1325, DOI 10.1093/infdis/jiu260
   Schafranski MD, 2008, MOL IMMUNOL, V45, P3827, DOI 10.1016/j.molimm.2008.05.013
   Seale AC, 2016, EMERG INFECT DIS, V22, P224, DOI 10.3201/eid2202.151358
   Settin A, 2007, PEDIATR CARDIOL, V28, P363, DOI 10.1007/s00246-006-0002-7
   Shea PR, 2011, EMERG INFECT DIS, V17, P2010, DOI 10.3201/eid1711.110159
   Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
   Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   Steer AC, 2008, EPIDEMIOL INFECT, V136, P621, DOI 10.1017/S095026880700917X
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
   Steer AC, 2009, NAT REV CARDIOL, V6, P689, DOI 10.1038/nrcardio.2009.162
   Tamayo E, 2014, J INFECTION, V68, P50, DOI 10.1016/j.jinf.2013.08.013
   Tanaka Y, 2016, J INFECT CHEMOTHER, V22, P727, DOI 10.1016/j.jiac.2016.06.013
   Tapia MD, 2015, PEDIATR INFECT DIS J, V34, P463, DOI 10.1097/INF.0000000000000608
   Tartof SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-327
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   Wani B A, 1997, Indian Heart J, V49, P152
   Williamson DA, 2014, NEW ZEAL MED J, V127, P55
NR 91
TC 5
Z9 5
U1 2
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2037
EI 1875-5550
J9 CURR PROTEIN PEPT SC
JI Curr. Protein Pept. Sci.
PY 2018
VL 19
IS 9
BP 900
EP 908
DI 10.2174/1389203718666170725115855
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA GN4AI
UT WOS:000438954300008
PM 28745221
DA 2020-11-26
ER

PT J
AU Ferreira, LRP
   Ferreira, FM
   Laugier, L
   Cabantous, S
   Navarro, IC
   Candido, DD
   Rigaud, VC
   Real, JM
   Pereira, GV
   Pereira, IR
   Ruivo, L
   Pandey, RP
   Savoia, M
   Kalil, J
   Lannes-Vieira, J
   Nakaya, H
   Chevillard, C
   Cunha-Neto, E
AF Pinto Ferreira, Ludmila Rodrigues
   Ferreira, Frederico Moraes
   Laugier, Laurie
   Cabantous, Sandrine
   Navarro, Isabela Cunha
   Candido, Darlan da Silva
   Rigaud, Vagner Carvalho
   Real, Juliana Monte
   Pereira, Glaucia Vilar
   Pereira, Isabela Resende
   Ruivo, Leonardo
   Pandey, Ramendra Pati
   Savoia, Marilda
   Kalil, Jorge
   Lannes-Vieira, Joseli
   Nakaya, Helder
   Chevillard, Christophe
   Cunha-Neto, Edecio
TI Integration of miRNA and gene expression profiles suggest a role for
   miRNAs in the pathobiological processes of acute Trypanosoma cruzi
   infection
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TISSUE-DAMAGE CONTROL; CHAGAS-DISEASE; INTERFERON-GAMMA; MESSENGER-RNA;
   IFN-GAMMA; MICRORNAS; CARDIOMYOPATHY; NRF2; GLOBALIZATION; DEFICIENCY
AB Chagas disease, caused by the parasite Trypanosoma cruzi, is endemic in Latin America. Its acute phase is associated with high parasitism, myocarditis and profound myocardial gene expression changes. A chronic phase ensues where 30% develop severe heart lesions. Mouse models of T. cruzi infection have been used to study heart damage in Chagas disease. The aim of this study was to provide an interactome between miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA expression profiling data from hearts of T. cruzi infected mice. Gene expression profiling revealed enrichment in biological processes and pathways associated with immune response and metabolism. Pathways, functional and upstream regulator analysis of the intersections between predicted targets of differentially expressed microRNAs and differentially expressed mRNAs revealed enrichment in biological processes and pathways such as IFN gamma, TNF alpha, NF-kappa B signaling signatures, CTL-mediated apoptosis, mitochondrial dysfunction, and Nrf2-modulated antioxidative responses. We also observed enrichment in other key heart disease-related processes like myocarditis, fibrosis, hypertrophy and arrhythmia. Our correlation study suggests that miRNAs may be implicated in the pathophysiological processes taking place the hearts of acutely T. cruzi-infected mice.
C1 [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Navarro, Isabela Cunha; Candido, Darlan da Silva; Rigaud, Vagner Carvalho; Pandey, Ramendra Pati; Savoia, Marilda; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Navarro, Isabela Cunha; Candido, Darlan da Silva; Rigaud, Vagner Carvalho; Pandey, Ramendra Pati; Savoia, Marilda; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Navarro, Isabela Cunha; Candido, Darlan da Silva; Rigaud, Vagner Carvalho; Pandey, Ramendra Pati; Savoia, Marilda; Kalil, Jorge; Cunha-Neto, Edecio] Iii INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Belo Horizonte, MG, Brazil.
   [Laugier, Laurie; Cabantous, Sandrine; Chevillard, Christophe] Aix Marseille Univ, INSERM, Fac Med, U1108, Marseille, France.
   [Real, Juliana Monte] Santa Marcelina Hosp, Dept Pediat Oncol, TUCCA Assoc Children & Adolescents Canc, Sao Paulo, Brazil.
   [Real, Juliana Monte] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil.
   [Pereira, Glaucia Vilar; Pereira, Isabela Resende; Ruivo, Leonardo; Lannes-Vieira, Joseli] Fiocruz MS, Oswaldo Cruz Inst, Lab Biol Interact, Rio De Janeiro, Brazil.
   [Nakaya, Helder] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Pathophysiol & Toxicol, BR-077010 Sao Paulo, Brazil.
   [Nakaya, Helder] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Chevillard, Christophe] Aix Marseille Univ, UMR1090, INSERM, Parc Sci Luminy Case 928,163 Ave Luminy, Marseille, France.
RP Ferreira, LRP (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Iii INCT, Inst Invest Immunol, Sao Paulo, Brazil.; Ferreira, LRP (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Belo Horizonte, MG, Brazil.; Chevillard, C (corresponding author), Aix Marseille Univ, INSERM, Fac Med, U1108, Marseille, France.; Chevillard, C (corresponding author), Aix Marseille Univ, UMR1090, INSERM, Parc Sci Luminy Case 928,163 Ave Luminy, Marseille, France.
EM lucamargo@gmail.com; christophe.chevillard@univ-amu.fr
RI Cunha-Neto, Edecio/B-4157-2009; Nakaya, Helder I/A-1397-2010; Rigaud,
   Vagner/I-4124-2013; Navarro, Isabela Cunha/V-7182-2017; Nakaya,
   Helder/AAF-1738-2020; Ferreira, Frederico Moraes/A-4622-2013; KALIL,
   JORGE/C-8029-2012; chevillard, christophe/A-7087-2015; Ferreira, Ludmila
   Rodrigues Pinto/B-4955-2015
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Nakaya, Helder
   I/0000-0001-5297-9108; Rigaud, Vagner/0000-0002-1194-9380; Navarro,
   Isabela Cunha/0000-0002-6844-2361; Nakaya, Helder/0000-0001-5297-9108;
   KALIL, JORGE/0000-0001-8415-4274; chevillard,
   christophe/0000-0002-5269-8813; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; da Silva Candido, Darlan/0000-0002-5080-3130
FU Institut National de la Sante et de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille University (Direction des Relations
   Internationales); USP-COFECUB; ARCUS II PACA; CNPq (Brazilian National
   Council for Scientific and Technological Development)National Council
   for Scientific and Technological Development (CNPq); FAPESP (Sao Paulo
   State Research Funding Agency-Brazil)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/50302-3]; plan << Laboratoire
   d'Excellence (LabEx) ParaFrap >> [ANR-11-LABX-0024]; French (Agence
   Nationale de Recherche-ANR)French National Research Agency (ANR);
   Brazilian (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM), Aix-Marseille University (Direction des
   Relations Internationales), the USP-COFECUB program, the ARCUS II PACA
   Bresil program, CNPq (the Brazilian National Council for Scientific and
   Technological Development), and FAPESP (Sao Paulo State Research Funding
   Agency-Brazil) << grant 2013/50302-3 >>. This work is supported by the
   plan << Laboratoire d'Excellence (LabEx) ParaFrap ANR-11-LABX-0024 >>.
   ECN and CC were recipients for an international program (Br-Fr-Chagas)
   funded by the French (Agence Nationale de Recherche-ANR) and the
   Brazilian (FAPESP) science funding agencies. ECN and JK are recipients
   of CNPq productivity awards.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Andrade DV, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003010
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   Brown DA, 2017, NAT REV CARDIOL, V14, P238, DOI 10.1038/nrcardio.2016.203
   Cardoso MS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002369
   Carod-Artal FJ, 2009, NEUROLOGIA, V24, P431
   Castaldi A, 2014, CIRC RES, V115, P273, DOI 10.1161/CIRCRESAHA.115.303252
   Cheng XH, 2013, FREE RADICAL BIO MED, V64, P4, DOI 10.1016/j.freeradbiomed.2013.07.025
   Chistiakov DA, 2016, J MOL CELL CARDIOL, V94, P107, DOI 10.1016/j.yjmcc.2016.03.015
   Coura J. R., 2014, MEM I O CRUZ
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   Ferreira LRP, 1999, J LEUKOCYTE BIOL, V66, P593
   Fillmore N, 2014, BRIT J PHARMACOL, V171, P2080, DOI 10.1111/bph.12475
   Garg N, 2003, BBA-MOL BASIS DIS, V1638, P106, DOI 10.1016/S0925-4439(03)00060-7
   Halkein J, 2013, J CLIN INVEST, V123, P2143, DOI 10.1172/JCI64365
   Healy Chris, 2015, Card Electrophysiol Clin, V7, P251, DOI 10.1016/j.ccep.2015.03.016
   Hotez PJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001498
   Hua YN, 2012, J CELL MOL MED, V16, P83, DOI 10.1111/j.1582-4934.2011.01307.x
   Kalil R, 2015, J AM COLL CARDIOL, V66, P1190, DOI 10.1016/j.jacc.2015.07.024
   Katz MG, 2016, AM J PHYSIOL-HEART C, V310, pH528, DOI 10.1152/ajpheart.00181.2015
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Keating SM, 2015, INT J CARDIOL, V199, P451, DOI 10.1016/j.ijcard.2015.07.040
   Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   Mensah GA, 2015, GLOB HEART, V10, P203, DOI 10.1016/j.gheart.2015.08.001
   Min PK, 2015, EUR J CLIN INVEST, V45, P860, DOI 10.1111/eci.12475
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Mukherjee S, 2003, PARASITOL RES, V91, P187, DOI 10.1007/s00436-003-0937-z
   Muraoka N, 2014, EMBO J, V33, P1565, DOI 10.15252/embj.201387605
   Navarro IC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003828
   Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pall ML, 2013, INT J MOL SCI, V14, P22274, DOI 10.3390/ijms141122274
   Perez-Molina JA, 2015, LANCET INFECT DIS, V15, P1347, DOI 10.1016/S1473-3099(15)00243-1
   Dias JCP, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/789758
   Ferreira LRP, 2014, WORLD J CARDIOL, V6, P782, DOI 10.4330/wjc.v6.i8.782
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Ropert C, 2002, MICROBES INFECT, V4, P1015, DOI 10.1016/S1286-4579(02)01609-X
   Satoh M, 2010, J CARD FAIL, V16, P404, DOI 10.1016/j.cardfail.2010.01.002
   Scalbert E, 2008, CURR OPIN PHARMACOL, V8, P181, DOI 10.1016/j.coph.2007.12.013
   Seeger T, 2016, J PHYSIOL-LONDON, V594, P2085, DOI 10.1113/JP270557
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Soares MP, 2015, BIOCHEM SOC T, V43, P663, DOI 10.1042/BST20150054
   Soares MP, 2014, TRENDS IMMUNOL, V35, P483, DOI 10.1016/j.it.2014.08.001
   Soares MBP, 2011, CELL CYCLE, V10, P1448, DOI 10.4161/cc.10.9.15487
   Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Tanowitz HB, 2015, EXPERT REV CARDIOVAS, V13, P1393, DOI 10.1586/14779072.2015.1103648
   Teixeira PC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001205
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Urbina JA, 2016, NEW ENGL J MED, V374, P189, DOI 10.1056/NEJMc1514453
   Vannucchi V, 2015, J CARDIOVASC MED, V16, P817, DOI 10.2459/JCM.0000000000000045
   Wan XX, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005954
   Wan XX, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003855
   Yu H, 2014, CURR DRUG TARGETS, V15, P817
NR 61
TC 8
Z9 8
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 21
PY 2017
VL 7
AR 17990
DI 10.1038/s41598-017-18080-9
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FQ7SE
UT WOS:000418562100030
PM 29269773
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Drug-Induced Anaphylaxis
SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Anaphylaxis; Drug allergy; Adverse drug reactions; Hypersensitivity;
   Nonsteroidal anti-inflammatory drugs; Epinephrine
ID WORLD-ALLERGY-ORGANIZATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   HYPERSENSITIVITY REACTIONS; DIAGNOSIS; MANAGEMENT; RISK;
   DESENSITIZATION; EPIDEMIOLOGY; ACTIVATION; ANESTHESIA
AB Drugs are among the main triggers of anaphylaxis, but identification of the culprit drug is frequently difficult. To confirm diagnosis of the causative agent, medical records and clinical history are fundamental. There are a few in vitro tests available in clinical practice, such as serum-specific IgE and basophil activation test. Skin tests are often useful for the diagnosis, although drug challenge is indicated in patients with inconclusive clinical history or to provide safe alternatives. Treatment of anaphylaxis is standard and intramuscular epinephrine is the main agent to prevent morbidity and mortality. Rapid desensitization may be indicated in selected cases.
C1 [Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Ave Eneas de Carvalho Aguiar 155,8th Floor, BR-05403900 Sao Paulo, Brazil.
RP Aun, MV (corresponding author), Ave Eneas de Carvalho Aguiar 155,8th Floor, BR-05403900 Sao Paulo, Brazil.
EM marcelovivoloaun@gmail.com
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
CR Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x
   Aranda A, 2011, ALLERGY, V66, P247, DOI 10.1111/j.1398-9995.2010.02460.x
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Aun MV, 2011, ALLERGY ASTHMA PROC, V32, P301, DOI 10.2500/aap.2011.32.3450
   Ayuso P, 2013, CLIN EXP ALLERGY, V43, P1097, DOI 10.1111/cea.12140
   Blatman KSH, 2017, J ALLER CL IMM-PRACT, V5, P587, DOI 10.1016/j.jaip.2017.03.016
   Bonadonna P, 2014, IMMUNOL ALLERGY CLIN, V34, P397, DOI 10.1016/j.iac.2014.01.014
   Bonamichi-Santos R, 2016, CURR PHARM DESIGN, V22, P6870, DOI 10.2174/1381612822666161025154506
   Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009
   Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142
   Caiado J, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0515-3
   Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P76, DOI 10.1016/j.jaip.2014.06.007
   Castells MC, 2015, J ALLER CL IMM-PRACT, V3, P350, DOI 10.1016/j.jaip.2015.03.015
   Decuyper II, 2017, DRUGS R&D, V17, P265, DOI 10.1007/s40268-017-0176-x
   Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350
   Ensina LF, 2014, J ALLER CL IMM-PRACT, V2, P825, DOI 10.1016/j.jaip.2014.08.016
   Faria E, 2014, J INVEST ALLERG CLIN, V24, P40
   Galvao VR, 2015, J ALLER CL IMM-PRACT, V3, P175, DOI 10.1016/j.jaip.2014.12.006
   Galvao VR, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0452-6
   Gaspar Ângela, 2012, Rev Port Imunoalergologia, V20, P173
   Giavina-Bianchi P, 2015, CURR TREAT OPTIONS A, V2, P268
   Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006
   Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P593, DOI 10.1016/j.jaip.2017.03.015
   Giavina-Bianchi P, 2016, CURR OPIN ALLERGY CL, V16, P323, DOI 10.1097/ACI.0000000000000292
   Gonzalez-Estrada A, 2017, ANN ALLERG ASTHMA IM, V118, P80, DOI 10.1016/j.anai.2016.10.025
   Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Jares EJ, 2015, J ALLER CL IMM-PRACT, V3, P780, DOI 10.1016/j.jaip.2015.05.012
   Karakaya G, 2013, RESP MED, V107, P967, DOI 10.1016/j.rmed.2013.03.014
   Kemp SF, 2011, ANAPHYLAXIS AND HYPERSENSITIVITY REACTIONS, P33, DOI 10.1007/978-1-60327-951-2_3
   Kim YJ, 2014, ALLERGY ASTHMA IMMUN, V6, P156, DOI 10.4168/aair.2014.6.2.156
   Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200
   Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x
   Krishna MT, 2014, CLIN EXP IMMUNOL, V178, P399, DOI 10.1111/cei.12424
   Kuruvilla M, 2015, IMMUNOL ALLERGY CLIN, V35, P303, DOI 10.1016/j.iac.2015.01.008
   Lee YS, 2017, ACTA ANAESTHESIOL TA
   Leone R, 2005, DRUG SAFETY, V28, P547, DOI 10.2165/00002018-200528060-00006
   Lieberman P, 2011, ANAPHYLAXIS AND HYPERSENSITIVITY REACTIONS, P1, DOI 10.1007/978-1-60327-951-2_1
   Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049
   McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022
   Mertes PM, 2011, J INVEST ALLERG CLIN, V21, P442
   Munoz-Cano R, 2016, J INVEST ALLERG CLIN, V26, P73, DOI 10.18176/jiaci.0046
   Park HK, 2017, ALLERGOL INT
   Picard M, 2017, J ALLER CL IMM-PRACT, V5, P600, DOI 10.1016/j.jaip.2016.12.001
   Picard M, 2016, J ALLERGY CLIN IMMUN, V137, P1154, DOI 10.1016/j.jaci.2015.10.039
   Garcia AP, 2010, J INVEST ALLERG CLIN, V20, P170
   Pumphrey RSH, 2011, ANAPHYLAXIS AND HYPERSENSITIVITY REACTIONS, P13, DOI 10.1007/978-1-60327-951-2_2
   Renaudin JM, 2013, ALLERGY, V68, P929, DOI 10.1111/all.12168
   Ribeiro-Vaz I, 2013, EUR J CLIN PHARMACOL, V69, P673, DOI 10.1007/s00228-012-1376-5
   Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303
   Simon RA, 2017, NSAIDS INCLUDING ASP
   Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1097/WOX.0b013e318211496c
   Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1
   Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9
   Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019
   Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051
   Tang MLK, 2009, CURR OPIN ALLERGY CL, V9, P351, DOI 10.1097/ACI.0b013e32832db95a
   Tanno LK, 2017, ALLERGY, V72, P120, DOI 10.1111/all.13006
   Techapornroong M, 2010, ASIAN PAC J ALLERGY, V28, P262
   VanDerKlauw MM, 1996, CLIN EXP ALLERGY, V26, P1355, DOI 10.1046/j.1365-2222.1996.d01-300.x
   Wang DY, 1998, PHARMACOEPIDEM DR S, V7, P269, DOI 10.1002/(SICI)1099-1557(199807/08)7:4<269::AID-PDS366>3.0.CO;2-3
   Yang MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005750
NR 62
TC 6
Z9 7
U1 1
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8561
EI 1557-8607
J9 IMMUNOL ALLERGY CLIN
JI Immunol. Allerg. Clin. North Am.
PD NOV
PY 2017
VL 37
IS 4
BP 629
EP +
DI 10.1016/j.iac.2017.06.002
PG 14
WC Allergy; Immunology
SC Allergy; Immunology
GA FL6UT
UT WOS:000414382400004
PM 28965631
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Kalil, J
AF Giavina-Bianchi, Pedro
   Kalil, Jorge
TI Diagnosis of Allergic Bronchopulmonary Aspergillosis Exacerbations
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Editorial Material
ID MANAGEMENT
C1 [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 Ap 211A, BR-01454010 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Agarwal R, 2013, CLIN EXP ALLERGY, V43, P850, DOI 10.1111/cea.12141
   Agarwal R, 2016, EXPERT REV RESP MED, V10, P1317, DOI 10.1080/17476348.2016.1249853
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   de Oliveira E, 2007, RESP MED, V101, P2352, DOI 10.1016/j.rmed.2007.06.018
   Giavina-Bianchi P, 2010, CLINICS, V65, P905, DOI 10.1590/S1807-59322010000900014
   Gothe F, 2017, J ALLER CL IMM-PRACT, V5, P1591, DOI 10.1016/j.jaip.2017.03.033
   Greenberger PA, 2014, J ALLER CL IMM-PRACT, V2, P703, DOI 10.1016/j.jaip.2014.08.007
   PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286
   Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525
NR 9
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD NOV-DEC
PY 2017
VL 5
IS 6
BP 1599
EP 1600
DI 10.1016/j.jaip.2017.06.024
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA FL9XW
UT WOS:000414614200017
PM 29122158
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Ricciardi, MJ
   Gonzalez-Nieto, L
   Pedreno-Lopez, N
   Bailey, VK
   Gutman, MJ
   Maxwell, HS
   Domingues, A
   Costa, PR
   Ferrari, L
   Goulart, R
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Kalil, J
   Timenetsky, MD
   Wrammert, J
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Ricciardi, Michael J.
   Gonzalez-Nieto, Lucas
   Pedreno-Lopez, Nuria
   Bailey, Varian K.
   Gutman, Martin J.
   Maxwell, Helen S.
   Domingues, Aline
   Costa, Priscilla R.
   Ferrari, Lilian
   Goulart, Raphaella
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Kalil, Jorge
   Timenetsky, Maria do Carmo
   Wrammert, Jens
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI Potent Plasmablast-Derived Antibodies Elicited by the National
   Institutes of Health Dengue Vaccine
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE B cell; Butantan-DV; TV003; dengue; monoclonal antibodies; plasmablast;
   vaccines
ID MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; B-CELLS; NEUTRALIZING
   ANTIBODIES; DISEASE SEVERITY; HIGHLY POTENT; EFFICACY; ENHANCEMENT;
   RECOMBINANT; RESPONSES
AB Exposure to dengue virus (DENV) is thought to elicit lifelong immunity, mediated by DENV-neutralizing antibodies (nAbs). However, Abs generated by primary infections confer serotype-specific protection, and immunity against other serotypes develops only after subsequent infections. Accordingly, the induction of these nAb responses acquired after serial DENV infections has been a long-sought-after goal for vaccination. Nonetheless, it is still unclear if tetravalent vaccines can elicit or recall nAbs. In this study, we have characterized the responses from a volunteer who had been previously exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, developed by the NIH and Butantan Institute. Eleven days after vaccination, we observed an similar to 70-fold expansion of the plasmablast population. We generated 21 monoclonal Abs (MAbs) from singly sorted plasmablasts. These MAbs were the result of clonal expansions and had significant levels of somatic hypermutation (SHM). Nineteen MAbs (90.5%) neutralized at least one DENV serotype at concentrations of 1 mu g/ml or less; 6 of the 21 MAbs neutralized three or more serotypes. Despite the tetravalent composition of the vaccine, we observed a neutralization bias in the induced repertoire: DENV3 was targeted by 18 of the 19 neutralizing MAbs (nMAbs). Furthermore, the P3D05 nMAb neutralized DENV3 with extraordinary potency (concentration to achieve half-maximal neutralization [Neut(50)] = 0.03 mu g/ml). Thus, the Butantan-DV vaccine engendered a mature, antigen-selected B cell repertoire. Our results suggest that preexisting responses elicited by a previous DENV3 infection were recalled by immunization.
   IMPORTANCE The dengue epidemic presents a global public health challenge that causes widespread economic burden and remains largely unchecked by existing control strategies. Successful control of the dengue epidemic will require effective prophylactic and therapeutic interventions. Several vaccine clinical efficacy trials are approaching completion, and the chances that one or more live attenuated tetravalent vaccines (LATVs) will be introduced worldwide is higher than ever. While it is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers are associated with protection, the Ab repertoire induced by LATVs remain uncharacterized. Here, we describe the isolation of potent (Neut(50) < 0.1 mu g/ml) nAbs from a DENV-seropositive volunteer immunized with the tetravalent vaccine Butantan-DV, which is currently in phase III trials.
C1 [Magnani, Diogo M.; Ricciardi, Michael J.; Gonzalez-Nieto, Lucas; Pedreno-Lopez, Nuria; Bailey, Varian K.; Gutman, Martin J.; Maxwell, Helen S.; Domingues, Aline; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Costa, Priscilla R.; Ferrari, Lilian; Goulart, Raphaella; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Univ, Sao Paulo, Brazil.
   [Timenetsky, Maria do Carmo] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Wrammert, Jens] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
   [Whitehead, Stephen S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA.
   [Burton, Dennis R.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.; Kallas, EG (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
EM esper.kalias@urp.br; dwatkins@med.miami.edu
RI Whitehead, Stephen/AAG-2787-2019; KALIL, JORGE/C-8029-2012; Martins,
   Mauricio/AAU-9226-2020
OI KALIL, JORGE/0000-0001-8415-4274; Martins, Mauricio/0000-0001-8336-216X;
   Kallas, Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406
FU Wallace H. Coulter Center for Translational Research, Miami, FL;
   Brazilian Development Bank (BNDES); Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases (NIAID, NIH);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI000987, ZIAAI000987, ZIAAI000987, ZIAAI000987, ZIAAI000987,
   ZIAAI000987, ZIAAI000987, ZIAAI000987, R01AI098446, R01AI098446,
   ZIAAI000987, R01AI098446, R01AI098446, R01AI098446, R01AI098446,
   ZIAAI000987, R01AI098446, ZIAAI000987] Funding Source: NIH RePORTER
FX This work was supported by funding from the Wallace H. Coulter Center
   for Translational Research, Miami, FL, the Brazilian Development Bank
   (BNDES), and the Intramural Research Program of the National Institute
   of Allergy and Infectious Diseases (NIAID, NIH).
CR Acosta EG, 2016, EXPERT REV VACCINES, V15, P467, DOI 10.1586/14760584.2016.1121814
   Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brien James D, 2013, Curr Protoc Microbiol, V31, DOI 10.1002/9780471729259.mc15d03s31
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Deng YQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016059
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Fibriansah G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7341
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Friberg H, 2012, VIRAL IMMUNOL, V25, P348, DOI 10.1089/vim.2012.0010
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halliley JL, 2010, VACCINE, V28, P3582, DOI 10.1016/j.vaccine.2010.02.088
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Halstead SB, 2013, VACCINE, V31, P4501, DOI 10.1016/j.vaccine.2013.06.079
   Halstead SB, 2012, LANCET, V380, P1535, DOI 10.1016/S0140-6736(12)61510-4
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109
   Nishiura H, 2007, J INFECT DIS, V195, P1007, DOI 10.1086/511825
   Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328
   Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Smith DP, 2013, MBIO, V4, DOI 10.1128/mBio.00133-12
   Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119
   Smith SA, 2012, J VIROL, V86, P2665, DOI 10.1128/JVI.06335-11
   Srikiatkhachorn A, 2016, EXPERT REV VACCINES, V15, P455, DOI 10.1586/14760584.2016.1116949
   Swaminathan S, 2013, LANCET INFECT DIS, V13, P191, DOI 10.1016/S1473-3099(13)70028-8
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032
   Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727
   Wilder-Smith A, 2016, EXPERT REV VACCINES, V15, P437, DOI 10.1586/14760584.2016.1143366
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
NR 48
TC 8
Z9 9
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2017
VL 91
IS 22
AR e00867-17
DI 10.1128/JVI.00867-17
PG 12
WC Virology
SC Virology
GA FL1WP
UT WOS:000414005400009
PM 28878078
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Terzian, ACB
   Schanoski, AS
   Mota, MTD
   Da Silva, RA
   Estofolete, CF
   Colombo, TE
   Rahal, P
   Hanley, KA
   Vasilakis, N
   Kalil, J
   Nogueiral, ML
AF Bernardes Terzian, Ana Carolina
   Schanoski, Alessandra Soares
   de Oliveira Mota, Minh' Tasso
   da Silva, Rafael Alves
   Estofolete, Cassia Fernanda
   Colombo, Tatiana Elias
   Rahal, Paula
   Hanley, Kathryn A.
   Vasilakis, Nikos
   Kalil, Jorge
   Nogueiral, Mauricio Lacerda
TI Viral Load and Cytokine Response Profile Does Not Support
   Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected
   Patients
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE ZIKV; DENV; ADE; cytokines
ID HEMORRHAGIC-FEVER; SHOCK-SYNDROME; DISEASE; STORMS
AB Background. The pathogenesis of severe dengue disease involves immune components as biomarkers. The mechanism by which some dengue virus (DENV)-infected individuals progress to severe disease is poorly understood. Most studies on the pathogenesis of severe dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk factor. With the circulation of Zika virus (ZIKV) in DENV-endemic areas, many people infected by ZIKV were likely exposed to DENV. The influence of such exposure on Zika disease outcomes remains unknown.
   Methods. We investigated whether patients previously exposed to DENV exhibited higher viremia when exposed to a subsequent, heterologous dengue or Zika infection than those patients not previously exposed to dengue. We measured viral loads and cytokine profile during patients' acute infections.
   Results. Neither dengue nor Zika viremia was higher in patients with prior DENV infection, although the power to detect such a difference was only adequate in the ZIKV analysis. Of the 10 cytokines measured, only 1 significant difference was detected: Levels of interleukin 1 beta (IL-1 beta) were lower in dengue-infected patients who had experienced a previous dengue infection than patients infected with dengue for the first time. However, power to detect differences between groups was low. In Zika-infected patients, levels of IL-1 beta showed a significant, positive correlation with viral load.
   Conclusions. No signs of ADE were observed in vivo in patients with acute ZIKV infection who had prior exposure to DENV.
C1 [Bernardes Terzian, Ana Carolina; de Oliveira Mota, Minh' Tasso; da Silva, Rafael Alves; Estofolete, Cassia Fernanda; Colombo, Tatiana Elias; Nogueiral, Mauricio Lacerda] Sao Paulo State Univ, Sao Jose do Rio Preto Sch Med, Sao Jose Do Rio Preto, Brazil.
   [Schanoski, Alessandra Soares] Sao Paulo State Univ, Butantan Inst, Sao Jose Do Rio Preto, Brazil.
   [Rahal, Paula] Sao Paulo State Univ, Dept Biol, Inst Biosci Letters & Exact Sci, Sao Jose Do Rio Preto, Brazil.
   [Hanley, Kathryn A.] New Mexico State Univ, Las Cruces, NM 88003 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Nogueiral, ML (corresponding author), Sao Jose do Rio Preto Sch Med FAMERP, Ave Brigadeiro Faria Lima,5416 Vila Sao Pedro, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM mnogueira@famerp.br
RI KALIL, JORGE/C-8029-2012; Schanoski, Alessandra/H-8144-2014; de Oliveira
   Mota, Manlio Tasso/E-2619-2013; Rahal, Paula/D-3871-2012; Vasilakis,
   Nikos/ABE-7318-2020; Nogueira, Mauricio L/B-7599-2012; Estofolete,
   Cassia/N-6673-2019
OI KALIL, JORGE/0000-0001-8415-4274; Schanoski,
   Alessandra/0000-0002-6514-8458; Rahal, Paula/0000-0001-5693-6148;
   Nogueira, Mauricio L/0000-0003-1102-2419; Estofolete,
   Cassia/0000-0001-7324-1591
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/21719-3, 2015/12295-0]; Butantan
   Institute; Brazilian National Institutes for Science and Technology for
   Dengue Studies (INCT em Dengue); FAPESP Zika Network; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U01AI115577-01];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI115577, R24AI120942, U01AI115577, U01AI115577, R24AI120942,
   R24AI120942, R24AI120942, R24AI120942, R24AI120942, U01AI115577] Funding
   Source: NIH RePORTER
FX This study was supported by the Sao Paulo Research Foundation (FAPESP)
   (grant number 2013/21719-3 to M. L. N. and fellowship grant number
   2015/12295-0 to A. C. B. T.); by the Butantan Institute; the Brazilian
   National Institutes for Science and Technology for Dengue Studies (INCT
   em Dengue); and the FAPESP Zika Network. M. L. N. is a Brazilian
   National Research Council (CNPq) fellow. N. V. and K. A. H. were
   supported by the National Institutes of Health (grant number
   1U01AI115577-01).
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Bronzoni RVD, 2005, J CLIN MICROBIOL, V43, P696, DOI 10.1128/JCM.43.2.696-702.2005
   Chutinimitkul S, 2005, J VIROL METHODS, V129, P8, DOI 10.1016/j.jviromet.2005.05.006
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guzman MG, 2005, SCIENCE, V309, P1495, DOI 10.1126/science.1115177
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   John DV, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0191-6
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Milligan GN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125476
   Montoya M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002357
   Nielsen DG, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-211
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Pawitan Jeanne A, 2011, Acta Med Indones, V43, P129
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Tsai TT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003320
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   Zompi S, 2012, VIRUSES-BASEL, V4, P62, DOI 10.3390/v4010062
NR 25
TC 54
Z9 55
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2017
VL 65
IS 8
BP 1260
EP 1265
DI 10.1093/cid/cix558
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FI5KR
UT WOS:000412022500002
PM 29017246
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Andrade, MC
   Almeida, M
   Pacheco, RR
   Agondi, RC
   Grecco, O
   Barreto, AK
   Kalil, J
   Barros, MT
   Kokron, CM
AF Andrade, Mayra Coutinho
   Almeida, Mila
   Pacheco, Rosilane R.
   Agondi, Rosana C.
   Grecco, Octavio
   Barreto, Ana Karolina
   Kalil, Jorge
   Barros, Myrthes T.
   Kokron, Cristina M.
TI Tomographic Pulmonary Progress in Patients with Antibody Defects
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Andrade, Mayra Coutinho; Almeida, Mila; Pacheco, Rosilane R.; Agondi, Rosana C.; Grecco, Octavio; Barreto, Ana Karolina; Kalil, Jorge; Barros, Myrthes T.; Kokron, Cristina M.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 043
BP S15
EP S15
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700041
DA 2020-11-26
ER

PT J
AU Cau, LP
   de Assis, JP
   Brugnolli, RM
   de Castro, RB
   Mouco, CC
   Grecco, O
   Kalil, J
   Barros, MT
   Kokron, CM
   Marinho, AKBB
AF Cau, Larissa Prando
   de Assis, Joao Paulo
   Brugnolli, Rebeca Mussi
   de Castro, Raisa Borges
   Mouco, Claudia Castilho
   Grecco, Octavio
   Kalil, Jorge
   Barros, Myrthes Toledo
   Kokron, Cristina Maria
   Barreto Berselli Marinho, Ana Karolina
TI Evolution of Patients with Hypogammaglobulinemia Secondary to the Use of
   Rituximab Accompanied in a Tertiary Outpatient Clinic
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Cau, Larissa Prando; de Assis, Joao Paulo; Brugnolli, Rebeca Mussi; de Castro, Raisa Borges; Mouco, Claudia Castilho; Grecco, Octavio; Kalil, Jorge; Barros, Myrthes Toledo; Kokron, Cristina Maria; Barreto Berselli Marinho, Ana Karolina] FMUSP, Hosp Clin, Clin Immunol & Allergy Serv, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 032
BP S11
EP S12
PG 2
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700030
DA 2020-11-26
ER

PT J
AU de Castro, RB
   Brugnolli, RM
   Penido, APC
   Grecco, JPDO
   Kalil, J
   Aun, MV
   Kokron, CM
   Marinho, AKBB
   Barros, MT
AF de Castro, Raisa Borges
   Brugnolli, Rebeca Mussi
   Costa Penido, Antonio Paulo
   de Assis Octavio Grecco, Joao Paulo
   Kalil, Jorge
   Aun, Marcelo Vivolo
   Kokron, Cristina Maria
   Barreto Berselli Marinho, Ana Karolina
   Barros, Myrthes Toledo
TI HIV Infection in a Patient with Hypogammaglobulinemia, Evolving with
   Severe Opportunistic Infections: Report of Two Cases
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [de Castro, Raisa Borges; Brugnolli, Rebeca Mussi; Costa Penido, Antonio Paulo; de Assis Octavio Grecco, Joao Paulo; Kalil, Jorge; Aun, Marcelo Vivolo; Kokron, Cristina Maria; Barreto Berselli Marinho, Ana Karolina; Barros, Myrthes Toledo] Univ Sao Paulo, MUSP, Hosp Clin,Immunol Dept, Discipline Clin Immunol & Allergy,Fac Med,Lab Med, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; Kokron, Cristina M/D-3140-2012
OI Aun, Marcelo V/0000-0001-9882-5200; Kokron, Cristina
   M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 031
BP S11
EP S11
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700029
DA 2020-11-26
ER

PT J
AU Goncalves, DG
   de Assis, JP
   Sini, B
   Marinho, AK
   Kokron, CM
   Grecco, O
   Kalil, J
   Barros, MT
AF Goncalves, Danilo Gois
   de Assis, Joao Paulo
   Sini, Bruno
   Marinho, Ana Karolina
   Kokron, Cristina Maria
   Grecco, Octavio
   Kalil, Jorge
   Barros, Myrthes Toledo
TI Thrombosis Association with Administration of Intravenous Human
   Immunoglobulin in Patients with Primary or Secondary Immunodeficiencies
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Goncalves, Danilo Gois; de Assis, Joao Paulo; Sini, Bruno; Marinho, Ana Karolina; Kokron, Cristina Maria; Grecco, Octavio; Kalil, Jorge; Barros, Myrthes Toledo] Univ Sao Paulo, Div Clin Immunol & Allergy, Fac Med, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 140
BP S55
EP S55
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700136
DA 2020-11-26
ER

PT J
AU Maia, LP
   Lopes, MM
   Dias, GMFS
   Penido, APC
   Grecco, O
   Marinho, AKBB
   Barros, MT
   Kalil, J
   Kokron, CM
AF Maia, L. P.
   Lopes, M. M.
   Dias, G. M. F. S.
   Penido, A. P. C.
   Grecco, O.
   Marinho, A. K. B. B.
   Barros, M. T.
   Kalil, J.
   Kokron, C. M.
TI Anxiety Disorder in Patients with Immunodeficiency of Antibodies Treated
   with Human Intravenous Immunoglobulin
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Maia, L. P.; Lopes, M. M.; Dias, G. M. F. S.; Penido, A. P. C.; Grecco, O.; Marinho, A. K. B. B.; Barros, M. T.; Kalil, J.; Kokron, C. M.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 023
BP S8
EP S8
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700021
DA 2020-11-26
ER

PT J
AU Mendonca, LO
   Grossi, A
   Cordova, PT
   Amorim, LC
   Kalil, J
   Castro, FM
   Pontillo, A
   Ceccherini, I
   Gattorno, M
   Barros, MTT
AF Mendonca, L. O.
   Grossi, A.
   Torres Cordova, P.
   Amorim, L. C.
   Kalil, J.
   Castro, F. M.
   Pontillo, A.
   Ceccherini, I.
   Gattorno, M.
   Toledo Barros, M. T.
TI A Case Report of a Novel Compound Heterozygous Mutation in a Brazilian
   Patient with Deficiency of IL1RA (DIRA)
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Mendonca, L. O.; Torres Cordova, P.; Amorim, L. C.; Kalil, J.; Castro, F. M.; Toledo Barros, M. T.] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Grossi, A.; Ceccherini, I.; Gattorno, M.] Univ Genoa, GianninaGaslini Inst, Mol Dept Unit, Genoa, Italy.
   [Pontillo, A.] Univ Sao Paulo, Immunogenet Lab, Sch Biomed Sci, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; Gattorno, Marco/AAL-2974-2020
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 052
BP S19
EP S19
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700049
DA 2020-11-26
ER

PT J
AU Lima, FMS
   Kokron, CM
   Barreto, AK
   Grecco, O
   Kalil, J
   Barros, MT
AF Souza Lima, Fabiana Mascarenhas
   Kokron, Cristina Maria
   Barreto, Ana Karolina
   Grecco, Octavio
   Kalil, Jorge
   Barros, Myrthes Toledo
TI Spleen-Portal Axis Abnormalities in Patients with Common Variable
   Immunodeficiency in a Tertiary Hospital in Sao Paulo, Brazil: Prevalence
   Analysis
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Souza Lima, Fabiana Mascarenhas; Barros, Myrthes Toledo] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012
OI Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 019
BP S7
EP S7
PG 1
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700017
DA 2020-11-26
ER

PT J
AU Laugier, L
   Frade, AF
   Ferreira, FM
   Baron, MA
   Teixeira, PC
   Cabantous, S
   Ferreira, LRP
   Louis, L
   Rigaud, VOC
   Gaiotto, FA
   Bacal, F
   Pomerantzeff, P
   Bocchi, E
   Kalil, J
   Santos, RHB
   Cunha-Neto, E
   Chevillard, C
AF Laugier, Laurie
   Frade, Amanda Farage
   Ferreira, Frederico Moraes
   Baron, Monique Andrade
   Teixeira, Priscila Camillo
   Cabantous, Sandrine
   Pinto Ferreira, Ludmila Rodrigues
   Louis, Laurence
   Carvalho Rigaud, Vagner Oliveira
   Gaiotto, Fabio Antonio
   Bacal, Fernando
   Pomerantzeff, Pablo
   Bocchi, Edimar
   Kalil, Jorge
   Barros Santos, Ronaldo Honorato
   Cunha-Neto, Edecio
   Chevillard, Christophe
TI Whole-Genome Cardiac DNA Methylation Fingerprint and Gene Expression
   Analysis Provide New Insights in the Pathogenesis of Chronic Chagas
   Disease Cardiomyopathy
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE epigenetic; methylation; cardiomyopathy; Chagas; gene expression
ID LYMPHOCYTES; DYSFUNCTION; WIDE
AB Background. Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and affects 10 million people worldwide. Approximately 12 000 deaths attributable to Chagas disease occur annually due to chronic Chagas disease cardiomyopathy (CCC), an inflammatory cardiomyopathy presenting with heart failure and arrythmia; 30% of infected subjects develop CCC years after infection. Genetic mechanisms play a role in differential progression to CCC, but little is known about the role of epigenetic modifications in pathological gene expression patterns in CCC patients' myocardium. DNA methylation is the most common modification in the mammalian genome.
   Methods. We investigated the impact of genome-wide cardiac DNA methylation on global gene expression in myocardial samples from end-stage CCC patients, compared to control samples from organ donors.
   Results. In total, 4720 genes were differentially methylated between CCC patients and controls, of which 399 were also differentially expressed. Several of them were related to heart function or to the immune response and had methylation sites in their promoter region. Reporter gene and in silico transcription factor binding analyses indicated promoter methylation modified expression of key genes. Among those, we found potassium channel genes KCNA4 and KCNIP4, involved in electrical conduction and arrythmia, SMOC2, involved in matrix remodeling, as well as enkephalin and RUNX3, potentially involved in the increased T-helper 1 cytokine-mediated inflammatory damage in heart.
   Conclusions. Results support that DNA methylation plays a role in the regulation of expression of pathogenically relevant genes in CCC myocardium, and identify novel potential disease pathways and therapeutic targets in CCC.
C1 [Laugier, Laurie; Cabantous, Sandrine; Chevillard, Christophe] Aix Marseille Univ, Genet & Immunol Malad Parasitaires, INSERM, Unite Mixte Rech S906,U906, Marseille, France.
   [Frade, Amanda Farage; Ferreira, Frederico Moraes; Baron, Monique Andrade; Teixeira, Priscila Camillo; Pinto Ferreira, Ludmila Rodrigues; Carvalho Rigaud, Vagner Oliveira; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Immunol, Inst Heart, Sao Paulo, Brazil.
   [Frade, Amanda Farage; Ferreira, Frederico Moraes; Baron, Monique Andrade; Teixeira, Priscila Camillo; Pinto Ferreira, Ludmila Rodrigues; Carvalho Rigaud, Vagner Oliveira; Kalil, Jorge; Cunha-Neto, Edecio] INCT, III, Sao Paulo, Brazil.
   [Frade, Amanda Farage] Brazil Univ, Dept Bioengn, Sao Paulo, Brazil.
   [Ferreira, Frederico Moraes; Pinto Ferreira, Ludmila Rodrigues] Univ Santo Amaro, Hlth Sci, Sao Paulo, Brazil.
   [Louis, Laurence] Aix Marseille Univ, Genet Med & Genom Fonct Plateforme Genom & Transc, INSERM, Unite Mixte Rech S910,U910, Marseille, France.
   [Gaiotto, Fabio Antonio; Barros Santos, Ronaldo Honorato] Univ Sao Paulo, Sch Med, Div Pathol, Inst Heart, Sao Paulo, Brazil.
   [Bacal, Fernando; Pomerantzeff, Pablo] Univ Sao Paulo, Sch Med, Div Heart Transplantat, Inst Heart, Sao Paulo, Brazil.
   [Bocchi, Edimar] Univ Sao Paulo, Sch Med, Div Heart Failure Unit, Inst Heart, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Chevillard, C (corresponding author), Univ Aix Marseille, INSERM, U906, Fac Med, 27 Bd Jean Moulin, F-13385 Marseille 05, France.
EM christophe.chevillard@univ-amu.fr
RI KALIL, JORGE/C-8029-2012; Rigaud, Vagner/I-4124-2013; chevillard,
   christophe/A-7087-2015; Ferreira, Ludmila Rodrigues Pinto/B-4955-2015;
   Cunha-Neto, Edecio/B-4157-2009; Frade, Amanda F/O-3322-2017
OI KALIL, JORGE/0000-0001-8415-4274; Rigaud, Vagner/0000-0002-1194-9380;
   chevillard, christophe/0000-0002-5269-8813; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Frade, Amanda F/0000-0002-9004-8811; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
FU Institut National de la Sante et de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille University (Direction des Relations
   Internationales); USP-COFECUB program; ARCUS II PACA Bresil program;
   CNPq (the Brazilian National Council for Scientific and Technological
   Development)National Council for Scientific and Technological
   Development (CNPq); FAPESP (Sao Paulo State Research Funding
   Agency-Brazil) [2013/50302-3]; plan Laboratoire d'Excellence (LabEx)
   ParaFrap [ANR-11-LABX-0024]; French (Agence Nationale de
   Recherche)French National Research Agency (ANR); Brazilian (FAPESP)
   science funding agency; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM); Aix-Marseille University (Direction des
   Relations Internationales); the USP-COFECUB program; the ARCUS II PACA
   Bresil program; CNPq (the Brazilian National Council for Scientific and
   Technological Development); and FAPESP (Sao Paulo State Research Funding
   Agency-Brazil) (grant 2013/50302-3). This work is supported by the plan
   Laboratoire d'Excellence (LabEx) ParaFrap ANR-11-LABX-0024. E. C.-N. and
   C. C. were recipients for an international program (Br-Fr-Chagas) funded
   by the French (Agence Nationale de Recherche) and Brazilian (FAPESP)
   science funding agencies. A. F. F. was a recipient of fellowships from
   FAPESP. E. C.-N. and J. K. are recipients of CNPq productivity awards.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Birlea SA, 2010, J INVEST DERMATOL, V130, P798, DOI 10.1038/jid.2009.347
   Cruz JS, 2016, AM J TROP MED HYG, V94, P1028, DOI 10.4269/ajtmh.15-0255
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   Davidson M, 2005, US patent, Patent No. 7223599
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   Dorri F, 2016, BIOINFORMATICS, V32, P1618, DOI 10.1093/bioinformatics/btw287
   Dotiwala F, 2016, NAT MED, V22, P210, DOI 10.1038/nm.4023
   Duygu Burcu, 2013, Frontiers in Genetics, V4, P219, DOI 10.3389/fgene.2013.00219
   Frade AF, 2016, J INFECT DIS, V214, P161, DOI 10.1093/infdis/jiw095
   Gerarduzzi C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90299
   Greenstein JL, 2000, CIRC RES, V87, P1026, DOI 10.1161/01.RES.87.11.1026
   Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73
   Haas J, 2013, EMBO MOL MED, V5, P413, DOI 10.1002/emmm.201201553
   Jo BS, 2016, GENOMICS, V108, P84, DOI 10.1016/j.ygeno.2016.07.001
   Karaji AG, 2011, J NEUROIMMUNE PHARM, V6, P608, DOI 10.1007/s11481-011-9314-3
   Ko HA, 2013, NEUROSCI LETT, V548, P44, DOI 10.1016/j.neulet.2013.05.020
   Le Bouter S, 2004, CIRCULATION, V110, P3028, DOI 10.1161/01.CIR.0000147187.78162.AC
   Rodriguez DAL, 2016, SCI REP-UK, V6, DOI 10.1038/srep31263
   Rodriguez DAL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004583
   Liang Xuan, 2016, Transl Perioper Pain Med, V1, P5
   MAJELLO B, 1995, ONCOGENE, V10, P1841
   Majumder P, 2011, GENES IMMUN, V12, P291, DOI 10.1038/gene.2010.77
   Navarro IC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003828
   Ng LL, 2017, J AM COLL CARDIOL, V69, P56, DOI 10.1016/j.jacc.2016.10.038
   Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Nunes MCP, 2013, J AM COLL CARDIOL, V62, P767, DOI 10.1016/j.jacc.2013.05.046
   Ferreira LRP, 2014, INT J CARDIOL, V175, P409, DOI 10.1016/j.ijcard.2014.05.019
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Rhodes KJ, 2004, J NEUROSCI, V24, P7903, DOI 10.1523/JNEUROSCI.0776-04.2004
   Roman-Campos D, 2013, MEM I OSWALDO CRUZ, V108, P243, DOI 10.1590/0074-0276108022013019
   Safe S, 2014, EXPERT OPIN THER TAR, V18, P759, DOI 10.1517/14728222.2014.914173
   Seo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078776
   Tang YQ, 2013, J BIOL CHEM, V288, P14727, DOI 10.1074/jbc.M113.466052
   Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
   Zou Q, 2015, J EXP MED, V212, P1323, DOI 10.1084/jem.20150110
NR 40
TC 8
Z9 8
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 1
PY 2017
VL 65
IS 7
BP 1103
EP 1111
DI 10.1093/cid/cix506
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FG8JB
UT WOS:000410675900007
PM 28575239
OA Green Published, Other Gold
DA 2020-11-26
ER

PT J
AU Galvao, CES
   Graudenz, GS
   Kalil, J
   Castro, FFM
AF Santos Galvao, Clovis Eduardo
   Graudenz, Gustavo Silveira
   Kalil, Jorge
   Morato Castro, Fabio Fernandes
TI Sensitization to cat allergen and its association with respiratory
   allergies: cross-sectional study
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE Immunization; Fel d 1 protein; Felis domesticus [supplementary concept];
   Skin tests; Allergy and immunology
ID EXPOSURE; PETS
AB Cats are a significant source of allergens that contribute towards worsening of allergic diseases. The aim of this study was to investigate the association between sensitization to cat allergens and allergic respiratory diseases. This was an observational retrospective study based on the skin prick tests results of patients at a tertiary-level hospital in Sao Paulo. A total of 1,985 test results were assessed. The prevalence of sensitization to cat allergen was 20% (399 patients). Our data indicated that in this population of atopic patients, a positive skin prick test result for cat allergen was not associated significantly with a diagnosis of respiratory allergy.
C1 [Santos Galvao, Clovis Eduardo; Graudenz, Gustavo Silveira; Kalil, Jorge; Morato Castro, Fabio Fernandes] Univ Sao Paulo HCFMUSP, Hosp Clin, Sao Paulo, SP, Brazil.
   [Santos Galvao, Clovis Eduardo; Graudenz, Gustavo Silveira; Kalil, Jorge; Morato Castro, Fabio Fernandes] Univ Sao Paulo HCFMUSP, Hosp Clin, Clin Immunol & Allergy Serv, Ave Dr Eneas de Carvalho Aguiar 155,8 Andar, BR-05403000 Sao Paulo, SP, Brazil.
RP Galvao, CES (corresponding author), Univ Sao Paulo HCFMUSP, Hosp Clin, Clin Immunol & Allergy Serv, Ave Dr Eneas de Carvalho Aguiar 155,8 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM cdgalvao@usp.br
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x
   De Vera MJ, 2003, ANN ALLERG ASTHMA IM, V91, P455, DOI 10.1016/S1081-1206(10)61513-X
   Gulbahar O, 2003, ANN ALLERG ASTHMA IM, V90, P635, DOI 10.1016/S1081-1206(10)61868-6
   Liccardi G, 2000, RESP MED, V94, P1109, DOI 10.1053/rmed.2000.0922
   Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x
NR 5
TC 0
Z9 0
U1 0
U2 2
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD SEP-OCT
PY 2017
VL 135
IS 5
BP 488
EP 490
DI 10.1590/1516-3180.2017.0072170617
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA FO9QC
UT WOS:000417223700012
PM 29116310
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Garcia, JF
   Aun, MV
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
AF Garcia, J. F.
   Aun, M., V
   Motta, A. A.
   Kalil, J.
   Giavina-Bianchi, P.
TI Intradermal test is a relevant biomarker of the outcome of rapid
   desensitization in penicillin allergy
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 17-21, 2017
CL Helsinki, FINLAND
SP European Acad Allergy & Clin Immunol
C1 [Garcia, J. F.; Aun, M., V; Motta, A. A.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 1
Z9 1
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2017
VL 72
SU 103
SI SI
MA 0256
BP 222
EP 222
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA FF3CM
UT WOS:000408773101144
DA 2020-11-26
ER

PT J
AU Garcia, JF
   Takejima, PM
   Aun, MV
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
AF Garcia, J. F.
   Takejima, P. M.
   Aun, M., V
   Motta, A. A.
   Kalil, J.
   Giavina-Bianchi, P.
TI Gender influence on hereditary angioedema with C1-inhibitor deficiency
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 17-21, 2017
CL Helsinki, FINLAND
SP European Acad Allergy & Clin Immunol
C1 [Garcia, J. F.; Takejima, P. M.; Aun, M., V; Motta, A. A.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2017
VL 72
SU 103
SI SI
MA 0735
BP 451
EP 452
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA FF3CM
UT WOS:000408773103129
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Vieira, VA
   Sauer, MM
   Tomiyama, HI
   Kalil, J
   Kallas, EG
AF Tarosso, Leandro F.
   Vieira, Vinicius A.
   Sauer, Mariana M.
   Tomiyama, Helena I.
   Kalil, Jorge
   Kallas, Esper G.
TI Conserved HIV-1 Gag p24 Epitopes Elicit Cellular Immune Responses That
   Impact Disease Outcome
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE antigen processing and presentation; Gag; immune response; T cells
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; VIRAL LOAD;
   HIV-1-SPECIFIC CD4(+); FUNCTIONAL PROFILE; ESCAPE MUTATIONS; INFECTION;
   VACCINE; NONPROGRESSORS; REPLICATION
AB Although the breadth of the human immunodeficiency virus type 1 (HIV-1)-specific cellular immune response and its impact on the control of viral replication have already been addressed, reported data have proven controversial. We hypothesize that the nature of targeted epitopes, rather than the simple breadth or magnitude of responses, correlates with disease outcome. In this study, we explore the occurrence of patterns of Gag p24 recognition among untreated HIV-1-infected patients by identifying the epitopes that compose such patterns and how they distinctly associate with disease progression. Utilizing enzyme-linked immunospot (ELISPOT) interferon gamma (IFN-gamma), we screened cellular responses of 27 HIV-1-infected subjects against 15-mer peptides encompassing the whole Gag p24 protein. Obtained data were used to develop a clustering analysis that allowed definition of two groups of individuals with totally distinct patterns of recognition. Although targeted Gag p24 peptides were completely different between the two groups, the breadth and magnitude of the responses were not. Interestingly, viral control and preservation of CD4(+) T cells were increased in one group. In addition, we compared genetic conservation of amino acid sequences of the recognized peptides, as well as of the human leucocyte antigen class I (HLA-I)-restricted epitopes within them. Subjects presenting higher control of HIV-1 replication targeted more conserved epitopes, and higher genetic variation was present mainly in anchor residues for HLA-I molecules. We strengthen the existing evidence from cases of HIV-1 infection in humans that, cellular immune responses targeting conserved epitopes, rather than the magnitude and breadth of responses, associate with a better control of viral replication and maintenance of peripheral CD4(+) T cell counts.
C1 [Tarosso, Leandro F.; Vieira, Vinicius A.; Sauer, Mariana M.; Tomiyama, Helena I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Tarosso, Leandro F.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Ribeirao Preto, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kallas, Esper/0000-0003-2026-6925
FU Ministry of HealthMinistry of Health - Turkey [914/BRA/3014]; Sao Paulo
   City Health Department [2004-0.168.922-7]; FAPESP (Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo)Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2010/51609-7, 04/15856-9]
FX The authors are especially grateful to Amelia Raj, Laurel Stewart, and
   David O'Connor for their critical reading of our article and suggestions
   for writing improvements. We also thank Douglas Nixon, Raphael R
   Almeida, and Maria Teresa Giret for valuable discussion on the presented
   data. The authors were supported and granted by Brazilian Program for
   STD and AIDS-Ministry of Health Grant 914/BRA/3014 and the Sao Paulo
   City Health Department Grant 2004-0.168.922-7 (to E.G.K.), and the
   FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) Grants
   2010/51609-7 (to L.F.T.), 04/15856-9 (to E.G.K.). The NIH AIDS Research
   and Reference Reagent Program, Division of AIDS, NIAID, NIH, provided
   the complete HIV-1 Gag Consensus subtype B 15-mer peptide set.
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Daucher M, 2008, J VIROL, V82, P4102, DOI 10.1128/JVI.02212-07
   Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002
   Engram JC, 2009, J IMMUNOL, V183, P706, DOI 10.4049/jimmunol.0803746
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Gray CM, 2009, J VIROL, V83, P470, DOI 10.1128/JVI.01678-08
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Honeyborne I, 2007, J VIROL, V81, P3667, DOI 10.1128/JVI.02689-06
   Huang SH, 2008, J IMMUNOL, V181, P8103, DOI 10.4049/jimmunol.181.11.8103
   Jin X, 2002, J VIROL, V76, P12603, DOI 10.1128/JVI.76.24.12603-12610.2002
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Koup RA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009015
   Kunwar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064405
   Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001
   Liepe J, 2014, BIOMOLECULES, V4, P585, DOI 10.3390/biom4020585
   Liu JY, 2006, J VIROL, V80, P11991, DOI 10.1128/JVI.01348-06
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Murakoshi H, 2015, J VIROL, V89, P5330, DOI 10.1128/JVI.00020-15
   Natarajan K, 1999, Rev Immunogenet, V1, P32
   Perez CL, 2013, AIDS RES HUM RETROV, V29, P602, DOI [10.1089/aid.2012.0171, 10.1089/AID.2012.0171]
   Peut V, 2007, J VIROL, V81, P13125, DOI 10.1128/JVI.01408-07
   Rolland M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001424
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Shalekoff S, 2008, JAIDS-J ACQ IMM DEF, V48, P245, DOI 10.1097/QAI.0b013e31816fdc77
   Sunshine J, 2014, J VIROL, V88, P1354, DOI 10.1128/JVI.02361-13
   Turk G, 2008, J VIROL, V82, P2853, DOI 10.1128/JVI.02260-07
   Wang YYE, 2009, J VIROL, V83, P1845, DOI 10.1128/JVI.01061-08
NR 37
TC 1
Z9 1
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2017
VL 33
IS 8
SI SI
BP 832
EP 842
DI 10.1089/aid.2016.0168
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FD0DN
UT WOS:000407210100012
PM 28594230
OA Green Published
DA 2020-11-26
ER

PT J
AU Iahn-Aun, M
   Aun, MV
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
   Hayashida, SA
   Baracat, EC
   Maciel, GA
AF Iahn-Aun, Marina
   Aun, Marcelo Vivolo
   Motta, Antonio Abilio
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Hayashida, Sylvia Asaka
   Baracat, Edmund Chada
   Maciel, Gustavo Arantes
TI The Complex Interaction Between Polycystic Ovary Syndrome and Hereditary
   Angioedema: Case Reports and Review of the Literature
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; MOLECULAR-WEIGHT KININOGEN;
   ANGIONEUROTIC-EDEMA; C1 INHIBITOR; POSTMENOPAUSAL WOMEN; NORMAL
   C1-INHIBITOR; CONTACT ACTIVATION; IN-VIVO; MANAGEMENT; DIAGNOSIS
AB Importance Hereditary angioedema (HAE) is a rare but severe disease, with high risk of death, and attacks have been associated to high estrogen levels. Polycystic ovary syndrome (PCOS) is a common hyperandrogenic condition, which is frequently treated with combined oral contraceptives.
   Objective The aim of this study was to describe 2 clinical cases of young women diagnosed as having PCOS who developed HAE attacks after the introduction of combined estrogen-progestin pills to treat PCOS symptoms.
   Evidence Acquisition Literature review of sex hormones' role in genesis of HAE attacks and possible mechanisms involved.
   Results In the cases reported, after initiation of combined contraceptives, patients presented with facial swelling with airway involvement (laryngeal edema) and abdominal pain. They had a familial history of angioedema and normal C1 inhibitor (C1-INH) levels, leading to the diagnosis of HAE with normal C1-INH (HAEnC1-INH) or HAE type III. After suspension of exogenous estrogen, patients remained asymptomatic from HAE.
   Conclusions and Relevance HAEnC1-INH is an estrogen-dependent form of HAE. It is well established that exogenous estrogen triggers attacks of all types of HAE. However, this is the first description of the association between PCOS and HAE, in which PCOS could be masking HAE symptoms. We propose that PCOS might have a protective role regarding HAE attacks, because of its particular hormonal features, that is, hyperandrogenism and relative stable levels of estradiol. The use of combined estrogen-progestin compounds in women with PCOS and HAE must be avoided, and treatment must be individualized.
   Target Audience Obstetricians and gynecologists, family physicians.
   Learning Objectives After completing this activity, the learner should be better able to evaluate for hereditary angioedema (HAE) in patients with recurrent angioedema attacks and abdominal pain, particularly when they are under exogenous estrogen treatment; ask patients about personal or familial history of angioedema attacks before prescribing exogenous estrogen; recall that isolated progestins can be used as long-term prophylaxis to HAE patients; and explain that hyperandrogenism of polycystic ovary syndrome could mask HAE symptoms.
C1 [Iahn-Aun, Marina; Hayashida, Sylvia Asaka; Baracat, Edmund Chada; Maciel, Gustavo Arantes] Univ Sao Paulo, Fac Med, Disciplina Ginecol, Sao Paulo, Brazil.
   [Aun, Marcelo Vivolo; Motta, Antonio Abilio; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
RP Iahn-Aun, M (corresponding author), Ave Brigadeiro Luis Antonio 4267, Sao Paulo, SP, Brazil.
EM marinaiahn@gmail.com
RI KALIL, JORGE/C-8029-2012; Hayashhida, Sylvia Asaka/AAI-8701-2020; Aun,
   Marcelo V/E-6775-2014; Baracat, Edmund C/H-3800-2012; Maciel, Gustavo
   A/D-2291-2009
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Baracat, Edmund C/0000-0003-0111-9030; 
CR Azziz R, 2004, J CLIN ENDOCR METAB, V89, P2745, DOI 10.1210/jc.2003-032046
   Azziz R, 2003, OBSTET GYNECOL, V101, P995, DOI 10.1016/S0029-7844(02)02725-4
   Azziz R, 2009, FERTIL STERIL, V91, P456, DOI 10.1016/j.fertnstert.2008.06.035
   Betschel S, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-50
   Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546
   Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7
   Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064
   Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1
   Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648
   Bouillet Laurence, 2010, Allergy Asthma Clin Immunol, V6, P17, DOI 10.1186/1710-1492-6-17
   Broekmans FJ, 2006, BJOG-INT J OBSTET GY, V113, P1210, DOI 10.1111/j.1471-0528.2006.01008.x
   Caballero T, 2011, J INVEST ALLERG CLIN, V21, P333
   Caccia S, 2014, PEDIAT ALLER IMM PUL, V27, P159, DOI 10.1089/ped.2014.0425
   Christiansen SC, 2015, ALLERGY ASTHMA PROC, V36, P145, DOI 10.2500/aap.2015.36.3831
   Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380
   Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510
   Craig T, 2012, WORLD ALLERGY ORGAN, V5, P182, DOI 10.1097/WOX.0b013e318279affa
   DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115
   Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028
   de Maat S, 2014, INT J LAB HEMATOL, V36, P374, DOI 10.1111/ijlh.12222
   Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092
   DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1
   DONALDSON VH, 1966, PEDIATRICS, V37, P1017
   Eckes B, 1999, EUR J INTERN MED S1, V10, P187
   FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076
   Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098
   FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580
   GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602
   Giavina-Bianchi P, 2015, CLIN EXP ALLERGY, V45, P1142, DOI 10.1111/cea.12551
   Giavina-Bianchi P, 2011, CLINICS, V66, P1627, DOI 10.1590/S1807-59322011000900021
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211
   Huang A, 2010, FERTIL STERIL, V93, P1938, DOI 10.1016/j.fertnstert.2008.12.138
   Jayasena CN, 2014, NAT REV ENDOCRINOL, V10, P624, DOI 10.1038/nrendo.2014.102
   Joseph K, 2013, J ALLERGY CLIN IMMUN, V132, P470, DOI 10.1016/j.jaci.2013.03.026
   Joseph K, 2009, J ALLERGY CLIN IMMUN, V124, P143, DOI 10.1016/j.jaci.2009.02.006
   LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1
   LEVI M, 1991, J CLIN INVEST, V88, P1155, DOI 10.1172/JCI115416
   Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X
   OSLER W, 1888, AM J MED SCI, V95, P362, DOI DOI 10.1097/00000441-188804000-00004
   PERRICONE R, 1992, CLIN EXP IMMUNOL, V90, P401
   PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1
   Renne T, 2005, J IMMUNOL, V175, P3377, DOI 10.4049/jimmunol.175.5.3377
   Riedl MA, 2013, J ALLER CL IMM-PRACT, V1, P427, DOI 10.1016/j.jaip.2013.06.004
   ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708
   SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802
   Schunkert H, 1997, CIRCULATION, V95, P39, DOI 10.1161/01.CIR.95.1.39
   Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6
   Yip J, 1992, Australas J Dermatol, V33, P35, DOI 10.1111/j.1440-0960.1992.tb00050.x
   Zawadski J. K., 1992, POLYCYSTIC OVARY SYN, P377
   Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313
   Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977
NR 52
TC 1
Z9 1
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD JUL
PY 2017
VL 72
IS 7
BP 417
EP 424
DI 10.1097/OGX.0000000000000457
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FA3GE
UT WOS:000405330200012
PM 28715060
DA 2020-11-26
ER

PT J
AU Hill, J
   Janko, M
   Angell, KF
   Day, K
   Noujaim, MG
   Kalil, J
   Steele, SR
AF Hill, Jeremy
   Janko, Matthew
   Angell, Kelsey F.
   Day, Kathy
   Noujaim, Michael G.
   Kalil, Jennifer
   Steele, Scott R.
TI Hospital text paging communication as a surgical quality improvement
   initiative
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Pager; Text paging; Quality improvement; Communication; Surgery
ID EFFICACY
AB Background: Studies on medicine wards have shown that numeric pages can be disruptive of workflow and patient care. We created a quality improvement program among surgical ward nurses and residents and hypothesized that a text-based, urgency-stratified initiative would improve communication at no detriment to patient care.
   Methods: Surgery residents recorded preintervention data for 1 mo including number of total pages, text pages, and numeric pages received from surgical floors. Nurses and residents completed surveys to assess preintervention satisfaction with communication, responsiveness, and workflow. Nurses were then instructed to use text paging for nonurgent issues. Paging data were again recorded for 1 mo, surveys repeated, and patient safety and satisfaction data collected. Primary endpoints evaluated included patient safety and satisfaction data. Secondary endpoints included communication satisfaction of nurses and residents.
   Results: After text paging implementation, 40.1% of nonurgent pages sent from nurses to resident physicians were alphanumeric texts versus only 17.9% before implementation (P < 0.0001). There was a 19.5% reduction in the number of nonurgent numeric pages sent (P < 0.0001). Overall, 70% of nurses responded postintervention that text paging was the preferred method of contacting a physician and that the text paging initiative improved efficiency. After implementation, 62% of nurses thought that overall communication with clinicians improved. In addition, there was no change in patient safety issues or patient satisfaction.
   Conclusions: Our text paging initiative for all nonurgent pages from nurses to residents improved physiciane-nurse workflow and communication on the surgical ward with no decrease in patient satisfaction or safety. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Hill, Jeremy; Janko, Matthew; Angell, Kelsey F.; Day, Kathy; Kalil, Jennifer] Univ Hosp Cleveland Med Ctr, Dept Surg, Cleveland, OH USA.
   [Hill, Jeremy; Janko, Matthew; Angell, Kelsey F.; Day, Kathy; Kalil, Jennifer] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Noujaim, Michael G.] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA USA.
   [Steele, Scott R.] Cleveland Clin, Dept Colorectal Surg, 9500 Euclid Ave A30, Cleveland, OH 44195 USA.
RP Steele, SR (corresponding author), Cleveland Clin, Dept Colorectal Surg, 9500 Euclid Ave A30, Cleveland, OH 44195 USA.
EM steeles3@ccf.org
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Noujaim, Michael/0000-0001-9329-5765;
   Steele, Scott/0000-0002-4510-0289; Kalil, Jennifer/0000-0001-6304-4690
CR Khanna RR, 2016, JAMA-J AM MED ASSOC, V315, P22
   Plant MA, 2015, TEACH LEARN MED, V27, P215, DOI 10.1080/10401334.2015.1011646
   Prochaska Micah T, 2015, JMIR Med Inform, V3, pe37, DOI 10.2196/medinform.4797
   Przybylo JA, 2014, J HOSP MED, V9, P573, DOI 10.1002/jhm.2228
   Smith AD, 2016, SURGERY, V159, P930, DOI 10.1016/j.surg.2015.06.066
   The Joint Commission, SENT EV DAT ROOT CAU
   Wu RC, 2012, INT J MED INFORM, V81, P723, DOI 10.1016/j.ijmedinf.2012.05.014
NR 7
TC 4
Z9 4
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD JUN 1
PY 2017
VL 213
BP 84
EP 89
DI 10.1016/j.jss.2017.02.008
PG 6
WC Surgery
SC Surgery
GA FA3RV
UT WOS:000405363000012
PM 28601337
DA 2020-11-26
ER

PT J
AU Gil, JM
   Weber, R
   Rosales, CB
   Rodrigues, H
   Sennes, LU
   Kalil, J
   Chagury, A
   Miziara, ID
AF Gil, Julio M.
   Weber, Raimar
   Rosales, Claudia B.
   Rodrigues, Helcio
   Sennes, Luiz U.
   Kalil, Jorge
   Chagury, Azis
   Miziara, Ivan D.
TI Study of the association between human leukocyte antigens (HLA) and
   pemphigus vulgaris in Brazilian patients
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID ASHKENAZI JEWISH PATIENTS; II MOLECULAR ALLELES; DRB1-ASTERISK-14
   ALLELES; HLA-DRB1 POLYMORPHISMS; JAPANESE PATIENTS; ITALIAN PATIENTS;
   SUSCEPTIBILITY; HAPLOTYPES; FOLIACEUS; PEPTIDES
AB BackgroundPemphigus vulgaris is a mucocutaneous blistering autoimmune disease that manifests as painful blisters or erosions on the skin and/or mucosal surfaces. IgG autoantibodies target desmoglein, playing a major role in disease pathogenesis. Genetic predisposal to pemphigus vulgaris, especially the HLA DR and DQ alleles, has been known since the 1980s. The unique constitution of the Brazilian population favors exploratory genetic studies.
   MethodsThe study group included 51 patients with a confirmed diagnosis of pemphigus vulgaris from a tertiary hospital in Sao Paulo city, Sao Paulo, southeast Brazil. DNA was extracted from peripheral blood, and HLA A, B, C, DR, and DQ typing was performed. The control group was composed of a database of 297 deceased donors from the city of SAo Paulo typed with the same method. The statistical significance level was adjusted using the Bonferroni correction depending on the phenotypic frequencies evaluated for HLA A, HLA B, HLA C, HLA DRB1, DQA1, and HLA DQB1.
   ResultsThe alleles HLA-B*57, HLA-C*15, HLA-DRB1*04:02, HLA-DRB1*08:04, HLA-DRB1*14:01, DQA1*03:01, DQB1*03:02, and DQB1*05:03 were associated with susceptibility. Alleles HLA DRB1*04:02 and HLA-DRB1*14:01 and their respective haplotypes DRB1*04-DQA1*03:01-DQB1*03:02, and DRB1*14-DQA1*01:01-DQB1*05:03 conferred a risk of the disease.
   ConclusionsThe DRB1*04:02 and DQB1*05:03 alleles are associated with pemphigus vulgaris in our study as well as in various populations. The association with HLA-DRB1*08:04 in our study was confirmed to be specific to this allele and not to linkage disequilibrium to any adjacent gene. The association between HLA-B*57 and pemphigus vulgaris is reported for the first time in the present study.
C1 [Gil, Julio M.; Weber, Raimar; Sennes, Luiz U.; Chagury, Azis; Miziara, Ivan D.] Univ Sao Paulo, ENT Dept Sch Med, Ave Dr Eneas Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
   [Rosales, Claudia B.; Rodrigues, Helcio; Kalil, Jorge] Univ Sao Paulo, Transplant Immunol & Immunogenet Lab, Heart Inst INCOR, Sao Paulo, Brazil.
RP Gil, JM (corresponding author), Univ Sao Paulo, ENT Dept Sch Med, Ave Dr Eneas Carvalho Aguiar 255, BR-05403000 Sao Paulo, Brazil.
EM juliogil@usp.br
RI Sennes, Luiz/AAN-2955-2020; KALIL, JORGE/C-8029-2012; Miziara, Ivan
   D/L-8422-2013; Sennes, Luiz U/E-6815-2012
OI Sennes, Luiz/0000-0002-7378-9490; KALIL, JORGE/0000-0001-8415-4274;
   Sennes, Luiz U/0000-0002-7378-9490
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/23678-2]
FX The Labtype kits that made this work possible were supported by FAPESP
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) process #
   2013/23678-2.
CR AHMED AR, 1990, P NATL ACAD SCI USA, V87, P7658, DOI 10.1073/pnas.87.19.7658
   Black M, 2005, ORAL DIS, V11, P119, DOI 10.1111/j.1601-0825.2005.01139.x
   Carcassi C, 1996, TISSUE ANTIGENS, V48, P662, DOI 10.1111/j.1399-0039.1996.tb02689.x
   Delgado JC, 1997, HUM IMMUNOL, V57, P110, DOI 10.1016/S0198-8859(97)00203-6
   Dey-Rao R, 2013, GENES IMMUN, V14, P487, DOI 10.1038/gene.2013.44
   Brochado MJF, 2016, J AUTOIMMUN, V72, P19, DOI 10.1016/j.jaut.2016.04.007
   Glorio R, 2002, J CUTAN MED SURG, V6, P422, DOI 10.1007/s10227-001-0157-z
   Gokdemir G, 2006, INT J DERMATOL, V45, P170, DOI 10.1111/j.1365-4632.2004.02589.x
   Gonzalez-Escribano MF, 1998, TISSUE ANTIGENS, V52, P275, DOI 10.1111/j.1399-0039.1998.tb03043.x
   Hahn-Ristic K, 2002, J EUR ACAD DERMATOL, V16, P68, DOI 10.1046/j.1468-3083.2002.00384.x
   Harfouch E, 2014, INT J DERMATOL, V53, P1460, DOI 10.1111/ijd.12184
   Klein HS, 2002, HOMOBRASILIS ASPECTO, P92
   Koc CK, 2013, INT J DERMATOL, V52, P53, DOI 10.1111/j.1365-4632.2012.05541.x
   Lee E, 2006, HUM IMMUNOL, V67, P125, DOI 10.1016/j.humimm.2005.09.003
   Loiseau P, 2000, J AUTOIMMUN, V15, P67, DOI 10.1006/jaut.2000.0388
   Lombardi ML, 1996, TISSUE ANTIGENS, V47, P228, DOI 10.1111/j.1399-0039.1996.tb02545.x
   Lombardi ML, 1999, J INVEST DERMATOL, V113, P107, DOI 10.1046/j.1523-1747.1999.00626.x
   Miyagawa S, 1997, J INVEST DERMATOL, V109, P615, DOI 10.1111/1523-1747.ep12337585
   Miyagawa S, 2002, BRIT J DERMATOL, V146, P52, DOI 10.1046/j.1365-2133.2002.04564.x
   Miyagawa S, 1999, TISSUE ANTIGENS, V54, P333, DOI 10.1034/j.1399-0039.1999.540402.x
   Mobini N, 1997, HUM IMMUNOL, V57, P62, DOI 10.1016/S0198-8859(97)00182-1
   Mortazavi H, 2013, J DERMATOL, V40, P244, DOI 10.1111/1346-8138.12071
   NIIZEKI H, 1994, TISSUE ANTIGENS, V44, P248, DOI 10.1111/j.1399-0039.1994.tb02390.x
   Orouji E, 2014, J DERMATOL SCI, V76, P153, DOI 10.1016/j.jdermsci.2014.08.006
   Parnicka Z, 2013, INT J IMMUNOGENET, V40, P471, DOI 10.1111/iji.12052
   RIBEIRO Darcy, 1995, POVO BRASILEIRO FORM, P470
   Saenz-Cantele AM, 2007, TISSUE ANTIGENS, V69, P318, DOI 10.1111/j.1399-0039.2007.00826.x
   SCHARF SJ, 1988, P NATL ACAD SCI USA, V85, P3504, DOI 10.1073/pnas.85.10.3504
   SCHARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215, DOI 10.1073/pnas.86.16.6215
   Scully C, 1999, BRIT J DERMATOL, V140, P84
   Shoimer I, 2015, J AM ACAD DERMATOL, V72, pAB30
   Tallab T, 2001, INT J DERMATOL, V40, P570, DOI 10.1046/j.1365-4362.2001.01247.x
   Tsankov N, 2000, INT J DERMATOL, V39, P104, DOI 10.1046/j.1365-4362.2000.00864.x
   Vega-Memije M E, 2001, Gac Med Mex, V137, P535
   Weber R, 2011, TISSUE ANTIGENS, V78, P92, DOI 10.1111/j.1399-0039.2011.01705.x
   Weinberg MA, 1997, ORAL SURG ORAL MED O, V84, P517, DOI 10.1016/S1079-2104(97)90269-9
   WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935
   Yamamoto T, 2011, J DERMATOL, V38, P711, DOI 10.1111/j.1346-8138.2010.01057.x
   Yan L, 2012, BRIT J DERMATOL, V167, P768, DOI 10.1111/j.1365-2133.2012.11040.x
NR 39
TC 6
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD MAY
PY 2017
VL 56
IS 5
BP 557
EP 562
DI 10.1111/ijd.13577
PG 6
WC Dermatology
SC Dermatology
GA ER3PE
UT WOS:000398708500024
PM 28197992
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kailas, EG
   Kalil, J
   Passero, LFD
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan Pereira
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kailas, Esper G.
   Kalil, Jorge
   Passero, Luiz Felipe D.
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI p16(INK4a) Expression and Immunologic Aging in Chronic HIV Infection
   (vol 11, e0166759, 2016)
SO PLOS ONE
LA English
DT Correction
RI Hunt, Peter W./P-2976-2017; KALIL, JORGE/C-8029-2012; Nixon,
   Douglas/AAU-5734-2020; Cunha-Neto, Edecio/B-4157-2009
OI Hunt, Peter W./0000-0002-4571-4870; KALIL, JORGE/0000-0001-8415-4274;
   Nixon, Douglas/0000-0002-2801-1786; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Kallas, Esper/0000-0003-2026-6925
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH RePORTER;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30 AI027763] Funding Source: Medline
CR PEREIRARIBEIRO S, 2016, PLOS ONE, V11
   Ribeiro SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166759
NR 2
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2017
VL 12
IS 4
AR e0176509
DI 10.1371/journal.pone.0176509
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES9KM
UT WOS:000399875900134
PM 28426830
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Lavini-Ramos, C
   Silva, HM
   Soares-Schanoski, A
   Monteiro, SM
   Ferreira, LRP
   Pacanaro, AP
   Gomes, S
   Batista, J
   Fae, K
   Kalil, J
   Coelho, V
AF Lavini-Ramos, Carolina
   Silva, Hernandez Moura
   Soares-Schanoski, Alessandra
   Monteiro, Sandra Maria
   Ferreira, Ludmila Rodrigues Pinto
   Pacanaro, Ana Paula
   Gomes, Samirah
   Batista, Janaina
   Fae, Kellen
   Kalil, Jorge
   Coelho, Veronica
TI MMP9 integrates multiple immunoregulatory pathways that discriminate
   high suppressive activity of human mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VERSUS-HOST-DISEASE; REGULATORY T-CELLS; BONE-MARROW; INDOLEAMINE
   2,3-DIOXYGENASE; LYMPHOCYTE-PROLIFERATION; STROMAL CELLS; IFN-GAMMA;
   PROTEIN NETWORKS; PROGENITOR CELLS; GENE-EXPRESSION
AB The mechanisms underlying mesenchymal stem cells' (MSC) suppressive potency are largely unknown. We here show that highly suppressive human adipose tissue-derived MSC (AdMSC) display and induce a differential immunologic profile, upon ongoing AdMSC suppressive activity, promoting: (i) early correlated inhibition of IFN-gamma and TNF-alpha production, along IL-10 increase, (ii) CD73(+) Foxp3(+) Treg subset expansion, and (iii) specific correlations between gene expression increases, such as: MMP9 correlated with CCL22, TNF, FASL, RUNX3, and SEMAD4 in AdMSC and, in T cells, MMP9 upregulation correlated with CCR4, IL4 and TBX21, among others, whereas MMP2 correlated with BCL2 and LRRC31. MMP9 emerged as an integrating molecule for both AdMSC and T cells in molecular networks built with our gene expression data, and we confirmed upregulation of MMP9 and MMP2 at the protein level, in AdMSC and T cells, respectively. MMP2/9 inhibition significantly decreased AdMSC suppressive effect, confirming their important role in suppressive acitivity. We conclude that MMP9 and 2 are robust new players involved in human MSC immunoregulatory mechanisms, and the higher suppressive activity correlates to their capacity to trigger a coordinated action of multiple specific molecules, mobilizing various immunoregulatory mechanisms.
C1 [Lavini-Ramos, Carolina; Silva, Hernandez Moura; Soares-Schanoski, Alessandra; Monteiro, Sandra Maria; Ferreira, Ludmila Rodrigues Pinto; Pacanaro, Ana Paula; Batista, Janaina; Fae, Kellen; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.
   [Lavini-Ramos, Carolina; Silva, Hernandez Moura; Soares-Schanoski, Alessandra; Monteiro, Sandra Maria; Ferreira, Ludmila Rodrigues Pinto; Pacanaro, Ana Paula; Batista, Janaina; Fae, Kellen; Kalil, Jorge; Coelho, Veronica] Iii INCT Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Gomes, Samirah; Coelho, Veronica] Univ Sao Paulo, Ctr Cellular & Mol Therapy Studies NETCEM, Sao Paulo, Brazil.
   [Ferreira, Ludmila Rodrigues Pinto] Univ Santo Amaro UNISA, Sao Paulo, Brazil.
   [Gomes, Samirah] Univ Sao Paulo, Renal Div, Lab Cellular Genet & Mol Nephrol, Sao Paulo, SP, Brazil.
   [Fae, Kellen] Crucell Holland & BV, Bacterial Vaccines Discovery & Early Dev, Leiden, Netherlands.
   [Silva, Hernandez Moura] NYU, Sch Med, Skirball Inst, Mol Pathogenesis Program,Kimmel Ctr Biol & Med, New York, NY 10016 USA.
   [Soares-Schanoski, Alessandra] Butantan Inst, Biotechnol Ctr, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.; Coelho, V (corresponding author), Iii INCT Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.; Coelho, V (corresponding author), Univ Sao Paulo, Ctr Cellular & Mol Therapy Studies NETCEM, Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Ferreira, Ludmila Rodrigues Pinto/B-4955-2015; KALIL, JORGE/C-8029-2012;
   Soares Schanoski, Alessandra/H-8144-2014
OI Ferreira, Ludmila Rodrigues Pinto/0000-0001-9944-6691; KALIL,
   JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581; Soares
   Schanoski, Alessandra/0000-0002-6514-8458
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [830058/2008-7]
FX The authors thank Dr. Fabio Kamanoto for plastic surgeries and
   liposuction material. We thank "Hemocentro do Hospital das Clinicas",
   Sao Paulo, Brazil for providing us with blood samples. We also thank
   Claudia Barros for statistical analysis and Vinicius Bassaneze for help
   with differentiation assays and Helder Nakaya for critically reading
   this manuscript. We also thank CNPq for the provided fellowship
   (830058/2008-7) and financial support.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Aksu AE, 2008, CLIN IMMUNOL, V127, P348, DOI 10.1016/j.clim.2008.02.003
   Augello A, 2005, EUR J IMMUNOL, V35, P1482, DOI 10.1002/eji.200425405
   Batten P, 2006, TISSUE ENG, V12, P2263, DOI 10.1089/ten.2006.12.2263
   Ben-Ami E, 2014, AUTOIMMUN REV, V13, P187, DOI 10.1016/j.autrev.2013.09.007
   Benson HL, 2011, AM J RESP CELL MOL, V44, P700, DOI 10.1165/rcmb.2010-0125OC
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916
   Campeau PM, 2009, BLOOD, V114, P3181, DOI 10.1182/blood-2009-02-205708
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657
   Crop MJ, 2010, CLIN EXP IMMUNOL, V162, P474, DOI 10.1111/j.1365-2249.2010.04256.x
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dazzi F, 2008, EUR J IMMUNOL, V38, P1479, DOI 10.1002/eji.200838433
   Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512
   DelaRosa O, 2009, TISSUE ENG PT A, V15, P2795, DOI [10.1089/ten.tea.2008.0630, 10.1089/ten.TEA.2008.0630]
   Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007
   Ding YC, 2009, DIABETES, V58, P1797, DOI 10.2337/db09-0317
   Djouad F, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2153
   Dorronsoro A, 2014, EUR J IMMUNOL, V44, P480, DOI 10.1002/eji.201343668
   Duffy MM, 2011, EUR J IMMUNOL, V41, P2840, DOI 10.1002/eji.201141499
   English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001
   Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189
   Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002
   Gramaglia I, 1998, J IMMUNOL, V161, P6510
   Granero-Molto F., STEM CELLS
   Grigoropoulos NF, 2006, CURR OPIN PHARMACOL, V6, P169, DOI 10.1016/j.coph.2005.11.006
   Hansen JA, 2010, CURR OPIN HEMATOL, V17, P483, DOI 10.1097/MOH.0b013e32833eb770
   He XL, 2006, PLOS GENET, V2, P826, DOI 10.1371/journal.pgen.0020088
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Hutloff A, 1999, NATURE, V397, P263
   Igura K, 2004, CYTOTHERAPY, V6, P543, DOI 10.1080/14653240410005366-1
   Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138
   Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373-004-8183-7
   Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780
   Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008
   Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365-2796.2007.01844.x
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Lei HL, 2013, MOL BIOL REP, V40, P885, DOI 10.1007/s11033-012-2129-3
   Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150
   Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007
   Nasef A, 2007, TRANSPLANTATION, V84, P231, DOI 10.1097/01.tp.0000267918.07906.08
   Nasef A, 2007, GENE EXPRESSION, V13, P217
   Phinney DG, 2012, J CELL BIOCHEM, V113, P2806, DOI 10.1002/jcb.24166
   Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Ren GW, 2010, J IMMUNOL, V184, P2321, DOI 10.4049/jimmunol.0902023
   Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060
   Riezu-Boj JI, 2011, J HEPATOL, V54, P422, DOI 10.1016/j.jhep.2010.07.014
   Saldanha-Araujo F, 2011, STEM CELL RES, V7, P66, DOI 10.1016/j.scr.2011.04.001
   Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554
   Shankland SJ, 2006, KIDNEY INT, V69, P2131, DOI 10.1038/sj.ki.5000410
   Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997
   Stoltz JF, 2006, BIO-MED MATER ENG, V16, pS3
   Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496
NR 54
TC 5
Z9 5
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 13
PY 2017
VL 7
AR 874
DI 10.1038/s41598-017-00923-0
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ER8AI
UT WOS:000399036900015
PM 28408751
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Anagusko, CLY
   Lopes, MM
   Cau, LP
   Marques, PQ
   Salles, PD
   Castro, FM
   Kalil, J
   Yang, AC
AF Anagusko, Claudia Leiko Yonekura
   Lopes, Mariele Morandin
   Cau, Larissa Prando
   Marques, Paula Quadros
   Salles, Pamella Diogo
   Castro, Fabio M.
   Kalil, Jorge
   Yang, Ariana Campos
TI Severity profile of cow milk protein allergy IgE mediated
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Anagusko, Claudia Leiko Yonekura; Lopes, Mariele Morandin; Cau, Larissa Prando; Marques, Paula Quadros; Salles, Pamella Diogo; Castro, Fabio M.; Kalil, Jorge; Yang, Ariana Campos] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 457
BP AB143
EP AB143
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800359
DA 2020-11-26
ER

PT J
AU Cordova, PT
   Pedroso, NF
   Mello, MF
   Salles-Cunha, P
   Kalil, J
   Castro, FM
   Yang, AC
AF Cordova, Pablo Torres
   Pedroso, Natalia Falci
   Mello, Marcella Fonseca
   Salles-Cunha, Patricia
   Kalil, Jorge
   Castro, Fabio M.
   Yang, Ariana Campos
TI Safety to Extensively Heated Cow's Milk Challenge in Children with
   Severe Cow's Milk Allergy
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Cordova, Pablo Torres; Pedroso, Natalia Falci; Mello, Marcella Fonseca; Salles-Cunha, Patricia; Kalil, Jorge; Castro, Fabio M.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Yang, Ariana Campos] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, SP, Brazil.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 387
BP AB123
EP AB123
DI 10.1016/j.jaci.2016.12.398
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800289
OA Bronze
DA 2020-11-26
ER

PT J
AU Garcia, JFB
   Aun, MV
   Garro, LS
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Garcia, Juliana F. B.
   Aun, Marcelo V.
   Garro, Laila Sabino
   Kalil, Jorge
   Motta, Antonio Abilio
   Giavina-Bianchi, Pedro
TI Risk Stratification for Penicillin Desensitization in Allergic Pregnant
   Women with Syphilis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Garcia, Juliana F. B.; Aun, Marcelo V.; Garro, Laila Sabino; Kalil, Jorge; Motta, Antonio Abilio; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 102
BP AB31
EP AB31
DI 10.1016/j.jaci.2016.12.159
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800005
OA Bronze
DA 2020-11-26
ER

PT J
AU Lopes, MM
   Salles, PD
   Dantas, P
   Kalil, J
   Motta, AA
   Agondi, RC
AF Lopes, Mariele Morandin
   Salles, Pamella Diogo
   Dantas, Paula
   Kalil, Jorge
   Motta, Antonio Abilio
   Agondi, Rosana Camara
TI Chronic Spontaneous Urticaria: Response to Antileukotriene
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Lopes, Mariele Morandin; Salles, Pamella Diogo] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Dantas, Paula; Kalil, Jorge; Motta, Antonio Abilio; Agondi, Rosana Camara] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 772
BP AB246
EP AB246
DI 10.1016/j.jaci.2016.12.792
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800671
OA Bronze
DA 2020-11-26
ER

PT J
AU Takejima, P
   Garcia, JFB
   Aun, MV
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Takejima, Priscila
   Garcia, Juliana F. B.
   Aun, Marcelo V.
   Kalil, Jorge
   Motta, Antonio Abilio
   Giavina-Bianchi, Pedro
TI Gender Influence on Hereditary Angioedema with C1-inhibitor Deficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Takejima, Priscila; Garcia, Juliana F. B.; Aun, Marcelo V.; Kalil, Jorge; Motta, Antonio Abilio; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 743
BP AB237
EP AB237
DI 10.1016/j.jaci.2016.12.762
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800643
OA Bronze
DA 2020-11-26
ER

PT J
AU Teixeira, AR
   Saraiva, BM
   Kalil, J
   Castro, FM
   Galvao, CES
AF Teixeira, Adriana Rodrigues
   Saraiva, Beatriz M.
   Kalil, Jorge
   Castro, Fabio M.
   Galvao, Clovis Eduardo S.
TI Local production of IgE and other immune mediators in the nasal lavage
   fluid of allergic rhinitis patients before and after specific
   immunotherapy with Dermatophagoides pteronyssinus
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Teixeira, Adriana Rodrigues; Saraiva, Beatriz M.; Galvao, Clovis Eduardo S.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Castro, Fabio M.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Castro, Fabio/AAP-5433-2020
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 486
BP AB152
EP AB152
DI 10.1016/j.jaci.2016.12.499
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EV4AF
UT WOS:000401699800388
OA Bronze
DA 2020-11-26
ER

PT J
AU Lima, CFM
   Saraiva, BM
   Kalil, J
   Castro, FM
   Galvao, CES
AF Mafra Lima, Cynthia F.
   Saraiva, Beatriz M.
   Kalil, Jorge
   Castro, Fabio M.
   Galvao, Clovis Eduardo S.
TI Inflammatory cell response, functional and biochemical features of the
   airways of professional cleaning workers upon exposure in the workplace
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Mafra Lima, Cynthia F.; Saraiva, Beatriz M.; Galvao, Clovis Eduardo S.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Castro, Fabio M.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 79
BP AB24
EP AB24
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EO8NM
UT WOS:000396946000080
DA 2020-11-26
ER

PT J
AU Ferreira, LRP
   Ferreira, FM
   Nakaya, HI
   Deng, XT
   Cndido, DD
   de Oliveira, LC
   Billaud, JN
   Lanteri, MC
   Rigaud, VOC
   Seielstad, M
   Kalil, J
   Fernandes, F
   Ribeiro, ALP
   Sabino, EC
   Cunha-Neto, E
AF Pinto Ferreira, Ludmila Rodrigues
   Ferreira, Frederico Moraes
   Nakaya, Helder Imoto
   Deng, Xutao
   Cndido, Darlan da Silva
   de Oliveira, Lea Campos
   Billaud, Jean-Noel
   Lanteri, Marion C.
   Rigaud, Vagner Oliveira-Carvalho
   Seielstad, Mark
   Kalil, Jorge
   Fernandes, Fabio
   Ribeiro, Antonio Luiz P.
   Sabino, Ester Cerdeira
   Cunha-Neto, Edecio
TI Blood Gene Signatures of Chagas Cardiomyopathy With or Without
   Ventricular Dysfunction
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Chagas disease; whole-blood transcriptome; Cardiomyopathy; NK cells
ID TRYPANOSOMA-CRUZI INFECTION; SET ENRICHMENT ANALYSIS; T-CELLS;
   HEART-DISEASE; NK CELLS; LYMPHOCYTES; BIOMARKERS; MICROARRAY; MORBIDITY;
   FAILURE
AB Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects 7 million people in Latin American areas of endemicity. About 30% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopathy characterized by hypertrophy, fibrosis, and myocarditis. Further studies are necessary to understand the molecular mechanisms of disease progression. Transcriptome analysis has been increasingly used to identify molecular changes associated with disease outcomes. We thus assessed the whole-blood transcriptome of patients with Chagas disease. Microarray analysis was performed on blood samples from 150 subjects, of whom 30 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2 groups had CCC with either a preserved or reduced left ventricular ejection fraction [LVEF]). Each Chagas disease group displayed distinct gene expression and functional pathway profiles. The most different expression patterns were between CCC groups with a preserved or reduced LVEF. A more stringent analysis indicated that 27 differentially expressed genes, particularly those related to natural killer (NK)/CD8(+) T-cell cytotoxicity, separated the 2 groups. NK/CD8(+) T-cell cytotoxicity could play a role in determining Chagas disease progression. Understanding genes associated with disease may lead to improved insight into CCC pathogenesis and the identification of prognostic factors for CCC progression.
C1 [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Cndido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Kalil, Jorge; Fernandes, Fabio] Univ Sao Paulo, Inst Heart, Cardiomyopathy Unit, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes; Cndido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nakaya, Helder Imoto] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Pathophysiol & Toxicol, Sao Paulo, Brazil.
   [de Oliveira, Lea Campos; Sabino, Ester Cerdeira] Univ Sao Paulo, Inst Trop Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Cndido, Darlan da Silva; Rigaud, Vagner Oliveira-Carvalho; Kalil, Jorge; Cunha-Neto, Edecio] Natl Inst Sci & Technol, Inst Invest Immunol, Berhampur, Orissa, India.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes] Univ Santo Amaro, Sao Paulo, Brazil.
   [Ribeiro, Antonio Luiz P.] Univ Fed Minas Gerais, Hosp Clin, Minas Gerais, Brazil.
   [Ribeiro, Antonio Luiz P.] Univ Fed Minas Gerais, Fac Med, Minas Gerais, Brazil.
   [Nakaya, Helder Imoto] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Deng, Xutao; Lanteri, Marion C.; Seielstad, Mark] Blood Syst Res Inst, Berhampur, Orissa, India.
   [Deng, Xutao] Dept Lab Med, San Francisco, CA USA.
   [Lanteri, Marion C.; Seielstad, Mark] Univ Calif San Francisco, Inst Human Genet, Dept Lab Med, San Francisco, CA 94143 USA.
   [Billaud, Jean-Noel] Qiagen, Dept BioInformat, Redwood City, CA USA.
RP Cunha-Neto, E (corresponding author), Heart Inst InCor, Immunol Lab, Ave Dr Eneas Carvalho Aguiar 44,Bloco II,9 Andar, BR-05403900 Sao Paulo, Brazil.
EM ede-cunha@usp.br
RI Rigaud, Vagner/I-4124-2013; Ferreira, Frederico Moraes/A-4622-2013;
   Sabino, Ester Cerdeira/F-7750-2010; Ribeiro, Antonio L/C-2707-2009;
   Ferreira, Ludmila Rodrigues Pinto/B-4955-2015; Seielstad,
   Mark/T-7841-2019; Candido, Darlan/F-7209-2017; Cunha-Neto,
   Edecio/B-4157-2009; Nakaya, Helder I/A-1397-2010; Nakaya,
   Helder/AAF-1738-2020; KALIL, JORGE/C-8029-2012
OI Rigaud, Vagner/0000-0002-1194-9380; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Ribeiro, Antonio L/0000-0002-2740-0042;
   Ferreira, Ludmila Rodrigues Pinto/0000-0001-9944-6691; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Nakaya, Helder I/0000-0001-5297-9108;
   Nakaya, Helder/0000-0001-5297-9108; KALIL, JORGE/0000-0001-8415-4274;
   Seielstad, Mark/0000-0001-5783-1401; da Silva Candido,
   Darlan/0000-0002-5080-3130
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI098461]; National Heart, Lung, and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI)
   [HHSN268200417175C]; Sao Paulo (Brazil) Research Foundation (FAPESP)
   [2013/50302-3]; Brazilian National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI098461, U19AI098461,
   P50AI098461, P50AI098461, P50AI098461, U19AI098461, P50AI098461,
   P50AI098461, P50AI098461, U19AI098461, U19AI098461, P50AI098461,
   U19AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   U19AI098461, U19AI098461, P50AI098461, P50AI098461, U19AI098461,
   U19AI098461, P50AI098461, U19AI098461, U19AI098461, P50AI098461,
   P50AI098461, U19AI098461, P50AI098461, P50AI098461, U19AI098461,
   U19AI098461, P50AI098461, P50AI098461, U19AI098461, P50AI098461,
   P50AI098461, P50AI098461, U19AI098461, U19AI098461, P50AI098461,
   U19AI098461, U19AI098461] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (grant P50AI098461), the National Heart, Lung, and
   Blood Institute (grant HHSN268200417175C), the Sao Paulo (Brazil)
   Research Foundation (FAPESP) (grant 2013/50302-3 to E. C.- N.), and the
   Brazilian National Council for Scientific and Technological Development
   (CNPq) (research productivity awards to H. I. N., A. L. R., E. C.- N.,
   E. S., and J. K.).
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bjorkstrom NK, 2012, BLOOD, V120, P3455, DOI 10.1182/blood-2012-03-416867
   Brodskyn CI, 1996, CLIN EXP IMMUNOL, V105, P450, DOI 10.1046/j.1365-2249.1996.d01-785.x
   Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996
   Coura JR, 2015, MEM I OSWALDO CRUZ, V110, P275, DOI 10.1590/0074-0276150001
   Cunha-Neto E, 2006, AUTOIMMUNITY, V39, P41, DOI 10.1080/08916930500485002
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   Dotiwala F, 2016, NAT MED, V22, P210, DOI 10.1038/nm.4023
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Gascon J, 2014, EXPERT REV ANTI-INFE, V12, P393, DOI 10.1586/14787210.2014.896194
   Giraldo NA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002038
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Hidron A, 2010, CLIN MICROBIOL REV, V23, P324, DOI 10.1128/CMR.00054-09
   Higuchi M L, 1995, Arq Bras Cardiol, V64, P251
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Abel LCJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/345659
   Kalil R, 2015, J AM COLL CARDIOL, V66, P1190, DOI 10.1016/j.jacc.2015.07.024
   Kauffmann A, 2009, BIOINFORMATICS, V25, P2092, DOI 10.1093/bioinformatics/btp354
   Keating SM, 2015, INT J CARDIOL, V199, P451, DOI 10.1016/j.ijcard.2015.07.040
   Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789
   Li SZ, 2013, SEMIN IMMUNOL, V25, P209, DOI 10.1016/j.smim.2013.05.003
   Lieke T, 2006, CLIN EXP IMMUNOL, V145, P357, DOI 10.1111/j.1365-2249.2006.03118.x
   Longhi SA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002906
   Maciejak A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0149-z
   Marin-Neto JA, 2009, REV ESP CARDIOL, V62, P1211, DOI 10.1016/S0300-8932(09)73071-4
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
   Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067
   Padilla AM, 2009, CURR OPIN IMMUNOL, V21, P385, DOI 10.1016/j.coi.2009.07.006
   Pedrotty DM, 2012, PROG CARDIOVASC DIS, V55, P64, DOI 10.1016/j.pcad.2012.06.003
   Nunes MCP, 2013, J AM COLL CARDIOL, V62, P767, DOI 10.1016/j.jacc.2013.05.046
   Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X
   Rassi A, 2009, MEM I OSWALDO CRUZ, V104, P152, DOI 10.1590/S0074-02762009000900021
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sabino EC, 2015, EUR J HEART FAIL, V17, P416, DOI 10.1002/ejhf.220
   Sabino EC, 2013, CIRCULATION, V127, P1105, DOI 10.1161/CIRCULATIONAHA.112.123612
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Silva CP, 2008, ARQ BRAS CARDIOL, V91, P358
   Song JS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r178
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   Talvani A, 2004, MEM I OSWALDO CRUZ, V99, P645, DOI 10.1590/S0074-02762004000600020
   Vitelli-Avelar DM, 2006, CLIN EXP IMMUNOL, V145, P81, DOI 10.1111/j.1365-2249.2006.03123.x
   Vitelli-Avelar DM, 2005, SCAND J IMMUNOL, V62, P297, DOI 10.1111/j.1365-3083.2005.01668.x
NR 49
TC 16
Z9 16
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 1
PY 2017
VL 215
IS 3
BP 387
EP 395
DI 10.1093/infdis/jiw540
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EP2HT
UT WOS:000397204700008
PM 28003350
OA Green Published
DA 2020-11-26
ER

PT J
AU Martins, CD
   Demarchi, L
   Ferreira, FM
   Pomerantzeff, PMA
   Brandao, C
   Sampaio, RO
   Spina, GS
   Kalil, J
   Cunha-Neto, E
   Guilherme, L
AF Martins, Carlo de Oliveira
   Demarchi, Lea
   Ferreira, Frederico Moraes
   Alberto Pomerantzeff, Pablo Maria
   Brandao, Carlos
   Sampaio, Roney Orismar
   Spina, Guilherme Sobreira
   Kalil, Jorge
   Cunha-Neto, Edecio
   Guilherme, Luiza
TI Rheumatic Heart Disease and Myxomatous Degeneration: Differences and
   Similarities of Valve Damage Resulting from Autoimmune Reactions and
   Matrix Disorganization
SO PLOS ONE
LA English
DT Article
ID GROUP-A STREPTOCOCCUS; COLLAGEN; IDENTIFICATION; FEVER; PROTEIN;
   VITRONECTIN; VIMENTIN; CELLS
AB Autoimmune inflammatory reactions leading to rheumatic fever (RF) and rheumatic heart disease (RHD) result from untreated Streptococcus pyogenes throat infections in individuals who exhibit genetic susceptibility. Immune effector mechanisms have been described that lead to heart tissue damage culminating in mitral and aortic valve dysfunctions. In myxomatous valve degeneration (MXD), the mitral valve is also damaged due to non-inflammatory mechanisms. Both diseases are characterized by structural valve disarray and a previous proteomic analysis of them has disclosed a distinct profile of matrix/structural proteins differentially expressed. Given their relevance in organizing valve tissue, we quantitatively evaluated the expression of vimentin, collagen VI, lumican, and vitronectin as well as performed immunohistochemical analysis of their distribution in valve tissue lesions of patients in both diseases. We identified abundant expression of two isoforms of vimentin (45 kDa, 42 kDa) with reduced expression of the full-size protein (54 kDa) in RHD valves. We also found increased vitronectin expression, reduced collagen VI expression and similar lumican expression between RHD and MXD valves. Immunohistochemical analysis indicated disrupted patterns of these proteins in myxomatous degeneration valves and disorganized distribution in rheumatic heart disease valves that correlated with clinical manifestations such as valve regurgitation or stenosis. Confocal microscopy analysis revealed a diverse pattern of distribution of collagen VI and lumican into RHD and MXD valves. Altogether, these results demonstrated distinct patterns of altered valve expression and tissue distribution/ organization of structural/matrix proteins that play important pathophysiological roles in both valve diseases.
C1 [Martins, Carlo de Oliveira; Demarchi, Lea; Ferreira, Frederico Moraes; Alberto Pomerantzeff, Pablo Maria; Brandao, Carlos; Sampaio, Roney Orismar; Spina, Guilherme Sobreira; Kalil, Jorge; Cunha-Neto, Edecio; Guilherme, Luiza] Univ Sao Paulo, Heart Inst InCor, Sch Med, Sao Paulo, SP, Brazil.
   [Martins, Carlo de Oliveira; Ferreira, Frederico Moraes; Kalil, Jorge; Cunha-Neto, Edecio; Guilherme, Luiza] Univ Sao Paulo, Inst Invest Immunol, Natl Inst Sci & Technol, Sao Paulo, SP, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Heart Inst InCor, Sch Med, Sao Paulo, SP, Brazil.; Guilherme, L (corresponding author), Univ Sao Paulo, Inst Invest Immunol, Natl Inst Sci & Technol, Sao Paulo, SP, Brazil.
EM luizagui@usp.br
RI Martins, Carlo/D-4008-2018; KALIL, JORGE/C-8029-2012; Ferreira,
   Frederico Moraes/A-4622-2013; SAMPAIO, RONEY O/L-1643-2016; Cunha-Neto,
   Edecio/B-4157-2009; de Almeida Brandao, Carlos Manuel/H-5208-2013
OI Martins, Carlo/0000-0003-1287-8884; KALIL, JORGE/0000-0001-8415-4274;
   SAMPAIO, RONEY O/0000-0001-6524-9614; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Guilherme, Luiza/0000-0003-0997-1498
FU Committee for the improvement of post graduation students (CAPES);
   Immunology Investigation Institute (iii) from National Institute for
   Science and Technology (INCT) through FAPESP-Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo [2008/573879]; CNPQ-ConselhoNacional de
   PesquisaCNPq [2008/57881-0]
FX Committee for the improvement of post graduation students (CAPES);
   Immunology Investigation Institute (iii) from National Institute for
   Science and Technology (INCT) through FAPESP-Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo-2008/573879 and CNPQ-ConselhoNacional de
   PesquisaCNPq 2008/57881-0. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Banerjee T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090527
   Bella J, 2016, BIOCHEM J, V473, P1001, DOI 10.1042/BJ20151169
   Bober M, 2010, J INNATE IMMUN, V2, P160, DOI 10.1159/000232587
   Caira FC, 2006, J AM COLL CARDIOL, V47, P1707, DOI 10.1016/j.jacc.2006.02.040
   Carapetis JR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.84
   Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277
   Challa AA, 2011, MOL CELL BIOL, V31, P3773, DOI 10.1128/MCB.05263-11
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   Dinkla K, 2003, J CLIN INVEST, V111, P1905, DOI 10.1172/JCI200317247
   Dinkla K, 2007, J BIOL CHEM, V282, P18686, DOI 10.1074/jbc.M701047200
   Fae KC, 2008, J AUTOIMMUN, V31, P136, DOI 10.1016/j.jaut.2008.04.023
   Gildner CD, 2014, MATRIX BIOL, V34, P33, DOI 10.1016/j.matbio.2014.01.017
   Guilherme L, 2011, ADV CLIN CHEM, V53, P31, DOI 10.1016/S0065-2423(11)53002-1
   He YH, 2011, J AM SOC ECHOCARDIOG, V24, P399, DOI 10.1016/j.echo.2011.01.001
   Jiang L, 2009, CLIN EXP IMMUNOL, V155, P216, DOI 10.1111/j.1365-2249.2008.03747.x
   Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001
   Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000
   Martins CDO, 2014, CLIN MED INSIGHTS-CA, V8, P79, DOI 10.4137/CMC.S17622
   Pellerin D, 2002, HEART, V88, P20
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2
   PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275
   Remenyi B, 2016, LANCET, V387, P1335, DOI 10.1016/S0140-6736(16)00547-X
   Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978
   Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
   Tandon R, 2013, NAT REV CARDIOL, V10, P171, DOI 10.1038/nrcardio.2012.197
NR 25
TC 1
Z9 1
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2017
VL 12
IS 1
AR e0170191
DI 10.1371/journal.pone.0170191
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7FK
UT WOS:000396167300053
PM 28121998
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kaslow, DC
   Kalil, J
   Bloom, D
   Breghi, G
   Colucci, AM
   De Gregorio, E
   Madhavan, G
   Meier, G
   Seabrook, R
   Xu, XN
AF Kaslow, David C.
   Kalil, Jorge
   Bloom, David
   Breghi, Gianluca
   Colucci, Anna Maria
   De Gregorio, Ennio
   Madhavan, Guru
   Meier, Genevieve
   Seabrook, Richard
   Xu, Xiaoning
TI The role of vaccines and vaccine decision-making to achieve the goals of
   the Grand Convergence in public health
SO VACCINE
LA English
DT Article
DE Grand Convergence; Global Health; Vaccines; SMART vaccines; Workshop
AB On 17 and 18 July 2015, a meeting in Siena jointly sponsored by ADITEC and GlaxoSmithKline (GSK) was held to review the goals of the Global Health 2035 Grand Convergence, to discuss current vaccine evaluation methods, and to determine the feasibility of reaching consensus on an assessment framework for comprehensively and accurately capturing the full benefits of vaccines. Through lectures and workshops, participants reached a consensus that Multi-Criteria-Decision-Analysis is a method suited to systematically account for the many variables needed to evaluate the broad benefits of vaccination, which include not only health system savings, but also societal benefits, including benefits to the family and increased productivity. Participants also agreed on a set of "core values" to be used in future assessments of vaccines for development and introduction. These values include measures of vaccine efficacy and safety, incident cases prevented per year, the results of cost-benefit analyses, preventable mortality, and the severity of the target disease. Agreement on this set of core assessment parameters has the potential to increase alignment between manufacturers, public health agencies, non-governmental organizations (NGOs), and policy makers (see Global Health 2035 Mission Grand Convergence [1]).
   The following sections capture the deliberations of a workshop (Working Group 4) chartered to: (1) review the list of 24 parameters selected from SMART vaccines (see the companion papers by Timmis et al. and Madhavan et al., respectively) to determine which represent factors (see Table 1) that should be taken into account when evaluating the role of vaccines in maximizing the success of the Global Health 2035 Grand Convergence; (2) develop 3-5 "core values" that should be taken into account when evaluating vaccines at various stages of development; and (3) determine how vaccines can best contribute to the Global Health 2035 Grand Convergence effort.
C1 [Kaslow, David C.] PATH, 2201 Westlake Blvd,Suite 200, Seattle, WA 98121 USA.
   [Kalil, Jorge] Inst Butantan, Sao Paulo, SP, Brazil.
   [Bloom, David] Harvard Sch Publ Hlth, Boston, MA USA.
   [Breghi, Gianluca; Colucci, Anna Maria; De Gregorio, Ennio; Meier, Genevieve] GSK, Siena, Italy.
   [Madhavan, Guru] Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.
   [Seabrook, Richard] Wellcome Trust Res Labs, London, England.
   [Xu, Xiaoning] Imperial Coll, London, England.
RP Kaslow, DC (corresponding author), PATH, 2201 Westlake Blvd,Suite 200, Seattle, WA 98121 USA.
EM dkaslow@path.org; jkalil@butantan.gov.br; debloom1@aol.com;
   breghi@sclavo.org; anna.m.colucci@gsk.com; ennio.x.de-gregorio@gsk.com;
   gmadhavan@gmail.com; GENEVIEVE.C.MEIER@GSK.COM;
   r.seabrook@wellcome.ac.uk; x.xu@imperial.ac.uk
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Global Health 2035, MISS GRAND CONV MULT
   Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4
   Madhavan G, 2015, RANKING VACCINES APP
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
NR 4
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 20
PY 2017
VL 35
SU 1
BP A10
EP A15
DI 10.1016/j.vaccine.2016.10.088
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA EJ5KU
UT WOS:000393257700004
PM 28017438
DA 2020-11-26
ER

PT J
AU Pandey, RP
   Savoia, M
   Sabino, E
   Kalil, J
   Neto, EC
AF Pandey, Ramendra P.
   Savoia, Marilda
   Sabino, Ester
   Kalil, Jorge
   Cunha-Neto, Edecio
TI POTENTIATION OF BENZNIDAZOLE EFFECT BY COADMINISTRATION OF REPURPOSED
   DRUGS ACTING IN THE INVASION OF HOST CELLS BY TRYPANOSOMA CRUZI
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Pandey, Ramendra P.; Savoia, Marilda; Sabino, Ester; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sao Paulo, Brazil.
RI Sabino, Ester Cerdeira/F-7750-2010; KALIL, JORGE/C-8029-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1234
BP 384
EP 384
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215203601
DA 2020-11-26
ER

PT J
AU Terzian, A
   Schanoski, A
   Mota, M
   Silva, R
   Estofolete, C
   Colombo, T
   Hanley, KA
   Vasilakis, N
   Kalil, J
   Nogueira, ML
AF Terzian, Ana
   Schanoski, Alessandra
   Mota, Manlio
   Silva, Rafael
   Estofolete, Cassia
   Colombo, Tatiana
   Hanley, Kathryn A.
   Vasilakis, Nikos
   Kalil, Jorge
   Nogueira, Mauricio L.
TI VIRAL LOAD DOES NOT SUPPORT ADE HYPOTHESIS IN DENGUE-PRIMED
   ZIKA-INFECTED PATIENTS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Terzian, Ana; Schanoski, Alessandra; Mota, Manlio; Silva, Rafael; Estofolete, Cassia; Colombo, Tatiana; Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Hanley, Kathryn A.] New Mexico State Univ, Las Cruces, NM 88003 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Kalil, Jorge] Univ Sao Paulo, Sao Paulo, Brazil.
RI Vasilakis, Nikos/ABE-7318-2020; Estofolete, Cassia/N-6673-2019; KALIL,
   JORGE/C-8029-2012; de Oliveira Mota, Manlio Tasso/E-2619-2013
OI Estofolete, Cassia/0000-0001-7324-1591; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1335
BP 415
EP 415
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215204051
DA 2020-11-26
ER

PT J
AU Aun, MV
   Bonamichi-Santos, R
   Arantes-Costa, FM
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Bonamichi-Santos, Rafael
   Arantes-Costa, Fernanda Magalhaes
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Animal models of asthma: utility and limitations
SO JOURNAL OF ASTHMA AND ALLERGY
LA English
DT Review
DE asthma; animal models; airway hyperresponsiveness; allergen;
   sensitization; challenge
ID HOUSE-DUST MITE; EOSINOPHILIC AIRWAY INFLAMMATION; ALLERGIC-ASTHMA;
   MOUSE MODELS; GUINEA-PIGS; MURINE MODEL; MEDIATOR RELEASE;
   IMMUNOGLOBULIN-E; RAT MODEL; MICE
AB Clinical studies in asthma are not able to clear up all aspects of disease pathophysiology. Animal models have been developed to better understand these mechanisms and to evaluate both safety and efficacy of therapies before starting clinical trials. Several species of animals have been used in experimental models of asthma, such as Drosophila, rats, guinea pigs, cats, dogs, pigs, primates and equines. However, the most common species studied in the last two decades is mice, particularly BALB/c. Animal models of asthma try to mimic the pathophysiology of human disease. They classically include two phases: sensitization and challenge. Sensitization is traditionally performed by intraperitoneal and subcutaneous routes, but intranasal instillation of allergens has been increasingly used because human asthma is induced by inhalation of allergens. Challenges with allergens are performed through aerosol, intranasal or intratracheal instillation. However, few studies have compared different routes of sensitization and challenge. The causative allergen is another important issue in developing a good animal model. Despite being more traditional and leading to intense inflammation, ovalbumin has been replaced by aeroallergens, such as house dust mites, to use the allergens that cause human disease. Finally, researchers should define outcomes to be evaluated, such as serum-specific antibodies, airway hyperresponsiveness, inflammation and remodeling. The present review analyzes the animal models of asthma, assessing differences between species, allergens and routes of allergen administration.
C1 [Aun, Marcelo Vivolo; Bonamichi-Santos, Rafael; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Internal Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Aun, Marcelo Vivolo; Bonamichi-Santos, Rafael; Arantes-Costa, Fernanda Magalhaes] Univ Sao Paulo, Dept Internal Med, Lab Expt Therapeut LIM20, Sao Paulo, Brazil.
RP Aun, MV (corresponding author), Univ Sao Paulo, Sch Med, Dept Internal Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM marcelovivoloaun@gmail.com
RI Costa, Fernanda Magalhaes A/F-2727-2012; Aun, Marcelo V/E-6775-2014;
   KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   Arantes-Costa, Fernanda/0000-0001-9448-4357
CR Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033
   Alberca-Custodio RW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00237
   ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563
   Asai-Tajiri Y, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0132-z
   Aun MV, 2015, EINSTEIN-SAO PAULO, V13, P560, DOI 10.1590/S1679-45082015AO3389
   Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119
   Blonder JP, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-3
   Blume C, 2013, EUR J PHARM BIOPHARM, V84, P394, DOI 10.1016/j.ejpb.2012.12.014
   Bonamichi-Santos R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/614758
   Boskabady MH, 1999, PHARMACOLOGY, V58, P300, DOI 10.1159/000028295
   BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x
   Buels KS, 2012, BRIT J PHARMACOL, V165, P1501, DOI 10.1111/j.1476-5381.2011.01632.x
   Canning BJ, 2008, PULM PHARMACOL THER, V21, P702, DOI 10.1016/j.pupt.2008.01.004
   Carvalho C, 1999, EXP LUNG RES, V25, P303
   Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384
   Chapman DG, 2014, J CELL BIOCHEM, V115, P2055, DOI 10.1002/jcb.24881
   Conrad ML, 2009, CLIN EXP ALLERGY, V39, P1246, DOI 10.1111/j.1365-2222.2009.03260.x
   DeClue AE, 2009, INFLAMM RES, V58, P457, DOI 10.1007/s00011-009-0010-1
   Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131
   FORNHEM C, 1995, EUR RESPIR J, V8, P1100, DOI 10.1183/09031936.95.08071100
   Fuchs B, 2008, CURR DRUG TARGETS, V9, P495, DOI 10.2174/138945008784533589
   GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337
   Giavina-Bianchi P, 2016, J ASTHMA ALLERGY, V9, P93, DOI 10.2147/JAA.S81541
   Global Initiative for Asthma, 2016, GLOB STRAT ASTHM MAN
   Gour N, 2015, CYTOKINE, V75, P68, DOI 10.1016/j.cyto.2015.05.014
   Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659
   Han RT, 2017, J ASTHMA ALLERGY, V10, P181, DOI 10.2147/JAA.S124902
   Herszberg B, 2006, J ALLERGY CLIN IMMUN, V118, P382, DOI 10.1016/j.jaci.2006.03.044
   Hesselmar B, 2012, J ALLERGY CAIRO, V2012
   Hoffman SM, 2016, AM J RESP CELL MOL, V55, P377, DOI 10.1165/rcmb.2015-0401OC
   Hoffman SM, 2016, ANN AM THORAC SOC, V13, pS97, DOI 10.1513/AnnalsATS.201510-656MG
   Ishida W, 2011, IMMUNOL LETT, V136, P49, DOI 10.1016/j.imlet.2010.12.002
   Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC
   KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441
   Kim CH, 2006, J ASTHMA, V43, P345, DOI 10.1080/02770900600701424
   Kirschvink N, 2008, CURR DRUG TARGETS, V9, P470, DOI 10.2174/138945008784533525
   Kirschvink N, 2007, VET J, V174, P541, DOI 10.1016/j.tvjl.2006.11.004
   Korn A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142622
   Krieger SM, 2013, FOOD CHEM TOXICOL, V59, P165, DOI 10.1016/j.fct.2013.05.037
   Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561
   Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x
   Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1394, DOI 10.1046/j.1365-2745.2002.01517.x
   Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248
   KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807
   Kurup Viswanath P, 2007, Clin Mol Allergy, V5, P1, DOI 10.1186/1476-7961-5-1
   Lavoie-Lamoureux A, 2010, AM J PHYSIOL-LUNG C, V299, pL472, DOI 10.1152/ajplung.00135.2009
   Le DD, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-73
   Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615
   Lewis CA, 1996, INT J IMMUNOPHARMACO, V18, P415, DOI 10.1016/S0192-0561(96)00055-0
   Liao EC, 2013, J INVEST ALLERG CLIN, V23, P20
   Liravi B, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0097-9
   Lloyd CM, 2007, CURR ALLERGY ASTHM R, V7, P231, DOI 10.1007/s11882-007-0077-0
   LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915
   Lundblad LKA, 2017, PULM PHARMACOL THER, V45, P80, DOI 10.1016/j.pupt.2017.05.003
   Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x
   MISAWA M, 1987, JPN J PHARMACOL, V45, P63, DOI 10.1254/jjp.45.63
   Mitchell PD, 2017, CHEST, V151, P1338, DOI 10.1016/j.chest.2016.10.042
   Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255
   Mullane K, 2014, BIOCHEM PHARMACOL, V87, P131, DOI 10.1016/j.bcp.2013.06.026
   Nesi RT, 2017, INFLAMMATION, V40, P1166, DOI 10.1007/s10753-017-0560-2
   Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323
   ODONNELL IJ, 1978, AUST J BIOL SCI, V31, P459, DOI 10.1071/BI9780459
   OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0
   OHRUI T, 1992, J ALLERGY CLIN IMMUN, V89, P933, DOI 10.1016/0091-6749(92)90215-N
   Out TA, 2002, IMMUNOLOGY, V105, P499, DOI 10.1046/j.1365-2567.2002.01383.x
   OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289
   Pacholewska A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136103
   Patel KN, 2014, J PHARM RES OPIN, V1, P139
   PERINI A, 1973, IMMUNOLOGY, V25, P297
   Peters M, 2016, AM J RESP CELL MOL, V54, P350, DOI 10.1165/rcmb.2014-0429OC
   Pineiro-Hermida S, 2017, ALLERGY, V72, P1317, DOI 10.1111/all.13142
   REGAL JF, 1984, J PHARMACOL EXP THER, V228, P116
   Riihimaki M, 2008, VET IMMUNOL IMMUNOP, V122, P256, DOI 10.1016/j.vetimm.2007.12.001
   Rodrigues AM, 2012, J BRAS PNEUMOL, V38, P595, DOI 10.1590/S1806-37132012000500009
   Roeder T, 2009, AM J RESP CRIT CARE, V179, P979, DOI 10.1164/rccm.200811-1777PP
   Sagar S, 2015, EUR J PHARMACOL, V759, P272, DOI 10.1016/j.ejphar.2015.03.037
   Schmit D, CELL TISSUE RES
   Shapiro SD, 2008, PULM PHARMACOL THER, V21, P699, DOI 10.1016/j.pupt.2008.01.006
   Shima I, 2017, ALLERGOL INT, V66, P89, DOI 10.1016/j.alit.2016.05.012
   Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC
   Stevenson CS, 2011, PHARMACOL THERAPEUT, V130, P93, DOI 10.1016/j.pharmthera.2010.10.008
   Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017
   Szelenyi I, 2000, INFLAMM RES, V49, P639, DOI 10.1007/s000110050642
   Takazono T, 2017, MED MYCOL, V55, P39, DOI 10.1093/mmy/myw117
   Taramarcaz P, 2005, SWISS MED WKLY, V135, P538
   Toledo AC, 2013, BRIT J PHARMACOL, V168, P1736, DOI 10.1111/bph.12062
   Toledo AC, 2011, RESP PHYSIOL NEUROBI, V177, P155, DOI 10.1016/j.resp.2011.03.016
   Ulrich K, 2008, PULM PHARMACOL THER, V21, P637, DOI 10.1016/j.pupt.2008.02.006
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Vandenplas O, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0682-5
   Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600
   Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003
   Wagh AD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00082
   Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8
   *WHO, 2000, WHO FACT SHEET BRONC
   Williams K, 2016, J PATHOL, V238, P220, DOI 10.1002/path.4658
   Zaffini R, 2016, N-S ARCH PHARMACOL, V389, P1301, DOI 10.1007/s00210-016-1294-7
   Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x
NR 98
TC 47
Z9 49
U1 3
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6965
J9 J ASTHMA ALLERGY
JI J. ASTHMA ALLERGY
PY 2017
VL 10
BP 293
EP 301
DI 10.2147/JAA.S121092
PG 9
WC Allergy; Immunology; Respiratory System
SC Allergy; Immunology; Respiratory System
GA FM0XW
UT WOS:000414692900001
PM 29158683
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Takejima, P
   Agondi, RC
   Rodrigues, H
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Takejima, Priscila
   Agondi, Rosana Camara
   Rodrigues, Helcio
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Allergic and Nonallergic Asthma Have Distinct Phenotypic and Genotypic
   Features
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE Asthma; Human leukocyte antigens; Allergic asthma; Nonatopic
ID BRONCHIAL-ASTHMA; NONATOPIC ASTHMA; CLUSTER-ANALYSIS; HLA ANTIGENS;
   REVISED NOMENCLATURE; INTRINSIC ASTHMA; RESEARCH-PROGRAM; ATOPIC ASTHMA;
   NASAL POLYPS; CLASS-II
AB Background: Identification of asthma phenotypes enables a better understanding and management of this heterogeneous disease. Studies have reported associations between human leukocyte antigens (HLA) and asthma in different populations, but the results have been inconclusive and they have rarely considered the distinct disease phenotypes. Our objective was to characterize allergic and nonallergic asthma phenotypes and evaluate possible associations with the HLA system. Methods: A total of 109 patients with asthma were prospectively followed during 2 years. They were divided into 2 groups, i.e., allergic and nonallergic asthma, according to their clinical history and skin prick test and serum-specific immunoglobulin E (IgE) results. The control group comprised 297 deceased donors of solid organs. Patients' features and HLA class I and II genotypes were assessed and compared. Results: This study showed different features between asthma phenotypes. Nonallergic patients were older at the onset of asthma symptoms and had a higher rate of intolerance to nonsteroidal anti-inflammatory drugs. Allergic patients had higher total serum IgE levels, reported atopic dermatitis and rhinoconjunctivitis more frequently, and, unexpectedly, had a greater disease severity. New associations between the HLA genotypes and allergic and nonallergic asthma were identified. The HLA-B*42, HLA-C*17, HLA-DPA1*03, and HLA-DPB1*105 genotypes were associated with allergic asthma and the HLA-B*48 genotype with the nonallergic phenotype. The presence of the haplotype HLA-DPA1*03 DQA*05 was associated with allergic asthma, and the presence of HLA-DPA1*03 and the absence of HLA-DQA*05 with nonallergic asthma. Conclusions: Allergic and nonallergic asthma have distinct phenotypic and genotypic features. New associations between asthma phenotypes and HLA class I and II were identified. (C) 2017 S. Karger AG, Basel
C1 [Takejima, Priscila; Agondi, Rosana Camara; Rodrigues, Helcio; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, R Manuel Guedes 517 Ap12 Jd Europa, BR-04536070 Sao Paulo, SP, Brazil.
RP Aun, MV (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, R Manuel Guedes 517 Ap12 Jd Europa, BR-04536070 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Agondi, Rosana Camara/0000-0002-0503-5179
CR Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903
   Apostolakis J, 1996, RESP MED, V90, P201, DOI 10.1016/S0954-6111(96)90287-5
   Bousquet PJ, 2015, INT ARCH ALLERGY IMM, V166, P231, DOI 10.1159/000381339
   Bradding P, 2010, CURR OPIN ALLERGY CL, V10, P54, DOI 10.1097/ACI.0b013e32833489a9
   Breiman L, 1984, CLASSIFICATION REGRE
   BROSTOFF J, 1976, LANCET, V2, P872
   Brunner E, 2000, BIOMETRICAL J, V42, P17, DOI 10.1002/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U
   CARABALLO L, 1991, HUM IMMUNOL, V32, P157, DOI 10.1016/0198-8859(91)90051-A
   Charpin D, 2003, J ASTHMA, V40, P87, DOI 10.1081/JAS-120017211
   Comi AL, 2007, RESP MED, V101, P2526, DOI 10.1016/j.rmed.2007.07.010
   DiCiccio TJ, 1996, STAT SCI, V11, P189
   Dombrowicz D, 2002, IGE ANTI IGE THERAPY, P69
   Esmaeilzadeh H, 2015, AM J RHINOL ALLERGY, V29, pE63, DOI 10.2500/ajra.2015.29.4154
   Gao JM, 2003, CHINESE MED J-PEKING, V116, P1078
   Giavina-Bianchi P, 2015, J ALLERGY CLIN IMMUN, V135, P151, DOI 10.1016/j.jaci.2014.10.029
   Giavina-Bianchi P, 2013, J ALLERGY CLIN IMMUN, V131, P1261, DOI 10.1016/j.jaci.2013.01.050
   Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Hallstrand T, 2001, CLIN IMMUNOLOGY PRIN
   Heck S, 2015, INT ARCH ALLERGY IMM, V168, P241, DOI 10.1159/000443930
   HSIEH KH, 1991, TISSUE ANTIGENS, V38, P181, DOI 10.1111/j.1399-0039.1991.tb01893.x
   Ivkovic-Jurekovic I, 2011, COLLEGIUM ANTROPOL, V35, P1243
   Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318
   Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Kontakioti E, 2014, HUM IMMUNOL, V75, P930, DOI 10.1016/j.humimm.2014.06.022
   Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x
   LEOPOLD HC, 1965, J ALLERGY, V36, P175, DOI 10.1016/0021-8707(65)90165-6
   Leung DYM, 2004, J ALLERGY CLIN IMMUN, V113, P1
   Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018
   Lockey RF, 2014, J ALLER CL IMM-PRACT, V2, P682, DOI 10.1016/j.jaip.2014.09.008
   MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775
   MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603
   Martyn MB, 2010, ALLERGY ASTHMA PROC, V31, P120, DOI 10.2500/aap.2010.31.3321
   Menz G, 1998, ALLERGY, V53, P15, DOI 10.1111/j.1398-9995.1998.tb04934.x
   Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041
   Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312
   MOLONEY JR, 1980, CLIN OTOLARYNGOL, V5, P183, DOI 10.1111/j.1365-2273.1980.tb01645.x
   Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Morris M J, 1977, Monogr Allergy, V11, P30
   MORRIS MJ, 1980, CLIN ALLERGY, V10, P173, DOI 10.1111/j.1365-2222.1980.tb02094.x
   Nahm DH, 2001, J KOREAN MED SCI, V16, P407, DOI 10.3346/jkms.2001.16.4.407
   Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170
   OSTERGAARD PA, 1979, EUR J PEDIATR, V131, P263, DOI 10.1007/BF00444347
   Parapanissiou E, 2005, TISSUE ANTIGENS, V65, P481, DOI 10.1111/j.1399-0039.2005.00392.x
   Pereira CAC, 2002, J PNEUMOL, V28, P1
   Pillai P, 2011, ISRN ALLERGY, V2011, DOI DOI 10.5402/2011/195846
   RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0
   Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x
   SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3
   SIBBALD B, 1979, THORAX, V34, P332, DOI 10.1136/thx.34.3.332
   Smit LAM, 2014, EUR RESPIR J, V44, P1234, DOI 10.1183/09031936.00068014
   SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733
   THORSBY E, 1971, Tissue Antigens, V1, P147
   Toledo M F, 2016, Allergol Immunopathol (Madr), V44, P439, DOI 10.1016/j.aller.2016.02.006
   Torio A, 2000, EUR J IMMUNOGENET, V27, P81, DOI 10.1046/j.1365-2370.2000.00205.x
   TURTON CWG, 1979, THORAX, V34, P670, DOI 10.1136/thx.34.5.670
   ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638
   WANG WX, 1988, TISSUE ANTIGENS, V32, P215, DOI 10.1111/j.1399-0039.1988.tb01658.x
NR 59
TC 7
Z9 7
U1 1
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-2438
EI 1423-0097
J9 INT ARCH ALLERGY IMM
JI Int. Arch. Allergy Immunol.
PY 2017
VL 172
IS 3
BP 150
EP 160
DI 10.1159/000458151
PG 11
WC Allergy; Immunology
SC Allergy; Immunology
GA EU6SH
UT WOS:000401163600003
PM 28380482
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kallas, EG
   Kalil, J
   Passero, LFD
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan Pereira
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kallas, Esper G.
   Kalil, Jorge
   Passero, Luiz Felipe D.
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI p16(INK4a) Expression and Immunologic Aging in Chronic HIV Infection
SO PLOS ONE
LA English
DT Article
ID IMMUNOSENESCENCE; MECHANISMS; SENESCENCE
AB Chronic HIV infection is characterized by increased immune activation and immunosenescence. p16(INK4a) (p16) is a member of the cyclin-dependent kinase antagonist family that inhibits cellular proliferation, and its protein expression increases during normal chronological aging. However, some infectious diseases can increase the expression of this anti-proliferative protein, potentially accelerating immunological aging and dysfunction. In order to investigate the immunological aging in HIV patients, p16 protein expression was evaluated by flow cytometry, in T cell subsets in a cohort of chronically HIV-infected patients on and off ART as well as age-matched healthy controls. Results showed that untreated HIV-infected subjects exhibited increased per-cell p16 protein expression that was discordant with chronological aging. ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment, but not in CD8 T cells, which can be an indicative of an irreversible activation/exhaustion status on these cells. Additionally, the frequency of activated CD4+ and CD8+ T cells was positively correlated with p16 expression in CD4+ and CD8+ T cells in untreated subjects. In contrast to healthy controls, untreated HIV-infected individuals had increased p16 levels within the effector memory (T-EM) subset, indicating a possible role for this marker in impaired clonal expansion during antiviral effector function. Taken together, these data demonstrate that chronic HIV infection is associated with elevated expression of the cellular aging marker p16 in T cells. ART restored normal p16 levels in the CD4+ T cell compartment, indicating that use of therapy can be of fundamental importance to normal cell cycling and maintaining immune homeostasis.
C1 [Ribeiro, Susan Pereira; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] INCT, Iii, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Milush, Jeffrey M.; SenGupta, Devi] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Inst, Sao Paulo, SP, Brazil.
   [Passero, Luiz Felipe D.] Sao Paulo State Univ Julio de Mesquite Filho, Sao Vicent Unit, Paulista Coastal Campus, Sao Paulo, Brazil.
   [Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco Gen Hosp, HIV AIDS Div, San Francisco, CA USA.
   [Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
RP Ribeiro, SP (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.; Ribeiro, SP (corresponding author), INCT, Iii, Sao Paulo, Brazil.; Ribeiro, SP (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
EM Susan.pereiraribeiro@case.edu
RI Hunt, Peter W./P-2976-2017; Nixon, Douglas/AAU-5734-2020; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Passero,
   Felipe/B-9549-2012
OI Hunt, Peter W./0000-0002-4571-4870; Nixon, Douglas/0000-0002-2801-1786;
   Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Passero, Felipe/0000-0002-5986-6381; Deeks,
   Steven/0000-0001-6371-747X; Ribeiro, Susan/0000-0002-3127-3138; Kallas,
   Esper/0000-0003-2026-6925
FU Delaney AIDS Research Enterprise (DARE) [AI096109]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K24 AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR
   [P30 AI027763]; UCSF Clinical and Translational Research Institute
   Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention
   Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24
   AI067039]; NIH NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K08 A120071]; Brazilian
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq); Sao Paulo
   State Research Funding Agency (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/05845-0/EGK/DFN]; CNPq/CAPESNational Council for Scientific and
   Technological Development (CNPq)CAPES [056/2012]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, K24AI069994,
   K24AI069994, U19AI096109, U19AI096109, P30AI027763, U19AI096109,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, K24AI069994,
   U19AI096109, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   U19AI096109, P30AI027763, K24AI069994, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   R24AI067039, P30AI027763, R24AI067039, P30AI027763, R24AI067039,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   U19AI096109, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, U19AI096109, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   U19AI096109, P30AI027763, P30AI027763, K24AI069994, U19AI096109,
   P30AI027763, P30AI027763, R24AI067039, P30AI027763, P30AI027763,
   R24AI067039, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, K24AI069994, P30AI027763, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   R24AI067039, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, K24AI069994, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   R24AI067039, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, R24AI067039, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH RePORTER
FX This work was supported by the Delaney AIDS Research Enterprise (DARE;
   AI096109), NIAID (K24 AI069994), the UCSF/Gladstone Institute of
   Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and
   Translational Research Institute Clinical Research Center (UL1
   RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the
   CFAR Network of Integrated Systems (R24 AI067039). DS was supported by
   NIH NIAID K08 A120071. This research was supported by the Brazilian
   Council for Scientific and Technological Development (CNPq) and the Sao
   Paulo State Research Funding Agency (FAPESP). Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (2010/05845-0/EGK/DFN), CNPq/CAPES
   056/2012 (DFN). ECN and JK are recipients of productivity awards from
   the Brazilian Council for Scientific and Technological Development
   (CNPq). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aberg Judith A, 2012, Top Antivir Med, V20, P101
   Appay V, 2007, EXP GERONTOL, V42, P432, DOI 10.1016/j.exger.2006.12.003
   Chinula L, 2016, CURR OPIN HIV AIDS
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Dock JN, 2011, AGING DIS, V2, P382
   Liu Y, 2009, CURR OPIN IMMUNOL, V21, P431, DOI 10.1016/j.coi.2009.05.011
   Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327
   Migliaccio M, 2006, J IMMUNOL, V176, P2173, DOI 10.4049/jimmunol.176.4.2173
   Migliaccio M, 2005, J IMMUNOL, V174, P3335, DOI 10.4049/jimmunol.174.6.3335
   Nasi M, 2014, IMMUNOL LETT, V162, P329, DOI 10.1016/j.imlet.2014.06.012
   Nelson JAE, 2012, AGING CELL, V11, P916, DOI 10.1111/j.1474-9726.2012.00856.x
NR 11
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2016
VL 11
IS 11
AR e0166759
DI 10.1371/journal.pone.0166759
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC7WC
UT WOS:000388350300102
PM 27861555
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Goncalves, F
   Alcantara, K
   Moura, V
   Nolasco, P
   Kalil, J
   Hernandez, M
AF Goncalves, F.
   Alcantara, K.
   Moura, V.
   Nolasco, P.
   Kalil, J.
   Hernandez, M.
TI EFFECTS OF OXIDAZED LDL IN M2 MACROPHAGES. IMPLICATIONS IN
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 29-JUN 01, 2016
CL Innsbruck, AUSTRIA
SP European Atherosclerosis Soc
C1 [Goncalves, F.; Alcantara, K.; Moura, V.; Hernandez, M.] Univ Sao Paulo, Heart Inst, Sch Med, Immunol Lab, Sao Paulo, Brazil.
   [Goncalves, F.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Goncalves, F.; Alcantara, K.; Moura, V.; Kalil, J.; Hernandez, M.] Inst Immunol Invest, Inst Heart, Sao Paulo, Brazil.
   [Nolasco, P.] HCFMUSP, Heart Inst, Vasc Biol Lab, Sao Paulo, Brazil.
   [Kalil, J.] HCFMUSP, Heart Inst, Immunol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD SEP
PY 2016
VL 252
MA EAS16-0105
BP E170
EP E171
DI 10.1016/j.atherosclerosis.2016.07.807
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA ED6PR
UT WOS:000388978400575
DA 2020-11-26
ER

PT J
AU Silva, RA
   Giordano, RJ
   Gutierrez, PS
   Rocha, VZ
   Rudnicki, M
   Kee, P
   Abdalla, DSP
   Puech-Leao, P
   Caramelli, B
   Arap, W
   Pasqualini, R
   Meneghetti, JC
   Marques, FLN
   Khoobchandani, M
   Katti, KV
   Lugao, AB
   Kalil, J
AF Silva, Rosemeire A.
   Giordano, Ricardo J.
   Gutierrez, Paulo S.
   Rocha, Viviane Z.
   Rudnicki, Martina
   Kee, Patrick
   Abdalla, Dulcineia S. P.
   Puech-Leao, Pedro
   Caramelli, Bruno
   Arap, Wadih
   Pasqualini, Renata
   Meneghetti, Jose C.
   Marques, Fabio L. N.
   Khoobchandani, Menka
   Katti, Kattesh V.
   Lugao, Ademar B.
   Kalil, Jorge
TI CTHRSSVVC Peptide as a Possible Early Molecular Imaging Target for
   Atherosclerosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE atherosclerosis; CD163; macrophages; theranostics; peptide
ID HEMOGLOBIN SCAVENGER RECEPTOR; PHAGE DISPLAY; CANDIDATE TARGET;
   DRUG-DELIVERY; GROWTH-FACTOR; CD163; MACROPHAGES; MOUSE; IDENTIFICATION;
   VASCULATURE
AB The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr-/-) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr-/-) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with (InCl3)-In-111 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.
C1 [Silva, Rosemeire A.; Kalil, Jorge] Univ Sao Paulo, Heart Inst InCor, Hosp Clin, Lab Immunol,Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Giordano, Ricardo J.] Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508000 Sao Paulo, Brazil.
   [Gutierrez, Paulo S.] Univ Sao Paulo, Heart Inst InCor, Hosp Clin, Lab Pathol,Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Rocha, Viviane Z.; Caramelli, Bruno] Univ Sao Paulo, Heart Inst InCor, Hosp Clin, Clin Div,Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Rudnicki, Martina; Abdalla, Dulcineia S. P.] Univ Sao Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, BR-05508000 Sao Paulo, Brazil.
   [Kee, Patrick] Univ Texas Hlth Sci Ctr Houston, Div Cardiol, Dept Internal Med, Houston, TX 77054 USA.
   [Puech-Leao, Pedro] Univ Sao Paulo, Div Vasc & Endovasc Surg, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Arap, Wadih; Pasqualini, Renata] Univ New Mexico, Ctr Comprehens Canc, Div Hematol Oncol, Albuquerque, NM 87131 USA.
   [Arap, Wadih; Pasqualini, Renata] Univ New Mexico, Div Mol Med, Dept Internal Med, Sch Med, Albuquerque, NM 87131 USA.
   [Meneghetti, Jose C.] Univ Sao Paulo, Nucl Med Serv, Heart Inst InCor, Hosp Clin,Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Meneghetti, Jose C.] Univ Sao Paulo, Mol Image, Heart Inst InCor, Hosp Clin,Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Marques, Fabio L. N.] Univ Sao Paulo LIM43, Dept Radiol & Oncol, Fac Med, BR-05403911 Sao Paulo, Brazil.
   [Khoobchandani, Menka; Katti, Kattesh V.] Univ Missouri, Inst Green Nanotechnol, Dept Radiol & Chem, Columbia, MO 65211 USA.
   [Lugao, Ademar B.] CNEN, Nucl & Energy Res Inst IPEN, BR-05508000 Sao Paulo, Brazil.
RP Silva, RA; Kalil, J (corresponding author), Univ Sao Paulo, Heart Inst InCor, Hosp Clin, Lab Immunol,Fac Med, BR-05403000 Sao Paulo, Brazil.
EM uitroseme@gmail.com; giordano@iq.usp.br; paulo.gutierrez@incor.usp.br;
   vzrocha@hotmail.com; martina.rudnicki@gmail.com;
   patrick.kee@uth.tmc.edu; dspabdalla@gmail.com; pedro@puech.com.br;
   bcaramel@usp.br; warap@salud.unm.edu; rpasqual@salud.unm.edu;
   meneghetti@incor.usp.br; fabio.marques@fm.usp.br;
   khoobchandanim@health.missouri.edu; kattik@health.missouri.edu;
   ablugao@gmail.com; jkalil@usp.br
RI Caramelli, Bruno/B-9916-2008; Giordano, Ricardo/A-2074-2010; PUECH-LEAO,
   PEDRO/AAW-8801-2020; KALIL, JORGE/C-8029-2012; Katti, Kattesh
   V/G-4167-2017; Rudnicki, Martina/AAB-6509-2019; Rudnicki,
   Martina/V-7357-2018; Silva, Rosemeire A/B-8486-2012; Leao, Pedro
   P/B-5495-2016; Lugao, Ademar B/B-6847-2013; Marques, Fabio
   LN/C-4153-2012
OI Caramelli, Bruno/0000-0001-6718-8456; Giordano,
   Ricardo/0000-0001-8116-6771; PUECH-LEAO, PEDRO/0000-0002-6974-9509;
   KALIL, JORGE/0000-0001-8415-4274; Katti, Kattesh V/0000-0003-4171-7051;
   Rudnicki, Martina/0000-0002-7863-5044; Marques, Fabio
   LN/0000-0001-7383-926X; Silva, Rosemeire/0000-0003-1901-5678
FU State of Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2004/02721-8]; Brazil's
   Science without Borders Scholarship Program-CNPq [401438/2014-7]
FX This work was supported by The State of Sao Paulo Research Foundation
   (FAPESP), grant 2004/02721-8 to JK, and Brazil's Science without Borders
   Scholarship Program-CNPq, grant 401438/2014-7 to AL. We would like to
   thank the Nuclear Energy Research Institute Nuclear and Energy Research
   Institute (IPEN)/CNEN, Sao Paulo, Brazil that provided 111InCl3 samples;
   the International Atomic Energy Agency (IAEA); Daniel Lebre for mass
   spectrometry analysis; Daniele P. Faria, and graduation students Marcela
   F. Cavalcante and Camila G. Carneiro, for care and handling of the
   laboratory animals and images; Andrea Q. Maranhao, Sandra A. Drigo,
   Simone G. Fonseca, and Hernandez M. Silva for critical readings and
   suggestions on some of the earlier drafts of the manuscript; Telesforo
   Bacchella and Su Chao who contributed with materials and general support
   for this study; and the important scientific contributions from Whady
   Hueb and Fernando Cesena.
CR Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121
   Aristoteli LP, 2006, ATHEROSCLEROSIS, V184, P342, DOI 10.1016/j.atherosclerosis.2005.05.004
   Bowen MA, 2000, PROTEINS, V40, P420
   Boyle JJ, 2009, AM J PATHOL, V174, P1097, DOI 10.2353/ajpath.2009.080431
   Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
   de Vries HE, 1999, J PHARMACOL EXP THER, V289, P528
   Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692
   Giordano RJ, 2008, J BIOL CHEM, V283, P29447, DOI 10.1074/jbc.M804595200
   Giordano Ricardo J, 2009, Proc Am Thorac Soc, V6, P411, DOI 10.1513/pats.200903-014AW
   Giordano RJ, 2010, P NATL ACAD SCI USA, V107, P5112, DOI 10.1073/pnas.0915141107
   Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249
   Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3
   Hong HY, 2008, J CELL MOL MED, V12, P2003, DOI 10.1111/j.1582-4934.2008.00189.x
   Houston P, 2001, FEBS LETT, V492, P73, DOI 10.1016/S0014-5793(01)02191-3
   Kelly KA, 2006, MOL IMAGING BIOL, V8, P201, DOI 10.1007/s11307-006-0043-6
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Lipinski MJ, 2006, MAGN RESON MED, V56, P601, DOI 10.1002/mrm.20995
   Liu C, 2003, AM J PATHOL, V163, P1859, DOI 10.1016/S0002-9440(10)63545-6
   Madsen M, 2004, J BIOL CHEM, V279, P51561, DOI 10.1074/jbc.M409629200
   Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171
   Molenaar TJM, 2003, BIOCHEM PHARMACOL, V66, P859, DOI 10.1016/S0006-2952(03)00387-3
   Moreno JA, 2010, ARTERIOSCL THROM VAS, V30, P1253, DOI 10.1161/ATVBAHA.110.203364
   Nielsen MJ, 2010, ANTIOXID REDOX SIGN, V12, P261, DOI 10.1089/ars.2009.2792
   Owen A, 2014, NANOMEDICINE-UK, V9, P1291, DOI [10.2217/NNM.14.93, 10.2217/nnm.14.93]
   Ozawa MG, 2008, TRENDS CARDIOVAS MED, V18, P126, DOI 10.1016/j.tcm.2008.03.001
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0
   Pedersen SF, 2015, ARTERIOSCL THROM VAS, V35, P1696, DOI 10.1161/ATVBAHA.114.305067
   Perschinka H, 2007, ATHEROSCLEROSIS, V194, P79, DOI 10.1016/j.atherosclerosis.2006.09.028
   REEVES PG, 1993, J NUTR, V123, P1939
   Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55
   Sainz J, 2010, CARDIOVASC RES, V86, P4, DOI 10.1093/cvr/cvq037
   Segers FME, 2013, ARTERIOSCL THROM VAS, V33, P1812, DOI 10.1161/ATVBAHA.112.300707
   Staquicini FI, 2010, PROTEOM CLIN APPL, V4, P626, DOI 10.1002/prca.200900213
   Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858
   Vinchi F, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00094
   Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675
NR 37
TC 1
Z9 1
U1 0
U2 8
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2016
VL 17
IS 9
AR 1383
DI 10.3390/ijms17091383
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA DZ0JU
UT WOS:000385525500011
PM 27563889
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Garcia, JFB
   Aun, MV
   Garro, LS
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Garcia, J. F. B.
   Aun, M., V
   Garro, L. S.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Risk stratification for penicillin desensitization in allergic pregnant
   women with syphilis
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Garcia, J. F. B.; Aun, M., V; Garro, L. S.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] Univ Sao Paulo, Clin Immunol & Allergy, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 267
BP 146
EP 146
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679801075
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Kanamori, K
   Dantas, P
   Barros, MT
   Kalil, J
   Motta, AA
AF Agondi, R. C.
   Kanamori, K.
   Dantas, P.
   Barros, M. T.
   Kalil, J.
   Motta, A. A.
TI CU-Q2oL assessment in patients with chronic urticaria
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Agondi, R. C.; Kanamori, K.; Dantas, P.; Barros, M. T.; Kalil, J.; Motta, A. A.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 606
BP 305
EP 305
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679802014
DA 2020-11-26
ER

PT J
AU Garcia, JFB
   Kokron, CM
   Kalil, J
   Giavina-Bianchi, P
AF Garcia, J. F. B.
   Kokron, C. M.
   Kalil, J.
   Giavina-Bianchi, P.
TI Inlterleukin-2 as adjuvant treatment in a patient with idiopathic CD4
   lymphocytopenia and disseminated tuberculosis
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Garcia, J. F. B.; Kokron, C. M.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Clin Immunol & Allergy, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 633
BP 312
EP 312
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679802035
DA 2020-11-26
ER

PT J
AU Mello, M
   Pereira, ARF
   Pacheco, RDR
   Kalil, J
   Mota, AA
   Agondi, RC
AF Mello, M.
   Pereira, A. R. F.
   Pacheco, R. D. R.
   Kalil, J.
   Mota, A. A.
   Agondi, R. C.
TI Autologous serum skin testing and thyroid disease in patients with
   recalcitrat chronic urticaria
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Mello, M.; Pereira, A. R. F.; Pacheco, R. D. R.; Kalil, J.; Mota, A. A.; Agondi, R. C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 1526
BP 409
EP 409
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679802289
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Ribeiro, S
   Rosa, DS
   Almeida, R
   Kalil, J
AF Cunha-Neto, E.
   Ribeiro, S.
   Santoro Rosa, D.
   Almeida, R.
   Kalil, J.
TI Vaccine antigen design to maximize anti-HIV CD4+T cell responses
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Cunha-Neto, E.; Ribeiro, S.; Almeida, R.; Kalil, J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Santoro Rosa, D.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Rosa, Daniela S/D-2190-2012; Cunha-Neto,
   Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Rosa, Daniela S/0000-0003-4536-891X;
   Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 3617
BP 327
EP 327
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400658
DA 2020-11-26
ER

PT J
AU Marin, MLC
   Coelho, V
   Rached, MR
   Kalil, J
   Abrao, MS
AF Carnevale Marin, M. L.
   Coelho, V
   Rached Rached, M.
   Kalil, J.
   Simoes Abrao, M.
TI Potential involvement of MICA (Major Histocompatibility Class I-related
   Chain A) in the pathogenesis of endometriosis
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Carnevale Marin, M. L.; Coelho, V; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Carnevale Marin, M. L.; Coelho, V] Univ Sao Paulo, Sch Med, Histocompatibil & Cellular Immunol Lab, LIM 19, Sao Paulo, Brazil.
   [Coelho, V; Kalil, J.] Univ Sao Paulo, Natl Inst Sci & Technol Iii INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Rached Rached, M.; Kalil, J.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Simoes Abrao, M.] Univ Sao Paulo, Sch Med, Sch Med, Dept Obstet & Gynecol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Abrao, Mauricio S/L-3387-2017
OI KALIL, JORGE/0000-0001-8415-4274; Abrao, Mauricio S/0000-0003-1320-3010
NR 0
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 306
BP 384
EP 384
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400772
DA 2020-11-26
ER

PT J
AU Ferreira, LRP
   Laugier, L
   Ferreira, FM
   Cabantous, S
   Candido, DDS
   Rozanski, A
   Lannes-Vieira, J
   Chevillard, C
   Kalil, J
   Cunha-Neto, E
AF Ferreira, L. R. P.
   Laugier, L.
   Ferreira, F. M.
   Cabantous, S.
   Candido, D. D. S.
   Rozanski, A.
   Lannes-Vieira, J.
   Chevillard, C.
   Kalil, J.
   Cunha-Neto, E.
TI System biology approaches to identify Gene-microRNA pathophysiology
   related networks in Chagas disease
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Ferreira, L. R. P.; Ferreira, F. M.; Candido, D. D. S.; Kalil, J.; Cunha-Neto, E.] Heart Inst Sao Paulo InCor, Immunol Lab, Sao Paulo, Brazil.
   [Ferreira, L. R. P.; Ferreira, F. M.; Candido, D. D. S.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Ferreira, L. R. P.; Ferreira, F. M.; Candido, D. D. S.; Kalil, J.; Cunha-Neto, E.] Inst Invest Immunol, Iii INCT, Sao Paulo, Brazil.
   [Ferreira, L. R. P.; Ferreira, F. M.] Univ Santo Amaro UNISA, Sao Paulo, Brazil.
   [Laugier, L.; Cabantous, S.; Chevillard, C.] AMU, INSERM, U906, Fac Med, Marseille, France.
   [Rozanski, A.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Lannes-Vieira, J.] Oswaldo Cruz Inst FIOCRUZ, Lab Biol Interact, Rio De Janeiro, Brazil.
RI Candido, Darlan/F-7209-2017; Ferreira, Ludmila Rodrigues
   Pinto/B-4955-2015; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012
OI Ferreira, Ludmila Rodrigues Pinto/0000-0001-9944-6691; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 3727
BP 561
EP 561
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401319
DA 2020-11-26
ER

PT J
AU Pandey, RP
   Kuramoto, A
   Kalil, J
   Cunha-Neto, E
AF Pandey, R. P.
   Kuramoto, A.
   Kalil, J.
   Cunha-Neto, E.
TI Therapeutic evaluation of drug combination against Trypanosoma cruzi
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Pandey, R. P.; Kuramoto, A.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 541
BP 619
EP 619
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401434
DA 2020-11-26
ER

PT J
AU Kalil, J
   Ho, P
   Precioso, AR
AF Kalil, J.
   Ho, P.
   Precioso, A. R.
TI Zika Virus Program at Butantan Institute
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Kalil, J.; Ho, P.; Precioso, A. R.] Inst Butantan, Sao Paulo, Brazil.
RI Precioso, Alexander Roberto/A-9712-2013; KALIL, JORGE/C-8029-2012
OI Precioso, Alexander Roberto/0000-0001-8657-9292; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
BP 998
EP 998
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402402
DA 2020-11-26
ER

PT J
AU D'Ancona, C
   Kalil, J
   Moser, D
   Moro, J
AF D'Ancona, C.
   Kalil, J.
   Moser, D.
   Moro, J.
TI A COMPARISON STUDY OF METHODS IN THE DIAGNOSIS OF DETRUSOR UNDERACTIVITY
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Continence-Society (ICS)
CY SEP 13-16, 2016
CL Tokyo, JAPAN
SP Int Continence Soc
C1 [D'Ancona, C.; Kalil, J.; Moser, D.] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Moro, J.] Unicamo, Campinas, SP, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Abrams P, 2016, STANDARDIZATION TERM
   Rademakers K, 2016, DETRUSOR UNDERACTIVI, V26
NR 2
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
EI 1520-6777
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD AUG
PY 2016
VL 35
SU 4
MA 445
BP S400
EP S401
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA DR4XQ
UT WOS:000379907200268
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Jares, EJ
   Kalil, J
AF Giavina-Bianchi, Pedro
   Aun, Marcelo Vivolo
   Jose Jares, Edgardo
   Kalil, Jorge
TI Angioedema associated with nonsteroidal anti-inflammatory drugs
SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Review
DE Anaphylaxis; angioedema; hypersensitivity reactions; NSAIDs; urticaria
ID URTICARIA AND/OR ANGIOEDEMA; ASPIRIN-INDUCED URTICARIA; HYPERSENSITIVITY
   REACTIONS; NONIMMEDIATE REACTIONS; INDUCED ANAPHYLAXIS;
   GENETIC-VARIANTS; CLASSIFICATION; NSAIDS; DIAGNOSIS; IMMEDIATE
AB Purpose of review
   The review critically assesses the different phenotypes of angioedemas associated with NSAIDs. Angioedemas exacerbated or induced by NSAIDs have high morbidity and, when they affect the larynx, can lead to death by asphyxiation.
   Recent findings
   Angioedema can present as a manifestation of a syndrome such as anaphylaxis or it can be a separate entity, which comprises different forms that can be diagnosed based on specific criteria. NSAIDs are the drugs most used worldwide and they are also one of the leading causes of angioedema.
   Summary
   The manuscript addresses the pathophysiology and pharmacogenetics of angioedema, reviews its classification and assesses the diagnosis and management of angioedemas exacerbated and induced by NSAIDs.
C1 [Giavina-Bianchi, Pedro; Aun, Marcelo Vivolo; Kalil, Jorge] Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Giavina-Bianchi, Pedro; Aun, Marcelo Vivolo; Kalil, Jorge] Univ Sao Paulo, Sao Paulo, Brazil.
   [Jose Jares, Edgardo] CMP SA, Libra Fdn, Allergy Unit, Buenos Aires, DF, Argentina.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178,Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Jares, Edgardo/0000-0001-9411-0582
FU Division of Clinical Immunology and Allergy, University of Sao Paulo,
   Sao Paulo, Brazil
FX This work was supported by the Division of Clinical Immunology and
   Allergy, University of Sao Paulo, Sao Paulo, Brazil.
CR Cornejo-Garcia JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090966
   Cornejo-Garcia JA, 2013, PHARMACOGENOMICS, V14, P1857, DOI 10.2217/pgs.13.166
   Cornejo-Garcia JA, 2009, CURR DRUG METAB, V10, P971, DOI 10.2174/138920009790711841
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Aun MV, 2011, ALLERGY ASTHMA PROC, V32, P301, DOI 10.2500/aap.2011.32.3450
   Ayuso P, 2013, CLIN EXP ALLERGY, V43, P1097, DOI 10.1111/cea.12140
   Ayuso P, 2015, PHARMACOGENET GENOM, V25, P618, DOI 10.1097/FPC.0000000000000179
   Ayuso P, 2013, PHARMACOGENOMICS, V14, P1871, DOI 10.2217/pgs.13.155
   Bircher AJ, 2012, J ALLERGY CLIN IMMUN, V129, P263, DOI 10.1016/j.jaci.2011.08.042
   Blanca-Lopez N, 2014, CURR OPIN ALLERGY CL, V14, P271, DOI 10.1097/ACI.0000000000000077
   Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380
   Cornejo-Garcia JA, 2012, CLIN EXP ALLERGY, V42, P1772, DOI 10.1111/j.1365-2222.2012.04078.x
   de Paramo BJ, 2000, ANN ALLERG ASTHMA IM, V85, P508
   Plaza-Seron MD, 2016, PHARMACOGENET GENOM, V26, P280, DOI 10.1097/FPC.0000000000000216
   del Pozo MD, 2000, ALLERGY, V55, P412, DOI 10.1034/j.1398-9995.2000.00562.x
   Dona I, 2014, ALLERGY, V69, P438, DOI 10.1111/all.12335
   Dona I, 2012, J INVEST ALLERG CLIN, V22, P363
   Dona I, 2011, CLIN EXP ALLERGY, V41, P86, DOI 10.1111/j.1365-2222.2010.03651.x
   Canto MG, 2009, CURR OPIN ALLERGY CL, V9, P293, DOI 10.1097/ACI.0b013e32832db943
   Gador B, 2016, J INVEST AL IN PRESS
   Giavina-Bianchi P, 2015, CLIN EXP ALLERGY, V45, P1142, DOI 10.1111/cea.12551
   Giavina-Bianchi P, 2015, CURR TREAT OPTIONS A, V2, P268
   Gomes E, 2004, CLIN EXP ALLERGY, V34, P1597, DOI 10.1111/j.1365-2222.2004.02070.x
   Himly M, 2003, J ALLERGY CLIN IMMUN, V111, P882, DOI 10.1067/mai.2003.163
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Jares EJ, 2015, J ALLER CL IMM-PRACT, V3, P780, DOI 10.1016/j.jaip.2015.05.012
   Kim JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013818
   Kim SH, 2011, BRIT J DERMATOL, V165, P976, DOI 10.1111/j.1365-2133.2011.10467.x
   Kim SH, 2013, IMMUNOL ALLERGY CLIN, V33, P177, DOI 10.1016/j.iac.2012.10.003
   Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260
   Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x
   Perez-Sanchez N, 2016, J ALLER CL IMM-PRACT, V4, P524, DOI 10.1016/j.jaip.2015.11.017
   Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x
   Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047
   Setkowicz M, 2009, J ALLERGY CLIN IMMUN, V123, P174, DOI 10.1016/j.jaci.2008.09.005
   Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1
   TERRADOS S, 1995, ALLERGY, V50, P563, DOI 10.1111/j.1398-9995.1995.tb01200.x
NR 37
TC 7
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-4050
EI 1473-6322
J9 CURR OPIN ALLERGY CL
JI Curr. Opin. Allergy Clin. Immunol.
PD AUG
PY 2016
VL 16
IS 4
BP 323
EP 332
DI 10.1097/ACI.0000000000000292
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA DR0HE
UT WOS:000379587800005
PM 27362320
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Barsotti, NS
   Santos, BAN
   Marinho, AKBB
   Kokron, CM
   Carvalho, KI
   Barros, MT
   Kalil, J
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Barsotti, Nathalia Silveira
   Santos, Bianca A. N.
   Marinho, Ana Karolina B. B.
   Kokron, Cristina M.
   Carvalho, Karina I.
   Barros, Myrthes T.
   Kalil, Jorge
   Nixon, Douglas F.
   Kallas, Esper G.
TI Inversion of the V delta 1 to V delta 2 gamma delta T cell ratio in CVID
   is not restored by IVIg and is associated with immune activation and
   exhaustion
SO MEDICINE
LA English
DT Article
DE CVID; gamma delta T cells; immune activation; IVIg; PD-1; V delta 1; V
   delta 2
ID COMMON VARIABLE IMMUNODEFICIENCY; MICROBIAL TRANSLOCATION; B-CELLS;
   DEFICIENCY; RECEPTOR; PATIENT; MEMORY
AB Common variable immunodeficiency (CVID) is defined by low levels of IgG and IgA, but perturbations in T cells are also commonly found. However, there is limited information on gamma delta T cells in CVID patients. Newly diagnosed CVID patients (n=15) were enrolled before and after intravenous IgG (IVIg) replacement therapy. Cryopreserved peripheral blood mononuclear cells were then used to study gamma delta T cells and CVID patients were compared to healthy controls (n=22). The frequency and absolute count of V delta 1 gamma delta T cells was found to be increased in CVID (median 0.60% vs 2.64%, P<0.01 and 7.5 vs 39, P<0.01 respectively), while they were decreased for V delta 2 gamma delta T cells (median, 2.36% vs 0.74%, P<0.01 and 37.8 vs 13.9, P<0.01 respectively) resulting in an inversion of the V delta 1 to V delta 2 ratio (0.24 vs 1.4, P<0.001). Markers of immune activation were elevated on all subsets of gamma delta T cells, and HLA-DR expression was associated with an expansion of V delta 1 gamma delta T cells (r=0.73, P=0.003). Elevated PD-1 expression was found only on V delta 2 gamma delta T cells (median 1.15% vs 3.08%, P<0.001) and was associated with the decrease of V delta 2 gamma delta T cells (r=-0.67, P=0.007). IVIg had no effect on the frequency of V delta 1 and V delta 2 gamma delta T cells or HLA-DR expression, but alleviated CD38 expression on V delta 1 gamma delta T cells (median MFI 965 vs 736, P<0.05). These findings suggest that immunological perturbations of gamma delta T cells are a general feature associated with CVID and are only partially reversed by IVIg therapy.
C1 [Paquin-Proulx, Dominic; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
   [Barsotti, Nathalia Silveira; Santos, Bianca A. N.; Marinho, Ana Karolina B. B.; Kokron, Cristina M.; Barros, Myrthes T.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Carvalho, Karina I.] Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
EM dpaquin_proulx@gwu.edu
RI Kokron, Cristina M/D-3140-2012; Carvalho, Karina IL/J-6789-2012; KALIL,
   JORGE/C-8029-2012; Nixon, Douglas/AAU-5734-2020; Marinho, Ana
   Karolina/C-8395-2017
OI Kokron, Cristina M/0000-0002-9080-0305; Carvalho, Karina
   IL/0000-0002-7763-8139; KALIL, JORGE/0000-0001-8415-4274; Nixon,
   Douglas/0000-0002-2801-1786; Marinho, Ana Karolina/0000-0001-9369-8222;
   Paquin Proulx, Dominic/0000-0003-1407-3414; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of Health grant of the District of Columbia Center
   for AIDS Research [P30AI087714, P30AI117970]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/15856-9/EGK, 2010/05845-0/EGK/DFN];
   CNPq/CAPESNational Council for Scientific and Technological Development
   (CNPq)CAPES [056/2012]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970] Funding Source: NIH
   RePORTER
FX This work was partially supported by the National Institutes of Health
   grant of the District of Columbia Center for AIDS Research (P30AI087714
   and P30AI117970), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (04/15856-9/EGK and 2010/05845-0/EGK/DFN), CNPq/CAPES 056/2012 (DFN).
CR Adams EJ, 2015, CELL IMMUNOL, V296, P31, DOI 10.1016/j.cellimm.2015.04.008
   Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531
   Barsotti NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151761
   Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Capitani N, 2012, INT J IMMUNOPATH PH, V25, P811, DOI 10.1177/039463201202500332
   Capitani N, 2010, J ALLERGY CLIN IMMUN, V126, P671, DOI 10.1016/j.jaci.2010.05.033
   Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052
   DEPAOLI P, 1991, CLIN EXP IMMUNOL, V83, P187, DOI 10.1111/j.1365-2249.1991.tb05612.x
   Duraisingham SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100324
   Fulcher DA, 2009, CLIN EXP IMMUNOL, V157, P365, DOI 10.1111/j.1365-2249.2009.03973.x
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003
   Harris LD, 2010, BLOOD, V116, P4148, DOI 10.1182/blood-2010-05-283549
   Hart M, 2007, J IMMUNOL, V178, P8212, DOI 10.4049/jimmunol.178.12.8212
   Katial RI, 1997, J CLIN IMMUNOL, V17, P34, DOI 10.1023/A:1027384311897
   Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0
   Muto M, 2015, CANCER IMMUNOL IMMUN, V64, P941, DOI 10.1007/s00262-015-1700-x
   Paquin-Proulx D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00637
   Paquin-Proulx D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075199
   Paquin-Proulx D, 2013, BLOOD, V121, P4963, DOI 10.1182/blood-2013-04-499442
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687
   Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039
   Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945
   Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033
   Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383
   Tyler CJ, 2015, CELL IMMUNOL, V296, P10, DOI 10.1016/j.cellimm.2015.01.008
   van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020
   Viallard JF, 2002, CLIN INFECT DIS, V35, pE134, DOI 10.1086/344469
   Vlkova M, 2015, CLIN IMMUNOL, V160, P292, DOI 10.1016/j.clim.2015.06.013
   Wallace M, 1997, MOL MED, V3, P60, DOI 10.1007/BF03401668
   Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394
NR 36
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL
PY 2016
VL 95
IS 30
AR e4304
DI 10.1097/MD.0000000000004304
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS4RO
UT WOS:000380768900043
PM 27472706
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Frade, AF
   Laugier, L
   Ferreira, LRP
   Baron, MA
   Benvenuti, LA
   Teixeira, PC
   Navarro, IC
   Cabantous, S
   Ferreira, FM
   Candido, DD
   Gaiotto, FA
   Bacal, F
   Pomerantzeff, P
   Santos, RHB
   Kalil, J
   Cunha-Neto, E
   Chevillard, C
AF Frade, Amanda Farage
   Laugier, Laurie
   Pinto Ferreira, Ludmila Rodrigues
   Baron, Monique Andrade
   Benvenuti, Luiz Alberto
   Teixeira, Priscila Camillo
   Navarro, Isabela Cunha
   Cabantous, Sandrine
   Ferreira, Frederico Moraes
   Candido, Darlan da Silva
   Gaiotto, Fabio Antonio
   Bacal, Fernando
   Pomerantzeff, Pablo
   Barros Santos, Ronaldo Honorato
   Kalil, Jorge
   Cunha-Neto, Edecio
   Chevillard, Christophe
TI Myocardial Infarction-Associated Transcript, a Long Noncoding RNA, Is
   Overexpressed During Dilated Cardiomyopathy Due to Chronic Chagas
   Disease
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE dilated; cardiomyopathy; Chagas disease; lncRNA; MIAT; biomarker
ID MIAT; HEART; RISK
AB Long noncoding RNAs (lncRNAs) modulate gene expression at the epigenetic, transcriptional, and posttranscriptional levels. Dysregulation of the lncRNA known as myocardial infarction-associated transcript (MIAT) has been associated with myocardial infarction. Chagas disease causes a severe inflammatory dilated chronic cardiomyopathy (CCC). We investigated the role of MIAT in CCC. A whole-transcriptome analysis of heart biopsy specimens and formalin-fixed, paraffin-embedded samples revealed that MIAT was overexpressed in patients with CCC, compared with subjects with noninflammatory dilated cardiomyopathy and controls. These results were confirmed in a mouse model. Results suggest that MIAT is a specific biomarker of CCC.
C1 [Frade, Amanda Farage; Laugier, Laurie; Cabantous, Sandrine; Kalil, Jorge; Chevillard, Christophe] Aix Marseille Univ, INSERM, GIMP, UMR S906, F-13385 Marseille, France.
   [Frade, Amanda Farage; Pinto Ferreira, Ludmila Rodrigues; Baron, Monique Andrade; Teixeira, Priscila Camillo; Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Immunol, Sao Paulo, Brazil.
   [Benvenuti, Luiz Alberto; Gaiotto, Fabio Antonio; Barros Santos, Ronaldo Honorato] Univ Sao Paulo, Sch Med, Div Pathol, Sao Paulo, Brazil.
   [Bacal, Fernando; Pomerantzeff, Pablo] Univ Sao Paulo, Sch Med, Inst Heart, Div Heart Transplantat, Sao Paulo, Brazil.
   [Frade, Amanda Farage; Pinto Ferreira, Ludmila Rodrigues; Baron, Monique Andrade; Teixeira, Priscila Camillo; Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Frade, Amanda Farage; Pinto Ferreira, Ludmila Rodrigues; Baron, Monique Andrade; Teixeira, Priscila Camillo; Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Candido, Darlan da Silva; Cunha-Neto, Edecio] Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Ferreira, Frederico Moraes] Univ Santo Amaro, Sao Paulo, Brazil.
RP Chevillard, C (corresponding author), Univ Aix Marseille, U906, INSERM, Fac Med, 27 Bd Jean Moulin, F-13385 Marseille 05, France.
EM christophe.chevillard@univ-amu.fr
RI Navarro, Isabela Cunha/V-7182-2017; Candido, Darlan/F-7209-2017;
   Cunha-Neto, Edecio/B-4157-2009; Ferreira, Ludmila Rodrigues
   Pinto/B-4955-2015; Bacal, Fernando/H-7952-2012; KALIL,
   JORGE/C-8029-2012; Ferreira, Frederico Moraes/A-4622-2013; Frade, Amanda
   F/O-3322-2017; chevillard, christophe/A-7087-2015
OI Navarro, Isabela Cunha/0000-0002-6844-2361; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; KALIL, JORGE/0000-0001-8415-4274; Frade,
   Amanda F/0000-0002-9004-8811; chevillard,
   christophe/0000-0002-5269-8813; Camillo Teixeira,
   Priscila/0000-0002-9698-4563; da Silva Candido,
   Darlan/0000-0002-5080-3130
FU Institut National de la Sante et de la Recherche Medicale, Aix-Marseille
   University (Direction des Relations Internationales); USP-COFECUB
   program; ARCUS II PACA Bresil program; Brazilian National Research
   CouncilNational Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); French National
   Research AgencyFrench National Research Agency (ANR); FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale, Aix-Marseille University (Direction des Relations
   Internationales), the USP-COFECUB program, the ARCUS II PACA Bresil
   program, the Brazilian National Research Council (productivity award to
   E. C.-N. and J. K.), the Sao Paulo State Research Funding Agency
   (FAPESP; fellowships to A. F. F., M. A. B., and L. G. N.), and the
   French National Research Agency and FAPESP (to E. C.-N. and C. C. on
   behalf of Br Fr Chagas).
CR Eicher JD, 2016, PLATELETS, V27, P230, DOI 10.3109/09537104.2015.1083543
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Grote P, 2013, RNA BIOL, V10, P1579, DOI 10.4161/rna.26165
   Han P, 2014, NATURE, V514, P102, DOI 10.1038/nature13596
   Ishii N, 2006, J HUM GENET, V51, P1087, DOI 10.1007/s10038-006-0070-9
   Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Navarro IC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003828
   Ferreira LRP, 2014, INT J CARDIOL, V175, P409, DOI 10.1016/j.ijcard.2014.05.019
   Rao SQ, 2015, SCHIZOPHR RES, V166, P125, DOI 10.1016/j.schres.2015.04.032
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Silva CP, 2008, ARQ BRAS CARDIOL, V91, P358
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Zhou L, 2015, BIOCHEM BIOPH RES CO, V468, P726, DOI 10.1016/j.bbrc.2015.11.023
NR 15
TC 22
Z9 24
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2016
VL 214
IS 1
BP 161
EP 165
DI 10.1093/infdis/jiw095
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DR3SF
UT WOS:000379822200022
PM 26951817
OA Other Gold
DA 2020-11-26
ER

PT J
AU Aparecida-Silva, R
   Borges, LF
   Kessler, K
   Dias, RR
   Moreira, LFP
   Kalil, J
   Gutierrez, PS
AF Aparecida-Silva, Rosemeire
   Borges, Luciano Figueiredo
   Kessler, Ketty
   Dias, Ricardo Ribeiro
   Pinho Moreira, Luiz Felipe
   Kalil, Jorge
   Gutierrez, Paulo Sampaio
TI Transforming growth factor-beta 1 SMAD effectors and medial cell number
   in ascending aorta diseases
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Article
DE Aorta; Aneurysms; Immunoperoxidase; Extracellular matrix; TGF-beta;
   SMADs
ID SMOOTH-MUSCLE-CELLS; MARFAN-SYNDROME; GROWTH; DISSECTIONS; PATHOLOGY;
   ANEURYSMS; COLLAGEN
AB In ascending aorta aneurysms and dissections, the extracellular matrix is degraded. Transforming growth factor (TGF)-beta 1 modulates its synthesis. The production and presence of SMADs, intracellular effectors of TGF-beta 1 signaling, were analyzed in patients with these diseases. To verify whether medial cells are lost, their total numbers were computed. Ascending aorta samples from 19 patients and 18 controls underwent immunoperoxidase reactions to SMADs 2, 3, 4, and 7. Positive and negative cells were counted, and total numbers of cells and positive/total ratios were calculated. Samples from other 14 patients and 7 normal controls were used for the quantification of SMAD3, SMAD4, and SMAD7 mRNA. For SMAD4, both mRNA (2.36 vs. 0.37, P=. 03) and ratio of positive cells (0.94 vs. 0.73, P=. 02) are increased in patients with ascending aortic diseases. SMAD3 mRNA was also increased (1.19 vs. 0.20, P=. 05). The cell ratios of this and the other SMADs, SMAD7 mRNA, and the total cell count did not differ between groups. In conclusion, in ascending aortic aneurysms and dissections, there is an increase in SMAD4, implicated in extracellular matrix production, possibly as an attempt to compensate for extracellular matrix deficiency. Lost medial cells are replaced, since their number is not diminished. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Aparecida-Silva, Rosemeire; Kalil, Jorge] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Immunol,Heart Inst InCor, Ave Dr Eneas C Aguiar 44, BR-05403000 Sao Paulo, Brazil.
   [Borges, Luciano Figueiredo] Univ Fed Minas Gerais, Dept Morphol, Ave Antonio Carlos 6627, BR-31270910 Belo Horizonte, MG, Brazil.
   [Kessler, Ketty] Univ Paris Diderot, INSERM, Sorbonne Paris Cite, U698, F-75018 Paris, France.
   [Dias, Ricardo Ribeiro; Pinho Moreira, Luiz Felipe] Univ Sao Paulo, Fac Med, Hosp Clin, Surg Div,Heart Inst InCor, Ave Dr Eneas C Aguiar 44, BR-05403000 Sao Paulo, Brazil.
   [Gutierrez, Paulo Sampaio] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Pathol,Heart Inst InCor, Ave Dr Eneas C Aguiar 44, BR-05403000 Sao Paulo, Brazil.
RP Gutierrez, PS (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Pathol,Heart Inst InCor, Ave Dr Eneas C Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM anppaulo@incor.usp.br
RI Borges, Luciano F/S-3583-2016; KALIL, JORGE/C-8029-2012; Moreira, Luiz
   Felipe Pinho/F-9882-2012; Dias, Ricardo R/D-5992-2012; Gutierrez, Paulo
   S/E-6783-2012
OI KALIL, JORGE/0000-0001-8415-4274; Moreira, Luiz Felipe
   Pinho/0000-0003-0179-4976; Gutierrez, Paulo S/0000-0002-9544-2359;
   Silva, Rosemeire/0000-0003-1901-5678
FU State of Sao Paulo Research Foundation (FAPESP), BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/06,671-3];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX The State of Sao Paulo Research Foundation (FAPESP), Brazil, Grant
   07/06,671-3. P.S.G. received a grant from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.
CR August P, 2006, NEW ENGL J MED, V354, P2721, DOI 10.1056/NEJMcibr062143
   Borges LF, 2005, CELL TISSUE RES, V320, P551, DOI 10.1007/s00441-005-1108-6
   Borges LD, 2008, HUM PATHOL, V39, P437, DOI 10.1016/j.humpath.2007.08.003
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Curci JA, 2009, VASCULAR, V17, pS21, DOI 10.2310/6670.2008.00085
   Dingemans KP, 2006, CARDIOVASC PATHOL, V15, P203, DOI 10.1016/j.carpath.2006.03.004
   Doetschman T, 2012, CELL TISSUE RES, V347, P203, DOI 10.1007/s00441-011-1241-3
   Fukui D, 2003, EUR J VASC ENDOVASC, V25, P540, DOI 10.1053/ejvs.2002.1857
   Gomez D, 2009, J PATHOL, V218, P131, DOI 10.1002/path.2516
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   HIRST AE, 1976, CIRCULATION, V53, P915, DOI 10.1161/01.CIR.53.6.915
   Humphrey JD, 2013, J VASC RES, V50, P1, DOI 10.1159/000342436
   Ince H, 2007, NAT CLIN PRACT CARD, V4, P418, DOI 10.1038/ncpcardio0937
   Jones JA, 2009, J VASC RES, V46, P119, DOI 10.1159/000151766
   LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0
   Lesauskaite V, 2001, HUM PATHOL, V32, P1003, DOI 10.1053/hupa.2001.27107
   Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695
   Medina C, 2011, J PATHOL, V224, P461, DOI 10.1002/path.2870
   Nakerakanti Sashidhar, 2012, Open Rheumatol J, V6, P156, DOI 10.2174/1874312901206010156
   Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9
   ROBERTS WC, 1981, AM HEART J, V101, P195, DOI 10.1016/0002-8703(81)90666-9
   Yuan SM, 2011, REV BRAS CIR CARDIOV, V26, P393, DOI 10.5935/1678-9741.20110014
   Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035
   Zhang P, 2016, CIRC RES, V118, P388, DOI 10.1161/CIRCRESAHA.115.308040
NR 24
TC 3
Z9 4
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1054-8807
EI 1879-1336
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD MAY-JUN
PY 2016
VL 25
IS 3
BP 240
EP 246
DI 10.1016/j.carpath.2016.02.003
PG 7
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA DL7ZZ
UT WOS:000375860400013
PM 26978681
DA 2020-11-26
ER

PT J
AU Palacios, R
   Poland, GA
   Kalil, J
AF Palacios, Ricardo
   Poland, Gregory A.
   Kalil, Jorge
TI Another emerging arbovirus, another emerging vaccine: Targeting Zika
   virus
SO VACCINE
LA English
DT Editorial Material
ID INFECTION; OUTBREAK; BRAZIL
C1 [Palacios, Ricardo; Kalil, Jorge] Inst Butantan, Ave Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Poland, Gregory A.] Mayo Clin, Dept Internal Med, Mayo Vaccine Res Grp, Rochester, MN USA.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Kalil, J (corresponding author), Inst Butantan, Ave Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM jorge.kalil@butantan.gov.br
RI Palacios, Ricardo/B-7248-2018; Palacios, Ricardo/AAN-7606-2020; KALIL,
   JORGE/C-8029-2012
OI Palacios, Ricardo/0000-0002-1410-8579; Palacios,
   Ricardo/0000-0002-1410-8579; KALIL, JORGE/0000-0001-8415-4274
CR [Anonymous], 2015, EV SAUD PUBL REL AOS
   [Anonymous], 2016, MON CAS MICR BRAS
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Boseley S, 2014, WHO SEVERAL 100 1000
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau V. M., 2016, LANCET
   da Saude Ministerio, 2015, B EP, V46, P1
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Direction de la sante, 2015, B SURVEILL SANIT
   Dixit R., 2016, VACCINE
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   European Centre for Disease Prevention and Control, 2016, ZIK VIR EP AM POT AS
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   GESER A, 1970, Bulletin of the World Health Organization, V43, P539
   Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224
   Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X
   Mallet HP, 2015, BISES B INFORM SANIT, P1
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Plotkin SA, 2006, CLIN INFECT DIS, V43, pS164, DOI 10.1086/505950
   Revello MG, 2014, NEW ENGL J MED, V370, P1316, DOI 10.1056/NEJMoa1310214
   Sencer DJ, 2006, EMERG INFECT DIS, V12, P29
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 23
TC 8
Z9 8
U1 0
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2016
VL 34
IS 20
BP 2291
EP 2293
DI 10.1016/j.vaccine.2016.03.059
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DL3AF
UT WOS:000375505900001
PM 27015734
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Kalil, J
AF Giavina-Bianchi, Pedro
   Kalil, Jorge
TI Mycoplasma pneumoniae infection induces asthma onset
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Editorial Material
DE Asthma
ID PREVALENCE; CHILDREN; HYGIENE; ALLERGY
C1 [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, AV Reboucas 1117, BR-05401150 Sao Paulo, SP, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy, AV Reboucas 1117, BR-05401150 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0
   Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589
   Hansbro PM, 2004, PHARMACOL THERAPEUT, V101, P193, DOI 10.1016/j.pharmthera.2003.10.007
   Jankovic D, 2001, TRENDS IMMUNOL, V22, P450, DOI 10.1016/S1471-4906(01)01975-5
   Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP
   Koh YY, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e39
   Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012
   MOK JYQ, 1979, ARCH DIS CHILD, V54, P506, DOI 10.1136/adc.54.7.506
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025
   SABATO AR, 1984, ARCH DIS CHILD, V59, P1034, DOI 10.1136/adc.59.11.1034
   Shapiro H, 2014, CURR OPIN IMMUNOL, V30, P54, DOI 10.1016/j.coi.2014.07.003
   STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259
   VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030
   Ye Q, 2014, SCI WORLD J, DOI 10.1155/2014/986527
   Yeh JJ, 2016, J ALLERGY CLIN IMMUN, V137, P1017, DOI 10.1016/j.jaci.2015.09.032
NR 16
TC 4
Z9 6
U1 1
U2 13
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2016
VL 137
IS 4
BP 1024
EP 1025
DI 10.1016/j.jaci.2015.11.011
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA DI2TG
UT WOS:000373351200007
PM 26792205
OA Bronze
DA 2020-11-26
ER

PT J
AU Pinto, LHE
   Aun, MV
   Cukier-Blaj, S
   Stelmach, R
   Cukier, A
   Kalil, J
   Agondi, RC
   Giavina-Bianchi, P
AF Eduardo Pinto, Lucia Helena
   Aun, Marcelo Vivolo
   Cukier-Blaj, Sabrina
   Stelmach, Rafael
   Cukier, Alberto
   Kalil, Jorge
   Agondi, Rosana Camara
   Giavina-Bianchi, Pedro
TI Vocal cord dysfunction diagnosis may be improved by a screening check
   list
SO ALLERGOLOGY INTERNATIONAL
LA English
DT Article
DE Airflow limitation; Asthma; Asthma attack; Lung function tests;
   Questionnaire
ID FOLD MOVEMENT; CHRONIC COUGH; SEVERE ASTHMA; DISEASE; MOTION; LARYNX
AB Background: Many patients with vocal cord dysfunction (VCD), with or without asthma, receive inappropriate treatment because they are misdiagnosed as having difficult-to-control asthma alone. We developed a clinical screening check list designed to aid the diagnosis of VCD.
   Methods: A prospective observational study involving 80 patients aged >= 8 years, diagnosed with severe asthma. After anamnesis and physical examination, physicians completed a check list with 6 questions to identify VCD, for which the answer "yes" counted one point. Then patients underwent spirometry and laryngoscopy. On the basis of the laryngoscopic findings, we created three patient groups: VCD (vocal cord adduction during inspiration, n = 14); unconfirmed VCD (inconclusive findings, n = 29); and control (normal findings, n = 37). We attempted to determine whether any of those groups were associated with the responses to individual questions or sets of questions on the check list.
   Results: The proportion of affirmative answers to the question "Does pulmonary auscultation reveal wheezing, predominantly in the cervical region, and/or stridor?" was significantly higher for the VCD group than for the other two groups (P = 0.006), notably in elderly patients. The variable "4 or more affirmative answers" was more common in VCD and unconfirmed VCD groups in comparison to controls (P = 0.022).
   Conclusions: A finding of wheezing or stridor on auscultation of the cervical region is suggestive of vocal cord dysfunction, especially in elderly patients, and such dysfunction can be confirmed through laryngoscopy. Our VCD screening check list proved to be useful in the screening of VCD among patients with severe asthma. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
C1 [Eduardo Pinto, Lucia Helena; Aun, Marcelo Vivolo; Kalil, Jorge; Agondi, Rosana Camara; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Cukier-Blaj, Sabrina; Stelmach, Rafael; Cukier, Alberto] Univ Sao Paulo, Dept Pulmonol, Sao Paulo, Brazil.
RP Aun, MV (corresponding author), R Manuel Guedes 517 Ap 12, BR-04536070 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012; Cukier,
   Alberto/C-6101-2012; stelmach, rafael/AAH-1638-2019
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   Cukier, Alberto/0000-0002-7217-9498; stelmach,
   rafael/0000-0002-5132-1934
CR Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903
   Balkissoon Ron, 2007, Clin Allergy Immunol, V19, P411
   Benninger C, 2011, CURR OPIN PULM MED, V17, P45, DOI 10.1097/MCP.0b013e32834130ee
   Bisaccioni C, 2009, ALLERGOL IMMUNOPATH, V37, P217, DOI 10.1016/j.aller.2009.02.002
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019
   BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4
   CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605
   de la Hoz RE, 2008, AM J IND MED, V51, P161, DOI 10.1002/ajim.20541
   Gavin LA, 1998, J ASTHMA, V35, P409, DOI 10.3109/02770909809048949
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, pS165, DOI 10.1016/j.jaci.2006.12.007
   Giavina-Bianchi P, 2010, CLINICS, V65, P905, DOI 10.1590/S1807-59322010000900014
   Holmes PW, 2009, RESPIROLOGY, V14, P1106, DOI 10.1111/j.1440-1843.2009.01629.x
   Kenn K, 2011, EUR RESPIR J, V37, P194, DOI 10.1183/09031936.00192809
   Morris MJ, 2010, CHEST, V138, P1213, DOI 10.1378/chest.09-2944
   Morrison M, 1999, J VOICE, V13, P447, DOI 10.1016/S0892-1997(99)80049-6
   Murry T, 2010, LARYNGOSCOPE, V120, P1576, DOI 10.1002/lary.20985
   NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399
   OCONNELL MA, 1995, ANN ALLERG ASTHMA IM, V74, P341
   Patel NJ, 2004, OTOLARYNG HEAD NECK, V130, P686, DOI 10.1016/j.otohns.2004.01.003
   Rosen CA, 2009, LARYNGOSCOPE, V119, pS185, DOI 10.1002/lary.20712
   Rothe TB, 1998, EUR RESPIR J, V11, P498, DOI 10.1183/09031936.98.11020498
   Sterner JB, 2009, RESP CARE, V54, P461
   Taramarcaz P, 2004, J ALLERGY CLIN IMMUN, V114, P1471, DOI 10.1016/j.jaci.2004.08.038
   Tervonen H, 2009, LARYNGOSCOPE, V119, P1776, DOI 10.1002/lary.20558
   Traister RS, 2014, J ALLER CL IMM-PRACT, V2, P65, DOI 10.1016/j.jaip.2013.09.002
   Vertigan AE, 2006, J VOICE, V20, P466, DOI 10.1016/j.jvoice.2005.08.001
   Vertigan AE, 2008, INT J SPEECH-LANG PA, V10, P231, DOI 10.1080/17549500801932089
   Watson MA, 2009, RESP CARE, V54, P467
   Wood RP, 1996, J ALLERGY CLIN IMMUN, V98, P481, DOI 10.1016/S0091-6749(96)70079-9
   Yelken K, 2009, RESPIROLOGY, V14, P729, DOI 10.1111/j.1440-1843.2009.01568.x
NR 31
TC 12
Z9 12
U1 0
U2 5
PU JAPANESE SOCIETY ALLERGOLOGY
PI TOKYO
PA MY BLDG 4F, 1-13-3, UENO, TAITO-KU, TOKYO, 110-0005, JAPAN
SN 1323-8930
EI 1440-1592
J9 ALLERGOL INT
JI Allergol. Int.
PD APR
PY 2016
VL 65
IS 2
BP 180
EP 185
DI 10.1016/j.alit.2015.11.001
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA DI6LS
UT WOS:000373611000011
PM 26666470
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Barsotti, NS
   Almeida, RR
   Barros, MT
   Kalil, J
   Kokron, CM
AF Barsotti, Nathalia Silveira
   Almeida, Rafael Ribeiro
   Barros, Myrthes Toledo
   Kalil, Jorge
   Kokron, Cristina M.
TI IL-10-PRODUCING REGULATORY B CELLS ARE DECREASED IN PATIENTS WITH COMMON
   VARIABLE IMMUNODEFICIENCY
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT CIS Annual Meeting on Immune Deficiency and Dysregulation North American
   Conference
CY APR 14-17, 2016
CL Boston, MA
SP Clin Immunol Soc
C1 [Barsotti, Nathalia Silveira; Almeida, Rafael Ribeiro; Barros, Myrthes Toledo; Kalil, Jorge; Kokron, Cristina M.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2016
VL 36
IS 3
MA 4445
BP 266
EP 267
PG 2
WC Immunology
SC Immunology
GA DG6AT
UT WOS:000372165300086
DA 2020-11-26
ER

PT J
AU Barsotti, NS
   Almeida, RR
   Costa, PR
   Barros, MT
   Kalil, J
   Kokron, CM
AF Barsotti, Nathalia Silveira
   Almeida, Rafael Ribeiro
   Costa, Priscilla Ramos
   Barros, Myrthes Toledo
   Kalil, Jorge
   Kokron, Cristina Maria
TI IL-10-Producing Regulatory B Cells Are Decreased in Patients with Common
   Variable Immunodeficiency
SO PLOS ONE
LA English
DT Article
ID T-CELLS; B10 CELLS; IN-VITRO; AUTOIMMUNITY; DISEASE; FREQUENCY;
   INFLAMMATION; COMPARTMENT; ACTIVATION; EXPRESSION
AB Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults. CVID patients often present changes in the frequency and function of B lymphocytes, reduced number of Treg cells, chronic immune activation, recurrent infections, high incidence of autoimmunity and increased risk for malignancies. We hypothesized that the frequency of B10 cells would be diminished in CVID patients because these cells play an important role in the development of Treg cells and in the control of T cell activation and autoimmunity. Therefore, we evaluated the frequency of B10 cells in CVID patients and correlated it with different clinical and immunological characteristics of this disease. Forty-two CVID patients and 17 healthy controls were recruited for this study. Cryo-preserved PBMCs were used for analysis of T cell activation, frequency of Treg cells and characterization of B10 cells by flow cytometry. IL-10 production by sorted B cells culture and plasma sCD14 were determined by ELISA. We found that CVID patients presented decreased frequency of IL-10-producing CD24(hi)CD38(hi) B cells in different cell culture conditions and decreased frequency of IL-10-producing CD24(hi)CD27(+) B cells stimulated with CpG+PIB. Moreover, we found that CVID patients presented lower secretion of IL-10 by sorting-purified B cells when compared to healthy controls. The frequency of B10 cells had no correlation with autoimmunity, immune activation and Treg cells in CVID patients. This work suggests that CVID patients have a compromised regulatory B cell compartment which is not correlated with clinical and immunological characteristics presented by these individuals.
C1 [Barsotti, Nathalia Silveira; Almeida, Rafael Ribeiro; Costa, Priscilla Ramos; Kalil, Jorge; Kokron, Cristina Maria] Univ Sao Paulo, Sch Med, Dept Med, Lab Clin Immunol & Allergy LIM60,Div Clin Immunol, Sao Paulo, Brazil.
   [Barros, Myrthes Toledo; Kalil, Jorge; Kokron, Cristina Maria] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, InCor, Inst Heart, Sao Paulo, Brazil.
   [Barros, Myrthes Toledo; Kokron, Cristina Maria] HC FMUSP, Clin Immunol & Allergy Div, Primary Immunodeficiency Outpatient Clin, Sao Paulo, Brazil.
RP Barsotti, NS (corresponding author), Univ Sao Paulo, Sch Med, Dept Med, Lab Clin Immunol & Allergy LIM60,Div Clin Immunol, Sao Paulo, Brazil.
EM nathalia.btt@usp.br
RI Almeida, Rafael/F-8014-2014; Kokron, Cristina M/D-3140-2012; KALIL,
   JORGE/C-8029-2012
OI Almeida, Rafael/0000-0003-3984-7527; Kokron, Cristina
   M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274; Silveira
   Barsotti, Nathalia/0000-0003-3513-5258
CR Agarwal S, 2009, CURR ALLERGY ASTHM R, V9, P347, DOI 10.1007/s11882-009-0051-0
   Arumugakani G, 2010, J CLIN IMMUNOL, V30, P292, DOI 10.1007/s10875-009-9351-3
   Audo R, 2014, ARTHRITIS RHEUMATOL, V66, pS168, DOI 10.1002/art.38666
   Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009
   Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527
   Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x
   Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673
   Brouet JC, 2000, EUR J IMMUNOL, V30, P2516, DOI 10.1002/1521-4141(200009)30:9<2516::AID-IMMU2516>3.0.CO;2-Z
   Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284
   Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545
   Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Fevang B, 2007, CLIN EXP IMMUNOL, V147, P521, DOI 10.1111/j.1365-2249.2006.03314.x
   Genre J, 2009, CLIN IMMUNOL, V132, P215, DOI 10.1016/j.clim.2009.03.519
   Goode I, 2014, TRANSPL P, V46, P3, DOI 10.1016/j.transproceed.2013.08.075
   Hel Z, 2014, J CLIN IMMUNOL, V34, P971, DOI 10.1007/s10875-014-0099-z
   Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249
   Kalampokis I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3907
   Kofod-Olsen E, 2016, CLIN IMMUNOL, V162, P49, DOI 10.1016/j.clim.2015.11.003
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Kondratenko I, 1997, CLIN EXP IMMUNOL, V108, P9, DOI 10.1046/j.1365-2249.1997.d01-993.x
   LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071
   Li XJ, 2012, BLOOD, V120, P3318, DOI 10.1182/blood-2012-05-432575
   Litzman J, 2012, CLIN EXP IMMUNOL, V170, P321, DOI 10.1111/j.1365-2249.2012.04655.x
   Lopes-da-Silva S, 2008, J CLIN IMMUNOL, V28, pS46, DOI 10.1007/s10875-008-9172-9
   Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934
   Mauri C, 2010, CURR OPIN IMMUNOL, V22, P761, DOI 10.1016/j.coi.2010.10.009
   Melo KM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006269
   Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3
   Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106
   Siewe B, 2013, J LEUKOCYTE BIOL, V93, P811, DOI 10.1189/jlb.0912436
   Vlkova M, 2015, CLIN IMMUNOL, V160, P292, DOI 10.1016/j.clim.2015.06.013
   Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544
   Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270
   Yang M, 2013, CELL MOL IMMUNOL, V10, P122, DOI 10.1038/cmi.2012.60
   Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501
   Zha BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049835
NR 37
TC 21
Z9 22
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2016
VL 11
IS 3
AR e0151761
DI 10.1371/journal.pone.0151761
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH1ZE
UT WOS:000372582800098
PM 26991898
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Aun, MV
   Arantes-Costa, F
   Almeida, FM
   Bruggermann, TR
   Saraiva-Romanholo, BM
   Genaro, IS
   Martins, MA
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Arantes-Costa, Fernanda
   Almeida, Francine Maria
   Bruggermann, Thayse Regina
   Saraiva-Romanholo, Beatriz Mangueira
   Genaro, Isabella S.
   Martins, Milton Arruda
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Inhibition of Inflammation and Mucus Production By Bordetella Pertussis
   Whole-Cell Vaccine in a Murine Model of Allergic Rhinitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 04-07, 2016
CL Los Angeles, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Arantes-Costa, Fernanda; Almeida, Francine Maria; Bruggermann, Thayse Regina; Genaro, Isabella S.; Martins, Milton Arruda] Univ Sao Paulo, Dept Internal Med, Sch Med, Sao Paulo, Brazil.
   [Saraiva-Romanholo, Beatriz Mangueira; Genaro, Isabella S.] Hosp Publ Employee Sao Paulo IAMSPE, Sao Paulo, Brazil.
   [Saraiva-Romanholo, Beatriz Mangueira] Univ City Sao Paulo UNICID, Sao Paulo, Brazil.
RI Costa, Fernanda Magalhaes A/F-2727-2012; KALIL, JORGE/C-8029-2012;
   Almeida, Francine Maria/H-3733-2013; Saraiva-Romanholo, Beatriz
   M/I-5482-2013; de Almeida, Francine Maria/S-2314-2019; Aun, Marcelo
   V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Almeida, Francine
   Maria/0000-0001-9755-5034; de Almeida, Francine
   Maria/0000-0001-9755-5034; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2016
VL 137
IS 2
SU S
MA 84
BP AB27
EP AB27
DI 10.1016/j.jaci.2015.12.088
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DK6BI
UT WOS:000375005401023
OA Bronze
DA 2020-11-26
ER

PT J
AU Kanamori, KY
   Alcantara, CT
   Motta, AA
   Kalil, J
   Agondi, RC
AF Kanamori, Kelly Yoshimi
   Alcantara, Carolina Tavares
   Motta, Antonio Abilio
   Kalil, Jorge
   Agondi, Rosana C.
TI Quality of Life Assessment in Patients with Chronic Urticaria
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 04-07, 2016
CL Los Angeles, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Kanamori, Kelly Yoshimi; Alcantara, Carolina Tavares; Motta, Antonio Abilio; Kalil, Jorge; Agondi, Rosana C.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2016
VL 137
IS 2
SU S
MA 842
BP AB258
EP AB258
DI 10.1016/j.jaci.2015.12.929
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DK6BI
UT WOS:000375005404038
OA Bronze
DA 2020-11-26
ER

PT J
AU Mendonca, JG
   Castro, RA
   Cordova, PT
   Meireles, PR
   Figo, DD
   Santos, KS
   Kalil, J
   Castro, FFM
   Yang, AC
AF Mendonca, Juliana Guimaraes
   Castro, Roberta Almeida
   Cordova, Pablo Torres
   Meireles, Paula Rezende
   Figo, Daniele Danella
   Santos, Keity Souza
   Kalil, Jorge
   Morato Castro, Fabio Fernandes
   Yang, Ariana C.
TI Cross-Reactivity Among Cereal Grains
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 04-07, 2016
CL Los Angeles, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Mendonca, Juliana Guimaraes; Castro, Roberta Almeida; Cordova, Pablo Torres; Meireles, Paula Rezende; Figo, Daniele Danella] Univ Sao Paulo, Sao Paulo, Brazil.
   [Santos, Keity Souza] Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Morato Castro, Fabio Fernandes; Yang, Ariana C.] Univ Sao Paulo, Allergy & Immunopathol Div, BR-05508 Sao Paulo, Brazil.
RI Castro, Fabio FM/C-1082-2017; Santos, Keity Souza/Q-5704-2019; Castro,
   Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012
OI Castro, Fabio FM/0000-0002-6211-5773; Santos, Keity
   Souza/0000-0001-5271-4011; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2016
VL 137
IS 2
SU S
MA 774
BP AB237
EP AB237
DI 10.1016/j.jaci.2015.12.961
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DK6BI
UT WOS:000375005403220
OA Bronze
DA 2020-11-26
ER

PT J
AU Takejima, PM
   Agondi, RC
   Rodrigues, H
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Takejima, Priscila Megumi
   Agondi, Rosana C.
   Rodrigues, Helcio
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI New Associations Between HLA Genotypes and Asthma Phenotypes
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 04-07, 2016
CL Los Angeles, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Takejima, Priscila Megumi; Agondi, Rosana C.; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Rodrigues, Helcio] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2016
VL 137
IS 2
SU S
MA 337
BP AB104
EP AB104
DI 10.1016/j.jaci.2015.12.464
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DK6BI
UT WOS:000375005402028
OA Bronze
DA 2020-11-26
ER

PT J
AU Apostolico, JD
   Boscardin, SB
   Yamamoto, MM
   de Oliveira, JN
   Kalil, J
   Cunha-Neto, E
   Rosa, DS
AF Apostolico, Juliana de Souza
   Boscardin, Silvia Beatriz
   Yamamoto, Marcio Massao
   de Oliveira-Filho, Jethe Nunes
   Kalil, Jorge
   Cunha-Neto, Edecio
   Rosa, Daniela Santoro
TI HIV Envelope Trimer Specific Immune Response Is Influenced by Different
   Adjuvant Formulations and Heterologous Prime-Boost
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; HEPATITIS-B-VACCINE; NEUTRALIZING ANTIBODIES;
   GLYCOPROTEIN TRIMERS; PRIMARY ISOLATE; PROTEIN; PHASE; DNA;
   IMMUNOGENICITY; TRIAL
AB The development of a preventive vaccine against human immunodeficiency virus (HIV-1) infection is the most efficient method to control the epidemic. The ultimate goal is to develop a vaccine able to induce specific neutralizing, non-neutralizing antibodies and cellular mediated immunity (CMI). Humoral and CMI responses can be directed to glycoproteins that are normally presented as a trimeric spike on the virus surface (gp140). Despite safer, subunit vaccines are normally less immunogenic/effective and need to be delivered together with an adjuvant. The choice of a suitable adjuvant can induce effective humoral and CMI that utterly lead to full protection against disease. In this report, we established a hierarchy of adjuvant potency on humoral and CMI when admixed with the recombinant HIV gp140 trimer. We show that vaccination with gp140 in the presence of different adjuvants can induce high-affinity antibodies, follicular helper T cells and germinal center B cells. The data show that poly (I:C) is the most potent adjuvant to induce specific CMI responses evidenced by IFN-gamma production and CD4(+)/CD8(+) T cell proliferation. Furthermore, we demonstrate that combining some adjuvants like MPL plus Alum and MPL plus MDP exert additive effects that impact on the magnitude and quality of humoral responses while mixing MDP with poly (I:C) or with R848 had no impact on total IgG titers but highly impact IgG subclass. In addition, heterologous DNA prime-protein boost yielded higher IgG titers when compare to DNA alone and improved the quality of humoral response when compare to protein immunization as evidenced by IgG1/IgG2a ratio. The results presented in this paper highlight the importance of selecting the correct adjuvant-antigen combination to potentiate desired cells for optimal stimulation.
C1 [Apostolico, Juliana de Souza; de Oliveira-Filho, Jethe Nunes; Rosa, Daniela Santoro] Fed Univ Sao Paulo UNIFESP EPM, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
   [Boscardin, Silvia Beatriz; Yamamoto, Marcio Massao] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio; Rosa, Daniela Santoro] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
RP Rosa, DS (corresponding author), Fed Univ Sao Paulo UNIFESP EPM, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
EM dsantororosa@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; Apostolico, Juliana/W-8804-2018;
   Boscardin, Silvia Beatriz/C-3397-2012; KALIL, JORGE/C-8029-2012; Rosa,
   Daniela S/D-2190-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Apostolico,
   Juliana/0000-0002-3507-3117; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110; KALIL, JORGE/0000-0001-8415-4274; Rosa,
   Daniela S/0000-0003-4536-891X
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/10154-0]; Conselho
   Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for
   Scientific and Technological Development (CNPq) [474729/2011-7];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (grant number: 2011/10154-0), url: http://www.fapesp.br,
   author responsible for funding DSR; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (grant number: 474729/2011-7), url:
   www.cnpq.br, author responsible for funding DSR, FAPESP fellowship JSA.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arias MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041144
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bansal GP, 2010, CURR OPIN MOL THER, V12, P39
   Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384
   Baum Linda L, 2010, Curr HIV/AIDS Rep, V7, P11, DOI 10.1007/s11904-009-0036-6
   Beddows S, 2007, VIROLOGY, V360, P329, DOI 10.1016/j.virol.2006.10.032
   Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08
   Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125
   Buffa V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050529
   Burke B, 2009, VIROLOGY, V387, P147, DOI 10.1016/j.virol.2009.02.005
   Chakrabarti BK, 2013, J VIROL, V87, P13239, DOI 10.1128/JVI.01247-13
   Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cooper CL, 2008, CLIN INFECT DIS, V46, P1310, DOI 10.1086/533467
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   De Rosa SC, 2008, CURR OPIN HIV AIDS, V3, P375, DOI 10.1097/COH.0b013e3282fbaaa7
   de Souza MS, 2012, J IMMUNOL, V188, P5166, DOI 10.4049/jimmunol.1102756
   Demberg T, 2007, J VIROL, V81, P3414, DOI 10.1128/JVI.02453-06
   Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08
   Douagi I, 2010, J VIROL, V84, P1683, DOI 10.1128/JVI.01896-09
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Galli G, 2009, P NATL ACAD SCI USA, V106, P3877, DOI 10.1073/pnas.0813390106
   Gottardo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075665
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grundner C, 2004, VIROLOGY, V330, P233, DOI 10.1016/j.virol.2004.08.037
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hasegawa Hideki, 2009, Ther Clin Risk Manag, V5, P125
   Hope TJ, 2011, NAT MED, V17, P1195, DOI 10.1038/nm.2528
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322
   Jost S, 2012, MICROBES INFECT, V14, P904, DOI 10.1016/j.micinf.2012.05.001
   Karasavvas N, 2012, AIDS RES HUM RETROV, V28, P1444, DOI 10.1089/aid.2012.0103
   Khayat R, 2013, J VIROL, V87, P9865, DOI 10.1128/JVI.01222-13
   Kim SK, 2000, VACCINE, V19, P530, DOI 10.1016/S0264-410X(00)00195-X
   Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018
   Kong NCT, 2008, KIDNEY INT, V73, P856, DOI 10.1038/sj.ki.5002725
   Kovacs JM, 2012, P NATL ACAD SCI USA, V109, P12111, DOI 10.1073/pnas.1204533109
   Kwong PD, 2009, CELL HOST MICROBE, V6, P292, DOI 10.1016/j.chom.2009.09.008
   Lai L, 2007, VIROLOGY, V369, P153, DOI 10.1016/j.virol.2007.07.017
   Lai RPJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035083
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Li Y, 2006, J VIROL, V80, P1414, DOI 10.1128/JVI.80.3.1414-1426.2006
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Mouquet H, 2013, NATURE, V496, P441, DOI 10.1038/nature12091
   Mouquet H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024078
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Nkolola JP, 2014, VACCINE, V32, P2109, DOI 10.1016/j.vaccine.2014.02.001
   Park H, 2013, J IMMUNOL, V190, P4103, DOI 10.4049/jimmunol.1202958
   Petrovas C, 2012, J CLIN INVEST, V122, P3281, DOI 10.1172/JCI63039
   Pitisuttithum P, 2004, JAIDS-J ACQ IMM DEF, V37, P1160, DOI 10.1097/01.qai.0000136091.72955.4b
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Ranasinghe S, 2012, J VIROL, V86, P277, DOI 10.1128/JVI.05577-11
   Ratto-Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115582
   Ratto-Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045840
   Rerks-Ngarm S, 2013, J INFECT DIS, V207, P1195, DOI 10.1093/infdis/jis478
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Scheid JF, 2011, P NATL ACAD SCI USA, V108, P18044, DOI 10.1073/pnas.1113395108
   Schonning K, 1998, AIDS RES HUM RETROV, V14, P1451, DOI 10.1089/aid.1998.14.1451
   Sealy R, 2009, INT REV IMMUNOL, V28, P49, DOI 10.1080/08830180802495605
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Siegrist CA, 2004, VACCINE, V23, P615, DOI 10.1016/j.vaccine.2004.07.014
   Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165
   Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373
   Stephenson KE, 2013, IMMUNOL REV, V254, P295, DOI 10.1111/imr.12073
   Sundling C, 2010, J EXP MED, V207, P2003, DOI 10.1084/jem.20100025
   Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005
   Vaine M, 2010, VACCINE, V28, P2999, DOI 10.1016/j.vaccine.2010.02.006
   Walker BD, 2011, NAT MED, V17, P1194, DOI 10.1038/nm.2529
   Wang SX, 2006, VIROLOGY, V350, P34, DOI 10.1016/j.virol.2006.02.032
   Wang SX, 2005, J VIROL, V79, P7933, DOI 10.1128/JVI.79.12.7933-7937.2005
   Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
   Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001
   Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000
   Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730
   Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572
NR 86
TC 9
Z9 9
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 4
PY 2016
VL 11
IS 1
AR e0145637
DI 10.1371/journal.pone.0145637
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA3FF
UT WOS:000367681500026
PM 26727218
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Cestari, JAF
   Fabri, GMC
   Kalil, J
   Nitrini, R
   Jacob, W
   de Siqueira, JTT
   Siqueira, SRDT
AF Cestari, Jose Augusto Ferrari
   Fabri, Gisele Maria Campos
   Kalil, Jorge
   Nitrini, Ricardo
   Jacob-Filho, Wilson
   de Siqueira, Jose Tadeu Tesseroli
   Siqueira, Silvia Regina D. T.
TI Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease
   and Mild Cognitive Impairment Compared with Controls (vol 52, pg 1479,
   2016)
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Correction
RI Nitrini, Ricardo/B-8703-2013; FABRI, Gisele Maria C/I-2703-2013;
   Siqueira, Silvia RDT/B-8990-2012
OI Nitrini, Ricardo/0000-0002-5721-1525; FABRI, Gisele Maria
   C/0000-0002-8396-0722; Siqueira, Silvia RDT/0000-0003-0207-0072
CR Cestari JAF, 2016, J ALZHEIMERS DIS, V52, P1479, DOI 10.3233/JAD-160212
NR 1
TC 6
Z9 7
U1 1
U2 8
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2016
VL 54
IS 2
BP 845
EP 845
DI 10.3233/JAD-169006
PG 1
WC Neurosciences
SC Neurosciences & Neurology
GA DX0WO
UT WOS:000384087200037
PM 27612073
OA Bronze
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Takejima, P
   Kalil, J
   Agondi, RC
AF Giavina-Bianchi, Pedro
   Aun, Marcelo Vivolo
   Takejima, Priscila
   Kalil, Jorge
   Agondi, Rosana Camara
TI United airway disease: current perspectives
SO JOURNAL OF ASTHMA AND ALLERGY
LA English
DT Review
DE ARIA; united airway disease; rhinitis; asthma; allergy; atopy; immediate
   hypersensitivity reaction; guideline
ID TREATING ALLERGIC RHINITIS; SEVERE EOSINOPHILIC ASTHMA; INDEPENDENT
   RISK-FACTOR; FOLLOW-UP; BRONCHIAL HYPERRESPONSIVENESS; SUBLINGUAL
   IMMUNOTHERAPY; NONALLERGIC RHINITIS; COLLEGE-STUDENTS; NASAL POLYPOSIS;
   CHILDREN
AB Upper and lower airways are considered a unified morphological and functional unit, and the connection existing between them has been observed for many years, both in health and in disease. There is strong epidemiologic, pathophysiologic, and clinical evidence supporting an integrated view of rhinitis and asthma: united airway disease in the present review. The term "united airway disease" is opportune, because rhinitis and asthma are chronic inflammatory diseases of the upper and lower airways, which can be induced by allergic or nonallergic reproducible mechanisms, and present several phenotypes. Management of rhinitis and asthma must be jointly carried out, leading to better control of both diseases, and the lessons of the Allergic Rhinitis and Its Impact on Asthma initiative cannot be forgotten.
C1 [Giavina-Bianchi, Pedro; Aun, Marcelo Vivolo; Takejima, Priscila; Kalil, Jorge; Agondi, Rosana Camara] Univ Sao Paulo, Clin Immunol & Allergy Div, Fac Med, 178 Rua Prof Artur Ramos,Apartment 211A, BR-01454904 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Fac Med, 178 Rua Prof Artur Ramos,Apartment 211A, BR-01454904 Sao Paulo, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Agondi, Rosana Camara/0000-0002-0503-5179
CR Agondi RC, 2008, J ASTHMA, V45, P754, DOI 10.1080/02770900802249149
   Antonicelli L, 2007, ALLERGY, V62, P1064, DOI 10.1111/j.1398-9995.2007.01470.x
   Aubier M, 2001, ALLERGY, V56, P35, DOI 10.1034/j.1398-9995.2001.00629.x
   Baraniuk JN, 2008, CURR ALLERGY ASTHM R, V8, P147, DOI 10.1007/s11882-008-0025-7
   Benninger M, 2010, ANN ALLERG ASTHMA IM, V104, P13, DOI 10.1016/j.anai.2009.11.020
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121
   BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314
   Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108, DOI 10.1164/ajrccm.163.5.2005086
   Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026
   Chung KF, 2015, CURR OPIN ALLERGY CL, V15, P56, DOI 10.1097/ACI.0000000000000134
   Cingi C, 2015, WORLD J CLIN CASES, V3, P499, DOI 10.12998/wjcc.v3.i6.499
   Ciprandi G, 2012, ALLERGY ASTHMA IMMUN, V4, P171, DOI 10.4168/aair.2012.4.4.171
   CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554
   DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1
   Eccles C, 2008, MIDDLETONS ALLERGY P, P701
   Feng CH, 2012, AM J RHINOL ALLERGY, V26, P187, DOI 10.2500/ajra.2012.26.3762
   FitzGerald JM, 2015, GLOB STRAT ASTHM MAN
   Fontanari P, 1996, J APPL PHYSIOL, V81, P1739
   Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250
   Gaga M, 2000, CLIN EXP ALLERGY, V30, P663
   Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047
   Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056
   GHERSON G, 1986, EUR J RESPIR DIS, V69, P24
   Giavina-Bianchi P, 2010, CLINICS, V65, P905, DOI 10.1590/S1807-59322010000900014
   Greisner WA, 2000, ALLERGY ASTHMA PROC, V21, P371, DOI 10.2500/108854100778249123
   Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701
   Halpern MT, 2004, J ASTHMA, V41, P117, DOI 10.1081/JAS-120026069
   Inal A, 2007, J INVEST ALLERG CLIN, V17, P85
   Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x
   KALINER M, 1988, IMMUNOLOGIC DISEASES, P1067
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2
   Lieberman P, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0439-3
   Lin SY, 2013, ALLERGEN SPECIFIC IM
   Lohia S, 2013, ALLERGY, V68, P569, DOI 10.1111/all.12124
   MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4
   Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6
   Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317
   Morjaria JB, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0412-6
   Nayak A, 2007, DRUGS, V67, P887, DOI 10.2165/00003495-200767060-00005
   Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x
   Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012
   Okano M, 2015, ALLERGOL INT, V64, P131, DOI 10.1016/j.alit.2015.01.004
   Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
   Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x
   Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309
   Robinson DS, 2013, EXPERT REV RESP MED, V7, P13, DOI [10.1586/ERS.12.84, 10.1586/ers.12.84]
   Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008
   Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341
   Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600
   SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634
   Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4
   Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x
   Stelmach R, 2005, CHEST, V128, P3140, DOI 10.1378/chest.128.5.3140
   Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017
   Taramarcaz P, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003570
   Togias A, 1999, ALLERGY, V54, P94, DOI 10.1111/j.1398-9995.1999.tb04410.x
   Vanna AT, 2001, PEDIATR ALLERGY IMMU, V12, P95, DOI 10.1034/j.1399-3038.2001.012002095.x
   Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003
   Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030
   Xie JX, 2015, ALLERGY ASTHMA IMMUN, V7, P76, DOI 10.4168/aair.2015.7.1.76
   Yamamoto H, 2012, ALLERGY ASTHMA PROC, V33, P397, DOI 10.2500/aap.2012.33.3594
   Yusuf OM, 2012, PRIM CARE RESP J, V21, P126, DOI 10.4104/pcrj.2012.00034
   Zuberbier T, 2010, ALLERGY, V65, P1525, DOI 10.1111/j.1398-9995.2010.02474.x
NR 69
TC 52
Z9 54
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6965
J9 J ASTHMA ALLERGY
JI J. ASTHMA ALLERGY
PY 2016
VL 9
BP 93
EP 100
DI 10.2147/JAA.S81541
PG 8
WC Allergy; Immunology; Respiratory System
SC Allergy; Immunology; Respiratory System
GA DW3KU
UT WOS:000383541300001
PM 27257389
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Cestari, JAF
   Fabri, GMC
   Kalil, J
   Nitrini, R
   Jacob, W
   de Siqueira, JTT
   Siqueira, SRDT
AF Ferrari Cestari, Jose Augusto
   Campos Fabri, Gisele Maria
   Kalil, Jorge
   Nitrini, Ricardo
   Jacob-Filho, Wilson
   Tesseroli de Siqueira, Jose Tadeu
   Siqueira, Silvia Regina D. T.
TI Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease
   and Mild Cognitive Impairment Compared with Controls
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; IL-6; inflammation; mild cognitive impairment; oral
   infection; periodontitis; TNF-alpha
ID INFLAMMATORY MARKERS; HEALTH; RISK; ANTIBODIES; DEMENTIA; BRAIN; TNF
AB Background: Oral infections are prevalent in the adult population. Their impact includes the implication as a risk factor for Alzheimer's disease (AD), altering its progression. One of the potential mechanisms involves immune mediators such as circulating cytokines.
   Objective: The goal of the present study was to investigate the prevalence of oral infections and blood levels of IL-1 beta, TNF-alpha, and IL-6 in patients with AD, mild cognitive impairment (MCI), and controls.
   Methods: Sixty-five elderly were evaluated (25 AD, 19 MCI, and 21 controls) by the following methods: Mini Mental State Exam, Questionnaire of Functional Activities, periodontal and oral evaluation, and blood concentrations of IL-1 beta, TNF-alpha and IL-6.
   Results: Patients with AD had high serum IL-6 levels (p = 0.029), and patients with periodontitis had high serum TNF-alpha levels (p = 0.005). There was an association between IL-6 and TNF-alpha in patients with AD/MCI and periodontitis (p = 0.023).
   Conclusion: The increased levels of TNF-alpha and IL-6 in this study suggests their implication in the overlapping mechanisms between oral infections and AD. Longitudinal studies are necessary for further investigation.
C1 [Ferrari Cestari, Jose Augusto; Nitrini, Ricardo; Siqueira, Silvia Regina D. T.] Univ Sao Paulo, Sch Med, Dept Neurol, BR-05508 Sao Paulo, Brazil.
   [Campos Fabri, Gisele Maria; Tesseroli de Siqueira, Jose Tadeu; Siqueira, Silvia Regina D. T.] Univ Sao Paulo, Sch Med, Hosp Clin, Orofacial Pain Team,Dent Div, BR-05508 Sao Paulo, Brazil.
   [Campos Fabri, Gisele Maria] Univ Fed Juiz de Fora, Juiz De Fora, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Lab Med Invest Immunol, BR-05508 Sao Paulo, Brazil.
   [Jacob-Filho, Wilson] Univ Sao Paulo, Sch Med, Dept Clin Med, Geriatr Clin, BR-05508 Sao Paulo, Brazil.
   [Siqueira, Silvia Regina D. T.] Univ Sao Paulo, Sch Arts Sci & Med, Gerontol, BR-05508 Sao Paulo, Brazil.
RP Siqueira, SRDT (corresponding author), R Dr Haberbeck Brandao 68,Ap 93, BR-04027040 Sao Paulo, SP, Brazil.
EM silviadowgan@hotmail.com
RI Fabri, Gisele Maria C/N-4907-2017; FABRI, Gisele Maria C/I-2703-2013;
   Nitrini, Ricardo/B-8703-2013; Siqueira, Silvia RDT/B-8990-2012; KALIL,
   JORGE/C-8029-2012
OI FABRI, Gisele Maria C/0000-0002-8396-0722; Nitrini,
   Ricardo/0000-0002-5721-1525; Siqueira, Silvia RDT/0000-0003-0207-0072;
   KALIL, JORGE/0000-0001-8415-4274
FU FAPESP (Foundation for Research of the State of Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/18756-9]
FX This study was supported by FAPESP (Foundation for Research of the State
   of Sao Paulo - 2011/18756-9).
CR [Anonymous], 2000, J Periodontol, V71 Suppl 5S, P853, DOI 10.1902/jop.2000.71.5-S.853
   [Anonymous], 2000, J Periodontol, V71 Suppl 5S, P856, DOI 10.1902/jop.2000.71.5-S.856
   Avlund Kirsten, 2004, Gerodontology, V21, P17, DOI 10.1046/j.1741-2358.2003.00003.x
   Bird TD, 2005, NEW ENGL J MED, V352, P862, DOI 10.1056/NEJMp058027
   Bretz WA, 2005, J AM GERIATR SOC, V53, P1532, DOI 10.1111/j.1532-5415.2005.53468.x
   Dimopoulos N, 2006, NEUROSCI LETT, V398, P118, DOI 10.1016/j.neulet.2005.12.064
   Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668
   Gosselin D, 2007, BRAIN BEHAV IMMUN, V21, P281, DOI 10.1016/j.bbi.2006.12.004
   Hatipoglu MG, 2011, GERODONTOLOGY, V28, P302, DOI 10.1111/j.1741-2358.2010.00401.x
   Kamer AR, 2008, ALZHEIMERS DEMENT, V4, P242, DOI 10.1016/j.jalz.2007.08.004
   Kamer AR, 2010, NEUROLOGY, V74, P1157, DOI 10.1212/WNL.0b013e3181d5df7f
   Kamer AR, 2009, J NEUROIMMUNOL, V216, P92, DOI 10.1016/j.jneuroim.2009.08.013
   Kravitz BA, 2009, ALZHEIMERS DEMENT, V5, P318, DOI 10.1016/j.jalz.2009.04.1230
   Mancini M, 2010, CURR ALZHEIMER RES, V7, P368, DOI 10.2174/156720510791162359
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Okamoto N, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-77
   Pietruski Jan Krzysztof, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P101
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rethman Michael P, 2010, J Calif Dent Assoc, V38, P247
   Riviere GR, 2002, ORAL MICROBIOL IMMUN, V17, P113, DOI 10.1046/j.0902-0055.2001.00100.x
   Rogers J, 2008, J PERIODONTOL, V79, P1535, DOI 10.1902/jop.2008.080171
   Rolim TD, 2014, J ALZHEIMERS DIS, V38, P823, DOI 10.3233/JAD-131283
   Rosenberg PB, 2006, INT REV PSYCHIATR, V17, P503, DOI 10.1080/02646830500382037
   Stein PS, 2012, ALZHEIMERS DEMENT, V8, P196, DOI 10.1016/j.jalz.2011.04.006
   Stewart R, 2008, PSYCHOSOM MED, V70, P936, DOI 10.1097/PSY.0b013e3181870aec
   Syrjala AMH, 2007, ACTA ODONTOL SCAND, V65, P103, DOI 10.1080/00016350601083521
   Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da
   Tatakis Dimitris N, 2005, Dent Clin North Am, V49, P491, DOI 10.1016/j.cden.2005.03.001
   Watts Amber, 2008, Neuropsychiatr Dis Treat, V4, P865
NR 29
TC 19
Z9 18
U1 1
U2 29
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2016
VL 52
IS 4
BP 1479
EP 1485
DI 10.3233/JAD-160212
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DP9BQ
UT WOS:000378792100028
PM 27104907
DA 2020-11-26
ER

PT J
AU Precioso, AR
   Palacios, R
   Thome, B
   Mondini, G
   Braga, P
   Kalil, J
AF Precioso, Alexander Roberto
   Palacios, Ricardo
   Thome, Beatriz
   Mondini, Gabriella
   Braga, Patricia
   Kalil, Jorge
TI Clinical evaluation strategies for a live attenuated tetravalent dengue
   vaccine
SO VACCINE
LA English
DT Article
DE Tetravalent dengue vaccine; Butantan Institute; Clinical trial
ID HEALTHY ADULT VOLUNTEERS; VIRUS TYPE-4; 3'-UNTRANSLATED REGION; NAIVE
   ADULTS; CANDIDATES; SAFE; MOSQUITOS; DELETION; MONKEYS
AB Butantan Institute is a public Brazilian biomedical research-manufacturer center affiliated to the Sao Paulo State Secretary of Health. Currently, Butantan is one of the main public producers of vaccines, antivenoms, and antitoxins in Latin America. The partnership between Butantan and the National Institutes of Health (NIH) of the United Sates has been one of the longest and most successful partnerships in the development and manufacturing of new vaccines. Recently, Butantan Institute has developed and manufactured a lyophilized tetravalent live attenuated dengue vaccine with the four dengue viruses attenuated and licensed from the Laboratory of Infectious Diseases at The National Institutes of Allergy and Infectious Diseases (LID/NIAID/NIH). The objective of this paper is to describe the clinical evaluation strategies of a live attenuated tetravalent dengue vaccine (Butantan-DV) developed and manufactured by Butantan Institute. These clinical strategies will be used to evaluate the Butantan-DV Phase III trial to support the Butantan-DV licensure for protection against any symptomatic dengue caused by any serotype in people aged 2 to 59 years. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Precioso, Alexander Roberto; Palacios, Ricardo; Thome, Beatriz; Mondini, Gabriella; Braga, Patricia] Inst Butantan, Div Clin Trials & Pharmacovigilance, BR-05503900 Sao Paulo, Brazil.
   [Precioso, Alexander Roberto] Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Kalil, Jorge] Inst Butantan, BR-05503900 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Precioso, AR (corresponding author), Inst Butantan, Div Clin Trials & Pharmacovigilance, Ave Vital Brasil 1500, BR-05503900 Sao Paulo, Brazil.
EM alexander.precioso@butantan.gov.br
RI Palacios, Ricardo/B-7248-2018; thome, beatriz C/B-7337-2018; Precioso,
   Alexander Roberto/A-9712-2013; Braga, Patricia/B-7806-2018; Palacios,
   Ricardo/AAN-7606-2020; KALIL, JORGE/C-8029-2012; MONDINI,
   GABRIELLA/B-7958-2018
OI Palacios, Ricardo/0000-0002-1410-8579; thome, beatriz
   C/0000-0002-3941-3756; Precioso, Alexander Roberto/0000-0001-8657-9292;
   Palacios, Ricardo/0000-0002-1410-8579; KALIL, JORGE/0000-0001-8415-4274;
   
FU Banco Nacional de Desenvolvimento Economico e Social-BNDES
FX The authors thank Drs. Stephen Whitehead (Laboratory of Infectious
   Diseases at The National Institutes of Allergy and Infectious
   Diseases-LID/NIAID/NIH), Anna P. Durbin (Johns Hopkins Bloomberg School
   of Public Health), and Donald Francis (Global Solutions for Infectious
   Diseases) for their extremely important support for the development of
   the clinical evaluation strategies of the live attenuated tetravalent
   dengue vaccine (Butantan-DV) developed and manufactured by Butantan
   Institute. Dr. Joao Luis Miraglia, former Butantan employee, also
   provided valuable inputs on the clinical development of this product.
   Drs Giovanini Evelim Coelho and Sulamita Branctao Barbiratto from the
   Health Surveillance Secretariat of the Brazilian Ministry of Health
   provided the dengue epidemiological surveillance database. Banco
   Nacional de Desenvolvimento Economico e Social-BNDES has offered
   financial support for the development of this vaccine.
CR [Anonymous], 2012, POL NAC AT BAS, P110
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Blaney JE, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-39
   Blaney JE, 2008, VACCINE, V26, P817, DOI 10.1016/j.vaccine.2007.11.082
   Durbin AP, 2006, HUM VACCINES, V2, P167, DOI 10.4161/hv.2.4.2944
   Durbin AP, 2006, HUM VACCINES, V2, P255, DOI 10.4161/hv.2.6.3494
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Durbin AP, 2011, VACCINE, V29, P7242, DOI 10.1016/j.vaccine.2011.07.023
   Durbin AP, 2005, J INFECT DIS, V191, P710, DOI 10.1086/427780
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Kapczynski A., 2005, BERKELEY TECHNOLOGY, V20, P1031
   Kesselheim AS, 2011, MILBANK Q, V89, P450, DOI 10.1111/j.1468-0009.2011.00636.x
   Krattiger A, 2012, PATENT INFORM FREEDO
   Macinko J, 2015, NEW ENGL J MED, V372, P2177, DOI 10.1056/NEJMp1501140
   Troyer JM, 2001, AM J TROP MED HYG, V65, P414, DOI 10.4269/ajtmh.2001.65.414
   Whitehead SS, 2003, VACCINE, V21, P4307, DOI 10.1016/S0264-410X(03)00488-2
   Whitehead SS, 2003, J VIROL, V77, P1653, DOI 10.1128/JVI.77.2.1653-1657.2003
NR 17
TC 22
Z9 22
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 10
PY 2015
VL 33
IS 50
SI SI
BP 7121
EP 7125
DI 10.1016/j.vaccine.2015.09.105
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CZ0CA
UT WOS:000366771500010
PM 26458796
DA 2020-11-26
ER

PT J
AU Santana, VC
   Almeida, RR
   Ribeiro, SP
   Ferreira, LCD
   Kalil, J
   Rosa, DS
   Cunha-Neto, E
AF Santana, Vinicius Canato
   Almeida, Rafael Ribeiro
   Ribeiro, Susan Pereira
   de Souza Ferreira, Lius Carlos
   Kalil, Jorge
   Rosa, Daniela Santoro
   Cunha-Neto, Edecio
TI Co-administration of plasmid-encoded granulocyte-macrophage
   colony-stimulating factor increases human immunodeficiency virus-1 DNA
   vaccine-induced polyfunctional CD4(+) T-cell responses
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE granulocyte-macrophage colony-stimulating factor; DNA vaccine;
   polyfunctional CD4(+) T-cells; HIV
ID GM-CSF; PROTECTIVE IMMUNITY; INFECTION; ADJUVANT; REPLICATION;
   CORRELATE; EFFICACY; ANTIGEN; PROTEIN; ABILITY
AB T-cell based vaccines against human immunodeficiency virus (HIV) generate specific responses that may limit both transmission and disease progression by controlling viral load. Broad, polyfunctional, and cytotoxic CD4(+) T-cell responses have been associated with control of simian immunodeficiency virus/HIV-1 replication, supporting the inclusion of CD4(+) T-cell epitopes in vaccine formulations. Plasmid-encoded granulocyte-macrophage colony-stimulating factor (pGM-CSF) co-administration has been shown to induce potent CD4(+) T-cell responses and to promote accelerated priming and increased migration of antigen-specific CD4(+) T-cells. However, no study has shown whether co-immunisation with pGM-CSF enhances the number of vaccine-induced polyfunctional CD4(+) T-cells. Our group has previously developed a DNA vaccine encoding conserved, multiple human leukocyte antigen (HLA)-DR binding HIV-1 subtype B peptides, which elicited broad, polyfunctional and long-lived CD4(+) T-cell responses. Here, we show that pGM-CSF co-immunisation improved both magnitude and quality of vaccine-induced T-cell responses, particularly by increasing proliferating CD4(+) T-cells that produce simultaneously interferon-gamma, tumour necrosis factor-alpha and interleukin-2. Thus, we believe that the use of pGM-CSF may be helpful for vaccine strategies focused on the activation of anti-HIV CD4(+) T-cell immunity.
C1 [Santana, Vinicius Canato; Almeida, Rafael Ribeiro; Ribeiro, Susan Pereira; Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
   [Santana, Vinicius Canato; Almeida, Rafael Ribeiro; Ribeiro, Susan Pereira; Kalil, Jorge; Rosa, Daniela Santoro; Cunha-Neto, Edecio] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, SP, Brazil.
   [de Souza Ferreira, Lius Carlos] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508 Sao Paulo, SP, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Inst Coracao, Sao Paulo, SP, Brazil.
   [Rosa, Daniela Santoro] Univ Fed Sao Paulo, Fac Med, Div Imunol, Sao Paulo, SP, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Div Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
EM edecunha@gmail.com
RI Almeida, Rafael/F-8014-2014; Rosa, Daniela S/D-2190-2012; KALIL,
   JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Ferreira,
   Luis/M-3954-2014
OI Almeida, Rafael/0000-0003-3984-7527; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Ferreira, Luis/0000-0002-4883-1693
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [420166/2005-0]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2004/15856-9, 2006/50096-0, 2008/57881-0]
FX CNPq (420166/2005-0), FAPESP (2004/15856-9, 2006/50096-0, 2008/57881-0)
CR Ahlers JD, 2002, P NATL ACAD SCI USA, V99, P13020, DOI 10.1073/pnas.192251199
   Arens R, 2010, IMMUNOL REV, V235, P190, DOI 10.1111/j.0105-2896.2010.00899.x
   Barouch DH, 2002, J IMMUNOL, V168, P562, DOI 10.4049/jimmunol.168.2.562
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Diniz MO, 2010, CLIN VACCINE IMMUNOL, V17, P1576, DOI 10.1128/CVI.00264-10
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Gloster SE, 2004, AIDS, V18, P749, DOI 10.1097/00002030-200403260-00005
   Haddad D, 2000, J IMMUNOL, V165, P3772, DOI 10.4049/jimmunol.165.7.3772
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lai LL, 2011, J INFECT DIS, V204, P164, DOI 10.1093/infdis/jir199
   Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Rodriguez AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037801
   McKay PF, 2004, EUR J IMMUNOL, V34, P1011, DOI 10.1002/eji.200324840
   Nambiar JK, 2010, EUR J IMMUNOL, V40, P153, DOI 10.1002/eji.200939665
   Pahar B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-160
   Porichis F, 2011, CURR OPIN HIV AIDS, V6, P174, DOI 10.1097/COH.0b013e3283454058
   Qiu JT, 2007, VACCINE, V25, P253, DOI 10.1016/j.vaccine.2006.07.034
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Robinson HL, 2006, VIROLOGY, V352, P285, DOI 10.1016/j.virol.2006.02.011
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165
   Song RJ, 2006, J INTERF CYTOK RES, V26, P380, DOI 10.1089/jir.2006.26.380
   Tenbusch M, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-13
   Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   Weiss WR, 1998, J IMMUNOL, V161, P2325
   Xu R, 2008, VACCINE, V26, P4819, DOI 10.1016/j.vaccine.2008.06.103
   Zhai YZ, 2015, MOL MED REP, V12, P199, DOI 10.3892/mmr.2015.3419
   Zheng N, 2009, J VIROL, V83, P7668, DOI 10.1128/JVI.00513-09
NR 35
TC 7
Z9 8
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD DEC
PY 2015
VL 110
IS 8
BP 1010
EP 1016
DI 10.1590/0074-02760150283
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DA0IM
UT WOS:000367480800009
PM 26602876
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Raposo, RAS
   Coirada, FC
   da Silva, JR
   Ferreira, LCD
   Kalil, J
   Nixon, DF
   Cunha-Neto, E
AF Almeida, Rafael Ribeiro
   Raposo, Rui Andre Saraiva
   Coirada, Fernanda Caroline
   da Silva, Jamile Ramos
   de Souza Ferreira, Luis Carlos
   Kalil, Jorge
   Nixon, Douglas F.
   Cunha-Neto, Edecio
TI Modulating APOBEC expression enhances DNA vaccine immunogenicity
SO IMMUNOLOGY AND CELL BIOLOGY
LA English
DT Article
ID POLYPEPTIDE 2 APOBEC2; RNA-EDITING ENZYME; PROTEIN-KINASE-C;
   INTRACELLULAR DNA; MESSENGER-RNA; I INTERFERON; IMMUNE-RESPONSES;
   IFN-ALPHA; INNATE; MUSCLE
AB DNA vaccines have failed to induce satisfactory immune responses in humans. Several mechanisms of double-stranded DNA (dsDNA) sensing have been described, and modulate DNA vaccine immunogenicity at many levels. We hypothesized that the immunogenicity of DNA vaccines in humans is suppressed by APOBEC (apolipoprotein B (APOB) mRNA-editing, catalytic polypeptide)-mediated plasmid degradation. We showed that plasmid sensing via STING (stimulator of interferon (IFN) genes) and TBK-1 (TANK-binding kinase 1) leads to IFN-beta induction, which results in APOBEC3A mRNA upregulation through a mechanism involving protein kinase C signaling. We also showed that murine APOBEC2 expression in HEK293T cells led to a 10-fold reduction in intracellular plasmid levels and plasmid-encoded mRNA, and a 2.6-fold reduction in GFP-expressing cells. A bicistronic DNA vaccine expressing an immunogen and an APOBEC2-specific shRNA efficiently silenced APOBEC2 both in vitro and in vivo, increasing the frequency of induced IFN-gamma-secreting T cells. Our study brings new insights into the intracellular machinery involved in dsDNA sensing and how to modulate it to improve DNA vaccine immunogenicity in humans.
C1 [Almeida, Rafael Ribeiro; Coirada, Fernanda Caroline; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
   [Almeida, Rafael Ribeiro; Kalil, Jorge; Cunha-Neto, Edecio] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Raposo, Rui Andre Saraiva; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
   [da Silva, Jamile Ramos; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
RP Almeida, RR (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM rafaelbio13@yahoo.com.br
RI Cunha-Neto, Edecio/B-4157-2009; Nixon, Douglas/AAU-5734-2020; Almeida,
   Rafael/F-8014-2014; KALIL, JORGE/C-8029-2012; Ferreira, Luis/M-3954-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Nixon,
   Douglas/0000-0002-2801-1786; Almeida, Rafael/0000-0003-3984-7527; KALIL,
   JORGE/0000-0001-8415-4274; Ferreira, Luis/0000-0002-4883-1693; Raposo,
   R. Andre/0000-0001-5435-0290
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [420166/2005-0]; Sao
   Paulo State Research Funding Agency (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2004/15856-9, 2006/50096-0,
   2008/57881-0]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI093179]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI093179, R33AI093179, R33AI093179, R21AI093179, R21AI093179]
   Funding Source: NIH RePORTER
FX This research was supported by the Brazilian National Research Council
   (CNPq), grant 420166/2005-0, the Sao Paulo State Research Funding Agency
   (FAPESP), grants 2004/15856-9, 2006/50096-0 and 2008/57881-0, and from
   the NIH, grant AI093179. Rafael Ribeiro Almeida is a recipient of Sao
   Paulo State Research Funding Agency (FAPESP) fellowship.
CR Abdulhaqq SA, 2008, IMMUNOL RES, V42, P219, DOI 10.1007/s12026-008-8076-3
   Bergman PJ, 2006, VACCINE, V24, P4582, DOI 10.1016/j.vaccine.2005.08.027
   Coban C, 2008, HUM VACCINES, V4, P453, DOI 10.4161/hv.4.6.6200
   Coban C, 2011, CURR GENE THER, V11, P479, DOI 10.2174/156652311798192815
   Davidson AH, 2005, JAVMA-J AM VET MED A, V226, P240, DOI 10.2460/javma.2005.226.240
   Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247
   Etard C, 2010, J CELL BIOL, V189, P527, DOI 10.1083/jcb.200912125
   Garver KA, 2005, DIS AQUAT ORGAN, V64, P13, DOI 10.3354/dao064013
   Geiben-Lynn R, 2011, CLIN VACCINE IMMUNOL, V18, P533, DOI 10.1128/CVI.00390-10
   Harper MS, 2013, J IMMUNOL, V190, P1583, DOI 10.4049/jimmunol.1202920
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Huang B, 2008, HUM GENE THER, V19, P763, DOI 10.1089/hum.2007.059
   Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317
   Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476
   Kostrzak A, 2015, GENE THER, V22, P96, DOI 10.1038/gt.2014.88
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Li L, 2012, J BIOTECHNOL, V162, P171, DOI 10.1016/j.jbiotec.2012.08.012
   Li LM, 2007, RNA, V13, P1765, DOI 10.1261/rna.599107
   Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925
   MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194
   Mehta HV, 2012, J IMMUNOL, V189, P4088, DOI 10.4049/jimmunol.1200777
   Muckenfuss H, 2006, J BIOL CHEM, V281, P22161, DOI 10.1074/jbc.M601716200
   Narvaiza I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000439
   Okeoma CM, 2009, J VIROL, V83, P3486, DOI 10.1128/JVI.02347-08
   Okuyama S, 2012, INT J CANCER, V130, P1294, DOI 10.1002/ijc.26114
   Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512
   Pillai SK, 2012, P NATL ACAD SCI USA, V109, P3035, DOI 10.1073/pnas.1111573109
   Powell C, 2014, J BIOL CHEM, V289, P28924, DOI 10.1074/jbc.M114.603043
   QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Sato Y, 2010, J BIOL CHEM, V285, P7111, DOI 10.1074/jbc.M109.052977
   Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939
   Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102
   Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013
   Unterholzner L, 2010, NAT IMMUNOL, V11, P997, DOI 10.1038/ni.1932
   Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x
   Wang ST, 2011, GENE THER, V18, P372, DOI 10.1038/gt.2010.146
   Williams JA, 2009, BIOTECHNOL ADV, V27, P353, DOI 10.1016/j.biotechadv.2009.02.003
   Yang PY, 2010, NAT IMMUNOL, V11, P487, DOI 10.1038/ni.1876
   Zhang ZQ, 2011, NAT IMMUNOL, V12, P959, DOI 10.1038/ni.2091
NR 47
TC 3
Z9 3
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0818-9641
EI 1440-1711
J9 IMMUNOL CELL BIOL
JI Immunol. Cell Biol.
PD NOV
PY 2015
VL 93
IS 10
BP 868
EP 876
DI 10.1038/icb.2015.53
PG 9
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CY3AX
UT WOS:000366281300006
PM 25953029
DA 2020-11-26
ER

PT J
AU Rosa, DS
   Ribeiro, SP
   Fonseca, SG
   Almeida, RR
   Santana, VC
   Apostolico, JD
   Kalil, J
   Cunha-Neto, E
AF Rosa, Daniela Santoro
   Ribeiro, Susan Pereira
   Fonseca, Simone Goncalves
   Almeida, Rafael Ribeiro
   Santana, Vinicius Canato
   Apostolico, Juliana de Souza
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Multiple Approaches for Increasing the Immunogenicity of an
   Epitope-Based Anti-HIV Vaccine
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; COLONY-STIMULATING
   FACTOR; CLASS-II MOLECULES; DNA VACCINE; IMMUNE-RESPONSES; GM-CSF;
   IMMUNODOMINANT EPITOPES; NEUTRALIZING ACTIVITY; PEPTIDES BINDING
AB The development of a highly effective vaccine against the human immunodeficiency virus (HIV) will likely be based on rational vaccine design, since traditional vaccine approaches have failed so far. In recent years, an understanding of what type of immune response is protective against infection and/or disease facilitated vaccine design. T cell-based vaccines against HIV have the goal of limiting both transmission and disease progression by inducing broad and functionally relevant T cell responses. In this context, CD4(+) T cells play a direct cytotoxic role and are also important for the generation and maintenance of functional CD8(+) T and B cell responses. The use of MHC-binding algorithms has allowed the identification of novel CD4(+) T cell epitopes that could be used in vaccine design, the so-called epitope-driven vaccine design. Epitope-based vaccines have the ability to focus the immune response on highly antigenic, conserved epitopes that are fully recognized by the target population. We have recently mapped a set of conserved multiple HLA-DR-binding HIV-1 CD4 epitopes and observed interferon (IFN)--producing CD4(+) T cells when we tested these peptides in peripheral blood mononuclear cells (PBMCs) from HIV-infected individuals. We then designed multiepitopic DNA vaccines that induced broad and polyfunctional T cell responses in immunized mice. In this review we will focus on alternative strategies to increase the immunogenicity of an epitope-based vaccine against HIV infection.
C1 [Rosa, Daniela Santoro; Apostolico, Juliana de Souza] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, UNIFESP, BR-04023062 Sao Paulo, SP, Brazil.
   [Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Apostolico, Juliana de Souza; Kalil, Jorge; Cunha-Neto, Edecio] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira; Almeida, Rafael Ribeiro; Santana, Vinicius Canato; Cunha-Neto, Edecio] Univ Sao Paulo, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
   [Fonseca, Simone Goncalves; Almeida, Rafael Ribeiro; Santana, Vinicius Canato] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Jatai, Go, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
RP Rosa, DS (corresponding author), Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, UNIFESP, Rua Botucatu 862,4 Andar, BR-04023062 Sao Paulo, SP, Brazil.
EM dsantororosa@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; FONSECA,
   SIMONE GONCALVES/U-9278-2019; Apostolico, Juliana/W-8804-2018; Rosa,
   Daniela S/D-2190-2012; Almeida, Rafael/F-8014-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Apostolico, Juliana/0000-0002-3507-3117;
   Rosa, Daniela S/0000-0003-4536-891X; Almeida, Rafael/0000-0003-3984-7527
FU Sao Paulo State Research Funding Agency (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Brazilian National Research
   Council (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by the Sao Paulo State Research Funding Agency
   (FAPESP) and Brazilian National Research Council (CNPq).
CR Abdulhaqq SA, 2008, IMMUNOL RES, V42, P219, DOI 10.1007/s12026-008-8076-3
   Aboud S, 2010, CLIN VACCINE IMMUNOL, V17, P1124, DOI 10.1128/CVI.00008-10
   Ahlers JD, 1997, J IMMUNOL, V158, P3947
   Almeida RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045267
   [Anonymous], 2013, 2013 GRUROTGAGE GLOB
   Apostolopoulos V, 2009, EXPERT REV VACCINES, V8, P1133, DOI [10.1586/erv.09.94, 10.1586/ERV.09.94]
   Asokan A, 2012, MOL THER, V20, P699, DOI 10.1038/mt.2011.287
   Baden LR, 2011, J INFECT DIS, V204, P1541, DOI 10.1093/infdis/jir615
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Balazs AB, 2014, NAT MED, V20, P296, DOI 10.1038/nm.3471
   Barouch D H, 2000, Dev Biol (Basel), V104, P85
   Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Barouch DH, 1998, J IMMUNOL, V161, P1875
   Barouch DH, 2002, J IMMUNOL, V168, P562, DOI 10.4049/jimmunol.168.2.562
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   Braga-Neto UM, 2006, PLOS COMPUT BIOL, V2, P651, DOI 10.1371/journal.pcbi.0020081
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258
   Chevalier MF, 2011, J VIROL, V85, P733, DOI 10.1128/JVI.02030-10
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   Damico FM, 2005, INVEST OPHTH VIS SCI, V46, P2465, DOI 10.1167/iovs.04-1273
   DANKO I, 1994, GENE THER, V1, P114
   de Souza MS, 2012, J IMMUNOL, V188, P5166, DOI 10.4049/jimmunol.1102756
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Dimitrov I, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/705821
   Diniz MO, 2013, HUM GENE THER, V24, P861, DOI 10.1089/hum.2013.102
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gowthaman U, 2008, J PROTEOME RES, V7, P154, DOI 10.1021/pr070527b
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Halwani R, 2008, J IMMUNOL, V180, P7969, DOI 10.4049/jimmunol.180.12.7969
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Jaffee EM, 2001, J CLIN ONCOL, V19, P145, DOI 10.1200/JCO.2001.19.1.145
   Jin HL, 2004, VACCINE, V22, P2925, DOI 10.1016/j.vaccine.2003.12.026
   Johnson JA, 2013, CURR OPIN HIV AIDS, V8, P412, DOI 10.1097/COH.0b013e328363d3b7
   Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967
   Jost S, 2014, J VIROL, V88, P8349, DOI 10.1128/JVI.00924-14
   Julg B, 2011, J INFECT DIS, V203, P803, DOI 10.1093/infdis/jiq122
   Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199
   Khosroshahi KH, 2012, PARASITOL RES, V111, P403, DOI 10.1007/s00436-012-2852-7
   Klatt NR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003862
   Kraynyak KA, 2009, HUM GENE THER, V20, P1143, DOI 10.1089/hum.2009.025
   Kwissa M, 2007, J EXP MED, V204, P2733, DOI 10.1084/jem.20071211
   Lai LL, 2011, J INFECT DIS, V204, P164, DOI 10.1093/infdis/jir199
   Lasaro MO, 2008, NAT MED, V14, P205, DOI 10.1038/nm1704
   Lewis AD, 2002, J VIROL, V76, P8769, DOI 10.1128/JVI.76.17.8769-8775.2002
   Liao HX, 2006, VIROLOGY, V353, P268, DOI 10.1016/j.virol.2006.04.043
   Lin HP, 2007, J VIROL, V81, P11840, DOI 10.1128/JVI.01253-07
   Lin JP, 2009, J VIROL, V83, P12738, DOI 10.1128/JVI.01441-09
   Malhotra U, 2001, J CLIN INVEST, V107, P505, DOI 10.1172/JCI11275
   Mast TC, 2010, VACCINE, V28, P950, DOI 10.1016/j.vaccine.2009.10.145
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Morrow MP, 2008, AIDS, V22, P333, DOI 10.1097/QAD.0b013e3282f42461
   Nimal S, 2006, VACCINE, V24, P3298, DOI 10.1016/j.vaccine.2006.01.020
   Nimal S, 2005, VACCINE, V23, P3984, DOI 10.1016/j.vaccine.2005.01.160
   Ortiz AM, 2011, J CLIN INVEST, V121, P4433, DOI 10.1172/JCI46023
   Ott G, 2002, J CONTROL RELEASE, V79, P1, DOI 10.1016/S0168-3659(01)00545-4
   Pachuk CJ, 2000, BBA-BIOMEMBRANES, V1468, P20, DOI 10.1016/S0005-2736(00)00242-X
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   Parks CL, 2013, CURR OPIN HIV AIDS, V8, P402, DOI 10.1097/COH.0b013e328363d389
   Plotkin SA, 2013, CLIN INFECT DIS, V56, P1458, DOI 10.1093/cid/cit048
   Potter SJ, 2007, J VIROL, V81, P13904, DOI 10.1128/JVI.01401-07
   Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993
   Ranasinghe S, 2013, NAT MED, V19, P930, DOI 10.1038/nm.3229
   Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3
   Rappuoli R, 2014, VACCINE, V32, P4705, DOI 10.1016/j.vaccine.2014.06.071
   Rappuoli R, 2011, LANCET, V378, P360, DOI 10.1016/S0140-6736(11)60440-6
   Ratto-Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115582
   Rerks-Ngarm S, 2013, J INFECT DIS, V207, P1195, DOI 10.1093/infdis/jis478
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2014, TRIALS VACCINOL, V3, P95
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Robinson HL, 2006, VIROLOGY, V352, P285, DOI 10.1016/j.virol.2006.02.011
   Rolland M, 2007, PLOS PATHOG, V3, P1551, DOI 10.1371/journal.ppat.0030157
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0
   Rosa DS, 2011, J VACCINES VACCIN, V2
   Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/erv.11.188, 10.1586/ERV.11.188]
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Santana VC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071322
   Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105
   Schnepp BC, 2014, CURR OPIN HIV AIDS, V9, P250, DOI 10.1097/COH.0000000000000056
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Shen L, 2004, CANCER IMMUNOL IMMUN, V53, P391, DOI 10.1007/s00262-003-0455-y
   Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tenbusch M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039038
   TOP FH, 1971, J INFECT DIS, V124, P148, DOI 10.1093/infdis/124.2.148
   Toubaji A, 2007, VACCINE, V25, P5882, DOI 10.1016/j.vaccine.2007.05.040
   Vellinga J, 2014, HUM GENE THER, V25, P318, DOI 10.1089/hum.2014.007
   Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898
   VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11
   Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944
   WATSON RJ, 1982, SCIENCE, V218, P381, DOI 10.1126/science.6289440
   Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05
   Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433
   Xin KQ, 2006, J VIROL, V80, P11899, DOI 10.1128/JVI.00890-06
   Xu R, 2008, VACCINE, V26, P4819, DOI 10.1016/j.vaccine.2008.06.103
   Zhai YZ, 2009, INTERVIROLOGY, V52, P152, DOI 10.1159/000224643
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 108
TC 12
Z9 13
U1 0
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2015
VL 31
IS 11
BP 1077
EP 1088
DI 10.1089/aid.2015.0101
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CV5SJ
UT WOS:000364331100004
PM 26149745
DA 2020-11-26
ER

PT J
AU Cordova, PT
   Lima, FMS
   Boufleur, K
   Grecco, O
   Cohon, A
   Marinho, AK
   Kalil, J
   Barros, MT
   Kokron, CM
AF Cordova, Pablo Torres
   Souza Lima, Fabiana Mascarenhas
   Boufleur, Karla
   Grecco, Octavio
   Cohon, Andrea
   Marinho, Anna Karolina
   Kalil, Jorge
   Barros, Myrthes Toledo
   Kokron, Cristina Maria
TI Retrospective Analysis of 31 Adult Patients with Selective IGM
   Deficiency
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY NOV 18-21, 2015
CL Buenos Aires, ARGENTINA
SP Latin Amer Soc Immunodeficiencies
DE Selective IgM deficiency; Immunodeficiency; Autoimmunity; Malignancy
C1 [Cordova, Pablo Torres; Souza Lima, Fabiana Mascarenhas; Boufleur, Karla; Grecco, Octavio; Cohon, Andrea; Marinho, Anna Karolina; Kalil, Jorge; Barros, Myrthes Toledo; Kokron, Cristina Maria] Univ Sao Paulo, Sch Med, Hosp Clin, Clin Immunol & Allergy Dept, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge] Inst Coracao, Lab Immunol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2015
VL 35
SU 1
MA PL078
BP S35
EP S35
PG 1
WC Immunology
SC Immunology
GA CV0XR
UT WOS:000363977700075
DA 2020-11-26
ER

PT J
AU Silva, DCD
   Barsotti, NS
   de Oliveira, AKB
   Zilinski, FR
   Barros, MT
   Kalil, J
   Kokron, CM
AF de Oliveira Silva, Diana Cordeiro
   Barsotti, Nathalia Silveira
   Barreto de Oliveira, Ana Karolina
   Zilinski, Fernando Ramon
   Barros, Myrthes Toledo
   Kalil, Jorge
   Kokron, Cristina Maria
TI Altered Expression of BAFF-R and TACI in Common Variable
   Immunodeficiency (CVID) Patients
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY NOV 18-21, 2015
CL Buenos Aires, ARGENTINA
SP Latin Amer Soc Immunodeficiencies
C1 [de Oliveira Silva, Diana Cordeiro; Barsotti, Nathalia Silveira; Zilinski, Fernando Ramon; Kokron, Cristina Maria] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Barreto de Oliveira, Ana Karolina; Barros, Myrthes Toledo; Kokron, Cristina Maria] Univ Sao Paulo, Sch Med, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2015
VL 35
SU 1
MA PL069
BP S30
EP S31
PG 2
WC Immunology
SC Immunology
GA CV0XR
UT WOS:000363977700066
DA 2020-11-26
ER

PT J
AU Garcia, G
   Torres, P
   Marinho, AK
   Cohon, A
   Grecco, O
   Kalil, J
   Barros, MT
   Kokron, CM
AF Garcia, Giane
   Torres, Pablo
   Marinho, Anna Karolina
   Cohon, Andrea
   Grecco, Octavio
   Kalil, Jorge
   Barros, Myrthes Toledo
   Kokron, Cristina Maria
TI Causes of Death in Common Variable Immunodeficiency (CVID) Patients
   Followed at the Primary Immunodeficiency Outpatient Clinic Between 1995
   and 2015
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY NOV 18-21, 2015
CL Buenos Aires, ARGENTINA
SP Latin Amer Soc Immunodeficiencies
C1 [Garcia, Giane; Torres, Pablo; Marinho, Anna Karolina; Cohon, Andrea; Grecco, Octavio; Kalil, Jorge; Barros, Myrthes Toledo; Kokron, Cristina Maria] Univ Sao Paulo, Sch Med, Hosp Clin, Clin Immunol & Allergy Dept, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge] Inst Coracao, Lab Immunol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Marinho, Ana Karolina/C-8395-2017; Kokron,
   Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Marinho, Ana
   Karolina/0000-0001-9369-8222; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2015
VL 35
SU 1
MA PL009
BP S4
EP S5
PG 2
WC Immunology
SC Immunology
GA CV0XR
UT WOS:000363977700010
DA 2020-11-26
ER

PT J
AU Garcia, JB
   Spengler, AL
   Kokron, CM
   de Oliveira, AKB
   Grecco, O
   Kalil, J
   Barros, MT
AF Garcia, Juliana Bianchini
   Spengler, Ana Laura
   Kokron, Cristina Maria
   Barreto de Oliveira, Ana Karolina
   Grecco, Octavio
   Kalil, Jorge
   Barros, Myrthes Toledo
TI Thromboembolic Phenomena Related to the Intravenous Infusion of
   Immunoglobulin in Patients with Primary Immunodeficiencies
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY NOV 18-21, 2015
CL Buenos Aires, ARGENTINA
SP Latin Amer Soc Immunodeficiencies
C1 [Garcia, Juliana Bianchini; Spengler, Ana Laura; Kokron, Cristina Maria; Barreto de Oliveira, Ana Karolina; Grecco, Octavio; Kalil, Jorge; Barros, Myrthes Toledo] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2015
VL 35
SU 1
MA PL022
BP S9
EP S10
PG 2
WC Immunology
SC Immunology
GA CV0XR
UT WOS:000363977700021
DA 2020-11-26
ER

PT J
AU Lima, FMS
   Boufleur, K
   Torres, P
   Cohon, A
   Barros, MT
   Kalil, J
   Kokron, CM
AF Souza Lima, Fabiana Mascarenhas
   Boufleur, Karla
   Torres, Pablo
   Cohon, Andrea
   Barros, Myrthes Toledo
   Kalil, Jorge
   Kokron, Cristina Maria
TI Retrospective Analysis of 14 Adult Patients with X-Linked
   Agammaglobulinemia in a Tertiary Hospital in Sao Paulo, Brasil
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY NOV 18-21, 2015
CL Buenos Aires, ARGENTINA
SP Latin Amer Soc Immunodeficiencies
C1 [Souza Lima, Fabiana Mascarenhas; Boufleur, Karla; Torres, Pablo; Cohon, Andrea; Barros, Myrthes Toledo; Kalil, Jorge; Kokron, Cristina Maria] Univ Sao Paulo, Fac Med, Hosp Clin, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD NOV
PY 2015
VL 35
SU 1
MA PL056
BP S25
EP S25
PG 1
WC Immunology
SC Immunology
GA CV0XR
UT WOS:000363977700053
DA 2020-11-26
ER

PT J
AU Luque, MCA
   Gutierrez, PS
   Debbas, V
   Kalil, J
   Stolf, BS
AF Luque, Maria Carolina A.
   Gutierrez, Paulo S.
   Debbas, Victor
   Kalil, Jorge
   Stolf, Beatriz S.
TI CD100 and plexins B2 and B1 mediate monocyte-endothelial cell adhesion
   and might take part in atherogenesis
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Monocyte adhesion; SEMA4D; Plexins; Atherosclerosis
ID SURFACE EXPRESSION; IMMUNE-SYSTEM; SOLUBLE CD100; IFN-GAMMA;
   ATHEROSCLEROSIS; SEMAPHORIN; RECEPTORS; CD72; LYMPHOCYTES; VERTEBRATES
AB Leukocyte migration is essential for the function of the immune system. Their recruitment from the vessels to the tissues involves sequential molecular interactions between leukocytes and endothelial cells (ECs). Many adhesion molecules involved in this process have already been described. However, additional molecules may be important in this interaction, and here we explore the potential role for CD100 and plexins in monocyte-EC binding.
   CD100 was shown to be involved in platelet-endothelial cell interaction, an important step in atherogenesis and thrombus formation. In a recent work we have described CD100 expression in monocytes and in macrophages and foam cells of human atherosclerotic plaques. In the present work, we have identified plexin B2 as a putative CD100 receptor in these cells. We have detected CD100 expression in the endothelium as well as in in vitro cultured endothelial cells. Blocking of CD 100, plexin B1 and/or B2 in adhesion experiments have shown that both CD100 and plexins act as adhesion molecules involved in monocyte-endothelial cell binding. This effect may be mediated by CD100 expressed in both cell types, probably coupled to the receptors endothelial plexin B1 and monocytic plexin B2. These results can bring new insights about a possible biological activity of CD100 in monocyte adhesion and atherosclerosis, as well as a future candidate for targeting therapeutics. (C) 2015 The Authors. Published by Elsevier Ltd.
C1 [Luque, Maria Carolina A.; Gutierrez, Paulo S.; Debbas, Victor; Kalil, Jorge] HC FMUSP, Heart Inst Sao Paulo InCor, Sao Paulo, SP, Brazil.
   [Luque, Maria Carolina A.; Kalil, Jorge] Univ Sao Paulo, Med Sch HC FMUSP, Dept Clin Med, Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Kalil, Jorge] Natl Inst Sci & Technol, INCT, Inst Invest Immunol, Sao Paulo, SP, Brazil.
   [Stolf, Beatriz S.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, SP, Brazil.
RP Stolf, BS (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, SP, Brazil.
EM bstolf@usp.br
RI KALIL, JORGE/C-8029-2012; Stolf, Beatriz S/H-7943-2012; Gutierrez, Paulo
   S/E-6783-2012
OI KALIL, JORGE/0000-0001-8415-4274; Stolf, Beatriz S/0000-0001-7661-3311;
   Gutierrez, Paulo S/0000-0002-9544-2359
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Financial support was obtained mainly from FAPESP (Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo). We would like to thank Dr. Veronica
   Coelho and Prof. Francisco Laurindo for discussing the data and Dr.
   Edilberto Postol for the help with adhesion experiment control
   conditions.
CR Luque MCA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075772
   Arita-Okubo S, 2015, CARDIOVASC RES, V105, P361, DOI 10.1093/cvr/cvv003
   AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244
   Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126
   BERNARD G, 1994, J IMMUNOL, V152, P5161
   BOUGERET C, 1992, J IMMUNOL, V148, P318
   Chabbert-de Ponnat I, 2005, INT IMMUNOL, V17, P439, DOI 10.1093/intimm/dxh224
   Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252
   Elhabazi A, 2003, CRIT REV IMMUNOL, V23, P65, DOI 10.1615/CritRevImmunol.v23.i12.40
   Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341
   Granziero L, 2003, BLOOD, V101, P1962, DOI 10.1182/blood-2002-05-1339
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Heemskerk N, 2014, CELL ADHES MIGR, V8, P67, DOI 10.4161/cam.28244
   Hirschberg A, 2010, MOL CELL BIOL, V30, P764, DOI 10.1128/MCB.01458-09
   Hu Y, 2008, J IMMUNOL, V180, P8057, DOI 10.4049/jimmunol.180.12.8057
   Hwang J, 2003, J BIOL CHEM, V278, P47291, DOI 10.1074/jbc.M305150200
   Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375
   Ishida I, 2003, INT IMMUNOL, V15, P1027, DOI 10.1093/intimm/dxg098
   Ji JD, 2009, HUM IMMUNOL, V70, P211, DOI 10.1016/j.humimm.2009.01.026
   Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740
   Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5
   Li M, 2009, IMMUNOLOGY, V128, P114, DOI 10.1111/j.1365-2567.2009.03098.x
   Mehta JL, 1998, J AM COLL CARDIOL, V31, P1217, DOI 10.1016/S0735-1097(98)00093-X
   Mizrahi S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000818
   Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4
   Roney KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024795
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   Sun QM, 2009, J BIOL CHEM, V284, P32066, DOI 10.1074/jbc.M109.057166
   Sun XH, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0372-2
   Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X
   van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400
   Witherden DA, 2012, IMMUNITY, V37, P314, DOI 10.1016/j.immuni.2012.05.026
   Yu D, 2008, IMMUNOL CELL BIOL, V86, P3, DOI 10.1038/sj.icb.7100123
   Yukawa K, 2010, INT J MOL MED, V26, P39, DOI 10.3892/ijmm_00000432
   Zhu L, 2007, P NATL ACAD SCI USA, V104, P1621, DOI 10.1073/pnas.0606344104
   Zhu L, 2009, ARTERIOSCL THROM VAS, V29, P1039, DOI 10.1161/ATVBAHA.109.185405
   Zielonka M, 2010, EXP CELL RES, V316, P2477, DOI 10.1016/j.yexcr.2010.05.007
NR 37
TC 19
Z9 21
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2015
VL 67
IS 2
BP 559
EP 567
DI 10.1016/j.molimm.2015.07.028
PN B
PG 9
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA CS2SQ
UT WOS:000361922400041
PM 26275342
OA Other Gold
DA 2020-11-26
ER

PT J
AU Aun, MV
   Saraiva-Romanholo, BM
   de Almeida, FM
   Bruggemann, TR
   Martins, JKMD
   Arantes-Costa, FM
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Saraiva-Romanholo, Beatriz Mangueira
   de Almeida, Francine Maria
   Brueggemann, Thayse Regina
   Milton de Arruda Martins, Jorge Kalil
   Arantes-Costa, Fernanda Magalhaes
   Giavina-Bianchi, Pedro
TI Sensitization by subcutaneous route is superior to intraperitoneal route
   in induction of asthma by house dust mite in a murine mode
SO EINSTEIN-SAO PAULO
LA English
DT Article
DE Models, animal; Asthma/chemically induced; Pyroglyphidae
AB Objective: To develop a new experimental model of chronic allergic pulmonary disease induced by house dust mite, with marked production of specific immunoglobulin E (IgE), eosinophilic inflammatory infiltrate in the airways and remodeling, comparing two different routes of sensitization. Methods: The protocol lasted 30 days. BALB/c mice were divided into six groups and were sensitized subcutaneously or intraperitoneally with saline (negative control), Dermatophagoides pteronyssinus (Der p) 50 or 500mcg in three injections. Subsequently they underwent intranasal challenge with Der p or saline for 7 days and were sacrificed 24 hours after the last challenge. We evaluated the titration of specific IgE antiDer p, eosinophilic density in peribronchovascular space and airway remodeling. Results: Both animals sensitized intraperitoneally and subcutaneously produced specific IgE anti-Der p. Peribronchovascular eosinophilia increased only in mice receiving lower doses of Der p. However, only the group sensitized with Der p 50mcg through subcutaneously route showed significant airway remodeling. Conclusion: In this murine model of asthma, both pathways of sensitization led to the production of specific IgE and eosinophilia in the airways. However, only the subcutaneously route was able to induce remodeling. Furthermore, lower doses of Der p used in sensitization were better than higher ones, suggesting immune tolerance. Further studies are required to evaluate the efficacy of this model in the development of bronchial hyperresponsiveness, but it can already be replicated in experiments to create new therapeutic drugs or immunotherapeutic strategies.
C1 [Aun, Marcelo Vivolo; Saraiva-Romanholo, Beatriz Mangueira; de Almeida, Francine Maria; Brueggemann, Thayse Regina; Milton de Arruda Martins, Jorge Kalil; Arantes-Costa, Fernanda Magalhaes; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
RP Aun, MV (corresponding author), Ave Brigadeiro Luis Antonio 4-267 Jardim Paul, BR-01401002 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI Saraiva-Romanholo, Beatriz M/I-5482-2013; de Almeida, Francine
   Maria/S-2314-2019; Costa, Fernanda Magalhaes A/F-2727-2012; Aun, Marcelo
   V/E-6775-2014; Almeida, Francine Maria/H-3733-2013; KALIL,
   JORGE/C-8029-2012
OI de Almeida, Francine Maria/0000-0001-9755-5034; Aun, Marcelo
   V/0000-0001-9882-5200; Almeida, Francine Maria/0000-0001-9755-5034;
   KALIL, JORGE/0000-0001-8415-4274; Arantes-Costa,
   Fernanda/0000-0001-9448-4357
CR [Anonymous], 2014, GLOB STRAT ASTHM MAN
   Baqueiro T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-51
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Bates JHT, 2009, AM J PHYSIOL-LUNG C, V297, pL401, DOI 10.1152/ajplung.00027.2009
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Braun A, 2008, CURR DRUG TARGETS, V9, P436, DOI 10.2174/138945008784533516
   Clarke AH, 1999, INT ARCH ALLERGY IMM, V120, P126, DOI 10.1159/000024230
   Conrad ML, 2009, CLIN EXP ALLERGY, V39, P1246, DOI 10.1111/j.1365-2222.2009.03260.x
   Egito EST, 2003, PATHOL RES PRACT, V199, P521, DOI 10.1078/0344-0338-00457
   Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131
   Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755
   Giavina-Bianchi P, 2008, ACTA OPHTHALMOL, V86, P670, DOI 10.1111/j.1600-0420.2007.01134.x
   Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731
   Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC
   Kelada SNP, 2011, AM J RESP CELL MOL, V45, P817, DOI 10.1165/rcmb.2010-0315OC
   Lourenco O, 2007, ALLERGOL IMMUNOPATH, V35, P177, DOI 10.1157/13110312
   Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332
   MOTA I, 1969, LIFE SCI PT 1 PHYSI, V8, P813, DOI 10.1016/0024-3205(69)90099-X
   Ogawa H, 2011, CLIN EXP ALLERGY, V41, P104, DOI 10.1111/j.1365-2222.2010.03564.x
   OVARY Z, 1958, J IMMUNOL, V81, P355
   Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6
   Rigaux P, 2009, ALLERGY, V64, P406, DOI 10.1111/j.1398-9995.2008.01825.x
   Rodrigues AM, 2012, J BRAS PNEUMOL, V38, P595, DOI 10.1590/S1806-37132012000500009
   Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x
NR 24
TC 4
Z9 4
U1 0
U2 5
PU INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
PI SAO PAULO SP
PA AVENIDA ALBERT EINSTEIN, 627 701, SAO PAULO SP, 05651-901, BRAZIL
SN 1679-4508
EI 2317-6385
J9 EINSTEIN-SAO PAULO
JI Einstein
PD OCT-DEC
PY 2015
VL 13
IS 4
BP 560
EP 566
DI 10.1590/S1679-45082015AO3389
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA V7W6N
UT WOS:000421358400014
PM 26761554
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tanno, LK
   Kerr, DS
   dos Santos, B
   Talib, LL
   Yamaguti, C
   Rodrigues, H
   Gattaz, WF
   Kalil, J
AF Tanno, Luciana Kase
   Kerr, Daniel Shikanai
   dos Santos, Bernardo
   Talib, Leda Leme
   Yamaguti, Celia
   Rodrigues, Helcio
   Gattaz, Wagner Farid
   Kalil, Jorge
TI The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants
   Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects
   (vol 10, e0136141, 2015)
SO PLOS ONE
LA English
DT Correction
RI Tanno, Luciana Kase/J-9981-2014
OI Tanno, Luciana Kase/0000-0003-3236-1225
CR Tanno LK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136141
NR 1
TC 0
Z9 0
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2015
VL 10
IS 9
AR e0139861
DI 10.1371/journal.pone.0139861
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6EV
UT WOS:000362171400104
PM 26418418
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU De Amicis, KM
   Watanabe, AS
   Galvao, CE
   Figo, DD
   dos Santos-Pinto, JRA
   Palma, MS
   Castro, FF
   Kalil, J
   Ferreira-Briza, F
   Gadermaier, G
   Santos, KS
AF De Amicis, K. M.
   Watanabe, A. S.
   Galvao, C. E.
   Figo, D. D.
   dos Santos-Pinto, J. R. A.
   Palma, M. S.
   Castro, F. F.
   Kalil, J.
   Ferreira-Briza, F.
   Gadermaier, G.
   Santos, K. S.
TI Multi-sensitization to hymenoptera venoms in a group of Brazilian
   patients
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 06-10, 2015
CL Barcelona, SPAIN
SP European Acad Allergy & Clin Immunol
C1 [De Amicis, K. M.; Figo, D. D.; Castro, F. F.; Santos, K. S.] Univ Sao Paulo, Allergy & Immunopathol LIM 60, Sao Paulo, Brazil.
   [De Amicis, K. M.; Watanabe, A. S.; Galvao, C. E.; Figo, D. D.; dos Santos-Pinto, J. R. A.; Palma, M. S.; Castro, F. F.; Kalil, J.; Santos, K. S.] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [De Amicis, K. M.; Ferreira-Briza, F.; Gadermaier, G.] Salzburg Univ, Mol Biol, Div Allergy & Immunol, A-5020 Salzburg, Austria.
   [Watanabe, A. S.; Galvao, C. E.; Castro, F. F.; Kalil, J.] Univ Sao Paulo, Clin Hosp, Sch Med, Sao Paulo, Brazil.
   [dos Santos-Pinto, J. R. A.; Palma, M. S.] Univ Sao Paulo State UNESP, Inst Biosci, Rio Claro, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; Santos, Keity Souza/Q-5704-2019; KALIL,
   JORGE/C-8029-2012; Castro, Fabio FM/C-1082-2017; De Amicis Lima,
   Karine/D-3890-2013
OI Santos, Keity Souza/0000-0001-5271-4011; KALIL,
   JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773; De
   Amicis Lima, Karine/0000-0002-9936-2436
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2015
VL 70
SU 101
SI SI
MA 464
BP 205
EP 205
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DD5GM
UT WOS:000369950701240
DA 2020-11-26
ER

PT J
AU Arun, MV
   Longen, E
   Portilho, NC
   Agondi, RC
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Arun, M., V
   Longen, E.
   Portilho, N. C.
   Agondi, R. C.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Hereditary angioedema with normal C1 inhibitor: prevalence, clinical
   features and treatment of patients in a University Hospital in Brazil
SO ALLERGY
LA English
DT Meeting Abstract
CT Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 06-10, 2015
CL Barcelona, SPAIN
SP European Acad Allergy & Clin Immunol
C1 [Arun, M., V; Longen, E.; Portilho, N. C.; Agondi, R. C.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2015
VL 70
SU 101
SI SI
MA 593
BP 255
EP 255
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DD5GM
UT WOS:000369950701365
DA 2020-11-26
ER

PT J
AU Tanno, LK
   Kerr, DS
   dos Santos, B
   Talib, LL
   Yamaguti, C
   Rodrigues, H
   Gattaz, WF
   Kalil, J
AF Tanno, Luciana Kase
   Kerr, Daniel Shikanai
   dos Santos, Bernardo
   Talib, Leda Leme
   Yamaguti, Celia
   Rodrigues, Helcio
   Gattaz, Wagner Farid
   Kalil, Jorge
TI The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants
   Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects
SO PLOS ONE
LA English
DT Article
ID STEVENS-JOHNSON-SYNDROME; MICROSOMAL EPOXIDE HYDROLASE; CARBAMAZEPINE;
   PHENOTYPE; EXPRESSION; VARIANTS; EPILEPSY
AB Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous adverse drug reactions in up to 10% of patients. The clinical manifestations of the antiepileptics-induced hypersensitivity reactions (AHR) vary from mild skin rashes to severe cutaneous drug adverse reactions which are related to high mortality and significant morbidity. Genetic polymorphisms in cytochrome P450 genes are associated with altered enzymatic activity and may contribute to the risk of AHR. Here we present a case-control study in which we genotyped SNPs of CYP2C19, 2C9 and 3A5 of 55 individuals with varying severities of AHR, 83 tolerant, and 366 healthy control subjects from Sao Paulo, Brazil. Clinical characterization was based on standardized scoring systems and drug patch test. All in vivo investigation followed the ENDA (European Network of Drug Allergy) recommendations. Genotype was determined by real time PCR using peripheral blood DNA as a template. Of all 504 subjects, 65% were females, 45% self-identified as Afro-American, 38% as Caucasian and 17% as having non-African mixed ascendancy. Amongst 55 subjects with AHR, 44 had severe cutaneous drug adverse reactions. Of the 46 drug patch tests performed, 29 (63%) were positive. We found a strong association between the absence of CYP3A5*3 and tolerant subjects when compared to AHR (p = 0.0002, OR = 5.28 [CI95% 2.09-14.84]). None of our groups presented positive association with CYP2C19 and 2C9 polymorphisms, however, both SNPs contributed to separation of cases and tolerants in a Classification and Regression Tree. Our findings indicate that drug metabolism genes can contribute in the tolerability of antiepileptics. CYP3A5*3 is the most prevalent CYP3A5 allele associated with reduced enzymatic function. The current study provides evidence that normal CYP3A5 activity might be a protective factor to aromatic antiepileptics-induced hypersensitivity reactions in Brazilian subjects.
C1 [Tanno, Luciana Kase; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kerr, Daniel Shikanai; Talib, Leda Leme; Gattaz, Wagner Farid] Univ Sao Paulo, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, Brazil.
   [Yamaguti, Celia; Rodrigues, Helcio; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Lab Immunol LIM 19, Sao Paulo, Brazil.
   [dos Santos, Bernardo] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil.
   [Kerr, Daniel Shikanai; Talib, Leda Leme; Gattaz, Wagner Farid] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo, Brazil.
RP Tanno, LK (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM luciana.tanno@gmail.com
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/22748-1]
FX This work received funding from Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP - http://fapesp.br/) under the grant number
   2011/22748-1. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019
   Barbaud A, 2013, BRIT J DERMATOL, V168, P555, DOI 10.1111/bjd.12125
   Baron JM, 2008, CURR MED CHEM, V15, P2258, DOI 10.2174/092986708785747535
   Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142
   Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350
   Edwards SGM, 1999, POSTGRAD MED J, V75, P680, DOI 10.1136/pgmj.75.889.680
   GAEDIGK A, 1994, PHARMACOGENETICS, V4, P142, DOI 10.1097/00008571-199406000-00005
   Goldstein JA, 1997, PHARMACOGENETICS, V7, P59, DOI 10.1097/00008571-199702000-00008
   Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166
   GREEN VJ, 1995, BIOCHEM PHARMACOL, V50, P1353, DOI 10.1016/0006-2952(95)02009-8
   Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a
   Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005
   LAITINEN J, 1994, BIOTECHNIQUES, V17, P316
   Lee AY, 2003, CONTACT DERMATITIS, V48, P137, DOI 10.1034/j.1600-0536.2003.00065.x
   LERTRATANANGKOON K, 1982, DRUG METAB DISPOS, V10, P1
   Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356
   Madden S, 1996, DRUG METAB DISPOS, V24, P469
   Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9
   McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297
   Mockenhaupt M, 2014, INCLUSION CRITERIA
   Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732
   Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369
   Ozawa Shogo, 2004, Drug Metab Pharmacokinet, V19, P83, DOI 10.2133/dmpk.19.83
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Pirmohamed M, 2011, CLIN PHARMACOL THER, V89, P896, DOI 10.1038/clpt.2011.79
   Posadas SJ, 2007, CLIN EXP ALLERGY, V37, P989, DOI 10.1111/j.1365-2222.2007.02742.x
   ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906
   ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404
   Santiago F, 2010, CONTACT DERMATITIS, V62, P47, DOI 10.1111/j.1600-0536.2009.01659.x
   Sim Sarah C., 2010, Human Genomics, V4, P278
   SPIELBERG SP, 1981, J PHARMACOL EXP THER, V217, P386
   Suarez-Kurtz G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083472
   Thorn CF, 2012, PHARMACOGENET GENOM, V22, P466, DOI 10.1097/FPC.0b013e32834aeedb
   Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56
   Wiffen PJ, 2011, COCHRANE DATABASE SY
   Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005
   Xie HG, 2002, ADV DRUG DELIVER REV, V54, P1257, DOI 10.1016/S0169-409X(02)00076-5
NR 37
TC 7
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2015
VL 10
IS 8
AR e0136141
DI 10.1371/journal.pone.0136141
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP5KH
UT WOS:000359919900058
PM 26291084
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU de Barros, SF
   De Amicis, KM
   Alencar, R
   Smeesters, PR
   Trunkel, A
   Postol, E
   Almeida, JN
   Rossi, F
   Pignatari, ACC
   Kalil, J
   Guilherme, L
AF de Barros, Samar Freschi
   De Amicis, Karine Marafigo
   Alencar, Raquel
   Smeesters, Pierre Robert
   Trunkel, Ariel
   Postol, Edilberto
   Almeida Junior, Joao Nobrega
   Rossi, Flavia
   Campos Pignatari, Antonio Carlos
   Kalil, Jorge
   Guilherme, Luiza
TI Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular
   characterization as a basis for StreptInCor coverage capacity analysis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID GROUP-A STREPTOCOCCUS; SUPERANTIGEN GENE PROFILE; EMM TYPES; VACCINE
   DEVELOPMENT; INFECTIONS; DIVERSITY; EPIDEMIOLOGY; ANTIBODIES;
   RESISTANCE; CANDIDATE
AB Background: Several human diseases are caused by Streptococcus pyogenes, ranging from common infections to autoimmunity. Characterization of the most prevalent strains worldwide is a useful tool for evaluating the coverage capacity of vaccines under development. In this study, a collection of S. pyogenes strains from Sao Paulo, Brazil, was analyzed to describe the diversity of strains and assess the vaccine coverage capacity of StreptInCor.
   Methods: Molecular epidemiology of S. pyogenes strains was performed by emm-genotyping the 229 isolates from different clinical sites, and PCR was used for superantigen profile analysis. The emm-pattern and tissue tropism for these M types were also predicted and compared based on the emm-cluster classification.
   Results: The strains were fit into 12 different emm-clusters, revealing a diverse phylogenetic origin and, consequently, different mechanisms of infection and escape of the host immune system. Forty-eight emm-types were distinguished in 229 samples, and the 10 most frequently observed types accounted for 69 % of all isolates, indicating a diverse profile of circulating strains comparable to other countries under development. A similar proportion of E and A-C emm-patterns were observed, whereas pattern D was less frequent, indicating that the strains of this collection primarily had a tissue tropism for the throat. In silico analysis of the coverage capacity of StreptInCor, an M protein-conserved regionally based vaccine candidate developed by our group, had a range of 94.5 % to 59.7 %, with a mean of 71.0 % identity between the vaccine antigen and the predicted amino acid sequence of the emm-types included here.
   Conclusions: This is the first report of S. pyogenes strain characterization in Sao Paulo, one of the largest cities in the world; thus, the strain panel described here is a representative sample for vaccine coverage capacity analysis. Our results enabled evaluation of StreptInCor candidate vaccine coverage capacity against diverse M-types, indicating that the vaccine candidate likely would induce protection against the diverse strains worldwide.
C1 [de Barros, Samar Freschi; De Amicis, Karine Marafigo; Alencar, Raquel; Trunkel, Ariel; Postol, Edilberto; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-01246000 Sao Paulo, Brazil.
   [de Barros, Samar Freschi; De Amicis, Karine Marafigo; Alencar, Raquel; Trunkel, Ariel; Postol, Edilberto; Kalil, Jorge; Guilherme, Luiza] Natl Inst Sci & Technol, Inst Immunol Invest, BR-01246000 Sao Paulo, Brazil.
   [Almeida Junior, Joao Nobrega; Rossi, Flavia] Univ Sao Paulo, Sch Med, Clin Hosp, Microbiol Lab, BR-01246000 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246000 Sao Paulo, Brazil.
   [Smeesters, Pierre Robert] Univ Libre Bruxelles, Fac Sci, Inst Biol & Med Mol, Lab Genet & Physiol Bacterienne, B-1050 Brussels, Belgium.
   [Smeesters, Pierre Robert] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Campos Pignatari, Antonio Carlos] Univ Fed Sao Paulo, Special Clin Microbiol Lab LEMC, UNIFESP, Sao Paulo, Brazil.
   [Guilherme, Luiza] Heart Inst HC FMUSP, Clin Hosp, Immunol Lab, BR-05403000 Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-01246000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; de Barros, Samar Freschi/Q-4970-2018; De
   Amicis Lima, Karine/D-3890-2013; Pignatari, Antonio CC/C-8427-2012;
   Smeesters, Pierre/I-7723-2012
OI KALIL, JORGE/0000-0001-8415-4274; De Amicis Lima,
   Karine/0000-0002-9936-2436; Smeesters, Pierre/0000-0002-2642-9919;
   Pignatari, Antonio/0000-0002-2146-8476; Nobrega de Almeida Junior,
   Joao/0000-0002-3766-026X
FU "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico"
   [CNPq]National Council for Scientific and Technological Development
   (CNPq) [557814/2009-0]; "Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo" [FAPESP], BrazilFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2007/59262-3]
FX This work was supported by the "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico" [CNPq 557814/2009-0] and "Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo" [FAPESP 2007/59262-3], Brazil.
CR Batzloff MR, 2003, J INFECT DIS, V187, P1598, DOI 10.1086/374800
   Bessen DE, 2000, J INFECT DIS, V182, P1109, DOI 10.1086/315842
   Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Commons RJ, 2014, TRENDS MOL MED, V20, P48, DOI 10.1016/j.molmed.2013.10.004
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Dale JB, 2011, VACCINE, V29, P8175, DOI 10.1016/j.vaccine.2011.09.005
   De Amicis KM, 2014, VACCINE, V32, P4104, DOI 10.1016/j.vaccine.2013.08.043
   Friaes A, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-280
   Grundmann H, 2001, J CLIN MICROBIOL, V39, P4190, DOI 10.1128/JCM.39.11.4190-4192.2001
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Imohl M, 2010, FEMS IMMUNOL MED MIC, V58, P389, DOI 10.1111/j.1574-695X.2010.00652.x
   Lintges M, 2010, J INFECT DIS, V202, P20, DOI 10.1086/653082
   Luca-Harari B, 2008, J CLIN MICROBIOL, V46, P79, DOI 10.1128/JCM.01626-07
   Ma Y, 2009, EPIDEMIOL INFECT, V137, P1414, DOI 10.1017/S0950268809002118
   Maripuu L, 2008, FEMS IMMUNOL MED MIC, V54, P236, DOI 10.1111/j.1574-695X.2008.00469.x
   McGregor KF, 2004, J BACTERIOL, V186, P4285, DOI 10.1128/JB.186.13.4285-4294.2004
   McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   Meisal R, 2010, J CLIN MICROBIOL, V48, P842, DOI 10.1128/JCM.01312-09
   Michaelsen TE, 2011, SCAND J IMMUNOL, V74, P423, DOI 10.1111/j.1365-3083.2011.02594.x
   Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
   Rantala S, 2012, EUR J CLIN MICROBIOL, V31, P859, DOI 10.1007/s10096-011-1385-9
   Rivera A, 2006, J MED MICROBIOL, V55, P1115, DOI 10.1099/jmm.0.46481-0
   Rogers S, 2007, J INFECT DIS, V195, P1625, DOI 10.1086/513875
   Sanderson-Smith M, 2014, J INFECT DIS, V210, P1325, DOI 10.1093/infdis/jiu260
   Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
   Smeesters PR, 2010, TRENDS MICROBIOL, V18, P275, DOI 10.1016/j.tim.2010.02.007
   Smeesters PR, 2010, VACCINE, V28, P883, DOI 10.1016/j.vaccine.2009.10.137
   Smeesters PR, 2009, EXPERT REV VACCINES, V8, P1705, DOI [10.1586/erv.09.133, 10.1586/ERV.09.133]
   Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
   Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
   Tartof SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-327
   Teixeira LM, 2001, J CLIN MICROBIOL, V39, P3290, DOI [10.1128/JCM.39.9.3290-3295.2001, 10.1128/JCM.39.4.1241-1246.2001]
NR 36
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 5
PY 2015
VL 15
AR 308
DI 10.1186/s12879-015-1052-3
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA CO1IB
UT WOS:000358906700002
PM 26243278
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Franca-Pinto, A
   Mendes, FAR
   de Carvalho-Pinto, RM
   Agondi, RC
   Cukier, A
   Stelmach, R
   Saraiva-Romanholo, BM
   Kalil, J
   Martins, MA
   Giavina-Bianchi, P
   Carvalho, CRF
AF Franca-Pinto, Andrezza
   Mendes, Felipe A. R.
   de Carvalho-Pinto, Regina Maria
   Agondi, Rosana Camara
   Cukier, Alberto
   Stelmach, Rafael
   Saraiva-Romanholo, Beatriz M.
   Kalil, Jorge
   Martins, Milton A.
   Giavina-Bianchi, Pedro
   Carvalho, Celso R. F.
TI Aerobic training decreases bronchial hyperresponsiveness and systemic
   inflammation in patients with moderate or severe asthma: a randomised
   controlled trial
SO THORAX
LA English
DT Article
ID QUALITY-OF-LIFE; AIRWAY INFLAMMATION; EXERCISE; EXACERBATIONS;
   METHACHOLINE
AB Background The benefits of aerobic training for the main features of asthma, such as bronchial hyperresponsiveness (BHR) and inflammation, are poorly understood. We investigated the effects of aerobic training on BHR (primary outcome), serum inflammatory cytokines (secondary outcome), clinical control and asthma quality of life (Asthma Quality of Life Questionnaire (AQLQ)) (tertiary outcomes).
   Methods Fifty-eight patients were randomly assigned to either the control group (CG) or the aerobic training group (TG). Patients in the CG (educational programme+breathing exercises (sham)) and the TG (same as the CG+aerobic training) were followed for 3 months. BHR, serum cytokine, clinical control, AQLQ, induced sputum and fractional exhaled nitric oxide (FeNO) were evaluated before and after the intervention.
   Results After 12 weeks, 43 patients (21 CG/22 TG) completed the study and were analysed. The TG improved in BHR by 1 doubling dose (dd) (95% CI 0.3 to 1.7 dd), and they experienced reduced interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) and improved AQLQ and asthma exacerbation (p<0.05). No effects were seen for IL-5, IL-8, IL-10, sputum cellularity, FeNO or Asthma Control Questionnaire 7 (ACQ-7; p>0.05). A within-group difference was found in the ACQ-6 for patients with non-well-controlled asthma and in sputum eosinophil and FeNO in patients in the TG who had worse airway inflammation.
   Conclusions Aerobic training reduced BHR and serum proinflammatory cytokines and improved quality of life and asthma exacerbation in patients with moderate or severe asthma. These results suggest that adding exercise as an adjunct therapy to pharmacological treatment could improve the main features of asthma.
C1 [Franca-Pinto, Andrezza; Agondi, Rosana Camara; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Clin Immunol, Sao Paulo, Brazil.
   [Franca-Pinto, Andrezza; Agondi, Rosana Camara; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Allergy, Sao Paulo, Brazil.
   [Mendes, Felipe A. R.; Carvalho, Celso R. F.] Univ Sao Paulo, Sch Med, Dept Phys Therapy, Sao Paulo, Brazil.
   [de Carvalho-Pinto, Regina Maria; Cukier, Alberto; Stelmach, Rafael] Univ Sao Paulo, Sch Med, Pulm Div, Heart Inst InCor, Sao Paulo, Brazil.
   [Saraiva-Romanholo, Beatriz M.; Martins, Milton A.] Univ Sao Paulo, Sch Med, Dept Med, Lab Expt Therapeut LIM 20, Sao Paulo, Brazil.
RP Carvalho, CRF (corresponding author), Univ Sao Paulo, Sch Med, Dept Med, Av Dr Arnaldo 455,Room 1210, BR-01246903 Sao Paulo, SP, Brazil.
EM cscarval@usp.br
RI Mendes, Felipe A R/C-2995-2015; Cukier, Alberto/C-6101-2012; KALIL,
   JORGE/C-8029-2012; Saraiva-Romanholo, Beatriz M/I-5482-2013; Martins,
   Milton A/L-7541-2017; stelmach, rafael/AAH-1638-2019; Carvalho, Celso
   Ricardo Fernandes/B-7626-2012
OI Mendes, Felipe A R/0000-0001-8202-7503; Cukier,
   Alberto/0000-0002-7217-9498; KALIL, JORGE/0000-0001-8415-4274; stelmach,
   rafael/0000-0002-5132-1934; Carvalho, Celso Ricardo
   Fernandes/0000-0003-3046-3412
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2009/53904-9, 2009/53817-9]; Ministerio da
   Ciencia, Tecnologia e Inovacao-Conselho Nacional de Pesquisa (CNPq)
   [305987/2010-0]
FX The study was supported by the Sao Paulo Research Foundation (FAPESP;
   Grants 2009/53904-9 and 2009/53817-9) and Ministerio da Ciencia,
   Tecnologia e Inovacao-Conselho Nacional de Pesquisa (CNPq Grants
   305987/2010-0).
CR American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST
   [Anonymous], 2012, GLOB STRAT ASTHM MAN
   Arandelovic M, 2007, THESCIENTIFICWORLDJO, V7, P1182, DOI 10.1100/tsw.2007.221
   Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130
   Brasholt M, 2010, J ALLERGY CLIN IMMUN, V125, P1007, DOI 10.1016/j.jaci.2010.02.002
   Carson KV, 2013, COCHRANE DB SYST REV, V9
   COCHRANE LM, 1990, THORAX, V45, P345, DOI 10.1136/thx.45.5.345
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Disabella V, 1998, PHYSICIAN SPORTSMED, V26, P75, DOI 10.3810/psm.1998.06.1041
   Dogra S, 2011, EUR RESPIR J, V37, P318, DOI 10.1183/09031936.00182209
   Eichenberger PA, 2013, SPORTS MED, V43, P1157, DOI 10.1007/s40279-013-0077-2
   Fanelli A, 2007, MED SCI SPORT EXER, V39, P1474, DOI 10.1249/mss.0b013e3180d099ad
   Gibbons RJ, 2002, J AM COLL CARDIOL, V40, P1531, DOI 10.1016/S0735-1097(02)02164-2
   Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041
   Global Strategy for Asthma Management and Prevention, 2005, GLOB STRAT ASTHM MAN
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Hewitt M, 2010, AM J RESP CELL MOL, V42, P243, DOI 10.1165/rcmb.2009-0038OC
   Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5
   Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012
   JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76
   Mendes FAR, 2010, CHEST, V138, P331, DOI 10.1378/chest.09-2389
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   O'Byrne PM, 2009, CLIN EXP ALLERGY, V39, P181, DOI 10.1111/j.1365-2222.2008.03172.x
   Olivo CR, 2012, RESP PHYSIOL NEUROBI, V182, P81, DOI 10.1016/j.resp.2012.05.004
   Pakhale S, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-38
   Pastva A, 2004, J IMMUNOL, V172, P4520, DOI 10.4049/jimmunol.172.7.4520
   Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST
   Mendes FAR, 2011, MED SCI SPORT EXER, V43, P197, DOI 10.1249/MSS.0b013e3181ed0ea3
   Saraiva-Romanholo BM, 2003, CHEST, V124, P1060, DOI 10.1378/chest.124.3.1060
   Scott HA, 2013, CLIN EXP ALLERGY, V43, P36, DOI 10.1111/cea.12004
   Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC
   Silva RA, 2010, EUR RESPIR J, V35, P994, DOI 10.1183/09031936.00049509
   Turner S, 2011, RESPIRATION, V81, P302, DOI 10.1159/000315142
   Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC
   Villa F, 2011, ARCH DIS CHILD, V96, P554, DOI 10.1136/adc.2011.212431
NR 35
TC 76
Z9 79
U1 1
U2 25
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD AUG
PY 2015
VL 70
IS 8
BP 732
EP 739
DI 10.1136/thoraxjnl-2014-206070
PG 8
WC Respiratory System
SC Respiratory System
GA CM7UA
UT WOS:000357900800007
PM 26063507
OA Bronze
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Motta, AA
   Kalil, J
   Castells, M
AF Giavina-Bianchi, P.
   Aun, M. V.
   Motta, A. A.
   Kalil, J.
   Castells, M.
TI Classification of angioedema by endotypes
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Letter
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PHENOTYPES; MANAGEMENT; DIAGNOSIS;
   ASTHMA
C1 [Giavina-Bianchi, P.; Aun, M. V.; Motta, A. A.; Kalil, J.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Castells, M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 Ap-211A,Jd Amer, BR-01454904 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
CR Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036
   Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X
   Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380
   Giavina-Bianchi P, 2015, J ALLERGY CLIN IMMUN, V135, P151, DOI 10.1016/j.jaci.2014.10.029
   Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260
   Powell RJ, 2015, CLIN EXP ALLERGY, V45, P547, DOI 10.1111/cea.12494
NR 7
TC 8
Z9 8
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-7894
EI 1365-2222
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD JUN
PY 2015
VL 45
IS 6
BP 1142
EP 1143
DI 10.1111/cea.12551
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA CI2FQ
UT WOS:000354561200015
PM 25981351
DA 2020-11-26
ER

PT J
AU Navarro, IC
   Ferreira, FM
   Nakaya, HI
   Baron, MA
   Vilar-Pereira, G
   Pereira, IR
   Silva, AMG
   Real, JM
   De Brito, T
   Chevillard, C
   Lannes-Vieira, J
   Kalil, J
   Cunha-Neto, E
   Ferreira, LRP
AF Navarro, Isabela Cunha
   Ferreira, Frederico Moraes
   Nakaya, Helder I.
   Baron, Monique Andrade
   Vilar-Pereira, Glaucia
   Pereira, Isabela Resende
   Goncalves Silva, Ana Maria
   Real, Juliana Monte
   De Brito, Thales
   Chevillard, Christophe
   Lannes-Vieira, Joseli
   Kalil, Jorge
   Cunha-Neto, Edecio
   Pinto Ferreira, Ludmila Rodrigues
TI MicroRNA Transcriptome Profiling in Heart of Trypanosoma cruzi-Infected
   Mice: Parasitological and Cardiological Outcomes
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CHAGAS-DISEASE; GENE-EXPRESSION; PARASITE LOAD; CHRONIC PHASE;
   CARDIOMYOPATHY; ABNORMALITIES; PARAMETERS; MORTALITY; RNAS
AB Chagas disease is caused by the parasite Trypanosoma cruzi, and it begins with a short acute phase characterized by high parasitemia followed by a life-long chronic phase with scarce parasitism. Cardiac involvement is the most prominent manifestation, as 30% of infected subjects will develop abnormal ventricular repolarization with myocarditis, fibrosis and cardiomyocyte hypertrophy by undefined mechanisms. Nevertheless, follow-up studies in chagasic patients, as well as studies with murine models, suggest that the intensity of clinical symptoms and pathophysiological events that occur during the acute phase of disease are associated with the severity of cardiac disease observed during the chronic phase. In the present study we investigated the role of microRNAs (miRNAs) in the disease progression in response to T. cruzi infection, as alterations in miRNA levels are known to be associated with many cardiovascular disorders. We screened 641 rodent miRNAs in heart samples of mice during an acute infection with the Colombiana T.cruzi strain and identified multiple miRNAs significantly altered upon infection. Seventeen miRNAs were found significantly deregulated in all three analyzed time points post infection. Among these, six miRNAs had their expression correlated with clinical parameters relevant to the disease, such as parasitemia and maximal heart rate-corrected QT (QTc) interval. Computational analyses identified that the gene targets for these six miRNAs were involved in networks and signaling pathways related to increased ventricular depolarization and repolarization times, important factors for QTc interval prolongation. The data presented here will guide further studies about the contribution of microRNAs to Chagas heart disease pathogenesis.
C1 [Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio; Pinto Ferreira, Ludmila Rodrigues] Univ Sao Paulo, Heart Inst InCor, Immunol Lab, Sch Med, Sao Paulo, Brazil.
   [Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio; Pinto Ferreira, Ludmila Rodrigues] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Navarro, Isabela Cunha; Ferreira, Frederico Moraes; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio; Pinto Ferreira, Ludmila Rodrigues] Iii INCT, Inst Investigat Immunol, Sao Paulo, Brazil.
   [Nakaya, Helder I.] Univ Sao Paulo, Dept Clin Anal & Toxicol, Sch Pharmaceut Sci, Sao Paulo, Brazil.
   [Vilar-Pereira, Glaucia; Pereira, Isabela Resende; Lannes-Vieira, Joseli] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Interact, BR-21045900 Rio De Janeiro, Brazil.
   [Goncalves Silva, Ana Maria; De Brito, Thales] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Goncalves Silva, Ana Maria; De Brito, Thales] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   [Real, Juliana Monte] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Chevillard, Christophe] Aix Marseille Univ, Fac Med, INSERM, U906, Marseille, France.
RP Navarro, IC (corresponding author), Univ Sao Paulo, Heart Inst InCor, Immunol Lab, Sch Med, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI da Silva, Ana Maria Goncalves/ABD-3920-2020; De Brito,
   Thales/L-2865-2017; chevillard, christophe/A-7087-2015; Ferreira,
   Frederico Moraes/A-4622-2013; Navarro, Isabela Cunha/V-7182-2017;
   Ferreira, Ludmila Rodrigues Pinto/B-4955-2015; Nakaya, Helder
   I/A-1397-2010; Nakaya, Helder/AAF-1738-2020; Ferreira,
   Ludmila/C-4100-2012; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012
OI De Brito, Thales/0000-0003-1106-7254; chevillard,
   christophe/0000-0002-5269-8813; Navarro, Isabela
   Cunha/0000-0002-6844-2361; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; Nakaya, Helder I/0000-0001-5297-9108; Nakaya,
   Helder/0000-0001-5297-9108; Ferreira, Ludmila/0000-0001-9944-6691;
   Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Silva, Ana Maria/0000-0001-7554-0894
FU Sao Paulo state Foundation for Scientific Research (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/08107-6,
   2013/50302-3]; Brazilian National Research Council (CNPq)National
   Council for Scientific and Technological Development (CNPq); National
   Institute of Allergy and Infectious DiseaseUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [1P50AI098461-01]; CNPq fellowshipNational Council for Scientific and
   Technological Development (CNPq) [151045/2013-5]; FAPESP
   fellowshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Rio de Janeiro Foundation for Scientific Research (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Medical Investigation Laboratory; CNPqNational Council for
   Scientific and Technological Development (CNPq) [474234/20126-Universal,
   302534/2008-3]; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [APQ1-E-26/111.756/2008,
   CNE/E-26/101.549/2010, E-26/110.153/2013, E-26/111.709/2013]; National
   Institute for Science and Technology for Vaccines (INCTV/CNPq)
   [403979/2012-9-DECIT]; Institut National de la Sante et de la Recherche
   Medicale (INSERM)Institut National de la Sante et de la Recherche
   Medicale (Inserm); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461] Funding Source: NIH RePORTER
FX This work has been supported by grants of Sao Paulo state Foundation for
   Scientific Research (FAPESP) - Grants number 2012/08107-6 and
   2013/50302-3 - the Brazilian National Research Council (CNPq), National
   Institute of Allergy and Infectious Disease - Grant Number
   1P50AI098461-01. LRPF was recipient of a CNPq fellowship
   (#151045/2013-5); ICN and MAB are recipients of a FAPESP fellowship. GVP
   is recipient of a Coordination of Improvement of Higher Level Personnel
   (CAPES) fellowship, IRP is recipient of a Rio de Janeiro Foundation for
   Scientific Research (FAPERJ) "Bolsa Nota 10" fellowship; AMGS and TDB
   are recipients of a Medical Investigation Laboratory 06 (LIM/06)
   financial support. JLV, ECN and JK are recipients of CNPq productivity
   awards. JLV has also received grants from FAPERJ
   (#APQ1-E-26/111.756/2008, CNE/E-26/101.549/2010, E-26/110.153/2013 and
   E-26/111.709/2013) and CNPq (Grants #474234/20126-Universal and
   #302534/2008-3); National Institute for Science and Technology for
   Vaccines (INCTV/CNPq); (#403979/2012-9-DECIT). CC is a recipient for
   Institut National de la Sante et de la Recherche Medicale (INSERM)
   financial support. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alvarado-Tapias E, 2012, INVEST CLIN, V53, P378
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bern C, 2011, ADV PARASIT, V75, P19, DOI 10.1016/B978-0-12-385863-4.00002-2
   Bilate AM, 2008, J INFECT DIS, V198, P614, DOI 10.1086/590347
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bostjancic E, 2010, FOLIA BIOL-PRAGUE, V56, P27
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   Caldas IS, 2008, PARASITOL RES, V103, P413, DOI 10.1007/s00436-008-0992-6
   Camandaroba Edson Luiz Paes, 2001, Revista da Sociedade Brasileira de Medicina Tropical, V34, P151, DOI 10.1590/S0037-86822001000200001
   Eickhoff CS, 2010, J PARASITOL, V96, P758, DOI 10.1645/GE-2396.1
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995
   Gollob MH, 2006, NEW ENGL J MED, V354, P2677, DOI 10.1056/NEJMoa052800
   Itokawa K, 1999, MOL BRAIN RES, V71, P354, DOI 10.1016/S0169-328X(99)00194-1
   Latronico M. V. G., 2009, NATURE REV, V6, P419, DOI DOI 10.1038/NRCARDIO.2009.56
   Lee CT, 2007, DNA CELL BIOL, V26, P209, DOI 10.1089/dna.2006.0545
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   Moncayo A, 2006, ANN TROP MED PARASIT, V100, P663, DOI 10.1179/136485906X112248
   Newton-Cheh C, 2009, NAT GENET, V41, P399, DOI 10.1038/ng.364
   Oliveira-Carvalho V, 2012, ARQ BRAS CARDIOL, V98, P362, DOI 10.1590/S0066-782X2012000400011
   Ferreira LRP, 2014, INT J CARDIOL, V175, P409, DOI 10.1016/j.ijcard.2014.05.019
   Rao PK, 2009, CIRC RES, V105, P585, DOI 10.1161/CIRCRESAHA.109.200451
   Rassi A, 2012, INFECT DIS CLIN N AM, V26, P275, DOI 10.1016/j.idc.2012.03.002
   Ribeiro AL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002078
   Roman-Campos D, 2013, MEM I OSWALDO CRUZ, V108, P243, DOI 10.1590/0074-0276108022013019
   Roman-Campos D, 2009, BASIC RES CARDIOL, V104, P238, DOI 10.1007/s00395-009-0776-x
   Salles G, 2003, CIRCULATION, V108, P305, DOI 10.1161/01.CIR.0000079174.13444.9C
   Salles GF, 2004, AM J CARDIOL, V93, P1136, DOI 10.1016/j.amjcard.2004.01.040
   Salles GF, 2003, PACE, V26, P1326, DOI 10.1046/j.1460-9592.2003.t01-1-00190.x
   Sayed D, 2007, CIRC RES, V100, P416, DOI 10.1161/01.RES.0000257913.42552.23
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Silverio JC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002645
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Wulff H, 2009, NAT REV DRUG DISCOV, V8, P982, DOI 10.1038/nrd2983
NR 37
TC 20
Z9 20
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2015
VL 9
IS 6
AR e0003828
DI 10.1371/journal.pntd.0003828
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CM0VX
UT WOS:000357398100032
PM 26086673
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Sakata, VM
   da Silva, FT
   Hirata, CE
   Marin, MLC
   Rodrigues, H
   Kalil, J
   Costa, RA
   Yamamoto, JH
AF Sakata, Viviane M.
   da Silva, Felipe T.
   Hirata, Carlos E.
   Marin, Maria Lucia C.
   Rodrigues, Helcio
   Kalil, Jorge
   Costa, Rogerio A.
   Yamamoto, Joyce H.
TI High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada
   disease treated with early high-dose corticosteroids
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Vogt-Koyanagi-Harada disease; Clinical course; Subretinal fibrosis;
   Disease outcome
ID SUBRETINAL FIBROSIS; PROGNOSTIC-FACTORS; SPECTRUM
AB To analyse the rate of clinical recurrences in Brazilian patients with Vogt-Koyanagi-Harada (VKH) disease after early high-dose corticosteroid treatment.
   Retrospective study including patients treated with early high-dose corticosteroids (prednisone, 1-1.5 mg/kg/day, or 3-day 1 g methylprednisolone pulsetherapy) within 1 month from disease onset followed by slow taper (at least 6 months). Patients with a minimum 12-month follow-up were subdivided based on the presence of disease recurrence or persistence after 6 months from initial presentation into: acute-resolved (AR, no recurrences), chronic-recurrent (CR), and chronic-recurrent with subretinal fibrosis (SRF). Recurrences were defined as the presence of clinical and/or fluorescein angiography findings.
   Twenty-nine patients (58 eyes) with a median follow-up of 65 months were included. Six (21 %), 11 (38 %) and 12 (41 %) patients were allocated to AR, CR, and SRF groups respectively. Though having received treatment within 1 month of onset, median time to initial treatment differed among groups (11, 15, and 25 days, in AR, CR, and SRF groups respectively). Intensity of immunosuppression, cataract development, and longer time to achieve logMAR visual acuity a parts per thousand currency sign0.8 differed significantly among the groups, being more severe in SRF group. HLA-DRB1*0405 allele followed the same trend, though not reaching significance (0.5 in AR group, 0.6 in CR, and 0.8 in SRF).
   VKH disease in Brazilian patients evolved to chronic-recurrent disease in 79 % of cases; 38 % developed subretinal fibrosis, in spite of similar initial treatment regimens. Time to initiate treatment influenced outcomes.
C1 [Sakata, Viviane M.; Hirata, Carlos E.; Yamamoto, Joyce H.] Univ Sao Paulo, Dept Ophthalmol, Fac Med, BR-05019000 Sao Paulo, SP, Brazil.
   [da Silva, Felipe T.] Univ Planalto Catarinense, PPGAS, Lages, SC, Brazil.
   [Marin, Maria Lucia C.; Rodrigues, Helcio; Kalil, Jorge] Univ Sao Paulo, Immunol Lab, Heart Inst InCor, Fac Med, BR-05019000 Sao Paulo, SP, Brazil.
   [Costa, Rogerio A.] Ctr Brasileiro Ciencias Visuais, Div Macula Imaging & Treatment, Belo Horizonte, MG, Brazil.
   [Costa, Rogerio A.] Univ Sao Paulo, Dept Ophthalmol, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
RP Yamamoto, JH (corresponding author), Univ Sao Paulo, Dept Ophthalmol, Fac Med, Rua Diana 863 Apto 91J, BR-05019000 Sao Paulo, SP, Brazil.
EM joycehy@uol.com.br
RI Yamamoto, Joyce H/B-6192-2015; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Yamamoto, Joyce/0000-0001-6869-2988
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [11/50936-7/scholarship,
   07/57154-9]
FX This work was supported in part by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo grant number #11/50936-7/scholarship # 07/57154-9.
CR Abu El-Asrar AM, 2013, ACTA OPHTHALMOL, V91, pe486, DOI 10.1111/aos.12127
   Al-Kharashi Abdullah S., 2007, International Ophthalmology, V27, P201, DOI 10.1007/s10792-007-9062-9
   Bignon JD, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P584
   Chee Soon-Phaik, 2007, International Ophthalmology, V27, P137, DOI 10.1007/s10792-006-9009-6
   Chee SP, 2009, AM J OPHTHALMOL, V147, P154, DOI 10.1016/j.ajo.2008.07.044
   da Silva FT, 2009, AM J OPHTHALMOL, V148, P939, DOI 10.1016/j.ajo.2009.06.029
   da Silva FTBGC, 2009, AM J OPHTHALMOL, V147
   Damico FM, 2005, INVEST OPHTH VIS SCI, V46, P2465, DOI 10.1167/iovs.04-1273
   Gass JDM, 1996, AM J OPHTHALMOL, V122, P76, DOI 10.1016/S0002-9394(14)71966-X
   Goldberg AC, 1998, HUM IMMUNOL, V59, P183, DOI 10.1016/S0198-8859(97)00265-6
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   ISLAM SMM, 1994, INVEST OPHTH VIS SCI, V35, P752
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Kim MH, 2000, AM J OPHTHALMOL, V129, P173, DOI 10.1016/S0002-9394(99)00434-1
   Kuo IC, 2000, OPHTHALMOLOGY, V107, P1721, DOI 10.1016/S0161-6420(00)00244-X
   Lertsumitkul S, 1999, GRAEF ARCH CLIN EXP, V237, P1039, DOI 10.1007/s004170050342
   MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   RUBSAMEN PE, 1991, ARCH OPHTHALMOL-CHIC, V109, P682, DOI 10.1001/archopht.1991.01080050096037
   STERNBERG P, 1984, AM J OPHTHALMOL, V98, P456, DOI 10.1016/0002-9394(84)90131-4
   Tugal-Tutkun Ilknur, 2007, International Ophthalmology, V27, P117, DOI 10.1007/s10792-006-9001-1
NR 21
TC 23
Z9 25
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2015
VL 253
IS 5
BP 785
EP 790
DI 10.1007/s00417-014-2904-z
PG 6
WC Ophthalmology
SC Ophthalmology
GA CH1RZ
UT WOS:000353800400016
PM 25592477
DA 2020-11-26
ER

PT J
AU Nogueira, LG
   Frade, AF
   Ianni, BM
   Laugier, L
   Pissetti, CW
   Cabantous, S
   Baron, M
   Peixoto, GD
   Borges, AD
   Donadi, E
   Marin-Neto, JA
   Schmidt, A
   Dias, F
   Saba, B
   Wang, HTL
   Fragata, A
   Sampaio, M
   Hirata, MH
   Buck, P
   Mady, C
   Martinelli, M
   Lensi, M
   Siqueira, SF
   Pereira, AC
   Rodrigues, V
   Kalil, J
   Chevillard, C
   Cunha-Neto, E
AF Nogueira, Luciana Gabriel
   Frade, Amanda Farage
   Ianni, Barbara Maria
   Laugier, Laurie
   Pissetti, Cristina Wide
   Cabantous, Sandrine
   Baron, Monique
   Peixoto, Gisele de Lima
   Borges, Ariana de Melo
   Donadi, Eduardo
   Marin-Neto, Jose A.
   Schmidt, Andre
   Dias, Fabricio
   Saba, Bruno
   Wang, Hui-Tzu Lin
   Fragata, Abilio
   Sampaio, Marcelo
   Hirata, Mario Hiroyuki
   Buck, Paula
   Mady, Charles
   Martinelli, Martino
   Lensi, Mariana
   Siqueira, Sergio Freitas
   Pereira, Alexandre Costa
   Rodrigues, Virmondes, Jr.
   Kalil, Jorge
   Chevillard, Christophe
   Cunha-Neto, Edecio
TI Functional IL18 polymorphism and susceptibility to Chronic Chagas
   Disease
SO CYTOKINE
LA English
DT Article
DE Chagas; IL18; Cardiomyopathy; polymorphism; Severity
ID MAJOR HISTOCOMPATIBILITY COMPLEX; GENE POLYMORPHISMS; ENDOMYOCARDIAL
   BIOPSIES; CARDIOMYOPATHY PATIENTS; HEART-DISEASE; HLA ANTIGENS; T-CELLS;
   INTERLEUKIN-18; ALPHA; ASSOCIATION
AB Background: Chronic Chagas Disease cardiomyopathy (CCC), a life-threatening inflammatory dilated cardiomyopathy, affects 30% of the approximately 8 million patients infected by Trypanosoma cruzi, the rest of the infected subjects remaining asymptomatic (ASY). The Th1 T cell-rich myocarditis plays a pivotal role in CCC pathogenesis. Local expression of IL-18 in CCC myocardial tissue has recently been described. IL-18 could potentially amplify the process by inducing increased expression of IFN-gamma which in turn can increase the production of IL-18, thereby creating a positive feedback mechanism. In order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy.
   Methods and results: We analyzed the rs2043055 marker in the 118 gene in a cohort of Chagas disease cardiomyopathy patients (n = 849) and asymptomatic subjects (n = 202). We found a significant difference in genotype frequencies among moderate and severe CCC patients with ventricular dysfunction.
   Conclusions: Our analysis suggests that the 118 rs2043055 polymorphism- or a SNP in tight linkage disequilibrium with it- may contribute to modulating the Chagas cardiomyopathy outcome. (c) 2015 Elsevier Ltd. All rights reserved.
C1 [Nogueira, Luciana Gabriel; Frade, Amanda Farage; Baron, Monique; Pereira, Alexandre Costa; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Frade, Amanda Farage; Baron, Monique; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Frade, Amanda Farage; Baron, Monique; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Ianni, Barbara Maria; Buck, Paula; Mady, Charles] Univ Sao Paulo, Sch Med, Myocardiopathies Unit, Heart Inst InCor, Sao Paulo, Brazil.
   [Laugier, Laurie; Cabantous, Sandrine; Chevillard, Christophe] Univ Aix Marseille, INSERM, INSERM, GIMP UMR S906, F-13385 Marseille 05, France.
   [Pissetti, Cristina Wide; Borges, Ariana de Melo; Rodrigues, Virmondes, Jr.] Univ Fed Triangulo Mineiro, Immunol Lab, BR-48036180 Uberaba, MG, Brazil.
   [Peixoto, Gisele de Lima; Martinelli, Martino; Lensi, Mariana; Siqueira, Sergio Freitas] Univ Sao Paulo, Sch Med, Pacemaker Clin, Heart Inst InCor, Sao Paulo, Brazil.
   [Donadi, Eduardo; Marin-Neto, Jose A.; Schmidt, Andre; Dias, Fabricio] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Sao Paulo, Brazil.
   [Saba, Bruno; Wang, Hui-Tzu Lin; Fragata, Abilio; Sampaio, Marcelo; Hirata, Mario Hiroyuki] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil.
   [Saba, Bruno; Wang, Hui-Tzu Lin; Fragata, Abilio; Sampaio, Marcelo; Hirata, Mario Hiroyuki] Heart Failure Unit, Sao Paulo, Brazil.
RP Chevillard, C (corresponding author), Univ Aix Marseille, Fac Med, INSERM, U906, 27 Bd Jean Moulin, F-13385 Marseille 05, France.
EM luciananogueira@usp.br; affrade@yahoo.com.br;
   barbara.ianni@incor.usp.br; laugier.laurie@yahoo.fr;
   cristinawpissetti@gmail.com; sandrine.ambard@univ-amu.fr;
   moni.baron@hotmail.com; gisellepeixoto@ig.com.br;
   ariana_borges@hotmail.com; eadonadi@fmrp.usp.br; jamneto@fmrp.usp.br;
   aschmidt@fmrp.usp.br; diasfc@gmail.com; brunosaba@hotmail.com;
   lin.ht.wang@gmail.com; a.frag@terra.com.br; msampaio@cardiol.br;
   mhhirata@usp.br; paula.buck@uol.com.br; charles.mady@incor.usp.br;
   martino.filho@incor.usp.br; marilensi@hotmail.com;
   siqueira@incor.usp.br; alexandre.pereira@incor.usp.br;
   vrodrigues@mednet.com.br; jkalil@usp.br;
   christophe.chevillard@univ-amu.fr; edecunha@gmail.com
RI Ianni, Barbara Maria/C-7689-2012; Siqueira, Sergio/AAI-5542-2020;
   Schmidt, Andre/G-1569-2011; Marin-Neto, Jose Antonio/F-6099-2012;
   Cunha-Neto, Edecio/B-4157-2009; Mady, Charles/C-8870-2012; Buck, Paula
   C/F-8781-2012; donadi, eduardo A/H-7080-2013; Martinelli,
   Martino/D-9785-2012; de Siqueira, Sergio Freitas/E-4836-2012; Frade,
   Amanda F/O-3322-2017; KALIL, JORGE/C-8029-2012; Hirata, Mario
   Hiroyuki/C-9718-2013; chevillard, christophe/A-7087-2015
OI Ianni, Barbara Maria/0000-0002-1588-5492; Schmidt,
   Andre/0000-0002-1090-8165; Cunha-Neto, Edecio/0000-0002-3699-3345; Mady,
   Charles/0000-0002-8838-199X; Buck, Paula C/0000-0002-1411-4485; donadi,
   eduardo A/0000-0002-9457-9601; Martinelli, Martino/0000-0003-4440-8078;
   Frade, Amanda F/0000-0002-9004-8811; KALIL, JORGE/0000-0001-8415-4274;
   Hirata, Mario Hiroyuki/0000-0002-9521-7979; chevillard,
   christophe/0000-0002-5269-8813; Siqueira, Sergio/0000-0001-9660-253X;
   Lin Wang, Hui Tzu/0000-0002-7027-7748; Rodrigues Jr,
   Virmondes/0000-0001-8706-4223
FU Institut National de la Sante et de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille University (Direction des Relations
   Internationales); USP-COFECUB program; ARCUS II PACA Bresil program;
   CNPq (the Brazilian National Research Council)National Council for
   Scientific and Technological Development (CNPq); FAPESP (Sao Paulo State
   Research Funding Agency-Brazil); French ANR agency (Br-Fr-CHAGAS)French
   National Research Agency (ANR); Brazilian FAPESP agencyFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX We thank Dr. Maria Lucia Carnevale Mann and Dr. Lea Campos de Oliveira
   for helping in SNP analysis. This work was supported by the Institut
   National de la Sante et de la Recherche Medicale (INSERM), Aix-Marseille
   University (Direction des Relations Internationales), the USP-COFECUB
   program, the ARCUS II PACA Bresil program, CNPq (the Brazilian National
   Research Council), and FAPESP (Sao Paulo State Research Funding
   Agency-Brazil). ECN and CC received support from an international
   program funded by the French ANR agency (Br-Fr-CHAGAS) and the Brazilian
   FAPESP agency. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Calzada JE, 2001, TISSUE ANTIGENS, V58, P154, DOI 10.1034/j.1399-0039.2001.580302.x
   Campelo V, 2007, DIGEST DIS SCI, V52, P3334, DOI 10.1007/s10620-006-9699-7
   Chandrasekar B, 2006, BIOCHEM BIOPH RES CO, V339, P956, DOI 10.1016/j.bbrc.2005.11.100
   Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Cruz-Robles D, 2009, IMMUNOL INVEST, V38, P231, DOI 10.1080/08820130902729637
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   Dinarello CA, 2003, J INFECT DIS, V187, pS370, DOI 10.1086/374751
   Drigo SA, 2007, IMMUNOL LETT, V108, P109, DOI 10.1016/j.imlet.2006.10.008
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197
   Fernandez-Mestre MT, 2004, HUM IMMUNOL, V65, P725, DOI 10.1016/j.humimm.2004.05.002
   Florez O, 2011, PARASITE IMMUNOL, V33, P506, DOI 10.1111/j.1365-3024.2011.01314.x
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Frade AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083446
   Frade AF, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-587
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Kruse S, 2003, J ALLERGY CLIN IMMUN, V111, P117, DOI 10.1067/mai.2003.43
   Layrisse Z, 2000, HUM IMMUNOL, V61, P925, DOI 10.1016/S0198-8859(00)00161-0
   LLOP E, 1988, AM J HUM GENET, V43, P770
   LLOP E, 1991, REV MED CHILE, V119, P633
   MILEI J, 1992, CARDIOLOGY, V80, P424, DOI 10.1159/000175035
   Moreno M, 2004, TISSUE ANTIGENS, V64, P18, DOI 10.1111/j.1399-0039.2004.00260.x
   Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346
   Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Nolan KF, 1998, GENOMICS, V51, P161, DOI 10.1006/geno.1998.5336
   Pissetti CW, 2013, J INTERF CYTOK RES, V33, P130, DOI 10.1089/jir.2012.0024
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   Ramasawmy R, 2007, J INFECT DIS, V196, P1836, DOI 10.1086/523653
   Ramasawmy R, 2008, MOL IMMUNOL, V45, P283, DOI 10.1016/j.molimm.2007.04.015
   Ramasawmy R, 2009, J INFECT DIS, V199, P1838, DOI 10.1086/599212
   Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Teixeira PC, 2012, WORLD J CLIN INFECT, V2, P39, DOI DOI 10.5495/WJCID.V2.I3.39
   Thompson SR, 2007, GENES IMMUN, V8, P91, DOI 10.1038/sj.gene.6364366
   Torres OA, 2010, INFECT GENET EVOL, V10, P682, DOI 10.1016/j.meegid.2010.03.009
   Torres OA, 2009, HUM IMMUNOL, V70, P543, DOI 10.1016/j.humimm.2009.04.022
   Vasconcelos RHT, 2012, CYTOKINE, V59, P203, DOI 10.1016/j.cyto.2012.04.035
   Zafra G, 2007, MICROBES INFECT, V9, P1049, DOI 10.1016/j.micinf.2007.04.010
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 56
TC 20
Z9 20
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD MAY
PY 2015
VL 73
IS 1
BP 79
EP 83
DI 10.1016/j.cyto.2015.01.037
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA CG2AY
UT WOS:000353078500012
PM 25743241
DA 2020-11-26
ER

PT J
AU Wen, FH
   Monteiro, WM
   da Silva, AMM
   Tambourgi, DV
   da Silva, IM
   Sampaio, VS
   dos Santos, MC
   Sachett, J
   Ferreira, LCL
   Kalil, J
   Lacerda, M
AF Wen, Fan Hui
   Monteiro, Wuelton Marcelo
   Moura da Silva, Ana Maria
   Tambourgi, Denise V.
   da Silva, Iran Mendonca
   Sampaio, Vanderson S.
   dos Santos, Maria Cristina
   Sachett, Jacqueline
   Ferreira, Luiz Carlos L.
   Kalil, Jorge
   Lacerda, Marcus
TI Snakebites and Scorpion Stings in the Brazilian Amazon: Identifying
   Research Priorities for a Largely Neglected Problem
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID BOTHROPS; SNAKES; STATE; REGION; VENOMS; BITES; JURUA; ACRE
C1 [Wen, Fan Hui; Moura da Silva, Ana Maria; Tambourgi, Denise V.; Kalil, Jorge] Secretaria Estado Saude Sao Paulo, Inst Butantan, Sao Paulo, Brazil.
   [Monteiro, Wuelton Marcelo; da Silva, Iran Mendonca; Sampaio, Vanderson S.; Sachett, Jacqueline; Ferreira, Luiz Carlos L.; Lacerda, Marcus] Fundacao Med Trop Doutor Heitor Vieira Dourado, Dept Ensino & Pesquisa, Manaus, Amazonas, Brazil.
   [Monteiro, Wuelton Marcelo; da Silva, Iran Mendonca; Sampaio, Vanderson S.; Sachett, Jacqueline; Ferreira, Luiz Carlos L.; Lacerda, Marcus] Univ Estado Amazonas, Escola Super Ciencias Saude, Manaus, Amazonas, Brazil.
   [dos Santos, Maria Cristina] Univ Fed Amazonas, Inst Ciencias Biol, Manaus, Amazonas, Brazil.
   [Lacerda, Marcus] Fiocruz MS, Ctr Pesquisas Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
RP Wen, FH (corresponding author), Secretaria Estado Saude Sao Paulo, Inst Butantan, Sao Paulo, Brazil.
EM wueltonmm@ibest.com.br
RI Sachett, Jacqueline AG/I-5642-2017; Center of Toxins,
   Immune-response/J-5731-2015; Moura-da-Silva, Ana M/A-5247-2008; Sampaio,
   Vanderson/AAQ-1418-2020; Tambourgi, Denise/H-7114-2016; Sampaio,
   Vanderson/M-4337-2015; KALIL, JORGE/C-8029-2012; Fan, Hui
   Wen/F-8649-2015
OI Sachett, Jacqueline AG/0000-0001-5723-9977; Moura-da-Silva, Ana
   M/0000-0003-1787-6634; Sampaio, Vanderson/0000-0001-7307-8851;
   Tambourgi, Denise/0000-0003-1896-9074; Sampaio,
   Vanderson/0000-0001-7307-8851; KALIL, JORGE/0000-0001-8415-4274; Fan,
   Hui Wen/0000-0002-8191-559X
FU Panamerican Health Organization, National Institute for Science and
   Technology of Toxins [CNPq 573790/2008-6, Fapesp 2008/57898-0];
   PPSUS-FAPEAM [287/2013 Decision]
FX The meeting, discussions and writing leading to this article were
   supported by funding from the Panamerican Health Organization, National
   Institute for Science and Technology of Toxins [CNPq 573790/2008-6 and
   Fapesp 2008/57898-0] and from the PPSUS-FAPEAM [287/2013 Decision]. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bernarde Paulo Sérgio, 2012, Acta Amaz., V42, P65, DOI 10.1590/S0044-59672012000100008
   Borges C. C., 1999, Revista da Sociedade Brasileira de Medicina Tropical, V32, P637, DOI 10.1590/S0037-86821999000600005
   Brazilian Ministry of Health, 2014, SIST INF AGR NOT SIN, DOI [10.1111/famp.12079, DOI 10.1111/FAMP.12079]
   Brazilian Ministry of Health, 2009, CAD 14 AC POR AN PEC, P23, DOI DOI 10.1016/J.SMRV.2014.10.006
   Calvete JJ, 2011, J PROTEOMICS, V74, P510, DOI 10.1016/j.jprot.2011.01.003
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   de Carvalho M A, 1998, Cad Saude Publica, V14, P753, DOI 10.1590/S0102-311X1998000400017
   de Silva HA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000435
   Feitosa ES, 2015, REV SOC BRA IN PRESS
   Furtado MDD, 2010, TOXICON, V55, P881, DOI 10.1016/j.toxicon.2009.12.014
   Guercio RAP, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-11
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Muniz EG, 2000, TOXICON, V38, P1859, DOI 10.1016/S0041-0101(00)00082-9
   Nascimento S P, 2000, Cad Saude Publica, V16, P271
   Pardal Pedro Pereira de Oliveira, 2003, Rev Soc Bras Med Trop, V36, P349
   Pardal PPD, 2004, T ROY SOC TROP MED H, V98, P28, DOI 10.1016/S0035-9203(03)00005-1
   Pardal PPO, 2014, REV PAN-AMAZ SAUDE, V5, P65, DOI DOI 10.5123/S2176-62232014000300008
   Pierini SV, 1996, TOXICON, V34, P225, DOI 10.1016/0041-0101(95)00125-5
   Lima ACSF, 2009, REV SOC BRAS MED TRO, V42, P329, DOI 10.1590/S0037-86822009000300017
   SILVA W D D, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P153
   Waldez Fabiano, 2009, Acta Amaz., V39, P681, DOI 10.1590/S0044-59672009000300025
   WHO, 2007, RAB ENV NEGL PUBL HL, P32
   World Health Organization, 2010, GUID PROD CONTR REG, P134
NR 23
TC 34
Z9 35
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2015
VL 9
IS 5
AR e0003701
DI 10.1371/journal.pntd.0003701
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CJ2HA
UT WOS:000355303600011
PM 25996940
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Navarro-Rodriguez, T
   Barbuti, R
   Bisaccioni, C
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana C.
   Navarro-Rodriguez, Tomas
   Barbuti, Ricardo
   Bisaccioni, Carla
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Esophagogastroduodenal Mucosal Behavior after Bronchial Challenge with
   House Dust Mites in Allergic Asthmatic Patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 20-24, 2015
CL Houston, TX
SP Amer Acad Allergy, Asthma & Immunol
C1 [Agondi, Rosana C.; Barbuti, Ricardo; Bisaccioni, Carla; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Navarro-Rodriguez, Tomas] Univ Sao Paulo, Div Gastroenterol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Rodriguez, TOMAS
   NAVARRO/I-3170-2012; Barbuti, Ricardo/AAK-5495-2020
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Rodriguez, TOMAS NAVARRO/0000-0002-3458-699X; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2015
VL 135
IS 2
SU S
MA 577
BP AB179
EP AB179
DI 10.1016/j.jaci.2014.12.1518
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA CR2BN
UT WOS:000361129600576
DA 2020-11-26
ER

PT J
AU Aun, MV
   Arantes-Costa, F
   Saraiva-Romanholo, BM
   Almeida, FM
   Regina-Bruggermann, T
   Martins, MA
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Arantes-Costa, Fernanda
   Saraiva-Romanholo, Beatriz Mangueira
   Almeida, Francine Maria
   Regina-Brueggermann, Thayse
   Martins, Milton Arruda
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Bordetella Pertussis Whole-Cell Vaccine Inhibits Specific IgE,
   Inflammation and Airway Remodeling in a Murine Model of Asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 20-24, 2015
CL Houston, TX
SP Amer Acad Allergy, Asthma & Immunol
C1 [Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Arantes-Costa, Fernanda; Saraiva-Romanholo, Beatriz Mangueira; Almeida, Francine Maria; Regina-Brueggermann, Thayse; Martins, Milton Arruda] Univ Sao Paulo, Sch Med, Dept Internal Med, Sao Paulo, Brazil.
RI Costa, Fernanda Magalhaes A/F-2727-2012; de Almeida, Francine
   Maria/S-2314-2019; Aun, Marcelo V/E-6775-2014; Saraiva-Romanholo,
   Beatriz M/I-5482-2013; Almeida, Francine Maria/H-3733-2013; KALIL,
   JORGE/C-8029-2012
OI de Almeida, Francine Maria/0000-0001-9755-5034; Aun, Marcelo
   V/0000-0001-9882-5200; Almeida, Francine Maria/0000-0001-9755-5034;
   KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2015
VL 135
IS 2
SU S
MA 197
BP AB61
EP AB61
DI 10.1016/j.jaci.2014.12.1133
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA CR2BN
UT WOS:000361129600198
DA 2020-11-26
ER

PT J
AU Perissinotti, PP
   Ethington, EA
   Almazan, E
   Martinez-Hernandez, E
   Kalil, J
   Koob, MD
   Piedras-Renteria, ES
AF Perissinotti, Paula P.
   Ethington, Elizabeth A.
   Almazan, Erik
   Martinez-Hernandez, Elizabeth
   Kalil, Jennifer
   Koob, Michael D.
   Piedras-Renteria, Erika S.
TI Calcium current homeostasis and synaptic deficits in hippocampal neurons
   from Kelch-like 1 knockout mice
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Article
DE actin-binding proteins; Kelch-like 1 protein; T-type voltage-gated
   calcium channels; P/Q-type voltage-gated calcium channels; LVA; HVA;
   synapsin I; SCA8
ID CA2+ CHANNELS; TRANSMITTER RELEASE; GLUTAMATE RELEASE; PROTEIN; P/Q;
   TRANSMISSION; EXPRESSION; ENTRY; PSD-95/SAP90; TERMINALS
AB Kelch-like 1 (KLHL1) is a neuronal actin-binding protein that modulates voltage-gated Ca(V)2.1 (P/O-type) and Cav3.2 (alpha(1H) T-type) calcium channels; KLHL1 knockdown experiments (KD) cause down regulation of both channel types and altered synaptic properties in cultured rat hippocampal neurons (Perissinotti et al., 2014). Here, we studied the effect of ablation of KLHL1 on calcium channel function and synaptic properties in cultured hippocampal neurons from KLHL1 knockout (KO) mice. Western blot data showed the P/Q-type channel alpha(1A) subunit was less abundant in KO hippocarnpus compared to wildtype (WT); and RIO-type calcium currents were smaller in KO neurons than WT during early days in vitro, although this decrease was compensated for at late stages by increases in L-type calcium current. In contrast, T-type currents did not change in culture. However, biophysical properties and western blot analysis revealed a differential contribution of T-type channel isoforms in the KO, with Ca(V)3.2 oil) subunit being down-regulated and Ca(V)3.1 alpha(1G) up-regulated. Synapsin I levels were also reduced in the KO hippocampus and cultured neurons displayed a concomitant reduction in synapsin I puncta and decreased miniature excitatory postsynaptic current (mEPSC) frequency. In summary, genetic ablation of the calcium channel modulator resulted in compensatory mechanisms to maintain calcium current homeostasis in hippocampal KO neurons; however, synaptic alterations resulted in a reduction of excitatory synapse number, causing an imbalance of the excitatory-inhibitory synaptic input ratio favoring inhibition.
C1 [Perissinotti, Paula P.; Ethington, Elizabeth A.; Almazan, Erik; Martinez-Hernandez, Elizabeth; Kalil, Jennifer; Piedras-Renteria, Erika S.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell & Mol Physiol, Maywood, IL 60153 USA.
   [Koob, Michael D.] Univ Minnesota, Dept Lab Med & Pathol, Inst Translat Neurosci, Minneapolis, MN 55455 USA.
   [Piedras-Renteria, Erika S.] Loyola Univ Chicago, Stritch Sch Med, Inst Neurosci, Maywood, IL 60153 USA.
RP Piedras-Renteria, ES (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Cell & Mol Physiol, 2160 S First Ave, Maywood, IL 60153 USA.
EM epiedra@luc.edu
OI Almazan, Erik/0000-0001-8625-0083; Kalil, Jennifer/0000-0001-6304-4690;
   Martinez-Hernandez, Elizabeth/0000-0002-5004-2239; Piedras-Renteria,
   Erika/0000-0001-7983-585X
FU National Science FoundationNational Science Foundation (NSF) [1022075]
FX We thank all members of the Piedras laboratory for helpful comments and
   discussions. This paper is based upon work supported by the National
   Science Foundation under Grant no. 1022075 (EPR).
CR Aromolaran KA, 2007, NEUROSCIENCE, V145, P841, DOI 10.1016/j.neuroscience.2006.12.046
   Aromolaran KA, 2010, AM J PHYSIOL-CELL PH, V298, pC1353, DOI 10.1152/ajpcell.00235.2009
   Aromolaran KA, 2009, CHANNELS, V3, P402, DOI 10.4161/chan.3.6.9858
   Aromolaran Kelly A, 2012, J Signal Transduct, V2012, P505346, DOI 10.1155/2012/505346
   Bao JP, 1998, J NEUROSCI, V18, P8740
   BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Brodbeck J, 2002, J BIOL CHEM, V277, P7684, DOI 10.1074/jbc.M109404200
   Bykhovskaia M, 2011, SEMIN CELL DEV BIOL, V22, P387, DOI 10.1016/j.semcdb.2011.07.003
   Cain SM, 2010, CHANNELS, V4, P475, DOI 10.4161/chan.4.6.14106
   Chameu P, 1999, NEUROSCIENCE, V90, P383, DOI 10.1016/S0306-4522(98)00457-6
   Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269
   Chen WL, 2008, BRAIN RES, V1233, P176, DOI 10.1016/j.brainres.2008.07.096
   Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020
   Danglot L, 2003, MOL CELL NEUROSCI, V23, P264, DOI 10.1016/S1044-7431(03)00069-1
   Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847
   Djouhri L, 1999, J PHYSIOL-LONDON, V520, P565, DOI 10.1111/j.1469-7793.1999.t01-1-00565.x
   Ermolyuk YS, 2013, NAT NEUROSCI, V16, P1754, DOI 10.1038/nn.3563
   Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025
   Evergren E, 2007, J NEUROSCI RES, V85, P2648, DOI 10.1002/jnr.21176
   Fekete A, 2014, J NEUROSCI, V34, P14032, DOI 10.1523/JNEUROSCI.0905-14.2014
   Ferreira A, 2002, CELL MOL LIFE SCI, V59, P589, DOI 10.1007/s00018-002-8451-5
   FLORIO V, 1992, METHOD ENZYMOL, V207, P529
   Giugovaz-Tropper B, 2011, NEUROSCIENCE, V192, P219, DOI 10.1016/j.neuroscience.2011.06.021
   Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0
   Goswami SP, 2012, J NEUROSCI, V32, P14294, DOI 10.1523/JNEUROSCI.6104-11.2012
   He Y, 2006, J NEUROSCI, V26, P9975, DOI 10.1523/JNEUROSCI.2595-06.2006
   Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378
   Ikeda Y., 2007, GENEREVIEWS
   Inchauspe CG, 2004, J NEUROSCI, V24, P10379, DOI 10.1523/JNEUROSCI.2104-04.2004
   Isaeva EV, 1998, NEUROPHYSIOLOGY+, V30, P297, DOI 10.1007/BF02462842
   Jacus MO, 2012, J NEUROSCI, V32, P9374, DOI 10.1523/JNEUROSCI.0068-12.2012
   Jiang SX, 2007, J BIOL CHEM, V282, P12319, DOI 10.1074/jbc.M701019200
   KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4
   Kasumu A, 2012, CEREBELLUM, V11, P630, DOI 10.1007/s12311-010-0182-9
   Klockner U, 1999, EUR J NEUROSCI, V11, P4171, DOI 10.1046/j.1460-9568.1999.00849.x
   KOHLER C, 1983, ANAT EMBRYOL, V167, P53, DOI 10.1007/BF00304600
   Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710
   Kortekaas P, 1997, DEV BRAIN RES, V101, P139, DOI 10.1016/S0165-3806(97)00059-X
   Kozlov AS, 1999, EUR J NEUROSCI, V11, P4149, DOI 10.1046/j.1460-9568.1999.00841.x
   Kurshan PT, 2009, NAT NEUROSCI, V12, P1415, DOI 10.1038/nn.2417
   Lau CG, 2012, J NEUROSCI, V32, P8521, DOI 10.1523/JNEUROSCI.1245-12.2012
   Lin H.-Y., 2007, BIOFORMOSA, V42, P25
   MCCOBB DP, 1991, NEURON, V7, P119, DOI 10.1016/0896-6273(91)90080-J
   McKay BE, 2006, EUR J NEUROSCI, V24, P2581, DOI 10.1111/j.1460-9568.2006.05136.x
   McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200
   Nemes JP, 2000, HUM MOL GENET, V9, P1543, DOI 10.1093/hmg/9.10.1543
   Nishimune H, 2004, NATURE, V432, P580, DOI 10.1038/nature03112
   Nishimune H, 2011, CHANNELS, V5, P430, DOI 10.4161/chan.5.5.16472
   Nudler S, 2003, ANN NY ACAD SCI, V998, P11, DOI 10.1196/annals.1254.003
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002
   Perissinotti PP, 2014, CELL CALCIUM, V55, P269, DOI 10.1016/j.ceca.2014.03.002
   Piedras-Renteria ES, 2004, P NATL ACAD SCI USA, V101, P3609, DOI 10.1073/pnas.0308188100
   Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42
   Pravettoni E, 2000, DEV BIOL, V227, P581, DOI 10.1006/dbio.2000.9872
   Rasband W.S., 1997, IMAGEJ
   Rozanski GM, 2013, J PHYSIOL-LONDON, V591, P5575, DOI 10.1113/jphysiol.2013.260281
   SCHOLZ KP, 1995, J NEUROSCI, V15, P4612
   Seng S, 2006, MOL CELL BIOL, V26, P8371, DOI 10.1128/MCB.02167-05
   Shao M, 2003, J NEUROPHYSIOL, V90, P1182, DOI 10.1152/jn.00076.2003
   Sudhof TC, 2012, NEURON, V75, P11, DOI 10.1016/j.neuron.2012.06.012
   Szczot M, 2010, J PHYSIOL PHARMACOL, V61, P501
   Turrigiano G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005736
   Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657
   Wheeler DB, 1995, PROG BRAIN RES, V105, P65
   WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7
NR 67
TC 3
Z9 3
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JAN 7
PY 2015
VL 8
AR 444
DI 10.3389/fncel.2014.00444
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA CA0ZJ
UT WOS:000348641700001
PM 25610372
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU de Oliveira, LC
   Goldberg, AC
   Marin, MLC
   Schneidwind, KR
   Frade, AF
   Kalil, J
   Miura, IK
   Pugliese, RPS
   Danesi, VLB
   Porta, G
AF de Oliveira, Lea Campos
   Goldberg, Anna Carla
   Carnevale Marin, Maria Lucia
   Schneidwind, Karina Rosa
   Frade, Amanda Farage
   Kalil, Jorge
   Miura, Irene Kasue
   Sustovich Pugliese, Renata Pereira
   Baggio Danesi, Vera Lucia
   Porta, Gilda
TI Autoimmune Hepatitis in Brazilian Children: IgE and Genetic
   Polymorphisms in Associated Genes
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID SERUM IGE; RECEPTOR-ALPHA; GRAVES-DISEASE; SUSCEPTIBILITY; POPULATIONS;
   ANTIBODIES; FIBROSIS; TYPE-1; AUTOANTIBODIES; INTERLEUKIN-5
AB Pediatric autoimmune hepatitis (AIH) patients present hypergammaglobulinemia, periportal CD8(+) cytotoxic T cell infiltration, and cirrhosis. Autoantibody profile defines AIH types 1 and 2 in addition to strong association with HLA-DRB1. We previously detected increased IgE serum levels and sought to compare clinical and histological features according to IgE levels in AIH (n = 74, ages 1-14 years) patients. Additionally, we typed 117 patients and 227 controls for functional polymorphisms of IL4, IL13, IL5, and IL4RA genes involved in IgE switching and eosinophil maturation that might contribute to overall genetic susceptibility to AIH. Serum IgE levels were high in 55% of AIH-1, but only in 12% of AIH-2 (P = 0.003) patients. Liver IgE was present in 91.3% of AIH-1 patients. The A alleles at both IL13 rs20541 and IL4RA rs1805011 were associated with AIH-1 (P = 0.024, OR = 1.55 and P < 0.0001, OR = 2.15, resp.). Furthermore, individuals presenting homozygosis for the A allele at IL4RA rs1805011 and HLA-DRB1*03 and/or *13 allele had sixfold greater risk to develop the disease (OR = 14.00, P < 0.001). The novel association suggests an additional role for IgE-linked immune response genes in the pathogenesis of AIH.
C1 [de Oliveira, Lea Campos] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Med Lab LIM03, BR-05403000 Sao Paulo, SP, Brazil.
   [Goldberg, Anna Carla] Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, SP, Brazil.
   [Goldberg, Anna Carla; Kalil, Jorge] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, BR-05403000 Sao Paulo, SP, Brazil.
   [Carnevale Marin, Maria Lucia; Kalil, Jorge] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao InCor, BR-05403000 Sao Paulo, SP, Brazil.
   [Schneidwind, Karina Rosa; Kalil, Jorge] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Histocompatibilidade & Imunidade Celular LIM1, BR-05403000 Sao Paulo, SP, Brazil.
   [Schneidwind, Karina Rosa; Miura, Irene Kasue; Sustovich Pugliese, Renata Pereira; Baggio Danesi, Vera Lucia; Porta, Gilda] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Hepatol,Inst Crianca, BR-05403000 Sao Paulo, SP, Brazil.
   [Frade, Amanda Farage; Kalil, Jorge] Univ Sao Paulo, Fac Med, Div Alergia & Imunol Clin, BR-05403000 Sao Paulo, SP, Brazil.
RP Goldberg, AC (corresponding author), Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, SP, Brazil.
EM goldberg@einstein.br
RI Frade, Amanda F/O-3322-2017; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012
OI Frade, Amanda F/0000-0002-9004-8811; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Brazilian National Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Sao Paulo State Research Foundation (FAPESP)Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX The authors thank Venancio Avancini Ferreira Alves, M.D., Ph.D., and
   Evandro Sobroza de Mello, M.D., Ph.D., for histological and
   immunohistochemical analysis and thank Paulo Lisboa Bittencourt, M.D.,
   Ph.D., for his review of the paper. Anna Carla Goldberg and Jorge Kalil
   are recipients of personal grants for scientific achievement from CNPq.
   All phases of this study were supported by the Brazilian National
   Council for Scientific and Technological Development (CNPq) and Sao
   Paulo State Research Foundation (FAPESP).
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Atta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293
   BACCHI CE, 1993, BRAZ J MED BIOL RES, V26, P677
   Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035
   Bignon J. D., 1997, GENETIC DIVERSITY HL, P584
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   BOTTAZZO GF, 1976, J CLIN PATHOL, V29, P403, DOI 10.1136/jcp.29.5.403
   Bridoux-Henno L, 2004, CLIN GASTROENTEROL H, V2, P825, DOI 10.1016/S1542-3565(04)00354-4
   Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044
   Chernavsky AC, 2004, HUM IMMUNOL, V65, P683, DOI 10.1016/j.humimm.2004.03.004
   Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325
   Czaja AJ, 1996, HEPATOLOGY, V24, P1068
   Czaja AJ, 2004, HEPATOLOGY, V39, P1631, DOI 10.1002/hep.20235
   De Biasio MB, 2006, J CLIN PATHOL, V59, P417, DOI 10.1136/jcp.2005.028613
   Fairley JA, 2005, J INVEST DERMATOL, V125, P467, DOI 10.1111/j.0022-202X.2005.23853.x
   Farahi N, 2012, BLOOD, V120, P4068, DOI 10.1182/blood-2012-07-443424
   GAYOTTO LCC, 2001, DOENCAS FIGADO VIAS
   Ghosh Subhasish, 2011, Indian J Dermatol, V56, P718, DOI 10.4103/0019-5154.91836
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Hirano K, 2010, WORLD J GASTROENTERO, V16, P5241, DOI 10.3748/wjg.v16.i41.5241
   Hiromatsu Y, 2005, J CLIN ENDOCR METAB, V90, P296, DOI 10.1210/jc.2004-0931
   Kargili AE, 2004, RHEUMATOL INT, V24, P321, DOI 10.1007/s00296-004-0469-6
   Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007
   Mitsuyasu H, 1999, J IMMUNOL, V162, P1227
   Porta G., 2000, JPGN, V31, pS4
   Porta G., 2004, J PEDIAT GASTROEN S2, V39, pS175
   PUNNONEN J, 1993, J IMMUNOL, V151, P1280
   Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006
   Schuerwegh AJM, 2010, P NATL ACAD SCI USA, V107, P2586, DOI 10.1073/pnas.0913054107
   Shibata N, 2002, NEUROSCI LETT, V323, P161, DOI 10.1016/S0304-3940(02)00008-3
   Shimomura I, 1996, J GASTROENTEROL, V31, P737, DOI 10.1007/BF02347627
   Shpirer Z. Ben-Ari, 1995, TRANSPLANT INT, V8, P346
   Suzuki A, 2011, HEPATOLOGY, V54, P931, DOI 10.1002/hep.24481
   Takatsu K, 1998, CYTOKINE GROWTH F R, V9, P25, DOI 10.1016/S1359-6101(97)00034-8
   VANEPPS E, 1976, CLIN EXP IMMUNOL, V23, P444
   Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142
   Yabiku K, 2007, CLIN EXP IMMUNOL, V148, P425, DOI 10.1111/j.1365-2249.2007.03366.x
NR 41
TC 4
Z9 4
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2015
VL 2015
AR 679813
DI 10.1155/2015/679813
PG 9
WC Immunology
SC Immunology
GA CX7WX
UT WOS:000365914800001
PM 26693492
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Bonamichi-Santos, R
   Aun, MV
   Agondi, RC
   Kalil, J
   Giavina-Bianchi, P
AF Bonamichi-Santos, R.
   Aun, M. V.
   Agondi, R. C.
   Kalil, J.
   Giavina-Bianchi, P.
TI Microbiome and Asthma: What Have Experimental Models Already Taught Us?
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Review
ID ALLERGIC AIRWAY INFLAMMATION; HOUSE-DUST MITE; ANIMAL-MODELS;
   EARLY-LIFE; CHLAMYDOPHILA-PNEUMONIAE; IMMUNE-RESPONSES; MURINE MODEL;
   EXPOSURE; DISEASE; RISK
AB Asthma is a chronic inflammatory disease that imposes a substantial burden on patients, their families, and the community. Although many aspects of the pathogenesis of classical allergic asthma are well known by the scientific community, other points are not yet understood. Experimental asthma models, particularly murine models, have been used for over 100 years in order to better understand the immunopathology of asthma. It has been shown that human microbiome is an important component in the development of the immune system. Furthermore, the occurrence of many inflammatory diseases is influenced by the presence of microbes. Again, experimental models of asthma have helped researchers to understand the relationship between the microbiome and respiratory inflammation. In this review, we discuss the evolution of murine models of asthma and approach the major studies involving the microbiome and asthma.
C1 [Bonamichi-Santos, R.; Aun, M. V.; Agondi, R. C.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, BR-01454010 Sao Paulo, SP, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, BR-01454010 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
CR Abt MC, 2009, CURR OPIN GASTROEN, V25, P496, DOI 10.1097/MOG.0b013e328331b6b4
   Acencio M. M. P., 2003, REV BRASILEIRA ALERG, V26, P134
   Agache IO, 2013, CURR OPIN ALLERGY CL, V13, P249, DOI 10.1097/ACI.0b013e32836093dd
   Ai CQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109461
   Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X
   Ano S, 2013, J IMMUNOL, V190, P1056, DOI 10.4049/jimmunol.1202386
   Barnes PJ, 2012, J ALLERGY CLIN IMMUN, V129, P48, DOI 10.1016/j.jaci.2011.11.006
   Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632
   Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060
   Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057
   Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC
   Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302
   Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384
   Evans H, 2015, J ALLERGY CLIN IMMUN, V135, P343, DOI 10.1016/j.jaci.2014.07.007
   Fujimura KE, 2010, EXPERT REV ANTI-INFE, V8, P435, DOI [10.1586/eri.10.14, 10.1586/ERI.10.14]
   Gaitanis G, 2012, CLIN MICROBIOL REV, V25, P106, DOI 10.1128/CMR.00021-11
   Global Initiative for Asthma, 2014, GLOB STRAT ASTHM MAN
   Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568
   HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225
   Harb H, 2013, CLIN EXP ALLERGY, V43, P353, DOI 10.1111/cea.12047
   Harris JK, 2007, P NATL ACAD SCI USA, V104, P20529, DOI 10.1073/pnas.0709804104
   Hartmann C, 2015, IMMUNOL LETT, V164, P44, DOI 10.1016/j.imlet.2014.12.001
   Havstad S, 2011, J ALLERGY CLIN IMMUN, V128, P880, DOI 10.1016/j.jaci.2011.06.039
   Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC
   Herszberg B, 2006, J ALLERGY CLIN IMMUN, V118, P382, DOI 10.1016/j.jaci.2006.03.044
   Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578
   Holgate ST, 2013, BRIT J CLIN PHARMACO, V76, P277, DOI 10.1111/bcp.12036
   Holmes AM, 2011, DRUG DISCOV TODAY, V16, P659, DOI 10.1016/j.drudis.2011.05.014
   Huang YJ, 2013, CURR ALLERGY ASTHM R, V13, P453, DOI 10.1007/s11882-013-0355-y
   Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048
   Huang YJ, 2010, OMICS, V14, P9, DOI 10.1089/omi.2009.0100
   Hyde DM, 2006, EUR RESPIR REV, V15, P122, DOI 10.1183/09059180.00010103
   Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC
   Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237
   Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC
   KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555
   Ke X, 2010, CLIN INVEST MED, V33, pE196
   Kim HY, 2015, BMB REP, V48, P178, DOI 10.5483/BMBRep.2015.48.3.257
   Kocabas A, 2008, J ASTHMA, V45, P39, DOI 10.1080/02770900701815735
   Kola I, 2008, CLIN PHARMACOL THER, V83, P227, DOI 10.1038/sj.clpt.6100479
   Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166
   MacSharry J, 2012, PULM PHARMACOL THER, V25, P325, DOI 10.1016/j.pupt.2012.05.011
   Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013
   Martin JG, 2003, RESP PHYSIOL NEUROBI, V137, P251, DOI 10.1016/S1569-9048(03)00151-4
   Martin RA, 2014, RESPIROLOGY, V19, P823, DOI 10.1111/resp.12315
   Martin RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074730
   Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956
   McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC
   McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089
   McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012
   Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056
   Nelson KE, 2010, SCIENCE, V328, P994, DOI 10.1126/science.1183605
   Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328
   Ota K, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/602846
   Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754
   Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963
   Padrid P, 1992, Probl Vet Med, V4, P320
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Rogers GB, 2004, J CLIN MICROBIOL, V42, P5176, DOI 10.1128/JCM.42.11.5176-5183.2004
   Round JL, 2010, J AUTOIMMUN, V34, pJ220, DOI 10.1016/j.jaut.2009.11.007
   Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32
   Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056
   Shapiro SD, 2008, PULM PHARMACOL THER, V21, P699, DOI 10.1016/j.pupt.2008.01.006
   Smith K, 2009, J ASTHMA, V46, P234, DOI 10.1080/02770900802627294
   Sogin ML, 2006, P NATL ACAD SCI USA, V103, P12115, DOI 10.1073/pnas.0605127103
   Specjalski K, 2011, ALLERGY ASTHMA PROC, V32, pE9, DOI 10.2500/aap.2011.32.3431
   Stevenson CS, 2011, PHARMACOL THERAPEUT, V130, P93, DOI 10.1016/j.pharmthera.2010.10.008
   Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x
   Szelenyi I, 2000, INFLAMM RES, V49, P639, DOI 10.1007/s000110050642
   Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40
   Vael Carl, 2008, BMC Pulm Med, V8, P19, DOI 10.1186/1471-2466-8-19
   Van Woerden H. C., 2013, BMC INFECT DIS, V13
   Watson L, 2007, RESP MED, V101, P1659, DOI 10.1016/j.rmed.2007.03.006
   Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x
   Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691
   Zhang B, 2012, INT J MOL MED, V30, P248, DOI 10.3892/ijmm.2012.1010
   Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x
NR 79
TC 10
Z9 11
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2015
VL 2015
AR 614758
DI 10.1155/2015/614758
PG 8
WC Immunology
SC Immunology
GA CO1CB
UT WOS:000358889400001
PM 26266269
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, M
   Giavina-Bianchi, P
   Sotto, MN
   Muzikansky, A
   Kalil, J
   Festa-Neto, C
   Duncan, LM
AF Giavina-Bianchi, Mara
   Giavina-Bianchi, Pedro
   Sotto, Mirian Nacagami
   Muzikansky, Alona
   Kalil, Jorge
   Festa-Neto, Cyro
   Duncan, Lyn M.
TI Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+T Cells in
   Cutaneous Melanoma
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID CANCER-TESTIS ANTIGENS; LYMPHOCYTE GRADE; TUMOR; SURVIVAL; STAGE;
   RESPONSES; IMMUNOGENICITY; IMMUNOTHERAPY; DACARBAZINE; CARCINOMA
AB NY-ESO-1 is a cancer-testis antigen aberrantly expressed in melanomas, which may serve as a robust and specific target in immunotherapy. NY-ESO-1 antigen expression, tumor features, and the immune profile of tumor infiltrating lymphocytes were assessed in primary cutaneous melanoma. NY-ESO-1 protein was detected in 20% of invasive melanomas (16/79), rarely in in situ melanoma (1/10) and not in benign nevi (0/20). Marked intratumoral heterogeneity of NY-ESO-1 protein expression was observed. NY-ESO-1 expression was associated with increased primary tumor thickness (P = 0.007) and inversely correlated with superficial spreading melanoma (P < 0.02). NY-ESO-1 expression was also associated with reduced numbers and density of CD3+ tumor infiltrating lymphocytes (P = 0.017). When NY-ESO-1 protein was expressed, CD3+ T cells were less diffusely infiltrating the tumor and were more often arranged in small clusters (P = 0.010) or as isolated cells (P = 0.002) than in large clusters of more than five lymphocytes. No correlation of NY-ESO-1 expression with gender, age, tumor site, ulceration, lymph node sentinel status, or survival was observed. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes.
C1 [Giavina-Bianchi, Mara; Sotto, Mirian Nacagami; Festa-Neto, Cyro] Univ Sao Paulo, Dept Dermatol, BR-05403900 Sao Paulo, SP, Brazil.
   [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05403900 Sao Paulo, SP, Brazil.
   [Muzikansky, Alona] MGH Biostat Ctr, Boston, MA 02114 USA.
   [Duncan, Lyn M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dermatopathol Unit,Pathol Serv, Boston, MA 02114 USA.
RP Giavina-Bianchi, M (corresponding author), Univ Sao Paulo, Dept Dermatol, Ave Dr Eneas de Carvalho Aguiar 255,3 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM clinicadermato@ig.com.br
RI KALIL, JORGE/C-8029-2012; Sotto, Mirian Nacagami/C-3475-2013
OI KALIL, JORGE/0000-0001-8415-4274; Sotto, Mirian
   Nacagami/0000-0001-6380-7192
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPQ (Conselho
   Nacional de Pesquisa), BrazilNational Council for Scientific and
   Technological Development (CNPq)
FX The authors acknowledge Ludwig Institute for Cancer Research, Brazil,
   for the donation of antibody E978 and also recognized the expert
   technical support of the Laboratorio Diagnostika, Brazil, for performing
   immunohistochemical stains and controls. They want to thank Patricia
   Della Pelle for T cell immunohistochemical staining. This study was
   supported by grants from FAPESP (Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo), and CNPQ (Conselho Nacional de Pesquisa), Brazil, and the
   consultative funds of one of the authors (Lyn M. Duncan).
CR Andrade Valeria C C, 2008, Cancer Immun, V8, P2
   ARMSTRONG BK, 1994, CANCER SURV, V20, P219
   Azimi F, 2012, J CLIN ONCOL, V30, P2678, DOI 10.1200/JCO.2011.37.8539
   Barrow C, 2006, CLIN CANCER RES, V12, P764, DOI 10.1158/1078-0432.CCR-05-1544
   Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chitale DA, 2005, MODERN PATHOL, V18, P119, DOI 10.1038/modpathol.3800232
   CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893
   Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
   Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101
   Duncan LM, 1998, J CUTAN PATHOL, V25, P11, DOI 10.1111/j.1600-0560.1998.tb01683.x
   Fox M. C., 2013, J AM ACAD DERMATOL, V68, p1 e1
   Fujita S, 2004, CLIN CANCER RES, V10, P6551, DOI 10.1158/1078-0432.CCR-04-0819
   Gnjatic S, 2002, P NATL ACAD SCI USA, V99, P11813, DOI 10.1073/pnas.142417699
   Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189
   Goydos JS, 2001, J SURG RES, V98, P76, DOI 10.1006/jsre.2001.6148
   Hemminger JA, 2013, MODERN PATHOL, V26, P282, DOI 10.1038/modpathol.2012.133
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497
   Juretic A, 2003, LANCET ONCOL, V4, P104, DOI 10.1016/S1470-2045(03)00982-3
   KASPER CS, 1987, J AM ACAD DERMATOL, V16, P326, DOI 10.1016/S0190-9622(87)70044-9
   Keilholz U, 2005, J CLIN ONCOL, V23, P6747, DOI 10.1200/JCO.2005.03.202
   Konishi J, 2004, ONCOL REP, V11, P1063
   Kruger S, 2007, PATHOL ONCOL RES, V13, P91
   Kurashige T, 2001, CANCER RES, V61, P4671
   Linos E, 2009, J INVEST DERMATOL, V129, P1666, DOI 10.1038/jid.2008.423
   Luftl M, 2004, BRIT J DERMATOL, V151, P1213, DOI 10.1111/j.1365-2133.2004.06260.x
   Nakada Tetsuya, 2003, Cancer Immun, V3, P10
   Neuman HB, 2008, ANN SURG ONCOL, V15, P2034, DOI 10.1245/s10434-008-9915-0
   Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813
   Odunsi K, 2003, CANCER RES, V63, P6076
   Odunsi K, 2012, P NATL ACAD SCI USA, V109, P5797, DOI 10.1073/pnas.1117208109
   Pellacani G, 2008, J EUR ACAD DERMATOL, V22, P213, DOI 10.1111/j.1468-3083.2007.02388.x
   Peng JR, 2005, CANCER LETT, V219, P223, DOI 10.1016/j.canlet.2004.07.028
   Piras F, 2005, CANCER-AM CANCER SOC, V104, P1246, DOI 10.1002/cncr.21283
   Piris A, 2012, DERMATOL CLIN, V30, P581, DOI 10.1016/j.det.2012.06.001
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001
   Scott AM, 1997, LANCET, V349, pS19, DOI 10.1016/S0140-6736(97)90016-7
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Stratigos AJ, 2012, BRIT J DERMATOL, V167, P99, DOI 10.1111/j.1365-2133.2012.11092.x
   Svobodova S, 2011, EUR J CANCER, V47, P460, DOI 10.1016/j.ejca.2010.09.042
   Thomas NE, 2013, J CLIN ONCOL, V31, P4252, DOI 10.1200/JCO.2013.51.3002
   van Houdt IS, 2008, INT J CANCER, V123, P609, DOI 10.1002/ijc.23543
   Vaughan HA, 2004, CLIN CANCER RES, V10, P8396, DOI 10.1158/1078-0432.CCR-04-0809
   Velazquez Elsa F, 2007, Cancer Immun, V7, P11
   Wang Yu, 2004, Cancer Immun, V4, P11
   Weide B, 2012, J CLIN ONCOL, V30, P1835, DOI 10.1200/JCO.2011.40.2271
   Yakirevich E, 2003, CLIN CANCER RES, V9, P6453
NR 49
TC 9
Z9 10
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2015
VL 2015
AR 761378
DI 10.1155/2015/761378
PG 8
WC Immunology
SC Immunology
GA CG7JR
UT WOS:000353479700001
PM 25954764
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU dos Santos-Pinto, JRA
   dos Santos, LD
   Arcuri, HA
   Menegasso, ARD
   Pego, PN
   Santos, KS
   Castro, FM
   Kalil, JE
   De-Simone, SG
   Palma, MS
AF Aparecido dos Santos-Pinto, Jose Roberto
   dos Santos, Lucilene Delazari
   Arcuri, Helen Andrade
   da Silva Menegasso, Anally Ribeiro
   Pego, Paloma Napoleao
   Santos, Keity Souza
   Castro, Fabio Morato
   Kalil, Jorge Elias
   De-Simone, Salvatore Giovanni
   Palma, Mario Sergio
TI B-cell linear epitopes mapping of antigen-5 allergen from Polybia
   paulista wasp venom
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID HYMENOPTERA VENOM; IGE
C1 [Aparecido dos Santos-Pinto, Jose Roberto; da Silva Menegasso, Anally Ribeiro; Palma, Mario Sergio] Univ Sao Paulo State, UNESP, Inst Biosci Rio Claro, Rio Claro, Brazil.
   [Pego, Paloma Napoleao; De-Simone, Salvatore Giovanni] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [dos Santos, Lucilene Delazari] Univ Sao Paulo State, UNESP, CEVAP, Botucatu, SP, Brazil.
   [Aparecido dos Santos-Pinto, Jose Roberto; dos Santos, Lucilene Delazari; Arcuri, Helen Andrade; da Silva Menegasso, Anally Ribeiro; Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias; Palma, Mario Sergio] INCT, Sao Paulo, Brazil.
   [Arcuri, Helen Andrade; Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias] Discipline Allergy & Immunol HC Incor FMUSP, Sao Paulo, Brazil.
RP dos Santos-Pinto, JRA (corresponding author), Univ Sao Paulo State, UNESP, Inst Biosci Rio Claro, Rio Claro, Brazil.
EM mspalma@rc.unesp.br
RI De-Simone, Salvatore/I-2989-2013; Castro, Fabio/AAP-5433-2020; Palma,
   Mario Sergio/E-7800-2012; KALIL, JORGE/C-8029-2012; Santos, Keity
   Souza/Q-5704-2019; Santos-Pinto, Jose Roberto Aparecido dos/V-8745-2019;
   Castro, Fabio FM/C-1082-2017; Santos, Keity/M-9401-2015
OI De-Simone, Salvatore/0000-0002-2172-656X; Palma, Mario
   Sergio/0000-0002-7363-8211; KALIL, JORGE/0000-0001-8415-4274; Santos,
   Keity Souza/0000-0001-5271-4011; Santos-Pinto, Jose Roberto Aparecido
   dos/0000-0003-3172-0097; Castro, Fabio FM/0000-0002-6211-5773; 
CR dos Santos-Pinto JRA, 2014, J PROTEOME RES, V13, P855, DOI 10.1021/pr4008927
   Castro FFM, 2009, ALERGIA VENENOS INSE
   De-Simone SG, 2014, TOXICON, V78, P83, DOI 10.1016/j.toxicon.2013.12.001
   dos Santos LD, 2010, J PROTEOME RES, V9, P3867, DOI 10.1021/pr1000829
   Pinto JRAD, 2012, J PROTEOME RES, V11, P4643, DOI 10.1021/pr300451g
   Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109
   HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5
   Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017
   Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x
   Winkler B, 2003, IMMUNOLOGY, V110, P376, DOI 10.1046/j.1365-2567.2003.01751.x
NR 10
TC 13
Z9 13
U1 0
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2015
VL 135
IS 1
BP 264
EP U404
DI 10.1016/j.jaci.2014.07.006
PG 13
WC Allergy; Immunology
SC Allergy; Immunology
GA AY0PG
UT WOS:000347298200033
PM 25129676
DA 2020-11-26
ER

PT J
AU da Silva, BCM
   Grassi, MFR
   Coutinho, R
   Mascarenhas, REM
   Olavarria, VN
   Coutinho-Borgo, A
   Kalil, J
   Cunha-Neto, E
   Fonseca, SG
AF Maciel da Silva, Bosco Christiano
   Rios Grassi, Maria Fernanda
   Coutinho, Raimundo
   Moreira Mascarenhas, Rita Elizabeth
   Olavarria, Viviana Nilla
   Coutinho-Borgo, Adriana
   Kalil, Jorge
   Cunha-Neto, Edecio
   Fonseca, Simone Goncalves
TI Mycobacterium tuberculosis epitope-specific interferon-gamma production
   in healthy Brazilians reactive and non-reactive to tuberculin skin test
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Mycobacterium tuberculosis; epitopes; IFN-gamma ELISPOT; latent
   tuberculosis; Mantoux tuberculin skin test
ID T-CELL EPITOPES; LATENT TUBERCULOSIS; RELEASE ASSAYS; IMMUNODOMINANT
   EPITOPES; ACTIVE TUBERCULOSIS; DIAGNOSTIC-TESTS; HIV EPIDEMIC;
   WHOLE-GENOME; INFECTION; IDENTIFICATION
AB The interferon (IFN)-gamma response to peptides can be a useful diagnostic marker of Mycobacterium tuberculosis (MTB) latent infection. We identified promiscuous and potentially protective CD4(+) T-cell epitopes from the most conserved regions of MTB antigenic proteins by scanning the MTB antigenic proteins GroEL2, phosphate-binding protein 1 precursor and 19 kDa antigen with the TEPITOPE algorithm. Seven peptide sequences predicted to bind to multiple human leukocyte antigen (HLA)-DR molecules were synthesised and tested with IFN-gamma enzyme-linked immunospot (ELISPOT) assays using peripheral blood mononuclear cells (PBMCs) from 16 Mantoux tuberculin skin test (TST)-positive and 16 TST-negative healthy donors. Eighty-eight percent of TST-positive donors responded to at least one of the peptides, compared to 25% of TST-negative donors. Each individual peptide induced IFN-gamma production by PBMCs from at least 31% of the TST-positive donors. The magnitude of the response against all peptides was 182 +/- 230 x 10(6) IFN-gamma spot forming cells (SFC) among TST-positive donors and 36 +/- 62 x 10(6) SFC among TST-negative donors (p = 0.007). The response to GroEL2 (463-477) was only observed in the TST-positive group. This combination of novel MTB CD4 T-cell epitopes should be tested in a larger cohort of individuals with latent tuberculosis (TB) to evaluate its potential to diagnose latent TB and it may be included in ELISPOT-based IFN-gamma assays to identify individuals with this condition.
C1 [Maciel da Silva, Bosco Christiano; Coutinho-Borgo, Adriana; Kalil, Jorge; Cunha-Neto, Edecio; Fonseca, Simone Goncalves] Univ Fed Sao Paulo, Fac Med, Inst Coracao, Immunol Lab, Sao Paulo, Brazil.
   [Coutinho-Borgo, Adriana; Kalil, Jorge; Cunha-Neto, Edecio] Univ Fed Sao Paulo, Fac Med, Dept Med, Div Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Rios Grassi, Maria Fernanda; Coutinho, Raimundo; Moreira Mascarenhas, Rita Elizabeth; Olavarria, Viviana Nilla] Fundacao Oswaldo Cruz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   [Rios Grassi, Maria Fernanda; Moreira Mascarenhas, Rita Elizabeth; Olavarria, Viviana Nilla] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio; Fonseca, Simone Goncalves] Inst Invest Immunol, Sao Paulo, Brazil.
RP Fonseca, SG (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
EM fonseca.simone@gmail.com
RI Grassi, Fernanda/X-7360-2019; DA SILVA, Bosco Christiano
   MACIEL/C-6380-2013; FONSECA, SIMONE GONCALVES/U-9278-2019; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Grassi, Fernanda/0000-0002-7356-5569; DA SILVA, Bosco Christiano
   MACIEL/0000-0002-3883-7178; Cunha-Neto, Edecio/0000-0002-3699-3345;
   KALIL, JORGE/0000-0001-8415-4274
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX FAPESP
CR ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989
   ASHBRIDGE KR, 1989, NUCLEIC ACIDS RES, V17, P1249, DOI 10.1093/nar/17.3.1249
   Atherton E, 1989, SOLID PHASE PEPTIDE
   Bartalesi F, 2009, EUR RESPIR J, V33, P586, DOI 10.1183/09031936.00107608
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   Blanc L, 2007, B WORLD HEALTH ORGAN, V85, P326, DOI 10.2471/BLT.07.041996
   Brock L, 2004, AM J RESP CRIT CARE, V170, P65, DOI 10.1164/rccm.200402-232OC
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Damico FM, 2005, INVEST OPHTH VIS SCI, V46, P2465, DOI 10.1167/iovs.04-1273
   Diel R, 2007, CHEST, V131, P1424, DOI 10.1378/chest.06-2728
   Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11030
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Fietta A, 2003, AM J INFECT CONTROL, V31, P347, DOI 10.1016/S0196-6553(02)48240-5
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Girardi E, 2009, EUROSURVEILLANCE, V14, P29
   Girardi E, 2000, AIDS, V14, pS47
   Idh J, 2010, SCAND J INFECT DIS, V42, P650, DOI 10.3109/00365548.2010.482942
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Lewinsohn DA, 2010, CURR OPIN PEDIATR, V22, P71, DOI 10.1097/MOP.0b013e3283350301
   Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001
   MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E
   Mendelson M, 2005, TUBERCULOSIS, V85, P407, DOI 10.1016/j.tube.2005.08.004
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Redelman-Sidi G, 2013, AM J RESP CRIT CARE, V188, P422, DOI 10.1164/rccm.201209-1621CI
   Richeldi L, 2009, CHEST, V136, P198, DOI 10.1378/chest.08-2575
   Schroers R, 2002, CANCER RES, V62, P2600
   SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987
   Soborg B, 2009, J RHEUMATOL, V36, P1876, DOI 10.3899/jrheum.081292
   Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sun Y, 2003, J IMMUNOL METHODS, V272, P23, DOI 10.1016/S0022-1759(02)00328-9
   Tanghe A, 1999, J IMMUNOL, V162, P1113
   Wilkinson KA, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-93
   Xie J, 2010, AIDS, V24, P2323, DOI 10.1097/QAD.0b013e32833e5009
   Zhang HW, 2009, SCI CHINA SER C, V52, P841, DOI 10.1007/s11427-009-0117-1
   Zhang S, 2010, CLIN VACCINE IMMUNOL, V17, P1985, DOI 10.1128/CVI.00294-10
NR 40
TC 1
Z9 1
U1 0
U2 18
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD DEC
PY 2014
VL 109
IS 8
BP 999
EP 1004
DI 10.1590/0074-0276140193
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AY4DI
UT WOS:000347528000005
PM 25494469
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kallas, EG
   Kalil, J
   Somsouk, M
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan P.
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kallas, Esper G.
   Kalil, Jorge
   Somsouk, Ma
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI The CD8(+) Memory Stem T Cell (T-SCM) Subset Is Associated with Improved
   Prognosis in Chronic HIV-1 Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRUS TYPE-1 INFECTION; CD4(+); LYMPHOCYTES; ACTIVATION
AB Memory stem T cells (T-SCM) constitute a long-lived, self-renewing lymphocyte population essential for the maintenance of functional immunity. The hallmarks of HIV-1 pathogenesis are CD4(+) T cell depletion and abnormal cellular activation. We investigated the impact of HIV-1 infection on the T-SCM compartment, as well as any protective role these cells may have in disease progression, by characterizing this subset in a cohort of 113 subjects with various degrees of viral control on and off highly active antiretroviral therapy (HAART). We observed that the frequency of CD8(+) T-SCM was decreased in all individuals with chronic, untreated HIV-1 infection and that HAART had a restorative effect on this subset. In contrast, natural controllers of HIV-1 had the highest absolute number of CD4(+) T-SCM cells among all of the infected groups. The frequency of CD4(+) T-SCM predicted higher CD8(+) T-SCM frequencies, consistent with a role for the CD4(+) subset in helping to maintain CD8(+) memory T cells. In addition, T-SCM appeared to be progenitors for effector T cells (TEM), as these two compartments were inversely correlated. Increased frequencies of CD8(+) T-SCM predicted lower viral loads, higher CD4(+) counts, and less CD8(+) T cell activation. Finally, we found that T-SCM express the mucosal homing integrin alpha(4)beta(7) and can be identified in gut-associated lymphoid tissue (GALT). The frequency of mucosal CD4(+) T-SCM was inversely correlated with that in the blood, potentially reflecting the ability of these self-renewing cells to migrate to a crucial site of ongoing viral replication and CD4(+) T cell depletion.
   IMPORTANCE
   HIV-1 infection leads to profound impairment of the immune system. T-SCM constitute a recently identified lymphocyte subset with stem cell-like qualities, including the ability to generate other memory T cell subtypes, and are therefore likely to play an important role in controlling viral infection. We investigated the relationship between the size of the CD8(+) T-SCM compartment and HIV-1 disease progression in a cohort of chronically infected individuals. Our results suggest that HAART restores a normal frequency of CD8(+) T-SCM and that the natural preservation of this subset in the setting of untreated HIV-1 infection is associated with improved viral control and immunity. Therefore, the CD8(+) T-SCM population may represent a correlate of protection in chronic HIV-1 infection that is directly relevant to the design of T cell-based vaccines, adoptive immunotherapy approaches, or the pharmacologic induction of T-SCM.
C1 [Ribeiro, Susan P.; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, LIM60, Lab Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Ribeiro, Susan P.; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Milush, Jeffrey M.; SenGupta, Devi] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Inst, Sao Paulo, Brazil.
   [Somsouk, Ma] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA.
   [Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA.
   [Nixon, Douglas F.] George Washington Univ, Dept microbiol Immunol & Trop Med, Washington, DC USA.
RP SenGupta, D (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM devi.sengupta@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009; Hunt, Peter W./P-2976-2017
OI Nixon, Douglas/0000-0002-2801-1786; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Hunt, Peter
   W./0000-0002-4571-4870; Kallas, Esper/0000-0003-2026-6925; Deeks,
   Steven/0000-0001-6371-747X
FU Delaney AIDS Research Enterprise (DARE) [AI096109]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K24 AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR
   [P30 AI027763]; UCSF Clinical and Translational Research Institute
   Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention
   Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24
   AI067039]; NIH NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [K23 CA157929]; NIH NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [K08
   A120071]; Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2010/05845-0/EGK]; CNPq/CAPESNational Council for
   Scientific and Technological Development (CNPq)CAPES [056/2012];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [K23CA157929, K23CA157929, K23CA157929, K23CA157929]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000004, UL1TR000004,
   UL1TR000004, UL1TR000004, UL1TR000004, UL1TR000004, UL1TR000004] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI027763, P30AI027763, R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, K24AI069994, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, U19AI096109, U19AI096109, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   U19AI096109, R24AI067039, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, K24AI069994, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, K24AI069994, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, K24AI069994, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, U19AI096109, P30AI027763,
   K24AI069994, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, R24AI067039,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, K24AI069994, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   U19AI096109, U19AI096109, R24AI067039, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, R24AI067039, U19AI096109, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding
   Source: NIH RePORTER
FX This work was supported by the Delaney AIDS Research Enterprise (DARE;
   AI096109), NIAID (K24 AI069994), the UCSF/Gladstone Institute of
   Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and
   Translational Research Institute Clinical Research Center (UL1
   RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the
   CFAR Network of Integrated Systems (R24 AI067039). M.S. was supported by
   NIH NCI K23 CA157929. D.S. was supported by NIH NIAID K08 A120071. This
   research was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) and the Sao Paulo State Research
   Funding Agency (FAPESP) and by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (2010/05845-0/EGK) (D.F.N.) and CNPq/CAPES 056/2012
   (D.F.N.). E.C.-N. and J.K. are recipients of productivity awards from
   the Brazilian Council for Scientific and Technological Development
   (CNPq).
CR Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Emu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085613
   Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446
   Ghiglione Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104235
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Grelli S, 2003, ANN NY ACAD SCI, V1010, P560, DOI 10.1196/annals.1299.104
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Klatt NR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004345
   Klatt NR, 2013, TRENDS MICROBIOL, V21, P6, DOI 10.1016/j.tim.2012.09.001
   Koelsch KK, 2008, J INFECT DIS, V197, P411, DOI 10.1086/525283
   Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327
   Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Tabler CO, 2014, J VIROL, V88, P4976, DOI 10.1128/JVI.00324-14
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
NR 18
TC 25
Z9 29
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 23
BP 13836
EP 13844
DI 10.1128/JVI.01948-14
PG 9
WC Virology
SC Virology
GA AT3CI
UT WOS:000344812800027
PM 25253339
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU de Souza, PS
   David-Neto, E
   Panajotopolous, N
   Agena, F
   Rodrigues, H
   Ronda, C
   David, DR
   Kalil, J
   Nahas, WC
   de Castro, MCR
AF de Souza, Patricia Soares
   David-Neto, Elias
   Panajotopolous, Nicolas
   Agena, Fabiana
   Rodrigues, Helcio
   Ronda, Carla
   David, Daisa Ribeiro
   Kalil, Jorge
   Nahas, Wiliam Carlos
   Ribeiro de Castro, Maria Cristina
TI Dynamics of anti-human leukocyte antigen antibodies after renal
   transplantation and their impact on graft outcome
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE antibody-mediated rejection; anti-HLA antibodies; graft function; graft
   survival
ID DONOR-SPECIFIC ANTIBODIES; HLA CLASS-I; KIDNEY-TRANSPLANT; FOLLOW-UP;
   MEDIATED REJECTION; LONG-TERM; RECIPIENTS; RISK; PRETRANSPLANT;
   SENSITIZATION
AB The purpose of this study was to sequentially monitor anti-HLA antibodies and correlate the results with antibody-mediated rejection (AMR), graft survival (GS), and graft function (GF). We collected sera from 111 kidney transplant recipients on transplant days 0, 7, 14, 30, 60, 90, 180, and 360 and analyzed PRA levels by ELISA. DSAs were analyzed by single-antigen beads in rejecting kidneys. At pre-transplant, 79.3% of the patients were non-sensitized (PRA=0%) and 20.7% were sensitized (PRA>1%). After transplant, patients were grouped by PRA profile: no anti-HLA antibodies pre- or post-transplant (group HLApre-/post-; n=80); de novo anti-HLA antibodies post-transplant (group HLApre-/post+; n=8); sensitized pre-transplant/increased PRA post-transplant (group HLApre+/post; n=9); and sensitized pre-transplant/decreased PRA post-transplant (group HLApre+/post; n=14). De novo anti-HLA antibodies were detected at 7-180d. In sensitized patients, PRA levels changed within the first 30d post-transplant. Incidence of AMR was higher in HLApre-/post+ and HLApre+/post than in HLApre-/post-, and HLApre+/post (p<0.001) groups. One-yr death-censored GS was 36% in group HLApre+/post, compared with 98%, 88% and 100% in groups HLApre-/post-, HLApre-/post+, and HLApre+/post, respectively (p<0.001). Excluding first-year graft losses, GF and GS were similar among the groups. In conclusion, post-transplant antibody monitoring can identify recipients at higher risk of AMR.
C1 [de Souza, Patricia Soares; David-Neto, Elias; Agena, Fabiana; Ribeiro de Castro, Maria Cristina] Univ Sao Paulo, Hosp Clin Sao Paulo, Div Urol, Renal Transplantat Serv, Sao Paulo, Brazil.
   [de Souza, Patricia Soares; David-Neto, Elias; Agena, Fabiana; Nahas, Wiliam Carlos; Ribeiro de Castro, Maria Cristina] Univ Sao Paulo, Hosp Clin Sao Paulo, Dept Nephrol, Sao Paulo, Brazil.
   [Panajotopolous, Nicolas; Rodrigues, Helcio; Ronda, Carla; Kalil, Jorge] Univ Sao Paulo, Hosp Clin Sao Paulo, Inst Coracao InCor, Immunol Lab, Sao Paulo, Brazil.
   [David, Daisa Ribeiro] Univ Sao Paulo, Hosp Clin Sao Paulo, Div Pathol, Sao Paulo, Brazil.
RP de Castro, MCR (corresponding author), Rua Jose Rodrigues Alves Sobrinho Alves 150-222, Sao Paulo, Brazil.
EM mcrc@usp.br
RI Agena, Fabiana/F-5807-2012; Neto, Elias David/O-3866-2018; Agena,
   Fabiana/C-5819-2015; KALIL, JORGE/C-8029-2012; de castro, maria cristina
   ribeiro/B-6648-2009
OI Agena, Fabiana/0000-0002-4526-4857; KALIL, JORGE/0000-0001-8415-4274; de
   castro, maria cristina ribeiro/0000-0002-6731-8369; Castro, Maria
   Priscila/0000-0002-8803-2896
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This study was sponsored by FAPESP (Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo).
CR Akalin E, 2006, CLIN J AM SOC NEPHRO, V1, P433, DOI 10.2215/CJN.01751105
   Bartel G, 2008, AM J TRANSPLANT, V8, P2652, DOI 10.1111/j.1600-6143.2008.02428.x
   Bums JM, 2008, AM J TRANSPLANT, V8, P2684, DOI 10.1111/j.1600-6143.2008.02441.x
   Cardarelli F, 2005, TRANSPLANT INT, V18, P532, DOI 10.1111/j.1432-2277.2005.00085.x
   Collins AB, 1999, J AM SOC NEPHROL, V10, P2208
   David-Neto E, 2007, TRANSPLANTATION, V84, P1391, DOI 10.1097/01.tp.0000288807.52520.5e
   David-Neto E, 2012, CLINICS, V67, P355, DOI 10.6061/clinics/2012(04)09
   Everly MJ, 2009, HUM IMMUNOL, V70, P655, DOI 10.1016/j.humimm.2009.04.019
   Gill JS, 2010, TRANSPLANTATION, V89, P178, DOI 10.1097/TP.0b013e3181c3503e
   Gombos P, 2013, AM J TRANSPLANT, V13, P2075, DOI 10.1111/ajt.12332
   Hourmant M, 2005, J AM SOC NEPHROL, V16, P2804, DOI 10.1681/ASN.2004121130
   KAO KJ, 1993, TRANSPLANTATION, V55, P192, DOI 10.1097/00007890-199301000-00036
   Kimball PM, 2011, KIDNEY INT, V79, P1131, DOI 10.1038/ki.2010.556
   Kobayashi T, 2008, TRANSPLANTATION, V85, P1595, DOI 10.1097/TP.0b013e318170f79f
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Mao Q, 2007, AM J TRANSPLANT, V7, P864, DOI 10.1111/j.1600-6143.2006.01711.x
   Minucci PB, 2011, EXP CLIN TRANSPLANT, V9, P381
   Monteiro F, 1997, TRANSPLANTATION, V63, P542, DOI 10.1097/00007890-199702270-00010
   Nickeleit V, 2002, J AM SOC NEPHROL, V13, P242
   Ozawa M, 2007, Clin Transpl, P255
   Pei R, 1999, HUM IMMUNOL, V60, P1293, DOI 10.1016/S0198-8859(99)00121-4
   Piazza Antonina, 2006, Clin Transpl, P323
   Racusen LC, 2003, AM J TRANSPLANT, V3, P708, DOI 10.1034/j.1600-6143.2003.00072.x
   Solez K, 2007, AM J TRANSPLANT, V7, P518, DOI 10.1111/j.1600-6143.2006.01688.x
   Stegall MD, 2009, AM J TRANSPLANT, V9, P998, DOI 10.1111/j.1600-6143.2009.02612.x
   Susal C, 2013, TRANSFUS MED HEMOTH, V40, P190, DOI 10.1159/000351314
   Susal C, 2009, HUM IMMUNOL, V70, P569, DOI 10.1016/j.humimm.2009.04.013
   Takemoto SK, 2004, AM J TRANSPLANT, V4, P1033, DOI 10.1111/j.1600-6143.2004.00500.x
   Terasaki PI, 2007, AM J TRANSPLANT, V7, P408, DOI 10.1111/j.1600-6143.2006.01644.x
   Terasaki PI, 2008, TRANSPLANTATION, V86, P377, DOI 10.1097/TP.0b013e31817c4cb8
   Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x
   van den Berg-Loonen Ella M, 2006, Clin Transpl, P305
   Zhang QH, 2005, TRANSPLANTATION, V79, P591, DOI 10.1097/01.TP.0000155246.52249.AC
NR 33
TC 8
Z9 9
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD NOV
PY 2014
VL 28
IS 11
BP 1234
EP 1243
DI 10.1111/ctr.12451
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AT3SX
UT WOS:000344854900003
PM 25142061
DA 2020-11-26
ER

PT J
AU Aun, MV
   Blanca, M
   Garro, LS
   Ribeiro, MR
   Kalil, J
   Motta, AA
   Castells, M
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Blanca, Miguel
   Garro, Laila Sabino
   Ribeiro, Marisa Rosimeire
   Kalil, Jorge
   Motta, Antonio Abilio
   Castells, Mariana
   Giavina-Bianchi, Pedro
TI Drug-induced anaphylaxis in children: Nonsteroidal anti-inflammatory
   drugs and drug provocation test REPLY
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID HYPERSENSITIVITY REACTIONS; DIAGNOSIS
C1 [Aun, Marcelo Vivolo; Garro, Laila Sabino; Ribeiro, Marisa Rosimeire; Kalil, Jorge; Motta, Antonio Abilio; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Allergy & Clin Immunol, BR-05403900 Sao Paulo, SP, Brazil.
   [Blanca, Miguel] Hosp Civil, Allergy Serv, Malaga, Spain.
   [Castells, Mariana] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Av Dr Eneas de Carvalho Aguiar,255,8 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com; pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
CR Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P826, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
   Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044
   Ensina LF, 2014, J ALLERGY CLIN IMMUN, V2, P822
   Faria E, 2014, J INVEST ALLERG CLIN, V24, P40
   Kowalski ML, 1999, ALLERGY ASTHMA PROC, V20, P347, DOI 10.2500/108854199778251799
   Ribeiro-Vaz I, 2013, EUR J CLIN PHARMACOL, V69, P673, DOI 10.1007/s00228-012-1376-5
   Torres MJ, 2014, IMMUNOL ALLERGY CLIN, V34, P507, DOI 10.1016/j.iac.2014.04.001
   Zambonino MA, 2013, PEDIAT ALLERG IMM-UK, V24, P151, DOI 10.1111/pai.12039
NR 8
TC 68
Z9 71
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD NOV-DEC
PY 2014
VL 2
IS 6
BP 826
EP 826
DI 10.1016/j.jaip.2014.08.015
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7HW
UT WOS:000354207600040
PM 25017529
DA 2020-11-26
ER

PT J
AU Luque, MC
   Santos, CC
   Mairena, EC
   Wilkinson, P
   Boucher, G
   Segurado, AC
   Fonseca, LA
   Sabino, E
   Kalil, JE
   Cunha-Neto, E
AF Luque, Maria Carolina
   Santos, Camila C.
   Mairena, Eliane C.
   Wilkinson, Peter
   Boucher, Genevieve
   Segurado, Aluisio C.
   Fonseca, Luiz A.
   Sabino, Ester
   Kalil, Jorge E.
   Cunha-Neto, Edecio
TI Gene expression profile in long-term non progressor HIV infected
   patients: In search of potential resistance factors
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE HIV; Long-term nonprogressors; Gene expression profiling; CD4+T cells;
   Cell survival
ID CD8(+) T-CELLS; MHC CLASS-II; SYSTEMS BIOLOGY; HLA-B; NONPROGRESSOR;
   KINASE; PATHOGENESIS; ACTIVATION; CARCINOMA; SEQUENCES
AB Long-term non-progressors (LTNP) represent a minority (1-5%) of HIV-infected individuals characterized by documented infection for more than 7-10 years, a stable CD4+ T cell count over 500/mm(3) and low viremia in the absence of antiretroviral treatment. Protective factors described so far such as the CCR5delta32 deletion, protective HLA alleles, or defective viruses fail to fully explain the partial protection phenotype. The existence of additional host resistance mechanisms in LTNP patients was investigated here using a whole human genome microarray study comparing gene expression profiles of unstimulated peripheral blood mononuclear cells from LTNP patients, HIV-1 infected patients under antiretroviral therapy with CD4+ T cell levels above 500/mm(3) (ST), as well as healthy individuals. Genes that were up- or downregulated exclusively in LTNP, ST or in both groups in comparison to controls were identified and classified in functional categories using Ingenuity Pathway Analysis. ST and LTNP patient groups revealed distinct genetic profiles, regarding gene number in each category and up- or downregulation of specific genes, which could have a bearing on the outcome of each group. We selected some relevant genes to validate the differential expression using quantitative real-time qRT-PCR. Among others, we found several genes related to the canonical Wnt/beta-catenin signaling pathway. Our results identify new possible host genes and molecules that could be involved in the mechanisms leading to the slower progression to AIDS and sustained CD4+ T cell counts that is peculiar to LTNP patients. (C) 2014 Published by Elsevier Ltd.
C1 [Luque, Maria Carolina; Fonseca, Luiz A.; Kalil, Jorge E.; Cunha-Neto, Edecio] Univ Sao Paulo, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Santos, Camila C.; Mairena, Eliane C.; Kalil, Jorge E.; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, HCFMUSP, Heart Inst Incor, Sao Paulo, Brazil.
   [Luque, Maria Carolina; Mairena, Eliane C.; Kalil, Jorge E.; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Segurado, Aluisio C.; Sabino, Ester] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Wilkinson, Peter] Vaccine & Gene Therapy Inst, Collaborat Genom Ctr, Port St Lucie, FL USA.
   [Boucher, Genevieve] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM edecunha@usp.br
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Fonseca, Luiz
   Augusto M/F-9344-2012; Segurado, Aluisio C/K-2229-2012; Sabino, Ester
   Cerdeira/F-7750-2010
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Segurado, Aluisio C/0000-0002-6311-8036;
   Sabino, Ester Cerdeira/0000-0003-2623-5126; Boucher,
   Genevieve/0000-0001-6389-9007
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Bottarel F, 2001, Hematol J, V2, P220, DOI 10.1038/sj.thj.6200105
   Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004
   Burgener Adam, 2010, Curr HIV/AIDS Rep, V7, P53, DOI 10.1007/s11904-010-0039-3
   D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Dyer WB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-112
   Hadi K, 2014, J GEN VIROL, V95, P700, DOI 10.1099/vir.0.059576-0
   Harari A, 2007, P NATL ACAD SCI USA, V104, P16233, DOI 10.1073/pnas.0707570104
   Harman AN, 2009, BLOOD, V114, P85, DOI 10.1182/blood-2008-12-194845
   Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x
   Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06
   Kaur Ravinder, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P146, DOI 10.1177/1545109710397767
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Lafeuillade A, 1996, INFECTION, V24, P245, DOI 10.1007/BF01781103
   Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789
   Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200
   Mao CD, 2011, CRIT REV EUKAR GENE, V21, P207, DOI 10.1615/CritRevEukarGeneExpr.v21.i3.10
   Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320
   Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883
   Mehla R, 2012, CURR HIV-AIDS REP, V9, P34, DOI 10.1007/s11904-011-0100-x
   Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654
   O'Brien SJ, 2004, NAT GENET, V36, P565, DOI 10.1038/ng1369
   Pancre V, 2007, VACCINE, V25, P5927, DOI 10.1016/j.vaccine.2007.05.038
   PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.iy.13.040195.002415
   Peretz Y, 2012, CURR OPIN HIV AIDS, V7, P17, DOI 10.1097/COH.0b013e32834ddb0e
   Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659
   Petrovas C, 2004, CURR HIV RES, V2, P153, DOI 10.2174/1570162043484960
   Saifuddin M, 2000, CLIN EXP IMMUNOL, V121, P324, DOI 10.1046/j.1365-2249.2000.01290.x
   Saito-Diaz K, 2013, GROWTH FACTORS, V31, P1, DOI 10.3109/08977194.2012.752737
   Salgado M, 2011, VIROLOGY, V411, P103, DOI 10.1016/j.virol.2010.12.037
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Schwartz DH, 1996, IMMUNOL LETT, V51, P3, DOI 10.1016/0165-2478(96)02547-3
   Sekaly R, 2012, CURR OPIN HIV AIDS, V7, P1, DOI 10.1097/COH.0b013e32834e0667
   Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120
   Visco-Comandini U, 1998, J Hum Virol, V1, P320
   Wang XH, 2011, HEPATO-GASTROENTEROL, V58, P487
   Wu JQ, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-18
   Yan JY, 2013, J VIROL, V87, P5170, DOI 10.1128/JVI.02379-12
   Yang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053939
NR 44
TC 8
Z9 10
U1 0
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD NOV
PY 2014
VL 62
IS 1
BP 63
EP 70
DI 10.1016/j.molimm.2014.05.016
PG 8
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA AQ1NI
UT WOS:000342547700008
PM 24967879
DA 2020-11-26
ER

PT J
AU Bossa, AS
   Salemi, VMC
   Ribeiro, SP
   Rosa, DS
   Ferreira, LRP
   Ferreira, SC
   Nishiya, AS
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Bossa, Aline S.
   Salemi, Vera M. C.
   Ribeiro, Susan P.
   Rosa, Daniela S.
   Pinto Ferreira, Ludmila Rodrigues
   Ferreira, Suzete C.
   Nishiya, Anna Shoko
   Mady, Charles
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Plasma Cytokine Profile in Tropical Endomyocardial Fibrosis:
   Predominance of TNF-a, IL-4 and IL-10
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEART-FAILURE; NECROSIS-FACTOR-ALPHA; DISEASE; EOSINOPHILIA;
   ACTIVATION; CARDIOMYOPATHY; INTERLEUKIN-10; ASSOCIATION; MORTALITY
AB Background: The participation of immune/inflammatory mechanisms in the pathogenesis of tropical endomyocardial fibrosis (EMF) has been suggested by the finding of early blood and myocardial eosinophilia. However, the inflammatory activation status of late-stage EMF patients is still unknown.
   Methodology/Principal findings: We evaluated pro- and anti-inflammatory cytokine levels in plasma samples from late stage EMF patients. Cytokine levels of Tumor Necrosis Factor (TNF)-alpha, Interferon (IFN)-gamma, Interleukin (IL)-2, IL-4, IL-6, and IL-10 were assayed in plasma samples from 27 EMF patients and compared with those of healthy control subjects. All EMF patients displayed detectable plasma levels of at least one of the cytokines tested. We found that TNF-alpha, IL-6, IL-4, and IL-10 were each detected in at least 74% of tested sera, and plasma levels of IL-10, IL-4, and TNF-alpha were significantly higher than those of controls. Plasma levels of such cytokines positively correlated with each other.
   Conclusions/Significance: The mixed pro-and anti-inflammatory/Th2circulating cytokine profile in EMF is consistent with the presence of a persistent inflammatory stimulus. On the other hand, the detection of increased levels of TNF-alpha may be secondary to the cardiovascular involvement observed in these patients, whereas IL-4 and IL-10 may have been upregulated as a homeostatic mechanism to buffer both production and deleterious cardiovascular effects of pro-inflammatory cytokines. Further studies might establish whether these findings play a role in disease pathogenesis.
C1 [Bossa, Aline S.; Pinto Ferreira, Ludmila Rodrigues; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Inst Heart InCor, Immunol Lab, Sao Paulo, Brazil.
   [Bossa, Aline S.; Ribeiro, Susan P.; Pinto Ferreira, Ludmila Rodrigues; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Salemi, Vera M. C.; Ferreira, Suzete C.; Mady, Charles] Univ Sao Paulo, Sch Med, Inst Heart InCor, Cardiomyopathy Unit, Sao Paulo, Brazil.
   [Nishiya, Anna Shoko] ProSangue Fdn, Sao Paulo, Brazil.
   [Nishiya, Anna Shoko] Inst Investigat Immunol, INCT, Sao Paulo, Brazil.
   [Rosa, Daniela S.] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Div Immunol, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart InCor, Immunol Lab, Sao Paulo, Brazil.
EM edecunha@usp.br
RI Salemi, Vera/AAY-5024-2020; Mady, Charles/C-8870-2012; Ferreira, Ludmila
   Rodrigues Pinto/B-4955-2015; Salemi, Vera MC/C-9104-2013; Ferreira,
   Ludmila/C-4100-2012; Cunha-Neto, Edecio/B-4157-2009; Nishiya,
   Anna/Q-8156-2016; KALIL, JORGE/C-8029-2012; Rosa, Daniela S/D-2190-2012
OI Mady, Charles/0000-0002-8838-199X; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; Salemi, Vera MC/0000-0002-7152-1810;
   Ferreira, Ludmila/0000-0001-9944-6691; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274; Rosa,
   Daniela S/0000-0003-4536-891X
FU Brazilian Council for Scientific and Technological Development -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Sao Paulo State
   Research Funding Agency - FAPESP fellowship
FX This research was supported by the Brazilian Council for Scientific and
   Technological Development - CNPq and the Sao Paulo State Research
   Funding Agency - FAPESP. ASB is recipient of a Sao Paulo State Research
   Funding Agency - FAPESP fellowship. ECN and JK are recipients of
   Brazilian Council for Scientific and Technological Development - CNPq
   productivity awards. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amir O, 2010, ISR MED ASSOC J, V12, P158
   Andy JJ, 1998, ACTA TROP, V69, P127, DOI 10.1016/S0001-706X(97)00125-3
   Anker SD, 2004, HEART, V90, P464, DOI 10.1136/hrt.2002.007005
   Aukrust P, 2005, ANN MED, V37, P74, DOI 10.1080/07853890510007232
   BROCKING.IF, 1972, POSTGRAD MED J, V48, P740, DOI 10.1136/pgmj.48.566.740
   DAVIES J N P, 1948, East Afr Med J, V25, P454
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Gage JR, 2004, NEUROIMMUNOMODULAT, V11, P173, DOI 10.1159/000076766
   Guinjoan SM, 2009, WORLD J BIOL PSYCHIA, V10, P913, DOI 10.1080/15622970802432153
   Haudek SB, 2007, J CLIN INVEST, V117, P2692, DOI 10.1172/JCI29134
   Iglezias SD, 2008, VIRCHOWS ARCH, V453, P233, DOI 10.1007/s00428-008-0652-3
   IVE FA, 1967, Q J MED, V36, P495
   MacDonald AS, 2002, INFECT IMMUN, V70, P427, DOI 10.1128/IAI.70.2.427-433.2002
   Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249
   Mehra VC, 2005, J LEUKOCYTE BIOL, V78, P805, DOI 10.1189/jlb.0405182
   Mocelin AO, 2005, EUR J HEART FAIL, V7, P869, DOI 10.1016/j.ejheart.2004.10.014
   Muller-Werdan U, 1998, EUR CYTOKINE NETW, V9, P689
   Orus J, 2000, J HEART LUNG TRANSPL, V19, P419, DOI 10.1016/S1053-2498(00)00083-8
   PATEL AK, 1977, BRIT HEART J, V39, P238
   Rauchhaus M, 2000, CIRCULATION, V102, P3060
   ROBERTS WC, 1969, AM J MED, V46, P28, DOI 10.1016/0002-9343(69)90055-2
   Salemi VMC, 2011, CIRC-CARDIOVASC IMAG, V4, P304, DOI 10.1161/CIRCIMAGING.110.950675
   Salemi VM, 2009, EUR J ECHOCARDIOGR, V10, P400, DOI 10.1093/ejechocard/jen297
   Salemi VMC, 2004, ARTIF ORGANS, V28, P343, DOI 10.1111/j.1525-1594.2004.47352.x
   Sato Y, 1999, CLIN CARDIOL, V22, P811, DOI 10.1002/clc.4960221211
   Satoh Mamoru, 2008, Curr Heart Fail Rep, V5, P69, DOI 10.1007/s11897-008-0012-2
   Schopf LR, 2002, J IMMUNOL, V168, P2383, DOI 10.4049/jimmunol.168.5.2383
   Sliwa K, 2010, CLIN RES CARDIOL, V99, P65, DOI 10.1007/s00392-009-0094-1
   Sun L, 2011, AM J PHYSIOL-LUNG C, V300, pL341, DOI 10.1152/ajplung.00122.2010
   TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7
   Yamaoka M, 1999, JPN CIRC J, V63, P951, DOI 10.1253/jcj.63.951
   Yu LP, 2012, PARASITOL RES, V110, P1547, DOI 10.1007/s00436-011-2661-4
NR 32
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2014
VL 9
IS 10
AR e108984
DI 10.1371/journal.pone.0108984
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6ZS
UT WOS:000343730400039
PM 25303100
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Lima, FMS
   Mendonca, LO
   Kokron, CM
   Kalil, J
   Cordova, PT
   Barros, MT
AF Lima, F. M. S.
   Mendonca, L. O.
   Kokron, C. M.
   Kalil, J.
   Cordova, P. T.
   Barros, M. T.
TI Role of Autoimmunity in Hepatitis C Virus Infection: A Case Report and a
   Brief Review of Literature
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 16th Biennial Meeting of the European-Society-for-Immunodeficiencies
CY OCT 29-NOV 01, 2014
CL Prague, CZECH REPUBLIC
SP European Soc Immunodeficiencies
C1 [Lima, F. M. S.; Mendonca, L. O.; Kokron, C. M.; Kalil, J.; Cordova, P. T.; Barros, M. T.] FMUSP, Hosp Clin, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2014
VL 34
SU 2
MA ESID-0610
BP S217
EP S217
PG 1
WC Immunology
SC Immunology
GA AY1ZS
UT WOS:000347389100156
DA 2020-11-26
ER

PT J
AU Mendonca, L
   Mascarenhas, F
   Cohon, A
   Kokron, C
   Grecco, O
   Kalil, J
   Barros, M
AF Mendonca, L.
   Mascarenhas, F.
   Cohon, A.
   Kokron, C.
   Grecco, O.
   Kalil, J.
   Barros, M.
TI Descriptive Review of Clinical Data from 186 Records of Outpatients with
   IgA Deficiency Accompanied at a Quaternary Hospital in Brazil
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 16th Biennial Meeting of the European-Society-for-Immunodeficiencies
CY OCT 29-NOV 01, 2014
CL Prague, CZECH REPUBLIC
SP European Soc Immunodeficiencies
C1 [Mendonca, L.; Mascarenhas, F.; Cohon, A.; Kokron, C.; Grecco, O.; Kalil, J.; Barros, M.] HCFMUSP, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2014
VL 34
SU 2
MA ESID-0331
BP S415
EP S415
PG 1
WC Immunology
SC Immunology
GA AY1ZS
UT WOS:000347389100595
DA 2020-11-26
ER

PT J
AU Mendonca, L
   Mascarenhas, F
   Kokron, C
   Kalil, J
   Barros, M
AF Mendonca, L.
   Mascarenhas, F.
   Kokron, C.
   Kalil, J.
   Barros, M.
TI Complement Activation in a Group of Patients with IGG 4 Related Disease
   at Hospital Das Clincas - University of Sao Paulo
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 16th Biennial Meeting of the European-Society-for-Immunodeficiencies
CY OCT 29-NOV 01, 2014
CL Prague, CZECH REPUBLIC
SP European Soc Immunodeficiencies
C1 [Mendonca, L.; Mascarenhas, F.; Kokron, C.; Kalil, J.; Barros, M.] HCFMUSP, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2014
VL 34
SU 2
MA ESID-0336
BP S218
EP S219
PG 2
WC Immunology
SC Immunology
GA AY1ZS
UT WOS:000347389100160
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Ribeiro, S
   Santoro-Rosa, D
   Almeida, R
   Santana, V
   Kalil, J
AF Cunha-Neto, Edecio
   Ribeiro, Susan
   Santoro-Rosa, Daniela
   Almeida, Rafael
   Santana, Vinicius
   Kalil, Jorge
TI Vaccine Antigen Design to Maximize anti-HIV CD4+T-cell Responses: From
   Mice to Non-human Primates
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Symposium on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Cunha-Neto, Edecio; Ribeiro, Susan; Almeida, Rafael; Santana, Vinicius; Kalil, Jorge] Univ Sao Paulo, Sao Paulo, Brazil.
   [Santoro-Rosa, Daniela] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA P41.04
BP A241
EP A241
DI 10.1089/aid.2014.5533.abstract
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774403073
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Oliveira, Ana Karolina B.
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI Invariant natural killer T cells in patients with common variable
   immunodeficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID DEFICIENCY
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
   [Santos, Bianca A. N.; Toledo-Barros, Myrthes; Oliveira, Ana Karolina B.; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Carvalho, Karina I.] Hosp Albert Einstein, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
EM dominic.paquin-proulx@ki.se
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012; Marinho, Ana
   Karolina/C-8395-2017; Carvalho, Karina IL/J-6789-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL,
   JORGE/0000-0001-8415-4274; Marinho, Ana Karolina/0000-0001-9369-8222;
   Carvalho, Karina IL/0000-0002-7763-8139; Sandberg,
   Johan/0000-0002-6275-0750; Moll, Markus/0000-0003-4592-3063; Kallas,
   Esper/0000-0003-2026-6925; Paquin Proulx, Dominic/0000-0003-1407-3414
CR Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Fulcher DA, 2009, CLIN EXP IMMUNOL, V157, P365, DOI 10.1111/j.1365-2249.2009.03973.x
   Gao YF, 2014, J ALLERGY CLIN IMMUN, V133, P1420, DOI 10.1016/j.jaci.2013.10.059
   Paquin-Proulx D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075199
   Paquin-Proulx D, 2013, BLOOD, V121, P4963, DOI 10.1182/blood-2013-04-499442
NR 5
TC 3
Z9 3
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD OCT
PY 2014
VL 134
IS 4
BP 989
EP 990
DI 10.1016/j.jaci.2014.06.039
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA AQ9GC
UT WOS:000343155700038
PM 25159463
DA 2020-11-26
ER

PT J
AU Tanno, LK
   Kerr, DS
   Santos, B
   Talib, LL
   Rodrigues, H
   Gattaz, WF
   Kalil, J
AF Tanno, L. K.
   Kerr, D. S.
   Santos, B.
   Talib, L. L.
   Rodrigues, H.
   Gattaz, W. F.
   Kalil, J.
TI Polymorfism of CYP3A5, CYP2C9 AND CYP2C19 and antiepileptic
   hypersensitivity reactions in Brazilian subjects
SO ALLERGY
LA English
DT Meeting Abstract
CT European-Academy-of-Allergy-and-Clinical-Immunology Congress
CY JUN 07-11, 2014
CL Copenhagen, DENMARK
SP European Acad Allergy & Clin Immunol
C1 [Tanno, L. K.; Kalil, J.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kerr, D. S.; Talib, L. L.] Univ Sao Paulo, LIM 27 Psychiat Inst, Sao Paulo, Brazil.
   [Santos, B.] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil.
   [Rodrigues, H.] Univ Sao Paulo, LIM 19 Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Gattaz, W. F.] Univ Sao Paulo, Inst Psychiat, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012; Gattaz,
   Wagner F/C-4456-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2014
VL 69
SU 99
SI SI
MA 275
BP 133
EP 133
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA AO2HL
UT WOS:000341139400305
DA 2020-11-26
ER

PT J
AU Bruni, FM
   Kalil, J
   Rodrigues, NRD
   Arantes-Costa, FM
   Morato-Castro, FF
AF Bruni, F. M.
   Kalil, J.
   Damaceno Rodrigues, N. R.
   Arantes-Costa, F. M.
   Morato-Castro, F. F.
TI Experimental food allergy: murine model that mimics the food allergen
   natural exposure as a tool to investigate the allergens involved in
   anaphylaxis induced by fruit Carica papaya
SO ALLERGY
LA English
DT Meeting Abstract
CT European-Academy-of-Allergy-and-Clinical-Immunology Congress
CY JUN 07-11, 2014
CL Copenhagen, DENMARK
SP European Acad Allergy & Clin Immunol
C1 [Bruni, F. M.; Kalil, J.; Damaceno Rodrigues, N. R.; Morato-Castro, F. F.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Bruni, F. M.; Kalil, J.; Morato-Castro, F. F.] Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Arantes-Costa, F. M.] Univ Sao Paulo, Sch Med, Lab Expt Therapeut, Sao Paulo, Brazil.
RI Costa, Fernanda Magalhaes A/F-2727-2012; KALIL, JORGE/C-8029-2012;
   Bruni, Fernanda/F-6087-2012
OI KALIL, JORGE/0000-0001-8415-4274; Bruni, Fernanda/0000-0002-9572-2799
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2014
VL 69
SU 99
SI SI
MA 666
BP 266
EP 267
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA AO2HL
UT WOS:000341139400669
DA 2020-11-26
ER

PT J
AU Carvalho, CRF
   Franca-Pinto, A
   Mendes, FAR
   Stelmach, R
   Cukier, A
   Agondi, RC
   Martins, MA
   Saraiva-Romanholo, BM
   Kalil, J
   Giavina-Bianchi, P
AF Carvalho, Celso R. F.
   Franca-Pinto, Andrezza
   Mendes, Felipe A. R.
   Stelmach, Rafael
   Cukier, Alberto
   Agondi, Rosana C.
   Martins, Milton A.
   Saraiva-Romanholo, Beatriz M.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Aerobic training decrease bronchial hyperresponsiveness and systemic
   inflammation in patients with moderate or severe asthma: A randomized
   controlled trial
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Asthma - management; Exercise; Rehabilitation
RI Saraiva-Romanholo, Beatriz M/I-5482-2013; Cukier, Alberto/C-6101-2012;
   stelmach, rafael/AAH-1638-2019
OI Cukier, Alberto/0000-0002-7217-9498; stelmach,
   rafael/0000-0002-5132-1934
NR 0
TC 0
Z9 0
U1 0
U2 2
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP
PY 2014
VL 44
SU 58
MA 1707
PG 4
WC Respiratory System
SC Respiratory System
GA V44XU
UT WOS:000209782500042
DA 2020-11-26
ER

PT J
AU Ferreira, LRP
   Frade, AF
   Santos, RHB
   Teixeira, PC
   Baron, MA
   Navarro, IC
   Benvenuti, LA
   Fiorelli, AI
   Bocchi, EA
   Stolf, NA
   Chevillard, C
   Kalil, J
   Cunha-Neto, E
AF Pinto Ferreira, Ludmila Rodrigues
   Frade, Amanda Farage
   Barros Santos, Ronaldo Honorato
   Teixeira, Priscila Camillo
   Baron, Monique Andrade
   Navarro, Isabela Cunha
   Benvenuti, Luiz Alberto
   Fiorelli, Alfredo Inacio
   Bocchi, Edimar Alcides
   Stolf, Noedir Antonio
   Chevillard, Christophe
   Kalil, Jorge
   Cunha-Neto, Edecio
TI MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are
   dysregulated in Chronic Chagas disease Cardiomyopathy
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Chagas disease; Trypanosoma cruzi; miRNA; Heart
ID HEART-FAILURE; CARDIAC-HYPERTROPHY; EXPRESSION; DYSFUNCTION; BIOMARKERS;
   REGULATOR; CYCLINS
AB Background/methods: Chagas disease is caused by an intracellular parasite, Trypanosoma cruzi, and it is a leading cause of heart failure in Latin America. The main clinical consequence of the infection is the development of a Chronic Chagas disease Cardiomyopathy (CCC), which is characterized by myocarditis, hypertrophy and fibrosis and affects about 30% of infected patients. CCC has a worse prognosis than other cardiomyopathies, like idiopathic dilated cardiomyopathy (DCM). It is well established that myocardial gene expression patterns are altered in CCC, but the molecular mechanisms underlying these differences are not clear. MicroRNAs are recently discovered regulators of gene expression, and are recognized as important factors in heart development and cardiovascular disorders (CD). We analyzed the expression of nine different miRNAs inmyocardial tissue samples of CCC patients in comparison to DCM patients and samples from heart transplant donors. Using the results of a cDNA microarray database on CCC and DCM myocardium, signaling networks were built and nodal molecules were identified. Results: We observed that five miRNAs were significantly altered in CCC and three in DCM; importantly, three miRNAs were significantly reduced in CCC as compared to DCM. We observed that multiple gene targets of the differentially expressed miRNAs showed a concordant inverse expression in CCC. Significantly, most gene targets and involved networks belong to crucial disease-related signaling pathways. Conclusion: These results suggest that miRNAs may play a major role in the regulation of gene expression in CCC pathogenesis, with potential implication as diagnostic and prognostic tools. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Pinto Ferreira, Ludmila Rodrigues; Frade, Amanda Farage; Teixeira, Priscila Camillo; Baron, Monique Andrade; Navarro, Isabela Cunha; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Frade, Amanda Farage; Teixeira, Priscila Camillo; Baron, Monique Andrade; Navarro, Isabela Cunha; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Frade, Amanda Farage; Teixeira, Priscila Camillo; Baron, Monique Andrade; Navarro, Isabela Cunha; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, BR-05403001 Sao Paulo, Brazil.
   [Barros Santos, Ronaldo Honorato; Fiorelli, Alfredo Inacio; Bocchi, Edimar Alcides; Stolf, Noedir Antonio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Div Surg, Sao Paulo, Brazil.
   [Benvenuti, Luiz Alberto] Univ Sao Paulo, Sch Med, Heart Inst InCor, Div Pathol, Sao Paulo, Brazil.
   [Chevillard, Christophe] Aix Marseille Univ, Fac Med, INSERM, U906, Marseille, France.
RP Cunha-Neto, E (corresponding author), Heart Inst Incor, Immunol Lab, Ave Dr Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403900 Sao Paulo, Brazil.
EM edecunha@usp.br
RI Ferreira, Ludmila Rodrigues Pinto/B-4955-2015; Cunha-Neto,
   Edecio/B-4157-2009; Frade, Amanda F/O-3322-2017; KALIL,
   JORGE/C-8029-2012; Ferreira, Ludmila/C-4100-2012; chevillard,
   christophe/A-7087-2015; Navarro, Isabela Cunha/V-7182-2017
OI Ferreira, Ludmila Rodrigues Pinto/0000-0001-9944-6691; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Frade, Amanda F/0000-0002-9004-8811; KALIL,
   JORGE/0000-0001-8415-4274; Ferreira, Ludmila/0000-0001-9944-6691;
   chevillard, christophe/0000-0002-5269-8813; Navarro, Isabela
   Cunha/0000-0002-6844-2361; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
FU Brazilian Council for Scientific and Technological
   Development-CNPqNational Council for Scientific and Technological
   Development (CNPq) [57.3879/2008-7]; Sao Paulo State Research Funding
   Agency-FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2008/57881-0, 2012/08107-6, 2013/50302-3]; Institut National
   de la Sante et de la Recherche Medicale (INSERM)Institut National de la
   Sante et de la Recherche Medicale (Inserm); Aix-Marseille University
   (Direction des Relations Internationales); USP-COFECUB program; ARCUS II
   PACA Bresil program; CNPq fellowshipNational Council for Scientific and
   Technological Development (CNPq); Brazilian Council for Scientific and
   Technological Development-CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPESP fellowshipFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); French ANR
   (Br-Fr-CHAGAS)French National Research Agency (ANR); Brazilian FAPESP
   agencyFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   French consulate in Brazil; University of Sao Paulo (USP)
FX This research was supported by Brazilian Council for Scientific and
   Technological Development-CNPq (57.3879/2008-7) and the Sao Paulo State
   Research Funding Agency-FAPESP (grant numbers 2008/57881-0;
   2012/08107-6; 2013/50302-3). Authors also received financial assistance
   from the Institut National de la Sante et de la Recherche Medicale
   (INSERM), the Aix-Marseille University (Direction des Relations
   Internationales), USP-COFECUB program, and the ARCUS II PACA Bresil
   program. LRPF is recipient of a CNPq fellowship. ECN and JK are
   recipients of the Brazilian Council for Scientific and Technological
   Development-CNPq productivity awards, AFF, MAB, ICN are recipients of a
   FAPESP fellowship. ECN and CC are recipients of an international program
   funded by both, the French ANR (Br-Fr-CHAGAS) and the Brazilian FAPESP
   agencies. CC was a recipient of a temporary professor position supported
   by the French consulate in Brazil and the University of Sao Paulo (USP).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Ambros V, 2011, CURR OPIN GENET DEV, V21, P511, DOI 10.1016/j.gde.2011.04.003
   Bhaskaran M, 2014, VET PATHOL, V51, P759, DOI 10.1177/0300985813502820
   Bocchi EA, 2009, HEART, V95, P181, DOI 10.1136/hrt.2008.151225
   Busk PK, 2003, CELL CYCLE, V2, P91, DOI 10.4161/cc.2.2.298
   Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154
   Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582
   Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242
   Cortez J, 2012, WORLD J CARDIOL, V4, P234, DOI 10.4330/wjc.v4.i7.234
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Elzenaar I, 2013, CLIN PHARMACOL THER, V94, P480, DOI 10.1038/clpt.2013.138
   Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Glass C, 2011, MOL CELL BIOCHEM, V357, P135, DOI 10.1007/s11010-011-0883-5
   Hagiwara S, 2014, CURR PHARM DESIGN, V20, P2347, DOI 10.2174/13816128113199990495
   Hotchkiss A, 2012, CAN J PHYSIOL PHARM, V90, P1197, DOI [10.1139/y2012-037, 10.1139/Y2012-037]
   Hua YN, 2012, J CELL MOL MED, V16, P83, DOI 10.1111/j.1582-4934.2011.01307.x
   Kang MJ, 1997, MOL CELLS, V7, P360
   Karp X, 2005, SCIENCE, V310, P1288, DOI 10.1126/science.1121566
   Kumarswamy R, 2012, EUR HEART J, V33, P1067, DOI 10.1093/eurheartj/ehs043
   Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974
   Matsui T, 2006, AM J PHYSIOL-ENDOC M, V290, pE789, DOI 10.1152/ajpendo.00564.2004
   Nagajyothi F, 2006, CELL CYCLE, V5, P107, DOI 10.4161/cc.5.1.2284
   Nascimento CAS, 2013, J AM SOC ECHOCARDIOG, V26, P1424, DOI 10.1016/j.echo.2013.08.018
   Predmore JM, 2010, CIRCULATION, V121, P997, DOI 10.1161/CIRCULATIONAHA.109.904557
   Schlossarek S, 2011, CURR OPIN CARDIOL, V26, P190, DOI 10.1097/HCO.0b013e32834598fe
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Vogel B, 2013, EUR HEART J, V34, P2812, DOI 10.1093/eurheartj/eht256
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
   Yu XC, 2010, CARDIOVASC RES, V85, P312, DOI 10.1093/cvr/cvp309
   Zhang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041478
NR 31
TC 44
Z9 47
U1 1
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD AUG 20
PY 2014
VL 175
IS 3
BP 409
EP 417
DI 10.1016/j.ijcard.2014.05.019
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AN0DC
UT WOS:000340251600008
PM 24910366
DA 2020-11-26
ER

PT J
AU De Amicis, KM
   de Barros, SF
   Alencar, RE
   Postol, E
   Martins, CD
   Arcuri, HA
   Goulart, C
   Kalil, J
   Guilherme, L
AF De Amicis, Karine M.
   de Barros, Samar Freschi
   Alencar, Raquel E.
   Postol, Edilberto
   Martins, Carlo de Oliveira
   Arcuri, Helen Andrade
   Goulart, Cibelly
   Kalil, Jorge
   Guilherme, Luiza
TI Analysis of the coverage capacity of the StreptInCor candidate vaccine
   against Streptococcus pyogenes
SO VACCINE
LA English
DT Article
DE Streptococcus pyogenes; Vaccine; Rheumatic fever; Immunization coverage;
   Immune response
ID RHEUMATIC HEART-DISEASE; PROTEINS; PATHOGENESIS; INFECTIONS; FEVER
AB Streptococcus pyogenes is responsible for infections as pharyngitis, sepsis, necrotizing fasciitis and streptococcal toxic shock syndrome. The M protein is the major bacterial antigen and consists of both polymorphic N-terminal portion and a conserved region. In the present study, we analyzed the in vitro ability of StreptInCor a C-terminal candidate vaccine against S. pyogenes to induce antibodies to neutralize/opsonize the most common S. pyogenes strains in Sao Paulo by examining the recognition by sera from StreptInCor immunized mice. We also evaluated the presence of cross-reactive antibodies against human heart valve tissue. Anti-StreptInCor antibodies were able to neutralize/opsonize at least 5 strains, showing that immunization with StreptInCor is effective against several S. pyogenes strains and can prevent infection and subsequent sequelae without causing autoimmune reactions. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [De Amicis, Karine M.; de Barros, Samar Freschi; Alencar, Raquel E.; Postol, Edilberto; Martins, Carlo de Oliveira; Arcuri, Helen Andrade; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [De Amicis, Karine M.; de Barros, Samar Freschi; Alencar, Raquel E.; Postol, Edilberto; Martins, Carlo de Oliveira; Arcuri, Helen Andrade; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Natl Inst Sci & Technol, Immunol Invest Inst, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Goulart, Cibelly] Butantan Inst, Ctr Biotechnol, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), HC FMUSP, Inst Coracao, Lab Imunol, Av Dr Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Goulart, Cibelly/B-6666-2014; Martins, Carlo/D-4008-2018; De Amicis
   Lima, Karine/D-3890-2013; de Barros, Samar Freschi/Q-4970-2018; KALIL,
   JORGE/C-8029-2012
OI Martins, Carlo/0000-0003-1287-8884; De Amicis Lima,
   Karine/0000-0002-9936-2436; KALIL, JORGE/0000-0001-8415-4274; Goulart,
   Cibelly/0000-0003-2981-1934
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
FX This work was supported by grants from "Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)". Karine De Amicis's benefits were
   supported by "Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)".
CR Barbosa PJB, 2009, ARQ BRAS CARDIOL, V93, P1
   Bessen DE, 2000, J INFECT DIS, V182, P1109, DOI 10.1086/315842
   Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045
   Dale JB, 2013, VACCINE, V31, P1576, DOI 10.1016/j.vaccine.2013.01.019
   Goulart C, 2011, VACCINE, V29, P1634, DOI 10.1016/j.vaccine.2010.12.074
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
   Guilherme L, 2011, ANN PEDIAT CARDIOL, V4, P13, DOI 10.4103/0974-2069.79617
   Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2011, UPDATE GLOMERULOPATH
   Guilherme L, 2011, S PYOGENES INFECT IT, P468
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   McGregor KF, 2004, J BACTERIOL, V186, P4285, DOI 10.1128/JB.186.13.4285-4294.2004
   McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
   McMillan DJ, 2012, AUTHORS CLIN MICROBI, V5, P222
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   Narula J, 1999, RHEUMATIC FEVER
   Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
   Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
   Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
   Smeesters PR, 2010, TRENDS MICROBIOL, V18, P275, DOI 10.1016/j.tim.2010.02.007
   Smeesters PR, 2009, EXPERT REV VACCINES, V8, P1705, DOI [10.1586/erv.09.133, 10.1586/ERV.09.133]
   Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
   Steer AC, 2013, PEDIATR INFECT DIS J, V32, P180, DOI 10.1097/INF.0b013e318281da11
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
   Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
   Tartof SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-327
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
NR 34
TC 17
Z9 18
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 7
PY 2014
VL 32
IS 32
BP 4104
EP 4110
DI 10.1016/j.vaccine.2013.08.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AL5AW
UT WOS:000339146900014
PM 23994376
DA 2020-11-26
ER

PT J
AU Aun, MV
   Blanca, M
   Garro, LS
   Ribeiro, MR
   Kalil, J
   Motta, AA
   Castells, M
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Blanca, Miguel
   Garro, Laila Sabino
   Ribeiro, Marisa Rosimeire
   Kalil, Jorge
   Motta, Antonio Abilio
   Castells, Mariana
   Giavina-Bianchi, Pedro
TI Nonsteroidal Anti-Inflammatory Drugs are Major Causes of Drug-Induced
   Anaphylaxis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Anaphylaxis; Hypertensively reaction; Nonsteroidal anti-inflammatory
   drugs; Adverse drug reaction; Epinephrine; IgE mediated
ID WORLD-ALLERGY-ORGANIZATION; HYPERSENSITIVITY REACTIONS; PROVOCATION
   TESTS; BETA-LACTAMS; DIAGNOSIS; GUIDELINES; MANAGEMENT; PENICILLINS;
   ANESTHESIA; PATTERNS
AB BACKGROUND: Drugs are responsible for 40% to 60% of anaphylactic reactions treated in the emergency department. A global research agenda to address uncertainties in anaphylaxis includes studies that identify factors associated with morbidity and mortality.
   OBJECTIVE: The present study investigated drug-induced anaphylaxis, etiologies, aggravating factors, and treatment.
   METHODS: A total of 806 patients with adverse drug reactions were screened, and those who had a clinical diagnosis of anaphylaxis were included in the study. Clinical and demographic characteristics of anaphylaxis were described, including etiologies, pathophysiologic mechanisms involved in the reactions, and a personal history of atopy and asthma. Factors associated with disease severity also were identified.
   RESULTS: Anaphylaxis was diagnosed in 117 patients (14.5%). The etiologies were defined in 76% of the cases, nonsteroidal anti-inflammatory drugs being the most frequent. Seventy-eight patients (66.7%) reported a previous reaction to the drug involved in the current reaction or to a drug from the same class and/or group. Epinephrine was used to treat 34.2% of patients who presented with anaphylaxis, and 40.8% of those with anaphylactic reactions with cardiovascular involvement. IgE-mediated reactions were associated with greater severity, manifested by the rates of cardiovascular dysfunction, hospitalization, and use of epinephrine.
   CONCLUSIONS: The prevalence of anaphylaxis is high in patients who seek medical assistance for drug reactions, but its diagnosis is missed in emergency services, and adrenaline is underused. Drugs were prescribed to many patients despite a history of previous reaction. Nonsteroidal anti-inflammatory drugs were implicated in most cases of anaphylaxis induced by drugs, and IgE-mediated reactions were less frequent but more severe. (C) 2014 American Academy of Allergy, Asthma & Immunology
C1 [Aun, Marcelo Vivolo; Garro, Laila Sabino; Ribeiro, Marisa Rosimeire; Kalil, Jorge; Motta, Antonio Abilio; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Clin Immunol & Allergy, BR-05403900 Sao Paulo, SP, Brazil.
   [Blanca, Miguel] Hosp Civil, Allergy Serv, Malaga, Spain.
   [Castells, Mariana] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Av Dr Eneas de Carvalho Aguiar 255,8 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
FU MerckMerck & Company; SanofiSanofi-Aventis; National Institutes of
   Health Desensitization
FX M. Castells has received consultancy fees from Merck and Sanofi; is
   employed by Brigham and Women's Hospital; has a pending grant from
   National Institutes of Health Desensitization; has received royalties
   from UpToDate; has received travel support from the American Academy of
   Allergy, Asthma & Immunology Board of Directors. The rest of the authors
   declare that they have no relevant conflicts of interest.
CR Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x
   Antunez C, 2006, CURR PHARM DESIGN, V12, P3327, DOI 10.2174/138161206778194042
   Antunez C, 2006, ALLERGY, V61, P940, DOI 10.1111/j.1398-9995.2006.01120.x
   Aun MV, 2011, ALLERGY ASTHMA PROC, V32, P301, DOI 10.2500/aap.2011.32.3450
   Beyer K, 2012, ALLERGY, V67, P1451, DOI 10.1111/all.12012
   Blanca-Lopez N, 2013, CLIN EXP ALLERGY, V43, P85, DOI 10.1111/cea.12013
   Campo P, 2013, ALLERGY, V68, P1001, DOI 10.1111/all.12187
   Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060
   Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x
   Dona I, 2012, J INVEST ALLERG CLIN, V22, P363
   Dona I, 2011, ALLERGY, V66, P1428, DOI 10.1111/j.1398-9995.2011.02684.x
   Dona I, 2011, CLIN EXP ALLERGY, V41, P86, DOI 10.1111/j.1365-2222.2010.03651.x
   Farnam K, 2012, INT ARCH ALLERGY IMM, V159, P327, DOI 10.1159/000339690
   Grabenhenrich L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035778
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x
   Laroche D, 1999, ALLERGY, V54, P13, DOI 10.1111/j.1398-9995.1999.tb04742.x
   Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049
   Mertes PM, 2011, J INVEST ALLERG CLIN, V21, P442
   Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003
   Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009
   Mita H, 1998, ALLERGY, V53, P1133, DOI 10.1111/j.1398-9995.1998.tb03832.x
   Pichler WJ, 2010, MED CLIN N AM, V94, P645, DOI 10.1016/j.mcna.2010.04.003
   Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x
   Renaudin JM, 2013, ALLERGY, V68, P929, DOI 10.1111/all.12168
   Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047
   Sala-Cunill A, 2013, INT ARCH ALLERGY IMM, V160, P192, DOI 10.1159/000339749
   Simons FER, 2012, CURR OPIN ALLERGY CL, V12, P389, DOI 10.1097/ACI.0b013e328355b7e4
   Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038
   Techapornroong M, 2010, ASIAN PAC J ALLERGY, V28, P262
   Thong BYH, 2011, BRIT J CLIN PHARMACO, V71, P684, DOI 10.1111/j.1365-2125.2010.03774.x
   Torres MJ, 2010, MED CLIN N AM, V94, P805, DOI 10.1016/j.mcna.2010.04.006
   Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x
   Viola M, 2011, CLIN EXP ALLERGY, V41, P96, DOI 10.1111/j.1365-2222.2010.03648.x
NR 34
TC 68
Z9 71
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2014
VL 2
IS 4
BP 414
EP 420
DI 10.1016/j.jaip.2014.03.014
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7GG
UT WOS:000354203300008
PM 25017529
DA 2020-11-26
ER

PT J
AU De Franco, M
   Kalil, J
AF De Franco, Marcelo
   Kalil, Jorge
TI The Butantan Institute: History and Future Perspectives
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ANTIVENOMOUS SEROTHERAPY; BRAZIL; VENOM; SNAKES; VACCINES
C1 [De Franco, Marcelo; Kalil, Jorge] Inst Butantan, Sao Paulo, Brazil.
RP De Franco, M (corresponding author), Inst Butantan, Sao Paulo, Brazil.
EM marcelo.franco@butantan.gov.br
RI KALIL, JORGE/C-8029-2012; DE FRANCO, MARCELO/S-5870-2019
OI KALIL, JORGE/0000-0001-8415-4274; DE FRANCO, MARCELO/0000-0002-0417-8215
CR BRAZIL V, 1950, An Paul Med Cir, V60, P463
   Camargo ACM, 2012, TOXICON, V59, P516, DOI 10.1016/j.toxicon.2011.07.013
   Carvalho Eneas, 2012, Recent Pat DNA Gene Seq, V6, P160
   Cury Y, 2011, NITRIC OXIDE-BIOL CH, V25, P243, DOI 10.1016/j.niox.2011.06.004
   da Silva Wilmar Dias, 2011, Inflammation & Allergy Drug Targets, V10, P343
   Dias da SW, 2010, VET IMMUNOL IMMUNOP, V135, P173, DOI [10.1016/j.vetimm.2009.12.011, DOI 10.1016/J.VETIMM.2009.12.011]
   do Nascimento DR, 2011, DYNAMIS, V31, P65
   Furtado MDD, 2010, TOXICON, V55, P881, DOI 10.1016/j.toxicon.2009.12.014
   HAWGOOD BJ, 1992, TOXICON, V30, P573, DOI 10.1016/0041-0101(92)90851-U
   Hawgood BJ, 1999, TOXICON, V37, P1241, DOI 10.1016/S0041-0101(99)00086-0
   Hawgood BJ, 2001, TOXICON, V39, P1277, DOI 10.1016/S0041-0101(00)00264-6
   Higashi HG, 2009, REV INST MED TROP SP, V51, P131, DOI 10.1590/S0036-46652009000300002
   Ho PL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001300
   LUCAS S, 1988, TOXICON, V26, P759, DOI 10.1016/0041-0101(88)90317-0
   Miyaji EN, 2013, CELL MOL LIFE SCI, V70, P3303, DOI 10.1007/s00018-012-1234-8
   Miyaki C, 2011, VACCINE, V29, pA12, DOI 10.1016/j.vaccine.2011.04.127
   Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711
   Nascimento ALTO, 2004, BRAZ J MED BIOL RES, V37, P459, DOI 10.1590/S0100-879X2004000400003
   Queiroz GP, 2008, TOXICON, V52, P842, DOI 10.1016/j.toxicon.2008.10.002
   Quintilio W, 2009, VACCINE, V27, P4219, DOI 10.1016/j.vaccine.2009.04.047
   Sampaio SC, 2010, TOXICON, V55, P1045, DOI 10.1016/j.toxicon.2010.01.011
   Sant'Anna OA, 2007, SCAND J IMMUNOL, V66, P106, DOI 10.1111/j.1365-3083.2007.01960.x
   Saravia P, 2002, REV BIOL TROP, V50, P337
   Serrano SMT, 2013, TOXICON, V62, P19, DOI 10.1016/j.toxicon.2012.09.003
   Tambourgi DV, 2010, TOXICON, V56, P1113, DOI 10.1016/j.toxicon.2010.01.021
   Tanaka-Azevedo AM, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/641025
   Valencia IM, 2013, HUM VACC IMMUNOTHER, V9, P2019, DOI 10.4161/hv.25946
NR 27
TC 11
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2014
VL 8
IS 7
AR e2862
DI 10.1371/journal.pntd.0002862
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AN4IQ
UT WOS:000340551500002
PM 24992341
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Sini, BC
   Bydlowski, SP
   Levy, D
   Maselli, LMF
   Cohon, A
   Kokron, CM
   Oliveira, AKB
   Kalil, J
   Barros, MT
AF Sini, B. C.
   Bydlowski, S. P.
   Levy, Debora
   Maselli, Luciana M. F.
   Cohon, Andrea
   Kokron, Cristina M.
   Barreto Oliveira, Ana Karolina
   Kalil, Jorge
   Barros, Myrthes Toledo
TI Was the PON1-55MM Polymorphism Associated to Higher Disease Severity in
   Common Variable Deficiency Patients?
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Primary Immune Deficiency Diseases North American Conference of the
   Clinical-Immunology-Society (CIS)
CY APR 10-13, 2014
CL Baltimore, MD
SP Clin Immunol Soc
C1 [Sini, B. C.; Cohon, Andrea; Barreto Oliveira, Ana Karolina; Kalil, Jorge; Barros, Myrthes Toledo] Univ Sao Paulo, Sch Med, Primary Immunodeficiency Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Bydlowski, S. P.] Univ Sao Paulo, Sch Med, Lab Genet & Hematol Mol LIM31, Sao Paulo, Brazil.
   [Levy, Debora; Maselli, Luciana M. F.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kokron, Cristina M.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012; Marinho, Ana
   Karolina/C-8395-2017
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL,
   JORGE/0000-0001-8415-4274; Marinho, Ana Karolina/0000-0001-9369-8222
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2014
VL 34
IS 3
BP 373
EP 373
PG 1
WC Immunology
SC Immunology
GA AH3SX
UT WOS:000336046800102
DA 2020-11-26
ER

PT J
AU Mendonca, LO
   Simis, N
   Kokron, CM
   Barros, MT
   Yang, AC
   Grecco, O
   Kalil, J
AF Mendonca, Leonardo Oliveira
   Simis, Nathalia
   Kokron, C. M.
   Barros, Myrthes Toledo
   Yang, Ariana Campos
   Grecco, Octavio
   Kalil, Jorge
TI Eosinophilic Gastrointestinal Disorders in a Group of Patients with
   Common Variable Immunodeficiency
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Primary Immune Deficiency Diseases North American Conference of the
   Clinical-Immunology-Society (CIS)
CY APR 10-13, 2014
CL Baltimore, MD
SP Clin Immunol Soc
C1 [Mendonca, Leonardo Oliveira; Simis, Nathalia; Grecco, Octavio; Kalil, Jorge] HCFMUSP, Sao Paulo, Brazil.
   [Kokron, C. M.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Barros, Myrthes Toledo] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Primary Immunodeficiency Clin, Sao Paulo, Brazil.
   [Yang, Ariana Campos] HCFMUSP, Food Allergy Grp, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2014
VL 34
IS 3
BP 390
EP 390
PG 1
WC Immunology
SC Immunology
GA AH3SX
UT WOS:000336046800166
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Saliba, B
   Bisaccioni, C
   Aun, MV
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana C.
   Saliba, Bruna
   Bisaccioni, Carla
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Sensitization In Patients With Allergic Difficult-To-Control Asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 28-MAR 04, 2014
CL San Diego, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Agondi, Rosana C.; Saliba, Bruna; Bisaccioni, Carla; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Boston, MA USA.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2014
VL 133
IS 2
SU S
MA 833
BP AB241
EP AB241
DI 10.1016/j.jaci.2013.12.857
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 297FO
UT WOS:000330241301149
DA 2020-11-26
ER

PT J
AU Crespo-Magalhaes, M
   Aun, MV
   Almeida-Castro, R
   Ribeiro, MR
   Garro, LSS
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Crespo-Magalhaes, Manoela
   Aun, Marcelo Vivolo
   Almeida-Castro, Roberta
   Ribeiro, Marisa Rosimeire
   Sabino Garro, Laila Sabino
   Kalil, Jorge
   Motta, Antonio Abilio
   Giavina-Bianchi, Pedro
TI Allergy To Betalactams In Brazil: Placebo Effect Or Misdiagnosis?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY FEB 28-MAR 04, 2014
CL San Diego, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Crespo-Magalhaes, Manoela; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Almeida-Castro, Roberta; Ribeiro, Marisa Rosimeire; Sabino Garro, Laila Sabino; Motta, Antonio Abilio] Univ Sao Paulo, Clin Imunnol & Allergy Div, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; Aun, Marcelo V/E-6775-2014; KALIL,
   JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; Aun, Marcelo
   V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2014
VL 133
IS 2
SU S
MA 921
BP AB267
EP AB267
DI 10.1016/j.jaci.2013.12.946
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 297FO
UT WOS:000330241301237
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Sanabani, SS
   Ribeiro, SP
   Sauer, MM
   Tomiyama, HI
   Sucupira, MC
   Diaz, RS
   Sabino, EC
   Kalil, J
   Kallas, EG
AF Tarosso, Leandro F.
   Sanabani, Sabri S.
   Ribeiro, Susan P.
   Sauer, Mariana M.
   Tomiyama, Helena I.
   Sucupira, Maria C.
   Diaz, Ricardo S.
   Sabino, Ester C.
   Kalil, Jorge
   Kallas, Esper G.
TI Short Communication: HIV Type 1 Subtype BF Leads to Faster CD4(+) T Cell
   Loss Compared to Subtype B
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID DISEASE PROGRESSION; VIRUS TYPE-1; EPIDEMIOLOGY; INFECTION; FREQUENCY
AB Although it has been suggested that biological differences among HIV-1 subtypes exist, their possible influence on disease progression has not been fully revealed. In particular, the increasing emergence of recombinants stresses the need to characterize disease presentation in persons infected by these diverse HIV-1 forms. We explored this issue among 83 Brazilian subjects infected with either HIV-1 subtype B or recombinant subtype BF, all followed since incident infection in a cohort study. Viral subtypes were assigned by full length sequencing of HIV-1 genomes. We observed that the baseline measures for CD4(+) T cells and viral load did not differ between the groups. However, longitudinal analysis revealed that subtype BF was clearly associated with a faster CD4(+) T cell decline compared to infection with subtype B, in spite of a similar plasma HIV-1 load. While subtype B-infected subjects presented a loss of 3.6 CD4(+) T cells/l per month, subtype BF-infected individuals showed a monthly decay of 6.3 CD4(+) T cells/l (p<0.01). The time to reach 350 CD4(+) T cells/l and the time to start antiretroviral treatment were also shorter in subtype BF-infected persons. The elucidation of an accelerated CD4(+) T cell loss associated with subtype BF suggests that this HIV-1 genetic form could be more pathogenic than subtype B.
C1 [Tarosso, Leandro F.; Ribeiro, Susan P.; Sauer, Mariana M.; Tomiyama, Helena I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Sanabani, Sabri S.] Univ Sao Paulo, Sch Med, Hosp Clin, Clin Lab,Dept Pathol,LIM 03, BR-01246903 Sao Paulo, Brazil.
   [Sauer, Mariana M.; Tomiyama, Helena I.] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-01246903 Sao Paulo, Brazil.
RP Tarosso, LF (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Av Dr Arnaldo,455,3 Floor,Room 3209, BR-01246903 Sao Paulo, Brazil.
EM tarosso@usp.br
RI KALIL, JORGE/C-8029-2012; Sabino, Ester Cerdeira/F-7750-2010; Sanabani,
   Sabri Saeed/F-5600-2012; Araripe Sucupira, Maria Cecilia/K-1931-2012
OI KALIL, JORGE/0000-0001-8415-4274; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Sanabani, Sabri Saeed/0000-0002-8876-8262;
   Kallas, Esper/0000-0003-2026-6925; Araripe Sucupira, Maria
   Cecilia/0000-0002-1114-5382
FU Brazilian Program for STD/AIDS-Ministry of Health [914/BRA/3014]; Sao
   Paulo City Health Department [2004-0.168.922-7]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2004/15856-9, 2010/51609-7]
FX We thank all the study participants and the dedicated clinical research
   staff at the collaborating sites. This study was supported by the
   Brazilian Program for STD/AIDS-Ministry of Health (914/BRA/3014 to E. G.
   K.), the Sao Paulo City Health Department (2004-0.168.922-7 to E. G.
   K.), and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (2004/15856-9 to E. G. K. and 2010/51609-7 to L.F.T.).
CR Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682
   Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Hu DJ, 2005, AIDS, V19, P303
   Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
   KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641
   Leal E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011833
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Martinez-Cajas JL, 2008, AIDS REV, V10, P212
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Secretaria Municipal da Saude do Municipio de SAo Paulo (SMS-SP), 2003, B EP AIDS MUN SAO PA, VVII
   UNAIDS, 2010, GLOB REP UNAIDS REP
NR 18
TC 6
Z9 7
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB 1
PY 2014
VL 30
IS 2
BP 190
EP 194
DI 10.1089/aid.2012.0243
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AA6NI
UT WOS:000331214600013
PM 23906381
DA 2020-11-26
ER

PT J
AU dos Santos-Pinto, JRA
   dos Santos, LD
   Arcuri, HA
   Castro, FM
   Kalil, JE
   Palma, MS
AF Aparecido dos Santos-Pinto, Jose Roberto
   dos Santos, Lucilene Delazari
   Arcuri, Helen Andrade
   Castro, Fabio Morato
   Kalil, Jorge Elias
   Palma, Mario Sergio
TI Using Proteomic Strategies for Sequencing and Post-Translational
   Modifications Assignment of Antigen-5, a Major Allergen from the Venom
   of the Social Wasp Polybia paulista
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE allergen; mass spectrometry; peptide sequence; post-translational
   modification; molecular modeling
ID HYMENOPTERA VENOM; CROSS-REACTIVITY; STRUCTURAL-CHARACTERIZATION;
   PROTEIN; PHOSPHOPROTEOME; SIALOME; HORNET; EPITOPES; REVEALS; CASEIN
AB Antigen-5 is one of the major allergens identified in wasp venoms, and despite the fact that its biological function is still unknown, many studies have demonstrated its allergenicity. In this study, the biochemical and structural characterization of antigen-5 from the venom of the social wasp Polybia paulista are reported. A gel-based mass spectrometry strategy with CID fragmentation methods and classical protocols of protein chemistry, which included N- and C-terminal sequencing, were used to assign the complete sequence and determine the presence/location of the post-translational modifications (PTMs) of this protein. Six different isoforms of antigen-5 were identified in the crude venom of P. paulista; the most abundant, which corresponds to the intact form of this protein, was recognized by the pool of human specific-IgE. This protein was extensively sequenced through CID mass spectrometry, and a series of PTMs were observed such as hydroxylation, phosphorylation, and glycosylation. Sequence data revealed that this protein has 59.3-93.7% identity with antigen-5 proteins from other known vespid venoms. The molecular model of P. paulista antigen-5 shows that this protein has three alpha-helices, one 3(10), helix, and four beta-sheets covering 28 and 17.9% of the sequence, respectively. The identification and characterization of allergenic compounds is essential for the development of advanced component-resolved allergy diagnostics and treatment.
C1 [Aparecido dos Santos-Pinto, Jose Roberto; Palma, Mario Sergio] Univ Sao Paulo State UNESP, Ctr Study Social Insects, Inst Biosci Rio Claro, Dept Biol, Rio Claro, SP, Brazil.
   [dos Santos, Lucilene Delazari] Univ Sao Paulo State UNESP, Ctr Study Venoms & Venomous Anim CEVAP, Botucatu, SP, Brazil.
   [Aparecido dos Santos-Pinto, Jose Roberto; dos Santos, Lucilene Delazari; Arcuri, Helen Andrade; Castro, Fabio Morato; Kalil, Jorge Elias; Palma, Mario Sergio] INCT iii, Sao Paulo, Brazil.
   [Arcuri, Helen Andrade; Castro, Fabio Morato; Kalil, Jorge Elias] Discipline Allergy & Immunol HC Incor FMUSP, Sao Paulo, SP, Brazil.
RP Palma, MS (corresponding author), Univ Sao Paulo State UNESP, Ctr Study Social Insects, Inst Biosci Rio Claro, Dept Biol, Rio Claro, SP, Brazil.
EM mspalma@rc.unesp.br
RI Fapesp, Biota/F-8655-2017; Palma, Mario Sergio/E-7800-2012; Castro,
   Fabio FM/C-1082-2017; Santos, Lucilene Delazari dos/AAY-5226-2020;
   KALIL, JORGE/C-8029-2012; Santos-Pinto, Jose Roberto Aparecido
   dos/V-8745-2019; Castro, Fabio/AAP-5433-2020
OI Fapesp, Biota/0000-0002-9887-8449; Palma, Mario
   Sergio/0000-0002-7363-8211; Castro, Fabio FM/0000-0002-6211-5773;
   Santos, Lucilene Delazari dos/0000-0001-5832-1825; KALIL,
   JORGE/0000-0001-8415-4274; Santos-Pinto, Jose Roberto Aparecido
   dos/0000-0003-3172-0097; 
FU BIOprospecTA/FAPESP program [Proc. 2011/51684-1]; CNPqNational Council
   for Scientific and Technological Development (CNPq); CAPESCAPES
FX This work was supported by grants from the BIOprospecTA/FAPESP program
   (Proc. 2011/51684-1), CNPq, and CAPES. M.S.P. is a researcher from the
   National Research Council of Brazil-CNPq. L.D.S. and H.A.A. were
   Postdoctoral fellows from FAPESP, and J.R.A.S.P is a Ph.D. student
   fellow from FAPESP.
CR Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114
   Pinto JRAD, 2012, PROTEIN PEPTIDE LETT, V19, P625
   Bernard H, 2000, FEBS LETT, V467, P239, DOI 10.1016/S0014-5793(00)01164-9
   Bohle B, 2005, CLIN EXP ALLERGY, V35, P367, DOI 10.1111/j.1365-2222.2005.02180.x
   Calvo E, 2007, INSECT BIOCHEM MOLEC, V37, P164, DOI 10.1016/j.ibmb.2006.11.005
   Cascone O., 1995, TOXICON, V38, P1367
   Cases B, 2011, J INVEST ALLERG CLIN, V21, P398
   Charlab R, 1999, P NATL ACAD SCI USA, V96, P15155, DOI 10.1073/pnas.96.26.15155
   Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430
   Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q
   de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017
   Delano WL, 2002, THE PYMOL MOLECULAR
   Dereeper A., 2008, NUCLEIC ACIDS RES, V1, pW465
   dos Santos LD, 2011, PROTEOMICS, V11, P1403, DOI 10.1002/pmic.201000414
   dos Santos LD, 2010, J PROTEOME RES, V9, P3867, DOI 10.1021/pr1000829
   Erzen R, 2009, WIEN KLIN WOCHENSCHR, V121, P349, DOI 10.1007/s00508-009-1171-1
   Eyers C. E., 2008, WILEY ENCY CHEM BIOL, DOI [10.1002/9780470048672.wecb469, DOI 10.1002/9780470048672.WECB469]
   Fenaille F, 2009, J PROTEOME RES, V8, P4014, DOI 10.1021/pr900359p
   Resende VMF, 2013, PROTEOMICS, V13, P2638, DOI 10.1002/pmic.201300038
   Gelin L. F. F., 2009, ANALISE JILOGENETICA, P63
   Gibbs GM, 2008, ENDOCR REV, V29, P865, DOI 10.1210/er.2008-0032
   Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160
   Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109
   HOFFMAN DR, 1984, ANN ALLERGY, V52, P276
   HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5
   Huecas S, 2001, J BIOL CHEM, V276, P27959, DOI 10.1074/jbc.M103041200
   Johansen MB, 2006, GLYCOBIOLOGY, V16, P844, DOI 10.1093/glycob/cwl009
   KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016
   KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X
   King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3
   King TP, 1997, J ALLERGY CLIN IMMUN, V99, P630, DOI 10.1016/S0091-6749(97)70025-3
   Kolarich D, 2005, FEBS J, V272, P5182, DOI 10.1111/j.1742-4658.2005.04841.x
   Kovalick GE, 1998, INSECT BIOCHEM MOLEC, V28, P491, DOI 10.1016/S0965-1748(98)00031-9
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li JX, 2010, PROTEIN SCI, V19, P174, DOI 10.1002/pro.295
   LU G, 1993, J IMMUNOL, V150, P2823
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Mans BJ, 2008, INSECT BIOCHEM MOLEC, V38, P42, DOI 10.1016/j.ibmb.2007.09.003
   Milne TJ, 2003, J BIOL CHEM, V278, P31105, DOI 10.1074/jbc.M304843200
   Pantera B, 2003, BBA-GEN SUBJECTS, V1623, P72, DOI 10.1016/j.bbagen.2003.07.001
   Petersen A, 1998, CLIN EXP ALLERGY, V28, P315
   Pirpignani ML, 2002, ARCH BIOCHEM BIOPHYS, V407, P224, DOI 10.1016/S0003-9861(02)00554-4
   Poth AG, 2008, J PROTEOME RES, V7, P5017, DOI 10.1021/pr800387s
   Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812
   RICHARDS O. W., 1951, TRANS ROY ENT SOC LONDON, V102, P1
   Santos LD, 2007, TOXICON, V50, P923, DOI 10.1016/j.toxicon.2007.06.027
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   Skov LK, 2006, ACTA CRYSTALLOGR D, V62, P595, DOI 10.1107/S0907444906010687
   Thaysen-Andersen M, 2007, MOL CELL PROTEOMICS, V6, P638, DOI 10.1074/mcp.M600407-MCP200
   Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4
   Van Vaerenbergh M, 2013, INSECT MOL BIOL, V22, P199, DOI 10.1111/imb.12013
   Winningham KM, 2004, J ALLERGY CLIN IMMUN, V114, P928, DOI 10.1016/j.jaci.2004.07.043
   Zielinska DF, 2009, J PROTEOME RES, V8, P4039, DOI 10.1021/pr900384k
NR 53
TC 20
Z9 20
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD FEB
PY 2014
VL 13
IS 2
BP 855
EP 865
DI 10.1021/pr4008927
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA AA5UC
UT WOS:000331164100045
PM 24308509
DA 2020-11-26
ER

PT J
AU Regnier, V
   Aun, MV
   Kalil, J
   Castells, M
   Giavina-Bianchi, P
AF Regnier, Violeta
   Aun, Marcelo Vivolo
   Kalil, Jorge
   Castells, Mariana
   Giavina-Bianchi, Pedro
TI Clinical and laboratory improvement after intravenous immunoglobulin in
   drug reaction with eosinophilia and systemic symptoms
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID INDUCED HYPERSENSITIVITY SYNDROME; DRESS
C1 [Regnier, Violeta; Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, BR-01454904 Sao Paulo, SP, Brazil.
   [Castells, Mariana] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy, R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, SP, Brazil.
EM pbianchi@usp.br
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
CR Camous X, 2012, CURR OPIN IMMUNOL, V24, P730, DOI 10.1016/j.coi.2012.07.010
   Joly P, 2012, ARCH DERMATOL, V148, P543, DOI [10.1001/archderm.148.4.dlt120002-c, 10.1001/archdermatol.2011.1937]
   Kano Y, 2005, TOXICOLOGY, V209, P165, DOI 10.1016/j.tox.2004.12.013
   Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x
   Kito Y, 2012, ACTA DERM-VENEREOL, V92, P100, DOI 10.2340/00015555-1168
   Pritchett JC, 2012, INT J HEPATOL, V2012, P1
   Santhamoorthy P, 2012, ANN INDIAN ACAD NEUR, V15, P320, DOI 10.4103/0972-2327.104348
   Shiohara Tetsuo, 2006, Allergol Int, V55, P1, DOI 10.2332/allergolint.55.1
   Yazicioglu M, 2012, PEDIAT ALLERG IMM-UK, V23, P289, DOI 10.1111/j.1399-3038.2012.01268.x
NR 9
TC 15
Z9 15
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JAN-FEB
PY 2014
VL 2
IS 1
BP 107
EP 110
DI 10.1016/j.jaip.2013.11.008
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA CH7EB
UT WOS:000354197300020
PM 24565781
DA 2020-11-26
ER

PT J
AU Nogueira, LG
   Santos, RHB
   Fiorelli, AI
   Mairena, EC
   Benvenuti, LA
   Bocchi, EA
   Stolf, NA
   Kalil, J
   Cunha-Neto, E
AF Nogueira, Luciana Gabriel
   Barros Santos, Ronaldo Honorato
   Fiorelli, Alfredo Inacio
   Mairena, Eliane Conti
   Benvenuti, Luiz Alberto
   Bocchi, Edimar Alcides
   Stolf, Noedir Antonio
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Myocardial Gene Expression of T-bet, GATA-3, Ror-gamma t, FoxP3, and
   Hallmark Cytokines in Chronic Chagas Disease Cardiomyopathy: An
   Essentially Unopposed T(H)1-Type Response
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID CHEMOKINE RECEPTOR EXPRESSION; INTERFERON-GAMMA; HEART-DISEASE; CELLS;
   IMMUNE; INTERLEUKIN-18; INFLAMMATION; PATHOGENESIS; ACTIVATION;
   SURROGATE
AB Background. Chronic Chagas disease cardiomyopathy (CCC), a late consequence of Trypanosoma cruzi infection, is an inflammatory cardiomyopathy with prognosis worse than those of noninflammatory etiology (NIC). Although the T cell-rich myocarditis is known to play a pathogenetic role, the relative contribution of each of the functional T cell subsets has never been thoroughly investigated. We therefore assessed gene expression of cytokines and transcription factors involved in differentiation and effector function of each functional T cell subset (T(H)1/T(H)2/T(H)17/Treg) in CCC, NIC, and heart donor myocardial samples. Methods and Results. Quantitative PCR showed markedly upregulated expression of IFN-gamma and transcription factor T-bet, and minor increases of GATA-3; FoxP3 and CTLA-4; IL-17 and IL-18 in CCC as compared with NIC samples. Conversely, cytokines expressed by T(H)2 cells (IL-4, IL-5, and IL-13) or associated with Treg (TGF-beta and IL-10) were not upregulated in CCC myocardium. Expression of T(H)1-related genes such as T-bet, IFN-gamma, and IL-18 correlated with ventricular dilation, FoxP3, and CTLA-4. Conclusions. Results are consistent with a strong local T(H)1-mediated response in most samples, possibly associated with pathological myocardial remodeling, and a proportionally smaller FoxP3(+)CTLA4(+) Treg cell population, which is unable to completely curb IFN-gamma production in CCC myocardium, therefore fueling inflammation.
C1 [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, INCT, Inst Invest Immunol, BR-05403000 Sao Paulo, Brazil.
   [Barros Santos, Ronaldo Honorato; Fiorelli, Alfredo Inacio; Stolf, Noedir Antonio] Univ Sao Paulo, Sch Med, Div Surg, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   [Benvenuti, Luiz Alberto] Univ Sao Paulo, Sch Med, Div Pathol, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   [Bocchi, Edimar Alcides] Univ Sao Paulo, Sch Med, Transplantat & Heart Failure Unit, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Araujo-Jorge TC, 2002, J INFECT DIS, V186, P1823, DOI 10.1086/345882
   Arguello RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035966
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   de Araujo FF, 2012, IMMUNOBIOLOGY, V217, P768, DOI 10.1016/j.imbio.2012.04.008
   de Araujo FF, 2011, HUM PATHOL, V42, P299, DOI 10.1016/j.humpath.2010.10.002
   Dinarello CA, 2003, J INFECT DIS, V187, pS370, DOI 10.1086/374751
   Dong L, 2006, CHINESE MED J-PEKING, V119, P1396, DOI 10.1097/00029330-200608020-00013
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Frade AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083446
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Hunter CA, 2012, IMMUNITY, V37, P960, DOI 10.1016/j.immuni.2012.11.003
   Jiang HK, 2010, CIRC J, V74, P2410, DOI 10.1253/circj.CJ-10-0234
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Kmieciak M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-89
   Magalhaes LMD, 2013, J INFECT DIS, V207, P661, DOI 10.1093/infdis/jis724
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Miller SA, 2009, IMMUNOLOGY, V126, P306, DOI 10.1111/j.1365-2567.2008.03040.x
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Rodrigues DBR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/361730
   Sakaguchi S, 2009, INT IMMUNOL, V21, P1105, DOI 10.1093/intimm/dxp095
   Saraiva RM, 2013, T ROY SOC TROP MED H, V107, P518, DOI 10.1093/trstmh/trt050
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Talvani A, 2004, J INFECT DIS, V189, P214, DOI 10.1086/380803
   Teixeira LK, 2005, MEM I OSWALDO CRUZ, V100, P137, DOI 10.1590/S0074-02762005000900024
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Tone M, 1997, J IMMUNOL, V159, P6156
   Torzewski M, 2012, AM J PATHOL, V180, P73, DOI 10.1016/j.ajpath.2011.09.006
NR 49
TC 32
Z9 35
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 914326
DI 10.1155/2014/914326
PG 9
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AN0LS
UT WOS:000340276700001
PM 25152568
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Abel, LCJ
   Ferreira, LRP
   Navarro, IC
   Baron, MA
   Kalil, J
   Gazzinelli, RT
   Rizzo, LV
   Cunha-Neto, E
AF Jamli Abel, Lucia Cristina
   Pinto Ferreira, Ludmila Rodrigues
   Navarro, Isabela Cunha
   Baron, Monique Andrade
   Kalil, Jorge
   Gazzinelli, Ricardo Tostes
   Rizzo, Luiz Vicente
   Cunha-Neto, Edecio
TI Induction of IL-12 Production in Human Peripheral Monocytes by
   Trypanosoma cruzi Is Mediated by Glycosylphosphatidylinositol-Anchored
   Mucin-Like Glycoproteins and Potentiated by IFN-gamma and CD40-CD40L
   Interactions
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID CHAGAS-DISEASE CARDIOMYOPATHY; PROINFLAMMATORY CYTOKINES;
   ACQUIRED-IMMUNITY; TISSUE PARASITISM; INTERFERON-GAMMA; GENE-EXPRESSION;
   T-BET; INFECTION; INTERLEUKIN-12; CELLS
AB Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is characterized by immunopathology driven by IFN-gamma secreting Th1-like T cells. T. cruzi has a thick coat of mucin-like glycoproteins covering its surface, which plays an important role in parasite invasion and host immunomodulation. It has been extensively described that T. cruzi or its products-like GPI anchors isolated from GPI-anchored mucins from the trypomastigote life cycle stage (tGPI-mucins)-are potent inducers of proinflammatory responses (i.e., cytokines and NO production) by IFN-gamma primed murine macrophages. However, little is known about whether T. cruzi or GPI-mucins exert a similar action in human cells. We therefore decided to further investigate the in vitro cytokine production profile from human mononuclear cells from uninfected donors exposed to T. cruzi as well as tGPI-mucins. We observed that both living T. cruzi trypomastigotes and tGPI-mucins are potent inducers of IL-12 by human peripheral blood monocytes and this effect depends on CD40-CD40L interaction and IFN-gamma. Our findings suggest that the polarized T1-type cytokine profile seen in T. cruzi infected patients might be a long-term effect of IL-12 production induced by lifelong exposure to T. cruzi tGPI-mucins.
C1 [Jamli Abel, Lucia Cristina; Pinto Ferreira, Ludmila Rodrigues; Navarro, Isabela Cunha; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, BR-05403001 Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Navarro, Isabela Cunha; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246000 Sao Paulo, Brazil.
   [Pinto Ferreira, Ludmila Rodrigues; Navarro, Isabela Cunha; Baron, Monique Andrade; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Gazzinelli, Ricardo Tostes] Oswaldo Cruz Fdn FIOCRUZ, Res Ctr Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
   [Gazzinelli, Ricardo Tostes] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Immunopathol Lab, BR-31270910 Belo Horizonte, MG, Brazil.
   [Gazzinelli, Ricardo Tostes] Univ Massachusetts, Div Infect Dis & Immunol, Dept Med, Sch Med, Worcester, MA 01605 USA.
   [Rizzo, Luiz Vicente] Hosp Israelita Albert Einstein, BR-05651901 Sao Paulo, Brazil.
RP Rizzo, LV (corresponding author), Hosp Israelita Albert Einstein, Ave Albert Einstein 627-701,2 Subsolo Bloco A, BR-05651901 Sao Paulo, Brazil.
EM lvrizzo@einstein.br; edecunha@gmail.com
RI Rizzo, Luiz Vicente/B-4458-2009; Navarro, Isabela Cunha/V-7182-2017;
   Ferreira, Ludmila/C-4100-2012; Cunha-Neto, Edecio/B-4157-2009; Ferreira,
   Ludmila Rodrigues Pinto/B-4955-2015; KALIL, JORGE/C-8029-2012; Abel,
   Lucia Cristina Jamli/P-8816-2014
OI Navarro, Isabela Cunha/0000-0002-6844-2361; Ferreira,
   Ludmila/0000-0001-9944-6691; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Ferreira, Ludmila Rodrigues Pinto/0000-0001-9944-6691; KALIL,
   JORGE/0000-0001-8415-4274; Gazzinelli, Ricardo/0000-0003-2427-7699;
   Abel, Lucia Cristina Jamli/0000-0003-4915-4265
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Paulo State Foundation
   for Scientific Research (FAPESP); National Institute of Allergy and
   Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [1P50AI098461-01]; Instituto
   Nacional de Ciencia e Tecnologia de Vacinas (INCT/Vacinas); CNPq
   fellowshipNational Council for Scientific and Technological Development
   (CNPq); FAPESP fellowshipFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); Brazilian Council for Scientific and Technological
   Development-CNPq productivity awardNational Council for Scientific and
   Technological Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461, P50AI098461, P50AI098461,
   P50AI098461, P50AI098461, P50AI098461] Funding Source: NIH RePORTER
FX This work has been supported by grants of the Brazilian National
   Research Council (CNPq), Sao Paulo State Foundation for Scientific
   Research (FAPESP), National Institute of Allergy and Infectious Disease
   (Grant no. 1P50AI098461-01), and Instituto Nacional de Ciencia e
   Tecnologia de Vacinas (INCT/Vacinas). LRPF is recipient of a CNPq
   fellowship; ICN and MAB are recipients of a FAPESP fellowship. LVR, ECN,
   and JK are recipients of Brazilian Council for Scientific and
   Technological Development-CNPq productivity award. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the paper.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794
   Aliberti JCS, 1996, INFECT IMMUN, V64, P1961, DOI 10.1128/IAI.64.6.1961-1967.1996
   Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Camargo MM, 1997, J IMMUNOL, V158, P5890
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996
   Chaussabel D, 1999, INFECT IMMUN, V67, P1929
   Chen GH, 2010, AM J PATHOL, V177, P2459, DOI 10.2353/ajpath.2010.100141
   Cosyns M, 1998, INFECT IMMUN, V66, P603, DOI 10.1128/IAI.66.2.603-607.1998
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M
   Frosch S, 1996, MED MICROBIOL IMMUN, V185, P189, DOI 10.1007/s004300050030
   Gazzinelli RT, 2006, NAT REV IMMUNOL, V6, P895, DOI 10.1038/nri1978
   Golgher D, 2004, AUTOIMMUNITY, V37, P399, DOI 10.1080/08916930410001713115
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Graefe SEB, 2003, MICROBES INFECT, V5, P833, DOI 10.1016/S1286-4579(03)00176-X
   Gravina HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063100
   Hoft DF, 2005, INFECT IMMUN, V73, P4934, DOI 10.1128/IAI.73.8.4934-4940.2005
   Hotez PJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001498
   Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598
   MacDonald AS, 2002, J IMMUNOL, V168, P4643, DOI 10.4049/jimmunol.168.9.4643
   Machado FS, 2012, CARDIOL REV, V20, P53, DOI 10.1097/CRD.0b013e31823efde2
   Marinho CRF, 2009, MICROBES INFECT, V11, P1037, DOI 10.1016/j.micinf.2009.07.011
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Nguyen P, 1999, TRANSFUSION, V39, P975, DOI 10.1046/j.1537-2995.1999.39090975.x
   Rassi A, 2012, INFECT DIS CLIN N AM, V26, P275, DOI 10.1016/j.idc.2012.03.002
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Rodrigues DBR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/361730
   Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Teixeira MMG, 2006, TROP MED INT HEALTH, V11, P294, DOI 10.1111/j.1365-3156.2006.01575.x
   TORRICO F, 1991, J IMMUNOL, V146, P3626
   WILEY JA, 1995, J IMMUNOL, V155, P3525
NR 43
TC 10
Z9 10
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 345659
DI 10.1155/2014/345659
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AL5ZM
UT WOS:000339211900001
PM 25120285
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Frade, AF
   Teixeira, PC
   Ianni, BM
   Pissetti, CW
   Saba, B
   Wang, LHT
   Kuramoto, A
   Nogueira, LG
   Buck, P
   Dias, F
   Giniaux, H
   Llored, A
   Alves, S
   Schmidt, A
   Donadi, E
   Marin-Neto, JA
   Hirata, M
   Sampaio, M
   Fragata, A
   Bocchi, EA
   Stolf, AN
   Fiorelli, AI
   Santos, RHB
   Rodrigues, V
   Pereira, AC
   Kalil, J
   Cunha-Neto, E
   Chevillard, C
AF Frade, Amanda Farage
   Teixeira, Priscila Camilo
   Ianni, Barbara Maria
   Pissetti, Cristina Wide
   Saba, Bruno
   Tzu Wang, Lin Hui
   Kuramoto, Andreia
   Nogueira, Luciana Gabriel
   Buck, Paula
   Dias, Fabricio
   Giniaux, Helene
   Llored, Agnes
   Alves, Sthefanny
   Schmidt, Andre
   Donadi, Eduardo
   Marin-Neto, Jose Antonio
   Hirata, Mario
   Sampaio, Marcelo
   Fragata, Abilio
   Bocchi, Edimar Alcides
   Stolf, Antonio Noedir
   Fiorelli, Alfredo Inacio
   Barros Santos, Ronaldo Honorato
   Rodrigues, Virmondes
   Pereira, Alexandre Costa
   Kalil, Jorge
   Cunha-Neto, Edecio
   Chevillard, Christophe
TI Polymorphism in the Alpha Cardiac Muscle Actin 1 Gene Is Associated to
   Susceptibility to Chronic Inflammatory Cardiomyopathy
SO PLOS ONE
LA English
DT Article
ID CHRONIC CHAGAS-DISEASE; NECROSIS-FACTOR-ALPHA; MYOSIN HEAVY-CHAIN;
   HEART-FAILURE; DILATED CARDIOMYOPATHY; EXPRESSION; MYOCARDITIS;
   CHEMOKINES; INFECTION; CYTOKINES
AB Aims: Chagas disease, caused by the protozoan Trypanosoma cruzi is endemic in Latin America, and may lead to a life-threatening inflammatory dilated, chronic Chagas cardiomyopathy (CCC). One third of T. cruzi-infected individuals progress to CCC while the others remain asymptomatic (ASY). A possible genetic component to disease progression was suggested by familial aggregation of cases and the association of markers of innate and adaptive immunity genes with CCC development. Since mutations in multiple sarcomeric genes, including alpha-cardiac actin (ACTC1) have been involved in hereditary dilated cardiomyopathy, we investigated the involvement of the ACTC1 gene in CCC pathogenesis.
   Methods and Results: We conducted a proteomic and genetic study on a Brazilian study population. The genetic study was done on a main cohort including 118 seropositive asymptomatic subjects and 315 cases and the replication was done on 36 asymptomatic and 102 CCC cases. ACTC1 protein and mRNA levels were lower in myocardial tissue from patients with end-stage CCC than those found in hearts from organ donors. Genotyping a case-control cohort of CCC and ASY subjects for all informative single nucleotide polymorphism (SNP) in the ACTC1 gene identified rs640249 SNP, located at the 5' region, as associated to CCC. Associations are borderline after correction for multiple testing. Correlation and haplotype analysis led to the identification of a susceptibility haplotype. Functional assays have shown that the rs640249A/C polymorphism affects the binding of transcriptional factors in the promoter regions of the ACTC1 gene. Confirmation of the detected association on a larger independent replication cohort will be useful.
   Conclusions: Genetic variations at the ACTC1 gene may contribute to progression to chronic Chagas Cardiomyopathy among T. cruzi-infected patients, possibly by modulating transcription factor binding to ACTC1 promoter regions.
C1 [Frade, Amanda Farage; Teixeira, Priscila Camilo; Ianni, Barbara Maria; Kuramoto, Andreia; Nogueira, Luciana Gabriel; Buck, Paula; Alves, Sthefanny; Fiorelli, Alfredo Inacio; Barros Santos, Ronaldo Honorato; Pereira, Alexandre Costa; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Frade, Amanda Farage; Teixeira, Priscila Camilo; Kuramoto, Andreia; Nogueira, Luciana Gabriel; Kalil, Jorge; Cunha-Neto, Edecio] Inst Nacl Ciencias & Tecnol, Inst Invest Immunol 3, Sao Paulo, Brazil.
   [Pissetti, Cristina Wide] Univ Fed Triangulo Mineiro, Immunol Lab, Uberaba, MG, Brazil.
   [Saba, Bruno; Tzu Wang, Lin Hui; Hirata, Mario; Sampaio, Marcelo; Fragata, Abilio] Inst Cardiol Dante Pazzanese, Sao Paulo, Brazil.
   [Dias, Fabricio; Schmidt, Andre; Donadi, Eduardo; Marin-Neto, Jose Antonio] Univ Sao Paulo, Sch Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Frade, Amanda Farage; Giniaux, Helene; Llored, Agnes; Chevillard, Christophe] Aix Marseille Univ, Marseille, France.
   [Bocchi, Edimar Alcides; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Chevillard, C (corresponding author), Aix Marseille Univ, Marseille, France.
EM christophe.chevillard@univ-amu.fr
RI Marin-Neto, Jose Antonio/F-6099-2012; Cunha-Neto, Edecio/B-4157-2009;
   Frade, Amanda F/O-3322-2017; chevillard, christophe/A-7087-2015; Ianni,
   Barbara Maria/C-7689-2012; KALIL, JORGE/C-8029-2012; Schmidt,
   Andre/G-1569-2011; Buck, Paula C/F-8781-2012; donadi, eduardo
   A/H-7080-2013; Hirata, Mario Hiroyuki/C-9718-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Frade, Amanda
   F/0000-0002-9004-8811; chevillard, christophe/0000-0002-5269-8813;
   Ianni, Barbara Maria/0000-0002-1588-5492; KALIL,
   JORGE/0000-0001-8415-4274; Schmidt, Andre/0000-0002-1090-8165; Buck,
   Paula C/0000-0002-1411-4485; donadi, eduardo A/0000-0002-9457-9601;
   Hirata, Mario Hiroyuki/0000-0002-9521-7979; Lin Wang, Hui
   Tzu/0000-0002-7027-7748; Rodrigues Jr, Virmondes/0000-0001-8706-4223;
   Camillo Teixeira, Priscila/0000-0002-9698-4563
FU Institut National de la Sante et de la Recherche Medicale (INSERM),
   Aix-Marseille University (Direction des Relations Internationales);
   USP-COFECUB program; ARCUS II PACA Brasil program; CNPq (the Brazilian
   National Research Council)National Council for Scientific and
   Technological Development (CNPq); FAPESP (Sao Paulo State Research
   Funding Agency-Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); French ANR agencyFrench National Research Agency (ANR);
   Brazilian FAPESP agencyFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM), Aix-Marseille University (Direction des
   Relations Internationales), the USP-COFECUB program, the ARCUS II PACA
   Brasil program, CNPq (the Brazilian National Research Council), and
   FAPESP (Sao Paulo State Research Funding Agency-Brazil). ECN and CC
   received support from an international program funded by the French ANR
   agency and the Brazilian FAPESP agency. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Ahmad F, 2005, ANNU REV GENOM HUM G, V6, P185, DOI 10.1146/annurev.genom.6.080604.162132
   Barretto A C, 1993, Arq Bras Cardiol, V60, P225
   BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
   BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bilate AM, 2008, J INFECT DIS, V198, P614, DOI 10.1086/590347
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   Dellefave L, 2010, CURR OPIN CARDIOL, V25, P198, DOI 10.1097/HCO.0b013e328337ba52
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569
   Gregorio CC, 1997, CELL STRUCT FUNCT, V22, P191, DOI 10.1247/csf.22.191
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Isnard A, 2011, GENES IMMUN, V12, P31, DOI 10.1038/gene.2010.43
   Januzzi JL, 2013, J AM COLL CARDIOL, V61, P1507, DOI 10.1016/j.jacc.2013.01.039
   Jiang HK, 2010, CIRC J, V74, P2410, DOI 10.1253/circj.CJ-10-0234
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Knoll R, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/569628
   Kruger M, 2009, J MOL CELL CARDIOL, V46, P490, DOI 10.1016/j.yjmcc.2009.01.004
   Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518
   LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035
   LU MH, 1992, J CELL BIOL, V117, P1007, DOI 10.1083/jcb.117.5.1007
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   MARTIN UO, 1987, MEDICINA-BUENOS AIRE, V47, P159
   Mocelin AO, 2005, EUR J HEART FAIL, V7, P869, DOI 10.1016/j.ejheart.2004.10.014
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Nyholt DR, 2005, HUM HERED, V60, P61, DOI 10.1159/000087919
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750
   Pulkki KJ, 1997, ANN MED, V29, P339, DOI 10.3109/07853899708999358
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348
   Reifenberg K, 2007, AM J PATHOL, V171, P463, DOI 10.2353/ajpath.2007.060906
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070
   Sakai N, 2006, P NATL ACAD SCI USA, V103, P14098, DOI 10.1073/pnas.0511200103
   Salvatella R, 2007, MEM I OSWALDO CRUZ, V102, P39, DOI 10.1590/S0074-02762007005000105
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Teixeira PC, 2012, WORLD J CLIN INFECT, V2, P39, DOI DOI 10.5495/WJCID.V2.I3.39
   Teixeira PC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001205
   Tostes S, 2005, INT J CARDIOL, V99, P233, DOI 10.1016/j.ijcard.2004.01.026
   van Veldhuisen DJ, 2013, J AM COLL CARDIOL, V61, P1498, DOI 10.1016/j.jacc.2012.12.044
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 52
TC 18
Z9 18
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2013
VL 8
IS 12
AR e83446
DI 10.1371/journal.pone.0083446
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HY
UT WOS:000328741900018
PM 24367596
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Frade, AF
   Pissetti, CW
   Ianni, BM
   Saba, B
   Lin-Wang, HT
   Nogueira, LG
   Borges, AD
   Buck, P
   Dias, F
   Baron, M
   Ferreira, LRP
   Schmidt, A
   Marin-Neto, JA
   Hirata, M
   Sampaio, M
   Fragata, A
   Pereira, AC
   Donadi, E
   Kalil, J
   Rodrigues, V
   Cunha-Neto, E
   Chevillard, C
AF Frade, Amanda Farage
   Pissetti, Cristina Wide
   Ianni, Barbara Maria
   Saba, Bruno
   Lin-Wang, Hui Tzu
   Nogueira, Luciana Gabriel
   Borges, Ariana de Melo
   Buck, Paula
   Dias, Fabricio
   Baron, Monique
   Pinto Ferreira, Ludmila Rodrigues
   Schmidt, Andre
   Marin-Neto, Jose Antonio
   Hirata, Mario
   Sampaio, Marcelo
   Fragata, Abilio
   Pereira, Alexandre Costa
   Donadi, Eduardo
   Kalil, Jorge
   Rodrigues, Virmondes
   Cunha-Neto, Edecio
   Chevillard, Christophe
TI Genetic susceptibility to Chagas disease cardiomyopathy: involvement of
   several genes of the innate immunity and chemokine-dependent migration
   pathways
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Chagas disease; Susceptibility; CCR5; CCL2; TIRAP
ID NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY COMPLEX;
   TRYPANOSOMA-CRUZI INFECTION; T-CELLS; HEART-DISEASE; DILATED
   CARDIOMYOPATHY; ELICITED MYOCARDITIS; RECEPTOR EXPRESSION; EJECTION
   FRACTION; HLA ANTIGENS
AB Background: Chagas disease, caused by the protozoan Trypanosoma cruzi is endemic in Latin America. Thirty percent of infected individuals develop chronic Chagas cardiomyopathy (CCC), an inflammatory dilated cardiomyopathy that is, by far, the most important clinical consequence of T. cruzi infection. The others remain asymptomatic (ASY). A possible genetic component to disease progression was suggested by familial aggregation of cases and the association of markers of innate and adaptive immunity genes with CCC development. Migration of Th1-type T cells play a major role in myocardial damage.
   Methods: Our genetic analysis focused on CCR5, CCL2 and MAL/TIRAP genes. We used the Tag SNPs based approach, defined to catch all the genetic information from each gene. The study was conducted on a large Brazilian population including 315 CCC cases and 118 ASY subjects.
   Results: The CCL2rs2530797A/A and TIRAPrs8177376A/A were associated to an increase susceptibility whereas the CCR5rs3176763C/C genotype is associated to protection to CCC. These associations were confirmed when we restricted the analysis to severe CCC, characterized by a left ventricular ejection fraction under 40%.
   Conclusions: Our data show that polymorphisms affecting key molecules involved in several immune parameters (innate immunity signal transduction and T cell/monocyte migration) play a role in genetic susceptibility to CCC development. This also points out to the multigenic character of CCC, each polymorphism imparting a small contribution. The identification of genetic markers for CCC will provide information for pathogenesis as well as therapeutic targets.
C1 [Frade, Amanda Farage; Ianni, Barbara Maria; Nogueira, Luciana Gabriel; Buck, Paula; Baron, Monique; Pinto Ferreira, Ludmila Rodrigues; Pereira, Alexandre Costa; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med FMUSP, Heart Inst InCor, BR-06504000 Sao Paulo, Brazil.
   [Frade, Amanda Farage; Nogueira, Luciana Gabriel; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Pissetti, Cristina Wide; Borges, Ariana de Melo; Rodrigues, Virmondes] Univ Fed Triangulo Mineiro, Immunol Lab, BR-48036180 Uberaba, MG, Brazil.
   [Saba, Bruno; Lin-Wang, Hui Tzu; Hirata, Mario; Sampaio, Marcelo; Fragata, Abilio] Inst Cardiol Dante Pazzanese IDPC, BR-04012909 Sao Paulo, Brazil.
   [Dias, Fabricio; Schmidt, Andre; Marin-Neto, Jose Antonio; Donadi, Eduardo] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, BR-15059900 Ribeirao Preto, SP, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-06504000 Sao Paulo, Brazil.
   [Frade, Amanda Farage; Chevillard, Christophe] Aix Marseille Univ, INSERM, GIMP UMR S906, Fac Med, F-13385 Marseille 05, France.
RP Chevillard, C (corresponding author), Aix Marseille Univ, INSERM, GIMP UMR S906, Fac Med, 27 Bd Jean Moulin, F-13385 Marseille 05, France.
EM christophe.chevillard@univ-amu.fr
RI Frade, Amanda F/O-3322-2017; Ianni, Barbara Maria/C-7689-2012; Schmidt,
   Andre/G-1569-2011; donadi, eduardo A/H-7080-2013; Ferreira, Ludmila
   Rodrigues Pinto/B-4955-2015; Buck, Paula C/F-8781-2012; Marin-Neto, Jose
   Antonio/F-6099-2012; chevillard, christophe/A-7087-2015; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Ferreira,
   Ludmila/C-4100-2012; Hirata, Mario Hiroyuki/C-9718-2013
OI Frade, Amanda F/0000-0002-9004-8811; Ianni, Barbara
   Maria/0000-0002-1588-5492; Schmidt, Andre/0000-0002-1090-8165; donadi,
   eduardo A/0000-0002-9457-9601; Ferreira, Ludmila Rodrigues
   Pinto/0000-0001-9944-6691; Buck, Paula C/0000-0002-1411-4485;
   chevillard, christophe/0000-0002-5269-8813; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274; Ferreira,
   Ludmila/0000-0001-9944-6691; Hirata, Mario Hiroyuki/0000-0002-9521-7979;
   Rodrigues Jr, Virmondes/0000-0001-8706-4223; Lin Wang, Hui
   Tzu/0000-0002-7027-7748
FU Institut National de la Sante et de la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille University (Direction des Relations
   Internationales); USP-COFECUB program; ARCUS II PACA Bresil program;
   CNPq (the Brazilian National Research Council)National Council for
   Scientific and Technological Development (CNPq); FAPESP (Sao Paulo State
   Research Funding Agency-Brazil); French ANRFrench National Research
   Agency (ANR); Brazilian FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Sao Paulo State Research Funding Agency,
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Council for Scientific and Technological Development - CNPqNational
   Council for Scientific and Technological Development (CNPq); French
   consulate in Brazil; University of Sao Paulo (USP)
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM), Aix-Marseille University (Direction des
   Relations Internationales), the USP-COFECUB program, the ARCUS II PACA
   Bresil program, CNPq (the Brazilian National Research Council), and
   FAPESP (Sao Paulo State Research Funding Agency-Brazil). ECN and CC were
   recipient for an international program funded either by the French ANR
   and the Brazilian FAPESP agencies. AFF MB and LGN hold fellowships from
   the Sao Paulo State Research Funding Agency, FAPESP. ECN and JK have
   received a Council for Scientific and Technological Development - CNPq
   productivity award. CC is a recipient of a temporary professor position
   supported by the French consulate in Brazil and the University of Sao
   Paulo (USP). We thank for the access to the genotyping platform (Denis
   Milan, Cecile Donnadieu, and Frederic Martins).
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Barbosa AP, 2011, ARQ BRAS CARDIOL, V97, P517, DOI 10.1590/S0066-782X2011005000112
   Barretto A C, 1993, Arq Bras Cardiol, V60, P225
   Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Calzada JE, 2001, TISSUE ANTIGENS, V58, P154, DOI 10.1034/j.1399-0039.2001.580302.x
   Campelo V, 2007, DIGEST DIS SCI, V52, P3334, DOI 10.1007/s10620-006-9699-7
   Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Cruz-Robles D, 2009, IMMUNOL INVEST, V38, P231, DOI 10.1080/08820130902729637
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Cunha-Neto E, 1995, Sao Paulo Med J, V113, P757
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   Drigo SA, 2007, IMMUNOL LETT, V108, P109, DOI 10.1016/j.imlet.2006.10.008
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197
   Fernandez-Mestre MT, 2004, HUM IMMUNOL, V65, P725, DOI 10.1016/j.humimm.2004.05.002
   Florez O, 2011, PARASITE IMMUNOL, V33, P506, DOI 10.1111/j.1365-3024.2011.01314.x
   Florez O, 2012, HUM IMMUNOL, V73, P852, DOI 10.1016/j.humimm.2012.04.005
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Januzzi JL, 2013, J AM COLL CARDIOL, V61, P1507, DOI 10.1016/j.jacc.2013.01.039
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Layrisse Z, 2000, HUM IMMUNOL, V61, P925, DOI 10.1016/S0198-8859(00)00161-0
   LLOP E, 1988, AM J HUM GENET, V43, P770
   LLOP E, 1991, REV MED CHILE, V119, P633
   Magalhaes LMD, 2013, J INFECT DIS, V207, P661, DOI 10.1093/infdis/jis724
   Marino APMP, 2005, MEM I OSWALDO CRUZ, V100, P93, DOI 10.1590/S0074-02762005000900015
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630
   Medeiros GA, 2009, MICROBES INFECT, V11, P264, DOI 10.1016/j.micinf.2008.11.012
   Moreno M, 2004, TISSUE ANTIGENS, V64, P18, DOI 10.1111/j.1399-0039.2004.00260.x
   Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346
   Nogueira LG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001867
   Pissetti CW, 2013, J INTERF CYTOK RES, V33, P130, DOI 10.1089/jir.2012.0024
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   Ramasawmy R, 2007, J INFECT DIS, V196, P1836, DOI 10.1086/523653
   Ramasawmy R, 2008, MOL IMMUNOL, V45, P283, DOI 10.1016/j.molimm.2007.04.015
   Ramasawmy R, 2009, J INFECT DIS, V199, P1838, DOI 10.1086/599212
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Rodrigues DB Rocha, 2013, CLIN DEV IMMUNOL, V2012
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Talvani A, 2004, J INFECT DIS, V189, P214, DOI 10.1086/380803
   Teixeira PC, 2012, WORLD J CLIN INFECT, V2, P39, DOI DOI 10.5495/WJCID.V2.I3.39
   Torres OA, 2010, INFECT GENET EVOL, V10, P682, DOI 10.1016/j.meegid.2010.03.009
   Torres OA, 2009, HUM IMMUNOL, V70, P543, DOI 10.1016/j.humimm.2009.04.022
   van Veldhuisen DJ, 2013, J AM COLL CARDIOL, V61, P1498, DOI 10.1016/j.jacc.2012.12.044
   Vasconcelos RHT, 2012, CYTOKINE, V59, P203, DOI 10.1016/j.cyto.2012.04.035
   Weitzel T, 2012, AM J TROP MED HYG, V86, P229, DOI 10.4269/ajtmh.2012.11-0539
   Zafra G, 2007, MICROBES INFECT, V9, P1049, DOI 10.1016/j.micinf.2007.04.010
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 64
TC 33
Z9 36
U1 1
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 12
PY 2013
VL 13
AR 587
DI 10.1186/1471-2334-13-587
PG 17
WC Infectious Diseases
SC Infectious Diseases
GA 278SJ
UT WOS:000328909700002
PM 24330528
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Terra, LF
   Teixeira, PC
   Wailemann, RAM
   Zelanis, A
   Palmisano, G
   Cunha-Neto, E
   Kalil, J
   Larsen, MR
   Labriola, L
   Sogayar, MC
AF Terra, Leticia F.
   Teixeira, Priscila C.
   Wailemann, Rosangela A. M.
   Zelanis, Andre
   Palmisano, Giuseppe
   Cunha-Neto, Edecio
   Kalil, Jorge
   Larsen, Martin R.
   Labriola, Leticia
   Sogayar, Mari C.
TI Proteins differentially expressed in human beta-cells-enriched
   pancreatic islet cultures and human insulinomas
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Islets; lnsulinomas; Mammalian biology; Mass spectrometry; Diabetes;
   Pancreatic cell biology
ID VASCULAR SMOOTH-MUSCLE; TRANSFORMED-CELLS; NUCLEAR RECEPTOR;
   LUNG-CANCER; CHROMOSOMAL LOCALIZATION; ANTIMICROBIAL PEPTIDES; NONMUSCLE
   CALDESMON; GLUCOSE-TRANSPORT; BINDING PROTEINS; SURVIVAL FACTOR
AB In view of the great demand for human beta-cells for physiological and medical studies, we generated cell lines derived from human insulinomas which secrete insulin, C-peptide and express neuroendocrine and islet markers. In this study, we set out to characterize their proteomes, comparing them to those of primary beta-cells using DIGE followed by MS. The results were validated by Western blotting. An average of 1800 spots was detected with less than 1% exhibiting differential abundance. Proteins more abundant in human islets, such as Caldesmon, are involved in the regulation of cell contractility, adhesion dependent signaling, and cytoskeletal organization. In contrast, almost all proteins more abundant in insulinoma cells, such as MAGE2, were first described here and could be related to cell survival and resistance to chemotherapy. Our proteomic data provides, for the first time, a molecular snapshot of the orchestrated changes in expression of proteins involved in key processes which could be correlated with the altered phenotype of human beta-cells. Collectively our observations prompt research towards the establishment of bioengineered human beta-cells providing a new and needed source of cultured human beta-cells for beta-cell researeh, along with the development of new therapeutic strategies for detection, characterization and treatment of insulinomas. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Terra, Leticia F.; Wailemann, Rosangela A. M.; Labriola, Leticia; Sogayar, Mari C.] Univ Sao Paulo, Dept Bioquim, Inst Quim, BR-05508900 Sao Paulo, Brazil.
   [Teixeira, Priscila C.; Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Fac Med, Inst Coracao, BR-05508900 Sao Paulo, Brazil.
   [Zelanis, Andre] Inst Butantan, Lab Especial Toxinol Aplicada CAT CEPID, Sao Paulo, Brazil.
   [Palmisano, Giuseppe; Larsen, Martin R.] Univ Southern Denmark, Biochem & Mol Biol Dept, Odense, Denmark.
   [Palmisano, Giuseppe] Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil.
RP Labriola, L (corresponding author), Univ Sao Paulo, Dept Bioquim, Inst Quim, Av Prof Lineu Prestes 748,Bloco 9 Inf,Sala 908, BR-05508900 Sao Paulo, Brazil.
EM labriola@iq.usp.br; mcsoga@iq.usp.br
RI Wailemann, Rosangela/Y-6796-2019; Terra, Leticia F./L-6980-2019;
   Cunha-Neto, Edecio/B-4157-2009; Labriola, Leticia/E-9059-2012; Zelanis,
   Andre/AAD-4618-2019; Terra, Leticia/E-7332-2011; Sogayar, Mari
   C/B-3980-2017; KALIL, JORGE/C-8029-2012; Palmisano,
   Giuseppe/N-3602-2013; Larsen, Martin Rossel/F-1411-2015
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Labriola,
   Leticia/0000-0003-3899-6088; Zelanis, Andre/0000-0003-3066-6527;
   Sogayar, Mari C/0000-0003-4805-4609; KALIL, JORGE/0000-0001-8415-4274;
   Palmisano, Giuseppe/0000-0003-1336-6151; Larsen, Martin
   Rossel/0000-0001-6203-0123; Terra, Leticia Ferreira/0000-0002-4419-6872;
   Camillo Teixeira, Priscila/0000-0002-9698-4563
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   ADCOCK K, 1975, DIABETOLOGIA, V11, P527, DOI 10.1007/BF01222102
   Agoulnik IY, 1998, FEBS LETT, V424, P73, DOI 10.1016/S0014-5793(98)00142-2
   Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005
   BODEN G, 1989, GASTROENTEROL CLIN N, V18, P831
   BRODER LE, 1973, ANN INTERN MED, V79, P101, DOI 10.7326/0003-4819-79-1-101
   BUCHANAN KD, 1986, AM J MED, V81, P14, DOI 10.1016/0002-9343(86)90581-4
   CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434
   Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003
   Chomez P, 2001, CANCER RES, V61, P5544
   Dash-Wagh S, 2011, MOL CELL NEUROSCI, V48, P195, DOI 10.1016/j.mcn.2011.07.005
   DC and CTR group, 1993, NEW ENGL J MED, V329, P977
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677
   DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446
   Dong HJ, 2001, TRENDS ENDOCRIN MET, V12, P441, DOI 10.1016/S1043-2760(01)00491-X
   Duan ZF, 2003, CLIN CANCER RES, V9, P2778
   Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21
   EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188
   Eizirik DL, 1996, DIABETOLOGIA, V39, P875
   Eves R, 2006, J CELL SCI, V119, P1691, DOI 10.1242/jcs.02881
   Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090
   FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882
   Gartner W, 2006, NEUROENDOCRINOLOGY, V83, P123, DOI 10.1159/000094875
   Ghosh R, 2011, J THROMB THROMBOLYS, V31, P13, DOI 10.1007/s11239-010-0515-z
   Gragnoli C, 2008, J CELL PHYSIOL, V216, P569, DOI 10.1002/jcp.21453
   Greenberg MJ, 2008, CELL MOTIL CYTOSKEL, V65, P156, DOI 10.1002/cm.20251
   Gu ZZ, 2007, EXP CELL RES, V313, P849, DOI 10.1016/j.yexcr.2006.12.005
   GYLFE E, 1986, BIOCHEM J, V233, P865, DOI 10.1042/bj2330865
   Hai CM, 2006, EUR J CELL BIOL, V85, P305, DOI 10.1016/j.ejcb.2005.08.008
   Hay CW, 2006, DIABETES, V55, P3201, DOI 10.2337/db06-0788
   HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771
   HILL RS, 1987, DIABETES, V36, P440, DOI 10.2337/diabetes.36.4.440
   Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6
   INOUE H, 1995, INT J CANCER, V64, P76, DOI 10.1002/ijc.2910640115
   Kaczirek K, 2003, EUR J CLIN INVEST, V33, P488, DOI 10.1046/j.1365-2362.2003.01158.x
   Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364
   Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918
   Keller A, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100024
   Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917
   Kilani RT, 2007, J RHEUMATOL, V34, P1650
   Koganehira Y, 2003, BRIT J DERMATOL, V148, P971, DOI 10.1046/j.1365-2133.2003.05238.x
   Labriola L, 2007, MOL CELL ENDOCRINOL, V264, P16, DOI 10.1016/j.mce.2006.10.004
   Labriola L, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-49
   Lan ZJ, 2009, BIOL REPROD, V80, P905, DOI 10.1095/biolreprod.107.067322
   Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105
   Liang G, 2002, CANCER RES, V62, P961
   MacFarlane WM, 1999, J BIOL CHEM, V274, P34059, DOI 10.1074/jbc.274.48.34059
   Machado M C, 1998, Rev Assoc Med Bras (1992), V44, P159
   Maria-Engler SS, 2004, J ENDOCRINOL, V183, P455, DOI 10.1677/joe.1.05703
   Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662
   Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200
   MEGLASSON MD, 1986, DIABETES, V35, P1340, DOI 10.2337/diabetes.35.12.1340
   MENEGAUX F, 1993, AM J SURG, V165, P243, DOI 10.1016/S0002-9610(05)80519-7
   Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103
   Morita T, 2007, J BIOL CHEM, V282, P8454, DOI 10.1074/jbc.M609983200
   Motoyama JPL, 2007, BIOCHEM BIOPH RES CO, V357, P828, DOI 10.1016/j.bbrc.2007.03.112
   Mukamal KJ, 1999, AM HEART J, V137, P1120, DOI 10.1016/S0002-8703(99)70372-8
   Mukhopadhyay UK, 2009, MOL CELL BIOL, V29, P3088, DOI 10.1128/MCB.01816-08
   Nielsen K, 1999, DIABETES, V48, P2324, DOI 10.2337/diabetes.48.12.2324
   Nielsen K, 2004, DIABETOLOGIA, V47, P62, DOI 10.1007/s00125-003-1277-3
   NOVY RE, 1991, J BIOL CHEM, V266, P16917
   Oberg K, 2005, BEST PRACT RES CL GA, V19, P753, DOI 10.1016/j.bpg.2005.06.002
   Ortis F, 2008, DIABETOLOGIA, V51, P1213, DOI 10.1007/s00125-008-0999-7
   Ortis F, 2010, DIABETES, V59, P358, DOI 10.2337/db09-1159
   OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133
   Porter D, 2003, P NATL ACAD SCI USA, V100, P10931, DOI 10.1073/pnas.1932980100
   Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003
   PROYE C, 1987, ACTA CHIR SCAND, V153, P481
   Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492
   RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732
   Schittek B., 2012, J INNATE IMMUN
   Schittek Birgit, 2008, Infectious Disorders - Drug Targets, V8, P135
   SHAPIRO ME, 1995, TRANSPLANT P, V27, P613
   Shen SL, 2011, BBA-MOL BASIS DIS, V1812, P703, DOI 10.1016/j.bbadis.2011.03.004
   SOBUE K, 1991, J BIOL CHEM, V266, P12115
   Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376
   SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7
   TANAKA J, 1993, J CELL SCI, V104, P595
   Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169
   TRAUTMANN ME, 1987, BIOCHEM J, V242, P625, DOI 10.1042/bj2420625
   Tucker ON, 2006, BRIT J SURG, V93, P264, DOI 10.1002/bjs.5280
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   VERSPOHL EJ, 1995, CELL SIGNAL, V7, P505, DOI 10.1016/0898-6568(95)00020-P
   Wang XC, 2004, ENDOCR-RELAT CANCER, V11, P295, DOI 10.1677/erc.0.0110295
   WATKINS D, 1985, J BIOL CHEM, V260, P5161
   Wiesner J, 2010, VIRULENCE, V1, P440, DOI 10.4161/viru.1.5.12983
   Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015
   YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0
   YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0
   Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3
   Yoshio T, 2007, FEBS LETT, V581, P3777, DOI 10.1016/j.febslet.2007.06.073
   Zang DY, 2010, CLIN EXP MED, V10, P221, DOI 10.1007/s10238-009-0089-2
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
NR 96
TC 3
Z9 3
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 5
PY 2013
VL 381
IS 1-2
BP 16
EP 25
DI 10.1016/j.mce.2013.07.004
PG 10
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 260AU
UT WOS:000327568200003
PM 23891624
DA 2020-11-26
ER

PT J
AU Santos, KS
   Stephano, MA
   Marcelino, JR
   Ferreira, VMR
   Rocha, T
   Caricati, C
   Higashi, HG
   Moro, AM
   Kalil, JE
   Malaspina, O
   Castro, FFM
   Palma, MS
AF Santos, Keity Souza
   Stephano, Marco Antonio
   Marcelino, Jose Roberto
   Resende Ferreira, Virginia Maria
   Rocha, Thalita
   Caricati, Celso
   Higashi, Hisako Gondo
   Moro, Ana Maria
   Kalil, Jorge Elias
   Malaspina, Osmar
   Morato Castro, Fabio Fernandes
   Palma, Mario Sergio
TI Production of the First Effective Hyperimmune Equine Serum Antivenom
   against Africanized Bees
SO PLOS ONE
LA English
DT Article
ID APIS-MELLIFERA VENOM; PHOSPHOLIPASE A(2); LETHALITY; MELITTIN
AB Victims of massive bee attacks become extremely ill, presenting symptoms ranging from dizziness and headache to acute renal failure and multiple organ failure that can lead to death. Previous attempts to develop specific antivenom to treat these victims have been unsuccessful. We herein report a F(ab)'(2)-based antivenom raised in horse as a potential new treatment for victims of multiple bee stings. The final product contains high specific IgG titers and is effective in neutralizing toxic effects, such as hemolysis, cytotoxicity and myotoxicity. The assessment of neutralization was revised and hemolysis, the primary toxic effect of these stings, was fully neutralized in vivo for the first time.
C1 [Santos, Keity Souza; Resende Ferreira, Virginia Maria; Kalil, Jorge Elias; Morato Castro, Fabio Fernandes] Univ Sao Paulo, Sch Med, FMUSP, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Santos, Keity Souza; Resende Ferreira, Virginia Maria; Moro, Ana Maria; Kalil, Jorge Elias; Malaspina, Osmar; Morato Castro, Fabio Fernandes; Palma, Mario Sergio] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Stephano, Marco Antonio] Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, Brazil.
   [Marcelino, Jose Roberto] Butantan Inst, Div Hyperimmune Plasmas, Sao Paulo, Brazil.
   [Rocha, Thalita] Univ Sao Francisco, Sch Med, BR-12900000 Braganca Paulista, SP, Brazil.
   [Caricati, Celso] Butantan Inst, Special Pilot Lab Res & Dev Vet Immunobiol, Sao Paulo, Brazil.
   [Higashi, Hisako Gondo] Inst Technol Parana, Curitiba, Parana, Brazil.
   [Moro, Ana Maria] Butantan Inst, Lab Biopharmaceut Anim Cells, Sao Paulo, Brazil.
   [Santos, Keity Souza; Kalil, Jorge Elias; Morato Castro, Fabio Fernandes] Univ Sao Paulo, Sch Med, Heart Inst InCor, LIM 19, Sao Paulo, Brazil.
   [Malaspina, Osmar; Palma, Mario Sergio] Univ Sao Paulo State UNESP, Ctr Study Social Insects, Inst Biosci, Dept Biol, Rio Claro, SP, Brazil.
RP Palma, MS (corresponding author), Inst Invest Immunol INCT, Sao Paulo, Brazil.
EM mspalma@rc.unesp.br
RI KALIL, JORGE/C-8029-2012; Rocha, Thalita/T-6408-2019; Palma,
   Mario/N-3903-2019; Palma, Mario Sergio/E-7800-2012; Stephano,
   Marco/H-3980-2013; Castro, Fabio FM/C-1082-2017; Santos,
   Keity/M-9401-2015; Fapesp, Biota/F-8655-2017; Castro,
   Fabio/AAP-5433-2020; Santos, Keity Souza/Q-5704-2019; Moro, Ana
   Maria/A-5134-2012
OI KALIL, JORGE/0000-0001-8415-4274; Rocha, Thalita/0000-0002-2731-9586;
   Palma, Mario Sergio/0000-0002-7363-8211; Stephano,
   Marco/0000-0003-2927-0584; Castro, Fabio FM/0000-0002-6211-5773; Fapesp,
   Biota/0000-0002-9887-8449; Santos, Keity Souza/0000-0001-5271-4011;
   Moro, Ana Maria/0000-0002-0650-7764; Malaspina,
   Osmar/0000-0002-1650-257X
FU FAPESP/BIOprospecTAFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/51684-1]; CNPq (INCT-III)National Council for Scientific
   and Technological Development (CNPq); FINEP (CT-BIOTEC-Anticorpos
   -MCTFINEP); National Research Council of Brazil-CNPqNational Council for
   Scientific and Technological Development (CNPq); Butantan Institute;
   CAPESCAPES
FX This work was supported by grants from FAPESP/BIOprospecTA
   (2011/51684-1), CNPq (INCT-iii) and FINEP (CT-BIOTEC-Anticorpos
   -MCTFINEP 01/2003). JEK, OM and MSP were awarded a research grant from
   the National Research Council of Brazil-CNPq. KSS was awarded PhD
   fellowship from Butantan Institute, and VMRF has a PhD student
   fellowship from CAPES. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript
CR Christensen P. A., 1968, P437
   COVELL DG, 1986, CANCER RES, V46, P3969
   de Oliveira F A, 2000, Rev Soc Bras Med Trop, V33, P403, DOI 10.1590/S0037-86822000000400012
   de Roodt Adolfo R, 2005, Gac Med Mex, V141, P215
   Delori P, 1977, B I PASTEUR, V74, P6
   Ewan PW, 1998, BRIT MED J, V316, P1442, DOI 10.1136/bmj.316.7142.1442
   Ferreira RS, 2010, TOXICON, V56, P355, DOI 10.1016/j.toxicon.2010.03.023
   Fitzgerald KT, 2006, CLIN TECH SMALL AN P, V21, P194, DOI 10.1053/j.ctsap.2006.10.002
   FRANCA FOS, 1994, Q J MED, V87, P269
   Ismail M, 1996, TOXICON, V34, P1011, DOI 10.1016/0041-0101(96)00055-4
   Jones RGA, 1999, AM J TROP MED HYG, V61, P361, DOI 10.4269/ajtmh.1999.61.361
   Kerr W. E., 1967, S AFR BEE J, V39, P3
   Kolecki P, 1999, ANN EMERG MED, V33, P114, DOI 10.1016/S0196-0644(99)70428-2
   Lee YJ, 2007, CHEM-BIOL INTERACT, V169, P189, DOI 10.1016/j.cbi.2007.06.036
   Leon G, 1997, TOXICON, V35, P1627, DOI 10.1016/S0041-0101(97)00034-2
   LONGROWE KO, 1994, TOXICON, V32, P165, DOI 10.1016/0041-0101(94)90105-8
   MCKENNA WR, 1992, PEDIATR ASTHMA ALLER, V6, P275, DOI 10.1089/pai.1992.6.275
   Mejia-Velez G, 2010, NEFROLOGIA, V30, P531, DOI 10.3265/Nefrologia.pre2010.May.10269
   OCONNOR R, 1980, J CHEM EDUC, V57, P206, DOI 10.1021/ed057p206
   Ownby CL, 1997, TOXICON, V35, P67, DOI 10.1016/S0041-0101(96)00078-5
   Patterson M K Jr, 1979, Methods Enzymol, V58, P141
   Pope CG, 1939, BRIT J EXP PATHOL, V20, P132
   Prado M, 2009, REV PANAM SALUD PUBL, V25, P389, DOI 10.1590/S1020-49892009000500002
   Robertson ML, 1998, EMERGEN MED, V10, P5
   Rocha T, 2007, TOXICON, V50, P589, DOI 10.1016/j.toxicon.2007.05.003
   SCHUMACHER MJ, 1990, AM J TROP MED HYG, V43, P79, DOI 10.4269/ajtmh.1990.43.79
   SCHUMACHER MJ, 1995, ARCH INTERN MED, V155, P2038, DOI 10.1001/archinte.155.19.2038
   Schumacher MJ, 1996, AM J TROP MED HYG, V55, P197, DOI 10.4269/ajtmh.1996.55.197
   Souza BM, 2005, PEPTIDES, V26, P2157, DOI 10.1016/j.peptides.2005.04.026
   SPIVAK M, 1991, AFRICAN HONEYBEE
   WINSTON ML, 1994, Q J MED, V87, P263
   Winston ML, 1992, KILLER BEES AFRICANI
NR 32
TC 6
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 13
PY 2013
VL 8
IS 11
AR e79971
DI 10.1371/journal.pone.0079971
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255QK
UT WOS:000327254700167
PM 24236166
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Milagres, LG
   Costa, PR
   Santos, BAN
   Silva, GP
   Cruz, AC
   Pereira-Manfro, WF
   Ferreira, B
   Barreto, DM
   Frota, ACC
   Kalil, J
   Hofer, CB
   Kallas, EG
AF Milagres, Lucimar G.
   Costa, Priscilla R.
   Santos, Bianca A. N.
   Silva, Giselle P.
   Cruz, Aline C.
   Pereira-Manfro, Wania F.
   Ferreira, Bianca
   Barreto, Daniella M.
   Frota, Ana Cristina C.
   Kalil, Jorge
   Hofer, Cristina B.
   Kallas, Esper G.
TI CD4(+) T-cell activation impairs serogroup C Neisseria meningitis
   vaccine response in HIV-infected children
SO AIDS
LA English
DT Article
DE bactericidal antibody; CD4(+) T-lymphocyte activation; children; HIV;
   meningococcal vaccine; regulatory T cell; seroconversion
ID MENINGOCOCCAL CONJUGATE VACCINE; IMMUNOGENICITY; SAFETY; DISEASE;
   ANTIGEN; HAART
AB Objective:To investigate the influence of CD4(+) T-cell activation and regulatory populations in HIV-infected children antibody response to vaccination with a conjugate C polysaccharide vaccine.Design:CD4(+) T-cell activation was evaluated by expression of CD38, HLA-DR and CCR5 molecules. Regulatory CD4(+) T cells (T-Reg) were characterized as FoxP3(+)CD127(-)CD25(+) and inducer T cells (T-Ind) as CD4(+)FoxP3(-)CD25(-)CD39(+).Methods:All patients (n=36) were HIV-vertically infected, aged 2-17 years-old and were vaccinated with one vaccine injection. Blood samples were obtained before and after immunization to determine bactericidal antibody titers (SBA), CD4(+) T-cell activation and frequency of T-Reg and T-Ind subsets (multiparametric flow cytometry).Results:Children not-responding (n=18) to MenC vaccine expressed higher frequency of activated CD4(+) T cells (HLA-DR(+)CD38(+)CCR5(+)) than responders (n=18), both before and after vaccination (P<0.05). A significant higher frequency of T-Reg was detected in responders compared with nonresponders (P=0.0001). We also detected an inverse correlation between CD4(+)DR(+)CD38(+)CCR5(+) (P=0.01) or CD4(+)DR(+)CD38(+) (P=0.02) T cells and T-Reg cell frequency after vaccination. CD4(+) T-cell activation negatively correlated (P=0.006) with postvaccination SBA titers but a positive correlation (P=0.0001) was detected between T-Reg cells and SBA. T-Reg and T-Ind subsets were inversely correlated (P=0.04).Conclusion:Our findings suggest that higher CD4(+) T-cell activation leads to poor vaccine response in children living with HIV, which may be associated with a T-Reg/T-Ind disequilibrium.
C1 [Milagres, Lucimar G.; Silva, Giselle P.; Cruz, Aline C.; Pereira-Manfro, Wania F.] Univ Estado Rio De Janeiro, Dept Microbiol Immunol & Parasitol, Rio De Janeiro, Brazil.
   [Costa, Priscilla R.; Santos, Bianca A. N.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Ferreira, Bianca; Barreto, Daniella M.; Frota, Ana Cristina C.; Hofer, Cristina B.] Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Sch Med, Rio De Janeiro, Brazil.
   [Hofer, Cristina B.] Univ Fed Rio de Janeiro, Sch Med, Dept Prevent Med, Rio De Janeiro, Brazil.
RP Milagres, LG (corresponding author), Disciplina Microbiol, Av Prof Manoel de Abreu 444,Terceiro Andar, BR-20550170 Rio De Janeiro, RJ, Brazil.
EM lucimar@uerj.br
RI Frota, Ana Cristina/L-3644-2018; KALIL, JORGE/C-8029-2012; Manfro, Wania
   FP/M-5882-2013
OI Frota, Ana Cristina/0000-0002-2825-4374; KALIL,
   JORGE/0000-0001-8415-4274; Manfro, Wania/0000-0003-0166-8144; Kallas,
   Esper/0000-0003-2026-6925
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [573879/2008-7, 552497/2011-8]; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/112.645/2012]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2009/54055-5]; CNPqNational Council for Scientific
   and Technological Development (CNPq); CAPESCAPES; Fogarty Institute of
   the National Institutes of Health [5R01TW008397]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R01TW008397, R01TW008397, R01TW008397, R01TW008397, R01TW008397]
   Funding Source: NIH RePORTER
FX This work was funded by CNPq grants (#573879/2008-7 to J.K. and E.G.K.
   and #552497/2011-8 (Edital Casadinho) to L.G.M. and E.G.K.), FAPERJ
   (#E-26/112.645/2012 to L.G.M.) and FAPESP (#2009/54055-5 to E.G.K.).
   P.R.C. and B.N.S. received scholarship support from CNPq; G.S.P. and
   A.C.C. received scholarship support from CAPES. We are also grateful to
   Fogarty Institute of the National Institutes of Health under award
   number 5R01TW008397 to CBH. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3
   Chang Qiuzhi, 2012, Clin Epidemiol, V4, P237, DOI 10.2147/CLEP.S28410
   Cohen C, 2010, AIDS, V24, P1351, DOI 10.1097/QAD.0b013e32833a2520
   COVER/SVS/MS, COORD VIG DOENC TRAN
   De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375
   Balado MDD, 2010, J INFECT DIS, V202, P362, DOI 10.1086/653707
   DICKOVER RE, 1994, J INFECT DIS, V170, P1279, DOI 10.1093/infdis/170.5.1279
   Frota ACC, 2013, 7 IAS C HIV PATH TRE
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Goicoechea M, 2006, J INFECT DIS, V194, P29, DOI 10.1086/504718
   Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924
   Imamichi H, 2012, J INFECT DIS, V205, P1479, DOI 10.1093/infdis/jis238
   Kared H, 2008, AIDS, V22, P2451, DOI 10.1097/QAD.0b013e328319edc0
   Kinter AL, 2007, AIDS RES HUM RETROV, V23, P438, DOI 10.1089/aid.2006.0162
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314
   Lujan-Zilbermann J, 2012, J PEDIATR-US, V161, P676, DOI 10.1016/j.jpeds.2012.04.005
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156, DOI 10.1128/CDLI.4.2.156-167.1997
   Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12
   Ndhlovu LC, 2010, EUR J IMMUNOL, V40, P134, DOI 10.1002/eji.200939258
   Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110
   Obaro SK, 2004, LANCET INFECT DIS, V4, P510, DOI 10.1016/S1473-3099(04)01106-5
   OBRIEN WA, 1995, BLOOD, V86, P1082
   Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Siberry GK, 2012, PEDIATR INFECT DIS J, V31, P47, DOI 10.1097/INF.0b013e318236c67b
   Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903
   Westrop SJ, 2012, MOL MED, V18, P1240, DOI 10.2119/molmed.2012.00206
   Westrop SJ, 2010, J VIRAL ENTRY, V4, P1
   Zaccarelli CA, 2007, CYTOM PART B-CLIN CY, V72B, P14, DOI 10.1002/cyto.b.20152
NR 31
TC 9
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2013
VL 27
IS 17
BP 2697
EP 2705
DI 10.1097/QAD.0000000000000007
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 250HR
UT WOS:000326841800004
PM 24149087
DA 2020-11-26
ER

PT J
AU Malta, FM
   Bruno, FR
   Carvalho, KI
   Nastri, ACSS
   Kalil, J
   Carrilho, FJ
   Kallas, EG
   Pinho, JRR
AF Malta, F. M.
   Bruno, F. R.
   Carvalho, K. I.
   Nastri, A. C. S. S.
   Kalil, J.
   Carrilho, F. J.
   Kallas, E. G.
   Pinho, J. R. R.
TI HCV Viremia Drives an Increment of CD86 Expression by Myeloid Dendritic
   Cells
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis C virus; innate immunity; dendritic cell; chronic infection;
   CD86
ID HEPATITIS-C VIRUS; GENETIC-VARIATION; FUNCTIONAL-CAPACITY;
   IMMUNE-RESPONSES; INFECTION; INNATE; IL28B; ASSOCIATION; MATURATION;
   CLEARANCE
AB The host immune response, including innate and adaptive immunity, plays a critical role in determining the outcome of viral infection. Nevertheless, little is known about the exact reasons for the failure of the host immune system in controlling hepatitis C virus (HCV) infection. Impairment of dendritic cells (DCs) function is probably one of the mechanisms responsible for immune evasion of HCV. In this study, the frequency and phenotype of DCs subsets were analyzed in three groups: HCV-infected individuals who developed viral persistence (1), HCV-infected individuals who spontaneously cleared the virus (2) and HCV-seronegative uninfected subjects (3). The results showed that the frequency of DCs subsets was not statistically significant between groups. Plasmacytoid DCs circulating exhibited an immature phenotype characterized by low expression of CD86. On the other hand, CD86 expression in myeloid DCs was significantly higher in chronic infected individuals compared to healthy controls (P=0.037). A positive correlation was observed between CD86(+) myeloid DC (mDC) and HCV viral load (r=0.4121, P=0.0263). These results suggest that HCV did not have an inhibitory effect on mDC maturation and the HCV viremia drives the increase of CD86 expression in mDC. The regulation of DCs maturation and migration lies at the level of intracellular signaling. HCV can activate or block intracellular signaling pathways and alter DC function. In conclusion, the present study suggests that imbalance of DC maturation by the virus represents a mechanism of evasion of the immune system despite the fact that HCV viremia appears to exert a stimulatory effect on cell-surface immune phenotype. J Med. Virol. 85:1919-1924, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Malta, F. M.; Nastri, A. C. S. S.; Carrilho, F. J.; Pinho, J. R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Bruno, F. R.; Carvalho, K. I.; Kalil, J.; Kallas, E. G.] Univ Sao Paulo, Clin Immunol & Allergy Branch, Dept Internal Med, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Carvalho, K. I.; Pinho, J. R. R.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nastri, A. C. S. S.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05403000 Sao Paulo, Brazil.
RP Malta, FM (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Eneas Carvalho Aguiar,500-2 Andar IMT II, BR-05403000 Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Carvalho, Karina IL/J-6789-2012; KALIL, JORGE/C-8029-2012; Pinho, Joao
   R. R./G-2850-2012; Malta, Fernanda/B-1316-2013; Carrilho, Flair
   J/I-3046-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; KALIL,
   JORGE/0000-0001-8415-4274; Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Kallas, Esper/0000-0003-2026-6925
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [09/53.270-0, 09/53.306-4.]; FFM; HC-FMUSP; Alves de Queiroz Family
   Fund; Tropical Medicine Institute of Sao Paulo
FX Grant sponsor: FAPESP; Grant numbers: 09/53.270-0, 09/53.306-4.; Grant
   sponsor: FFM; Grant sponsor: HC-FMUSP; Grant sponsor: Alves de Queiroz
   Family Fund; Grant sponsor: Tropical Medicine Institute of Sao Paulo
CR Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171
   Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barchet W, 2005, SEMIN IMMUNOL, V17, P253, DOI 10.1016/j.smim.2005.05.008
   Barnes E, 2008, J VIRAL HEPATITIS, V15, P219, DOI 10.1111/j.1365-2893.2007.00934.x
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Della Bella S, 2007, IMMUNOLOGY, V121, P283, DOI 10.1111/j.1365-2567.2007.02577.x
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Harrison RJ, 2010, CLIN EXP IMMUNOL, V161, P306, DOI 10.1111/j.1365-2249.2010.04169.x
   Jo J, 2011, J GEN VIROL, V92, P477, DOI 10.1099/vir.0.027987-0
   Kanto T, 2004, J INFECT DIS, V190, P1919, DOI 10.1086/425425
   Kanto T, 1999, J IMMUNOL, V162, P5584
   Landi A, 2011, J VIRAL HEPATITIS, V18, P700, DOI 10.1111/j.1365-2893.2010.01357.x
   LARSEN CP, 1994, J IMMUNOL, V152, P5208
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Longman RS, 2005, J INFECT DIS, V192, P497, DOI 10.1086/431523
   Longman RS, 2004, BLOOD, V103, P1026, DOI 10.1182/blood-2003-04-1339
   Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482
   Pachiadakis I, 2009, CLIN IMMUNOL, V131, P415, DOI 10.1016/j.clim.2009.02.001
   Pachiadakis L, 2005, LANCET INFECT DIS, V5, P296, DOI 10.1016/S1473-3099(05)70114-6
   Piccioli D, 2005, J HEPATOL, V42, P61, DOI 10.1016/j.jhep.2004.09.014
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056
   Rehermann B, 2000, SEMIN LIVER DIS, V20, P127, DOI 10.1055/s-2000-9946
   Rehermann B, 2000, CURR TOP MICROBIOL, V242, P299
   Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133
   Reizis B, 2011, NAT REV IMMUNOL, V11, P558, DOI 10.1038/nri3027
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Ryan EJ, 2011, J VIRAL HEPATITIS, V18, P601, DOI 10.1111/j.1365-2893.2011.01453.x
   Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
   Sun JR, 2001, J VIROL, V75, P11992, DOI 10.1128/JVI.75.24.11992-11998.2001
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006
NR 36
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2013
VL 85
IS 11
BP 1919
EP 1924
DI 10.1002/jmv.23692
PG 6
WC Virology
SC Virology
GA 282UG
UT WOS:000329198500008
PM 23926073
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Rosa, DS
   Ribeiro, SP
   Santana, VC
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Almeida, R. R.
   Rosa, D. S.
   Ribeiro, S. P.
   Santana, V. C.
   Kallas, E. G.
   Sidney, J.
   Sette, A.
   Kalil, J.
   Cunha-Neto, E.
TI Broad and Cross-clade CD4+T-Cell Responses Elicited by a DNA Vaccine
   Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus
   Peptides
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY OCT 07-10, 2013
CL Barcelona, SPAIN
C1 [Almeida, R. R.; Ribeiro, S. P.; Santana, V. C.; Kallas, E. G.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Rosa, D. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Sidney, J.; Sette, A.] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Kalil, J.] Inst Heart, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; KALIL,
   JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP A145
EP A145
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500380
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Rosa, DS
   Ribeiro, S
   Almeida, RR
   Santana, VC
   Kalil, J
AF Cunha-Neto, E.
   Rosa, D. S.
   Ribeiro, S.
   Almeida, R. R.
   Santana, V. C.
   Kalil, J.
TI Antigen Design to Maximize Anti-HIV CD4+T Cell Responses: Provision of
   Cognate Help, Increased Coverage and Coping with HIV Genetic Variability
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY OCT 07-10, 2013
CL Barcelona, SPAIN
C1 [Cunha-Neto, E.; Ribeiro, S.; Almeida, R. R.; Santana, V. C.; Kalil, J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Rosa, D. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Rosa, Daniela
   S/D-2190-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Rosa, Daniela S/0000-0003-4536-891X
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP A189
EP A189
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500492
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Rosa, DS
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Rosa, D. S.
   Kalil, J.
   Cunha-Neto, E.
TI HIV CD4 Based Vaccine Increases CD8 T Cell Responses and Confers
   Protection Against Challenge with Recombinant Vaccinia Encoding HIV
   Gag-Pol Proteins
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY OCT 07-10, 2013
CL Barcelona, SPAIN
C1 [Ribeiro, S. P.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Rosa, D. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Kalil, J.] Butantan Inst, Inst Heart, Sao Paulo, Brazil.
   [Cunha-Neto, E.] Heart Inst Iii INCT, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; KALIL,
   JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP A185
EP A185
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500482
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   de Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Barreto de Oliveira, Ana Karolina
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI IVIg Immune Reconstitution Treatment Alleviates the State of Persistent
   Immune Activation and Suppressed CD4 T Cell Counts in CVID
SO PLOS ONE
LA English
DT Article
ID COMMON VARIABLE IMMUNODEFICIENCY; CD1D-RESTRICTED NKT CELLS; MICROBIAL
   TRANSLOCATION; DENDRITIC CELLS; HIV-INFECTION; DISEASE PROGRESSION;
   REPLACEMENT THERAPY; MECHANISMS; EXPRESSION; FREQUENCY
AB Common variable immunodeficiency (CVID) is characterized by defective B cell function, impaired antibody production, and increased susceptibility to bacterial infections. Here, we addressed the hypothesis that poor antibody-mediated immune control of infections may result in substantial perturbations in the T cell compartment. Newly diagnosed CVID patients were sampled before, and 6-12 months after, initiation of intravenous immunoglobulin (IVIg) therapy. Treatment-naive CVID patients displayed suppressed CD4 T cell counts and myeloid dendritic cell (mDC) levels, as well as high levels of immune activation in CD8 T cells, CD4 T cells, and invariant natural killer T (iNKT) cells. Expression of co-stimulatory receptors CD80 and CD83 was elevated in mDCs and correlated with T cell activation. Levels of both FoxP3+ T regulatory (Treg) cells and iNKT cells were low, whereas soluble CD14 (sCD14), indicative of monocyte activation, was elevated. Importantly, immune reconstitution treatment with IVIg partially restored the CD4 T cell and mDC compartments. Treatment furthermore reduced the levels of CD8 T cell activation and mDC activation, whereas levels of Treg cells and iNKT cells remained low. Thus, primary deficiency in humoral immunity with impaired control of microbial infections is associated with significant pathological changes in cell-mediated immunity. Furthermore, therapeutic enhancement of humoral immunity with IVIg infusions alleviates several of these defects, indicating a relationship between poor antibody-mediated immune control of infections and the occurrence of abnormalities in the T cell and mDC compartments. These findings help our understanding of the immunopathogenesis of primary immunodeficiency, as well as acquired immunodeficiency caused by HIV-1 infection.
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden.
   [Santos, Bianca A. N.; Carvalho, Karina I.; Toledo-Barros, Myrthes; Barreto de Oliveira, Ana Karolina; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Sandberg, JK (corresponding author), Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden.
EM johan.sandberg@ki.se
RI Carvalho, Karina IL/J-6789-2012; KALIL, JORGE/C-8029-2012; Kokron,
   Cristina M/D-3140-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; KALIL,
   JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305;
   Paquin Proulx, Dominic/0000-0003-1407-3414; Moll,
   Markus/0000-0003-4592-3063; Sandberg, Johan/0000-0002-6275-0750; Kallas,
   Esper/0000-0003-2026-6925
FU Swedish Research CouncilSwedish Research Council; Swedish Cancer
   Foundation; Stockholm County CouncilStockholm County Council; Karolinska
   InstitutetKarolinska Institutet; US National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [AI52731]; Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR); Conselho Nacional
   de Pesquisa (CNPq), Brazilian Ministry of Science and TechnologyNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) through the PNPD
   Program, Brazilian Ministry of EducationCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX The study was supported by the Swedish Research Council, the Swedish
   Cancer Foundation, Stockholm County Council, Karolinska Institutet, and
   the US National Institutes of Health grant AI52731. DPP is the recipient
   of a postdoctoral fellowship from the Canadian Institutes of Health
   Research. BANS is the recipient of a master fellowship from the Conselho
   Nacional de Pesquisa (CNPq), Brazilian Ministry of Science and
   Technology. KIC is the recipient of a postdoctoral fellowship from the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   through the PNPD Program, Brazilian Ministry of Education. The group at
   the University of Sao Paulo coordinates one of the Brazilian National
   Institutes of Science and Technology (Instituto de Investigacao em
   Imunologia - iii), funded by the CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aukrust P, 1997, J INFECT DIS, V176, P913, DOI 10.1086/516510
   Ballow M, 2011, CLIN IMMUNOL, V139, P208, DOI 10.1016/j.clim.2011.02.006
   Barbosa RR, 2012, CLIN EXP IMMUNOL, V169, P263, DOI 10.1111/j.1365-2249.2012.04620.x
   Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957
   Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001
   Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Eller MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018779
   Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433
   Genre J, 2009, CLIN IMMUNOL, V132, P215, DOI 10.1016/j.clim.2009.03.519
   GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932
   Gouilleux-Gruart V, 2013, CLIN EXP IMMUNOL, V171, P186, DOI 10.1111/cei.12002
   Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Kasztalska K, 2011, CLIN DRUG INVEST, V31, P299, DOI 10.2165/11586710-000000000-00000
   Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515
   Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771
   Kaveri SV, 2011, CLIN EXP IMMUNOL, V164, P2, DOI 10.1111/j.1365-2249.2011.04387.x
   Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0
   Klatt NR, 2012, TRENDS MICROBIOL
   Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134
   Litzman J, 2012, CLIN EXP IMMUNOL, V170, P321, DOI 10.1111/j.1365-2249.2012.04655.x
   Melo KM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006269
   Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780
   Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Nordoy I, 1998, CLIN EXP IMMUNOL, V114, P258
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x
   Sandberg JK, 2005, TRENDS IMMUNOL, V26, P347, DOI 10.1016/j.it.2005.05.006
   Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002
   Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848
   Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
   Van Kaer L, 2012, TRENDS IMMUNOL
   Vermeulen JN, 2007, AIDS RES HUM RETROV, V23, P1348, DOI 10.1089/aid.2006.0210
   Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599
NR 46
TC 35
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2013
VL 8
IS 10
AR e75199
DI 10.1371/journal.pone.0075199
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236PJ
UT WOS:000325810900021
PM 24130688
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Luque, MCA
   Gutierrez, PS
   Debbas, V
   Martins, WK
   Puech-Leao, P
   Porto, G
   Coelho, V
   Boumsell, L
   Kalil, J
   Stolf, B
AF Aquino Luque, Maria Carolina
   Gutierrez, Paulo Sampaio
   Debbas, Victor
   Martins, Waleska Kerllen
   Puech-Leao, Pedro
   Porto, Georgia
   Coelho, Veronica
   Boumsell, Laurence
   Kalil, Jorge
   Stolf, Beatriz
TI Phage Display Identification of CD100 in Human Atherosclerotic Plaque
   Macrophages and Foam Cells
SO PLOS ONE
LA English
DT Article
ID AMERICAN-HEART-ASSOCIATION; SURFACE EXPRESSION; SCAVENGER RECEPTORS;
   VASCULAR-LESIONS; SOLUBLE CD100; ARTERIOSCLEROSIS; DEFINITION;
   ACTIVATION; COMMITTEE; COUNCIL
AB Atherosclerosis is a complex disease in which vessels develop plaques comprising dysfunctional endothelium, monocyte derived lipid laden foam cells and activated lymphocytes. Considering that humans and animal models of the disease develop quite distinct plaques, we used human plaques to search for proteins that could be used as markers of human atheromas. Phage display peptide libraries were probed to fresh human carotid plaques, and a bound phage homologous to plexin B1, a high affinity receptor for CD100, was identified. CD100 is a member of the semaphorin family expressed by most hematopoietic cells and particularly by activated T cells. CD100 expression was analyzed in human plaques and normal samples. CD100 mRNA and protein were analyzed in cultured monocytes, macrophages and foam cells. The effects of CD100 in oxLDL-induced foam cell formation and in CD36 mRNA abundance were evaluated. Human atherosclerotic plaques showed strong labeling of CD100/SEMA4D. CD100 expression was further demonstrated in peripheral blood monocytes and in in vitro differentiated macrophages and foam cells, with diminished CD100 transcript along the differentiation of these cells. Incubation of macrophages with CD100 led to a reduction in oxLDL-induced foam cell formation probably through a decrease of CD36 expression, suggesting for the first time an atheroprotective role for CD100 in the human disease. Given its differential expression in the numerous foam cells and macrophages of the plaques and its capacity to decrease oxLDL engulfment by macrophages we propose that CD100 may have a role in atherosclerotic plaque development, and may possibly be employed in targeted treatments of these atheromas.
C1 [Aquino Luque, Maria Carolina; Gutierrez, Paulo Sampaio; Debbas, Victor; Puech-Leao, Pedro; Porto, Georgia; Coelho, Veronica; Kalil, Jorge; Stolf, Beatriz] HC FMUSP, Heart Inst Sao Paulo InCor, Sao Paulo, Brazil.
   [Aquino Luque, Maria Carolina; Coelho, Veronica; Kalil, Jorge; Stolf, Beatriz] Univ Sao Paulo, Sch Med, Dept Clin Med, HC FMUSP, Sao Paulo, Brazil.
   [Coelho, Veronica; Kalil, Jorge] Natl Inst Sci & Technol, INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Boumsell, Laurence] Univ Paris 05, Inst Cochin, INSERM, U567, Paris, France.
   [Martins, Waleska Kerllen] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil.
   [Stolf, Beatriz] Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, Sao Paulo, Brazil.
RP Luque, MCA (corresponding author), HC FMUSP, Heart Inst Sao Paulo InCor, Sao Paulo, Brazil.
EM bstolf@usp.br
RI PUECH-LEAO, PEDRO/AAW-8801-2020; Leao, Pedro P/B-5495-2016; Stolf,
   Beatriz S/H-7943-2012; Martins, Waleska Kerllen/L-5187-2018; Gutierrez,
   Paulo S/E-6783-2012; KALIL, JORGE/C-8029-2012
OI PUECH-LEAO, PEDRO/0000-0002-6974-9509; Stolf, Beatriz
   S/0000-0001-7661-3311; Martins, Waleska Kerllen/0000-0003-1502-4606;
   Gutierrez, Paulo S/0000-0002-9544-2359; KALIL,
   JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by FAPESP (Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018
   BANKA CL, 1991, J LIPID RES, V32, P35
   BOUGERET C, 1992, J IMMUNOL, V148, P318
   Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183
   Chabbert-de Ponnat I, 2005, INT IMMUNOL, V17, P439, DOI 10.1093/intimm/dxh224
   Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633
   Elhabazi A, 2003, CRIT REV IMMUNOL, V23, P65, DOI 10.1615/CritRevImmunol.v23.i12.40
   Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341
   Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hong HY, 2008, J CELL MOL MED, V12, P2003, DOI 10.1111/j.1582-4934.2008.00189.x
   Houston P, 2001, FEBS LETT, V492, P73, DOI 10.1016/S0014-5793(01)02191-3
   Hu Y, 2008, J IMMUNOL, V180, P8057, DOI 10.4049/jimmunol.180.12.8057
   Ji JD, 2009, HUM IMMUNOL, V70, P211, DOI 10.1016/j.humimm.2009.01.026
   Kamperidis P, 2011, ARTHRITIS RHEUM-US, V63, P3758, DOI 10.1002/art.30650
   Karjalainen K, 2011, BLOOD, V117, P920, DOI 10.1182/blood-2010-05-282921
   Kikutani H, 2007, ADV IMMUNOL, V93, P121, DOI 10.1016/S0065-2776(06)93003-X
   KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z
   Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0
   Porto G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021702
   Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008
   Rekhter MD, 2001, CELL BIOCHEM BIOPHYS, V35, P103, DOI 10.1385/CBB:35:1:103
   Robert R, 2006, J BIOL CHEM, V281, P40135, DOI 10.1074/jbc.M609344200
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Sierra JR, 2008, J EXP MED, V205, P1673, DOI 10.1084/jem.20072602
   STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963
   Yacoby I, 2008, EXPERT OPIN DRUG DEL, V5, P321, DOI [10.1517/17425247.5.3.321, 10.1517/17425247.5.3.321 ]
   Yukawa K, 2010, INT J MOL MED, V26, P39, DOI 10.3892/ijmm_00000432
   Zhu L, 2007, P NATL ACAD SCI USA, V104, P1621, DOI 10.1073/pnas.0606344104
   Zhu L, 2009, ARTERIOSCL THROM VAS, V29, P1039, DOI 10.1161/ATVBAHA.109.185405
NR 34
TC 10
Z9 11
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2013
VL 8
IS 9
AR e75772
DI 10.1371/journal.pone.0075772
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231NL
UT WOS:000325423500093
PM 24098722
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tanno, LK
   Kerr, DS
   Yamamoto, VJ
   Prado, CM
   Talib, LL
   Gattaz, WF
   Motta, AA
   Kalil, JE
AF Tanno, L. K.
   Kerr, D. S.
   Yamamoto, V. J.
   Prado, C. M.
   Talib, L. L.
   Gattaz, W. F.
   Motta, A. A.
   Kalil, J. E.
TI Human leukocyte antigen genotype in antiepileptics hypersensitivity
   reactions: a pilot study in Brazilian patients
SO ALLERGY
LA English
DT Meeting Abstract
CT World Allergy and Asthma Congress of the
   European-Academy-of-Allergy-and-Clinical-Immunology and
   World-Allergy-Organization
CY JUN 22-26, 2013
CL Milan, ITALY
SP European Acad Allergy & Clin Immunol, World Allergy Org
C1 [Tanno, L. K.; Motta, A. A.; Kalil, J. E.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Kerr, D. S.; Yamamoto, V. J.; Prado, C. M.; Talib, L. L.; Gattaz, W. F.] Univ Sao Paulo, Neurosci Lab, LIM Psychiat Inst 27, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012; Gattaz,
   Wagner F/C-4456-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2013
VL 68
SU 97
SI SI
BP 29
EP 29
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 227VH
UT WOS:000325142900064
DA 2020-11-26
ER

PT J
AU Aun, MV
   Saraiva-Romanholo, BM
   Arantes-Costa, FM
   Almeida, FM
   Martins, MA
   Kalil, J
   Giavina-Bianchi, P
AF Aun, M., V
   Saraiva-Romanholo, B. M.
   Arantes-Costa, F. M.
   Almeida, F. M.
   Martins, M. A.
   Kalil, J.
   Giavina-Bianchi, P.
TI Sensitisation by subcutaneous route is superior to intraperitoneal route
   in the induction of asthma by house dust mite in a murine model
SO ALLERGY
LA English
DT Meeting Abstract
CT World Allergy and Asthma Congress of the
   European-Academy-of-Allergy-and-Clinical-Immunology and
   World-Allergy-Organization
CY JUN 22-26, 2013
CL Milan, ITALY
SP European Acad Allergy & Clin Immunol, World Allergy Org
C1 [Aun, M., V; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Saraiva-Romanholo, B. M.; Arantes-Costa, F. M.; Almeida, F. M.; Martins, M. A.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI de Almeida, Francine Maria/S-2314-2019; Martins, Milton A/D-6658-2012;
   KALIL, JORGE/C-8029-2012; Almeida, Francine Maria/H-3733-2013;
   Saraiva-Romanholo, Beatriz M/I-5482-2013; Giavina-Bianchi,
   Pedro/I-3112-2014; Aun, Marcelo V/E-6775-2014; Costa, Fernanda Magalhaes
   A/F-2727-2012
OI de Almeida, Francine Maria/0000-0001-9755-5034; KALIL,
   JORGE/0000-0001-8415-4274; Almeida, Francine Maria/0000-0001-9755-5034;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580; Aun, Marcelo
   V/0000-0001-9882-5200; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2013
VL 68
SU 97
SI SI
BP 236
EP 236
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 227VH
UT WOS:000325142901306
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Garro, LS
   Peluzo, F
   Kalil, J
   Motta, AA
AF Giavina-Bianchi, P.
   Garro, L. S.
   Peluzo, F.
   Kalil, J.
   Motta, A. A.
TI Clinical SCORE for screening of latex allergy
SO ALLERGY
LA English
DT Meeting Abstract
CT World Allergy and Asthma Congress of the
   European-Academy-of-Allergy-and-Clinical-Immunology and
   World-Allergy-Organization
CY JUN 22-26, 2013
CL Milan, ITALY
SP European Acad Allergy & Clin Immunol, World Allergy Org
C1 [Giavina-Bianchi, P.; Garro, L. S.; Kalil, J.; Motta, A. A.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Peluzo, F.] AACD, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2013
VL 68
SU 97
SI SI
BP 593
EP 593
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 227VH
UT WOS:000325142905259
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Garro, LS
   Peluzo, F
   Kalil, J
   Motta, AA
AF Giavina-Bianchi, P.
   Garro, L. S.
   Peluzo, F.
   Kalil, J.
   Motta, A. A.
TI Associated factors with sensitisation and allergy to latex
SO ALLERGY
LA English
DT Meeting Abstract
CT World Allergy and Asthma Congress of the
   European-Academy-of-Allergy-and-Clinical-Immunology and
   World-Allergy-Organization
CY JUN 22-26, 2013
CL Milan, ITALY
SP European Acad Allergy & Clin Immunol, World Allergy Org
C1 [Giavina-Bianchi, P.; Garro, L. S.; Kalil, J.; Motta, A. A.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Peluzo, F.] AACD, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2013
VL 68
SU 97
SI SI
BP 593
EP 593
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 227VH
UT WOS:000325142905258
DA 2020-11-26
ER

PT J
AU Franca-Pinto, A
   Mendes, FAR
   Cukier, A
   Stelmach, R
   Martins, MA
   Kalil, J
   Carvalho, CRF
   Giavina-Bianchi, P
AF Franca-Pinto, Andrezza
   Mendes, Felipe A. R.
   Cukier, Alberto
   Stelmach, Rafael
   Martins, Milton A.
   Kalil, Jorge
   Carvalho, Celso R. F.
   Giavina-Bianchi, Pedro
TI Aerobic training promotes benefits in patients with moderate and severe
   asthma independent of seasonal variation
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Asthma - management; Exercise; Quality of life
C1 [Franca-Pinto, Andrezza; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Mendes, Felipe A. R.; Carvalho, Celso R. F.] Univ Sao Paulo, Phys Therapy, Sao Paulo, Brazil.
   [Cukier, Alberto; Stelmach, Rafael] Univ Sao Paulo, InCor Pulm, Sao Paulo, Brazil.
   [Martins, Milton A.] Univ Sao Paulo, Clin Med, Sao Paulo, Brazil.
EM andrezzafpinto@gmail.com; felipearm@pop.com.br;
   alberto.cukier@incor.usp.br; rafael.stelmach@incor.usp.br;
   mmartins@usp.br; jkalil@usp.br; cscarval@usp.br; saudesos@terra.com
RI KALIL, JORGE/C-8029-2012; Cukier, Alberto/C-6101-2012; stelmach,
   rafael/AAH-1638-2019
OI KALIL, JORGE/0000-0001-8415-4274; Cukier, Alberto/0000-0002-7217-9498;
   stelmach, rafael/0000-0002-5132-1934
NR 0
TC 0
Z9 0
U1 0
U2 5
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2013
VL 42
SU 57
MA 3099
PG 1
WC Respiratory System
SC Respiratory System
GA V38VH
UT WOS:000209370401036
DA 2020-11-26
ER

PT J
AU Mendes, F
   Franca-Pinto, A
   Cukier, A
   Stelmach, R
   Agondi, R
   Martins, MA
   Kalil, J
   Giavina-Bianchi, P
   Carvalho, CRF
AF Mendes, Felipe
   Franca-Pinto, Andrezza
   Cukier, Alberto
   Stelmach, Rafael
   Agondi, Rosana
   Martins, Milton A.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Carvalho, Celso R. F.
TI Aerobic training decreases bronchial hyperresponsiveness, serum
   chemokines and symptoms in asthmatic patients: Randomized controlled
   trial
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Asthma - management; Exercise; Rehabilitation
C1 [Mendes, Felipe; Carvalho, Celso R. F.] Univ Sao Paulo, Phys Therapy, Sao Paulo, Brazil.
   [Franca-Pinto, Andrezza; Agondi, Rosana; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Cukier, Alberto; Stelmach, Rafael] Univ Sao Paulo, Incor Pulm, Sao Paulo, Brazil.
   [Martins, Milton A.] Univ Sao Paulo, Med Clin, Sao Paulo, Brazil.
EM felipearm@pop.com; andrezzafpinto@gmail.com;
   alberto.cukier@incor.usp.br; rafael.stelmach@incor.usp.br;
   ragondi@gmail.com; mmartins@usp.br; jkalil@usp.br;
   saudesos@terra.com.br; cscarval@usp.br
RI stelmach, rafael/AAH-1638-2019; KALIL, JORGE/C-8029-2012; Cukier,
   Alberto/C-6101-2012
OI stelmach, rafael/0000-0002-5132-1934; KALIL, JORGE/0000-0001-8415-4274;
   Cukier, Alberto/0000-0002-7217-9498
NR 0
TC 0
Z9 0
U1 0
U2 5
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2013
VL 42
SU 57
MA 3218
PG 1
WC Respiratory System
SC Respiratory System
GA V38VH
UT WOS:000209370400362
DA 2020-11-26
ER

PT J
AU Baldassin, MPM
   Oliveira, AKB
   Barros, MT
   Cohon, A
   Kalil, J
   Kokron, M
AF Baldassin, M. P. M.
   Oliveira, A. K. B.
   Barros, M. T.
   Cohon, A.
   Kalil, J.
   Kokron, M.
TI Evaluation of B lymphocyte Profile from Common Variable Immunodeficiency
   Patients Before and After Immunization with Antigens
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 3rd Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 17-19, 2013
CL Santiago, CHILE
SP Latin Amer Soc Immunodeficiencies
C1 Clin Hosp, Div Clin Immunol & Allergy, Lab Clin Immunol & Allergy LIM 60, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Invest Immunol 3, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Marinho, Ana Karolina/C-8395-2017
OI KALIL, JORGE/0000-0001-8415-4274; Marinho, Ana
   Karolina/0000-0001-9369-8222
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD SEP
PY 2013
VL 33
SU 3
MA 22
BP S107
EP S108
PG 2
WC Immunology
SC Immunology
GA AY1ZI
UT WOS:000347388100010
DA 2020-11-26
ER

PT J
AU Kokron, CM
   Barros, MT
   Gomes, J
   Grecco, O
   de Oliveira, AKB
   Cohon, A
   Kalil, J
AF Kokron, C. M.
   Toledo Barros, M.
   Gomes, J.
   Grecco, O.
   Barreto de Oliveira, A. K.
   Cohon, A.
   Kalil, J.
TI Autoimmunity and Family History of PID as Risk Factors for the Evolution
   of IgA Deficiency to CVID
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 3rd Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 17-19, 2013
CL Santiago, CHILE
SP Latin Amer Soc Immunodeficiencies
C1 [Kokron, C. M.; Toledo Barros, M.; Gomes, J.; Grecco, O.; Barreto de Oliveira, A. K.; Cohon, A.; Kalil, J.] Univ Sao Paulo, Fac Med, BR-05508 Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD SEP
PY 2013
VL 33
SU 3
MA 77
BP S123
EP S123
PG 1
WC Immunology
SC Immunology
GA AY1ZI
UT WOS:000347388100054
DA 2020-11-26
ER

PT J
AU Fae, KC
   Palacios, SA
   Nogueira, LG
   Oshiro, SE
   Demarchi, LMF
   Bilate, AMB
   Pomerantzeff, PMA
   Brandao, C
   Thomaz, PG
   dos Reis, M
   Sampaio, R
   Tanaka, AC
   Cunha-Neto, E
   Kalil, J
   Guilherme, L
AF Fae, Kellen C.
   Palacios, Selma A.
   Nogueira, Luciana G.
   Oshiro, Sandra E.
   Demarchi, Lea M. F.
   Bilate, Angelina M. B.
   Pomerantzeff, Pablo M. A.
   Brandao, Carlos
   Thomaz, Petronio G.
   dos Reis, Maxwell
   Sampaio, Roney
   Tanaka, Ana C.
   Cunha-Neto, Edecio
   Kalil, Jorge
   Guilherme, Luiza
TI CXCL9/Mig Mediates T cells Recruitment to Valvular Tissue Lesions of
   Chronic Rheumatic Heart Disease Patients
SO INFLAMMATION
LA English
DT Article
DE rheumatic fever; rheumatic heart disease; chemokines; CXCL9 (Mig);
   valvular lesions
ID A STREPTOCOCCAL INFECTIONS; CHEMOKINE RECEPTORS; MONONUCLEAR-CELLS;
   IMMUNE-RESPONSES; IN-VIVO; EXPRESSION; CARDITIS; LYMPHOCYTES; I-309;
   IDENTIFICATION
AB Rheumatic fever (RF) is an autoimmune disease triggered by Streptococcus pyogenes infection frequently observed in infants from developing countries. Rheumatic heart disease (RHD), the major sequel of RF, leads to chronic inflammation of the myocardium and valvular tissue. T cells are the main population infiltrating cardiac lesions; however, the chemokines that orchestrate their recruitment are not clearly defined. Here, we investigated the expression of chemokines and chemokine receptors in cardiac tissue biopsies obtained from chronic RHD patients. Our results showed that CCL3/MIP1 alpha gene expression was upregulated in myocardium while CCL1/I-309 and CXCL9/Mig were highly expressed in valvular tissue. Auto-reactive T cells that infiltrate valvular lesions presented a memory phenotype (CD4(+)CD45RO(+)) and migrate mainly toward CXCL9/Mig gradient. Collectively, our results show that a diverse milieu of chemokines is expressed in myocardium and valvular tissue lesions and emphasize the role of CXCL9/Mig in mediating T cell recruitment to the site of inflammation in the heart.
C1 [Fae, Kellen C.; Palacios, Selma A.; Nogueira, Luciana G.; Oshiro, Sandra E.; Demarchi, Lea M. F.; Bilate, Angelina M. B.; Pomerantzeff, Pablo M. A.; Brandao, Carlos; Sampaio, Roney; Tanaka, Ana C.; Cunha-Neto, Edecio; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Inst Heart, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Fae, Kellen C.; Palacios, Selma A.; Nogueira, Luciana G.; Oshiro, Sandra E.; Cunha-Neto, Edecio; Kalil, Jorge; Guilherme, Luiza] Natl Inst Sci & Technol, Inst Immunol Invest, Sao Paulo, Brazil.
   [Thomaz, Petronio G.; dos Reis, Maxwell] Sao Joao Del Rei Fed Univ UFSJ, BR-36307352 Sao Joao Del Rei, MG, Brazil.
   [Thomaz, Petronio G.; dos Reis, Maxwell] Marcio Cunha Hosp, Ipatinga, MG, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Guilherme, Luiza] Inst Coracao HC FMUSP, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Thomaz, Petronio/I-5219-2013; de Almeida Brandao, Carlos
   Manuel/H-5208-2013; Pomerantzeff, Pablo M A/L-5525-2016; KALIL,
   JORGE/C-8029-2012; SAMPAIO, RONEY O/L-1643-2016; Cunha-Neto,
   Edecio/B-4157-2009
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; KALIL,
   JORGE/0000-0001-8415-4274; SAMPAIO, RONEY O/0000-0001-6524-9614;
   Cunha-Neto, Edecio/0000-0002-3699-3345
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); "Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)", BrazilNational Council
   for Scientific and Technological Development (CNPq)
FX This work was supported by "Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)", Brazil. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akashi S, 2005, TRANSPLANTATION, V80, P378, DOI 10.1097/01.tp.0000166338.99933.e1
   AMOILS B, 1986, CLIN EXP IMMUNOL, V66, P88
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Bernardini G, 2000, BLOOD, V96, P4039, DOI 10.1182/blood.V96.13.4039.h8004039_4039_4045
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Cunningham MW, 2008, ADV EXP MED BIOL, V609, P29, DOI 10.1007/978-0-387-73960-1_3
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Gross I., 1934, AM J PATHOL, V10, P467
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786
   Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   Lee JY, 2009, INT J INFECT DIS, V13, P117, DOI 10.1016/j.ijid.2008.06.016
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   MARBOE CC, 1985, HUM PATHOL, V16, P332, DOI 10.1016/S0046-8177(85)80227-6
   MILLER MD, 1989, J IMMUNOL, V143, P2907
   NARULA J, 1993, CIRCULATION, V88, P2198, DOI 10.1161/01.CIR.88.5.2198
   Park MK, 2002, J IMMUNOL, V169, P1433, DOI 10.4049/jimmunol.169.3.1433
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593
   Schnickel GT, 2008, J IMMUNOL, V180, P4714, DOI 10.4049/jimmunol.180.7.4714
   Yoshioka M, 2006, NAT MED, V12, P1151, DOI 10.1038/nm1476
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 29
TC 16
Z9 17
U1 0
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
J9 INFLAMMATION
JI Inflammation
PD AUG
PY 2013
VL 36
IS 4
BP 800
EP 811
DI 10.1007/s10753-013-9606-2
PG 12
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 181AV
UT WOS:000321641300003
PM 23417848
OA Other Gold, Green Published
DA 2020-11-26
ER

PT J
AU Aun, MV
   Chung, TM
   Santos, KS
   Battistella, LMR
   Rizzo, LV
   Kalil, J
   Giavina-Bianchi, P
AF Aun, M. V.
   Chung, T. M.
   Santos, K. S.
   Battistella, L. M. R.
   Rizzo, L. V.
   Kalil, J.
   Giavina-Bianchi, P.
TI Is age associated with the development of antibodies against botulinum
   toxin?
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Letter
ID NEUTRALIZING ANTIBODIES; THERAPY FAILURE; INJECTION; BOTOX(R)
C1 [Aun, M. V.; Santos, K. S.; Rizzo, L. V.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Chung, T. M.; Battistella, L. M. R.] Univ Sao Paulo, Physiatry Dept, Sch Med, BR-05508 Sao Paulo, Brazil.
RP Aun, MV (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05508 Sao Paulo, Brazil.
EM marcelovivoloaun@yahoo.com.br
RI Santos, Keity Souza/Q-5704-2019; Giavina-Bianchi, Pedro/I-3112-2014;
   KALIL, JORGE/C-8029-2012; Santos, Keity/M-9401-2015; Aun, Marcelo
   V/E-6775-2014; Rizzo, Luiz Vicente/B-4458-2009
OI Santos, Keity Souza/0000-0001-5271-4011; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274; Aun,
   Marcelo V/0000-0001-9882-5200; 
CR Brin MF, 1997, MUSCLE NERVE, pS146
   Dressler D, 2006, EUR J NEUROL, V13, P11, DOI 10.1111/j.1468-1331.2006.01439.x
   Dressler D, 2004, MOVEMENT DISORD, V19, pS92, DOI 10.1002/mds.20022
   Dressler D, 2002, EUR NEUROL, V47, P118, DOI 10.1159/000047963
   Huang W, 2000, J AM ACAD DERMATOL, V43, P249, DOI 10.1067/mjd.2000.105567
   Kessler KR, 1999, J NEUROL, V246, P265, DOI 10.1007/s004150050345
   Kranz G, 2008, NEUROLOGY, V70, P133, DOI 10.1212/01.wnl.0000287087.99612.e5
   Lange O, 2009, CLIN NEUROPHARMACOL, V32, P213, DOI 10.1097/WNF.0b013e3181914d0a
   Schulte-Baukloh H, 2011, UROL INT, V87, P434, DOI 10.1159/000331726
   SCOTT AB, 1980, OPHTHALMOLOGY, V87, P1044
NR 10
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD JUL-AUG
PY 2013
VL 41
IS 4
BP 276
EP 279
DI 10.1016/j.aller.2012.05.002
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA 191QK
UT WOS:000322427500012
PM 23031658
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   de Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Barreto de Oliveira, Ana Karolina
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI Dysregulated CD1 profile in myeloid dendritic cells in CVID is
   normalized by IVIg treatment
SO BLOOD
LA English
DT Letter
ID COMMON VARIABLE IMMUNODEFICIENCY; T-CELLS; SUBSETS; DISEASE; BLOOD
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ, Huddinge Hosp, Dept Med, Ctr Infect Med,Karolinska Inst, S-14186 Stockholm, Sweden.
   [Santos, Bianca A. N.; Carvalho, Karina I.; Toledo-Barros, Myrthes; Barreto de Oliveira, Ana Karolina; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Sandberg, JK (corresponding author), Karolinska Univ, Huddinge Hosp, Dept Med, Ctr Infect Med,Karolinska Inst, F59, S-14186 Stockholm, Sweden.
EM johan.sandberg@ki.se
RI Kokron, Cristina M/D-3140-2012; Carvalho, Karina IL/J-6789-2012; KALIL,
   JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; Carvalho, Karina
   IL/0000-0002-7763-8139; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925; Paquin Proulx, Dominic/0000-0003-1407-3414;
   Moll, Markus/0000-0003-4592-3063; Sandberg, Johan/0000-0002-6275-0750
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052731, R37AI052731, R01AI052731, R01AI052731, R37AI052731,
   R37AI052731, R37AI052731, R37AI052731, R37AI052731, R01AI052731,
   R01AI052731, R37AI052731, R37AI052731, R01AI052731, R37AI052731,
   R37AI052731] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI52731] Funding Source: Medline
CR Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369
   De Libero G, 2012, TRENDS IMMUNOL, V33, P103, DOI 10.1016/j.it.2012.01.005
   Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037
   MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097
   Moody DB, 2006, ADV IMMUNOL, V89, P87, DOI 10.1016/S0065-2776(05)89003-0
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Romani N, 2003, APMIS, V111, P725, DOI 10.1034/j.1600-0463.2003.11107805.x
   Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x
   Smed-Sorensen A, 2008, BLOOD, V111, P5037
NR 9
TC 12
Z9 12
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 13
PY 2013
VL 121
IS 24
BP 4963
EP 4964
DI 10.1182/blood-2013-04-499442
PG 2
WC Hematology
SC Hematology
GA 184NB
UT WOS:000321896300025
PM 23766460
OA Green Published
DA 2020-11-26
ER

PT J
AU Santos, KS
   Gadermaier, G
   Vejvar, E
   Arcuri, HA
   Galvao, CE
   Yang, AC
   Resende, VMF
   Martins, CD
   Himly, M
   Mari, A
   Liso, M
   Pomponi, D
   Breiteneder, H
   Wagner, S
   Kalil, J
   Ferreira, F
   Castro, FFM
AF Santos, Keity Souza
   Gadermaier, Gabriele
   Vejvar, Eva
   Arcuri, Helen Andrade
   Galvao, Clovis Eduardo
   Yang, Ariana Campos
   Ferreira Resende, Virginia Maria
   Martins, Carlo de Oliveira
   Himly, Martin
   Mari, Adriano
   Liso, Marina
   Pomponi, Debora
   Breiteneder, Heimo
   Wagner, Stefan
   Kalil, Jorge
   Ferreira, Fatima
   Morato Castro, Fabio Fernandes
TI Novel allergens from ancient foods: Man e 5 from manioc (Manihot
   esculenta Crantz) cross reacts with Hev b 5 from latex
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Food allergy; Hev b 5; IgE cross-reactivity; Intrinsically disordered
   protein; Latex-fruit syndrome; New allergen
ID NATIVELY UNFOLDED PROTEINS; IGE-BINDING EPITOPES; ANAPHYLACTIC REACTION;
   REACTIVITY; CASSAVA; IDENTIFICATION; REGIONS
AB Scope Manioc (Manihot esculenta) is a tuber mainly consumed in the Southern Hemisphere and used worldwide by food and chemistry industry. We aimed to recombinantly produce and characterize the first manioc allergen and evaluate its IgE reactivity in sera of Brazilian and Italian patients. Methods and results The molecule, termed Man e5, was expressed in E. coli, characterized by amino acid analysis, mass spectrometry, circular dichroism, HPLC, and dynamic light scattering. A tertiary structural model of the protein was produced using bioinformatics and susceptibility to pepsin digestion was analyzed in vitro. Based on its high content of charged residues, heat stability, flexibility and lack of secondary structure elements, the allergen was determined a member of the intrinsically disordered protein family. Brazilian patients were selected based on manioc allergy and Italians based on latex allergy and sensitization to Hev b 5.71% of Brazilians and 40% of Italians were in vitro IgE positive to Man e5. Cross-inhibition assays suggest a possible involvement of this allergen in the latex-fruit syndrome. Conclusion Man e5, the first purified allergen from manioc demonstrates IgE cross-reactivity with Hev b 5. Data suggest Hev b 5 might act as primary sensitizer and could therefore lead to allergic manifestations upon manioc consumption without prior exposition.
C1 [Santos, Keity Souza; Arcuri, Helen Andrade; Ferreira Resende, Virginia Maria; Martins, Carlo de Oliveira; Kalil, Jorge; Morato Castro, Fabio Fernandes] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med,FMUSP, Sao Paulo, Brazil.
   [Santos, Keity Souza; Arcuri, Helen Andrade; Ferreira Resende, Virginia Maria; Kalil, Jorge; Morato Castro, Fabio Fernandes] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Gadermaier, Gabriele; Vejvar, Eva; Himly, Martin; Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria.
   [Galvao, Clovis Eduardo; Yang, Ariana Campos; Morato Castro, Fabio Fernandes] Clin Hosp FMUSP, Div Allergy, Sao Paulo, Brazil.
   [Mari, Adriano; Liso, Marina; Pomponi, Debora] IDI IRCCS, Ctr Mol Allergol, Rome, Italy.
   [Breiteneder, Heimo; Wagner, Stefan] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.
   [Martins, Carlo de Oliveira; Kalil, Jorge] Univ Sao Paulo, Sch Med, LIM 19, Heart Inst InCor, Sao Paulo, Brazil.
RP Santos, KS (corresponding author), Inst Coracao INCOR, Av Dr Eneas de Carvalho Aguiar,155-9 Andar Bloco, BR-05403900 Sao Paulo, Brazil.
EM keity@usp.br
RI Castro, Fabio FM/C-1082-2017; Liso, Marina/AAB-3723-2019; Santos, Keity
   Souza/Q-5704-2019; Ferreira, Fatima/E-4889-2011; Martins,
   Carlo/D-4008-2018; Castro, Fabio/AAP-5433-2020; KALIL,
   JORGE/C-8029-2012; Santos, Keity/M-9401-2015; Resende,
   Virginia/H-5417-2013; Gadermaier, Gabriele/L-5997-2015; Ferreira,
   Fatima/AAB-4321-2019; Himly, Martin/D-1568-2015
OI Castro, Fabio FM/0000-0002-6211-5773; Santos, Keity
   Souza/0000-0001-5271-4011; Ferreira, Fatima/0000-0003-0989-2335;
   Martins, Carlo/0000-0003-1287-8884; KALIL, JORGE/0000-0001-8415-4274;
   Resende, Virginia/0000-0002-9225-5654; Gadermaier,
   Gabriele/0000-0002-4886-417X; Ferreira, Fatima/0000-0003-0989-2335;
   Himly, Martin/0000-0001-5416-085X; LISO, MARINA/0000-0002-8766-1869
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2008/05595-4]; INCT-Instituto Nacional de Ciencia e Tecnologia;
   Thermofisher Scientific, Brazil; Austrian Science Fund (FWF)Austrian
   Science Fund (FWF); Christian Doppler Research Association; Biomay AG
FX This project was funded by FAPESP (Process number 2008/05595-4),
   INCT-Instituto Nacional de Ciencia e Tecnologia, and Phadia Diagnostics,
   now Thermofisher Scientific, Brazil. Christian Doppler Laboratory for
   Allergy Diagnosis and Therapy, Biomay AG, Vienna, Austria and the
   Italian Ministry of Health, Current Research program 2009-2010. Fatima
   Ferreira has received research support from the Austrian Science Fund
   (FWF), the Christian Doppler Research Association and Biomay AG, and
   provides legal consultation or expert witness testimony for the
   AllergenOnline Database, Indoor Biotechnologies, and HAL Allergy.
CR Bardini G, 2011, J ALLERGY CLIN IMMUN, V127, pAB171, DOI 10.1016/j.jaci.2010.12.679
   Barre A, 2009, MOL IMMUNOL, V46, P1595, DOI 10.1016/j.molimm.2008.12.007
   Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6
   Beezhold DH, 2004, INT ARCH ALLERGY IMM, V134, P334, DOI 10.1159/000079537
   Beezhold DH, 2001, J ALLERGY CLIN IMMUN, V107, P1069, DOI 10.1067/mai.2001.115482
   Beltran J, 2010, PLANTA, V231, P1413, DOI 10.1007/s00425-010-1144-7
   Blanco C, 2003, CURR ALLERGY ASTHM R, V3, P47, DOI 10.1007/s11882-003-0012-y
   Chiron R, 2001, J ALLERGY CLIN IMMUN, V107, pS270
   Dosztanyi Z, 2009, BIOINFORMATICS, V25, P2745, DOI 10.1093/bioinformatics/btp518
   GalvAo C., 2004, J ALLERGY CLIN IMMUN, V113, P144
   Ganglberger E, 2001, INT ARCH ALLERGY IMM, V125, P216, DOI 10.1159/000053819
   Gaspar A, 2003, ALLERGY, V58, P683, DOI 10.1034/j.1398-9995.2003.00184.x
   Himly M, 2009, ALLERGY, V64, P1038, DOI 10.1111/j.1398-9995.2009.01957.x
   Ibero M, 2007, J INVEST ALLERG CLIN, V17, P409
   Ishida T, 2007, NUCLEIC ACIDS RES, V35, pW460, DOI 10.1093/nar/gkm363
   Mari A, 2007, INT ARCH ALLERGY IMM, V143, P135, DOI 10.1159/000099080
   Merwat SN, 2009, AM J GASTROENTEROL, V104, P1897, DOI 10.1038/ajg.2009.87
   MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C
   Niggemann B, 1998, PEDIATR ALLERGY IMMU, V9, P36, DOI 10.1111/j.1399-3038.1998.tb00298.x
   Niggemann B, 2002, PEDIATR ALLERGY IMMU, V13, P64, DOI 10.1034/j.1399-3038.2002.00032.x
   Pali-Scholl I, 2011, ALLERGY, V66, P469, DOI 10.1111/j.1398-9995.2010.02511.x
   Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925
   Salcedo G, 2001, CURR OPIN ALLERGY CL, V1, P177, DOI 10.1097/01.all.0000011004.49250.bc
   Santos KS, 2011, J ALLERGY CLIN IMMUN, V128, P1367, DOI 10.1016/j.jaci.2011.07.019
   Schmidt MHH, 2002, ANN ALLERG ASTHMA IM, V89, P613, DOI 10.1016/S1081-1206(10)62110-2
   SCHWEERS O, 1994, J BIOL CHEM, V269, P24290
   Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394
   Tangphatsornruang S, 2005, PLANT PHYSIOL BIOCH, V43, P821, DOI 10.1016/j.plaphy.2005.07.014
   Uversky VN, 2009, PROTEIN J, V28, P305, DOI 10.1007/s10930-009-9201-4
   Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200
   Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z
   Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102
   Wagner S, 2002, BIOCHEM SOC T, V30, P935, DOI 10.1042/BST0300935
   Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342
   Zhang P, 2003, PLANTA, V218, P192, DOI 10.1007/s00425-003-1098-0
NR 35
TC 8
Z9 8
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD JUN
PY 2013
VL 57
IS 6
SI SI
BP 1100
EP 1109
DI 10.1002/mnfr.201200433
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA 160JD
UT WOS:000320114800017
PM 23526605
DA 2020-11-26
ER

PT J
AU Murata, VM
   Schmidt, MCB
   Kalil, J
   Tsuruta, LR
   Moro, AM
AF Murata, Viviane Midori
   Braga Schmidt, Mariana Costa
   Kalil, Jorge
   Tsuruta, Lilian Rumi
   Moro, Ana Maria
TI Anti-Digoxin Fab Variants Generated by Phage Display
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article
DE Digoxin; Phage display; CDR; Framework; Biacore; Affinity; Cardiac
   dysfunction
ID DIGOXIN-SPECIFIC ANTIBODIES; MONOCLONAL-ANTIBODY; VARIABLE DOMAINS;
   LIGHT-CHAINS; IN-VITRO; FRAGMENTS; AFFINITY; HEAVY; EXPRESSION;
   LIBRARIES
AB Digoxin is a pharmaceutical used in the control of cardiac dysfunction. Its therapeutic window is narrow, with effect dosage very close to the toxic dosage. To counteract the toxic effect, polyclonal Fab fragments are commercially available. Our study is based on a monoclonal anti-digoxin antibody, which would provide a product with a specific potency and more precise dosage for the detoxification of patients under digoxin treatment. Phage display technology was used to select variants with high affinity. From an anti-digoxin hybridoma, RNA was extracted for subsequent cDNA synthesis. Specific primers were used for the LC and Fd amplifications, then cloned sequentially in a phagemid vector (pComb3X) for the combinatorial Fab library construction. Clones were selected for their ability to bind to digoxin-BSA. The presence of light and heavy chains was checked, randomly selected clones then sequenced and induced to produce soluble Fabs, and subsequently analyzed for anti-digoxin expression. Out of ten clones randomly chosen, six resulted positive expression of the product. The sequencing of these revealed two identical clones and one presenting a pseudogene in the LC. Four clones presenting variations in the framework1 showed binding to digoxin-BSA by ELISA and western blotting. The specific binding was further confirmed by Biacore(A (R)), which allowed ranking of the clones. The development of these clones allowed the selection of variants with higher affinity than the original version.
C1 [Murata, Viviane Midori; Braga Schmidt, Mariana Costa; Tsuruta, Lilian Rumi; Moro, Ana Maria] Inst Butantan, Lab Biofarmacos Celulas Anim, BR-05503900 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, InCor, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
   [Kalil, Jorge; Moro, Ana Maria] INCT, Inst Immunol Invest, Sci & Technol Natl Inst, Sao Paulo, Brazil.
RP Moro, AM (corresponding author), Inst Butantan, Lab Biofarmacos Celulas Anim, BR-05503900 Sao Paulo, Brazil.
EM anamoro@butantan.gov.br
RI KALIL, JORGE/C-8029-2012; Tsuruta, Lilian R/C-9100-2014; Moro, Ana
   Maria/A-5134-2012
OI KALIL, JORGE/0000-0001-8415-4274; Tsuruta, Lilian R/0000-0001-9647-7687;
   Moro, Ana Maria/0000-0002-0650-7764
FU CNPq (Brazilian Council for Research)National Council for Scientific and
   Technological Development (CNPq)
FX This work received support from CNPq (Brazilian Council for Research) as
   part of Ana Maria Moro grants. We are thankful to Dr. Carlos F. Barbas
   for providing the pComb3X vector under license. The skillful technical
   help of Andre Luis Inocencio, Angelica Garbuio, and Rose Campos Targino
   is appreciated.
CR Adams KF, 2005, AM HEART J, V149, P209, DOI 10.1016/j.ahj.2004.08.005
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Andres VLG, 2000, REV ESP CARDIOL, V53, P49
   ANTMAN EM, 1985, ANNU REV MED, V36, P357
   Arap MA, 2005, GENET MOL BIOL, V28, P1, DOI 10.1590/S1415-47572005000100001
   Argiriadi MA, 2009, J BIOL CHEM, V284, P24478, DOI 10.1074/jbc.M109.023887
   BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978
   Barbas III C. F., 2001, PHAGE DISPLAY LAB MA
   Bong YS, 1998, BBA-GEN SUBJECTS, V1380, P156, DOI 10.1016/S0304-4165(98)00007-5
   BUTLER VP, 1967, P NATL ACAD SCI USA, V57, P71, DOI 10.1073/pnas.57.1.71
   BUTLER VP, 1977, J CLIN INVEST, V59, P345, DOI 10.1172/JCI108647
   Caldas C, 2003, MOL IMMUNOL, V39, P941, DOI 10.1016/S0161-5890(03)00022-1
   CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0
   Costagliola S, 2004, MOL ENDOCRINOL, V18, P3020, DOI 10.1210/me.2004-0231
   Eichhorn EJ, 2002, PROG CARDIOVASC DIS, V44, P251, DOI 10.1053/pcad.2002.31591
   ERLANGER BF, 1964, P NATL ACAD SCI USA, V52, P68, DOI 10.1073/pnas.52.1.68
   Flanagan RJ, 2004, DRUG SAFETY, V27, P1115, DOI 10.2165/00002018-200427140-00004
   Gheorghiade M, 2006, CIRCULATION, V113, P2556, DOI 10.1161/CIRCULATIONAHA.105.560110
   Golinelli-Pimpaneau B, 2000, P NATL ACAD SCI USA, V97, P9892, DOI 10.1073/pnas.97.18.9892
   Goncalves O, 2000, BIOCHEM J, V346, P691, DOI 10.1042/0264-6021:3460691
   HORWITZ AH, 1994, MOL IMMUNOL, V31, P683, DOI 10.1016/0161-5890(94)90178-3
   HUNTER MM, 1982, J IMMUNOL, V129, P1165
   Kabat E, 1991, SEQUENCES PROTEINS I
   Kuba H, 2008, PROTEIN EXPRES PURIF, V58, P292, DOI 10.1016/j.pep.2007.10.019
   Kwong K. Y, 2009, CURRENT PROTOCOLS PR, V55, P6101
   Lai YS, 2002, VACCINE, V20, P3221, DOI 10.1016/S0264-410X(02)00239-6
   Lapostolle F, 2008, CRIT CARE MED, V36, P3014, DOI 10.1097/CCM.0b013e31818b341c
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Levy R, 2007, J IMMUNOL METHODS, V321, P164, DOI 10.1016/j.jim.2007.01.017
   MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4
   ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833
   PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080
   Paula De F. J, 1993, THESIS U SAO PAULO S
   Rinderknecht M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011941
   Schasfoort RBM, 2008, HANDBOOK OF SURFACE PLASMON RESONANCE, P1, DOI 10.1039/9781847558220
   SCHILDBACH JF, 1994, PROTEIN SCI, V3, P737
   SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739
   SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640
   SHORT MK, 1995, J BIOL CHEM, V270, P28541, DOI 10.1074/jbc.270.48.28541
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501
   Tsuruta LR, 2003, PROSTAG LEUKOTR ESS, V68, P273, DOI 10.1016/S0952-3278(03)00006-1
NR 44
TC 1
Z9 3
U1 2
U2 22
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1073-6085
EI 1559-0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD JUN
PY 2013
VL 54
IS 2
BP 269
EP 277
DI 10.1007/s12033-012-9564-1
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 135SI
UT WOS:000318308400017
PM 23359127
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Bisaccioni, C
   Aun, MV
   Cajuela, E
   Agondi, RC
   Kalil, J
AF Giavina-Bianchi, P.
   Bisaccioni, C.
   Vivolo Aun, M.
   Cajuela, E.
   Agondi, R. C.
   Kalil, J.
TI Rhinoconjunctivitis elicited by skin prick test (vol 38, pg 345, 2010)
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Correction
C1 [Giavina-Bianchi, P.; Bisaccioni, C.; Vivolo Aun, M.; Cajuela, E.; Agondi, R. C.; Kalil, J.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
EM saudesos@terra.com.br
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
CR Giavina-Bianchi P, 2010, ALLERGOL IMMUNOPATH, V38, P345, DOI 10.1016/j.aller.2010.03.002
NR 1
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD MAY-JUN
PY 2013
VL 41
IS 3
BP 212
EP 212
DI 10.1016/j.aller.2013.05.001
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 163NC
UT WOS:000320343200017
DA 2020-11-26
ER

PT J
AU Carneiro-Sampaio, M
   Moraes-Vasconcelos, D
   Kokron, CM
   Jacob, CMA
   Toledo-Barros, M
   Dorna, MB
   Watanabe, LA
   Marinho, AKBB
   Castro, APM
   Pastorino, AC
   Silva, CAA
   Ferreira, MD
   Rizzo, LV
   Kalil, JE
   Duarte, AJS
AF Carneiro-Sampaio, Magda
   Moraes-Vasconcelos, Dewton
   Kokron, Cristina M.
   Jacob, Cristina M. A.
   Toledo-Barros, Myrthes
   Dorna, Mayra B.
   Watanabe, Leticia A.
   Marinho, Ana Karolina B. B.
   Moschione Castro, Ana Paula
   Pastorino, Antonio C.
   Silva, Clovis Artur A.
   Ferreira, Mauricio D.
   Rizzo, Luiz V.
   Kalil, Jorge E.
   Duarte, Alberto J. S.
TI Primary Immunodeficiency Diseases in Different Age Groups: A Report on
   1,008 Cases from a Single Brazilian Reference Center
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE Primary immunodeficiencies; antibody deficiencies; SCID; age groups;
   adolescence; gender
ID SELECTIVE IGA DEFICIENCY; NATIONAL-REGISTRY; LATIN-AMERICA; 1ST REPORT;
   CHILDREN; UPDATE; AUTOIMMUNITY; PREVALENCE; DISORDERS; FREQUENCY
AB Primary immunodeficiencies (PIDs) represent a large group of diseases that affect all age groups. Although PIDs have been recognized as rare diseases, there is epidemiological evidence suggesting that their real prevalence has been underestimated. We performed an evaluation of a series of 1,008 infants, children, adolescents and adults with well-defined PIDs from a single Brazilian center, regarding age at diagnosis, gender and PID category according to the International Union of Immunological Societies classification. Antibody deficiencies were the most common category in the whole series (61 %) for all age groups, with the exception of <2-year-old patients (only 15 %). In the >30-year-old group, antibody deficiencies comprised 84 % of the diagnoses, mostly consisting of common variable immunodeficiency, IgA deficiency and IgM deficiency. Combined immunodeficiencies represented the most frequent category in <2-years-old patients. Most congenital defects of phagocytes were identified in patients <5 -years of age, as were the diseases of immune dysregulation, with the exception of APECED. DiGeorge syndrome and ataxia-telangiectasia were the most frequent entities in the category of well-defined syndromes, which were mostly identified in patients <10-years of age. Males represented three-quarters and two-thirds of <2 -years-old and 2-5-years -old patients, respectively, whereas females predominated among the >30-year-old patients. Our data indicated that some PIDs were only detected at early ages, likely because affected patients do not survive long. In addition, our data pointed out that different strategies should be used to search for PIDs in infants and young children as compared to older patients.
C1 [Carneiro-Sampaio, Magda; Jacob, Cristina M. A.; Dorna, Mayra B.; Watanabe, Leticia A.; Moschione Castro, Ana Paula; Pastorino, Antonio C.; Silva, Clovis Artur A.] Univ Sao Paulo HC FMUSP, Dept Pediat, Div Allergy & Immunol, Sao Paulo, Brazil.
   [Carneiro-Sampaio, Magda; Jacob, Cristina M. A.; Dorna, Mayra B.; Watanabe, Leticia A.; Moschione Castro, Ana Paula; Pastorino, Antonio C.; Silva, Clovis Artur A.] Univ Sao Paulo HC FMUSP, Div Rheumatol, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Moraes-Vasconcelos, Dewton; Ferreira, Mauricio D.; Duarte, Alberto J. S.] Univ Sao Paulo HC FMUSP, Dept Dermatol, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Kokron, Cristina M.; Toledo-Barros, Myrthes; Marinho, Ana Karolina B. B.; Rizzo, Luiz V.; Kalil, Jorge E.] Univ Sao Paulo HC FMUSP, Dept Internal Med, Div Clin Immunol & Allergy, Hosp Clin,Fac Med, Sao Paulo, Brazil.
   [Carneiro-Sampaio, Magda] Hosp Clin FMUSP, Inst Crianca, BR-05403900 Sao Paulo, Brazil.
RP Carneiro-Sampaio, M (corresponding author), Hosp Clin FMUSP, Inst Crianca, Av Dr Eneas Carvalho Aguiar 647, BR-05403900 Sao Paulo, Brazil.
EM magda.carneiro@hc.fm.usp.br
RI Marinho, Ana Karolina/C-8395-2017; Sampaio, Magda/AAU-6748-2020; KALIL,
   JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009; Kokron, Cristina
   M/D-3140-2012; Duarte, Alberto J S/D-4382-2012
OI Marinho, Ana Karolina/0000-0001-9369-8222; Sampaio,
   Magda/0000-0002-1924-4043; KALIL, JORGE/0000-0001-8415-4274; Kokron,
   Cristina M/0000-0002-9080-0305; PASTORINO, ANTONIO/0000-0002-2756-627X
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/58238-4]; CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)National
   Council for Scientific and Technological Development (CNPq)
   [302647/2011-2]; Institute for Investigation in Immunology-INCT, Sao
   Paulo, Brazil
FX The authors are thankful to Dr. Ulysses Doria Filho for his valuable
   assistance in statistical analysis. Financial support: FAPESP (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo) - grant 2008/58238-4; CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) - grant
   302647/2011-2; and Institute for Investigation in Immunology-INCT, Sao
   Paulo, Brazil.
CR Abuzakouk M, 2005, J CLIN IMMUNOL, V25, P73, DOI 10.1007/s10875-005-0360-9
   Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054
   Alcais A, 2009, J CLIN INVEST, V119, P2506, DOI 10.1172/JCI38111
   Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021
   Bousfiha AA, 2012, J CLIN IMMUNOL
   Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1
   Carneiro-Sampaio M, 2011, J CLIN IMMUNOL S1, V31, pS6
   Carneiro-Sampaio M, 2007, ADV IMMUNOL, V95, P51, DOI 10.1016/S0065-2776(07)95002-6
   Carneiro-Sampaio M, 2011, PEDIAT ALLERG IMM-UK, V22, P345, DOI 10.1111/j.1399-3038.2010.01084.x
   CARNEIROSAMPAIO MMS, 1989, ALLERGOL IMMUNOPATH, V17, P213
   Chase NM, 2010, CURR OPIN ALLERGY CL, V10, P521, DOI 10.1097/ACI.0b013e32833fd6fe
   De Moraes-Vasconcelos D, 2001, CLIN EXP IMMUNOL, V123, P247, DOI 10.1046/j.1365-2249.2001.01430.x
   Errante PR, 2012, ANN NY ACAD SCI, V1250, P62, DOI 10.1111/j.1749-6632.2011.06289.x
   Flori NM, 1997, J CLIN IMMUNOL, V17, P333, DOI 10.1023/A:1027382916924
   Gathmann B, 2012, CLIN EXP IMMUNOL, V167, P479, DOI 10.1111/j.1365-2249.2011.04542.x
   Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053
   Glocker E, 2010, CURR OPIN ALLERGY CL, V10, P542, DOI 10.1097/ACI.0b013e32833fd74f
   Golan H, 2002, ISR MED ASSOC J, V4, P868
   Grumach AS, 1997, J CLIN IMMUNOL, V17, P340, DOI 10.1023/A:1027335000994
   HAYAKAWA H, 1981, J CLIN IMMUNOL, V1, P31, DOI 10.1007/BF00915474
   Jacob CMA, 2008, J CLIN IMMUNOL, V28, pS56, DOI 10.1007/s10875-007-9163-2
   Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014
   Jesus AA, 2011, LUPUS, V20, P1275, DOI 10.1177/0961203311411598
   Jesus AA, 2012, J CLIN IMMUNOL, V32, P922, DOI 10.1007/s10875-012-9688-x
   Johnson N.L., 1970, CONTINUOUS UNIVARIAT
   Joshi AY, 2009, MAYO CLIN PROC, V84, P16, DOI 10.1016/S0025-6196(11)60802-1
   Keles S, 2010, PEDIAT ALLERG IMM-UK, V21, P843, DOI 10.1111/j.1399-3038.2010.01010.x
   Kirkpatrick P, 2007, J CLIN IMMUNOL, V27, P517, DOI 10.1007/s10875-007-9105-z
   Leiva LE, 2007, J CLIN IMMUNOL, V27, P101, DOI 10.1007/s10875-006-9052-0
   Lim D. L., 2003, SMJ Singapore Medical Journal, V44, P579
   LUZI G, 1983, J CLIN IMMUNOL, V3, P316, DOI 10.1007/BF00915792
   Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013
   Oliveira AKB, 2009, REV INST MED TROP SP, V51, P52
   Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
   Rezaei N, 2006, J CLIN IMMUNOL, V26, P519, DOI 10.1007/s10875-006-9047-x
   Rhim JW, 2012, J KOREAN MED SCI, V27, P788, DOI 10.3346/jkms.2012.27.7.788
   RYSER O, 1988, J CLIN IMMUNOL, V8, P479, DOI 10.1007/BF00916954
   Sanal O, 2011, ANN NY ACAD SCI, V1238, P15, DOI 10.1111/j.1749-6632.2011.06242.x
   Santos RV, 2009, CURR ANTHROPOL, V50, P787, DOI 10.1086/644532
   Shkalim V, 2010, J CLIN IMMUNOL, V30, P761, DOI 10.1007/s10875-010-9438-x
   Stiehm RE, 2007, ADV EXP MED BIOL, V601, P15
   Stray-Pedersen A, 2000, J CLIN IMMUNOL, V20, P477, DOI 10.1023/A:1026416017763
   Wang N, 2011, MOL MED, V17, P1383, DOI 10.2119/molmed.2011.00195
   Yel L, 2009, INT ARCH ALLERGY IMM, V150, P291, DOI 10.1159/000222682
NR 44
TC 17
Z9 17
U1 0
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD MAY
PY 2013
VL 33
IS 4
BP 716
EP 724
DI 10.1007/s10875-013-9865-6
PG 9
WC Immunology
SC Immunology
GA 201FC
UT WOS:000323125100002
PM 23354909
DA 2020-11-26
ER

PT J
AU Postol, E
   Alencar, R
   Higa, FT
   de Barros, SF
   Demarchi, LMF
   Kalil, J
   Guilherme, L
AF Postol, Edilberto
   Alencar, Raquel
   Higa, Fabio T.
   de Barros, Samar Freschi
   Demarchi, Lea M. F.
   Kalil, Jorge
   Guilherme, Luiza
TI StreptInCor: A Candidate Vaccine Epitope against S. pyogenes Infections
   Induces Protection in Outbred Mice
SO PLOS ONE
LA English
DT Article
ID A STREPTOCOCCAL INFECTION; M-PROTEIN; RHEUMATIC-FEVER; CARDIAC MYOSIN;
   PATHOGENESIS; INTRANASAL; BURDEN; IMMUNOGENICITY; EPIDEMIOLOGY;
   PHARYNGITIS
AB Infection with Streptococcus pyogenes (S. pyogenes) can result in several diseases, particularly in children. S. pyogenes M protein is the major virulence factor, and certain regions of its N-terminus can trigger autoimmune sequelae such as rheumatic fever in susceptible individuals with untreated group A streptococcal pharyngitis. In a previous study, we utilized a large panel of human peripheral blood cells to define the C-terminal protective epitope StreptInCor (medical identity), which does not induce autoimmune reactions. We recently confirmed the results in HLA-transgenic mice. In the present study, we extended the experimental assays to outbred animals (Swiss mice). Herein, we demonstrate high titers of StreptInCor-specific antibodies, as well as appropriate T-cell immune responses. No cross-reaction to cardiac myosin was detected. Additionally, immunized Swiss mice exhibited 87% survival one month after challenge with S. pyogenes. In conclusion, the data presented herein reinforce previous results in humans and animals and further emphasize that StreptInCor could be an effective and safe vaccine for the prevention of S. pyogenes infections.
C1 [Postol, Edilberto; Alencar, Raquel; Higa, Fabio T.; de Barros, Samar Freschi; Demarchi, Lea M. F.; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   [Postol, Edilberto; Alencar, Raquel; Higa, Fabio T.; de Barros, Samar Freschi; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Natl Inst Sci & Technol, Inst Immunol Invest, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
EM luizagui@usp.br
RI de Barros, Samar Freschi/Q-4970-2018; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Financiadora de Estudos
   e Projetos (FINEP), BrazilCiencia Tecnologia e Inovacao (FINEP)
FX This study was supported by grants from the "Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)", "Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)" and "Financiadora de
   Estudos e Projetos (FINEP)", Brazil. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Batzloff MR, 2005, J INFECT DIS, V192, P1450, DOI 10.1086/466528
   BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945
   Bisno AL, 2005, CLIN INFECT DIS, V41, P1150, DOI 10.1086/444505
   Bronze MS, 2010, AM J MED SCI, V340, P218, DOI 10.1097/MAJ.0b013e3181e939ab
   Brook I, 2007, INT J PEDIATR OTORHI, V71, P1501, DOI 10.1016/j.ijporl.2007.06.006
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   Cunningham MW, 2001, AM J PATHOL, V159, P5, DOI 10.1016/S0002-9440(10)61665-3
   DAJANI A, 1995, PEDIATRICS, V96, P758
   Dale JB, 2011, VACCINE, V29, P8175, DOI 10.1016/j.vaccine.2011.09.005
   Danchin MH, 2007, PEDIATRICS, V120, P950, DOI 10.1542/peds.2006-3368
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2011, ANN PEDIAT CARDIOL, V4, P13, DOI 10.4103/0974-2069.79617
   Guilherme L, 2011, ADV CLIN CHEM, V53, P31, DOI 10.1016/S0065-2423(11)53002-1
   Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Guilherme L, 2010, J CLIN IMMUNOL, V30, P17, DOI 10.1007/s10875-009-9332-6
   Jaine R, 2008, J PAEDIATR CHILD H, V44, P564, DOI 10.1111/j.1440-1754.2008.01384.x
   Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926
   Kotloff KL, 2005, INFECT IMMUN, V73, P2360, DOI 10.1128/IAI.73.4.2360-2366.2005
   Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
   Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   O'Loughlin RE, 2007, CLIN INFECT DIS, V45, P853, DOI 10.1086/521264
   Olive C, 2007, VACCINE, V25, P1789, DOI 10.1016/j.vaccine.2006.11.031
   Olive C, 2005, VACCINE, V23, P2298, DOI 10.1016/j.vaccine.2005.01.041
   Pfoh E, 2008, PEDIATRICS, V121, P229, DOI 10.1542/peds.2007-0484
   Quinn A, 1998, INFECT IMMUN, V66, P4418
   Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
   Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
   Sociedade Brasileira de Cardiologia, 2009, Arq Bras Cardiol, V93, P3
   Tart AH, 2007, TRENDS MICROBIOL, V15, P318, DOI 10.1016/j.tim.2007.05.001
   Vohra H, 2005, RES MICROBIOL, V156, P575, DOI 10.1016/j.resmic.2004.12.009
NR 38
TC 19
Z9 19
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2013
VL 8
IS 4
AR e60969
DI 10.1371/journal.pone.0060969
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130FG
UT WOS:000317898000087
PM 23593359
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Sini, BC
   Kokron, CM
   Levy, D
   Pereira, J
   Oliveira, AKB
   Cohon, A
   Kalil, J
   Bydlowski, SP
   Barros, MT
AF Sini, B. C.
   Kokron, C. M.
   Levy, D.
   Pereira, Juliana
   Barreto Oliveira, Ana Karolina
   Cohon, Andrea
   Kalil, Jorge
   Bydlowski, S. P.
   Barros, Myrthes Toledo
TI FREQUENCY OF LYMPHOMAS IN A COHORT OF PATIENTS WITH COMMON VARIABLE
   IMMUNODEFICIENCY
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Sini, B. C.; Kokron, C. M.; Barreto Oliveira, Ana Karolina; Cohon, Andrea; Kalil, Jorge; Barros, Myrthes Toledo] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Primary Immunodeficiency Clin, Sao Paulo, Brazil.
   [Levy, D.; Bydlowski, S. P.] Univ Sao Paulo, Sch Med, Lab Genet & Hematol Mol LIM31, Sao Paulo, Brazil.
   [Pereira, Juliana] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Bydlowski, Sergio Paulo/D-5171-2013; Kokron,
   Cristina M/D-3140-2012; Marinho, Ana Karolina/C-8395-2017; PEREIRA,
   JULIANA/C-2742-2014
OI KALIL, JORGE/0000-0001-8415-4274; Bydlowski, Sergio
   Paulo/0000-0002-7582-5942; Kokron, Cristina M/0000-0002-9080-0305;
   Marinho, Ana Karolina/0000-0001-9369-8222; PEREIRA,
   JULIANA/0000-0002-0655-2821
NR 0
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 684
EP 684
PG 1
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700052
DA 2020-11-26
ER

PT J
AU Barros, MT
   Trindade, MB
   Sini, BC
   Oliveira, AKB
   Sanchez, JA
   Kalil, J
   Kokron, CM
AF Barros, Myrthes Toledo
   Trindade, M. B.
   Sini, B. C.
   Barreto Oliveira, Ana Karolina
   Sanchez, J. A.
   Kalil, Jorge
   Kokron, C. M.
TI CASE REPORT: LEPROSY ASSOCIATED TO COMMON VARIABLE IMMUNODEFICIENCY
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Barros, Myrthes Toledo; Sini, B. C.; Barreto Oliveira, Ana Karolina; Kalil, Jorge; Kokron, C. M.] Univ Sao Paulo, Sch Med, Primary Immunodeficiency Clin, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Trindade, M. B.; Sanchez, J. A.] Univ Sao Paulo, Sch Med, Dept Dermatol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012; Marinho, Ana
   Karolina/C-8395-2017
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina
   M/0000-0002-9080-0305; Marinho, Ana Karolina/0000-0001-9369-8222
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 702
EP 702
PG 1
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700102
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Agondi, RC
   Kalil, J
AF Giavina-Bianchi, Pedro
   Agondi, Rosana Camara
   Kalil, Jorge
TI Asthma studies should be phenotype specific
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID CLUSTER-ANALYSIS; ENDOTYPES
C1 [Giavina-Bianchi, Pedro; Agondi, Rosana Camara; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM pbianchi@usp.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
CR Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC
   Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037
   Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC
   Myers RA, 2012, J ALLERGY CLIN IMMUN, V130, P1294, DOI 10.1016/j.jaci.2012.07.054
   Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x
NR 5
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2013
VL 131
IS 4
BP 1261
EP 1262
DI 10.1016/j.jaci.2013.01.050
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA 120QT
UT WOS:000317187200054
PM 23453136
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Barros, MT
   Kokron, CM
   Cohon, A
   Oliveira, AKB
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana C.
   Barros, Myrthes T.
   Kokron, Cristina M.
   Cohon, Andrea
   Oliveira, Ana K. B.
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Can patients with common variable immunodeficiency have allergic
   rhinitis?
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article; Proceedings Paper
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)
CY FEB 25-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy Asthma and Immunol (AAAAI)
ID BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY-INFECTIONS; CHRONIC
   RHINOSINUSITIS; ASTHMA; DEFICIENCY; IGE; MANAGEMENT; ADULTS; GUIDELINES;
   SINUSITIS
AB Background: Rhinosinusitis is highly prevalent in patients with common variable immunodeficiency (CVID), and probably allergic rhinitis (AR) may be masked by a history of repeated respiratory infections. The diagnosis of AR is based on the patient's symptoms and detection of specific immunoglobulin E (IgE) to aeroallergens. This study was designed to identify rhinitis of probable allergic cause in patients with CVID.
   Methods: This study included 72 adult CVID patients. The patients were divided into three groups according to their history: suggestive of AR, nonallergic rhinitis, and without rhinitis. They were tested for total and specific IgE (in vivo and in vitro).
   Results: The patients' mean age was 38.2 years. A history of chronic rhinitis was observed in 59 (81.9%) of the cases, 31 of which (43%) had a history suggestive of AR. Patients with a history of rhinitis (whether allergic or nonallergic) presented an earlier onset of symptoms and diagnosis of CVID. Total IgE was undetectable in 86.1% of patients. AR was confirmed by detection of specific IgE to aeroallergens in only 5.6% of the patients.
   Conclusion: In CVID patients, chronic rhinitis may be allergic, because many have personal and family histories suggestive of atopy. However, in this study, allergy was confirmed by specific IgE detection in only 5.6% of cases. CVID patients with a history suggestive of AR commonly present negative results on traditional testing, so additional experiments may be necessary. One suggestion for the investigation of AR in CVID patients would be nasal provocation with the most prevalent allergens.
C1 [Agondi, Rosana C.; Barros, Myrthes T.; Kokron, Cristina M.; Cohon, Andrea; Oliveira, Ana K. B.; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-04012140 Sao Paulo, Brazil.
RP Agondi, RC (corresponding author), Univ Sao Paulo, Rua Bage 100-152, BR-04012140 Sao Paulo, Brazil.
EM ragondi@gmail.com
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014; Marinho,
   Ana Karolina/C-8395-2017; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; Marinho, Ana Karolina/0000-0001-9369-8222;
   Kokron, Cristina M/0000-0002-9080-0305; Agondi, Rosana
   Camara/0000-0002-0503-5179
CR Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P130, DOI 10.1007/s10875-008-9229-9
   Agondi RC, 2010, ALLERGY, V65, P510, DOI 10.1111/j.1398-9995.2009.02211.x
   Agondi RC, 2008, J ASTHMA, V45, P754, DOI 10.1080/02770900802249149
   Bernatowska E, 2006, INT J PEDIATR OTORHI, V70, P1587, DOI 10.1016/j.ijporl.2006.04.013
   Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x
   Bondioni MP, 2007, J COMPUT ASSIST TOMO, V31, P620, DOI 10.1097/RCT.0b013e31802e3c11
   Bonilla FA, 2009, PEDIATR RES, V65, p13R, DOI 10.1203/PDR.0b013e31819dbf88
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Buehring I, 1997, CLIN EXP IMMUNOL, V109, P468, DOI 10.1046/j.1365-2249.1997.4831379.x
   Calabria CW, 2009, ALLERGY ASTHMA PROC, V30, P386, DOI 10.2500/aap.2009.30.3258
   Carr TF, 2011, AM J RHINOL ALLERGY, V25, P241, DOI 10.2500/ajra.2011.25.3653
   Ciprandi G, 2011, AM J RHINOL ALLERGY, V25, pE72, DOI 10.2500/ajra.2011.25.3607
   Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   DEMOLY P, 2003, MIDDLETONS ALLERGY P, P631
   Durham SR, 2000, AM J RHINOL, V14, P305, DOI 10.2500/105065800781329492
   Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989
   Favre O, 2005, ALLERGY, V60, P385, DOI 10.1111/j.1398-9995.2005.00756.x
   Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053
   Global Initiative for Asthma (GINA), DIAGN CLASS GLOB STR
   Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2
   Mete N, 2004, ANN ALLERG ASTHMA IM, V93, P193, DOI 10.1016/S1081-1206(10)61475-5
   Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a
   PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218
   Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153
   Popa V, 1999, ANN ALLERG ASTHMA IM, V82, P567, DOI 10.1016/S1081-1206(10)63168-7
   Quillen DM, 2006, AM FAM PHYSICIAN, V73, P1583
   Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1
   Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x
   Shabestari MS, 2008, J INVEST ALLERG CLIN, V18, P300
   SOLE D, 2006, REV BRAS ALERG IMUNO, V29, P29
   Unsworth DJ, 2011, ANN CLIN BIOCHEM, V48, P459, DOI 10.1258/acb.2011.011052
   Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003
   Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339
NR 36
TC 11
Z9 11
U1 0
U2 7
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAR-APR
PY 2013
VL 27
IS 2
BP 79
EP 83
DI 10.2500/ajra.2013.27.3855
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 193GR
UT WOS:000322547600005
PM 23562193
DA 2020-11-26
ER

PT J
AU Batista, MD
   Tincati, C
   Milush, JM
   Ho, EL
   Ndhlovu, LC
   York, VA
   Kallas, EG
   Kalil, J
   Keating, SM
   Norris, PJ
   Chang, D
   Unemori, P
   Leslie, KS
   Maurer, T
   Liao, W
   Nixon, DF
AF Batista, Mariana D.
   Tincati, Camilla
   Milush, Jeffrey M.
   Ho, Emily L.
   Ndhlovu, Lishomwa C.
   York, Vanessa A.
   Kallas, Esper G.
   Kalil, Jorge
   Keating, Sheila M.
   Norris, Philip J.
   Chang, David
   Unemori, Patrick
   Leslie, Kieron S.
   Maurer, Toby
   Liao, Wilson
   Nixon, Douglas F.
TI CD57 Expression and Cytokine Production by T Cells in Lesional and
   Unaffected Skin from Patients with Psoriasis
SO PLOS ONE
LA English
DT Article
ID HUMAN KERATINOCYTES; ATOPIC-DERMATITIS; GENE-EXPRESSION; IL-22;
   DIFFERENTIATION; LYMPHOCYTES; IMMUNOPATHOGENESIS; ACTIVATION; IMMUNITY;
   SUBSET
AB Background: The immunopathogenic mechanisms leading to psoriasis remain unresolved. CD57 is a marker of replicative inability and immunosenescence on CD8+ T cells and the proportion of CD57 expressing CD8+ T cells is increased in a number of inflammatory conditions.
   Methodology: We examined the expression of CD57 on T cells in the skin of patients affected with psoriasis, comparing lesional and unaffected skin. We also assessed functionality of the T cells by evaluating the secretion of several inflammatory cytokines (IL-17A, IFN-gamma, IL-2, IL-33, TNF-alpha, IL-21, IL-22, and IL-27), from cell-sorted purified CD4+ and CD8+ T cells isolated from lesional and unaffected skin biopsies of psoriasis patients.
   Principal Findings: We observed that the frequency of CD57+CD4+ and CD57+CD8+ T cells was significantly higher in unaffected skin of psoriasis patients compared to lesional skin. Sorted CD4+ T cells from psoriatic lesional skin produced higher levels of IL-17A, IL-22, and IFN-gamma compared to unaffected skin, while sorted CD8+ T cells from lesional skin produced higher levels of IL-17, IL-22, IFN-gamma, TNF-alpha, and IL-2 compared to unaffected skin.
   Conclusions/Significance: These findings suggest that T cells in unaffected skin from psoriasis patients exhibit a phenotype compatible with replicative inability. As they have a lower replicative capacity, CD57+ T cells are less frequent in lesional tissue due to the high cellular turnover.
C1 [Batista, Mariana D.; Tincati, Camilla; Milush, Jeffrey M.; Ho, Emily L.; Ndhlovu, Lishomwa C.; York, Vanessa A.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Batista, Mariana D.; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Inst Invest Imunol, Sao Paulo, Brazil.
   [Keating, Sheila M.; Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Keating, Sheila M.; Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA.
   [Norris, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Chang, David] Calif Pacific Med Ctr, San Francisco, CA USA.
   [Unemori, Patrick; Leslie, Kieron S.; Maurer, Toby; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
RP Batista, MD (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM maridiasbatista@gmail.com
RI KALIL, JORGE/C-8029-2012; n, l/AAX-3992-2020; Nixon,
   Douglas/AAU-5734-2020; TINCATI, CAMILLA/K-4501-2018
OI KALIL, JORGE/0000-0001-8415-4274; Nixon, Douglas/0000-0002-2801-1786;
   Keating, Sheila/0000-0002-8324-3694; Kallas, Esper/0000-0003-2026-6925;
   TINCATI, CAMILLA/0000-0002-3083-2962; Milush, Jeffrey
   M./0000-0002-0773-6411; Ndhlovu, Lishomwa/0000-0001-5427-4187
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI64520,
   5T32HL007185]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas, 2010/05845-0/Kallas]; Peter and Shelagh Godsoe
   Family Foundation; UCSF REAC [37710/521717]; American Academy of
   Neurology Clinical Research Training Fellowship; National Institute of
   Musculoskeletal and Skin DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
   [5K08AR057763]; International AIDS Society; U.S. National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; UW Institute of Translational Health
   Sciences; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [K08AR057763, K08AR057763,
   K08AR057763, K08AR057763, K08AR057763, K08AR057763] Funding Source: NIH
   RePORTER
FX This work was supported in part by the National Institutes of Health
   (grants AI64520), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (04/15856-9/Kallas and 2010/05845-0/Kallas and Nixon), and the Peter and
   Shelagh Godsoe Family Foundation. DN was supported in part by UCSF REAC
   grant no. 37710/521717. ELH was a recipient of the American Academy of
   Neurology Clinical Research Training Fellowship. JMM was supported in
   part by the National Institutes of Health (grant 5T32HL007185). WL was
   supported in part by grants from the National Institute of
   Musculoskeletal and Skin Diseases (5K08AR057763) and the International
   AIDS Society in collaboration with the NIH-funded Centers for AIDS
   Research, U.S. National Institutes of Health, and the UW Institute of
   Translational Health Sciences. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arai K, 1998, CLIN EXP IMMUNOL, V111, P345
   Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Cameron AL, 2002, ARCH DERMATOL RES, V294, P363, DOI 10.1007/s00403-002-0349-4
   Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995
   Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107
   Clark RA, 2011, J INVEST DERMATOL, V131, P283, DOI 10.1038/jid.2010.374
   Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
   Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59
   Evans TG, 1999, AIDS, V13, P1139, DOI 10.1097/00002030-199906180-00019
   Focosi D, 2010, J LEUKOCYTE BIOL, V87, P107, DOI 10.1189/jlb.0809566
   Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173
   Iking-Konert C, 2009, CLIN EXP RHEUMATOL, V27, pS19
   Le Priol Y, 2006, J IMMUNOL, V177, P5145, DOI 10.4049/jimmunol.177.8.5145
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213
   Mak RKH, 2009, ACTAS DERMO-SIFILOGR, V100, P2, DOI 10.1016/S0001-7310(09)73372-1
   Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
   Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x
   Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041
   Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/JLB.0109046, 10.1189/jlb.0109046]
   Palmer BE, 2005, J IMMUNOL, V175, P8415, DOI 10.4049/jimmunol.175.12.8415
   Plant D, 2006, EXP DERMATOL, V15, P900, DOI 10.1111/j.1600-0625.2006.00486.x
   Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108
   Sabat R, 2007, EXP DERMATOL, V16, P779, DOI 10.1111/j.1600-0625.2007.00629.x
   Shibata S, J INVEST DERMATOL, V130, P1034
   Simpson RJ, 2008, BRAIN BEHAV IMMUN, V22, P544, DOI 10.1016/j.bbi.2007.11.002
   Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948
   Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124
   Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280
   Tarazona R, 2000, MECH AGEING DEV, V121, P77
   Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x
   Theoharides TC, P NATL ACAD SCI US, V107, P4448
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503
   Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
   Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505
NR 37
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2013
VL 8
IS 2
AR e52144
DI 10.1371/journal.pone.0052144
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098DA
UT WOS:000315524900002
PM 23468834
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Galvao, V
   Aun, M
   Bisaccioni, C
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana C.
   Galvao, Violeta
   Aun, Marcelo
   Bisaccioni, Carla
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Characterization of Asthmatic Patients with Vocal Cord Dysfunction
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
   (AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Agondi, Rosana C.; Galvao, Violeta; Aun, Marcelo; Bisaccioni, Carla; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB63
EP AB63
DI 10.1016/j.jaci.2012.12.887
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800226
DA 2020-11-26
ER

PT J
AU Bittar, RP
   Aun, M
   Garro, LS
   Ribeiro, MR
   Kalil, J
   Giavina-Bianchi, P
   Motta, AA
AF Bittar, Renata P.
   Aun, Marcelo
   Garro, Laila Sabino
   Ribeiro, Marisa Rosimeire
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Motta, Antonio Abilio
TI Acetaminophen Hypersensitivity: Myth or Reality
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
   (AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Bittar, Renata P.; Aun, Marcelo; Garro, Laila Sabino; Ribeiro, Marisa Rosimeire; Kalil, Jorge; Giavina-Bianchi, Pedro; Motta, Antonio Abilio] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; Giavina-Bianchi, Pedro/I-3112-2014; KALIL,
   JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB170
EP AB170
DI 10.1016/j.jaci.2012.12.1270
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800602
DA 2020-11-26
ER

PT J
AU Garro, LS
   Carmona, MJC
   Soares, ISC
   Aun, MV
   Ribeiro, MR
   Rodrigues, AT
   Kalil, J
   Giavina-Bianchi, P
   Motta, AA
AF Garro, Laila Sabino
   Carvalho Carmona, Maria Jose
   Correa Soares, Iracy Silvia
   Aun, Marcelo Vivolo
   Ribeiro, Marisa Rosimeire
   Rodrigues, Adriana Teixeira
   Kalil, Jorge
   Giavina-Bianchi, Pedro
   Motta, Antonio Abilio
TI Incidence of Intraoperative Anaphylaxis in A University General Hospital
   in Brazil
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
   (AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Garro, Laila Sabino; Aun, Marcelo Vivolo; Ribeiro, Marisa Rosimeire; Rodrigues, Adriana Teixeira; Kalil, Jorge; Giavina-Bianchi, Pedro; Motta, Antonio Abilio] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
   [Carvalho Carmona, Maria Jose; Correa Soares, Iracy Silvia] Univ Sao Paulo, Anesthesia Div, BR-05508 Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012; Giavina-Bianchi,
   Pedro/I-3112-2014
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB177
EP AB177
DI 10.1016/j.jaci.2012.12.1294
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800625
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, M
   Sotto, MN
   Kanashiro, L
   Simpson, AJ
   Giavina-Bianchi, P
   Kalil, J
   Festa, C
AF Giavina-Bianchi, Mara
   Sotto, Miriam Nacagamo
   Kanashiro, Luciane
   Simpson, Andrew J.
   Giavina-Bianchi, Pedro
   Kalil, Jorge
   Festa, Cyro
TI NY-ESO-1 Expression Is Associated with Melanoma Thickness, but Not
   Mortality
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
   (AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Giavina-Bianchi, Mara; Sotto, Miriam Nacagamo; Festa, Cyro] Univ Sao Paulo, Div Dermatol, Sao Paulo, Brazil.
   [Kanashiro, Luciane] Univ Sao Paulo, Sao Paulo, Brazil.
   [Simpson, Andrew J.] Ludwig Inst Canc Res, Sao Paulo, Brazil.
   [Giavina-Bianchi, Pedro; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB66
EP AB66
DI 10.1016/j.jaci.2012.12.901
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800240
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Garro, LS
   Kalil, J
   Motta, AA
AF Giavina-Bianchi, Pedro
   Garro, Laila Sabino
   Kalil, Jorge
   Motta, Antonio Abilio
TI High Rate of Food Sensitization, but Not Food Allergy, in Latex Allergy
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
   (AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Giavina-Bianchi, Pedro; Garro, Laila Sabino; Kalil, Jorge; Motta, Antonio Abilio] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 1
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB22
EP AB22
DI 10.1016/j.jaci.2012.12.758
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800081
DA 2020-11-26
ER

PT J
AU Coelho, V
   Saitovitch, D
   Kalil, J
   Silva, HM
AF Coelho, Veronica
   Saitovitch, David
   Kalil, Jorge
   Silva, Hernandez Moura
TI Rethinking the multiple roles of B cells in organ transplantation
SO CURRENT OPINION IN ORGAN TRANSPLANTATION
LA English
DT Review
DE alloantibodies; autoantibodies; B cells; regulatory B cells; reshaping
   the B-cell compartment; transplantation tolerance
ID HUMAN-LEUKOCYTE ANTIGEN; DOSE CYCLOSPORINE MONOTHERAPY; RENAL-ALLOGRAFT
   RECIPIENTS; REGULATORY T-CELLS; CHRONIC REJECTION; OPERATIONAL
   TOLERANCE; PERIPHERAL-BLOOD; INDIRECT ALLOSPECIFICITY; HUMORAL IMMUNITY;
   LUNG-TRANSPLANT
AB Purpose of review
   To discuss the B-cell diverse functions in organ transplantation, highlighting the emerging debate on the role of regulatory B cells (Bregs). We underscore the need to re-examine and integrate data on B-cell functional activities, aiming to discriminate their regulatory (REG) and inflammatory (INFLAMMA) functions and to translate this knowledge for the development of novel immunomodulatory therapeutic strategies and to rethink the current ones.
   Recent findings
   Data from both experimental models and clinical trials point that B cells of various phenotypes have immunoregulatory activity and play an important role in controlling graft inflammation. Data on the state of operational tolerance, in kidney transplantation, suggest the relevance of preserving a healthy B-cell compartment - in numbers and in the Breg capacity to activate the CD40/STAT3 signalling pathway - for achieving and maintaining homeostasis. Moreover, autoantibodies also comprise transplant immunobiology and it seems that not all alloantibodies are deleterious.
   Summary
   The role of B cells, in organ transplantation, can no longer be taken as mere generators of plasma cells, which produce alloantibodies deleterious to the graft. B cells also seem to integrate a complex immunoregulatory network in organ transplantation, with Bregs of various phenotypes and possibly also antibodies. The functional discrimination of REG/INFLAMMA B-cell roles needs to be considered in the clinical setting.
C1 [Coelho, Veronica; Kalil, Jorge] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Coelho, Veronica; Saitovitch, David; Kalil, Jorge; Silva, Hernandez Moura] Natl Inst Sci & Technol INCT, III, Sao Paulo, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Div Nephrol, Sao Lucas Hosp, Porto Alegre, RS, Brazil.
   [Silva, Hernandez Moura] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY USA.
RP Coelho, V (corresponding author), Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Saitovitch,
   David/H-8863-2013
OI KALIL, JORGE/0000-0001-8415-4274; Saitovitch, David/0000-0003-2315-1314;
   Coelho, Veronica/0000-0002-0989-2581
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/59290-7]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; iii/INCT)
   [573879-2008-7]
FX The authors thank the other participants of the Brazilian Multicenter
   Study on Operational Tolerance: Francine Lemos, Irene Noronha, Sandra M
   Monteiro, Cristina Castro, Daisa S. R. David, Florencia Maria
   Barbe-Tuana, Fabiana Agena. The authors also thank Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP; 07/59290-7) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; iii/INCT,
   573879-2008-7) for financially supporting our studies related to this
   review.
CR [Anonymous], 2010, Drugs R D, V10, P55, DOI 10.2165/11538300-000000000-00000
   Ashton-Chess J, 2009, TRANSPLANTATION, V87, pS95, DOI 10.1097/TP.0b013e3181a2e295
   Azimzadeh AM, 2005, AM J TRANSPLANT, V5, P2349, DOI 10.1111/j.1600-6143.2005.01022.x
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Becker YT, 2006, TRANSPL INT, V19, P621, DOI 10.1111/j.1432-2277.2006.00345.x
   Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009
   Bloom D, 2009, AM J TRANSPLANT, V9, P1835, DOI 10.1111/j.1600-6143.2009.02710.x
   Brouard S, 2007, P NATL ACAD SCI USA, V104, P15448, DOI 10.1073/pnas.0705834104
   Buggins AGS, 2002, BLOOD, V100, P1715, DOI 10.1182/blood.V100.5.1715.h81702001715_1715_1720
   Calne R, 1999, TRANSPLANTATION, V68, P1613, DOI 10.1097/00007890-199911270-00032
   Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4
   Cherukuri A, 2012, AM J TRANSPLANT, V12, P919, DOI 10.1111/j.1600-6143.2011.03891.x
   Chong AS, 2011, AM J TRANSPLANT, V11, P2555, DOI 10.1111/j.1600-6143.2011.03773.x
   Clatworthy MR, 2011, AM J TRANSPLANT, V11, P1359, DOI 10.1111/j.1600-6143.2011.03554.x
   Clatworthy MR, 2009, NEW ENGL J MED, V360, P2683, DOI 10.1056/NEJMc0808481
   Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3
   Cohen IR, 2007, J AUTOIMMUN, V29, P246, DOI 10.1016/j.jaut.2007.07.016
   Cohen IR, 2007, NAT REV IMMUNOL, V7, P569, DOI 10.1038/nri2102
   Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498
   Danger R, 2012, J AM SOC NEPHROL, V23, P597, DOI 10.1681/ASN.2011060543
   DiLillo DJ, 2011, J IMMUNOL, V186, P2643, DOI 10.4049/jimmunol.1002983
   Ding Q, 2011, J CLIN INVEST, V121, P3645, DOI 10.1172/JCI46274
   Dragun D, 2005, NEW ENGL J MED, V352, P558, DOI 10.1056/NEJMoa035717
   Dunn TB, 2011, AM J TRANSPLANT, V11, P2132, DOI 10.1111/j.1600-6143.2011.03640.x
   Everly MJ, 2008, TRANSPLANTATION, V86, P1754, DOI 10.1097/TP.0b013e318190af83
   Fehr T, 2009, TRANSPLANTATION, V87, P1837, DOI 10.1097/TP.0b013e3181a6bac5
   Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833
   Gasser M, 2002, TRANSPLANT P, V34, P2244, DOI 10.1016/S0041-1345(02)03221-9
   Goers TA, 2008, J IMMUNOL, V180, P4487, DOI 10.4049/jimmunol.180.7.4487
   Graff RJ, 2009, HUM IMMUNOL, V70, P502, DOI 10.1016/j.humimm.2009.04.002
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hagedorn PH, 2010, IMMUNOLOGY, V130, P427, DOI 10.1111/j.1365-2567.2010.03246.x
   HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x
   Hale G, 1983, Mol Biol Med, V1, P321
   Hanaway MJ, 2011, NEW ENGL J MED, V364, P1909, DOI 10.1056/NEJMoa1009546
   Harris DP, 2005, J IMMUNOL, V174, P6781, DOI 10.4049/jimmunol.174.11.6781
   Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717
   Hashimoto Y, 2002, BLOOD, V100, P3504, DOI 10.1182/blood-2002-03-0733
   Heidt S, 2012, AM J TRANSPLANT, V12, P1784, DOI 10.1111/j.1600-6143.2012.04012.x
   Iwata T, 2008, J IMMUNOL, V181, P5738, DOI 10.4049/jimmunol.181.8.5738
   Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249
   Jindra PT, 2006, TRANSPLANTATION, V82, pS33, DOI 10.1097/01.tp.0000231447.34240.3c
   Jonker M, 2005, TRANSPLANTATION, V80, P385, DOI 10.1097/01.tp.0000166920.18998.15
   Kamburova EG, 2012, AM J TRANSPLANT, V12, P341, DOI 10.1111/j.1600-6143.2011.03833.x
   Kaneku H, 2012, LIVER TRANSPLANT, V18, P984, DOI 10.1002/lt.23451
   Kokko KE, 2012, AM J TRANSPLANT, V12, P1077, DOI 10.1111/j.1600-6143.2012.04016.x
   Kweon MN, 1998, J IMMUNOL, V160, P1687
   Kwun J, 2012, SEMIN IMMUNOL, V24, P96, DOI 10.1016/j.smim.2011.08.022
   LaMattina JC, 2012, TRANSPL INT, V25, P518, DOI 10.1111/j.1432-2277.2012.01448.x
   Le Texier L, 2011, AM J TRANSPLANT, V11, P429, DOI 10.1111/j.1600-6143.2010.03336.x
   Lechler R, 2001, IMMUNITY, V14, P357, DOI 10.1016/S1074-7613(01)00116-9
   Linton PJ, 2000, J IMMUNOL, V165, P5558, DOI 10.4049/jimmunol.165.10.5558
   Lund FE, 2010, NAT REV IMMUNOL, V10, P236, DOI 10.1038/nri2729
   Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844
   Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152
   Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572
   Mann MK, 2007, J IMMUNOL, V178, P3447, DOI 10.4049/jimmunol.178.6.3447
   Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293
   Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934
   Mauri C, 2010, NAT REV RHEUMATOL, V6, P636, DOI 10.1038/nrrheum.2010.140
   Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258
   Merbl Y, 2007, J CLIN INVEST, V117, P712, DOI 10.1172/JCI29943
   Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1
   Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705
   Moraes-Vieira PMM, 2012, CLIN IMMUNOL, V142, P117, DOI 10.1016/j.clim.2011.08.015
   Moraes-Vieira PMM, 2010, HUM IMMUNOL, V71, P442, DOI 10.1016/j.humimm.2010.01.022
   Morrow WR, 2012, TRANSPLANTATION, V93, P319, DOI 10.1097/TP.0b013e31823f7eea
   Nath DS, 2011, TRANSPLANTATION, V91, P1036, DOI 10.1097/TP.0b013e318211d2f4
   Newell KA, 2011, CURR OPIN IMMUNOL, V23, P655, DOI 10.1016/j.coi.2011.07.008
   Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933
   Noorchashm H, 2006, J IMMUNOL, V177, P7715, DOI 10.4049/jimmunol.177.11.7715
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Olofsson PS, 2012, IMMUNOL REV, V248, P188, DOI 10.1111/j.1600-065X.2012.01138.x
   Otto C, 2001, TRANSPL P, V33, P431, DOI 10.1016/S0041-1345(00)02079-0
   Pallier A, 2010, KIDNEY INT, V78, P503, DOI 10.1038/ki.2010.162
   Parsons RF, 2012, TRANSPLANTATION, V93, P676, DOI 10.1097/TP.0b013e318246621d
   PIERCE SK, 1988, IMMUNOL REV, V106, P149, DOI 10.1111/j.1600-065X.1988.tb00778.x
   Porcheray F, 2010, TRANSPLANTATION, V89, P1239, DOI 10.1097/TP.0b013e3181d72091
   Portugal K, 2001, INT IMMUNOL, V13, P747, DOI 10.1093/intimm/13.6.747
   Qin ZQ, 2011, TRANSPLANTATION, V92, P829, DOI 10.1097/TP.0b013e31822d0977
   Quintana FJ, 2006, LUPUS, V15, P428, DOI 10.1191/0961203306lu2328oa
   Redfield RR, 2011, CURR OPIN IMMUNOL, V23, P685, DOI 10.1016/j.coi.2011.07.011
   Riewaldt J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00141
   Rogers NJ, 2001, AM J TRANSPLANT, V1, P97, DOI 10.1034/j.1600-6143.2001.001002097.x
   Rowe V, 2006, BLOOD, V108, P2485, DOI 10.1182/blood-2006-04-016063
   Sagoo P, 2010, J CLIN INVEST, V120, P1848, DOI 10.1172/JCI39922
   Silva HM, 2012, MOL MED, V18, P733, DOI 10.2119/molmed.2011.00281
   Spadafora-Ferreira M, 2007, SCAND J IMMUNOL, V66, P352, DOI 10.1111/j.1365-3083.2007.01976.x
   Stastny P, 2009, HUM IMMUNOL, V70, P600, DOI 10.1016/j.humimm.2009.04.017
   Sun QQ, 2008, CLIN J AM SOC NEPHRO, V3, P1479, DOI 10.2215/CJN.04451007
   Sun QQ, 2011, KIDNEY INT, V79, P655, DOI 10.1038/ki.2010.437
   Sun QQ, 2005, TRANSPLANTATION, V79, P1759, DOI 10.1097/01.TP.0000163290.19788.E7
   SWAIN SL, 1987, IMMUNOL REV, V99, P263, DOI 10.1111/j.1600-065X.1987.tb01180.x
   Thaunat O, 2012, KIDNEY INT, V81, P207, DOI 10.1038/ki.2011.317
   Thaunat O, 2011, TRANSPLANTATION, V92, P121, DOI 10.1097/TP.0b013e31821f74fe
   Thaunat O, 2010, J IMMUNOL, V185, P717, DOI 10.4049/jimmunol.0903589
   Thibault-Espitia A, 2012, AM J TRANSPLANT, V12, P2754, DOI 10.1111/j.1600-6143.2012.04194.x
   Thiyagarajan UM, 2012, TRANSPL P, V44, P1231, DOI 10.1016/j.transproceed.2011.10.054
   Trivedi HL, 2009, TRANSPLANTATION, V87, P1555, DOI 10.1097/TP.0b013e3181a4b91b
   Tsang JYS, 2008, J CLIN INVEST, V118, P3619, DOI 10.1172/JCI33185
   Tsang JYS, 2009, TRANSPL IMMUNOL, V21, P203, DOI 10.1016/j.trim.2009.05.003
   Tyden G, 2009, TRANSPLANTATION, V87, P1325, DOI 10.1097/TP.0b013e3181a235fd
   UCKUN FM, 1990, BLOOD, V76, P1908
   Venetz JP, 2007, EXPERT OPIN INV DRUG, V16, P625, DOI 10.1517/13543784.16.5.625
   Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x
   Walsh RC, 2012, KIDNEY INT, V81, P1067, DOI 10.1038/ki.2011.502
   Walsh RC, 2010, TRANSPLANTATION, V89, P277, DOI 10.1097/TP.0b013e3181c6ff8d
   Walters S, 2009, J IMMUNOL, V182, P793, DOI 10.4049/jimmunol.182.2.793
   Wiebe C, 2012, AM J TRANSPLANT, V12, P1157, DOI 10.1111/j.1600-6143.2012.04013.x
   Wilkes DS, 2012, SEMIN IMMUNOL, V24, P131, DOI 10.1016/j.smim.2011.08.020
   Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271
   Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017
   Zarkhin V, 2010, TRANSPLANT REV-ORLAN, V24, P67, DOI 10.1016/j.trre.2010.01.004
   Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001
NR 114
TC 15
Z9 20
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1087-2418
EI 1531-7013
J9 CURR OPIN ORGAN TRAN
JI Curr. Opin. Organ Transpl.
PD FEB
PY 2013
VL 18
IS 1
BP 13
EP 21
DI 10.1097/MOT.0b013e32835c8043
PG 9
WC Transplantation
SC Transplantation
GA 076NO
UT WOS:000313963400003
PM 23254702
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Ferreira, FM
   Kohler, KF
   Postol, E
   Kalil, J
AF Guilherme, Luiza
   Ferreira, Frederico Moraes
   Koehler, Karen Francine
   Postol, Edilberto
   Kalil, Jorge
TI A Vaccine against Streptococcus pyogenes The Potential to Prevent
   Rheumatic Fever and Rheumatic Heart Disease
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Article
ID M-PROTEIN; IMMUNOGENICITY; PROTECTION; INFECTION; CANDIDATE; REGION;
   SAFETY; MICE
AB Streptococcus pyogenes causes severe, invasive infections such as the sequelae associated with acute rheumatic fever, rheumatic heart disease, acute glomerulonephritis, uncomplicated pharyngitis, and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. We have developed a vaccine candidate peptide, StreptInCor, comprising 55 amino acid residues of the C-terminal portion of the M protein and encompassing both the T- and B-cell protective epitopes. The present article summarizes data from the previous 5 years during which we tested the immunogenicity and safety of StreptInCor in different animal models. We showed that StreptInCor overlapping peptides induced cellular and humoral immune responses of individuals bearing different HLA class II molecules. These results are consistent with peptides that have a universal vaccine epitope. The tridimensional molecular structure of StreptInCor was elucidated by nuclear magnetic resonance spectroscopy, which showed that its structure is composed of two microdomains linked by an 18-residue alpha-helix. Additionally, we comprehensively evaluated the structural stability of the StreptInCor peptide in different physicochemical conditions using circular dichroism. Additional experiments were performed with inbred, outbred, and HLA class II transgenic mice. Analysis of several organs of these mice showed neither deleterious nor autoimmune reactions even after a long period of vaccination, indicating that the StreptInCor candidate peptide could be considered as an immunogenic and safe vaccine.
C1 [Guilherme, Luiza; Ferreira, Frederico Moraes; Koehler, Karen Francine; Postol, Edilberto; Kalil, Jorge] Univ Sao Paulo, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Guilherme, Luiza; Ferreira, Frederico Moraes; Koehler, Karen Francine; Postol, Edilberto; Kalil, Jorge] Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Guilherme, Luiza] Inst Coracao HC FMUSP, Lab Imunol, BR-05403903 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Dept Clin Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar,44-9 Andar, BR-05403903 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; Ferreira, Frederico Moraes/A-4622-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Brazil.
CR Acevedo R, 2009, METHODS, V49, P309, DOI 10.1016/j.ymeth.2009.03.027
   Barbosa PJB, 2009, ARQ BRAS CARDIOL, V93, P1
   Batzloff M, 2004, INDIAN J MED RES, V119, P104
   Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   FISCHETTI VA, 1988, J IMMUNOL, V141, P3592
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   Olive C, 2002, VACCINE, V20, P2816, DOI 10.1016/S0264-410X(02)00205-0
   Pandey M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005147
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
NR 16
TC 11
Z9 13
U1 0
U2 17
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1175-3277
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PY 2013
VL 13
IS 1
BP 1
EP 4
DI 10.1007/s40256-013-0005-8
PG 4
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 133KV
UT WOS:000318138200001
PM 23355360
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Kalil, J
AF Guilherme, Luiza
   Kalil, Jorge
TI Rheumatic heart disease: molecules involved in valve tissue inflammation
   leading to the autoimmune process and anti-S. pyogenes vaccine
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE S. pyogenes; genes; adhesion molecules; chemokines; Th1 and Th17
   cytokines; T and B cells; valve proteins; anti-S. pyo genes vaccine
AB The major events leading to both rheumatic fever (RE) and rheumatic heart disease (RHD) are reviewed. Several genes are involved in the development of RE and RHD. The inflammatory process that results from S. pyogenes infection involves the activation of several molecules such as VCAM and ICAM, which play a role in the migration of leukocytes to the heart, particularly to the valves. Specific chemokines, such as CXCL3/MIP1a as well as CCL1/I-309 and CXCL9/Mig, attractT cells to the myocardium and valves, respectively. The autoimmune reactions are mediated by both the B- and T-cell responses that begin at the periphery, followed by the migration of T cell clones to the heart and the infiltration of heart lesions in RHD patients. These cells recognize streptococcal antigens and humantissue proteins. Molecular mimicry between streptococcal M protein and human proteins has been proposed as the triggering factor leading to autoimmunity in RE and RHD. The production of cytokines from peripheral and heart-infiltrating mononuclear cells suggests that T helper 1 and Th17 cytokines are the mediators of RHD heart lesions. The low numbers of 1154 producing cells in the valvular tissue might contribute to the maintenance and progression of the valve lesions. The identification of a vaccine epitope opens a perspective of development of an effective and safe vaccine to prevent S. pyogenes infections, consequently RE and RHD.
C1 [Guilherme, Luiza; Kalil, Jorge] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05403903 Sao Paulo, Brazil.
   [Guilherme, Luiza; Kalil, Jorge] Univ Sao Paulo, Natl Inst Sci & Technol, Immunol Invest Inst, BR-05403903 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, BR-05403903 Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Av Dr Eneas Carvalho Aguiar 44, BR-05403903 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior"
   (CAPES), BrazilCAPES
FX We acknowledge collaborators and students from the Heart Institute
   (InCor) School of Medicine from the University of Sao Paulo who
   contributed to the scientific data that were published elsewhere and are
   described in this review. This work was supported by grants from
   "Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)" and
   "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)"
   and "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior"
   (CAPES), Brazil.
CR Azevedo PM, 2010, CYTOKINE, V49, P109, DOI 10.1016/j.cyto.2009.09.003
   Barbosa PJB, 2009, BRAZ ARCH CARDIOL, V93, P1
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   BHATIA R, 1989, CLIN CARDIOL, V12, P34, DOI 10.1002/clc.4960120106
   Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2
   Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   DALE JB, 1981, J IMMUNOL, V126, P1499
   DAMIAN RT, 1964, AM NAT, V98, P129, DOI 10.1086/282313
   De Amicis Marafigo K, 2013, VACCINE, DOI [10.1016/j.vaccine.2013.08.043, DOI 10.1016/J.VACCINE.2013.08.043.[]
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Fae KC, 2005, J AUTOIMMUN, V24, P101, DOI 10.1016/j.jaut.2005.01.007
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Fae KC, 2013, INFLAMMATION, V36, P800, DOI 10.1007/s10753-013-9606-2
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2011, ADV CLIN CHEM, V53, P31, DOI 10.1016/S0065-2423(11)53002-1
   Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Kamal H, 2010, ACTA CARDIOL, V65, P177, DOI 10.2143/AC.65.2.2047051
   KAPLAN MH, 1964, J EXP MED, V119, P651, DOI 10.1084/jem.119.4.651
   Kikly K, 2006, CURR OPIN IMMUNOL, V18, P670, DOI 10.1016/j.coi.2006.09.008
   Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892
   Messias-Reason IJ, 2009, CLIN EXP IMMUNOL, V157, P395, DOI 10.1111/j.1365-2249.2009.03975.x
   Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
   Ramasawmy R, 2008, CLIN VACCINE IMMUNOL, V15, P932, DOI 10.1128/CVI.00324-07
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   Settin A, 2007, PEDIATR CARDIOL, V28, P363, DOI 10.1007/s00246-006-0002-7
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
   Zabriskie J B, 1967, Adv Immunol, V7, P147, DOI 10.1016/S0065-2776(08)60128-5
   ZABRISKIE JB, 1970, CLIN EXP IMMUNOL, V7, P147
NR 41
TC 30
Z9 31
U1 0
U2 3
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2013
VL 4
AR UNSP 352
DI 10.3389/fimmu.2013.00352
PG 6
WC Immunology
SC Immunology
GA V38WS
UT WOS:000209374100344
PM 24198818
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Borba, SC
   Giordano, R
   Rizzo, LV
   Rodrigues, H
   Nahas, WC
   Ronda, C
   David-Neto, E
   Castro, MCR
   Kalil, J
   Panajotopoulos, N
AF Borba, S. C.
   Giordano, R.
   Rizzo, L., V
   Rodrigues, H.
   Nahas, W. C.
   Ronda, C.
   David-Neto, E.
   Castro, M. C. R.
   Kalil, J.
   Panajotopoulos, N.
TI Non-HLA (Megalin?) Antibodies in Kidney Transplantation
SO TRANSPLANTATION
LA English
DT Meeting Abstract
C1 [Borba, S. C.; Rodrigues, H.; Ronda, C.; Kalil, J.; Panajotopoulos, N.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Giordano, R.] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil.
   [Rizzo, L., V] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nahas, W. C.; David-Neto, E.; Castro, M. C. R.] Univ Med Sch, Hosp Clin, Div Urol, Sao Paulo, Brazil.
RI Neto, Elias David/O-3866-2018; Rizzo, Luiz Vicente/B-4458-2009; de
   castro, maria cristina ribeiro/B-6648-2009; KALIL, JORGE/C-8029-2012
OI de castro, maria cristina ribeiro/0000-0002-6731-8369; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD NOV 27
PY 2012
VL 94
IS 10
SU S
MA 2541
BP 578
EP 578
DI 10.1097/00007890-201211271-01116
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA V45WJ
UT WOS:000209846402405
DA 2020-11-26
ER

PT J
AU Penterich, V
   Yang, A
   Pereira, R
   Takayama, L
   Kalil, J
   Castro, F
AF Penterich, V
   Yang, A.
   Pereira, R.
   Takayama, L.
   Kalil, J.
   Castro, F.
TI Food consumption and nutritional status evaluation of children with
   atopic dermatitis
SO ALLERGY
LA English
DT Meeting Abstract
CT 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 16-20, 2012
CL Geneva, SWITZERLAND
SP European Acad Allergy & Clin Immunol (EAACI)
C1 [Penterich, V; Yang, A.; Kalil, J.; Castro, F.] Univ Sao Paulo, Allergy & Immunol Dept, Sao Paulo, Brazil.
   [Pereira, R.; Takayama, L.] Univ Sao Paulo, Div Rheumatol, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
J9 ALLERGY
JI Allergy
PD NOV
PY 2012
VL 67
SU 96
SI SI
MA 235
BP 106
EP 107
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 026CA
UT WOS:000310247700226
DA 2020-11-26
ER

PT J
AU Nogueira, LG
   Santos, RHB
   Ianni, BM
   Fiorelli, AI
   Mairena, EC
   Benvenuti, LA
   Frade, A
   Donadi, E
   Dias, F
   Saba, B
   Wang, HTL
   Fragata, A
   Sampaio, M
   Hirata, MH
   Buck, P
   Mady, C
   Bocchi, EA
   Stolf, NA
   Kalil, J
   Cunha-Neto, E
AF Nogueira, Luciana Gabriel
   Barros Santos, Ronaldo Honorato
   Ianni, Barbara Maria
   Fiorelli, Alfredo Inacio
   Mairena, Eliane Conti
   Benvenuti, Luiz Alberto
   Frade, Amanda
   Donadi, Eduardo
   Dias, Fabricio
   Saba, Bruno
   Wang, Hui-Tzu Lin
   Fragata, Abilio
   Sampaio, Marcelo
   Hirata, Mario Hiroyuki
   Buck, Paula
   Mady, Charles
   Bocchi, Edimar Alcides
   Stolf, Noedir Antonio
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Myocardial Chemokine Expression and Intensity of Myocarditis in Chagas
   Cardiomyopathy Are Controlled by Polymorphisms in CXCL9 and CXCL10
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DISEASE CARDIOMYOPATHY; GENE-EXPRESSION; T-CELLS; HEART LESIONS;
   IFN-GAMMA; RECEPTORS; CYTOKINES; CXCR3; CCR5; PROMOTER
AB Background: Chronic Chagas cardiomyopathy (CCC), a life-threatening inflammatory dilated cardiomyopathy, affects 30% of the approximately 8 million patients infected by Trypanosoma cruzi. Even though the Th1 T cell-rich myocarditis plays a pivotal role in CCC pathogenesis, little is known about the factors controlling inflammatory cell migration to CCC myocardium.
   Methods and Results: Using confocal immunofluorescence and quantitative PCR, we studied cell surface staining and gene expression of the CXCR3, CCR4, CCR5, CCR7, CCR8 receptors and their chemokine ligands in myocardial samples from end-stage CCC patients. CCR5+, CXCR3+, CCR4+, CCL5+ and CXCL9+ mononuclear cells were observed in CCC myocardium. mRNA expression of the chemokines CCL5, CXCL9, CXCL10, CCL17, CCL19 and their receptors was upregulated in CCC myocardium. CXCL9 mRNA expression directly correlated with the intensity of myocarditis, as well as with mRNA expression of CXCR3, CCR4, CCR5, CCR7, CCR8 and their ligands. We also analyzed single-nucleotide polymorphisms for genes encoding the most highly expressed chemokines and receptors in a cohort of Chagas disease patients. CCC patients with ventricular dysfunction displayed reduced genotypic frequencies of CXCL9 rs10336 CC, CXCL10 rs3921 GG, and increased CCR5 rs1799988CC as compared to those without dysfunction. Significantly, myocardial samples from CCC patients carrying the CXCL9/CXCL10 genotypes associated to a lower risk displayed a 2-6 fold reduction in mRNA expression of CXCL9, CXCL10, and other chemokines and receptors, along with reduced intensity of myocarditis, as compared to those with other CXCL9/CXCL10 genotypes.
   Conclusions: Results may indicate that genotypes associated to reduced risk in closely linked CXCL9 and CXCL10 genes may modulate local expression of the chemokines themselves, and simultaneously affect myocardial expression of other key chemokines as well as intensity of myocarditis. Taken together our results may suggest that CXCL9 and CXCL10 are master regulators of myocardial inflammatory cell migration, perhaps affecting clinical progression to the life-threatening form of CCC.
C1 [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Frade, Amanda; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Frade, Amanda; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nogueira, Luciana Gabriel; Mairena, Eliane Conti; Frade, Amanda; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol 3, Sao Paulo, Brazil.
   [Barros Santos, Ronaldo Honorato; Fiorelli, Alfredo Inacio; Stolf, Noedir Antonio] Univ Sao Paulo, Sch Med, Div Surg, Heart Inst InCor, Sao Paulo, Brazil.
   [Ianni, Barbara Maria; Buck, Paula; Mady, Charles] Univ Sao Paulo, Sch Med, Myocardiopathies Unit, Heart Inst InCor, Sao Paulo, Brazil.
   [Benvenuti, Luiz Alberto] Univ Sao Paulo, Sch Med, Div Pathol, Heart Inst InCor, Sao Paulo, Brazil.
   [Donadi, Eduardo; Dias, Fabricio] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Sao Paulo, Brazil.
   [Saba, Bruno; Wang, Hui-Tzu Lin; Fragata, Abilio; Sampaio, Marcelo; Hirata, Mario Hiroyuki] Dante Pazzanese Inst, Cardiol & Heart Failure Unit, Sao Paulo, Brazil.
   [Bocchi, Edimar Alcides] Univ Sao Paulo, Sch Med, Transplantat & Heart Failure Unit, Heart Inst InCor, Sao Paulo, Brazil.
RP Nogueira, LG (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
EM edecunha@usp.br
RI Ianni, Barbara Maria/C-7689-2012; Benvenuti, Luiz/C-6614-2014; Buck,
   Paula C/F-8781-2012; Mady, Charles/C-8870-2012; Cunha-Neto,
   Edecio/B-4157-2009; donadi, eduardo A/H-7080-2013; KALIL,
   JORGE/C-8029-2012; Hirata, Mario Hiroyuki/C-9718-2013; Frade, Amanda
   F/O-3322-2017
OI Ianni, Barbara Maria/0000-0002-1588-5492; Buck, Paula
   C/0000-0002-1411-4485; Mady, Charles/0000-0002-8838-199X; Cunha-Neto,
   Edecio/0000-0002-3699-3345; donadi, eduardo A/0000-0002-9457-9601;
   KALIL, JORGE/0000-0001-8415-4274; Hirata, Mario
   Hiroyuki/0000-0002-9521-7979; Frade, Amanda F/0000-0002-9004-8811; Lin
   Wang, Hui Tzu/0000-0002-7027-7748
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Sao Paulo State
   Research Funding Agency [FAPESP 05/54507-2, FAPESP 08/58844-1]
FX This research was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) and the Sao Paulo State Research
   Funding Agency (FAPESP). LGN is recipient of Sao Paulo State Research
   Funding Agency (FAPESP 05/54507-2 and FAPESP 08/58844-1) fellowship. ED,
   ECN, MHH, EAB, and JK are recipients of grants from the Brazilian
   Council for Scientific and Technological Development (CNPq). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556
   Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Anez N, 1999, AM J TROP MED HYG, V60, P726, DOI 10.4269/ajtmh.1999.60.726
   Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Barbosa AP, 2011, ARQ BRAS CARDIOL, V97, P517, DOI 10.1590/S0066-782X2011005000112
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Bruck P, 2009, HUM IMMUNOL, V70, P552, DOI 10.1016/j.humimm.2009.04.031
   Bujak M, 2009, CIRC RES, V105, P973, DOI 10.1161/CIRCRESAHA.109.199471
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Calzada JE, 2001, TISSUE ANTIGENS, V58, P154, DOI 10.1034/j.1399-0039.2001.580302.x
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   D'Ambrosio D, 1998, J IMMUNOL, V161, P5111
   Deng GH, 2008, GASTROENTEROLOGY, V134, P716, DOI 10.1053/j.gastro.2007.12.044
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Erdel M, 2001, IMMUNOGENETICS, V53, P611, DOI 10.1007/s002510100363
   Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246
   Florez O, 2012, HUM IMMUNOL
   Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Gong JH, 2010, CELL IMMUNOL, V261, P105, DOI 10.1016/j.cellimm.2009.11.007
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Guedes PMM, 2010, VET IMMUNOL IMMUNOP, V138, P106, DOI 10.1016/j.vetimm.2010.06.010
   Hart AL, 2010, INFLAMM BOWEL DIS, V16, P1969, DOI 10.1002/ibd.21304
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kakuta Y, 2012, TRANSPLANTATION, V93, P24, DOI 10.1097/TP.0b013e31823aa585
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Klich Izabela, 2011, Pediatr Endocrinol Diabetes Metab, V17, P10
   Lacher M, 2007, BIOCHEM BIOPH RES CO, V363, P701, DOI 10.1016/j.bbrc.2007.09.020
   Lee HH, 1996, CYTOGENET CELL GENET, V74, P255, DOI 10.1159/000134428
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Manque PA, 2011, INFECT IMMUN, V79, P1855, DOI 10.1128/IAI.00643-10
   Marin-Neto JA, 2008, AM HEART J, V156, P37, DOI 10.1016/j.ahj.2008.04.001
   Marino APMP, 2005, MEM I OSWALDO CRUZ, V100, P93, DOI 10.1590/S0074-02762005000900015
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   MARTIN UO, 1987, MEDICINA-BUENOS AIRE, V47, P159
   McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0
   MILEI J, 1992, CARDIOLOGY, V80, P424, DOI 10.1159/000175035
   Morato MJF, 1998, BRAZ J MED BIOL RES, V31, P123, DOI 10.1590/S0100-879X1998000100016
   Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   Soares MBP, 2010, J INFECT DIS, V202, P416, DOI 10.1086/653481
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070
   Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Sekiya T, 2003, IMMUNOGENETICS, V54, P742, DOI 10.1007/s00251-002-0520-2
   Soto-Sanchez J, 2010, CYTOKINE, V50, P114, DOI 10.1016/j.cyto.2010.01.006
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Troia-Cancio P, 2011, EXPERT REV ANTI-INFE, V9, P649, DOI [10.1586/ERI.11.52, 10.1586/eri.11.52]
   Turner JE, 2007, MINI-REV MED CHEM, V7, P1089, DOI 10.2174/138955707782331768
   Yates CC, 2007, AM J PATHOL, V171, P484, DOI 10.2353/ajpath.2007.061092
   Zhernakova A, 2006, GENES IMMUN, V7, P544, DOI 10.1038/sj.gene.6364326
NR 69
TC 59
Z9 61
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2012
VL 6
IS 10
AR e1867
DI 10.1371/journal.pntd.0001867
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 029WH
UT WOS:000310527200032
PM 23150742
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Rodrigues, H
   Kalil, J
   Castro, MC
   Panajotopoulos, N
   Paredes, M
   Massarolo, P
   Mies, S
AF Monteiro, F.
   Rodrigues, H.
   Kalil, J.
   Castro, M. C.
   Panajotopoulos, N.
   Paredes, M.
   Massarolo, P.
   Mies, S.
TI Pre- and Posttransplant Monitoring of Alloantibodies by
   Complement-Dependent Cytotoxicity and Luminex Methodologies in Liver
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Brazilian Transplant Congress of the
   Brazilian-Association-for-Organ-Transplantation / Luso-Brazilian
   Congress of Transplantation / Meeting of Transplant Nursing /
   Multidisciplinary Transplant Meeting / ABH's Histocompatibility Forum
CY OCT 01-04, 2011
CL Belem, BRAZIL
SP Brazilian Assoc Organ Transplantat (ABTO)
ID ANTIBODIES
AB Background. This study evaluated the influence of circulating anti-HLA antibodies on outcomes of 97 liver allografts from deceased donors.
   Methods. Human leukocyte antigen (HLA) antibody screening was performed by both complement-dependent cytotoxicity (CDC) and multiparameter Luminex microsphere-based assays (Luminex assay).
   Results. The agreements between T- and B- cell CDC and Luminex assays were 67% and 77% for pre- and posttransplant specimens, respectively. Graft dysfunction was not associated with either positive pretransplant CDC or Luminex panel-reactive antibody (PRA) values. Likewise, positive posttransplant T- or B- cell CDC PRA values were not associated with graft dysfunction. In contrast, posttransplant Luminex PRA values were significantly higher among patients with graft dysfunction compared with subjects with good outcomes (P = .017).
   Conclusion. Posttransplant monitoring of HLA antibodies with Luminex methodology allowed identification of patients at high-risk for poor graft outcomes.
C1 [Monteiro, F.; Rodrigues, H.; Kalil, J.; Castro, M. C.; Panajotopoulos, N.] Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Sao Paulo, Brazil.
   [Paredes, M.; Massarolo, P.; Mies, S.] Univ Sao Paulo, Sch Med, Liver Unitk, Sao Paulo, Brazil.
RP Monteiro, F (corresponding author), Immunol Lab, Av Dr Eneas Carvalho Aguiar,44-9 Andar, Sao Paulo, Brazil.
EM frmonte@usp.br
RI de castro, maria cristina ribeiro/B-6648-2009; Massarollo,
   Paulo/I-2283-2013; KALIL, JORGE/C-8029-2012; Massarollo,
   Paulo/AAS-3567-2020
OI de castro, maria cristina ribeiro/0000-0002-6731-8369; Massarollo,
   Paulo/0000-0001-6398-1027; KALIL, JORGE/0000-0001-8415-4274; Massarollo,
   Paulo/0000-0001-6398-1027
CR Mao Q, 2007, AM J TRANSPLANT, V7, P864, DOI 10.1111/j.1600-6143.2006.01711.x
   van den Berg-Loonen EM, 2008, TRANSPLANTATION, V85, P1086, DOI 10.1097/TP.0b013e31816b3ed1
   Zeevi A, 2010, LIVER TRANSPLANT, V16, P259, DOI 10.1002/lt.22025
NR 3
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2012
VL 44
IS 8
BP 2411
EP 2412
DI 10.1016/j.transproceed.2012.07.005
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 019JX
UT WOS:000309736900041
PM 23026608
DA 2020-11-26
ER

PT J
AU Terra, LF
   Teixeira, PC
   Wailemann, RAM
   Zelanis, A
   Palmisano, G
   Cunha-Neto, E
   Kalil, J
   Labriola, L
   Sogayar, MC
AF Terra, L. F.
   Teixeira, P. C.
   Wailemann, R. A. M.
   Zelanis, A.
   Palmisano, G.
   Cunha-Neto, E.
   Kalil, J.
   Labriola, L.
   Sogayar, M. C.
TI Proteomic approach to search for differentially expressed proteins
   between human pancreatic islets and human insulinomas
SO DIABETOLOGIA
LA English
DT Meeting Abstract
C1 [Terra, L. F.; Wailemann, R. A. M.; Labriola, L.; Sogayar, M. C.] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508 Sao Paulo, Brazil.
   [Terra, L. F.; Wailemann, R. A. M.; Labriola, L.; Sogayar, M. C.] Univ Sao Paulo, NUCEL, BR-05508 Sao Paulo, Brazil.
   [Teixeira, P. C.; Cunha-Neto, E.; Kalil, J.] FM USP, InCor, Sao Paulo, Brazil.
   [Zelanis, A.] Inst Butantan, Sao Paulo, Brazil.
   [Palmisano, G.] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark.
RI KALIL, JORGE/C-8029-2012; Sogayar, Mari C/B-3980-2017; Cunha-Neto,
   Edecio/B-4157-2009; Zelanis, Andre/AAD-4618-2019; Terra,
   Leticia/E-7332-2011; Labriola, Leticia/E-9059-2012
OI KALIL, JORGE/0000-0001-8415-4274; Sogayar, Mari C/0000-0003-4805-4609;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Zelanis,
   Andre/0000-0003-3066-6527; Labriola, Leticia/0000-0003-3899-6088
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD OCT
PY 2012
VL 55
SU 1
MA 404
BP S172
EP S173
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V30OY
UT WOS:000208826501151
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Rosa, DS
   Ribeiro, SP
   Santana, VC
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Almeida, Rafael Ribeiro
   Rosa, Daniela Santoro
   Ribeiro, Susan Pereira
   Santana, Vinicius Canato
   Kallas, Esper Georges
   Sidney, John
   Sette, Alessandro
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Broad and Cross-Clade CD4(+) T-Cell Responses Elicited by a DNA Vaccine
   Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus
   Peptides
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RHESUS-MONKEYS; IMMUNE-RESPONSES;
   DISCORDANT ASSOCIATIONS; LYMPHOCYTE RESPONSES; SIV REPLICATION;
   PATHOGENIC SIV; VIRAL LOAD; EPITOPES; INFECTION
AB T-cell based vaccine approaches have emerged to counteract HIV-1/AIDS. Broad, polyfunctional and cytotoxic CD4(+) T-cell responses have been associated with control of HIV-1 replication, which supports the inclusion of CD4(+) T-cell epitopes in vaccines. A successful HIV-1 vaccine should also be designed to overcome viral genetic diversity and be able to confer immunity in a high proportion of immunized individuals from a diverse HLA-bearing population. In this study, we rationally designed a multiepitopic DNA vaccine in order to elicit broad and cross-clade CD4(+) T-cell responses against highly conserved and promiscuous peptides from the HIV-1 M-group consensus sequence. We identified 27 conserved, multiple HLA-DR-binding peptides in the HIV-1 M-group consensus sequences of Gag, Pol, Nef, Vif, Vpr, Rev and Vpu using the TEPITOPE algorithm. The peptides bound in vitro to an average of 12 out of the 17 tested HLA-DR molecules and also to several molecules such as HLA-DP, -DQ and murine IA(b) and IA(d). Sixteen out of the 27 peptides were recognized by PBMC from patients infected with different HIV-1 variants and 72% of such patients recognized at least 1 peptide. Immunization with a DNA vaccine (HIVBr27) encoding the identified peptides elicited IFN-gamma secretion against 11 out of the 27 peptides in BALB/c mice; CD4(+) and CD8(+) T-cell proliferation was observed against 8 and 6 peptides, respectively. HIVBr27 immunization elicited cross-clade T-cell responses against several HIV-1 peptide variants. Polyfunctional CD4(+) and CD8(+) T cells, able to simultaneously proliferate and produce IFN-gamma and TNF-alpha, were also observed. This vaccine concept may cope with HIV-1 genetic diversity as well as provide increased population coverage, which are desirable features for an efficacious strategy against HIV-1/AIDS.
C1 [Almeida, Rafael Ribeiro; Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Santana, Vinicius Canato; Kallas, Esper Georges; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, InCor, Sch Med, Inst Heart, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro] Univ Fed Sao Paulo, UNIFESP, Div Immunol, Sao Paulo, Brazil.
   [Sidney, John] La Jolla Inst Allergy & Immunol, Ctr Infect Dis Allergy & Asthma Res, La Jolla, CA USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; Almeida,
   Rafael/F-8014-2014; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; Almeida, Rafael/0000-0003-3984-7527; KALIL,
   JORGE/0000-0001-8415-4274; Kallas, Esper/0000-0003-2026-6925
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [420166/2005-0]; Sao
   Paulo State Research Funding Agency (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2004/15856-9, 2006/50096-0,
   2008/57881-0]; Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Brazilian Council for Scientific and
   Technological Development - CNPq productivity awards
FX This research was supported by the Brazilian National Research Council
   (CNPq), grant 420166/2005-0; Sao Paulo State Research Funding Agency
   (FAPESP), grants 2004/15856-9, 2006/50096-0 and 2008/57881-0; Brazilian
   Program for STD and AIDS, Ministry of Health
   (914/BRA/3014-UNESCO/Kallas); and the Sao Paulo City Health Department
   (2004-0.168.922-7/Kallas). RRA, SPR and VCS are recipients of Sao Paulo
   State Research Funding Agency (FAPESP) fellowships. EGK, JK and ECN are
   recipients of Brazilian Council for Scientific and Technological
   Development - CNPq productivity awards. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67
   Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Batista MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005613
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Bijker MS, 2007, J IMMUNOL, V179, P5033, DOI 10.4049/jimmunol.179.8.5033
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Chevalier MF, 2011, J VIROL, V85, P733, DOI 10.1128/JVI.02030-10
   Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
   de Lalla C, 1999, J IMMUNOL, V163, P1725
   Depil S, 2007, J IMMUNOTHER, V30, P215, DOI 10.1097/01.cji.0000211338.99137.4f
   Depla E, 2008, J VIROL, V82, P435, DOI 10.1128/JVI.01505-07
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Egan MA, 2000, J VIROL, V74, P7485, DOI 10.1128/JVI.74.16.7485-7495.2000
   Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Fuller DH, 2007, VIROLOGY, V364, P245, DOI 10.1016/j.virol.2007.02.024
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gauduin MC, 2006, J EXP MED, V203, P2661, DOI 10.1084/jem.20060134
   Gloster SE, 2004, AIDS, V18, P749, DOI 10.1097/00002030-200403260-00005
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGLAND J MED, P366
   Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85
   Ishioka GY, 1999, J IMMUNOL, V162, P3915
   Iwai LK, 2007, CLIN VACCINE IMMUNOL, V14, P474, DOI 10.1128/CVI.00458-06
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Kallas EG, 2004, BRAZ J INFECT DIS, V8, P8
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kovjazin R, 2011, VACCINE, V29, P4676, DOI 10.1016/j.vaccine.2011.04.103
   Lacap PA, 2008, AIDS, V22, P1029, DOI 10.1097/QAD.0b013e3282ffb3db
   Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984
   Liao HX, 2006, VIROLOGY, V353, P268, DOI 10.1016/j.virol.2006.04.043
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Ngumbela KC, 2008, AIDS RES HUM RETROV, V24, P72, DOI 10.1089/aid.2007.0124
   Pettersen FO, 2010, CLIN EXP IMMUNOL, V161, P315, DOI 10.1111/j.1365-2249.2010.04179.x
   Porichis F, 2011, CURR OPIN HIV AIDS, V6, P174, DOI 10.1097/COH.0b013e3283454058
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Ranasinghe S, 2012, J VIROL, V86, P277, DOI 10.1128/JVI.05577-11
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Rolland M, 2007, PLOS PATHOG, V3, P1551, DOI 10.1371/journal.ppat.0030157
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sa D, 2007, AIDS RES HUM RETROV, V23, P1087, DOI 10.1089/aid.2006.0173
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Samri A, 2006, CLIN VACCINE IMMUNOL, V13, P684, DOI 10.1128/CVI.00387-05
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105
   Schroers R, 2002, CANCER RES, V62, P2600
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Sidney J, 2001, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s31
   Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Suhrbier Andreas, 2002, Expert Rev Vaccines, V1, P207, DOI 10.1586/14760584.1.2.207
   Sui YJ, 2010, P NATL ACAD SCI USA, V107, P9843, DOI 10.1073/pnas.0911932107
   Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
   Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05
   Wilson CC, 2003, J IMMUNOL, V171, P5611, DOI 10.4049/jimmunol.171.10.5611
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zheng N, 2009, J VIROL, V83, P7668, DOI 10.1128/JVI.00513-09
NR 72
TC 22
Z9 23
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2012
VL 7
IS 9
AR e45267
DI 10.1371/journal.pone.0045267
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 040HS
UT WOS:000311313900110
PM 23028895
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Pinto, A
   Mendes, F
   Agondi, R
   Saraiva-Romanholo, B
   Stelmach, R
   Cukier, A
   Martins, M
   Kalil, J
   Carvalho, C
   Giavina-Bianchi, P
AF Pinto, Andrezza
   Mendes, Felipe
   Agondi, Rosana
   Saraiva-Romanholo, Beatriz
   Stelmach, Rafael
   Cukier, Alberto
   Martins, Milton
   Kalil, Jorge
   Carvalho, Celso
   Giavina-Bianchi, Pedro
TI Effect of aerobic exercise training on bronchial hyperresponsiveness,
   airway inflammation and health related quality of life in asthmatic
   patients: A pilot study
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Asthma - management; Anti-inflammatory; Exercise
C1 [Pinto, Andrezza; Agondi, Rosana; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Mendes, Felipe; Carvalho, Celso] Univ Sao Paulo, Sch Med, Phys Therapy, Sao Paulo, SP, Brazil.
   [Saraiva-Romanholo, Beatriz; Martins, Milton] Univ Sao Paulo, Sch Med, Clin Med, Sao Paulo, SP, Brazil.
   [Stelmach, Rafael; Cukier, Alberto] Univ Sao Paulo, Sch Med, InCor Pulm Div, Sao Paulo, SP, Brazil.
EM andrezzafranca@usp.br; felipemendes@usp.br; ragondi@gmail.com;
   beatriz@experimental.fm.usp.br; rafael.stelmach@incor.usp.br;
   alberto.cukier@incor.usp.br; mmartins@usp.br; jkalil@usp.br;
   cscarval@usp.br; saudesos@terra.com.br
RI stelmach, rafael/AAH-1638-2019
OI stelmach, rafael/0000-0002-5132-1934
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2012
VL 40
SU 56
MA 2944
PG 1
WC Respiratory System
SC Respiratory System
GA VH0IH
UT WOS:000449650900301
DA 2020-11-26
ER

PT J
AU Fernandes, KS
   Kokron, CM
   Barros, MT
   Kalil, J
   Gallottini, M
AF Fernandes, Karin Sa
   Kokron, Cristina Maria
   Barros, Myrthes Toledo
   Kalil, Jorge
   Gallottini, Marina
TI Oral manifestations in patients with hypogammaglobulinemia
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID COMMON VARIABLE IMMUNODEFICIENCY; RECURRENT APHTHOUS STOMATITIS;
   DENTAL-CARIES; DEFICIENCY; ANTIBODY; FEATURES; CRITERIA; DISEASE; HEALTH
AB Objective. The overall objective of this study was to assess the oral manifestations and their association with immunologic status and health history, of individuals with hypogammaglobulinemia.
   Study Design. A case-controlled study of 100 subjects with hypogammaglobulinemia and 93 control individuals was performed. All participants were examined for dental caries, periodontal disease, mucosal lesions/infections, and general oral health problems. Decayed, missing, filled teeth and community periodontal index were recorded. Complete blood count, serum immunoglobulins, and lymphocyte immunophenotyping were measured on the same day of the oral health assessment.
   Results. Individuals with hypogammaglobulinemia showed higher prevalence of enamel hypoplasia and complaints of dry mouth, and lower prevalence of dental caries and periodontal disease.
   Conclusions. The systemic conditions associated with hypogammaglobulinemia were not associated with enhanced susceptibility to caries, gingivitis, or periodontitis; however, individuals with hypogammaglobulinemia were more likely to report more episodes of recurrent aphthous ulcers compared with control individuals. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:e19-e24)
C1 [Fernandes, Karin Sa; Gallottini, Marina] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, BR-05508000 Sao Paulo, Brazil.
   [Kokron, Cristina Maria; Barros, Myrthes Toledo; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05508000 Sao Paulo, Brazil.
RP Gallottini, M (corresponding author), Univ Sao Paulo, Sch Dent, Dept Oral Pathol, Lineu Prestes 2227, BR-05508000 Sao Paulo, Brazil.
EM mhcgmaga@usp.com.br
RI Kokron, Cristina M/D-3140-2012; gallottini, marina/B-8893-2011; KALIL,
   JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; gallottini,
   marina/0000-0001-6071-5110; KALIL, JORGE/0000-0001-8415-4274
CR Beentjes V E, 2002, Eur J Paediatr Dent, V3, P9
   Bonhomme D, 2000, J IMMUNOL, V165, P4725, DOI 10.4049/jimmunol.165.8.4725
   Brandt D, 2006, AUTOIMMUN REV, V5, P465, DOI 10.1016/j.autrev.2006.03.010
   Chinen J, 2010, J ALLERGY CLIN IMMUN, V125, pS195, DOI 10.1016/j.jaci.2009.08.040
   COLE MF, 1977, J DENT RES, V56, P198, DOI 10.1177/00220345770560030201
   Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417
   DAHLEN G, 1993, J CLIN PERIODONTOL, V20, P7, DOI 10.1111/j.1600-051X.1993.tb01752.x
   Deane S, 2009, INT ARCH ALLERGY IMM, V150, P311, DOI 10.1159/000226232
   Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2
   ENGSTROM GN, 1992, J PERIODONTOL, V63, P984, DOI 10.1902/jop.1992.63.12.984
   Jalevik B, 2001, EUR J ORAL SCI, V109, P230, DOI 10.1034/j.1600-0722.2001.00047.x
   KIRSTILA V, 1994, J CLIN IMMUNOL, V14, P229, DOI 10.1007/BF01552309
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Laisi S, 2009, J DENT RES, V88, P132, DOI 10.1177/0022034508328334
   LEGLER DW, 1982, J AM DENT ASSOC, V105, P803, DOI 10.14219/jada.archive.1982.0472
   Magalhaes MG, 2007, J AM DENT ASSOC, V138, P1468, DOI 10.14219/jada.archive.2007.0083
   Marcotte H, 1998, MICROBIOL MOL BIOL R, V62, P71, DOI 10.1128/MMBR.62.1.71-109.1998
   McCullough MJ, 2007, J ORAL PATHOL MED, V36, P615, DOI 10.1111/j.1600-0714.2007.00589.x
   Natah SS, 2000, J ORAL PATHOL MED, V29, P19, DOI 10.1034/j.1600-0714.2000.290104.x
   Nisengard R. J., 1994, ORAL MICROBIOLOGY IM
   Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x
   PORTER SR, 1993, J ORAL PATHOL MED, V22, P157, DOI 10.1111/j.1600-0714.1993.tb01049.x
   Rogers RS, 1997, SEMIN CUTAN MED SURG, V16, P278, DOI 10.1016/S1085-5629(97)80017-X
   ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707
   Scully C, 2003, J AM DENT ASSOC, V134, P200, DOI 10.14219/jada.archive.2003.0134
   SMITH DJ, 1994, ORAL MICROBIOL IMMUN, V9, P65, DOI 10.1111/j.1399-302X.1994.tb00036.x
   STOKES CR, 1975, NATURE, V255, P745, DOI 10.1038/255745a0
   Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
NR 30
TC 3
Z9 4
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212-4403
EI 1528-395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD SEP
PY 2012
VL 114
IS 3
BP E19
EP E24
DI 10.1016/j.oooo.2012.02.006
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 992WK
UT WOS:000307810700004
PM 22703644
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Bisaccioni, C
   Aun, MV
   Ribeiro, MR
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R. C.
   Bisaccioni, C.
   Aun, M. V.
   Ribeiro, M. R.
   Kalil, J.
   Giavina-Bianchi, P.
TI Spirometric values in elderly asthmatic patients are not influenced by
   obesity
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; GENOME-WIDE ASSOCIATION; LUNG-FUNCTION
   DECLINE; GENERAL-POPULATION; ENVIRONMENTAL DETERMINANTS; GENETIC
   EPIDEMIOLOGY; FAMILIAL AGGREGATION; SMOKING-BEHAVIOR; LINKAGE ANALYSIS;
   SERPINE2 GENE
AB Background Studies have suggested that asthma in obese individuals differs from the classic asthma phenotype, presenting as a disease that is more difficult to control.
   Objective The objective of the present study was to determine whether obesity, age or a combination of the two are associated with worse spirometry parameters in patients with asthma.
   Methods This was an observational cross-sectional study involving patients over 18 years of age who had been diagnosed with asthma (allergic or nonallergic). We evaluated the results of their spirometric tests. The patients were classified in accordance with two criteria: body mass index (BMI) and age. Based on their BMIs, the patients were divided into three groups: normal weight, overweight and obese. Patients were also separated into two categories by age: 18-59 years of age; and >= 60 years of age.
   Results We evaluated 451 patients with asthma and their spirometry tests. In the present study, the pulmonary function parameters were negatively correlated with BMI and age (P < 0.05). We found that there was a statistically significant correlation between spirometric values and BMI among patients 18-59 years of age (P < 0.001), however, among patients over 60, we did not observe this negative association.
   Conclusions and Clinical Relevance The spirometric values decreased significantly in proportion to the increase of BMI and age in patients with asthma, especially among young adults. There was no negative correlation between BMI and FEV1 in the group >= 60 years of age, suggesting that perhaps the time of disease is a major factor in the loss of lung function than weight gain in the elderly.
C1 [Agondi, R. C.; Bisaccioni, C.; Aun, M. V.; Ribeiro, M. R.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Agondi, RC (corresponding author), R Bage 100,Ap 152, BR-04212140 Sao Paulo, Brazil.
EM ragondi@gmail.com
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; Aun,
   Marcelo V/E-6775-2014
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200; Agondi,
   Rosana Camara/0000-0002-0503-5179
CR Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Artigas MS, 2011, AM J RESP CRIT CARE, V184, P786, DOI 10.1164/rccm.201102-0192OC
   BECK GJ, 1981, AM REV RESPIR DIS, V123, P149
   Bourbeau Jean, 2009, Proc Am Thorac Soc, V6, P553, DOI 10.1513/pats.200906-039DS
   Burton PR, 2005, LANCET, V366, P941, DOI 10.1016/S0140-6736(05)67322-9
   Castaldi PJ, 2011, AM J RESP CELL MOL, V45, P1147, DOI 10.1165/rcmb.2011-0055OC
   Castaldi PJ, 2010, HUM MOL GENET, V19, P526, DOI 10.1093/hmg/ddp519
   Celedon JC, 2004, HUM MOL GENET, V13, P1649, DOI 10.1093/hmg/ddh171
   Chazaud C, 2003, MECH DEVELOP, V120, P691, DOI 10.1016/S0925-4773(03)00048-0
   Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535
   DeMeo Dawn, 2006, Proc Am Thorac Soc, V3, P502, DOI 10.1513/pats.200603-070MS
   Demeo DL, 2009, AM J HUM GENET, V85, P493, DOI 10.1016/j.ajhg.2009.09.004
   DeMeo DL, 2004, AM J RESP CRIT CARE, V170, P1294, DOI 10.1164/rccm.200404-524OC
   Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569
   Furberg H, 2010, NAT GENET, V42, P441, DOI 10.1038/ng.571
   Gottlieb DJ, 2001, AM J RESP CRIT CARE, V164, P1655, DOI 10.1164/ajrccm.164.9.2010122
   Hall IP, 2010, THORAX, V65, P760, DOI 10.1136/thx.2010.147173
   Hall IP, 2009, CURR OPIN PHARMACOL, V9, P256, DOI 10.1016/j.coph.2009.03.003
   Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892
   Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x
   Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569
   Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC
   Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012
   LARSON RK, 1965, ANN INTERN MED, V63, P1001, DOI 10.7326/0003-4819-63-6-1001
   LEBOWITZ MD, 1984, AM REV RESPIR DIS, V129, P8
   LEWITTER FI, 1984, AM J EPIDEMIOL, V120, P518, DOI 10.1093/oxfordjournals.aje.a113912
   Liu JZ, 2010, NAT GENET, V42, P436, DOI 10.1038/ng.572
   Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802
   Loos RJF, 2008, NAT GENET, V40, P768, DOI 10.1038/ng.140
   Makrygiannakis D, 2008, ANN RHEUM DIS, V67, P1488, DOI 10.1136/ard.2007.075192
   Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674
   Marciniak SJ, 2009, THORAX, V64, P359, DOI 10.1136/thx.2008.099408
   Massaro GD, 2000, PHYSIOL GENOMICS, V4, P51, DOI 10.1152/physiolgenomics.2000.4.1.51
   Matheson MC, 2006, J HUM GENET, V51, P196, DOI 10.1007/s10038-005-0344-7
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Minematsu N, 2001, BIOCHEM BIOPH RES CO, V289, P116, DOI 10.1006/bbrc.2001.5936
   Moriguchi T, 2004, GENES CELLS, V9, P549, DOI 10.1111/j.1356-9597.2004.00743.x
   Morin C, 2007, AM J PHYSIOL-LUNG C, V293, pL1037, DOI 10.1152/ajplung.00145.2007
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Obeidat M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019382
   Palmer LJ, 2003, HUM MOL GENET, V12, P1199, DOI 10.1093/hmg/ddg125
   Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960
   Park EJ, 2011, ENVIRON RES, V111, P348, DOI 10.1016/j.envres.2010.11.001
   Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501
   Sakao S, 2001, AM J RESP CRIT CARE, V163, P420, DOI 10.1164/ajrccm.163.2.2006031
   Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177
   Silverman Edwin K, 2011, COPD, V8, P121, DOI 10.3109/15412555.2011.558864
   Silverman EK, 1996, MED CLIN N AM, V80, P501, DOI 10.1016/S0025-7125(05)70451-X
   Silverman EK, 2002, AM J HUM GENET, V70, P1229, DOI 10.1086/340316
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Smolonska J, 2009, AM J RESP CRIT CARE, V180, P618, DOI 10.1164/rccm.200905-0722OC
   Soler Artigas M, 2011, THORAX, V2011, P19
   Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941
   TAGER I, 1978, INT J EPIDEMIOL, V7, P55, DOI 10.1093/ije/7.1.55
   Talmud PJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4838
   Thorgeirsson TE, 2010, NAT GENET, V42, P448, DOI 10.1038/ng.573
   van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC
   van Diemen CC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-89
   Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727
   Wain LV, 2009, LANCET, V374, P340, DOI 10.1016/S0140-6736(09)60249-X
   Wilk JB, 2000, GENET EPIDEMIOL, V19, P81, DOI 10.1002/1098-2272(200007)19:1<81::AID-GEPI6>3.0.CO;2-8
   Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429
   Yang A, 2010, VASC PHARMACOL, V53, P122, DOI 10.1016/j.vph.2010.05.001
   Yang J, 2002, J CELL BIOL, V159, P431, DOI 10.1083/jcb.200207153
   Yucesoy B, 2008, J OCCUP ENVIRON MED, V50, P642, DOI 10.1097/JOM.0b013e31816515e1
   Zhou M, 2004, CHINESE MED J-PEKING, V117, P1481
   Zhu G, 2007, AM J RESP CRIT CARE, V176, P167, DOI 10.1164/rccm.200611-1723OC
NR 77
TC 4
Z9 4
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-7894
EI 1365-2222
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD AUG
PY 2012
VL 42
IS 8
BP 1183
EP 1189
DI 10.1111/j.1365-2222.2011.03951.x
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 974AR
UT WOS:000306402600006
PM 22805465
DA 2020-11-26
ER

PT J
AU Kalil, J
AF Kalil, Jorge
TI Antivenom Production by Instituto Butantan: 110 Years of Experience
SO TOXICON
LA English
DT Meeting Abstract
CT 17th World Congress of the International-Society-on-Toxinology
   (IST)/Venom Week/4th International Scientific Symposium on All Things
   Venomous
CY JUL 08-13, 2012
CL Honolulu, HI
SP Int Soc Toxinol (IST), Rare Dis Therapeut, Inc, BTG Int Ltd, Inst Bioclon, Silanes Labs, SA, Toxicon Amer Int Rattlesnake Museum, Chiricahua Desert Museum, Elsevier BV, Univ Hawaii, Coll Pharm, Univ New Mexico Hlth Sci Ctr, Midwest Tongs
DE antivenom; Instituto Butantan; immunology; vaccines; blood products;
   venomous animals
C1 [Kalil, Jorge] Butantan Inst, Sao Paulo, Brazil.
EM jkalil@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2012
VL 60
IS 2
SI SI
MA 87
BP 139
EP 140
DI 10.1016/j.toxicon.2012.04.088
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 964UI
UT WOS:000305721800089
DA 2020-11-26
ER

PT J
AU Gama, L
   Shirk, EN
   Russell, JN
   Carvalho, KI
   Li, M
   Queen, SE
   Kalil, J
   Zink, MC
   Clements, JE
   Kallas, EG
AF Gama, Lucio
   Shirk, Erin N.
   Russell, Julia N.
   Carvalho, Karina I.
   Li, Ming
   Queen, Suzanne E.
   Kalil, Jorge
   Zink, M. Christine
   Clements, Janice E.
   Kallas, Esper G.
TI Expansion of a subset of CD14(high)CD16(neg)CCR2(low/neg) monocytes
   functionally similar to myeloid-derived suppressor cells during SIV and
   HIV infection
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE macrophages; AIDS
ID SIMIAN IMMUNODEFICIENCY VIRUS; PERIPHERAL-BLOOD MONOCYTES; CHEMOKINE
   RECEPTOR EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DENDRITIC CELLS;
   CC-CHEMOKINE; CHEMOATTRACTANT PROTEIN-1; CEREBROSPINAL-FLUID;
   INFLAMMATORY SITES; PHENOTYPIC CHANGES
AB Monocytes have been categorized in three main subpopulations based on CD14 and CD16 surface expression. Classical monocytes express the CD14(++)CD16(-) CCR2(+) phenotype and migrate to inflammatory sites by quickly responding to CCL2 signaling. Here, we identified and characterized the expansion of a novel monocyte subset during HIV and SIV infection, which were undistinguishable from classical monocytes, based on CD14 and CD16 expression, but expressed significantly lower surface CCR2. Transcriptome analysis of sorted cells demonstrated that the CCR2(low/neg) cells are a distinct subpopulation and express lower levels of inflammatory cytokines and activation markers than their CCR2(high) counterparts. They exhibited impaired phagocytosis and greatly diminished chemotaxis in response to CCL2 and CCL7. In addition, these monocytes are refractory to SIV infection and suppress CD8(+) T cell proliferation in vitro. These cells express higher levels of STAT3 and NOS2, suggesting a phenotype similar to monocytic myeloid-derived cells, which suppress expansion of CD8(+) T cells in vivo. They may reflect an antiproliferative response against the extreme immune activation observed during HIV and SIV infections. In addition, they may suppress antiviral responses and thus, have a role in AIDS pathogenesis. Antiretroviral therapy in infected macaque and human subjects caused this population to decline, suggesting that this atypical phenotype is linked to viral replication. J. Leukoc. Biol. 91: 803-816; 2012.
C1 [Gama, Lucio; Shirk, Erin N.; Russell, Julia N.; Li, Ming; Queen, Suzanne E.; Zink, M. Christine; Clements, Janice E.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21287 USA.
   [Gama, Lucio; Carvalho, Karina I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Gama, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, BRB 831, Baltimore, MD 21287 USA.
EM lucio@jhmi.edu
RI KALIL, JORGE/C-8029-2012; Carvalho, Karina IL/J-6789-2012
OI KALIL, JORGE/0000-0001-8415-4274; Carvalho, Karina
   IL/0000-0002-7763-8139; Gama, Lucio/0000-0001-9511-012X; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [MH070306, NS055648,
   MH085554]; Ministry of HealthMinistry of Health - Turkey
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Brazilian Ministry of Education; Brazilian
   Program for STD and AIDS; NATIONAL INSTITUTE OF MENTAL HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, R01MH085554, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, R01MH085554, P01MH070306,
   R01MH085554, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, R01MH085554, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   R01MH085554, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS055648,
   R01NS055648, R01NS055648, R01NS055648, R01NS055648] Funding Source: NIH
   RePORTER
FX This study was supported by National Institutes of Health grants
   MH070306, NS055648, and MH085554. This study was partially supported
   with funding from the Brazilian Program for STD and AIDS, Ministry of
   Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo City Health
   Department (2004-0.168.922-7/Kallas), and the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (04/15856-9/Kallas). K.I.C.'s
   scholarship is supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education,
   through the Programa Nacional de Pos Doutorado (PNPD) program. We thank
   Brandon B. Bullock for technical assistance as well as the rest of the
   Retrovirus Laboratory for helpful discussion. Special thanks to Jasmeet
   Sethi and the Microarray Core at the Johns Hopkins School of Medicine
   for help with NanoString data acquisition and Ada Tam for assistance
   with cytometry sorting. Medical Editor Michael E. Linde made substantial
   contributions to the editing of the manuscript. We also thank Daniela S.
   Rosa, Bianca N. Santos, Helena Tomiyama, Priscilla Costa, and Claudia
   Tomiyama at Laboratorio de Investigacao Medica 60, School of Medicine,
   University of Sao Paulo, for valuable support in the sample repository
   constitution and the monocyte experiments.
CR Ancuta P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-403
   Barber SA, 2004, J NEUROVIROL, V10, P15, DOI 10.1080/13550280490268179
   Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459
   Bissel SJ, 2006, J NEUROIMMUNOL, V177, P85, DOI 10.1016/j.jneuroim.2006.04.017
   Burdo TH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000842
   Carter DL, 1999, CYTOMETRY, V37, P41, DOI 10.1002/(SICI)1097-0320(19990901)37:1<41::AID-CYTO5>3.3.CO;2-W
   Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
   Clay CC, 2007, J VIROL, V81, P12040, DOI 10.1128/JVI.00133-07
   Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768
   Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Filipazzi P., 2010, CANCER IMMUNOL IMMUN, V61, P255
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19
   Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48
   Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kamp W, 2001, EUR J CLIN INVEST, V31, P984, DOI 10.1046/j.1365-2362.2001.00895.x
   KAZAZI F, 1989, J GEN VIROL, V70, P2661, DOI 10.1099/0022-1317-70-10-2661
   Kim WK, 2010, J LEUKOCYTE BIOL, V87, P557, DOI 10.1189/jlb.0209082
   Lafferty MK, 2010, BLOOD, V115, P1564, DOI 10.1182/blood-2009-06-226423
   Laforge M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002087
   Lewin SR, 1998, AIDS, V12, P719, DOI 10.1097/00002030-199807000-00008
   Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500
   Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820
   Margulies BJ, 2001, AIDS RES HUM RETROV, V17, P981, DOI 10.1089/088922201750290104
   Merino A, 2011, J IMMUNOL, V186, P1809, DOI 10.4049/jimmunol.1001866
   MIKOVITS JA, 1992, J CLIN INVEST, V90, P1486, DOI 10.1172/JCI116016
   Mizuno K, 2005, CLIN EXP IMMUNOL, V142, P461, DOI 10.1111/j.1365-2005.02932.x
   Nagaraj Srinivas, 2009, Cancer Res, V69, P7503, DOI 10.1158/0008-5472.CAN-09-2152
   Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529
   Otani I, 1998, AIDS RES HUM RETROV, V14, P1181, DOI 10.1089/aid.1998.14.1181
   Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
   Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x
   Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
   Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08
   Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191
   Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
   Takeda S, 2010, DIGEST DIS SCI, V55, P1886, DOI 10.1007/s10620-009-0974-2
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Van Grol J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011733
   Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
   Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011
   Velasco F, 2000, MATH GEOL, V32, P439, DOI 10.1023/A:1007573815959
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078
   Weber C, 2000, J LEUKOCYTE BIOL, V67, P699
   Witwer KW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008129
   Xu LL, 2000, EUR J IMMUNOL, V30, P227, DOI 10.1002/1521-4141(200001)30:1<227::AID-IMMU227>3.0.CO;2-X
   Yachie A, 2003, EXP BIOL MED, V228, P550, DOI 10.1177/15353702-0322805-26
   Yona S, 2010, CURR OPIN HEMATOL, V17, P53, DOI 10.1097/MOH.0b013e3283324f80
   Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
   Zink MC, 1999, J VIROL, V73, P10480, DOI 10.1128/JVI.73.12.10480-10488.1999
   Zink MC, 2001, J INFECT DIS, V184, P1015, DOI 10.1086/323478
NR 67
TC 40
Z9 40
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAY
PY 2012
VL 91
IS 5
BP 803
EP 816
DI 10.1189/jlb.1111579
PG 14
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 939TH
UT WOS:000303837200015
PM 22368280
OA Green Published
DA 2020-11-26
ER

PT J
AU Silva, HM
   Takenaka, MCS
   Moraes-Vieira, PMM
   Monteiro, SM
   Hernandez, MO
   Chaara, W
   Six, A
   Agena, F
   Sesterheim, P
   Barbe-Tuana, FM
   Saitovitch, D
   Lemos, F
   Kalil, J
   Coelho, V
AF Silva, Hernandez M.
   Takenaka, Maisa C. S.
   Moraes-Vieira, Pedro M. M.
   Monteiro, Sandra M.
   Hernandez, Maristela O.
   Chaara, Wahiba
   Six, Adrien
   Agena, Fabiana
   Sesterheim, Patricia
   Barbe-Tuana, Florencia Maria
   Saitovitch, David
   Lemos, Francine
   Kalil, Jorge
   Coelho, Veronica
TI Preserving the B-Cell Compartment Favors Operational Tolerance in Human
   Renal Transplantation
SO MOLECULAR MEDICINE
LA English
DT Article
ID T-CELLS; LIVER-TRANSPLANT; CHRONIC REJECTION; PERIPHERAL-BLOOD; MIXED
   CHIMERISM; RECEPTOR; RECIPIENTS; IDENTIFICATION; ANTIGEN; SUBSET
AB Transplanted individuals in operational tolerance (OT) maintain long-term stable graft function after completely stopping immunosuppression. Understanding the mechanisms involved in OT can provide valuable information about pathways to human transplantation tolerance. Here we report that operationally tolerant individuals display quantitative and functional preservation of the B-c ell compartment in renal transplantation. OT exhibited normal numbers of circulating total B cells, naive, memory and regulatory B cells (Bregs) as well as preserved B-cell receptor repertoire, similar to healthy individuals. In addition, OT also displayed conserved capacity to activate the cluster of differentiation 40 (CD40)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in Bregs, in contrast, with chronic rejection. Rather than expansion or higher activation, we show that the preservation of the B-cell compartment favors OT. Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00281
C1 [Silva, Hernandez M.; Takenaka, Maisa C. S.; Moraes-Vieira, Pedro M. M.; Monteiro, Sandra M.; Hernandez, Maristela O.; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Silva, Hernandez M.; Takenaka, Maisa C. S.; Moraes-Vieira, Pedro M. M.; Monteiro, Sandra M.; Hernandez, Maristela O.; Sesterheim, Patricia; Barbe-Tuana, Florencia Maria; Saitovitch, David; Kalil, Jorge; Coelho, Veronica] INCT Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Moraes-Vieira, Pedro M. M.] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Sao Paulo, Brazil.
   [Chaara, Wahiba; Six, Adrien] Univ Paris 06, UMR 7211, Paris, France.
   [Chaara, Wahiba; Six, Adrien] CNRS, UMR 7211, Paris, France.
   [Chaara, Wahiba; Agena, Fabiana] Hop La Pitie Salpetriere, AP HP, Serv Biotherapie, Paris, France.
   [Sesterheim, Patricia; Barbe-Tuana, Florencia Maria; Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Div Nephrol, Sao Lucas Hosp, Porto Alegre, RS, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Agena, Fabiana/C-5819-2015; COELHO, VERONICA/D-1433-2013; Barbe-Tuana,
   Florencia/L-4881-2015; Takenaka, Maisa/J-5788-2014; Agena,
   Fabiana/F-5807-2012; Moraes-Vieira, Pedro M/C-8701-2014; KALIL,
   JORGE/C-8029-2012; Hernandez, Maristela/J-2271-2014
OI Agena, Fabiana/0000-0002-4526-4857; Barbe-Tuana,
   Florencia/0000-0002-5358-3524; Moraes-Vieira, Pedro
   M/0000-0002-8263-786X; KALIL, JORGE/0000-0001-8415-4274; Six,
   Adrien/0000-0001-5898-555X; Coelho, Veronica/0000-0002-0989-2581;
   SESTERHEIM, PATRICIA/0000-0002-9287-8640
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/59290-7]; Conselho
   Nacional de Desenvolvimento Cientffico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq) [iii/INCT,
   573879-2008-7]
FX The authors thank the Brazilian Multicenter Study on Operational
   Tolerance group. The authors also thank Elisangela S Prado for
   collecting samples and clinical data. The authors are grateful to the
   Ludwig Institute for Cancer Research and the researchers Ana Maria
   Camargo and Anna Christina Salim for sharing the sequencing facility to
   perform the B-cell receptor repertoire analysis. We also thank Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; 07/59290-7) for
   providing the fellowship and Conselho Nacional de Desenvolvimento
   Cientffico e Tecnologico (CNPq; iii/INCT, 573879-2008-7) for financial
   support.
CR Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009
   Blair PA, 2009, J IMMUNOL, V182, P3492, DOI 10.4049/jimmunol.0803052
   Braudeau C, 2008, TRANSPLANTATION, V86, P130, DOI 10.1097/TP.0b013e31817b8dc5
   Braudeau C, 2007, TRANSPL INT, V20, P845, DOI 10.1111/j.1432-2277.2007.00537.x
   Brouard S, 2007, P NATL ACAD SCI USA, V104, P15448, DOI 10.1073/pnas.0705834104
   Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x
   COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Collette A, 2003, J IMMUNOL METHODS, V278, P105, DOI 10.1016/S0022-1759(03)00225-4
   Collette A, 2002, BIOINFORMATICS, V18, P329, DOI 10.1093/bioinformatics/18.2.329
   Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508
   Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1
   Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833
   Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407
   Fuchimoto Y, 2000, J CLIN INVEST, V105, P1779, DOI 10.1172/JCI8721
   Golshayan D, 2008, DRUGS, V68, P2113, DOI 10.2165/00003495-200868150-00004
   Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901
   Harris DP, 2005, J IMMUNOL, V174, P6781, DOI 10.4049/jimmunol.174.11.6781
   Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717
   Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401
   Hori S, 2002, J IMMUNOL METHODS, V268, P159, DOI 10.1016/S0022-1759(02)00187-4
   Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249
   Kawai T, 2004, AM J TRANSPLANT, V4, P1391, DOI 10.1111/j.1600-6143.2004.00523.x
   Lim A, 2008, INT IMMUNOL, V20, P105, DOI 10.1093/intimm/dxm125
   Louis S, 2006, TRANSPLANTATION, V81, P398, DOI 10.1097/01.tp.0000203166.44968.86
   Martinez-Llordella M, 2008, J CLIN INVEST, V118, P2845, DOI 10.1172/JCI35342
   Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293
   Mizoguchi A, 1997, J EXP MED, V186, P1749, DOI 10.1084/jem.186.10.1749
   Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1
   Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705
   Moraes-Vieira PMM, 2010, HUM IMMUNOL, V71, P442, DOI 10.1016/j.humimm.2010.01.022
   Nankivell BJ, 2004, TRANSPLANTATION, V78, P557, DOI 10.1097/01.TP.0000128636.70499.6E
   Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933
   Pallier A, 2010, KIDNEY INT, V78, P503, DOI 10.1038/ki.2010.162
   PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319
   Pascual M, 2002, NEW ENGL J MED, V346, P580, DOI 10.1056/NEJMra011295
   PIERCE SK, 1988, IMMUNOL REV, V106, P149, DOI 10.1111/j.1600-065X.1988.tb00778.x
   Pons JA, 2008, TRANSPLANTATION, V86, P1370, DOI 10.1097/TP.0b013e318188d3e6
   Racusen Lorraine C, 2004, Am J Transplant, V4, P1562, DOI 10.1111/j.1600-6143.2004.00585.x
   Roberts CA, 2002, TRANSPLANTATION, V74, P817, DOI 10.1097/00007890-200209270-00015
   Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003
   Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284
   Solez K, 2007, AM J TRANSPLANT, V7, P518, DOI 10.1111/j.1600-6143.2006.01688.x
   Steinmetz Oliver M, 2009, Front Biosci (Schol Ed), V1, P13, DOI 10.2741/e2
   Steinmetz OM, 2005, KIDNEY INT, V67, P1616, DOI 10.1111/j.1523-1755.2005.00244.x
   SWAIN SL, 1987, IMMUNOL REV, V99, P263, DOI 10.1111/j.1600-065X.1987.tb01180.x
   van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202
   Vieira PM, 2010, HUM IMMUNOL, V71, P442
   Wehner JR, 2010, TRANSPLANTATION, V89, P1141, DOI 10.1097/TP.0b013e3181d3f271
   Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731
   Wu CJ, 2000, BLOOD, V95, P352
   Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017
   ZOLLER KM, 1980, KIDNEY INT, V18, P110, DOI 10.1038/ki.1980.116
NR 53
TC 60
Z9 63
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD MAY
PY 2012
VL 18
IS 5
BP 733
EP 743
DI 10.2119/molmed.2011.00281
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 983TY
UT WOS:000307142800001
PM 22252714
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Machado, C
   Malheiros, DMAC
   Antonopoulus, I
   Saito, F
   Urban, CD
   Kalil, J
   Lemos, FBC
   Nahas, WC
AF Machado, Christiano
   Malheiros, Denise Maria Avancini C.
   Antonopoulus, Ioannis
   Saito, Fernando
   Urban, Cero de Andrade
   Kalil, Jorge
   Lemos, Francine Brambate Carvalhinho
   Nahas, William Carlos
TI KIDNEY TISSUE PROTECTIVE RESPONSE OF LIVING RENAL TRANSPLANTATION:
   COMPARISON TO OPEN AND LAPAROSCOPIC DONOR NEPHRECTOMY.
SO JOURNAL OF UROLOGY
LA English
DT Meeting Abstract
CT AUA Annual Meeting
CY MAY 19-23, 2012
CL Atlanta, GA
SP AUA
RI Urban, Cicero A/D-1578-2011
OI Urban, Cicero A/0000-0001-8964-9487
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD APR
PY 2012
VL 187
IS 4
SU S
MA 2128
BP E859
EP E859
DI 10.1016/j.juro.2012.02.2298
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 927MT
UT WOS:000302912503424
DA 2020-11-26
ER

PT J
AU Pedreschi, M
   Oliveira, AKB
   Barros, MT
   Cohon, A
   Celestino, AT
   Vilas-Boas, LS
   Felix, AC
   Pannuti, CS
   Kalil, J
   Kokron, CM
AF Pedreschi, Maira
   Barreto Oliveira, Ana Karolina
   Barros, Myrthes Toledo
   Cohon, Andrea
   Celestino, A. T.
   Vilas-Boas, L. S.
   Felix, A. C.
   Pannuti, C. S.
   Kalil, Jorge
   Kokron, Cristina M.
TI Evaluation of Clinical and Laboratory Response to Influenza and H1N1
   Vaccines in a Group of Brazilian CVID Patients
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Clinical-Immunology-Society (CIS)/North American
   Conference on Primary Immune Deficiency Diseases
CY MAY 17-20, 2012
CL Chicago, IL
SP Clin Immunol Soc (CIS)
C1 [Pedreschi, Maira] Univ Sao Paulo, Clin Immunol & Allergy Lab LIM 60, Sao Paulo, Brazil.
   [Barreto Oliveira, Ana Karolina; Barros, Myrthes Toledo; Cohon, Andrea; Kalil, Jorge; Kokron, Cristina M.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Celestino, A. T.; Vilas-Boas, L. S.; Felix, A. C.; Pannuti, C. S.] Univ Sao Paulo, Lab Virol LIM 52, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Marinho, Ana Karolina/C-8395-2017; Kokron,
   Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Marinho, Ana
   Karolina/0000-0001-9369-8222; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2012
VL 32
IS 2
BP 395
EP 395
PG 1
WC Immunology
SC Immunology
GA 923JI
UT WOS:000302615200150
DA 2020-11-26
ER

PT J
AU Gutierrez, PS
   Aparecida-Silva, R
   Borges, LF
   Moreira, LFP
   Dias, RR
   Kalil, J
   Stolf, NAG
AF Gutierrez, P. S.
   Aparecida-Silva, R.
   Borges, L. F.
   Moreira, L. F. P.
   Dias, R. R.
   Kalil, J.
   Stolf, N. A. G.
TI Expression of SMAD proteins, intracellular effectors of TGF-beta
   signalling, in non-Marfan patients with thoracic aortic aneurysms and
   dissections
SO CARDIOVASCULAR RESEARCH
LA English
DT Meeting Abstract
CT 2nd Congress of the European-Society-of-Cardiology Council on Basic
   Cardiovascular Science - Frontiers in Cardiovascular Biology
CY MAR 30-APR 01, 2012
CL London, ENGLAND
SP European Soc Cardiol
C1 [Gutierrez, P. S.; Aparecida-Silva, R.; Moreira, L. F. P.; Dias, R. R.; Kalil, J.; Stolf, N. A. G.] Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst InCor, Sao Paulo, Brazil.
   [Borges, L. F.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RI KALIL, JORGE/C-8029-2012; Borges, Luciano F/S-3583-2016; Gutierrez,
   Paulo S/E-6783-2012; Dias, Ricardo R/D-5992-2012
OI KALIL, JORGE/0000-0001-8415-4274; Gutierrez, Paulo
   S/0000-0002-9544-2359; 
NR 0
TC 0
Z9 0
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD MAR 15
PY 2012
VL 93
SU 1
BP S82
EP S83
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 914TQ
UT WOS:000301975800351
DA 2020-11-26
ER

PT J
AU Boettler, T
   Cunha-Neto, E
   Kalil, J
   von Herrath, M
AF Boettler, Tobias
   Cunha-Neto, Edecio
   Kalil, Jorge
   von Herrath, Matthias
TI Can an immune-regulatory vaccine prevent HIV infection?
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE HIV; immune regulation; T cells; vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; NONPATHOGENIC SIV
   INFECTION; AFRICAN-GREEN MONKEYS; HUMAN INTERLEUKIN-10; DISEASE
   PROGRESSION; VIRAL REPLICATION; SOOTY MANGABEYS; DENDRITIC CELLS;
   DOUBLE-BLIND
AB Developing vaccines to prevent the establishment of HIV infection has been fraught with difficulties. It might therefore be important to consider other new strategies. Since several studies suggest that anti-inflammatory stimuli can protect from HIV infection and because HIV replicates preferably in activated T cells, we suggest here that the reduction of immune activation through a HIV-specific regulatory T-cell vaccine might thwart early viral replication. Thus, because immune activation is a good predictor of disease progression and the immune activation set point has been shown to be an early event during HIV infection, vaccinating to achieve control of early virus-specific immune activation might be advantageous.
C1 [Boettler, Tobias; von Herrath, Matthias] La Jolla Inst Allergy & Immunol, Div Dev Immunol, La Jolla, CA 92037 USA.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP von Herrath, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.
EM matthias@liai.org
RI KALIL, JORGE/C-8029-2012; Boettler, Tobias/E-3331-2012; Cunha-Neto,
   Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Boettler, Tobias/0000-0002-1195-055X;
   Cunha-Neto, Edecio/0000-0002-3699-3345
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01 AI058105-05S1, R01 AI068818, P01
   AI058105, R01 AI068818-04] Funding Source: Medline; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI058105,
   P01AI058105, P01AI058105, P01AI058105, P01AI058105, P01AI058105,
   R01AI068818, R01AI068818, P01AI058105, P01AI058105, P01AI058105,
   P01AI058105, P01AI058105, R01AI068818, P01AI058105, P01AI058105,
   P01AI058105, P01AI058105, R01AI068818, P01AI058105, P01AI058105,
   P01AI058105, P01AI058105, P01AI058105, P01AI058105, P01AI058105,
   P01AI058105, P01AI058105, R01AI068818, P01AI058105, P01AI058105] Funding
   Source: NIH RePORTER
CR Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004
   Angel JB, 2000, AIDS, V14, P2503, DOI 10.1097/00002030-200011100-00012
   [Anonymous], 2007, NATURE, V449
   Battaglia M, 2009, IMMUNITY, V30, P763, DOI 10.1016/j.immuni.2009.06.006
   Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Bento CAM, 2009, AIDS, V23, P9, DOI 10.1097/QAD.0b013e328317461e
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801
   Chakrabarti LA, 2004, FRONT BIOSCI-LANDMRK, V9, P521, DOI 10.2741/1123
   Chase AJ, 2008, J VIROL, V82, P8307, DOI 10.1128/JVI.00520-08
   Coon B, 1999, J CLIN INVEST, V104, P189, DOI 10.1172/JCI7209
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Douek Daniel, 2007, Top HIV Med, V15, P114
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Dunham RM, 2008, J IMMUNOL, V180, P5582, DOI 10.4049/jimmunol.180.8.5582
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Erikstrup C, 2007, AIDS, V21, P2283, DOI 10.1097/QAD.0b013e3282f153ed
   Fauci AS, FAUCI WHY THERE IS N
   Favre D, 2009, PLOS PATHOG, V5
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006
   Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020
   Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093
   Jennes W, 2006, CLIN EXP IMMUNOL, V143, P435, DOI 10.1111/j.1365-2249.2006.03017.x
   Jiang Q, 2008, BLOOD, V112, P2858, DOI 10.1182/blood-2008-03-145946
   Johnston MI, 2008, NEW ENGL J MED, V359, P888, DOI 10.1056/NEJMp0806162
   Kanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1
   Kollmann TR, 1996, P NATL ACAD SCI USA, V93, P3126, DOI 10.1073/pnas.93.7.3126
   Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117
   Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006
   Kosmrlj A, 2010, NATURE, V465, P350, DOI 10.1038/nature08997
   Legrand FA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000102
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968
   Monteiro P, 2011, J IMMUNOL, V186, P4618, DOI 10.4049/jimmunol.1004151
   Moreno-Fernandez ME, 2011, BLOOD, V117, P5372, DOI 10.1182/blood-2010-12-323162
   Naicker DD, 2012, CLIN INFECT DIS, V54, P294, DOI 10.1093/cid/cir811
   Naicker DD, 2009, J INFECT DIS, V200, P448, DOI 10.1086/600072
   Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576
   Onanga R, 2002, J VIROL, V76, P10256, DOI 10.1128/JVI.76.20.10256-10263.2002
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Roncarolo MG, 2006, IMMUNOL REV, V212, P28
   Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Ruprecht RM, 2009, METHOD MOL BIOL, V525, pxiv
   Ruprecht Ruth M., 2009, V525, P559, DOI 10.1007/978-1-59745-554-1_31
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4
   Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Shin HD, 2000, P NATL ACAD SCI USA, V97, P14467, DOI 10.1073/pnas.97.26.14467
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400
   Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949
   Than S, 1997, J INFECT DIS, V175, P47, DOI 10.1093/infdis/175.1.47
   van Asten L, 2004, AIDS, V18, P1885, DOI 10.1097/00002030-200409240-00004
   Walker LM, 2010, CURR OPIN IMMUNOL, V22, P358, DOI 10.1016/j.coi.2010.02.012
   Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365
   Weissman D, 1997, 4 C RETR OPP INF JAN
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
NR 63
TC 3
Z9 3
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD MAR
PY 2012
VL 10
IS 3
BP 299
EP 305
DI 10.1586/ERI.11.178
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 937AB
UT WOS:000303630300016
PM 22397564
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Agondi, R
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R.
   Kalil, J.
   Giavina-Bianchi, P.
TI Gastroesophageal Reflux in Patients with Chronic Cough
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 02-06, 2012
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol (AAAAI)
C1 [Agondi, R.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2012
VL 129
IS 2
SU S
BP AB9
EP AB9
DI 10.1016/j.jaci.2011.12.893
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 903QL
UT WOS:000301133400034
DA 2020-11-26
ER

PT J
AU Aun, MV
   Rodrigues, AT
   Ribeiro, MR
   Garro, LS
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Aun, M. V.
   Rodrigues, A. T.
   Ribeiro, M. R.
   Garro, L. S.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Is Severity Of Drug Induced Anaphylaxis Dependent Of Its Etiology?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 02-06, 2012
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol (AAAAI)
C1 [Aun, M. V.; Rodrigues, A. T.; Ribeiro, M. R.; Garro, L. S.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] FMUSP, Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; KALIL, JORGE/C-8029-2012; Giavina-Bianchi,
   Pedro/I-3112-2014
OI Aun, Marcelo V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2012
VL 129
IS 2
SU S
BP AB181
EP AB181
DI 10.1016/j.jaci.2011.12.242
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 903QL
UT WOS:000301133400685
DA 2020-11-26
ER

PT J
AU Garro, LS
   Rodrigues, AT
   Ribeiro, MR
   Aun, MV
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Garro, L. S.
   Rodrigues, A. T.
   Ribeiro, M. R.
   Aun, M. V.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Perioperative Anaphylaxis: Clinical Features of 51 Patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 02-06, 2012
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol (AAAAI)
C1 [Garro, L. S.; Rodrigues, A. T.; Ribeiro, M. R.; Aun, M. V.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] FMUSP, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2012
VL 129
IS 2
SU S
BP AB180
EP AB180
DI 10.1016/j.jaci.2011.12.238
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 903QL
UT WOS:000301133400680
DA 2020-11-26
ER

PT J
AU Penterich, VRA
   Yang, AC
   Pereira, RMR
   Kalil, J
   Castro, FFM
AF Penterich, V. R. A.
   Yang, A. C.
   Pereira, R. M. R.
   Kalil, J.
   Castro, F. F. M.
TI Nutritional Status and Bone Metabolism in Children With Atopic
   Dermatitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
   (AAAAI)
CY MAR 02-06, 2012
CL Orlando, FL
SP Amer Acad Allergy Asthma & Immunol (AAAAI)
C1 [Penterich, V. R. A.; Yang, A. C.; Pereira, R. M. R.; Kalil, J.; Castro, F. F. M.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773
NR 0
TC 1
Z9 1
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2012
VL 129
IS 2
SU S
BP AB40
EP AB40
DI 10.1016/j.jaci.2011.12.811
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 903QL
UT WOS:000301133400152
DA 2020-11-26
ER

PT J
AU Moraes-Vieira, PMM
   Takenaka, MCS
   Silva, HM
   Monteiro, SM
   Agena, F
   Lemos, F
   Saitovitch, D
   Kalil, J
   Coelho, V
AF Moraes-Vieira, Pedro Manoel M.
   Takenaka, Maisa C. S.
   Silva, Hernandez M.
   Monteiro, Sandra Maria
   Agena, Fabiana
   Lemos, Francine
   Saitovitch, David
   Kalil, Jorge
   Coelho, Veronica
TI GATA3 and a dominant regulatory gene expression profile discriminate
   operational tolerance in human transplantation
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Kidney transplantation; Operational tolerance; GATA-3; TGF-beta
ID KIDNEY-TRANSPLANTATION; PERIPHERAL-BLOOD; IMMUNE TOLERANCE; TARGET
   GENES; TH2 CLONES; T-BET; RECIPIENTS; INDIVIDUALS; ACCEPTANCE; REJECTION
AB Some organ-transplanted patients achieve a state of "operational tolerance" (01) in which graft function is maintained after the complete withdrawal of immunosuppressive drugs. We used a gene panel of regulatory/inflammatory molecules (FOXP3, GATA3, 100, TGFB1, TGFBR1/TBX21, TNF and IFNG) to investigate the gene expression profile in peripheral blood mononuclear cells of renal-transplanted individuals experiencing OT compared to transplanted individuals not displaying OT and healthy individuals (HI). OT subjects showed a predominant regulatory (REG) profile with higher gene expression of GATA3, FOXP3, TGFB1 and TGFB receptor 1 compared to the other groups. This predominant REG gene expression profile displayed stability over time. The significant GATA3 gene and protein expressions in OT individuals suggest that a Th2 deviation may be a relevant pathway to OT. Moreover, the capacity of the REG/INFLAMMA gene panel to discriminate OT by peripheral blood analysis indicates that this state has systemic repercussions. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Moraes-Vieira, Pedro Manoel M.; Takenaka, Maisa C. S.; Silva, Hernandez M.; Monteiro, Sandra Maria; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Moraes-Vieira, Pedro Manoel M.; Takenaka, Maisa C. S.; Silva, Hernandez M.; Monteiro, Sandra Maria; Kalil, Jorge; Coelho, Veronica] Iii INCT Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Agena, Fabiana; Lemos, Francine] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Div Nephrol, Porto Alegre, RS, Brazil.
RP Coelho, V (corresponding author), Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI COELHO, VERONICA/D-1433-2013; Moraes-Vieira, Pedro M/C-8701-2014; KALIL,
   JORGE/C-8029-2012; Agena, Fabiana/F-5807-2012; Takenaka,
   Maisa/J-5788-2014; Agena, Fabiana/C-5819-2015; Saitovitch,
   David/H-8863-2013
OI Moraes-Vieira, Pedro M/0000-0002-8263-786X; KALIL,
   JORGE/0000-0001-8415-4274; Agena, Fabiana/0000-0002-4526-4857; Coelho,
   Veronica/0000-0002-0989-2581; Saitovitch, David/0000-0003-2315-1314
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX The authors thank Patricia Sesterheim and Elisangela S. Prado for
   helping to collect samples and clinical data, and FAPESP and CNPq for
   funding.
CR Berlanda M, 2008, TRANSPL P, V40, P1847, DOI 10.1016/j.transproceed.2008.05.013
   Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6
   Braud C, 2008, J CELL BIOCHEM, V103, P1681, DOI 10.1002/jcb.21574
   Brouard S, 2005, AM J TRANSPLANT, V5, P330, DOI 10.1111/j.1600-6143.2004.00700.x
   Brouard S, 2007, P NATL ACAD SCI USA, V104, P15448, DOI 10.1073/pnas.0705834104
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508
   Golshayan D, 2008, DRUGS, V68, P2113, DOI 10.2165/00003495-200868150-00004
   Jenner RG, 2009, P NATL ACAD SCI USA, V106, P17876, DOI 10.1073/pnas.0909357106
   Kist-van Holthe JE, 2002, KIDNEY INT, V62, P627
   Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731
   Lee WC, 2000, TRANSPLANT P, V32, P2076, DOI 10.1016/S0041-1345(00)01575-X
   Louis S, 2006, TRANSPLANTATION, V81, P398, DOI 10.1097/01.tp.0000203166.44968.86
   Moraes-Vieira PMM, 2010, HUM IMMUNOL, V71, P442, DOI 10.1016/j.humimm.2010.01.022
   PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pons JA, 2008, TRANSPLANTATION, V86, P1370, DOI 10.1097/TP.0b013e318188d3e6
   Sivozhelezov V, 2008, J CELL BIOCHEM, V103, P1693, DOI 10.1002/jcb.21557
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   VanBuskirk AM, 2000, J CLIN INVEST, V106, P145, DOI 10.1172/JCI9171
   Vieira PM, 2009, CLIN IMMUNOL, V131, pS165, DOI 10.1016/j.clim.2009.03.489
   Waaga AM, 2001, J CLIN INVEST, V107, P909, DOI 10.1172/JCI11427
   Zheng JA, 2011, EUR J IMMUNOL, V41, P128, DOI 10.1002/eji.201040724
NR 24
TC 27
Z9 29
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD FEB
PY 2012
VL 142
IS 2
BP 117
EP 126
DI 10.1016/j.clim.2011.08.015
PG 10
WC Immunology
SC Immunology
GA 893WK
UT WOS:000300388200006
PM 22019771
DA 2020-11-26
ER

PT J
AU David-Neto, E
   Souza, PS
   Panajotopoulos, N
   Rodrigues, H
   Ventura, CG
   David, DSR
   Lemos, FBC
   Agena, F
   Nahas, WC
   Kalil, JE
   Castro, MCR
AF David-Neto, Elias
   Souza, Patricia Soares
   Panajotopoulos, Nicolas
   Rodrigues, Helcio
   Ventura, Carlucci Gualberto
   Ribeiro David, Daisa Silva
   Carvalhinho Lemos, Francine Brambate
   Agena, Fabiana
   Nahas, William Carlos
   Kalil, Jorge Elias
   Ribeiro Castro, Maria Cristina
TI The impact of pretransplant donor-specific antibodies on graft outcome
   in renal transplantation: a six-year follow-up study
SO CLINICS
LA English
DT Article
DE Renal Transplantation; Donor-Specific Antibodies; Solid-Phase Assay;
   Luminex; DSA
ID CLINICAL-RELEVANCE; MEDIATED REJECTION; ALLOGRAFTS; ANTIGEN
AB OBJECTIVE: The significance of pretransplant, donor-specific antibodies on long-term patient outcomes is a subject of debate. This study evaluated the impact and the presence or absence of donor-specific antibodies after kidney transplantation on short-and long-term graft outcomes.
   METHODS: We analyzed the frequency and dynamics of pretransplant donor-specific antibodies following renal transplantation from a randomized trial that was conducted from 2002 to 2004 and correlated these findings with patient outcomes through 2009. Transplants were performed against a complement-dependent T-and B-negative crossmatch. Pre- and posttransplant sera were available from 94 of the 118 patients (80%). Antibodies were detected using a solid-phase (Luminex (R)), single-bead assay, and all tests were performed simultaneously.
   RESULTS: Sixteen patients exhibited pretransplant donor-specific antibodies, but only 3 of these patients (19%) developed antibody-mediated rejection and 2 of them experienced early graft losses. Excluding these 2 losses, 6 of 14 patients exhibited donor-specific antibodies at the final follow-up exam, whereas 8 of these patients (57%) exhibited complete clearance of the donor-specific antibodies. Five other patients developed "de novo'' posttransplant donor-specific antibodies. Death-censored graft survival was similar in patients with pretransplant donor-specific and non-donor-specific antibodies after a mean follow-up period of 70 months.
   CONCLUSION: Pretransplant donor-specific antibodies with a negative complement-dependent cytotoxicity crossmatch are associated with a risk for the development of antibody-mediated rejection, although survival rates are similar when patients transpose the first months after receiving the graft. Our data also suggest that early posttransplant donor-specific antibody monitoring should increase knowledge of antibody dynamics and their impact on long-term graft outcome.
C1 [David-Neto, Elias; Souza, Patricia Soares; Ventura, Carlucci Gualberto; Ribeiro David, Daisa Silva; Carvalhinho Lemos, Francine Brambate; Agena, Fabiana; Nahas, William Carlos] Univ Sao Paulo, Fac Med, Hosp Clin, Renal Transplantat Serv, Sao Paulo, Brazil.
   [Panajotopoulos, Nicolas; Rodrigues, Helcio; Kalil, Jorge Elias; Ribeiro Castro, Maria Cristina] Univ Sao Paulo, Fac Med, Hosp Clin, Immunol Lab, Sao Paulo, Brazil.
   [Ribeiro David, Daisa Silva] Univ Sao Paulo, Fac Med, Hosp Clin, Div Pathol, Sao Paulo, Brazil.
RP David-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Renal Transplantat Serv, Sao Paulo, Brazil.
EM elias.david.neto@attglobal.net
RI Ventura, Carlucci/C-8226-2012; David, Daisa/G-6272-2012; Neto, Elias
   David/O-3866-2018; Agena, Fabiana/F-5807-2012; de castro, maria cristina
   ribeiro/B-6648-2009; KALIL, JORGE/C-8029-2012; Agena,
   Fabiana/C-5819-2015; David-Neto, Elias/C-9112-2012
OI de castro, maria cristina ribeiro/0000-0002-6731-8369; KALIL,
   JORGE/0000-0001-8415-4274; Agena, Fabiana/0000-0002-4526-4857; 
CR Amico P, 2009, TRANSPLANTATION, V87, P1681, DOI 10.1097/TP.0b013e3181a5e034
   Aubert V, 2009, HUM IMMUNOL, V70, P580, DOI 10.1016/j.humimm.2009.04.011
   David-Neto E, 2007, TRANSPLANTATION, V84, P1391, DOI 10.1097/01.tp.0000288807.52520.5e
   Gupta A, 2008, TRANSPLANTATION, V85, P1200, DOI 10.1097/TP.0b013e31816b1c37
   Ho EK, 2008, TRANSPL IMMUNOL, V20, P61, DOI 10.1016/j.trim.2008.09.013
   Kedainis RL, 2009, AM J TRANSPLANT, V9, P812, DOI 10.1111/j.1600-6143.2009.02555.x
   Lachmann N, 2009, TRANSPLANTATION, V87, P1505, DOI 10.1097/TP.0b013e3181a44206
   Lefaucheur C, 2009, CONTRIB NEPHROL, V162, P1, DOI 10.1159/000170788
   Lefaucheur C, 2010, J AM SOC NEPHROL, V21, P1398, DOI 10.1681/ASN.2009101065
   Loupy A, 2009, AM J TRANSPLANT, V9, P2561, DOI 10.1111/j.1600-6143.2009.02813.x
   Nadasdy GM, 2005, HUM PATHOL, V36, P1178, DOI 10.1016/j.humpath.2005.08.002
   Patel AM, 2007, AM J TRANSPLANT, V7, P2371, DOI 10.1111/j.1600-6143.2007.01944.x
   Pereira LM, 2005, AM J TRANSPLANT, V5, P466
   Rafiq MA, 2009, CLIN TRANSPLANT, V23, P951, DOI 10.1111/j.1399-0012.2009.01036.x
   Seemayer CA, 2007, NEPHROL DIAL TRANSPL, V22, P568, DOI 10.1093/ndt/gfl594
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   Vlad G, 2009, HUM IMMUNOL, V70, P589, DOI 10.1016/j.humimm.2009.04.018
NR 17
TC 7
Z9 8
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 4
BP 355
EP 361
DI 10.6061/clinics/2012(04)09
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 931EV
UT WOS:000303199300009
PM 22522761
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU de Carvalho, GC
   Regis, CD
   Kalil, JR
   Cerqueira, LA
   Barbosa, DS
   Motta, MP
   Nery, MD
   Soares, MAP
   Zollinger, CC
   Bittencourt, PL
AF de Carvalho, Grazielle Cerqueira
   Regis, Catarina de Andrade
   Kalil, Jamile Rosario
   Cerqueira, Liv Aparicio
   Barbosa, Daniel Silva
   Motta, Marina Pamponet
   Nery, Marilia da Silva
   Pires Soares, Maria Alice
   Zollinger, Claudio Celestino
   Bittencourt, Paulo Lisboa
TI Causes of renal failure in patients with decompensated cirrhosis and its
   impact in hospital mortality
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Bacterial infections; End-stage liver disease; Hepatorenal syndrome;
   Liver cirrhosis; Renal failure
ID SPONTANEOUS BACTERIAL PERITONITIS; CRITICALLY-ILL PATIENTS;
   INTENSIVE-CARE-UNIT; HEPATORENAL-SYNDROME; RIFLE CLASSIFICATION; OUTCOME
   PREDICTORS; CLINICAL-COURSE; PROGNOSIS; MELD; DYSFUNCTION
AB Background. Renal failure (RF) is reported to occur in 11-49% of the patients with decompensated end-stage liver disease (ESLD) and has been associated with increased mortality, particularly in the occurrence of hepatorenal syndrome (FIRS) type 1. Aims. To evaluate the frequency and outcome of RE in patients admitted to the hospital due to decompensated ESLD and to assess the impact of the underlying cause of RE on survival. Material and methods. Four hundred and six patients (65% males, mean age 62 +/- 12 years) with decompensated ESLD were evaluated for the occurrence of RE (defined as serum creatinine(3) 1.5 mg/mL). The underlying cause of RE was reckoned in each subject and compared to outcome. Results. Renal failure was observed in 39% of the patients at admission and in 10% of the subjects during hospitalization. Mortality was significantly higher in subjects with RF (26 vs. 1%, p < 0.000001). Hypovolemia, bacterial infections, parenchymal kidney diseases and HRS were identified as causes of RE in, respectively, 40, 32, 15 and 12% of the cases. Mortality was significantly higher in those subjects with HRS type 1 and bacterial infections, when compared to other causes of RE Conclusions. Renal failure occurs in nearly half of the patients with decompensated ESLD. It is most commonly caused by hypovolemia and bacterial infections. Occurrence of RE has an adverse impact in patient survival, particularly in those subjects with bacterial infections and FIRS type 1, prone to develop progressive renal dysfunction despite intensive medical care.
C1 [de Carvalho, Grazielle Cerqueira; Regis, Catarina de Andrade; Kalil, Jamile Rosario; Cerqueira, Liv Aparicio; Barbosa, Daniel Silva; Motta, Marina Pamponet; Nery, Marilia da Silva; Pires Soares, Maria Alice; Zollinger, Claudio Celestino; Bittencourt, Paulo Lisboa] Portuguese Hosp Salvador, Unit Gastroenterol & Hepatol, Salvador, BA, Brazil.
RP Bittencourt, PL (corresponding author), Rua Prof Clementino Fraga 220,Apto 1901, Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI BITTENCOURT, PAULO l/I-5817-2014; KALIL, JORGE/C-8029-2012
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274
CR Alessandria C, 2005, HEPATOLOGY, V41, P1282, DOI 10.1002/hep.20687
   Arabi Y, 2004, EUR J GASTROEN HEPAT, V16, P333, DOI 10.1097/01.meg.0000108286.74393.57
   Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164
   Austin MJ, 2008, CURR OPIN CRIT CARE, V14, P202, DOI 10.1097/MCC.0b013e3282f6a40d
   Cardenas A, 2001, HEPATOLOGY, V34, P671, DOI 10.1053/jhep.2001.27830
   Cholongitas E, 2009, J GASTROEN HEPATOL, V24, P1639, DOI 10.1111/j.1440-1746.2009.05908.x
   Cholongitas E, 2009, EUR J GASTROEN HEPAT, V21, P744, DOI 10.1097/MEG.0b013e328308bb9c
   D'Amico G, 2006, J HEPATOL, V44, P217, DOI 10.1016/j.jhep.2005.10.013
   Das V, 2010, CRIT CARE MED, V38, P2108, DOI 10.1097/CCM.0b013e3181f3dea9
   du Cheyron D, 2005, INTENS CARE MED, V31, P1693, DOI 10.1007/s00134-005-2842-7
   Fang JT, 2008, NEPHROL DIAL TRANSPL, V23, P1961, DOI 10.1093/ndt/gfm914
   Fasolato S, 2007, HEPATOLOGY, V45, P223, DOI 10.1002/hep.21443
   Fernandez J, 2002, HEPATOLOGY, V35, P140, DOI 10.1053/jhep.2002.30082
   FOLLO A, 1994, HEPATOLOGY, V20, P1495, DOI 10.1002/hep.1840200619
   Garcia-Tsao G, 2008, HEPATOLOGY, V48, P2064, DOI 10.1002/hep.22605
   Jenq CC, 2007, INTENS CARE MED, V33, P1921, DOI 10.1007/s00134-007-0760-6
   Juneja D, 2011, J INTENSIVE CARE MED, V24
   Kalil Jamile Rosário, 2009, Arq. Gastroenterol., V46, P214, DOI 10.1590/S0004-28032009000300014
   Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563
   Martin-Llahi M, 2011, GASTROENTEROLOGY, V140, P488, DOI 10.1053/j.gastro.2010.07.043
   Montoliu S, 2010, CLIN GASTROENTEROL H, V8, P616, DOI 10.1016/j.cgh.2010.03.029
   Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704
   Salerno F, 2007, GUT, V56, P1310, DOI 10.1136/gut.2006.107789
   Schepke M, 2006, LIVER INT, V26, P834, DOI 10.1111/j.1478-3231.2006.01302.x
   Sola E, 2010, J HEPATOL, V53, P1135, DOI 10.1016/j.jhep.2010.08.001
   Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603
   Terra C, 2005, GASTROENTEROLOGY, V129, P1944, DOI 10.1053/j.gastro.2005.09.024
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
NR 28
TC 25
Z9 27
U1 0
U2 1
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD JAN-FEB
PY 2012
VL 11
IS 1
BP 90
EP 95
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 891JR
UT WOS:000300213500011
PM 22166566
DA 2020-11-26
ER

PT J
AU de Andrade, CR
   Stolf, BS
   Debbas, V
   Rosa, DS
   Kalil, J
   Coelho, V
   Laurindo, FRM
AF de Andrade, Claudia R.
   Stolf, Beatriz S.
   Debbas, Victor
   Rosa, Daniela S.
   Kalil, Jorge
   Coelho, Veronica
   Laurindo, Francisco R. M.
TI Quiescin sulfhydryl oxidase (QSOX) is expressed in the human atheroma
   core: possible role in apoptosis
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE QSOX; Atherosclerosis; Apoptosis; Microparticles; HUVEC; THP-1
ID PROTEIN DISULFIDE-ISOMERASE; Q6 GENE FAMILY; CELLS; MEMBER;
   MICROPARTICLES; IDENTIFICATION; MECHANISM; DISEASE; BINDING; ENZYME
AB Quiescin sulfhydryl oxidases (QSOXs) catalyze the formation of disulfide bonds in peptides and proteins, and in vertebrates comprise two proteins: QSOX1 and QSOX2. QSOX1, the most extensively studied type, has been implicated in protein folding, production of extracellular matrix, redox regulation, protection from apoptosis, angiogenesis, and cell differentiation. Atherosclerosis is an immunopathological condition in which redox processes, apoptosis, cell differentiation, and matrix secretion/maturation have critical roles. Considering these data, we hypothesized that QSOX1 could be involved in this disease, possibly reducing apoptosis and angiogenesis inside the plaque. QSOX1 labeling in normal human carotid vessels showed predominant expression by endothelium, subendothelium, and adventitia. In atherosclerotic plaques, however, QSOX1 was highly expressed in macrophages at the lipid core. QSOX1 expression was also studied in terms of mRNA and protein in cell types present in plaques under apoptotic or activating stimuli, emulating conditions found in the atherosclerotic process. QSOX1 mRNA increased in endothelial cells and macrophages after the induction of apoptosis. At the protein level, the correlation between apoptosis and QSOX1 expression was not evident in all cell types, possibly because of a rapid secretion of QSOX1. Our results propose for the first time possible roles for QSOX1 in atherosclerosis, being upregulated in endothelial cells and macrophages by apoptosis and cell activation, and possibly controlling these processes, as well as angiogenesis. The quantitative differences in QSOX1 induction may depend on the cell type and also on local factors.
C1 [de Andrade, Claudia R.; Debbas, Victor; Laurindo, Francisco R. M.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Vasc Biol Lab, Sao Paulo, Brazil.
   [Stolf, Beatriz S.; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Rosa, Daniela S.] Univ Sao Paulo, Dept Clin Med, Lab Clin Immunol & Allergy LIM 60, Sao Paulo, Brazil.
   [Kalil, Jorge; Coelho, Veronica] Natl Inst Sci & Technol, INCT Inst Investigat Immunol, Sao Paulo, Brazil.
RP de Andrade, CR (corresponding author), Fed Univ Ceara UFC, Dept Anim Sci, Reprod Biol Lab, Ave Mr Hull S-N, BR-60365001 Fortaleza, Ceara, Brazil.
EM claudiarandrade@gmail.com
RI Laurindo, Francisco R/J-6575-2015; Rosa, Daniela S/D-2190-2012; COELHO,
   VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Stolf, Beatriz
   S/H-7943-2012; Debbas, Victor/J-9475-2012
OI Rosa, Daniela S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274;
   Stolf, Beatriz S/0000-0001-7661-3311; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CAPESCAPES; CNPq (Institutos do Milenio Redoxoma)
FX This work was supported by FAPESP, CAPES, and CNPq (Institutos do
   Milenio Redoxoma).
CR Alon A, 2010, FEBS LETT, V584, P1521, DOI 10.1016/j.febslet.2010.03.001
   Ang SK, 2009, J BIOL CHEM, V284, P28754, DOI 10.1074/jbc.M109.021113
   Antwi K, 2009, J PROTEOME RES, V8, P4722, DOI 10.1021/pr900414f
   Bach RD, 2008, J ORG CHEM, V73, P12, DOI 10.1021/jo702051f
   Baker KM, 2008, EMBO J, V27, P2988, DOI 10.1038/emboj.2008.230
   Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200
   Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5
   CHANG TSK, 1975, BIOCHEM BIOPH RES CO, V66, P309, DOI 10.1016/S0006-291X(75)80329-9
   Coppock D, 2000, BIOCHEM BIOPH RES CO, V269, P604, DOI 10.1006/bbrc.2000.2324
   COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483
   Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605
   Coppock DL, 2006, ANTIOXID REDOX SIGN, V8, P300, DOI 10.1089/ars.2006.8.300
   Distler JHW, 2011, ARTHRITIS RHEUM-US, V63, P2067, DOI 10.1002/art.30361
   FRANCAVILLA A, 1994, HEPATOLOGY, V20, P747, DOI 10.1016/0270-9139(94)90113-9
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Heckler EJ, 2008, BBA-MOL CELL RES, V1783, P567, DOI 10.1016/j.bbamcr.2007.10.002
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018
   Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759
   Houston NL, 2005, PLANT PHYSIOL, V137, P762, DOI 10.1104/pp.104.056507
   Jaje J, 2007, BIOCHEMISTRY-US, V46, P13031, DOI 10.1021/bi7016975
   Jordan PA, 2006, ANTIOXID REDOX SIGN, V8, P312, DOI 10.1089/ars.2006.8.312
   Kockx MM, 1998, EUR HEART J, V19, pG23
   Kodali VK, 2010, ANTIOXID REDOX SIGN, V13, P1217, DOI 10.1089/ars.2010.3098
   Laurindo FRM, 2008, ANTIOXID REDOX SIGN, V10, P1101, DOI 10.1089/ars.2007.2011
   Liberman M, 2008, ARTERIOSCL THROM VAS, V28, P463, DOI 10.1161/ATVBAHA.107.156745
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mairet-Coello G, 2002, NEUROREPORT, V13, P2049, DOI 10.1097/00001756-200211150-00012
   Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735
   Morel C, 2007, EXP CELL RES, V313, P3971, DOI 10.1016/j.yexcr.2007.09.003
   Musard JF, 2001, BIOCHEM BIOPH RES CO, V287, P83, DOI 10.1006/bbrc.2001.5440
   OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Portes KF, 2008, J MOL HISTOL, V39, P217, DOI 10.1007/s10735-007-9156-8
   PORTO I, 2011, CURR VASC P IN PRESS, V10
   Rautou PE, 2011, CIRC RES, V108, P335, DOI 10.1161/CIRCRESAHA.110.237420
   SIMAK J, 2002, BMC CELL BIOL, V28, P3
   Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5
   Thorpe C, 2007, J BIOL CHEM, V282, P13929, DOI 10.1074/jbc.R600037200
   Tury A, 2006, CELL TISSUE RES, V323, P91, DOI 10.1007/s00441-005-0043-x
   Wang WZ, 2007, BIOCHEMISTRY-US, V46, P3246, DOI 10.1021/bi602499t
   Wittke I, 2003, CANCER RES, V63, P7742
   Zanata SM, 2005, REDOX REP, V10, P319, DOI 10.1179/135100005X83699
   Zheng WY, 2011, J BIOCHEM, V149, P293, DOI 10.1093/jb/mvq143
NR 44
TC 8
Z9 9
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD DEC
PY 2011
VL 47
IS 10
BP 716
EP 727
DI 10.1007/s11626-011-9461-0
PG 12
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 864HP
UT WOS:000298229300006
PM 22069028
DA 2020-11-26
ER

PT J
AU Santos, KS
   Galvao, CE
   Gadermaier, G
   Resende, VMF
   Martins, CD
   Misumi, DS
   Yang, AC
   Ferreira, F
   Palma, MS
   Kalil, J
   Castro, FFM
AF Santos, Keity Souza
   Galvao, Clovis Eduardo
   Gadermaier, Gabriele
   Ferreira Resende, Virginia Maria
   Martins, Carlo de Oliveira
   Misumi, Denise Shimbo
   Yang, Ariana Campos
   Ferreira, Fatima
   Palma, Mario Sergio
   Kalil, Jorge
   Morato Castro, Fabio Fernandes
TI Allergic reactions to manioc (Manihot esculenta Crantz): Identification
   of novel allergens with potential involvement in latex-fruit syndrome
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID CROSS-REACTIVITY; CASSAVA; FOOD
C1 [Santos, Keity Souza; Ferreira Resende, Virginia Maria; Martins, Carlo de Oliveira; Misumi, Denise Shimbo; Kalil, Jorge; Morato Castro, Fabio Fernandes] Univ Sao Paulo, Sch Med, FMUSP, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
   [Santos, Keity Souza; Ferreira Resende, Virginia Maria; Martins, Carlo de Oliveira; Palma, Mario Sergio; Kalil, Jorge; Morato Castro, Fabio Fernandes] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Galvao, Clovis Eduardo; Yang, Ariana Campos; Morato Castro, Fabio Fernandes] FMUSP, Clin Hosp, Div Allergy, Sao Paulo, Brazil.
   [Gadermaier, Gabriele; Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria.
   [Palma, Mario Sergio] Univ Sao Paulo State UNESP, Inst Biosci Rio Claro, Dept Biol, Ctr Study Social Insects, Sao Paulo, Brazil.
   [Kalil, Jorge] Heart Inst INCOR, Sao Paulo, Brazil.
RP Santos, KS (corresponding author), Univ Sao Paulo, Sch Med, FMUSP, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
EM keity@usp.br
RI Martins, Carlo/D-4008-2018; Santos, Keity/M-9401-2015; Gadermaier,
   Gabriele/L-5997-2015; Palma, Mario/N-3903-2019; Castro, Fabio
   FM/C-1082-2017; Palma, Mario Sergio/E-7800-2012; Ferreira,
   Fatima/AAB-4321-2019; Santos, Keity Souza/Q-5704-2019; Resende,
   Virginia/H-5417-2013; KALIL, JORGE/C-8029-2012; Castro,
   Fabio/AAP-5433-2020; Santos, Keity/E-2553-2012; Ferreira,
   Fatima/E-4889-2011
OI Martins, Carlo/0000-0003-1287-8884; Gadermaier,
   Gabriele/0000-0002-4886-417X; Castro, Fabio FM/0000-0002-6211-5773;
   Palma, Mario Sergio/0000-0002-7363-8211; Ferreira,
   Fatima/0000-0003-0989-2335; Santos, Keity Souza/0000-0001-5271-4011;
   Resende, Virginia/0000-0002-9225-5654; KALIL, JORGE/0000-0001-8415-4274;
   Ferreira, Fatima/0000-0003-0989-2335
CR de Souza CRB, 2008, PROTEIN PEPTIDE LETT, V15, P900
   Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6
   Benndorf D, 2008, ALLERGY, V63, P454, DOI 10.1111/j.1398-9995.2007.01603.x
   Chen YH, 2005, ALLERGY, V60, P1518, DOI 10.1111/j.1398-9995.2005.00918.x
   D'Amato A, 2010, J PROTEOMICS, V73, P1368, DOI 10.1016/j.jprot.2010.03.002
   GALVAO CES, 2003, J ALLERGY CLIN IMMUN, pS61
   Gaspar A, 2003, ALLERGY, V58, P683, DOI 10.1034/j.1398-9995.2003.00184.x
   Ibero M, 2007, J INVEST ALLERG CLIN, V17, P409
   Nakamura R, 2009, REGUL TOXICOL PHARM, V55, P300, DOI 10.1016/j.yrtph.2009.08.002
   Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x
   Wagner S, 2005, INT ARCH ALLERGY IMM, V136, P90, DOI 10.1159/000082938
NR 11
TC 12
Z9 12
U1 0
U2 14
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD DEC
PY 2011
VL 128
IS 6
BP 1367
EP 1369
DI 10.1016/j.jaci.2011.07.019
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA 865WX
UT WOS:000298342700036
PM 21855976
DA 2020-11-26
ER

PT J
AU Miraglia, JL
   Abdala, E
   Hoff, PM
   Luiz, AM
   Oliveira, DS
   Saad, CGS
   Laurindo, IMM
   Viso, ATR
   Tayra, A
   Pierrotti, LC
   Azevedo, LS
   Campos, LMA
   Aikawa, NE
   Timenetsky, MDST
   Luna, E
   Cardoso, MRA
   Guedes, JD
   Raw, I
   Kalil, J
   Precioso, AR
AF Miraglia, Joao L.
   Abdala, Edson
   Hoff, Paulo M.
   Luiz, Andre M.
   Oliveira, Danise S.
   Saad, Carla G. S.
   Laurindo, Ieda M. M.
   Viso, Ana T. R.
   Tayra, Angela
   Pierrotti, Ligia C.
   Azevedo, Luiz S.
   Campos, Lucia Maria A.
   Aikawa, Nadia E.
   Timenetsky, Maria do Carmo S. T.
   Luna, Expedito
   Cardoso, Maria Regina A.
   Guedes, Jose da S.
   Raw, Isaias
   Kalil, Jorge
   Precioso, Alexander R.
TI Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated
   Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised
   Patients
SO PLOS ONE
LA English
DT Article
ID RHEUMATIC-DISEASES; INFECTION; ARTHRITIS; CLASSIFICATION; CHILDREN
AB Background: Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety and immunogenicity of influenza vaccination among them.
   Methods: This multicenter cohort study evaluated the immunogenicity and reactogenicity of an inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine among the elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney transplant, and juvenile idiopathic arthritis (JIA) patients. Participants were included during routine clinical visits, and vaccinated according to conventional influenza vaccination schedules. Antibody response was measured by the hemagglutination-inhibition assay, before and 21 days after vaccination.
   Results: 319 patients with cancer, 260 with RA, 256 HIV-infected, 149 elderly individuals, 85 kidney transplant recipients, and 83 with JIA were included. The proportions of seroprotection, seroconversion, and the geometric mean titer ratios postvaccination were, respectively: 37.6%, 31.8%, and 3.2 among kidney transplant recipients, 61.5%, 53.1%, and 7.5 among RA patients, 63.1%, 55.7%, and 5.7 among the elderly, 59.0%, 54.7%, and 5.9 among HIV-infected patients, 52.4%, 49.2%, and 5.3 among cancer patients, 85.5%, 78.3%, and 16.5 among JIA patients. The vaccine was well tolerated, with no reported severe adverse events.
   Conclusions: The vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA patients, however new vaccination strategies should be explored to improve the immune response of immunocompromised adult patients.
C1 [Miraglia, Joao L.; Guedes, Jose da S.; Raw, Isaias; Kalil, Jorge; Precioso, Alexander R.] Butantan Inst, Clin Trials Div, Sao Paulo, Brazil.
   [Abdala, Edson; Hoff, Paulo M.] Univ Sao Paulo, Fac Med, ICESP, Sao Paulo, Brazil.
   [Luiz, Andre M.; Oliveira, Danise S.] Univ Sao Paulo, Hosp Clin, CRIE, Sao Paulo, Brazil.
   [Saad, Carla G. S.; Laurindo, Ieda M. M.] Univ Sao Paulo, Fac Med, Div Rheumatol, Sao Paulo, Brazil.
   [Viso, Ana T. R.; Tayra, Angela] Ctr Referencia & Treinamento DST AIDS CRT DST AID, Sao Paulo, Brazil.
   [Pierrotti, Ligia C.; Azevedo, Luiz S.] Univ Sao Paulo, Fac Med, Renal Transplantat Unit, Sao Paulo, Brazil.
   [Campos, Lucia Maria A.; Aikawa, Nadia E.] Univ Sao Paulo, Pediat Rheumatol Unit, Childrens Inst, Hosp Clin,Fac Med, Sao Paulo, Brazil.
   [Timenetsky, Maria do Carmo S. T.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Luna, Expedito] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Cardoso, Maria Regina A.] Univ Sao Paulo, Dept Epidemiol, Fac Saude Publ, Sao Paulo, Brazil.
   [Precioso, Alexander R.] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Pediat,Inst Crianco, Sao Paulo, Brazil.
RP Miraglia, JL (corresponding author), Butantan Inst, Clin Trials Div, Sao Paulo, Brazil.
EM joaomiraglia@gmail.com
RI Saad, Carla/P-5230-2014; Pierrotti, Ligia/C-5804-2015; Abdala,
   Edson/H-5165-2012; TIMENETSKY, MARIA/I-7593-2013; Miraglia,
   Joao/H-5294-2013; KALIL, JORGE/C-8029-2012; Aikawa, Nadia/I-5962-2013;
   Cardoso, Maria Regina A/J-7280-2012; Precioso, Alexander
   Roberto/A-9712-2013; Luna, Expedito J A/B-7948-2012; Azevedo,
   Luiz/M-4147-2014; Pierrotti, Ligia Camera/U-9225-2017; Hoff, Paulo M.
   PH/M-7662-2017
OI Saad, Carla/0000-0001-9720-0719; Abdala, Edson/0000-0003-0765-6654;
   KALIL, JORGE/0000-0001-8415-4274; Aikawa, Nadia/0000-0002-7585-4348;
   Precioso, Alexander Roberto/0000-0001-8657-9292; Luna, Expedito J
   A/0000-0002-1145-9672; Pierrotti, Ligia Camera/0000-0002-0216-3028;
   Hoff, Paulo M. PH/0000-0002-0065-2194; Miraglia, Joao
   Luiz/0000-0002-4788-6254
FU Fundacao Butantan
FX Fundacao Butantan funded the study, and employed several of the authors.
   The funder had a role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2005, Wkly Epidemiol Rec, V80, P277
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P249
   [Anonymous], 1996, INT C HARM TECHN REQ
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Baguelin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017074
   Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P467
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Crum-Cianflone NF, 2011, CLIN INFECT DIS, V52, P138, DOI 10.1093/cid/ciq019
   EMA, 1996, EUR MED AG PUBL
   EMA, 2004, CPMPVEG471703 EMA EU
   Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Huber Peter J., 1967, P 5 BERK S MATH STAT, V1, P221
   Kanakoudi-Tsakalidou F, 2001, CLIN EXP RHEUMATOL, V19, P589
   KENDAL AP, 1982, CONCEPTS PROCEDURES, pB17
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   Liang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1
   MALLESON PN, 1993, J RHEUMATOL, V20, P1769
   McElhaney JE, 2011, AGEING RES REV, V10, P379, DOI 10.1016/j.arr.2010.10.008
   Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7
   MS, 2010, BAL PARC VAC GRIP A
   MS/SVS/DVE/PNI, 2010, ESTR NAC VAC VIR INF
   Ogimi C, 2011, PEDIATR INFECT DIS J, V30, P208, DOI 10.1097/INF.0b013e3181f7ce44
   Petty RE, 2004, J RHEUMATOL, V31, P390
   Plennevaux E, 2011, VACCINE, V29, P1569, DOI 10.1016/j.vaccine.2010.12.116
   Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2
   Saad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250
   Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   U.S.F.D.A, 2007, GUID IND CLIN DAT NE
   Weng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
   World Health Organization, 2009, GLOB AL RESP WHO REC
   Yanagisawa N, 2011, VACCINE, V29, P5694, DOI 10.1016/j.vaccine.2011.06.003
   Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535
NR 35
TC 28
Z9 32
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2011
VL 6
IS 11
AR e27214
DI 10.1371/journal.pone.0027214
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 852HZ
UT WOS:000297349700019
PM 22087267
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Guerino, MT
   Postol, E
   Demarchi, LMF
   Martins, CO
   Mundel, LR
   Kalil, J
   Guilherme, L
AF Guerino, Milton T.
   Postol, Edilberto
   Demarchi, Lea M. F.
   Martins, Carlo O.
   Mundel, Luiz R.
   Kalil, Jorge
   Guilherme, Luiza
TI HLA class II transgenic mice develop a safe and long lasting immune
   response against StreptInCor, an anti-group A streptococcus vaccine
   candidate
SO VACCINE
LA English
DT Article
DE S. pyogenes; Vaccine; HLA class II transgenic mice; Humoral immune
   response; Histopathology
ID RHEUMATIC HEART-DISEASE; COLLAGEN-INDUCED ARTHRITIS; CROSS-REACTIVE
   EPITOPES; AMINO-ACID-SEQUENCES; T-CELL RESPONSE; M-PROTEIN; CARDIAC
   MYOSIN; AUTOIMMUNE VALVULITIS; LEWIS RATS; FEVER
AB Streptococcus pyogenes infections remain a health problem in several countries because of post-streptococcal sequelae, such as rheumatic fever and rheumatic heart disease. We developed a vaccine epitope (StreptInCor) composed of 55 amino acid residues of the C-terminal portion of the M protein that encompasses both T and B cell protective epitopes. Recently, by using human blood samples, we showed that the StreptInCor epitope is able to bind to different HLA class 11 molecules and that it could be considered a universal vaccine epitope. In the present work, we evaluated the immune response of HLA class II transgenic mice against aluminum hydroxide-absorbed StreptInCor. After a period of one year, several organs were analyzed histologically to verify the safety of the candidate vaccine epitope. Our results showed that StreptInCor is able to induce robust and safe and long lasting immune response without deleterious reactions in several organs. In conclusion, the results presented here indicate that StreptInCor could be considered a safe vaccine against severe streptococcus-induced diseases. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Guerino, Milton T.; Postol, Edilberto; Demarchi, Lea M. F.; Martins, Carlo O.; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Guerino, Milton T.; Postol, Edilberto; Martins, Carlo O.; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Natl Inst Sci & Technol, Immunol Invest Inst, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), HC FMUSP, Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; Martins, Carlo/D-4008-2018; KALIL,
   JORGE/C-8029-2012; Demarchi, Lea/K-3105-2012
OI Martins, Carlo/0000-0003-1287-8884; KALIL, JORGE/0000-0001-8415-4274; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX We acknowledge Prof. Dr. Chella S. David from Department of Immunology,
   Mayo Clinic and Julie Hanson, Supervisor of Immunogenetics Mouse Colony
   from Mayo Clinic, Rochester, USA for provided the transgenic mice used
   in this study and Prof Patrick Cleary, University of Minnesota Medical
   School, MN, USA for provided the M1 recombinant clone). This work was
   supported by grants from "Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)".
CR Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002
   Bradley DS, 1997, J CLIN INVEST, V100, P2227, DOI 10.1172/JCI119760
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   CARDIOLOGIA SBD, 2009, ARQ BRAS CARDIOL S4, V93, P3
   Chapoval SP, 1998, J IMMUNOL, V161, P2032
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103
   Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8
   GonzalezGay MA, 1996, HUM IMMUNOL, V50, P54, DOI 10.1016/0198-8859(96)00123-1
   GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659
   Gorton D, 2010, J IMMUNOL METHODS, V355, P80, DOI 10.1016/j.jim.2010.02.013
   Gorton D, 2009, INFECT IMMUN, V77, P2177, DOI 10.1128/IAI.01514-08
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2011, ADV CLIN CHEM, V53, P31, DOI 10.1016/S0065-2423(11)53002-1
   Guilherme L, 2007, CURR PROTEIN PEPT SC, V8, P39, DOI 10.2174/138920307779941488
   Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   JONES KF, 1986, J EXP MED, V164, P1226, DOI 10.1084/jem.164.4.1226
   KAPLAN MH, 1963, AM HEART J, V65, P426, DOI 10.1016/0002-8703(63)90020-6
   Kotloff KL, 2004, PEDIATR INFECT DIS J, V23, P765, DOI 10.1097/01.inf.0000136296.98686.c5
   Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
   KRAUS W, 1989, INFECT IMMUN, V57, P2457, DOI 10.1128/IAI.57.8.2457-2461.1989
   KRAUS W, 1989, J EXP MED, V169, P481, DOI 10.1084/jem.169.2.481
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lymbury RS, 2003, J AUTOIMMUN, V20, P211, DOI 10.1016/S0896-8411(03)00026-X
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   Martins TB, 2008, INT IMMUNOL, V20, P445, DOI 10.1093/intimm/dxn004
   Nabozny GH, 1996, J EXP MED, V183, P27, DOI 10.1084/jem.183.1.27
   Olive C, 2007, VACCINE, V25, P1789, DOI 10.1016/j.vaccine.2006.11.031
   Pan SC, 1998, J IMMUNOL, V161, P2925
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   SARGENT SJ, 1987, J IMMUNOL, V139, P1285
   Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
NR 42
TC 19
Z9 19
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 26
PY 2011
VL 29
IS 46
BP 8250
EP 8256
DI 10.1016/j.vaccine.2011.08.113
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 847QV
UT WOS:000296988500012
PM 21907752
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Ribeiro, SP
   Rosa, DS
   Kalil, J
   Cunha-Neto, E
AF Almeida, R. R.
   Ribeiro, S. P.
   Rosa, D. S.
   Kalil, J.
   Cunha-Neto, E.
TI Immunogenicity of a DNA Vaccine Containing Multiple HLA-DR Binding,
   Conserved M Group HIV-1 Epitopes in BALB/c Mice
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Almeida, R. R.; Ribeiro, S. P.; Rosa, D. S.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela
   S/D-2190-2012
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Rosa, Daniela S/0000-0003-4536-891X
NR 0
TC 0
Z9 0
U1 0
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A99
EP A100
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500255
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Almeida, RR
   Rosa, DS
   Mairena, EC
   Kallas, EG
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Almeida, R. R.
   Rosa, D. S.
   Mairena, E. C.
   Kallas, E. G.
   Kalil, J.
   Cunha-Neto, E.
TI DNA Vaccine Encoding HIV CD4 T Cell Epitopes Enhances CD8 T Cell
   Responses Induced by Immunization with DNA Vaccines Encoding Whole Gag
   (p55) and Vif
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Ribeiro, S. P.; Almeida, R. R.; Rosa, D. S.; Mairena, E. C.; Kallas, E. G.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo FMUSP, Fac Med, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; Kallas,
   Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A101
EP A102
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500260
DA 2020-11-26
ER

PT J
AU Porto, G
   Giordano, RJ
   Marti, LC
   Stolf, B
   Pasqualini, R
   Arap, W
   Kalil, J
   Coelho, V
AF Porto, Georgia
   Giordano, Ricardo J.
   Marti, Luciana C.
   Stolf, Beatriz
   Pasqualini, Renata
   Arap, Wadih
   Kalil, Jorge
   Coelho, Veronica
TI Identification of Novel Immunoregulatory Molecules in Human Thymic
   Regulatory CD4(+)CD25(+) T Cells by Phage Display
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D-RECEPTOR; IMMUNOLOGICAL SELF-TOLERANCE; AUTOIMMUNE-DISEASES;
   RETINOIC-ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN
   D-3; INTERLEUKIN-11 RECEPTOR; MEDIATED TRANSCRIPTION; DENDRITIC CELLS;
   IMMUNE-SYSTEM
AB Thymic CD4(+)CD25(+) cells play an important role in immune regulation and are continuously developed in the thymus as an independent lineage. How these cells are generated, what are their multiple pathways of suppressive activity and which are their specific markers are questions that remain unanswered. To identify molecules involved in the function and development of human CD4(+)CD25(+) T regulatory cells we targeted thymic CD4(+)CD25(+) cells by peptide phage display. A phage library containing random peptides was screened ex vivo for binding to human thymic CD4(+)CD25(+) T cells. After four rounds of selection on CD4(+)CD25(+) enriched populations of thymocytes, we sequenced several phage displayed peptides and selected one with identity to the Vitamin D Receptor (VDR). We confirmed the binding of the VDR phage to active Vitamin D in vitro, as well as the higher expression of VDR in CD4(+)CD25(+) cells. We suggest that differential expression of VDR on natural Tregs may be related to the relevance of Vitamin D in function and ontogeny of these cells.
C1 [Porto, Georgia; Stolf, Beatriz; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Inst Coracao InCor, Inst Heart, Sao Paulo, Brazil.
   [Porto, Georgia; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kalil, Jorge; Coelho, Veronica] Natl Inst Sci & Technol Iii INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Giordano, Ricardo J.; Pasqualini, Renata; Arap, Wadih] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr, Houston, TX 77030 USA.
   [Marti, Luciana C.] Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
   [Stolf, Beatriz] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil.
   [Giordano, Ricardo J.] Univ Sao Paulo, Inst Chem, Sao Paulo, Brazil.
RP Porto, G (corresponding author), Univ Sao Paulo, Sch Med, Inst Coracao InCor, Inst Heart, Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Marti, Luciana/Z-2555-2019; Giordano, Ricardo/A-2074-2010; Stolf,
   Beatriz S/H-7943-2012; COELHO, VERONICA/D-1433-2013; Marti,
   Luciana/E-8242-2010; KALIL, JORGE/C-8029-2012
OI Marti, Luciana/0000-0002-3890-0827; Giordano,
   Ricardo/0000-0001-8116-6771; Stolf, Beatriz S/0000-0001-7661-3311;
   Marti, Luciana/0000-0002-3890-0827; KALIL, JORGE/0000-0001-8415-4274;
   Coelho, Veronica/0000-0002-0989-2581
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2003/04721-2]
FX This work was supported by FAPESP under grant number: 2003/04721-2. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adorini L, 2002, INT IMMUNOPHARMACOL, V2, P1017, DOI 10.1016/S1567-5769(02)00049-8
   Adorini L, 2008, NAT CLIN PRACT RHEUM, V4, P404, DOI 10.1038/ncprheum0855
   Adorini L, 2006, CURR TOP MED CHEM, V6, P1297, DOI 10.2174/156802606777864890
   Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121
   Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434
   Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974
   Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002
   Dias-Neto E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008338
   Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249
   Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945
   Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004-0116
   Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3
   Itoh M, 1999, J IMMUNOL, V162, P5317
   Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217
   Kang I, 2010, J IMMUNOL, V184
   Levings MK, 2000, J ALLERGY CLIN IMMUN, V106, pS109, DOI 10.1067/mai.2000.106635
   Lewis VO, 2009, CANCER RES, V69, P1995, DOI 10.1158/0008-5472.CAN-08-4845
   Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3
   Mizwicki MT, 2004, P NATL ACAD SCI USA, V101, P12876, DOI 10.1073/pnas.0403606101
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Mucida D, 2007, CELL ADHES MIGR, V1, P142, DOI 10.4161/cam.1.3.5062
   NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159
   Nezbedova P, 2004, Endocr Regul, V38, P29
   Norman AW, 2006, ENDOCRINOLOGY, V147, P5542, DOI 10.1210/en.2006-0946
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Penna G, 2007, J BONE MINER RES, V22, pV69, DOI 10.1359/JBMR.07S217
   Powrie Fiona, 2003, Novartis Found Symp, V252, P92
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004
   Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799
   Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969
   Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028
   Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8
   Velappan N, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp809
   Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Yu Y, 2008, J BIOMOL SCREEN, V13, P968, DOI 10.1177/1087057108326537
   Zhang XM, 2004, INT IMMUNOL, V16, P249, DOI 10.1093/intimm/dxh029
   Zhao GS, 2010, STEROIDS, V75, P555, DOI 10.1016/j.steroids.2009.12.001
   Zurita AJ, 2004, CANCER RES, V64, P435, DOI 10.1158/0008-5472.CAN-03-2675
NR 47
TC 7
Z9 8
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2011
VL 6
IS 8
AR e21702
DI 10.1371/journal.pone.0021702
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 802LA
UT WOS:000293511200003
PM 21829599
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Weber, R
   Monteiro, F
   Preuhs, G
   Rodrigues, H
   Kalil, J
   Miziara, ID
AF Weber, R.
   Monteiro, F.
   Preuhs-Filho, G.
   Rodrigues, H.
   Kalil, J.
   Miziara, I. D.
TI HLA-DRB1*04:02, DRB1*08:04 and DRB1*14 alleles associated to pemphigus
   vulgaris in southeastern Brazilian population
SO TISSUE ANTIGENS
LA English
DT Letter
DE Brazilian; human leukocyte antigens; pemphigus; pemphigus vulgaris
ID HLA-DQB1 AND-DRB1 ALLELES; SOUTH EAST BRAZIL; CYTOKINE POLYMORPHISMS;
   ANTIBODY SPECIFICITIES; STRATIFICATION; IDENTIFICATION; FREQUENCIES;
   BIAS
C1 [Weber, R.; Miziara, I. D.] Univ Sao Paulo, Sch Med, ENT Dept, Sao Paulo, Brazil.
   [Monteiro, F.; Preuhs-Filho, G.; Rodrigues, H.; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Transplant Immunol & Immunogenet Lab, Sao Paulo, Brazil.
RP Weber, R (corresponding author), Univ Sao Paulo, Sch Med, ENT Dept, Sao Paulo, Brazil.
EM raimar.weber@hotmail.com
RI KALIL, JORGE/C-8029-2012; Miziara, Ivan D/L-8422-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Black M, 2005, ORAL DIS, V11, P119, DOI 10.1111/j.1601-0825.2005.01139.x
   Cesbron-Gautier A, 2004, ANN BIOL CLIN-PARIS, V62, P93
   HALDANE JBS, 1956, ANN HUM GENET, V20, P309
   Louzada-Junior P, 2001, TISSUE ANTIGENS, V57, P158, DOI 10.1034/j.1399-0039.2001.057002158.x
   Morgun A, 2004, HUM IMMUNOL, V65, P879, DOI 10.1016/j.humimm.2004.08.017
   Nyholt DR, 2001, HUM GENET, V109, P564, DOI 10.1007/s00439-001-0611-4
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Pei R, 2003, TRANSPLANTATION, V75, P43, DOI 10.1097/00007890-200301150-00008
   Pimenta JR, 2006, HUM HERED, V62, P190, DOI 10.1159/000096872
   Temin J, 2004, HUM IMMUNOL, V65, P882, DOI 10.1016/j.humimm.2004.08.018
   Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151
   Wang YT, 2004, GENET EPIDEMIOL, V27, P14, DOI 10.1002/gepi.20003
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
NR 15
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD AUG
PY 2011
VL 78
IS 2
BP 92
EP 93
DI 10.1111/j.1399-0039.2011.01705.x
PG 2
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 788NC
UT WOS:000292450700003
PM 21554253
DA 2020-11-26
ER

PT J
AU Aun, MV
   Bisaccioni, C
   Garro, LS
   Rodrigues, AT
   Tanno, LK
   Ensina, LFC
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Bisaccioni, Carla
   Garro, Laila Sabino
   Rodrigues, Adriana Teixeira
   Tanno, Luciana Kase
   Chiaverirti Ensina, Luis Felipe
   Kalil, Jorge
   Motta, Antonio Abilio
   Giavina-Bianchi, Pedro
TI Outcomes and safety of drug provocation tests
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article
ID PENICILLIN-ALLERGIC PATIENTS; DIAGNOSIS; HYPERSENSITIVITY;
   CEPHALOSPORINS
AB Drug provocation tests (DPTs) are considered the gold standard for identifying adverse drug reactions (ADRs). The aim of this study was to analyze DPT results and discuss severe systemic reactions associated with them. This was a retrospective analysis of 500 patients with ADRs who sought treatment and were submitted to DPTs when indicated between 2006 and 2010. We performed DPTs according to the European Network for Drug Allergy recommendations. Single-blind, placebo-controlled DPTs were performed with antibiotics, local anesthetics, and nonsteroidal anti-inflammatory drugs, as well as with other drugs. Patient characteristics, DPT results, and reactions were analyzed. The sample comprised 198 patients (80.8% of whom were female patients) submitted to 243 DPTs. Ages ranged from 9 to 84 years (mean, 39.9 years). The 243 DPTs were performed with local anesthetics (n = 93), antibiotics (n = 19), acetaminophen (n = 44), benzydamine (n = 33), COX-2 inhibitors (n = 26), dipyrone (n = 7), aspirin (n = 4), or other drugs (n = 17). The results of 4 tests (1.6%) were inconclusive, whereas those of 10 (4.1%) revealed positive reactions to antibiotics (2/19), COX-2 inhibitors (2/26), acetaminophen (3/44), and local anesthetics (3/93). Two severe reactions were observed: cephalexin-induced anaphylactic shock and bupivacaine-induced anaphylaxis without shock. Four patients (2.0%) reacted to the placebo before administration of the drug. Drug provocation tests are safe for use in clinical practice but they should be placebo-controlled and should be performed under the supervision of an allergist. To confirm a presumptive diagnosis and to manage allergies appropriately, it is crucial to perform DPTs. (Allergy Asthma Proc 32:301-306, 2011; doi: 10.2500/aap.2011.32.3450)
C1 [Aun, Marcelo Vivolo; Bisaccioni, Carla; Garro, Laila Sabino; Rodrigues, Adriana Teixeira; Tanno, Luciana Kase; Chiaverirti Ensina, Luis Felipe; Kalil, Jorge; Motta, Antonio Abilio; Giavina-Bianchi, Pedro] Univ Sao Paulo, Dept Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Prof Artur Ramos 178,Ap 211A, BR-01454904 Sao Paulo, Brazil.
EM saudesos@terra.com.br
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012; ENSINA, LUIS
   FELIPE/N-4545-2014; Giavina-Bianchi, Pedro/I-3112-2014; Aun, Marcelo
   V/E-6775-2014
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274; ENSINA, LUIS FELIPE/0000-0001-8652-3619;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580; Aun, Marcelo
   V/0000-0001-9882-5200
CR Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x
   Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032
   Bousquet PJ, 2008, CURR PHARM DESIGN, V14, P2792, DOI 10.2174/138161208786369731
   Brockow K, 2002, ALLERGY, V57, P45
   Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x
   Demoly P, 2002, ALLERGY, V57, P37, DOI 10.1034/j.1398-9995.57.s72.7.x
   DePestel DD, 2008, J AM PHARM ASSOC, V48, P530, DOI 10.1331/JAPhA.2008.07006
   Dietrich JJ, 2009, ALLERGY ASTHMA PROC, V30, P69, DOI 10.2500/aap.2009.30.3195
   Hermes B, 2006, J EUR ACAD DERMATOL, V20, P800, DOI 10.1111/j.1468-3083.2006.01634.x
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   McClimon B, 2011, ALLERGY ASTHMA PROC, V32, P95, DOI 10.2500/aap.2011.32.3417
   Meissner K, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-3
   Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009
   Nagao-Dias AT, 2009, ALLERGOL IMMUNOPATH, V37, P98, DOI 10.1016/S0301-0546(09)71112-7
   Nettis E, 2001, ORAL SURG ORAL MED O, V91, P402, DOI 10.1067/moe.2001.113348
   Otto HF, 2010, ALLERGY ASTHMA PROC, V31, P244, DOI 10.2500/aap.2010.31.3331
   Palma-Carlos S, 2007, REV PORT IMUNOALERGO, V15, P485
   Pichichero ME, 2007, DIAGN MICR INFEC DIS, V57, p13S, DOI 10.1016/j.diagmicrobio.2006.12.004
   Pichichero ME, 2007, OTOLARYNG HEAD NECK, V136, P340, DOI 10.1016/j.otohns.2006.10.007
   Romano A, 2007, CURR OPIN ALLERGY CL, V7, P299, DOI 10.1097/ACI.0b013e328216f4d4
   Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x
NR 21
TC 20
Z9 21
U1 0
U2 3
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD JUL-AUG
PY 2011
VL 32
IS 4
BP 301
EP 306
DI 10.2500/aap.2011.32.3450
PG 6
WC Allergy
SC Allergy
GA 802ER
UT WOS:000293492600005
PM 21781406
DA 2020-11-26
ER

PT J
AU Frade, AF
   de Oliveira, LC
   Costa, DL
   Costa, CHN
   Aquino, D
   Van Weyenbergh, J
   Barral-Netto, M
   Barral, A
   Kalil, J
   Goldberg, AC
AF Frade, Amanda Farage
   de Oliveira, Lea Campos
   Costa, Dorcas Lamounier
   Nery Costa, Carlos Henrique
   Aquino, Dorlene
   Van Weyenbergh, Johan
   Barral-Netto, Manoel
   Barral, Aldina
   Kalil, Jorge
   Goldberg, Anna Carla
TI TGFB1 and IL8 gene polymorphisms and susceptibility to visceral
   leishmaniasis
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Visceral leishmaniasis; Cytokines; Gene polymorphisms; Disease
   susceptibility
ID GROWTH-FACTOR-BETA; INTERFERON-GAMMA; AMPHOTERICIN-B; ASSOCIATION;
   PROMOTER; CHAGASI; INTERLEUKIN-6; INFECTION; DONOVANI; BALANCE
AB Visceral leishmaniasis (VL) or Kala-azar is a serious protozoan infectious disease caused by an obligate intracellular parasite. Cytokines have a major role in determining progression and severity of clinical manifestations in VL. We investigated polymorphisms in the TGFB1 and IL8 genes, which are cytokines known to have a role in onset and severity of the disease. Polymorphisms at TGFB1 -509 C/T and +869 T/C, and IL8 -251 A/T were analyzed by a PCR-RFLP technique, in 198 patients with VL, 98 individuals with asymptomatic infection positive for a delayed-type hypersensitivity test (DTH+) and in 101 individuals with no evidence of infection (DTH-). The presence of the T allele in position -509 of the TGFB1 gene conferred a two-fold risk to develop infection both when including those with clinical symptoms (DTH+ and VL, grouped) or when considering DTH+ only, respectively p = 0.007, OR = 1.9 [1.19-3.02] and p = 0.012, OR = 2.01 [1.17-3.79], when compared with DTH- individuals. In addition, occurrence of hemorrhage was associated with TGFB1 -509 T allele. We suggest that the -509 T allele of the TGFB1 gene, a cytokine with a biologically relevant role in the natural history of the disease, may contribute to overall susceptibility to infection by Leishmania and to severity of the clinical disease. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Barral, Aldina; Goldberg, Anna Carla] Albert Einstein Inst Educ & Res, BR-05652000 Sao Paulo, Brazil.
   [Frade, Amanda Farage; Kalil, Jorge] FMUSP, Heart Inst InCor HC, Immunol Lab, Sao Paulo, SP, Brazil.
   [de Oliveira, Lea Campos] Univ Sao Paulo, Lab Med Lab LIM03, Gen Hosp, Cent Inst,Sch Med, BR-05508 Sao Paulo, Brazil.
   [Aquino, Dorlene] Univ Fed Maranhao, Sao Luis, Brazil.
   [Van Weyenbergh, Johan; Barral-Netto, Manoel; Barral, Aldina; Kalil, Jorge; Goldberg, Anna Carla] CNPq, INCT, Inst Invest Immunol 3, Campinas, SP, Brazil.
RP Goldberg, AC (corresponding author), Albert Einstein Inst Educ & Res, Av Albert Einstein 627-701,Piso Chinuch 2S, BR-05652000 Sao Paulo, Brazil.
EM goldberg@einstein.br
RI Van Weyenbergh, Johan/B-4187-2009; Frade, Amanda F/O-3322-2017;
   Goldberg, Anna Carla/H-8594-2014; Van Weyenbergh, Johan/Q-3829-2019;
   KALIL, JORGE/C-8029-2012; Barral-Netto, Manoel/B-3904-2009
OI Van Weyenbergh, Johan/0000-0003-3234-8426; Frade, Amanda
   F/0000-0002-9004-8811; Goldberg, Anna Carla/0000-0003-2600-7940; Van
   Weyenbergh, Johan/0000-0003-3234-8426; KALIL, JORGE/0000-0001-8415-4274;
   Barral-Netto, Manoel/0000-0002-5823-7903
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); CAPESCAPES;
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX This study received financial support from the Brazilian National
   Research Council (CNPq). A.F.F. was supported by a CAPES fellowship and
   A.C.G., J.K., A.B., M.B-N., C.H.N.C. are recipients of personal
   achievement grants from CNPq.
CR Ansari NA, 2006, CLIN IMMUNOL, V119, P339, DOI 10.1016/j.clim.2006.01.017
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   Belluco C, 2003, CLIN CANCER RES, V9, P2173
   Berman J, 2006, INDIAN J MED RES, V123, P289
   Bern C, 2006, AM J TROP MED HYG, V75, P744, DOI 10.4269/ajtmh.2006.75.744
   Blackwell JM, 1998, INT J PARASITOL, V28, P21, DOI 10.1016/S0020-7519(97)00175-6
   Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118
   BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   Caldas AJM, 2002, T ROY SOC TROP MED H, V96, P21, DOI 10.1016/S0035-9203(02)90227-0
   CASTELL JV, 1989, ANN NY ACAD SCI, V557, P87
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Farouk S, 2010, PUBLIC HEALTH GENOM, V13, P362, DOI 10.1159/000272457
   Gantt KR, 2003, J IMMUNOL, V170, P2613, DOI 10.4049/jimmunol.170.5.2613
   Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190
   Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559
   Hulkkonen J, 2001, ARTHRITIS RHEUM, V44, P176, DOI 10.1002/1529-0131(200101)44:1<176::AID-ANR23>3.0.CO;2-K
   Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x
   Jeronimo SMB, 2007, GENES IMMUN, V8, P539, DOI 10.1038/sj.gene.6364422
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x
   Kumar D, 2009, ANTIMICROB AGENTS CH, V53, P835, DOI 10.1128/AAC.01233-08
   Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942
   Lurje G, 2008, ANN ONCOL, V19, P1734, DOI 10.1093/annonc/mdn368
   Malla N, 2006, INDIAN J MED RES, V123, P267
   Mohamed HS, 2003, GENES IMMUN, V4, P351, DOI 10.1038/sj.gene.6363977
   Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y
   Rodrigues V, 1998, INFECT IMMUN, V66, P1233, DOI 10.1128/IAI.66.3.1233-1236.1998
   Saha S, 2007, J IMMUNOL, V179, P5592, DOI 10.4049/jimmunol.179.8.5592
   Sainz J, 2008, CYTOKINE, V41, P268, DOI 10.1016/j.cyto.2007.11.018
   SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   VANDERPOLL T, 1995, CLIN IMMUNOL IMMUNOP, V77, P111, DOI 10.1016/0090-1229(95)90144-2
   Wong TYH, 2003, KIDNEY INT, V63, P1831, DOI 10.1046/j.1523-1755.2003.00919.x
NR 39
TC 26
Z9 28
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2011
VL 11
IS 5
BP 912
EP 916
DI 10.1016/j.meegid.2011.02.014
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 785UP
UT WOS:000292256800015
PM 21376140
OA Green Published
DA 2020-11-26
ER

PT J
AU Tanno, L
   Ensina, L
   Aun, W
   Mello, J
   Kalil, J
   Motta, A
AF Tanno, L.
   Ensina, L.
   Aun, W.
   Mello, J.
   Kalil, J.
   Motta, A.
TI Drug patch test in severe cutaneous adverse reactions: is it useful for
   clinical practice?
SO ALLERGY
LA English
DT Meeting Abstract
CT 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 11-15, 2011
CL Istanbul, TURKEY
SP European Acad Allergy & Clin Immunol (EAACI)
C1 [Tanno, L.; Ensina, L.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Tanno, L.] Hosp Servidor Publ Estadual Francisco Morato de O, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Tanno, Luciana Kase/J-9981-2014
OI KALIL, JORGE/0000-0001-8415-4274; Tanno, Luciana
   Kase/0000-0003-3236-1225
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUN
PY 2011
VL 66
SU 94
SI SI
MA 178
BP 86
EP 86
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 286IS
UT WOS:000329462200179
DA 2020-11-26
ER

PT J
AU Teixeira, PC
   Santos, RHB
   Fiorelli, AI
   Bilate, AMB
   Benvenuti, LA
   Stolf, NA
   Kalil, J
   Cunha-Neto, E
AF Teixeira, Priscila Camillo
   Barros Santos, Ronaldo Honorato
   Fiorelli, Alfredo Inacio
   Bianchi Bilate, Angelina Morand
   Benvenuti, Luiz Alberto
   Stolf, Noedir Antonio
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Selective Decrease of Components of the Creatine Kinase System and ATP
   Synthase Complex in Chronic Chagas Disease Cardiomyopathy
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID IDIOPATHIC DILATED CARDIOMYOPATHY; MITOCHONDRIAL RESPIRATORY-CHAIN;
   TRYPANOSOMA-CRUZI INFECTION; HEART-FAILURE; ISCHEMIA-REPERFUSION;
   ENERGY-METABOLISM; CARDIAC DISEASE; NITRIC-OXIDE; MYOCARDITIS;
   EXPRESSION
AB Background: Chronic Chagas disease cardiomyopathy (CCC) is an inflammatory dilated cardiomyopathy with a worse prognosis than other cardiomyopathies. CCC occurs in 30 % of individuals infected with Trypanosoma cruzi, endemic in Latin America. Heart failure is associated with impaired energy metabolism, which may be correlated to contractile dysfunction. We thus analyzed the myocardial gene and protein expression, as well as activity, of key mitochondrial enzymes related to ATP production, in myocardial samples of end-stage CCC, idiopathic dilated (IDC) and ischemic (IC) cardiomyopathies.
   Methodology/Principal Findings: Myocardium homogenates from CCC (N = 5), IC (N = 5) and IDC (N = 5) patients, as well as from heart donors (N = 5) were analyzed for protein and mRNA expression of mitochondrial creatine kinase (CKMit) and muscular creatine kinase (CKM) and ATP synthase subunits aplha and beta by immunoblotting and by real-time RT-PCR. Total myocardial CK activity was also assessed. Protein levels of CKM and CK activity were reduced in all three cardiomyopathy groups. However, total CK activity, as well as ATP synthase alpha chain protein levels, were significantly lower in CCC samples than IC and IDC samples. CCC myocardium displayed selective reduction of protein levels and activity of enzymes crucial for maintaining cytoplasmic ATP levels.
   Conclusions/Significance: The selective impairment of the CK system may be associated to the loss of inotropic reserve observed in CCC. Reduction of ATP synthase alpha levels is consistent with a decrease in myocardial ATP generation through oxidative phosphorylation. Together, these results suggest that the energetic deficit is more intense in the myocardium of CCC patients than in the other tested dilated cardiomyopathies.
C1 [Teixeira, Priscila Camillo; Bianchi Bilate, Angelina Morand; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   [Teixeira, Priscila Camillo; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Teixeira, Priscila Camillo; Kalil, Jorge; Cunha-Neto, Edecio] INCT, III, Sao Paulo, Brazil.
   [Barros Santos, Ronaldo Honorato; Fiorelli, Alfredo Inacio; Stolf, Noedir Antonio] Univ Sao Paulo, Div Surg, Inst Heart, Sch Med, Sao Paulo, Brazil.
   [Benvenuti, Luiz Alberto] Univ Sao Paulo, Div Pathol, Inst Heart, Sch Med, Sao Paulo, Brazil.
RP Teixeira, PC (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
EM edecunha@usp.br
RI KALIL, JORGE/C-8029-2012; Teixeira, Priscila C/D-7426-2013; Cunha-Neto,
   Edecio/B-4157-2009; Benvenuti, Luiz/C-6614-2014
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
FU Brazilian Council for Scientific and Technological Development -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This research was supported by the Brazilian Council for Scientific and
   Technological Development - CNPq and the Sao Paulo State Research
   Funding Agency - FAPESP. PCT is recipient of a Sao Paulo State Research
   Funding Agency - FAPESP fellowship. ECN and JK are recipients of
   Brazilian Council for Scientific and Technological Development - CNPq
   productivity awards. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Acquatella H, 1999, J AM COLL CARDIOL, V33, P522, DOI 10.1016/S0735-1097(98)00569-5
   BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bocchi E A, 1994, Arq Bras Cardiol, V63, P523
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   Bowling J, 2009, EXPERT REV ANTI-INFE, V7, P1223, DOI 10.1586/ERI.09.107
   Carvajal K, 2003, ARCH MED RES, V34, P89, DOI 10.1016/S0188-4409(03)00004-3
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Dias J C, 2000, Cad Saude Publica, V16 Suppl 2, P43, DOI 10.1590/S0102-311X2000000800005
   Garg N, 2003, BBA-MOL BASIS DIS, V1638, P106, DOI 10.1016/S0925-4439(03)00060-7
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   INGWALL JS, 1982, AM J PHYSIOL, V242, pH729
   INGWALL JS, 1990, EUR HEART J, V11, P108, DOI 10.1093/eurheartj/11.suppl_B.108
   Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0
   KALOVIDOURIS AE, 1993, J RHEUMATOL, V20, P1718
   LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035
   Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378
   Liao RL, 1996, CIRC RES, V78, P893, DOI 10.1161/01.RES.78.5.893
   LUSS H, 1995, J MOL CELL CARDIOL, V27, P2015, DOI 10.1016/0022-2828(95)90023-3
   Lygate CA, 2007, J MOL CELL CARDIOL, V42, P1129, DOI 10.1016/j.yjmcc.2007.03.899
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913
   Nahrendorf M, 2005, CARDIOVASC RES, V65, P419, DOI 10.1016/j.cardiores.2004.10.006
   Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894
   Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052
   Ning XH, 2000, J AM COLL CARDIOL, V36, P282, DOI 10.1016/S0735-1097(00)00689-6
   Quigley AF, 2000, J CARD FAIL, V6, P47, DOI 10.1016/S1071-9164(00)00011-7
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Silva CP, 2008, ARQ BRAS CARDIOL, V91, P358
   Spindler M, 2004, AM J PHYSIOL-HEART C, V287, pH1039, DOI 10.1152/ajpheart.01016.2003
   TEIXEIRA ARL, 1990, J INFECT DIS, V162, P1420, DOI 10.1093/infdis/162.6.1420
   Teixeira PC, 2006, BRAZ J MED BIOL RES, V39, P1549, DOI 10.1590/S0100-879X2006005000050
   Tian R, 1996, J MOL CELL CARDIOL, V28, P755, DOI 10.1006/jmcc.1996.0070
   Ventura-Clapier R, 2004, J PHYSIOL-LONDON, V555, P1, DOI 10.1113/jphysiol.2003.055095
   Vyatkina G, 2004, BBA-MOL BASIS DIS, V1689, P162, DOI 10.1016/j.bbadis.2004.03.005
   Wang DC, 1996, LAB INVEST, V75, P809
   Weiss RG, 2005, P NATL ACAD SCI USA, V102, P808, DOI 10.1073/pnas.0408962102
NR 46
TC 12
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2011
VL 5
IS 6
AR e1205
DI 10.1371/journal.pntd.0001205
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 784EZ
UT WOS:000292139600041
PM 21738806
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ronda, C
   Borba, SCP
   Ferreira, SCP
   Glotz, D
   Ianhez, LE
   Rodrigues, H
   Viggiani, CS
   Nahas, W
   David-Neto, E
   Castro, MCR
   Daisa, SRD
   Kalil, J
   Panajotopoulos, N
AF Ronda, C.
   Borba, S. C. P.
   Ferreira, S. C. P.
   Glotz, D.
   Ianhez, L. E.
   Rodrigues, H.
   Viggiani, C. S.
   Nahas, W.
   David-Neto, E.
   Castro, M. C. R.
   David Daisa, S. R.
   Kalil, J.
   Panajotopoulos, N.
TI Non-Human Leukocyte Antigen Antibodies Reactive with Endothelial Cells
   Could Be Involved in Early Loss of Renal Allografts
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID TRANSPLANT REJECTION
AB Preformed donor-specific human leukocyte antigen (HLA) antibodies have been associated with allograft dysfunction and failure. However, recipients of HLA-identical kidneys can develop acute humoral rejection, implicating putative pathogenic antibodies that are directed against non-HLA antigens. We investigated the presence of endothelial cell reactive antibodies in 11 patients who experienced early loss of their transplanted kidneys owing to humoral rejection and 1 loss from renal venal thrombosis. We examined the potential efficacy of intravenous immunoglobulin to block the binding of these antibodies, as previously suggested for anti-HLA antibodies.
C1 [Ronda, C.; Borba, S. C. P.; Ferreira, S. C. P.; Rodrigues, H.; Kalil, J.; Panajotopoulos, N.] Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   [Ianhez, L. E.; David-Neto, E.; Castro, M. C. R.; David Daisa, S. R.] Univ Sao Paulo, Renal Transplant Unit, Sao Paulo, Brazil.
   [David Daisa, S. R.] Univ Sao Paulo, Div Pathol, Sao Paulo, Brazil.
   [Glotz, D.] Hosp St Louis, Dept Nephrol & Transplantat, Paris, France.
RP Ronda, C (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Ave Dr Eneas de Carvalho Aguiar 44, Sao Paulo, Brazil.
EM cronda51@hotmail.com
RI Glotz, Denis/F-7881-2011; Neto, Elias David/O-3866-2018; David-Neto,
   Elias/C-9112-2012; de castro, maria cristina ribeiro/B-6648-2009; KALIL,
   JORGE/C-8029-2012; Ferreira, Susanne/N-9638-2015
OI de castro, maria cristina ribeiro/0000-0002-6731-8369; KALIL,
   JORGE/0000-0001-8415-4274; Glotz, Denis/0000-0001-5258-4237
CR CERILLI GL, 1987, TRANSPL P, V19, P4468
   DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   Ferry BL, 1997, TRANSPL IMMUNOL, V5, P17, DOI 10.1016/S0966-3274(97)80021-4
   Glotz D, 2004, TRANSPLANT INT, V17, P1, DOI 10.1007/s00147-003-0674-3
   KALIL J, 1989, TRANSPLANT P, V21, P711
   Lefaucheur C, 2008, Nephrol Ther, V4 Suppl 3, pS188, DOI 10.1016/S1769-7255(08)74233-0
   Lucchiari N, 2000, HUM IMMUNOL, V61, P518, DOI 10.1016/S0198-8859(00)00109-9
   Rocha PN, 2003, IMMUNOL REV, V196, P51, DOI 10.1046/j.1600-065X.2003.00090.x
   Sacks SH, 2003, CURR OPIN IMMUNOL, V15, P487, DOI 10.1016/S0952-7915(03)00100-6
   Valujskikh A, 2003, CURR OPIN IMMUNOL, V15, P493, DOI 10.1016/S0952-7915(03)00110-9
   Vo AA, 2010, TRANSPLANTATION, V89, P1095, DOI 10.1097/TP.0b013e3181d21e7f
NR 12
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2011
VL 43
IS 4
BP 1345
EP 1348
DI 10.1016/j.transproceed.2011.03.059
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 773EI
UT WOS:000291289400103
PM 21620126
DA 2020-11-26
ER

PT J
AU Lemos, F
   Marin, M
   Takaki, KM
   Agena, F
   Nahas, W
   Kalil, J
AF Lemos, F.
   Marin, M.
   Takaki, K. M.
   Agena, F.
   Nahas, W.
   Kalil, J.
TI Interferon-gamma Reduces the Heme Oxygenase-1 Expression in Proximal
   Tubular Epithelial Cells during Ischemia.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Lemos, F.; Takaki, K. M.; Agena, F.; Nahas, W.] Hosp Clin FMUSP, Renal Transplantat Serv, Sao Paulo, Brazil.
   [Marin, M.; Kalil, J.] Hosp Clin FMUSP, Lab Imunol INCOR, Sao Paulo, Brazil.
RI Agena, Fabiana/F-5807-2012; Agena, Fabiana/C-5819-2015; KALIL,
   JORGE/C-8029-2012
OI Agena, Fabiana/0000-0002-4526-4857; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 1121
BP 360
EP 360
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318401335
DA 2020-11-26
ER

PT J
AU dos Santos, LD
   Menegasso, ARD
   Pinto, JRAD
   Santos, KS
   Castro, FM
   Kalil, JE
   Palma, MS
AF dos Santos, Lucilene Delazari
   da Silva Menegasso, Anally Ribeiro
   Aparecido dos Santos Pinto, Jose Roberto
   Santos, Keity Souza
   Castro, Fabio Morato
   Kalil, Jorge Elias
   Palma, Mario Sergio
TI Proteomic characterization of the multiple forms of the PLAs from the
   venom of the social wasp Polybia paulista
SO PROTEOMICS
LA English
DT Article
DE Animal proteomics; Immunoreactivity; Phospholipase A(1); PTM; Wasp venom
ID ANTIGENIC CROSS-REACTIVITY; PHOSPHOLIPASE A(2); HONEYBEE VENOM;
   HYMENOPTERA; PURIFICATION; PROTEIN; HORNET; ALLERGENS; BEE
AB The phospholipases A(1) (PLA(1)s) from the venom of the social wasp Polybia paulista occur as a mixture of different molecular forms. To characterize the molecular origin of these structural differences, an experimental strategy was planned combining the isolation of the pool of PLAs from the wasp venom with proteomic approaches by using 2-D, MALDI-TOF-TOF MS and classical protocols of protein chemistry, which included N- and C-terminal sequencing. The existence of an intact form of PLA(1) and seven truncated forms was identified, apparently originating from controlled proteolysis of the intact protein; in addition to this, four of these truncated forms also presented carbohydrates attached to their molecules. Some of these forms are immunoreactive to specific-IgE, while others are not. These observations permit to raise the hypothesis that naturally occurring proteolysis of PLA(1), combined with protein glycosylation may create a series of different molecular forms of these proteins, with different levels of allergenicity. Two forms of PLA(2)s, apparently related to each other, were also identified; however, it was not possible to determine the molecular origin of the differences between both forms, except that one of them was glycosylated. None of these forms were immunoreactive to human specific IgE.
C1 [dos Santos, Lucilene Delazari; da Silva Menegasso, Anally Ribeiro; Aparecido dos Santos Pinto, Jose Roberto; Palma, Mario Sergio] Univ Sao Paulo State UNESP, Dept Biol, Ctr Study Social Insects, Inst Biosci Rio Claro, Rio Claro, SP, Brazil.
   [Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias] Discipline Allergy & Immunol HC FMUSP INCor, Sao Paulo, Brazil.
RP Palma, MS (corresponding author), CEIS IBRC UNESP, Av 24A 1515, BR-13506900 Bela Vista Rio Claro, SP, Brazil.
EM mspalma@rc.unesp.br
RI Castro, Fabio FM/C-1082-2017; Santos-Pinto, Jose Roberto Aparecido
   dos/V-8745-2019; Santos, Keity/M-9401-2015; Santos, Lucilene Delazari
   dos/AAY-5226-2020; Santos, Keity Souza/Q-5704-2019; Santos,
   Keity/E-2553-2012; Castro, Fabio/AAP-5433-2020; KALIL,
   JORGE/C-8029-2012; Palma, Mario Sergio/E-7800-2012; Palma,
   Mario/N-3903-2019
OI Castro, Fabio FM/0000-0002-6211-5773; Santos-Pinto, Jose Roberto
   Aparecido dos/0000-0003-3172-0097; Santos, Lucilene Delazari
   dos/0000-0001-5832-1825; Santos, Keity Souza/0000-0001-5271-4011; KALIL,
   JORGE/0000-0001-8415-4274; Palma, Mario Sergio/0000-0002-7363-8211; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [05/00982-1]; BIOprospecTA/FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [06/57122-7]; CNPqNational Council for Scientific
   and Technological Development (CNPq); CAPESCAPES
FX This work was supported by grants from FAPESP (Proc. 05/00982-1) and
   BIOprospecTA/FAPESP program (Proc. 06/57122-7), CNPq and CAPES. M. S. P.
   and J. E. K. are researchers awardees from the National Research Council
   of Brazil - CNPq; L. D. S and K. S. S. are postdoctoral fellows from
   FAPESP; J. R. A. S. P. and A. R. S. M. are postgraduation fellows from
   CNPq.
CR Abe T, 2000, TOXICON, V38, P1803, DOI 10.1016/S0041-0101(00)00109-4
   Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8
   ARAUJO A L D, 1987, Toxicon, V25, P1181
   Baek JH, 2009, ARCH INSECT BIOCHEM, V71, P205, DOI 10.1002/arch.20316
   BANKS BEC, 1986, VENOMS HYMENOPTERA, P319
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CASTRO FFM, 1994, J INVEST ALLERG CLIN, V4, P37
   CHARPIN D, 1992, J ALLERGY CLIN IMMUN, V90, P331, DOI 10.1016/S0091-6749(05)80011-9
   Costa H, 2000, TOXICON, V38, P1367, DOI 10.1016/S0041-0101(99)00199-3
   de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017
   de Souza BM, 2009, PEPTIDES, V30, P1387, DOI 10.1016/j.peptides.2009.05.008
   dos Santos LD, 2010, J PROTEOME RES, V9, P3867, DOI 10.1021/pr1000829
   DOTIMAS EM, 1987, BEE WORLD, V68, P51, DOI 10.1080/0005772X.1987.11098915
   Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V
   HO CL, 1988, BIOCHIM BIOPHYS ACTA, V963, P414, DOI 10.1016/0005-2760(88)90309-8
   Hoffman DR, 2005, J ALLERGY CLIN IMMUN, V115, P611, DOI 10.1016/j.jaci.2004.11.020
   Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109
   JONES D, 1992, J BIOL CHEM, V267, P14871
   King TP, 2003, INT ARCH ALLERGY IMM, V131, P25, DOI 10.1159/000070431
   King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3
   King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440
   Kolecki P, 1999, ANN EMERG MED, V33, P114, DOI 10.1016/S0196-0644(99)70428-2
   KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x
   LU G, 1993, J IMMUNOL, V150, P2823
   Mendes MA, 2006, PEPTIDES, V27, P2632, DOI 10.1016/j.peptides.2006.05.018
   Moawad TI, 2005, ACTA BIOL HUNG, V56, P261, DOI 10.1556/ABiol.56.2005.3-4.9
   MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5
   Nittner-Marszalska M, 2004, MED SCI MONITOR, V10, pCR324
   OLIVEIRA MR, 1988, TOXICON, V36, P189
   Palma MS, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P389, DOI 10.1016/B978-012369442-3/50059-3
   Pantera B, 2003, BBA-GEN SUBJECTS, V1623, P72, DOI 10.1016/j.bbagen.2003.07.001
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Santos LD, 2007, TOXICON, V50, P923, DOI 10.1016/j.toxicon.2007.06.027
   SELBY DS, 2008, PROTEOMIC SAMPLE PRE, P328
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Souza BM, 2005, PEPTIDES, V26, P2157, DOI 10.1016/j.peptides.2005.04.026
   TUNGET CL, 1993, POSTGRAD MED, V94, P92
   Vetter RS, 1999, WESTERN J MED, V170, P223
NR 38
TC 32
Z9 32
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD APR
PY 2011
VL 11
IS 8
BP 1403
EP 1412
DI 10.1002/pmic.201000414
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 750EV
UT WOS:000289528800004
PM 21365748
DA 2020-11-26
ER

PT J
AU Silva, H
   Takenaka, M
   Vieira, P
   Monteiro, S
   Lemos, F
   Saitovitch, D
   Kalil, J
   Coelho, V
AF Silva, Hernandez
   Takenaka, Maisa
   Vieira, Pedro
   Monteiro, Sandra
   Lemos, Francine
   Saitovitch, David
   Kalil, Jorge
   Coelho, Veronica
TI Operationally tolerant kidney recipients exhibit higher numbers of
   suppressive CD19+CD24hiCD38hi b cells in relation to chronic rejection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Silva, Hernandez; Takenaka, Maisa; Monteiro, Sandra; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Immunol, Sao Paulo, Brazil.
   [Silva, Hernandez; Takenaka, Maisa; Monteiro, Sandra; Saitovitch, David; Kalil, Jorge; Coelho, Veronica] INCT Natl Inst Sci & Technol, Inst Invest Immunol 3, Sao Paulo, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Div Nephrol, Porto Alegre, RS, Brazil.
   [Vieira, Pedro] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR
PY 2011
VL 186
SU 1
MA 169.25
PG 1
WC Immunology
SC Immunology
GA V44LY
UT WOS:000209751708094
DA 2020-11-26
ER

PT J
AU Danoviz, ME
   Bassaneze, V
   Nakamuta, JS
   dos Santos, GR
   Saint-Clair, D
   Bajgelman, MC
   Fae, KC
   Kalil, J
   Miyakawa, AA
   Krieger, JE
AF Danoviz, Maria Elena
   Bassaneze, Vinicius
   Nakamuta, Juliana Sanajotti
   dos Santos-Junior, Gabriel Ribeiro
   Saint-Clair, Danilo
   Bajgelman, Marcio Chaim
   Fae, Kellen Cristhina
   Kalil, Jorge
   Miyakawa, Ayumi Aurea
   Krieger, Jose Eduardo
TI Adipose Tissue-Derived Stem Cells from Humans and Mice Differ in
   Proliferative Capacity and Genome Stability in Long-Term Cultures
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID MARROW STROMAL CELLS; GFP TRANSGENIC MICE; BONE-MARROW; IN-VITRO;
   GENE-EXPRESSION; RETINOIC ACID; LIFE-SPAN; DIFFERENTIATION; GROWTH; VIVO
AB Adipose tissue-derived stem cells (ASCs) are among the more attractive adult stem cell options for potential therapeutic applications. Here, we studied and compared the basic biological characteristics of ASCs isolated from humans (hASCs) and mice (mASCs) and maintained in identical culture conditions, which must be examined prior to considering further potential clinical applications. hASCs and mASCs were compared for immunophenotype, differentiation potential, cell growth characteristics, senescence, nuclear morphology, and DNA content. Although both strains of ASCs displayed a similar immunophenotype, the percentage of CD73(+) cells was markedly lower and CD31(+) was higher in mASC than in hASC cultures. The mean population doubling time was 98.08 +/- 6.15 h for hASCs and 52.58 +/- 3.74 h for mASCs. The frequency of nuclear aberrations was noticeably lower in hASCs than in mASCs regardless of the passage number. Moreover, as the cells went through several in vitro passages, mASCs showed changes in DNA content and cell cycle kinetics (frequency of hypodiploid, G0/G1, G2/M, and hyperdiploid cells), whereas all of these parameters remained constant in hASCs. Collectively, these results suggest that mASCs display higher proliferative capacity and are more unstable than hASCs in long-term cultures. These results underscore the need to consider specificities among model systems that may influence outcomes when designing potential human applications.
C1 [Krieger, Jose Eduardo] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet Mol Cardiol,LIM 13, BR-05403000 Sao Paulo, Brazil.
RP Krieger, JE (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet Mol Cardiol,LIM 13, Av Dr Eneas C Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM krieger@incor.usp.br
RI Bajgelman, Marcio/A-8146-2019; Bassaneze, Vinicius/E-5577-2012; Krieger,
   Jose E/C-3117-2011; KALIL, JORGE/C-8029-2012; Miyakawa, Ayumi
   A/M-4343-2015
OI Bajgelman, Marcio/0000-0003-3371-1143; Bassaneze,
   Vinicius/0000-0002-3481-2408; KALIL, JORGE/0000-0001-8415-4274;
   Miyakawa, Ayumi A/0000-0003-3911-3259; Krieger, Jose/0000-0001-5464-1792
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [01/0009-0,
   05/54695-3, 05/57591-4, 04/06784-4, 06/57937-0]; Ministerio da Ciencia e
   Tecnologia/Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/Ministerio da Saude/Departamento Ciencia e Tecnologia
   (MCT/CNPq/MS/DE-CIT)National Council for Scientific and Technological
   Development (CNPq) [552324/20005-1, 10120104096700]
FX The authors thank Tiago da Veiga Pereira for the assistance with
   statistical data analyses. They also thank Giancarlo Fatobene, Carolina
   Lavini-Ramos, and Paulo Sampaio Gutierrez for technical assistance, and
   Aurelio Silvestroni for critical revision of the manuscript. This study
   was funded by grants from Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP; No. 01/0009-0) and Ministerio da Ciencia e
   Tecnologia/Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/Ministerio da Saude/Departamento Ciencia e Tecnologia
   (MCT/CNPq/MS/DE-CIT No. 552324/20005-1 and 10120104096700). M.E.D.,
   V.B., J.S.N., and G.R.S.J. were recipients of fellowships from FAPESP
   (05/54695-3, 05/57591-4, 04/06784-4, and 06/57937-0, respectively).
CR Aguilar S, 2007, STEM CELLS, V25, P1586, DOI 10.1634/stemcells.2006-0762
   Bajgelman MC, 2008, VIROLOGY, V371, P8, DOI 10.1016/j.virol.2007.11.015
   Bassaneze V, 2008, ANAL BIOCHEM, V372, P198, DOI 10.1016/j.ab.2007.08.016
   Bassaneze V, 2010, STEM CELLS DEV, V19, P371, DOI 10.1089/scd.2009.0195
   Blande IS, 2009, TRANSFUSION, V49, P2680, DOI 10.1111/j.1537-2995.2009.02346.x
   Crisostomo PR, 2006, SHOCK, V26, P575, DOI 10.1097/01.shk.0000235087.45798.93
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Duggal S, 2009, TISSUE ENG PT A, V15, P1763, DOI 10.1089/ten.tea.2008.0306
   Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270
   FRESHNEY R.I., 2000, CULTURE ANIMAL CELLS
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hattori H, 2004, CELLS TISSUES ORGANS, V178, P2, DOI 10.1159/000081088
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Javazon EH, 2001, STEM CELLS, V19, P219, DOI 10.1634/stemcells.19-3-219
   Jeon ES, 2008, CIRC RES, V103, P635, DOI 10.1161/CIRCRESAHA.108.180885
   Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X
   Kang SK, 2004, J CELL SCI, V117, P4289, DOI 10.1242/jcs.01264
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Malladi P, 2006, TISSUE ENG, V12, P2031, DOI 10.1089/ten.2006.12.2031
   Martinez-Estrada OM, 2005, CARDIOVASC RES, V65, P328, DOI 10.1016/j.cardiores.2004.11.015
   Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0
   Mizuno H, 2002, PLAST RECONSTR SURG, V109, P199, DOI 10.1097/00006534-200201000-00030
   Mummery CL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000558
   Ogawa R, 2004, BIOCHEM BIOPH RES CO, V319, P511, DOI 10.1016/j.bbrc.2004.05.021
   Ogawa R, 2004, BIOCHEM BIOPH RES CO, V313, P871, DOI 10.1016/j.bbrc.2003.12.017
   Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024
   Peng LY, 2008, STEM CELLS DEV, V17, P761, DOI 10.1089/scd.2007.0217
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61
   Planat-Benard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47
   Qiao C, 2008, CELL BIOL INT, V32, P8, DOI 10.1016/j.cellbi.2007.08.002
   Rangappa S, 2003, ANN THORAC SURG, V75, P775, DOI 10.1016/S0003-4975(02)04568-X
   Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194
   Seo MJ, 2005, BIOCHEM BIOPH RES CO, V328, P258, DOI 10.1016/j.bbrc.2004.12.158
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stocum DL, 2001, WOUND REPAIR REGEN, V9, P429, DOI 10.1046/j.1524-475x.2001.00429.x
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tholpady SS, 2003, ANAT REC PART A, V272A, P398, DOI 10.1002/ar.a.10039
   TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   Winter A, 2003, ARTHRITIS RHEUM-US, V48, P418, DOI 10.1002/art.10767
   Yang LY, 2004, CHINESE MED J-PEKING, V117, P425
   Zhang L, 2005, WORLD J GASTROENTERO, V11, P2906, DOI 10.3748/wjg.v11.i19.2906
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 45
TC 20
Z9 21
U1 2
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD APR
PY 2011
VL 20
IS 4
BP 661
EP 670
DI 10.1089/scd.2010.0231
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 743XO
UT WOS:000289053000010
PM 20698764
DA 2020-11-26
ER

PT J
AU Muller, NG
   Alencar, R
   Jamal, L
   Hammer, J
   Sidney, J
   Sette, A
   Brindeiro, RM
   Kalil, J
   Cunha-Neto, E
   Moraes, SL
AF Muller, N. G.
   Alencar, R.
   Jamal, L.
   Hammer, J.
   Sidney, J.
   Sette, A.
   Brindeiro, R. M.
   Kalil, J.
   Cunha-Neto, E.
   Moraes, S. L.
TI CD4+T cells from HIV-1-infected patients recognize wild-type and mutant
   human immunodeficiency virus-1 protease epitopes
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE antigens; epitopes; CD4 T cells (T helper; Th0; Th1; Th2; Th3; Th17);
   flow cytometry; FACS; human immunodeficiency virus (AIDS; HIV-1; HIV-2);
   proliferation
ID CD4(+) T-CELLS; IMMUNE-RESPONSES; HIV-1; IDENTIFICATION; INFECTION;
   VIREMIA; INDIVIDUALS; FREQUENCY; PEPTIDES; PRESSURE
AB P>Human immunodeficiency virus (HIV)-1 protease is a known target of CD8+ T cell responses, but it is the only HIV-1 protein in which no fully characterized HIV-1 protease CD4 epitopes have been identified to date. We investigated the recognition of HIV-1 protease by CD4+ T cells from 75 HIV-1-infected, protease inhibitor (PI)-treated patients, using the 5,6-carboxyfluorescein diacetate succinimidyl ester-based proliferation assay. In order to identify putative promiscuous CD4+ T cell epitopes, we used the TEPITOPE algorithm to scan the sequence of the HXB2 HIV-1 protease. Protease regions 4-23, 45-64 and 73-95 were identified; 32 sequence variants of the mentioned regions, encoding frequent PI-induced mutations and polymorphisms, were also tested. On average, each peptide bound to five of 15 tested common human leucocyte antigen D-related (HLA-DR) molecules. More than 80% of the patients displayed CD4+ as well as CD8+ T cell recognition of at least one of the protease peptides. All 35 peptides were recognized. The response was not associated with particular HLA-DR or -DQ alleles. Our results thus indicate that protease is a frequent target of CD4+ along with CD8+ proliferative T cell responses by the majority of HIV-1-infected patients under PI therapy. The frequent finding of matching CD4+ and CD8+ T cell responses to the same peptides may indicate that CD4+ T cells provide cognate T cell help for the maintenance of long-living protease-specific functional CD8+ T cells.
C1 [Cunha-Neto, E.] Univ Sao Paulo, Lab Clin Immunol & Allergy LIM 60, Sch Med, Div Clin Immunol & Allergy,Dept Med, BR-01246000 Sao Paulo, Brazil.
   [Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Heart Inst InCor, BR-01246000 Sao Paulo, Brazil.
   [Moraes, S. L.] Univ Sao Paulo, Inst Trop Med, BR-01246000 Sao Paulo, Brazil.
   [Muller, N. G.; Kalil, J.; Cunha-Neto, E.; Moraes, S. L.] Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Alencar, R.; Jamal, L.] Ctr Training Sexually Transmitted Dis & AIDS, Sao Paulo, Brazil.
   [Brindeiro, R. M.] Univ Fed Rio de Janeiro, Mol Virol Lab, Inst Biol, Rio De Janeiro, Brazil.
   [Hammer, J.] Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA.
   [Sidney, J.; Sette, A.] La Jolla Inst Allergy & Immunol, San Diego, CA USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Lab Clin Immunol & Allergy LIM 60, Sch Med, Div Clin Immunol & Allergy,Dept Med, Ave Dr Arnaldo,455 S 3209, BR-01246000 Sao Paulo, Brazil.
EM edecunha@usp.br; sands@usp.br
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
FU National Institutes of Health (NIH, USA)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [5R03AI066961-03]; International Center for Genetic Engineering and
   Biotechnology-ICGEB (Italy); Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP, Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R03AI066961, R03AI066961,
   R03AI066961] Funding Source: NIH RePORTER
FX We thank the patients who participated in this study and Dr Edna Souza
   Barbosa for technical assistance. This work was supported by grants from
   the National Institutes of Health (NIH, USA; grant number:
   5R03AI066961-03), International Center for Genetic Engineering and
   Biotechnology-ICGEB (Italy), Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP, Brazil), and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq, Brazil).
CR Atherton E, 1989, SOLID PHASE PEPTIDE
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825
   Colinas RJ, 2000, CLIN CHEM, V46, P996
   Corbet S, 2003, J GEN VIROL, V84, P2409, DOI 10.1099/vir.0.19152-0
   Deeks SG, 2004, J INFECT DIS, V189, P312, DOI 10.1086/380098
   Ferrari G, 2000, AIDS RES HUM RETROV, V16, P1433, DOI 10.1089/08892220050140982
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Garcia TCM, 2008, ACTA TROP, V106, P162, DOI 10.1016/j.actatropica.2008.03.003
   Hogan CM, 2001, ANN INTERN MED, V134, P761, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00013
   Iwai LK, 2007, CLIN VACCINE IMMUNOL, V14, P474, DOI 10.1128/CVI.00458-06
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199
   Karlsson AC, 2007, J VIROL, V81, P11543, DOI 10.1128/JVI.00779-07
   Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4
   Mahnke Lisa, 2006, AIDS Res Ther, V3, P21, DOI 10.1186/1742-6405-3-21
   Mason RA, 2004, J IMMUNOL, V172, P7212, DOI 10.4049/jimmunol.172.11.7212
   McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598
   Mueller SM, 2007, J VIROL, V81, P2887, DOI 10.1128/JVI.01547-06
   Ndongala ML, 2010, VIRAL IMMUNOL, V23, P159, DOI 10.1089/vim.2009.0084
   Palmer BE, 2002, J VIROL, V76, P5925, DOI 10.1128/JVI.76.12.5925-5936.2002
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Ramduth D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005013
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000
   Schmitt M, 2000, AIDS, V14, P653, DOI 10.1097/00002030-200004140-00004
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   SIDNEY J, 1998, CURRENT PROTOCOLS IM
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tahara H, 2010, XENOTRANSPLANTATION, V17, P188, DOI 10.1111/j.1399-3089.2010.00575.x
   Wilson JDK, 2000, J INFECT DIS, V182, P792, DOI 10.1086/315764
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
NR 37
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 2011
VL 164
IS 1
BP 90
EP 99
DI 10.1111/j.1365-2249.2011.04319.x
PG 10
WC Immunology
SC Immunology
GA 732TU
UT WOS:000288213400011
PM 21352200
OA Green Published
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Alba, MP
   Ferreira, FM
   Oshiro, SE
   Higa, F
   Patarroyo, ME
   Kalil, J
AF Guilherme, Luiza
   Alba, Martha P.
   Ferreira, Frederico Moraes
   Oshiro, Sandra Emiko
   Higa, Fabio
   Patarroyo, Manuel E.
   Kalil, Jorge
TI Anti-Group A Streptococcal Vaccine Epitope STRUCTURE, STABILITY, AND ITS
   ABILITY TO INTERACT WITH HLA CLASS II MOLECULES
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RHEUMATIC HEART-DISEASE; M-PROTEIN; SECONDARY-STRUCTURE; COIL
   TRANSITION; CELL EPITOPES; INTRANASAL; HELIX; IMMUNOGENICITY;
   ANTIBODIES; INFECTION
AB Streptococcus pyogenes infections remain a health problem in several countries due to poststreptococcal sequelae. We developed a vaccine epitope (StreptInCor) composed of 55 amino acids residues of the C-terminal portion of the M protein that encompasses both T and B cell protective epitopes. The nuclear magnetic resonance (NMR) structure of the StreptInCor peptide showed that the structure was composed of two microdomains linked by an 18-residue alpha-helix. A chemical stability study of the StreptInCor folding/unfolding process using far-UV circular dichroism showed that the structure was chemically stable with respect to pH and the concentration of urea. The T cell epitope is located in the first microdomain and encompasses 11 out of the 18 alpha-helix residues, whereas the B cell epitope is in the second microdomain and showed no alpha-helical structure. The prediction of StreptInCor epitope binding to different HLA class II molecules was evaluated based on an analysis of the 55 residues and the theoretical possibilities for the processed peptides to fit into the P1, P4, P6, and P9 pockets in the groove of several HLA class II molecules. We observed 7 potential sites along the amino acid sequence of StreptInCor that were capable of recognizing HLA class II molecules (DRB1*, DRB3*, DRB4*, and DRB5*). StreptInCoroverlapping peptides induced cellular and humoral immune responses of individuals bearing different HLA class II molecules and could be considered as a universal vaccine epitope.
C1 [Guilherme, Luiza; Oshiro, Sandra Emiko; Higa, Fabio; Kalil, Jorge] Univ Sao Paulo, Heart Inst InCor, BR-5403903 Sao Paulo, Brazil.
   [Guilherme, Luiza; Oshiro, Sandra Emiko; Higa, Fabio; Kalil, Jorge] Univ Sao Paulo, Inst Invest Immunol, Natl Inst Sci & Technol, BR-5403903 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Dept Clin Med, Sch Med, BR-01246000 Sao Paulo, Brazil.
   [Ferreira, Frederico Moraes] Univ Sao Paulo, Lab Cellular Genet & Mol Nephrol, Dept Clin Med, Sch Med, BR-01246000 Sao Paulo, Brazil.
   [Alba, Martha P.; Patarroyo, Manuel E.] Fdn Inst Immunol Colombia FIDIC, Bogota 020304, Zona Can, Colombia.
   [Alba, Martha P.] Univ Rosario, Bogota 020304, Zona Can, Colombia.
   [Patarroyo, Manuel E.] Univ Nacl Colombia, Bogota 020304, Zona Can, Colombia.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar,44-9 Andar, BR-05403903 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; Murillo, Manuel Elkin M.E
   Patarroyo/S-1422-2017; Ferreira, Frederico Moraes/A-4622-2013;
   Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; Murillo, Manuel Elkin M.E
   Patarroyo/0000-0002-1119-6040; Alba, Martha patricia/0000-0003-0641-5162
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); "Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)," BrazilNational Council
   for Scientific and Technological Development (CNPq); "Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)," ColombiaNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by "Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)," Brazil and Colombia.
CR [Anonymous], 2008, WORLD HLTH REP 2008
   Batzloff MR, 2005, J INFECT DIS, V192, P1450, DOI 10.1086/466528
   BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6
   BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988
   Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296
   Brandt ER, 2000, NAT MED, V6, P455
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916
   Dale JB, 2005, CLIN DIAGN LAB IMMUN, V12, P833, DOI 10.1128/CDLI.12.7.833-836.2005
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   FISCHETTI VA, 1988, REV INFECT DIS, V10, pS356
   Gasteiger E, 2005, PROTEIN IDENTIFICATI
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kaufmann SHE, 2007, NAT REV MICROBIOL, V5, P491, DOI 10.1038/nrmicro1688
   Kotloff KL, 2005, INFECT IMMUN, V73, P2360, DOI 10.1128/IAI.73.4.2360-2366.2005
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Olive C, 2005, VACCINE, V23, P2298, DOI 10.1016/j.vaccine.2005.01.041
   OOI T, 1991, P NATL ACAD SCI USA, V88, P2859, DOI 10.1073/pnas.88.7.2859
   Pace C N, 1986, Methods Enzymol, V131, P266
   Pandey M, 2009, IMMUNOL CELL BIOL, V87, P391, DOI 10.1038/icb.2009.29
   PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235
   RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   Roccatano D, 2002, P NATL ACAD SCI USA, V99, P12179, DOI 10.1073/pnas.182199699
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854
   SEGREST JP, 1992, J LIPID RES, V33, P141
   Shaila MS, 2007, VACCINE, V25, P3567, DOI 10.1016/j.vaccine.2007.01.079
   Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
   Vohra H, 2005, RES MICROBIOL, V156, P575, DOI 10.1016/j.resmic.2004.12.009
   WUTHRICK K, 1986, NMR PROTEINS NUCL AC
NR 46
TC 17
Z9 17
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 4
PY 2011
VL 286
IS 9
BP 6989
EP 6998
DI 10.1074/jbc.M110.132118
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 726PH
UT WOS:000287737300015
PM 21169359
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Rosa, DS
   Ribeiro, SP
   Almeida, RR
   Mairena, EC
   Postol, E
   Kalil, J
   Cunha-Neto, E
AF Rosa, Daniela Santoro
   Ribeiro, Susan Pereira
   Almeida, Rafael Ribeiro
   Mairena, Eliane Conti
   Postol, Edilberto
   Kalil, Jorge
   Cunha-Neto, Edecio
TI A DNA Vaccine Encoding Multiple HIV CD4 Epitopes Elicits Vigorous
   Polyfunctional, Long-Lived CD4(+) and CD8(+) T Cell Responses
SO PLOS ONE
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; PROTECTIVE IMMUNITY; ELITE CONTROLLERS;
   RHESUS-MONKEYS; CENTRAL MEMORY; INFECTION; CHALLENGE; STEP; PREDICTION;
   CORRELATE
AB T-cell based vaccines against HIV have the goal of limiting both transmission and disease progression by inducing broad and functionally relevant T cell responses. Moreover, polyfunctional and long-lived specific memory T cells have been associated to vaccine-induced protection. CD4(+) T cells are important for the generation and maintenance of functional CD8(+) cytotoxic T cells. We have recently developed a DNA vaccine encoding 18 conserved multiple HLA-DR-binding HIV-1 CD4 epitopes (HIVBr18), capable of eliciting broad CD4(+) T cell responses in multiple HLA class II transgenic mice. Here, we evaluated the breadth and functional profile of HIVBr18-induced immune responses in BALB/c mice. Immunized mice displayed high-magnitude, broad CD4(+)/CD8(+) T cell responses, and 8/18 vaccine-encoded peptides were recognized. In addition, HIVBr18 immunization was able to induce polyfunctional CD4(+) and CD8(+) T cells that proliferate and produce any two cytokines (IFN gamma/TNF alpha, IFN gamma/IL-2 or TNF alpha/IL-2) simultaneously in response to HIV-1 peptides. For CD4(+) T cells exclusively, we also detected cells that proliferate and produce all three tested cytokines simultaneously (IFN gamma/TNF alpha/IL-2). The vaccine also generated long-lived central and effector memory CD4(+) T cells, a desirable feature for T-cell based vaccines. By virtue of inducing broad, polyfunctional and long-lived T cell responses against conserved CD4(+) T cell epitopes, combined administration of this vaccine concept may provide sustained help for CD8(+) T cells and antibody responses-elicited by other HIV immunogens.
C1 [Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Almeida, Rafael Ribeiro; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Med,Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
   [Mairena, Eliane Conti; Postol, Edilberto; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Mairena, Eliane Conti; Postol, Edilberto; Kalil, Jorge; Cunha-Neto, Edecio] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro] Fed Univ Sao Paulo UNIFESP, Div Immunol, Sao Paulo, Brazil.
RP Rosa, DS (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Med,Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI KALIL, JORGE/C-8029-2012; Almeida, Rafael/F-8014-2014; Cunha-Neto,
   Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012
OI KALIL, JORGE/0000-0001-8415-4274; Almeida, Rafael/0000-0003-3984-7527;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo State
   Research Funding Agency (FAPESP)Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); International Centre of Genetic Engineering and
   Biotechnology (ICGEB); Brazilian Ministry of Health (Brazil)
FX This research was supported by the Brazilian National Research Council
   (CNPq), Sao Paulo State Research Funding Agency (FAPESP), International
   Centre of Genetic Engineering and Biotechnology (ICGEB) and by the
   Brazilian Ministry of Health (Brazil). D. S. Rosa, S. P. Ribeiro and R.
   R. Almeida are recipients of a Sao Paulo State Research Funding Agency
   (FAPESP) fellowship. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   ATHERTON ND, 1989, CLIN CHEM, V35, P975
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
   FERRE AL, 2010, J VIROL
   Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Giraldo-Vela JP, 2008, J VIROL, V82, P859, DOI 10.1128/JVI.01816-07
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Kannanganat S, 2007, J VIROL, V81, P12071, DOI 10.1128/JVI.01261-07
   Khanolkar A, 2004, J IMMUNOL, V172, P2834, DOI 10.4049/jimmunol.172.5.2834
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320
   Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258
   Novy P, 2007, J IMMUNOL, V179, P8243, DOI 10.4049/jimmunol.179.12.8243
   Okoye A, 2009, J EXP MED, V206, P1575, DOI 10.1084/jem.20090356
   Pancre V, 2007, VACCINE, V25, P5927, DOI 10.1016/j.vaccine.2007.05.038
   Pike R, 2009, J VIROL, V83, P11211, DOI 10.1128/JVI.01225-09
   Potter SJ, 2007, J VIROL, V81, P13904, DOI 10.1128/JVI.01401-07
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Rajasagi NK, 2009, J VIROL, V83, P5256, DOI 10.1128/JVI.01997-08
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
   Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898
   von Gegerfelt A, 2010, J IMMUNOL, V185, P3348, DOI 10.4049/jimmunol.1000572
   Wang M, 2009, CLIN EXP IMMUNOL, V155, P441, DOI 10.1111/j.1365-2249.2008.03856.x
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
   Yamamoto T, 2009, J VIROL, V83, P5514, DOI 10.1128/JVI.00145-09
   Yang XD, 2009, REV MED VIROL, V19, P77, DOI 10.1002/rmv.602
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
NR 56
TC 30
Z9 30
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2011
VL 6
IS 2
AR e16921
DI 10.1371/journal.pone.0016921
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 721OO
UT WOS:000287364500013
PM 21347287
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Roso, MG
   Lima, GP
   Portilho, NC
   Borges, DB
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R. C.
   Roso, M. G.
   Lima, G. P.
   Portilho, N. C.
   Borges, D. B.
   Kalil, J.
   Giavina-Bianchi, P.
TI Clinical and Laboratory Features of Asthmatic Patients with Aspirin
   Exacerbated Respiratory Disease (AERD)
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Agondi, R. C.; Roso, M. G.; Lima, G. P.; Portilho, N. C.; Borges, D. B.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB224
EP AB224
DI 10.1016/j.jaci.2010.12.893
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846401008
DA 2020-11-26
ER

PT J
AU Castro-Coelho, AP
   Montenegro, FG
   Gaia, FD
   Bisaccioni, C
   Aun, MV
   Agondi, RC
   Kalil, J
   Giavina-Bianchi, P
AF Castro-Coelho, A. P.
   Montenegro, F. G.
   Gaia, F. D.
   Bisaccioni, C.
   Aun, M. V.
   Agondi, R. C.
   Kalil, J.
   Giavina-Bianchi, P.
TI Mold Allergens Sensitization and Severity of Asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Castro-Coelho, A. P.; Montenegro, F. G.; Gaia, F. D.; Bisaccioni, C.; Aun, M. V.; Agondi, R. C.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; Aun,
   Marcelo V/E-6775-2014
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB157
EP AB157
DI 10.1016/j.jaci.2010.12.622
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846400604
DA 2020-11-26
ER

PT J
AU Garro, LS
   Peluzzo, F
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF Garro, L. S.
   Peluzzo, F.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Identification of Factors Associated with Latex Sensitization and
   Allergy in Patients with Spina Bifida
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [Garro, L. S.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Peluzzo, F.] AACD, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB250
EP AB250
DI 10.1016/j.jaci.2010.12.995
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846401109
DA 2020-11-26
ER

PT J
AU Oliveira, LC
   Porta, G
   Marin, MLC
   Bittencourt, PL
   Kalil, J
   Goldberg, AC
AF Oliveira, Lea Campos
   Porta, Gilda
   Marin, Maria Lucia C.
   Bittencourt, Paulo Lisboa
   Kalil, Jorge
   Goldberg, Anna Carla
TI Autoimmune hepatitis, HLA and extended haplotypes
SO AUTOIMMUNITY REVIEWS
LA English
DT Review
DE Autoimmune hepatitis; Genetic susceptibility; HLA-DR; Extended MHC
   haplotypes
ID T-CELLS; HISTOCOMPATIBILITY COMPLEX; SUSCEPTIBILITY LOCUS; GENE
   POLYMORPHISMS; ENDOTHELIAL-CELLS; LIVER; TYPE-1; ASSOCIATION; FREQUENCY;
   IDENTIFICATION
AB Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease. Characteristic liver-infiltrating immune cells in portal and periportal areas, hypergammaglobulinemia and typical autoantibodies indicate an ongoing autoimmune reaction against liver self antigens, which lead to irreversible cellular damage and ultimately to severe hepatic failure. A significant part of adult, but not pediatric AIH patients, exhibit concurrent autoimmune diseases, further strengthening the immunological etiology of the disease. Genetic susceptibility to autoimmune hepatitis is strongly associated with HL4-DRB1 alleles. In Caucasian European and North American patients, AIH-1 is associated with the presence of DRB1*0301, DRB3*0101 and DRB1*0401 alleles, while AIH-2 is associated with DRB1*0301 or DRB1*07. In Brazil, the primary susceptibility allele for AIH-1 is DRB1*1301, but a secondary association with DRB1*0301 has also been identified. We looked for additional susceptibility factors in the extended MHC region. We genotyped 107 AIH-1 children and up to 326 healthy subjects for TNFA G-308A, TNFA G-238A, LTA A + 252 G, LTA A + 80 C, NFKBIL1 T-63A, BAT1 C-348 T, BAT1 G-22 C, MICA, and HLA-B polymorphisms. The TNFA-308 A allele was significantly increased in AIH-1 when compared with healthy controls, confirming data from other studies. Linkage disequilibrium analysis was carried out. The ancestral haplotype comprising TNFA-308A, TNFA-238 G, LTA +252 G, LTA + 80 C, NFKBIL1-63A, BAT1-348 C, BAT1-22 C, HLA-B*08, MICA*08 was more common in DRB1*03 positive patients than in controls (40% vs. 14%), showing a seven-fold increased risk for the disease [OR = 7.8 (95%CI 2.04-29.9.2, p = 0.0021). In contrast, the remaining patients carrying DRB1*03 exhibited varied haplotypes. Finally, a variety of class III haplotypes was also present in HLA-DRB1*13 patients, without a predominant pattern. The most common of the 98 haplotypes present in patients were completely absent in controls. The extended haplotype analysis in this sample of AIH-1 patients highlights not only the genetic diversity present in the Brazilian population, but is also in accordance with the previously documented microdiversity within the MHC region. The present knowledge of AIH suggests that the same or a very similar disease can be induced by yet unknown, but different, triggers followed by presentation on different HLA-DR molecules of the epitopes derived from the corresponding autoantigens, characterizing a much more complex disease than previously thought. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Marin, Maria Lucia C.; Kalil, Jorge; Goldberg, Anna Carla] Univ Sao Paulo, Inst Coracao, Fac Med, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
   [Oliveira, Lea Campos] Univ Sao Paulo, Hosp Clin, Fac Med, Lab Pediat Clin LIM 36, BR-05403000 Sao Paulo, Brazil.
   [Porta, Gilda] Univ Sao Paulo, Inst Crianca, Fac Med, Depto Hepatol, BR-05403000 Sao Paulo, Brazil.
   [Bittencourt, Paulo Lisboa] Hosp Portugues, Salvador, BA, Brazil.
   [Goldberg, Anna Carla] Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Inst Coracao, Fac Med, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM goldberg@einstein.br
RI BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna Carla/H-8594-2014;
   KALIL, JORGE/C-8029-2012
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274
FU Sao Paulo State Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); National Council for
   Scientific and Technologic Development (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX The data reported here were the subject of Ph.D. thesis of Dr. L.C.O.,
   and were supported by grants from the Sao Paulo State Research
   Foundation (FAPESP). A.C.G. and J.K. are recipients of grants for
   scientific achievement from the National Council for Scientific and
   Technologic Development (CNPq).
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   BADENHOOP K, 1989, DIABETOLOGIA, V32, P445, DOI 10.1007/BF00271265
   Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055
   Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711
   Bittencourt PL, 2008, J CLIN GASTROENTEROL, V42, P300, DOI 10.1097/MCG.0b013e31802dbdfc
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 2002, AUTOIMMUNITY, V35, P475, DOI 10.1080/0891693021000054101
   Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0
   Czaja AJ, 2008, CLIN GASTROENTEROL H, V6, P379, DOI 10.1016/j.cgh.2007.12.048
   Czaja AJ, 2008, DIGEST DIS SCI, V53, P522, DOI 10.1007/s10620-007-9859-4
   de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885
   De Biasio MB, 2006, J CLIN PATHOL, V59, P417, DOI 10.1136/jcp.2005.028613
   Djilali-Saiah I, 2006, J HEPATOL, V45, P844, DOI 10.1016/j.jhep.2006.07.034
   Dorak MT, 2006, GENES IMMUN, V7, P450, DOI 10.1038/sj.gene.6364315
   Duarte-Rey C, 2009, AUTOIMMUN REV, V8, P325, DOI 10.1016/j.autrev.2008.11.005
   Fainboim L, 2001, HEPATOLOGY, V33, P1512, DOI 10.1053/jhep.2001.24562
   GABBIANI G, 1973, AM J PATHOL, V72, P473
   Goldberg AC, 2007, SCAND J IMMUNOL, V66, P208, DOI 10.1111/j.1365-3083.2007.01967.x
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322
   Klugewitz K, 2002, J IMMUNOL, V169, P2407, DOI 10.4049/jimmunol.169.5.2407
   Koch W, 2007, HUM MOL GENET, V16, P1821, DOI 10.1093/hmg/ddm130
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   Lapierre P, 1999, GASTROENTEROLOGY, V116, P643, DOI 10.1016/S0016-5085(99)70186-1
   Lau AH, 2003, GUT, V52, P307, DOI 10.1136/gut.52.2.307
   Limmer A, 2000, NAT MED, V6, P1348
   Longhi MS, 2006, J IMMUNOL, V176, P4484, DOI 10.4049/jimmunol.176.7.4484
   Mackay IR, 2002, IMMUNOL CELL BIOL, V80, P36, DOI 10.1046/j.1440-1711.2002.01063.x
   MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949
   Mieli-Vergani G, 2009, J PEDIATR GASTR NUTR, V49, P158, DOI 10.1097/MPG.0b013e3181a1c265
   MURATORI L, 1995, GUT, V37, P406, DOI 10.1136/gut.37.3.406
   Okamoto K, 2003, AM J HUM GENET, V72, P303, DOI 10.1086/346067
   Onoe T, 2005, J IMMUNOL, V175, P139, DOI 10.4049/jimmunol.175.1.139
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Soares A, 2009, AUTOIMMUN REV, V8, P713, DOI 10.1016/j.autrev.2009.02.023
   Teufel A, 2010, J CLIN GASTROENTEROL, V44, P208, DOI 10.1097/MCG.0b013e3181c74e0d
   Zignego AL, 2008, AUTOIMMUN REV, V8, P107, DOI 10.1016/j.autrev.2008.07.012
NR 42
TC 44
Z9 48
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-9972
EI 1873-0183
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD FEB
PY 2011
VL 10
IS 4
BP 189
EP 193
DI 10.1016/j.autrev.2010.09.024
PG 5
WC Immunology
SC Immunology
GA 742DG
UT WOS:000288919700002
PM 20933106
DA 2020-11-26
ER

PT J
AU D'Ottaviano, FL
   Tanno, LK
   Kalil, J
   Motta, AA
   Giavina-Bianchi, P
AF D'Ottaviano, F. L.
   Tanno, L. K.
   Kalil, J.
   Motta, A. A.
   Giavina-Bianchi, P.
TI Clinical Features and Outcome of 52 Patients with Hereditary Angioedema
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting
CY MAR 18-22, 2011
CL San Francisco, CA
SP Amer Acad Allergy Asthma & Immunol
C1 [D'Ottaviano, F. L.; Tanno, L. K.; Kalil, J.; Motta, A. A.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; Giavina-Bianchi, Pedro/I-3112-2014;
   KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2011
VL 127
IS 2
SU S
BP AB233
EP AB233
DI 10.1016/j.jaci.2010.12.927
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 832YI
UT WOS:000295846401042
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Motta, A
   Kalil, J
AF Giavina-Bianchi, Pedro
   Motta, Abilio
   Kalil, Jorge
TI Therapeutic Agents for Hereditary Angioedema
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID C1 INHIBITOR CONCENTRATE
C1 [Giavina-Bianchi, Pedro; Motta, Abilio; Kalil, Jorge] Univ Sao Paulo, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714
   Schuklenk U, 1998, BIOETHICS, V12, P312, DOI 10.1111/1467-8519.00120
   Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503
NR 3
TC 3
Z9 3
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 6
PY 2011
VL 364
IS 1
BP 85
EP 85
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 702UY
UT WOS:000285922600021
PM 21208116
DA 2020-11-26
ER

PT S
AU Guilherme, L
   Kohler, KF
   Kalil, J
AF Guilherme, L.
   Koehler, K. F.
   Kalil, J.
BE Makowski, GS
TI RHEUMATIC HEART DISEASE: MEDIATION BY COMPLEX IMMUNE EVENTS
SO ADVANCES IN CLINICAL CHEMISTRY, VOL 53
SE Advances in Clinical Chemistry
LA English
DT Review; Book Chapter
ID T-CELL-CLONES; GROWTH-FACTOR-BETA-1 GENE C-509T; CLINICALLY HOMOGENEOUS
   PATIENTS; CLASS-II ASSOCIATIONS; NECROSIS-FACTOR-ALPHA; MYELIN
   BASIC-PROTEIN; GROUP-A STREPTOCOCCI; HLA CLASS-I; MOLECULAR MIMICRY;
   BRAZILIAN POPULATION
AB Rheumatic fever (RF) is an autoimmune disease caused by the Gram-positive bacteria Streptococcus pyogenes following an untreated throat infection in susceptible children. Rheumatic heart disease (RHD), the most serious complication, occurs in 30-45% of RF patients and leads to chronic valvular lesions. Here, we focus on the genes that confer susceptibility for developing this disease. Molecular mimicry mediates the cross-reactions between streptococcal antigens and human proteins. Several autoantigens have been identified, including cardiac myosin epitopes, vimentin, and other intracellular proteins. In heart tissue, antigen-driven oligoclonal T cell expansions probably cause the rheumatic heart lesions. These cells are CD4(+) and produce inflammatory cytokines (TNF alpha and IFN gamma). IL-4(+) cells are found in the myocardium; however, these cells are very scarce in the valve lesions of RHD patients. IL-4 is a Th2-type cytokine and plays a regulatory role in the inflammatory response mediated by Th1 cytokines. Our findings indicate that the Th1/Th2 cytokine balance has a role in healing myocarditis while the low numbers of IL-4-producing cells in the valves probably induced the progressive and permanent valve damage.
C1 [Guilherme, L.; Koehler, K. F.; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Guilherme, L.; Koehler, K. F.; Kalil, J.] Univ Sao Paulo, Immunol Invest Inst, Natl Inst Sci & Technol, Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Azevedo PM, 2010, CYTOKINE, V49, P109, DOI 10.1016/j.cyto.2009.09.003
   Barbosa PJB, 2009, ARQ BRAS CARDIOL, V93, P1
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   Berdeli A, 2004, CLIN BIOCHEM, V37, P925, DOI 10.1016/j.clinbiochem.2004.06.007
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   DAMIAN RT, 1964, AM NAT, V98, P129, DOI 10.1086/282313
   DEMESSIASREASON IJ, 2009, CLIN EXP IMMUNOL, V157, P395
   Donadi EA, 2000, J NEUROL, V247, P122, DOI 10.1007/s004150070191
   ElDemellawy M, 1997, INFECT IMMUN, V65, P2197, DOI 10.1128/IAI.65.6.2197-2205.1997
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Fae KC, 2008, J AUTOIMMUN, V31, P136, DOI 10.1016/j.jaut.2008.04.023
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FISCHETTI VA, 1985, J EXP MED, V161, P1384, DOI 10.1084/jem.161.6.1384
   FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guilherme Luiza, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S146239940501015X
   Haydardedeoglu FE, 2006, TISSUE ANTIGENS, V68, P293, DOI 10.1111/j.1399-0039.2006.00678.x
   Hernandez-Pacheco G, 2003, INT J CARDIOL, V92, P49, DOI 10.1016/S0167-5273(03)00040-8
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   Kamal H, 2010, ACTA CARDIOL, V65, P177, DOI 10.2143/AC.65.2.2047051
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   Luo YH, 2010, LAB INVEST, V90, P1492, DOI 10.1038/labinvest.2010.93
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   Mason D, 1998, IMMUNOLOGIST, V6, P220
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   MILLER L, 1988, J BIOL CHEM, V263, P5668
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x
   MORRIS K, 1993, CLIN EXP IMMUNOL, V91, P429
   Mota C., 2009, PEDIAT CARDIOLOGY, P1091
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   OLMEZ U, 1993, SCAND J RHEUMATOL, V22, P49
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   Peterson LK, 2007, AUTOANTIBODIES, 2ND EDITION, P13, DOI 10.1016/B978-044452763-9/50007-X
   RAIZADA V, 1983, AM J MED, V74, P225
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Ramasawmy R, 2008, CLIN VACCINE IMMUNOL, V15, P932, DOI 10.1128/CVI.00324-07
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Runza VL, 2008, IMMUNOBIOLOGY, V213, P297, DOI 10.1016/j.imbio.2007.10.009
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   Schafranski MD, 2008, MOL IMMUNOL, V45, P3827, DOI 10.1016/j.molimm.2008.05.013
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   Settin A, 2007, PEDIATR CARDIOL, V28, P363, DOI 10.1007/s00246-006-0002-7
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
   Yegin O, 1997, EUR J PEDIATR, V156, P25
NR 65
TC 31
Z9 35
U1 0
U2 13
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-2423
BN 978-0-12-385855-9
J9 ADV CLIN CHEM
JI Advan. Clin. Chem.
PY 2011
VL 53
BP 31
EP 50
DI 10.1016/S0065-2423(11)53002-1
PG 20
WC Chemistry, Applied; Medical Laboratory Technology
SC Chemistry; Medical Laboratory Technology
GA BTI79
UT WOS:000287046300002
PM 21404913
DA 2020-11-26
ER

PT S
AU Cunha-Neto, E
   Teixeira, PC
   Nogueira, LG
   Kalil, J
AF Cunha-Neto, Edecio
   Teixeira, Priscila Camillo
   Nogueira, Luciana Gabriel
   Kalil, Jorge
BE Weiss, LM
   Tanowitz, HB
TI Autoimmunity
SO ADVANCES IN PARASITOLOGY, VOL 76: CHAGAS DISEASE, PT B
SE Advances in Parasitology
LA English
DT Review; Book Chapter
ID CHRONIC CHAGAS-DISEASE; TRYPANOSOMA-CRUZI INFECTION;
   RIBOSOMAL-P-PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; 2ND
   EXTRACELLULAR LOOP; NECROSIS-FACTOR-ALPHA; CARDIAC MYOSIN; T-CELLS;
   MONOCLONAL-ANTIBODY; MOLECULAR MIMICRY
AB The scarcity of Trypanosoma cruzi in inflammatory lesions of chronic Chagas disease led early investigators to suggest that tissue damage had an autoimmune nature. In spite of parasite persistence in chronic Chagas disease, several reports indicate that inflammatory tissue damage may not be correlated to the local presence of T. cruzi. A significant number of reports have described autoantibodies and self-reactive T cells, often cross-reactive with I cruzi antigens, both in patients and in animal models. Evidence for a direct pathogenetic role of autoimmunity was suggested by the development of lesions after immunization with T. cruzi antigens or passive transfer of lymphocytes from infected animals, and the amelioration of chronic myocarditis in animals made tolerant to myocardial antigens. Autoimmune and T. cruzi-specific innate or adaptative responses are not incompatible or mutually exclusive, and it is likely that a combination of both is involved in the pathogenesis of chronic Chagas disease cardiomyopathy. The association between persistent infection and autoimmune diseases such as multiple sclerosis or diabetes mellitus-suggests that post-infectious autoimmunity may be a frequent finding. Here, we critically review evidence for autoimmune phenomena and their possible pathogenetic role in human Chagas disease and animal models, with a focus on chronic Chagas disease cardiomyopathy.
C1 [Cunha-Neto, Edecio; Teixeira, Priscila Camillo; Nogueira, Luciana Gabriel; Kalil, Jorge] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Teixeira, Priscila Camillo; Nogueira, Luciana Gabriel; Kalil, Jorge] Inst Invest Imunol INCT, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Teixeira,
   Priscila C/D-7426-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Abel LCJ, 2005, MICROBES INFECT, V7, P1184, DOI 10.1016/j.micinf.2005.03.033
   Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Ablashi DV, 1998, MULT SCLER, V4, P490, DOI 10.1191/135245898678845133
   ACOSTA AM, 1983, P SOC EXP BIOL MED, V172, P364, DOI 10.3181/00379727-172-41571
   ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255
   Aiello VD, 2002, J PATHOL, V197, P224, DOI 10.1002/path.1095
   Al-Sabbagh A, 1998, EXP PARASITOL, V89, P304, DOI 10.1006/expr.1998.4279
   Amorim D D, 1995, Sao Paulo Med J, V113, P772
   Anez N, 1999, AM J TROP MED HYG, V60, P726, DOI 10.4269/ajtmh.1999.60.726
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Bach-Elias M, 1998, PARASITOL RES, V84, P796, DOI 10.1007/s004360050490
   Barbosa AA, 1984, REV SOC BRAS MED TRO, V17, P123, DOI DOI 10.1590/S0037-86821984000300003
   Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6
   Bergami PL, 2001, FASEB J, V15, P2602, DOI 10.1096/fj.01-0132com
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   BONFA E, 1993, J IMMUNOL, V150, P3917
   Bonney KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014571
   BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679
   Britto C, 1995, EXP PARASITOL, V81, P462, DOI 10.1006/expr.1995.1139
   CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734
   Camargo MM, 1997, J IMMUNOL, V158, P5890
   Albareda MC, 2009, J IMMUNOL, V183, P4103, DOI 10.4049/jimmunol.0900852
   CETRON MS, 1992, ACTA TROP, V50, P259, DOI 10.1016/0001-706X(92)90082-9
   CHAMBO JG, 1990, EXPERIENTIA, V46, P977, DOI 10.1007/BF01939394
   COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13
   Costa RP, 2000, SCAND J IMMUNOL, V51, P511, DOI 10.1046/j.1365-3083.2000.00706.x
   CREMASCHI G, 1995, FASEB J, V9, P1482
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E., 1998, MEM I O CRUZ S1, V93, P40
   Cunha-Neto E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000900032
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   de Araujo FF, 2011, HUM PATHOL, V42, P299, DOI 10.1016/j.humpath.2010.10.002
   deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   el-Zayadi A R, 1998, Trop Gastroenterol, V19, P141
   Elias FE, 2003, AM J TROP MED HYG, V68, P242, DOI 10.4269/ajtmh.2003.68.242
   FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   GATTASS CR, 1988, INFECT IMMUN, V56, P1402, DOI 10.1128/IAI.56.5.1402-1405.1988
   GEA S, 1993, AM J TROP MED HYG, V49, P581, DOI 10.4269/ajtmh.1993.49.581
   Giordanengo L, 2000, MUSCLE NERVE, V23, P1407, DOI 10.1002/1097-4598(200009)23:9<1407::AID-MUS12>3.0.CO;2-3
   Giordanengo L, 2000, EUR J IMMUNOL, V30, P3181, DOI 10.1002/1521-4141(200011)30:11&lt;3181::AID-IMMU3181&gt;3.0.CO;2-A
   Giordanengo L, 2002, EUR J IMMUNOL, V32, P1003, DOI 10.1002/1521-4141(200204)32:4<1003::AID-IMMU1003>3.0.CO;2-P
   Giordanengo L, 2001, CLIN EXP IMMUNOL, V124, P266, DOI 10.1046/j.1365-2249.2001.01512.x
   Girones N, 2001, J CLIN INVEST, V107, P985, DOI 10.1172/JCI10734
   Girones N, 2001, CLIN DIAGN LAB IMMUN, V8, P1039, DOI 10.1128/CDLI.8.6.1039-1043.2001
   GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7
   GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244
   Goin JC, 1997, FASEB J, V11, P77
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   Ribeiro CH, 2009, MOL IMMUNOL, V46, P1092, DOI 10.1016/j.molimm.2008.10.034
   HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343
   HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6
   Hernandez CCQ, 2003, CARDIOVASC RES, V58, P55, DOI 10.1016/S0008-6363(02)00811-8
   HERNANDEZMUNAIN C, 1992, J EXP MED, V175, P1473, DOI 10.1084/jem.175.6.1473
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   HONTEBEYRIEJOSKOWICZ M, 1987, EUR J IMMUNOL, V17, P1027, DOI 10.1002/eji.1830170720
   Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006
   Iwai LK, 2001, PEPTIDES, V22, P853, DOI 10.1016/S0196-9781(01)00409-0
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301
   KERNER N, 1991, EXP PARASITOL, V73, P451, DOI 10.1016/0014-4894(91)90069-9
   KHOURY EL, 1983, CLIN IMMUNOL IMMUNOP, V27, P283, DOI 10.1016/0090-1229(83)90078-8
   Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8
   LAGUENS RP, 1981, MEDICINA-BUENOS AIRE, V41, P40
   Laucella SA, 1996, ACTA TROP, V61, P223, DOI 10.1016/0001-706X(96)00004-6
   Laucella SA, 1996, ACTA TROP, V62, P151, DOI 10.1016/S0001-706X(96)00032-0
   Leiros CP, 1997, J BIOL CHEM, V272, P12989, DOI 10.1074/jbc.272.20.12989
   Leon JS, 2004, INFECT IMMUN, V72, P3410, DOI 10.1128/IAI.72.6.3410-3417.2004
   Leon JS, 2003, J IMMUNOL, V171, P4271, DOI 10.4049/jimmunol.171.8.4271
   Leon JS, 2001, INFECT IMMUN, V69, P5643, DOI 10.1128/IAI.69.9.5643-5649.2001
   LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530
   LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x
   LIAO L, 1993, J CLIN INVEST, V92, P2877, DOI 10.1172/JCI116909
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   MARTIN UO, 1987, MEDICINA-BUENOS AIRE, V47, P159
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Masuda MO, 1998, FASEB J, V12, P1551
   MCCORMICK TS, 1989, EXP PARASITOL, V69, P393, DOI 10.1016/0014-4894(89)90088-X
   Mengel J., 1998, MEM I OSWALDO CRU S1, V93, P28
   Mijares A, 1996, MOL CELL BIOCHEM, V164, P107, DOI 10.1007/BF00408646
   MILEI J, 1992, CARDIOLOGY, V80, P424, DOI 10.1159/000175035
   MINOPRIO P, 1988, SCAND J IMMUNOL, V28, P553, DOI 10.1111/j.1365-3083.1988.tb01487.x
   Minoprio P, 2001, INT J PARASITOL, V31, P588, DOI 10.1016/S0020-7519(01)00171-0
   Motran CC, 1998, EXP PARASITOL, V88, P223, DOI 10.1006/expr.1998.4255
   NEU N, 1987, CLIN EXP IMMUNOL, V69, P566
   NEU N, 1990, J IMMUNOL, V145, P4094
   NEU N, 1987, J IMMUNOL, V139, P3630
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   Oliveira EC, 2009, NEUROIMMUNOMODULAT, V16, P54, DOI 10.1159/000179667
   Oliveira MF, 2001, PARASITOL RES, V87, P1043
   Palomino SAP, 2000, ANN TROP MED PARASIT, V94, P571, DOI 10.1080/00034983.2000.11813580
   Pereira J B, 1992, Rev Soc Bras Med Trop, V25, P101, DOI 10.1590/S0037-86821992000200003
   PETRY K, 1987, ACTA TROP, V44, P381
   Petry K, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P498, DOI 10.1590/S0074-02761988000500057
   PETRY K, 1988, MOL BIOCHEM PARASIT, V30, P113, DOI 10.1016/0166-6851(88)90104-1
   PETRY K, 1987, J NEUROIMMUNOL, V16, P237, DOI 10.1016/0165-5728(87)90078-6
   PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5
   Ribeiro ALP, 2007, INT J CARDIOL, V117, P59, DOI 10.1016/j.ijcard.2006.04.053
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   Ramasawmy R, 2008, CLIN VACCINE IMMUNOL, V15, P932, DOI 10.1128/CVI.00324-07
   Ramasawmy R, 2009, J INFECT DIS, V199, P1838, DOI 10.1086/599212
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Riarte A, 1999, CLIN INFECT DIS, V29, P561, DOI 10.1086/598634
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Ribeiro-Dos-Santos R, 2001, PARASITE IMMUNOL, V23, P93, DOI 10.1046/j.1365-3024.2001.00368.x
   RIBEIRODOSSANTOS R, 1979, TROPENMED PARASITOL, V30, P19
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   RUIZ AM, 1985, ACTA TROP, V42, P299
   SANTOSBU.CA, 1974, J EXP MED, V140, P38, DOI 10.1084/jem.140.1.38
   SANTOSBUCH CA, 1985, CLIN IMMUNOL IMMUNOP, V37, P334, DOI 10.1016/0090-1229(85)90103-5
   Sartori AMC, 1998, CLIN INFECT DIS, V26, P177, DOI 10.1086/516257
   SilvaBarbosa SD, 1997, J IMMUNOL, V159, P997
   SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131
   SMITH SC, 1991, J IMMUNOL, V147, P2141
   SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617
   Sterin-Borda L, 2001, GUT, V49, P699, DOI 10.1136/gut.49.5.699
   STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932
   TEIXEIRA ARL, 1975, IMMUNOLOGY, V28, P401
   TEIXEIRA ARL, 1978, AM J TROP MED HYG, V27, P1097, DOI 10.4269/ajtmh.1978.27.1097
   TERNYNCK T, 1990, J IMMUNOL, V144, P1504
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   Torres C.M., 1929, 5 REUN SOC ARG PAT R, P902
   VANVOORHIS WC, 1989, J EXP MED, V169, P641, DOI 10.1084/jem.169.3.641
   VANVOORHIS WC, 1993, J EXP MED, V178, P681, DOI 10.1084/jem.178.2.681
   VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993
   VASHISHTHA A, 1993, J IMMUNOL, V150, P4693
   VAZQUEZ MC, 1993, TRANSPL P, V25, P3259
   Vazquez MC, 1996, TRANSPL P, V28, P3301
   VEGA MTDL, 1976, J PARASITOL, V62, P129, DOI 10.2307/3279068
   Vermelho AB, 1997, ACTA TROP, V64, P131, DOI 10.1016/S0001-706X(96)00627-4
   Wallukat G, 2010, J AM COLL CARDIOL, V55, P463, DOI 10.1016/j.jacc.2009.06.064
   WOOD JN, 1982, NATURE, V296, P34, DOI 10.1038/296034a0
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
   ZWIRNER NW, 1994, INFECT IMMUN, V62, P2483, DOI 10.1128/IAI.62.6.2483-2489.1994
NR 158
TC 37
Z9 37
U1 0
U2 9
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-308X
BN 978-0-12-385895-5
J9 ADV PARASIT
JI Adv.Parasitol.
PY 2011
VL 76
BP 129
EP 152
DI 10.1016/B978-0-12-385895-5.00006-2
PG 24
WC Parasitology
SC Parasitology
GA BYT75
UT WOS:000300197700007
PM 21884890
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Teixeira, PC
   Fonseca, SG
   Bilate, AM
   Kalil, J
AF Cunha-Neto, Edecio
   Teixeira, Priscila C.
   Fonseca, Simone G.
   Bilate, Angelina M.
   Kalil, Jorge
TI Myocardial gene and protein expression profiles after autoimmune injury
   in Chagas' disease cardiomyopathy
SO AUTOIMMUNITY REVIEWS
LA English
DT Review
DE Chagas disease cardiomyopathy; Autoimmunity; Crossreactive T cells;
   Inflammatory cytokines; Proteomic analysis; Gene expression
ID TRYPANOSOMA-CRUZI ANTIGEN; HEART-DISEASE; T-CELLS; CARDIAC MYOSIN;
   DILATED CARDIOMYOPATHY; MOLECULAR MIMICRY; IMMUNE-RESPONSE;
   IDENTIFICATION; CYTOKINES; SURVIVAL
AB One third of the 16 million of individuals infected by the protozoan Trypanosoma cruzi in Latin America eventually develop chronic Chagas' disease cardiomyopathy (CCC), an inflammatory dilated cardiomyopathy with shorter survival than non-inflammatory cardiomyopathies. The presence of a T cell-rich mononuclear inflammatory infiltrate and the relative scarcity of parasites in the heart suggested that chronic inflammation secondary to the autoimmune recognition of cardiac proteins could be a major pathogenetic mechanism. Sera from CCC patients crossreactively recognize cardiac myosin and T. cruzi protein B13. T cell clones elicited from peripheral blood with T. cruzi B13 protein or its peptides could crossreactively recognize epitopes from cardiac myosin heavy chain. Likewise, CD4+ T cell clones infiltrating CCC myocardium crossreactively recognize cardiac myosin and T. cruzi protein B13, and intralesional T cell lines produce the inflammatory cytokines IFN-gamma and TNF-alpha. Conversely, IFN-gamma-induced genes and chemokines were found to be upregulated in CCC heart samples, and IFN-gamma is able to induce cardiomyocyte expression of atrial natriuretic factor, a key member of the hypertrophy/heart failure signature. Proteomic analysis of CCC heart tissue showed reduced expression of the energy metabolism enzymes. It can be hypothesized that cytokine-induced modulation of cardiomyocyte gene/protein expression may be a novel disease mechanism in CCC, in addition to direct inflammatory damage. (C) 2010 Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Inst Nacl Ciencia & Tecnol, Inst Invest Immunol, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
EM edecunha@usp.br
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; FONSECA,
   SIMONE GONCALVES/U-9278-2019; Teixeira, Priscila C/D-7426-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bilate AMB, 2007, MICROBES INFECT, V9, P1104, DOI 10.1016/j.micinf.2007.05.014
   Bocchi E A, 1994, Arq Bras Cardiol, V63, P523
   Cunha-Neto E, 2006, AUTOIMMUNITY, V39, P41, DOI 10.1080/08916930500485002
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   KALOVIDOURIS AE, 1993, J RHEUMATOL, V20, P1718
   Leon JS, 2001, INFECT IMMUN, V69, P5643, DOI 10.1128/IAI.69.9.5643-5649.2001
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   Teixeira PC, 2006, BRAZ J MED BIOL RES, V39, P1549, DOI 10.1590/S0100-879X2006005000050
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   Wang DC, 1996, LAB INVEST, V75, P809
NR 30
TC 21
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-9972
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD JAN
PY 2011
VL 10
IS 3
BP 163
EP 165
DI 10.1016/j.autrev.2010.09.019
PG 3
WC Immunology
SC Immunology
GA 722KY
UT WOS:000287432300008
PM 20883825
DA 2020-11-26
ER

PT J
AU Gomieiro, LTY
   Nascimento, A
   Tanno, LK
   Agondi, R
   Kalil, J
   Giavina-Bianchi, P
AF Yazbek Gomieiro, Ludmila Tais
   Nascimento, Andreia
   Tanno, Luciana Kase
   Agondi, Rosana
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Respiratory exercise program for elderly individuals with asthma
SO CLINICS
LA English
DT Article
DE Asthma; Respiratory exercise program; Maximum inspiratory pressure;
   Maximum expiratory pressure; Respiratory training program
ID ADAPTATIONS
AB INTRODUCTION: Asthma in older adults is frequently underdiagnosed, as reflected by approximately 60% of asthma deaths occurring in people older than age 65.
   OBJECTIVE: The present study evaluates the effects of a respiratory exercise program tailored for elderly individuals with asthma. We are not aware of any other reports examining breathing exercises in this population.
   METHODS: Fourteen patients concluded the 16-week respiratory exercise program. All the patients were evaluated with regard to lung function, respiratory muscle strength, aerobic capacity, quality of life and clinical presentation.
   RESULTS: After 16 weeks of this open-trial intervention, significant increases in maximum inspiratory pressure and maximum expiratory pressure (27.6% and 20.54%, respectively) were demonstrated. Considerable improvement in quality of life was also observed. The clinical evaluations and daily recorded-symptoms diary also indicated significant improvements and fewer respiratory symptoms. A month after the exercises were discontinued, however, detraining was observed.
   DISCUSSION: In conclusion, a respiratory exercise program increased muscle strength and was associated with a positive effect on patient health and quality of life. Therefore, a respiratory training program could be included in the therapeutic approach in older adults with asthma.
C1 [Yazbek Gomieiro, Ludmila Tais; Tanno, Luciana Kase; Agondi, Rosana; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Nascimento, Andreia] Hosp Alemao Oswaldo Cruz, Inst Educ & Sci, Hlth Technol Assessment Unit, Sao Paulo, Brazil.
RP Gomieiro, LTY (corresponding author), Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; Tanno, Luciana Kase/J-9981-2014;
   KALIL, JORGE/C-8029-2012; Nascimento, Andreia/H-3564-2012; Yazbek,
   Guilherme/H-6378-2015
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; Tanno, Luciana
   Kase/0000-0003-3236-1225; KALIL, JORGE/0000-0001-8415-4274; Nascimento,
   Andreia/0000-0002-4746-3200; 
CR Asher MI, 1998, EUR RESPIR J, V12, P315
   BANERJEE DK, 1987, BRIT J DIS CHEST, V81, P23, DOI 10.1016/0007-0971(87)90104-5
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   Braman SS, 2007, CLIN CHEST MED, V28, P685, DOI 10.1016/j.ccm.2007.08.007
   BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336
   Bruton A, 2006, THORAX, V61, P643, DOI 10.1136/thx.2005.057422
   Choy DKL, 2002, CLIN EXP ALLERGY, V32, P702, DOI 10.1046/j.1365-2222.2002.01395.x
   CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410
   Cress ME, 2004, MED SCI SPORT EXER, V36, P1997, DOI 10.1249/01.MSS.0000145451.08166.97
   DECRAMER M, 1989, EUR RESPIR J, V2, P299
   Enoka RM, 1997, J BIOMECH, V30, P447, DOI 10.1016/S0021-9290(96)00170-4
   FERNANDES ALG, 1997, J PNEUMOL, V23, P148
   Giavina-Bianchi P, 2010, CLINICS, V65, P905, DOI 10.1590/S1807-59322010000900014
   Jack CIA, 1996, GERONTOLOGY, V42, P61, DOI 10.1159/000213774
   LEE HY, 1972, BMJ-BRIT MED J, V4, P93, DOI 10.1136/bmj.4.5832.93
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   MORITANI T, 1979, AM J PHYS MED REHAB, V58, P115
   Mujika I, 2000, SPORTS MED, V30, P79, DOI 10.2165/00007256-200030020-00002
   Pearson MG, 2007, THORAX, V62, P1033, DOI 10.1136/thx.2007.084707
   RAM FSP, 2008, CHOCHRANE LIB
   SALE DG, 1988, MED SCI SPORT EXER, V20, pS135, DOI 10.1249/00005768-198810001-00009
   STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693
   STRUNK RC, 1991, J ALLERGY CLIN IMMUN, V87, P601, DOI 10.1016/0091-6749(91)90374-W
   Veiga J, 2009, CLINICS, V64, P649, DOI 10.1590/S1807-59322009000700008
   WEINER P, 1992, CHEST, V102, P1357, DOI 10.1378/chest.102.5.1357
NR 25
TC 17
Z9 19
U1 0
U2 13
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 7
BP 1165
EP 1169
DI 10.1590/S1807-59322011000700007
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 814GQ
UT WOS:000294436800007
PM 21876968
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Rego, FXM
   Giavina-Bianchi, P
   Kalil, J
   Arruda, LK
   Toledo-Barros, M
AF Rego, Francisca X. M.
   Giavina-Bianchi, Pedro
   Kalil, Jorge
   Arruda, L. Karla
   Toledo-Barros, Myrthes
TI The hammock: a reservoir of allergens
SO CLINICS
LA English
DT Article
DE Asthma; Mite allergens; Cockroach allergens; Exposure; Sensitization;
   Skin tests; Allergen levels; Home dust; Hammock; Environmental control
ID INNER-CITY CHILDREN; DUST-MITE ALLERGEN; COCKROACH ALLERGENS;
   DERMATOPHAGOIDES-PTERONYSSINUS; BLOMIA-TROPICALIS; TEST REACTIVITY;
   MAJOR ALLERGEN; ASTHMA; IDENTIFICATION; SENSITIZATION
AB INTRODUCTION: Asthma affects approximately 10% of the world's population. Sensitization to allergens is an important risk factor, and exposure to allergens is associated with disease severity. \ METHODS: We performed skin tests to evaluate allergen sensitization to mites, cockroaches, cats, dogs, and molds in 73 asthmatic patients. Enzyme Linked Immunosorbent Assay was used to assay the mite and cockroach allergens found in dust from the bedding, hammocks, bedroom floors, living rooms, and kitchens of 29 patients and 14 controls.
   RESULTS: Fifty patients (68.5%) had positive skin test responses. There were positive responses to D. pteronyssinus (52.0%), B. tropicalis (53.4%), T. putrescentiae (15.0%), E. maynei (12.3%), L. destructor (8.2%), B. germanica (20.5%), P. americana (21.9%), Felis catus (10.9%), C. herbarium (2.7%), A. alternata (4.1%), and P. notatun (1.3%). The exposure to mite and cockroach allergens was similar in the patients and the controls. The Dermatophagoides pteronyssinus Group 1 levels were highest in the beds and hammocks. The Blattella germanica Group 1 levels were highest in the kitchens, living rooms and hammocks.
   DISCUSSION: The positive skin tests to mites, cockroaches and cats were consistent with previous studies. D pteronyssinus was the most prevalent home dust mite, and hammocks were a source of allergens. To improve asthma prophylaxis, it is important to determine its association with mite allergen exposure in hammocks.
C1 [Rego, Francisca X. M.; Giavina-Bianchi, Pedro; Kalil, Jorge; Toledo-Barros, Myrthes] Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Arruda, L. Karla] Univ Sao Paulo, Sch Med Ribeirao Preto, Clin Immunol & Allergy Div, BR-14049 Ribeirao Preto, SP, Brazil.
RP Rego, FXM (corresponding author), Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Arruda, L. Karla/D-5845-2013; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Arruda, L. Karla/0000-0002-7505-210X;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
CR Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7
   Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670
   Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334
   Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854
   Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb04579.x
   BERND LAG, 1994, REV BRAS ALERG IMUNO, V17, P23
   Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832
   Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x
   Chew GL, 2009, INDOOR AIR, V19, P193, DOI 10.1111/j.1600-0668.2008.00578.x
   DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x
   Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6
   FELD L, 2001, REV BRAS ALERG IMUNO, V24, P54
   Filho NAR, 1999, REV BRAS ALERG IMUNO, V22, P151
   GIAVINABIANCHI P, 1996, ARCH ARGENT INMUNOL, V27, P12
   Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079
   LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0
   Medeiros M, 1997, REV BRAS ALERG IMUNO, V20, P143
   MOREIRA MR, 2001, REV BRAS ALERGIA IMU, V24, P11
   Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6
   POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L
   Rizzo M C, 1995, J Pediatr (Rio J), V71, P31
   Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904
   Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1
   SARINHO E, 1996, REV BRAS ALERG IMUNO, V19, P228
   Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2
   Serravalle K., 1998, REV BRAS ALERG IMUNO, V22, P19
   Sopelete MC, 2000, INT ARCH ALLERGY IMM, V122, P257, DOI 10.1159/000024407
   SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590
   Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026
   STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259
   TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630
NR 31
TC 1
Z9 1
U1 0
U2 3
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 7
BP 1199
EP 1202
DI 10.1590/S1807-59322011000700013
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 814GQ
UT WOS:000294436800013
PM 21876974
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Trotta, MBF
   Azul, JBS
   Wajngarten, M
   Fonseca, SG
   Goldberg, AC
   Kalil, JE
AF Trotta, Maria B. F.
   Serro Azul, Joao B.
   Wajngarten, Mauricio
   Fonseca, Simone G.
   Goldberg, Anna C.
   Kalil, Jorge E.
TI Inflammatory and Immunological parameters in adults with Down syndrome
SO IMMUNITY & AGEING
LA English
DT Article
AB Background: The increase in life expectancy within the general population has resulted in an increasing number of elderly adults, including patients with Down syndrome (DS), with a current life expectancy of about 50 years. We evaluate the parameters of humoral and cellular immune response, the quantitative expression of the regulator of calcineurin1 gene (RCAN1) and the production of cytokines. The study group consisted of adults DS (n = 24) and a control group with intellectual disability without Down syndrome (ID) (n = 21) and living in a similar environmental background. It was evaluated serology, immunophenotyping, the quantitative gene expression of RCAN1 and the production of cytokines.
   Results: In the DS group, the results showed an increase in NK cells, CD8, decreased CD19 (p < 0.05) and an increase spontaneous production of IFNgamma, TNFalpha and IL-10 (p < 0.05). There was not any difference in RCAN1 gene expression between the groups.
   Conclusions: These data suggest a similar humoral response in the two groups. The immunophenotyping suggests sign of premature aging of the immune system and the cytokine production show a proinflammatory profile.
C1 [Trotta, Maria B. F.; Serro Azul, Joao B.; Wajngarten, Mauricio; Fonseca, Simone G.; Kalil, Jorge E.] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   [Goldberg, Anna C.] Albert Einstein Hosp, Sao Paulo, Brazil.
RP Trotta, MBF (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
EM mbfortunato1@hotmail.com
RI FONSECA, SIMONE GONCALVES/U-9278-2019; KALIL, JORGE/C-8029-2012;
   Goldberg, Anna Carla/H-8594-2014; Wajngarten, Mauricio/G-3702-2012
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; 
CR BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
   BURGIO GR, 1975, EUR J IMMUNOL, V5, P600, DOI 10.1002/eji.1830050904
   Corsi MM, 2003, INT J TISSUE REACT, V25, P117
   COSSARIZZA A, 1990, AM J MED GENET, P213
   Costa-Carvalho BT, 2006, BRAZ J MED BIOL RES, V39, P1587, DOI 10.1590/S0100-879X2006005000047
   Cuadrado E, 1996, CLIN IMMUNOL IMMUNOP, V78, P209, DOI 10.1006/clin.1996.0031
   do Canto C L, 2000, Rev Inst Med Trop Sao Paulo, V42, P179, DOI 10.1590/S0036-46652000000400001
   Dogliotti Giada, 2010, Immun Ageing, V7, P2, DOI 10.1186/1742-4933-7-2
   Elsayed Solaf M, 2009, Immun Ageing, V6, P2, DOI 10.1186/1742-4933-6-2
   Epstein L B, 1987, Prog Clin Biol Res, V246, P163
   Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200
   Ewart J L, 1992, Dev Immunol, V2, P215, DOI 10.1155/1992/72627
   Ferreira CT, 2004, J PEDIATR GASTR NUTR, V39, P337, DOI 10.1097/00005176-200410000-00007
   Franceschi C, 2003, BIOCHEM SOC T, V31, P457, DOI 10.1042/BST0310457
   Franciotta D, 2006, NEUROSCI LETT, V395, P67, DOI 10.1016/j.neulet.2005.10.048
   FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686
   Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681
   Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866
   Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4
   Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2
   HAWKES RA, 1978, CLIN EXP IMMUNOL, V31, P298
   Iizuka M, 2004, J VASC RES, V41, P334, DOI 10.1159/000079832
   Kaszubowska L, 2008, J PHYSIOL PHARMACOL, V59, P169
   Kim YS, 2006, J BIOL CHEM, V281, P39051, DOI 10.1074/jbc.M604659200
   Licastro F, 2006, INT J IMMUNOPATH PH, V19, P181
   Licastro F, 2005, INT J IMMUNOPATH PH, V18, P165, DOI 10.1177/039463200501800117
   Licastro F, 2001, BRAIN RES BULL, V55, P313, DOI 10.1016/S0361-9230(01)00476-2
   Licastro F, 2006, ARCH GERONTOL GERIAT, V43, P381, DOI 10.1016/j.archger.2006.01.003
   Lio D, 2004, J MED GENET, V41, P790, DOI 10.1136/jmg.2004.019885
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LiVolti S, 1996, CHILD NERV SYST, V12, P100, DOI 10.1007/BF00819505
   Martin GM, 2005, CELL, V120, P523, DOI 10.1016/j.cell.2005.01.031
   MCKAY E, 1978, J HYG-CAMBRIDGE, V81, P25, DOI 10.1017/S0022172400053730
   MURDOCH JC, 1977, BRIT MED J, V2, P226, DOI 10.1136/bmj.2.6081.226
   MURPHY M, 1992, J IMMUNOL, V149, P2506
   Murphy M, 1995, Prog Clin Biol Res, V393, P147
   MURPHY M, 1990, AM J MED GENET, P234
   Patterson D, 2009, HUM GENET, V126, P195, DOI 10.1007/s00439-009-0696-8
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PHILIP R, 1986, J IMMUNOL, V136, P1661
   ROBERTST.IC, 1974, LANCET, V2, P368
   SANSONI P, 1993, BLOOD, V82, P2767
   Saran NG, 2003, HUM MOL GENET, V12, P2013, DOI 10.1093/hmg/ddg217
   SEGER R, 1977, EUR J PEDIATR, V124, P77, DOI 10.1007/BF00477543
   Shapiro BL, 2001, J NEURAL TRANSM-SUPP, P11
   TROISI CL, 1985, JAMA-J AM MED ASSOC, V254, P3196, DOI 10.1001/jama.254.22.3196
   UGAZIO AG, 1990, AM J MED GENET, P204
   VAZIRI H, 1993, AM J HUM GENET, V52, P661
   Yahya-Graison EA, 2007, AM J HUM GENET, V81, P475, DOI 10.1086/520000
   Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61
   Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3
   Yasui K, 1999, AM J MED GENET, V84, P406, DOI 10.1002/(SICI)1096-8628(19990611)84:5<406::AID-AJMG4>3.0.CO;2-4
   YLAHERTTUALA S, 1989, ATHEROSCLEROSIS, V76, P269, DOI 10.1016/0021-9150(89)90110-X
NR 54
TC 24
Z9 24
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PY 2011
VL 8
AR 4
DI 10.1186/1742-4933-8-4
PG 7
WC Geriatrics & Gerontology; Immunology
SC Geriatrics & Gerontology; Immunology
GA V30IM
UT WOS:000208809700004
PM 21496308
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Pomiecinski, F
   Yang, AC
   Navarro-Rodrigues, T
   Kalil, J
   Castro, FFM
AF Pomiecinski, Fabiane
   Yang, Ariana Campos
   Navarro-Rodrigues, Thomas
   Kalil, Jorge
   Morato Castro, Fabio Fernandes
TI Sensitization to foods in gastroesophageal reflux disease and its
   relation to eosinophils in the esophagus: is it of clinical importance?
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Article
ID PATCH TESTS; ALLERGY; EPIDEMIOLOGY; DISORDERS; FEATURES
AB Background: Refractory gastroesophageal reflux disease (GERD) can be related to greater sensitization to foods.
   Objective: To evaluate sensitization to foods in patients with refractory GERD.
   Methods: Patients with refractory GERD after using at least 40 mg of a proton pump inhibitor were given a restriction diet based on the results of skin prick testing and atopy patch testing with foods. The characteristics of sensitized patients were compared with those of nonsensitized patients in relation to atopy and number of eosinophils in the esophageal mucosa.
   Results: The prevalence of sensitization to foods was 27.7%. Asthmatic patients showed higher sensitization to foods (P = .008). Eosinophils were determined to be present in the esophageal mucosa in 15.8% of patients, and this correlated with greater sensitization to foods (P = .01). One case of eosinophilic esophagitis was confirmed. A diet excluding identified sensitizing foods led to clinical improvement regarding GERD symptoms (P = .004).
   Conclusion: The presence of eosinophils in esophageal mucosa associated with greater sensitization to foods and the response to a restriction diet in patients with positive test results suggest that refractory GERD can represent an initial stage of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2010;105:359-363.
C1 [Pomiecinski, Fabiane] Univ Fortaleza, Sch Med, BR-60811690 Fortaleza, Ceara, Brazil.
   [Pomiecinski, Fabiane; Yang, Ariana Campos; Kalil, Jorge; Morato Castro, Fabio Fernandes] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Navarro-Rodrigues, Thomas] Univ Sao Paulo, Sch Med, Div Gastroenterol, Sao Paulo, Brazil.
RP Pomiecinski, F (corresponding author), Univ Fortaleza, Sch Med, R Desembargador Floriano Benevides 221, BR-60811690 Fortaleza, Ceara, Brazil.
EM fabiane2212@yahoo.com.br
RI Castro, Fabio FM/C-1082-2017; Rodriguez, TOMAS NAVARRO/I-3170-2012;
   KALIL, JORGE/C-8029-2012; Castro, Fabio/AAP-5433-2020
OI Castro, Fabio FM/0000-0002-6211-5773; Rodriguez, TOMAS
   NAVARRO/0000-0002-3458-699X; KALIL, JORGE/0000-0001-8415-4274; 
FU NovartisNovartis; AstraZenecaAstraZeneca; MSD;
   Sanofi-AventisSanofi-Aventis; Boeringher; Ache
FX Dr. Morato Castro has received research support from Novartis,
   AstraZeneca, MSD, Sanofi-Aventis, Boeringher, and Ache and has consulted
   for Sanofi-Aventis, Schering-Plough, and Phadia Brazil. Dr. Kalil is a
   member of the Council for EMS. Drs. Pomiecinski, Campos Yang, and
   Navarro-Rodrigues have nothing to disclose.
CR Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016
   Croese J, 2003, GASTROINTEST ENDOSC, V58, P516, DOI 10.1067/S0016-5107(03)01870-4
   Fass R, 2005, ALIMENT PHARM THER, V22, P79, DOI 10.1111/j.1365-2036.2005.02531.x
   Fornari Fernando, 2004, Arq. Gastroenterol., V41, P263, DOI 10.1590/S0004-28032004000400012
   Foroutan M, 2010, DIGEST DIS SCI, V55, P28, DOI 10.1007/s10620-008-0706-z
   FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013
   Richter JE, 2007, NAT CLIN PRACT GASTR, V4, P658, DOI 10.1038/ncpgasthep0979
   Roberts Graham, 2003, Paediatr Respir Rev, V4, P205, DOI 10.1016/S1526-0542(03)00058-7
   Rolland AMGASAS, 2004, J PEDIATR GASTR NUTR, V39, P373, DOI 10.1097/00005176-200410000-00013
   Ronchetti R, 2008, PEDIAT ALLERG IMM-UK, V19, P599, DOI 10.1111/j.1399-3038.2007.00712.x
   Rothenberg MA, 2001, J ALLERGY CLIN IMMUN, V108, P891, DOI 10.1067/mai.2001.120095
   Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047
   Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2
   Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014
   Sgouros SN, 2006, DIGESTION, V73, P218, DOI 10.1159/000094789
   Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028
   Spechler SJ, 2007, AM J GASTROENTEROL, V102, P1301, DOI 10.1111/j.1572-0241.2007.01179.x
   Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9
   Steiner SJ, 2004, AM J GASTROENTEROL, V99, P801, DOI 10.1111/j.1572-0241.2004.04170.x
   Tobey NA, 1996, GASTROENTEROLOGY, V111, P1200, DOI 10.1053/gast.1996.v111.pm8898633
   Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x
   Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]
   Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025
NR 23
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
EI 1534-4436
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD NOV
PY 2010
VL 105
IS 5
BP 359
EP 363
DI 10.1016/j.anai.2010.08.021
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA 701PO
UT WOS:000285834000007
PM 21055661
DA 2020-11-26
ER

PT J
AU Lima, CMF
   Schroeder, JT
   Galvao, CES
   Castro, FM
   Kalil, J
   Adkinson, NF
AF Lima, C. M. F.
   Schroeder, J. T.
   Galvao, C. E. S.
   Castro, F. M.
   Kalil, J.
   Adkinson, N. F., Jr.
TI Functional changes of dendritic cells in hypersensitivity reactions to
   amoxicillin
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Dendritic cells; beta-lactam hypersensitivity; Plasmacytoid dendritic
   cells; Drug allergy
ID T-CELLS; HISTAMINE-RELEASE; SECRETION; RESPONSES
AB A better understanding of dendritic cell (DC) involvement in responses to haptenic drugs is needed, because it represents a possible approach to the development of an in vitro test, which could identify patients prone to drug allergies. There are two main DC subsets: plasmacytoid DC (pDC) and myeloid DC (mDC). beta-lactams form hapten-carrier conjugates and may provide a suitable model to study DC behavior in drug allergy reactions. It has been demonstrated that drugs interact differently with DC in drug allergic and non-allergic patients, but there are no studies regarding these subsets. Our aim was to assess the functional changes of mDC and pDC harvested from an amoxicillin-hypersensitive 32-year-old woman who experienced a severe maculopapular exanthema as reflected in interleukin-6 (IL-6) production after stimulation with this drug and penicillin. We also aim to demonstrate, for the first time, the feasibility of this method for dendritic cell isolation followed by in vitro stimulation for studies of drug allergy physiopathology. DC were harvested using a double Percoll density gradient, which generates a basophil-depleted cell (BDC) suspension. Further, pDC were isolated by blood DC antigen 4-positive magnetic selection and gravity filtration through magnetized columns. After stimulation with amoxicillin, penicillin and positive and negative controls, IL-6 production was measured by ELISA. A positive dose-response curve for IL-6 after stimulation with amoxicillin and penicillin was observed for pDC, but not for mDC or BDC suspension. These preliminary results demonstrate the feasibility of this methodology to expand the knowledge of the effect of dendritic cell activation by drug allergens.
C1 [Lima, C. M. F.; Schroeder, J. T.; Adkinson, N. F., Jr.] Johns Hopkins Univ, Dept Med, Div Allergy & Immunol, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA.
   [Galvao, C. E. S.; Castro, F. M.; Kalil, J.] Univ Sao Paulo, Dept Alergia & Imunol Clin, Hosp Clin, Sao Paulo, Brazil.
RP Lima, CMF (corresponding author), Rua Padre Machado 96,Apto 52, BR-04127000 Sao Paulo, Brazil.
EM mafracynthia@hotmail.com
RI KALIL, JORGE/C-8029-2012; Castro, Fabio FM/C-1082-2017; Castro,
   Fabio/AAP-5433-2020
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773; 
CR Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030
   Aubert N, 2004, ALLERGY, V59, P1022, DOI 10.1111/j.1398-9995.2004.00486.x
   Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027
   Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037
   Le T, 2009, J ALLERGY CLIN IMMUN, V123, P217, DOI 10.1016/j.jaci.2008.09.013
   Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633
   Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0
   Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047
   Piqueras B, 2006, BLOOD, V107, P2613, DOI 10.1182/blood-2005-07-2965
   Rodriguez-Pena R, 2006, J ALLERGY CLIN IMMUN, V118, P949, DOI 10.1016/j.jaci.2006.07.013
   Sanderson JP, 2007, J IMMUNOL, V178, P5533, DOI 10.4049/jimmunol.178.9.5533
   Schnyder B, 2000, CLIN EXP ALLERGY, V30, P590
   Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724
   SCHROEDER JT, 1994, J IMMUNOL, V153, P1808
   Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C
NR 15
TC 3
Z9 3
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD OCT
PY 2010
VL 43
IS 10
BP 964
EP 968
DI 10.1590/S0100-879X2010007500096
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 668JB
UT WOS:000283263500007
PM 20878012
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Bisaccioni, C
   Agondi, R
   Kalil, J
AF Giavina-Bianchi, Pedro
   Aun, Marcelo Vivolo
   Bisaccioni, Carla
   Agondi, Rosana
   Kalil, Jorge
TI Difficult-to-control asthma management through the use of a specific
   protocol
SO CLINICS
LA English
DT Review
DE Difficult-to-control; Asthma; difficult-to-treat; Asthma; severe asthma;
   Resistant asthma; Protocol; Management
ID CHURG-STRAUSS-SYNDROME; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS;
   VOCAL-CORD DYSFUNCTION; QUALITY-OF-LIFE; ANTI-IGE;
   GASTROESOPHAGEAL-REFLUX; BRONCHIAL HYPERRESPONSIVENESS; NEUTROPHILIC
   INFLAMMATION; INHALED CORTICOSTEROIDS; ESOPHAGEAL CANDIDIASIS
AB The present study is a critical review of difficult-to-control asthma, highlighting the characteristics and severity of the disease. It also presents a protocol for the management of patients with this asthma phenotype. The protocol, which was based on relevant studies in the literature, is described and analyzed.
C1 [Giavina-Bianchi, Pedro; Aun, Marcelo Vivolo; Bisaccioni, Carla; Agondi, Rosana; Kalil, Jorge] Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Fac Med, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
EM saudesos@terra.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; Aun, Marcelo V/E-6775-2014; KALIL,
   JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; Aun, Marcelo
   V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
CR Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903
   Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489
   Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347
   Agondi RC, 2010, ALLERGY, V65, P510, DOI 10.1111/j.1398-9995.2009.02211.x
   Agondi RC, 2008, J ASTHMA, V45, P754, DOI 10.1080/02770900802249149
   Almeida Marina B., 2006, J. Pediatr. (Rio J.), V82, P215, DOI [10.2223/JPED.1479, 10.1590/S0021-75572006000300011]
   Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x
   Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407
   [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1
   [Anonymous], 2007, GUID DIAGN MAN ASTHM
   Antonicelli L, 2007, ALLERGY, V62, P1064, DOI 10.1111/j.1398-9995.2007.01470.x
   Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904
   Aun MV, 2009, J ASTHMA, V46, P399, DOI 10.1080/02770900902777783
   AUN MV, 2010, J ALLERGY C IN PRESS
   Awad OG, 2008, AM J RHINOL, V22, P197, DOI 10.2500/ajr.2008.22.3148
   Ayres JG, 1998, THORAX, V53, P315, DOI 10.1136/thx.53.4.315
   Bargagli E, 2008, INT ARCH ALLERGY IMM, V145, P268, DOI 10.1159/000109296
   Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209
   Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC
   Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9
   Bettiol J, 2002, ALLERGY, V57, P1145, DOI 10.1034/j.1398-9995.2002.23586.x
   Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010
   Black PN, 2007, CURR OPIN PHARMACOL, V7, P266, DOI 10.1016/j.coph.2006.11.013
   Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0
   Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   BRITO GS, 2004, REV BRASILEIRA ALERG, V27, P163
   Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023
   BUSSE WW, 1993, AM REV RESPIR DIS, V147, pS20, DOI 10.1164/ajrccm/147.6_Pt_2.S20
   CALABRARO LTY, 2008, THESIS U SAO PAULO S
   Carvalho Neide Suzane, 2007, J. bras. pneumol., V33, P1, DOI 10.1590/S1806-37132007000100004
   Ceylan E, 2007, RESPIROLOGY, V12, P272, DOI 10.1111/j.1440-1843.2006.00964.x
   Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4
   CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605
   Chung KF, 1999, EUR RESPIR J, V13, P1198
   Cochrane GM, 1999, RESP MED, V93, P763, DOI 10.1016/S0954-6111(99)90260-3
   CORREN J, 1992, POSTGRAD MED, V92, P153
   Corrigan Chris J, 2002, Am J Respir Med, V1, P47
   Coughlan J. L., 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001496
   Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889
   Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373
   Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   DAMASCENO MAS, 2002, THESIS U SAO PAULO S
   de Oliveira E, 2007, RESP MED, V101, P2352, DOI 10.1016/j.rmed.2007.06.018
   Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC
   Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643
   Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082
   FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, pS165, DOI 10.1016/j.jaci.2006.12.007
   Giavina-Bianchi P, 2009, THORAX, V64, P272
   Giavina-Bianchi P, 2008, ACTA OPHTHALMOL, V86, P670, DOI 10.1111/j.1600-0420.2007.01134.x
   Giavina-Bianchi P, 2008, J ALLERGY CLIN IMMUN, V122, P217, DOI 10.1016/j.jaci.2008.05.024
   Giavina-Bianchi P, 2008, J ALLERGY CLIN IMMUN, V122, P214, DOI 10.1016/j.jaci.2008.04.004
   Giavina-Bianchi P, 2008, INT ARCH ALLERGY IMM, V146, P176, DOI 10.1159/000113524
   Giavina-Bianchi P, 2007, INT ARCH ALLERGY IMM, V144, P155, DOI 10.1159/000103228
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, P1279, DOI 10.1016/j.jaci.2007.01.041
   Giavina-Bianchi Pedro, 2009, Eur J Intern Med, V20, pe139, DOI 10.1016/j.ejim.2008.12.008
   Giavina-Bianchi PF, 1997, ANN ALLERG ASTHMA IM, V79, P449, DOI 10.1016/S1081-1206(10)63042-6
   GIAVINABIANCHI P, 1996, ARCH ARGENT INMUNOL, V27, P12
   Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329
   GOTZSCHE PC, 2004, COCHRANE DB SYST REV, V4
   Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179
   Guillevin L, 2004, SEMIN RESP CRIT CARE, V25, P535, DOI 10.1055/s-2004-836145
   Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003
   Hall IP, 2006, CHEST, V130, P1873, DOI 10.1378/chest.130.6.1873
   HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5
   Hansel NN, 2006, ANN ALLERG ASTHMA IM, V97, P409, DOI 10.1016/S1081-1206(10)60809-5
   HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487
   Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x
   Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170
   JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206
   Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x
   Kainulainen L, 1999, J ALLERGY CLIN IMMUN, V104, P1031, DOI 10.1016/S0091-6749(99)70085-0
   Kanda N, 2003, AM J GASTROENTEROL, V98, P2146, DOI [10.1016/S0002-9270(03)00537-9, 10.1111/j.1572-0241.2003.07626.x]
   Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518
   Kim SH, 2008, PHARMACOGENOMICS, V9, P85, DOI 10.2217/14622416.9.1.85
   Kobayashi Y, 2006, INT J CLIN PHARM TH, V44, P193
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Kourilsky P, 2001, TRENDS IMMUNOL, V22, P502, DOI 10.1016/S1471-4906(01)02012-9
   Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30
   Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099
   Leal OM, 1998, THESIS U SAO PAULO S
   Leggett JJ, 2005, CHEST, V127, P1227, DOI 10.1378/chest.127.4.1227
   Leung DYM, 2004, J ALLERGY CLIN IMMUN, V113, P1
   Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033
   Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201
   Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x
   Lopez-Vina A, 2005, Arch Bronconeumol, V41, P513, DOI 10.1016/S1579-2129(06)60272-3
   MARTIN RJ, 1987, SEMIN RESPIR MED, V8, P332, DOI 10.1055/s-2007-1012672
   MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
   Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733
   Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041
   MOHOVIC JZ, 2008, THESIS U SAO PAULO S
   Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   MORAL VP, 2003, ARCH BRONCONEUMOL, V39, pS1, DOI DOI 10.1157/13042409
   Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097
   MOSBECH H, 1987, ALLERGY, V42, P456, DOI 10.1111/j.1398-9995.1987.tb00363.x
   MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5
   Naspitz CK, 1997, LANCET, V349, P404, DOI 10.1016/S0140-6736(97)80026-8
   National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94
   Neffen H, 2005, REV PANAM SALUD PUBL, V17, P191, DOI 10.1590/S1020-49892005000300007
   Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15
   NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399
   Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x
   Nordenstedt H, 2006, CHEST, V129, P1051, DOI 10.1378/chest.129.4.1051
   O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x
   OCONNELL MA, 1995, ANN ALLERG ASTHMA IM, V74, P341
   Oh MJ, 2006, J KOREAN MED SCI, V21, P265, DOI 10.3346/jkms.2006.21.2.265
   Oppenheimer J, 2008, CURR OPIN PULM MED, V14, P64, DOI 10.1097/MCP.0b013e3282f1980b
   Papadopoulou A, 2005, PEDIAT ALLERG IMM-UK, V16, P495, DOI 10.1111/j.1399-3038.2005.00316.x
   PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pfaar O, 2006, CURR OPIN ALLERGY CL, V6, P161, DOI 10.1097/01.all.0000225153.45027.6a
   PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218
   Puechal X, 2008, EUR J INTERN MED, V19, P364, DOI 10.1016/j.ejim.2007.09.001
   Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200
   Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC
   Rackemann FM, 1918, ARCH INTERN MED, V22, P517
   RAM FSP, 2008, CHOCHRANE LIB
   ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7
   Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5
   ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405
   Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926
   SANTING RE, 1994, J ALLERGY CLIN IMMUN, V93, P1021, DOI 10.1016/S0091-6749(94)70051-6
   Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053
   Senna G, 2007, ALLERGY, V62, P207, DOI 10.1111/j.1398-9995.2006.01250.x
   SERPA SF, 1997, THESIS UFRJ RIO DE J
   Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322
   Shuto Hiroshi, 2003, Arerugi, V52, P1053
   SIEVERT W, 1992, LANCET, V339, P1551, DOI 10.1016/0140-6736(92)91326-4
   Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x
   Singh M, 2002, COCHRANE DB SYST REV, V2
   Smith JR, 2005, J ASTHMA, V42, P437, DOI 10.1081/JAS-200067949
   Sole D, 1999, J ASTHMA, V36, P205, DOI 10.3109/02770909909056318
   Sole D, 2001, J INVEST ALLERG CLIN, V11, P123
   SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511
   Stelmach R, 2005, CHEST, V128, P3140, DOI 10.1378/chest.128.5.3140
   Stelmach R, 2007, J ASTHMA, V44, P765, DOI 10.1080/02770900701645694
   STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693
   STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259
   STRUNK RC, 1991, J ALLERGY CLIN IMMUN, V87, P601, DOI 10.1016/0091-6749(91)90374-W
   Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504
   SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713
   Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x
   Taramarcaz P, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003570
   Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3195, DOI 10.1517/14656566.8.18.3195
   Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655
   Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004
   Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592
   Tsurikisawa N, 2004, ANN ALLERG ASTHMA IM, V92, P80, DOI 10.1016/S1081-1206(10)61714-0
   Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88
   van der Veen MJ, 1998, J ALLERGY CLIN IMMUN, V102, P24, DOI 10.1016/S0091-6749(98)70051-X
   Varkey B, 1998, IMMUNOL ALLERGY CLIN, V18, P479, DOI 10.1016/S0889-8561(05)70018-7
   VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x
   Vieira J E, 2001, Sao Paulo Med J, V119, P101
   Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490
   Warman K, 2006, ANN ALLERG ASTHMA IM, V97, pS11, DOI 10.1016/S1081-1206(10)60779-X
   WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8
   Wechsler ME, 2009, CHEST, V136, P507, DOI 10.1378/chest.08-2990
   Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110
   Wenzel SE, 2000, AM J RESP CRIT CARE, V162, P2341
   Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112
   Winchester DE, 2006, NEW ENGL J MED, V355, P1281
   WOOLCOCK AJ, 1993, EUR RESPIR J, V6, P743
   2006, DRUGS TODAY, V42, P1
   2008, DRUGS TODAY S3, V44, P1
   2000, AM J RESP CRITICAL C, V161, P309
NR 172
TC 15
Z9 15
U1 0
U2 6
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD SEP
PY 2010
VL 65
IS 9
BP 905
EP 918
DI 10.1590/S1807-59322010000900014
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 675TK
UT WOS:000283858300014
PM 21049219
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU dos Santos, LD
   Santos, KS
   Pinto, JRA
   Dias, NB
   de Souza, BM
   dos Santos, MF
   Perales, J
   Domont, GB
   Castro, FM
   Kalil, JE
   Palma, MS
AF dos Santos, Lucilene Delazari
   Santos, Keity Souza
   Aparecido Pinto, Jose Roberto
   Dias, Nathalia Baptista
   de Souza, Bibiana Monson
   dos Santos, Manse Fonseca
   Perales, Jonas
   Domont, Gilberto Barbosa
   Castro, Fabio Morato
   Kalil, Jorge Elias
   Palma, Mario Sergio
TI Profiling the Proteome of the Venom from the Social Wasp Polybia
   paulista: A Clue to Understand the Envenoming Mechanism
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE social wasp venom; Polybia paulista; Hymenoptera; allergy;
   immunoreactivity; 2-D electrophoresis; mass spectrometry; envenoming
   mechanism
ID MAJOR ALLERGENS; HYMENOPTERA; BEE; PATHOGENESIS; DIAGNOSIS; SEQUENCE
AB The study reported here is a classical bottom-up proteomic approach where proteins from wasp venom were extracted and separated by 2-DE; the individual protein spots were proteolytically digested and subsequently identified by using tandem mass spectrometry and database query with the protein search engine MASCOT. Eighty-four venom proteins belonging to 12 different molecular functions were identified. These proteins were classified into three groups; the first is constituted of typical venom proteins: antigens-5, hyaluronidases, phospholipases, heat shock proteins, metalloproteinases, metalloproteinase-desintegrin like proteins, serine proteinases, proteinase inhibitors, vascular endothelial growth factor-related protein, arginine kinases, Sol i-II and -II like proteins, alpha-glucosidase, and superoxide dismutases. The second contained proteins structurally related to the muscles that involves the venom reservoir. The third group, associated with the housekeeping of cells from venom glands, was composed of enzymes, membrane proteins of different types, and transcriptional factors. The composition of P. paulista venom permits us to hypothesize about a general envenoming mechanism based on five actions: (i) diffusion of venom through the tissues and to the blood, (ii) tissue, (iii) hemolysis, (iv) inflammation, and (v) allergy-played by antigen-5, PLA1, hyaluronidase, HSP 60, HSP 90, and arginine kinases.
C1 [dos Santos, Lucilene Delazari; Aparecido Pinto, Jose Roberto; Dias, Nathalia Baptista; de Souza, Bibiana Monson; Palma, Mario Sergio] Univ Sao Paulo State UNESP, Ctr Study Social Insects, Dept Biol, Inst Biosci Rio Claro, Rio Claro, SP, Brazil.
   [dos Santos, Manse Fonseca; Domont, Gilberto Barbosa] Univ Fed Rio de Janeiro, Dept Biochem, BR-21941 Rio De Janeiro, Brazil.
   [Perales, Jonas] Fiocruz MS, Dept Physiol & Pharmacodynam, Rio De Janeiro, Brazil.
   [Santos, Keity Souza; Castro, Fabio Morato; Kalil, Jorge Elias; Palma, Mario Sergio] Discipline Allergy & Immunol InCor HC FMUSP, Sao Paulo, Brazil.
RP Palma, MS (corresponding author), CEIS IBRC UNESP, Av 24A 1515, BR-13506900 Rio Claro, SP, Brazil.
EM mspalma@rc.unesp.br
RI Santos-Pinto, Jose Roberto Aparecido dos/V-8745-2019; Castro, Fabio
   FM/C-1082-2017; KALIL, JORGE/C-8029-2012; Palma, Mario/N-3903-2019;
   Castro, Fabio/AAP-5433-2020; Santos, Lucilene Delazari
   dos/AAY-5226-2020; Palma, Mario Sergio/E-7800-2012; Santos,
   Keity/E-2553-2012; Santos, Keity Souza/Q-5704-2019; Santos,
   Marise/B-9832-2012; Santos, Keity/M-9401-2015
OI Santos-Pinto, Jose Roberto Aparecido dos/0000-0003-3172-0097; Castro,
   Fabio FM/0000-0002-6211-5773; KALIL, JORGE/0000-0001-8415-4274; Santos,
   Lucilene Delazari dos/0000-0001-5832-1825; Palma, Mario
   Sergio/0000-0002-7363-8211; Santos, Keity Souza/0000-0001-5271-4011;
   Santos, Marise Fonseca dos/0000-0002-1214-5667
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [05/00982-1]; BIOprospecTA/FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [06/57122-7]; INCT/CNPq-Instituto de Investigacoes
   em Imunologia (iii); CNPqNational Council for Scientific and
   Technological Development (CNPq); CAPESCAPES; National Research Council
   of Brazil-CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by grants from FAPESP (Proc. 05/00982-1) and
   BIOprospecTA/FAPESP program (Proc. 06/57122-7), INCT/CNPq-Instituto de
   Investigacoes em Imunologia (iii), CNPq and CAPES. M.S.P., J.E.K., J.P.
   and G.B.D. are researchers awardees from the National Research Council
   of Brazil-CNPq; L.D.S., K.S.S. and B.M.S. are postdoctoral fellows from
   FAPESP; N.B.D. is a student fellow from FAPESP and J.R.A.S.P. is from
   CNPq.
CR Anderson JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-52
   Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023
   Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x
   BOUSQUET J, 1979, ANN ALLERGY, V43, P110
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CASTRO FFM, 1994, J INVEST ALLERG CLIN, V4, P37
   Chen DM, 2004, AM J MED, V116, P567, DOI 10.1016/j.amjmed.2003.08.036
   de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017
   De Oliveira MR, 1998, TOXICON, V36, P189, DOI 10.1016/S0041-0101(97)00053-6
   de Souza BM, 2009, PEPTIDES, V30, P1387, DOI 10.1016/j.peptides.2009.05.008
   DOTIMAS EM, 1987, BEE WORLD, V68, P51, DOI 10.1080/0005772X.1987.11098915
   Gallagher P, 2005, ARCH BIOCHEM BIOPHYS, V441, P1, DOI 10.1016/j.abb.2005.06.007
   Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V
   Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9
   Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109
   Junghanss T, 2006, CLIN INFECT DIS, V43, P1309, DOI 10.1086/508279
   King TP, 2003, INT ARCH ALLERGY IMM, V131, P25, DOI 10.1159/000070431
   Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.02217.x
   Kolarich D, 2005, FEBS J, V272, P5182, DOI 10.1111/j.1742-4658.2005.04841.x
   Kolarich D, 2007, PROTEOMICS, V7, P1615, DOI 10.1002/pmic.200600800
   Kolecki P, 1999, ANN EMERG MED, V33, P114, DOI 10.1016/S0196-0644(99)70428-2
   KREIL G, 1980, EUR J BIOCHEM, V111, P49, DOI 10.1111/j.1432-1033.1980.tb06073.x
   Liska AJ, 2003, PROTEOMICS, V3, P19, DOI 10.1002/pmic.200390004
   LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457
   Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X
   Mendes MA, 2006, PEPTIDES, V27, P2632, DOI 10.1016/j.peptides.2006.05.018
   Nittner-Marszalska M, 2004, MED SCI MONITOR, V10, pCR324
   Palma MS, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P389, DOI 10.1016/B978-012369442-3/50059-3
   Pantera B, 2003, BBA-GEN SUBJECTS, V1623, P72, DOI 10.1016/j.bbagen.2003.07.001
   Peiren N, 2006, INSECT MOL BIOL, V15, P577, DOI 10.1111/j.1365-2583.2006.00669.x
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Peiren N, 2008, TOXICON, V52, P72, DOI 10.1016/j.toxicon.2008.05.003
   PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377
   Santos LD, 2007, TOXICON, V50, P923, DOI 10.1016/j.toxicon.2007.06.027
   Sharmila RR, 2007, INDIAN J PEDIATR, V74, P1111, DOI 10.1007/s12098-007-0208-6
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   SNUTCH TP, 1988, GENE, V64, P241, DOI 10.1016/0378-1119(88)90339-3
   Stiprija V., 1972, LANCET, V1, P749
   TUNGET CL, 1993, POSTGRAD MED, V94, P92
   Valenta R, 2007, J INVEST ALLERG CLIN, V17, P36
   Vetter RS, 1999, WESTERN J MED, V170, P223
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445
NR 43
TC 51
Z9 52
U1 0
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD AUG
PY 2010
VL 9
IS 8
BP 3867
EP 3877
DI 10.1021/pr1000829
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 634LT
UT WOS:000280583700010
PM 20540563
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Sauer, MM
   Sanabani, S
   Giret, MT
   Tomiyama, HI
   Sidney, J
   Piaskowski, SM
   Diaz, RS
   Sabino, EC
   Sette, A
   Kalil, J
   Watkins, DI
   Kallas, EG
AF Tarosso, Leandro F.
   Sauer, Mariana M.
   Sanabani, Sabri
   Giret, Maria Teresa
   Tomiyama, Helena I.
   Sidney, John
   Piaskowski, Shari M.
   Diaz, Ricardo S.
   Sabino, Ester C.
   Sette, Alessandro
   Kalil-Filho, Jorge
   Watkins, David I.
   Kallas, Esper G.
TI Unexpected Diversity of Cellular Immune Responses against Nef and Vif in
   HIV-1-Infected Patients Who Spontaneously Control Viral Replication
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; HIV-INFECTION; IN-VIVO;
   NONPROGRESSORS; PEPTIDE; VIREMIA; PROTEIN; GENE; HLA
AB Background: HIV-1-infected individuals who spontaneously control viral replication represent an example of successful containment of the AIDS virus. Understanding the anti-viral immune responses in these individuals may help in vaccine design. However, immune responses against HIV-1 are normally analyzed using HIV-1 consensus B 15-mers that overlap by 11 amino acids. Unfortunately, this method may underestimate the real breadth of the cellular immune responses against the autologous sequence of the infecting virus.
   Methodology and Principal Findings: Here we compared cellular immune responses against nef and vif-encoded consensus B 15-mer peptides to responses against HLA class I-predicted minimal optimal epitopes from consensus B and autologous sequences in six patients who have controlled HIV-1 replication. Interestingly, our analysis revealed that three of our patients had broader cellular immune responses against HLA class I-predicted minimal optimal epitopes from either autologous viruses or from the HIV-1 consensus B sequence, when compared to responses against the 15-mer HIV-1 type B consensus peptides.
   Conclusion and Significance: This suggests that the cellular immune responses against HIV-1 in controller patients may be broader than we had previously anticipated.
C1 [Tarosso, Leandro F.; Kalil-Filho, Jorge; Kallas, Esper G.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Sauer, Mariana M.; Giret, Maria Teresa; Tomiyama, Helena I.; Diaz, Ricardo S.; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Sanabani, Sabri; Sabino, Ester C.] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Piaskowski, Shari M.; Watkins, David I.] Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53706 USA.
RP Tarosso, LF (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Sanabani, Sabri Saeed/F-5600-2012; Sabino, Ester Cerdeira/F-7750-2010;
   Diaz, Ricardo/K-3978-2012; Tarosso, Leandro F./H-6267-2012; Kallas,
   Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R24 RR015371];
   Ministry of HealthMinistry of Health - Turkey [914/BRA/3014-UNESCO]; Sao
   Paulo City Health Department [2004-0.168.922-7]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/15856-9]; Coordenacao de Aperfeicoamento de
   Pessoal de Ni-vel Superior (CAPES), Brazilian Ministry of
   EducationCAPES; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR) [R24RR015371,
   R24RR015371, R24RR015371, R24RR015371, R24RR015371, R24RR015371,
   R24RR015371, R24RR015371, R24RR015371, R24RR015371, R24RR015371,
   R24RR015371, R24RR015371] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI073230, R21AI073230] Funding Source: NIH RePORTER
FX This study was supported by the National Institutes of Health Grant R24
   RR015371 (to D. I. W.), Brazilian Program for STD and AIDS - Ministry of
   Health Grant 914/BRA/3014-UNESCO and the Sao Paulo City Health
   Department Grant 2004-0.168.922-7 (to E. G. K.), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo Grant 04/15856-9 (to E. G. K.,
   E. C. S., and R. S. D.). L. F. T., M. T. M. G., and M. M. S. were
   supported by the Coordenacao de Aperfeicoamento de Pessoal de Ni-vel
   Superior (CAPES), Brazilian Ministry of Education. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. The following reagents were obtained
   through the NIH AIDS Research and Reference Reagent Program, Division of
   AIDS, NIAID, NIH: complete HIV-1 Consensus subtype B peptide sets
   (15-mers overlapping by 11 acids) of Nef (Cat# 5189, Lot# 8) and Vif
   (Cat# 6446, Lot# 7).
CR Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000
   Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996
   Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Harrer T, 1996, J IMMUNOL, V156, P2616
   Hassaine G, 2000, VIROLOGY, V276, P169, DOI 10.1006/viro.2000.0543
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kern F, 2000, EUR J IMMUNOL, V30, P1676, DOI 10.1002/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V
   Kiecker F, 2004, HUM IMMUNOL, V65, P523, DOI 10.1016/j.humimm.2004.02.017
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   KORBER BT, 2005, HIV MOL IMMUNOLOGY 2
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004
   Lum JJ, 2003, J CLIN INVEST, V111, P1547, DOI 10.1172/JCI200316233
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   Miura T, 2008, J VIROL, V82, P8422, DOI 10.1128/JVI.00535-08
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Peters B, 2006, PLOS COMPUT BIOL, V2, P574, DOI 10.1371/journal.pcbi.0020065
   Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Saez-Cirion A, 2007, TRENDS IMMUNOL, V28, P532, DOI 10.1016/j.it.2007.09.002
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999
   SOVA P, 1995, J VIROL, V69, P2557, DOI 10.1128/JVI.69.4.2557-2564.1995
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Walker Bruce D, 2007, Top HIV Med, V15, P134
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006
   You LW, 2007, LECT NOTES COMPUT SC, V4774, P337
   Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254
   Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a
NR 48
TC 10
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2010
VL 5
IS 7
AR e11436
DI 10.1371/journal.pone.0011436
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 619YH
UT WOS:000279465700017
PM 20625436
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Menezes, E
   Magalhaes, A
   Oliveira, J
   Castellucci, L
   Almeida, R
   Rosa, MEA
   Guimaraes, LH
   Lessa, M
   Noronha, E
   Wilson, ME
   Jamieson, SE
   Kalil, J
   Blackwell, JM
   Carvalho, EM
   de Jesus, AR
AF Ramasawmy, Rajendranath
   Menezes, Eliane
   Magalhaes, Andrea
   Oliveira, Joyce
   Castellucci, Lea
   Almeida, Roque
   Rosa, Maria Elisa A.
   Henrique Guimaraes, Luiz
   Lessa, Marcus
   Noronha, Elza
   Wilson, Mary E.
   Jamieson, Sarra E.
   Kalil, Jorge
   Blackwell, Jenefer M.
   Carvalho, Edgar M.
   Ribeiro de Jesus, Amelia
TI The-2518 bp promoter polymorphism at CCL2/MCP1 influences susceptibility
   to mucosal but not localized cutaneous leishmaniasis in Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Mucosal leishmaniasis; Genetic association; MCP-1; CCL2
ID PULMONARY TUBERCULOSIS; EXPRESSION; MCP-1; ASSOCIATION; INFECTION;
   RESPONSES; RECEPTOR; DISEASE; HUMANS; BAHIA
AB Mucosal leishmaniasis (ML) follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis. Proinflammatory responses mediate CL self-healing but are exaggerated in ML Proinflammatory monocyte chemoattractant protein 1 (MCP-1; encoded by CCL2) is associated with CL We explore its role in CL/ML through analysis of the regulatory CCL2 -2518 bp promoter polymorphism in CL/ML population samples and families from Brazil. Genotype frequencies were compared among ML/CL cases and control groups using logistic regression and the family-based association test (FBAT). MCP-1 was measured in plasma and macrophages. The GG recessive genotype at CCL2 -2518 bp was more common in patients with ML (N = 67) than in neighborhood control (NC; N = 60) subjects (OR 1.78; 95% Cl 1.01-3.14; P = 0.045), than in NC combined with leishmanin skin-test positive (N = 60) controls (OR 4.40; 95% CI 1.42-13.65; P = 0.010), and than in controls combined with CL (N = 60) patients (OR 2.78; 95% CI 1.13-6.85; P = 0.045). No associations were observed for CL compared to any groups. FBAT (91 ML and 223 CL cases in families) confirmed recessive association of ML with allele G (Z = 2.679; P = 0.007). Higher levels of MCP-1 occurred in plasma (P = 0.03) and macrophages (P < 0.0001) from GG compared to AA individuals. These results suggest that high MCP-1 increases risk of ML (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ramasawmy, Rajendranath; Menezes, Eliane; Magalhaes, Andrea; Oliveira, Joyce; Castellucci, Lea; Almeida, Roque; Rosa, Maria Elisa A.; Henrique Guimaraes, Luiz; Lessa, Marcus; Carvalho, Edgar M.; Ribeiro de Jesus, Amelia] Univ Fed Bahia, Salvador, BA, Brazil.
   [Ramasawmy, Rajendranath; Kalil, Jorge] Univ Sao Paulo, Lab Imunol InCor, BR-09500900 Sao Paulo, Brazil.
   [Ramasawmy, Rajendranath; Kalil, Jorge] Inst Invest Imunol, Sao Paulo, Brazil.
   [Almeida, Roque; Ribeiro de Jesus, Amelia] Univ Fed Sergipe, Aracaju, Brazil.
   [Noronha, Elza] Univ Fed Brasilia, Brasilia, DF, Brazil.
   [Wilson, Mary E.] Univ Iowa, Iowa City, IA USA.
   [Wilson, Mary E.] VA Med Ctr, Iowa City, IA USA.
   [Jamieson, Sarra E.; Blackwell, Jenefer M.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Subiaco, WA, Australia.
   [Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 0XY, England.
RP de Jesus, AR (corresponding author), HUPES, Serv Immunol, 5 Andar,Rua Joao das Botas S-N, Salvador, BA, Brazil.
EM jblackwell@ichr.uwa.edu.au; amelia.jesus@pq.cnpq.br
RI almeida, roque/F-5609-2012; Blackwell, Jenefer M/H-3015-2015; KALIL,
   JORGE/C-8029-2012; Ramasawmy, Rajendranath/V-4926-2019; Henrique,
   Luiz/ABA-2621-2020
OI KALIL, JORGE/0000-0001-8415-4274; Wilson, Mary/0000-0001-8680-7275
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P50 AI-30639, R03AI070909];
   NIH/FICUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1 D43 TW007127-01, R01 AI076233, R01AI067874]; CNPqNational Council for
   Scientific and Technological Development (CNPq); VA Merit Review grantUS
   Department of Veterans Affairs; Wellcome TrustWellcome Trust; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW007127, D43TW007127, R03TW001369,
   D43TW007127, D43TW007127, D43TW007127, D43TW007127, R03TW001369,
   R03TW001369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI067874, R01AI048822,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, R03AI070909,
   R01AI067874, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI067874, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI048822, P50AI030639,
   P50AI030639, P50AI030639, R01AI048822, P50AI030639, P50AI030639,
   R01AI048822, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI067874, P50AI030639, R01AI076233,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI076233, P50AI030639, P50AI030639, P50AI030639,
   R01AI076233, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI067874, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI048822, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R03AI070909, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI076233, P50AI030639] Funding
   Source: NIH RePORTER
FX We thank Ednaldo Lima do Lago and other staff at the Health Post of
   Corte de Pedra for helping with patient recruitment. We thank Paulo
   Machado and Albert Schriefer for help in diagnosis of patients. We thank
   Elbe M. Silva and Lucia Reis for secretarial assistance. This work was
   funded in part by NIH grants P50 AI-30639 and R03AI070909 (LC, EMC,
   MEW), NIH/FIC 1 D43 TW007127-01 (JO, AM), R01 AI076233 (JMB and MEW),
   R01AI067874 (JMB and MEW), CNPq (ARJ, RA, EMC), a VA Merit Review grant
   (MEW), and grants from The Wellcome Trust (JMB). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the NIAID or the National Institutes of Health.
CR Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Antoniazi S, 2004, INFECT IMMUN, V72, P5168, DOI 10.1128/IAI.72.9.5168-5174.2004
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   Bhattacharyya S, 2002, J INFECT DIS, V185, P1704, DOI 10.1086/340820
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007
   Cuba C. C., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P161, DOI 10.1590/S0037-86821984000400002
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem.20050126
   Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499
   Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Marsden PD, 1998, AM J TROP MED HYG, V59, P543, DOI 10.4269/ajtmh.1998.59.543
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ritter U, 2000, EUR J IMMUNOL, V30, P3111, DOI 10.1002/1521-4141(200011)30:11&lt;3111::AID-IMMU3111&gt;3.0.CO;2-O
   Ritter U, 1996, J INFECT DIS, V173, P699, DOI 10.1093/infdis/173.3.699
   ROSA AC, 1988, T ROY SOC TROP MED H, V82, P409, DOI 10.1016/0035-9203(88)90138-1
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
   Sambrook J, 1989, MOL CLONING LAB MANU
   Thye T, 2009, HUM MOL GENET, V18, P381, DOI 10.1093/hmg/ddn352
NR 29
TC 27
Z9 28
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2010
VL 10
IS 5
BP 607
EP 613
DI 10.1016/j.meegid.2010.04.006
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 614DP
UT WOS:000279035800003
PM 20430117
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Serpieri, F
   Inocencio, A
   de Oliveira, JM
   Pimenta, AA
   Garbuio, A
   Kalil, J
   Brigido, MM
   Moro, AM
AF Serpieri, Flavia
   Inocencio, Andre
   de Oliveira, Jose Marcelino
   Pimenta, Alecio A., Jr.
   Garbuio, Angelica
   Kalil, Jorge
   Brigido, Marcelo M.
   Moro, Ana Maria
TI Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies
   Expressed in CHO Cells
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article
DE Antibody humanization; Anti-CD3; FvFc; CHO cells; Flow cytometry
ID THERAPY
AB Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monoclonal antibody, whole IgG and FvFc, were expressed in CHO cells. Random and site-specific integration were used resulting in similar expression levels. The transfectants were selected with appropriate selection agent, and the surviving cells were plated in semi-solid medium for capture with FITC-conjugated anti-human IG antibody and picked with the robotic ClonePix FL. Conditioned media from selected clones were purified by affinity chromatography and characterized by SDS-PAGE, Western-blot, SEC-HPLC, and isoelectric focusing. Binding to the target present in healthy human mononuclear cells was assessed by flow cytometry, as well as by competition between the two constructs and the original murine monoclonal antibody. The humanized constructs were not able to dislodge the murine antibody while the murine anti-CD3 antibody could dislodge around 20% of the FvFc or IgG humanized versions. Further in vitro and in vivo pre-clinical analyses will be carried out to verify the ability of the humanized versions to demonstrate the immunoregulatory profile required for a humanized anti-CD3 monoclonal antibody.
C1 [Serpieri, Flavia; Inocencio, Andre; de Oliveira, Jose Marcelino; Pimenta, Alecio A., Jr.; Garbuio, Angelica; Moro, Ana Maria] Inst Butantan, Lab Biofarm Celulas Anim, BR-05503900 Brasilia, SP, Brazil.
   [Brigido, Marcelo M.] Univ Brasilia, Mol Biol Lab, BR-70910900 Brasilia, DF, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, InCor, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
   [Kalil, Jorge; Brigido, Marcelo M.; Moro, Ana Maria] INCT, Inst Immunol Invest, Sci & Technol Natl Inst, Brasilia, DF, Brazil.
RP Moro, AM (corresponding author), Inst Butantan, Lab Biofarm Celulas Anim, BR-05503900 Brasilia, SP, Brazil.
EM anamoro@butantan.gov.br
RI KALIL, JORGE/C-8029-2012; Moro, Ana Maria/A-5134-2012; Brigido,
   Marcelo/N-9277-2019; Brigido, Marcelo/A-1972-2015; Inocencio,
   Andre/F-5966-2013; Serpieri, Flavia/L-5453-2019; Brigido,
   Marcelo/H-2718-2019
OI KALIL, JORGE/0000-0001-8415-4274; Moro, Ana Maria/0000-0002-0650-7764;
   Brigido, Marcelo/0000-0002-7136-7059; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FINEP (Brazilian Ministry for Science and Technology)Ciencia
   Tecnologia e Inovacao (FINEP)
FX The authors thank Andrea Maranhao for helpful discussion on the vectors,
   Claudia T. P. de Moraes and Ana Carolina Pavanelli for technical
   assistance, CNPq for Flavia Serpieri's PhD studentship and FINEP
   (Brazilian Ministry for Science and Technology) for financial support.
CR Caldas C, 2000, PROTEIN ENG, V13, P353, DOI 10.1093/protein/13.5.353
   CHATENOUD L, 1992, CLIN NEPHROL, V38, pS53
   Clark M, 2000, IMMUNOL TODAY, V21, P397, DOI 10.1016/S0167-5699(00)01680-7
   FARGES O, 1992, TRANSPLANTATION SCI, V2, P16
   Filpula D, 2007, BIOMOL ENG, V24, P201, DOI 10.1016/j.bioeng.2007.03.004
   GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337
   Henry ML, 2001, CLIN TRANSPLANT, V15, P410, DOI 10.1034/j.1399-0012.2001.150608.x
   Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980
   LEMOS F, 2006, BRASILIAN J TRANSPLA, V9, P572
   RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0
   Sevmis S, 2005, TRANSPL P, V37, P3016, DOI 10.1016/j.transproceed.2005.07.052
   Silva HM, 2009, IMMUNOL LETT, V125, P129, DOI 10.1016/j.imlet.2009.06.009
NR 14
TC 16
Z9 16
U1 0
U2 5
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1073-6085
EI 1559-0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD JUL
PY 2010
VL 45
IS 3
BP 218
EP 225
DI 10.1007/s12033-010-9269-2
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 607AJ
UT WOS:000278470300004
PM 20336495
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Rosa, DS
   Fonseca, SG
   Mairena, EC
   Postol, E
   Oliveira, SC
   Guilherme, L
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, Susan Pereira
   Rosa, Daniela Santoro
   Fonseca, Simone Goncalves
   Mairena, Eliane Conti
   Postol, Edilberto
   Oliveira, Sergio Costa
   Guilherme, Luiza
   Kalil, Jorge
   Cunha-Neto, Edecio
TI A Vaccine Encoding Conserved Promiscuous HIV CD4 Epitopes Induces Broad
   T Cell Responses in Mice Transgenic to Multiple Common HLA Class II
   Molecules
SO PLOS ONE
LA English
DT Article
ID IN-VIVO; SIVMAC251 INFECTION; IMMUNE-RESPONSE; RHESUS-MONKEYS; MEMORY;
   STEP; PROTECTION; CHALLENGE; IMMUNOGENICITY; IDENTIFICATION
AB Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that mainly elicit cytotoxic CD8+ responses. Mounting evidence points toward a critical role for CD4+ T cells in the control of immunodeficiency virus replication, probably due to cognate help. Vaccine-induced CD4+ T cell responses might, therefore, have a protective effect in HIV replication. In addition, successful vaccines may have to elicit responses to multiple epitopes in a high proportion of vaccinees, to match the highly variable circulating strains of HIV. Using rational vaccine design, we developed a DNA vaccine encoding 18 algorithm-selected conserved, "promiscuous" ( multiple HLA-DR-binding) B-subtype HIV CD4 epitopes - previously found to be frequently recognized by HIV-infected patients. We assessed the ability of the vaccine to induce broad T cell responses in the context of multiple HLA class II molecules using different strains of HLA class II-transgenic mice (-DR2, -DR4, -DQ6 and -DQ8). Mice displayed CD4+ and CD8+ T cell responses of significant breadth and magnitude, and 16 out of the 18 encoded epitopes were recognized. By virtue of inducing broad responses against conserved CD4+ T cell epitopes that can be recognized in the context of widely diverse, common HLA class II alleles, this vaccine concept may cope both with HIV genetic variability and increased population coverage. The vaccine may thus be a source of cognate help for HIV-specific CD8+ T cells elicited by conventional immunogens, in a wide proportion of vaccinees.
C1 [Ribeiro, Susan Pereira; Rosa, Daniela Santoro; Fonseca, Simone Goncalves; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
   [Fonseca, Simone Goncalves; Mairena, Eliane Conti; Postol, Edilberto; Guilherme, Luiza; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira; Rosa, Daniela Santoro; Mairena, Eliane Conti; Postol, Edilberto; Guilherme, Luiza; Kalil, Jorge; Cunha-Neto, Edecio] Inst Invest Immunol INCT, Sao Paulo, Brazil.
   [Oliveira, Sergio Costa] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
RP Ribeiro, SP (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Rosa, Daniela S/D-2190-2012; FONSECA, SIMONE GONCALVES/U-9278-2019;
   Cunha-Neto, Edecio/B-4157-2009; Guglielmi, Luiza G/E-7676-2013; KALIL,
   JORGE/C-8029-2012
OI Rosa, Daniela S/0000-0003-4536-891X; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo State
   Research Funding Agency (FAPESP)Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); International Centre of Genetic Engineering and
   Biotechnology (ICGEB); Brazilian Ministry of Health (Brazil)
FX This research was supported by the Brazilian National Research Council
   (CNPq), Sao Paulo State Research Funding Agency (FAPESP), International
   Centre of Genetic Engineering and Biotechnology (ICGEB) and from the
   Brazilian Ministry of Health (Brazil). S. P. Ribeiro and D. S. Rosa are
   recipients of a Sao Paulo State Research Funding Agency (FAPESP)
   fellowship. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   ATHERTON ND, 1989, CLIN CHEM, V35, P975
   Barouch DH, 2010, ANNU REV MED, V61, P153, DOI 10.1146/annurev.med.042508.093728
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Call MJ, 2009, J IMMUNOL, V182, P6342, DOI 10.4049/jimmunol.0803464
   Chapoval SP, 1998, J IMMUNOL, V161, P2032
   Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
   DaSilva L, 2002, J INFECT DIS, V185, P1754, DOI 10.1086/340828
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Fuller DH, 2007, VIROLOGY, V364, P245, DOI 10.1016/j.virol.2007.02.024
   Gandhi RT, 2002, ANNU REV MED, V53, P149, DOI 10.1146/annurev.med.53.082901.104011
   Garcia TCM, 2008, ACTA TROP, V106, P162, DOI 10.1016/j.actatropica.2008.03.003
   Gauduin MC, 2006, J EXP MED, V203, P2661, DOI 10.1084/jem.20060134
   Geluk A, 1998, P NATL ACAD SCI USA, V95, P10797, DOI 10.1073/pnas.95.18.10797
   Giraldo-Vela JP, 2008, J VIROL, V82, P859, DOI 10.1128/JVI.01816-07
   GonzalezGay MA, 1996, HUM IMMUNOL, V50, P54, DOI 10.1016/0198-8859(96)00123-1
   Gregory SH, 2009, VACCINE, V27, P5299, DOI 10.1016/j.vaccine.2009.06.101
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Ishioka GY, 1999, J IMMUNOL, V162, P3915
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Kawamura K, 2000, J CLIN INVEST, V105, P977, DOI 10.1172/JCI8407
   Khanolkar A, 2007, IMMUNOL RES, V39, P94, DOI 10.1007/s12026-007-0081-4
   KORBER BTM, 2006, THEORETICAL BIOL BIO
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320
   Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
   MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   OCONNOR SL, SCI TRANSL MED, V22
   Pan SC, 1998, J IMMUNOL, V161, P2925
   Pancre V, 2007, VACCINE, V25, P5927, DOI 10.1016/j.vaccine.2007.05.038
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   RESTIFO NP, 1995, J IMMUNOL, V154, P4414
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Suhrbier Andreas, 2002, Expert Rev Vaccines, V1, P207, DOI 10.1586/14760584.1.2.207
   Tenzer S, 2009, NAT IMMUNOL, V10, P636, DOI 10.1038/ni.1728
   Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005
   Vaccari M, 2008, MUCOSAL IMMUNOL, V1, P497, DOI 10.1038/mi.2008.60
   Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
   Watkins DI, 2008, MEM I OSWALDO CRUZ, V103, P119, DOI 10.1590/S0074-02762008000200001
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   Wilson DB, 2004, MOL IMMUNOL, V40, P1047, DOI 10.1016/j.molimm.2003.11.022
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
   Wong FS, 2004, DIABETOLOGIA, V47, P1476, DOI 10.1007/s00125-004-1505-5
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 58
TC 37
Z9 37
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2010
VL 5
IS 6
AR e11072
DI 10.1371/journal.pone.0011072
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 609NG
UT WOS:000278662900012
PM 20552033
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tanno, L
   Ensina, L
   Rodrigues, F
   Giavina-Bianchi, P
   Kalil, J
   Aun, W
   Mello, J
   Motta, A
AF Tanno, L.
   Ensina, L.
   Rodrigues, F.
   Giavina-Bianchi, P.
   Kalil, J.
   Aun, W.
   Mello, J.
   Motta, A.
TI Drug hypersensitivity reactions: clinical and epidemiological
   differences between allergy clinics of two services in Sao Paulo, Brazil
SO ALLERGY
LA English
DT Meeting Abstract
CT 29th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
   (EAACI)
CY JUN 05-09, 2010
CL London, ENGLAND
SP European Acad Allergy and Clin Immunol
C1 [Tanno, L.] Univ Sao Paulo, Hostital Clin, Sao Paulo, Brazil.
   [Tanno, L.] Univ Sao Paulo, Hosp Servidor Publ Estadual Francisco Morato de O, Sao Paulo, Brazil.
   [Tanno, L.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Ensina, L.; Giavina-Bianchi, P.; Kalil, J.; Motta, A.] Univ Sao Paulo, Hostital Clin, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Rodrigues, F.; Aun, W.; Mello, J.] Hosp Servidor Publ Estadual Francisco Morato de O, Allergy & Immunol Serv, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012;
   Giavina-Bianchi, Pedro/I-3112-2014
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274; Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUN
PY 2010
VL 65
SU 92
SI SI
MA 568
BP 227
EP 227
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 286IR
UT WOS:000329462101053
DA 2020-11-26
ER

PT J
AU Pedreschi, M
   Oliveira, AK
   Barros, MT
   Aun, MV
   Cohon, A
   Kalil, J
   Kokron, CM
AF Pedreschi, M.
   Oliveira, A. K.
   Barros, M. T.
   Aun, M. V.
   Cohon, A.
   Kalil, J.
   Kokron, C. M.
TI An Attempt to Classify A Brazilian Cohort of Common Variable
   Immunodeficiency Patients Based on the Euroclass Trial
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 1st North American Primary Immune Deficiency National Conference
CY MAY 20-23, 2010
CL Philadelphia, PA
C1 [Pedreschi, M.; Oliveira, A. K.; Barros, M. T.; Aun, M. V.; Cohon, A.; Kalil, J.; Kokron, C. M.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012; Aun, Marcelo
   V/E-6775-2014
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL,
   JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAY
PY 2010
VL 135
IS 2
SI SI
MA 37
BP 299
EP 299
PG 1
WC Immunology
SC Immunology
GA 588ZH
UT WOS:000277112900049
DA 2020-11-26
ER

PT J
AU de Moraes-Vasconcelos, D
   Barros, MMT
   Jacob, CA
   Kokron, CM
   Grumach, AS
   Dorna, MB
   Domingues-Ferreira, M
   Pastorino, AC
   Rizzo, LV
   Duarte, AS
   Kalil, JE
   Carneiro-Sampaio, MM
AF de Moraes-Vasconcelos, D.
   Toledo Barros, M. M.
   Abe Jacob, C.
   Kokron, C. M.
   Grumach, A. S.
   Dorna, M. B.
   Domingues-Ferreira, M.
   Pastorino, A. C.
   Rizzo, L. V.
   Silva Duarte, A.
   Kalil, J. E.
   Carneiro-Sampaio, M. M.
TI Primary Immunodeficiency Diseases in A Single Tertiary University
   Hospital in Sao Paulo, Brazil
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 1st North American Primary Immune Deficiency National Conference
CY MAY 20-23, 2010
CL Philadelphia, PA
C1 [de Moraes-Vasconcelos, D.; Toledo Barros, M. M.; Abe Jacob, C.; Kokron, C. M.; Grumach, A. S.; Dorna, M. B.; Domingues-Ferreira, M.; Pastorino, A. C.; Rizzo, L. V.; Silva Duarte, A.; Kalil, J. E.; Carneiro-Sampaio, M. M.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI Moraes-Vasconcelos, Dewton/G-2209-2012; Rizzo, Luiz Vicente/B-4458-2009;
   Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012
OI Moraes-Vasconcelos, Dewton/0000-0002-3930-3354; Kokron, Cristina
   M/0000-0002-9080-0305; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAY
PY 2010
VL 135
IS 2
SI SI
MA 47
BP 304
EP 304
PG 1
WC Immunology
SC Immunology
GA 588ZH
UT WOS:000277112900059
DA 2020-11-26
ER

PT J
AU Moraes-Vieira, PMM
   Silva, HM
   Takenaka, MCS
   Monteiro, SM
   Lemos, F
   Saitovitch, D
   Kalil, J
   Coelho, V
AF Moraes-Vieira, Pedro Manoel M.
   Silva, Hernandez M.
   Takenaka, Maisa C. S.
   Monteiro, Sandra Maria
   Lemos, Francine
   Saitovitch, David
   Kalil, Jorge
   Coelho, Veronica
TI Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells
   in kidney operational tolerance transplanted individuals
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE Kidney transplantation; Operational tolerance; Foxp3; STAT6; Monocytes
ID PERIPHERAL-BLOOD; DENDRITIC CELLS; INDUCTION; EXPRESSION; FOXP3;
   TRANSCRIPTION; MACROPHAGES; SUPPRESSION; INHIBITION; REJECTION
AB In organ transplantation, the immunosuppression withdrawal leads, in most cases, to rejection. Nonetheless, a special group of patients maintain stable graft function after complete withdrawal of immunosuppression, achieving a state called "operational tolerance." The study of such patients may be important to understand the mechanisms involved in human transplantation tolerance. We compared the profile of CD4(+)CD25(+)Foxp3(+) T cells and the signaling pathways IL-6/STAT3 (signal transducers and activators of transcription) and IL-4/STAT6 in peripheral blood mononuclear cells of four kidney transplant groups: (i) operational tolerance (OT), (ii) chronic allograft nephropathy (CR), (iii) stable graft function under standard immunosuppression (Sta), (iv) stable graft function under low immunosuppression, and (v) healthy individuals. Both CR and Sta displayed lower numbers and percentages of CD4(+)CD25(+)Foxp3(+) T cells compared with all other groups (p < 0.05). The OT patients displayed a reduced activation of the IL-4/STAT6 pathway in monocytes, compared with all other groups (p < 0.05). The lower numbers of CD4(+)CD25(+)Foxp3(+) T cells observed in CR individuals may be a feature of chronic allograft nephropathy. The differential OT signaling profile, with reduced phosphorylation of STAT6, in monocytes' region, suggests that some altered function of STAT6 signaling may be important for the operational tolerance state. Crown copyright (C) 2010 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics. All rights reserved.
C1 [Moraes-Vieira, Pedro Manoel M.; Silva, Hernandez M.; Takenaka, Maisa C. S.; Monteiro, Sandra Maria; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Moraes-Vieira, Pedro Manoel M.; Silva, Hernandez M.; Takenaka, Maisa C. S.; Monteiro, Sandra Maria; Saitovitch, David; Kalil, Jorge; Coelho, Veronica] III Natl Inst Sci & Technol, Inst Invest Immunol, Sao Paulo, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil.
   [Saitovitch, David] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Div Nephrol, Porto Alegre, RS, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Takenaka, Maisa/J-5788-2014; KALIL, JORGE/C-8029-2012; Moraes-Vieira,
   Pedro M/C-8701-2014; COELHO, VERONICA/D-1433-2013; Saitovitch,
   David/H-8863-2013
OI KALIL, JORGE/0000-0001-8415-4274; Moraes-Vieira, Pedro
   M/0000-0002-8263-786X; Coelho, Veronica/0000-0002-0989-2581; Saitovitch,
   David/0000-0003-2315-1314
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/04133-7]; CNPq MCT/BID (Brazilian Ministry of Science and
   Technology)National Council for Scientific and Technological Development
   (CNPq)
FX The authors thank Patricia Sesterheim, Elisangela S. Prado and Fabiana
   Agena in helping collecting samples and clinical data. We also thank
   FAPESP (06/04133-7) for the provided studentship. This work was
   supported by grants from CNPq MCT/BID (Brazilian Ministry of Science and
   Technology). Authors contributions: Vieira P.M.M.M.-experimental
   procedures, data analysis and interpretation, and writing the
   manuscript; Silva H.M.-collection and/or assembly of data and discussion
   of the manuscript; Takenaka M.-collection and/or assembly of data and
   discussion of the manuscript; Monteiro S.M.-collection and/or assembly
   of data; Lemos F.-provision of study materials, discussion of clinical
   data and discussion of the manuscript; Saitovitch D.-provision of study
   materials, discussion of clinical data and discussion of the manuscript;
   Kalil J.-discussion of data; Coelho V.-conception of study,
   interpretation of data and writing the manuscript.
CR Adeegbe D, 2006, J IMMUNOL, V176, P7149, DOI 10.4049/jimmunol.176.12.7149
   Ahn JS, 2005, INT IMMUNOL, V17, P1337, DOI 10.1093/intimm/dxh312
   Akl A, 2005, TRANSPL IMMUNOL, V14, P225, DOI 10.1016/j.trim.2005.03.011
   Alvarez CM, 2004, TRANSPLANTATION, V78, P1541, DOI 10.1097/01.TP.0000140968.17770.C1
   Bennett BL, 1997, J BIOL CHEM, V272, P10212
   Berlanda M, 2008, TRANSPL P, V40, P1847, DOI 10.1016/j.transproceed.2008.05.013
   Braudeau C, 2007, TRANSPL INT, V20, P845, DOI 10.1111/j.1432-2277.2007.00537.x
   Brouard S, 2005, AM J TRANSPLANT, V5, P330, DOI 10.1111/j.1600-6143.2004.00700.x
   Brouard S, 2007, P NATL ACAD SCI USA, V104, P15448, DOI 10.1073/pnas.0705834104
   Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4
   Chatenoud L, 2005, CURR OPIN IMMUNOL, V17, P632, DOI 10.1016/j.coi.2005.09.011
   Chen NX, 1996, TRANSPLANTATION, V61, P1076, DOI 10.1097/00007890-199604150-00016
   Csencsits K, 2005, EUR J IMMUNOL, V35, P843, DOI 10.1002/eji.200425685
   Davidson C, 2007, TRANSPL IMMUNOL, V17, P178, DOI 10.1016/j.trim.2006.09.035
   Deszo EL, 2004, CELL SIGNAL, V16, P271, DOI 10.1016/S0898-6568(03)00137-2
   Ebner S, 2001, J IMMUNOL, V166, P633, DOI 10.4049/jimmunol.166.1.633
   Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x
   Ganschow R, 2001, TRANSPLANTATION, V72, P929, DOI 10.1097/00007890-200109150-00031
   Golshayan D, 2008, DRUGS, V68, P2113, DOI 10.2165/00003495-200868150-00004
   Hahn BH, 2005, J IMMUNOL, V175, P7728, DOI 10.4049/jimmunol.175.11.7728
   Hale MB, 2006, CURR OPIN MOL THER, V8, P215
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575
   Huber M, 2008, INT IMMUNOL, V20, P223, DOI 10.1093/intimm/dxm139
   Louis S, 2006, TRANSPLANTATION, V81, P398, DOI 10.1097/01.tp.0000203166.44968.86
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Pillemer BBL, 2009, J IMMUNOL, V183, P155, DOI 10.4049/jimmunol.0803733
   Pons JA, 2008, TRANSPLANTATION, V86, P1370, DOI 10.1097/TP.0b013e318188d3e6
   Racusen Lorraine C, 2004, Am J Transplant, V4, P1562, DOI 10.1111/j.1600-6143.2004.00585.x
   Sanchez-Guajardo V, 2007, J IMMUNOL, V178, P7550, DOI 10.4049/jimmunol.178.12.7550
   SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869
   SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401
   Schulz K.R., 2007, CURR PROTOC IMMUNOL, V8, P1
   Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006
   Takaki H, 2008, J BIOL CHEM, V283, P14955, DOI 10.1074/jbc.M801123200
   Takeda K, 1996, J IMMUNOL, V157, P3220
   Velasquez-Lopera MM, 2008, TRANSPL IMMUNOL, V19, P127, DOI 10.1016/j.trim.2008.02.003
   Vieira PM, 2009, CLIN IMMUNOL, V131, pS165, DOI 10.1016/j.clim.2009.03.489
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   Wurtz O, 2004, INT IMMUNOL, V16, P501, DOI 10.1093/intimm/dxh050
   Xu QY, 2007, J IMMUNOL, V178, P3983, DOI 10.4049/jimmunol.178.6.3983
   Yi HF, 2007, CYTOKINE, V37, P35, DOI 10.1016/j.cyto.2007.02.012
   Zhang Feng, 2006, Zhonghua Wai Ke Za Zhi, V44, P1463
NR 45
TC 26
Z9 29
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAY
PY 2010
VL 71
IS 5
BP 442
EP 450
DI 10.1016/j.humimm.2010.01.022
PG 9
WC Immunology
SC Immunology
GA 588QV
UT WOS:000277089300002
PM 20122976
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Barros, MT
   Rizzo, LV
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R. C.
   Barros, M. T.
   Rizzo, L. V.
   Kalil, J.
   Giavina-Bianchi, P.
TI Allergic asthma in patients with common variable immunodeficiency
SO ALLERGY
LA English
DT Article
DE allergens; asthma; bronchial provocation tests; common variable
   immunodeficiency; immunoglobulin E
ID ATOPIC ASTHMATICS; INDUCED INCREASE; CHALLENGE; IGE; PULMONARY; MODEL;
   HYPERRESPONSIVENESS; STANDARDIZATION; RESPONSIVENESS; METHACHOLINE
AB P>Background:
   Many patients with common variable immunodeficiency (CVID) have a clinical history suggestive of allergic respiratory disease. However, in such individuals, the prevalence of asthma and the role of atopy have not been well established. The objective of this study was to evaluate pulmonary function and identify asthma in patients with CVID. We also investigated the role of IgE as a trigger of asthma in these patients.
   Methods:
   Sixty-two patients diagnosed with CVID underwent spirometry, as well as skin prick testing and in vitro determination of serum-specific IgE levels for aeroallergens, together with bronchial provocation with histamine and allergen.
   Results:
   The most common alteration identified through spirometry was obstructive lung disease, which was observed in 29 (47.5%) of the 62 patients evaluated. Eighteen (29.0%) of the 62 patients had a clinical history suggestive of allergic asthma. By the end of the study, asthma had been diagnosed in nine (14.5%) patients and atopy had been identified in six (9.7%). In addition, allergic asthma had been diagnosed in four patients (6.5% of the sample as a whole; 22.2% of the 18 patients with a clinical history suggestive of the diagnosis).
   Conclusion:
   In this study, CVID patients testing negative for specific IgE antibodies and suspected of having allergic asthma presented a positive response to bronchial provocation tests with allergens. To our knowledge, this is the first such study. When CVID patients with a history suggestive of allergic asthma test negative on traditional tests, additional tests designed to identify allergic asthma might be conducted.
C1 [Agondi, R. C.; Barros, M. T.; Rizzo, L. V.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Dept Allergy & Clin Immunol, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 Ap 211A Jd Amer, BR-01454010 Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; Rizzo,
   Luiz Vicente/B-4458-2009
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274; Agondi, Rosana Camara/0000-0002-0503-5179
CR [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1
   Bondioni MP, 2007, J COMPUT ASSIST TOMO, V31, P620, DOI 10.1097/RCT.0b013e31802e3c11
   Busse PJ, 2007, ANN ALLERG ASTHMA IM, V98, P1, DOI 10.1016/S1081-1206(10)60853-8
   Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999
   CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0
   Celestin J, 1999, J ALLERGY CLIN IMMUN, V103, pS146
   Cockcroft DW, 2003, CLIN REV ALLERG IMMU, V24, P19, DOI 10.1385/CRIAI:24:1:19
   COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x
   Corry DB, 1999, NATURE, V402, pB18
   Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   DEMOLY P, 2003, MIDDLETONS ALLERGY P, P631
   FREEZER NJ, 1995, EUR RESPIR J, V8, P1488
   GIAVINABIANCHI P, 1996, ARCH ARGENT INMUNOL, V27, P12
   Global Initiative for Asthma (GINA), 2006, GLOB STRAT ASTHM MAN
   Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN
   Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832
   Kainulainen L, 1999, J ALLERGY CLIN IMMUN, V104, P1031, DOI 10.1016/S0091-6749(99)70085-0
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   MACINTYRE D, 1984, CLIN ALLERGY, V14, P311, DOI 10.1111/j.1365-2222.1984.tb02211.x
   Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344
   Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x
   METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Notarangelo L, 2006, J ALLERGY CLIN IMMUN, V117, P883, DOI 10.1016/j.jaci.2005.12.1347
   Papadopoulou A, 2005, PEDIAT ALLERG IMM-UK, V16, P495, DOI 10.1111/j.1399-3038.2005.00316.x
   *PHIAD, IMMUNOCAPTM TECHN
   PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218
   STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693
   Tanaka N, 2006, J COMPUT ASSIST TOMO, V30, P828, DOI 10.1097/01.rct.0000228163.08968.26
   Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655
   van de Rijn M, 1998, J ALLERGY CLIN IMMUN, V102, P65, DOI 10.1016/S0091-6749(98)70056-9
   Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112
NR 35
TC 47
Z9 48
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD APR
PY 2010
VL 65
IS 4
BP 510
EP 515
DI 10.1111/j.1398-9995.2009.02211.x
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 562ZA
UT WOS:000275093500013
PM 19839975
DA 2020-11-26
ER

PT J
AU Yang, AC
   Arruda, LK
   Santos, ABR
   Barbosa, MCR
   Chapman, MD
   Galvao, CES
   Kalil, J
   Morato-Castro, FF
AF Yang, Ariana C.
   Arruda, L. Karla
   Santos, Ana Beatriz R.
   Barbosa, Michelle C. R.
   Chapman, Martin D.
   Galvao, Clovis E. S.
   Kalil, Jorge
   Morato-Castro, Fabio F.
TI Measurement of IgE antibodies to shrimp tropomyosin is superior to skin
   prick testing with commercial extract and measurement of IgE to shrimp
   for predicting clinically relevant allergic reactions after shrimp
   ingestion
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Food allergy; shrimp; tropomyosin; food challenge; skin prick test;
   specific IgE
ID COMPONENT-RESOLVED DIAGNOSIS; ORAL FOOD CHALLENGES; RECOMBINANT
   ALLERGENS; CROSS-REACTIVITY; PENAEUS-MONODON; SEAFOOD ALLERGY; MAJOR
   ALLERGEN; APPLE ALLERGY; MITE; CHILDREN
AB Background: Shrimp is a frequent cause of food allergy. Tropomyosin is the major allergen in shrimp, and it shares homology to tropomyosins from other crustaceans, dust mites, cockroach, and parasites.
   Objective: The aim of this study was to determine the value of detection of IgE to shrimp tropomyosin in the diagnosis of shrimp allergy.
   Methods: We have studied 35 patients with asthma, rhinitis, or both who were sensitized to Dermatophagoides pteronyssinus. All subjects underwent skin prick testing in addition to double-blind, placebo-controlled food challenges (DBPCFC); oral open challenges; or both with shrimp. Measurements of IgE to shrimp and shrimp tropomyosin were carried out by means of CAP and chimeric ELISA, respectively.
   Results: Oral challenges confirmed the diagnosis of shrimp allergy in 7 patients. IgE measurement to shrimp tropomyosin was positive in 71.4% of the patients with shrimp allergy. Of the 28 patients without shrimp allergy, only 7.1% (2/28) had IgE to shrimp tropomyosin compared with 25% (7/28) who had IgE to shrimp and 35.7% (10/28) who had positive skin prick test responses to shrimp. Sensitivity was similar for all 3 methods (71.4%); in contrast, specificity of IgE to shrimp tropomyosin (92.8%) was greater than that of IgE to shrimp (75%) and skin prick testing (64.2%). With regard to diagnostic efficiency, measurement of IgE to shrimp tropomyosin was superior to measurement of IgE to shrimp and skin prick testing (88.5%, 74.2%, and 65.7%, respectively).
   Conclusion: Use of measurements of IgE to shrimp tropomyosin provided added value to the diagnosis of shrimp allergy. (J Allergy Clin Immunol 2010;125:872-8.)
C1 [Arruda, L. Karla] Univ Sao Paulo, Dept Med, Sch Med Ribeirao Preto, Div Clin Immunol, BR-14110000 Ribeirao Preto, SP, Brazil.
   [Yang, Ariana C.; Galvao, Clovis E. S.; Kalil, Jorge; Morato-Castro, Fabio F.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA.
RP Arruda, LK (corresponding author), Univ Sao Paulo, Dept Med, Sch Med Ribeirao Preto, Div Clin Immunol, Av Bandeirantes 3900, BR-14110000 Ribeirao Preto, SP, Brazil.
EM karla@fmrp.usp.br
RI Arruda, L. Karla/D-5845-2013; KALIL, JORGE/C-8029-2012
OI Arruda, L. Karla/0000-0002-7505-210X; KALIL, JORGE/0000-0001-8415-4274;
   Chapman, Martin/0000-0002-0845-3632
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Institute of
   Investigative Immunology; National Institute of Science and Technology;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX Supported by grants front Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) and by the Institute of Investigative Immunology, iii, a
   National Institute of Science and Technology, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.; Disclosure of
   potential conflict of interest: L. K. Arruda has received research
   support from FAPESP and CNPq, and received honoraria from Novartis and
   Mantecorp. A. B. R. Santos and M. C. R. Barbosa have received research
   support from FAPESP. M. D. Chapman is a co-owner of Indoor
   Biotechnologies, Inc, and has received support front the National
   Institute of Environmental Health Sciences. J. Kalil is a member of the
   Council for EMS. F. F. Morato-Castro has received research support front
   Novartis, AstraZeneca, MSD, Sanofi-Aventis, Boeringher, and Ache and has
   consulted for Sanofi-Aventis. Schering-Plough, and Phadia Brazil. The
   rest of the authors have declared that they have no conflict of
   interest.
CR Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016
   Anibarro B, 2007, J INVEST ALLERG CLIN, V17, P168
   Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105
   Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053
   Audicana MT, 2008, CLIN MICROBIOL REV, V21, P360, DOI 10.1128/CMR.00012-07
   Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023
   Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x
   Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601
   Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5
   Bohle B, 2004, METHODS, V32, P292, DOI 10.1016/j.ymeth.2003.08.008
   Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x
   CHEGINI S, 2003, FOOD ALLERGY ADVERSE, P487
   Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x
   Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x
   Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012
   Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592
   Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610
   Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005
   Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047
   Jirapongsananuruk O, 2008, CLIN EXP ALLERGY, V38, P1038, DOI 10.1111/j.1365-2222.2008.02979.x
   Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6
   Lopata AL, 2009, CURR OPIN ALLERGY CL, V9, P270, DOI 10.1097/ACI.0b013e32832b3e6f
   Ma Y, 2006, CLIN EXP ALLERGY, V36, P1087, DOI 10.1111/j.1365-2222.2006.02541.x
   Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014
   Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116
   Niggemann B, 2007, J PEDIATR GASTR NUTR, V45, P399, DOI 10.1097/MPG.0b013e318054b0c3
   Niggemenn B, 2007, ALLERGY, V62, P729, DOI 10.1111/j.1398-9995.2007.01396.x
   Ott H, 2008, ALLERGY, V63, P1521, DOI 10.1111/j.1398-9995.2008.01748.x
   Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844
   Purohit A, 2007, Eur Ann Allergy Clin Immunol, V39, P85
   Reese G, 2006, CLIN EXP ALLERGY, V36, P517, DOI 10.1111/j.1365-2222.2006.02454.x
   Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201
   Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708
   Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1
   Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147
   Shiomi K, 2008, INT ARCH ALLERGY IMM, V146, P91, DOI 10.1159/000113512
   Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018
   Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021
   Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x
   vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x
   vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x
   Wild LG, 2005, CURR ALLERGY ASTHM R, V5, P74, DOI 10.1007/s11882-005-0059-z
   Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445
NR 43
TC 56
Z9 59
U1 3
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2010
VL 125
IS 4
BP 872
EP 878
DI 10.1016/j.jaci.2009.11.043
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 584XP
UT WOS:000276787900013
PM 20226506
DA 2020-11-26
ER

PT J
AU Bassaneze, V
   Barauna, VG
   Lavini-Ramos, C
   Kalil, J
   Schettert, IT
   Miyakawa, AA
   Krieger, JE
AF Bassaneze, Vinicius
   Barauna, Valerio Garrone
   Lavini-Ramos, Carolina
   Kalil, Jorge
   Schettert, Isolmar Tadeu
   Miyakawa, Ayumi Aurea
   Krieger, Jose Eduardo
TI Shear Stress Induces Nitric Oxide-Mediated Vascular Endothelial Growth
   Factor Production in Human Adipose Tissue Mesenchymal Stem Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID IMPROVE POSTNATAL NEOVASCULARIZATION; BONE-MARROW; DIFFERENTIATION;
   VEGF; EXPRESSION; SYNTHASE; PROLIFERATION; MECHANISMS; HYPOTHESIS;
   SECRETION
AB It has been demonstrated that human adipose tissue-derived mesenchymal stem cells (hASCs) enhance vascular density in ischemic tissues, suggesting that they can differentiate into vascular cells or release angiogenic factors that may stimulate neoangiogenesis. Moreover, there is evidence that shear stress (SS) may activate proliferation and differentiation of embryonic and endothelial precursor stem cells into endothelial cells (ECs). In this work, we investigated the effect of laminar SS in promoting differentiation of hASCs into ECs. SS (10 dyn/cm(2) up to 96 h), produced by a cone plate system, failed to induce EC markers (CD31, vWF, Flk-1) on hASC assayed by RT-PCR and flow cytometry. In contrast, there was a cumulative production of nitric oxide (determined by Griess Reaction) and vascular endothelial growth factor (VEGF; by ELISA) up to 96 h of SS stimulation ( NO2- in nmol/10(4) cells: static: 0.20 +/- 0.03; SS: 1.78 +/- 0.38, n = 6; VEGF in pg/10(4) cells: static: 191.31 +/- v35.29; SS: 372.80 +/- 46.74, n = 6, P < 0.05). Interestingly, the VEGF production was abrogated by 5 mM N(G)-L-nitro-arginine methyl ester (L-NAME) treatment (VEGF in pg/10(4) cells: SS: 378.80 +/- 46.74, n = 6; SS + L-NAME: 205.84 +/- 91.66, n = 4, P < 0.05). The results indicate that even though SS failed to induce EC surface markers in hASC under the tested conditions, it stimulated NO-dependent VEGF production.
C1 [Krieger, Jose Eduardo] Univ Sao Paulo, Sch Med, Inst Heart InCor, Lab Genet & Mol Cardiol, BR-05403000 Sao Paulo, Brazil.
RP Krieger, JE (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart InCor, Lab Genet & Mol Cardiol, Av Dr Eneas de Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM ayumi.miyakawa@incor.usp.br; krieger@incor.usp.br
RI Schettert, Isolmar/D-1355-2012; Bassaneze, Vinicius/E-5577-2012;
   Miyakawa, Ayumi A/M-4343-2015; Barauna, Valerio Jau/A-6115-2013;
   Krieger, Jose E/C-3117-2011; KALIL, JORGE/C-8029-2012
OI Bassaneze, Vinicius/0000-0002-3481-2408; Miyakawa, Ayumi
   A/0000-0003-3911-3259; KALIL, JORGE/0000-0001-8415-4274; Krieger,
   Jose/0000-0001-5464-1792
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [07/58942-0, 08/52436-9, 08/52335-8]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [573887/2008-0]
FX This work was funded by grants from FAPESP (07/58942-0, 08/52436-9,
   08/52335-8) and CNPq (573887/2008-0). The authors want to thank Laura I.
   V. Brandizzi for technical assistance in NO<INF>2</INF><SUP>-</SUP>
   measurements and Dr. Gustavo G. Duarte for assistance during the
   liposuction procedure.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Adamo L, 2009, NATURE, V459, P1131, DOI 10.1038/nature08073
   Azuma N, 2001, AM J PHYSIOL-HEART C, V280, pH189
   Becker C, 2006, INT J CARDIOL, V113, P348, DOI 10.1016/j.ijcard.2005.11.060
   Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5
   BLANDE IS, 2009, TRANSFUSION
   Cao Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI 10.1016/j.bbrc.2005.04.135
   Cao Ying, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P678
   Choi K, 1998, DEVELOPMENT, V125, P725
   Cleaver O, 1998, DEVELOPMENT, V125, P3905
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   DING AH, 1988, J IMMUNOL, V141, P2407
   Dulak J, 2003, ANTIOXID REDOX SIGN, V5, P123, DOI 10.1089/152308603321223612
   Dulak J, 2000, ARTERIOSCL THROM VAS, V20, P659, DOI 10.1161/01.ATV.20.3.659
   Eming SA, 2006, J INVEST DERM SYMP P, V11, P79, DOI 10.1038/sj.jidsymp.5650016
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   GONCALVES GA, GENE THERAP IN PRESS
   Guo J, 2007, INFLAMMATION, V30, P97, DOI 10.1007/s10753-007-9025-3
   Jones EAV, 2006, PHYSIOLOGY, V21, P388, DOI 10.1152/physiol.00020.2006
   Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008-6363(01)00344-3
   Kimura H, 2003, ACTA BIOCHIM POL, V50, P49
   Kimura H, 2002, BIOCHEM BIOPH RES CO, V296, P976, DOI 10.1016/S0006-291X(02)02029-6
   Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197
   Knippenberg M, 2005, TISSUE ENG, V11, P1780, DOI 10.1089/ten.2005.11.1780
   Komori K, 2008, J SEX MED, V5, P1623, DOI 10.1111/j.1743-6109.2008.00772.x
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Lozito TP, 2009, J CELL BIOCHEM, V107, P714, DOI 10.1002/jcb.22167
   Mais A, 2006, J CELL BIOCHEM, V98, P798, DOI 10.1002/jcb.20786
   MALEK A, 1992, AM J PHYSIOL, V263, pC389
   Martinez-Estrada OM, 2005, CARDIOVASC RES, V65, P328, DOI 10.1016/j.cardiores.2004.11.015
   Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0
   Miyakawa AA, 2004, PHYSIOL GENOMICS, V17, P107, DOI 10.1152/physiolgenomics.00169.2003
   Moon MH, 2006, CELL PHYSIOL BIOCHEM, V17, P279, DOI 10.1159/000094140
   Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI14940
   Moroz LL, 1998, BIOCHEM BIOPH RES CO, V253, P571, DOI 10.1006/bbrc.1998.9810
   Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Riha GM, 2005, ANN BIOMED ENG, V33, P772, DOI 10.1007/s10439-005-3310-9
   RUBANYI GM, 1990, BLOOD VESSELS, V27, P246
   Sasaki T, 2005, VIRCHOWS ARCH, V446, P525, DOI 10.1007/s00428-005-1247-x
   Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246
   Stolberg S, 2009, BIOTECHNOL PROGR, V25, P10, DOI 10.1002/btpr.124
   Tjabringa GS, 2006, STEM CELLS, V24, P2262, DOI 10.1634/stemcells.2005-0625
   Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879
   Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001
   Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371
   Wang H, 2005, ARTERIOSCL THROM VAS, V25, P1817, DOI 10.1161/01.ATV.0000175840.90510.a8
   Wang H, 2006, BIOCHEM BIOPH RES CO, V346, P860, DOI 10.1016/j.bbrc.2006.05.196
   Wang MJ, 2007, J MOL CELL CARDIOL, V42, P1009, DOI 10.1016/j.yjmcc.2007.04.010
   Wang Y, 2008, SHOCK, V30, P527, DOI 10.1097/SHK.0b013e31816f1ec9
   Wu CC, 2008, J BIOMECH, V41, P813, DOI 10.1016/j.jbiomech.2007.11.008
   Yamamoto K, 2003, J APPL PHYSIOL, V95, P2081, DOI 10.1152/japplphysiol.00232.2003
   Yamamoto K, 2005, AM J PHYSIOL-HEART C, V288, pH1915, DOI 10.1152/ajpheart.00956.2004
   Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113
   ZHANG P, 2009, STEM CELLS DEV
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 57
TC 51
Z9 51
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAR
PY 2010
VL 19
IS 3
BP 371
EP 378
DI 10.1089/scd.2009.0195
PG 8
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 569EL
UT WOS:000275579000010
PM 19754225
DA 2020-11-26
ER

PT J
AU Agondi, R
   Toledo-Barros, M
   Kokron, C
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R.
   Toledo-Barros, M.
   Kokron, C.
   Kalil, J.
   Giavina-Bianchi, P.
TI Allergic Rhinitis in Common Variable Immunodeficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Agondi, R.; Toledo-Barros, M.; Kokron, C.; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014; Kokron,
   Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB8
EP AB8
DI 10.1016/j.jaci.2009.12.062
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100031
DA 2020-11-26
ER

PT J
AU Aun, MV
   Bisaccioni, C
   Castro-Coelho, A
   Montenegro, FG
   Kalil, J
   Agondi, R
   Giavina-Bianchi, P
AF Aun, M. V.
   Bisaccioni, C.
   Castro-Coelho, A.
   Montenegro, F. G.
   Kalil, J.
   Agondi, R.
   Giavina-Bianchi, P.
TI Hypogammaglobulinemia: Adverse Effect of Systemic Corticosteroid in
   Severe Asthma Patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Aun, M. V.; Bisaccioni, C.; Castro-Coelho, A.; Montenegro, F. G.; Kalil, J.; Agondi, R.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014; Aun,
   Marcelo V/E-6775-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; Aun, Marcelo V/0000-0001-9882-5200
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB70
EP AB70
DI 10.1016/j.jaci.2009.12.275
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100276
DA 2020-11-26
ER

PT J
AU Castro-Coelho, A
   Aun, MV
   Montenegro, FG
   Bisaccioni, C
   Kalil, J
   Agondi, R
   Giavina-Bianchi, P
AF Castro-Coelho, A.
   Aun, M. V.
   Montenegro, F. G.
   Bisaccioni, C.
   Kalil, J.
   Agondi, R.
   Giavina-Bianchi, P.
TI Prevalence of Esophageal Candidiasis Induced by Inhaled Corticosteroids
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Castro-Coelho, A.; Aun, M. V.; Montenegro, F. G.; Bisaccioni, C.; Kalil, J.; Agondi, R.; Giavina-Bianchi, P.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Aun, Marcelo V/E-6775-2014; Giavina-Bianchi,
   Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Aun, Marcelo V/0000-0001-9882-5200;
   Giavina-Bianchi, Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB70
EP AB70
DI 10.1016/j.jaci.2009.12.273
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100274
DA 2020-11-26
ER

PT J
AU Kokron, CM
   Nicoletti, BC
   Galvao, CE
   Giavina-Bianchi, P
   Santos, BFC
   Castro, FFM
   Kalil, J
AF Kokron, C. M.
   Nicoletti, B. C.
   Galvao, C. E.
   Giavina-Bianchi, P.
   Santos, B. F. C.
   Castro, F. F. M.
   Kalil, J.
TI Evaluation of the Prevalence of Rat and Mouse Allergens Sensitization in
   Asthmatic Patients Followed at Hospital das Clinicas at Sao Paulo,
   Brazil
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Kokron, C. M.; Nicoletti, B. C.; Galvao, C. E.; Giavina-Bianchi, P.; Castro, F. F. M.; Kalil, J.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Santos, B. F. C.] Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; Castro, Fabio FM/C-1082-2017; KALIL,
   JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; Castro, Fabio
   FM/0000-0002-6211-5773; KALIL, JORGE/0000-0001-8415-4274; Kokron,
   Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB18
EP AB18
DI 10.1016/j.jaci.2009.12.101
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100070
DA 2020-11-26
ER

PT J
AU Penterich, VRA
   Matte, MH
   Yang, AC
   Castro, FFM
   Kalil, J
   Silva, MEMPE
AF Penterich, V. R. A.
   Matte, M. H.
   Yang, A. C.
   Castro, F. F. M.
   Kalil, J.
   Pinto e Silva, M. E. M.
TI Development of an Infant Formula with Chicken Hydrolysate for Children
   from 0 to 12 months with Adverse Reaction to Milk
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Penterich, V. R. A.; Matte, M. H.; Pinto e Silva, M. E. M.] Unnivers Sao Paulo, Inst Publ Hlth, Sao Paulo, Brazil.
   [Penterich, V. R. A.; Yang, A. C.; Castro, F. F. M.; Kalil, J.] Unnivers Sao Paulo, Sch Med, Dept Allergy & Immunol, Sao Paulo, Brazil.
RI Pinto-e-Silva, Maria Elisabeth Machado/A-8004-2010; Castro,
   Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017
OI Pinto-e-Silva, Maria Elisabeth Machado/0000-0003-0755-6290; KALIL,
   JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB220
EP AB220
DI 10.1016/j.jaci.2009.12.859
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100859
DA 2020-11-26
ER

PT J
AU Yang, AC
   Arruda, LK
   Santos, ABR
   Barbosa, MCR
   Chapman, MD
   Kalil, J
   Castro, FFM
AF Yang, A. C.
   Arruda, L. K.
   Santos, A. B. R.
   Barbosa, M. C. R.
   Chapman, M. D.
   Kalil, J.
   Castro, F. F. M.
TI Cross-reactivity Between Mite And Shrimp: The Effect Of Immunotherapy
   With Dust Mite Extract
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 26-MAR 02, 2010
CL New Orleans, LA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Yang, A. C.; Castro, F. F. M.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Arruda, L. K.; Santos, A. B. R.; Barbosa, M. C. R.] Univ Sao Paulo, Sch Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Chapman, M. D.] Indoor Biothecnol Inc, Charlottesville, VA USA.
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017; Arruda, L. Karla/D-5845-2013
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773;
   Arruda, L. Karla/0000-0002-7505-210X
NR 0
TC 2
Z9 2
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2010
VL 125
IS 2
SU 1
BP AB35
EP AB35
DI 10.1016/j.jaci.2009.12.168
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 629MS
UT WOS:000280204100137
DA 2020-11-26
ER

PT J
AU Watanabe, AS
   Fonseca, LAM
   Galvao, CES
   Kalil, J
   Castro, FFM
AF Watanabe, Alexandra Sayuri
   Marcondes Fonseca, Luiz Augusto
   Santos Galvao, Clovis Eduardo
   Kalil, Jorge
   Morato Castro, Fabio Fernandes
TI Specific immunotherapy using Hymenoptera venom: systematic review
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Review
DE Hymenoptera; Insects; Immunotherapy; Meta-analysis [publication type];
   Review [publication type]
ID IMPORTED FIRE ANT; INSECT STING ALLERGY; NATURAL-HISTORY;
   HYPERSENSITIVITY; CHILDREN; EPIDEMIOLOGY; ANAPHYLAXIS; MANAGEMENT;
   SYMPTOMS; QUALITY
AB CONTEXT AND OBJECTIVE: The only effective treatment for patients who have severe reactions after Hymenoptera stings is venom immunotherapy. The aim of this study was to review the literature to assess the effects of venom immunotherapy among patients presenting severe reactions after Hymenoptera stings.
   DESIGN AND SETTING: Randomized controlled trials in the worldwide literature were reviewed. The manuscript was produced in the Discipline of Allergy and Clinical Immunology, Universidade de Sao Paulo (USP).
   METHODS: Randomized controlled trials involving venom immunotherapy versus placebo or only patient follow-up were evaluated. The risk of systemic reactions after specific immunotherapy was evaluated by calculating odds ratios (OR) and their 95% confidence intervals.
   RESULTS: 2,273 abstracts were identified by the keywords search. Only four studies were included in this review. The chi-square test for heterogeneity showed that two studies were homogeneous and could be included in a meta-analysis. By combining the two studies, the odds ratio became significant: 0.29 (0.10-0.87). However, analysis on the severity of the reactions after immunotherapy showed that the benefits may not be so significant because the reactions were mostly similar to or milder than the original reaction.
   CONCLUSIONS: Specific immunotherapy should be recommended for adults and children with moderate to severe reactions, but there is no need to prescribe it for children with skin reactions alone, especially if the exposure is very sporadic. On the other hand, the risk-benefit relation should always be assessed in each case.
C1 [Watanabe, Alexandra Sayuri] Univ Sao Paulo, Discipline Allergy & Clin Immunol, BR-01246903 Sao Paulo, Brazil.
   [Marcondes Fonseca, Luiz Augusto; Santos Galvao, Clovis Eduardo; Kalil, Jorge; Morato Castro, Fabio Fernandes] Hosp Clin Sao Paulo, Clin Immunol & Allergy Serv, Sao Paulo, Brazil.
RP Watanabe, AS (corresponding author), Univ Sao Paulo, Fac Med, Dept Clin Med, Av Dr Endes Carvalho Aguiar 155, BR-01246903 Sao Paulo, Brazil.
EM ale.watanabe@ig.com.br
RI KALIL, JORGE/C-8029-2012; Castro, Fabio FM/C-1082-2017; Castro,
   Fabio/AAP-5433-2020; Fonseca, Luiz Augusto M/F-9344-2012
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773; 
CR Antonicelli L, 2002, CURR OPIN ALLERGY CL, V2, P341, DOI 10.1097/00130832-200208000-00008
   Blaauw PJ, 1996, J ALLERGY CLIN IMMUN, V98, P39, DOI 10.1016/S0091-6749(96)70224-5
   Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9
   CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x
   Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827
   FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B
   Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005
   Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952
   GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5
   GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240
   Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7
   Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x
   HOFFMAN DR, 1991, ANN ALLERGY, V66, P29
   HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401
   Incorvaia C, 1999, ALLERGY, V54, P50, DOI 10.1111/j.1398-9995.1999.tb04751.x
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6
   Kipper D J, 1998, J Pediatr (Rio J), V74, P243
   Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8
   Lui CL, 1995, ASIAN PAC J ALLERGY, V13, P95
   Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046
   Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125, DOI 10.1016/S1081-1206(10)63098-0
   REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0
   RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9
   Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9
   SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0
   Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956
   TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7
   TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019
   VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305
NR 30
TC 18
Z9 19
U1 0
U2 6
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD JAN 7
PY 2010
VL 128
IS 1
BP 30
EP 37
DI 10.1590/S1516-31802010000100007
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 599PB
UT WOS:000277924500007
PM 20512278
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Kalil, J
AF Guilherme, Luiza
   Kalil, Jorge
TI Rheumatic Fever and Rheumatic Heart Disease: Cellular Mechanisms Leading
   Autoimmune Reactivity and Disease
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE S. pyogenes; M protein; T cells; T cell receptor; cytokines; heart
   tissue proteins; autoimmunity
ID MANNOSE-BINDING LECTIN; NECROSIS-FACTOR-ALPHA; GENE POLYMORPHISM;
   ASSOCIATION; PATHOGENESIS; LYMPHOCYTES; CARDITIS; MIMICRY; CELLS;
   SPECIFICITY
AB Rheumatic fever (RF) is an autoimmune disease caused by the gram-positive bacteria Streptococcus pyogenes that follows a nontreated throat infection in susceptible children. The disease manifests as polyarthritis, carditis, chorea, erythema marginatum, and/or subcutaneous nodules. Carditis, the most serious complication, occurs in 30% to 45% of RF patients and leads to chronic rheumatic heart disease (RHD), which is characterized by progressive and permanent valvular lesions. In this review, we will focus on the genes that confer susceptibility for developing the disease, as well as the innate and adaptive immune responses against S. pyogenes during the acute rheumatic fever episode that leads to RHD autoimmune reactions.
   The disease is genetically determined, and some human leukocyte antigen class II alleles are involved with susceptibility. Other single nucleotide polymorphisms for TNF-alpha and mannan-binding lectin genes were reported as associated with RF/RHD. T cells play an important role in RHD heart lesions. Several autoantigens were already identified, including cardiac myosin epitopes, vimentin, and other intracellular proteins. In the heart tissue, antigen-driven oligoclonal T cell expansions were probably the effectors of the rheumatic heart lesions. These cells are CD4(+) and produced inflammatory cytokines (TNF alpha and IFN gamma).
   Molecular mimicry is the mechanism that mediated the cross-reactions between streptococcal antigens and human proteins. The elucidation of chemokines and their receptors involved with the recruitment of Th1, Th2, and Th17 cells, as well as the function of T regulatory cells in situ will certainly contribute to the delineation of the real picture of the heart lesion process that leads to RHD.
C1 [Guilherme, Luiza; Kalil, Jorge] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05403903 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, BR-05403903 Sao Paulo, Brazil.
   [Guilherme, Luiza; Kalil, Jorge] CNPq, INCT Natl Inst Sci & Technol, Inst Immunol Invest, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Av Dr Eneas de Carvalho Aguiar 44, BR-05403903 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX We acknowledge all of the people at the Heart Institute (InCor), School
   of Medicine from the University of Sao Paulo that contributed to the
   scientific data published elsewhere and described in this review. This
   work was supported by grants from "Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)".
CR Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guilherme L, 2007, SCAND J IMMUNOL, V66, P199, DOI 10.1111/j.1365-3083.2007.01974.x
   Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guillard C, 2005, INT J PHOTOENERGY, V7, P1, DOI 10.1155/S1110662X05000012
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873
   Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1
   NIGAM SK, 1994, J BIOL CHEM, V269, P1744
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Ramasawmy R, 2008, CLIN VACCINE IMMUNOL, V15, P932, DOI 10.1128/CVI.00324-07
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Schafranski MD, 2008, MOL IMMUNOL, V45, P3827, DOI 10.1016/j.molimm.2008.05.013
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   YOSHINAGA M, 1995, J AUTOIMMUN, V8, P601, DOI 10.1016/0896-8411(95)90011-X
NR 32
TC 96
Z9 101
U1 2
U2 25
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD JAN
PY 2010
VL 30
IS 1
SI SI
BP 17
EP 23
DI 10.1007/s10875-009-9332-6
PG 7
WC Immunology
SC Immunology
GA 555OH
UT WOS:000274521300003
PM 19802690
DA 2020-11-26
ER

PT J
AU Porta, G
   Oliveira, LC
   Marin, ML
   Kalil, J
   Goldberg, AC
AF Porta, G.
   Oliveira, L. C.
   Marin, M. L.
   Kalil, J.
   Goldberg, A. C.
TI CTLA-4 HAPLOTYPE ASSOCIATED WITH ADDITIONAL SUSCEPTIBILITY FACTOR IN
   PEDIATRIC TYPE-1 AUTOIMMUNE HEPATITIS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Porta, G.] Univ Sao Paulo, Sch Med, Clin Hosp, Children Inst,Dept Hepatol, BR-05508 Sao Paulo, Brazil.
   [Oliveira, L. C.] Univ Sao Paulo, Sch Med, Clin Hosp, Lab Pediat Invest LIM 36, BR-05508 Sao Paulo, Brazil.
   [Marin, M. L.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, BR-05508 Sao Paulo, Brazil.
   [Marin, M. L.] Univ Sao Paulo, Sch Med, Lab Histocompatibil & Immun LIM19, BR-05508 Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, BR-05508 Sao Paulo, Brazil.
   [Goldberg, A. C.] Albert Einstein Inst Educ & Res, Sao Paulo, Brazil.
   [Goldberg, A. C.] Natl Inst Sci & Technol INCT, Inst Invest Immunol, Sao Paulo, Brazil.
EM gildaporta@gmail.com
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S430
EP S430
DI 10.1016/S0168-8278(10)61113-0
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018002312
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Postol, E
   de Barros, SF
   Higa, F
   Alencar, R
   Lastre, M
   Zayas, C
   Puschel, CR
   Silva, WR
   Sa-Rocha, LC
   Sa-Rocha, VM
   Perez, O
   Kalil, J
AF Guilherme, L.
   Postol, E.
   de Barros, S. Freschi
   Higa, F.
   Alencar, R.
   Lastre, M.
   Zayas, C.
   Puschel, C. R.
   Silva, W. R.
   Sa-Rocha, L. C.
   Sa-Rocha, V. M.
   Perez, O.
   Kalil, J.
TI A vaccine against S. pyogenes: Design and experimental immune response
SO METHODS
LA English
DT Article
DE S. pyogenes; M protein; Vaccine; Autoimmunity; Adjuvant; Experimental
   assays; Immune response; Antibodies; Cytokines
ID A STREPTOCOCCAL VACCINE; RHEUMATIC HEART-DISEASE; M-PROTEIN; FEVER;
   IMMUNOGENICITY; ANTIBODIES; PROGRESS
AB Streptococcus pyogenes causes severe invasive infections: the post-streptococcal sequelae of acute rheumatic fever (RF) and rheumatic heart disease (RHD), acute glomerulonephritis, and uncomplicated pharyngitis and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. Here, we describe the methodology used in the development of a new vaccine model, consisting of both T and B protective epitopes constructed as synthetic peptides and recombinant proteins. Two adjuvants were tested in an experimental inbred mouse model: a classical Freund's adjuvant and a new adjuvant (AFCo1) that induces mucosal immune responses and is obtained by calcium precipitation of a proteoliposome derived from the outer membrane of Neisseria meningitides B. The StreptInCor vaccine epitope co-administrated with AFCo1 adjuvant induced mucosal (IgA) and systemic (IgG) antibodies as preferential Th1-mediated immune responses. No autoimmune reactions were observed, suggesting that the vaccine epitope is safe. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Guilherme, L.; Postol, E.; de Barros, S. Freschi; Higa, F.; Alencar, R.; Puschel, C. R.; Silva, W. R.; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05508 Sao Paulo, Brazil.
   [Guilherme, L.; Postol, E.; de Barros, S. Freschi; Higa, F.; Alencar, R.; Puschel, C. R.; Silva, W. R.; Kalil, J.] Univ Sao Paulo, Sch Med, Inst Invest Immunol, BR-05508 Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   [Lastre, M.; Zayas, C.; Perez, O.] Finlay Inst, Havana, Cuba.
   [Sa-Rocha, L. C.; Sa-Rocha, V. M.] Univ Sao Paulo, Sch Vet Med, BR-05508 Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), HC FMUSP, Inst Coracao, Lab Imunol, Av Dr Eneas Carvalho Aguiar,44-9 Andar, BR-05403903 Sao Paulo, Brazil.
EM luizagui@usp.br
RI de Barros, Samar Freschi/Q-4970-2018; Guglielmi, Luiza G/E-7676-2013;
   KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Sa-Rocha, Luiz
   Carlos/0000-0002-2449-1903
FU "Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)"Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); "Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)" from BrazilNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by grants from "Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)" from Brazil.
CR Batzloff MR, 2003, J INFECT DIS, V187, P1598, DOI 10.1086/374800
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   COX JC, 1997, VACCINE, V15, P228
   Dale JB, 2008, ADV EXP MED BIOL, V609, P53, DOI 10.1007/978-0-387-73960-1_5
   Dale JB, 2005, CLIN DIAGN LAB IMMUN, V12, P833, DOI 10.1128/CDLI.12.7.833-836.2005
   Esposito D, 2006, CURR OPIN BIOTECH, V17, P353, DOI 10.1016/j.copbio.2006.06.003
   Good MF, 2002, INTERN MED J, V32, P132, DOI 10.1046/j.1444-0903.2001.00203.x
   Guilherme L, 2007, SCAND J IMMUNOL, V66, P199, DOI 10.1111/j.1365-3083.2007.01974.x
   Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868
   Olive C, 2007, CURR OPIN MOL THER, V9, P25
   Perez O, 2004, IMMUNOL CELL BIOL, V82, P603, DOI 10.1111/j.1440-1711.2004.01293.x
   PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235
   Sambrook JF, 2001, LAB MANUAL
NR 16
TC 32
Z9 32
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD DEC
PY 2009
VL 49
IS 4
BP 316
EP 321
DI 10.1016/j.ymeth.2009.03.024
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 524FP
UT WOS:000272129500004
PM 19409999
DA 2020-11-26
ER

PT J
AU Blande, IS
   Bassaneze, V
   Lavini-Ramos, C
   Fae, KC
   Kalil, J
   Miyakawa, AA
   Schettert, IT
   Krieger, JE
AF Blande, Ivan Souza
   Bassaneze, Vinicius
   Lavini-Ramos, Carolina
   Fae, Kellen Cristhina
   Kalil, Jorge
   Miyakawa, Ayumi Aurea
   Schettert, Isolmar Tadeu
   Krieger, Jose Eduardo
TI Adipose tissue mesenchymal stem cell expansion in animal serum-free
   medium supplemented with autologous human platelet lysate
SO TRANSFUSION
LA English
DT Article
ID IN-VITRO EXPANSION; FETAL CALF SERUM; STROMAL CELLS; THERAPY; FISTULA;
   DIFFERENTIATION; TRANSPLANTATION; DISEASE; SAFETY
AB BACKGROUND: Mesenchymal stem cells (MSCs) have been considered for human regenerative therapy applications, and safe culture and expansion protocols are needed especially in the context of interspecies contamination. Human platelet lysate (PL) has been proposed as animal serum substitute during in vitro MSC expansion. In this work, a simplified and efficient method to obtain autologous PL to replace animal serum in cell culture applications is described.
   STUDY DESIGN AND METHODS: PL obtained by freezing and centrifugation procedures was tested as medium supplement for human adipose mesenchymal stem cell (hASC) culture. Differential proliferation, immunophenotypic changes, and differentiation under PL or fetal bovine serum (FBS) were assessed.
   RESULTS: In contrast to 10% FBS supplementation, cell population doubling time was significantly lower when hASCs were cultured with the same concentration of PL ( PL 22.9 +/- 1.5 hr vs. FBS 106.7 +/- 6.5 hr, t test, p < 0.05). Furthermore, hASCs maintained with 2.5% PL supplementation also showed satisfactory results. Immunophenotypic analysis revealed no differences between hASCs cultivated with PL or FBS supplementation and both cultures retained the potential to differentiate into adipose cells. These results demonstrate that autologous PL obtained from the same donor can be used as animal serum substitute in hASC culture.
   CONCLUSIONS: Taken together, evidence is provided that platelets provided by a single donor are sufficient to obtain PL for hASC propagation for clinical-scale applications mitigating the potential untoward side effects associated with the use of animal-derived reagents.
C1 [Krieger, Jose Eduardo] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet & Mol Cardiol LIM 13, BR-05403000 Sao Paulo, Brazil.
RP Krieger, JE (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet & Mol Cardiol LIM 13, Av Dr Eneas de Carvalho Aguiar,44-10 Andar, BR-05403000 Sao Paulo, Brazil.
EM krieger@incor.usp.br
RI Miyakawa, Ayumi A/M-4343-2015; KALIL, JORGE/C-8029-2012; Schettert,
   Isolmar/D-1355-2012; Bassaneze, Vinicius/E-5577-2012; Krieger, Jose
   E/C-3117-2011
OI Miyakawa, Ayumi A/0000-0003-3911-3259; KALIL, JORGE/0000-0001-8415-4274;
   Bassaneze, Vinicius/0000-0002-3481-2408; Krieger,
   Jose/0000-0001-5464-1792
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [08/52436-9, 2006/55707-8,
   2005/57591-4]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq) [552324/2005-1, 100041/2006-0]
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo ( FAPESP 08/52436-9) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico ( CNPq 552324/2005-1). ISB, VB,
   and CLR are recipients of training fellowships of FAPESP 2006/55707-8,
   2005/57591-4, and CNPq 100041/2006-0, respectively.
CR Bernardo ME, 2007, J CELL PHYSIOL, V211, P121, DOI 10.1002/jcp.20911
   Black LL, 2007, VET THER, V8, P272
   Chapman WC, 2007, J AM COLL SURGEONS, V205, P252, DOI 10.1016/j.jamcollsurg.2007.03.020
   Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391
   Fang BJ, 2007, PEDIATR TRANSPLANT, V11, P814, DOI 10.1111/j.1399-3046.2007.00780.x
   Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-005-0052-6
   Garcia-Olmo D, 2003, INT J COLORECTAL DIS, V18, P451, DOI 10.1007/s00384-003-0490-3
   Garcia-Olmo D, 2009, DIS COLON RECTUM, V52, P79, DOI 10.1007/DCR.0b013e3181973487
   Heffernan JK, 2007, REGUL TOXICOL PHARM, V47, P48, DOI 10.1016/j.yrtph.2006.07.006
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kocaoemer A, 2007, STEM CELLS, V25, P1270, DOI 10.1634/stemcells.2006-0627
   Lawson JH, 2005, ANN THORAC SURG, V79, P1037, DOI 10.1016/j.athoracsur.2003.09.110
   Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   Ortel TL, 2001, ANN SURG, V233, P88, DOI 10.1097/00000658-200101000-00014
   Preti RA, 2001, CANCER J, V7, pS62
   Ringden O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Schallmoser K, 2007, TRANSFUSION, V47, P1436, DOI 10.1111/j.1537-2995.2007.01220.x
   Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005-0094
   Stute N, 2004, EXP HEMATOL, V32, P1212, DOI 10.1016/j.exphem.2004.09.003
   Trivedi HL, 2008, TRANSPL P, V40, P1135, DOI 10.1016/j.transproceed.2008.03.113
NR 20
TC 77
Z9 84
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2009
VL 49
IS 12
BP 2680
EP 2685
DI 10.1111/j.1537-2995.2009.02346.x
PG 6
WC Hematology
SC Hematology
GA 527CT
UT WOS:000272344900020
PM 19694997
DA 2020-11-26
ER

PT J
AU Silva, HM
   Vieira, PMMM
   Costa, PLN
   Pimentel, BMS
   Moro, AM
   Kalil, J
   Maranhao, AQ
   Coelho, V
   Brigido, MM
AF Silva, Hernandez M.
   Vieira, Pedro M. M. M.
   Costa, Patricia L. N.
   Pimentel, Barbara M. S.
   Moro, Ana M.
   Kalil, Jorge
   Maranhao, Andrea Q.
   Coelho, Veronica
   Brigido, Marcelo M.
TI Novel humanized anti-CD3 antibodies induce a predominantly
   immunoregulatory profile in human peripheral blood mononuclear cells
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Antibody engineering; Antibody humanization; Anti-CD3; CD3; IL-10
ID RENAL-ALLOGRAFT REJECTION; MONOCLONAL-ANTIBODY; T-CELLS; PHASE-I;
   TOLERANCE; THERAPY; ANTIGEN; BINDING; CD3; EXPRESSION
AB Strategies to minimize the immunogenicity and toxicity of murine anti-CD3 antibodies (e.g. OKT3) are of special interest for organ transplantation and for the treatment of autoimmune diseases. In the present work, we have developed two humanized anti-CD3 antibodies. These molecules were shown to bind to human CD3, though less efficiently, and display less mitogenic activity than CKT3. These results prompted us to investigate whether this reduced mitogenic potential was associated with the development of anti-inflammatory properties. Indeed, in peripheral blood mononuclear cells (PBMCs), the humanized antibody versions induced a predominantly anti-inflammatory cytokine profile, in contrast with the pro-inflammatory profile induced by OKT3. Neither OKT3 nor the humanized versions induced the expression of IL-4, IL-2 or TGF-beta. Both humanized antibodies induced significantly lower production of IFN-gamma and IL-5 and slightly higher production of IL-10 than OKT3. This immunomodulatory profile was most evident by the 80-fold higher ratio of IL-10/IFN-gamma production in PBMCs cultured in the presence of the humanized antibodies, compared to those stimulated with CKT3. Furthermore, these humanized anti-CD3 antibodies induced a late FOXP3 gene expression while OKT3 led to a more transient expression of FOXP3. Taken our results, we suggest that these humanized anti-CD3 antibodies may promote the development of T cells with immunoregulatory activity. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Silva, Hernandez M.; Costa, Patricia L. N.; Pimentel, Barbara M. S.; Maranhao, Andrea Q.; Brigido, Marcelo M.] Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil.
   [Silva, Hernandez M.; Vieira, Pedro M. M. M.; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   [Silva, Hernandez M.; Vieira, Pedro M. M. M.; Moro, Ana M.; Kalil, Jorge; Maranhao, Andrea Q.; Coelho, Veronica; Brigido, Marcelo M.] Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   [Moro, Ana M.] Inst Butantan, Lab Especial Biofarm Celula Anim, BR-05503900 Sao Paulo, Brazil.
RP Brigido, MM (corresponding author), Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil.
EM brigido@unb.br
RI KALIL, JORGE/C-8029-2012; Maranh\\xc3\\xa3o, Andrea Queiroz/S-8696-2019;
   Brigido, Marcelo/N-9277-2019; Brigido, Marcelo/H-2718-2019; Maranhao,
   Andrea Q/L-4474-2013; Maranhao, Andrea/AAC-3560-2019; COELHO,
   VERONICA/D-1433-2013; Moraes-Vieira, Pedro M/C-8701-2014; Moro, Ana
   Maria/A-5134-2012; Brigido, Marcelo/A-1972-2015
OI KALIL, JORGE/0000-0001-8415-4274; Brigido, Marcelo/0000-0002-7136-7059;
   Maranhao, Andrea Q/0000-0002-1946-7191; Maranhao,
   Andrea/0000-0002-1946-7191; Moraes-Vieira, Pedro M/0000-0002-8263-786X;
   Moro, Ana Maria/0000-0002-0650-7764; Coelho,
   Veronica/0000-0002-0989-2581
FU MCT/BID (Brazilian Ministry of Science and Technology)
FX We thank Sandra Maria Monteiro for help in the FACS analyses and CNPq
   for the provided studentship. This work was supported by grants from
   MCT/BID (Brazilian Ministry of Science and Technology).
CR ALTSHUL SF, 1997, NUCLEIC ACIDS RES, V25, P402
   Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45
   Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924
   Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6
   Caldas C, 2003, MOL IMMUNOL, V39, P941, DOI 10.1016/S0161-5890(03)00022-1
   Caldas C, 2000, PROTEIN ENG, V13, P353, DOI 10.1093/protein/13.5.353
   Carpenter PA, 2002, BLOOD, V99, P2712, DOI 10.1182/blood.V99.8.2712
   Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000
   Chatenoud L, 2007, NAT REV IMMUNOL, V7, P622, DOI 10.1038/nri2134
   COSIMI AB, 1981, TRANSPLANTATION, V32, P535, DOI 10.1097/00007890-198112000-00018
   Costa P. L. N., 2003, Molecular & Cellular Proteomics, V2, P760
   de Andrade EV, 2000, J BIOCHEM-TOKYO, V128, P891, DOI 10.1093/oxfordjournals.jbchem.a022838
   Friend PJ, 1999, TRANSPLANTATION, V68, P1632, DOI 10.1097/00007890-199912150-00005
   Group OMTS, 1985, NEW ENGL J MED, V313, P337
   Herold KC, 2005, DIABETES, V54, P1763, DOI 10.2337/diabetes.54.6.1763
   Herrero C, 2003, J IMMUNOL, V171, P5034, DOI 10.4049/jimmunol.171.10.5034
   Higgins DG, 1996, METHOD ENZYMOL, V266, P383
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   HUBER C, 1993, EUR J IMMUNOL, V23, P2868, DOI 10.1002/eji.1830231121
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Kabat E, 1991, SEQUENCES PROTEINS I
   Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525
   Li BH, 2005, IMMUNOLOGY, V116, P487, DOI 10.1111/j.1365-2567.2005.02247.x
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4
   NICOLLS MR, 1993, TRANSPLANTATION, V55, P459, DOI 10.1097/00007890-199303000-00001
   Pavlinkova G, 2001, INT J CANCER, V94, P717, DOI 10.1002/ijc.1523
   Pearson W R, 2000, Methods Mol Biol, V132, P185
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   RECHAVI G, 1983, P NATL ACAD SCI-BIOL, V80, P855, DOI 10.1073/pnas.80.3.855
   RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8
   Sambrook J, 2001, MOL CLONING LAB MANU
   Schwarz M, 2004, FASEB J, V18, P1704, DOI 10.1096/fj.04-1513fje
   Utset TO, 2002, J RHEUMATOL, V29, P1907
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003
   You S, 2007, P NATL ACAD SCI USA, V104, P6335, DOI 10.1073/pnas.0701171104
   Zheng DX, 2007, CELL RES, V17, P303, DOI 10.1038/cr.2007.13
NR 39
TC 8
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD AUG 15
PY 2009
VL 125
IS 2
BP 129
EP 136
DI 10.1016/j.imlet.2009.06.009
PG 8
WC Immunology
SC Immunology
GA 491RX
UT WOS:000269598200008
PM 19573559
DA 2020-11-26
ER

PT J
AU Bisaccioni, C
   Cajuela, E
   Agondi, RC
   Kalil, J
   Giavina-Bianchi, P
AF Bisaccioni, C.
   Cajuela, E.
   Agondi, R. Camara
   Kalil, J.
   Giavina-Bianchi, P.
TI Vocal Cord Dysfunction in a Patient with Schizophrenia
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Letter
C1 [Bisaccioni, C.; Cajuela, E.; Agondi, R. Camara; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR CORREN J, 1992, POSTGRAD MED, V92, P153
   Freedman R, 2003, NEW ENGL J MED, V349, P1738, DOI 10.1056/NEJMra035458
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, pS165, DOI 10.1016/j.jaci.2006.12.007
   Hicks DM, 2002, J VOICE, V16, P564, DOI 10.1016/S0892-1997(02)00132-7
   Koufman J.A., 1994, VISIBLE VOICE, V3, P49
   Mohamed S, 2008, AM J PSYCHIAT, V165, P978, DOI 10.1176/appi.ajp.2008.07111713
   Morrison M, 1999, J VOICE, V13, P447, DOI 10.1016/S0892-1997(99)80049-6
   NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399
   OCONNELL MA, 1995, ANN ALLERG ASTHMA IM, V74, P341
   TRUDEAU MD, 1998, NEWSLETTER, V8, P11
NR 10
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD JUL-AUG
PY 2009
VL 37
IS 4
BP 217
EP 219
DI 10.1016/j.aller.2009.02.002
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA 509RI
UT WOS:000271035500011
PM 19912980
DA 2020-11-26
ER

PT J
AU Victora, GD
   Socorro-Silva, A
   Volsi, EC
   Abdallah, K
   Lima, FD
   Smith, RB
   Moyses, RA
   Zarate-Blades, CR
   Michaluart, P
   Silva, CL
   Kalil, J
   Coelho, V
AF Victora, G. D.
   Socorro-Silva, A.
   Volsi, E. C.
   Abdallah, K.
   Lima, F. D.
   Smith, R. B.
   Moyses, R. A.
   Zarate-Blades, C. R.
   Michaluart, P.
   Silva, C. L.
   Kalil, J.
   Coelho, V.
TI Immune response to vaccination with DNA-hsp65 in a phase I clinical
   trial with head and neck cancer patients
SO CANCER GENE THERAPY
LA English
DT Article
DE cancer immunotherapy; head and neck malignancies; heat shock proteins;
   autoimmunity; immune response to vaccination
ID MYCOBACTERIUM-TUBERCULOSIS; SHOCK PROTEINS; T-CELLS; DNA VACCINES;
   ARTHRITIS; THERAPY; INDUCTION; HEAT-SHOCK-PROTEIN-60; ATHEROSCLEROSIS;
   AUTOREACTIVITY
AB DNA-hsp65, a DNA vaccine encoding the 65-kDa heat-shock protein of Mycobacterium leprae (Hsp65) is capable of inducing the reduction of established tumors in mouse models. We conducted a phase I clinical trial of DNA-hsp65 in patients with advanced head and neck carcinoma. In this article, we report on the vaccine's potential to induce immune responses to Hsp65 and to its human homologue, Hsp60, in these patients. Twenty-one patients with unresectable squamous cell carcinoma of the head and neck received three doses of 150, 400 or 600 mu g naked DNA-hsp65 plasmid by ultrasound-guided intratumoral injection. Vaccination did not increase levels of circulating anti-hsp65 IgG or IgM antibody, or lead to detectable Hsp65-specific cell proliferation or interferon-gamma (IFN-gamma) production by blood mononuclear cells. Frequency of antigen-induced IL-10-producing cells increased after vaccination in 4 of 13 patients analyzed. Five patients showed disease stability or regression following immunization; however, we were unable to detect significant differences between these patients and those with disease progression using these parameters. There was also no increase in antibody or IFN-gamma responses to human Hsp60 in these patients. Our results suggest that although DNA-hsp65 was able to induce some degree of immunostimulation with no evidence of pathological autoimmunity, we were unable to differentiate between patients with different clinical outcomes based on the parameters measured. Future studies should focus on characterizing more reliable correlations between immune response parameters and clinical outcome that may be used as predictors of vaccine success in immunosuppressed individuals. Cancer Gene Therapy (2009) 16, 598-608; doi:10.1038/cgt.2009.9; published online 6 February 2009
C1 [Victora, G. D.; Socorro-Silva, A.; Volsi, E. C.; Kalil, J.; Coelho, V.] Univ Sao Paulo, Sch Med, Immunol Lab, Heart Inst InCor, Sao Paulo, Brazil.
   [Victora, G. D.; Socorro-Silva, A.; Volsi, E. C.; Abdallah, K.; Lima, F. D.; Kalil, J.; Coelho, V.] Univ Sao Paulo, Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   [Victora, G. D.] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.
   [Socorro-Silva, A.; Volsi, E. C.; Abdallah, K.; Lima, F. D.; Kalil, J.; Coelho, V.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Smith, R. B.; Moyses, R. A.; Michaluart, P.] Univ Sao Paulo, Sch Med, Dept Surg, Div Head & Neck Surg, Sao Paulo, Brazil.
   [Zarate-Blades, C. R.; Silva, C. L.] Univ Sao Paulo, REDE TB Millennium Inst, Ctr TB Res, Sch Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.
RP Coelho, V (corresponding author), HC FMUSP, Immunol Lab, Inst Coracao, Av Dr Eneas Carvalho Aguiar 44,9O Andar,BL 2, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Silva, Celio/C-4639-2012; Moyses, Raquel/N-4376-2015; Victora,
   Gabriel/C-5946-2011; Zarate-Blades, Carlos R/C-9663-2015; KALIL,
   JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013
OI Silva, Celio/0000-0002-0043-4568; Moyses, Raquel/0000-0002-0872-9870;
   Zarate-Blades, Carlos R/0000-0002-7728-7869; KALIL,
   JORGE/0000-0001-8415-4274; Victora, Gabriel/0000-0001-8807-348X; Coelho,
   Veronica/0000-0002-0989-2581
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq)
FX This study was supported by grants from CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico).
CR Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262
   AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Bonato VLD, 1998, INFECT IMMUN, V66, P169, DOI 10.1128/IAI.66.1.169-175.1998
   Bonato VLD, 2004, IMMUNOLOGY, V113, P130, DOI 10.1111/j.1365-2567.2004.01931.x
   Caldas C, 2006, CLIN EXP IMMUNOL, V146, P66, DOI 10.1111/j.1365-2249.2006.03195.x
   Chen W, 1999, J IMMUNOL, V162, P3212
   DEGRAEFFMEEDER ER, 1991, LANCET, V337, P1368, DOI 10.1016/0140-6736(91)93057-G
   dos Santos RR, 2007, CLIN EXP IMMUNOL, V149, P570, DOI 10.1111/j.1365-2249.2007.03433.x
   ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576
   Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2
   Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896
   KLEINDIENST R, 1993, AM J PATHOL, V142, P1927
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001
   Liu MA, 2006, HUM GENE THER, V17, P1051, DOI 10.1089/hum.2006.17.1051
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326
   Lukacs KV, 1997, GENE THER, V4, P346, DOI 10.1038/sj.gt.3300386
   Mayr M, 1999, CIRCULATION, V99, P1560, DOI 10.1161/01.CIR.99.12.1560
   Michaluart P, 2008, CANCER GENE THER, V15, P676, DOI 10.1038/cgt.2008.35
   Murshid A, 2008, EXPERT REV VACCINES, V7, P1019, DOI 10.1586/14760584.7.7.1019
   Santos-Junior RR, 2005, HUM GENE THER, V16, P1338, DOI 10.1089/hum.2005.16.1338
   Schalk JAC, 2006, HUM VACCINES, V2, P45, DOI 10.4161/hv.2.2.2620
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1
   Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Ulmer JB, 2006, TRENDS MOL MED, V12, P216, DOI 10.1016/j.molmed.2006.03.007
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117
   VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   Whiteside TL, 2005, CANCER METAST REV, V24, P95, DOI 10.1007/s10555-005-5050-6
   XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789
NR 36
TC 27
Z9 28
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD JUL
PY 2009
VL 16
IS 7
BP 598
EP 608
DI 10.1038/cgt.2009.9
PG 11
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 458QQ
UT WOS:000267039000007
PM 19197326
OA Bronze
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Rodrigues, H
   Kalil, J
   Massarolo, P
   Baia, C
   Mies, S
AF Monteiro, Francisco
   Rodrigues, Helcio
   Kalil, Jorge
   Massarolo, Paulo
   Baia, Carlos
   Mies, Sergio
TI ALLOANTIBODIES DETECTED BY LUMINEX IgG-PRA AND THE OUTCOME OF LIVER
   ALLORAFTS
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT 15th Annual Congress of the International-Liver-Transplantation-Society
CY JUL 08-11, 2009
CL New York, NY
SP Int Liver Transplantat Soc
C1 [Monteiro, Francisco; Rodrigues, Helcio; Kalil, Jorge] Univ Sao Paulo, Lab Transplantat Immunol, Med Sch Sao Paulo, Sao Paulo, Brazil.
   [Massarolo, Paulo; Baia, Carlos; Mies, Sergio] Univ Sao Paulo, Med Sch Sao Paulo, Liver Unity, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2009
VL 15
IS 7
BP S263
EP S263
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 468CV
UT WOS:000267792300643
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Nogueira, LG
   Teixeira, PC
   Ramasawmy, R
   Drigo, SA
   Goldberg, AC
   Fonseca, SG
   Bilate, AM
   Kalil, J
AF Cunha-Neto, Edecio
   Nogueira, Luciana G.
   Teixeira, Priscila C.
   Ramasawmy, Rajendranath
   Drigo, Sandra A.
   Goldberg, Anna Carla
   Fonseca, Simone G.
   Bilate, Angelina M.
   Kalil, Jorge
TI Immunological and non-immunological effects of cytokines and chemokines
   in the pathogenesis of chronic Chagas disease cardiomyopathy
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT International Symposium on the Centennial of the Discovery of Chargas
   Disease
CY JUL 08-10, 2009
CL Rio de Janeiro, BRAZIL
DE Chagas disease cardiomyopathy; cytokines; chemokines; gene polymorphism;
   energy metabolism
ID TRYPANOSOMA-CRUZI INFECTION; NECROSIS-FACTOR-ALPHA; MYOSIN HEAVY-CHAIN;
   ENDOMYOCARDIAL BIOPSIES; GENE POLYMORPHISM; HEART-FAILURE; T-CELLS;
   DILATED CARDIOMYOPATHY; PROMOTER POLYMORPHISM; EXPRESSION PROFILE
AB The pathogenesis of Chagas disease cardiomyopathy (CCC) is not well understood. Since studies show that myocarditis is more frequent during the advanced stages of the disease, and the prognosis of CCC is worse than that of other dilated cardiomyopathies of non-inflammatory aetiology, which suggest that the inflammatory infiltrate plays a major role in myocardial damage. In the last decade, increasing evidence has shown that inflammatory cytokines and chemokines play a role in the generation of the inflammatory infiltrate and tissue damage. CCC patients have an increased peripheral production of the inflammatory Th1 cytokines IFN-gamma and TNF-alpha when compared to patients with the asymptomatic/indeterminate form. Moreover, Th1-T cells are the main producers of IFN-gamma and TNF-alpha and are frequently found in CCC myocardial inflammatory infiltrate. Over the past several years, our group has collected evidence that shows several cytokines and chemokines produced in the CCC myocardium may also have a non-immunological pathogenic effect via modulation of gene and protein expression in cardiomyocytes and other myocardial cell types. Furthermore, genetic polymorphisms of cytokine, chemokine and innate immune response genes have been associated with disease progression. We will review the molecular and immunological mechanisms of myocardial damage in human CCC in light of recent findings.
C1 [Cunha-Neto, Edecio; Nogueira, Luciana G.; Teixeira, Priscila C.; Ramasawmy, Rajendranath; Drigo, Sandra A.; Fonseca, Simone G.; Bilate, Angelina M.; Kalil, Jorge] Univ Sao Paulo, Hosp Clin, Inst Coracao, Lab Imunol, BR-05403001 Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Fonseca, Simone G.; Kalil, Jorge] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, BR-05403001 Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Nogueira, Luciana G.; Teixeira, Priscila C.; Ramasawmy, Rajendranath; Goldberg, Anna Carla; Fonseca, Simone G.; Bilate, Angelina M.; Kalil, Jorge] INCT, Inst Invest Imunol, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Hosp Clin, Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2-9O, BR-05403001 Sao Paulo, Brazil.
EM edecunha@usp.br
RI Drigo, Sandra A/I-6514-2012; Ramasawmy, Rajendranath/V-4926-2019; KALIL,
   JORGE/C-8029-2012; LINDE, SANDRA/S-3128-2019; FONSECA, SIMONE
   GONCALVES/U-9278-2019; Teixeira, Priscila C/D-7426-2013; Goldberg, Anna
   Carla/H-8594-2014; Oliveira, Claudia DL/G-8618-2011; Cunha-Neto,
   Edecio/B-4157-2009
OI Drigo, Sandra A/0000-0001-6747-6642; KALIL, JORGE/0000-0001-8415-4274;
   LINDE, SANDRA/0000-0001-6747-6642; Goldberg, Anna
   Carla/0000-0003-2600-7940; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Camillo Teixeira, Priscila/0000-0002-9698-4563
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Abel LCJ, 2005, MICROBES INFECT, V7, P1184, DOI 10.1016/j.micinf.2005.03.033
   Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Araujo FF, 2007, FRONT BIOSCI-LANDMRK, V12, P2797, DOI 10.2741/2273
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bilate AM, 2008, J INFECT DIS, V198, P614, DOI 10.1086/590347
   Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001
   Bilate AMB, 2007, MICROBES INFECT, V9, P1104, DOI 10.1016/j.micinf.2007.05.014
   Bocchi E A, 1994, Arq Bras Cardiol, V63, P523
   Calzada JE, 2002, TISSUE ANTIGENS, V59, P316, DOI 10.1034/j.1399-0039.2002.590411.x
   Calzada JE, 2001, TISSUE ANTIGENS, V58, P154, DOI 10.1034/j.1399-0039.2001.580302.x
   Calzada JE, 2001, TISSUE ANTIGENS, V57, P353, DOI 10.1034/j.1399-0039.2001.057004353.x
   Carvajal K, 2003, ARCH MED RES, V34, P89, DOI 10.1016/S0188-4409(03)00004-3
   Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Cruz-Robles D, 2004, HUM IMMUNOL, V65, P60, DOI 10.1016/j.humimm.2003.10.008
   CUNHA E, 1996, J CLIN INVEST, V8, P1709
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   Cuoco MAR, 2005, INT J CARDIOL, V99, P97, DOI 10.1016/j.ijcard.2003.12.026
   de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   Drigo SA, 2007, IMMUNOL LETT, V108, P109, DOI 10.1016/j.imlet.2006.10.008
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Florez O, 2006, HUM IMMUNOL, V67, P741, DOI 10.1016/j.humimm.2006.06.004
   Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Garg N, 2003, BBA-MOL BASIS DIS, V1638, P106, DOI 10.1016/S0925-4439(03)00060-7
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006
   JOHNSTON DL, 1991, CIRC RES, V68, P714, DOI 10.1161/01.RES.68.3.714
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   KALOVIDOURIS AE, 1993, J RHEUMATOL, V20, P1718
   Kolattukudy PE, 1998, AM J PATHOL, V152, P101
   Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518
   Layrisse Z, 2000, HUM IMMUNOL, V61, P925, DOI 10.1016/S0198-8859(00)00161-0
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Marin-Neto JA, 2008, AM HEART J, V156, P37, DOI 10.1016/j.ahj.2008.04.001
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   MILEI J, 1992, CARDIOLOGY, V80, P424, DOI 10.1159/000175035
   Moretti E, 2002, CLIN DIAGN LAB IMMUN, V9, P1324, DOI 10.1128/CDLI.9.6.1324-1327.2002
   Nieto A, 2000, TISSUE ANTIGENS, V55, P195, DOI 10.1034/j.1399-0039.2000.550301.x
   Pascuzzo-Lima C, 2009, REV ESP CARDIOL, V62, P320, DOI 10.1016/S0300-8932(09)70378-1
   PEREIRABARRETO AC, 1986, AM HEART J, V111, P307
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   RAMASAWMY R, 2009, J INFECT IN PRESS
   Ramasawmy R, 2007, J INFECT DIS, V196, P1836, DOI 10.1086/523653
   Ramasawmy R, 2008, MOL IMMUNOL, V45, P283, DOI 10.1016/j.molimm.2007.04.015
   Ramirez L E, 1994, Rev Soc Bras Med Trop, V27, P163, DOI 10.1590/S0037-86821994000300007
   Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348
   Reifenberg K, 2007, AM J PATHOL, V171, P463, DOI 10.2353/ajpath.2007.060906
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Sakai N, 2006, P NATL ACAD SCI USA, V103, P14098, DOI 10.1073/pnas.0511200103
   Samudio M, 1998, ACTA TROP, V69, P89, DOI 10.1016/S0001-706X(97)00118-6
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Vyatkina G, 2004, BBA-MOL BASIS DIS, V1689, P162, DOI 10.1016/j.bbadis.2004.03.005
   Wang DC, 1996, LAB INVEST, V75, P809
   Zafra G, 2007, MICROBES INFECT, V9, P1049, DOI 10.1016/j.micinf.2007.04.010
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 79
TC 66
Z9 67
U1 2
U2 8
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUL
PY 2009
VL 104
SU 1
BP 252
EP 258
DI 10.1590/S0074-02762009000900032
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 485LM
UT WOS:000269123500031
PM 19753481
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Cunha-Neto, E
   Fae, KC
   Borba, SCP
   Teixeira, PC
   Ferreira, SCP
   Goldberg, AC
   Ianni, B
   Mady, C
   Kalil, J
AF Ramasawmy, Rajendranath
   Cunha-Neto, Edecio
   Fae, Kellen C.
   Borba, Susan C. P.
   Teixeira, Priscila C.
   Ferreira, Susanne C. P.
   Goldberg, Anna C.
   Ianni, Barbara
   Mady, Charles
   Kalil, Jorge
TI Heterozygosity for the S180L Variant of MAL/TIRAP, a Gene Expressing an
   Adaptor Protein in the Toll-Like Receptor Pathway, Is Associated with
   Lower Risk of Developing Chronic Chagas Cardiomyopathy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID TRYPANOSOMA-CRUZI INFECTION; SINGLE-NUCLEOTIDE POLYMORPHISMS; DISEASE
   CARDIOMYOPATHY; LEGIONNAIRES-DISEASE; CUTTING EDGE; SUSCEPTIBILITY;
   ACTIVATION; TIRAP; TUBERCULOSIS; RESISTANCE
AB Background. Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. Among T. cruzi-infected individuals, only a subgroup develops severe chronic Chagas cardiomyopathy (CCC); the majority remain asymptomatic. T. cruzi displays numerous ligands for the Toll-like receptors (TLRs), which are an important component of innate immunity that lead to the transcription of proinflammatory cytokines by nuclear factor-kappa B. Because proinflammatory cytokines play an important role in CCC, we hypothesized that single-nucleotide polymorphisms (SNPs) in the genes that encode proteins in the TLR pathway could explain differential susceptibility to CCC among T. cruzi-infected individuals.
   Methods. For 169 patients with CCC and 76 T. cruzi-infected, asymptomatic individuals, we analyzed SNPs by use of polymerase chain reaction-restriction fragment length polymorphism analysis for the genes TLR1, TLR2, TLR4, TLR5, TLR9, and MAL/TIRAP, which encodes an adaptor protein.
   Results. Heterozygous carriers of the MAL/TIRAP variant S180L were more prevalent in the asymptomatic group (24 [32%] of 76 subjects) than in the CCC group (21 [12%] of 169) (chi(2) = 12.6; P = .0004 [adjusted P (P(c)) = .0084]; odds ratio [OR], 0.31 [95% confidence interval {CI}, 0.16-0.60]). Subgroup analysis showed a stronger association when asymptomatic patients were compared with patients who had severe CCC (i.e., patients with left-ventricular ejection fraction <= 40%) (chi(2) = 11.3; P = .0008 [P(c) = .017]; OR, 0.22 [95% CI, 0.09-0.56]) than when asymptomatic patients were compared with patients who had mild CCC (i.e., patients with left-ventricular ejection fraction >40%) (chi(2) = 7.7; P = .005 [P(c) = .11]; OR, 0.33 [95% CI, 0.15-0.73]).
   Conclusion. T. cruzi-infected individuals who are heterozygous for the MAL/TIRAP S180L variant that leads to a decrease in signal transduction upon ligation of TLR2 or TLR4 to their respective ligand may have a lower risk of developing CCC.
C1 [Ramasawmy, Rajendranath] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, BR-05403000 Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   [Ramasawmy, Rajendranath; Cunha-Neto, Edecio; Fae, Kellen C.; Borba, Susan C. P.; Teixeira, Priscila C.; Ferreira, Susanne C. P.; Goldberg, Anna C.; Kalil, Jorge] Inst Nacl Ciencia & Tecnol, Sao Paulo, Brazil.
   [Ramasawmy, Rajendranath] Univ Fed Bahia, Serv Imunol, Hosp Univ Prof Edgar Santos, Salvador, BA, Brazil.
RP Ramasawmy, R (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Av Dr Eneas de Carvalho Aguiar,44 Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM ramasawm@usp.br
RI Goldberg, Anna Carla/H-8594-2014; Mady, Charles/C-8870-2012; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Ianni, Barbara
   Maria/C-7689-2012; Ferreira, Susanne/N-9638-2015; Ramasawmy,
   Rajendranath/V-4926-2019; Teixeira, Priscila C/D-7426-2013
OI Goldberg, Anna Carla/0000-0003-2600-7940; Mady,
   Charles/0000-0002-8838-199X; Cunha-Neto, Edecio/0000-0002-3699-3345;
   KALIL, JORGE/0000-0001-8415-4274; Ianni, Barbara
   Maria/0000-0002-1588-5492; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
FU Sao Paulo State Research FoundationFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); Brazilian Council for Scientific and
   Technological DevelopmentNational Council for Scientific and
   Technological Development (CNPq) [410448/20060]
FX Sao Paulo State Research Foundation and Brazilian Council for Scientific
   and Technological Development (grant 410448/20060 to R.R. and E.C.-N.).
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Castiblanco J, 2008, INFECT GENET EVOL, V8, P541, DOI 10.1016/j.meegid.2008.03.001
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Gazzinelli RT, 2006, NAT REV IMMUNOL, V6, P895, DOI 10.1038/nri1978
   Hawn TR, 2006, J INFECT DIS, V194, P1127, DOI 10.1086/507907
   Hawn TR, 2005, P NATL ACAD SCI USA, V102, P2487, DOI 10.1073/pnas.0409831102
   Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180
   Johnson CM, 2007, J IMMUNOL, V178, P7520, DOI 10.4049/jimmunol.178.12.7520
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8
   Leoratti FMS, 2008, J INFECT DIS, V198, P772, DOI 10.1086/590440
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   Mockenhaupt FP, 2006, J INFECT DIS, V194, P184, DOI 10.1086/505152
   Nejentsev S, 2008, NAT GENET, V40, P261, DOI 10.1038/ng0308-261
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366
   Petersen CA, 2005, INFECT IMMUN, V73, P6974, DOI 10.1128/IAI.73.10.6974-6980.2005
   Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   Ramasawmy R, 2007, J INFECT DIS, V196, P1836, DOI 10.1086/523653
   Ramasawmy R, 2008, MOL IMMUNOL, V45, P283, DOI 10.1016/j.molimm.2007.04.015
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Ropert C, 2004, J ENDOTOXIN RES, V10, P425, DOI 10.1179/096805104225006507
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2
   Schroder NWJ, 2005, J IMMUNOL, V175, P2534, DOI 10.4049/jimmunol.175.4.2534
   Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096
   (WHO) World Health Organization, 2002, WHO TECHN REP SER, V905
   Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182
   ZICKER F, 1990, INT J EPIDEMIOL, V19, P182, DOI 10.1093/ije/19.1.182
NR 41
TC 49
Z9 51
U1 0
U2 7
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2009
VL 199
IS 12
BP 1838
EP 1845
DI 10.1086/599212
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 448BM
UT WOS:000266236500017
PM 19456234
OA Bronze
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Giavina-Bianchi, M
   Agondi, RC
   Kalil, J
AF Giavina-Bianchi, P.
   Giavina-Bianchi, M.
   Agondi, R. C.
   Kalil, J.
TI Anti-IgE in Churg-Strauss syndrome
SO THORAX
LA English
DT Letter
ID OMALIZUMAB; PATIENT
C1 [Giavina-Bianchi, P.; Giavina-Bianchi, M.; Agondi, R. C.; Kalil, J.] Univ Sao Paulo, Dept Allergy & Clin Immunol, BR-05508 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Dept Allergy & Clin Immunol, BR-05508 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
CR Giavina-Bianchi P, 2008, J ALLERGY CLIN IMMUN, V122, P217, DOI 10.1016/j.jaci.2008.05.024
   Giavina-Bianchi P, 2008, INT ARCH ALLERGY IMM, V146, P176, DOI 10.1159/000113524
   Giavina-Bianchi P, 2007, INT ARCH ALLERGY IMM, V144, P155, DOI 10.1159/000103228
   Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028
   Pabst S, 2008, THORAX, V63, P747, DOI 10.1136/thx.2006.076513
NR 5
TC 7
Z9 7
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD MAR
PY 2009
VL 64
IS 3
BP 272
EP 272
PG 1
WC Respiratory System
SC Respiratory System
GA 413KW
UT WOS:000263793000021
PM 19252033
DA 2020-11-26
ER

PT J
AU Vieira, PM
   Silva, H
   Takenaka, M
   Monteiro, S
   Lemos, F
   Saitovich, D
   Kalil, J
   Coelho, V
AF Vieira, Pedro Manoel
   Silva, Hernandez
   Takenaka, Maisa
   Monteiro, Sandra
   Lemos, Francine
   Saitovich, David
   Kalil, Jorge
   Coelho, Veronica
TI Differential Immune Molecular Profile in Kidney Operational Tolerance
   Transplanted Individuals: Towards a Regulatory Profile
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 11-14, 2009
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 [Vieira, Pedro Manoel; Silva, Hernandez; Takenaka, Maisa; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   [Lemos, Francine] Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil.
   [Saitovich, David] Univ Fed Rio Grande do Sul, Sch Med, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
RI Moraes-Vieira, Pedro M/C-8701-2014; COELHO, VERONICA/D-1433-2013; KALIL,
   JORGE/C-8029-2012
OI Moraes-Vieira, Pedro M/0000-0002-8263-786X; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 2
Z9 2
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2009
VL 131
BP S165
EP S165
DI 10.1016/j.clim.2009.03.489
PG 1
WC Immunology
SC Immunology
GA 449PK
UT WOS:000266342300481
DA 2020-11-26
ER

PT J
AU Volsi, EC
   Correa, S
   Takenaka, M
   Mundel, L
   Kalil, J
   Coelho, V
AF Volsi, Evelyn Cristina
   Correa, Simone
   Takenaka, Maisa
   Mundel, Luiz
   Kalil, Jorge
   Coelho, Veronica
TI Hsp60 Down Modulated Proliferation and Cytokine Production in Autologous
   Coculture of T Lymphocytes with Dendritic Cells (DCs) in Three Different
   Maturation Stage
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 11-14, 2009
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 [Volsi, Evelyn Cristina; Takenaka, Maisa; Mundel, Luiz; Kalil, Jorge; Coelho, Veronica] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Correa, Simone] Univ Sao Paulo, Inst Biomed Sci 4, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013; Correa-Silva,
   Simone/J-9540-2012
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2009
VL 131
BP S165
EP S165
DI 10.1016/j.clim.2009.03.488
PG 1
WC Immunology
SC Immunology
GA 449PK
UT WOS:000266342300480
DA 2020-11-26
ER

PT J
AU Ensina, LF
   Tanno, LK
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
AF Ensina, Luis Felipe
   Tanno, Luciana Kase
   Motta, Antonio Abilio
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI KETOCONAZOLE ALLERGY
SO CLINICS
LA English
DT Letter
ID HYPERSENSITIVITY
C1 [Ensina, Luis Felipe; Tanno, Luciana Kase; Motta, Antonio Abilio; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Hosp Clin, Serv Imunol Clin & Alergia, Sao Paulo, Brazil.
RP Ensina, LF (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Serv Imunol Clin & Alergia, Sao Paulo, Brazil.
EM lfensina@yahoo.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; ENSINA,
   LUIS FELIPE/N-4545-2014; Tanno, Luciana Kase/J-9981-2014
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274; ENSINA, LUIS FELIPE/0000-0001-8652-3619;
   Tanno, Luciana Kase/0000-0003-3236-1225
CR Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x
   Ensina L, 2008, ALLERGY, V63, P335
   GONZALEZDELGADO P, 1994, ANN ALLERGY, V73, P326
   Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x
   Martinez-Alonso JC, 2003, ALLERGY, V58, P1317, DOI 10.1046/j.0105-4538.2003.00316.x
   Wohrl S, 2006, ALLERGY, V61, P928, DOI 10.1111/j.1398-9995.2006.01148.x
NR 6
TC 2
Z9 2
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2009
VL 64
IS 4
BP 373
EP 374
DI 10.1590/S1807-59322009000400018
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 438HM
UT WOS:000265546500018
PM 19488598
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Bisaccioni, C
   Aun, MV
   Cajuela, E
   Kalil, J
   Agondi, RC
   Giavina-Bianchi, P
AF Bisaccioni, Carla
   Aun, Marcelo Vivolo
   Cajuela, Edcarlos
   Kalil, Jorge
   Agondi, Rosana Camara
   Giavina-Bianchi, Pedro
TI COMORBIDITIES IN SEVERE ASTHMA: FREQUENCY OF RHINITIS, NASAL POLYPOSIS,
   GASTROESOPHAGEAL REFLUX DISEASE, VOCAL CORD DYSFUNCTION AND
   BRONCHIECTASIS
SO CLINICS
LA English
DT Article
DE Severe Asthma; Rhinitis; NSAIDs Intolerance; Gastroesophageal Reflux
   Disease; Bronchiectasis
ID ALLERGIC RHINITIS; PREVALENCE; SYMPTOMS; THERAPY; IMPACT
AB OBJECTIVES: Severe asthma is found in approximately 10% of patients with asthma. Some factors associated with worse asthma control include rhinitis, gastroesophageal reflux disease, vocal cord dysfunction (VCD), nasal polyposis and bronchiectasis. Therefore, we evaluated the prevalence of these illnesses in patients with severe asthma.
   METHODS: We conducted a retrospective analysis of data obtained from electronic medical records of patients with severe asthma between January 2006 and June 2008. Symptoms of rhinitis and gastroesophageal reflux disease were evaluated as well as intolerance to nonsteroidal anti-inflammatory drugs. We evaluated the results of esophagogastroduodenoscopy, videolaryngoscopy and CT scans of the chest in order to confirm gastroesophageal reflux disease, nasal polyposis, vocal cord dysfunction and bronchiectasis.
   RESULTS: We evaluated 245 patients. Rhinitis symptoms were present in 224 patients (91.4%); 18 (7.3%) had intolerance to nonsteroidal anti-inflammatory drugs, and 8 (3.3%) had nasal polyposis. Symptoms of gastroesophageal reflux disease were reported for 173 (70.6%) patients, although the diagnosis of gastroesophageal reflux disease was confirmed based on esophagogastroduodenoscopy or laryngoscopy findings in just 58 (33.6%) patients. Vocal cord dysfunction was suspected in 16 (6.5%) and confirmed through laryngoscopy in 4 (1.6%). The patient records provided CT scans of the chest for 105 patients, and 26 (24.8%) showed bronchiectasis.
   DISCUSSION: Rhinitis and gastroesophageal reflux disease were the most common comorbidities observed, in addition to bronchiectasis. Therefore, in patients with severe asthma, associated diseases should be investigated as the cause of respiratory symptoms and uncontrolled asthma.
C1 [Bisaccioni, Carla; Aun, Marcelo Vivolo; Cajuela, Edcarlos; Kalil, Jorge; Agondi, Rosana Camara; Giavina-Bianchi, Pedro] Univ Sao Paulo, Fac Med, Dept Allergy & Clin Immunol, Sao Paulo, Brazil.
RP Bisaccioni, C (corresponding author), Univ Sao Paulo, Fac Med, Dept Allergy & Clin Immunol, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br; marcelovivoloaun@yahoo.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; Aun, Marcelo V/E-6775-2014; KALIL,
   JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; Aun, Marcelo
   V/0000-0001-9882-5200; KALIL, JORGE/0000-0001-8415-4274
CR Agondi RC, 2008, J ASTHMA, V45, P754, DOI 10.1080/02770900802249149
   Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904
   Awad OG, 2008, AM J RHINOL, V22, P197, DOI 10.2500/ajr.2008.22.3148
   Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209
   Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   Ceylan E, 2007, RESPIROLOGY, V12, P272, DOI 10.1111/j.1440-1843.2006.00964.x
   Coughlan J. L., 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001496
   Cukier A, 2001, Rev Hosp Clin Fac Med Sao Paulo, V56, P63
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, pS165, DOI 10.1016/j.jaci.2006.12.007
   Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9
   Ibrahim WH, 2007, POSTGRAD MED J, V83, P164, DOI 10.1136/pgmj.2006.052522
   Leggett JJ, 2005, CHEST, V127, P1227, DOI 10.1378/chest.127.4.1227
   Lima RG, 2007, CLINICS, V62, P225, DOI 10.1590/S1807-59322007000300005
   Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128
   NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399
   Nordenstedt H, 2006, CHEST, V129, P1051, DOI 10.1378/chest.129.4.1051
   Oguzulgen IK, 2007, SOUTH MED J, V100, P468, DOI 10.1097/SMJ.0b013e31802fa16f
   Pastorino AC, 2006, J ASTHMA, V43, P695, DOI 10.1080/02770900600925544
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pfaar O, 2006, CURR OPIN ALLERGY CL, V6, P161, DOI 10.1097/01.all.0000225153.45027.6a
   Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322
   Sharma B, 2007, WORLD J GASTROENTERO, V13, P1706, DOI 10.3748/wjg.v13.i11.1706
   Stelmach R, 2005, CHEST, V128, P3140, DOI 10.1378/chest.128.5.3140
   Stirling RG, 2001, ALLERGY, V56, P825, DOI 10.1034/j.1398-9995.2001.00143.x
   Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592
   Wenzel SE, 2000, AM J RESP CRIT CARE, V162, P2341
NR 27
TC 57
Z9 58
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2009
VL 64
IS 8
BP 769
EP 773
DI 10.1590/S1807-59322009000800010
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 489YZ
UT WOS:000269464400009
PM 19690661
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Aun, MV
   Ribeiro, MR
   Garcia, CLC
   Agondi, RC
   Kalil, J
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   Ribeiro, Marisa Rosimeire
   Costa Garcia, Claudia Leite
   Agondi, Rosana Camara
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Esophageal CandidiasisAn Adverse Effect of Inhaled Corticosteroids
   Therapy
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Esophageal candidiasis; inhaled corticosteroid; budesonide; asthma; drug
   adverse reaction
ID FLUTICASONE; COMPLICATION
AB Over the last few decades, inhaled corticosteroids (ICs) became the cornerstone in the treatment of persistent asthma. Their use improved asthma control, decreased mortality and also minimized adverse reactions associated with systemic steroid. Esophageal candidiasis is a rare complication resulting from the use of ICs. Although, in recent years, as their prescriptions has increased, more cases have been reported, especially in Japan. Listed are 4 case reports regarding esophageal candidiasis in asthmatic patients associated with inhaled budesonide administration. In the cases reported herein, the use of a different device of dry powder budesonide might have favored esophageal drug deposition and Candida infection. Patients denied using systemic corticosteroids in the previous 6 months. Furthermore, none of the patients presented Diabetes mellitus, malignant disease, HIV infection, or other immunosuppressive conditions. We conclude that patients treated with high doses of ICs are at higher risk of developing esophageal candidiasis. These patients should undergo upper gastrointestinal endoscopy whenever they present symptoms. Nevertheless, we must keep in mind that infection might also be asymptomatic and esophageal candidiasis prevalence may be higher than that reported thus far.
C1 [Aun, Marcelo Vivolo; Ribeiro, Marisa Rosimeire; Costa Garcia, Claudia Leite; Agondi, Rosana Camara; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178,Ap 211A Jd Amer, BR-01454010 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Aun, Marcelo V/E-6775-2014; Giavina-Bianchi, Pedro/I-3112-2014; KALIL,
   JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274
CR Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707
   Fukushima C, 2003, ANN ALLERG ASTHMA IM, V90, P646, DOI 10.1016/S1081-1206(10)61870-4
   HEMSTREET MPB, 1980, CLIN ALLERGY, V10, P733, DOI 10.1111/j.1365-2222.1980.tb02158.x
   Kanda N, 2003, AM J GASTROENTEROL, V98, P2146, DOI [10.1016/S0002-9270(03)00537-9, 10.1111/j.1572-0241.2003.07626.x]
   KESTEN S, 1988, DRUG INTEL CLIN PHAR, V22, P568, DOI 10.1177/106002808802200709
   Kobayashi Y, 2006, INT J CLIN PHARM TH, V44, P193
   Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346
   LIPWORTH BJ, 1995, THORAX, V50, P105, DOI 10.1136/thx.50.2.105
   Mullaoglu S, 2007, ALLERGY ASTHMA PROC, V28, P544, DOI 10.2500/aap2007.28.3046
   National Institute of Health, 2007, GUID DIAGN MAN ASTHM
   SALZMAN GA, 1988, J ALLERGY CLIN IMMUN, V81, P424, DOI 10.1016/0091-6749(88)90911-6
   Shuto Hiroshi, 2003, Arerugi, V52, P1053
   SIEVERT W, 1992, LANCET, V339, P1551, DOI 10.1016/0140-6736(92)91326-4
   Simon MR, 1997, ANN ALLERG ASTHMA IM, V79, P333, DOI 10.1016/S1081-1206(10)63024-4
   STEIN MR, 1979, J ALLERGY CLIN IMMUN, V63, P172
   TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89
   TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723
NR 17
TC 16
Z9 18
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PY 2009
VL 46
IS 4
BP 399
EP 401
AR PII 911835901
DI 10.1080/02770900902777783
PG 3
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 451RZ
UT WOS:000266489100016
PM 19484677
DA 2020-11-26
ER

PT J
AU Fonseca, S
   Coutinho-Silva, A
   Rodrigues, D
   Marti, L
   Moreira, C
   Segurado, A
   Kallas, E
   Kalil, J
   Cunha-Neto, E
AF Fonseca, S.
   Coutinho-Silva, A.
   Rodrigues, D.
   Marti, L.
   Moreira-Filho, C.
   Segurado, A.
   Kallas, E.
   Kalil, J.
   Cunha-Neto, E.
TI Distinct subsets of memory T lymphocytes from HIV-I-infected subjects
   secrete IFN-gamma and IL-2 in response to novel CD4+T-cell HIV-I
   epitopes
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Fonseca, S.; Coutinho-Silva, A.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
   [Marti, L.; Moreira-Filho, C.] USP IPT Butantan, Programa Interunidades Biotecnol, Sao Paulo, Brazil.
   [Rodrigues, D.] Inst Clemente Ferreira, Sao Paulo, Brazil.
   [Segurado, A.] FMUSP, Div Doencas Infeccisoas, Sao Paulo, Brazil.
   [Kallas, E.] FMUSP, Div Imunol Clin & Alergia, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Marti, Luciana/Z-2555-2019; Segurado, Aluisio
   C/K-2229-2012; Cunha-Neto, Edecio/B-4157-2009; Kallas, Esper
   G/C-9539-2012
OI KALIL, JORGE/0000-0001-8415-4274; Marti, Luciana/0000-0002-3890-0827;
   Segurado, Aluisio C/0000-0002-6311-8036; Cunha-Neto,
   Edecio/0000-0002-3699-3345; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P282
DI 10.1186/1742-4690-6-S3-P282
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300333
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Moraes, SL
   Muller, NG
   Paula, MO
   Arruda, MB
   Brindeiro, RM
   Alencar, R
   Jamal, L
   Kalil, J
   Cunha-Neto, E
AF Moraes, S. L.
   Muller, N. G.
   Paula, M. O.
   Arruda, M. B.
   Brindeiro, R. M.
   Alencar, R.
   Jamal, L.
   Kalil, J.
   Cunha-Neto, E.
TI T cell recognition of autologous and non-autologous HIV-1 protease
   peptides by HIV-1 infected patients undergoing PI therapy
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Moraes, S. L.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Muller, N. G.; Paula, M. O.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Arruda, M. B.; Brindeiro, R. M.] Fed Univ Rio De Janeiro Mol Virol, Rio De Janeiro, Brazil.
   [Alencar, R.; Jamal, L.] Ctr Reference & Training Dst Aids, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P268
DI 10.1186/1742-4690-6-S3-P268
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300319
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Almeida, RR
   Rosa, DS
   Kallas, EG
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Almeida, R. R.
   Rosa, D. S.
   Kallas, E. G.
   Kalil, J.
   Cunha-Neto, E.
TI Priming with a DNA vaccine enconding HIV CD4+T cell epitopes enhances
   responses against subsequent immunization with plasmid encoding Vif
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Ribeiro, S. P.; Almeida, R. R.; Rosa, D. S.; Kallas, E. G.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Kallas, Esper G/C-9539-2012; Rosa,
   Daniela S/D-2190-2012; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925
NR 0
TC 0
Z9 0
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P364
DI 10.1186/1742-4690-6-S3-P364
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300415
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Rosa, DS
   Ribeiro, SP
   Mairena, EC
   Kalil, J
   Cunha-Neto, E
AF Rosa, D. S.
   Ribeiro, S. P.
   Mairena, E. C.
   Kalil, J.
   Cunha-Neto, E.
TI Bupivacaine, a local anaesthetic, enhances immunogenicity of a
   multiepitopic DNA vaccine containing HIV promiscuous CD4 T cell epitopes
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Rosa, D. S.; Ribeiro, S. P.; Mairena, E. C.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Internal Med, Sao Paulo, Brazil.
RI Rosa, Daniela S/D-2190-2012; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009
OI Rosa, Daniela S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P17
DI 10.1186/1742-4690-6-S3-P17
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300070
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU de Jesus, AR
   Menezes, EP
   Ramaswmy, R
   Fae, KC
   Borba, SC
   Oliveira, J
   Magalhaes, A
   Castellucci, L
   Guimaraes, LH
   Lessa, M
   Noronha, E
   Wilson, ME
   Jamieson, SE
   Bales, A
   Kalil, J
   Blackwell, JM
   Carvalho, EM
AF Jesus, Amelia R. de
   Menezes, Eliane P.
   Ramaswmy, Rajendranath
   Fae, Kellen C.
   Borba, Susan C.
   Oliveira, Joyce
   Magalhaes, Andrea
   Castellucci, Lea
   Guimaraes, Luiz H.
   Lessa, Marcus
   Noronha, Elza
   Wilson, Mary E.
   Jamieson, Sarra E.
   Bales, Ashlee
   Kalil, Jorge
   Blackwell, Jenefer M.
   Carvalho, Edgar M.
TI FUNCTIONAL VARIATIONS IN CANDIDATE GENES FROM INNATE IMMUNE RESPONSE
   (MCP-1 AND MBL2 GENES) ARE ASSOCIATED WITH MUCOSAL LEISHMANIASIS OUTCOME
   IN CORTE DE PEDRA, BAHIA, BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Jesus, Amelia R. de] Univ Fed Sergipe, Aracaju, SE, Brazil.
   [Menezes, Eliane P.; Ramaswmy, Rajendranath; Oliveira, Joyce; Magalhaes, Andrea; Castellucci, Lea; Guimaraes, Luiz H.; Lessa, Marcus; Carvalho, Edgar M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Fae, Kellen C.; Borba, Susan C.; Kalil, Jorge] State Univ Sao Paulo, Sao Paulo, Brazil.
   [Noronha, Elza] Fed Univ Brasilia, Brasilia, DF, Brazil.
   [Wilson, Mary E.; Bales, Ashlee] Univ Iowa, Iowa City, IA USA.
   [Wilson, Mary E.; Bales, Ashlee] VA Med Ctr, Iowa City, IA USA.
   [Jamieson, Sarra E.; Blackwell, Jenefer M.] Univ Cambridge, Sch Clin Med, Cambridge, England.
RI KALIL, JORGE/C-8029-2012; Henrique, Luiz/ABA-2621-2020
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 161
BP 48
EP 48
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644600162
DA 2020-11-26
ER

PT J
AU Cordeiro, AC
   de Castro, I
   Pecoits, R
   Ramasawmy, R
   Rodrigues, H
   Borba, SCP
   Pereira, LM
   Romao, JE
   David-Neto, E
   Ianhez, LE
   Kalil, J
   Abensur, H
AF Cordeiro, A. C.
   de Castro, I.
   Pecoits-Filho, R.
   Ramasawmy, R.
   Rodrigues, H.
   Borba, S. C. P.
   Pereira, L. M.
   Romao, J. E., Jr.
   David-Neto, E.
   Ianhez, L. E.
   Kalil, J.
   Abensur, H.
TI Influence of Single-Nucleotide Polymorphisms on C-Reactive Protein
   Levels in Chronic Kidney Disease Before and After Kidney Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE; CARDIOVASCULAR MORTALITY;
   INFLAMMATORY MARKERS; OXIDATIVE STRESS; CRP LEVELS; DIALYSIS;
   ATHEROSCLEROSIS; PROMOTER; RISK
AB Introduction. We sought to evaluate 2 sing] e-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.
   Methods. Fifty CKD patients were evaluated before and at the first and second years after the graft. Two SNPs were studied, a bi-allelic (G -> A) at the -409 and a tri-allelic (C -> T -> A) variation at the -390 position in the CRP gene.
   Results. All patients presented the -409GG genotype. At the -390 position, the "A" allele was not found; there were 15 "CC" patients, 11 "TT" patients, and 24 "CT" patients. CRP levels were different among patients with various genotypes (P < .019). Also the presence of the allele "T" was sufficient to determine differences in CRP levels both in pretransplantation (P = .045) and at 1 year posttransplantation (P = .011), but not at the second year (P = .448).
   Conclusion. SNPs at the -390 position of the CRP gene promoter region influence CRP basal levels in such a way that the "C" allele correlated with the lowest and the "T" with the highest. We did not observe this influence in our patients at the second year posttransplantation.
C1 [Cordeiro, A. C.; de Castro, I.; Ramasawmy, R.; Rodrigues, H.; Borba, S. C. P.; Pereira, L. M.; Romao, J. E., Jr.; David-Neto, E.; Ianhez, L. E.; Kalil, J.; Abensur, H.] Univ Sao Paulo, BR-04206001 Sao Paulo, Brazil.
   [Pecoits-Filho, R.] Pontificia Univ Catolica Parana, Ctr Hlth & Biol Sci, Sao Paulo, Brazil.
RP Cordeiro, AC (corresponding author), Univ Sao Paulo, Rua Agostinho Gomes 2972,Apt 32, BR-04206001 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Pecoits-Filho, Roberto/K-7986-2013;
   David-Neto, Elias/C-9112-2012; Palma, Lilian Monteiro
   Pereira/U-6672-2018; Cordeiro, Antonio/G-9536-2013; Neto, Elias
   David/O-3866-2018; Castro, Isac/J-1984-2015; Ramasawmy,
   Rajendranath/V-4926-2019
OI KALIL, JORGE/0000-0001-8415-4274; Pecoits-Filho,
   Roberto/0000-0002-0255-6710; Palma, Lilian Monteiro
   Pereira/0000-0002-0334-8470; Cordeiro, Antonio/0000-0003-1695-7299; de
   Castro, Isac/0000-0002-1160-3064; ROMAO JUNIOR, JOAO
   EGIDO/0000-0001-5142-6771
CR Amore A, 2002, NEPHROL DIAL TRANSPL, V17, P16, DOI 10.1093/ndt/17.suppl_8.16
   Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Cottone S, 2006, TRANSPL P, V38, P1026, DOI 10.1016/j.transproceed.2006.02.009
   Cueto-Manzano AM, 2005, TRANSPLANTATION, V80, P47, DOI 10.1097/01.TP.0000164348.16689.03
   Kathiresan S, 2006, CIRCULATION, V113, P1415, DOI 10.1161/CIRCULATIONAHA.105.591271
   Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549
   MacGregor AJ, 2004, CLIN CHEM, V50, P130, DOI 10.1373/clinchem.2003.028258
   Miyata T, 1998, KIDNEY INT, V53, P416, DOI 10.1046/j.1523-1755.1998.00756.x
   Oflaz H, 2006, TRANSPL INT, V19, P333, DOI 10.1111/j.1432-2277.2006.00288.x
   Pankow JS, 2001, ATHEROSCLEROSIS, V154, P681, DOI 10.1016/S0021-9150(00)00586-4
   Pecoits R, 2003, AM J KIDNEY DIS, V41, P1212, DOI 10.1016/S0272-6386(03)00353-6
   Retterstol L, 2003, ATHEROSCLEROSIS, V169, P279, DOI 10.1016/S0021-9150(03)00192-8
   Romao JE, 2006, AM J NEPHROL, V26, P59, DOI 10.1159/000091806
   Simmons EM, 2005, TRANSPLANTATION, V79, P914, DOI 10.1097/01.TP.0000157773.96534.29
   Stenvinkel P, 2002, AM J KIDNEY DIS, V39, P274, DOI 10.1053/ajkd.2002.30546
   Stenvinkel P, 2001, BLOOD PURIFICAT, V19, P53, DOI 10.1159/000014479
   Szalai AJ, 2005, J MOL MED, V83, P440, DOI 10.1007/s00109-005-0658-0
   Wanner C, 2002, NEPHROL DIAL TRANSPL, V17, P29, DOI 10.1093/ndt/17.suppl_8.29
   Zhang L, 2007, AM J KIDNEY DIS, V49, P118, DOI 10.1053/j.ajkd.2006.10.008
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2008
VL 40
IS 10
BP 3349
EP 3353
DI 10.1016/j.transproceed.2008.04.021
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 389ZE
UT WOS:000262133300015
PM 19100387
DA 2020-11-26
ER

PT J
AU Santos, CC
   Mairena, E
   Fonseca, SG
   Sekaly, R
   Wilkinson, P
   Boucher, G
   Segurado, AC
   Fonseca, L
   Kalil, JE
   Cunha-Neto, E
AF Santos, C. C.
   Mairena, E.
   Fonseca, S. G.
   Sekaly, R.
   Wilkinson, P.
   Boucher, G.
   Segurado, A. C.
   Fonseca, L.
   Kalil, J. E.
   Cunha-Neto, E.
TI Gene Expression Profile in Long-Term Non-Progressor HIV plus Patients:
   Identification of HIG-2 as a Possible Natural Resistance Factor
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Sekaly, R.; Wilkinson, P.; Boucher, G.] Univ Montreal, Montreal, PQ H3C 3J7, Canada.
   [Santos, C. C.; Mairena, E.; Fonseca, S. G.; Segurado, A. C.; Fonseca, L.; Kalil, J. E.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Segurado, Aluisio C/K-2229-2012; Cunha-Neto,
   Edecio/B-4157-2009; Wilkinson, Peter/AAK-6426-2020
OI KALIL, JORGE/0000-0001-8415-4274; Segurado, Aluisio
   C/0000-0002-6311-8036; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Wilkinson, Peter/0000-0002-1365-0470
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 74
EP 74
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800185
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Felgueiras, C
   Manuel, ME
   Samri, A
   Coutinho, R
   Cortes, FH
   Coutinho-Silva, A
   Fonseca, SG
   Giacoia-Gripp, CB
   Ferreira, JL
   Rodrigues, R
   Chequer-Fernandez, S
   Brites, C
   Segurado, A
   Fonseca, LA
   Nunes, C
   Kalil, J
   Grassi, F
   Brigido, LF
   Morgado, MG
   Autran, B
AF Cunha-Neto, E.
   Felgueiras, C.
   Manuel, M. E.
   Samri, A.
   Coutinho, R.
   Cortes, F. H.
   Coutinho-Silva, A.
   Fonseca, S. G.
   Giacoia-Gripp, C. B.
   Ferreira, J. L.
   Rodrigues, R.
   Chequer-Fernandez, S.
   Brites, C.
   Segurado, A.
   Fonseca, L. A.
   Nunes, C.
   Kalil, J.
   Grassi, F.
   Brigido, L. F.
   Morgado, M. G.
   Autran, B.
TI T Cell Crossreactivity of Gag and Nef Epitopes Derived from Brazilian
   and European HIV-1 Strains among Brazilian and French HIV-1-Infected
   Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Cunha-Neto, E.; Felgueiras, C.; Coutinho-Silva, A.; Fonseca, S. G.; Segurado, A.; Fonseca, L. A.; Kalil, J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Manuel, M. E.; Samri, A.; Autran, B.] Hop La Pitie Salpetriere, Paris, Ile de France, France.
   [Coutinho, R.; Cortes, F. H.; Giacoia-Gripp, C. B.; Chequer-Fernandez, S.; Brites, C.; Nunes, C.; Grassi, F.; Morgado, M. G.] Fiocruz MS, Salvador, BA, Brazil.
   [Ferreira, J. L.; Rodrigues, R.; Brigido, L. F.] Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Fonseca, Luiz Augusto M/F-9344-2012;
   FONSECA, SIMONE GONCALVES/U-9278-2019; KALIL, JORGE/C-8029-2012; Cortes,
   Fernanda/AAF-9254-2020; Brites, Carlos/D-1353-2013; Segurado, Aluisio
   C/K-2229-2012; Brigido, Luis F M/C-2155-2011
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Brites, Carlos/0000-0002-4673-6991; Segurado,
   Aluisio C/0000-0002-6311-8036; Brigido, Luis F M/0000-0002-1022-7837
NR 0
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 124
EP 124
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800317
DA 2020-11-26
ER

PT J
AU Moraes, SL
   Muller, NG
   Alemcar, R
   Jamal, L
   Fonseca, SG
   Kalil, J
   Cunha-Neto, E
AF Moraes, S. L.
   Muller, N. G.
   Alemcar, R.
   Jamal, L.
   Fonseca, S. G.
   Kalil, J.
   Cunha-Neto, E.
TI Identification of CD4+T Cell Epitopes in HIV-1 Protease: Recognition of
   Protease Inhibitor-Induced Mutations
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Moraes, S. L.; Muller, N. G.; Fonseca, S. G.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Alemcar, R.; Jamal, L.] Ctr Referencia DST AIDS, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 134
EP 134
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800343
DA 2020-11-26
ER

PT J
AU Rosa, DS
   Ribeiro, SP
   Fonseca, SG
   Postol, E
   Guilherme, L
   Kalil, J
   Cunha-Neto, E
AF Rosa, D. S.
   Ribeiro, S. P.
   Fonseca, S. G.
   Postol, E.
   Guilherme, L.
   Kalil, J.
   Cunha-Neto, E.
TI Novel HIV Multiepitopic and Multiallelic Vaccine Formulations Elicit
   Strong CD4+and CD8+Immune Responses in BALB/c and HLA Class
   II-transgenic Mice
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Rosa, D. S.; Ribeiro, S. P.; Fonseca, S. G.; Postol, E.; Guilherme, L.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Rosa, Daniela
   S/D-2190-2012; Guglielmi, Luiza G/E-7676-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Rosa, Daniela S/0000-0003-4536-891X; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 139
EP 139
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800358
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Rosa, DS
   Fonseca, SG
   Postol, E
   Guilherme, L
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Rosa, D. S.
   Fonseca, S. G.
   Postol, E.
   Guilherme, L.
   Kalil, J.
   Cunha-Neto, E.
TI A Novel Epitope-Based HIV-1 Vaccine Using DNA and Ad5 Vectors Induces
   Multiepitopic and Multiallelic Responses in BALB/c and HLA-II Transgenic
   Mice
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Ribeiro, S. P.; Rosa, D. S.; Fonseca, S. G.; Postol, E.; Guilherme, L.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Rosa, Daniela S/D-2190-2012; Cunha-Neto,
   Edecio/B-4157-2009; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; Rosa, Daniela S/0000-0003-4536-891X;
   Cunha-Neto, Edecio/0000-0002-3699-3345; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 141
EP 142
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800364
DA 2020-11-26
ER

PT J
AU Michaluart, P
   Abdallah, KA
   Lima, FD
   Smith, R
   Moyses, RA
   Coelho, V
   Victora, GD
   Socorro-Silva, A
   Volsi, EC
   Zarate-Blades, CR
   Ferraz, AR
   Barreto, AK
   Chammas, MC
   Gomes, R
   Gebrim, E
   Arakawa-Sugueno, L
   Fernandes, KP
   Lotufo, PA
   Cardoso, MR
   Kalil, J
   Silva, CL
AF Michaluart, P.
   Abdallah, K. A.
   Lima, F. D.
   Smith, R.
   Moyses, R. A.
   Coelho, V.
   Victora, G. D.
   Socorro-Silva, A.
   Volsi, E. C.
   Zarate-Blades, C. R.
   Ferraz, A. R.
   Barreto, A. K.
   Chammas, M. C.
   Gomes, R.
   Gebrim, E.
   Arakawa-Sugueno, L.
   Fernandes, K. P.
   Lotufo, P. A.
   Cardoso, M. R.
   Kalil, J.
   Silva, C. L.
TI Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell
   carcinoma of the head and neck
SO CANCER GENE THERAPY
LA English
DT Article
DE immunotherapy; DNA vaccine; head and neck cancer; phase I trial
ID ANTIGEN-PROCESSING PATHWAY; SHOCK PROTEINS; DNA VACCINE; MOUSE MODEL;
   T-CELLS; CANCER; TUBERCULOSIS; THERAPY; CISPLATIN; ASSOCIATION
AB Considering that mycobacterial heat-shock protein 65 (hsp65) gene transfer can elicit a profound antitumoral effect, this study aimed to establish the safety, maximum-tolerated dose (MTD) and preliminary efficacy of DNA-hsp65 immunotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC). For this purpose, 21 patients with unresectable and recurrent HNSCC were studied. Each patient received three ultrasound-guided injections at 21-day intervals of: 150, 600 or 400 mu g of DNA-hsp65. Toxicity was graded according to CTCAE directions. Tumor volume was measured before and after treatment using computed tomography scan. The evaluation included tumor mass variation, delayed-type hypersensitivity response and spontaneous peripheral blood mononuclear cell proliferation before and after treatment. The MTD was 400 mg per dose. DNA-hsp65 immunotherapy was well tolerated with moderate pain, edema and infections as the most frequent adverse effects. None of the patients showed clinical or laboratory alterations compatible with autoimmune reactions. Partial response was observed in 4 out of 14 patients who completed treatment, 2 of which are still alive more than 3 years after the completion of the trial. Therefore, DNA-hsp65 immunotherapy is a feasible and safe approach at the dose of 400 mg per injection in patients with HNSCC refractory to standard treatment. Further studies in a larger number of patients are needed to confirm the efficacy of this novel strategy.
C1 [Zarate-Blades, C. R.; Silva, C. L.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biochem & Immunol, Ctr TB Res, BR-14049900 Sao Paulo, Brazil.
   [Michaluart, P.; Abdallah, K. A.; Lima, F. D.; Smith, R.; Moyses, R. A.; Coelho, V.; Victora, G. D.; Socorro-Silva, A.; Volsi, E. C.; Zarate-Blades, C. R.; Ferraz, A. R.; Barreto, A. K.; Chammas, M. C.; Gomes, R.; Gebrim, E.; Arakawa-Sugueno, L.; Fernandes, K. P.; Lotufo, P. A.; Cardoso, M. R.; Kalil, J.; Silva, C. L.] Univ Sao Paulo, Clin Trial Grp HSP65, BR-14049900 Sao Paulo, Brazil.
   [Michaluart, P.; Smith, R.; Moyses, R. A.; Ferraz, A. R.; Arakawa-Sugueno, L.; Fernandes, K. P.] Univ Sao Paulo, Sch Med, Dept Head & Neck Surg, BR-14049900 Sao Paulo, Brazil.
   [Abdallah, K. A.; Lima, F. D.; Coelho, V.; Victora, G. D.; Socorro-Silva, A.; Volsi, E. C.; Barreto, A. K.; Kalil, J.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Dept Immunol, BR-14049900 Sao Paulo, Brazil.
   [Michaluart, P.; Coelho, V.; Kalil, J.] Univ Sao Paulo, Millennium Inst, Inst Investigat Immunol, BR-14049900 Sao Paulo, Brazil.
   [Chammas, M. C.; Gomes, R.; Gebrim, E.] Univ Sao Paulo, Sch Med, Dept Radiol, BR-14049900 Sao Paulo, Brazil.
   [Lotufo, P. A.] Univ Sao Paulo, Sch Med, Dept Med, BR-14049900 Sao Paulo, Brazil.
   [Cardoso, M. R.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, BR-14049900 Sao Paulo, Brazil.
   [Silva, C. L.] Univ Sao Paulo, Millennium Inst TB Res, BR-14049900 Sao Paulo, Brazil.
   [Silva, C. L.] Farmacore Biotechnol Ltd, Sao Paulo, Brazil.
RP Silva, CL (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biochem & Immunol, Ctr TB Res, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM clsilva@cpt.fmrp.usp.br
RI Victora, Gabriel/C-5946-2011; Silva, Celio/C-4639-2012; Zarate-Blades,
   Carlos R/C-9663-2015; COELHO, VERONICA/D-1433-2013; KALIL,
   JORGE/C-8029-2012; Cardoso, Maria Regina A/J-7280-2012; Chammas, Maria
   Cristina/M-1960-2017; Lotufo, Paulo/A-9843-2008; Fernandes, Kristianne
   Porta Santos/I-4417-2016; Moyses, Raquel/N-4376-2015
OI Silva, Celio/0000-0002-0043-4568; Zarate-Blades, Carlos
   R/0000-0002-7728-7869; KALIL, JORGE/0000-0001-8415-4274; Chammas, Maria
   Cristina/0000-0001-7041-3079; Lotufo, Paulo/0000-0002-4856-8450;
   Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; Moyses,
   Raquel/0000-0002-0872-9870; Victora, Gabriel/0000-0001-8807-348X;
   Coelho, Veronica/0000-0002-0989-2581
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); FINEP ( Financiadora de Estudos e Projetos)Ciencia
   Tecnologia e Inovacao (FINEP)
FX We would like to thank Roger Chammas for his useful advice during the
   planning of the trial, Dr Jose Maciel Rodrigues Jr and Dr Karla Lima for
   their help in vaccine production. This work was supported by grants from
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) and
   FINEP ( Financiadora de Estudos e Projetos).
CR Amar Ali, 2003, Sao Paulo Med. J., V121, P155, DOI 10.1590/S1516-31802003000400003
   Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201
   Binder RJ, 2006, INT REV IMMUNOL, V25, P353, DOI 10.1080/08830180600992480
   Bonato VLD, 2004, IMMUNOLOGY, V113, P130, DOI 10.1111/j.1365-2567.2004.01931.x
   Castelli C, 2004, CANCER IMMUNOL IMMUN, V53, P227, DOI 10.1007/s00262-003-0481-9
   Chen XH, 2002, IMMUNOL LETT, V84, P81, DOI 10.1016/S0165-2478(02)00042-1
   Cross D, 2006, CLIN MED RES, V4, P218, DOI 10.3121/cmr.4.3.218
   He Y, 2006, VACCINE, V24, P2575, DOI 10.1016/j.vaccine.2005.12.030
   Herold-Mende C, 2005, ADV OTO-RHINO-LARYNG, V62, P173
   KAUFMANN SHE, 1987, EUR J IMMUNOL, V17, P351, DOI 10.1002/eji.1830170308
   Ku TKS, 2007, MOL CANCER RES, V5, P351, DOI 10.1158/1541-7786.MCR-06-0238
   Kunisawa J, 2003, MOL CELL, V12, P565, DOI 10.1016/j.molcel.2003.08.009
   Lima KM, 2003, VACCINE, V22, P49, DOI 10.1016/S0264-410X(03)00543-7
   Lowrie DB, 2006, VACCINE, V24, P1983, DOI 10.1016/j.vaccine.2005.11.010
   Lowrie DB, 1997, VACCINE, V15, P834, DOI 10.1016/S0264-410X(97)00073-X
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326
   LUKACS KV, 1993, J EXP MED, V178, P343, DOI 10.1084/jem.178.1.343
   Menoret A, 1999, BIOCHEM BIOPH RES CO, V262, P813, DOI 10.1006/bbrc.1999.1306
   Michaelsson J, 2002, J EXP MED, V196, P1403, DOI 10.1084/jem.20020797
   Mincheff M, 2000, EUR UROL, V38, P208, DOI 10.1159/000020281
   Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289
   Nuermberger E, 2005, AM J RESP CRIT CARE, V172, P1452, DOI 10.1164/rccm.200507-1047OC
   Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0
   Portaro FCV, 2002, BIOCHEMISTRY-US, V41, P7400, DOI 10.1021/bi011999l
   Prohaszka Z, 2007, ADV EXP MED BIOL, V594, P159
   ROBBINS KT, 1994, J CLIN ONCOL, V12, P2113, DOI 10.1200/JCO.1994.12.10.2113
   Segal BH, 2006, DRUG DISCOV TODAY, V11, P534, DOI 10.1016/j.drudis.2006.04.016
   SERSA G, 2007, EUR J SURG ONCOL, V2, P232
   Shin DM, 2002, J CLIN ONCOL, V20, P364, DOI 10.1200/JCO.20.2.364
   Silva CL, 2005, GENE THER, V12, P281, DOI 10.1038/sj.gt.3302418
   Siu LL, 2007, J CLIN ONCOL, V25, P2178, DOI 10.1200/JCO.2006.07.6547
   Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Todryk SM, 2000, IMMUNOLOGY, V99, P334, DOI 10.1046/j.1365-2567.2000.00002.x
   Tuomela M, 2005, GENE THER, V12, pS131, DOI 10.1038/sj.gt.3302627
   Vattemi E, 2006, DRUG NEWS PERSPECT, V19, P329, DOI 10.1358/dnp.2006.19.6.1015352
   VICTORA G, IMMUNE RESPONS UNPUB
   VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306
   WHITESIDE TL, 1993, CANCER RES, V53, P5654
   Winquist E, 2007, HEAD NECK-J SCI SPEC, V29, P38, DOI 10.1002/hed.20465
NR 40
TC 25
Z9 26
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD OCT
PY 2008
VL 15
IS 10
BP 676
EP 684
DI 10.1038/cgt.2008.35
PG 9
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 347EG
UT WOS:000259122800006
PM 18535616
OA Bronze
DA 2020-11-26
ER

PT J
AU Rizzo, LV
   Cunha-Neto, E
   Kalil, J
AF Rizzo, Luiz Vicente
   Cunha-Neto, Edecio
   Kalil, Jorge
TI Special section: A sample of Immunopharmacology at the 13th
   International Congress of Immunology, ImmunoRio 2007
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Editorial Material
C1 [Rizzo, Luiz Vicente] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RP Rizzo, LV (corresponding author), Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
EM lvrizzo@icb.usp.br
RI KALIL, JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009; Cunha-Neto,
   Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2008
VL 8
IS 10
SI SI
BP 1307
EP 1307
DI 10.1016/j.intimp.2008.04.009
PG 1
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 350XC
UT WOS:000259385900001
DA 2020-11-26
ER

PT J
AU Hounie, AG
   Cappi, C
   Cordeiro, Q
   Sampaio, AS
   Moraes, I
   do Rosario, MC
   Palacios, SA
   Goldberg, AC
   Vallada, HP
   Machado-Lima, A
   Nakano, E
   Kalil, J
   Pauls, D
   Pereira, CAB
   Guilherme, L
   Miguel, EC
AF Hounie, Ana Gabriela
   Cappi, Carolina
   Cordeiro, Quirino
   Sampaio, Aline Santos
   Moraes, Ivanil
   do Rosario, Maria Conceicao
   Palacios, Selma A.
   Goldberg, Anna Carla
   Vallada, Homero Pinto
   Machado-Lima, Ariane
   Nakano, Eduardo
   Kalil, Jorge
   Pauls, David
   Pereira, Carlos Alberto B.
   Guilherme, Luiza
   Miguel, Euripedes Constantino
TI TNF-alpha polymorphisms are associated with obsessive-compulsive
   disorder
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE case-control study; cytokine; autoimmune; molecular genetics; rheumatic
   fever
ID NECROSIS-FACTOR-ALPHA; RHEUMATIC-FEVER; PROMOTER POLYMORPHISMS;
   FUNCTIONAL-ANALYSIS; SPECTRUM DISORDERS; GENE POLYMORPHISM; GENOMIC
   ANCESTRY; MEXICAN PATIENTS; HEART-DISEASE; SCHIZOPHRENIA
AB Introduction: Several lines of evidence support an immunologic involvement in obsessive-compulsive disorder (OCD): the increased prevalence of OCD in patients with rheumatic fever (RF), and the aggregation of obsessive-compulsive spectrum disorders among relatives of RF probands. Tumor necrosis factor alpha is a proinflammatory cytokine involved in RF and other autoimmune diseases. Polymorphisms in the promoter region of the TNFA gene have been associated with RE Given the association between OCD and RF, the goal of the present study was to investigate a possible association between polymorphisms within the promoter region of TNFA and OCD. Materials and methods: Two polymorphisms were investigated: -308 G/A and -238 G/A. The allelic and genotypic frequencies of these polymorphisms were examined in 111 patients who fulfilled DSM-IV criteria for OCD and compared with the frequencies in 250 controls. Results: Significant associations were observed between both polymorphisms and OCD. For -238 G/A, an association between the A allele and OCD was observed (X-2 = 12.05, p = 0.0005). A significant association was also observed between the A allele of the -308 G/A polymorphism and OCD (X-2 = 7.09, p = 0.007). Finally, a haplotype consisting of genotypes of these two markers was also examined. Significant association was observed for the A-A haplotype (p = 0.0099 after correcting for multiple testing). Discussion: There is association between the -308 G/A and -238 G/A TNFA polymorphisms and OCD in our Brazilian sample. However, these results need to be replicated in larger samples collected from different populations. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Hounie, Ana Gabriela; Cappi, Carolina; Cordeiro, Quirino; Sampaio, Aline Santos; Moraes, Ivanil; do Rosario, Maria Conceicao; Vallada, Homero Pinto; Machado-Lima, Ariane; Nakano, Eduardo; Miguel, Euripedes Constantino] Univ Sao Paulo, Clin Hosp, Inst Psychiat, Dept Psychiat, BR-05508 Sao Paulo, Brazil.
   [Palacios, Selma A.; Goldberg, Anna Carla; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   [Palacios, Selma A.; Goldberg, Anna Carla; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05508 Sao Paulo, Brazil.
   [Pauls, David] Univ Sao Paulo, Dept Math & Stat, BR-05508 Sao Paulo, Brazil.
   [Pauls, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA USA.
   [do Rosario, Maria Conceicao] Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil.
RP Hounie, AG (corresponding author), FMUSP, Dept & Inst Psychiat, CEAPESQ, Rua Doutor Ovidio Pires Campos,785 3 Andar,Sala 0, BR-05403010 Sao Paulo, Brazil.
EM anah@protoc.com.br
RI Rosario, Maria Conceicao do/E-5213-2012; Machado-Lima,
   Ariane/F-4245-2012; Nakano, Eduardo Y/G-1660-2011; Goldberg, Anna
   Carla/H-8594-2014; Lima, Ariane Machado/O-1772-2019; Guglielmi, Luiza
   G/E-7676-2013; Miguel, Euripedes C/B-2871-2008; KALIL,
   JORGE/C-8029-2012; SAMPAIO, ALINE/M-1229-2013; Vallada,
   Homero/D-1333-2014; Pereira, Carlos Alberto de Braganca/O-5022-2015
OI Rosario, Maria Conceicao do/0000-0002-9687-0072; Machado-Lima,
   Ariane/0000-0002-5719-338X; Nakano, Eduardo Y/0000-0002-9071-8512;
   Goldberg, Anna Carla/0000-0003-2600-7940; Lima, Ariane
   Machado/0000-0002-5719-338X; KALIL, JORGE/0000-0001-8415-4274; SAMPAIO,
   ALINE/0000-0001-5568-6167; Vallada, Homero/0000-0001-5123-8295; Pereira,
   Carlos Alberto de Braganca/0000-0001-6315-7484
FU CAPES/PRODOC, FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)CAPES [98/15-013-9, 2005/55628-8]; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This work was supported by grants from CAPES/PRODOC, FAPESP (grants
   98/15-013-9 and 2005/55628-8), and CNPq. We thank Maria Alice and Maria
   Eugenia De Mathis, Juliana B Diniz, Pedro G Alvarenga, Andre A Seixas,
   Fernando Akkerman, Marcos S Vasconcelos, Maria C Bravo, Priscila Chacon,
   Sergio Broto, Yara Garzuzi, Rosemar Prota and Daniela Dourado for
   conducting the clinical evaluations. We also thank Maria Lucia Carnevale
   Marin, Lea Oliveira, Kellen Fae and Gabriel Victora for helping in the
   genotyping. We also thank Dr. Rajendranath Ramasawmy for his help and
   support.
CR Alvarenga PG, 2006, J NEUROPSYCH CLIN N, V18, P405, DOI 10.1176/appi.neuropsych.18.3.405
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P886
   BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6
   Bayley JP, 2001, CYTOKINE, V14, P316, DOI 10.1006/cyto.2001.0902
   Berdeli A, 2006, SCAND J RHEUMATOL, V35, P44, DOI 10.1080/03009740510026760
   BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625
   Brambilla F, 1997, BIOL PSYCHIAT, V42, P976, DOI 10.1016/S0006-3223(96)00495-7
   Brebner K, 2000, NEUROPSYCHOPHARMACOL, V22, P566, DOI 10.1016/S0893-133X(99)00166-9
   Brinkman BMN, 1996, J INFLAMM, V46, P32
   Carpenter LL, 2002, PSYCHIAT RES, V112, P257, DOI 10.1016/S0165-1781(02)00233-0
   Denys D, 2004, PSYCHONEUROENDOCRINO, V29, P945, DOI 10.1016/j.psyneuen.2003.08.008
   DROUET C, 1991, J IMMUNOL, V147, P1694
   Duan SW, 2004, NEUROSCI LETT, V366, P139, DOI 10.1016/j.neulet.2004.05.039
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108
   Guilherme L, 2007, SCAND J IMMUNOL, V66, P199, DOI 10.1111/j.1365-3083.2007.01974.x
   Haddy N, 2005, EUR J HUM GENET, V13, P109, DOI 10.1038/sj.ejhg.5201294
   Handoko HY, 2003, AM J MED GENET B, V121B, P1, DOI 10.1002/ajmg.b.20059
   Hemmings SMJ, 2006, PSYCHIAT CLIN N AM, V29, P411, DOI 10.1016/j.psc.2006.02.011
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Hounie AG, 2004, J CLIN PSYCHIAT, V65, P994
   Hounie AG, 2007, BIOL PSYCHIAT, V61, P266, DOI 10.1016/j.biopsych.2006.02.021
   Jun TY, 2003, PSYCHIAT GENET, V13, P179, DOI 10.1097/00041444-200309000-00008
   Jun TY, 2003, PSYCHIAT CLIN NEUROS, V57, P31, DOI 10.1046/j.1440-1819.2003.01076.x
   Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x
   KONUK N, 2007, HINDAWI PUBL CORP ME, V27, P1
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944
   McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022
   Meira-Lima IV, 2003, MOL PSYCHIATR, V8, P718, DOI 10.1038/sj.mp.4001309
   Mercadante MT, 2000, AM J PSYCHIAT, V157, P2036, DOI 10.1176/appi.ajp.157.12.2036
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   Miguel EC, 2005, MOL PSYCHIATR, V10, P258, DOI 10.1038/sj.mp.4001617
   Mittleman BB, 1997, J IMMUNOL, V159, P2994
   Monteleone P, 1998, NEUROPSYCHOBIOLOGY, V37, P182, DOI 10.1159/000026500
   Mossner R, 1998, NEUROCHEM INT, V33, P251, DOI 10.1016/S0197-0186(98)00026-6
   Ott J, 1999, J HERED, V90, P68, DOI 10.1093/jhered/90.1.68
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x
   R Development Core Team, 2007, R LANG ENV STAT COMP
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   Sawada M, 2006, J NEURAL TRANSM-SUPP, P373
   Settin A, 2007, PEDIATR CARDIOL, V28, P363, DOI 10.1007/s00246-006-0002-7
   Suarez-Kurtz G, 2007, PHARMACOGENET GENOM, V17, P765, DOI 10.1097/FPC.0b013e3281c10e52
   Swedo SE, 2002, MOL PSYCHIATR, V7, pS24, DOI 10.1038/sj.mp.4001170
   Szeszko JS, 2006, DIABETES, V55, P559, DOI 10.2337/diabetes.55.02.06.db05-0826
   Uglialoro AM, 1998, TISSUE ANTIGENS, V52, P359, DOI 10.1111/j.1399-0039.1998.tb03056.x
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
   Zai G, 2006, PSYCHIAT GENET, V16, P43, DOI 10.1097/01.ypg.0000185026.12687.92
   Zai G, 2004, AM J MED GENET B, V129B, P64, DOI 10.1002/ajmg.b.30077
   Zohar J, 2004, J CLIN PSYCHIAT, V65, P18
   Zuniga J, 2001, GENES IMMUN, V2, P363, DOI 10.1038/sj.gene.6363793
NR 53
TC 36
Z9 38
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD SEP 12
PY 2008
VL 442
IS 2
BP 86
EP 90
DI 10.1016/j.neulet.2008.07.022
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 344EP
UT WOS:000258909500002
PM 18639610
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Kalil, J
   Rizzo, LV
AF Giavina-Bianchi, Pedro
   Kalil, Jorge
   Rizzo, Luiz Vicente
TI Development of an animal model for allergic conjunctivitis: influence of
   genetic factors and allergen concentration on immune response
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE animal models of diseases; allergic conjunctivitis; immediate
   hypersensitivity; mice; mucosal immunity; mites
ID T-CELL-CLONES; MURINE MODEL; MOUSE MODEL; NUMBERS; ANTIGEN; IL-10;
   GAMMA; TH1
AB Purpose: Animal models of diseases are extremely important in the study of the physiopathogenesis of human diseases and for testing novel therapeutic interventions. The present study aimed to develop an animal model that simulates human allergic conjunctivitis and to study how allergic response may be influenced by the allergen dose used for immunization and by genetic factors.
   Methods: Sixty C57Bl/6 mice and 60 BALB/c mice were immunized with placebo, or 5 mu g or 500 mu g of allergen derived from Dermatophagoides pteronyssinus. After ocular challenge, the mice were examined in order to clinically verify the occurrence or not of conjunctivitis. Material obtained from animals was used for total and specific IgE and IgG1 dosage, for assays of Der p-specific lymphocyte proliferation and supernatant cytokine dosage, and for histopathological evaluation of conjunctiva.
   Results: We developed a murine model of allergic conjunctivitis induced by D. pteronyssinus. The model is similar to human disease both clinically and according to laboratory findings. In mouse, conjunctivitis was associated with a Th2 cytokine profile. However, IL-10 appeared to be involved with disease blockade. Mice of different strains have distinct immune responses, depending on the sensitization dose.
   Conclusions: The murine model developed is suitable for the study of immunopathogenesis and as a template for future therapies. Using BALB/c and C57BL/6 mice, we demonstrated that genetic factors play a role in determining susceptibility and resistance, as well as in establishing the allergen concentration needed to induce or to block disease development.
C1 [Giavina-Bianchi, Pedro; Kalil, Jorge; Rizzo, Luiz Vicente] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Rua Professor Artur Ramos 178,Ap 211A, BR-01454010 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Rizzo, Luiz Vicente/B-4458-2009; KALIL, JORGE/C-8029-2012;
   Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Akdis CA, 2001, MICROBES INFECT, V3, P891, DOI 10.1016/S1286-4579(01)01449-6
   BALLAS Z, 1993, SURV OPHTHALMOL, V38, P141, DOI 10.1016/0039-6257(93)90038-9
   Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9
   Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x
   BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6
   Bonini S, 2000, ACTA OPHTHALMOL SCAN, V78, P41, DOI 10.1034/j.1600-0420.2000.078s230041.x
   Bostock J, 1819, Med Chir Trans, V10, P161
   Calonge M, 1999, ACTA OPHTHALMOL SCAN, V77, P10, DOI 10.1111/j.1600-0420.1999.tb01164.x
   DELPRETE G, 1993, J IMMUNOL, V150, P353
   FILHO NAR, 1992, REV ALERG MEX, V39, P96
   FRIEDLAENDER MH, 1993, SURV OPHTHALMOL, V38, P105, DOI 10.1016/0039-6257(93)90035-6
   Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589
   Keane-Myers AM, 1999, INVEST OPHTH VIS SCI, V40, P3041
   LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343
   Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507
   MATSUSHITA S, 1992, CELL IMMUNOL, V143, P212, DOI 10.1016/0008-8749(92)90017-J
   MerayoLloves J, 1996, J ALLERGY CLIN IMMUN, V97, P1129, DOI 10.1016/S0091-6749(96)70268-3
   Metz DP, 1997, J ALLERGY CLIN IMMUN, V100, P817, DOI 10.1016/S0091-6749(97)70279-3
   MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135
   NAKAMURA T, 2003, CORNEA S7, V22, P13
   Ohbayashl M, 2007, EXP MOL PATHOL, V83, P216, DOI 10.1016/j.yexmp.2007.04.007
   Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X
   RIZZO LV, 1995, EUR J IMMUNOL, V25, P708, DOI 10.1002/eji.1830250312
   ROMAGNANI S, 1991, INT ARCH ALLER A IMM, V94, P133, DOI 10.1159/000235344
   Stern ME, 2005, INVEST OPHTH VIS SCI, V46, P3239, DOI 10.1167/iovs.05-0138
   Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336
   Tabbara KF, 1999, CAN J OPHTHALMOL, V34, P88
   Yasuda M, 1999, INFLAMM RES, V48, P325, DOI 10.1007/s000110050468
NR 28
TC 13
Z9 14
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2008
VL 86
IS 6
BP 670
EP 675
DI 10.1111/j.1600-0420.2007.01134.x
PG 6
WC Ophthalmology
SC Ophthalmology
GA 341PO
UT WOS:000258726900016
PM 18752518
DA 2020-11-26
ER

PT J
AU Fae, KC
   da Silva, DD
   Bilate, AMB
   Tanaka, AC
   Pomerantzeff, PMA
   Kiss, MH
   Silva, CAA
   Cunha-Neto, E
   Kalil, J
   Guilherme, L
AF Fae, Kellen C.
   da Silva, Danielle Diefenbach
   Bilate, Angelina M. B.
   Tanaka, Ana C.
   Pomerantzeff, Pablo M. A.
   Kiss, Maria Helena
   Silva, Clovis A. A.
   Cunha-Neto, Edecio
   Kalil, Jorge
   Guilherme, Luiza
TI PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular
   tissue, are the target antigens of peripheral and heart infiltrating T
   cells from chronic rheumatic heart disease patients
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Rheumatic heart disease; Autoantigen; Vimentin; Protein disulfide
   isomerase ER-60 precursor (PDIA3); 78 kD glucose-regulated protein
   precursor (HSPA5)
ID STREPTOCOCCAL M-PROTEIN; MONOCLONAL-ANTIBODIES; CLONES; MYOSIN;
   AUTOANTIBODIES; LYMPHOCYTES; RECOGNIZE; ARTHRITIS; PEPTIDES; CARDITIS
AB Rheumatic fever (RF) is a post-infectious autoimmune disease due to sequel of group A streptococcus (GAS) pharyngitis. Rheumatic heart disease (RHD), the major manifestation of RF, is characterized by inflammation of heart valves and myocardium. Molecular mimicry between GAS antigens and host proteins has been shown at B and T cell level. However the identification of the autoantigens recognized by B and T cells within the inflammatory microenvironment of heart tissue in patients with RHD is still incompletely elucidated. In the present study, we used two-dimensional gel electrophoresis (2-DE) and mass spectrometry to identify valvular tissue proteins tat-get of T cells from chronic RHD patients. We could identify three proteins recognized by heart infiltrating and peripheral T cells as protein disulfide isomerase ER-60 precursor (PDIA3), 78 kD glucose-regulated protein precursor (HSPA5) and vimentin, with coverage of 45%, 43 and 34%, respectively. These proteins were recognized in a proliferation assay by peripheral and heart infiltrating T cells from RHD patients suggesting that they may be involved in the autoimmune reactions that leads to valve damage. We also observed that several other proteins isolated by 2-DE but not identified by mass spectrometry were also recognized by T cells. The identified cardiac proteins are likely relevant antigens involved in T cell-mediated autoimmune responses in RF/RHD that may contribute to the development of RHD. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Guilherme, Luiza] Univ Sao Paulo, InCor HCFMUSP, Inst Coracao, Lab Immunol, BR-05403000 Sao Paulo, Brazil.
   [Kiss, Maria Helena; Silva, Clovis A. A.] Univ Sao Paulo, Childrens Inst, Unit Pediat Rheumatol, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge; Guilherme, Luiza] Millenium Inst, Inst Immunol Invest, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, InCor HCFMUSP, Inst Coracao, Lab Immunol, Av Dr Eneas de Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
RI Guglielmi, Luiza G/E-7676-2013; Pomerantzeff, Pablo M A/L-5525-2016;
   KALIL, JORGE/C-8029-2012; Sampaio, Magda/AAU-6748-2020; Cunha-Neto,
   Edecio/B-4157-2009
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; KALIL,
   JORGE/0000-0001-8415-4274; Sampaio, Magda/0000-0002-1924-4043;
   Cunha-Neto, Edecio/0000-0002-3699-3345
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX We acknowledge Dr. Rajendranath Ramasawmy and Dr. Antoine Toubert for
   fruitful discussions and corrections of the manuscript.; This work was
   supported by grants from "Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)" and "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)".
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   BAIRD RW, 1991, J IMMUNOL, V146, P3132
   Bisno AL, 2001, NEW ENGL J MED, V344, P205, DOI 10.1056/NEJM200101183440308
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Honore B, 2004, EXP CELL RES, V295, P91, DOI 10.1016/j.yexcr.2003.11.029
   Hsu HC, 2006, ARTHRITIS RHEUM-US, V54, P343, DOI 10.1002/art.21550
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873
   Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1
   Matsuo K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2085
   NIGAM SK, 1994, J BIOL CHEM, V269, P1744
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902
   Tontsch D, 2000, CLIN EXP IMMUNOL, V121, P270, DOI 10.1046/j.1365-2249.2000.01283.x
   Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485
   Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002
NR 25
TC 38
Z9 39
U1 0
U2 4
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD SEP
PY 2008
VL 31
IS 2
BP 136
EP 141
DI 10.1016/j.jaut.2008.04.023
PG 6
WC Immunology
SC Immunology
GA 357XO
UT WOS:000259880700007
PM 18541406
DA 2020-11-26
ER

PT J
AU Leoratti, FMS
   Farias, L
   Alves, FP
   Suarez-Mutis, MC
   Coura, JR
   Kalil, J
   Camargo, EP
   Moraes, SL
   Ramasawmy, R
AF Leoratti, Fabiana M. S.
   Farias, Lilian
   Alves, Fabiana P.
   Suarez-Mutis, Martha C.
   Coura, Jose R.
   Kalil, Jorge
   Camargo, Erney P.
   Moraes, Sandra L.
   Ramasawmy, Rajendranath
TI Variants in the toll-like receptor signaling pathway and clinical
   outcomes of malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; SINGLE-NUCLEOTIDE POLYMORPHISMS;
   ASYMPTOMATIC PLASMODIUM-VIVAX; HUMAN CEREBRAL MALARIA;
   TUMOR-NECROSIS-FACTOR; CYTOKINE EXPRESSION; FALCIPARUM-MALARIA; INNATE
   IMMUNITY; HIGH PREVALENCE; DISEASE
AB Background. Malaria is one of the most significant infectious diseases in the world and is responsible for a large proportion of infant deaths. Toll-like receptors (TLRs), key components of innate immunity, are central to countering infection. Variants in the TLR-signaling pathway are associated with susceptibility to infectious diseases.
   Methods. We genotyped single nucleotide polymorphisms ( SNPs) of the genes associated with the TLR-signaling pathway in patients with mild malaria and individuals with asymptomatic Plasmodium infections by means of polymerase chain reaction.
   Results. Genotype distributions for the TLR-1 I602S differed significantly between patients with mild malaria and persons with asymptomatic infection. The TLR-1 602S allele was associated with an odds ratio ( OR) of 2.2 ( P = .003; P-corrected = .015) for malaria among patients with mild malaria due to any Plasmodium species and 2.1 ( P = .015; P-corrected = .75) among patients with mild malaria due to Plasmodium falciparum only. The TLR-6 S249P SNP showed an excess of homozygotes for the TLR-6 249P allele in asymptomatic persons, compared with patients with mild malaria due to any Plasmodium species (OR 2.1; 95% confidence interval [CI], 1.1-4.2; P = .01; P-corrected = .05), suggesting that the TLR-6 249S allele may be a risk factor for malaria ( OR, 2.0; 95% CI, 1.1-3.7; P = 0.01; P-corrected = .05). The TLR-9-1486C allele showed a strong association with high parasitemia ( P < .001).
   Conclusions. Our findings indicate that the TLR-1 and TLR- 6 variants are significantly associated with mild malaria, whereas the TLR-9-1486C/T variants are associated with high parasitemia. These discoveries may bring additional understanding to the pathogenesis of malaria.
C1 [Leoratti, Fabiana M. S.; Farias, Lilian; Moraes, Sandra L.] Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05508 Sao Paulo, Brazil.
   [Camargo, Erney P.] Univ Sao Paulo, Inst Ciencias Biomed, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge; Moraes, Sandra L.; Ramasawmy, Rajendranath] Univ Sao Paulo, Sch Med, Heart Inst Incor, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge; Ramasawmy, Rajendranath] Inst Immunol Invest, Sao Paulo, Brazil.
   [Alves, Fabiana P.; Suarez-Mutis, Martha C.; Coura, Jose R.] Fiocruz MS, Rio de Janeiro, Brazil.
   [Ramasawmy, Rajendranath] Univ Fed Bahia, Hosp Univ Prof Edgar Santos, Serv Imunol, Salvador, BA, Brazil.
RP Ramasawmy, R (corresponding author), Incor FMUSP, Lab Imunol, 44 Av Dr Eneas Carvalho Aguiar,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM ramasawm@usp.br
RI Su\\xc3\\xa1rez-Mutis, Martha/T-9260-2019; KALIL, JORGE/C-8029-2012;
   Camargo, Erney P/A-6765-2009; Ramasawmy, Rajendranath/V-4926-2019;
   Suarez-Mutis, Martha/B-9189-2015
OI KALIL, JORGE/0000-0001-8415-4274; Camargo, Erney P/0000-0003-0011-5871;
   Suarez-Mutis, Martha/0000-0003-2809-6799
CR Adachi K, 2001, J IMMUNOL, V167, P5928, DOI 10.4049/jimmunol.167.10.5928
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Brown H, 1999, J INFECT DIS, V180, P1742, DOI 10.1086/315078
   Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Guerra CA, 2006, ADV PARASIT, V62, P157, DOI 10.1016/S0065-308X(05)62005-2
   Hawn TR, 2007, EUR J IMMUNOL, V37, P2280, DOI 10.1002/eji.200737034
   Hisaeda H, 2008, J IMMUNOL, V180, P2496, DOI 10.4049/jimmunol.180.4.2496
   Johnson CM, 2007, J IMMUNOL, V178, P7520, DOI 10.4049/jimmunol.178.12.7520
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673
   Kimura Masatsugu, 1997, Parasitology International, V46, P91, DOI 10.1016/S1383-5769(97)00013-5
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Kwiatkowski D, 1997, ANN TROP MED PARASIT, V91, P533, DOI 10.1080/00034989760905
   Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8
   Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102
   Mockenhaupt FP, 2006, J INFECT DIS, V194, P184, DOI 10.1086/505152
   Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab
   PORTA J, 1993, CLIN NEUROPATHOL, V12, P142
   Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102
   Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937
   Schofield L, 1996, J IMMUNOL, V156, P1886
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Suárez-Mutis Martha C., 2007, Rev. Inst. Med. trop. S. Paulo, V49, P159, DOI 10.1590/S0036-46652007000300005
   Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096
   TURNER GDH, 1994, AM J PATHOL, V145, P1057
   Turvey SE, 2006, CLIN IMMUNOL, V120, P1, DOI 10.1016/j.clim.2006.02.003
   Udomsangpetch R, 1997, AM J TROP MED HYG, V57, P501, DOI 10.4269/ajtmh.1997.57.501
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Wurfel MM, 2005, J IMMUNOL, V175, P2570, DOI 10.4049/jimmunol.175.4.2570
NR 40
TC 74
Z9 74
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2008
VL 198
IS 5
BP 772
EP 780
DI 10.1086/590440
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 336KW
UT WOS:000258363700021
PM 18662133
OA Bronze
DA 2020-11-26
ER

PT J
AU Souza, P
   Panajotopoulos, N
   Ronda, C
   Rodrigues, H
   David, D
   Agena, F
   Ianhez, LE
   David-Neto, E
   Kalil, J
   Castro, MC
AF Souza, P.
   Panajotopoulos, N.
   Ronda, C.
   Rodrigues, H.
   David, D.
   Agena, F.
   Ianhez, L. E.
   David-Neto, E.
   Kalil, J.
   Castro, M. C.
TI Monitoring of anti-HLA antibodies after kidney transplantation: a
   prognostic factor for acute rejection and graft loss
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 15th International Histocompatibility and Immunogenetics Workshop and
   Conference
CY SEP 13-20, 2008
CL Rio de Janeiro, BRAZIL
C1 [Souza, P.] Div Neurol, Sao Paulo, Brazil.
   [Panajotopoulos, N.; Ronda, C.; Rodrigues, H.; Kalil, J.] InCor, Immunol Lab, Sao Paulo, Brazil.
   [David, D.; Agena, F.; Ianhez, L. E.; David-Neto, E.; Castro, M. C.] Renal Transplant Unit, Div Urol, Sao Paulo, Brazil.
RI Agena, Fabiana/F-5807-2012; Agena, Fabiana/C-5819-2015; Neto, Elias
   David/O-3866-2018; de castro, maria cristina ribeiro/B-6648-2009;
   David-Neto, Elias/C-9112-2012; KALIL, JORGE/C-8029-2012
OI Agena, Fabiana/0000-0002-4526-4857; de castro, maria cristina
   ribeiro/0000-0002-6731-8369; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD SEP
PY 2008
VL 72
IS 3
BP 258
EP 258
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 337OD
UT WOS:000258444500075
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Marin, MLC
   Ramasawmy, R
   Oliveira, LC
   Savioli, CR
   Rodrigues, H
   Kalil, J
AF Goldberg, A. C.
   Marin, M. L. C.
   Ramasawmy, R.
   Oliveira, L. C.
   Savioli, C. R.
   Rodrigues, H.
   Kalil, J.
TI Conserved extended haplotypes in a population sample from Sao Paulo,
   Brazil, harbor variations in class IIISNP
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 15th International Histocompatibility and Immunogenetics Workshop and
   Conference
CY SEP 13-20, 2008
CL Rio de Janeiro, BRAZIL
C1 [Goldberg, A. C.] Univ Sao Paulo, Nucleo Terapia Celular & Mol, NUCEL, Sao Paulo, Brazil.
   [Marin, M. L. C.; Ramasawmy, R.; Savioli, C. R.; Rodrigues, H.; Kalil, J.] Univ Sao Paulo, Inst Coracao, HCFMUSP, Sao Paulo, Brazil.
   [Oliveira, L. C.] Univ Sao Paulo, Inst Crianca, HCFMUSP, Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Dept Clin Med, FMUSP, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Ramasawmy, Rajendranath/V-4926-2019; Goldberg,
   Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD SEP
PY 2008
VL 72
IS 3
BP 268
EP 269
PG 2
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 337OD
UT WOS:000258444500102
DA 2020-11-26
ER

PT J
AU Giret, MM
   Bermudez-Aza, E
   Gouvea, N
   Gouvea, C
   Tomiyama, H
   Sauer, MM
   Kalil, J
   Watkins, D
   Kallas, E
AF Giret, M. Maidana
   Bermudez-Aza, E.
   Gouvea, N.
   Gouvea, C.
   Tomiyama, H.
   Sauer, M. Melillo
   Kalil, J.
   Watkins, D.
   Kallas, E.
TI The HLA-B*57 allele is highly enriched in Brazilian elite controllers
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 15th International Histocompatibility and Immunogenetics Workshop and
   Conference
CY SEP 13-20, 2008
CL Rio de Janeiro, BRAZIL
C1 [Giret, M. Maidana; Bermudez-Aza, E.; Tomiyama, H.; Sauer, M. Melillo; Kallas, E.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Gouvea, N.; Gouvea, C.; Kalil, J.; Kallas, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Watkins, D.] Univ Wisconsin, Madison, WI 53706 USA.
RI Kallas, Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD SEP
PY 2008
VL 72
IS 3
BP 274
EP 274
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 337OD
UT WOS:000258444500116
DA 2020-11-26
ER

PT J
AU Bilate, AM
   Teixeira, PC
   Ribeiro, SP
   de Brito, T
   Silva, AM
   Russo, M
   Kalil, J
   Cunha-Neto, E
AF Bilate, Angelina M.
   Teixeira, Priscila C.
   Ribeiro, Susan P.
   de Brito, Thales
   Silva, Ana Maria
   Russo, Momtchilo
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Distinct outcomes of Trypanosoma cruzi infection in hamsters are related
   to myocardial parasitism, cytokine/chemokine gene expression, and
   protein expression profile
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 16th European Congress of Immunology (ECI)
CY SEP 06-09, 2006
CL Paris, FRANCE
ID CHAGAS-DISEASE CARDIOMYOPATHY; TISSUE PARASITISM; T-CELLS; HEART; GAMMA;
   MICE; CYTOKINE; CARDIOMYOCYTES; INFLAMMATION; DISRUPTION
AB Background. Trypanosoma cruzi-infected outbred hamsters reproduce the range of different outcomes of Chagas disease noted in humans. We tested whether myocarditis, its mediators, and myocardial protein expression are related to the severity of the acute phase of T. cruzi infection in the hamster model.
   Methods. Myocardium left ventricles (LVs) obtained from Syrian hamsters infected with T. cruzi were collected 21 days after infection. Myocarditis and the T. cruzi nest/antigen area were analyzed by histological and morphometric analysis. Cytokine and chemokine messenger RNA (mRNA) expression was analyzed using real-time reverse-transcriptase polymerase chain reaction. Differentially expressed proteins were identified by 2-dimensional electrophoresis, followed by mass spectrometry.
   Results. While in the acute phase of infection, 50% of animals displayed weight loss and signs of acute-phase infection (hereafter referred to as "acute-phase signs" [APS]) (e. g., lethargy, vomiting, and diarrhea). Both the T. cruzi nest/antigen area and the expression of interferon-gamma, tumor necrosis factor-alpha, interleukin-10, and CCL3 mRNA were significantly increased in the LVs of animals with APS, compared with the LVs of animals without APS. Animals with APS, those without APS, and uninfected animals demonstrated distinct myocardial expression of contractile, stress response, and metabolism proteins.
   Conclusions. The distinct outcomes of acute T. cruzi infection in Syrian hamsters are related to cardiac parasitism, cytokine expression, and changes in the expression of structural/contractile and stress response proteins that may be associated with alterations in the cardiomyocyte cytoskeleton.
C1 [Bilate, Angelina M.; Teixeira, Priscila C.; Ribeiro, Susan P.; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Immunol Lab, Inst Heart InCor, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Bilate, Angelina M.; Teixeira, Priscila C.; Ribeiro, Susan P.; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, SP, Brazil.
   [de Brito, Thales; Silva, Ana Maria] Univ Sao Paulo, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   [Russo, Momtchilo] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Immunol Lab, Inst Heart InCor, Sch Med, Av Dr Eneas Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM edecunha@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; da Silva, Ana Maria
   Goncalves/ABD-3920-2020; Teixeira, Priscila C/D-7426-2013; KALIL,
   JORGE/C-8029-2012; De Brito, Thales/L-2865-2017
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; De Brito, Thales/0000-0003-1106-7254; Silva,
   Ana Maria/0000-0001-7554-0894; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
CR Aliberti JCS, 2001, AM J PATHOL, V158, P1433, DOI 10.1016/S0002-9440(10)64094-1
   Andrade ZA, 1999, MEM I OSWALDO CRUZ, V94, P71, DOI 10.1590/S0074-02761999000700007
   Arrell DK, 2001, CIRC RES, V88, P763, DOI 10.1161/hh0801.090193
   Arrigo AP, 2002, EXP GERONTOL, V37, P1247, DOI 10.1016/S0531-5565(02)00131-6
   Augustus AS, 2006, J BIOL CHEM, V281, P8716, DOI 10.1074/jbc.M509890200
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   Cabrine-Santos M, 2001, EXP PARASITOL, V99, P160, DOI 10.1006/expr.2001.4661
   Chagas C., 1909, Memorias do Instituto Oswaldo Cruz, V1
   Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200
   Colmanetti FH, 2005, ULTRASTRUCT PATHOL, V29, P139, DOI 10.1080/019131290923974
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Delogu Giovanna, 2002, Curr Opin Crit Care, V8, P411, DOI 10.1097/00075198-200210000-00007
   Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000
   Jensen ON, 2006, NAT REV MOL CELL BIO, V7, P391, DOI 10.1038/nrm1939
   LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Melo TG, 2006, PARASITOLOGY, V133, P171, DOI 10.1017/S0031182006000011
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Morel CM, 2003, NAT REV MICROBIOL, V1, P14, DOI 10.1038/nrmicro735
   Parada H, 1997, INT J CARDIOL, V60, P49, DOI 10.1016/S0167-5273(97)02952-5
   PEREIRA MCS, 1993, J SUBMICR CYTOL PATH, V25, P559
   Proost P, 2006, BIOCHEM SOC T, V34, P997, DOI 10.1042/BST0340997
   Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219
   RAMEREZ LE, 1994, REV SOC BRAS MED TRO, V27, P163
   RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263
   RUSSO M, 1989, PARASITE IMMUNOL, V11, P385, DOI 10.1111/j.1365-3024.1989.tb00675.x
   Sardinha LR, 2006, INFECT IMMUN, V74, P2031, DOI 10.1128/IAI.74.4.2031-2042.2006
   Sheeran FL, 2006, BBA-BIOENERGETICS, V1757, P543, DOI 10.1016/j.bbabio.2006.03.008
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Taniwaki NN, 2005, PARASITOL RES, V97, P323, DOI 10.1007/s00436-005-1429-0
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Teixeira PC, 2006, BRAZ J MED BIOL RES, V39, P1549, DOI 10.1590/S0100-879X2006005000050
   Truyens C, 1999, INFECT IMMUN, V67, P5579, DOI 10.1128/IAI.67.11.5579-5586.1999
   Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765
NR 36
TC 16
Z9 16
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 15
PY 2008
VL 198
IS 4
BP 614
EP 623
DI 10.1086/590347
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 329TK
UT WOS:000257893300021
PM 18598198
OA Bronze
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Diniz, LC
   Agondi, RC
   Porter, MH
   Kalil, J
AF Giavina-Bianchi, Pedro
   Diniz, Lorena C.
   Agondi, Rosana C.
   Porter, Maria H.
   Kalil, Jorge
TI Urticaria after specific bronchial challenge
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID RESPONSES
C1 [Giavina-Bianchi, Pedro; Diniz, Lorena C.; Agondi, Rosana C.; Porter, Maria H.; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
CR HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487
   INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7
   Makowska JS, 2008, J ALLERGY CLIN IMMUN, V121, P348, DOI 10.1016/j.jaci.2007.09.039
   Melillo G, 1997, Allergy, V52, P1
NR 4
TC 4
Z9 4
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2008
VL 122
IS 1
BP 214
EP 215
DI 10.1016/j.jaci.2008.04.004
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 325RD
UT WOS:000257605100037
PM 18468673
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Giavina-Bianchi, M
   Agondi, R
   Kalil, J
AF Giavina-Bianchi, Pedro
   Giavina-Bianchi, Mara
   Agondi, Rosana
   Kalil, Jorge
TI Omalizumab and Churg-Strauss syndrome
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID ANTI-IGE; PATIENT; ASTHMA
C1 [Giavina-Bianchi, Pedro; Giavina-Bianchi, Mara; Agondi, Rosana; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Bargagli E, 2008, INT ARCH ALLERGY IMM, V145, P268, DOI 10.1159/000109296
   Giavina-Bianchi P, 2008, INT ARCH ALLERGY IMM, V146, P176, DOI 10.1159/000113524
   Giavina-Bianchi P, 2007, INT ARCH ALLERGY IMM, V144, P155, DOI 10.1159/000103228
   Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, P1279, DOI 10.1016/j.jaci.2007.01.041
   Ruppert AA, 2008, J ALLERGY CLIN IMMUN, V121, P253, DOI 10.1016/j.jaci.2007.10.040
   Winchester DE, 2006, NEW ENGL J MED, V355, P1281
NR 6
TC 15
Z9 18
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2008
VL 122
IS 1
BP 217
EP 217
DI 10.1016/j.jaci.2008.05.024
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 325RD
UT WOS:000257605100041
PM 18602576
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Spina, GS
   Fae, KC
   Pereira, AC
   Nisihara, R
   Reason, IJM
   Grinberg, M
   Tarasoutchi, F
   Kalil, J
   Guilherme, L
AF Ramasawmy, Rajendranath
   Spina, Guilherme S.
   Fae, Kellen C.
   Pereira, Alexandre C.
   Nisihara, Renato
   Messias Reason, Iara Jose
   Grinberg, Max
   Tarasoutchi, Flavio
   Kalil, Jorge
   Guilherme, Luiza
TI Association of mannose-binding lectin gene polymorphism but not of
   mannose-binding serine protease 2 with chronic severe aortic
   regurgitation of rheumatic etiology
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID STREPTOCOCCAL M-PROTEINS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   BETA-D-GLUCOSAMINE; T-CELL-CLONES; HEART-DISEASE; SERINE PROTEASE-2;
   VARIANT ALLELES; MOLECULAR-BASIS; ANTIBODY; RECOGNIZES
AB N-Acetylglucosamine (GlcNAc) is the major immunoepitope of group A streptococcal cell wall carbohydrates. Antistreptococcal antibodies cross-reactive with anti-GlcNAc and laminin are present in sera of patients with rheumatic fever. The cross-reactivity of these antibodies with human heart valvular endothelium and the underlying basement membrane has been suggested to be a possible cause of immune-mediated valve lesion. Mannose-binding lectin (MBL) encoded by the MBL2 gene, a soluble pathogen recognition receptor, has high affinity for GlcNAc. We postulated that mutations in exon 1 of the MBL2 gene associated with a deficient serum level of MBL may contribute to chronic severe aortic regurgitation (AR) of rheumatic etiology. We studied 90 patients with severe chronic AR of rheumatic etiology and 281 healthy controls (HC) for the variants of the MBL2 gene at codons 52, 54, and 57 by using a PCR-restriction fragment length polymorphism-based method. We observed a significant difference in the prevalence of defective MBL2 alleles between patients with chronic severe AR and HC. Sixteen percent of patients with chronic severe AR were homozygotes or compound heterozygotes for defective MBL alleles in contrast to 5% for HC (P = 0.0022; odds ratio, 3.5 [ 95% confidence interval, 1.6 to 7.7]). No association was detected with the variant of the MASP2 gene. Our study suggests that MBL deficiency may contribute to the development of chronic severe AR of rheumatic etiology.
C1 [Ramasawmy, Rajendranath; Spina, Guilherme S.; Fae, Kellen C.; Pereira, Alexandre C.; Grinberg, Max; Tarasoutchi, Flavio; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Inst Heart InCor, BR-05403000 Sao Carlos, SP, Brazil.
   [Ramasawmy, Rajendranath; Fae, Kellen C.; Kalil, Jorge; Guilherme, Luiza] Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   [Kalil, Jorge] Univ Sao Paulo, Sch Med, Clin Immunol & Allergy Dept, Sao Paulo, Brazil.
   [Nisihara, Renato; Messias Reason, Iara Jose] Univ Fed Parana, Clin Hosp, Dept Clin Pathol, Curitiba, Parana, Brazil.
RP Ramasawmy, R (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart InCor, Av Eneas De Carvalho Aguiar,44,Bloco 2-9 Andar, BR-05403000 Sao Carlos, SP, Brazil.
EM ramasawm@usp.br
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013; Tarasoutchi,
   F/I-2458-2013; Ramasawmy, Rajendranath/V-4926-2019; Spina, Guilherme
   S./I-3530-2013
OI KALIL, JORGE/0000-0001-8415-4274; Tarasoutchi, F/0000-0002-9964-3289; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo and "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico." We have no financial conflicts of interest.
CR Antone SM, 1997, J IMMUNOL, V159, P5422
   AYOUB EM, 1974, CIRCULATION, V50, P144, DOI 10.1161/01.CIR.50.1.144
   Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0
   BISNO AL, 2000, PRINCIPLES PRACTICE, P1799
   CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293
   CUNNINGHAM MW, 1988, J IMMUNOL, V141, P2760
   DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113
   DUDDING BA, 1968, J EXP MED, V128, P1081, DOI 10.1084/jem.128.5.1081
   Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FENDERSON PG, 1989, J IMMUNOL, V142, P2475
   Font J, 2007, RHEUMATOLOGY, V46, P76, DOI 10.1093/rheumatology/kel199
   Fraser DA, 2006, J LEUKOCYTE BIOL, V80, P107, DOI 10.1189/jlb.1105683
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   GOLDSTEI.I, 1967, NATURE, V213, P44, DOI 10.1038/213044a0
   Graudal NA, 2000, ARTHRITIS RHEUM, V43, P515, DOI 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guillard C, 2005, INT J PHOTOENERGY, V7, P1, DOI 10.1155/S1110662X05000012
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301
   KAPLAN MH, 1960, J EXP MED, V113, P1
   KRAUS W, 1989, INFECT IMMUN, V57, P2457, DOI 10.1128/IAI.57.8.2457-2461.1989
   LANNIGAN R, 1968, NATURE, V217, P173, DOI 10.1038/217173a0
   Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000
   Ohlenschlaeger T, 2004, NEW ENGL J MED, V351, P260, DOI 10.1056/NEJMoa033122
   Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296
   Saevarsdottir S, 2004, SCAND J IMMUNOL, V60, P23, DOI 10.1111/j.0300-9475.2004.01437.x
   SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902
   SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593
   SPAGNUOLO M, 1971, CIRCULATION, V44, P368, DOI 10.1161/01.CIR.44.3.368
   Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836
   SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9
   SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8
   Thiel S, 2007, GENES IMMUN, V8, P154, DOI 10.1038/sj.gene.6364373
   Thiel S, 2006, MOL IMMUNOL, V43, P86, DOI 10.1016/j.molimm.2005.06.018
   Turner M W, 2000, Rev Immunogenet, V2, P305
   VANDERIJN I, 1977, J EXP MED, V146, P579, DOI 10.1084/jem.146.2.579
   Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093
NR 40
TC 40
Z9 41
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2008
VL 15
IS 6
BP 932
EP 936
DI 10.1128/CVI.00324-07
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 340TD
UT WOS:000258667000005
PM 18400978
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Souza, PS
   Panajotopoulos, N
   Ronda, C
   David, DSR
   Rodrigues, H
   Agena, F
   Ianhez, LE
   David-Neto, E
   Kalil, J
   Castro, MCR
AF Souza, Patricia S.
   Panajotopoulos, Nicolas
   Ronda, Carla
   David, Daisa S. R.
   Rodrigues, Helcio
   Agena, Fabiana
   Ianhez, Luiz E.
   David-Neto, Elias
   Kalil, Jorge
   Castro, Maria Cristina R.
TI Monitoring of anti-HLA antibodies after renal transplantation - What is
   the clinical relevance?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 8th American Transplant Congress
CY MAY 31-JUN 04, 2008
CL Toronto, CANADA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 [Panajotopoulos, Nicolas; Ronda, Carla; Rodrigues, Helcio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Immunol Lab, Sao Paulo, SP, Brazil.
RI Agena, Fabiana/F-5807-2012; KALIL, JORGE/C-8029-2012; Agena,
   Fabiana/C-5819-2015; de castro, maria cristina ribeiro/B-6648-2009;
   David, Daisa/G-6272-2012; Neto, Elias David/O-3866-2018; David-Neto,
   Elias/C-9112-2012
OI KALIL, JORGE/0000-0001-8415-4274; Agena, Fabiana/0000-0002-4526-4857; de
   castro, maria cristina ribeiro/0000-0002-6731-8369; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2008
VL 8
SU 2
BP 510
EP 510
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 299NV
UT WOS:000255763202063
DA 2020-11-26
ER

PT J
AU Kuribayashi, JS
   Bombardieri, CR
   Baracho, GV
   Aliberti, J
   Machado, FS
   Kalil, J
   Guilherme, L
   Kokron, CM
   Rizzo, LV
   de Camargo, MM
AF Kuribayashi, Juliana S.
   Bombardieri, Cintia R.
   Baracho, Gisele V.
   Aliberti, Julio
   Machado, Fabiana S.
   Kalil, Jorge
   Guilherme, Luiza
   Kokron, Cristina M.
   Rizzo, Luiz V.
   de Camargo, Maristela M.
TI Slower rescue of ER homeostasis by the unfolded protein response pathway
   associated with common variable immunodeficiency
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE B lymphocyte; immunoglobulin; immunodeficiency; ER
ID PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR XBP-1; DISEASE GENE
   SH2D1A; B-CELLS; MESSENGER-RNA; PHARMACOLOGICAL CHAPERONES;
   HYPOGAMMAGLOBULINEMIA; IRE1; ANTIBODY; STRESS
AB Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia and recurrent infections. Herein we addressed the role of unfolded protein response (UPR) in the pathogenesis of the disease. Augmented unspliced X-box binding protein 1 (XBP-1) mRNA concurrent with co-localization of IgM and BiP/GRP78 were found in one CVID patient. At confocal microscopy analysis this patient's cells were enlarged and failed to present the typical surface distribution of IgM, which accumulated within an abnormally expanded endoplasmic reticulum. Sequencing did not reveal any mutation on XBP-1, neither on IRE-1 alpha that could potentially prevent the splicing to occur. Analysis of spliced XBP-1, IRE-1 alpha and BiP messages after LPS or Brefeldin A treatment showed that, unlike healthy controls that respond to these endoplasmic reticulum (ER) stressors by presenting waves of transcription of these three genes, this patient's cells presented lower rates of transcription, not reaching the same level of response of healthy subjects even after 48 h of ER stress. Treatment with DMSO rescued IgM and IgG secretion as well as the expression of spliced XBP-1. Our findings associate diminished splicing of XBP-1 mRNA with accumulation of IgM within the ER and lower rates of chaperone transcription, therefore providing a mechanism to explain the observed hypogammaglobulinemia. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Kuribayashi, Juliana S.; Bombardieri, Cintia R.; Baracho, Gisele V.; Rizzo, Luiz V.; de Camargo, Maristela M.] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil.
   [Baracho, Gisele V.; Kalil, Jorge; Guilherme, Luiza; Kokron, Cristina M.; Rizzo, Luiz V.] Univ Sao Paulo, Inst Invest Immunol 3, BR-05403001 Sao Paulo, Brazil.
   [Aliberti, Julio; Machado, Fabiana S.] Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA.
   [Aliberti, Julio; Machado, Fabiana S.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA.
   [Kalil, Jorge; Guilherme, Luiza; Kokron, Cristina M.; Rizzo, Luiz V.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05403001 Sao Paulo, Brazil.
RP de Camargo, MM (corresponding author), Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Ave Prof Lineu Prestes 1730, BR-05508900 Sao Paulo, Brazil.
EM mmcamar@usp.br
RI Aliberti, Julio/G-4565-2012; Guglielmi, Luiza G/E-7676-2013; Kokron,
   Cristina M/D-3140-2012; Aliberti, Julio/I-7354-2013; KALIL,
   JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009; Camargo,
   Maristela/G-8584-2011
OI Kokron, Cristina M/0000-0002-9080-0305; Aliberti,
   Julio/0000-0003-3420-8478; KALIL, JORGE/0000-0001-8415-4274; Camargo,
   Maristela/0000-0003-2815-125X; Simao Machado,
   Fabiana/0000-0001-9272-5209
CR Aghamohammadi A, 2003, INT J HEMATOL, V78, P45, DOI 10.1007/BF02983239
   Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003
   BIRD AG, 1981, NATURE, V289, P300, DOI 10.1038/289300a0
   BRAUN J, 1991, IMMUNOL LETT, V27, P205, DOI 10.1016/0165-2478(91)90152-Z
   BRAUN J, 1992, WESTERN J MED, V157, P158
   BRAUN J, 1992, J CLIN INVEST, V89, P1395, DOI 10.1172/JCI115728
   CABALLERO FM, 1984, J CLIN LAB IMMUNOL, V13, P59
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   ElenitobaJohnson KSJ, 1997, SEMIN DIAGN PATHOL, V14, P35
   FARRANT J, 1991, IMMUNOL INVEST, V20, P143, DOI 10.3109/08820139109050782
   Farrant J, 1994, Immunodeficiency, V5, P159
   FARRANT J, 1985, CLIN EXP IMMUNOL, V61, P189
   FARRANT J, 1989, CLIN IMMUNOL IMMUNOP, V51, P196, DOI 10.1016/0090-1229(89)90019-6
   Fontan Casariego G, 2001, Allergol Immunopathol (Madr), V29, P101
   Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004
   Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200
   Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   Kainulainen L, 2001, J CLIN IMMUNOL, V21, P145, DOI 10.1023/A:1011012023616
   Kaneko H, 2005, CLIN EXP IMMUNOL, V140, P520, DOI 10.1111/j.1365-2249.2005.02784.x
   Kim HJ, 1999, J IMMUNOL, V162, P3053
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3
   Morra M, 2001, BLOOD, V98, P1321, DOI 10.1182/blood.V98.5.1321
   Reimold AM, 1996, J EXP MED, V183, P393, DOI 10.1084/jem.183.2.393
   Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Sneller MC, 2001, AM J MED SCI, V321, P42, DOI 10.1097/00000441-200101000-00007
   Soresina A, 2002, EUR J PEDIATR, V161, P656, DOI 10.1007/s00431-002-1083-9
   Taubenheim N, 2005, J IMMUNOL, V175, P5498, DOI 10.4049/jimmunol.175.8.5498
   Tiller T L Jr, 2000, J S C Med Assoc, V96, P225
   Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400
   Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200
   Van Der Hilst JCH, 2002, NETH J MED, V60, P140
   Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
NR 38
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAY
PY 2008
VL 45
IS 10
BP 2990
EP 2997
DI 10.1016/j.molimm.2008.01.013
PG 8
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 307KW
UT WOS:000256318800029
PM 18325593
DA 2020-11-26
ER

PT J
AU Souza, PS
   Panajotopoulos, N
   David, DSR
   Ronda, C
   Agena, F
   Rodrigues, H
   Lanhez, LE
   David-Neto, E
   Kalil, JE
   Castro, MCR
AF Souza, P. S.
   Panajotopoulos, N.
   David, D. S. R.
   Ronda, C.
   Agena, F.
   Rodrigues, H.
   Lanhez, L. E.
   David-Neto, E.
   Kalil, J. E.
   Castro, M. C. R.
TI Clinical relevance of anti-HLA antibodies monitoring after kidney
   transplantation
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 22nd European Immunogenetics and Histocompatibility Conference
CY APR 02-05, 2008
CL Toulouse, FRANCE
C1 [Souza, P. S.; Panajotopoulos, N.; David, D. S. R.; Ronda, C.; Agena, F.; Rodrigues, H.; Lanhez, L. E.; David-Neto, E.; Kalil, J. E.; Castro, M. C. R.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Agena, Fabiana/F-5807-2012; Neto, Elias David/O-3866-2018; David,
   Daisa/G-6272-2012; KALIL, JORGE/C-8029-2012; Agena, Fabiana/C-5819-2015;
   David-Neto, Elias/C-9112-2012; de castro, maria cristina
   ribeiro/B-6648-2009
OI KALIL, JORGE/0000-0001-8415-4274; Agena, Fabiana/0000-0002-4526-4857; de
   castro, maria cristina ribeiro/0000-0002-6731-8369
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD APR
PY 2008
VL 71
IS 4
MA P004
BP 288
EP 288
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 283II
UT WOS:000254629500061
DA 2020-11-26
ER

PT J
AU de Medeiros, CR
   Barbaro, KC
   Lira, MS
   Franca, FOS
   Zaher, VL
   Kokron, CM
   Kalil, J
   Castro, FFM
AF de Medeiros, Carlos R.
   Barbaro, Katia C.
   Lira, Marcela S.
   Franca, Francisco O. S.
   Zaher, Vera L.
   Kokron, Cristina M.
   Kalil, Jorge
   Castro, Fabio F. M.
TI Predictors of Bothrops jararaca venom allergy in snake handlers and
   snake venom handlers
SO TOXICON
LA English
DT Article
DE Bothrops jararaca; snake handier; snake venom; allergy; immunoglobulin E
ID IGE ANTIBODIES; BITES
AB Since allergic sensitization to snake venom has been reported, anaphylactic reactions to snake venom might be an underestimated factor contributing to fatal snakebites, independently from the toxicity of the venom itself. However, little information is available on the determinants of such reaction. Hence, we studied a group of workers exposed to Bothrops jararaca venom (BJV), in order to clarify the factors related with snake venom allergy. The aim of this work was to investigate the prevalence and predictors of venom allergy among workers exposed to BJV and to confirm the involvement of IgE-mediated mechanisms in this condition. Workers exposed to BJV were assessed for venom allergy using questionnaires and immunological tests. The presence of BJV sensitization was determined through quantification of specific IgE. Allergens were studied using the Western blots and inhibition assays. Of the 67 workers evaluated, 7 (10.4%) presented specific IgE antibodies to BJV. Of those, 6 presented typical symptoms of an IgE-mediated allergic reaction when exposed to BJV. Venom sensitization was associated with length of employment (P = 0.042), high levels of total IgE (P = 0.034), atopy (P = 0.051), and specific tasks, primarily the handling of dried venom (P = 0.014). Our observations suggest that exposure to BJV can result in allergic sensitization in snake handlers through IgE-mediated mechanisms. The prevalence rate of this condition appears to be high among these workers, and the handling of dried venom, total IgE level above 100 kU/L, length of employment, and probably history of atopy were predictors of its occurrence. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [de Medeiros, Carlos R.; Franca, Francisco O. S.] Hosp Vital Brazil, Inst Butatan, BR-05503900 Sao Paulo, Brazil.
   [Barbaro, Katia C.; Lira, Marcela S.] Inst Butantan, Lab Imunopatol, BR-05503900 Sao Paulo, Brazil.
   [de Medeiros, Carlos R.; Kokron, Cristina M.; Kalil, Jorge; Castro, Fabio F. M.] Univ Sao Paulo, Fac Med, Dept Clin Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Zaher, Vera L.] Univ Sao Paulo, Fac Med, Lab Invest Med LIM 01, Sao Paulo, Brazil.
RP de Medeiros, CR (corresponding author), Hosp Vital Brazil, Inst Butatan, Av Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.
EM carlosrmedeiros@butantan.gov.br
RI KALIL, JORGE/C-8029-2012; de Siqueira Franca, Francisco
   Oscar/AAE-6314-2019; Barbaro, Katia/M-2664-2013; Kokron, Cristina
   M/D-3140-2012; Castro, Fabio/AAP-5433-2020; Castro, Fabio
   FM/C-1082-2017; Medeiros, Carlos Roberto de/F-6513-2015
OI KALIL, JORGE/0000-0001-8415-4274; de Siqueira Franca, Francisco
   Oscar/0000-0001-8510-7939; Kokron, Cristina M/0000-0002-9080-0305;
   Castro, Fabio FM/0000-0002-6211-5773; Medeiros, Carlos Roberto
   de/0000-0001-9533-0819
CR ALONSO A, 1995, J INVEST ALLERG CLIN, V5, P31
   Brooks DE, 2004, WILD ENVIRON MED, V15, P188, DOI 10.1580/1080-6032(2004)15[188:ACAFRE]2.0.CO;2
   Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515
   Dolen WK, 2003, ALLERGY, V58, P717, DOI 10.1034/j.1398-9995.2003.00281.x
   ELLIS EF, 1965, JAMA-J AM MED ASSOC, V193, P151
   Franca FOS, 2003, T ROY SOC TROP MED H, V97, P312, DOI 10.1016/S0035-9203(03)90158-1
   Gutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150
   Hamilton RG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1520
   Hamilton RG, 2004, CURR OPIN ALLERGY CL, V4, P297, DOI 10.1097/01.all.0000136755.13077.b5
   HOGAN DE, 1990, ANN EMERG MED, V19, P814, DOI 10.1016/S0196-0644(05)81710-X
   Jutel M, 2005, CURR OPIN ALLERGY CL, V5, P365, DOI 10.1097/01.all.0000173784.81024.7a
   KELLY JF, 1973, CLIN ALLERGY, V3, P385, DOI 10.1111/j.1365-2222.1973.tb01345.x
   KOPP P, 1993, CLIN EXP ALLERGY, V23, P231, DOI 10.1111/j.1365-2222.1993.tb00887.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lounsberry CR, 1934, ARCH DERMATOL SYPH, V29, P658, DOI 10.1001/archderm.1934.01460110016003
   MENDES E, 1960, J ALLERGY, V31, P68, DOI 10.1016/0021-8707(60)90025-3
   PARRISH HM, 1959, AM J MED SCI, V20, P257
   Prescott RA, 2005, ANN ALLERG ASTHMA IM, V94, P600, DOI 10.1016/S1081-1206(10)61140-4
   REID HA, 1983, B WORLD HEALTH ORGAN, V61, P885
   Reimers AR, 2000, CLIN EXP ALLERGY, V30, P276
   RYAN KC, 1994, J WILDERNESS MED, V5, P263, DOI 10.1580/0953-9859-5.3.263
   SCHMUTZ J, 1985, LANCET, V2, P1306
   STANIC M, 1956, VENOMS, P181
   Suarthana E, 2005, AM J IND MED, V48, P168, DOI 10.1002/ajim.20199
   THEAKSTON RDG, 1983, TOXICON, V21, P341, DOI 10.1016/0041-0101(83)90090-9
   THEAKSTON RDG, 1977, LANCET, V2, P639
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   WADEE AA, 1987, J ALLERGY CLIN IMMUN, V80, P695, DOI 10.1016/0091-6749(87)90289-2
   Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219
   YUNGINGER JW, 1983, J CLIN IMMUNOASSAY, V6, P155
   ZOZAYA JOSE, 1930, BULL ANTIVENIN INST AMER, V3, P93
NR 31
TC 14
Z9 15
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 15
PY 2008
VL 51
IS 4
BP 672
EP 680
DI 10.1016/j.toxicon.2007.11.022
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 294AU
UT WOS:000255377300019
PM 18207481
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Farias, AQ
   Porta, G
   Cancado, ELR
   Miura, I
   Pugliese, R
   Kalil, J
   Goldberg, AC
   Carrilho, FJ
AF Bittencourt, Paulo Lisboa
   Farias, Alberto Queiroz
   Porta, Gilda
   Cancado, Eduardo L. R.
   Miura, Irene
   Pugliese, Renata
   Kalil, Jorge
   Goldberg, Anna C.
   Carrilho, Flair J.
TI Frequency of concurrent autoimmune disorders in patients with autoimmune
   hepatitis - Effect of age, gender, and genetic background
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE autoimmune hepatitis; autoimmune diseases; autoantibodies; HLA antigens;
   CTLA-4; TNF-alpha
ID CHRONIC ACTIVE HEPATITIS; TYPE-1; HLA; SUSCEPTIBILITY; POLYMORPHISMS;
   HETEROGENEITY; DISTINCTIONS; ASSOCIATION; ANTIGEN; BRAZIL
AB Background: Concurrent autoimmune disorders (CAIDs) have been shown to occur in 22% to 34% of the patients with autoimmune hepatitis (AIH). Their presence has been linked to female gender, older age, and to certain HLA antigens, namely HLA-A11. DRB1*04, and DRB4*01.
   Aims: To assess the frequency and nature of CAID in Brazilian patients with AIH types 1 (AIH-1) and 2 (AIH-2) and to investigate the influence of age, gender, and genetic background in their occurrence.
   Patients and Methods: The presence and nature of CAID was studied in 143 patients [117 females, median age 11 (1.3 to 69)] with AIH-1 (n = 125) and AIH-2 (n = 28). HLA typing and tumor necrosis factor a gene promoter and exon I cytotoxic T lymphocyte associated antigen 4 (CTLA-4) gene polymorphisms were determined by polymerase chain reaction-based techniques.
   Results: The frequency of CAID was similar in patients with AIH-1 (14%) and AIH-2 (18%), but their nature was shown to vary. Arthritis was seen in half of the patients (n = 8) with CAID and AIH-1 and in none of those with AIH-2. Subjects with AIH-1 and CAID were shown to be older [24 (1.3 to 6 1) vs. 11 (1.3 to 69) y P = 0.02] and to have more often circulating antinuclear antibody (76% vs. 40%, P = 0.008) and less frequently antiactin antibodies (33% vs. 75%, P = 0.008) when compared with their counterparts without CAID. No particular HLA-DR and DQ alleles, as well as tumor necrosis factor a and CTLA-4 genotypes, were associated with CAID.
   Conclusions: The nature, but not the frequency, of CAID was shown to vary in AIH-1 and AIH-2. In subjects with AIH-1, CAID was linked to older subjects and to the presence of antinuclear antibody. No predisposition to CAID was associated to HLA-DRB1*04 or DDB4*01 alleles. The observed lower frequency of CAID could be attributed to the lower age of disease onset in Brazilians and to differences in HLA-encoded susceptibility to AIH-1 observed in South America.
C1 Univ Sao Paulo, Inst Chem,Dept Gastroenterol, Sch Med,Liver Unit,Childrens Inst, Inst Heart,Lab Immunol, Sao Paulo, Brazil.
   Portuguese Hosp Salvador, Salvador, BA, Brazil.
RP Bittencourt, PL (corresponding author), Rua Clementino Fraga 220,Apto 1901, Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI Farias, Alberto/ABB-1291-2020; BITTENCOURT, PAULO l/I-5817-2014;
   Cancado, Eduardo/K-1861-2016; Farias, Alberto Q/H-7873-2013; Goldberg,
   Anna Carla/H-8594-2014; Carrilho, Flair J/I-3046-2012; KALIL,
   JORGE/C-8029-2012
OI Farias, Alberto/0000-0002-5572-663X; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Cancado, Eduardo/0000-0002-9309-1524; Goldberg,
   Anna Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2003, AM J GASTROENTEROL, V98, P1616, DOI 10.1016/S0002-9270(03)00307-1
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   Czaja AJ, 2005, HEPATOLOGY, V41, P207, DOI 10.1002/hep.20539
   CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1502, DOI 10.1016/0016-5085(93)90157-8
   Czaja AJ, 2002, AM J GASTROENTEROL, V97, P2051
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Czaja AJ, 2000, IMMUNOL REV, V174, P250, DOI 10.1034/j.1600-0528.2002.017401.x
   CZAJA AJ, 1993, HEPATOLOGY, V18, P816, DOI 10.1002/hep.1840180411
   Djilali-Saiah I, 2004, J HEPATOL, V40, P904, DOI 10.1016/j.jhep.2004.02.023
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   MA X, 2001, WORLD J GASTROENTERO, V7, P1
   Manns MP, 2006, HEPATOLOGY, V43, pS132, DOI 10.1002/hep.21059
   MARCOS Y, 1994, HEPATOLOGY, V19, P1371, DOI 10.1016/0270-9139(94)90230-5
   Nishioka M, 2000, FALK SYMP, V114, P69
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   ONJI M, 1993, GASTROENTEROL JPN, V28, P134
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
NR 38
TC 35
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAR
PY 2008
VL 42
IS 3
BP 300
EP 305
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 270GN
UT WOS:000253709100014
PM 18223493
DA 2020-11-26
ER

PT J
AU Figueiredo, JP
   Pomiecinski, F
   Yang, AC
   Castro, FFM
   Kalil, J
   Galvao, CES
AF Figueiredo, Joanemile Pacheco
   Pomiecinski, Fabiane
   Yang, Ariana Campos
   Castro, Fabio F. M.
   Kalil, Jorge
   Galvao, Clovis E. S.
TI Diagnostic assessment of occupational asthma due to persulfate salts in
   a professional hairdresser - A case report
SO CLINICS
LA English
DT Letter
ID AMMONIUM PERSULFATE; HYPERSENSITIVITY; IMMEDIATE
C1 [Figueiredo, Joanemile Pacheco; Pomiecinski, Fabiane; Yang, Ariana Campos; Castro, Fabio F. M.; Kalil, Jorge; Galvao, Clovis E. S.] Univ Sao Paulo, Fac Med, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Figueiredo, JP (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM cdgalvao@usp.br
RI Castro, Fabio/AAP-5433-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017
OI KALIL, JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773
CR Aalto-Korte K, 2003, CONTACT DERMATITIS, V49, P22, DOI 10.1111/j.0105-1873.2003.00134.x
   Borelli S, 1999, ALLERGY, V54, P893, DOI 10.1034/j.1398-9995.1999.00281.x
   Kopferschmitt-Kubler MC, 2002, EUR RESPIR J, V19, P84, DOI 10.1183/09031936.02.00102202
   Munoz X, 2004, OCCUP ENVIRON MED, V61, P861, DOI 10.1136/oem.2004.013177
   Munoz X, 2003, CHEST, V123, P2124, DOI 10.1378/chest.123.6.2124
   PEPYS J, 1976, CLIN ALLERGY, V6, P399, DOI 10.1111/j.1365-2222.1976.tb01922.x
   Perfetti L, 2000, ALLERGY, V55, P94, DOI 10.1034/j.1398-9995.2000.00380.x
NR 7
TC 4
Z9 4
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PD FEB
PY 2008
VL 63
IS 1
BP 149
EP 150
DI 10.1590/S1807-59322008000100026
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 278YH
UT WOS:000254321700026
PM 18297222
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Agondi, R
   Barros, MT
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, R.
   Barros, M. Toledo
   Kalil, J.
   Giavina-Bianchi, P.
TI Function test in patients with common variable immunodeficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 14-18, 2008
CL Philadelphia, PA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Agondi, R.; Barros, M. Toledo; Kalil, J.; Giavina-Bianchi, P.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2008
VL 121
IS 2
SU 1
MA 339
BP S88
EP S88
DI 10.1016/j.jaci.2007.12.351
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 266HZ
UT WOS:000253426400340
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Garcia, CLC
   Ribeiro, MR
   Kalil, J
AF Giavina-Bianchi, P.
   Aun, M. Vivolo
   Garcia, C. Leite Costa
   Ribeiro, M. Rosimeire
   Kalil, J.
TI Underdiagnosis of Esophageal candidiasis in asthma patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 14-18, 2008
CL Philadelphia, PA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Giavina-Bianchi, P.; Aun, M. Vivolo; Garcia, C. Leite Costa; Ribeiro, M. Rosimeire; Kalil, J.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RI Aun, Marcelo V/E-6775-2014; Giavina-Bianchi, Pedro/I-3112-2014; KALIL,
   JORGE/C-8029-2012
OI Aun, Marcelo V/0000-0001-9882-5200; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2008
VL 121
IS 2
SU 1
MA 855
BP S222
EP S223
DI 10.1016/j.jaci.2007.12.878
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 266HZ
UT WOS:000253426401319
DA 2020-11-26
ER

PT J
AU Yang, A
   Galvao, C
   Pomiecinski, F
   Watanabe, A
   Kalil, J
   Castro, FM
AF Yang, A.
   Galvao, C.
   Pomiecinski, F.
   Watanabe, A.
   Kalil, J.
   Castro, Morato F.
TI Efficacy of pimecrolimus in one case of amyopathic dermatomyositis
SO ALLERGY
LA English
DT Meeting Abstract
CT 27th Congress of the
   European-Academy-of-Allergology-and-Clinical-Immunology
CY JUN 07-11, 2008
CL Barcelona, SPAIN
SP European Acad Allergol & Clinical Immunol
C1 [Yang, A.; Galvao, C.; Pomiecinski, F.; Watanabe, A.; Kalil, J.; Castro, Morato F.] Univ Sao Paulo, Sch Med, Div Clin Immunol, Sao Paulo, Brazil.
RI Castro, Fabio FM/C-1082-2017; Castro, Fabio/AAP-5433-2020; KALIL,
   JORGE/C-8029-2012
OI Castro, Fabio FM/0000-0002-6211-5773; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0105-4538
J9 ALLERGY
JI Allergy
PY 2008
VL 63
SU 88
MA 952
BP 352
EP 353
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 306GF
UT WOS:000256235600938
DA 2020-11-26
ER

PT J
AU Fae, KC
   Palacios, S
   Tanaka, A
   Pomerantzeff, P
   Kalil, J
   Guilherme, L
AF Fae, Kellen Cristhina
   Palacios, Selma
   Tanaka, Ana
   Pomerantzeff, Pablo
   Kalil, Jorge
   Guilherme, Luiza
TI CCL3/MIP1-alpha and CCL1/I-309 are the mediators of cellular
   infiltration of myocardium and vavular heart lesions in severe rheumatic
   carditis patients
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 05-09, 2008
CL Boston, MA
SP Federat Clinical Immunol Soc
C1 [Fae, Kellen Cristhina; Palacios, Selma; Tanaka, Ana; Pomerantzeff, Pablo; Kalil, Jorge; Guilherme, Luiza] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
RI Pomerantzeff, Pablo M A/L-5525-2016; Guglielmi, Luiza G/E-7676-2013;
   KALIL, JORGE/C-8029-2012
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2008
VL 127
SU S
BP S85
EP S85
DI 10.1016/j.clim.2008.03.236
PG 1
WC Immunology
SC Immunology
GA 296HD
UT WOS:000255533200241
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Agondi, R
   Kalil, J
AF Giavina-Bianchi, Pedro
   Agondi, Rosana
   Kalil, Jorge
TI One year administration of Anti-IgE to a patient with Churg-Strauss
   syndrome
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
LA English
DT Letter
C1 [Giavina-Bianchi, Pedro; Agondi, Rosana; Kalil, Jorge] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-01454010 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, R Prof Artur Ramos 178,Ap 211A Jd Amer, BR-01454010 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Bargagli E, 2008, INT ARCH ALLERGY IMM, V145, P268, DOI 10.1159/000109296
   Giavina-Bianchi P, 2007, INT ARCH ALLERGY IMM, V144, P155, DOI 10.1159/000103228
   Winchester DE, 2006, NEW ENGL J MED, V355, P1281
NR 3
TC 13
Z9 13
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-2438
EI 1423-0097
J9 INT ARCH ALLERGY IMM
JI Int. Arch. Allergy Immunol.
PY 2008
VL 146
IS 2
BP 176
EP 176
DI 10.1159/000113524
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 291EA
UT WOS:000255174800013
PM 18204287
DA 2020-11-26
ER

PT J
AU Agondi, RC
   Machado, ML
   Kalil, J
   Giavina-Bianchi, P
AF Agondi, Rosana Camara
   Machado, Maria Lavinea
   Kalil, Jorge
   Giavina-Bianchi, Pedro
TI Intranasal Corticosteroid Administration Reduces Nonspecific Bronchial
   Hyperresponsiveness and Improves Asthma Symptoms
SO JOURNAL OF ASTHMA
LA English
DT Article
DE ARIA; Allergic Rhinitis and its Impact on Asthma/guidelines; asthma;
   bronchial challenge provocation tests; steroids; rhinitis
ID ALLERGIC RHINITIS; LOWER AIRWAY; RESPONSIVENESS; EMERGENCY; RISK
AB Introduction. Rhinitis and asthma are currently recognized as manifestations of a single syndrome, the chronic allergic respiratory syndrome. Nearly all individuals with asthma have rhinitis, and severe rhinitis has been associated with worse outcomes in asthma patients. Intranasal treatment has been reported to be beneficial for the lower airways. Methods. This was a randomized, double-blind, placebo-controlled study. The objective was to evaluate the effects that treatment with intranasal beclomethasone dipropionate (BDP; 400 g/d) has on nasal and bronchial symptoms, as well as on lung function test results and bronchial responsiveness to histamine in patients with allergic rhinitis and asthma. We evaluated 33 patients, divided into two groups: treatment (n = 17); and placebo (n = 16). Over the course of the 125-day study period, each patient reported daily rhinitis and asthma symptoms, as well as the need for additional medication. All patients were submitted to spirometry and histamine challenge at baseline and at each subsequent evaluation (on days 50 and 75). Results. In comparison with the patients in the placebo group, those in the BDP treatment group presented significantly fewer nasal symptoms on day 50 and fewer asthma symptoms on day 75 (p 0.01 for both); required rescue medications less often; and presented a significantly lower degree of bronchial responsiveness to histamine on day 75 (p 0.01). Conclusion. In this study, intranasal BDP was effective in treating rhinitis as well as asthma. The benefits for the lower airways were observed only after prolonged treatment and might be better evaluated through nonspecific bronchial challenge.
C1 [Agondi, Rosana Camara; Machado, Maria Lavinea; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Dept Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178,Ap 211A, BR-01454904 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
CR Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237
   Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9
   Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H
   Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034
   CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z
   Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x
   Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554
   Hara J, 2006, INT ARCH ALLERGY IMM, V140, P327, DOI 10.1159/000093711
   Jani AL, 2005, J ASTHMA, V42, P1, DOI 10.1081/JAS-200044744
   PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6
   Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64
   Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC
   TARAMARCAZ P, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003570
   Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592
   Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88
   WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U
NR 18
TC 16
Z9 16
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PY 2008
VL 45
IS 9
BP 754
EP 757
DI 10.1080/02770900802249149
PG 4
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 366QE
UT WOS:000260497400006
PM 18972290
DA 2020-11-26
ER

PT J
AU Tani, CM
   Abrantes-Lemos, CR
   Nakhle, MC
   Preuhs-Filho, G
   Rodrigues, H
   Deguti, MM
   Kalil, J
   Carrilho, FJ
   Cancado, EL
AF Tani, C. M.
   Abrantes-Lemos, C. R.
   Nakhle, M. C.
   Preuhs-Filho, G.
   Rodrigues, H.
   Deguti, M. M.
   Kalil, J.
   Carrilho, F. J.
   Cancado, E. L.
TI Analysis of classe IIHLA in patients with chronic hepatitis C with
   characteristics of autoimmune hepatitis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 43rd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 23-27, 2008
CL Milan, ITALY
SP European Assoc Study Liver
C1 [Tani, C. M.; Deguti, M. M.; Carrilho, F. J.; Cancado, E. L.] Univ Sao Paulo, Dept Gastroenterol, Hepatol Branch, Hosp Clin,Sch Med, Sao Paulo, Brazil.
   [Abrantes-Lemos, C. R.; Nakhle, M. C.; Cancado, E. L.] Univ Sao Paulo, Sch Med, LIM 06, Sao Paulo, Brazil.
   [Preuhs-Filho, G.; Rodrigues, H.; Kalil, J.] Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
EM marta.deguti@uol.com.br
RI KALIL, JORGE/C-8029-2012; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016
OI KALIL, JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2008
VL 48
SU 2
MA 859
BP S322
EP S323
DI 10.1016/S0168-8278(08)60861-2
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 312PL
UT WOS:000256683201350
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Fae, KC
   Cunha-Neto, E
   Borba, SCP
   Ianni, B
   Mady, C
   Goldberg, AC
   Kalil, J
AF Ramasawmy, Rajendranath
   Fae, Kellen C.
   Cunha-Neto, Edecio
   Borba, Susan C. P.
   Ianni, Barbara
   Mady, Charles
   Goldberg, Anna C.
   Kalil, Jorge
TI Variants in the promoter region of IKBL/NFKBIL1 gene may mark
   susceptibility to the development of chronic Chagas' cardiomyopathy
   among Trypanosoma cruzi-infected individuals
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Chagas' disease; chronic chagas cardiomyopathy; trypanosoma cruzi;
   polymorphism
ID MAJOR HISTOCOMPATIBILITY COMPLEX; NECROSIS-FACTOR-ALPHA; KAPPA-BL;
   DISEASE; POLYMORPHISM; IKBL; PREDISPOSITION; ASSOCIATION; RESISTANCE;
   HAPLOTYPE
AB Chagas' disease, caused by Trypanosoma cruzi, is an inflammatory disorder leading to chronic Chagas cardiomyopathy (CCC). Only one third of T cruzi-infected individuals progress to CCC while the others are considered asymptomatic (ASY). The human inhibitory kappa B-like gene (KBLINFKBIL1), homologous to the I kappa B family of proteins that regulate the NF kappa B family of transcription factors, is suggested as a putative inhibitor of NFKB. We investigated two functional polymorphisms, -62A/T and -262A/G, in the promoter of IKBL by PCR-RFLP analysis in 169 patients with CCC and 76 ASY. Genotype distributions for both -62A/T and -262A/G differed between the CCC and ASY (X-2 = 7.3; P = 0.025 and X-2 = 6.8; P = 0.03, respectively). Subjects, homozygous for the -62A allele, had three-fold risk of developing CCC compared with those carrying the TT genotype (P = 0.0095; Odds Ratio [OR] = 2.9; [95% CI 1.2-7.3]). Similar trend was observed for the -262A homozygotes (P = 0.005; OR = 2.7 [95% CI 1.3-6.0]. The haplotype -262A -62A was prevalent in patients with CCC (40% versus 24%; OR 2.1 [95% C1 1.4-3.3j; Pc = 0.00 14). The I kappa BL locus itself or another critical gene in this region may confer susceptibility to the development of CCC. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Chem, Sao Paulo, Brazil.
RP Ramasawmy, R (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
EM ramasawm@usp.br
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Ianni, Barbara
   Maria/C-7689-2012; Goldberg, Anna Carla/H-8594-2014; Ramasawmy,
   Rajendranath/V-4926-2019; Mady, Charles/C-8870-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Ianni, Barbara Maria/0000-0002-1588-5492;
   Goldberg, Anna Carla/0000-0003-2600-7940; Mady,
   Charles/0000-0002-8838-199X
CR ALBERTELLA MR, 1994, HUM MOL GENET, V3, P793, DOI 10.1093/hmg/3.5.793
   Allcock RJN, 1999, HUM IMMUNOL, V60, P1266, DOI 10.1016/S0198-8859(99)00127-5
   Allcock RJN, 2001, IMMUNOGENETICS, V52, P289
   Boodhoo A, 2004, GENE EXPRESSION, V12, P1, DOI 10.3727/000000004783992206
   De La Concha EG, 2000, GASTROENTEROLOGY, V119, P1491, DOI 10.1053/gast.2000.20258
   Drigo SA, 2007, IMMUNOL LETT, V108, P109, DOI 10.1016/j.imlet.2006.10.008
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233
   Lehner B, 2004, GENOMICS, V83, P153, DOI 10.1016/S0888-7543(03)00235-0
   Lie BA, 1999, AM J HUM GENET, V64, P793, DOI 10.1086/302283
   Nejentsev S, 2000, DIABETES, V49, P2217, DOI 10.2337/diabetes.49.12.2217
   Okamoto K, 2003, AM J HUM GENET, V72, P303, DOI 10.1086/346067
   Price P, 2001, IMMUNOL CELL BIOL, V79, P602, DOI 10.1046/j.1440-1711.2001.01043.x
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Semple JI, 2002, BIOCHEM J, V361, P489, DOI 10.1042/0264-6021:3610489
   Shibata H, 2006, HUM IMMUNOL, V67, P363, DOI 10.1016/j.humimm.2006.03.022
   Shichi D, 2005, TISSUE ANTIGENS, V66, P200, DOI 10.1111/j.1399-0039.2005.00457.x
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Yamashita T, 2004, TISSUE ANTIGENS, V63, P223, DOI 10.1111/j.0001-2815.2004.00164.x
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 24
TC 24
Z9 24
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JAN
PY 2008
VL 45
IS 1
BP 283
EP 288
DI 10.1016/j.molimm.2007.04.015
PG 6
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 218KE
UT WOS:000250013600033
PM 17544510
DA 2020-11-26
ER

PT J
AU Kalil, J
   Postol, E
   Guerino, MT
   Higa, FT
   Mundel, LR
   Guilherme, L
AF Kalil, J.
   Postol, E.
   Guerino, M. T.
   Higa, F. T.
   Mundel, L. R.
   Guilherme, L.
TI Anti- S pyogenes vaccine candidate epitope was evaluated by using HLA
   class II DR and DQ transgenic mice
SO VACCINE
LA English
DT Meeting Abstract
CT 2nd Vaccine Congress
CY DEC 07-09, 2008
CL Boston, MA
DE S. pyogenes; HLA-class II transgenic mice; M proteim; rheumatic fever
C1 [Kalil, J.; Postol, E.; Guerino, M. T.; Higa, F. T.; Mundel, L. R.; Guilherme, L.] Univ Sao Paulo, Sch Med, Heart Inst Incor, BR-05508 Sao Paulo, Brazil.
   [Kalil, J.] Univ Sao Paulo, Sch Med, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PY 2008
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 480QF
UT WOS:000268750600130
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Fae, KC
   Cunha-Neto, E
   Muller, NG
   Cavalcanti, VL
   Ferreira, RC
   Drigo, SA
   Ianni, B
   Mady, C
   Goldberg, AC
   Kalil, J
AF Ramasawmy, Rajendranath
   Fae, Kellen C.
   Cunha-Neto, Edecio
   Muller, Natalie G.
   Cavalcanti, Vanessa L.
   Ferreira, Renata C.
   Drigo, Sandra A.
   Ianni, Barbara
   Mady, Charles
   Goldberg, Anna C.
   Kalil, Jorge
TI Polymorphisms in the gene for lymphotoxin-alpha predispose to chronic
   chagas cardiomyopathy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; HEART-FAILURE; MYOCARDIAL-INFARCTION; ADHESION
   MOLECULES; DISEASE; ATHEROSCLEROSIS; INFLAMMATION; MICE; ASSOCIATION;
   LYMPHOCYTES
AB Background. Chagas disease, caused by Trypanosoma cruzi infection, displays clinical heterogeneity and may be attributable to differential genetic susceptibility. Chronic Chagas cardiomyopathy (CCC) develops only in a subset of T. cruzi-infected individuals and may lead to heart failure that has a worse clinical course and that leads to reduced life expectancy, compared with heart failure of other etiologies. Proinflammatory cytokines play a key role in the development of CCC. Clinical, genetic, and epidemiological studies have linked lymphotoxin-alpha (LTA), a proinflammatory cytokine, to coronary artery disease and myocardial infarction.
   Methods. We used polymerase chain reaction to genotype the LTA +80A -> C and LTA +252A -> G variants in 169 patients with CCC and in 76 T. cruzi-infected asymptomatic (ASY) patients.
   Results. Homozygosity with respect to the LTA +80C and LTA +252G alleles was significantly more frequent in the patients with CCC than in the ASY patients (homozygosity for LTA +80C, 47% vs. 33%; homozygosity for LTA +252G, 16% vs. 8%). Haplotype LTA +80A-252A was associated with protection against CCC, whereas haplotype LTA +80C-252G was associated with susceptibility to CCC. Furthermore, homozygosity for the LTA +80A allele correlated with the lowest levels of plasmatic tumor-necrosis factor-alpha.
   Conclusions. Our results suggest that the study of genetic variations in patients with Chagas disease may help in the identification of individuals at increased risk of progressing to CCC and, by providing early treatment, reduce the morbidity and mortality associated with this disease.
C1 [Ramasawmy, Rajendranath; Fae, Kellen C.; Cunha-Neto, Edecio; Muller, Natalie G.; Cavalcanti, Vanessa L.; Ferreira, Renata C.; Drigo, Sandra A.; Ianni, Barbara; Mady, Charles; Kalil, Jorge] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Dept Clin Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Goldberg, Anna C.] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil.
   [Ramasawmy, Rajendranath; Fae, Kellen C.; Cunha-Neto, Edecio; Muller, Natalie G.; Cavalcanti, Vanessa L.; Goldberg, Anna C.; Kalil, Jorge] Millennium Inst, Inst Immunol Invest, Sao Paulo, Brazil.
RP Ramasawmy, R (corresponding author), Lab Imunol, Av Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil.
EM ramasawm@usp.br
RI Mady, Charles/C-8870-2012; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012; LINDE, SANDRA/S-3128-2019; Drigo, Sandra
   A/I-6514-2012; Ianni, Barbara Maria/C-7689-2012; Ramasawmy,
   Rajendranath/V-4926-2019; Goldberg, Anna Carla/H-8594-2014
OI Mady, Charles/0000-0002-8838-199X; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274; LINDE,
   SANDRA/0000-0001-6747-6642; Drigo, Sandra A/0000-0001-6747-6642; Ianni,
   Barbara Maria/0000-0002-1588-5492; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR Barretto A C, 1993, Arq Bras Cardiol, V60, P225
   Barretto ACP, 1998, INT J CARDIOL, V67, P19, DOI 10.1016/S0167-5273(98)00228-9
   Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
   Benvenuti LA, 2000, CARDIOVASC PATHOL, V9, P111, DOI 10.1016/S1054-8807(00)00027-2
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Browning JL, 1997, J IMMUNOL, V159, P3288
   Cuff CA, 1998, J IMMUNOL, V161, P6853
   Drigo SA, 2007, IMMUNOL LETT, V108, P109, DOI 10.1016/j.imlet.2006.10.008
   Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   Keso T, 2001, ATHEROSCLEROSIS, V154, P691, DOI 10.1016/S0021-9150(00)00602-X
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   Kubota T, 1998, CIRCULATION, V97, P2499, DOI 10.1161/01.CIR.97.25.2499
   Kumaraguru U, 2001, J IMMUNOL, V166, P1066, DOI 10.4049/jimmunol.166.2.1066
   Magez S, 2002, INFECT IMMUN, V70, P1342, DOI 10.1128/IAI.70.3.1342-1351.2002
   Menezes CAS, 2004, CLIN EXP IMMUNOL, V137, P129, DOI 10.1111/j.1365-2249.2004.02479.x
   MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Parada H, 1997, INT J CARDIOL, V60, P49, DOI 10.1016/S0167-5273(97)02952-5
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   ROSSI MA, 1995, CARDIOLOGY, V86, P1, DOI 10.1159/000176822
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174
   Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200
   Suen WE, 1997, J EXP MED, V186, P1233, DOI 10.1084/jem.186.8.1233
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Tanaka T, 2006, J HUM GENET, V51, P595, DOI 10.1007/s10038-006-0411-8
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H
   2002, 905 WHO EXP COMM
NR 36
TC 29
Z9 29
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2007
VL 196
IS 12
BP 1836
EP 1843
DI 10.1086/523653
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 245GH
UT WOS:000251922600018
PM 18190265
OA Bronze
DA 2020-11-26
ER

PT J
AU Santos, LD
   Santos, KS
   de Souza, BM
   Arcuri, HA
   Cunha-Neto, E
   Castro, FM
   Kalil, JE
   Palma, MS
AF Santos, Lucilene D.
   Santos, Keity S.
   de Souza, Bibiana M.
   Arcuri, Helen A.
   Cunha-Neto, Edecio
   Castro, Fabio Morato
   Kalil, Jorge Elias
   Palma, Mario S.
TI Purification, sequencing and structural characterization of the
   phospholipase A(1) from the venom of the social wasp Polybia paulista
   (Hymenoptera, Vespidae)
SO TOXICON
LA English
DT Article
DE wasp venom; phospholipase; immunoreactivity; IgE; molecular modeling;
   hymenoptera; hemolysin; allergen
ID PROTEIN; ALLERGEN; A(2)
AB The biochemical and functional characterization of wasp venom toxins is an important prerequisite for the development of new tools both for the therapy of the toxic reactions due to envenomation caused by multiple stinging accidents and also for the diagnosis and therapy of allergic reactions caused by this type of venom. PLA(1) was purified from the venom of the neotropical social wasp Polybia paulista by using molecular exclusion and cation exchange chromatographies; its amino acid sequence was determined by using automated Edman degradation and compared to the sequences of other vespid venom PLA(1)'s. The enzyme exists as a 33,961.40 Da protein, which was identified as a lipase of the GX class, liprotein lipase superfamily, pancreatic lipases (ab20.3) homologous family and RP2 sub-group of phospholipase. P. paulista PLA(1) is 53-82% identical to the phospholipases from wasp species from Northern Hemisphere. The use restrained-based modeling permitted to describe the 3-D structure of the enzyme, revealing that its molecule presents 23% alpha-helix, 28% beta-sheet and 49% coil. The protein structure has the alpha/beta fold common to many lipases; the core consists of a tightly packed beta-sheet constituted of six-stranded parallel and one anti-parallel beta-strand, surrounded by four alpha-helices. P. paulista PLA(1) exhibits direct hemolytic action against washed red blood cells with activity similar to the Cobra cardiotoxin from Naja naja atra. In addition to this, PLA(1) was immunoreactive to specific IgE from the sera of P. paulista-sensitive patients. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Nacl Estadual Sao Paulo, Ctr Study Social Insects, Inst Biosci Rio Claro, Dept Biol, BR-13506 Rio Claro, SP, Brazil.
   Univ Sao Paulo, Fac Med, Discipline Allergy & Immunol InCor, Sao Paulo, SP, Brazil.
   Univ Sao Paulo, SJRP, IBILCE, Dept Phys, Sao Paulo, Brazil.
RP Palma, MS (corresponding author), Univ Nacl Estadual Sao Paulo, Ctr Study Social Insects, Inst Biosci Rio Claro, Dept Biol, Av 24A No 1515,Bela Vista, BR-13506 Rio Claro, SP, Brazil.
EM mspalma@rc.unesp.br
RI Arcuri, Helen/E-5182-2012; Santos, Keity/M-9401-2015; Santos, Lucilene
   Delazari dos/AAY-5226-2020; KALIL, JORGE/C-8029-2012; Castro, Fabio
   FM/C-1082-2017; Palma, Mario Sergio/E-7800-2012; Santos,
   Keity/E-2553-2012; Castro, Fabio/AAP-5433-2020; Palma,
   Mario/N-3903-2019; Cunha-Neto, Edecio/B-4157-2009; Santos, Keity
   Souza/Q-5704-2019
OI Santos, Lucilene Delazari dos/0000-0001-5832-1825; KALIL,
   JORGE/0000-0001-8415-4274; Castro, Fabio FM/0000-0002-6211-5773; Palma,
   Mario Sergio/0000-0002-7363-8211; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Santos, Keity Souza/0000-0001-5271-4011
CR Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434
   Abe T, 2000, TOXICON, V38, P1803, DOI 10.1016/S0041-0101(00)00109-4
   Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8
   Aoki J, 2007, BIOCHIMIE, V89, P197, DOI 10.1016/j.biochi.2006.09.021
   ARAUJO A L D, 1987, Toxicon, V25, P1181
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Carriere F, 1997, BIOCHEMISTRY-US, V36, P239, DOI 10.1021/bi961991p
   Costa H, 2000, TOXICON, V38, P1367, DOI 10.1016/S0041-0101(99)00199-3
   De Oliveira MR, 1998, TOXICON, V36, P189, DOI 10.1016/S0041-0101(97)00053-6
   DOTIMAS EM, 1987, BEE WORLD, V68, P51, DOI 10.1080/0005772X.1987.11098915
   Fischer M, 2003, NUCLEIC ACIDS RES, V31, P319, DOI 10.1093/nar/gkg015
   Ho CL, 1999, TOXICON, V37, P1015, DOI 10.1016/S0041-0101(98)00229-3
   HO CL, 1988, BIOCHIM BIOPHYS ACTA, V963, P414, DOI 10.1016/0005-2760(88)90309-8
   Hoffman DR, 2005, J ALLERGY CLIN IMMUN, V115, P611, DOI 10.1016/j.jaci.2004.11.020
   HOFFMAN DR, 1978, ANN ALLERGY, V40, P171
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KING TP, 1980, ALLERGY, V35, P200, DOI 10.1111/j.1398-9995.1980.tb01744.x
   King TP, 2003, INT ARCH ALLERGY IMM, V131, P25, DOI 10.1159/000070431
   KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8
   King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440
   KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Moawad TI, 2005, ACTA BIOL HUNG, V56, P261, DOI 10.1556/ABiol.56.2005.3-4.9
   MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5
   Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357-4310(95)91170-7
   Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E
   Uchoa HB, 2004, BIOCHEM BIOPH RES CO, V325, P1481, DOI 10.1016/j.bbrc.2004.10.192
NR 31
TC 36
Z9 39
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD DEC 1
PY 2007
VL 50
IS 7
BP 923
EP 937
DI 10.1016/j.toxicon.2007.06.027
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 238VP
UT WOS:000251476400005
PM 17761205
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Dente, M
   Giavina-Bianchi, M
   Mota, AA
   Kalil, J
AF Giavina-Bianchi, P.
   Dente, M.
   Giavina-Bianchi, M.
   Mota, A. A.
   Kalil, J.
TI Codeine challenge in chronic urticaria patients
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Letter
C1 [Giavina-Bianchi, P.; Dente, M.; Giavina-Bianchi, M.; Mota, A. A.; Kalil, J.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P773
   Prieto-Lastra L, 2006, Allergol Immunopathol (Madr), V34, P224, DOI 10.1157/13094030
NR 2
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD NOV-DEC
PY 2007
VL 35
IS 6
BP 280
EP 280
DI 10.1157/13112997
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 277YQ
UT WOS:000254251000013
PM 18047822
DA 2020-11-26
ER

PT J
AU Michaluart, P
   Abdallah, K
   Lima, FD
   Smith, RB
   Moyses, RA
   Coelho, V
   Victora, GD
   Socorro-Silva, A
   Volsi, EC
   Kalil, J
   Zarate-Blades, CR
   Ferraz, AR
   Barreto, AK
   Chammas, MC
   Gomes, RL
   Gebrim, E
   Lica, AS
   Fernandes, KP
   Lotufo, P
   Cardoso, MR
   Silvan, CL
AF Michaluart, Pedro
   Abdallah, Kald
   Lima, Fanny D.
   Smith, Rodney B.
   Moyses, Raquel A.
   Coelho, Veronica
   Victora, Gabriel D.
   Socorro-Silva, Adalberto
   Volsi, Evelyn C.
   Kalil, Jorge
   Zarate-Blades, Carlos R.
   Ferraz, Alberto R.
   Barreto, Ana K.
   Chammas, Maria C.
   Gomes, Regina L.
   Gebrim, Eloisa
   Lica, Arakawa-Sugueno
   Fernandes, Kariane P.
   Lotufo, Paulo
   Cardoso, Maria R.
   Silvan, Celio L.
TI Phase I/II trial of DNA-HSP65 immunotherapy for advanced squamous cell
   carcinoma of the head and neck: Toxicity and response
SO JOURNAL OF IMMUNOTHERAPY
LA English
DT Meeting Abstract
CT 22nd Annual Scientific Meeting of the
   International-Society-for-Biological-Therapy-of-Cancer
CY NOV 02-04, 2007
CL Boston, MA
SP Int Soc Biol Therapy Canc
C1 [Michaluart, Pedro; Abdallah, Kald; Lima, Fanny D.; Smith, Rodney B.; Moyses, Raquel A.; Coelho, Veronica; Victora, Gabriel D.; Socorro-Silva, Adalberto; Volsi, Evelyn C.; Kalil, Jorge; Zarate-Blades, Carlos R.; Ferraz, Alberto R.; Barreto, Ana K.; Chammas, Maria C.; Gomes, Regina L.; Gebrim, Eloisa; Lica, Arakawa-Sugueno; Fernandes, Kariane P.; Lotufo, Paulo; Cardoso, Maria R.; Silvan, Celio L.] Univ Sao Paulo, HSP65 Clin Trail Grp, Sao Paulo, Brazil.
   [Coelho, Veronica; Kalil, Jorge] Millenium Inst Immunol, Sao Paulo, Brazil.
   [Silvan, Celio L.] Univ Sao Paulo, Ctr Tuberculosis Res, Sao Paulo, Brazil.
RI Moyses, Raquel/N-4376-2015; KALIL, JORGE/C-8029-2012; Chammas, Maria
   Cristina/M-1960-2017; Lotufo, Paulo/A-9843-2008; Victora,
   Gabriel/C-5946-2011; COELHO, VERONICA/D-1433-2013; Cardoso, Maria Regina
   A/J-7280-2012; Marinho, Ana Karolina/C-8395-2017; Zarate-Blades, Carlos
   R/C-9663-2015
OI Moyses, Raquel/0000-0002-0872-9870; KALIL, JORGE/0000-0001-8415-4274;
   Chammas, Maria Cristina/0000-0001-7041-3079; Lotufo,
   Paulo/0000-0002-4856-8450; Marinho, Ana Karolina/0000-0001-9369-8222;
   Zarate-Blades, Carlos R/0000-0002-7728-7869
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1524-9557
J9 J IMMUNOTHER
JI J. Immunother.
PD NOV-DEC
PY 2007
VL 30
IS 8
BP 898
EP 898
PG 1
WC Oncology; Immunology; Medicine, Research & Experimental
SC Oncology; Immunology; Research & Experimental Medicine
GA 223UB
UT WOS:000250396700150
DA 2020-11-26
ER

PT J
AU de Oliveira, E
   Giavina-Bianchi, P
   Marcondes Fonseca, LA
   Franca, AT
   Kalil, J
AF de Oliveira, Edilamara
   Giavina-Bianchi, Pedro
   Marcondes Fonseca, Luiz Augusto
   Franca, Alfeu Tavares
   Kalil, Jorge
TI Allergic bronchopulmonary aspergillosis' dagnosis remains a challenge
SO RESPIRATORY MEDICINE
LA English
DT Article
DE allergic bronchopulmonar aspergillosis; Aspergillus fumigatus; difficult
   to control asthma; recombinant allergen; specific IgE
ID CYSTIC-FIBROSIS PATIENTS; FUMIGATUS ALLERGENS; PULMONARY ASPERGILLOSIS;
   RECOMBINANT ALLERGENS; DIAGNOSIS; ASTHMA; IMMUNODIAGNOSIS; CRITERIA; IGE
AB Introduction: Allergic bronchopulmonary aspergillosis (ABPA) is a complex disease, triggered by a hypersensitivity reaction to the allergens of Aspergillus fumigatus, a fungus that opportunistically colonizes the lungs of patients with asthma. The diagnosis of ABPA is difficult. A major problem is the lack of standardized allergens used in the determination of specific IgE, but the use of recombinant allergens has been proposed to overcome this. The aim of the present study is to evaluate whether serological tests for IgE specific to recombinant allergens of A. fumigatus (rAsp) can aid in the detection of sensitization to this fungus and in the diagnosis of ABPA. Methods: This was an observational, cross-sectional study. The diagnosis of ABPA, using classical criteria, was searched in 65 asthmatics patients with immediate cutaneous reactivity to A. fumigatus. After that, serumtiters of IgE against rAsp f 1, rAsp f 2, rAsp f 3, rAsp f 4 and rAsp f 6 were determined. In order to compare the differences between patients with confirmed and excluded diagnosis of ABPA, the two-tailed Fisher's exact test was used. Results: Although 19 of 65 patients had IgE against at [east one recombinant, the disease was diagnosed in only six patients by classical criteria. One of them had IgE against all recombinant allergens tested and another one had antibody against Asp f 3. Discussion: The determination of serum IgE against recombinant A. fumigatus allergens in this group was not helpful to make the diagnosis of ABPA, neither to detect sensitization to fungus. (C) 2007 Published by Elsevier Ltd.
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, BR-01454904 Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Div Clin Immunol & Allergy, Rio De Janeiro, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, R Prof Artur Ramos 178 Ap 211A, BR-01454904 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Fonseca, Luiz Augusto M/F-9344-2012; KALIL, JORGE/C-8029-2012;
   Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Almeida Marina B., 2006, J. Pediatr. (Rio J.), V82, P215, DOI [10.2223/JPED.1479, 10.1590/S0021-75572006000300011]
   [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202
   Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889
   Dreborg S, 1989, ALLERGY S10, V44, P22
   Eaton T, 2000, CHEST, V118, P66, DOI 10.1378/chest.118.1.66
   GIAVINABIANCHI P, 1996, ARCH ARG ALERGIA INM, V27, P1
   GREENBERGER PA, 1986, ANN ALLERGY, V56, P444
   GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288
   Greenberger Paul A., 1997, P555
   Hemmann S, 1999, J ALLERGY CLIN IMMUN, V104, P601, DOI 10.1016/S0091-6749(99)70330-1
   HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513
   Knutsen AP, 2004, ALLERGY, V59, P198, DOI 10.1046/j.1398-9995.2003.00310.x
   Kurup Viswanath P, 2006, Clin Mol Allergy, V4, P11, DOI 10.1186/1476-7961-4-11
   KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991
   Kurup VP, 2000, CLIN EXP ALLERGY, V30, P988, DOI 10.1046/j.1365-2222.2000.00837.x
   LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119
   MCCARTHY DS, 1971, CLIN ALLERGY, V21, P261
   MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5
   Nikolaizik WH, 2002, AM J RESP CRIT CARE, V165, P916, DOI 10.1164/ajrccm.165.7.2109008
   NORMAN PS, 1983, ALLERGY PRINCIPLES P, V2, P295
   PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286
   PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V80, P663, DOI 10.1016/0091-6749(87)90285-5
   ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405
   Sarma UP, 2003, FRONT BIOSCI-LANDMRK, V8, pS1187, DOI 10.2741/991
   SCHWARTZ HJ, 1991, J LAB CLIN MED, V117, P138
   SERPA SF, 1997, THESIS RIO JANEIRO
   *SOC BRAS PNEUM TI, 1996, J PNEUMOL, V22, P137
   Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525
   Varkey B, 1998, IMMUNOL ALLERGY CLIN, V18, P479, DOI 10.1016/S0889-8561(05)70018-7
NR 29
TC 29
Z9 35
U1 0
U2 7
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD NOV
PY 2007
VL 101
IS 11
BP 2352
EP 2357
DI 10.1016/j.rmed.2007.06.018
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 223BH
UT WOS:000250344100017
PM 17689062
DA 2020-11-26
ER

PT J
AU Porta, G
   Oliveira, LC
   Ramasawmy, R
   Bittencourt, PL
   Miura, IK
   Pugliese, RS
   Danesi, VB
   Kalil, J
   Goldberg, AC
AF Porta, Gilda
   Oliveira, L. C.
   Ramasawmy, R.
   Bittencourt, P. L.
   Miura, I. K.
   Pugliese, R. S.
   Danesi, V. B.
   Kalil, J.
   Goldberg, A. C.
TI Lymphotoxin alpha gene polymorphisms in pediatric autoimmune hepatitis
   type 1
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 02-06, 2007
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 Univ Sao Paulo, Inst Chem, Sao Paulo, Brazil.
   Univ Sao Paulo, Med Invest Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Immunol Lab, InCor, Sao Paulo, Brazil.
   Portugues Hosp, Salvador, BA, Brazil.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; BITTENCOURT,
   PAULO l/I-5817-2014; Ramasawmy, Rajendranath/V-4926-2019
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; BITTENCOURT, PAULO l/0000-0003-0883-4870; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2007
VL 46
IS 4
SU S
MA 718
BP 556A
EP 556A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 216WT
UT WOS:000249910400724
DA 2020-11-26
ER

PT J
AU Rizzo, LV
   Rumjanek, V
   Kalil, J
AF Rizzo, Luiz V.
   Rumjanek, Vivian
   Kalil, Jorge
TI A brief insight to Brazilian immunology
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Editorial Material
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Inst Med Biochem, Rio De Janeiro, Brazil.
RP Rizzo, LV (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM Ivrizzo@icb.usp.br
RI Rizzo, Luiz Vicente/B-4458-2009; KALIL, JORGE/C-8029-2012; Rumjanek,
   Vivian Mary/V-8741-2019
OI KALIL, JORGE/0000-0001-8415-4274; 
CR Garcia VD, 2007, TRANSPL P, V39, P336, DOI 10.1016/j.transproceed.2007.01.018
   Rumjanek VM, 1996, BRAZ J MED BIOL RES, V29, P923
   Sant'Anna OA, 2007, SCAND J IMMUNOL, V66, P106, DOI 10.1111/j.1365-3083.2007.01960.x
NR 3
TC 0
Z9 0
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD SEP
PY 2007
VL 37
IS 9
BP 2358
EP 2359
PG 2
WC Immunology
SC Immunology
GA 214MV
UT WOS:000249743200002
DA 2020-11-26
ER

PT J
AU Victora, GD
   Bilate, AMB
   Socorro-Silva, A
   Caldas, C
   Lima, RC
   Kalil, J
   Coelho, V
   Victora, CG
AF Victora, Gabriel D.
   Bilate, Angelina M. B.
   Socorro-Silva, Adalberto
   Caldas, Cristina
   Lima, Rosangela C.
   Kalil, Jorge
   Coelho, Veronica
   Victora, Cesar G.
TI Mother-child immunological interactions in early life affect long-term
   humoral autoreactivity to heat shock protein 60 at age 18 years
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE autoantibodies; birthweight; breastfeeding; cohort studies; heat shock
   protein 60
ID HEAT-SHOCK PROTEINS; DIABETES-MELLITUS; ANTIBODIES; AUTOANTIBODIES;
   INDIVIDUALS; ATHEROSCLEROSIS; AUTOIMMUNITY; ASSOCIATION; REPERTOIRE;
   EPITOPES
AB The presence of anti-heat shock protein 60 (Hsp60) antibodies in healthy individuals and the association of these antibodies with diseases such as arthritis and atherosclerosis are well documented. However, there is limited population-level data on interindividual variation in anti-Hsp60 levels. We investigated the influence of early-life factors on IgG reactivity to human Hsp60 at age 18 years. A population-based prospective birth cohort study included 5914 births in the city of Pelotas, Brazil, in 1982. Early-life exposures were documented during home visits in childhood. In 2000, 79% of all males in the cohort were traced. Sera from a systematic 20% sample (411 subjects) were analyzed. Anti-Hsp60 total IgG reactivity was. determined by ELISA. Data were analyzed using analysis of variance and generalized linear models. Anti-Hsp60 reactivity was lognormally distributed and showed a significant direct correlation with low birthweight (p = 0.039) and total duration of breastfeeding (p = 0.018), of which only the latter remained significant after adjustment for potential confounders. Reactivity was not associated with asthma, pneumonia, diarrhea, or early-life malnutrition. Mother-child immunological interactions, rather than infection/disease factors seem to be associated with reactivity to Hsp60 later in life. This is in agreement with the hypothesis that maternal antibodies influence future antibody profile. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Lab Immunol, Heart Inst InCor, BR-05340000 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05340000 Sao Paulo, Brazil.
   Univ Fed Pelotas, Post Grad Program Epidemiol, Pelotas, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Sch Med, Lab Immunol, Heart Inst InCor, Av Dr Eneas de Carvalho Aguiar,44,Bloco 2,9o Anda, BR-05340000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI COELHO, VERONICA/D-1433-2013; Victora, Cesar Gomes/Y-2455-2019; Victora,
   Cesar G/D-4476-2013; KALIL, JORGE/C-8029-2012; Victora,
   Gabriel/C-5946-2011
OI Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar
   G/0000-0002-2465-2180; KALIL, JORGE/0000-0001-8415-4274; Coelho,
   Veronica/0000-0002-0989-2581; Victora, Gabriel/0000-0001-8807-348X
FU Wellcome TrustWellcome Trust Funding Source: Medline
CR COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9
   Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4
   DEGRAEFFMEEDER ER, 1993, PEDIATR RES, V34, P424, DOI 10.1203/00006450-199310000-00008
   Fust G, 2005, MOL IMMUNOL, V42, P79, DOI 10.1016/j.molimm.2004.07.003
   Handley HH, 1996, CLIN EXP IMMUNOL, V103, P429
   KILIDIREAS K, 1992, LANCET, V340, P569, DOI 10.1016/0140-6736(92)92105-O
   Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X
   Lemke H, 2004, TRENDS IMMUNOL, V25, P180, DOI 10.1016/j.it.2004.02.007
   Lemke H, 1999, SCAND J IMMUNOL, V50, P348, DOI 10.1046/j.1365-3083.1999.00620.x
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813
   Mouthon L, 1996, SCAND J IMMUNOL, V44, P243, DOI 10.1046/j.1365-3083.1996.d01-306.x
   Ozawa Y, 1996, J AUTOIMMUN, V9, P517, DOI 10.1006/jaut.1996.0069
   Perschinka H, 2003, ARTERIOSCL THROM VAS, V23, P1060, DOI 10.1161/01.ATV.0000071701.62486.49
   Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5
   Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1379/1466-1268(1999)004<0029:IOHHSP>2.3.CO;2
   Quintana FJ, 2004, BIOMED PHARMACOTHER, V58, P276, DOI 10.1016/j.biopha.2004.04.011
   Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427
   Shovman O, 2005, ISR MED ASSOC J, V7, P778
   Uray K, 2003, INT IMMUNOL, V15, P1229, DOI 10.1093/intimm/dxg122
   van Eden W, 2003, VACCINE, V21, P897, DOI 10.1016/S0264-410X(02)00538-8
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   Victora Cesar G., 2003, Cad. Saúde Pública, V19, P1241, DOI 10.1590/S0102-311X2003000500003
   Victora CG, 2003, BMJ-BRIT MED J, V327, P901, DOI 10.1136/bmj.327.7420.901
   Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224
   WHO Expert Committee, 1995, PHYS STAT US INT ANT
   Xiao QZ, 2005, STROKE, V36, P2571, DOI 10.1161/01.STR.0000189632.98944.ab
   Yang M, 2004, CELL STRESS CHAPERON, V9, P207, DOI 10.1379/CSC-12R.1
   Zhu JH, 2001, CIRCULATION, V103, P1071, DOI 10.1161/01.CIR.103.8.1071
NR 28
TC 11
Z9 11
U1 0
U2 3
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD AUG
PY 2007
VL 29
IS 1
BP 38
EP 43
DI 10.1016/j.jaut.2007.02.018
PG 6
WC Immunology
SC Immunology
GA 195LC
UT WOS:000248412700005
PM 17521883
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Ramasawmy, R
   Kalil, J
AF Guilherme, L.
   Ramasawmy, R.
   Kalil, J.
TI Rheumatic fever and rheumatic heart disease: Genetics and pathogenesis
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
ID NECROSIS-FACTOR-ALPHA; CLASS-II ANTIGENS; T-CELL-CLONES; STREPTOCOCCAL
   M-PROTEIN; MANNOSE-BINDING LECTIN; HLA CLASS-I; BLOOD-GROUPS;
   INSERTION/DELETION POLYMORPHISM; MONOCLONAL-ANTIBODIES; MEXICAN PATIENTS
AB Molecular mimicry between streptococcal and human proteins is considered as the triggering factor leading to autoimmunity in rheumatic fever (RF) and rheumatic heart disease (RHD). Here, we present a review of the genetic susceptibility markers involved in the development of RF/RHD and the major immunopathological events underlying the pathogenesis of RF and RHD. Several human leucocyte antigen (HLA) class II alleles are associated with the disease. Among these alleles, HLA-DR7 is predominantly observed in different ethnicities and is associated with the development of valvular lesions in RHD patients. Cardiac myosin is one of the major autoantigens involved in rheumatic heart lesions and several peptides from the LMM (light meromyosin) region were recognized by peripheral and intralesional T-cell clones from RF and RHD patients. The production of TNF-oc and IFN-gamma from heart-infiltrating mononuclear cells suggests that Th-1 type cytokines are the mediators of RHD heart lesions while the presence of few interleukin-4 producing cells in the valve tissue contributes to the maintenance and progression of the valvular lesions.
C1 Univ Sao Paulo, Sch Med, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Immunol Invest, Millenium Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), FMUSP, InCor, Lab Imunol, HC, Av Dr Eneas Carvalho Aguiar 44-9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; Ramasawmy, Rajendranath/V-4926-2019;
   KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   BAIRD RW, 1991, J IMMUNOL, V146, P3132
   Berdeli A, 2006, SCAND J RHEUMATOL, V35, P44, DOI 10.1080/03009740510026760
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   Berdeli A, 2004, CLIN BIOCHEM, V37, P925, DOI 10.1016/j.clinbiochem.2004.06.007
   BUCKWALTER J A, 1962, Br Med J, V2, P1023
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   CAUGHEY DE, 1975, J RHEUMATOL, V2, P319
   Chou HT, 2005, INT HEART J, V46, P397, DOI 10.1536/ihj.46.397
   Chou HT, 2004, JPN HEART J, V45, P949, DOI 10.1536/jhj.45.949
   Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032
   CLARKE CA, 1960, BRIT MED J, V1, P21, DOI 10.1136/bmj.1.5165.21
   CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   Davutoglu V, 2005, J HEART VALVE DIS, V14, P277
   Donadi EA, 2000, J NEUROL, V247, P122, DOI 10.1007/s004150070191
   Duzgun N, 2007, CLIN RHEUMATOL, V26, P915, DOI 10.1007/s10067-006-0432-x
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FALK JA, 1973, TISSUE ANTIGENS, V3, P173
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   GLYNN LE, 1961, ARTHRITIS RHEUM, V4, P203, DOI 10.1002/art.1780040210
   GOLDSTEIN I, 1968, NATURE, V219, P866, DOI 10.1038/219866a0
   GRAY FG, 1952, AM J MED, V13, P400, DOI 10.1016/0002-9343(52)90294-5
   GREENBERG LJ, 1975, J EXP MED, V141, P935, DOI 10.1084/jem.141.5.935
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   Guilherme L, 2001, J AUTOIMMUN, V16, P363, DOI 10.1006/jaut.2000.0487
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Haydardedeoglu FE, 2006, TISSUE ANTIGENS, V68, P293, DOI 10.1111/j.1399-0039.2006.00678.x
   Hernandez-Pacheco G, 2003, INT J CARDIOL, V92, P49, DOI 10.1016/S0167-5273(03)00040-8
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   JOYSEY VC, 1977, J RHEUMATOL, V4, P84
   KAPLAN MH, 1964, J EXP MED, V119, P651, DOI 10.1084/jem.119.4.651
   KAPLAN MH, 1964, J EXP MED, V119, P643, DOI 10.1084/jem.119.4.643
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   LEIRISALO M, 1980, J RHEUMATOL, V7, P506
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MATSUMORI A, 1979, JPN CIRC J, V43, P445, DOI 10.1253/jcj.43.445
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x
   MORRIS K, 1993, CLIN EXP IMMUNOL, V91, P429
   MURRAY GC, 1978, TISSUE ANTIGENS, V12, P337, DOI 10.1111/j.1399-0039.1978.tb01342.x
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   OLMEZ U, 1993, SCAND J RHEUMATOL, V22, P49
   Ozisik K, 2004, J HEART VALVE DIS, V13, P33
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   READ SE, 1977, TRANSPL P, V9, P543
   Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   SAMSONOV MY, 1995, CLIN IMMUNOL IMMUNOP, V74, P31, DOI 10.1006/clin.1995.1005
   SPAGNUOLO M, 1968, NEW ENGL J MED, V278, P183, DOI 10.1056/NEJM196801252780403
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   STEVENSON AC, 1953, ANN EUGENIC, V17, P177
   TANEJA V, 1989, CIRCULATION, V80, P335, DOI 10.1161/01.CIR.80.2.335
   UCHIDA IA, 1953, AM J HUM GENET, V5, P61
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   WILSON MG, 1954, CIRCULATION, V10, P699, DOI 10.1161/01.CIR.10.5.699
   Yegin O, 1997, EUR J PEDIATR, V156, P25
   YOSHINAGA M, 1995, J AUTOIMMUN, V8, P601, DOI 10.1016/0896-8411(95)90011-X
   YOSHINOYA S, 1980, J CLIN INVEST, V65, P136, DOI 10.1172/JCI109643
   Zabriskie J B, 1967, Adv Immunol, V7, P147, DOI 10.1016/S0065-2776(08)60128-5
   ZABRISKIE JB, 1985, ARTHRITIS RHEUM, V28, P1047, DOI 10.1002/art.1780280912
   ZABRISKIE JB, 1970, CLIN EXP IMMUNOL, V7, P147
NR 88
TC 74
Z9 78
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG-SEP
PY 2007
VL 66
IS 2-3
BP 199
EP 207
DI 10.1111/j.1365-3083.2007.01974.x
PG 9
WC Immunology
SC Immunology
GA 196TC
UT WOS:000248504100013
PM 17635797
OA Bronze
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Bittencourt, PL
   Oliveira, LC
   Ramasawmy, R
   Marin, MLC
   Palacios, SA
   Kalil, J
   Porta, G
AF Goldberg, A. C.
   Bittencourt, P. L.
   Oliveira, L. C.
   Ramasawmy, R.
   Marin, M. L. C.
   Palacios, S. A.
   Kalil, J.
   Porta, G.
TI Autoimmune hepatitis in Brazil: An overview
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
ID CHRONIC ACTIVE HEPATITIS; PRIMARY BILIARY-CIRRHOSIS; PRIMARY SCLEROSING
   CHOLANGITIS; SINUSOIDAL ENDOTHELIAL-CELLS; REGULATORY T-CELLS; GENE
   POLYMORPHISMS; CONFER SUSCEPTIBILITY; ANTIACTIN ANTIBODY; DENDRITIC
   CELLS; VIRUS-INFECTION
AB Autoimmune hepatitis is an immune cell-mediated chronic liver disease of unknown cause that leads, when untreated, to cirrhosis and liver failure. Importantly, this disease affects not only adults but children as well. Genetic susceptibility is clearly important and the major susceptibility factor identified up to now is the HLA-DRB1 locus, but other genes may play a role as well. HLA-DRB1 alleles present in South American patients differ from those found in patients in other parts of the world. In addition, we have recently identified two chromosomal regions where additional susceptibility factors may be found in Brazilian patients, namely, the class III MHC region and the 5q31 region where the IL-4 and IL-13 genes are located. This review discusses the current knowledge of the pathogenesis of this autoimmune disease occurring in the setting of an immune-privileged organ, the liver, and compares the data on gene polymorphisms studied in Brazil and in other parts of the world.
C1 Univ Sao Paulo, Dept Biochem, Inst Chem, Sao Paulo, Brazil.
   Hosp Portugues, Salvador, BA, Brazil.
   Univ Sao Paulo, Lab Med Invest, Childrens Inst, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Immunol Lab, Inst Heart, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Hepatol, Childrens Inst, Sch Med, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Av Prof Lineu Prestes 748,Bloco 8S,Sala 861, BR-05508900 Sao Paulo, Brazil.
EM goldberg@usp.br
RI Goldberg, Anna Carla/H-8594-2014; BITTENCOURT, PAULO l/I-5817-2014;
   Ramasawmy, Rajendranath/V-4926-2019; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; KALIL, JORGE/0000-0001-8415-4274
CR Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Avrameas S, 1988, Int Rev Immunol, V3, P1, DOI 10.3109/08830188809051179
   Barnes R, 1997, DIABETOLOGIA, V40, P194
   Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2003, AM J GASTROENTEROL, V98, P1616, DOI 10.1016/S0002-9270(03)00307-1
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   BITTENCOURT PL, 2007, IN PRESS J CLIN GAST
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cancado ELR, 2000, FALK SYMP, V114, P82
   CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0
   Chernavsky AC, 2004, HUM IMMUNOL, V65, P683, DOI 10.1016/j.humimm.2004.03.004
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 2002, AUTOIMMUNITY, V35, P475, DOI 10.1080/0891693021000054101
   Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Dalekos GN, 2003, J HEPATOL, V39, P800, DOI 10.1016/S0168-8278(03)00356-8
   De Biasio MB, 2006, J CLIN PATHOL, V59, P417, DOI 10.1136/jcp.2005.028613
   DEVRIES JE, 1993, RES IMMUNOL, V144, P597, DOI 10.1016/S0923-2494(05)80009-4
   Djilali-Saiah I, 2006, J HEPATOL, V45, P844, DOI 10.1016/j.jhep.2006.07.034
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   Donaldson Peter T, 2002, Clin Liver Dis, V6, P707, DOI 10.1016/S1089-3261(02)00023-5
   Fainboim L, 2001, HEPATOLOGY, V33, P1512, DOI 10.1053/jhep.2001.24562
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   Fiore G, 1997, MICROBIOS, V92, P73
   GABBIANI G, 1973, AM J PATHOL, V72, P473
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Harada M, 2006, J EXP MED, V203, P2929, DOI 10.1084/jem.20062206
   HASHIMOTO E, 1993, MAYO CLIN PROC, V68, P1049, DOI 10.1016/S0025-6196(12)60897-0
   Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549
   HODGSON HJF, 1978, P NATL ACAD SCI USA, V75, P1549, DOI 10.1073/pnas.75.3.1549
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   Honda M, 2005, J AUTOIMMUN, V25, P133, DOI 10.1016/j.jaut.2005.03.009
   Jeannin P, 1998, J IMMUNOL, V160, P3555
   Klugewitz K, 2002, J IMMUNOL, V169, P2407, DOI 10.4049/jimmunol.169.5.2407
   Knolle PA, 1999, J IMMUNOL, V162, P1401
   Knolle PA, 2001, TRENDS IMMUNOL, V22, P432, DOI 10.1016/S1471-4906(01)01957-3
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   Lalor PF, 2002, IMMUNOL CELL BIOL, V80, P52, DOI 10.1046/j.1440-1711.2002.01062.x
   Lapierre P, 1999, GASTROENTEROLOGY, V116, P643, DOI 10.1016/S0016-5085(99)70186-1
   LaRusso NF, 2006, HEPATOLOGY, V44, P746, DOI 10.1002/hep.21337
   Lau AH, 2003, GUT, V52, P307, DOI 10.1136/gut.52.2.307
   LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266
   Ligers A, 2001, GENES IMMUN, V2, P145, DOI 10.1038/sj.gene.6363752
   Limmer A, 2000, NAT MED, V6, P1348
   Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635
   Liu ZX, 2001, J IMMUNOL, V166, P3035, DOI 10.4049/jimmunol.166.5.3035
   LOHR H, 1990, HEPATOLOGY, V12, P1314, DOI 10.1002/hep.1840120611
   Lohr HF, 2003, SCAND J IMMUNOL, V57, P384, DOI 10.1046/j.1365-3083.2003.01236.x
   Longhi MS, 2006, J IMMUNOL, V176, P4484, DOI 10.4049/jimmunol.176.7.4484
   Longhi MS, 2005, J AUTOIMMUN, V25, P63, DOI 10.1016/j.jaut.2005.05.001
   Mackay IR, 2002, IMMUNOL CELL BIOL, V80, P36, DOI 10.1046/j.1440-1711.2002.01063.x
   MANNS M, 1991, HEPATOLOGY, V14, pA60
   Manns MP, 2006, HEPATOLOGY, V43, pS132, DOI 10.1002/hep.21059
   MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949
   Manns MP, 2001, GASTROENTEROLOGY, V120, P1502, DOI 10.1053/gast.2001.24227
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
   Mello A. L. R. de, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P165, DOI 10.1590/S0036-46651996000300001
   Muschen M, 1998, HEPATOLOGY, V27, P200, DOI 10.1002/hep.510270131
   O'Connell PJ, 2002, J IMMUNOL, V168, P143, DOI 10.4049/jimmunol.168.1.143
   Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9
   Onoe T, 2005, J IMMUNOL, V175, P139, DOI 10.4049/jimmunol.175.1.139
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   Pellicano R, 2004, DIGEST DIS SCI, V49, P395, DOI 10.1023/B:DDAS.0000020491.78450.82
   Porta G, 2000, J Pediatr (Rio J), V76 Suppl 1, pS181
   PORTA G, 2004, J PEDIAT GASTROEN S1, V39, pS185
   PUNNONEN J, 1993, J IMMUNOL, V151, P1280
   PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730
   Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060
   Rigopoulou Eirini I, 2007, J Autoimmune Dis, V4, P2, DOI 10.1186/1740-2557-4-2
   Sansonno D, 2004, EUR J IMMUNOL, V34, P126, DOI 10.1002/eji.200324328
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Skoog SM, 2002, AM J GASTROENTEROL, V97, P1568, DOI 10.1016/S0002-9270(02)04107-2
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Strettell MDJ, 1997, GASTROENTEROLOGY, V112, P2028, DOI 10.1053/gast.1997.v112.pm9178696
   Takaya Masatoshi, 1992, Tokai Journal of Experimental and Clinical Medicine, V17, P35
   Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Verma S, 2004, AM J GASTROENTEROL, V99, P1510, DOI 10.1111/j.1572-0241.2004.30457.x
   Vitral CL, 2006, MEM I OSWALDO CRUZ, V101, P119, DOI 10.1590/S0074-02762006000200001
   Vogel A, 2004, CLIN TRANSPLANT, V18, P62, DOI 10.1111/j.1399-0012.2004.00117.x
   Watanabe T, 2003, HEPATOLOGY, V38, P403, DOI 10.1053/jhep.2003.50343
   Zamanou A, 2003, J AUTOIMMUN, V20, P333, DOI 10.1016/S0896-8411(03)00036-2
NR 91
TC 14
Z9 16
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG-SEP
PY 2007
VL 66
IS 2-3
BP 208
EP 216
DI 10.1111/j.1365-3083.2007.01967.x
PG 9
WC Immunology
SC Immunology
GA 196TC
UT WOS:000248504100014
PM 17635798
DA 2020-11-26
ER

PT J
AU Spadafora-Ferreira, M
   Caldas, C
   Fae, KC
   Marrero, I
   Monteiro, SM
   Lin-Wang, HT
   Socorro-Silva, A
   Fonseca, SG
   Fonseca, JA
   Kalil, J
   Coelho, V
AF Spadafora-Ferreira, M.
   Caldas, C.
   Fae, K. C.
   Marrero, I.
   Monteiro, S. M.
   Lin-Wang, H. T.
   Socorro-Silva, A.
   Fonseca, S. G.
   Fonseca, J. A.
   Kalil, J.
   Coelho, V.
TI CD4(+)CD25(+)Foxp3(+) indirect alloreactive T cells from renal
   transplant patients suppress both the direct and indirect pathways of
   allorecognition
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES; CHRONIC ALLOGRAFT NEPHROPATHY;
   REGULATORY-CELLS; DENDRITIC CELLS; GROWTH-FACTOR; TGF-BETA; INDIRECT
   RECOGNITION; CHRONIC REJECTION; GRAFT RECIPIENTS; ORAL TOLERANCE
AB Alloreactive T cells recognize donor antigens by two routes: direct and indirect pathways of allorecognition. Although the direct pathway is reported to be dominant in allograft rejection, indirect allorecognition also plays an important role. Indirect alloreactivity is also observed in renal transplant patients irrespective of rejection. Previously we showed a predominance of interleukin (IL)-10 induced by indirect allorecognition of donor human leucocyte antigen (HLA)-DR peptides, suggesting the existence of indirect alloreactive T cells displaying regulatory activity. In the present work, our objective was to characterize these regulatory T cells. We detected indirect alloproliferation of peripheral blood mononuclear cells (PBMC) from renal transplant patients, induced by donor HLA-DR peptides, dependent on IL-4 or IL-10, suggesting regulatory activity as part of the alloreactive T-cell repertoire. PBMC-derived indirect alloreactive T-cell lines were established and produced both inflammatory and regulatory cytokines. We showed that two of these T-cell lines which were able to inhibit both direct and indirect alloproliferation of another T-cell line from the same patient presented a CD4(+)CD25(+)Foxp3(+) T-cell population. These data support the idea that indirect alloreactive T cells may also have regulatory activity and may contribute to the maintenance of the human renal allograft.
C1 Univ Sao Paulo, Sch Med, InCor, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Renal Transplantat Unit, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Clin Med, Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), FMUSP, HC, InCor, Lab Imunol, Av Dr Eneas Carvalho Aguiar 44,9 Andar,Bloco 2, BR-05403000 Sao Paulo, SP, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013; FONSECA, SIMONE
   GONCALVES/U-9278-2019; Spadafora-Ferreira, Monica/G-2635-2012
OI KALIL, JORGE/0000-0001-8415-4274; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929; Coelho, Veronica/0000-0002-0989-2581; Lin
   Wang, Hui Tzu/0000-0002-7027-7748
CR Asseman C, 1998, GUT, V42, P157, DOI 10.1136/gut.42.2.157
   AUCHINCLOSS H, 1993, P NATL ACAD SCI USA, V90, P3373, DOI 10.1073/pnas.90.8.3373
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245
   Benichou G, 1999, J IMMUNOL, V162, P352
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117
   Coelho V, 1999, CLIN IMMUNOL, V90, P220, DOI 10.1006/clim.1998.4626
   Colovai AI, 2003, HUM IMMUNOL, V64, P31, DOI 10.1016/S0198-8859(02)00742-5
   Cuhaci B, 1999, TRANSPLANTATION, V68, P785, DOI 10.1097/00007890-199909270-00010
   Davies JD, 1999, J IMMUNOL, V163, P5353
   Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303
   Ensminger SM, 2002, TRANSPLANTATION, V73, P279, DOI 10.1097/00007890-200201270-00022
   FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   Groux H, 1997, NATURE, V389, P737
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   He XY, 2001, TRANSPLANT P, V33, P703, DOI 10.1016/S0041-1345(00)02212-0
   Hornick PI, 2000, CIRCULATION, V101, P2405, DOI 10.1161/01.CIR.101.20.2405
   Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J
   Jiang SP, 2003, BLOOD, V102, P2180, DOI 10.1182/blood-2003-04-1164
   Jiang SP, 2003, AM J TRANSPLANT, V3, P516, DOI 10.1034/j.1600-6143.2003.00124.x
   Jiang SQ, 2004, CURR OPIN IMMUNOL, V16, P550, DOI 10.1016/j.coi.2004.07.011
   Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080
   Kist-van Holthe JE, 2002, KIDNEY INT, V62, P627
   LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31
   Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530
   Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596
   Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898
   Mendel I, 2002, EUR J IMMUNOL, V32, P3216, DOI 10.1002/1521-4141(200211)32:11<3216::AID-IMMU3216>3.0.CO;2-H
   Misra N, 2004, J IMMUNOL, V172, P4676, DOI 10.4049/jimmunol.172.8.4676
   Niederkorn JY, 2002, TRANSPLANTATION, V73, P1493, DOI 10.1097/00007890-200205150-00021
   Poggio ED, 2004, J AM SOC NEPHROL, V15, P1952, DOI 10.1097/01.asn.0000129980.83334.79
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Salama AD, 2003, J AM SOC NEPHROL, V14, P1643, DOI 10.1097/01.ASN.0000057540.98231.C1
   Sanchez-Fueyo A, 2006, J IMMUNOL, V176, P329, DOI 10.4049/jimmunol.176.1.329
   SAYEGH MH, 1993, TRANSPLANTATION, V56, P461, DOI 10.1097/00007890-199308000-00040
   Spadafora-Ferreira M, 2001, CLIN IMMUNOL, V101, P315, DOI 10.1006/clim.2001.5127
   Stegmann S, 2000, HUM IMMUNOL, V61, P1363, DOI 10.1016/S0198-8859(00)00215-9
   Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
   Verhasselt V, 2004, EUR J IMMUNOL, V34, P762, DOI 10.1002/eji.200324552
   Viklicky O, 2003, PHYSIOL RES, V52, P353
   Waaga AM, 1998, TRANSPLANTATION, V65, P876, DOI 10.1097/00007890-199804150-00004
   Wong W, 1997, TRANSPLANTATION, V63, P1490, DOI 10.1097/00007890-199705270-00020
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Yamazaki S, 2006, P NATL ACAD SCI USA, V103, P2758, DOI 10.1073/pnas.0510606103
   Zeller JC, 1999, J IMMUNOL, V163, P3684
   Zhou J, 2001, J IMMUNOL, V167, P107, DOI 10.4049/jimmunol.167.1.107
NR 51
TC 15
Z9 17
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG-SEP
PY 2007
VL 66
IS 2-3
BP 352
EP 361
DI 10.1111/j.1365-3083.2007.01976.x
PG 10
WC Immunology
SC Immunology
GA 196TC
UT WOS:000248504100029
PM 17635813
DA 2020-11-26
ER

PT J
AU Fonseca, SG
   Reis, MM
   Coelho, V
   Nogueira, LG
   Monteiro, SM
   Mairena, EC
   Bacal, F
   Bocchi, E
   Guilherme, L
   Zheng, XX
   Liew, FY
   Higuchi, ML
   Kalil, J
   Cunha-Neto, E
AF Fonseca, S. G.
   Reis, M. M.
   Coelho, V.
   Nogueira, L. G.
   Monteiro, S. M.
   Mairena, E. C.
   Bacal, F.
   Bocchi, E.
   Guilherme, L.
   Zheng, X. X.
   Liew, F. Y.
   Higuchi, M. L.
   Kalil, J.
   Cunha-Neto, E.
TI Locally produced survival cytokines IL-15 and IL-7 may be associated to
   the predominance of CD8(+) T cells at heart lesions of human chronic
   Chagas disease cardiomyopathy
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TRYPANOSOMA-CRUZI ANTIGENS; HOMEOSTATIC PROLIFERATION; GROWTH-FACTOR;
   IN-VIVO; MEMORY; INTERLEUKIN-15; EXPRESSION; NAIVE; MYOCARDITIS;
   RECEPTOR
AB Human chronic Chagas disease cardiomyopathy (CCC) is an inflammatory-dilated cardiomyopathy occurring years after infection by the protozoan Trypanosoma cruzi. The heart inflammatory infiltrate in CCC shows a 2:1 predominance of CD8(+) in relation to CD4(+) T cells, with a typical Th1-type cytokine profile. However, in vitro expansion of infiltrating T cells from heart biopsy-derived fragments with interleukin-2 (11-2) and phyto-haemagglutinin leads to the outgrowth of CD4(+) over CD8(+) T cells. We hypothesized that survival cytokines, such as IL-2, IL-7 and IL-15 might be differentially involved in the growth and maintenance of heart-infiltrating and peripheral CD8(+) T cells from CCC patients. We found that IL-7 and IL-15 were superior to IL-2 in the expansion and viability of CD8(+) T cells from both PBMC and heart-infiltrating T-cell lines from CCC patients, and the combination of the three cytokines showed synergic effects. Heart-infiltrating CD8(+) T cells showed higher expression of both IL-15R alpha and gamma(c) chain than CD4(+) T cells, which may explain the improvement of CD8(+) T-cell growth in the presence of IL-2 + IL-7 + IL-15. Immunohistochemical identification of IL-15 and the higher mRNA expression of IL-15R alpha, IL-7 and gamma(c) chain in CCC heart tissues compared with control individuals indicate in situ production of survival cytokines and their receptors in CCC hearts. Together, our results suggest that local production of IL-7 and IL-15 may be associated with the maintenance and predominance of CD8+ T cells, the cells effecting tissue damage in CCC hearts.
C1 Univ Sao Paulo, Inst Coracao, Lab Imunol, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Pathol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Heart Failure & Heart Transplantat Unit, Sao Paulo, Brazil.
   Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA USA.
   Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, Glasgow, Lanark, Scotland.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Inst Coracao, Lab Imunol, Sch Med, Av Dr Eneas Carvalho Aguiar,44 BL 2,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM edecunha@gmail.com
RI Guilherme, Luiz Roberto G/B-3998-2009; KALIL, JORGE/C-8029-2012; Bacal,
   Fernando/H-7952-2012; COELHO, VERONICA/D-1433-2013; Reis,
   Marcia/P-5850-2016; FONSECA, SIMONE GONCALVES/U-9278-2019; Guilherme,
   Luiz Roberto Guimaraes/V-6163-2019; Cunha-Neto, Edecio/B-4157-2009; de
   Lourdes Higuchi, Maria/K-3886-2017
OI Guilherme, Luiz Roberto G/0000-0002-5387-6028; KALIL,
   JORGE/0000-0001-8415-4274; Reis, Marcia/0000-0002-1020-757X; Guilherme,
   Luiz Roberto Guimaraes/0000-0002-5387-6028; Cunha-Neto,
   Edecio/0000-0002-3699-3345; de Lourdes Higuchi,
   Maria/0000-0002-1673-6456; Coelho, Veronica/0000-0002-0989-2581
FU Medical Research CouncilMedical Research Council UK (MRC) [G9818261]
   Funding Source: Medline
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Agostini C, 1996, J IMMUNOL, V157, P910
   Avice MN, 1998, J IMMUNOL, V161, P3408
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711
   Geiselhart LA, 2001, J IMMUNOL, V166, P3019, DOI 10.4049/jimmunol.166.5.3019
   GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155
   Gu XXJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000300
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Jullien D, 1997, J IMMUNOL, V158, P800
   Kanegane H, 1996, BLOOD, V88, P230
   Khan IA, 1996, J IMMUNOL, V157, P2103
   Kim YS, 1998, J IMMUNOL, V160, P5742
   Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269
   KOMSCHLIES KL, 1994, J IMMUNOL, V152, P5776
   Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675
   Liu ZJ, 2000, J IMMUNOL, V164, P3608, DOI 10.4049/jimmunol.164.7.3608
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0
   McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Sato N, 2007, P NATL ACAD SCI USA, V104, P588, DOI 10.1073/pnas.0610115104
   Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868
   Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423
   Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098
   Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066
   Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(09)00091-0
   Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901
   Weng NP, 2002, ANN NY ACAD SCI, V975, P46, DOI 10.1111/j.1749-6632.2002.tb05940.x
   Wuttge DM, 2001, AM J PATHOL, V159, P417, DOI 10.1016/S0002-9440(10)61712-9
   Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6
NR 42
TC 36
Z9 39
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG-SEP
PY 2007
VL 66
IS 2-3
BP 362
EP 371
DI 10.1111/j.1365-3083.2007.01987.x
PG 10
WC Immunology
SC Immunology
GA 196TC
UT WOS:000248504100030
PM 17635814
OA Bronze
DA 2020-11-26
ER

PT J
AU Cohon, A
   Arruda, LK
   Martins, MA
   Guilherme, L
   Kalil, J
AF Cohon, Andrea
   Arruda, L. Karla
   Martins, Milton A.
   Guilherme, Luiza
   Kalil, Jorge
TI Evaluation of BCG administration as an adjuvant to specific
   immunotherapy in asthmatic children with mite allergy
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID BACILLUS-CALMETTE-GUERIN
C1 Sch Med Sao Paulo, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med Ribeirao Preto, Sao Paulo, Brazil.
RP Cohon, A (corresponding author), Sch Med Sao Paulo, Sao Paulo, Brazil.
EM karla@fmrp.usp.br
RI Martins, Milton A/L-7541-2017; Martins, Milton A/D-6658-2012; Arruda, L.
   Karla/D-5845-2013; Guglielmi, Luiza G/E-7676-2013; KALIL,
   JORGE/C-8029-2012
OI Arruda, L. Karla/0000-0002-7505-210X; KALIL, JORGE/0000-0001-8415-4274
CR ABRAMSON MJ, 2006, ALLERGEN IMMUNOTHERA
   Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x
   Barlan I, 2006, IMMUNOL ALLERGY CLIN, V26, P365, DOI 10.1016/j.iac.2006.02.002
   Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919
   Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934
   Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x
   Taylor DR, 2006, J ALLERGY CLIN IMMUN, V117, P259, DOI 10.1016/j.jaci.2005.11.010
   Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338
   Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x
NR 9
TC 10
Z9 11
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2007
VL 120
IS 1
BP 210
EP 213
DI 10.1016/j.jaci.2007.04.018
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA 190NS
UT WOS:000248066400032
PM 17531299
DA 2020-11-26
ER

PT J
AU Bilate, AMB
   Salemi, VM
   Ramires, FJ
   de Brito, T
   Russo, M
   Fonseca, SG
   Fae, KC
   Martins, DG
   Silva, AM
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Bilate, Angelina M. B.
   Salemi, Vera M.
   Ramires, Felix J.
   de Brito, Thales
   Russo, Momtchilo
   Fonseca, Simone G.
   Fae, Kellen C.
   Martins, Daniel G.
   Silva, Ana Maria
   Mady, Charles
   Kalil, Jorge
   Cunha-Neto, Edecio
TI TNF blockade aggravates experimental chronic Chagas disease
   cardiomyopathy
SO MICROBES AND INFECTION
LA English
DT Article
DE cardiomyopathy; cytokines; infection; myocarditis; ventricular function;
   Trypanosoma cruzi
ID TUMOR-NECROSIS-FACTOR; HEART-FAILURE; TRYPANOSOMA-CRUZI; NITRIC-OXIDE;
   DILATED CARDIOMYOPATHY; FACTOR-ALPHA; EXPRESSION; INHIBITION; IL-10;
   GAMMA
AB Chronic Chagas disease cardiomyopathy (CCC), caused by Trypanosonra cruzi, is an inflammatory dilated eardiomyopathy associated with increased circulating levels of TNF-alpha. We investigate whether TNF blockade with Etanercept during the chronic phase of T. cruzi infection could attenuate experimental CCC development. The effect of Etanercept was evaluated after 11 months of T. cruzi infection on survival, parasitism, left ventricular function, intensity of myocarditis, fibrosis, and left ventricular mRNA expression of cytokines and TNF-alpha-induced genes. Left ventricular function was significantly reduced in treated animals as compared to infected untreated animals. Blood and cardiac parasitism as well as survival rate were not altered with Etanercept treatment. Inflammatory infiltrates were located predominantly in the subendocardic region in treated animals, whereas in untreated animals inflammation was scattered throughout the myocardium. Left ventricular mRNA IL-10 expression was significantly higher, and iNOS, significantly lower in treated than in untreated animals. mRNA expression of TNF-alpha, IFN-gamma, TGF-beta, A20 and ANP was similar in both groups. Our results suggest that TNF-alpha/LT-alpha blockade with Etanercept enhances left ventricular dysfunction in T. cruzi-induced chronic cardiomyopathy and the absence of TNF signaling may be deleterious to the failing heart in Chagas disease cardiomyopathy. (C) 2007 Elsevier Masson SAS. All rights reserved.
C1 Univ Sao Paulo, Inst Heart, Immunol Lab, BR-05403 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Heart, BR-05403 Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Inst Heart, Immunol Lab, Av Dr Eneas De Carvalho Aguiar,44 Bloco 11,9Andar, BR-05403 Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; Ramires, Felix JA/D-5996-2012; da Silva,
   Ana Maria Goncalves/ABD-3920-2020; KALIL, JORGE/C-8029-2012; De Brito,
   Thales/L-2865-2017; FONSECA, SIMONE GONCALVES/U-9278-2019; Fernandes,
   Fabio/D-5994-2012; Salemi, Vera MC/C-9104-2013; Russo,
   Momtchilo/D-8614-2012; Mady, Charles/C-8870-2012; Salemi,
   Vera/AAY-5024-2020
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Ramires, Felix
   JA/0000-0003-2437-2485; KALIL, JORGE/0000-0001-8415-4274; De Brito,
   Thales/0000-0003-1106-7254; Fernandes, Fabio/0000-0002-9323-8805;
   Salemi, Vera MC/0000-0002-7152-1810; Mady, Charles/0000-0002-8838-199X;
   Silva, Ana Maria/0000-0001-7554-0894
CR Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Aliberti JCS, 2001, AM J PATHOL, V158, P1433, DOI 10.1016/S0002-9440(10)64094-1
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   Champion HC, 2003, HEART FAIL REV, V8, P35, DOI 10.1023/A:1022142904202
   Cole MP, 2006, CARDIOVASC RES, V69, P186, DOI 10.1016/j.cardiores.2005.07.012
   Cook SA, 2003, CIRCULATION, V108, P664, DOI 10.1161/01.CIR.0000086978.95976.41
   Cunha-Neto E, 2006, AUTOIMMUNITY, V39, P41, DOI 10.1080/08916930500485002
   Eriksson U, 2001, CIRCULATION, V103, P18
   Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   Gurantz D, 2005, CARDIOVASC RES, V67, P106, DOI 10.1016/j.cardiores.2005.02.016
   Herrero C, 2003, J IMMUNOL, V171, P5034, DOI 10.4049/jimmunol.171.10.5034
   HOGAN MM, 1988, J IMMUNOL, V140, P513
   Kacimi R, 1998, CIRC RES, V82, P576, DOI 10.1161/01.RES.82.5.576
   Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518
   Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627
   Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297
   Li WM, 2002, CHINESE MED J-PEKING, V115, P1166
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MCMURRAY J, 2002, HOT LIN SESS OR PRES
   Mocellin S, 2003, TRENDS IMMUNOL, V24, P36, DOI 10.1016/S1471-4906(02)00009-1
   Moe GW, 2004, AM J PHYSIOL-HEART C, V287, pH1813, DOI 10.1152/ajpheart.00036.2004
   Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001
   Peng TQ, 2003, CARDIOVASC RES, V59, P893, DOI 10.1016/S0008-6363(03)00509-1
   Ramirez L E, 1994, Rev Soc Bras Med Trop, V27, P163, DOI 10.1590/S0037-86821994000300007
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072
   Salemi Vera M C, 2005, Eur J Echocardiogr, V6, P41, DOI 10.1016/j.euje.2004.06.001
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Wu CC, 1999, EUR J PHARMACOL, V373, P41, DOI 10.1016/S0014-2999(99)00265-4
NR 34
TC 29
Z9 30
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUL
PY 2007
VL 9
IS 9
BP 1104
EP 1113
DI 10.1016/j.micinf.2007.05.014
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 216TZ
UT WOS:000249903200009
PM 17644389
DA 2020-11-26
ER

PT J
AU Luna, E
   Postol, E
   Caldas, C
   Benvenuti, LA
   Rodrigues, JM
   Lima, K
   Kalil, J
   Coelho, V
AF Luna, E.
   Postol, E.
   Caldas, C.
   Benvenuti, L. A.
   Rodrigues Junior, J. M.
   Lima, K.
   Kalil, J.
   Coelho, V.
TI Treatment with encapsulated Hsp60 peptide (p277) prolongs skin graft
   survival in a murine model of minor antigen disparity
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HEAT-SHOCK-PROTEIN; BETA-CELL FUNCTION; T-CELLS; HUMAN
   HEAT-SHOCK-PROTEIN-60; DOUBLE-BLIND; NOD MOUSE; SYNOVIAL-FLUID; ORAL
   TOLERANCE; THERAPY; TRANSPLANTATION
AB The increased expression of heat shock protein (Hsp) 60 in different kinds of graft tissues has been associated with a proinflammatory role and rejection. However, there are very few reports in which treatment with Hsp60 delays skin allograft rejection. The aim of this work was to evaluate the capacity of encapsulated human Hsp60-derived peptide p277 to delay graft rejection in two murine models of skin transplantation with minor antigen disparities. Briefly, BALB/c mice and C57BL/6 were intranasally pre-treated with five doses of Hsp60 p277 peptide encapsulated in polylactide-co-glycolide acid microspheres (PLGM) ,and received skin grafts from DBA2 mice and 129/B6 (F1) mice respectively. The treatment with the peptide increased skin graft survival more than 20 days in both the mouse strains, mainly in C57BL/6 recipients (P < 0.05). Also, p277-treated BALB/c and C57BL/6 mice showed IL-10 and IFN-gamma production, induced by p277 peptide. For the first time, a mucosal schedule using the Hsp60 C-terminal peptide p277 encapsulated in PLGM showed some survival prolongation of skin grafts bearing minor antigen disparities. Our results suggest a potential role for Hsp60-based therapy and the mucosal route as a useful tool to control the inflammatory response to allografts.
C1 Univ Sao Paulo, Sch Med, InCor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Internal Med, Sch Med, BR-05508 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   NANOCORE Biotecnol Ltda, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), HC FMUSP, Inst Coracao, Immunol Lab, Av Dr Eneas Carvalho Aguiar 44,9 Andar,BL 2, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Benvenuti,
   Luiz/C-6614-2014
OI KALIL, JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Benichou G, 1997, IMMUNOL TODAY, V18, P67, DOI 10.1016/S0167-5699(97)01004-9
   BILLINGHAM RE, 1954, PROC R SOC SER B-BIO, V143, P43, DOI 10.1098/rspb.1954.0053
   Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159
   Birk OS, 1996, J AUTOIMMUN, V9, P159, DOI 10.1006/jaut.1996.0019
   Caldas C, 2006, CLIN EXP IMMUNOL, V146, P66, DOI 10.1111/j.1365-2249.2006.03195.x
   Caldas C, 2004, TRANSPL P, V36, P833, DOI 10.1016/j.transproceed.2004.04.069
   Chai JG, 2004, BLOOD, V103, P3951, DOI 10.1182/blood-2003-11-3763
   Chen W, 1999, J IMMUNOL, V162, P3212
   CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605
   Cohen IR, 2002, DIABETOLOGIA, V45, P1468, DOI 10.1007/s00125-002-0937-z
   Cohen IR, 2000, SEMIN IMMUNOL, V12, P215, DOI 10.1006/smim.2000.0234
   COHEN IR, 2000, SEMIN IMMUNOL, V12, P257, DOI DOI 10.1006/SMIM.2000.0234
   Cohen-Sfady M, 2005, J IMMUNOL, V175, P3594, DOI 10.4049/jimmunol.175.6.3594
   de Kleer IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/art.11174
   Dettino ALA, 2004, BRAZ J MED BIOL RES, V37, P435, DOI 10.1590/S0100-879X2004000300022
   Durai M, 2004, J IMMUNOL, V172, P2795, DOI 10.4049/jimmunol.172.5.2795
   ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2
   Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758
   ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576
   Fedoseyeva EV, 2002, J IMMUNOL, V169, P1168, DOI 10.4049/jimmunol.169.3.1168
   Feili-Hariri M, 2000, J AUTOIMMUN, V14, P133, DOI 10.1006/jaut.1999.0352
   Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340
   Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200
   GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   Habich C, 2005, J IMMUNOL, V174, P1298, DOI 10.4049/jimmunol.174.3.1298
   Huurman VAL, 2007, DIABETES-METAB RES, V23, P269, DOI 10.1002/dmrr.691
   JONES DB, 1993, IMMUNOL TODAY, V14, P115, DOI 10.1016/0167-5699(93)90210-C
   KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J
   Kumar R, 2004, IEEE ENG MED BIOL, V23, P80, DOI 10.1109/MEMB.2004.1317986
   Lazar L, 2007, DIABETES-METAB RES, V23, P286, DOI 10.1002/dmrr.711
   Lechler RI, 2003, NAT REV IMMUNOL, V3, P147, DOI 10.1038/nri1002
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   Lu X, 2004, TRANSPL P, V36, P2429, DOI 10.1016/j.transproceed.2004.08.033
   Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30
   Marrero I, 2005, IMMUNOLOGY, V115, P484, DOI 10.1111/j.1365-2567.2005.02182.x
   Matsunaga Y, 2000, VACCINE, V19, P579, DOI 10.1016/S0264-410X(00)00120-1
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P598
   MOLITERNO R, 1995, J HEART LUNG TRANSPL, V14, P329
   Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558
   Osterloh A, 2004, J BIOL CHEM, V279, P47906, DOI 10.1074/jbc.M408440200
   Paul AGA, 2000, INT IMMUNOL, V12, P1041, DOI 10.1093/intimm/12.7.1041
   Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270
   Phipps PA, 2003, EUR J IMMUNOL, V33, P224, DOI 10.1002/immu.200390025
   Raz I, 2007, DIABETES-METAB RES, V23, P292, DOI 10.1002/dmrr.712
   Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5
   Samsom JN, 2004, CRIT REV IMMUNOL, V24, P157, DOI 10.1615/CritRevImmunol.v24.i3.10
   Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9
   Song Yifan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P195, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.20
   Stanford M, 2004, CLIN EXP IMMUNOL, V137, P201, DOI 10.1111/j.1365-2249.2004.02520.x
   van Eden W, 2002, ANN RHEUM DIS, V61, P25
   vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553
   Wang H, 2003, J IMMUNOL, V171, P3823, DOI 10.4049/jimmunol.171.7.3823
   Zanin-Zhorov A, 2005, J IMMUNOL, V175, P276, DOI 10.4049/jimmunol.175.1.276
   Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227
   Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje
   Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423
   Zheng XX, 2003, IMMUNOL REV, V196, P75, DOI 10.1046/j.1600-065X.2003.00089.x
NR 60
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUL
PY 2007
VL 66
IS 1
BP 62
EP 70
DI 10.1111/j.1365-3083.2007.01951.x
PG 9
WC Immunology
SC Immunology
GA 182AR
UT WOS:000247478000008
PM 17587347
OA Bronze
DA 2020-11-26
ER

PT J
AU Ensina, L
   Tanno, L
   Oliveira, A
   Kalil, J
   Motta, A
AF Ensina, L.
   Tanno, L.
   Oliveira, A.
   Kalil, J.
   Motta, A.
TI Drug provocation test in nonsteroidal anti-inflammatory hypersensitivity
   reactions - suggestion of a practical approach
SO ALLERGY
LA English
DT Meeting Abstract
CT 26th Congress of the
   European-Academy-of-Allergology-and-Clinical-Immunology
CY JUN 09-13, 2007
CL Goteborg, SWEDEN
SP European Acad Allergology & Clin Immunol
C1 Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0105-4538
J9 ALLERGY
JI Allergy
PD JUN
PY 2007
VL 62
SU 83
BP 522
EP 522
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 172JK
UT WOS:000246800001489
DA 2020-11-26
ER

PT J
AU Tanno, L
   Ensina, L
   Barreto, A
   Kalil, J
   Motta, A
AF Tanno, L.
   Ensina, L.
   Barreto, A.
   Kalil, J.
   Motta, A.
TI Grand mal-type seizure induced by isolated use of diclofenac
SO ALLERGY
LA English
DT Meeting Abstract
CT 26th Congress of the
   European-Academy-of-Allergology-and-Clinical-Immunology
CY JUN 09-13, 2007
CL Goteborg, SWEDEN
SP European Acad Allergology & Clin Immunol
C1 FMUSP, Hosp Clin, Dept Allergy & Clin Immunol, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0105-4538
J9 ALLERGY
JI Allergy
PD JUN
PY 2007
VL 62
SU 83
BP 522
EP 522
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 172JK
UT WOS:000246800001488
DA 2020-11-26
ER

PT J
AU Barreto, A
   Tanno, L
   Ensina, L
   Kalil, J
   Motta, A
AF Barreto, A.
   Tanno, L.
   Ensina, L.
   Kalil, J.
   Motta, A.
TI Cutaneous eruption secondary the use of Teicoplanin: case report
SO ALLERGY
LA English
DT Meeting Abstract
CT 26th Congress of the
   European-Academy-of-Allergology-and-Clinical-Immunology
CY JUN 09-13, 2007
CL Goteborg, SWEDEN
SP European Acad Allergology & Clin Immunol
C1 Univ Sao Paulo, Hosp Clin, Fac Med, Dept Allergy & Clin Immunol, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0105-4538
J9 ALLERGY
JI Allergy
PD JUN
PY 2007
VL 62
SU 83
BP 540
EP 540
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 172JK
UT WOS:000246800001544
DA 2020-11-26
ER

PT J
AU Luna, E
   Postol, E
   Caldas, C
   Mundel, LR
   Porto, G
   Iwai, LK
   Ho, PL
   Kalil, J
   Coelho, V
AF Luna, Ernesto
   Postol, Edilberto
   Caldas, Cristina
   Mundel, Luiz R.
   Porto, Georgia
   Iwai, Leo K.
   Ho, Paulo Lee
   Kalil, Jorge
   Coelho, Veronica
TI Diversity of physiological cell reactivity to heat shock protein 60 in
   different mouse strains
SO CELL STRESS & CHAPERONES
LA English
DT Article
ID HEAT-SHOCK-PROTEIN; JUVENILE IDIOPATHIC ARTHRITIS; CHOLERA-TOXIN-B;
   T-CELLS; ADJUVANT ARTHRITIS; PEPTIDE THERAPY; NOD MOUSE; TERMINAL
   DETERMINANTS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ARTHRITIS
AB Heat shock proteins (Hsp) are families of highly conserved molecules and immunodominant antigens in some infections and in autoimmune diseases. Some reports suggest that different regions of the Hsp60 molecule induce distinct immune responses. However, there are no reports comparing physiological T-cell reactivity to Hsp60 in mice. In this study, we have analyzed T-cell proliferation and cytokine production induced by Hsp60, under physiological conditions, in three mouse strains bearing distinct major histocompatibility complex (MHC) backgrounds. Proliferative response predominantly was found in C57BL/6 mice, mostly induced by N-terminal and intermediate Hsp60 peptides (P < 0.0001). Interferon-gamma (IFN gamma) production was broadly induced by different regions of Hsp60 in all three mouse strains, although response was focused in different peptide groups in each strain. We did not observe an exclusive Th1 or Th2 cytokine profile induced by any particular region of Hsp60. However, we identified a strain hierarchy in IL-10 production induced by Hsp60 peptides from different regions, mostly detected in C3H/HePas, and in BALB/c, but not in C57BL/6 mice. In contrast, IL-4 production only was induced by the intermediate and C-terminal region peptides in both C3H/HePas and BALB/c mice. Our data give original information on physiological cellular reactivity to Hsp60. We also have identified peptides with the capacity to induce the production of anti-inflammatory cytokines, bringing perspectives for their use in immunotherapy of chronic inflammatory diseases and allograft rejection.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Butantan Inst, Ctr Biotechnol, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Inst Coracao, Lab Imunol, Av Dr Eneas de Carvalho Aguiar,44,9 Andar,Block 2, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; Ho, Paulo/P-8267-2015; COELHO,
   VERONICA/D-1433-2013; Iwai, Leo K/M-1734-2013
OI KALIL, JORGE/0000-0001-8415-4274; Ho, Paulo/0000-0003-3652-241X; Iwai,
   Leo K/0000-0002-1571-7763
CR Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x
   Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262
   AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159
   Birk OS, 1996, J AUTOIMMUN, V9, P159, DOI 10.1006/jaut.1996.0019
   Caldas C, 2006, CLIN EXP IMMUNOL, V146, P66, DOI 10.1111/j.1365-2249.2006.03195.x
   Chen W, 1999, J IMMUNOL, V162, P3212
   Cohen IR, 2004, ISRAEL MED ASSOC J, V6, P260
   Cohen IR, 2002, DIABETOLOGIA, V45, P1468, DOI 10.1007/s00125-002-0937-z
   Cohen-Sfady M, 2005, J IMMUNOL, V175, P3594, DOI 10.4049/jimmunol.175.6.3594
   de Kleer IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/art.11174
   Durai M, 2004, J IMMUNOL, V172, P2795, DOI 10.4049/jimmunol.172.5.2795
   ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2
   Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758
   ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576
   Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340
   Gao BC, 2004, BIOCHEM BIOPH RES CO, V317, P1149, DOI 10.1016/j.bbrc.2004.03.160
   GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831
   Habich C, 2005, J IMMUNOL, V174, P1298, DOI 10.4049/jimmunol.174.3.1298
   HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206
   JONES DB, 1993, IMMUNOL TODAY, V14, P115, DOI 10.1016/0167-5699(93)90210-C
   Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4
   KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J
   Kilmartin B, 2004, EUR J IMMUNOL, V34, P2041, DOI 10.1002/eji.200425108
   Lehner T, 2003, ADV EXP MED BIOL, V528, P173
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P598
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558
   Paul AGA, 2000, INT IMMUNOL, V12, P1041, DOI 10.1093/intimm/12.7.1041
   Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270
   Pockley AG, 2005, CONTRIB NEPHROL, V148, P122, DOI 10.1159/000086057
   Prohaszka Z, 2004, MOL IMMUNOL, V41, P29, DOI 10.1016/j.molimm.2004.02.001
   Quintana FJ, 2003, J IMMUNOL, V171, P3533, DOI 10.4049/jimmunol.171.7.3533
   Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5
   Stanford M, 2004, CLIN EXP IMMUNOL, V137, P201, DOI 10.1111/j.1365-2249.2004.02520.x
   van Eden W, 2005, INT REV IMMUNOL, V24, P181, DOI 10.1080/08830180590934958
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   van Eden W, 2006, HUM IMMUNOL, V67, P446, DOI 10.1016/j.humimm.2006.03.010
   VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0
   vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553
   Wellings DA, 1997, METHOD ENZYMOL, V289, P44
   Yung GLP, 2003, INFLAMM RES, V52, P443, DOI 10.1007/s00011-003-1204-6
   Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227
   Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje
NR 47
TC 5
Z9 6
U1 0
U2 4
PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA
SN 1355-8145
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD SUM
PY 2007
VL 12
IS 2
BP 112
EP 122
DI 10.1379/CSC-209R.1
PG 11
WC Cell Biology
SC Cell Biology
GA 189JG
UT WOS:000247984600003
PM 17688190
OA Green Published
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Oliveira, E
   Kalil, J
AF Giavina-Bianchi, Pedro
   Oliveira, Edilamara
   Kalil, Jorge
TI Specific IgE against recombinant allergens in allergic bronchopulmonary
   aspergillosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
ID CYSTIC-FIBROSIS PATIENTS
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Almeida Marina B., 2006, J. Pediatr. (Rio J.), V82, P215, DOI [10.2223/JPED.1479, 10.1590/S0021-75572006000300011]
   Greenberger Paul A., 1997, P555
   Knutsen AP, 2004, ALLERGY, V59, P198, DOI 10.1046/j.1398-9995.2003.00310.x
   Kraemer R, 2006, AM J RESP CRIT CARE, V174, P1211, DOI 10.1164/rccm.200603-423OC
   Nikolaizik WH, 2002, AM J RESP CRIT CARE, V165, P916, DOI 10.1164/ajrccm.165.7.2109008
   Sarma UP, 2003, FRONT BIOSCI-LANDMRK, V8, pS1187, DOI 10.2741/991
NR 6
TC 1
Z9 1
U1 0
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 1
PY 2007
VL 175
IS 9
BP 967
EP 967
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 164JH
UT WOS:000246229500017
PM 17446345
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Oliveira, CH
   Tribess, A
   Landgraf, RG
   Jancar, S
   Kalil, J
AF Graudenz, Gustavo Silveira
   Oliveira, Celso Henrique
   Tribess, Arlindo
   Landgraf, Richardt G.
   Jancar, Sonia
   Kalil, Jorge
TI Sudden temperature changes and respiratory symptoms - An experimental
   approach
SO AMERICAN JOURNAL OF RHINOLOGY
LA English
DT Article
DE air-conditioning; allergy; atmosphere exposure chamber; environmental
   exposure; occupational health; rhinitis
ID OFFICE BUILDINGS; AIR; PREVALENCE; WORKERS; HEALTH; COLD
AB Background: Exposure to air-conditioning systems and allergic phenotypes are consistent risk factors to develop indoor air quality (IAQ) respiratory complaints. The aim of this study was to compare the role of allergic rhinitis on respiratory complaints in individuals exposed to sudden temperature changes.
   Methods: To address this question, a case-control challenge study was performed in a laboratory of thermal comfort evaluation with twin isolated chambers set at 14 degrees C/57.2 degrees F (cold) and 26 degrees C/78.8 degrees F (hot) temperatures. A groups of 32 patients with persistent allergic rhinitis (rhinitis group) and 16 control subjects (control group) were exposed for 30 minutes, three times alternately in the chambers. Symptoms were reported using an analog visual scale and nasal and pulmonary peak flow measurements were taken during baseline at hot and cold temperatures and after the challenge.
   Results: The rhinitis group reported increased itching and stinging eyes when compared with the baseline during exposure to hot and cold temperatures and they also reported increased breathlessness during hot air exposure. In addition, there was a significant decrease in expiratory flow rates in this group during exposure to hot and cold temperatures that persisted for 24 hours after challenge.
   Conclusion: This study suggests that individuals with allergic rhinitis have a lower threshold than controls to develop respiratory and ocular symptoms after air-conditioning-induced sudden temperature changes.
C1 Univ Sao Paulo, Millemium Inst, Sch Med, Dept Internal Med,Div Allergy & Clin Immunol, BR-05508 Sao Paulo, Brazil.
   Univ San Francisco, Sch Med, Dept Internal Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Polytech Sch, Dept Mech Engn, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508 Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Rua Girassol 1317-21, BR-05433002 Sao Paulo, Brazil.
EM gustavog@usp.br
RI Jancar, Sonia/C-5153-2012; KALIL, JORGE/C-8029-2012; Landgraf, Richardt
   Gama/AAF-3568-2020
OI Jancar, Sonia/0000-0001-7983-3459; KALIL, JORGE/0000-0001-8415-4274;
   Landgraf, Richardt Gama/0000-0001-7774-7880; Tribess,
   Arlindo/0000-0001-9908-9233
CR Bavbek S, 2003, J INVEST ALLERG CLIN, V13, P252
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250
   Graudenz GS, 2005, INDOOR AIR, V15, P62, DOI 10.1111/j.1600-0668.2004.00324.x
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   Kildeso J, 1999, SCAND J WORK ENV HEA, V25, P361, DOI 10.5271/sjweh.446
   LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012
   LIGHT IM, 1980, AVIAT SPACE ENVIR MD, V51, P1100
   Lindgren T, 2005, INDOOR AIR, V15, P65, DOI 10.1111/j.1600-0668.2005.00353.x
   Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   Mendell MJ, 2003, AM J IND MED, V43, P630, DOI 10.1002/ajim.10211
   MENDES E, 1989, ALERGIA BRASIL, V67, P86
   Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629
   Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107
   Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397
   MORTIMER MJ, 1993, HEADACHE, V33, P427, DOI 10.1111/j.1526-4610.1993.hed3308427.x
   Rouadi P, 1999, J APPL PHYSIOL, V87, P400
   Schneider T, 1999, SCAND J WORK ENV HEA, V25, P574, DOI 10.5271/sjweh.483
   TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113
NR 21
TC 4
Z9 4
U1 1
U2 8
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1050-6586
J9 AM J RHINOL
JI Am. J. Rhinol.
PD MAY-JUN
PY 2007
VL 21
IS 3
BP 383
EP 387
DI 10.2500/ajr.2007.21.3023
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 175PR
UT WOS:000247026000024
PM 17621828
DA 2020-11-26
ER

PT J
AU Souza, PS
   Panajotopoulos, N
   Agena, F
   Ronda, C
   Rodrigues, H
   Viggiani, CS
   David, DSR
   Kalil, J
   Ianhez, LE
   David-Neto, E
   Castro, MCR
AF Souza, Patricia S.
   Panajotopoulos, Nicolas
   Agena, Fabiana
   Ronda, Carla
   Rodrigues, Helcio
   Viggiani, Carlos S.
   David, Daisa S. R.
   Kalil, Jorge
   Ianhez, Luiz E.
   David-Neto, Elias
   Castro, Maria Cristina R.
TI Monitoring of anti-HLA antibodies after kidney transplantation - A
   prognostic factor for rejection severity an graft loss.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT Annual American Transplant Congress
CY MAY 05-09, 2007
CL San Francisco, CA
C1 Univ Sao Paulo, Kidney Transplant Unit, Sao Paulo, Brazil.
   Heart Inst, Immunol Lab, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; de castro, maria cristina ribeiro/B-6648-2009;
   Agena, Fabiana/C-5819-2015; Agena, Fabiana/F-5807-2012; David,
   Daisa/G-6272-2012; Neto, Elias David/O-3866-2018; David-Neto,
   Elias/C-9112-2012
OI KALIL, JORGE/0000-0001-8415-4274; de castro, maria cristina
   ribeiro/0000-0002-6731-8369; Agena, Fabiana/0000-0002-4526-4857; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2007
VL 7
SU 2
MA 542
BP 288
EP 288
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 166HQ
UT WOS:000246370200542
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Giavina-Bianchi, M
   Agondi, R
   Kalil, J
AF Giavina-Bianchi, Pedro
   Giavina-Bianchi, Mara
   Agondi, Rosana
   Kalil, Jorge
TI Three months' administration of anti-IgE to a patient with Churg-Strauss
   syndrome
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID ALLERGIC-ASTHMA; OMALIZUMAB
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
CR Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC
   Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x
   Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518
   Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434
   Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028
   Winchester DE, 2006, NEW ENGL J MED, V355, P1281
NR 6
TC 21
Z9 21
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAY
PY 2007
VL 119
IS 5
BP 1279
EP 1279
DI 10.1016/j.jaci.2007.01.041
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 167CB
UT WOS:000246427200038
PM 17349685
DA 2020-11-26
ER

PT J
AU Iwai, LK
   Yoshida, M
   Sadahiro, A
   da Silva, WR
   Marin, ML
   Goldberg, AC
   Juliano, MA
   Juliano, L
   Shikanai-Yasuda, MA
   Kalil, J
   Cunha-Neto, E
   Travassos, LR
AF Iwai, Leo Kei
   Yoshida, Marcia
   Sadahiro, Aya
   da Silva, Washington Robert
   Marin, Maria Lucia
   Goldberg, Anna Carla
   Juliano, Maria Aparecida
   Juliano, Luiz
   Shikanai-Yasuda, Maria Aparecida
   Kalil, Jorge
   Cunha-Neto, Edecio
   Travassos, Luiz R.
TI T-cell recognition of Paracoccidioides brasiliensis gp43-derived
   peptides in patients with paracoccidioidomycosis and healthy individuals
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID MAJOR DIAGNOSTIC ANTIGEN; 43-KILODALTON GLYCOPROTEIN; GP43; EPITOPES;
   IDENTIFICATION; RESPONSES; BINDING; SERA; MICE
AB Vaccines with synthetic peptides induce the immune response to epitopes that bind to several RLA alleles. By using a TEPITOPE algorithm, we selected and analyzed the T-cell responses of peripheral blood mononuclear cells from 29 paracoccidioidomycosis (PCM) patients to peptides of the immunodominant gp43 antigen of Paracoccidioides brasiliensis, the causative agent of PCM.
C1 Univ Fed Sao Paulo, Disciplina Biol Celular, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil.
   Millennium Inst, Immunol Lab, Inst Heart, INCOR, Sao Paulo, Brazil.
   Millennium Inst, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Infect & Parasit Dis, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biophys, BR-04023062 Sao Paulo, Brazil.
RP Travassos, LR (corresponding author), Univ Fed Sao Paulo, Disciplina Biol Celular, Dept Microbiol Imunol & Parasitol, Rua Botucatu 862,8 Andar, BR-04023062 Sao Paulo, Brazil.
EM travassos@ecb.epm.br
RI Travassos, Luiz/V-2467-2019; Iwai, Leo K/M-1734-2013; Juliano,
   Luiz/D-7204-2012; Shikanai-Yasuda, Maria A/C-4268-2012; Travassos, Luiz
   R/J-3631-2012; Yasuda, Maria Aparecida Shikanai/AAX-7693-2020; KALIL,
   JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Cunha-Neto,
   Edecio/B-4157-2009; ShikanaiYasuda, Maria A/A-9000-2013
OI Iwai, Leo K/0000-0002-1571-7763; Juliano, Luiz/0000-0002-5589-2822;
   Yasuda, Maria Aparecida Shikanai/0000-0003-3864-041X; KALIL,
   JORGE/0000-0001-8415-4274; Goldberg, Anna Carla/0000-0003-2600-7940;
   Cunha-Neto, Edecio/0000-0002-3699-3345; ShikanaiYasuda, Maria
   A/0000-0003-3864-041X
CR Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   BRUMMER E, 1993, CLIN MICROBIOL REV, V6, P89, DOI 10.1128/CMR.6.2.89-117.1993
   Cisalpino PS, 1996, J BIOL CHEM, V271, P4553, DOI 10.1074/jbc.271.8.4553
   da Silva SHM, 2003, J CLIN MICROBIOL, V41, P3675, DOI 10.1128/JCM.41.8.3675-3680.2003
   DECAMARGO ZP, 1988, J CLIN MICROBIOL, V26, P2147, DOI 10.1128/JCM.26.10.2147-2151.1988
   Dias MFRG, 2000, J EUR ACAD DERMATOL, V14, P166
   GOLDBERG AC, 1997, HLA 1997, P330
   Hanna SA, 2000, MICROBES INFECT, V2, P877, DOI 10.1016/S1286-4579(00)00390-7
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200
   Marques AF, 2006, ANTIMICROB AGENTS CH, V50, P2814, DOI 10.1128/AAC.00220-06
   McEwen J G, 1995, Arch Med Res, V26, P305
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   MENDESGIANNINI MJS, 1989, J CLIN MICROBIOL, V27, P2842, DOI 10.1128/JCM.27.12.2842-2845.1989
   PUCCIA R, 1986, INFECT IMMUN, V53, P199, DOI 10.1128/IAI.53.1.199-206.1986
   PUCCIA R, 1991, J CLIN MICROBIOL, V29, P1610, DOI 10.1128/JCM.29.8.1610-1615.1991
   Restrepo A, 2001, MED MYCOL, V39, P233, DOI 10.1080/714031028
   SHIKANAIYASUDA MA, 1996, OXFORD TXB MED, P814
   TABORDA CP, 1993, J MED VET MYCOL, V31, P155
   Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998
   Travassos LR, 2004, MYCOTA, V12, P279
   VICENTINI AP, 1994, INFECT IMMUN, V62, P1465, DOI 10.1128/IAI.62.4.1465-1469.1994
NR 24
TC 16
Z9 16
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD APR
PY 2007
VL 14
IS 4
BP 474
EP 476
DI 10.1128/CVI.00458-06
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 159KC
UT WOS:000245863500020
PM 17329443
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Le Pape, P
   Fellous, A
   Valentin, A
   Andrade, S
   Kalil, J
   Veauvy, M
   Le Borgne, M
AF Le Pape, P.
   Fellous, A.
   Valentin, A.
   Andrade, S.
   Kalil, J.
   Veauvy, M.
   Le Borgne, M.
TI New antiprotozoal drugs refered as antimicrotubular
   haloacetamidobenzoates
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Meeting Abstract
CT 17th European Congress of Clinical Microbiology and Infectious
   Diseases/25th International Congress of Chemotherapy
CY MAR 31-APR 03, 2007
CL Munich, GERMANY
RI Le Borgne, Marc/H-1036-2014; Le Pape, Patrice/W-1472-2019
OI Le Borgne, Marc/0000-0003-1398-075X; Le Pape,
   Patrice/0000-0001-5059-6402
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAR
PY 2007
VL 29
SU 2
MA P1678
BP S475
EP S475
DI 10.1016/S0924-8579(07)71517-0
PG 1
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 270AP
UT WOS:000253692401738
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Fae, KC
   Spina, G
   Victora, GD
   Tanaka, AC
   Palacios, SA
   Hounie, AG
   Miguel, EC
   Oshiro, SE
   Goldberg, AC
   Kalil, J
   Guilherme, L
AF Ramasawmy, Rajendranath
   Fae, Kellen C.
   Spina, Guilherme
   Victora, Gabriel D.
   Tanaka, Ana Cristina
   Palacios, Selma A.
   Hounie, Ana G.
   Miguel, Euripides C.
   Oshiro, Sandra E.
   Goldberg, Anna C.
   Kalil, Jorge
   Guilherme, Luiza
TI Association of polymorphisms within the promoter region of the tumor
   necrosis factor-alpha with clinical outcomes of rheumatic fever
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE TNF-alpha; rheumatic fever; rheumatic heart disease; valve lesion; group
   A streptococci (GAS); polymorphism
ID CHRONIC HEART-FAILURE; TNF-ALPHA; LYMPHOTOXIN-ALPHA; PROINFLAMMATORY
   CYTOKINES; FUNCTIONAL-ANALYSIS; MULTIPLE-SCLEROSIS; MONONUCLEAR-CELLS;
   GENE PROMOTER; HLA-DR; DISEASE
AB Rheumatic fever (RF)/rheumatic heart disease (RHD) is an inflammatory disease with a complex etiology in which Group A streptococci within a genetically susceptible host untreated for strep-throat may deviate the innate and adaptive arms of the immune system towards recognition of autoantigens. The TNFA gene has been associated with a number of autoimmune diseases, including RE We investigated whether the G-308A and G-238A polymorphisms of the TNFA gene are associated with clinical outcomes of RF in a cohort of 318 patients and 281 healthy controls (HQ. Both polymorphisms showed borderline associations with RF (TNFA -308G/A, OR = 1.4 [1 -2.2], P = 0.026; TNFA -238G/A, OR = 1.9 [1-3.3], P = 0.015). The presence of either one of the minor alleles (-308A and -238A) was more common among patients with RF/RHD than controls (P = 0.0006). Stratification of patients according to clinical phenotype also showed significant associations between presence of either one of the minor alleles and RHD (Pc = 0.0006) when compared with controls. This association was stronger with the development of aortic valve lesions. In contrast, there was no association between genotype and Sydenham's chorea or RF patients with mild carditis. In conclusion, we show that the TNFA is a susceptibility locus for RF. The ability to predict which RF patients will develop valve lesion may have therapeutic, economic and social implications. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Chem, Sao Paulo, Brazil.
RP Ramasawmy, R (corresponding author), FMUSP, HC, Lab Imunol, InCor, Av Dr Eneas Carvalho Aguiar 44,90 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM ramasawm@usp.br
RI Goldberg, Anna Carla/H-8594-2014; Guglielmi, Luiza G/E-7676-2013;
   Ramasawmy, Rajendranath/V-4926-2019; Spina, Guilherme S./I-3530-2013;
   Miguel, Euripedes C/B-2871-2008; KALIL, JORGE/C-8029-2012; Victora,
   Gabriel/C-5946-2011
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Victora, Gabriel/0000-0001-8807-348X
CR ABRAHAM LJ, 1993, CLIN EXP IMMUNOL, V92, P14
   Allcock RJN, 1999, HUM IMMUNOL, V60, P1266, DOI 10.1016/S0198-8859(99)00127-5
   Bayley JP, 2001, CYTOKINE, V14, P316, DOI 10.1006/cyto.2001.0902
   Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607
   BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625
   Bouma G, 1996, SCAND J IMMUNOL, V43, P456, DOI 10.1046/j.1365-3083.1996.d01-65.x
   Brinkman B M, 1995, J Inflamm, V46, P32
   DISCIASCIO G, 1980, AM HEART J, V99, P635, DOI 10.1016/0002-8703(80)90739-5
   DROUET C, 1991, J IMMUNOL, V147, P1694
   FEINSTEIN AR, 1993, MEDICINE, V72, P272, DOI 10.1097/00005792-199307000-00006
   Field M, 2001, QJM-INT J MED, V94, P237, DOI 10.1093/qjmed/94.5.237
   FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guillard C, 2005, INT J PHOTOENERGY, V7, P1, DOI 10.1155/S1110662X05000012
   Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8
   Haddy N, 2005, EUR J HUM GENET, V13, P109, DOI 10.1038/sj.ejhg.5201294
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233
   Jawaheer D, 2002, AM J HUM GENET, V71, P585, DOI 10.1086/342407
   Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405
   Lie BA, 1999, AM J HUM GENET, V64, P793, DOI 10.1086/302283
   MANN DL, 1994, CHEST, V105, P897, DOI 10.1378/chest.105.3.897
   MATSUMORI A, 1994, BRIT HEART J, V72, P561
   MCMURRAY J, 1991, BRIT HEART J, V66, P356
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   Mycko M, 1998, J NEUROIMMUNOL, V84, P198, DOI 10.1016/S0165-5728(97)00255-5
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   Newton J, 2003, ARTHRITIS RHEUM, V48, P90, DOI 10.1002/art.10719
   Pickles W., 1943, LANCET, V2, P241
   POCIOT F, 1993, EUR J IMMUNOL, V23, P224, DOI 10.1002/eji.1830230135
   POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   SAMSONOV MY, 1995, CLIN IMMUNOL IMMUNOP, V74, P31, DOI 10.1006/clin.1995.1005
   Simmonds MJ, 2004, GENES IMMUN, V5, P267, DOI 10.1038/sj.gene.6364066
   Uglialoro AM, 1998, TISSUE ANTIGENS, V52, P359, DOI 10.1111/j.1399-0039.1998.tb03056.x
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Yegin O, 1997, EUR J PEDIATR, V156, P25
NR 41
TC 48
Z9 54
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAR
PY 2007
VL 44
IS 8
BP 1873
EP 1878
DI 10.1016/j.molimm.2006.10.001
PG 6
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 138GQ
UT WOS:000244351500007
PM 17079017
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Fae, KC
   Oshiro, SE
   Tanaka, AC
   Pomerantzeff, PMA
   Kalil, J
AF Guilherme, Luiza
   Fae, Kellen C.
   Oshiro, Sandra E.
   Tanaka, Ana C.
   Pomerantzeff, Pablo M. A.
   Kalil, Jorge
TI T cell response in rheumatic fever: Crossreactivity between
   streptococcal M protein peptides and heart tissue proteins
SO CURRENT PROTEIN & PEPTIDE SCIENCE
LA English
DT Review
DE rheumatic fever; rheumatic heart disease; Streptococcus pyogenes; T cell
   response; autoimmunity; molecular mimicry; M protein; heart proteins
ID COILED-COIL STRUCTURE; CLASS-II ANTIGENS; MEXICAN PATIENTS;
   IMMUNE-RESPONSE; HLA ANTIGENS; DISEASE; LYMPHOCYTES; EPITOPES; MYOSIN;
   POLYMORPHISMS
AB Molecular mimicry between streptococcal and human proteins has been proposed as the triggering factor leading to autoimmunity in rheumatic fever (RF) and rheumatic heart disease (RHD). In this review we focus on the studies on genetic susceptibility markers involved in the development of RF/RHD and molecular mimicry mediated by T cell responses of RHD patients against streptococcal antigens and human tissue proteins. We identified several M protein epitopes recognized by peripheral T cells of RF/RHD patients and by heart tissue infiltrating T cell clones of severe RHD patients. The regions of the M protein preferentially recognized by human T cells were also recognized by murine T cells. By analyzing the T cell receptor (TCR) we observed that some V beta families detected on the periphery were oligoclonal expanded in the heart lesions. These results allowed us to confirm the major role of T cells in the development of RHD lesions.
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Millennium Inst,Inst Immunol Invest, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), FMUSP, HC, Inst Coraclo, Lab Imunol, Av Dr Eneas de Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Pomerantzeff,
   Pablo M A/L-5525-2016
OI KALIL, JORGE/0000-0001-8415-4274; Pomerantzeff, Pablo M
   A/0000-0003-0566-1038
CR Alves Meira ZM, 1995, ARQ BRAS CARDIOL, V65, P331
   ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1984, CIRCULATION, V69, P197, DOI 10.1161/01.CIR.69.1.197
   BAIRD RW, 1991, J IMMUNOL, V146, P3132
   Berdeli A, 2005, J MOL MED, V83, P535, DOI 10.1007/s00109-005-0677-x
   Berdeli A, 2004, CLIN BIOCHEM, V37, P925, DOI 10.1016/j.clinbiochem.2004.06.007
   Bhat MS, 1997, INDIAN J MED RES, V105, P271
   CALVETI PA, 1945, P SOC EXP BIOL MED, V60, P706
   Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2
   Carapetis JR, 2004, WHOFCHCAH0507, P1
   Cheadle WB, 1889, LANCET, V1, P821
   Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032
   CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   Dale J B, 1982, Trans Assoc Am Physicians, V95, P286
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   DALE JB, 1987, J EXP MED, V166, P1825, DOI 10.1084/jem.166.6.1825
   ElDemellawy M, 1997, INFECT IMMUN, V65, P2197, DOI 10.1128/IAI.65.6.2197-2205.1997
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   GOLDSTEI.I, 1967, NATURE, V213, P44, DOI 10.1038/213044a0
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2004, INT ARCH ALLERGY IMM, V134, P56, DOI 10.1159/000077915
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Hernandez-Pacheco G, 2003, INT J CARDIOL, V92, P49, DOI 10.1016/S0167-5273(03)00040-8
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Hutto JH, 1980, STREPTOCOCCAL DISEAS, P733
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301
   KAPLAN MH, 1963, J IMMUNOL, V90, P595
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   READ SE, 1986, J CLIN IMMUNOL, V6, P433, DOI 10.1007/BF00915249
   READ SE, 1974, J CLIN INVEST, V54, P439, DOI 10.1172/JCI107780
   Reddy K S, 1990, Indian J Pediatr, V57, P693, DOI 10.1007/BF02728716
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   TANEJA V, 1989, CIRCULATION, V80, P335, DOI 10.1161/01.CIR.80.2.335
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
NR 58
TC 12
Z9 12
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2037
EI 1875-5550
J9 CURR PROTEIN PEPT SC
JI Curr. Protein Pept. Sci.
PD FEB
PY 2007
VL 8
IS 1
BP 39
EP 44
DI 10.2174/138920307779941488
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 128CE
UT WOS:000243632700005
PM 17305559
DA 2020-11-26
ER

PT J
AU Drigo, SA
   Cunha-Neto, E
   Ianni, B
   Mady, C
   Fae, KC
   Buck, P
   Kalil, J
   Goldberg, AC
AF Drigo, Sandra A.
   Cunha-Neto, Edecio
   Ianni, Barbara
   Mady, Charles
   Fae, Kellen C.
   Buck, Paula
   Kalil, Jorge
   Goldberg, Anna Carla
TI Lack of association of tumor necrosis factor-alpha polymorphisms with
   Chagas disease in Brazilian patients
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Chagas disease; tumor necrosis factor-alpha; TNF polymorphism;
   cardiomyopathy
ID FACTOR TNF; CARDIOMYOPATHY PATIENTS; HEART; GENE; BETA; ALLELES; CELLS
AB One third of Trypanosoma cruzi-infected individuals develop chronic Chagas disease cardiomyopathy (CCC) while the majority remains asymptomatic (ASY). About 30% of CCC patients develop heart failure due to end-stage inflammatory dilated cardiomyopathy. Increased production of tumor necrosis factor (TNF)-alpha has been described in all clinical forms of Chagas disease, and the highest levels are detected in CCC patients with severe ventricular dysfunction. Genetic susceptibility may play a role in the clinical outcome of Chagas disease. We investigated TNF as a candidate gene for susceptibility to development and/or progression of CCC. We analyzed the TNFa microsatellite and the -308 TNF promoter polymorphisms, in 166 CCC compared to 80 ASY geographically and age-matched patients in an association study. To analyze the association of TNF polymorphisms with progression of the cardiomyopathy, CCC patients were also grouped in three categories according to degree of left ventricular (LV) dysfunction into severe (n = 57), mild to moderate (n = 2 1) and absent (n = 88). Our results show no significant differences either between CCC and ASY patients, or among CCC patients according to severity of cardiomyopathy with respect to TNFa or -308 TNF promoter polymorphisms. These results indicate that TNF polymorphisms are associated neither to CCC development nor to progression to more severe forms of cardiomyopathy in Brazilian Chagas disease patients. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, BR-05403001 Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol 3, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, BR-05403001 Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Inst Chem, Dept Biochem, Av Prof Lineu Prestes 748,B8S,Sala 861, BR-05508900 Sao Paulo, Brazil.
EM goldberg@usp.br
RI Drigo, Sandra A/I-6514-2012; KALIL, JORGE/C-8029-2012; LINDE,
   SANDRA/S-3128-2019; Buck, Paula C/F-8781-2012; Ianni, Barbara
   Maria/C-7689-2012; Cunha-Neto, Edecio/B-4157-2009; Mady,
   Charles/C-8870-2012; Goldberg, Anna Carla/H-8594-2014
OI Drigo, Sandra A/0000-0001-6747-6642; KALIL, JORGE/0000-0001-8415-4274;
   LINDE, SANDRA/0000-0001-6747-6642; Buck, Paula C/0000-0002-1411-4485;
   Ianni, Barbara Maria/0000-0002-1588-5492; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Mady, Charles/0000-0002-8838-199X; Goldberg,
   Anna Carla/0000-0003-2600-7940
CR Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Drigo SA, 2006, MICROBES INFECT, V8, P598, DOI 10.1016/j.micinf.2005.08.009
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B
   NEDOSPASOV SA, 1991, J IMMUNOL, V147, P1053
   POCIOT F, 1993, EUR J IMMUNOL, V23, P224, DOI 10.1002/eji.1830230135
   Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2
   Ramasawmy R, 2006, J INFECT DIS, V193, P1394, DOI 10.1086/503368
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 15
TC 27
Z9 28
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD JAN 15
PY 2007
VL 108
IS 1
BP 109
EP 111
DI 10.1016/j.imlet.2006.10.008
PG 3
WC Immunology
SC Immunology
GA 134CY
UT WOS:000244061400014
PM 17141882
DA 2020-11-26
ER

PT B
AU Menezes, E
   Oliveira, J
   Magalhaes, A
   Ramasawmy, R
   Castellucci, L
   Jamielsen, S
   Blackwell, JM
   Almeida, R
   Lessa, M
   Kalil, J
   Carvalho, EM
   de Jesus, AR
AF Menezes, E.
   Oliveira, J.
   Magalhaes, A.
   Ramasawmy, R.
   Castellucci, L.
   Jamielsen, S.
   Blackwell, J. M.
   Almeida, R.
   Lessa, M.
   Kalil, J.
   Carvalho, E. M.
   de Jesus, A. Ribeiro
BE Kalil, J
   CunhaNeto, E
   Rizzo, LV
TI Association between polymorphisms in genes that influences the immune
   response with cutaneous and mucosal leishmaniasis
SO 13TH INTERNATIONAL CONGRESS OF IMMUNOLOGY
LA English
DT Proceedings Paper
CT 13th International Congress of Immunology
CY AUG 21-25, 2007
CL Rio de Janeiro, BRAZIL
ID MUCOCUTANEOUS LEISHMANIASIS; PROMOTER POLYMORPHISM;
   RHEUMATOID-ARTHRITIS; CHAGASI INFECTION; SUSCEPTIBILITY; BRAZIL; IL-6;
   RESISTANCE; LEPROSY; REGION
AB We examined the association of candidate genes (IL-6, Lymphotoxin-a, and MCP-1) with leishmaniasis outcome using a case-control design and family-based association test (FBAT). The C allele of the IL-6 -174 G/C was more common in mucosal leishmaniasis (NIL) as compared to cutaneous leishmaniasis (CL) cases, leishmanin skin-test positive or neighbourhood controls (NC). FBAT analysis confirmed association between allele C and ML under both additive and dominant models. Lower IL-6 was measured in un-stimulated macrophages from CC compared to GG individuals, and after stimulation with soluble leishmania antigen. Higher frequency of allele G of MCP1-2518 A/G was found in NIL as compared to NC. The FBAT confirmed the association of G allele of MCP-1 with NIL under recessive model. This studies demonstrated associations of polymorphisms in genes that induce high inflammatory response with NIL, suggesting that they might influence leishmaniasis clinical outcome.
C1 [Menezes, E.; Oliveira, J.; Magalhaes, A.; Castellucci, L.; Almeida, R.; Lessa, M.; Carvalho, E. M.; de Jesus, A. Ribeiro] Univ Fed Bahia, Serv Imunol, Salvador, BA, Brazil.
   [Ramasawmy, R.; Kalil, J.] Univ Sao Paulo, InCor, Lab Imunol, Sao Paulo, Brazil.
   [Ramasawmy, R.; Kalil, J.; Carvalho, E. M.; de Jesus, A. Ribeiro] III, Sao Paulo, Brazil.
   [Jamielsen, S.; Blackwell, J. M.] Univ Cambridge, Sch Clin Med, Cambridge, England.
RP Menezes, E (corresponding author), Univ Fed Bahia, Serv Imunol, Salvador, BA, Brazil.
RI Ramasawmy, Rajendranath/V-4926-2019; almeida, roque/F-5609-2012; KALIL,
   JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NIH-TMRCUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI-30639, AI-48822]; FAPESB;
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [1D43TW007127-01-NIH]
FX We thank Ednaldo Lima do Lago and other people from the Health Post of
   Corte de Pedra for helping patients recruitment. We thank Paulo Machado
   and Albert Schriefer that helped diagnosing the patients. We thank Elbe
   M. Silva and Lucia Reis for secretarial assistance. Financial Support:
   NIH-TMRC AI-30639 and AI-48822, FAPESB, CNPq, TGrant1D43TW007127-01-NIH.
CR Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Blackwell JM, 1999, PARASITOL TODAY, V15, P73, DOI 10.1016/S0169-4758(98)01355-6
   Blackwell JM, 1998, INT J PARASITOL, V28, P21, DOI 10.1016/S0020-7519(97)00175-6
   BLACKWELL JM, 1997, STUDY PHILOS T R S B, V352, P1331
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2005, SCAND J IMMUNOL, V61, P337, DOI 10.1111/j.1365-3083.2005.01581.x
   Castellucci LA, 2005, AM J TROP MED HYG, V73, P69, DOI 10.4269/ajtmh.2005.73.69
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   FLORESVILLANUEV.PO, 2005, JEXP MED, V202, P1
   Hajeer AH, 1998, SCAND J RHEUMATOL, V27, P142
   Jeronimo SMB, 2000, CLIN INFECT DIS, V30, P608, DOI 10.1086/313697
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Pawlik A, 2005, SCAND J RHEUMATOL, V34, P109, DOI 10.1080/03009740510026373
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282
   Sambrook J., 1989, MOL CLONING LAB MANU, V2
   Sawczenko A, 2005, P NATL ACAD SCI USA, V102, P13260, DOI 10.1073/pnas.0503589102
   TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788
   Testa R, 2006, DIABETES RES CLIN PR, V71, P299, DOI 10.1016/j.diabres.2005.07.007
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
NR 23
TC 0
Z9 0
U1 0
U2 3
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 978-88-7587-379-0
PY 2007
BP 423
EP +
PG 3
WC Immunology
SC Immunology
GA BGZ88
UT WOS:000251729100076
DA 2020-11-26
ER

PT S
AU Guilherme, L
   Kalil, J
AF Guilherme, L.
   Kalil, J.
BE Shoenfeld, Y
   Gershwin, ME
TI Rheumatic fever - From innate to acquired immune response
SO AUTOIMMUNITY, PT C: THE MOSAIC OF AUTOIMMUNITY
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 5th International Congress on Autoimmunity
CY NOV 29-DEC 03, 2006
CL Sorrento, ITALY
DE autoimmune disease; rheumatic fever; molecular mimicry; T lymphocytes;
   genetic polymorphism; cytokines
ID T-CELL-CLONES; CLASS-II ANTIGENS; HEART-DISEASE; ASSOCIATION;
   POLYMORPHISM; RECOGNITION; LYMPHOCYTES; CARDITIS; MIMICRY; VALVES
AB Rheumatic fever (R-F) is triggered by S. pyogenes and affects 3-4% of untreated susceptible children. The immune response against streptococcal antigens can lead cross-recognition of heart tissue proteins resulting in rheumatic heart disease (RHD). HLA class II alleles have been associated with the development of RF/RHD. Tumor necrosis factor (TNF)-alpha is also located in the same chromosomal region of HLA genes and has been investigated in RHD patients from Mexico, Turkey, and Brazil. Associations with the TNFA-308 allele were found and probably are related to the development of valvular lesions. A deficient mannose-binding lectin (MBL) allele was found in Brazilian patients. MBL is a protein important for the first line of host defense against the bacteria. The association with diverse genes probably indicates a role of certain molecules in both the innate and adaptive immune response. Antigen-presenting cells bearing the HLA-DR7 molecule from RHD patients preferentially recognized a heart-tissue protein cross-reactive M5 (81-96) peptide. The same peptide was also recognized by heart tissue T cell clones. Cardiac myosin peptides were recognized by high numbers of intralesional T cell clones. The cytokine pattern of infiltrating mononuclear cells in both myocardium and valvular tissue showed a predominance of proinflammatory cytokines (TNF-alpha and IFN-gamma) and scarce production of regulatory cytokines, such as IL-4, in the valve tissue. IL-10, a predominant regulatory cytokine, was also secreted by large numbers of cells in both valve and myocardium tissue. Data here indicate the complexity of immune reactions leading to autoimmune lesions in RF/RHD.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), HC FMUSP, Inst Coracao, Immunol Lab, Av Dr Eneas Carvalho Aguiar 44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guillard C, 2005, INT J PHOTOENERGY, V7, P1, DOI 10.1155/S1110662X05000012
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   Kravitz MS, 2006, NAT CLIN PRACT RHEUM, V2, P481, DOI 10.1038/ncprheum0290
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001
   Reason IJM, 2006, HUM IMMUNOL, V67, P991, DOI 10.1016/j.humimm.2006.08.296
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
NR 31
TC 13
Z9 14
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077-8923
BN 978-1-57331-662-0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1107
BP 426
EP 433
DI 10.1196/annals.1381.045
PG 8
WC Immunology; Multidisciplinary Sciences
SC Immunology; Science & Technology - Other Topics
GA BGO38
UT WOS:000248944300045
PM 17804571
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Giavina-Bianchi, M
   Agondi, R
   Kalil, J
AF Giavina-Bianchi, Pedro
   Giavina-Bianchi, Mara
   Agondi, Rosana
   Kalil, Jorge
TI Administration of anti-IgE to a Churg-Strauss syndrome patient
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE Anti-IgE; asthma; Churg-Strauss syndrome; eosinophilia; IgE; severe
   asthma; vasculitis
ID INTRAVENOUS IMMUNOGLOBULIN; SYSTEMIC VASCULITIS; ALLERGIC-ASTHMA;
   OMALIZUMAB
AB Background: Treatment of the Churg-Strauss syndrome (CCS) remains a challenge. Many patients relapse after achieving remission, and a substantial proportion of them present adverse drug reactions with relevant morbidity. In most patients, severe asthma and upper respiratory symptoms persist, requiring continuous therapy. The aim of the present study is to describe a patient with CSS who was administered anti-IgE.
   Case Report: A 46-year-old male patient with CSS followed up for 17 years is described. Upon treatment, CSS showed remission but asthma failed to improve despite high-dose inhaled corticosteroids, long-acting beta(2)-agonists and several courses of systemic steroids. In order to better control asthma, anti-IgE was administered. Following omalizumab administration, asthma symptoms ( according to clinical features and lung function tests) and eosinophilia improved.
   Conclusions: Anti-IgE offers the potential not only to decrease asthma activity but also to reduce the risk of morbidity that can result from currently available treatment options. Whether it can also affect the activity of other CSS components is an open question. As far as we know, there are no published reports about the prescription of omalizumab to patients with CSS and with non-allergic asthma. Anti-IgE improved our patient's asthma and decreasedthe eosinophil blood count but did not worsen the outcome of CSS. However, large and long-term studies are necessary before a more widespread utilization of anti-IgE in CSS patients can be implemented. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), R Prof Artur Ramos 178 ap 211A, BR-01454010 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR CHURG J, 1951, AM J PATHOL, V27, P277
   Danieli MG, 2004, ANN RHEUM DIS, V63, P1649, DOI 10.1136/ard.2003.015453
   Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC
   Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082
   Guillevin L, 2004, SEMIN RESP CRIT CARE, V25, P535, DOI 10.1055/s-2004-836145
   Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003
   Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x
   Jayne DRW, 2000, QJM-INT J MED, V93, P433, DOI 10.1093/qjmed/93.7.433
   JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206
   Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518
   LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001
   LANHAM JG, 1992, BRIT J HOSP MED, V47, P667
   MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
   Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434
   Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028
   Oh MJ, 2006, J KOREAN MED SCI, V21, P265, DOI 10.3346/jkms.2006.21.2.265
   Tsurikisawa N, 2004, ANN ALLERG ASTHMA IM, V92, P80, DOI 10.1016/S1081-1206(10)61714-0
   *US FDA, BRIF DOC SAF
   WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8
   Winchester DE, 2006, NEW ENGL J MED, V355, P1281
NR 20
TC 38
Z9 40
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-2438
EI 1423-0097
J9 INT ARCH ALLERGY IMM
JI Int. Arch. Allergy Immunol.
PY 2007
VL 144
IS 2
BP 155
EP 158
DI 10.1159/000103228
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA 203WC
UT WOS:000249003700009
PM 17536214
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Pinto, LE
   Sayed, S
   Cukier, A
   Kalil, J
AF Giavina-Bianchi, P.
   Pinto, L. Eduardo
   Sayed, S.
   Cukier, A.
   Kalil, J.
TI Development of a specific questionnaire for the suspicion of DPV
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 23-27, 2007
CL San Diego, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Giavina-Bianchi, P.; Pinto, L. Eduardo; Sayed, S.; Cukier, A.; Kalil, J.] FMUSP, Sao Paulo, Brazil.
RI SAYED, SHAHIN/F-8641-2016; KALIL, JORGE/C-8029-2012; Cukier,
   Alberto/C-6101-2012
OI KALIL, JORGE/0000-0001-8415-4274; Cukier, Alberto/0000-0002-7217-9498
NR 0
TC 4
Z9 4
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2007
VL 119
IS 1
SU 1
MA 645
BP S165
EP S165
DI 10.1016/j.jaci.2006.12.007
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 238PT
UT WOS:000251460401030
DA 2020-11-26
ER

PT J
AU Tanno, LK
   Pinto, LH
   Motta, AA
   Kalil, J
   Giavina-Bianchi, P
AF Tanno, L. K.
   Pinto, L. H.
   Motta, A. A.
   Kalil, J.
   Giavina-Bianchi, P.
TI Hereditary angioedema: Clinical characteristics and utcome of 36
   patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY FEB 23-27, 2007
CL San Diego, CA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Tanno, L. K.; Pinto, L. H.; Motta, A. A.; Kalil, J.; Giavina-Bianchi, P.] FMUSP, Sao Paulo, Brazil.
RI Tanno, Luciana Kase/J-9981-2014; Giavina-Bianchi, Pedro/I-3112-2014;
   KALIL, JORGE/C-8029-2012
OI Tanno, Luciana Kase/0000-0003-3236-1225; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2007
VL 119
IS 1
SU 1
MA 1075
BP S275
EP S275
DI 10.1016/j.jaci.2006.12.445
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 238PT
UT WOS:000251460401458
DA 2020-11-26
ER

PT J
AU Silva, ACC
   Pereira, LM
   Rodrigues, H
   Ramasawmy, R
   Borba, SCP
   Romao, JE
   David-Neto, E
   Ianhez, LE
   Kalil, J
   Abensur, H
AF Cordeiro Silva, Antonio Carlos, Jr.
   Pereira, Lilian Monteiro
   Rodrigues, Helcio
   Ramasawmy, Rajendranath
   Pinto Borba, Susan Caroline
   Romao, Joao Egidio, Jr.
   David-Neto, Elias
   Ianhez, Luis Estevam
   Kalil, Jorge
   Abensur, Hugo
TI Kidney transplantation and human C-reactive protein single-nucleotide
   polymorphisms influence CRP levels in chronic kidney disease patients
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Meeting Abstract
CT 44th ERA-EDTA Congress
CT 44th Annual Congress of the
   European-Renal-Association/European-Dialysis-and-Transplant-Association
   (ERA-EDTA)
CY JUN 22-24, 2007
CY JUN 21-24, 2007
CL Barcelona, SPAIN
CL Barcelona, SPAIN
SP ERA-EDTA
SP European Renal Assoc, European Dialysis & Transplant Assoc
C1 [Cordeiro Silva, Antonio Carlos, Jr.; Pereira, Lilian Monteiro; Rodrigues, Helcio; Ramasawmy, Rajendranath; Pinto Borba, Susan Caroline; Romao, Joao Egidio, Jr.; David-Neto, Elias; Ianhez, Luis Estevam; Kalil, Jorge; Abensur, Hugo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI Palma, Lilian Monteiro Pereira/U-6672-2018; Neto, Elias
   David/O-3866-2018; KALIL, JORGE/C-8029-2012; Ramasawmy,
   Rajendranath/V-4926-2019; David-Neto, Elias/C-9112-2012
OI Palma, Lilian Monteiro Pereira/0000-0002-0334-8470; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PY 2007
VL 22
SU 6
BP 330
EP 330
PG 1
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 264WH
UT WOS:000253320600927
DA 2020-11-26
ER

PT J
AU Teixeira, PC
   Iwai, LK
   Kuramoto, ACK
   Honorato, R
   Fiorelli, A
   Stolf, N
   Kalil, J
   Cunha-Neto, E
AF Teixeira, P. C.
   Iwai, L. K.
   Kuramoto, A. C. K.
   Honorato, R.
   Fiorelli, A.
   Stolf, N.
   Kalil, J.
   Cunha-Neto, E.
TI Proteomic inventory of myocardial proteins from patients with chronic
   Chagas' cardiornyopathy
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Chagas' disease; cardiomyopathy; proteomic analysis; two-dimensional
   electrophoresis; MALDI-ToF
ID HEAT-SHOCK PROTEINS; DISEASE CARDIOMYOPATHY; DILATED CARDIOMYOPATHY;
   GENE-EXPRESSION; FAILURE; APOPTOSIS; GRANZYME; CELLS; INFARCTION;
   ANTIGENS
AB Chronic Chagas' disease cardiomyopathy (CCC) is an often fatal outcome of Trypanosoma cruzi infection, with a poorer prognosis than other cardiomyopathies. CCC is refractory to heart failure treatments, and is the major indication of heart transplantation in Latin America. A diffuse myocarditis, plus intense myocardial hypertrophy, damage and fibrosis, in the presence of very few T. cruzi forms, are the histopathological hallmarks of CCC. To gain a better understanding of the pathophysiology of CCC, we analyzed the protein profile in the affected CCC myocardium. Homogenates from left ventricular myocardial samples of end-stage CCC hearts explanted during heart transplantation were subjected to two-dimensional electrophoresis with Coomassie blue staining; protein identification was performed by MALDI-ToF mass spectrometry and peptide mass fingerprinting. The identification of selected proteins was confirmed by immunoblotting. We demonstrated that 246 proteins matched in gels from two CCC patients. They corresponded to 112 distinct proteins. Along with structural/contractile and metabolism proteins, we also identified proteins involved in apoptosis (caspase 8, caspase 2), immune system (T cell receptor 8 chain, granzyme A, HLA class I) and stress processes (heat shock proteins, superoxide dismutases, and other oxidative stress proteins). Proteins involved in cell signaling and transcriptional factors were also identified. The identification of caspases and oxidative stress proteins suggests the occurrence of active apoptosis and significant oxidative stress in CCC myocardium. These results generated an inventory of myocardial proteins in CCC that should contribute to the generation of hypothesis-driven experiments designed on the basis of the classes of proteins identified here.
C1 USP, Fac Med, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
   USP, Fac Med, Hosp Clin, Div Cirurg Torac,Inst Coracao, BR-05403000 Sao Paulo, Brazil.
   USP, Fac Med, Disciplina Imunol Clin & Alergia, BR-05403000 Sao Paulo, Brazil.
   CNPq MCT, Inst Milenio, Inst Invest, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), USP, InCor HC FM, Lab Imunol, Bloco 2,9o Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Iwai, Leo K/M-1734-2013; Teixeira, Priscila C/D-7426-2013; KALIL,
   JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI Iwai, Leo K/0000-0002-1571-7763; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Camillo Teixeira,
   Priscila/0000-0002-9698-4563
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Arrell DK, 2001, CIRC RES, V88, P763, DOI 10.1161/hh0801.090193
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Carvajal K, 2003, ARCH MED RES, V34, P89, DOI 10.1016/S0188-4409(03)00004-3
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Corbett JM, 1998, ELECTROPHORESIS, V19, P2031, DOI 10.1002/elps.1150191123
   Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   Delogu Giovanna, 2002, Curr Opin Crit Care, V8, P411, DOI 10.1097/00075198-200210000-00007
   Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4
   Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   Freude B, 1998, BASIC RES CARDIOL, V93, P85, DOI 10.1007/s003950050066
   Frustaci A, 2000, CIRC RES, V87, P1123, DOI 10.1161/01.RES.87.12.1123
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360
   Janiszewski M, 2005, J BIOL CHEM, V280, P40813, DOI 10.1074/jbc.M509255200
   Li SR, 2004, SCIENCE, V305, P1619, DOI 10.1126/science.1098674
   MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815
   Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004
   Morel CM, 2003, NAT REV MICROBIOL, V1, P14, DOI 10.1038/nrmicro735
   Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9
   Pardo J, 2004, J CELL BIOL, V167, P457, DOI 10.1083/jcb.200406115
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   ROSSI MA, 1991, INT J CARDIOL, V30, P335, DOI 10.1016/0167-5273(91)90012-E
   SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364
   Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151
   Tanonaka K, 2001, BIOCHEM BIOPH RES CO, V283, P520, DOI 10.1006/bbrc.2001.4801
   Taylor SW, 2003, J BIOL CHEM, V278, P19587, DOI 10.1074/jbc.C300135200
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Tostes S, 2005, INT J CARDIOL, V99, P233, DOI 10.1016/j.ijcard.2004.01.026
   WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7
   Wen JJ, 2004, FREE RADICAL BIO MED, V37, P1821, DOI 10.1016/j.freeradbiomed.2004.08.018
NR 40
TC 21
Z9 22
U1 1
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD DEC
PY 2006
VL 39
IS 12
BP 1549
EP 1562
DI 10.1590/S0100-879X2006005000050
PG 14
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 120RJ
UT WOS:000243103300005
PM 17160263
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Fonseca, SG
   Coutinho-Silva, A
   Fonseca, LAM
   Segurado, AC
   Moraes, SL
   Rodrigues, H
   Hammer, J
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Fonseca, Simone G.
   Coutinho-Silva, Adriana
   Fonseca, Luiz Augusto M.
   Segurado, Aluisio C.
   Moraes, Sandra L.
   Rodrigues, Helcio
   Hammer, Juergen
   Kallas, Esper G.
   Sidney, John
   Sette, Alessandro
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1
   whole genome that are frequently recognized by HIV-1 infected patients
SO AIDS
LA English
DT Article
DE HIV-1; CD4+T cell epitopes; HLA binding; vaccine; consensus; conserved
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CLASS-II MOLECULES; ANTIRETROVIRAL
   THERAPY; MYCOBACTERIUM-TUBERCULOSIS; IMMUNODOMINANT EPITOPES; VIRAL
   LOAD; RESPONSES; INFECTION; VIREMIA; INDIVIDUALS
AB Objective: To identify promiscuous and potentially protective human CD4 T-cell epitopes in most conserved regions within the protein-coding genome of HIV-1 clade B consensus sequence.
   Design: We used the TEPITOPE algorithm to screen the most conserved regions of the whole genome of the HIV-1 subtype B consensus sequence to identify promiscuous human CD4 T-cell epitopes in HIV-1. The actual promiscuity of HLA binding of the 18 selected peptides was assessed by binding assays to nine prevalent HLA-DR molecules. Synthetic peptides were tested with interferon-gamma ELISPOT assays on peripheral blood mononuclear cells (PBMC) from 38 HIV-1 infected patients and eight uninfected controls.
   Results: Most peptides bound to multiple HLA-DR molecules. PBMC from 91% of chronically HIV-1 infected patients recognized at least one of the promiscuous peptides, while none of the healthy controls recognized peptides. All 18 peptides were recognized, and each peptide was recognized by at least 18% of patients; 44% of the patients recognized five or more peptides. This response was not associated to particular HLA-DR alleles. Similar responses were obtained in CD8 T-cell-depleted PBMC.
   Conclusion: In silico prediction of promiscuous epitopes led to the identification of naturally immunodominant CD4 T-cell epitopes recognized by PBMC from a significant proportion of a genetically heterogeneous patient population exposed to HIV-1. This combination of CD4 T-cell epitopes-11 of them not described before-may have the potential for inclusion in a vaccine against HIV-1, allowing the immunization of genetically distinct populations. (c) 2006 Lippincott Williams & Wilkins.
C1 Univ Sao Paulo, Sch Med, Heart Inst Incor, Immunol Lab, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Med, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA.
   Univ Fed Sao Paulo, Div Infect & Parasit Dis, Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst Incor, Immunol Lab, Av Dr Eneas Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Kallas, Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012; FONSECA, SIMONE
   GONCALVES/U-9278-2019; Cunha-Neto, Edecio/B-4157-2009; Segurado, Aluisio
   C/K-2229-2012; Fonseca, Luiz Augusto M/F-9344-2012
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Segurado, Aluisio C/0000-0002-6311-8036;
   Kallas, Esper/0000-0003-2026-6925
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01-AI-95362] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI095362, N01AI095362, N01AI095362, N01AI095362] Funding Source: NIH
   RePORTER
CR Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219
   Alatrakchi N, 2005, AIDS, V19, P25, DOI 10.1097/00002030-200501030-00003
   Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   BETTE TM, 2005, 5 MOL IMMUNOLOGY
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   BIGNON JD, 1997, GENETIC DIVERSITY HL, V1, P584
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376
   Caride E, 2001, VIRUS GENES, V23, P193, DOI 10.1023/A:1011812810397
   Cochlovius B, 2000, J IMMUNOL, V165, P4731, DOI 10.4049/jimmunol.165.8.4731
   Consogno G, 2003, BLOOD, V101, P1038, DOI 10.1182/blood-2002-03-0933
   Damico FM, 2005, INVEST OPHTH VIS SCI, V46, P2465, DOI 10.1167/iovs.04-1273
   De Groot AS, 2004, METHODS, V34, P476, DOI 10.1016/j.ymeth.2004.06.003
   De Groot AS, 2005, VACCINE, V23, P2136, DOI 10.1016/j.vaccine.2005.01.097
   de Lalla C, 1999, J IMMUNOL, V163, P1725
   Deeks SG, 2004, J INFECT DIS, V189, P312, DOI 10.1086/380098
   Fonseca CT, 2005, MICROBES INFECT, V7, P204, DOI 10.1016/j.micinf.2004.10.012
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   GOLDBERG AC, 1997, HLA 1997, P330
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Heeney JL, 1997, IMMUNOL TODAY, V18, P4, DOI 10.1016/S0167-5699(97)80005-9
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874
   McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598
   MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Schroers R, 2003, CLIN CANCER RES, V9, P3260
   Schroers R, 2002, CANCER RES, V62, P2600
   Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101
   SIDNEY J, 1998, CURRENT PROTOCOLS IM
   Smith CJ, 2003, AIDS, V17, P963, DOI 10.1097/00002030-200305020-00004
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   THERTON E, 1989, SOLID PHASE PEPTIDE
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
NR 50
TC 33
Z9 33
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 28
PY 2006
VL 20
IS 18
BP 2263
EP 2273
DI 10.1097/01.aids.0000253353.48331.5f
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 119UM
UT WOS:000243039400002
PM 17117012
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Landgraf, RG
   Jancar, S
   Tribess, A
   Fonseca, SG
   Fae, KC
   Kalil, J
AF Graudenz, Gustavo Silveira
   Landgraf, Richardt G.
   Jancar, Sonia
   Tribess, Arlindo
   Fonseca, Simone G.
   Fae, Kellen Cristhina
   Kalil, Jorge
TI The role of allergic rhinitis in nasal responses to sudden temperature
   changes
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE indoor air quality; environmental illness; air conditioning;
   inflammatory mediators
ID SICK BUILDING SYNDROME; OFFICE BUILDINGS; RESPIRATORY SYMPTOMS;
   RISK-FACTORS; EOSINOPHIL; INVOLVEMENT; CHALLENGE; SYSTEMS; WORKERS
AB Background: Air conditioning-induced rhinitis in allergic individuals is a common epidemiologic finding, but its physiopathology,is still controversial. The aim of this study was to describe and compare the effects of experimental air conditioning temperature changes on the nasal mucosa of individuals with persistent allergic rhinitis compared with a control group.
   Methods: A case-control challenge study was performed in a laboratory of thermal comfort with experimental twin challenge chambers set at a 12 C difference in temperature. A group of 32 patients with persistent allergic rhinitis and a group of 16 control subjects were exposed for 30 minutes, 3 times alternately in each chamber. Nasal symptom scores were recorded and nasal samples collected before, immediately after, and 24 and 48 hours after the challenge.
   Results: The rhinitis group showed a higher symptom score, epithelial shedding, percentage of eosinophils, total inflammatory cells, leukotriene C-4, eosinophil cationic protein, albumin, and tryptase levels compared with controls. There was also a significant increase in symptom score, total cells recovered, percentage of eosinophils, epithelial shedding, albumin, myeloperoxidase, and soluble intercellular adhesion molecule 1 in both groups compared with baseline levels.
   Conclusion: Sudden temperature changes led to a more pronounced inflammatory nasal response in the rhinitis group with the recruitment and activation of eosinophils.
   Clinical implications: Persistent allergic rhinitis is a risk factor for developing sudden temperature change-related rhinitis even in the absence of allergen exposure.
C1 State Univ Sao Paulo, Div Immunol & Clin Allergy, Dept Internal Med, Sao Paulo, Brazil.
   State Univ Sao Paulo, Dept Mech Engn, Polytech Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Sao Paulo, Brazil.
   Millennium Inst, Inst Immunol Invest, Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Av Dr Eneas Carvalho Aguiar 44-9 Andar Bloco 2, BR-05403002 Sao Paulo, Brazil.
EM gustavog@usp.br
RI Landgraf, Richardt Gama/AAF-3568-2020; FONSECA, SIMONE
   GONCALVES/U-9278-2019; Jancar, Sonia/C-5153-2012; KALIL,
   JORGE/C-8029-2012; Landgraf, Richardt Gama/F-7146-2012
OI Landgraf, Richardt Gama/0000-0001-7774-7880; Jancar,
   Sonia/0000-0001-7983-3459; KALIL, JORGE/0000-0001-8415-4274; Tribess,
   Arlindo/0000-0001-9908-9233
CR American Society of Heating Refrigerating and Air-Conditioning Engineers, 2001, ASHRAE 64
   Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283, DOI 10.1016/S1081-1206(10)63017-7
   Bonini S, 2001, ANN ALLERG ASTHMA IM, V87, P48, DOI 10.1016/S1081-1206(10)62341-1
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   CHURCH MK, 2003, MIDDLETONS ALLERGY P, P190
   Galvão Clóvis Eduardo Santos, 2004, Sao Paulo Med. J., V122, P204, DOI 10.1590/S1516-31802004000500005
   Gentile DA, 2003, ANN ALLERG ASTHMA IM, V91, P270, DOI 10.1016/S1081-1206(10)63529-6
   Giembycz MA, 1999, PHARMACOL REV, V51, P213
   Gilain L, 2000, Ann Otolaryngol Chir Cervicofac, V117, P91
   Graudenz GS, 2005, INDOOR AIR, V15, P62, DOI 10.1111/j.1600-0668.2004.00324.x
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   Haxel BR, 2004, AM J RHINOL, V18, P93, DOI 10.1177/194589240401800205
   Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS387, DOI 10.1016/j.jaci.2004.12.017
   Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134
   Kuwahara Y, 2001, ALLERGY, V56, P224, DOI 10.1034/j.1398-9995.2001.056003224.x
   LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012
   LIGHT IM, 1980, AVIAT SPACE ENVIR MD, V51, P1100
   MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2
   Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   Mendell MJ, 2003, AM J IND MED, V43, P630, DOI 10.1002/ajim.10211
   Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629
   Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107
   Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397
   MIDDLETON J, 2003, MIDDLETONS ALLERGY P, P1391
   MION O, 1998, P ISIAN C IT
   Ooi PL, 1997, INT J EPIDEMIOL, V26, P1243, DOI 10.1093/ije/26.6.1243
   Robertson A, 1986, Occup Health (Lond), V38, P78
   Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92
   Schneider T, 1999, SCAND J WORK ENV HEA, V25, P574, DOI 10.5271/sjweh.483
   Terada N, 2001, AM J RESP CRIT CARE, V164, P575, DOI 10.1164/ajrccm.164.4.2009046
   TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113
   Watanabe K, 1998, ANN OTO RHINOL LARYN, V107, P564, DOI 10.1177/000348949810700704
   Webster R O, 1978, Inflammation, V3, P129, DOI 10.1007/BF00910734
NR 35
TC 63
Z9 66
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD NOV
PY 2006
VL 118
IS 5
BP 1126
EP 1132
DI 10.1016/j.jaci.2006.07.005
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 137GY
UT WOS:000244282300019
PM 17088139
DA 2020-11-26
ER

PT J
AU Caldas, C
   Luna, E
   Spadafora-Ferreira, M
   Porto, G
   Iwai, LK
   Oshiro, SE
   Monteiro, SM
   Fonseca, JA
   Lemos, F
   Hammer, J
   Ho, PL
   Kalil, J
   Coelho, V
AF Caldas, C.
   Luna, E.
   Spadafora-Ferreira, M.
   Porto, G.
   Iwai, L. K.
   Oshiro, S. E.
   Monteiro, S. M.
   Fonseca, J. A.
   Lemos, F.
   Hammer, J.
   Ho, P. L.
   Kalil, J.
   Coelho, V.
TI Cellular autoreactivity against heat shock protein 60 in renal
   transplant patients: peripheral and graft-infiltrating responses
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE autoimmunity; cytokines/interleukins; heat shock proteins (Hsp); renal
   transplantation; T cells
ID HEAT-SHOCK-PROTEIN; CD8(+) T-CELLS; ALLOGRAFT-REJECTION; CARDIAC MYOSIN;
   V COLLAGEN; TERMINAL DETERMINANTS; AUTOIMMUNE ARTHRITIS;
   ESCHERICHIA-COLI; IMMUNE-RESPONSES; EXPRESSION
AB Autoreactivity to heat shock protein 60 (Hsp60) has been implicated in the pathogenesis and regulation of chronic inflammation, especially in autoimmune diseases. In transplantation, there is a lack of information regarding the cytokine profile and specificity of cells that recognize self-Hsp60 as well as the kinetics of autoreactivity following transplantation. We studied the cellular reactivity of peripheral and graft-infiltrating lymphocytes against Hsp60 in renal transplant patients. Cytokine production induced by this protein in peripheral blood mononuclear cells indicated a predominance of interleukin (IL)-10 during the late post-transplantation period, mainly in response to intermediate and C-terminal peptides. Patients with chronic rejection presented reactivity to Hsp60 with a higher IL-10/interferon (IFN)-gamma ratio compared to long-term clinically stable patients. Graft-infiltrating T cell lines, cocultured with antigen-presenting cells, preferentially produced IL-10 after Hsp60 stimulation. These results suggest that, besides its proinflammatory activity, autoreactivity to Hsp60 in transplantation may also have a regulatory role.
C1 Univ Sao Paulo, Heart Inst, InCor, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Renal Transplantat Unit, Sch Med, Sao Paulo, Brazil.
   Hoffmann La Roche Inc, Sect Bioinformat Genet & Genom, Nutley, NJ 07110 USA.
   Butantan Inst, Ctr Biotechnol, Sao Paulo, Brazil.
   Butantan Inst, Lab Immunochem, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), FMUSP, Lab Imunol, InCor, HC, Av Dr Eneas Carvalho Aguiar 44,9 Andar,Bloco 2, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Spadafora-Ferreira, Monica/G-2635-2012; KALIL, JORGE/C-8029-2012; Iwai,
   Leo K/M-1734-2013; COELHO, VERONICA/D-1433-2013; Ho, Paulo/P-8267-2015
OI Spadafora-Ferreira, Monica/0000-0001-8823-9929; KALIL,
   JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763; Ho,
   Paulo/0000-0003-3652-241X; Coelho, Veronica/0000-0002-0989-2581
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Barber LD, 2004, TRANSPLANTATION, V77, P1604, DOI 10.1097/01.tp.0000129068.03900.25
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   Binder RJ, 2004, TISSUE ANTIGENS, V64, P442, DOI 10.1111/j.1399-0039.2004.00299.x
   Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159
   Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315
   Brocchieri L, 2000, PROTEIN SCI, V9, P476
   Caldas C, 2004, TRANSPL P, V36, P833, DOI 10.1016/j.transproceed.2004.04.069
   Chen SF, 2005, P NATL ACAD SCI USA, V102, P7251, DOI 10.1073/pnas.0502407102
   COELHO V, 1995, TRANSPLANTATION, V60, P980
   Durai M, 2004, J IMMUNOL, V172, P2795, DOI 10.4049/jimmunol.172.5.2795
   El Gamel A, 1998, TRANSPLANT P, V30, P2387, DOI 10.1016/S0041-1345(98)00663-0
   Fedoseyeva EV, 1999, J IMMUNOL, V162, P6836
   Fedoseyeva EV, 2002, J IMMUNOL, V169, P1168, DOI 10.4049/jimmunol.169.3.1168
   Furukawa Y, 1999, AM J PATHOL, V155, P1929, DOI 10.1016/S0002-9440(10)65512-5
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   Haque MA, 2002, J IMMUNOL, V169, P1542, DOI 10.4049/jimmunol.169.3.1542
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006
   JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279
   Junqueira-de-Azevedo ID, 2003, BBA-PROTEINS PROTEOM, V1648, P90, DOI 10.1016/S1570-9639(03)00111-0
   Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4
   Katori M, 2000, TRANSPLANTATION, V69, P2530, DOI 10.1097/00007890-200006270-00011
   Li W, 1998, TRANSPLANTATION, V66, P1587, DOI 10.1097/00007890-199812270-00004
   Mia MY, 2005, J IMMUNOL, V175, P219, DOI 10.4049/jimmunol.175.1.219
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P598
   MOLITERNO R, 1995, J HEART LUNG TRANSPL, V14, P329
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   Nair S., 2004, Journal of Heart and Lung Transplantation, V23, pS132, DOI 10.1016/j.healun.2003.11.269
   Patel A, 2004, TRANSPLANTATION, V78, P1479, DOI 10.1097/01.TP.0000144182.27897.1E
   Pockley AG, 2005, CONTRIB NEPHROL, V148, P122, DOI 10.1159/000086057
   Pockley AG, 2001, TRANSPLANTATION, V71, P1503, DOI 10.1097/00007890-200106150-00001
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Ramos CRR, 2004, BRAZ J MED BIOL RES, V37, P1103, DOI 10.1590/S0100-879X2004000800001
   Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5
   Redaelli CA, 2002, NEPHRON, V90, P489, DOI 10.1159/000054739
   RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188
   Sindhi R, 2005, HUM IMMUNOL, V66, P252, DOI 10.1016/j.humimm.2004.05.017
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sumpter TL, 2004, AM J PHYSIOL-LUNG C, V286, pL1129, DOI 10.1152/ajplung.00330.2003
   TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1
   Trieb K, 1996, Transpl Immunol, V4, P43, DOI 10.1016/S0966-3274(96)80032-3
   van Eden W, 2003, VACCINE, V21, P897, DOI 10.1016/S0264-410X(02)00538-8
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   Wagner M, 2003, KIDNEY INT, V63, P1564, DOI 10.1046/j.1523-1755.2003.00897.x
   WEBER T, 1988, TRANSPLANT P, V20, P176
   Woodland DL, 2003, CURR OPIN IMMUNOL, V15, P336, DOI 10.1016/S0952-7915(03)00037-2
   Yoshida S, 2006, AM J TRANSPLANT, V6, P724, DOI 10.1111/j.1600-6143.2006.01236.x
   Zanin-Zhorov A, 2005, J IMMUNOL, V175, P276, DOI 10.4049/jimmunol.175.1.276
NR 49
TC 15
Z9 19
U1 0
U2 5
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD OCT
PY 2006
VL 146
IS 1
BP 66
EP 75
DI 10.1111/j.1365-2249.2006.03195.x
PG 10
WC Immunology
SC Immunology
GA 083XZ
UT WOS:000240493900010
PM 16968400
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Cunha-Neto, E
   Fae, KC
   Martello, FG
   Muller, NG
   Cavalcanti, VL
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
AF Ramasawmy, R
   Cunha-Neto, E
   Fae, KC
   Martello, FG
   Muller, NG
   Cavalcanti, VL
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
TI The monocyte chemoattractant protein-1 gene polymorphism is associated
   with cardiomyopathy in human Chagas disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID C-C-CHEMOKINES; TRYPANOSOMA-CRUZI; NITRIC-OXIDE; HEART-FAILURE;
   CHEMOTACTIC PROTEIN-1; TRYPANOCIDAL ACTIVITY; HUMAN MACROPHAGES; MCP-1
   EXPRESSION; IL-12 PRODUCTION; IMMUNE-RESPONSE
AB Background. Only a subset of individuals infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC). Familial aggregation of CCC in areas of endemicity indicates that susceptibility may be genetic, which may be a plausible explanation for why only one-third of T. cruzi-infected individuals develop CCC. The monocyte chemoattractant protein-1 (CCL2/MCP-1) has been shown to enhance the uptake of T. cruzi in murine macrophages and to up-regulate the inducible nitric oxide synthase/nitic oxide system, with a consequent increased production of nitric oxide that controls the replication of the parasite.
   Methods. We assessed CCL2 variants at position -2518A/G, which are known to influence transcriptional activity, by polymerase chain reaction and restriction fragment-length polymorphism in 245 individuals, all of whom were infected with T. cruzi. One hundred sixty-nine patients had CCC, and 76 were asymptomatic.
   Results. Genotype distributions differed between the CCC and asymptomatic groups (chi(2) = 9.4 P = 009), with an excess of genotypes with the A allele ( AA + AG) in the CCC group. Among patients with CCC, 5% were homozygous for the G allele, compared with 16% of the asymptomatic subjects (odds ratio [OR], 4.1; 95% confidence interval [CI], 1.7-11; P = .001). A similar trend was observed when individuals heterozygous for the G allele were compared with individuals homozygous for the G allele between the CCC and asymptomatic groups (OR, 2.7; 95% CI, 0.97-7.2; P =.025). The A allele seems to confer susceptibility to CCC ( OR, 1.9; 95% CI, 1.3 Pp. 026 2.9; P = .001)
   Conclusions. The CCL2 variant correlated with a low transcriptional level behaves as a genetic modifier of clinical outcome for T. cruzi infection, and subjects with the CCL2-2518AA genotype have a 4-fold greater risk of developing CCC than do those without this genotype.
C1 FMUSP, InCor, Lab Imunol, BR-05403000 Sao Paulo, Brazil.
   FMUSP, Sch Med, Div Clin Immunol, BR-05403000 Sao Paulo, Brazil.
   FMUSP, Sch Med, Dept Allergy, BR-05403000 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RP Ramasawmy, R (corresponding author), FMUSP, InCor, Lab Imunol, Av Eneas Carvalho Aguiar 44,Bloco 2-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM ramasawm@usp.br
RI Cunha-Neto, Edecio/B-4157-2009; Mady, Charles/C-8870-2012; Ianni,
   Barbara Maria/C-7689-2012; Goldberg, Anna Carla/H-8594-2014; Ramasawmy,
   Rajendranath/V-4926-2019; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Mady,
   Charles/0000-0002-8838-199X; Ianni, Barbara Maria/0000-0002-1588-5492;
   Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Aliberti JCS, 1999, INFECT IMMUN, V67, P4819, DOI 10.1128/IAI.67.9.4819-4826.1999
   Araujo-Jorge TC, 2002, J INFECT DIS, V186, P1823, DOI 10.1086/345882
   Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136
   Barretto A C, 1993, Arq Bras Cardiol, V60, P225
   BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bocchi E A, 1994, Arq Bras Cardiol, V63, P523
   Brandonisio O, 2002, CLIN EXP MED, V2, P125, DOI 10.1007/s102380200017
   Braun MC, 2000, J IMMUNOL, V164, P3009, DOI 10.4049/jimmunol.164.6.3009
   CARRASCO HA, 1987, AM HEART J, V113, P716
   Chensue SW, 1996, J IMMUNOL, V157, P4602
   Dias J C, 1993, Cad Saude Publica, V9, P201, DOI 10.1590/S0102-311X1993000200012
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem.20050126
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Jorge MT, 2003, ANN TROP MED PARASIT, V97, P139, DOI 10.1179/000349803235001561
   Kruger B, 2002, J AM SOC NEPHROL, V13, P2585, DOI 10.1097/01.ASN.0000031701.53792.54
   LOPES ER, 1975, REV SOC BRAS MED TRO, V9, P269
   MACEDO AM, 2002, EXPERT REV MOL MED, P1
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Mannheimer SB, 1996, FEMS IMMUNOL MED MIC, V14, P59, DOI 10.1111/j.1574-695X.1996.tb00268.x
   Omata N, 2002, J IMMUNOL, V169, P4861, DOI 10.4049/jimmunol.169.9.4861
   Parissis JT, 2002, J INTERF CYTOK RES, V22, P223, DOI 10.1089/107999002753536194
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeiro ALP, 2002, LANCET, V360, P461, DOI 10.1016/S0140-6736(02)09638-1
   Ritter U, 2000, EUR J IMMUNOL, V30, P3111, DOI 10.1002/1521-4141(200011)30:11&lt;3111::AID-IMMU3111&gt;3.0.CO;2-O
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   SYLVESTER I, 1993, J IMMUNOL, V151, P3292
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Tarzami ST, 2002, J MOL CELL CARDIOL, V34, P209, DOI 10.1006/jmcc.2001.1503
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994
   Villalta F, 1998, INFECT IMMUN, V66, P4690, DOI 10.1128/IAI.66.10.4690-4695.1998
   *WHO, 1997, UNDP WORLD BANK WHO, P112
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 40
TC 45
Z9 45
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2006
VL 43
IS 3
BP 305
EP 311
DI 10.1086/505395
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 057XK
UT WOS:000238628300007
PM 16804844
OA Bronze
DA 2020-11-26
ER

PT J
AU Marrero, I
   Huffman, D
   Kalil, J
   Sercarz, EE
   Coelho, V
AF Marrero, Idania
   Huffman, Donald
   Kalil, Jorge
   Sercarz, Eli E.
   Coelho, Veronica
TI TAP1(-/-) mice present oligoclonal BV-BJ expansions following the
   rejection of grafts bearing self antigens
SO IMMUNOLOGY
LA English
DT Article
DE autoimmunity; CDR3; graft rejection; H-2K b-derived peptides; T
   lymphocytes
ID T-CELL REPERTOIRE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; V-BETA
   REPERTOIRE; TAP1 MUTANT MICE; CLASS-I MOLECULES; DEFICIENT MICE;
   ALLOGRAFT-REJECTION; POSITIVE SELECTION; NEONATAL TOLERANCE; KIDNEY
   ALLOGRAFTS
AB Our previous work showed that transporter associated with antigen processing 1 (TAP1)(-/-) (H-2(b)) mice rejected grafts from H-2(b) mice which display a normal density of class I major histocompatibility complex (MHC) molecules at the cell surface. Our results indicated that H-2(b) molecules themselves may be a target in this kind of rejection and that CD4(+) T cells play a major role in this autoreactive process. Our data also suggested that TAP1(-/-) mice, in addition to the well-recognized phenotype of class I and CD8(+) T-cell deficiency, present a functional alteration in their autoreactive CD4(+) T-cell repertoires. In this model of inflammatory autoreactivity to modified self, we have analysed T-cell receptor (TCR) V-beta-J-beta (BV-BJ) usage by complementarity determining region 3 (CDR3) length spectratyping in splenocytes from naive TAP1(-/-) mice and transplanted TAP1(-/-) mice that rejected B6 heart grafts or responded to synthetic self H-2K(b) peptides. Importantly, oligoclonal T-cell expansions shared by different animals were detected in the peripheral T-cell repertoire of transplanted TAP1(-/-) mice. Such public expansions were also induced in vitro by H-2K(b) peptides, suggesting that dominant class I peptides can induce preferential expansions of restricted T-cell populations during rejection. Some of these public T-cell expansions were also detected in transplanted mice even before in vitro stimulation with peptides, indicating that post-transplantation expansion of these populations had occurred in vivo. The functional activity of these T-cell populations awaits elucidation, as do the underlying mechanisms involved in the inflammatory autoreactive process, in TAP1(-/-) mice.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol iii, Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, Div Immune Regulat, San Diego, CA USA.
   Torrey Pines Inst Mol Studies, Dept Immune Regulat, San Diego, CA USA.
RP Marrero, I (corresponding author), Inst Coracao, Immunol Lab, Ave Dr Eneas Carvalho Aguiar 44,9o Andar, BR-05403001 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
FU PHS HHSUnited States Public Health Service [R01-40877] Funding Source:
   Medline
CR ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525
   ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T
   Baron C, 2001, J IMMUNOL, V167, P4154, DOI 10.4049/jimmunol.167.8.4154
   Braciak TA, 2003, J IMMUNOL, V170, P765, DOI 10.4049/jimmunol.170.2.765
   BRUSIC V, 1994, NUCLEIC ACIDS RES, V22, P3663, DOI 10.1093/nar/22.17.3663
   CHAN SY, 1995, TRANSPLANTATION, V59, P1155, DOI 10.1097/00007890-199504270-00014
   Coelho V, 1999, TRANSPLANT P, V31, P900, DOI 10.1016/S0041-1345(98)01828-4
   Douillard P, 1998, INT IMMUNOL, V10, P71, DOI 10.1093/intimm/10.1.71
   Field AC, 2003, J IMMUNOL, V170, P2508, DOI 10.4049/jimmunol.170.5.2508
   Foucras G, 2000, J IMMUNOL, V165, P4994, DOI 10.4049/jimmunol.165.9.4994
   Freland S, 2000, SCAND J IMMUNOL, V51, P219
   Friedman TM, 1998, J IMMUNOL, V161, P41
   FULMER RI, 1963, AM J ANAT, V113, P273, DOI 10.1002/aja.1001130206
   Gagne K, 2000, J IMMUNOL, V164, P1553, DOI 10.4049/jimmunol.164.3.1553
   GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661
   Goebels N, 2000, BRAIN, V123, P508, DOI 10.1093/brain/123.3.508
   Goodall JC, 1999, HUM IMMUNOL, V60, P798, DOI 10.1016/S0198-8859(99)00063-4
   GOSS JA, 1993, P NATL ACAD SCI USA, V90, P9872, DOI 10.1073/pnas.90.21.9872
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Hu D, 2004, NAT IMMUNOL, V5, P516, DOI 10.1038/ni1063
   Jiang H, 1998, P NATL ACAD SCI USA, V95, P4533, DOI 10.1073/pnas.95.8.4533
   Jiang H, 2003, P NATL ACAD SCI USA, V100, P8378, DOI 10.1073/pnas.1432871100
   KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X
   Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6
   Kumar V, 1997, J IMMUNOL, V159, P5150
   Kumar V, 2001, IMMUNOL REV, V182, P113, DOI 10.1034/j.1600-065X.2001.1820109.x
   LJUNGGREN HG, 1995, EUR J IMMUNOL, V25, P174, DOI 10.1002/eji.1830250129
   Madakamutil LT, 2003, J IMMUNOL, V170, P2985, DOI 10.4049/jimmunol.170.6.2985
   MANNON RB, 1995, TRANSPLANTATION, V59, P746, DOI 10.1097/00007890-199503150-00019
   Marrero I, 2005, IMMUNOLOGY, V115, P484, DOI 10.1111/j.1365-2567.2005.02182.x
   Maverakis E, 2000, J EXP MED, V191, P695, DOI 10.1084/jem.191.4.695
   Noble A, 1998, J IMMUNOL, V160, P566
   PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0
   REYES AA, 1992, P NATL ACAD SCI USA, V79, P3270
   ROSSI MA, 1992, AM J PATHOL, V141, P183
   Sandberg JK, 1996, EUR J IMMUNOL, V26, P288, DOI 10.1002/eji.1830260203
   Shirwan H, 1997, TRANSPL P, V29, P1050, DOI 10.1016/S0041-1345(96)00367-3
   SHIRWAN H, 1993, J IMMUNOL, V151, P5228
   Suarez IM, 2002, TRANSPL IMMUNOL, V9, P101, DOI 10.1016/S0966-3274(02)00032-1
   TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0
   Tsukada C, 2003, IMMUNOLOGY, V109, P343, DOI 10.1046/j.1365-2567.2003.01654.x
   URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7
   van den Elzen P, 2004, AUTOIMMUN REV, V3, P524, DOI 10.1016/j.autrev.2004.07.008
   VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6
   Vignes C, 2000, J IMMUNOL, V165, P96, DOI 10.4049/jimmunol.165.1.96
   WADE T, 1988, J IMMUNOL, V141, P2165
   Waisman A, 1997, P NATL ACAD SCI USA, V94, P4620, DOI 10.1073/pnas.94.9.4620
   WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x
   Zhai Y, 2003, TRANSPLANTATION, V75, P514, DOI 10.1097/01.TP.0000046939.45400.43
NR 51
TC 0
Z9 1
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD AUG
PY 2006
VL 118
IS 4
BP 461
EP 471
PG 11
WC Immunology
SC Immunology
GA 076ME
UT WOS:000239961600004
PM 16895555
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Latorre, MRDO
   Tribess, A
   Oliveira, CH
   Kalil, J
AF Graudenz, G. S.
   Latorre, M. R. D. O.
   Tribess, A.
   Oliveira, C. H.
   Kalil, J.
TI Persistent allergic rhinitis and indoor air quality perception - an
   experimental approach
SO INDOOR AIR
LA English
DT Article
DE indoor air quality; building-related illness; air conditioning;
   experimental studies
ID SICK BUILDING SYNDROME; OFFICE WORKERS; VENTILATION SYSTEM; SYMPTOMS;
   HEALTH; ASTHMA; ATOPY; TEMPERATURE; SENSITIVITY; ENVIRONMENT
AB In order to compare patterns of indoor air perception, including perceptions of temperature, air movement, indoor air quality (IAQ), mental concentration, and comfort, 33 subjects either with persistent allergic rhinitis or controls were exposed to different temperatures and constant relative humidity in an experimental office environment. Results were obtained by means of a self-administered visual analogue scale, analyzed using mean score comparisons and principal component analysis. At 14 degrees C, the rhinitis group reported higher scores for sensations of air dryness than controls. At 18 degrees C, in the rhinitis group, there was a correlation between dry, stagnant air, and difficult mental concentration. This group also correlated heat, dry air, and poor IAQ, in contrast to the control group, which correlated comfort, easy mental concentration, and freshness. At 22 degrees C, the rhinitis group correlated heat, dryness, stagnant air, and overall discomfort. This group also correlated non-dry air, freshness, and comfort, whereas the control group correlated heat, humidity, good indoor air, freshness, and comfort. This study suggests that the rhinitis group perceives indoor temperatures of 14 degrees C as dryer than controls do, and that at 18 and 22 degrees C this group positively correlates different adverse perceptions of IAQ.
C1 Univ Sao Paulo, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Polytech Sch, Dept Engn Mech, Sao Paulo, Brazil.
   Univ San Francisco, Sch Med, Dept Internal Med, Braganca Paulista, SP, Brazil.
RP Graudenz, GS (corresponding author), Rua Girassol 1317-21, BR-05433002 Sao Paulo, Brazil.
EM gustavog@usp.br
RI Latorre, Maria RDO/J-5780-2014; KALIL, JORGE/C-8029-2012
OI Latorre, Maria RDO/0000-0002-5189-3457; KALIL,
   JORGE/0000-0001-8415-4274; Tribess, Arlindo/0000-0001-9908-9233
CR *ASHRAE, 2004, RAT MIN PHYS REQ RES, P34
   Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640, DOI 10.1164/ajrccm.164.9.2103086
   Assanasen P, 1999, J ALLERGY CLIN IMMUN, V104, P285, DOI 10.1016/S0091-6749(99)70368-4
   Bachert C, 2002, ALLERGY, V57, P1208
   Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283, DOI 10.1016/S1081-1206(10)63017-7
   Baroody FM, 2000, ARCH OTOLARYNGOL, V126, P749, DOI 10.1001/archotol.126.6.749
   BASCOM R, 1991, ENVIRON HEALTH PERSP, V95, P39, DOI 10.2307/3431104
   Bjornsson E, 1998, INT J TUBERC LUNG D, V2, P1023
   Brasche S, 2001, INDOOR AIR, V11, P217, DOI 10.1034/j.1600-0668.2001.110402.x
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   Csef H, 1998, Fortschr Med, V116, P18
   Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20
   Engelhart S, 1999, INDOOR AIR, V9, P139, DOI 10.1111/j.1600-0668.1999.t01-1-00009.x
   Fanger PO, 2000, INDOOR AIR, V10, P68, DOI 10.1034/j.1600-0668.2000.010002068.x
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   Gustafsson D, 1996, ALLERGY, V51, P789, DOI 10.1111/j.1398-9995.1996.tb04468.x
   Humes Larry E, 2003, Trends Amplif, V7, P41, DOI 10.1177/108471380300700202
   JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6
   Kildeso J, 1999, SCAND J WORK ENV HEA, V25, P361, DOI 10.5271/sjweh.446
   LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012
   LIGHT IM, 1980, AVIAT SPACE ENVIR MD, V51, P1100
   Lundin L, 1999, INDOOR AIR, V9, P92, DOI 10.1111/j.1600-0668.1999.t01-2-00004.x
   Matricardi PM, 2001, ANN ALLERG ASTHMA IM, V87, P24, DOI 10.1016/S1081-1206(10)62336-8
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   Mendell MJ, 2002, EPIDEMIOLOGY, V13, P296, DOI 10.1097/00001648-200205000-00010
   Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360, DOI 10.1080/00039899709602212
   Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629
   Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397
   Ooi PL, 1997, INT J EPIDEMIOL, V26, P1243, DOI 10.1093/ije/26.6.1243
   Pan ZW, 2000, INDOOR AIR, V10, P237, DOI 10.1034/j.1600-0668.2000.010004237.x
   PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x
   REINIKAINEN LM, 1991, ENVIRON INT, V17, P243, DOI 10.1016/0160-4120(91)90009-F
   Runeson R, 2003, INT ARCH OCC ENV HEA, V76, P29, DOI 10.1007/s00420-002-0372-y
   Shusterman D, 2003, INT ARCH OCC ENV HEA, V76, P577, DOI 10.1007/s00420-003-0459-0
   Thorn A, 1998, SOC SCI MED, V47, P1307, DOI 10.1016/S0277-9536(98)00206-8
   Zhang JF, 2003, BRIT MED BULL, V68, P209, DOI 10.1093/bmb/ldg029
NR 36
TC 7
Z9 7
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6947
EI 1600-0668
J9 INDOOR AIR
JI Indoor Air
PD AUG
PY 2006
VL 16
IS 4
BP 313
EP 319
DI 10.1111/j.1600-0668.2006.00428.x
PG 7
WC Construction & Building Technology; Engineering, Environmental; Public,
   Environmental & Occupational Health
SC Construction & Building Technology; Engineering; Public, Environmental &
   Occupational Health
GA 059TI
UT WOS:000238754700006
PM 16842611
DA 2020-11-26
ER

PT J
AU Rosa, DS
   Iwai, LK
   Tzelepis, F
   Bargieri, DY
   Medeiros, MA
   Soares, IS
   Sidney, J
   Sette, A
   Kalil, J
   Mello, LE
   Cunha, E
   Rodrigues, MM
AF Rosa, Daniela S.
   Iwai, Leo K.
   Tzelepis, Fanny
   Bargieri, Daniel Y.
   Medeiros, Magda A.
   Soares, Irene S.
   Sidney, John
   Sette, Alessandro
   Kalil, Jorge
   Mello, Luiz Eugenio
   Cunha-Neto, Edecio
   Rodrigues, Mauricio M.
TI Immunogenicity of a recombinant protein containing the Plasmodium vivax
   vaccine candidate MSP1(19) and two human CD4(+) T-cell epitopes
   administered to non-human primates (Callithrix jacchus jacchus)
SO MICROBES AND INFECTION
LA English
DT Article
DE Plasmodium vivax; recombinant vaccines; adjuvants
ID MEROZOITE SURFACE PROTEIN-1; C-TERMINAL REGIONS; MALARIA; ANTIBODIES;
   BINDING; IMMUNE; IMMUNIZATION; ADJUVANTS; RESPONSES; FRAGMENT
AB One of the most promising vaccine candidates against the erythrocytic forms of malaria is the 19 kDa C-terminal region of the merozoite surface protein 1 (MSP1(19)). As part of our studies aimed at the development of a Plasmodium vivax malaria vaccine, we characterized the immunogenic properties of a new bacterial recombinant protein containing the P. vivax MSPI 19 and two helper T-cell epitopes, the synthetic universal pan allelic DR epitope (PADRE) and a new internal MSP1 P. vivax epitope (DYDVVYLKPLAGMYK). We found that the recognition of HiS(6)MSP1(19)-DYDVVYLKPLAGMYK-PADRE was as good as the recognition of HiS(6)MSP1(19) indicating that the presence of the T-cell epitopes PADRE and DYDVVYLKPLAGMYK did not modify the MSP1(19) epitopes recognized by human IgG. The recombinant protein HiS(6)MSP1(19)-DYDVVYLKPLAGMYK-PADRE proved to be highly immunogenic in marmosets (Callithrix jacchus jacchus) when administered in incomplete Freund's adjuvant. However, when administered in other adjuvant formulations such as Quil A, CpG ODN 2006 or MPL/TDM, antibody titers to MSP1(19) were significantly lower. Among these three adjuvants, Quil A proved to be the most efficient one generating antibody titers significantly higher than the others. These results indicated that under the circumstances evaluated, adjuvants were key for the immumogenicity of the recombinant protein HiS(6)MSP1(19)-DYDVVYLKPLAGMYK-PADRE. (c) 2006 Elsevier SAS. All rights reserved.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, CINTERGEN, BR-04023062 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Lab Imunol, Inst Coracao, BR-05403000 Sao Paulo, Brazil.
   Univ Fed Rural Rio de Janeiro, Dept Ciencias Fisiol, BR-23890000 Seropedica, RJ, Brazil.
   Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Escola Paulista Med, Dept Fisiol, BR-04023062 Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, CINTERGEN, Rua Botucatu 862,6th Floor, BR-04023062 Sao Paulo, Brazil.
EM mrodrigues@ecb.epm.br
RI Rosa, Daniela S/D-2190-2012; Rodrigues, Mauricio M./B-8512-2012; Soares,
   Irene Silva/C-5974-2012; Cunha-Neto, Edecio/B-4157-2009; Mello, Luiz
   E/B-4177-2009; Bargieri, Daniel Youssef/A-4461-2013; KALIL,
   JORGE/C-8029-2012; Iwai, Leo K/M-1734-2013
OI Rosa, Daniela S/0000-0003-4536-891X; Soares, Irene
   Silva/0000-0002-3336-6856; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Mello, Luiz E/0000-0002-6969-1108; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; KALIL, JORGE/0000-0001-8415-4274; Iwai, Leo
   K/0000-0002-1571-7763
CR Atherton E, 1989, SOLID PHASE PEPTIDE
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   Bontrop RE, 1999, IMMUNOL REV, V167, P339, DOI 10.1111/j.1600-065X.1999.tb01403.x
   Caro-Aguilar I, 2002, INFECT IMMUN, V70, P3479, DOI 10.1128/IAI.70.7.3479-3492.2002
   Carvalho LJM, 2004, SCAND J IMMUNOL, V59, P363, DOI 10.1111/j.0300-9475.2004.01409.x
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993
   Genain CP, 2001, IMMUNOL REV, V183, P159, DOI 10.1034/j.1600-065x.2001.1830113.x
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97
   Miller LH, 2005, TRENDS PARASITOL, V21, P412, DOI 10.1016/j.pt.2005.07.005
   O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403
   O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595
   Perera KLRL, 1998, INFECT IMMUN, V66, P1500, DOI 10.1128/IAI.66.4.1500-1506.1998
   Pichyangkul S, 2004, VACCINE, V22, P3831, DOI 10.1016/j.vaccine.2004.07.023
   Putaporntip C, 2000, MOL BIOCHEM PARASIT, V109, P111, DOI 10.1016/S0166-6851(00)00238-3
   Putaporntip C, 2002, P NATL ACAD SCI USA, V99, P16348, DOI 10.1073/pnas.252348999
   ROCHA EMM, 1988, J PARASITOL, V74, P514, DOI 10.2307/3282072
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Rosa DS, 2004, IMMUNOL LETT, V92, P259, DOI 10.1016/j.imlet.2004.01.006
   Singh M, 2002, PHARM RES-DORDR, V19, P715, DOI 10.1023/A:1016104910582
   Soares IS, 1999, MOL MED, V5, P459
   Soares IS, 1999, AM J TROP MED HYG, V60, P357, DOI 10.4269/ajtmh.1999.60.357
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Stephens R, 2005, BLOOD, V106, P1676, DOI 10.1182/blood-2004-10-4047
   Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Valero LMS, 1998, INFECT IMMUN, V66, P3925, DOI 10.1128/IAI.66.8.3925-3930.1998
   van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005
NR 30
TC 31
Z9 31
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUL
PY 2006
VL 8
IS 8
BP 2130
EP 2137
DI 10.1016/j.micinf.2006.03.012
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 092RN
UT WOS:000241115100019
PM 16797207
DA 2020-11-26
ER

PT J
AU Blank, M
   Krause, I
   Magrini, L
   Spina, G
   Kalil, J
   Jacobsen, S
   Thiesen, HJ
   Cunningham, MW
   Guilherme, L
   Shoenfeld, Y
AF Blank, M.
   Krause, I.
   Magrini, L.
   Spina, G.
   Kalil, J.
   Jacobsen, S.
   Thiesen, H. J.
   Cunningham, M. W.
   Guilherme, L.
   Shoenfeld, Y.
TI Overlapping humoral autoimmunity links rheumatic fever and the
   antiphospholipid syndrome
SO RHEUMATOLOGY
LA English
DT Article
DE streptococcal infection; anti-beta 2GPI Abs; anti-M-protein Abs;
   carditis; chorea
ID STREPTOCOCCAL M-PROTEINS; LIBMAN-SACKS ENDOCARDITIS; ENDOTHELIAL-CELL
   ACTIVATION; ANTICARDIOLIPIN ANTIBODIES; BETA(2)-GLYCOPROTEIN I;
   MONOCLONAL-ANTIBODIES; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE;
   HEART-DISEASE; BETA-2-GLYCOPROTEIN-I
AB Objective: Rheumatic fever (RF) and the antiphospholipid syndrome (APS) are autoimmune diseases that share similar cardiac and neurological pathologies. We assessed the presence of shared epitopes between M protein, N-acetyl-beta-d-glucosamine (GlcNAc) and beta 2 glycoprotein-I (beta 2GPI), the pathogenic molecules engaged in these autoimmune conditions.
   Methods: Sera from the APS patients were affinity-purified on beta 2GPI and beta 2GPI-related peptide columns. Sera from RF patients were affinity-purified on protein G column. The beta 2GPI and M protein-related peptides were prepared by conventional solid-phase peptide synthesis. The enzyme-linked immunosorbent assay direct binding and inhibition studies were performed on the RF and APS sera for the presence, and cross-reactivity, of antibodies against beta 2GPI, beta 2GPI-related peptides, streptococcal M protein, M-derived peptides and GlcNAc.
   Results: Antibodies (Abs) to beta 2GPI were found in 24.4% of 90 RF patients. Antibodies against various beta 2GPI-related peptides were found in 1.1-36.7% of the patients. The immunoglobulin G sera from RF patients possessed significant anti-beta 2GPI activity, while sera from APS patients contained a considerable anti-streptococcal M protein as well as anti-GlcNAc activity. Furthermore, affinity-purified anti-beta 2GPI and anti-beta 2GPI-related peptide Abs from APS patients cross-reacted with streptococcal M protein and M5 peptide, while beta 2GPI and beta 2GPI-related peptides inhibited anti-streptococcal M protein activity from RF patients. The results were confirmed by immunoblot analyses. The beta 2GPI also inhibited anti-GlcNAc activity from APS patients with chorea.
   Conclusions: The results of our study, showing a considerable overlap of humoral immunity in RF and APS, support a hypothesis that common pathogenic mechanisms underlie the development of cardiac valve lesions and Central Nervous System abnormalities in both diseases.
C1 Chaim Sheba Med Ctr, Dept Med B, Res Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Fac Med, Dept Med E, Rabin Med Ctr, IL-69978 Tel Aviv, Israel.
   Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05508 Sao Paulo, Brazil.
   Millennium Inst, Inst Immunol Invest, Sao Paulo, Brazil.
   Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark.
   Univ Rostock, Inst Immunol, D-18055 Rostock, Germany.
   Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Biomed Res Ctr, Oklahoma City, OK 73104 USA.
   Tel Aviv Univ, Laura Schwarz Kipp Chair Autoimmun, IL-69978 Tel Aviv, Israel.
RP Shoenfeld, Y (corresponding author), Chaim Sheba Med Ctr, Dept Med B, Res Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel.
EM Shoenfel@post.tau.ac.il
RI Spina, Guilherme S./I-3530-2013; Guglielmi, Luiza G/E-7676-2013;
   Jacobsen, Soren/T-2491-2019; KALIL, JORGE/C-8029-2012
OI Jacobsen, Soren/0000-0002-5654-4993; KALIL, JORGE/0000-0001-8415-4274
CR Adderson EE, 1998, J IMMUNOL, V161, P2020
   AMIGO MC, 1993, RHEUM DIS CLIN N AM, V19, P333
   Amital H, 1999, CLIN EXP RHEUMATOL, V17, P99
   Arai T, 2001, BLOOD, V98, P1889, DOI 10.1182/blood.V98.6.1889
   Ardiles L, 1999, NEPHRON, V83, P47, DOI 10.1159/000045472
   ASHERSON RA, 1988, J NEUROL NEUROSUR PS, V51, P1458, DOI 10.1136/jnnp.51.11.1458
   AYOUB EM, 1991, J RHEUMATOL, V18, P6
   BadrEldin MK, 1996, ANN TROP PAEDIATR, V16, P113, DOI 10.1080/02724936.1996.11747813
   Balasubramanian K, 1998, J BIOL CHEM, V273, P29272, DOI 10.1074/jbc.273.44.29272
   BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106
   Blank M, 1999, P NATL ACAD SCI USA, V96, P5164, DOI 10.1073/pnas.96.9.5164
   Blank M, 2004, THROMB RES, V114, P589, DOI 10.1016/j.thromres.2004.06.039
   Blank M, 2004, J CLIN IMMUNOL, V24, P12, DOI 10.1023/B:JOCI.0000018058.28764.ce
   Blank M, 2002, J CLIN INVEST, V109, P797, DOI 10.1172/JCI200212337
   BLANK M, 1994, J AUTOIMMUN, V7, P441, DOI 10.1006/jaut.1994.1032
   Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166
   Brighton TA, 1996, BRIT J HAEMATOL, V93, P185, DOI 10.1046/j.1365-2141.1996.446981.x
   Cervera R, 2002, ARTHRITIS RHEUM-US, V46, P1019, DOI 10.1002/art.10187
   CERVERA R, 1991, LUPUS, V1, P43, DOI 10.1177/096120339100100108
   Cervera R, 2000, J AUTOIMMUN, V15, P123, DOI 10.1006/jaut.2000.0405
   Chapman J, 2003, LUPUS, V12, P514, DOI 10.1191/0961203303lu392oa
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   Cunningham MW, 2003, FRONT BIOSCI, V8, pS533, DOI 10.2741/1067
   DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036
   DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179
   DINIZ REAS, 1994, J RHEUMATOL, V21, P1367
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   FENDERSON PG, 1989, J IMMUNOL, V142, P2475
   FIGUEROA F, 1992, J RHEUMATOL, V19, P1175
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   George J, 1998, CIRCULATION, V97, P900, DOI 10.1161/01.CIR.97.9.900
   Gharavi AE, 1999, J IMMUNOL, V163, P2922
   Gharavi AE, 2002, ARTHRITIS RHEUM, V46, P545, DOI 10.1002/art.10130
   GHARAVI AE, 1992, J CLIN INVEST, V90, P1105, DOI 10.1172/JCI115927
   Gibofsky A, 1998, RHEUM DIS CLIN N AM, V24, P237, DOI 10.1016/S0889-857X(05)70007-7
   Guilherme L, 2004, INT ARCH ALLERGY IMM, V134, P56, DOI 10.1159/000077915
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Harraza H, 2001, LUPUS, V10, P873, DOI 10.1191/096120301701548526
   Hojnik M, 1996, CIRCULATION, V93, P1579, DOI 10.1161/01.CIR.93.8.1579
   Hong DP, 2001, BIOCHEMISTRY-US, V40, P8092, DOI 10.1021/bi010196v
   HUGHES GRV, 1986, J RHEUMATOL, V13, P486
   Katzav A, 2003, LUPUS, V12, P903, DOI 10.1191/0961203303lu500oa
   Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892
   Koike T, 2000, J AUTOIMMUN, V15, P97, DOI 10.1006/jaut.2000.0408
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   Lev S, 2002, CLIN REV ALLERG IMMU, V23, P341, DOI 10.1385/CRIAI:23:3:341
   Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974
   Libman E, 1924, ARCH INTERN MED, V33, P701, DOI 10.1001/archinte.1924.00110300044002
   Manfredi AA, 1998, ARTHRITIS RHEUM-US, V41, P215, DOI 10.1002/1529-0131(199802)41:2<215::AID-ART5>3.0.CO;2-X
   Narin N, 1996, CLIN EXP RHEUMATOL, V14, P567
   PIERANGELI SS, 1993, CLIN EXP IMMUNOL, V93, P269
   Raschi E, 2003, BLOOD, V101, P3495, DOI 10.1182/blood-2002-08-2349
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   SARGENT SJ, 1987, J IMMUNOL, V139, P1285
   Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228
   SHAPIRO RF, 1977, ANN RHEUM DIS, V36, P508, DOI 10.1136/ard.36.6.508
   SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902
   Shoenfeld Y, 2003, LUPUS, V12, P497, DOI 10.1191/0961203303lu396xx
   STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P131, DOI 10.1016/S0090-1229(05)80019-4
   Tamura N, 2002, ANN RHEUM DIS, V61, P374, DOI 10.1136/ard.61.4.374
   Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
   Zhang JW, 2005, BLOOD, V105, P1964, DOI 10.1182/blood-2004-05-1708
   Ziporen L, 1996, LUPUS, V5, P196, DOI 10.1177/096120339600500306
NR 67
TC 28
Z9 29
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUL
PY 2006
VL 45
IS 7
BP 833
EP 841
DI 10.1093/rheumatology/kel118
PG 9
WC Rheumatology
SC Rheumatology
GA 061XC
UT WOS:000238906000010
PM 16705050
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Fae, KC
   Higa, F
   Chaves, L
   Oshiro, SE
   De Barros, SF
   Puschel, C
   Juliano, MA
   Tanaka, AC
   Spina, G
   Kalil, J
AF Guilherme, L.
   Fae, K. C.
   Higa, F.
   Chaves, L.
   Oshiro, S. E.
   De Barros, S. Freschi
   Puschel, C.
   Juliano, M. A.
   Tanaka, A. C.
   Spina, G.
   Kalil, J.
TI Towards a vaccine against rheumatic fever
SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY
LA English
DT Article
DE rheumatic fever; Streptococcus pyogenes; T and B cell protective
   epitopes; vaccine
ID A STREPTOCOCCAL VACCINE; T-CELL-CLONES; M-PROTEIN; HEART-DISEASE;
   CONSERVED REGION; IMMUNIZATION; INTRANASAL; EPITOPES; MUCOSAL;
   IMMUNOGENICITY
AB Rheumatic fever (RF) is an autoimmune disease which affects more than 20 million children in developing countries. It is triggered by Streptococcus pyogenes throat infection in untreated susceptible individuals. Carditis, the most serious manifestation of the disease, leads to severe and permanent valvular lesions, causing chronic rheumatic heart disease (RHD). We have been studying the mechanisms leading to pathological autoimmunity in RF/RHD for the last 15 years. Our studies allowed us a better understanding of the cellular and molecular pathogenesis of RHD, paving the way for the development of a safe vaccine for a post-infection autoimmune disease. We have focused on the search for protective Tand B cell epitopes by testing 620 human blood samples against overlapping peptides spanning 99 residues of the C-terminal portion of the M protein, differing by one amino acid residue. We identified Tand B cell epitopes with 22 and 25 amino acid residues, respectively. Although these epitopes were from different regions of the C-terminal portion of the M protein, they showed an identical core of 16 amino acid residues. Antibodies against the B cell epitope inhibited bacterial invasion/adhesion in vitro. Our results strongly indicated that the selected T and B cell epitopes could potentially be protective against S. pyogenes.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), FMUSP, HC, Lab Imunol, Inst Coracao, Av Dr Eneas Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI de Barros, Samar Freschi/Q-4970-2018; Juliano, Maria/D-5289-2012; KALIL,
   JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013; Spina, Guilherme
   S./I-3530-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR Batzloff MR, 2005, J INFECT DIS, V192, P1450, DOI 10.1086/466528
   BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862
   BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945
   BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988
   Bisno AL, 2005, CLIN INFECT DIS, V41, P1150, DOI 10.1086/444505
   Brand Oliver, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009981
   Brandt ER, 2000, NAT MED, V6, P455
   Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2003, FRONT BIOSCI, V8, pS533, DOI 10.2741/1067
   DAJANI A, 1995, PEDIATRICS, V96, P758
   Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662
   FISCHETTI VA, 1988, REV INFECT DIS, V10, pS356
   Guilbault GG, 2006, ANAL LETT, V39, P1, DOI 10.1080/00032710500423336
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723
   Kotloff KL, 2005, INFECT IMMUN, V73, P2360, DOI 10.1128/IAI.73.4.2360-2366.2005
   Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868
   Olive C, 2005, VACCINE, V23, P2298, DOI 10.1016/j.vaccine.2005.01.041
   POLLY SM, 1975, J INFECT DIS, V131, P217, DOI 10.1093/infdis/131.3.217
   PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P33
   Shulman ST, 2004, CLIN INFECT DIS, V39, P325, DOI 10.1086/421949
   THERTON E, 1989, SOLID PHASE PEPTIDE, P152
   Vohra H, 2005, RES MICROBIOL, V156, P575, DOI 10.1016/j.resmic.2004.12.009
NR 32
TC 42
Z9 44
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1740-2522
EI 1740-2530
J9 CLIN DEV IMMUNOL
JI Clin. Dev. Immunol.
PD JUN-DEC
PY 2006
VL 13
IS 2-4
BP 125
EP 132
DI 10.1080/17402520600877026
PG 8
WC Immunology
SC Immunology
GA 120ZP
UT WOS:000243126000005
PM 17162355
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hiam, A
   Sebastien, D
   George, B
   Arlette, F
   Kalil, J
   Le Pape, P
AF Hiam, Abdala
   Sebastien, David
   George, Bekesi
   Arlette, Fellous
   Kalil, Jorge
   Le Pape, Patrice
TI Microtubule target for new antileishmanial drugs based on ethyl
   3-haloacetamidobenzoates
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article; Proceedings Paper
CT 14th Annual Conference on the Grouping of Pharmacochemisty of the
   Atlantic Arc
CY SEP 15-16, 2005
CL Angers, FRANCE
DE Leishmania; antileishmanials; benzoylureas; ethyl
   3-haloacetamidobenzoates; cytotoxicity; microtubule
ID VINBLASTINE-INDUCED AGGREGATION; BETA-TUBULIN; PARASITIC PROTOZOAN;
   DIFFERENTIAL EXPRESSION; CYCLE; TAU
AB A new family of antimicrotubule drugs named (3-haloacetamidobenzoyl) ureas and ethyl 3-haloacetamidobenzoates were found to be cytotoxic to the Leishmania parasite protozoa. While the benzoylureas were shown to strongly inhibit in vitro mammalian brain microtubule assembly, the ethyl ester derivatives were characterized as very poor inhibitors of this process. Ethyl 3-chloroacetamidobenzoate, MF29, was found to be the most efficient drug on the promastigote stage of three Leishmania species (IC50 : 0.3-1.8 mu M). MF29 maintained its activity against the clinical relevant intracellular stage of L. mexicana with IC50 value of 0.33 mu M. It was the only compound that exhibits a high activity on all the Leishmania species tested. This compound appeared to alter parasite microtubule organisation as demonstrated by using antibodies directed against microtubule components and more precisely the class of microtubule decorated by the MAP2-like protein. It is interesting to notice that this MAP2-like protein was identified for the first time in a Leishmania parasite
C1 Univ Nantes, Fac Pharm, Dept Parasitol & Mycol Med, BioCiT,UPRES EA 1155, F-44035 Nantes, France.
   Lab Expt & Clin Pharmacol, F-75010 Paris, France.
   NYU, Mt Sinai Sch Med, Div Med Oncol, New York, NY 10029 USA.
   Univ Sao Paulo, Fac Med, Lab Imunol, Sao Paulo, Brazil.
RP Le Pape, P (corresponding author), Univ Nantes, Fac Pharm, Dept Parasitol & Mycol Med, BioCiT,UPRES EA 1155, 1 Rue Gaston Veil, F-44035 Nantes, France.
EM patrice.le-pape@univ-nantes.fr
RI Le Pape, Patrice/W-1472-2019; KALIL, JORGE/C-8029-2012
OI Le Pape, Patrice/0000-0001-5059-6402; KALIL, JORGE/0000-0001-8415-4274
CR Abdala H, 2000, ARZNEIMITTEL-FORSCH, V50, P479
   BANERJEE A, 1992, J BIOL CHEM, V267, P13335
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   CHAN MMY, 1991, DIFFERENTIATION, V46, P15, DOI 10.1111/j.1432-0436.1991.tb00861.x
   CHAN MMY, 1990, SCIENCE, V249, P924, DOI 10.1126/science.2392684
   CHANDRASEKARAN EV, 1979, CANCER RES, V39, P870
   CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555
   Coulson RMR, 1996, MOL BIOCHEM PARASIT, V82, P227, DOI 10.1016/0166-6851(96)02739-9
   CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0
   Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m
   FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x
   FELLOUS A, 1985, CANCER RES, V45, P5004
   FONG D, 1981, P NATL ACAD SCI-BIOL, V78, P7624, DOI 10.1073/pnas.78.12.7624
   FONG D, 1984, P NATL ACAD SCI-BIOL, V81, P5782, DOI 10.1073/pnas.81.18.5782
   Fromes Y, 1996, J PROTEIN CHEM, V15, P561, DOI 10.1007/BF01908538
   Jiang JD, 1998, CANCER RES, V58, P5389
   Jiang JD, 1998, ANTI-CANCER DRUG DES, V13, P735
   JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302
   KALIL J, 1988, CULTURE CELLULES ANI, V199, P101
   KATIYAR SK, 1994, ANTIMICROB AGENTS CH, V38, P2086, DOI 10.1128/AAC.38.9.2086
   KHAW M, 1995, CLIN MICROBIOL REV, V8, P427, DOI 10.1128/CMR.8.3.427
   Laing N, 1997, BIOCHEMISTRY-US, V36, P871, DOI 10.1021/bi961445w
   Le Pape P, 2002, ACTA PARASITOL, V47, P79
   Le Pape P, 2000, CELL BIOL INT, V24, P51, DOI 10.1006/cbir.1999.0450
   Luduena RF, 1998, INT REV CYTOL, V178, P207
   LUDUENA RF, 1984, J BIOL CHEM, V259, P2890
   Moulay L, 1996, EXP CELL RES, V226, P283, DOI 10.1006/excr.1996.0229
   ROBERT ND, 1993, T ROY SOC TROP MED H, V87, P130
   RUSSELL D G, 1986, Parasitology Today, V2, P177, DOI 10.1016/0169-4758(86)90151-1
   SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765
   WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858
NR 31
TC 6
Z9 8
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475-6366
EI 1475-6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD JUN
PY 2006
VL 21
IS 3
BP 305
EP 312
DI 10.1080/14756360600700699
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 064KS
UT WOS:000239088900008
PM 16918078
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Cunha-Neto, E
   Fae, KC
   Muller, NG
   Cavalcanti, VL
   Drigo, SA
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
AF Ramasawmy, R
   Cunha-Neto, E
   Fae, KC
   Muller, NG
   Cavalcanti, VL
   Drigo, SA
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
TI BAT1, a putative anti-inflammatory gene, is associated with chronic
   chagas cardiomyopathy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY COMPLEX; DISEASE
   CARDIOMYOPATHY; HEART-FAILURE; PROMOTER; POLYMORPHISMS; TRANSCRIPTION;
   MYOCARDITIS; HAPLOTYPE; CLUSTER
AB Background. It is not understood why only a subset of individuals infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy ( CCC). Patients with CCC display high levels of circulating proinflammatory cytokines. Heart-infiltrating lymphocytes from patients with CCC also express proinflammatory cytokines ( tumor necrosis factor-alpha and interferon-gamma) that are detectable in biopsy samples and surgical heart-tissue samples. BAT1, a putative anti-inflammatory gene, presents functional polymorphisms in its promoter region that influence its transcriptional level.
   Methods. We assessed, by polymerase chain reaction restriction fragment-length polymorphism analysis, BAT1 variants in the promoter region at positions -22C/G and -348C/T in 154 patients with CCC and in 76 T. cruzi infected but asymptomatic ( ASY) patients.
   Results. Of the patients with CCC, 16% were homozygous for the -22C allele, compared with 4% of the ASY patients (P = .004; odds ratio [ OR], 4.7 [ 95% confidence interval {CI}, 1.4-16]). A similar trend was observed for the -348C homozygotes (P = .01; OR, 1.9 [ 95% CI, 1.0-3.5]). Susceptibility to CCC was conferred by the C variants at nt -22 (P = 0.003; OR, 1.8 [ 95% CI, 1.2-2.8]) and at nt -348 (; OR, 1.7 [ 95% CI, 1.0-2.8]).
   Conclusions. BAT1 variants previously associated with reduced expression of HLA-B-associated transcript 1 are predictive of the development of CCC. These variants may be less efficient in down-regulating inflammatory responses and may contribute to the elevated production of proinflammatory cytokines in patients with CCC.
C1 InCor FMUSP, Lab Imunol, BR-05403000 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Ramasawmy, R (corresponding author), InCor FMUSP, Lab Imunol, Av Eneas Carvalho Aguiar,44 Bloco 11 9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM ramasawm@usp.br
RI Mady, Charles/C-8870-2012; Ramasawmy, Rajendranath/V-4926-2019; LINDE,
   SANDRA/S-3128-2019; Ianni, Barbara Maria/C-7689-2012; Drigo, Sandra
   A/I-6514-2012; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014; Cunha-Neto, Edecio/B-4157-2009
OI Mady, Charles/0000-0002-8838-199X; LINDE, SANDRA/0000-0001-6747-6642;
   Ianni, Barbara Maria/0000-0002-1588-5492; Drigo, Sandra
   A/0000-0001-6747-6642; KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; Cunha-Neto, Edecio/0000-0002-3699-3345
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Allcock RJN, 2001, GENES CELLS, V6, P487, DOI 10.1046/j.1365-2443.2001.00435.x
   BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   BOCCHI EA, 1994, CIRCULATION, V90, P107
   CARRASCO HA, 1987, AM HEART J, V113, P716
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233
   Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682
   LOPES CBC, 2002, THESIS U SAO PAULO S
   LOPES ER, 1975, REV SOC BRAS MED TRO, V9, P269
   PEELMAN LJ, 1995, GENOMICS, V26, P210, DOI 10.1016/0888-7543(95)80203-X
   Price P, 1999, IMMUNOL REV, V167, P257, DOI 10.1111/j.1600-065X.1999.tb01398.x
   Price P, 2004, HUM MOL GENET, V13, P967, DOI 10.1093/hmg/ddh113
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   Wong AML, 2003, GENES CELLS, V8, P403, DOI 10.1046/j.1365-2443.2002.00641.x
   ZICKER F, 1990, INT J EPIDEMIOL, V19, P182, DOI 10.1093/ije/19.1.182
NR 26
TC 42
Z9 43
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2006
VL 193
IS 10
BP 1394
EP 1399
DI 10.1086/503368
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 036EI
UT WOS:000237053400009
PM 16619187
OA Bronze
DA 2020-11-26
ER

PT J
AU Fae, KC
   da Silva, DD
   Oshiro, SE
   Tanaka, AC
   Pomerantzeff, PMA
   Douay, C
   Charron, D
   Toubert, A
   Cunningham, MW
   Kalil, J
   Guilherme, L
AF Fae, Kellen C.
   da Silva, Danielle Diefenbach
   Oshiro, Sandra E.
   Tanaka, Ana C.
   Pomerantzeff, Pablo M. A.
   Douay, Corinne
   Charron, Dominique
   Toubert, Antoine
   Cunningham, Madeleine W.
   Kalil, Jorge
   Guilherme, Luiza
TI Mimicry in recognition of cardiac myosin peptides by heart-intralesional
   T cell clones from rheumatic heart disease
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID STREPTOCOCCAL M-PROTEIN; NONOBESE DIABETIC MICE; COILED-COIL STRUCTURE;
   MONOCLONAL-ANTIBODIES; MOLECULAR ANALYSIS; AUTOIMMUNITY; LYMPHOCYTES;
   EPITOPES; ANTIGEN; FEVER
AB Molecular mimicry between Streptococcus pyogenes Ags and human proteins has been considered as a mechanism leading to autoimmune reactions in rheumatic fever and rheumatic heart disease (RHD). Cardiac myosin has been shown as a putative autoantigen recognized by autoantibodies of rheumatic fever patients. We assessed the human heart-intralesional T cell response against human light meromyosin (LMM) and streptococcal M5 peptides and mitral-valve-derived proteins by proliferation assay. Cytokines induced by LMM peptides were also evaluated. The frequency of intralesional T cell clones that recognized LMM peptides was 63.2%. Thirty-four percent of T cell clones presented cross-reactivity with different patterns: 1) myosin and valve-derived proteins; 2) myosin and streptococcal M5 peptides; and 3) myosin, valve-derived proteins and M5 peptides. In addition, several LMM peptides were recognized simultaneously showing a multiple reactivity pattern of heart-infiltrating T cells. Inflammatory cytokines (IFN-gamma and TNF-alpha) were predominantly produced by heart-infiltrating T cells upon stimulation with LMM peptides. The alignment of LMM and streptococcal M5 peptides showed frequent homology among conserved amino acid substitutions. This is the first study showing the cellular response by human heart-infiltrating T cells against cardiac myosin epitopes in RHD patients. The high percentage of reactivity against cardiac myosin strengthens its role as one of the major autoantigens involved in rheumatic heart lesions. T cell reactivity toward myosin epitopes in RHD patients may also trigger the broad recognition of valvular proteins with structural or functional similarities.
C1 Univ Sao Paulo, Sch Med, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   Univ Paris 07, Hop St Louis, Inst Univ Hematol, AP HP,Ctr Invest Med,Lab Immunol & Histocompatibi, F-75221 Paris 05, France.
   Inst Immunol Invest, Millenium Inst, Sao Paulo, Brazil.
   Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Norman, OK 73019 USA.
   Univ Sao Paulo, Sch Med, Dept Clin Med, BR-05508 Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Imunol,Inst Coracao, Ave Dr Eneas Carvalho Aguiar,44-9o Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Pomerantzeff, Pablo M A/L-5525-2016; KALIL, JORGE/C-8029-2012; Toubert,
   Antoine/Q-3404-2017; Guglielmi, Luiza G/E-7676-2013
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; KALIL,
   JORGE/0000-0001-8415-4274; Toubert, Antoine/0000-0002-7308-7317; 
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 56267, HL 35280, R56 HL056267] Funding Source:
   Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL056267,
   R37HL035280, R01HL056267, R56HL056267, R01HL056267, R01HL056267,
   R01HL035280, R01HL056267, R01HL035280, R01HL035280, R37HL035280,
   R37HL035280, R01HL035280, R37HL035280, R01HL035280, R01HL035280,
   R01HL056267, R37HL035280, R01HL035280, R37HL035280, R37HL035280,
   R56HL056267, R01HL056267, R01HL035280, R01HL035280, R01HL056267,
   R01HL056267, R01HL035280, R01HL035280, R01HL056267, R01HL035280,
   R01HL035280, R01HL035280, R37HL035280, R01HL056267, R01HL056267,
   R01HL056267, R37HL035280, R01HL056267, R01HL035280, R37HL035280] Funding
   Source: NIH RePORTER
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   Bick RJ, 2003, LIFE SCI, V73, P2101, DOI 10.1016/S0024-3205(03)00560-5
   Cohen IR, 2001, J AUTOIMMUN, V16, P337, DOI 10.1006/jaut.2000.0481
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   DALE JB, 1987, J EXP MED, V166, P1825, DOI 10.1084/jem.166.6.1825
   DIEDERICH KW, 1989, HUM GENET, V81, P214
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   FEINSTEIN AR, 1993, MEDICINE, V72, P272, DOI 10.1097/00005792-199307000-00006
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8
   Graham CM, 2004, IMMUNOLOGY, V113, P194, DOI 10.1111/j.1365-2567.2004.01953.x
   Graham CM, 1998, J IMMUNOL, V161, P1094
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   GULIZIA JM, 1991, AM J PATHOL, V138, P285
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   Hutto JH, 1980, STREPTOCOCCAL DISEAS, P733
   Judkowski V, 2001, J IMMUNOL, V166, P908, DOI 10.4049/jimmunol.166.2.908
   KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301
   KAPLAN MH, 1969, AM J CARDIOL, V24, P459, DOI 10.1016/0002-9149(69)90489-5
   KAPLAN MH, 1963, J IMMUNOL, V90, P595
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Mertens NMJ, 2000, MOL IMMUNOL, V37, P901, DOI 10.1016/S0161-5890(01)00007-4
   NARULA J, 1999, RHEUMATIC FEVER, P504
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   Quinn A, 2001, CURR DIRECT AUTOIMMU, V4, P171
   Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   ROBINSON JH, 1993, INFECT IMMUN, V61, P1062, DOI 10.1128/IAI.61.3.1062-1068.1993
   SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593
   SMITH SC, 1991, J IMMUNOL, V147, P2141
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
   WUCHERPFENNING KW, 1995, J EXP MED, V81, P1597
   Zabriskie J B, 1967, Adv Immunol, V7, P147, DOI 10.1016/S0065-2776(08)60128-5
NR 48
TC 90
Z9 92
U1 0
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2006
VL 176
IS 9
BP 5662
EP 5670
DI 10.4049/jimmunol.176.9.5662
PG 9
WC Immunology
SC Immunology
GA 059YS
UT WOS:000238768700065
PM 16622036
OA Bronze
DA 2020-11-26
ER

PT J
AU Bilate, AM
   Teixeira, PC
   Ribeiro, S
   Silva, AM
   Brito, T
   Kalil, J
   Cunha-Neto, E
AF Bilate, AM
   Teixeira, PC
   Ribeiro, S
   Silva, AM
   Brito, T
   Kalil, J
   Cunha-Neto, E
TI Symptomatic acute phase of Trypanosoma cruzi infection in hamsters is
   related to increased parasitism, cytokine gene expression, and down
   regulation of energy metabolism proteins in the heart
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology 2006 Meeting
CY APR 01-05, 2006
CL San Francisco, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 Univ Sao Paulo, Inst Heart, BR-05403000 Sao Paulo, Brazil.
RI Teixeira, Priscila C/D-7426-2013; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 7
PY 2006
VL 20
IS 5
BP A1106
EP A1106
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 026GA
UT WOS:000236326202300
DA 2020-11-26
ER

PT J
AU Teixeira, PC
   Iwai, LK
   Honorato, R
   Fiorelli, A
   Stolf, N
   Kalil, J
   Cunha-Neto, E
AF Teixeira, PC
   Iwai, LK
   Honorato, R
   Fiorelli, A
   Stolf, N
   Kalil, J
   Cunha-Neto, E
TI Proteome analysis of myocardium from chronic Chagas' disease patients:
   Identification of immune response, oxidative stress, apoptosis, and
   metabolism proteins
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology 2006 Meeting
CY APR 01-05, 2006
CL San Francisco, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 Univ Sao Paulo, Inst Heart, BR-05403000 Sao Paulo, Brazil.
RI Fiorelli, Alfonso/AAO-2709-2020; Iwai, Leo K/M-1734-2013; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Teixeira, Priscila
   C/D-7426-2013
OI Iwai, Leo K/0000-0002-1571-7763; Cunha-Neto, Edecio/0000-0002-3699-3345;
   KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 7
PY 2006
VL 20
IS 5
BP A1105
EP A1105
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 026GA
UT WOS:000236326202298
DA 2020-11-26
ER

PT J
AU Drigo, SA
   Cunha-Neto, E
   Ianni, B
   Cardoso, MRA
   Braga, PE
   Fae, KC
   Nunes, VL
   Buck, P
   Mady, C
   Kalil, J
   Goldberg, AC
AF Drigo, Sandra A.
   Cunha-Neto, Edecio
   Ianni, Barbara
   Cardoso, Maria Regina A.
   Braga, Patricia E.
   Fae, Kellen C.
   Nunes, Vera Lopes
   Buck, Paula
   Mady, Charles
   Kalil, Jorge
   Goldberg, Anna Carla
TI TNF gene polymorphisms are associated with reduced survival in severe
   Chagas' disease cardiomyopathy patients
SO MICROBES AND INFECTION
LA English
DT Article
DE Chagas' disease; cardiomyopathy; heart failure; TNF-alpha; genetic
   polymorphism; mortality
ID NECROSIS-FACTOR-ALPHA; DILATED CARDIOMYOPATHY; PROMOTER POLYMORPHISM;
   HEART-FAILURE; RHEUMATOID-ARTHRITIS; FACTOR RECEPTORS; TRANSGENIC MICE;
   SUSCEPTIBILITY; ETANERCEPT; BETA
AB Chronic Chagas' disease cardiomyopathy (CCC) is the most important clinical outcome of infection by the parasite Trypanosoma cruzi, affecting 18 million individuals in Latin America. One-third of CCC patients develop heart failure due to end-stage dilated cardiomyopathy, and their survival is reduced by 50% compared to patients with other cardiomyopathies. Genetic susceptibility may play a role in the differential survival of severe CCC patients. Given the role of TNF-alpha in the progression of heart failure, and the increased TNF-alpha plasma and heart tissue levels observed in these patients, we chose TNF as a candidate gene for increased mortality in severe CCC patients. We typed the TNFa microsatellite and the -308 TNF promoter polymorphism and then analyzed the survival curves of 42 patients with severe ventricular dysfunction (left ventricular ejection fraction <= 40%) according to the presence of the TNF2 promoter allele or the TNFa2 microsatellite allele, both previously associated with high TNF-alpha production. Multivariate regression analysis (Cox proportional hazards model) revealed the TNF genotype and age of onset of severe CCC as independent predictors of mortality in severe CCC. We showed that patients positive for TNF2 or TNFa2 alleles display a significantly shorter survival time compared to those carrying other alleles; the median survival times were 2.9 and 8 months, respectively (HRadi = 2.28, p = 0.020). We have identified for the first time a genetic factor related to reduced survival in severe Chagas' disease cardiomyopathy. The association of TNF genotype with earlier death in CCC should be taken into account when planning therapeutic intervention. (c) 2005 Elsevier SAS. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05403001 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, BR-05403001 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, BR-01246904 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Av Prof Lineu Prestes 748,Bloco B8,Sala 861, BR-05508900 Sao Paulo, Brazil.
EM goldberg@usp.br
RI LINDE, SANDRA/S-3128-2019; Drigo, Sandra A/I-6514-2012; Cardoso, Maria
   Regina A/J-7280-2012; Mady, Charles/C-8870-2012; Buck, Paula
   C/F-8781-2012; Ianni, Barbara Maria/C-7689-2012; Goldberg, Anna
   Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Braga,
   Patricia/B-7806-2018; Cunha-Neto, Edecio/B-4157-2009
OI LINDE, SANDRA/0000-0001-6747-6642; Drigo, Sandra A/0000-0001-6747-6642;
   Mady, Charles/0000-0002-8838-199X; Buck, Paula C/0000-0002-1411-4485;
   Ianni, Barbara Maria/0000-0002-1588-5492; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   BIGNON JD, 1997, GENETIC DIVERSITY HL, V1, P587
   Bocchi EA, 2001, J HEART LUNG TRANSPL, V20, P637, DOI 10.1016/S1053-2498(00)00235-7
   Bradham WS, 2002, CARDIOVASC RES, V53, P822, DOI 10.1016/S0008-6363(01)00503-X
   Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Criswell LA, 2004, ARTHRITIS RHEUM-US, V50, P2750, DOI 10.1002/art.20469
   Densem CG, 2002, HEART, V87, P153, DOI 10.1136/heart.87.2.153
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   GIROIR BP, 1992, J CLIN INVEST, V90, P693, DOI 10.1172/JCI115939
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Higuchi MD, 1999, HEART, V82, P279, DOI 10.1136/hrt.82.3.279
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Hosmer DW, 1989, APPL LOGISTIC REGRES
   JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233
   Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627
   Mady C, 1999, AM J CARDIOL, V84, P354, DOI 10.1016/S0002-9149(99)00295-7
   Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2
   Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B
   Mann DL, 2002, J CARD FAIL, V8, pS379, DOI 10.1054/jcaf.2002.129253
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561
   NEDOSPASOV SA, 1991, J IMMUNOL, V147, P1053
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   POCIOT F, 1993, EUR J IMMUNOL, V23, P224, DOI 10.1002/eji.1830230135
   Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282
   Talvani A, 2004, CLIN INFECT DIS, V38, P943, DOI 10.1086/381892
   TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487
   TorreAmione G, 1996, CIRCULATION, V93, P704
   UDALOVA IA, 1993, GENOMICS, V16, P180, DOI 10.1006/geno.1993.1156
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   *WHO, 2002, WHO EXP COMM CONTR C
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Yunis EJ, 2003, TISSUE ANTIGENS, V62, P1, DOI 10.1034/j.1399-0039.2003.00098.x
   1999, ARQ BRAS CARDIOL, V73, P1
NR 43
TC 45
Z9 47
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD MAR
PY 2006
VL 8
IS 3
BP 598
EP 603
DI 10.1016/j.micinf.2005.08.009
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 045PL
UT WOS:000237754000002
PM 16427798
DA 2020-11-26
ER

PT J
AU Teixeira, MMG
   daSilva, FM
   Marcili, A
   Umezawa, ES
   Shikanai-Yasuda, MA
   Cunha-Neto, E
   Kalil, J
   Stolf, N
   Stolf, AMS
AF Teixeira, MMG
   daSilva, FM
   Marcili, A
   Umezawa, ES
   Shikanai-Yasuda, MA
   Cunha-Neto, E
   Kalil, J
   Stolf, N
   Stolf, AMS
TI Short communication: Trypanosoma cruzi lineage I in endomyocardial
   biopsy from a north-eastern Brazilian patient at end-stage chronic
   chagasic cardiomyopathy
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Trypanosoma cruzi; Chagas disease; genetic typing; cardiomyopathy;
   endomyocardial biopsy; T. cruzi lineages
ID RIBOSOMAL-RNA; DISEASE; EPIDEMIOLOGY
AB Trypanosoma cruzi, the agent of Chagas disease, is genetically classified into two major evolutionary lineages, T. cruzi I and T. cruzi II. In Southern American Cone countries it is T cruzi II which causes most cases of severe chronic Chagas disease. Contrary to this, we isolated T. cruzi I nested in endomyocardial biopsies of a chronic chagasic patient with end-stage heart failure. Our finding should alert clinicians to the possibility of severe Chagas disease in all regions where T. cruzi circulates, regardless of its lineage.
C1 Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Coracao, Div Cirurgia, BR-05508900 Sao Paulo, Brazil.
RP Teixeira, MMG (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Av Prof Lineu Prestes,1374, BR-05508900 Sao Paulo, Brazil.
EM mmgteix@icb.usp.br
RI Marcili, Arlei/E-2888-2013; Cunha-Neto, Edecio/B-4157-2009;
   Shikanai-Yasuda, Maria A/C-4268-2012; ShikanaiYasuda, Maria
   A/A-9000-2013; Teixeira, Marta M G/B-1115-2009; KALIL,
   JORGE/C-8029-2012; Yasuda, Maria Aparecida Shikanai/AAX-7693-2020
OI Marcili, Arlei/0000-0002-0478-6771; Cunha-Neto,
   Edecio/0000-0002-3699-3345; ShikanaiYasuda, Maria A/0000-0003-3864-041X;
   KALIL, JORGE/0000-0001-8415-4274; Yasuda, Maria Aparecida
   Shikanai/0000-0003-3864-041X
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Anez N, 2004, TROP MED INT HEALTH, V9, P1319, DOI 10.1111/j.1365-3156.2004.01333.x
   [Anonymous], 1999, MEM I OSWALDO CRUZ, V94, P429
   Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6
   Buscaglia CA, 2003, MICROBES INFECT, V5, P419, DOI 10.1016/S1286-4579(03)00050-9
   CAMANDAROBA ELP, 2002, J EXP MED, V195, P401
   Coura JR, 2002, TRENDS PARASITOL, V18, P171, DOI 10.1016/S1471-4922(01)02200-0
   Freitas JM, 2005, INT J PARASITOL, V35, P411, DOI 10.1016/j.ijpara.2004.10.023
   Miles MA, 2003, BMJ-BRIT MED J, V326, P1444, DOI 10.1136/bmj.326.7404.1444
   Montilla M, 2002, AM J TROP MED HYG, V66, P394, DOI 10.4269/ajtmh.2002.66.394
   Morel CM, 2003, NAT REV MICROBIOL, V1, P14, DOI 10.1038/nrmicro735
   Pinto Ana Yecê das Neves, 2004, Braz J Infect Dis, V8, P454, DOI 10.1590/S1413-86702004000600010
   SHIKANAIYASUDA MA, 1991, REV I MED TROP, V33, P351, DOI 10.1590/S0036-46651991000500003
   Yeo M, 2005, INT J PARASITOL, V35, P225, DOI 10.1016/j.ijpara.2004.10.024
   Zingales B, 1998, INT J PARASITOL, V28, P105, DOI 10.1016/S0020-7519(97)00178-1
   Zingales B, 1999, MEM I OSWALDO CRUZ, V94, P159, DOI 10.1590/S0074-02761999000700020
NR 16
TC 36
Z9 36
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2006
VL 11
IS 3
BP 294
EP 298
DI 10.1111/j.1365-3156.2006.01575.x
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 019NG
UT WOS:000235843200006
PM 16553909
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Kalil, J
   Cunningham, M
AF Guilherme, L
   Kalil, J
   Cunningham, M
TI Molecular mimicry in the autoimmune pathogenesis of rheumatic heart
   disease
SO AUTOIMMUNITY
LA English
DT Article
DE streptococci; myosin; autoimmunity; rheumatic fever
ID STREPTOCOCCAL-M-PROTEIN; T-CELL-CLONES; CLASS-II ASSOCIATIONS; GROUP-A
   STREPTOCOCCUS; BETA-D-GLUCOSAMINE; MONOCLONAL-ANTIBODIES; CARDIAC
   MYOSIN; IMMUNOLOGICAL RELATIONSHIP; TISSUE ANTIGENS; CROSS-REACTION
AB Molecular mimicry is a hallmark of the pathogenesis of rheumatic fever where the streptococcal group A carbohydrate epitope, N-acetyl glucosamine, and the alpha-helical coiled-coil streptococcal M protein structurally mimic cardiac myosin in the human disease, rheumatic carditis, and in animal models immunized with streptococcal M protein and cardiac myosin. Recent studies have unraveled the potential pathogenic mechanisms by which the immune response against the group A streptococcus attacks the rheumatic valve leading to chronic rheumatic heart disease. Both B- and T-cell responses are involved in the process, and evidence for the hypotheses of molecular mimicry and epitope spreading are reviewed.
C1 Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP Cunningham, M (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
EM madeleine-cunningham@ouhsc.edu
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   BARNETT LA, 1992, FASEB J, V6, P840
   Bisno AL, 1980, STREPTOCOCCAL DISEAS, P789
   BRONZE MS, 1988, J EXP MED, V167, P1849, DOI 10.1084/jem.167.6.1849
   CAVELTI PA, 1945, P SOC EXP BIOL MED, V60, P379
   CROMARTIE WJ, 1966, SCIENCE, V154, P285, DOI 10.1126/science.154.3746.285
   CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998
   CUNNINGHAM MW, 1988, J IMMUNOL, V141, P2760
   Cunningham MW, 2003, FRONT BIOSCI, V8, pS533, DOI 10.2741/1067
   DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036
   DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113
   Degnan B, 1997, HUM IMMUNOL, V53, P206, DOI 10.1016/S0198-8859(97)00028-1
   DUDDING BA, 1968, J EXP MED, V128, P1081, DOI 10.1084/jem.128.5.1081
   Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   FENDERSON PG, 1989, J IMMUNOL, V142, P2475
   FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8
   GOLDSTEI.I, 1967, NATURE, V213, P44, DOI 10.1038/213044a0
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   GUILHERME L, 1999, INFECT AUTOIMMUNITY, P321
   GULIZIA JM, 1992, P 11 LANC INT S NEW, V22, P267
   Hernandez-Pacheco G, 2003, INT J CARDIOL, V92, P49, DOI 10.1016/S0167-5273(03)00040-8
   Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9
   Huber SA, 1996, J IMMUNOL, V156, P3528
   Jones TD, 1944, J AMER MED ASSOC, V126, P481, DOI 10.1001/jama.1944.02850430015005
   KAPLAN MH, 1964, J EXP MED, V119, P651, DOI 10.1084/jem.119.4.651
   KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301
   KAPLAN MH, 1963, J IMMUNOL, V90, P595
   KAPLAN MH, 1962, LANCET, V1, P706
   KAPLAN MH, 1964, J EXP MED, V119, P643, DOI 10.1084/jem.119.4.643
   Kaur S, 1998, INT J CARDIOL, V64, P9, DOI 10.1016/S0167-5273(98)00009-6
   Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892
   KOTB M, 1990, J IMMUNOL, V145, P1332
   Koyanagi T, 1996, J MOL CELL CARDIOL, V28, P1349, DOI 10.1006/jmcc.1996.0125
   KRAUS W, 1989, INFECT IMMUN, V57, P2457, DOI 10.1128/IAI.57.8.2457-2461.1989
   KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225
   Kurahara D, 2002, J RHEUMATOL, V29, P379
   Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   MANJULA BN, 1980, J EXP MED, V151, P695, DOI 10.1084/jem.151.3.695
   MANJULA BN, 1986, BIOCHEM BIOPH RES CO, V140, P684, DOI 10.1016/0006-291X(86)90786-2
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   MASSELL BF, 1969, J AMER MED ASSOC, V207, P1115, DOI 10.1001/jama.207.6.1115
   Massell BF, 1997, RHEUMATIC FEVER STRE
   McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202
   MILLER L, 1988, J BIOL CHEM, V263, P5668
   MURPHY GE, 1949, J EXP MED, V89, P687, DOI 10.1084/jem.89.6.687
   MURPHY GE, 1950, J EXP MED, V91, P485, DOI 10.1084/jem.91.5.485
   NEU N, 1987, J IMMUNOL, V139, P3630
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235
   PRUKSAKORN S, 1994, LANCET, V344, P639, DOI 10.1016/S0140-6736(94)92083-4
   PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729
   Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29
   QUINN A, 1995, J IMMUNOL, V154, P4203
   Quinn A, 1998, INFECT IMMUN, V66, P4418
   Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   ROBINSON JH, 1993, INFECT IMMUN, V61, P1062, DOI 10.1128/IAI.61.3.1062-1068.1993
   SHIKHMAN AR, 1993, J IMMUNOL, V151, P3902
   SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375
   SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   Stollerman GH, 1997, LANCET, V349, P935, DOI 10.1016/S0140-6736(96)06364-7
   Stollerman GH, 1988, HEART DIS TXB CARDIO, P1706
   SWERLICK RA, 1986, J INVEST DERMATOL, V87, P367, DOI 10.1111/1523-1747.ep12524838
   TARANTA A, 1999, RHEUMATIC FEVER, P1
   TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359
   VEASY LG, 1995, CARDIOL YOUNG, V5, P293
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   YOSHINAGA M, 1995, J AUTOIMMUN, V8, P601, DOI 10.1016/0896-8411(95)90011-X
   Zabriskie J B, 1967, Adv Immunol, V7, P147, DOI 10.1016/S0065-2776(08)60128-5
   ZABRISKIE JB, 1970, CLIN EXP IMMUNOL, V7, P147
   ZABRISKIE JB, 1966, J EXP MED, V124, P661, DOI 10.1084/jem.124.4.661
NR 88
TC 101
Z9 103
U1 2
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891-6934
EI 1607-842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD FEB
PY 2006
VL 39
IS 1
BP 31
EP 39
DI 10.1080/08916930500484674
PG 9
WC Immunology
SC Immunology
GA 008OI
UT WOS:000235049900005
PM 16455580
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Bilate, AM
   Hyland, KV
   Fonseca, SG
   Kalil, J
   Engman, DM
AF Cunha-Neto, E
   Bilate, AM
   Hyland, KV
   Fonseca, SG
   Kalil, J
   Engman, DM
TI Induction of cardiac autoimmunity in Chagas heart disease: A case for
   molecular mimicry
SO AUTOIMMUNITY
LA English
DT Review
DE Chagas disease cardiomyopathy; autoimmunity; cardiomyocyte; Trypanosoma
   cruzi; molecular mimicry
ID TRYPANOSOMA-CRUZI INFECTION; MUSCARINIC ACETYLCHOLINE-RECEPTORS;
   RIBOSOMAL P2-BETA PROTEIN; POLYMERASE-CHAIN-REACTION;
   NECROSIS-FACTOR-ALPHA; MYOSIN-HEAVY-CHAIN; T-CELL; MONOCLONAL-ANTIBODY;
   IMMUNE-RESPONSE; GENE-EXPRESSION
AB Up to 18 million of individuals are infected by the protozoan parasite Trypanosoma cruzi in Latin America, one third of whom will develop chronic Chagas disease cardiomyopathy (CCC) up to 30 years after infection. Cardiomyocyte destruction is associated with a T cell-rich inflammatory infiltrate and fibrosis. The presence of such lesions in the relative scarcity of parasites in the heart, suggested that CCC might be due, in part, to a postinfectious autoimmune process. Over the last two decades, a significant amount of reports of autoimmune and molecular mimicry phenomena have been described in CCC. The authors will review the evidence in support of an autoimmune basis for CCC pathogenesis in humans and experimental animals, with a special emphasis on molecular mimicry as a fundamental mechanism of autoimmunity.
C1 Inst Heart, InCor, Immunol Lab, BR-05403000 Sao Paulo, SP, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.
   Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
   Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA.
RP Cunha-Neto, E (corresponding author), Inst Heart, InCor, Immunol Lab, Av Dr Eneas Carvalho Aguir,44,Bloco 2,9 Andar,Cer, BR-05403000 Sao Paulo, SP, Brazil.
EM d-engman@northwestern.edu
RI KALIL, JORGE/C-8029-2012; Engman, David/T-6747-2018; Cunha-Neto,
   Edecio/B-4157-2009; FONSECA, SIMONE GONCALVES/U-9278-2019
OI KALIL, JORGE/0000-0001-8415-4274; Engman, David/0000-0001-5869-9844;
   Cunha-Neto, Edecio/0000-0002-3699-3345; 
CR ABEL LC, 2005, IN PRESS MICROBES IN
   Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Ablashi DV, 1998, MULT SCLER, V4, P490, DOI 10.1191/135245898678845133
   ACOSTA AM, 1983, P SOC EXP BIOL MED, V172, P364, DOI 10.3181/00379727-172-41571
   ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255
   Aiello VD, 2002, J PATHOL, V197, P224, DOI 10.1002/path.1095
   Al-Sabbagh A, 1998, EXP PARASITOL, V89, P304, DOI 10.1006/expr.1998.4279
   Amorim D S, 1985, Heart Vessels Suppl, V1, P236, DOI 10.1007/BF02072401
   Andersson J, 2003, IMMUNOL LETT, V86, P207, DOI 10.1016/S0165-2478(03)00019-1
   Anez N, 1999, AM J TROP MED HYG, V60, P726, DOI 10.4269/ajtmh.1999.60.726
   Bach-Elias M, 1998, PARASITOL RES, V84, P796, DOI 10.1007/s004360050490
   BARR SC, 1991, VET IMMUNOL IMMUNOP, V29, P267, DOI 10.1016/0165-2427(91)90019-9
   BARR SC, 1993, INT J PARASITOL, V23, P961, DOI 10.1016/0020-7519(93)90064-6
   Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797
   Beraun Y, 1998, TISSUE ANTIGENS, V52, P81, DOI 10.1111/j.1399-0039.1998.tb03028.x
   Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6
   Bergami PL, 2001, FASEB J, V15, P2602, DOI 10.1096/fj.01-0132com
   Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
   Bocchi E A, 1994, Arq Bras Cardiol, V63, P523
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   BONFA E, 1993, J IMMUNOL, V150, P3917
   BONFA V, 1992, MEM I OSWALDO CRUZ, V87, P172
   BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679
   Bosetto MC, 2004, BRAZ J MED BIOL RES, V37, P37, DOI 10.1590/S0100-879X2004000100006
   Bustamante JM, 2002, INT J PARASITOL, V32, P889, DOI 10.1016/S0020-7519(02)00023-1
   Calzada JE, 2001, TISSUE ANTIGENS, V57, P353, DOI 10.1034/j.1399-0039.2001.057004353.x
   Camargo MM, 1997, J IMMUNOL, V158, P5890
   Camargos ERS, 2002, CLIN SCI, V103, p64S, DOI 10.1042/CS103S064S
   CHIALE PA, 1995, J AM COLL CARDIOL, V26, P864, DOI 10.1016/0735-1097(95)00262-2
   CHOCACIR PR, 1981, REV I MED SAO PAULO, P23
   Cihakova D, 2004, METH MOLEC MED, V102, P175
   Colmanetti FH, 2005, ULTRASTRUCT PATHOL, V29, P139, DOI 10.1080/019131290923974
   Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9
   COSSIO PM, 1984, CLIN IMMUNOL IMMUNOP, V33, P165, DOI 10.1016/0090-1229(84)90071-0
   Costa RP, 2000, SCAND J IMMUNOL, V51, P511, DOI 10.1046/j.1365-3083.2000.00706.x
   CREMASCHI G, 1995, FASEB J, V9, P1482
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto E, 2005, AM J PATHOL, V167, P305, DOI 10.1016/S0002-9440(10)62976-8
   Cunha-Neto E., 1998, MEM I O CRUZ S1, V93, P40
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   CUNHANETO E, 2004, INFECT AUTOIMMUNITY, P451
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2003, FRONT BIOSCI, V8, pS533, DOI 10.2741/1067
   Cunningham MW, 2001, AUTOIMMUNITY, V34, P193, DOI 10.3109/08916930109007384
   da Costa SCG, 1999, MEM I OSWALDO CRUZ, V94, P269, DOI 10.1590/S0074-02761999000700045
   De Souza W, 2002, CURR PHARM DESIGN, V8, P269, DOI 10.2174/1381612023396276
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031
   DESCHEERDER IK, 1989, AUTOIMMUNITY, V4, P51, DOI 10.3109/08916938909034359
   DosReis GA, 2005, TRENDS PARASITOL, V21, P237, DOI 10.1016/j.pt.2005.03.008
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   DOSSANTOS RR, 1979, TROPENMED PARASITOL, V30, P19
   DRIGO SA, 2005, IN PRESS MICROBES IN
   Dumonteil E, 2004, INFECT IMMUN, V72, P46, DOI 10.1128/IAI.72.1.46-53.2004
   Elias FE, 2003, AM J TROP MED HYG, V68, P242, DOI 10.4269/ajtmh.2003.68.242
   ELZAYADI AR, 1998, TROP GASTROENTEROL, V9, P141
   Engman DM, 2002, ACTA TROP, V81, P123, DOI 10.1016/S0001-706X(01)00202-9
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197
   FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59
   Ferrari I, 1997, MEM I OSWALDO CRUZ, V92, P843, DOI 10.1590/S0074-02761997000600021
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   Freitas JM, 2005, INT J PARASITOL, V35, P411, DOI 10.1016/j.ijpara.2004.10.023
   Garg N, 2003, BBA-MOL BASIS DIS, V1638, P106, DOI 10.1016/S0925-4439(03)00060-7
   GATTASS CR, 1988, INFECT IMMUN, V56, P1402, DOI 10.1128/IAI.56.5.1402-1405.1988
   GEA S, 1993, AM J TROP MED HYG, V49, P581, DOI 10.4269/ajtmh.1993.49.581
   Giordanengo L, 2000, MUSCLE NERVE, V23, P1407, DOI 10.1002/1097-4598(200009)23:9<1407::AID-MUS12>3.0.CO;2-3
   Giordanengo L, 2000, EUR J IMMUNOL, V30, P3181, DOI 10.1002/1521-4141(200011)30:11&lt;3181::AID-IMMU3181&gt;3.0.CO;2-A
   Giordanengo L, 2002, EUR J IMMUNOL, V32, P1003, DOI 10.1002/1521-4141(200204)32:4<1003::AID-IMMU1003>3.0.CO;2-P
   Giordanengo L, 2001, CLIN EXP IMMUNOL, V124, P266, DOI 10.1046/j.1365-2249.2001.01512.x
   Girones N, 2001, J CLIN INVEST, V107, P985, DOI 10.1172/JCI10734
   Girones N, 2001, CLIN DIAGN LAB IMMUN, V8, P1039, DOI 10.1128/CDLI.8.6.1039-1043.2001
   Godsel LM, 2001, CIRCULATION, V103, P1709, DOI 10.1161/01.CIR.103.12.1709
   GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7
   GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244
   Goin JC, 1997, FASEB J, V11, P77
   Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   Hernandez CCQ, 2003, CARDIOVASC RES, V58, P55, DOI 10.1016/S0008-6363(02)00811-8
   HERNANDEZMUNAIN C, 1992, J EXP MED, V175, P1473, DOI 10.1084/jem.175.6.1473
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   HontebeyrieJoskowicz M, 1997, PARASITOL TODAY, V13, P156, DOI 10.1016/S0169-4758(97)89814-6
   Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006
   Jahns R, 1999, CIRCULATION, V99, P649, DOI 10.1161/01.CIR.99.5.649
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   JORG M, 1992, ENFERMEDAD CHAGAS PU, P71
   JUNQUEIRA LF, 1992, CARDIOVASC RES, V26, P324, DOI 10.1093/cvr/26.4.324
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301
   KERNER N, 1991, EXP PARASITOL, V73, P451, DOI 10.1016/0014-4894(91)90069-9
   Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210
   Kierszenbaum F, 1996, PARASITOL TODAY, V12, P414, DOI 10.1016/0169-4758(96)20050-X
   Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255
   Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8
   Kohno K, 2001, AUTOIMMUNITY, V34, P177, DOI 10.3109/08916930109007382
   KYU B, 1992, CIRCULATION, V86, P522, DOI 10.1161/01.CIR.86.2.522
   LAGUENS RP, 1988, INFECT IMMUN, V56, P993, DOI 10.1128/IAI.56.4.993-997.1988
   LAGUENS RP, 1989, MEDICINA-BUENOS AIRE, V49, P197
   Laucella SA, 1996, ACTA TROP, V61, P223, DOI 10.1016/0001-706X(96)00004-6
   Laucella SA, 1996, ACTA TROP, V62, P151, DOI 10.1016/S0001-706X(96)00032-0
   LAYRISSE Z, 1988, HUM IMMUNOL, V23, P116, DOI 10.1016/0198-8859(88)90189-9
   Leiby DA, 2002, TRANSFUSION, V42, P549, DOI 10.1046/j.1537-2995.2002.00077.x
   Leiby DA, 1997, J INFECT DIS, V176, P1047, DOI 10.1086/516534
   Leiros CP, 1997, J BIOL CHEM, V272, P12989, DOI 10.1074/jbc.272.20.12989
   Leon JS, 2004, INFECT IMMUN, V72, P3410, DOI 10.1128/IAI.72.6.3410-3417.2004
   Leon JS, 2003, J IMMUNOL, V171, P4271, DOI 10.4049/jimmunol.171.8.4271
   Leon JS, 2003, CIRCULATION, V107, P2264, DOI 10.1161/01.CIR.0000062690.79456.D0
   Leon JS, 2003, FRONT BIOSCI-LANDMRK, V8, pE315, DOI 10.2741/1023
   Leon JS, 2001, INFECT IMMUN, V69, P5643, DOI 10.1128/IAI.69.9.5643-5649.2001
   LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530
   LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x
   LOPES MD, 1991, REV SOCIEDADE BRASIL, V24, P48
   Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J
   Marcipar IS, 2001, CLIN DIAGN LAB IMMUN, V8, P802, DOI 10.1128/CDLI.8.4.802-805.2001
   Marin-Neto JA, 1998, INT J CARDIOL, V65, P261, DOI 10.1016/S0167-5273(98)00132-6
   Masuda MO, 1998, FASEB J, V12, P1551
   MCCORMICK TS, 1993, EXP PARASITOL, V77, P273, DOI 10.1006/expr.1993.1085
   MCCORMICK TS, 1989, EXP PARASITOL, V69, P393, DOI 10.1016/0014-4894(89)90088-X
   MENDOZA V, 1986, AM J CARDIOL, V57, P423
   Mijares A, 1996, MOL CELL BIOCHEM, V164, P107, DOI 10.1007/BF00408646
   Mijares A, 1996, FEBS LETT, V399, P188, DOI 10.1016/S0014-5793(96)01321-X
   *MIN SAUD SECR VIG, 2005, DOENC CHAG AG REL IN
   MINOPRIO P, 1988, SCAND J IMMUNOL, V28, P553, DOI 10.1111/j.1365-3083.1988.tb01487.x
   Minoprio P, 2001, INT J PARASITOL, V31, P588, DOI 10.1016/S0020-7519(01)00171-0
   Moncayo A, 1999, MEM I OSWALDO CRUZ, V94, P401, DOI 10.1590/S0074-02761999000700079
   Moncayo A, 2003, MEM I OSWALDO CRUZ, V98, P577, DOI 10.1590/S0074-02762003000500001
   MOSCA W, 1985, J CLIN MICROBIOL, V22, P438, DOI 10.1128/JCM.22.3.438-441.1985
   Motran CC, 1998, EXP PARASITOL, V88, P223, DOI 10.1006/expr.1998.4255
   Motran CC, 2000, CLIN IMMUNOL, V97, P89, DOI 10.1006/clim.2000.4919
   Mukherjee S, 2003, PARASITOL RES, V91, P187, DOI 10.1007/s00436-003-0937-z
   NEU N, 1991, EUR HEART J, V12, P117, DOI 10.1093/eurheartj/12.suppl_D.117
   NEU N, 1993, CLIN IMMUNOL IMMUNOP, V68, P107, DOI 10.1006/clin.1993.1104
   NEUMANN DA, 1993, CLIN IMMUNOL IMMUNOP, V68, P181, DOI 10.1006/clin.1993.1116
   NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851
   Nitz N, 2004, CELL, V118, P175, DOI 10.1016/j.cell.2004.07.001
   NOMURA Y, 1994, PEDIATR CARDIOL, V15, P116
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   Oliveira MF, 2001, PARASITOL RES, V87, P1043
   Palomino SAP, 2000, ANN TROP MED PARASIT, V94, P571, DOI 10.1080/00034983.2000.11813580
   PASCUAL J, 1987, LIFE SCI, V40, P313, DOI 10.1016/0024-3205(87)90131-7
   Pereira J B, 1992, Rev Soc Bras Med Trop, V25, P101, DOI 10.1590/S0037-86821992000200003
   PETRY K, 1987, ACTA TROP, V44, P381
   Petry K, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P498, DOI 10.1590/S0074-02761988000500057
   PETRY K, 1987, J NEUROIMMUNOL, V16, P237, DOI 10.1016/0165-5728(87)90078-6
   PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5
   Piaggio E, 2001, PARASITOL RES, V87, P539, DOI 10.1007/s004360000357
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   POSTAN M, 1987, T ROY SOC TROP MED H, V81, P415, DOI 10.1016/0035-9203(87)90155-6
   PRATA A, 1994, INFECT DIS CLIN N AM, V8, P61
   Ramirez L E, 1994, Rev Soc Bras Med Trop, V27, P163, DOI 10.1590/S0037-86821994000300007
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   REVELLI S, 1995, MICROBIOL IMMUNOL, V39, P275, DOI 10.1111/j.1348-0421.1995.tb02201.x
   Riarte A, 1999, CLIN INFECT DIS, V29, P561, DOI 10.1086/598634
   Ribeiro-Dos-Santos R, 2001, PARASITE IMMUNOL, V23, P93, DOI 10.1046/j.1365-3024.2001.00368.x
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   Rodriguez-Perez JM, 2005, IMMUNOL LETT, V98, P97, DOI 10.1016/j.imlet.2004.10.017
   Rodriguez-Salas LA, 1998, ECHOCARDIOGR-J CARD, V15, P271, DOI 10.1111/j.1540-8175.1998.tb00607.x
   Rose NR, 1996, INT J CARDIOL, V54, P171, DOI 10.1016/0167-5273(96)02595-8
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   SANTOSBU.CA, 1974, J EXP MED, V140, P38, DOI 10.1084/jem.140.1.38
   SANTOSBUCH CA, 1985, CLIN IMMUNOL IMMUNOP, V37, P334, DOI 10.1016/0090-1229(85)90103-5
   Sartori AMC, 1998, CLIN INFECT DIS, V26, P177, DOI 10.1086/516257
   SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617
   Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5
   Sterin-Borda L, 2003, EUR J IMMUNOL, V33, P2459, DOI 10.1002/eji.200324009
   Sterin-Borda L, 2001, GUT, V49, P699, DOI 10.1136/gut.49.5.699
   STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349
   STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8
   Stull LB, 2000, J MOL CELL CARDIOL, V32, P2035, DOI 10.1006/jmcc.2000.1235
   TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992
   Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932
   Tarleton RL, 2001, INT J PARASITOL, V31, P550, DOI 10.1016/S0020-7519(01)00158-8
   TEIXEIRA ARL, 1978, AM J TROP MED HYG, V27, P1097, DOI 10.4269/ajtmh.1978.27.1097
   Tekiel V, 2001, PARASITE IMMUNOL, V23, P533, DOI 10.1046/j.1365-3024.2001.00415.x
   Tekiel VS, 1997, PARASITOLOGY, V115, P495, DOI 10.1017/S0031182097001625
   TERNYNCK T, 1990, J IMMUNOL, V144, P1504
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   TODD CW, 1983, INFECT IMMUN, V40, P832, DOI 10.1128/IAI.40.2.832-835.1983
   TOLEDO BM, 1979, CLIN EXP IMMUNOL, V38, P376
   TORRES CM, 1929, K REUN SOC ARG PAT R, V2, P902
   Tostes Junior S, 1994, Rev Soc Bras Med Trop, V27, P127, DOI 10.1590/S0037-86821994000300002
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   VANVOORHIS WC, 1989, J EXP MED, V169, P641, DOI 10.1084/jem.169.3.641
   VANVOORHIS WC, 1993, J EXP MED, V178, P681, DOI 10.1084/jem.178.2.681
   VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993
   Vasconcelos JR, 2004, HUM GENE THER, V15, P878, DOI 10.1089/hum.2004.15.878
   VEGA MTDL, 1976, J PARASITOL, V62, P129, DOI 10.2307/3279068
   Vermelho AB, 1997, ACTA TROP, V64, P131, DOI 10.1016/S0001-706X(96)00627-4
   Vyatkina G, 2004, BBA-MOL BASIS DIS, V1689, P162, DOI 10.1016/j.bbadis.2004.03.005
   Wang Z, 1999, J Tongji Med Univ, V19, P112
   WOOD JN, 1982, NATURE, V296, P34, DOI 10.1038/296034a0
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
   Zinkernagel RM, 2002, ANN NY ACAD SCI, V958, P3
   ZWIRNER NW, 1994, INFECT IMMUN, V62, P2483, DOI 10.1128/IAI.62.6.2483-2489.1994
NR 203
TC 83
Z9 86
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891-6934
EI 1607-842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD FEB
PY 2006
VL 39
IS 1
BP 41
EP 54
DI 10.1080/08916930500485002
PG 14
WC Immunology
SC Immunology
GA 008OI
UT WOS:000235049900006
PM 16455581
DA 2020-11-26
ER

PT J
AU Galvao, CES
   Iwai, LK
   Santos, LD
   Mendes, MA
   Palma, MS
   Castro, FFM
   Neto, EC
   Kalil, J
AF Galvao, CES
   Iwai, LK
   Santos, LD
   Mendes, MA
   Palma, MS
   Castro, FFM
   Neto, EC
   Kalil, J
TI Identification of the major allergens of the venom from the South
   American social wasp Agelaia pallipes
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 03-07, 2006
CL Miami Beach, FL
SP Amer Acad Allergy, Asthma & Immunol
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, InCor, Sao Paulo, Brazil.
   UNESP, Inst Biosci, Ctr Study Social Insects, Dept Biol, Rio Claro, Brazil.
RI Palma, Mario Sergio/E-7800-2012; Mendes, Maria Anita/C-6372-2014;
   Castro, Fabio FM/C-1082-2017; Castro, Fabio/AAP-5433-2020; KALIL,
   JORGE/C-8029-2012; Palma, Mario/N-3903-2019; Iwai, Leo K/M-1734-2013
OI Palma, Mario Sergio/0000-0002-7363-8211; Mendes, Maria
   Anita/0000-0002-2078-9286; Castro, Fabio FM/0000-0002-6211-5773; KALIL,
   JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763
NR 0
TC 3
Z9 3
U1 0
U2 6
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2006
VL 117
IS 2
SU S
MA 1189
BP S308
EP S308
DI 10.1016/j.jaci.2005.12.1216
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 019VR
UT WOS:000235865302267
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Silva, FCE
   Birolini, D
   Kalil, J
   Rizzo, LV
AF Giavina-Bianchi, P
   Silva, FCE
   Birolini, D
   Kalil, J
   Rizzo, LV
TI Rare intestinal manifestation in a patient with common variable
   immunodeficiency and strongyloidiasis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 03-07, 2006
CL Miami Beach, FL
SP Amer Acad Allergy, Asthma & Immunol
C1 FMUSP, Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; Rizzo,
   Luiz Vicente/B-4458-2009
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2006
VL 117
IS 2
SU S
MA 680
BP S174
EP S174
DI 10.1016/j.jaci.2005.12.696
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 019VR
UT WOS:000235865301177
DA 2020-11-26
ER

PT J
AU Oliveira, E
   Giavina-Bianchi, P
   Kalil, J
AF Oliveira, E
   Giavina-Bianchi, P
   Kalil, J
TI Value of determination of specific IgE against recombinant Aspergillus
   fumigatus allergens rAsp f1, 2, 3, 4 and 6 in the diagnosis of allergic
   bronchopulmonary aspergillosis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 03-07, 2006
CL Miami Beach, FL
SP Amer Acad Allergy, Asthma & Immunol
C1 FMUSP, Clin Immunol & Allergy, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2006
VL 117
IS 2
SU S
MA 378
BP S97
EP S97
DI 10.1016/j.jaci.2005.12.388
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 019VR
UT WOS:000235865300378
DA 2020-11-26
ER

PT J
AU Bessa, J
   Giordano, R
   Arap, W
   Pasqualini, R
   Kalil, J
   Guitherme, L
AF Bessa, Juliana
   Giordano, Ricardo
   Arap, Wady
   Pasqualini, Renato
   Kalil, Jorge
   Guitherme, Luiza
TI Characterization of cross reactive autoantigens in rheumatic heart
   disease using phage display methodology.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 Univ Sao Paulo, Inst Heart, Sch Med, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Immunol Lab, Inst Heart, Sch Med, Sao Paulo, Brazil.
   Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S84
EP S85
DI 10.1016/j.clim.2006.04.136
PG 2
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300218
DA 2020-11-26
ER

PT J
AU Fae, K
   Santos, S
   Tanaka, A
   Heuser, J
   Cunningham, M
   Kalil, J
   Guilherme, L
AF Fae, Kellen
   Santos, Simone
   Tanaka, Ana
   Heuser, Janet
   Cunningham, Madeleine
   Kalil, Jorge
   Guilherme, Luiza
TI Cardiac myosin a potential autoantigen that trigger the autoimmune
   lesions in rheumatic fever.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 Univ Sao Paulo, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Biomed Res Ctr, Oklahoma City, OK USA.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart,Allergy & Clin Immunol Dept, Sao Paulo, Brazil.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S83
EP S84
DI 10.1016/j.clim.2006.04.133
PG 2
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300215
DA 2020-11-26
ER

PT J
AU Fonseca, S
   Coutinho-Silva, A
   Ramasawmy, R
   Fonseca, L
   Mairena, E
   Fae, K
   Moraes, S
   Cunha-Neto, E
   Kalil, J
AF Fonseca, Simone
   Coutinho-Silva, Adriana
   Ramasawmy, Rajendranath
   Fonseca, Luis
   Mairena, Eliane
   Fae, Kellen
   Moraes, Sandra
   Cunha-Neto, Edecio
   Kalil, Jorge
TI Expression of toll-like receptors on T-cells, B-cells and monocytes from
   HIV infected patients.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 Univ Sao Paulo, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   Millenium Inst CNPq, Inst Invest Immunol, Sao Paulo, Brazil.
RI Ramasawmy, Rajendranath/V-4926-2019; KALIL, JORGE/C-8029-2012;
   Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S146
EP S146
DI 10.1016/j.clim.2006.04.348
PG 1
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300390
DA 2020-11-26
ER

PT J
AU Postol, E
   Higa, F
   Mundel, L
   Alencar, R
   Kalil, J
   Guilherme, L
AF Postol, Edil
   Higa, Fabio
   Mundel, Luiz
   Alencar, Raquel
   Kalil, Jorge
   Guilherme, Luiza
TI Experimental evaluation of m protein epitope selected by human T and B
   reactivity as candidate vaccine to prevent rheumatic fever.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 Univ Sao Paulo, Sch Med, Inst Heart, Lab Immunol,Allergy & Clin Immunol Dept, BR-05508 Sao Paulo, Brazil.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S60
EP S60
DI 10.1016/j.clim.2006.04.067
PG 1
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300149
DA 2020-11-26
ER

PT J
AU Ramasawmy, R
   Fae, K
   Spina, G
   Victora, G
   Tanaka, A
   Palacios, S
   Hounie, A
   Miguel, E
   Oshiro, S
   Goldberg, A
   Kalil, J
   Guilherme, L
AF Ramasawmy, Rajendranath
   Fae, Kellen
   Spina, Guilherme
   Victora, Gabriel
   Tanaka, Ana
   Palacios, Selma
   Hounie, Ana
   Miguel, Euripides
   Oshiro, Sandra
   Goldberg, Anna
   Kalil, Jorge
   Guilherme, Luiza
TI Association of polymorphisms within the promoter region of the tumor
   necrosis factor-alpha gene with clinical outcomes of rheumatic heart
   disease.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 01-05, 2006
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 InCor, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil.
   Inst Immunol, Inst Millenium, Sao Paulo, Brazil.
RI Ramasawmy, Rajendranath/V-4926-2019; Spina, Guilherme S./I-3530-2013;
   KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2006
VL 119
SU S
BP S185
EP S185
DI 10.1016/j.clim.2006.04.502
PG 1
WC Immunology
SC Immunology
GA 048CD
UT WOS:000237924300496
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, P
   Silva, FDCE
   Toledo-Barros, M
   Birolini, D
   Kalil, J
   Rizzo, LV
AF Giavina-Bianchi, Pedro
   de Salles Collet e Silva, Francisco
   Toledo-Barros, Myrthes
   Birolini, Dario
   Kalil, Jorge
   Rizzo, Luiz Vicente
TI A rare intestinal manifestation in a patient with common variable
   immunodeficiency and strongyloidiasis
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE common variable immunodeficiency; corticosteroid; immunodeficiency;
   infection; intestine; strongyloidiasis
ID STERCORALIS; DIAGNOSIS; INFECTION; SYSTEM; CELLS
AB We report an immunodeficient patient with a rare gastrointestinal manifestation. A 26-year-old male with common variable immunodeficiency (CVID) and bronchiolitis obliterans, who was on intravenous gamma-globulin and prednisone, presented diffuse abdominal pain, nausea, vomiting and constipation of 3 days' duration. He reported 5 years of recurrent respiratory infections and diarrhea with negative stool tests, including tests for Strongyloides stercoralis. A physical exam revealed a poor general condition, anemia, dehydration and a distended painful abdomen with guarding, without abdominal sounds. The radiological study showed marked dilation of the small bowel that was edematous. Resection of the affected loop was performed and the histopathologic study showed transmural infection with S. stercoralis and hemorrhagic necrosis of the muscular layer, without mucosal destruction. The patient developed malabsorption syndrome and septic shock; he was treated with antibiotics and thiabendazole and was finally discharged in a good general condition. CVID is a rare disease and its association with systemic strongyloidiasis is very uncommon, but it has been reported in patients on corticosteroids. Hemorrhagic necrosis of the muscular layer without mucosal destruction was not found in the literature studied. Copyright (c) 2006 S. Karger AG, Basel.
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, BR-01454010 Sao Paulo, Brazil.
   Univ Sao Paulo, Div Trauma Surg, BR-01454010 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Immunol & Allergy, Biomed Sci Inst, BR-01454010 Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, BR-01454010 Sao Paulo, Brazil.
EM saudesos@saudesos.com.br
RI KALIL, JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009;
   Giavina-Bianchi, Pedro/I-3112-2014
OI KALIL, JORGE/0000-0001-8415-4274; Giavina-Bianchi,
   Pedro/0000-0002-1034-7580
CR Adedayo O, 2002, SOUTH MED J, V95, P711, DOI 10.1097/00007611-200207000-00011
   ALBAHRANI ZR, 1995, J INFECTION, V30, P47, DOI 10.1016/S0163-4453(95)92847-2
   ALIKHAN Z, 1975, T ROY SOC TROP MED H, V69, P473, DOI 10.1016/0035-9203(75)90101-7
   Ashraf M, 1996, AM J MED SCI, V311, P178, DOI 10.1097/00000441-199604000-00005
   BORAM LH, 1981, AM J CLIN PATHOL, V76, P778
   BRADLEY SL, 1978, MAYO CLIN PROC, V53, P332
   Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X
   CRAVEN JL, 1971, T ROY SOC TROP MED H, V65, P532, DOI 10.1016/0035-9203(71)90169-6
   DRASIN GF, 1978, RADIOLOGY, V126, P619, DOI 10.1148/126.3.619
   EISENSTEIN EM, 1994, ANN ALLERGY, V73, P285
   EISENSTEIN EM, 1995, ADV EXP MED BIOL, V371, P699
   Goldberg AC, 2005, CLIN IMMUNOL, V114, P147, DOI 10.1016/j.clim.2004.09.002
   GOLDSMITH R, 2000, CURRENT MED DIAGNOSI, P1456
   Gutierrez Y, 1996, AM J SURG PATHOL, V20, P603, DOI 10.1097/00000478-199605000-00007
   HERBST EW, 1995, ADV EXP MED BIOL, V371, P705
   John HA, 1996, DIGEST DIS SCI, V41, P621, DOI 10.1007/BF02282351
   Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007
   Leung V K, 1995, Trop Gastroenterol, V16, P27
   Lim S, 2004, CAN MED ASSOC J, V171, P479, DOI 10.1503/cmaj.1031698
   Loutfy MR, 2002, AM J TROP MED HYG, V66, P749, DOI 10.4269/ajtmh.2002.66.749
   Meyers WM, 1976, PATHOLOGY TROPICAL E, V2, P428
   NETO JLA, 1996, TRATADO INFECTOLOGIA, P1373
   Newberry AM, 2005, CHEST, V128, P3681, DOI 10.1378/chest.128.5.3681
   OLIVEIRA RB, 1981, PARASITE IMMUNOL, V3, P165
   POWELL RW, 1980, ARCH INTERN MED, V140, P1061, DOI 10.1001/archinte.140.8.1061
   ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707
   Satoh M, 2002, ONCOGENE, V21, P2466, DOI 10.1038/sj.onc.1205329
   Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707
   Spickett GP, 1997, IMMUNOL TODAY, V18, P325, DOI 10.1016/S0167-5699(97)01086-4
   Uparanukraw P, 1999, AM J TROP MED HYG, V60, P967, DOI 10.4269/ajtmh.1999.60.967
   Viney ME, 2004, J INFECT DIS, V190, P2175, DOI 10.1086/425935
NR 31
TC 7
Z9 7
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-2438
EI 1423-0097
J9 INT ARCH ALLERGY IMM
JI Int. Arch. Allergy Immunol.
PY 2006
VL 140
IS 3
BP 199
EP 204
DI 10.1159/000093205
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 054DH
UT WOS:000238356500002
PM 16682801
DA 2020-11-26
ER

PT J
AU Fonseca, CT
   Cunha-Neto, E
   Goldberg, AC
   Kalil, J
   de Jesus, AR
   Carvalho, EM
   Correa-Oliveira, R
   Hammer, J
   Sidney, J
   Sette, A
   Oliveira, SC
AF Fonseca, CT
   Cunha-Neto, E
   Goldberg, AC
   Kalil, J
   de Jesus, AR
   Carvalho, EM
   Correa-Oliveira, R
   Hammer, J
   Sidney, J
   Sette, A
   Oliveira, SC
TI Identification of paramyosin T cell epitopes associated with human
   resistance to Schistosoma mansoni reinfection
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE paramyosin; Schistosoma mansoni; synthetic peptides; T cells; vaccine
ID IMMUNE-RESPONSES; PEPTIDE BINDING; VACCINE; INDUCTION; ANTIBODY; MICE
AB Paramyosin, a Schistosoma mansoni myoprotein associated with human resistance to infection and reinfection, is a candidate antigen to compose a subunit vaccine against schistosomiasis. In this study, 11 paramyosin peptides selected by TEPITOPE algorithm as promiscuous epitopes were produced synthetically and tested in proliferation and in vitro human leucocyte antigen (HLA)-DR binding assays. A differential proliferative response was observed in individuals resistant to reinfection compared to individuals susceptible to reinfection in response to Para (210-226) peptide stimulation. In addition, this peptide was able to bind to all HLA-DR molecules tested in HLA-DR binding assays, confirming its promiscuity. Para (6-22) and Para (355-371) were also shown to be promiscuous peptides, because they were able to bind to the six and eight most prevalent HLA-DR alleles used in HLA-DR binding assays, respectively, and were also recognized by T cells of the individuals studied. These results suggest that these paramyosin peptides are promising antigens to compose an anti-schistosomiasis vaccine.
C1 Univ Fed Minas Gerais, Inst Invest Imunol, Inst Milenio, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Sao Paulo, Inst Coracao Incor, Lab Imunol, Sao Paulo, Brazil.
   Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Inmunol, Salvador, BA, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol, BR-30190 Belo Horizonte, MG, Brazil.
   Hoffmann La Roche Inc, Dept Genome & Informat Sci, Nutley, NJ 07110 USA.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
RP Oliveira, SC (corresponding author), Univ Fed Minas Gerais, Inst Invest Imunol, Inst Milenio, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM scozeus@icb.ufmg.br
RI Cunha-Neto, Edecio/B-4157-2009; Fonseca, Cristina/M-8511-2019; KALIL,
   JORGE/C-8029-2012; Oliveira, Guilherme/E-2624-2014; Goldberg, Anna
   Carla/H-8594-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Fonseca,
   Cristina/0000-0003-1527-5050; KALIL, JORGE/0000-0001-8415-4274;
   Oliveira, Guilherme/0000-0003-0054-3438; Goldberg, Anna
   Carla/0000-0003-2600-7940; Correa-Oliveira, Rodrigo/0000-0001-6419-9459
CR Agiro L., 2000, VACCINE, V18, P2033
   Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5
   BERGQUIST NR, 1995, MEM I OSWALDO CRUZ, V90, P221, DOI 10.1590/S0074-02761995000200017
   BOROS DL, 1989, CLIN MICROBIOL REV, V2, P250, DOI 10.1128/CMR.2.3.250-269.1989
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001
   Capron A, 2005, TRENDS PARASITOL, V21, P143, DOI 10.1016/j.pt.2005.01.003
   Chitsulo L, 2004, NAT REV MICROBIOL, V2, P12, DOI 10.1038/nrmicro801
   COLES GC, 1986, T ROY SOC TROP MED H, V80, P347, DOI 10.1016/0035-9203(86)90055-6
   COLLEY DG, 1977, INT ARCH ALLER A IMM, V53, P420, DOI 10.1159/000231780
   Correa-Oliveira R, 1998, BRAZ J MED BIOL RES, V31, P171, DOI 10.1590/S0100-879X1998000100024
   CORREAOLIVEIRA R, 1989, T ROY SOC TROP MED H, V83, P798, DOI 10.1016/0035-9203(89)90334-9
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83
   FLANIGAN TP, 1989, J CLIN INVEST, V83, P1010, DOI 10.1172/JCI113942
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Gazarian KG, 2000, IMMUNOL LETT, V72, P191, DOI 10.1016/S0165-2478(00)00189-9
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144
   Lopez-Moreno HS, 2003, PARASITE IMMUNOL, V25, P513, DOI 10.1111/j.1365-3024.2003.00658.x
   McManus DP, 2004, PARASITOL INT, V53, P163, DOI 10.1016/j.parint.2004.01.006
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   Nara T, 1997, VACCINE, V15, P79, DOI 10.1016/S0264-410X(96)00100-4
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843
   PEARCE EJ, 1988, P NATL ACAD SCI USA, V85, P5678, DOI 10.1073/pnas.85.15.5678
   SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1
   SIDNEY J, 1998, CURR PROTOCOLS IMMUN, V18, P1
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tallima H, 2003, VACCINE, V21, P3290, DOI 10.1016/S0264-410X(03)00180-4
   Tarrab-Hazdai R, 1998, INFECT IMMUN, V66, P4526
   Vazquez-Talavera J, 2001, PARASITE IMMUNOL, V23, P575, DOI 10.1046/j.1365-3024.2001.00416.x
   Vilar MM, 2003, VACCINE, V22, P137, DOI 10.1016/S0264-410X(03)00300-1
NR 35
TC 22
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2005
VL 142
IS 3
BP 539
EP 547
DI 10.1111/j.1365-2249.2005.02941.x
PG 9
WC Immunology
SC Immunology
GA 982EC
UT WOS:000233139700018
PM 16297167
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Giordano, RJ
   Anobom, CD
   Cardo-Veila, M
   Kalil, J
   Valente, AP
   Pasqualini, R
   Almeida, FCL
   Arap, W
AF Giordano, RJ
   Anobom, CD
   Cardo-Veila, M
   Kalil, J
   Valente, AP
   Pasqualini, R
   Almeida, FCL
   Arap, W
TI Structural basis for the interaction of a vascular endothelial growth
   factor mimic peptide motif and its corresponding receptors
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID VEGF; BINDING; ANGIOGENESIS; NEUROPILIN-1; TARGET; CANCER; NEUROGENESIS;
   SPECTROSCOPY; BEVACIZUMAB; DISCOVERY
AB Vascular endothelial growth factor (VEGF) is central to the survival and development of the vascular and nervous systems. We screened phage display libraries and built a peptide-based ligand-receptor map of binding sites within the VEGF family. We then validated a cyclic peptide, CPQPRPLC, as a VEGF-mimic that binds specifically to neuropilin-1 and VEGF receptor-1. Here, we use NMR spectroscopy to understand the structural basis of the interaction between our mimic peptide and the VEGF receptors. We show that: (1) CPQPRPLC has multiple interactive conformations; (2) receptor binding is mediated by the motif Arg-Pro-Leu; and (3) the Pro residue within Arg-Pro-Leu participates in binding to neuropilin-1 but not to VEGF receptor-1, perhaps representing an evolutionary gain-of-function. Therefore, Arg-Pro-Leu is a differential ligand motif to VEGF receptors and a candidate peptidomimetic lead for VEGF pathway modulation.
C1 Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Univ Fed Rio de Janeiro, Inst Med Biochem, Natl Ctr Nucl Magnet Resonance, BR-21941 Rio De Janeiro, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, BR-05403 Sao Paulo, SP, Brazil.
RP Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
EM rpasqual@mdanderson.org; falmeida@cnrmn.bioqmed.ufrj.br;
   warap@mdanderson.org
RI Bom, Cristiane Dinis Ano/X-9461-2019; Valente, Ana Paula/J-3010-2017;
   Almeida, Fabio/O-4989-2018; Giordano, Ricardo/A-2074-2010; KALIL,
   JORGE/C-8029-2012
OI Valente, Ana Paula/0000-0001-7219-1123; Almeida,
   Fabio/0000-0001-6046-7006; Giordano, Ricardo/0000-0001-8116-6771; KALIL,
   JORGE/0000-0001-8415-4274
CR ABRAGAM A, 1961, INT SERIES MONOGRAPH, V32, P264
   Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6
   Burg MA, 1999, CANCER RES, V59, P2869
   Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   COOKE RM, 1996, NMR DRUG DESIGN, P245
   Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Folkman J, 2003, CANCER BIOL THER, V2, pS127
   Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Kawasaki T, 1999, DEVELOPMENT, V126, P4895
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217
   Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X
   Pasqualini R, 2000, CANCER RES, V60, P722
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199
   SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Stockman BJ, 2002, PROG NUCL MAG RES SP, V41, P187, DOI 10.1016/S0079-6565(02)00049-3
   Vogel G, 2005, SCIENCE, V307, P665, DOI 10.1126/science.307.5710.665
   Weinstein BM, 2005, CELL, V120, P299, DOI 10.1016/j.cell.2005.01.010
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yasuhara T, 2004, REV NEUROSCIENCE, V15, P293
NR 34
TC 36
Z9 36
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-5521
EI 1879-1301
J9 CHEM BIOL
JI Chem. Biol.
PD OCT
PY 2005
VL 12
IS 10
BP 1075
EP 1083
DI 10.1016/j.chembiol.2005.07.008
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 981GZ
UT WOS:000233077000006
PM 16242650
OA Bronze
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Marin, ML
   Porta, G
   Cancado, EL
   Miura, IK
   Carrilho, FJ
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Marin, ML
   Porta, G
   Cancado, EL
   Miura, IK
   Carrilho, FJ
   Kalil, J
   Goldberg, AC
TI Polymorphisms of MHC and non-MHC genes and susceptibility to primary
   sclerosing cholangitis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 11-15, 2005
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 Portuguese Hosp, Salvador, BA, Brazil.
   Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Chem, Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Carrilho,
   Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2005
VL 42
IS 4
SU 1
BP 296A
EP 296A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 972VC
UT WOS:000232480300248
DA 2020-11-26
ER

PT J
AU Barros, MT
   Acencio, MMP
   Garcia, MLB
   Soares, MFM
   Ibanez, OM
   Martins, MA
   Ribeiro, OG
   Kalil, J
   Perini, A
AF Barros, MT
   Acencio, MMP
   Garcia, MLB
   Soares, MFM
   Ibanez, OM
   Martins, MA
   Ribeiro, OG
   Kalil, J
   Perini, A
TI BCG modulation of anaphylactic antibody response, airway inflammation
   and lung hyperreactivity in genetically selected mouse strains
   (Selection IV-A)
SO LIFE SCIENCES
LA English
DT Article
DE BCG; anaphylactic antibodies; bronchial hyperresponsiveness; selected
   mice (Selection IV-A)
ID BACILLUS-CALMETTE-GUERIN; KILLED MYCOBACTERIUM-VACCAE; POLYGENIC
   CONTROL; ASTHMA MODEL; MICE; ANTIGEN; CELLS; HYPERRESPONSIVENESS;
   RESPONSIVENESS; EOSINOPHILIA
AB The effect of Bacillus Calmette-Guerin (BCG) treatment in allergic pulmonary reaction was studied in mice genetically selected accordingly to a High (H-IVA) or Low (L-IVA) antibody responsiveness. Mice were immunized with ovalbumin (OVA) or OVA plus BCG. Two days after nasal antigenic challenge, seric IgE and IgG1 anti-OVA, eosinophils in pulmonary tissue, inflammatory cells in bronchoalveolar lavage and the compliance and conductance of respiratory system were evaluated. H-IVA mice were found more susceptible than L-IVA, and BCG was able to inhibit simultaneously the production of IgE, the bronchopulmonary inflammation and bronchial hyperresponsiveness in these genetically selected mice. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Sao Paulo, Dept Med, Div Gen Internal Med, Div Clin Immunol & Alergy,Heart Inst,InCor, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Med, Div Gen Internal Med, Lab Pleura Div,Heart Inst,InCor, BR-01246903 Sao Paulo, Brazil.
   Butantan Inst, Immunopathol Lab, Sao Paulo, Brazil.
   Butantan Inst, Immunogenet Lab, Sao Paulo, Brazil.
RP Barros, MT (corresponding author), Univ Sao Paulo, Dept Med, Div Gen Internal Med, Div Clin Immunol & Alergy,Heart Inst,InCor, Av Dr Arnaldo,455,Cerqueira Cesar, BR-01246903 Sao Paulo, Brazil.
EM myrtb@uol.com.br
RI Martins, Milton A/L-7541-2017; Ibanez, Olga CM/B-9627-2015; KALIL,
   JORGE/C-8029-2012; de La Roca Soares, Monica Felts/AAJ-8769-2020; Bueno
   Garcia, Maria Lucia/G-5882-2013; Ribeiro, Orlando Garcia/B-5241-2016;
   Martins, Milton A/D-6658-2012
OI Ibanez, Olga CM/0000-0002-2672-4758; KALIL, JORGE/0000-0001-8415-4274;
   de La Roca Soares, Monica Felts/0000-0002-4873-915X; 
CR Akdis CA, 2004, ALLERGY, V59, P897, DOI 10.1111/j.1398-9995.2004.00587.x
   Biozzi G, 1979, Curr Top Microbiol Immunol, V85, P31
   CABRERA WH, 1995, SCAND J IMMUNOL, V41, P293, DOI 10.1111/j.1365-3083.1995.tb03567.x
   Chambers MA, 1997, J IMMUNOL, V158, P1742
   Coombs R.R.A., 1975, CLIN ASPECTS IMMUNOL, P761
   CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4
   DEVRIES JE, 1994, CURR OPIN IMMUNOL, V6, P835, DOI 10.1016/0952-7915(94)90001-9
   DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4
   Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561
   Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195
   Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051
   IBANEZ OM, 1988, IMMUNOGENETICS, V28, P6, DOI 10.1007/BF00372523
   Itami DM, 2003, ALLERGY, V58, P1117, DOI 10.1034/j.1398-9995.2003.00206.x
   JANEWAY CA, 1987, J IMMUNOL, V138, P1051
   KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129
   Kim M J, 1990, Kisaengchunghak Chapchi, V28, P143, DOI 10.3347/kjp.1990.28.3.143
   Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x
   LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994
   METZGER H, 1989, CIBA F SYMP, V147, P93
   Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2
   MOTA I, 1969, LIFE SCI PT 1 PHYSI, V8, P813, DOI 10.1016/0024-3205(69)90099-X
   Mouton D, 1976, Adv Exp Med Biol, V73 PT-A, P225
   Nahori MA, 2001, VACCINE, V19, P1484, DOI 10.1016/S0264-410X(00)00345-5
   OVARY Z, 1958, J IMMUNOL, V81, P355
   ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504
   Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9
   SANTANNA OA, 1985, IMMUNOGENETICS, V22, P131, DOI 10.1007/BF00563510
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Thurnher M, 1997, INT J CANCER, V70, P128
   Walker C, 2003, CURR OPIN ALLERGY CL, V3, P481, DOI 10.1097/01.all.0000104446.09202.3c
   Wang CC, 1998, IMMUNOLOGY, V93, P307
   WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067
   ZAR JH, 1998, BIOESTATICAL ANAL
   Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492
NR 34
TC 1
Z9 1
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD AUG 12
PY 2005
VL 77
IS 13
BP 1480
EP 1492
DI 10.1016/j.lfs.2005.04.003
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 949FJ
UT WOS:000230770100007
PM 15953620
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Dzao, VJ
   Allen, PD
   Stamatiou, D
   Benvenutti, L
   Higuchi, ML
   Koyama, NS
   Silva, JS
   Kalil, J
   Liew, CC
AF Cunha-Neto, E
   Dzao, VJ
   Allen, PD
   Stamatiou, D
   Benvenutti, L
   Higuchi, ML
   Koyama, NS
   Silva, JS
   Kalil, J
   Liew, CC
TI Cardiac gene expression profiling provides evidence for cytokinopathy as
   a molecular mechanism in Chagas' disease cardiomyopathy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID DENSITY OLIGONUCLEOTIDE ARRAYS; PANCREATIC BETA-CELLS;
   NECROSIS-FACTOR-ALPHA; TRYPANOSOMA-CRUZI; DILATED CARDIOMYOPATHY;
   SIGNALING PATHWAYS; HEART-FAILURE; NITRIC-OXIDE; IN-VIVO; MYOCARDITIS
AB Chronic Chagas' disease cardiomyopathy is a leading cause of congestive heart failure in Latin America, affecting more than 3 million people. Chagas' cardiomyopathy is more aggressive than other cardiomyopathies, but little is known of the molecular mechanisms responsible for its severity. We characterized gene expression profiles of human Chagas'cardiomyopathy and dilated cardiomyopathy to identify selective disease pathways and potential therapeutic targets. Both our customized cDNA microarray (Cardiochip) and real-time reverse transcriptase-polymerase chain reaction analysis showed that immune response, lipid metabolism, and mitochondrial oxidative phosphorylation genes were selectively upregulated in myocardial tissue of the tested Chagas' cardiomyopathy patients. Interferon (IFN)-gamma-inducible genes represented 15% of genes specifically upregulated in Chagas' cardiomyopathy myocardial tissue, indicating the importance of IFN-gamma signaling. To assess whether IFN-gamma can directly modulate cardiomyocyte gene expression, we exposed fetal murine cardiomyocytes to IFN-gamma and the IFN-gamma-inducible chemokine monocyte chemoattractant protein-1. Atrial natriuretic factor expression increased 15-fold in response to IFN-gamma whereas combined IFN-gamma and monocyte chemoattractant protein-1 increased atrial natriuretic factor expression 400-fold. Our results suggest IFN-gamma and chemokine signaling may directly up-regulate cardiomyocyte expression of genes involved in pathological hypertrophy, which may lead to heart failure. IFN-gamma and other cytokine pathways may thus be novel therapeutic targets in Chagas' cardiomyopathy.
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Univ Sao Paulo, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Pathol Serv, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Immunol, Sao Paulo, Brazil.
   Inst Invest Immunol, Millenium Inst, Sao Paulo, Brazil.
RP Liew, CC (corresponding author), Brigham & Womens Hosp, 77 Louis Pasteur Ave,NRB Room 0630K, Boston, MA 02115 USA.
EM cliew@rics.bwh.harvard.edu
RI KALIL, JORGE/C-8029-2012; de Lourdes Higuchi, Maria/K-3886-2017; Silva,
   Joao S/A-4484-2008; Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; de Lourdes Higuchi,
   Maria/0000-0002-1673-6456; Silva, Joao S/0000-0002-3410-3927;
   Cunha-Neto, Edecio/0000-0002-3699-3345
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL058516, P50HL059316,
   R37HL035610, R01HL058516, R01HL058516, P50HL059316, P50HL059316,
   R01HL058516, R01HL058516, P50HL059316, P50HL059316, P50HL059316,
   P50HL059316, P50HL059316, P50HL059316, P50HL059316, P50HL059316,
   P50HL059316, R01HL061661, P50HL059316, P50HL059316, R37HL035610,
   P50HL059316, P50HL059316, R01HL061661, P50HL059316, R37HL035610,
   R37HL035610, R01HL058516, U01HL066582, R37HL035610, U01HL066582,
   R37HL035610, P50HL059316, P50HL059316, U01HL066582, P50HL059316,
   R01HL061661, P50HL059316, P50HL059316, P50HL059316, R01HL058516,
   R37HL035610, P50HL059316, P50HL059316, R01HL058516, P50HL059316,
   P50HL059316, P50HL059316, P50HL059316, P50HL059316, P50HL059316,
   P50HL059316, R01HL058516, P50HL059316, U01HL066582, U01HL066582,
   R01HL058516, R37HL035610, R01HL061661] Funding Source: NIH RePORTER;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [5P5O-HL5931603, 5R01-HL6166102, HL66582-04,
   5R37-HL3561016, 5R01-HL5851603, U01 HL066582] Funding Source: Medline
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   ADAMS MD, 1995, NATURE, V377, P3
   Aukrust P, 2001, CLIN EXP IMMUNOL, V124, P343, DOI 10.1046/j.1365-2249.2001.01527.x
   Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200
   Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909
   Carvajal K, 2003, ARCH MED RES, V34, P89, DOI 10.1016/S0188-4409(03)00004-3
   Cunha-Neto E, 2001, AUTOIMMUNITY, V34, P187, DOI 10.3109/08916930109007383
   de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4
   Depre C, 2002, CIRC RES, V91, P1007, DOI 10.1161/01.RES.0000044380.54893.4B
   Garg N, 2003, BBA-MOL BASIS DIS, V1638, P106, DOI 10.1016/S0925-4439(03)00060-7
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706
   Hwang DM, 1997, CIRCULATION, V96, P4146
   Hwang JJ, 2002, PHYSIOL GENOMICS, V10, P31, DOI 10.1152/physiolgenomics.00122.2001
   KAWAI C, 1987, ANNU REV MED, V38, P221, DOI 10.1146/annurev.me.38.020187.001253
   Kolattukudy PE, 1998, AM J PATHOL, V152, P101
   LUSS H, 1995, J MOL CELL CARDIOL, V27, P2015, DOI 10.1016/0022-2828(95)90023-3
   Martinelli M, 2000, PACE, V23, P1944
   MEIRELLES MNL, 1986, EUR J CELL BIOL, V41, P198
   Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391
   Moschella F, 2001, BRIT J HAEMATOL, V114, P444, DOI 10.1046/j.1365-2141.2001.02953.x
   Mukherjee S, 2003, PARASITOL RES, V91, P187, DOI 10.1007/s00436-003-0937-z
   Patrone L, 2002, MOL IMMUNOL, V38, P597, DOI 10.1016/S0161-5890(01)00097-9
   Rajeevan MS, 2001, J MOL DIAGN, V3, P26, DOI 10.1016/S1525-1578(10)60646-0
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182
   Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5
   Steenman M, 2003, PHYSIOL GENOMICS, V12, P97, DOI 10.1152/physiolgenomics.00148.2002
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   TEIXEIRA PC, 2003, REV I MED TROP S S13, V45, P84
   Vyatkina G, 2004, BBA-MOL BASIS DIS, V1689, P162, DOI 10.1016/j.bbadis.2004.03.005
   Wang DC, 1996, LAB INVEST, V75, P809
   World Health Organization - WHO, 2002, WHO TECH REP SER, V905, p[i, 1]
   Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200
   Yang JC, 2000, CIRCULATION, V102, P3046
   Yokoyama T, 1997, CIRCULATION, V95, P1247
NR 40
TC 88
Z9 92
U1 3
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2005
VL 167
IS 2
BP 305
EP 313
DI 10.1016/S0002-9440(10)62976-8
PG 9
WC Pathology
SC Pathology
GA 951GN
UT WOS:000230917600003
PM 16049318
OA Green Published
DA 2020-11-26
ER

PT J
AU Marrero, I
   Benvenutti, LA
   Kalil, J
   Coelho, V
AF Marrero, I
   Benvenutti, LA
   Kalil, J
   Coelho, V
TI Autoreactivity to self H-2K(b) peptides in TAP1(-/-) mice. Intravenous
   administration of H-2K(b) class I-derived peptides induces long-term
   survival of grafts from C57BL/6 donors
SO IMMUNOLOGY
LA English
DT Article
DE autoreactivity; graft rejection; H-2Kb peptides; interleukin-10; major
   histocompatibility complex class I deficiency
ID CD8+ T-CELLS; TAP1 MUTANT MICE; SKIN ALLOGRAFT-REJECTION; POSITIVE
   SELECTION; CARDIAC ALLOGRAFTS; DEFICIENT MICE; MHC; LYMPHOCYTES;
   REPERTOIRE; ANTIGEN
AB We and others have previously shown that TAP1(-/-) mice (H-2(b)) reject grafts from donors without major histocompatibility complex (MHC) disparity that express wild-type levels of H-2(b) class I molecules (C57BL/6, TAP1(+/+) mice). In this same model, we also showed that subcutaneous priming of TAP1(-/-) mice with synthetic peptides derived from the H-2K(b) molecule accelerated graft rejection and that in vivo depletion of CD4(+) T cells induced a significant prolongation of graft survival, suggesting an important role for CD4 T cells. We hypothesize that, in this model, rejection is triggered by the recognition of class I molecules or derived peptides, in an inflammatory microenvironment, by a functionally altered autoreactive T-cell repertoire that escapes the control of peripheral regulatory mechanisms. In the present study, we analysed the cellular autoreactivity induced by synthetic peptides derived from the H-2K(b) sequence in naive and TAP1(-/-) mice transplanted with C57BL/6 grafts, and investigated whether intravenous modulation of autoreactivity to these peptides induced transplantation tolerance. We showed that TAP1(-/-) mice have peripheral autoreactive T cells that recognize H-2K(b) peptides. A significant amplification of proliferation against these peptides was detected in TAP1(-/-) mice that rejected grafts, indicating that the inflammatory context of transplantation induced peripheral expansion of these autoreactive T cells. Furthermore, intravenous injection of H-2K(b)-derived peptides significantly prolonged graft survival in some animals. In these mice (> 100 days graft survival), we observed intragraft inhibition of interferon-gamma and interleukin-10 expression, suggesting that these cytokines have an active role during the rejection. In conclusion, our present data indicate that inflammatory autoreactive T cells directed against H-2K(b) peptides can be inhibited in the periphery to prolong graft survival in TAP1(-/-) mice.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, BR-05403001 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Heart Inst InCor, BR-05403001 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), HC FMUSP, Inst Coracao InCor, Lab Imunol, Avenida Dr Eneas Carvalho Aguiar 44,9 Andar, BR-05403001 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581
CR Adachi O, 2002, TRANSPLANTATION, V74, P1603, DOI 10.1097/00007890-200212150-00019
   ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525
   APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837
   Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466
   ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T
   BILLINGHAM RE, 1951, J EXP BIOL, V28, P385
   Boehler A, 2002, TRANSPL IMMUNOL, V9, P121, DOI 10.1016/S0966-3274(02)00045-X
   Braun MY, 2000, EUR J IMMUNOL, V30, P1290
   BRUSIC V, 1994, NUCLEIC ACIDS RES, V22, P3663, DOI 10.1093/nar/22.17.3663
   Chan S, 1998, J EXP MED, V188, P2321, DOI 10.1084/jem.188.12.2321
   CHAN SY, 1995, TRANSPLANTATION, V59, P1155, DOI 10.1097/00007890-199504270-00014
   Coelho V, 1999, TRANSPLANT P, V31, P900, DOI 10.1016/S0041-1345(98)01828-4
   Danke NA, 2004, J IMMUNOL, V172, P5967, DOI 10.4049/jimmunol.172.10.5967
   Field AC, 2003, J IMMUNOL, V170, P2508, DOI 10.4049/jimmunol.170.5.2508
   Foucras G, 2000, J IMMUNOL, V165, P4994, DOI 10.4049/jimmunol.165.9.4994
   Freland S, 2000, SCAND J IMMUNOL, V51, P219
   Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2
   Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798
   GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661
   Goldman M, 2001, TRENDS IMMUNOL, V22, P247, DOI 10.1016/S1471-4906(01)01893-2
   Hu D, 2004, NAT IMMUNOL, V5, P516, DOI 10.1038/ni1063
   Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896
   Jiang H, 1998, P NATL ACAD SCI USA, V95, P4533, DOI 10.1073/pnas.95.8.4533
   Jiang H, 2003, P NATL ACAD SCI USA, V100, P8378, DOI 10.1073/pnas.1432871100
   Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6
   Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080
   Li W, 1998, TRANSPLANTATION, V66, P1587, DOI 10.1097/00007890-199812270-00004
   LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0
   LJUNGGREN HG, 1995, EUR J IMMUNOL, V25, P174, DOI 10.1002/eji.1830250129
   LJUNGGREN HG, 1995, IMMUNOLOGIST, V3, P136
   MacEachern MC, 1998, TRANSPLANTATION, V65, P1357, DOI 10.1097/00007890-199805270-00013
   May E, 2003, J IMMUNOL, V170, P1099, DOI 10.4049/jimmunol.170.2.1099
   MERVILLE P, 1995, TRANSPLANTATION, V59, P1113, DOI 10.1097/00007890-199504270-00007
   MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487
   NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042
   Noble A, 1998, J IMMUNOL, V160, P566
   PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1
   Qian SG, 1996, TRANSPLANTATION, V62, P1709, DOI 10.1097/00007890-199612270-00002
   REYES AA, 1992, P NATL ACAD SCI USA, V79, P3270
   ROSENBERG AS, 1991, J EXP MED, V173, P1463, DOI 10.1084/jem.173.6.1463
   ROSSI MA, 1992, AM J PATHOL, V141, P183
   Sandberg JK, 1996, EUR J IMMUNOL, V26, P288, DOI 10.1002/eji.1830260203
   Segal BM, 2002, J IMMUNOL, V168, P1, DOI 10.4049/jimmunol.168.1.1
   SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M
   Suarez IM, 2002, TRANSPL IMMUNOL, V9, P101, DOI 10.1016/S0966-3274(02)00032-1
   Surquin M, 2002, J IMMUNOL, V169, P500, DOI 10.4049/jimmunol.169.1.500
   TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0
   Trobonjaca Z, 2001, J IMMUNOL, V166, P3804, DOI 10.4049/jimmunol.166.6.3804
   VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6
   Yan J, 2002, J IMMUNOL, V168, P3188, DOI 10.4049/jimmunol.168.7.3188
   ZIJLSTRA M, 1992, J EXP MED, V175, P885, DOI 10.1084/jem.175.4.885
NR 51
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD AUG
PY 2005
VL 115
IS 4
BP 484
EP 494
DI 10.1111/j.1365-2567.2005.02182.x
PG 11
WC Immunology
SC Immunology
GA 943FI
UT WOS:000230337600006
PM 16011517
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Abel, LCJ
   Iwai, LK
   Viviani, W
   Bilate, AM
   Fae, KC
   Ferreira, RC
   Goldberg, AC
   Juliano, L
   Juliano, MA
   Ianni, B
   Mady, C
   Gruber, A
   Hammer, J
   Sinigaglia, F
   Kalil, J
   Cunha-Neto, E
AF Abel, LCJ
   Iwai, LK
   Viviani, W
   Bilate, AM
   Fae, KC
   Ferreira, RC
   Goldberg, AC
   Juliano, L
   Juliano, MA
   Ianni, B
   Mady, C
   Gruber, A
   Hammer, J
   Sinigaglia, F
   Kalil, J
   Cunha-Neto, E
TI T cell epitope characterization in tandemly repetitive Trypanosoma cruzi
   B13 protein
SO MICROBES AND INFECTION
LA English
DT Article
DE T cell epitope; B13 protein; Trypanosoma cruzi; tandemly repetitive
   proteins; immunodominant antigens
ID FALCIPARUM ANTIGEN PF332; MYOSIN HEAVY-CHAIN; HLA-DR MOLECULES;
   PLASMODIUM-FALCIPARUM; CHAGAS-DISEASE; CIRCUMSPOROZOITE PROTEIN; CARDIAC
   MYOSIN; CONFORMATIONAL PREFERENCES; IMMUNODOMINANT SITE;
   PERIPHERAL-BLOOD
AB Proteins containing tandemly repetitive sequences are present in several immunodominant protein antigens in pathogenic protozoan parasites. The tandemly repetitive Ttypanosoma cruzi B13 protein is recognized by IgG antibodies from 98% of Chagas' disease patients. Little is known about the molecular mechanisms that lead to the immunodominance of the repeated sequences, and there is limited information on T cell epitopes in such repetitive antigens. We finely characterized the T cell recognition of the tandemly repetitive, degenerate B13 protein by T cell lines, clones and PBMC from Chagas' disease cardiomyopathy (CCC), asymptomatic T cruzi infected (ASY) and non-infected individuals (N). PBMC proliferative responses to recombinant B 13 protein were restricted to individuals bearing HLA-DQA1*0501 (DQ7),-DR1, and -DR2; B13 peptides bound to the same HLA molecules in binding assays. The HLA-DQ7-restricted minimal T cell epitope [FGQAAAG(D/E)KP] was identified with an overlapping combinatorial peptide library including all B13 sequence variants in T cruzi Y strain B13 protein; the underlined small residues (G) under barQ (A) under bar were the major HLA contact residues. Among natural B 13 15-mer variant peptides, molecular modeling showed that several variant positions were solvent (TCR)-exposed, and substitutions at exposed positions abolished recognition. While natural B13 variant peptide S15.9 seems to be the immunodominant epitope for Chagas' disease patients, S15.4 was preferentially recognized by CCC rather than ASY patients, which may be pathogenically relevant. This is the first thorough characterization of T cell epitopes of a tandemly repetitive protozoan antigen and may suggest a role for T cell help in the immunodominance of protozoan repetitive antigens. (c) 2005 Elsevier SAS. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart,InCor, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Gen Cardiopathies Div, Inst Heart,InCor, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Med, BR-05403000 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
   Bioxell, Milan, Italy.
   Univ Sao Paulo, Fac Vet Med & Zoothechny, Dept Pathol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508 Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart,InCor, Av Dr Eneas Carvalho Aguiar,44 Bloco 2,9o Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunha@usp.br
RI Gruber, Arthur/B-4711-2011; Cunha-Neto, Edecio/B-4157-2009; Ianni,
   Barbara Maria/C-7689-2012; Mady, Charles/C-8870-2012; Goldberg, Anna
   Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Juliano, Luiz/D-7204-2012;
   Iwai, Leo K/M-1734-2013; Abel, Lucia Cristina Jamli/P-8816-2014
OI Gruber, Arthur/0000-0001-8093-2278; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Ianni, Barbara Maria/0000-0002-1588-5492;
   Mady, Charles/0000-0002-8838-199X; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274; Juliano,
   Luiz/0000-0002-5589-2822; Iwai, Leo K/0000-0002-1571-7763; Abel, Lucia
   Cristina Jamli/0000-0003-4915-4265
CR ABEL LC, 1999, THESIS U SAO PAULO S
   Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Ahlborg N, 1997, MOL IMMUNOL, V34, P379, DOI 10.1016/S0161-5890(97)00046-1
   Atherton E, 1989, SOLID PHASE PEPTIDE
   BIGNON JD, 1997, 12 INT HIST WORKSH, P584
   Buscaglia CA, 1999, BLOOD, V93, P2025, DOI 10.1182/blood.V93.6.2025.406k19_2025_2032
   BUSCHIAZZO A, 1992, MOL BIOCHEM PARASIT, V54, P125, DOI 10.1016/0166-6851(92)90105-S
   CalvoCalle JM, 1997, J IMMUNOL, V159, P1362
   CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0
   Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   Duranti MA, 1999, EXP PARASITOL, V93, P38, DOI 10.1006/expr.1999.4428
   DYSON HJ, 1985, NATURE, V318, P480
   DYSON HJ, 1995, FASEB J, V9, P37
   DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P7828, DOI 10.1021/bi00486a008
   EVAVOLD BD, 1992, J IMMUNOL, V148, P347
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   FERN J, 1992, J IMMUNOL, V148, P907
   FRASCH ACC, 1991, PARASITOL TODAY, V7, P148, DOI 10.1016/0169-4758(91)90284-U
   GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989
   IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6
   Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006
   Iwai LK, 2001, PEPTIDES, V22, P853, DOI 10.1016/S0196-9781(01)00409-0
   KEMP M, 1992, INFECT IMMUN, V60, P2246, DOI 10.1128/IAI.60.6.2246-2251.1992
   Kulane A, 1999, AM J TROP MED HYG, V61, P141, DOI 10.4269/ajtmh.1999.61.141
   Loftus DJ, 1997, CRIT REV IMMUNOL, V17, P419
   MATTERN T, 1994, J IMMUNOL, V153, P2996
   Moudgil KD, 1996, J AUTOIMMUN, V9, P227, DOI 10.1006/jaut.1996.0028
   NARDIN E, 1992, MEM I OSWALDO CRUZ, V87, P223, DOI 10.1590/S0074-02761992000700037
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Pinilla C, 2003, NAT MED, V9, P118, DOI 10.1038/nm0103-118
   PIUVEZAM MR, 1993, J IMMUNOL, V150, P916
   Raddrizzani L, 1997, J IMMUNOL, V159, P703
   SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L
   SIDNEY J, 1994, J IMMUNOL, V152, P4516
   SINIGAGLIA F, 1992, METHOD ENZYMOL, V203, P370
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
   Subbarao B, 1982, Immunol Rev, V69, P81
   TROYEBLOMBERG M, 1988, IMMUNOL LETT, V19, P229, DOI 10.1016/0165-2478(88)90147-2
   Uemura Y, 2003, J IMMUNOL, V170, P947, DOI 10.4049/jimmunol.170.2.947
   YANG YF, 1987, MOL BIOCHEM PARASIT, V26, P61, DOI 10.1016/0166-6851(87)90130-7
NR 44
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD AUG-SEP
PY 2005
VL 7
IS 11-12
BP 1184
EP 1195
DI 10.1016/j.micinf.2005.03.033
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 981PF
UT WOS:000233099800002
PM 15951215
DA 2020-11-26
ER

PT J
AU Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Hammer, J
   Kalil, J
   Yamamoto, JH
AF Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Hammer, J
   Kalil, J
   Yamamoto, JH
TI T-cell recognition and cytokine profile induced by melanocyte Epitopes
   in patients with HLA-DRB1*0405-positive and -negative
   Vogt-Koyanagi-Harada uveitis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MAJOR HISTOCOMPATIBILITY COMPLEX; TYROSINASE-RELATED PROTEIN-1;
   PERIPHERAL-BLOOD; GENETIC SUSCEPTIBILITY; DISEASE; IDENTIFICATION;
   ANTIGENS; CARDIOMYOPATHY; PREDICTION; MOLECULES
AB PURPOSE. Vogt-Koyanagi-Harada disease (VKH), an autoimmune disease targeted against melanocytes, is associated with HLA-DRB1*0405. This study was undertaken to analyze T-cell recognition and the cytokine expression profile induced by melanocyte epitopes in HLA-DRB1*0405-positive and -negative patients with VKH uveitis.
   METHODS. Peripheral blood mononuclear cells (PBMC) proliferation and Th1 (IFN-gamma) and Th2 (IL-4 and IL-5) cytokine production were analyzed in HLA-DRB1*0405-positive (n = 12) and -negative (n = 22) patients with VKH and HLA-DRB1*0405-positive (n = 9) and -negative (n = 8) control subjects in response to human melanoma cell line lysate (HMCLL) and 28 synthetic peptides derived from the human melanocyte differentiation proteins TYR, TRP1, TRP2, and Pmel17. The peptides were selected using the TEPITOPE algorithm, based on their predicted binding to HLA-DRB1*0405 and to the non-disease-related HLA-DRB1*15.
   RESULTS. HMCLL was recognized exclusively by the patients' PBMC (44%) but not by those of the control subjects (P < 0.01). PBMC from patients with VKH recognized an increased breadth of melanocyte-derived peptides at lower peptide concentrations than in the control subjects (68% vs. 25%; P < 0.01, at 1 mu M) and did not produce the Th2 cytokine IL-4 in response to disease-specific peptides (0% vs. 50%, P < 0.001). Five peptides were exclusively recognized in patients bearing HLA-DRB1*0405. Furthermore, HLA-DRB1*0405-bearing patients, but not those with HLA-DRB1*15, recognized an increased breadth of melanocyte epitopes in comparison to HLA-matched control subjects (60% vs. 28%; P < 0.05).
   CONCLUSIONS. These data indicate that patients with VKH are sensitized to melanocyte epitopes and display a peptide-specific Th1 cytokine response. In addition, the data indicate that patients bearing HLA-DRB1*0405 recognize a broader melanocyte-derived peptide repertoire, reinforcing the importance of this allele in susceptibility to the development of VKH disease.
C1 Univ Sao Paulo, Sch Med, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Ophthalmol, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA.
RP Yamamoto, JH (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Av Dr Eneas de Carvalho Aguiar,44 Bl 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM joycehy@uol.com.br
RI Cunha-Neto, Edecio/B-4157-2009; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012; Damico, Francisco Max/G-1175-2015; Yamamoto, Joyce
   H/B-6192-2015; Iwai, Leo K/M-1734-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274; Damico,
   Francisco Max/0000-0002-2594-0336; Iwai, Leo K/0000-0002-1571-7763;
   Yamamoto, Joyce/0000-0001-6869-2988
CR Atherton E, 1989, SOLID PHASE PEPTIDE
   BELFORT R, 1988, JPN J OPHTHALMOL, V32, P344
   Bignon JD, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P584
   CHAN CC, 1988, AM J OPHTHALMOL, V105, P607, DOI 10.1016/0002-9394(88)90052-9
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   DESMET MD, 1990, AM J OPHTHALMOL, V110, P135, DOI 10.1016/S0002-9394(14)76981-8
   Eriksson U, 2003, NAT MED, V9, P1484, DOI 10.1038/nm960
   FERN J, 1992, J IMMUNOL, V148, P907
   Gocho K, 2001, INVEST OPHTH VIS SCI, V42, P2004
   Goldberg AC, 1998, HUM IMMUNOL, V59, P183, DOI 10.1016/S0198-8859(97)00265-6
   GOMI CF, 1997, REV MED SAO PAULO, V76, P101
   HAMMER H, 1974, BRIT J OPHTHALMOL, V58, P773, DOI 10.1136/bjo.58.9.773
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353
   HEARING VJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P327, DOI 10.1016/0005-2744(78)90067-0
   Imai YM, 2001, CURR EYE RES, V22, P312, DOI 10.1076/ceyr.22.4.312.5510
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Iwai LK, 2001, PEPTIDES, V22, P853, DOI 10.1016/S0196-9781(01)00409-0
   JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993
   Kawakami Yutaka, 1996, Keio Journal of Medicine, V45, P100
   LUBIN J R, 1982, International Ophthalmology Clinics, V22, P141, DOI 10.1097/00004397-198202230-00011
   MAEZAWA N, 1984, MICROBIOL IMMUNOL, V28, P219, DOI 10.1111/j.1348-0421.1984.tb00673.x
   Maron R, 1999, INT IMMUNOL, V11, P1573, DOI 10.1093/intimm/11.9.1573
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5
   MURAKAMI S, 1994, JPN J OPHTHALMOL, V38, P208
   NEUMANN DA, 1993, CLIN IMMUNOL IMMUNOP, V68, P181, DOI 10.1006/clin.1993.1116
   NOROSE K, 1990, INVEST OPHTH VIS SCI, V31, P1210
   OHNO S, 1981, T OPHTHAL SOC UK, V101, P335
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   PEYMAN GA, 1996, RETINA, V16, P160
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   SAKAMOTO T, 1991, ARCH OPHTHALMOL-CHIC, V109, P1270, DOI 10.1001/archopht.1991.01080090096030
   Sercarz EE, 2000, J AUTOIMMUN, V14, P275, DOI 10.1006/jaut.2000.0380
   SHINDO Y, 1994, BRIT J OPHTHALMOL, V78, P223, DOI 10.1136/bjo.78.3.223
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sun B, 1997, J IMMUNOL, V159, P1004
   TAGAWA Y, 1978, JPN J OPHTHALMOL, V22, P36
   Tian J, 2001, J IMMUNOL, V166, P7144, DOI 10.4049/jimmunol.166.12.7144
   Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331
   Xu H, 1997, CELL IMMUNOL, V178, P69, DOI 10.1006/cimm.1997.1121
   Yamaki K, 2000, EXP EYE RES, V71, P361, DOI 10.1006/exer.2000.0893
   Yamaki K, 2000, J IMMUNOL, V165, P7323, DOI 10.4049/jimmunol.165.12.7323
   YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5
NR 45
TC 63
Z9 68
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2005
VL 46
IS 7
BP 2465
EP 2471
DI 10.1167/iovs.04-1273
PG 7
WC Ophthalmology
SC Ophthalmology
GA 939ZK
UT WOS:000230112800033
PM 15980237
DA 2020-11-26
ER

PT J
AU de Castilho, EA
   Kalil, J
AF de Castilho, EA
   Kalil, J
TI Ethics and medical research: principles, guidelines, and regulations
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE ethics; bioethics; medical research; clinical research; ethics and
   research
AB The issue of ethics in medical research grew in importance at the end of the World War II, after the Nuremberg Code. In this period, some cases in the United States had demonstrated the need for the establishment of rules and procedures in medical research. In this article, the authors discuss some ethical concepts and their philosophical basis, stressing aspects related to research. Ethics in medical research is based upon three items: peer approaches, subject informed consent, and confidentiality of individual obtained data. The authors also summarize the Brazilian laws and directives to follow the precepts and to control the process of ethical issues in research with human participants. Finally, they approach practical questions of the Informed Consent Form as a consequence of their experiences analyzing more than one thousand research projects per year as members of the Internal Review Board of the University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
C1 USP, FM, HC, Dept Prevent Med, BR-01246903 Sao Paulo, Brazil.
   USP, Fac Med, Hosp Clin, SP & Comite Et Pesquisa Complexo, BR-01246903 Sao Paulo, Brazil.
   USP, Fac Med, Dept Clin Med, BR-01246903 Sao Paulo, Brazil.
RP de Castilho, EA (corresponding author), USP, FM, HC, Dept Prevent Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM castil@usp.br
RI DE CASTILHO, EUCLIDES AYRES/K-7906-2016; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Castilho, Euclides/0000-0002-7352-8784
CR BEAUCHAMP TL, 2002, PRINCIPIOS ETICA
   EMANUEL EJ, 2004, ETHICAL REGULATORY A
   EMANUEL EJ, 2004, ETHICAL REGULATORY A, P30
   Hosne WS, 2003, BIOETICA SAUDE PUBLI, P95
   LOPES MAR, 1998, CODIGO PENAL
   OLIVEIRA F, 2002, BIOETICA FACE CIDADA
   OLIVEIRA J, 1996, CONSITUICAO REPUBLIC
   Zoboli EL, 2003, BIOETICA SAUDE PUBLI, P25
NR 8
TC 2
Z9 2
U1 0
U2 3
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JUL-AUG
PY 2005
VL 38
IS 4
BP 344
EP 347
DI 10.1590/S0037-86822005000400013
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 954MX
UT WOS:000231160300013
PM 16082484
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Fonseca, SG
   Moins-Teisserenc, H
   Clave, E
   Ianni, B
   Nunes, VL
   Mady, C
   Iwai, LK
   Sette, A
   Sidney, J
   Marin, MLC
   Goldberg, AC
   Guilherme, L
   Charron, D
   Toubert, A
   Kalil, J
   Cunha-Neto, E
AF Fonseca, SG
   Moins-Teisserenc, H
   Clave, E
   Ianni, B
   Nunes, VL
   Mady, C
   Iwai, LK
   Sette, A
   Sidney, J
   Marin, MLC
   Goldberg, AC
   Guilherme, L
   Charron, D
   Toubert, A
   Kalil, J
   Cunha-Neto, E
TI Identification of multiple HLA-A*0201-restricted cruzipain and FL-160
   CD8(+) epitopes recognized by T cells from chronically Trypanosoma
   cruzi-infected patients
SO MICROBES AND INFECTION
LA English
DT Article
DE CD8(+) T cells; Chagas disease; ELISPOT; tetramer; epitopes
ID MAJOR CYSTEINE PROTEINASE; CHAGAS-DISEASE; LYMPHOCYTE-RESPONSES;
   IFN-GAMMA; MICE; ANTIGEN; VACCINE; MOLECULES; FREQUENCY; BINDING
AB Chronic Chagas disease occurs in 16 million individuals chronically infected by the protozoan Trypanosoma cruzi in Latin America, and may lead to a dilated cardiomyopathy in 10-30% of patients. A vigorous cellular immune response holds parasitism in check. However, up to now, few T cruzi proteins have been shown to be recognized by CD8(+) T cells from Chagas disease patients. In this study, we designed 94 peptides derived from T cruzi proteins cruzipain and FL-160, predicted to bind to HLA-A2 molcules. After in vitro binding assays to HLA-A*0201, 26 peptides were selected, and their recognition by PBMC from Chagas disease patients was tested with the IFN-gamma ELISPOT assay. All 26 peptides were recognized by PBMC from at least one patient. Furthermore, a tetrameric HLA-A*0201 complex built with the cruzipain 60-68 peptide that was frequently recognized in the periphery also bound to CD8(+) T cells from a heart-infiltrating T cell line obtained from a single patient with Chagas disease cardiomyopathy. Thus, our results suggest that the recognition of CD8(+) T cell epitopes in cruzipain and FL-160 may have a pathogenic or protective role in chronic Chagas disease. (c) 2005 Elsevier SAS. All rights reserved.
C1 Univ Sao Paulo, Fac Med, InCor, Heart Inst,Lab Imunol, BR-05403000 Sao Paulo, SP, Brazil.
   Hop St Louis, INSERM, IUH, AP HP,Lab Immunol & Histocompatibil, Paris, France.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, InCor, Heart Inst,Lab Imunol, Av Dr Eneas Carvalho Aguiar,44 BL 2,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM edecunha@usp.br
RI Cunha-Neto, Edecio/B-4157-2009; FONSECA, SIMONE GONCALVES/U-9278-2019;
   Guglielmi, Luiza G/E-7676-2013; Goldberg, Anna Carla/H-8594-2014; Iwai,
   Leo K/M-1734-2013; Guilherme, Luiz Roberto Guimaraes/V-6163-2019;
   Guilherme, Luiz Roberto G/B-3998-2009; Mady, Charles/C-8870-2012; KALIL,
   JORGE/C-8029-2012; Clave, Emmanuel/ABD-8112-2020; Toubert,
   Antoine/Q-3404-2017; Clave, Emmanuel/ABD-8127-2020; Ianni, Barbara
   Maria/C-7689-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Goldberg, Anna
   Carla/0000-0003-2600-7940; Iwai, Leo K/0000-0002-1571-7763; Guilherme,
   Luiz Roberto Guimaraes/0000-0002-5387-6028; Guilherme, Luiz Roberto
   G/0000-0002-5387-6028; Mady, Charles/0000-0002-8838-199X; KALIL,
   JORGE/0000-0001-8415-4274; Clave, Emmanuel/0000-0001-8217-5039; Toubert,
   Antoine/0000-0002-7308-7317; Ianni, Barbara Maria/0000-0002-1588-5492;
   Moins-Teisserenc, helene/0000-0003-1602-7534
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI095362, N01AI095362, N01AI095362, N01AI095362] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01-AI-95362] Funding Source:
   Medline
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   ARNHOLDT ACV, 1993, J IMMUNOL, V151, P3171
   Atherton E, 1989, SOLID PHASE PEPTIDE
   BIGNON JD, 1997, 12 INT HIST WORKSH, P584
   CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A
   CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423
   CETRON MS, 1992, ACTA TROP, V50, P259, DOI 10.1016/0001-706X(92)90082-9
   Garcia F, 2003, MICROBES INFECT, V5, P351, DOI 10.1016/S1286-4579(03)00044-3
   Garg N, 1997, J IMMUNOL, V158, P3293
   Giordanengo L, 2000, EUR J IMMUNOL, V30, P3181, DOI 10.1002/1521-4141(200011)30:11&lt;3181::AID-IMMU3181&gt;3.0.CO;2-A
   Gruppi A, 1997, ACTA TROP, V63, P141, DOI 10.1016/S0001-706X(96)00616-X
   Gulukota K, 1997, J MOL BIOL, V267, P1258, DOI 10.1006/jmbi.1997.0937
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   HOWARD CR, 1995, J VIRAL HEPATITIS, V2, P165, DOI 10.1111/j.1365-2893.1995.tb00024.x
   Iwai LK, 2001, PEPTIDES, V22, P853, DOI 10.1016/S0196-9781(01)00409-0
   Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8
   Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682
   Martinez J, 1998, FEMS MICROBIOL LETT, V159, P35, DOI 10.1016/S0378-1097(97)00539-9
   Rodrigues MM, 1999, INFECT IMMUN, V67, P3855, DOI 10.1128/IAI.67.8.3855-3863.1999
   ROSALES T, 1992, BRAZ J MED BIOL RES, V25, P39
   ROTTENBERG ME, 1995, IMMUNOL LETT, V45, P53, DOI 10.1016/0165-2478(94)00221-C
   ROTTENBERG ME, 1993, INFECT IMMUN, V61, P5129, DOI 10.1128/IAI.61.12.5129-5133.1993
   RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3
   SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336
   SETTE A, 1994, J IMMUNOL, V153, P5586
   Sidney J, 2001, HUM IMMUNOL, V62, P1200, DOI 10.1016/S0198-8859(01)00319-6
   SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1016/0270-9139(95)90121-3
   Tan LC, 1999, J IMMUNOL, V162, P1827
   TARLETON RL, 1994, INFECT IMMUN, V62, P1820, DOI 10.1128/IAI.62.5.1820-1829.1994
   TARLETON RL, 1990, J IMMUNOL, V144, P717
   TARLETON RL, 1992, NATURE, V356, P291
   VANVOORHIS WC, 1993, J EXP MED, V178, P681, DOI 10.1084/jem.178.2.681
   WEBER T, 1989, TRANSPLANTATION, V48, P430, DOI 10.1097/00007890-198909000-00016
   Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996
   Wizel B, 1998, J CLIN INVEST, V102, P1062, DOI 10.1172/JCI3835
   Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51
NR 38
TC 57
Z9 59
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD APR
PY 2005
VL 7
IS 4
BP 688
EP 697
DI 10.1016/j.micinf.2005.01.001
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 932DO
UT WOS:000229534600015
PM 15848276
DA 2020-11-26
ER

PT J
AU Fae, KC
   Oshiro, SE
   Toubert, A
   Charron, D
   Kalil, J
   Guilherme, L
AF Fae, KC
   Oshiro, SE
   Toubert, A
   Charron, D
   Kalil, J
   Guilherme, L
TI How an autoimmune reaction triggered by molecular mimicry between
   streptococcal M protein and cardiac tissue proteins leads to heart
   lesions in rheumatic heart disease
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article; Proceedings Paper
CT 12th Annual International Congress of Immunology/4th Annual Conference
   of the Federation-of-Clinical-Immunology-Societies (FOCIS)
CY JUL 18-23, 2004
CL Montreal, CANADA
SP Federat Clin Immunol Soc
DE autoimmune disease; cytokine; molecular mimicry; rheumatic fever; T
   lymphocytes
ID COILED-COIL STRUCTURE; CLASS-II ANTIGENS; T-CELL-CLONES; VIRUS; FEVER;
   DEGENERACY; MYOSIN; TCR; PATHOGENESIS; RESTRICTION
AB Molecular mimicry between microbial antigens' and host tissue is suggested as a mechanism for post-infectious autoimmune disease. In the present work we describe the autoimmune reactions of two severe rheumatic heart disease (RHD) patients, through an analysis of heart-infiltrating T-cell repertoire, antigen recognition, and cytokine production induced by specific antigens. T-cell clones derived from oligoclonally expanded T cells in the heart cross-recognized M5 peptides, heart tissue-derived proteins, and myosin peptides. We show, using binding affinity assays, that an immunodominant streptococcal peptide (M5(81-96)) is capable of binding to the HLA-DR53 molecule. The same peptide was recognized by an infiltrating T-cell clone from a patient carrying HLADR 15, DR7, and DR53 molecules. This suggests that this peptide is probably presented to T cells in the context of the HLA-DR53 molecule. Cross-reactive heart-infiltrating T cells activated by the M5 protein and its peptides and by heart tissue-derived proteins produced predominantly inflammatory cytokines. Interteukin (IL)-4 was produced in small amounts by mitral valve intralesional T-cell lines and clones. Altogether, these results suggest that mimicry between streptococcal antigens and heart-tissue proteins, combined with-high inflammatory cytokine and low IL-4 production, leads to the development of autoimmune reactions and cardiac tissue damage in RHD patients. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Millenium Inst, Inst Immmunol Invest, Sao Paulo, Brazil.
   Inst Univ Hematol, Hop St Louis, INSERM U396, Lab Immunol & Histocompatibilite, Paris, France.
   Univ Sao Paulo, Sch Med, Dept Clin Med Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Inst Coracao, Lab Imunol, HC, FMUSP, Av Dr Eneas de Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Toubert, Antoine/Q-3404-2017; KALIL, JORGE/C-8029-2012; Guglielmi, Luiza
   G/E-7676-2013
OI Toubert, Antoine/0000-0002-7308-7317; KALIL, JORGE/0000-0001-8415-4274; 
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   AYOUB EM, 1984, CIRCULATION, V69, P197, DOI 10.1161/01.CIR.69.1.197
   Bhat MS, 1997, INDIAN J MED RES, V105, P271
   Cohen IR, 2004, MOL IMMUNOL, V40, P993, DOI 10.1016/j.molimm.2003.11.020
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023
   DIEDERICH KW, 1989, HUM GENET, V81, P214
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Figueroa F, 2002, J AUTOIMMUN, V19, P233, DOI 10.1006/jaut.2002.0620
   FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848
   Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Hausmann S, 1999, J IMMUNOL, V162, P338
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   Maverakis E, 2001, J AUTOIMMUN, V16, P201, DOI 10.1006/jaut.2000.0493
   Olsen JK, 2001, J CLIN INVEST, V108, P311
   Olson JK, 2002, J IMMUNOL, V169, P2719, DOI 10.4049/jimmunol.169.5.2719
   Olson JK, 2001, VIRAL IMMUNOL, V14, P227, DOI 10.1089/088282401753266756
   Olson JK, 2001, J VIROL, V75, P9780, DOI 10.1128/JVI.75.20.9780-9789.2001
   OZKAN M, 1993, CIRCULATION, V87, P1974, DOI 10.1161/01.CIR.87.6.1974
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   PANOUTSAKOPOULO.V, 2004, IMMUNITY, V15, P137
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Rose NR, 1998, SEMIN IMMUNOL, V10, P5, DOI 10.1006/smim.1997.0100
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344
NR 38
TC 35
Z9 37
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAR
PY 2005
VL 24
IS 2
BP 101
EP 109
DI 10.1016/j.jaut.2005.01.007
PG 9
WC Immunology
SC Immunology
GA 921RB
UT WOS:000228781200003
PM 15829402
DA 2020-11-26
ER

PT J
AU Iwai, LK
   Juliano, MA
   Juliano, L
   Kalil, J
   Cunha-Neto, E
AF Iwai, LK
   Juliano, MA
   Juliano, L
   Kalil, J
   Cunha-Neto, E
TI T-cell molecular mimicry in Chagas disease: identification and partial
   structural analysis of multiple cross-reactive epitopes between
   Trypanosoma cruzi B13 and cardiac myosin heavy chain
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article; Proceedings Paper
CT 12th Annual International Congress of Immunology/4th Annual Conference
   of the Federation-of-Clinical-Immunology-Societies (FOCIS)
CY JUL 18-23, 2004
CL Montreal, CANADA
SP Federat Clin Immunol Soc
DE B13 protein; Chagas disease cardiomyopathy; human cardiac myosin; T-cell
   molecular mimicry; Trypanosoma cruzi
ID MYELIN BASIC-PROTEIN; MONOCLONAL-ANTIBODIES; AUTOIMMUNITY; PEPTIDE;
   RECOGNITION; CARDIOMYOPATHY; MYOCARDITIS; ANTIGENS; CLONES; INFLAMMATION
AB Chagas disease cardiornyopathy (CCC) is one of the few examples of post-infectious autoimmunity, where infectious episodes with an established pathogen, the protozoan parasite Trypanosoma cruzi, clearly triggers molecular mimicry-related target organ immune damage. CD4(+) T-cell clones infiltrating hearts from CCC patients cross-reactively recognize human cardiac myosin, the major heart protein, and the immunodominam B 13 protein from T. cruzi. Moreover, in vitro priming with B 13 leads to the recovery of cardiac myosin cross-reactive T-cell clones. In order to identify cross-reactive epitopes between B 13 protein and human cardiac myosin, we used B13 peptide S15.4, preferentially recognized by CCC patients, to establish a T-cell clone from an HLA-DQ7 individual. The B13 S15.4 peptide- specific CD4(+) T-cell clone 3E5 was tested in proliferation assays against 15 Lys/His-substituted S15.4-derived peptides for TCR/HLA contact analysis. Together with previous HLA-binding data and molecular modeling of the HLA-DQ7-peptide S15.4 complex, Lys/His scanning analysis showed eight TCR/HLA contact positions. Clone 3E5 was also tested against 45 15-mer peptides from human beta-cardiac myosin heavy chain bearing the central HLA-DQ7 binding motif. Clone 3135 recognized 13 peptides from cardiac myosin. The alignment of cross-reactive peptides in cardiac myosin showed very limited sharing of residues or side chains with similar chemical/structural features at aligned positions, indicative of a very degenerate TCR recognition pattern. The existence of degenerate intramolecular recognition, with multiple low-homology, cross-reactive epitopes in a single autoantigenic protein may have implications in increasing the magnitude of the autoimmune response in CCC and other autoimmune diseases. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM educunha@usp.br
RI KALIL, JORGE/C-8029-2012; Juliano, Luiz/D-7204-2012; Cunha-Neto,
   Edecio/B-4157-2009; Iwai, Leo K/M-1734-2013
OI KALIL, JORGE/0000-0001-8415-4274; Juliano, Luiz/0000-0002-5589-2822;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Iwai, Leo K/0000-0002-1571-7763
CR ABEL LC, 1999, THESIS SAO PAULO U S
   Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X
   CREVAT D, 1983, ANN INST PASTEUR IMM, VC134, P31, DOI 10.1016/S0769-2625(83)80151-2
   Cunha-Neto Edecio, 1997, Memorias do Instituto Oswaldo Cruz, V92, P40
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   CUNHANETO E, 2004, INFECT AUTOIMMUNITY, P451
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Hemmer B, 1998, J IMMUNOL, V160, P3631
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   Leon JS, 2004, INFECT IMMUN, V72, P3410, DOI 10.1128/IAI.72.6.3410-3417.2004
   Leon JS, 2001, INFECT IMMUN, V69, P5643, DOI 10.1128/IAI.69.9.5643-5649.2001
   Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   Raddrizzani L, 1997, J IMMUNOL, V159, P703
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Uemura Y, 2003, J IMMUNOL, V170, P947, DOI 10.4049/jimmunol.170.2.947
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
   WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279
NR 29
TC 49
Z9 51
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAR
PY 2005
VL 24
IS 2
BP 111
EP 117
DI 10.1016/j.jaut.2005.01.006
PG 7
WC Immunology
SC Immunology
GA 921RB
UT WOS:000228781200004
PM 15829403
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Eliaschewitz, FG
   Montor, WR
   Baracho, GV
   Errante, PR
   Callero, MA
   Cardoso, MRA
   Braga, PE
   Kalil, J
   Sogayar, MC
   Rizzo, LV
AF Goldberg, AC
   Eliaschewitz, FG
   Montor, WR
   Baracho, GV
   Errante, PR
   Callero, MA
   Cardoso, MRA
   Braga, PE
   Kalil, J
   Sogayar, MC
   Rizzo, LV
TI Exogenous leptin restores in vitro T cell proliferation and cytokine
   synthesis in patients with Common Variable Immunodeficiency Syndrome
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE common variable immunodeficiency; peripheral blood mononuclear cells;
   leptin; apoptosis; cytokine; T cell proliferation
ID IMMUNE-RESPONSE; B-CELLS; APOPTOSIS; ACTIVATION; EXPRESSION;
   INTERLEUKIN-2; INFLAMMATION; GENERATION; PROTECTION; INCREASES
AB Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia. Leptin has been implicated as an antiapoptotic compound as well as a stimulant of the immune response. Leptin administration is capable of reversing the immune deficiency that occurs upon starvation. We investigated a possible role for leptin in CVID; a condition associated with lowered plasma leptin levels. Thirty-eight patients were studied. Addition of leptin to the tissue culture media of PBMC from CVID patients increased the proliferative response of lymphocytes to mitogens and decreased activation-induced apoptosis of these cells. IL-2 and specially IL-4 production also increased significantly upon addition of leptin to the PBMC cultures. Our results suggest that leptin may be involved in some of the cellular defects observed in CVID and indicate a novel therapeutic strategy to improve immune function in these patients. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Sao Paulo, Dept Biochem, Inst Chem, BR-05513970 Sao Paulo, Brazil.
   Hosp Heliopolis, Sao Paulo, Brazil.
   Albert Einstein Coll Med Hosp, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Epidemiol, Sch Publ Hlth, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Lab Invest Med 60, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Dept Biochem, Inst Chem, Av Prof Lineu Prestes 748,POB 26077, BR-05513970 Sao Paulo, Brazil.
EM goldberg@usp.br
RI KALIL, JORGE/C-8029-2012; Braga, Patricia/B-7806-2018; Goldberg, Anna
   Carla/H-8594-2014; Sogayar, Mari C/B-3980-2017; Rizzo, Luiz
   Vicente/B-4458-2009; Cardoso, Maria Regina A/J-7280-2012; Montor,
   Wagner/J-2568-2012
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; Sogayar, Mari C/0000-0003-4805-4609; Montor,
   Wagner/0000-0003-3746-9366
CR ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388
   Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947
   Banks Theresa A., 1994, Current Opinion in Biotechnology, V5, P604, DOI 10.1016/0958-1669(94)90082-5
   Brouet JC, 2000, EUR J IMMUNOL, V30, P2516, DOI 10.1002/1521-4141(200009)30:9<2516::AID-IMMU2516>3.0.CO;2-Z
   Busso N, 2002, J IMMUNOL, V168, P875, DOI 10.4049/jimmunol.168.2.875
   Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105
   CHANDRA RK, 1980, AM J CLIN NUTR, V33, P2694
   CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052
   CUNNINGHAMRUNDLES C, 1995, J INTERF CYTOK RES, V15, P269, DOI 10.1089/jir.1995.15.269
   EISENSTEIN EM, 1993, J CLIN IMMUNOL, V13, P247, DOI 10.1007/BF00919383
   Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437
   Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693
   FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099
   FERNANDES G, 1978, J CLIN INVEST, V61, P243, DOI 10.1172/JCI108933
   Fujita Y, 2002, CLIN EXP IMMUNOL, V128, P21, DOI 10.1046/j.1365-2249.2002.01797.x
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762
   KOKRON CM, 2004, ACAD BRAS CIENC, V76, P1
   Kratz M, 2002, J CLIN ENDOCR METAB, V87, P5008, DOI 10.1210/jc.2002-020496
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   Lord GM, 2002, J LEUKOCYTE BIOL, V72, P330
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155
   Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594
   Matarese G, 2000, EUR CYTOKINE NETW, V11, P7
   North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x
   Okuya S, 2001, ENDOCRINOLOGY, V142, P4827, DOI 10.1210/en.142.11.4827
   Palacio A, 2002, J CLIN ENDOCR METAB, V87, P3040, DOI 10.1210/jc.87.7.3040
   Prentice AM, 1999, BRIT J NUTR, V81, P345, DOI 10.1017/S0007114599000628
   RANDALL TD, 1993, MOL CELL BIOL, V13, P3929, DOI 10.1128/MCB.13.7.3929
   Reidy SP, 2000, COMP BIOCHEM PHYS A, V125, P285, DOI 10.1016/S1095-6433(00)00159-8
   ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707
   Sanchez-Margalet V, 2002, CLIN EXP IMMUNOL, V129, P119, DOI 10.1046/j.1365-2249.2002.01900.x
   Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490
   Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558
   Siegmund B, 2002, GASTROENTEROLOGY, V122, P2011, DOI 10.1053/gast.2002.33631
   SNELLER MC, 1990, J IMMUNOL, V144, P3762
   Sneller MC, 2001, AM J MED SCI, V321, P42, DOI 10.1097/00000441-200101000-00007
   Takeda K, 1998, J IMMUNOL, V161, P4652
   Thon V, 1997, CLIN EXP IMMUNOL, V110, P174
   Wurster AL, 2002, J BIOL CHEM, V277, P27169, DOI 10.1074/jbc.M201207200
   Yamamoto JH, 2000, J INFECT DIS, V181, P2018, DOI 10.1086/315494
   Zarkesh-Esfahani H, 2001, J IMMUNOL, V167, P4593, DOI 10.4049/jimmunol.167.8.4593
NR 44
TC 18
Z9 19
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD FEB
PY 2005
VL 114
IS 2
BP 147
EP 153
DI 10.1016/j.clim.2004.09.002
PG 7
WC Immunology
SC Immunology
GA 889KA
UT WOS:000226440700007
PM 15639648
DA 2020-11-26
ER

PT J
AU Fonseca, CT
   Cunha-Neto, E
   Goldberg, AC
   Kalil, J
   de Jesus, AR
   Carvalho, EM
   Correa-Oliveira, R
   Oliveira, SC
AF Fonseca, CT
   Cunha-Neto, E
   Goldberg, AC
   Kalil, J
   de Jesus, AR
   Carvalho, EM
   Correa-Oliveira, R
   Oliveira, SC
TI Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty
   acid-binding protein using cells from patients living in areas endemic
   for schistosomiasis
SO MICROBES AND INFECTION
LA English
DT Article
DE vaccine; human T cells; synthetic peptides; Schistosoma mansoni; Sm14
ID IFN-GAMMA; INTERFERON-GAMMA; IMMUNE-RESPONSES; VACCINE; RESISTANCE;
   MICE; IDENTIFICATION; POLYPEPTIDE; ANTIBODY
AB The development of a defined anti-schistosomiasis vaccine would contribute to the current control strategy mainly because immunization provides long-lasting immunity to the disease. Sm14, one of the six Schistosoma mansoni antigens selected by WHO as a candidate to compose a subunit vaccine against schistosomiasis, has been associated with resistance to S. mansoni infection in human beings and is able to induce protection in the murine model. To identify human T cell epitopes in Sm14, we used the TEPITOPE algorithm to select peptides that would most likely bind to several HLA-DR molecules. In this study, three Sm14 epitopes were selected and produced as synthetic peptides. Human T cell responses from schistosomiasis patients living in endemic areas in Brazil were determined by proliferation assay and IL-5 and IFN-gamma measurements. Differential peptide recognition and cytokine production in response to Sm14 epitopes were observed in individuals resistant to S. mansoni infection versus susceptible individuals. Sm14(32-48) and Sm14(53-69) peptides were preferentially recognized by peripheral blood mononuclear cells (PBMCs) of S. mansoni-resistant individuals, and Sm 14(53-69) induced significant production of IFN-gamma. Additionally, Sm14(32-48) and Sm14(53-69) were "promiscuous" peptides, since they were able to induce cellular immune responses in individuals carrying 10 and 8, respectively, of the 11 HLA-DR molecules expressed in the studied population. Among Sm 14 synthetic peptides tested in this study, we identified Sm 14(32-48) and Sm 14(53-69) as promising candidates to compose an anti-schistosomiasis vaccine, since they seem to be related to resistance to human schistosomiasis. (c) 2005 Elsevier SAS. All rights reserved.
C1 Univ Fed Minas Gerais, Inst Invest Imunol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Inst Milenio, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Sao Paulo, Lab Imunol, Inst Coracao, BR-05403000 Sao Paulo, SP, Brazil.
   Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Imunol, Salvador, BA, Brazil.
   Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Lab Imunol, BR-30190002 Belo Horizonte, MG, Brazil.
RP Oliveira, SC (corresponding author), Univ Fed Minas Gerais, Inst Invest Imunol, Dept Bioquim & Imunol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM scozeus@icb.ufmg.br
RI Goldberg, Anna Carla/H-8594-2014; Fonseca, Cristina/M-8511-2019; KALIL,
   JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI Goldberg, Anna Carla/0000-0003-2600-7940; Fonseca,
   Cristina/0000-0003-1527-5050; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Correa-Oliveira,
   Rodrigo/0000-0001-6419-9459
CR Agiro L., 2000, VACCINE, V18, P2033
   Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5
   Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2
   BOROS DL, 1989, CLIN MICROBIOL REV, V2, P250, DOI 10.1128/CMR.2.3.250-269.1989
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brito CFA, 2000, SCAND J IMMUNOL, V51, P595
   Brito CFA, 2002, BRAZ J MED BIOL RES, V35, P377, DOI 10.1590/S0100-879X2002000300014
   Brito CFA, 2000, PARASITE IMMUNOL, V22, P41
   Caldas IR, 2000, AM J TROP MED HYG, V62, P57, DOI 10.4269/ajtmh.2000.62.57
   COLES GC, 1986, T ROY SOC TROP MED H, V80, P347, DOI 10.1016/0035-9203(86)90055-6
   COLLEY DG, 1977, INT ARCH ALLER A IMM, V53, P420, DOI 10.1159/000231780
   Correa-Oliveira R, 2000, ACTA TROP, V77, P141, DOI 10.1016/S0001-706X(00)00127-3
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83
   Fonseca CT, 2004, VACCINE, V22, P503, DOI 10.1016/j.vaccine.2003.07.010
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   JAMES SL, 1989, J IMMUNOL, V143, P4208
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   MOSER D, 1991, J BIOL CHEM, V266, P8447
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843
   Ramos CRR, 2001, MEM I OSWALDO CRUZ, V96, P131, DOI 10.1590/S0074-02762001000900019
   SMYTHIES LE, 1992, J IMMUNOL, V149, P3654
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tallima H, 2003, VACCINE, V21, P3290, DOI 10.1016/S0264-410X(03)00180-4
   Tarrab-Hazdai R, 1998, INFECT IMMUN, V66, P4526
   VIANA IRC, 1994, T ROY SOC TROP MED H, V88, P466, DOI 10.1016/0035-9203(94)90436-7
   VIANA IRC, 1995, PARASITE IMMUNOL, V17, P297, DOI 10.1111/j.1365-3024.1995.tb00895.x
   Vilar MM, 2003, VACCINE, V22, P137, DOI 10.1016/S0264-410X(03)00300-1
   Wilson RA, 1998, BRAZ J MED BIOL RES, V31, P157, DOI 10.1590/S0100-879X1998000100022
NR 33
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD FEB
PY 2005
VL 7
IS 2
BP 204
EP 212
DI 10.1016/j.micinf.2004.10.012
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 916LG
UT WOS:000228385800009
PM 15725385
DA 2020-11-26
ER

PT S
AU Guilherme, L
   Fae, KC
   Oshiro, SE
   Tanaka, AC
   Pomerantzeff, PMA
   Kalil, J
AF Guilherme, L
   Fae, KC
   Oshiro, SE
   Tanaka, AC
   Pomerantzeff, PMA
   Kalil, J
BE Shoenfeld, Y
   Gershwin, ME
TI Rheumatic fever - How S pyogenes - Primed peripheral T cells trigger
   heart valve lesions
SO AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 4th International Congress of Autoimmunity
CY NOV 03-08, 2004
CL Budapest, HUNGARY
DE autoimmune disease; rheumatic fever; M protein; heart tissue proteins;
   molecular mimicry; T lymphocytes; T cell receptor; cytokines
ID DISEASE; LYMPHOCYTES; CYTOKINES; ANTIGEN; RESPONSES; CARDITIS; SUBSETS;
   CLONES; ALPHA; IL-2
AB The pathogenesis of rheumatic fever (RF) is related to autoimmune humoral and cellular responses against human tissues triggered by Streptococcus pyogenes. CD4(+) T cells are the ultimate effectors of chronic heart lesions in rheumatic heart disease (RHD). Heart-infiltrating CD4(+) T cell clones are able to recognize heart tissue and streptococcal antigens by molecular mimicry. The streptococcal M5(81-103) region, an immunodominant region, was recognized by both intralesional and peripheral T cell clones (62% and 38%, respectively). Peripheral T lymphocytes from Brazilian patients with severe RHD preferentially recognized the M5(81-96) peptide, in the context of HLA-DR7(+) and DR53(+) molecules. HLA-DR7 seems to be related to the development of multiple valvular lesions in RHD patients from different countries. In addition, the fact that peripheral and intralesional T cells recognized the M5(81-103) region points to this region as one of the streptococcal triggers of autoimmune reactions in RHD. T cell repertoire analysis from peripheral and intralesional T cell lines derived from RHD patients showed several oligoclonal expansions of BV families. Major expansions were found in the heart lesions, suggesting that such T cell populations preferentially migrate from the periphery to the heart. Some cross-reactive intralesional T cell clones displayed the same T cell receptor (TCR) BVBJ and CDR3 sequences, showing a degenerate pattern of antigen recognition. Heart tissue-infiltrating cells from myocardium and valvular tissue produced TNF-alpha, IFN-gamma, IL-10, and IL-4, whereas few cells from valvular tissue produced IL-4, showing that the lack of regulation in the valves could be responsible for the permanent and progressive valvular lesions.
C1 Univ Sao Paulo, Sch Med, Heart Inst, InCor, Sao Paulo, Brazil.
   Millennium Inst, Inst Immunol Invest, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), FMUSP, HC, Lab Imunol, Inst Coracao, Av Dr Eneas Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013; Pomerantzeff,
   Pablo M A/L-5525-2016
OI KALIL, JORGE/0000-0001-8415-4274; Pomerantzeff, Pablo M
   A/0000-0003-0566-1038
CR Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Degnan B, 1997, HUM IMMUNOL, V53, P206, DOI 10.1016/S0198-8859(97)00028-1
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   FLEISCHER B, 1992, INFECT IMMUN, V60, P1767, DOI 10.1128/IAI.60.5.1767-1770.1992
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Guilherme L, 2004, INFECT AUTOIMMUNITY, P321
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOTB M, 1989, J IMMUNOL, V142, P966
   LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   MORRIS K, 1993, CLIN EXP IMMUNOL, V91, P429
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   SAMSONOV MY, 1995, CLIN IMMUNOL IMMUNOP, V74, P31, DOI 10.1006/clin.1995.1005
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   WATANABEOHNISHI R, 1994, J IMMUNOL, V152, P2066
   Yegin O, 1997, EUR J PEDIATR, V156, P25
NR 25
TC 15
Z9 15
U1 0
U2 3
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-612-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2005
VL 1051
BP 132
EP 140
DI 10.1196/annals.1361.054
PG 9
WC Immunology; Multidisciplinary Sciences
SC Immunology; Science & Technology - Other Topics
GA BDG54
UT WOS:000233393100014
PM 16126952
DA 2020-11-26
ER

PT J
AU Alcantara, FF
   Postol, E
   Alencar, ER
   Assis, VR
   Demarchi, L
   Kalil, J
   Guilherme, L
AF Alcantara, FF
   Postol, E
   Alencar, ER
   Assis, VR
   Demarchi, L
   Kalil, J
   Guilherme, L
TI Rheumatic fever: Development of an animal model using streptococcal M1
   recombinant protein.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Immunol Invest, Sao Paulo, Brazil.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Alcantara,
   Flavio F/O-8954-2019; Demarchi, Lea/K-3105-2012
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S169
EP S170
PG 2
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400478
DA 2020-11-26
ER

PT J
AU Caldas, C
   Spadafora-Ferreira, M
   Oshiro, SE
   Fonseca, JA
   Luna, E
   Ho, PL
   Kalil, J
   Coelho, V
AF Caldas, C
   Spadafora-Ferreira, M
   Oshiro, SE
   Fonseca, JA
   Luna, E
   Ho, PL
   Kalil, J
   Coelho, V
TI Peripheral and graft infiltrating T cell responses to self heat shock
   protein 60 in renal transplant patients.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Renal Transplantat Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
   Butantan Inst, Sao Paulo, Brazil.
RI Ho, Paulo/P-8267-2015; Spadafora-Ferreira, Monica/G-2635-2012; KALIL,
   JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013
OI Ho, Paulo/0000-0003-3652-241X; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929; KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S281
EP S281
PG 1
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400793
DA 2020-11-26
ER

PT J
AU Coelho, V
   Luna, E
   Benvenuti, LA
   Mundel, LR
   Bueno, V
   Iwai, LK
   Caldas, C
   Kalil, J
AF Coelho, V
   Luna, E
   Benvenuti, LA
   Mundel, LR
   Bueno, V
   Iwai, LK
   Caldas, C
   Kalil, J
TI Cellular reactivity to human Hsp60 in murine skin and heart
   transplantation.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Univ Sao Paulo, Inst Heart, Incor, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Internal Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   UNIFESP, Paulista Sch Med, Dept Med, Div Nephrol, Sao Paulo, Brazil.
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Iwai, Leo
   K/M-1734-2013; Benvenuti, Luiz/C-6614-2014
OI KALIL, JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S278
EP S278
PG 1
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400786
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Oshiro, SE
   Puschel, C
   Silva, WR
   Higa, F
   Chaves, L
   Tanaka, AC
   Spina, G
   Pomerantzeff, PMA
   Kalil, J
AF Guilherme, L
   Oshiro, SE
   Puschel, C
   Silva, WR
   Higa, F
   Chaves, L
   Tanaka, AC
   Spina, G
   Pomerantzeff, PMA
   Kalil, J
TI Intralesional T cell lines obtained from rheumatic heart disease lesions
   can be used as a tool for searching for non-autoimmune M protein
   epitopes for developing a safe vaccine against group A streptococci.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Immunol Invest, Sao Paulo, Brazil.
RI Guglielmi, Luiza G/E-7676-2013; Spina, Guilherme S./I-3530-2013; KALIL,
   JORGE/C-8029-2012; Pomerantzeff, Pablo M A/L-5525-2016
OI KALIL, JORGE/0000-0001-8415-4274; Pomerantzeff, Pablo M
   A/0000-0003-0566-1038
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S171
EP S171
PG 1
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400482
DA 2020-11-26
ER

PT J
AU Luna, E
   Postol, E
   Benvenuti, LA
   Rodrigues, JM
   Lima, KM
   Caldas, C
   Kalil, J
   Coelho, V
AF Luna, E
   Postol, E
   Benvenuti, LA
   Rodrigues, JM
   Lima, KM
   Caldas, C
   Kalil, J
   Coelho, V
TI Evaluation of skin graft survival using the encapsulated Hsp60 peptide
   (p277) in a murine model of minor antigen disparities.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Univ Sao Paulo, Inst Heart, Incor, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Internal Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Ctr TB Res, Ribeirao Preto, SP, Brazil.
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Benvenuti,
   Luiz/C-6614-2014
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S278
EP S279
PG 2
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400787
DA 2020-11-26
ER

PT J
AU Strozzi, D
   Toledo-Barros, M
   Rizzo, LV
   Saldiva, PHN
   Caldini, EG
   Kalil, J
   Kokron, CM
AF Strozzi, D
   Toledo-Barros, M
   Rizzo, LV
   Saldiva, PHN
   Caldini, EG
   Kalil, J
   Kokron, CM
TI Association of IgA deficiency and ciliary dyskinesia: Report of a
   familiar case.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society
CY MAY 12-16, 2005
CL Boston, MA
SP Fed Clin Immunol Soc
C1 Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Inst Invest Immunol, Sao Paulo, Brazil.
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012; Caldini, Elia
   G/F-1105-2011; Saldiva, Paulo HN/D-7385-2012; Rizzo, Luiz
   Vicente/B-4458-2009
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL,
   JORGE/0000-0001-8415-4274; Saldiva, Paulo HN/0000-0003-2005-8253; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2005
VL 115
SU 1
BP S251
EP S251
PG 1
WC Immunology
SC Immunology
GA 926DY
UT WOS:000229104400705
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Oliveira, CH
   Tribess, A
   Mendes, C
   Latorre, MRDO
   Kalil, J
AF Graudenz, GS
   Oliveira, CH
   Tribess, A
   Mendes, C
   Latorre, MRDO
   Kalil, J
TI Association of air-conditioning with respiratory symptoms in office
   workers in tropical climate
SO INDOOR AIR
LA English
DT Article
DE air-conditioning; air pollution; indoor; environmental exposure;
   occupational health; allergy
ID SICK-BUILDING SYNDROME; VENTILATION SYSTEM; CHILDHOOD ISAAC; SAO-PAULO;
   PREVALENCE; ASTHMA; ALLERGIES; SCHOOLCHILDREN; EPIDEMIOLOGY; BRAZIL
AB To evaluate the association of heating, ventilation and air-conditioning systems (HVAC) and respiratory symptoms in a tropical city, self-administered questionnaires were given to 2000 individuals working in air-conditioned office buildings and to 500 control workers in naturally ventilated buildings. Reported symptoms from the two populations were analyzed using chi-square tests, univariate and multiple logistic regressions models. Symptoms were the outcome variable and the odds ratios were adjusted by gender, age, accumulated work time, smoking habits and atopic background. There was a 79.8% response rate and there was a positive association of nasal symptoms (odds ratio, OR = 1.59, 95% confidence interval, CI = 1.11-2.28), naso-ocular symptoms (OR = 1.58, 95% CI = 1.05-2.38), persistent cough (OR = 3.04, 95% CI = 2.00-4.63) sinusitis symptoms (OR = 1.85, 95% CI = 1.27-2.71) and building-related worsening of the symptoms (OR = 4.92, 95% CI = 2.93-8.27) with working in air-conditioned buildings. In conclusion, our study suggests that artificial air-conditioning is a matter of concern for respiratory symptoms in cities with hot and humid climate.
C1 Univ Sao Paulo, Millennium Inst, Sch Med, Internal Med Dept,Div Allergy & Clin Immunol, Sao Paulo, Brazil.
   Univ Estadual Campinas, Sch Med, Dept Pediat, Campinas, SP, Brazil.
   Univ Sao Paulo, Polytech Sch, Dept Mech Engn, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Rua Girassol 1317-21, BR-05433002 Sao Paulo, Brazil.
EM gustavog@usp.br
RI KALIL, JORGE/C-8029-2012; Latorre, Maria RDO/J-5780-2014
OI KALIL, JORGE/0000-0001-8415-4274; Latorre, Maria
   RDO/0000-0002-5189-3457; Tribess, Arlindo/0000-0001-9908-9233
CR Allermann L, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.9.e5
   APTER A, 1994, J ALLERGY CLIN IMMUN, V94, P277, DOI 10.1016/0091-6749(94)90087-6
   ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483
   Bjornsson E, 1998, INT J TUBERC LUNG D, V2, P1023
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   BURGE PS, 1985, THORAX, V40, P248, DOI 10.1136/thx.40.4.248
   Costa MDB, 2000, ARCH ENVIRON HEALTH, V55, P279, DOI 10.1080/00039890009603419
   Crawford JO, 1996, SCAND J WORK ENV HEA, V22, P243, DOI 10.5271/sjweh.138
   ESTEVES AR, 1999, BRAZ PEDIAT NEWS, V1, P1
   ESTEVES AR, 1999, REV BRAS ALERG IMUNO, V22, P106
   FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   GRAUDENZ GS, 2002, REV BRAS ALERG IMUNO, V25, P99
   JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498
   Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223
   LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012
   Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107
   Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5
   Ooi PL, 1996, LANCET, V347, P841, DOI 10.1016/S0140-6736(96)90927-7
   ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373
   SANTOS UP, 1992, REV SAUDE PUBL, V26, P400, DOI 10.1590/S0034-89101992000600005
   Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x
   SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286, DOI 10.5271/sjweh.1851
   Sole D, 2001, J INVEST ALLERG CLIN, V11, P123
   SPAUL WA, 1994, J ALLERGY CLIN IMMUN, V94, P385
   Vanna AT, 2001, PEDIATR ALLERGY IMMU, V12, P95, DOI 10.1034/j.1399-3038.2001.012002095.x
   Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P58, DOI 10.1080/00039899909602238
   World Health Organization, 1983, IND AIR POLL EXP HLT
NR 30
TC 38
Z9 39
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6947
EI 1600-0668
J9 INDOOR AIR
JI Indoor Air
PD JAN
PY 2005
VL 15
IS 1
BP 62
EP 66
DI 10.1111/j.1600-0668.2004.00324.x
PG 5
WC Construction & Building Technology; Engineering, Environmental; Public,
   Environmental & Occupational Health
SC Construction & Building Technology; Engineering; Public, Environmental &
   Occupational Health
GA 890ME
UT WOS:000226514500006
PM 15660569
DA 2020-11-26
ER

PT B
AU Graudenz, GS
   do Rosario, M
   Latorre, DO
   Tribess, A
   Oliveira, CH
   Kalil, J
AF Graudenz, GS
   do Rosario, M
   Latorre, DO
   Tribess, A
   Oliveira, CH
   Kalil, J
BE Yang, X
   Zhao, B
   Zhao, R
TI Perception patterns of indoor air quality from volunteers with
   persistent allergic rhinitis
SO INDOOR AIR 2005: PROCEEDINGS OF THE 10TH INTERNATIONAL CONFERENCE ON
   INDOOR AIR QUALITY AND CLIMATE, VOLS 1-5
LA English
DT Proceedings Paper
CT 10th International Conference on Indoor Air Quality and Climate (Indoor
   Air 2005)
CY SEP 04-09, 2005
CL Beijing, PEOPLES R CHINA
SP Tsinghua Univ, Minist Educ China, Natl Nat Sci Fdn China, Beijing Municipal Commiss Sci & Technol, Shanghai Municipal Commiss Sci & Technol, US EPA, Amer Ind Hyg Assoc, Amer Soc Heating, Refrigerating & Air Conditioning Engineers, Int Commiss Occupat Hlth, SC Indoor Air Qual & Hlth, Int Council Res & Innovat Bldg & Construct, European Commiss Asia Pro Eco Programme Promot Sustainable Solut Environm Europe & Asia, Korean Soc Indoor Environm, Soc Indoor Environm
DE indoor air quality; thermal comfort; allergic rhinitis
ID SICK BUILDING SYNDROME; ARTIFICIALLY VENTILATED OFFICES; RESPIRATORY
   SYMPTOMS; SAO-PAULO; WORKERS; INTERVENTION; POLLUTION; BRAZIL; COLD
AB Thirty-three subjects either with persistent allergic rhinitis or controls were exposed to different temperatures and constant relative humidity in an experimental office environment in order to compare patterns of indoor air perception obtained by principal component analysis, using an visual analogue scale. At 18 degrees C, in the Rhinitis group, there was a correlation between dryness, stagnant air, and difficult mental concentration. This group also correlated heat, dry air, and bad indoor air quality, in opposition to the Control group, which correlated well-being, easy mental concentration, and freshness. At 22 degrees C, the Rhinitis group correlated heat, dryness, stagnant indoor air perception, and overall discomfort. This group also correlated non-dry air, freshness, and well-being. The Control group correlated heat.. humidity, good indoor air, freshness and well-being. This study suggests that the Rhinitis group perceives indoor temperatures of 18 degrees C and 22 degrees C as dryer and more adverse than controls do.
C1 Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Internal Med, Sch Med, Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Internal Med, Sch Med, Sao Paulo, Brazil.
EM gustavog@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640, DOI 10.1164/ajrccm.164.9.2103086
   Bachert C, 2002, ALLERGY, V57, P1208
   BACHMANN MO, 1995, SOC SCI MED, V40, P245, DOI 10.1016/0277-9536(94)E0068-4
   Baroody FM, 2000, ARCH OTOLARYNGOL, V126, P749, DOI 10.1001/archotol.126.6.749
   Bjornsson E, 1998, INT J TUBERC LUNG D, V2, P1023
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   Graudenz GS, 2004, CHEST, V125, P326, DOI 10.1378/chest.125.1.326
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6
   Kildeso J, 1999, SCAND J WORK ENV HEA, V25, P361, DOI 10.5271/sjweh.446
   Lundin L, 1999, INDOOR AIR, V9, P92, DOI 10.1111/j.1600-0668.1999.t01-2-00004.x
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   Mendell MJ, 2002, EPIDEMIOLOGY, V13, P296, DOI 10.1097/00001648-200205000-00010
   Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629
   Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5
   NACLERIO RM, 1995, J APPL PHYSIOL, V79, P467
   Ooi PL, 1997, INT J EPIDEMIOL, V26, P1243, DOI 10.1093/ije/26.6.1243
   TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113
   Zhang JF, 2003, BRIT MED BULL, V68, P209, DOI 10.1093/bmb/ldg029
NR 19
TC 0
Z9 0
U1 0
U2 1
PU TSINGHUA UNIV PRESS
PI BEIJING
PA TSINGHUA UNIV HAIDIANQU, BEIJING 100084, PEOPLES R CHINA
BN 978-7-89494-830-4
PY 2005
BP 6
EP 10
PG 5
WC Construction & Building Technology; Engineering, Environmental; Public,
   Environmental & Occupational Health
SC Construction & Building Technology; Engineering; Public, Environmental &
   Occupational Health
GA BDJ55
UT WOS:000233831200010
DA 2020-11-26
ER

PT J
AU Kokron, CM
   Errante, PR
   Barros, MT
   Baracho, GV
   Camargo, MM
   Kalil, J
   Rizzo, LV
AF Kokron, CM
   Errante, PR
   Barros, MT
   Baracho, GV
   Camargo, MM
   Kalil, J
   Rizzo, LV
TI Clinical and laboratory aspects of common variable immunodeficiency
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Review
DE immunodeficiency; humans; antibody; cytokines; clinical features
ID PERIPHERAL-BLOOD LYMPHOCYTES; B-CELL DIFFERENTIATION; DISEASE GENE
   SH2D1A; IGA DEFICIENCY; T-CELLS; IMMUNOGLOBULIN PRODUCTION;
   LYMPHOPROLIFERATIVE DISEASE; INTERFERON-GAMMA; SUSCEPTIBILITY LOCUS;
   ANTIBODY DEFICIENCY
AB Common variable immunodeficiency (CVID) is an immunological disorder characterized by defective antibody production, recurrent infections, most notably of the respiratory tract, autoimmune phenomena and cancer. Some CVID patients may also present disturbances of the cellular immune response such as a decrease in the number and proportion of different lymphocyte populations, diminished lymphoproliferative response to mitogens and antigens, altered production of cytokines, and deficient expression of cell-surface molecules. Most Brazilian CVID patients included in this study show a decrease in T and B lymphocyte counts in the peripheral blood. Furthermore, their lymphocytes are more susceptible to apoptosis following activation than normal individuals, and they have a decrease in the expression of activation molecules like CD25, CD69, CD40L and CD70. Moreover, they show a decreased synthesis of IL-4 and IL-5 in comparison with normal individuals. The increase in susceptibility to apoptosis following activation, may also be responsible for the decrease in the expression of activation molecules and CD40L, decrease in Th2 cytokines synthesis, and in the number of T and B circulating cells. In this study we discuss some of these immunological disturbances correlating them to the patients' clinical features and comparing our patients' findings to the literature.
C1 Univ Sao Paulo, ICB, Dept Immunol, BR-05508900 Sao Paulo, Brazil.
   Serv Imunol, BR-05403010 Sao Paulo, Brazil.
   Inst Invest Immunol, BR-05403010 Sao Paulo, Brazil.
   Edif Cal Ctr, Fundacao Zerbini, BR-01451000 Sao Paulo, Brazil.
RP Rizzo, LV (corresponding author), Univ Sao Paulo, ICB, Dept Immunol, Av Prof Lineu Prestes 1730, BR-05508900 Sao Paulo, Brazil.
EM lvrizzo@icb.usp.br
RI KALIL, JORGE/C-8029-2012; Camargo, Maristela/G-8584-2011; Rizzo, Luiz
   Vicente/B-4458-2009; Kokron, Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Camargo,
   Maristela/0000-0003-2815-125X; Kokron, Cristina M/0000-0002-9080-0305
CR Abonia JP, 2002, ALLERGY ASTHMA PROC, V23, P53
   Aghamohammadi A, 2003, INT J HEMATOL, V78, P45, DOI 10.1007/BF02983239
   Aghamohammadi A, 2002, J CLIN IMMUNOL, V22, P375, DOI 10.1023/A:1020660416865
   Akai M, 1996, Nihon Kyobu Shikkan Gakkai Zasshi, V34, P829
   ASHMAN RF, 1992, J CLIN IMMUNOL, V12, P406, DOI 10.1007/BF00918852
   Aukrust P, 2000, EUR J CLIN INVEST, V30, P252, DOI 10.1046/j.1365-2362.2000.00619.x
   BELMONTE E, 1989, MED CLIN-BARCELONA, V92, P597
   Boncristiano M, 2000, EUR J IMMUNOL, V30, P2632, DOI 10.1002/1521-4141(200009)30:9<2632::AID-IMMU2632>3.0.CO;2-C
   Bonhomme D, 2000, J IMMUNOL, V165, P4725, DOI 10.4049/jimmunol.165.8.4725
   Bonilla HF, 1997, CLIN INFECT DIS, V24, P222, DOI 10.1093/clinids/24.2.222
   BRAUN J, 1991, IMMUNOL LETT, V27, P205, DOI 10.1016/0165-2478(91)90152-Z
   BRAUN J, 1992, WESTERN J MED, V157, P158
   BRAUN J, 1992, J CLIN INVEST, V89, P1395, DOI 10.1172/JCI115728
   Byrne MF, 2003, EUR J GASTROEN HEPAT, V15, P1051, DOI 10.1097/00042737-200309000-00019
   CABALLERO FM, 1984, J CLIN LAB IMMUNOL, V13, P59
   Cambronero R, 2000, J IMMUNOL, V164, P488, DOI 10.4049/jimmunol.164.1.488
   Carvalho Neves Forte W, 2000, Allergol Immunopathol (Madr), V28, P18
   CASARIEGO GF, 2001, ALLERGOL IMMUNOPATH, V29, P101
   Cham B, 2002, SEMIN HEMATOL, V39, P107, DOI 10.1053/shem.2002.31916
   Chuhjo T, 1999, AM J HEMATOL, V60, P222, DOI 10.1002/(SICI)1096-8652(199903)60:3<222::AID-AJH9>3.0.CO;2-K
   COOPER MD, 1971, LANCET, V2, P791
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2001, Curr Allergy Asthma Rep, V1, P421, DOI 10.1007/s11882-001-0027-1
   Cunningham-Rundles C, 2002, BLOOD REV, V16, P61, DOI 10.1054/blre.2001.0185
   Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052
   CUNNINGHAMRUNDLES C, 1995, J INTERF CYTOK RES, V15, P269, DOI 10.1089/jir.1995.15.269
   D'Addio Francesco, 2001, Recenti Progressi in Medicina, V92, P392
   Davis WC, 2000, VET IMMUNOL IMMUNOP, V74, P103, DOI 10.1016/S0165-2427(00)00167-7
   Day MJ, 1997, J SMALL ANIM PRACT, V38, P311, DOI 10.1111/j.1748-5827.1997.tb03473.x
   de la Concha EG, 1999, CLIN EXP IMMUNOL, V116, P516
   De Vera M, 2003, ANN ALLERG ASTHMA IM, V91, P244, DOI 10.1016/S1081-1206(10)63525-9
   Della Bella S, 1997, INT J CLIN LAB RES, V27, P79, DOI 10.1007/BF02827249
   Denz A, 2000, EUR J IMMUNOL, V30, P1069, DOI 10.1002/(SICI)1521-4141(200004)30:4<1069::AID-IMMU1069>3.0.CO;2-M
   DOUGLAS SD, 1974, LANCET, V2, P955
   DUARTE A J D, 1990, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V45, P95
   Durandy A, 2001, CURR OPIN ALLERGY CL, V1, P519, DOI 10.1097/00130832-200112000-00005
   EISENSTEIN EM, 1994, J IMMUNOL, V152, P5957
   EISENSTEIN EM, 1995, ADV EXP MED BIOL, V371, P699
   ElenitobaJohnson KSJ, 1997, SEMIN DIAGN PATHOL, V14, P35
   ESOLEN LM, 1992, NEW ENGL J MED, V326, P999, DOI 10.1056/NEJM199204093261506
   Falcon FA, 1999, REV ESP ENFERM DIG, V91, P54
   FARRANT J, 1991, IMMUNOL INVEST, V20, P143, DOI 10.3109/08820139109050782
   Farrant J, 1994, Immunodeficiency, V5, P159
   FARRANT J, 1985, CLIN EXP IMMUNOL, V61, P189
   FARRANT J, 1989, CLIN IMMUNOL IMMUNOP, V51, P196, DOI 10.1016/0090-1229(89)90019-6
   FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099
   FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I
   Flaminio MJBF, 2002, J AM VET MED ASSOC, V221, P1296, DOI 10.2460/javma.2002.221.1296
   FUNAUCHI M, 1995, CLIN EXP IMMUNOL, V101, P82
   Garcia MAM, 2001, RESP MED, V95, P191, DOI 10.1053/rmed.2000.1020
   GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101
   Gompels MM, 2003, CLIN EXP IMMUNOL, V134, P314, DOI 10.1046/j.1365-2249.2003.02253.x
   Gottesman SRS, 1999, LEUKEMIA LYMPHOMA, V32, P589, DOI 10.3109/10428199909058418
   Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902
   Grimbacher B, 2003, CURR OPIN ALLERGY CL, V3, P409, DOI 10.1097/01.all.0000104458.09202.24
   HAUSSER C, 1983, AM J DIS CHILD, V137, P833, DOI 10.1001/archpedi.1983.02140350011004
   Hawkins CA, 2003, PATHOLOGY, V35, P81, DOI 10.1080/0031302021000062398
   Heeney MM, 2003, J PEDIATR-US, V143, P662, DOI 10.1067/S0022-3476(03)00445-1
   HERBST EW, 1994, CLIN EXP IMMUNOL, V95, P215
   Holm AM, 2003, J IMMUNOL, V170, P5772, DOI 10.4049/jimmunol.170.11.5772
   JAFFE JS, 1993, BLOOD, V82, P192, DOI 10.1182/blood.V82.1.192.bloodjournal821192
   JAFFE JS, 1993, PEDIATR RES, V33, pS24
   JANEWAY CA, 1953, T ASSOC AM PHYSICIAN, V66, P200
   KACZMARSKI RS, 1994, J CLIN PATHOL, V47, P364, DOI 10.1136/jcp.47.4.364
   Kainulainen L, 2001, J CLIN IMMUNOL, V21, P145, DOI 10.1023/A:1011012023616
   Kainulainen L, 1999, AM J RESP CRIT CARE, V159, P1199, DOI 10.1164/ajrccm.159.4.9807067
   KAMIN RM, 1968, P NATL ACAD SCI USA, V60, P881, DOI 10.1073/pnas.60.3.881
   Kaneko H, 2000, EXP CLIN IMMUNOGENET, V17, P173, DOI 10.1159/000019136
   Kart L, 2003, Monaldi Arch Chest Dis, V59, P84
   KIRKPATRICK CH, 1967, J AMER MED ASSOC, V200, P105
   Kondratenko I, 1997, CLIN EXP IMMUNOL, V108, P9, DOI 10.1046/j.1365-2249.1997.d01-993.x
   Kralovicova J, 2003, J IMMUNOL, V170, P2765, DOI 10.4049/jimmunol.170.5.2765
   LEE AH, 1993, SEMIN ARTHRITIS RHEU, V22, P252, DOI 10.1016/0049-0172(93)80073-O
   Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135
   LINDE A, 1988, CLIN IMMUNOL IMMUNOP, V49, P341, DOI 10.1016/0090-1229(88)90124-9
   Litzman J, 1996, Allergol Immunopathol (Madr), V24, P174
   Litzman J, 1996, Allerg Immunol (Paris), V28, P81
   Lobetti R, 2000, J VET DIAGN INVEST, V12, P39, DOI 10.1177/104063870001200107
   Macura AB, 2003, COMP IMMUNOL MICROB, V26, P223, DOI 10.1016/S0147-9571(02)00051-6
   Majolini MB, 1997, CLIN IMMUNOL IMMUNOP, V84, P98, DOI 10.1006/clin.1997.4372
   Manson DE, 2000, PEDIATR RADIOL, V30, P501, DOI 10.1007/s002470000237
   MATRICARDI PM, 1984, J CLIN IMMUNOL, V4, P388, DOI 10.1007/BF00917142
   MISBAH SA, 1992, J CLIN GASTROENTEROL, V15, P354, DOI 10.1097/00004836-199212000-00021
   Morra M, 2001, BLOOD, V98, P1321, DOI 10.1182/blood.V98.5.1321
   Mullighan CG, 1996, J CLIN IMMUNOL, V16, P272, DOI 10.1007/BF01541392
   MUSHIAKE K, 1994, BIOTHERAPY, V7, P101
   Naspitz C K, 1987, Rev Paul Med, V105, P47
   NONOYAMA S, 1993, J CLIN INVEST, V92, P1282, DOI 10.1172/JCI116701
   NONOYAMA S, 1994, CLIN IMMUNOL IMMUNOP, V72, P373, DOI 10.1006/clin.1994.1155
   North ME, 1998, CLIN EXP IMMUNOL, V111, P70
   North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x
   PAGANELLI R, 1988, CLIN EXP IMMUNOL, V72, P124
   PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334
   PASTORELLI G, 1990, CLIN EXP IMMUNOL, V82, P120
   PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P341
   PEREZ VE, 1991, REV CLIN ESP, V188, P142
   Pfluger H, 2000, SCHWEIZ MED WSCHR, V130, P1590
   Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374
   Punnonen J, 1997, SCAND J IMMUNOL, V45, P203, DOI 10.1046/j.1365-3083.1997.d01-381.x
   Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509
   Rump JA, 1997, CLIN EXP IMMUNOL, V110, P167
   Rusconi F, 2003, ARCH DIS CHILD, V88, P1101, DOI 10.1136/adc.88.12.1101
   SAAVEDRA A, 1996, ANGRE BARC, V41, P404
   SAXON A, 1993, IMMUNOLOGY, V80, P477
   SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015
   Schroeder HW, 1998, MOL MED, V4, P72, DOI 10.1007/BF03401731
   Schroeder HW, 2000, CLIN REV ALLERG IMMU, V19, P127, DOI 10.1385/CRIAI:19:2:127
   Schwartz R, 1999, CLIN DIAGN LAB IMMUN, V6, P856, DOI 10.1128/CDLI.6.6.856-860.1999
   SEGAL R, 1989, J ALLERGY CLIN IMMUN, V84, P753, DOI 10.1016/0091-6749(89)90305-9
   Sewell WAC, 1998, POSTGRAD MED J, V74, P503, DOI 10.1136/pgmj.74.874.503
   Sewell WAC, 1999, CLIN EXP IMMUNOL, V116, P509
   SNELLER MC, 1990, J IMMUNOL, V144, P3762
   SNELLER MC, 1990, T ASSOC AM PHYSICIAN, V103, P163
   Sneller MC, 2001, AM J MED SCI, V321, P42, DOI 10.1097/00000441-200101000-00007
   SO ALP, 1997, SEMIN GASTROINTEST D, V8, P22
   Soresina A, 2002, EUR J PEDIATR, V161, P656, DOI 10.1007/s00431-002-1083-9
   Sporici RA, 2001, CLIN IMMUNOL, V100, P263, DOI 10.1006/clim.2001.5093
   Stagg A, 1993, Immunodeficiency, V4, P13
   STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48
   STEVENS RH, 1980, CLIN IMMUNOL IMMUNOP, V16, P336, DOI 10.1016/0090-1229(80)90139-7
   Strober W, 2000, CLIN REV ALLERG IMMU, V19, P157, DOI 10.1385/CRIAI:19:2:157
   Tarr PE, 2001, MEDICINE, V80, P123, DOI 10.1097/00005792-200103000-00005
   Tiller T L Jr, 2000, J S C Med Assoc, V96, P225
   TZIPORI S, 1988, ADV PARASIT, V27, P63, DOI 10.1016/S0065-308X(08)60353-X
   Van Der Hilst JCH, 2002, NETH J MED, V60, P140
   Vorechovsky I, 1991, J Hyg Epidemiol Microbiol Immunol, V35, P17
   Vorechovsky I, 2001, ADV EXP MED BIOL, V495, P183
   Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408
   WALL RL, 1955, ARCH INTERN MED, V95, P33, DOI 10.1001/archinte.1955.00250070049005
   Webster ADB, 2001, IMMUNOL ALLERGY CLIN, V21, P1, DOI 10.1016/S0889-8561(05)70190-9
   Witte T, 2000, IMMUNOBIOLOGY, V202, P194, DOI 10.1016/S0171-2985(00)80066-2
   WOLLHEIM F, 1961, LANCET, V1, P316
   Zhou Z, 1998, CLIN IMMUNOL IMMUNOP, V86, P298, DOI 10.1006/clin.1997.4483
   Zullo A, 1999, GUT, V45, P77, DOI 10.1136/gut.45.1.77
NR 134
TC 53
Z9 55
U1 0
U2 3
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2004
VL 76
IS 4
BP 707
EP 726
DI 10.1590/S0001-37652004000400007
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 877UK
UT WOS:000225598600007
PM 15558152
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Cury, P
   Demarchi, LMF
   Coelho, V
   Abel, L
   Lopez, AP
   Oshiro, SE
   Aliotti, S
   Cunha-Neto, E
   Pomerantzeff, PMA
   Tanaka, AC
   Kalil, J
AF Guilherme, L
   Cury, P
   Demarchi, LMF
   Coelho, V
   Abel, L
   Lopez, AP
   Oshiro, SE
   Aliotti, S
   Cunha-Neto, E
   Pomerantzeff, PMA
   Tanaka, AC
   Kalil, J
TI Rheumatic heart disease - Proinflammatory cytokines play a role in the
   progression and maintenance of valvular lesions
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; VIRAL MYOCARDITIS; TNF-ALPHA;
   CELLS; AUTOIMMUNE; FEVER; INTERLEUKIN-1; LYMPHOCYTES; EXPRESSION
AB Heart lesions of rheumatic heart disease (RHD) patients contain T-cell clones that recognize heart proteins and streptococcal M peptides. To functionally characterize heart-infiltrating T lymphocytes, we evaluated their cytokine profile, both directly in situ and in T-cell lines derived from the heart (HIL). interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-4, and IL-10 expressions were characterized in 20 heart tissue infiltrates from 14 RHD patients by immunohistochemistry. IFN-gamma-, TNF-alpha-, and IL-10-positive cells were consistently predominant, whereas IL-4 was scarce in the valves. in agreement with these data, the in vitro experiments, in which 13 HILs derived from heart samples of eight patients were stimulated with M5 protein and the immunodominant M5 (81-96) peptide, IL-4 was detected in HIL derived from the atrium (three of six) but not from the valve (zero of seven). IFN-gamma and IL-10 production were detected in culture supernatants in 11 of 13 and 6 of 12 HILs, respectively. The predominant IFN-gamma and TNF-alpha expression in the heart suggests that Th1-type cytokines could mediate RHD. Unlike in reversible myocardium inflammation, the significantly lower IL-4 expression in the valvular tissue (P = 0.02) may contribute to the progression of the RHD leading to permanent valvular damage (relative risk, 4.3; odds ratio, 15.8). The lack of IL-4 in vitro production by valve-derived HIL also emphasizes the more severe tissue destruction in valves observed in RHD.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Clin Med Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), HC FMUSP, Lab Imunol, Inst Coracao, Av Dr Eneas Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM luizagui@usp.br
RI Demarchi, Lea/K-3105-2012; Guglielmi, Luiza G/E-7676-2013; Pomerantzeff,
   Pablo M A/L-5525-2016; COELHO, VERONICA/D-1433-2013; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Abel, Lucia Cristina
   Jamli/P-8816-2014
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274; Abel,
   Lucia Cristina Jamli/0000-0003-4915-4265
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   CAMPBELL IL, 1988, J IMMUNOL, V140, P1111
   Cunningham MW, 2003, FRONT BIOSCI, V8, pS533, DOI 10.2741/1067
   DAJANI AS, 1993, CIRCULATION, V87, P302
   Dibbs Z, 1999, J AM COLL CARDIOL, V33, P1935, DOI 10.1016/S0735-1097(99)00130-8
   Falcone M, 1999, CURR OPIN IMMUNOL, V11, P670, DOI 10.1016/S0952-7915(99)00035-7
   Ferreira RC, 2003, MEM I OSWALDO CRUZ, V98, P407, DOI 10.1590/S0074-02762003000300021
   Fraser WJ, 1997, HISTOPATHOLOGY, V31, P460, DOI 10.1046/j.1365-2559.1997.2990883.x
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   Guilherme L, 2001, J AUTOIMMUN, V16, P363, DOI 10.1006/jaut.2000.0487
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   Herrera-Garza EH, 1999, CHEST, V115, P1170, DOI 10.1378/chest.115.4.1170
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   Kapadia Samir, 1998, Cardiology Clinics, V16, P645, DOI 10.1016/S0733-8651(05)70041-2
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KEVASAN S, 1997, CURR OPIN CARDIOL, V12, P218
   Kourilsky P, 2001, TRENDS IMMUNOL, V22, P502, DOI 10.1016/S1471-4906(01)02012-9
   LANE JR, 1992, J EXP MED, V175, P1123, DOI 10.1084/jem.175.4.1123
   LIBIAU RS, 1995, IMMUNOL TODAY, V16, P34
   Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   Mann DL, 2001, CIRCULATION, V103, P626
   MATSUMORI A, 1994, BRIT HEART J, V72, P561
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   MILLER LC, 1987, PATHOL IMMUNOPATH R, V6, P22, DOI 10.1159/000157039
   MORRIS K, 1993, CLIN EXP IMMUNOL, V91, P429
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   Oral H, 2003, CIRCULATION, V107, P831, DOI 10.1161/01.CIR.0000049745.38594.6D
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x
   SAMSONOV MY, 1995, CLIN IMMUNOL IMMUNOP, V74, P31, DOI 10.1006/clin.1995.1005
   SMITH SC, 1992, CIRC RES, V70, P856, DOI 10.1161/01.RES.70.4.856
   Song HK, 2003, J AUTOIMMUN, V21, P295, DOI 10.1016/S0896-8411(03)00110-0
   STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P131, DOI 10.1016/S0090-1229(05)80019-4
   VIRMANI R, 1999, RHEUMATIC FEVER, P217
   Wada H, 2001, CIRCULATION, V103, P743
   Yegin O, 1997, EUR J PEDIATR, V156, P25
NR 41
TC 119
Z9 127
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2004
VL 165
IS 5
BP 1583
EP 1591
DI 10.1016/S0002-9440(10)63415-3
PG 9
WC Pathology
SC Pathology
GA 865XF
UT WOS:000224736800013
PM 15509528
OA Green Published
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Escaleira, MTF
   Cunha-Neto, E
   Palacios, SA
   Kalil, J
   Marchiori, PE
AF Guilherme, L
   Escaleira, MTF
   Cunha-Neto, E
   Palacios, SA
   Kalil, J
   Marchiori, PE
TI HLA-DR frequency in myasthenia gravis patients from Brazil: evidence for
   association with HLA-DR5 and influence of gender and clinical parameters
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Meeting Abstract
CT 7th International Congress of the
   International-Society-of-Neuroimmunology
CY SEP 28-OCT 02, 2004
CL Venice, ITALY
SP Int Soc Neuroimmunol
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Clin Hosp, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Dotto,
   Guilherme L/I-8271-2015
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Dotto, Guilherme L/0000-0002-4413-8138
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD SEP
PY 2004
VL 154
IS 1-2
SI SI
MA 90
BP 28
EP 28
PG 1
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 855VO
UT WOS:000224003200094
DA 2020-11-26
ER

PT J
AU Escaleira, MTF
   Guilherme, L
   Cunha-Neto, E
   Orue, I
   Sette, A
   Sidney, J
   Iwai, LK
   Palacios, SA
   Kalil, J
   Marchiori, PE
AF Escaleira, MTF
   Guilherme, L
   Cunha-Neto, E
   Orue, I
   Sette, A
   Sidney, J
   Iwai, LK
   Palacios, SA
   Kalil, J
   Marchiori, PE
TI T cell recognition of novel synthetic AchR epitopes in Brazilian
   myasthenia gravis patients: correlation with gender, clinical parameters
   and therapy response
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Meeting Abstract
CT 7th International Congress of the
   International-Society-of-Neuroimmunology
CY SEP 28-OCT 02, 2004
CL Venice, ITALY
SP Int Soc Neuroimmunol
C1 Univ Sao Paulo, Sch Med, Clin Hosp, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
RI Guglielmi, Luiza G/E-7676-2013; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012; Iwai, Leo K/M-1734-2013; Dotto, Guilherme
   L/I-8271-2015
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763; Dotto,
   Guilherme L/0000-0002-4413-8138
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD SEP
PY 2004
VL 154
IS 1-2
SI SI
MA 496
BP 149
EP 149
PG 1
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 855VO
UT WOS:000224003200501
DA 2020-11-26
ER

PT J
AU Caldas, C
   Spadafora-Ferreira, M
   Fonseca, JA
   Luna, E
   Iwai, LK
   Kalil, J
   Coelho, V
AF Caldas, C
   Spadafora-Ferreira, M
   Fonseca, JA
   Luna, E
   Iwai, LK
   Kalil, J
   Coelho, V
TI T-Cell response to self HSP60 peptides in renal transplant recipients: A
   regulatory role
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the
   International-Pancreas-and-Islet-Transplant-Association
CY JUL 08-11, 2003
CL DUBLIN, IRELAND
SP Int Pancreas & Islet Transplant Assoc
ID HEAT-SHOCK-PROTEIN; REACTIVITY
AB T-cell responses to heat shock proteins (Hsp) have been suggested to play a role not only in inflammatory conditions, but also in various human autoimmune diseases and in the allograft response. Previous data from our group suggested that during the early posttransplantation (post-Tx) period (<6 months post-Tx), the anti-Hsp60 T-cell repertoires in renal transplant recipients were predominantly proinflammatory. In the later period, they were predominantly regulatory. In agreement with our results, diversification of the T-cell responses toward the carboxy-terminal determinants of Hsp60, related to the resolution of the inflammatory process, was shown in an experimental model of adjuvant arthritis. It has not been clarified whether this diversification is also present in transplantation. In this context, our objective was to analyze cytokine production against autologous Hsp60 peptides from different regions of the protein, using peripheral blood mononuclear cells of 9 renal transplant recipients at 2 timepoints after transplantation: early (<6 months) and late (>1 year). IFN-gamma production induced by Hsp60 peptides was observed in 71% and 75% of the patients in the early and late post-Tx periods, respectively. Interleukin (IL)-10 production induced by Hsp60 peptides was observed in 28% of the patients in the early period and in 62% in the late period. Interestingly, the production of IL-10 was induced mainly by peptides of the intermediate and the C-terminal regions. This suggests a predominance of autoreactive regulatory anti-Hsp T-cell repertoire in the late post-Tx period, which predominantly recognize peptides from the intermediate and C-terminal regions of the protein.
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Renal Transplantat Unit, BR-05508 Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Av Dr Eneas Carvalho Aguiar,44 Bloco 2 9 Andar, BR-05403000 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; Iwai, Leo K/M-1734-2013; COELHO,
   VERONICA/D-1433-2013; Spadafora-Ferreira, Monica/G-2635-2012
OI KALIL, JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763;
   Spadafora-Ferreira, Monica/0000-0001-8823-9929; Coelho,
   Veronica/0000-0002-0989-2581
CR ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576
   GEORGOPOULOS C, 1993, IMMUNOL TODAY, V14, P373, DOI 10.1016/0167-5699(93)90135-8
   Granja C, 2004, HUM IMMUNOL, V65, P124, DOI 10.1016/j.humimm.2003.10.007
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P598
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   Pockley AG, 2001, TRANSPLANTATION, V71, P1503, DOI 10.1097/00007890-200106150-00001
   RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7
NR 8
TC 7
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 833
EP 835
DI 10.1016/j.transproceed.2004.04.069
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800011
PM 15194286
DA 2020-11-26
ER

PT J
AU Marrero, I
   Benvenutti, LA
   Noronha, I
   Kalil, J
   Coelho, V
AF Marrero, I
   Benvenutti, LA
   Noronha, I
   Kalil, J
   Coelho, V
TI Rejection of grafts without histocompatibility antigen disparity by
   TAP1-/-mice: A role for CD4+T cells
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the
   International-Pancreas-and-Islet-Transplant-Association
CY JUL 08-11, 2003
CL DUBLIN, IRELAND
SP Int Pancreas & Islet Transplant Assoc
ID TAP1 MUTANT MICE; T-CELLS
AB We have previously shown that TAP1-/- mice reject heart and skin grafts lacking an H-2 disparity. TAP1-/- mice, which are deficient for MHC-I molecules, probably have a T-cell repertoire with distinct reactivity to these molecules. We speculated that this rejection could be mediated by CD4+ T cells reactive to H-2(b) class I molecules, or to class I-derived peptides presented by self-APC. This hypothesis was tested in the present work. Presensitization of TAP1-/- mice with H-2k(b) peptides accelerated the rejection of C57BL/6 (H-2(b)) skin grafts (MST 13 days, P < .0057), indicating that these peptides were able to mobilize effector T cells that participate in rejection. In addition, CD4 T-cell depletion before transplantation induced a significant delay in rejection (P < .0011), showing, that CD4 T cells have a major role in the rejection process, though other cells may also contribute. In conclusion, these results support our hypothesis that H-2(b) molecules may be targeted in graft rejection without an H-2 disparity. The low expression of MHC-I molecules on TAP1-/- mice may determine the selection of a T-cell repertoire that is reactive to self-MHC-I molecules, a phenomenon that is probably beyond the control of peripheral regulatory mechanisms.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Inst Invest Immunol,Millennium Inst, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol,InCor, Inst Invest Immunol,Millennium Inst,Heart Inst, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Renal, Inst Invest Immunol,Millennium Inst, BR-05508 Sao Paulo, Brazil.
RP Coelho, V (corresponding author), HC FMUSP, Lab Imunol, Inst Coracao, InCor, Av Dr Eneas Carvalho Aguiar 44,9o Andar, BR-05403001 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013
OI KALIL, JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581
CR ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T
   Coelho V, 1999, TRANSPLANT P, V31, P900, DOI 10.1016/S0041-1345(98)01828-4
   LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975
   REYES AA, 1992, P NATL ACAD SCI USA, V79, P3270
   VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6
   ZIJLSTRA M, 1992, J EXP MED, V175, P885, DOI 10.1084/jem.175.4.885
NR 6
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 999
EP 1000
DI 10.1016/j.transproceed.2004.03.049
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800072
PM 15194347
DA 2020-11-26
ER

PT J
AU Marin, MLC
   Savioli, CR
   Yamamoto, JH
   Kalil, J
   Goldberg, AC
AF Marin, MLC
   Savioli, CR
   Yamamoto, JH
   Kalil, J
   Goldberg, AC
TI MICA polymorphism in a sample of the Sao Paulo population, Brazil
SO EUROPEAN JOURNAL OF IMMUNOGENETICS
LA English
DT Article
ID TRIPLET REPEAT POLYMORPHISM; HLA-B ALLELES; BEHCETS-DISEASE; T-CELLS;
   GENE; ASSOCIATION; EXPRESSION; NKG2D; ACTIVATION; HAPLOTYPE
AB The major histocompatibility complex (MHC) class I chain-related A (MICA) gene, located near HLA-B, codes for protein products with structural similarities to those of classical MHC class I genes, but which neither bind beta(2)-microglobulin nor present peptide. Expressed predominantly on gastrointestinal and tumour epithelial cells, they are stress-induced and interact with C-type lectin like receptor (NKG2D) on gammadelta, alphabeta CD8+ T cells and natural killer (NK) cells. MICA is highly polymorphic, with 54 extracellular allelic sequences described. We typed 200 healthy subjects in a sample of the Sao Paulo population by extended polymerase chain reaction-sequence-specific primers (PCR-SSP) to characterize the MICA polymorphism and analysed MICA/HLA-B linkage disequilibrium. The MICA*008 group (g) was predominant (47%), with several HLA-B associations. Rare combinations MICA*008g-HLA-B37, MICA*008g-B72 and MICA*010-HLA-B52 were detected. Given the extent of this polymorphism and its possible relevance for disease association, we determined MICA and HLA-B alleles in 33 Behcet's patients, in an attempt to clarify the associated genetic marker. Our results showed an increase of MICA*006, but not MICA*009, in the patient group (6/33) compared with controls (3/200) (18.2% vs. 1.5%; P-c = 0.005). Both alleles were always in association with HLA-B51, suggesting that HLA-B is indeed the primary susceptibility locus (P = 0.00008) and that MICA*006 may be an additional risk factor.
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor,Lab Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Histocompatibil & Cellular Immunol, Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), FMUSP, HC, InCor, Lab Imunol, Ave Dr Eneas Carvalho Aguiar 44,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM goldberg@usp.br
RI Goldberg, Anna Carla/H-8594-2014; Yamamoto, Joyce H/B-6192-2015; KALIL,
   JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Yamamoto, Joyce/0000-0001-6869-2988
CR BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259
   Bahram S, 2000, Adv Immunol, V76, P1
   Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727
   BAUR MP, 1980, HISTOCOMPATIBILITY T, P955
   *BEHC DIS RES COMM, 1974, JPN J OPHTHALMOL, V18, P291
   BIGNON JD, 1997, GENETIC DIVERSITY HL, V1, P584
   BODMER W, 1997, HLA 1997, P1
   Choi HB, 2000, TISSUE ANTIGENS, V56, P548, DOI 10.1034/j.1399-0039.2000.560609.x
   Esin S, 1997, CLIN EXP IMMUNOL, V107, P520, DOI 10.1046/j.1365-2249.1997.d01-947.x
   Fodil N, 1999, IMMUNOGENETICS, V49, P557, DOI 10.1007/s002510050536
   Gambelunghe G, 1999, J CLIN ENDOCR METAB, V84, P3701, DOI 10.1210/jc.84.10.3701
   Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857
   GOLDBERG AC, 1998, HLA 1998, P241
   Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879
   Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112
   Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445
   Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321
   Hankey KG, 2002, TRANSPLANTATION, V73, P304, DOI 10.1097/00007890-200201270-00029
   Imanishi T., 1992, HLA 1991, P76
   Kilmartin DJ, 1997, BRIT J OPHTHALMOL, V81, P649, DOI 10.1136/bjo.81.8.649
   Komatsu-Wakui M, 1999, IMMUNOGENETICS, V49, P620, DOI 10.1007/s002510050658
   Mendoza-Rincon J, 1999, IMMUNOGENETICS, V49, P471, DOI 10.1007/s002510050523
   Mizuki N, 1999, ARTHRITIS RHEUM, V42, P1961, DOI 10.1002/1529-0131(199909)42:9<1961::AID-ANR23>3.0.CO;2-7
   Mizuki N, 2000, INVEST OPHTH VIS SCI, V41, P3702
   Mizuki N, 1997, P NATL ACAD SCI USA, V94, P1298, DOI 10.1073/pnas.94.4.1298
   MORAES JR, 1996, HEMATOLOGIA HEMOTERA, V1, P18
   OHNO S, 1982, ARCH OPHTHALMOL-CHIC, V100, P1455
   Orchard TR, 2001, CLIN EXP IMMUNOL, V126, P437, DOI 10.1046/j.1365-2249.2001.01662.x
   Ota M, 2000, TISSUE ANTIGENS, V56, P268, DOI 10.1034/j.1399-0039.2000.560309.x
   Petersdorf EW, 1999, IMMUNOGENETICS, V49, P605, DOI 10.1007/s002510050655
   ROSALES T, 1992, BRAZ J MED BIOL RES, V25, P39
   Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707
   Shiina T, 1999, P NATL ACAD SCI USA, V96, P13282, DOI 10.1073/pnas.96.23.13282
   Stephens HAF, 1999, TISSUE ANTIGENS, V53, P167, DOI 10.1034/j.1399-0039.1999.530207.x
   SUZUKI Y, 1992, J RHEUMATOL, V19, P588
   SVEJGAARD A, 1994, TISSUE ANTIGENS, V43, P18, DOI 10.1111/j.1399-0039.1994.tb02291.x
   Tian W, 2001, IMMUNOGENETICS, V53, P724, DOI 10.1007/s00251-001-0392-x
   Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x
   Wallace GR, 1999, IMMUNOGENETICS, V49, P613, DOI 10.1007/s002510050656
   Williams F, 2001, HUM IMMUNOL, V62, P645, DOI 10.1016/S0198-8859(01)00247-6
   Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730
   Yabuki K, 1999, INVEST OPHTH VIS SCI, V40, P1921
   Yabuki K, 1999, HUM IMMUNOL, V60, P83, DOI 10.1016/S0198-8859(98)00092-5
   Zhang YZ, 2003, HUM IMMUNOL, V64, P130, DOI 10.1016/S0198-8859(02)00743-7
   Zhang YZ, 2002, IMMUNOGENETICS, V53, P900, DOI 10.1007/s00251-001-0426-4
   Zwirner NW, 1999, HUM IMMUNOL, V60, P323, DOI 10.1016/S0198-8859(98)00128-1
   Zwirner NW, 2000, HUM IMMUNOL, V61, P917, DOI 10.1016/S0198-8859(00)00162-2
NR 47
TC 23
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7420
J9 EUR J IMMUNOGENET
JI Eur. J. Immunogenet.
PD APR
PY 2004
VL 31
IS 2
BP 63
EP 71
DI 10.1111/j.1365-2370.2004.00446.x
PG 9
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 812RN
UT WOS:000220856700002
PM 15086345
DA 2020-11-26
ER

PT J
AU Bilate, AM
   Salemi, VC
   Ramires, FJ
   Gregio, D
   Kalil, J
   Cunha-Neto, E
AF Bilate, AM
   Salemi, VC
   Ramires, FJ
   Gregio, D
   Kalil, J
   Cunha-Neto, E
TI Soluble tumor necrosis factor receptor (Etanercept) treatment enhances
   left ventricular dysfunction in an experimental model of chronic chagas
   disease cardiomyopathy
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 54th Annual Scientific Session of the American-College-of-Cardiology
CY MAR 07-10, 2004
CL New Orleans, LA
SP Amer Coll Cardiol
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
RI Salemi, Vera/AAY-5024-2020; Salemi, Vera MC/C-9104-2013; KALIL,
   JORGE/C-8029-2012; Ramires, Felix JA/D-5996-2012; Cunha-Neto,
   Edecio/B-4157-2009
OI Salemi, Vera MC/0000-0002-7152-1810; KALIL, JORGE/0000-0001-8415-4274;
   Ramires, Felix JA/0000-0003-2437-2485; Cunha-Neto,
   Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAR 3
PY 2004
VL 43
IS 5
SU A
BP 225A
EP 226A
DI 10.1016/S0735-1097(04)90959-X
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 780NW
UT WOS:000189388500961
OA Bronze
DA 2020-11-26
ER

PT J
AU Granja, C
   Moliterno, RA
   Ferreira, MS
   Fonseca, JA
   Kalil, J
   Coelho, V
AF Granja, C
   Moliterno, RA
   Ferreira, MS
   Fonseca, JA
   Kalil, J
   Coelho, V
TI T-cell autoreactivity to Hsp in human transplantation may involve both.
   proinflammatory and regulatory functions
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE Hsp; autoreactivity; rejection; immunoregulation; IL-4
ID HEAT-SHOCK-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   ALLOGRAFT-REJECTION; NORMAL INDIVIDUALS; IMMUNOLOGICAL HOMUNCULUS;
   ADJUVANT ARTHRITIS; DENDRITIC CELLS; IMMUNE-SYSTEM; CUTTING EDGE; NOD
   MOUSE
AB Heat shock proteins (Hsp) are moving from the category of basically intracellular chaperone molecules to important proteins in both innate and acquired immune responses, with great potential for clinical application as immunomodulators. Both proinflammatory and regulatory Hsp-reactive T cells have been described in animal models of autoimmune diseases. To investigate the role of autoreactivity to Hsp60 and Hsp70 in human transplantation, we analyzed, sequentially, peripheral blood mononuclear cell proliferation and cytokine production before and at different time points after renal transplantation, as well as the modulation of proliferation to Hsp in the presence of exogenous cytokines. Proliferation to Hsp60 and Hsp70 in the pretransolantation (pre-Tx) period was significantly associated with rejection episodes in the first months post-Tx. In contrast, IL-4 production was significantly associated with absence of rejection. Addition of exogeneous IL-4 distinctly modulated the proliferative response to Hsp60; inhibiting proliferation in 83% of patients in the early post-Tx period (0-6 months), in which rejection episodes occurred, and inducing proliferation in 62.5% of patients in the later period (> 12-24 months), when no rejection was observed. Characterization of autoreactive anti-Hsp60 regulatory T cells may permit new approaches to control the proinflammatory response to the graft, as well as aggressive autoimmunity.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Estadual Maringa, Clin Anal Dept, Maringa, Parana, Brazil.
   Univ Sao Paulo, Hosp Clin, Div Renal Transplantat, Sao Paulo, Brazil.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), HC FMUSP, Inst Coracao, Lab Imunol, Av Dr Eneas Carvalho Aguiar 44,9 Andar,BL 2, BR-05403001 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI Spadafora-Ferreira, Monica/G-2635-2012; KALIL, JORGE/C-8029-2012;
   COELHO, VERONICA/D-1433-2013
OI Spadafora-Ferreira, Monica/0000-0001-8823-9929; KALIL,
   JORGE/0000-0001-8415-4274; Coelho, Veronica/0000-0002-0989-2581
CR Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262
   Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539
   Beech JT, 1997, J IMMUNOL, V159, P3692
   BIGNON JD, 1997, HLA GENETIC DIVERSIT
   Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029
   Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159
   BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
   Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3
   Cohen I. R., 2000, TENDING ADAMS GARDEN
   COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2
   Cohen IR, 1997, CLIN IMMUNOL IMMUNOP, V84, P103, DOI 10.1006/clin.1997.4396
   Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3
   COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9
   Cohen IR, 2000, SEMIN IMMUNOL, V12, P215, DOI 10.1006/smim.2000.0234
   Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758
   ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576
   FEIGE U, 1994, EXPERIENTIA, V50, P979, DOI 10.1007/BF01923452
   Feili-Hariri M, 2000, J AUTOIMMUN, V14, P133, DOI 10.1006/jaut.1999.0352
   Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982
   Kimura Y, 1998, INT IMMUNOL, V10, P117, DOI 10.1093/intimm/10.2.117
   Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13
   Kumar V, 1998, J IMMUNOL, V161, P6585
   KUMAR V, 1993, J EXP MED, V178, P909, DOI 10.1084/jem.178.3.909
   Kumar V, 2001, INT IMMUNOL, V13, P835, DOI 10.1093/intimm/13.6.835
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   MARESCA B, 1994, EXPERIENTIA, V50, P1067, DOI 10.1007/BF01923463
   Mendel I, 2002, EUR J IMMUNOL, V32, P3216, DOI 10.1002/1521-4141(200211)32:11<3216::AID-IMMU3216>3.0.CO;2-H
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P598
   MOLITERNO RA, 1995, J HEART LUNG TRANSPL, V14, P1
   Moudgil KD, 1998, IMMUNOL REV, V164, P175, DOI 10.1111/j.1600-065X.1998.tb01219.x
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   MUNK ME, 1988, EUR J IMMUNOL, V18, P1835, DOI 10.1002/eji.1830181128
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1379/1466-1268(1999)004<0029:IOHHSP>2.3.CO;2
   Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710
   Pockley AG, 2001, TRANSPLANTATION, V71, P1503, DOI 10.1097/00007890-200106150-00001
   Poole KL, 2001, TRANSPL IMMUNOL, V8, P259, DOI 10.1016/S0966-3274(01)00030-2
   Portugal K, 2001, INT IMMUNOL, V13, P747, DOI 10.1093/intimm/13.6.747
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5
   Sackett DL, 1991, CLIN EPIDEMIOLOGY BA
   Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9
   SELMAJ K, 1992, NEUROLOGY, V42, P795, DOI 10.1212/WNL.42.4.795
   Shevach EM, 2000, CURR BIOL, V10, pR572, DOI 10.1016/S0960-9822(00)00617-5
   SIRAK H, 1988, TRANSPLANTATION, V65, P1352
   Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844
   STANFORD MR, 1994, CLIN EXP IMMUNOL, V97, P226
   *STAT CORP, 1997, STAT STAT STAT SOFTW
   Stephanou A, 1998, SEMIN ARTHRITIS RHEU, V28, P155, DOI 10.1016/S0049-0172(98)80032-2
   Trieb K, 1996, Transpl Immunol, V4, P43, DOI 10.1016/S0966-3274(96)80032-3
   Van Hoffen E, 2000, Transpl Int, V13 Suppl 1, pS216
   Van Parijs L, 1998, SCIENCE, V280, P243
   VANEDEN W, 1989, CURR TOP MICROBIOL, V145, P27
   VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0
   vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553
   Weiner HL, 1997, RES IMMUNOL, V148, P528, DOI 10.1016/S0923-2494(98)80146-6
   Wendling U, 2000, J IMMUNOL, V164, P2711, DOI 10.4049/jimmunol.164.5.2711
   Xia DY, 2001, TRANSPLANTATION, V72, P907, DOI 10.1097/00007890-200109150-00028
NR 58
TC 18
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2004
VL 65
IS 2
BP 124
EP 134
DI 10.1016/j.humimm.2003.10.007
PG 11
WC Immunology
SC Immunology
GA 777RM
UT WOS:000189191400004
PM 14969767
DA 2020-11-26
ER

PT J
AU Fae, K
   Kalil, J
   Toubert, A
   Guilherme, L
AF Fae, K
   Kalil, J
   Toubert, A
   Guilherme, L
TI Heart infiltrating T cell clones from a rheumatic heart disease patient
   display a common TCR usage and a degenerate antigen recognition pattern
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE rheumatic heart disease; molecular mimicry; T cell degeneracy; heart
   tissue antigens; M protein
ID MYELIN BASIC-PROTEIN; IMMUNOLOGICAL HOMUNCULUS; CROSS-REACTIVITY;
   AUTOIMMUNITY; RECEPTOR; LYMPHOCYTES; PERIPHERY; MIMICRY; TISSUE; FEVER
AB CD4(+) T cells are most likely the ultimate effectors of chronic heart lesions in rheumatic heart disease (RHD). We have demonstrated that infiltrating CD4(+) T cell clones were able to recognize several heart tissue and streptococcal antigens by molecular mimicry. Clonality analysis of the mitral valve and myocardium infiltrating T cell lines showed several oligoclonal expansions, some of which were found in both sites of the lesions. The results presented in this study showed a degenerate pattern of reactivity of intralesional T cell clones from one RHD patient. Four mitral valve and one papillar muscle-derived T cell clones, presenting the same TCR-BV13 BJ2S7 with same sequences of the CDR3 region recognized different antigens. They expressed two alpha chains at the RNA level and the AV AJ segments were the same for mitral valve T cell clones, but not for the papillar muscle-derived T cell clone. Two other intralesional T cell clones using the same TCR-BV3 JB2S1 segments with identical CDR3 sequences also recognized different antigens. These results indicate that intralesional T cell clones with common TCR usage can recognize several epitopes that probably amplify the deleterious immune reaction. These data. allow us to hypothesize that degenerate T cell recognition may lead to intramolecular degenerate reactivity against epitopes with low homology. This can be a novel mechanism of epitope spreading, of relevance in the increase of epitopes targets that can activate cross-reactive autoimmune T cells. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   FMUSP, HC, Lab Imunol, BR-05403000 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Clin Immunol & Allergy, Sao Paulo, Brazil.
   Hop St Louis, Inst Univ Hematol, Lab Immunol & Histocompatibilite, INSERM,U396, Paris, France.
RP Guilherme, L (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
EM luizagui@usp.br
RI Toubert, Antoine/Q-3404-2017; Guglielmi, Luiza G/E-7676-2013; KALIL,
   JORGE/C-8029-2012
OI Toubert, Antoine/0000-0002-7308-7317; KALIL, JORGE/0000-0001-8415-4274
CR COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2
   COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9
   Cohen IR, 2001, J AUTOIMMUN, V16, P337, DOI 10.1006/jaut.2000.0481
   Figueroa F, 2002, J AUTOIMMUN, V19, P233, DOI 10.1006/jaut.2002.0620
   FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848
   Gavin MA, 2002, NAT IMMUNOL, V3, P109, DOI 10.1038/ni0202-109
   Guilherme L, 2001, J AUTOIMMUN, V16, P363, DOI 10.1006/jaut.2000.0487
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   He X, 2002, NAT IMMUNOL, V3, P127, DOI 10.1038/ni751
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Mason D, 1998, IMMUNOLOGIST, V6, P220
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
NR 21
TC 30
Z9 32
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD FEB
PY 2004
VL 40
IS 14-15
BP 1129
EP 1135
DI 10.1016/j.molimm.2003.11.007
PG 7
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 800BB
UT WOS:000220002800021
PM 15036919
DA 2020-11-26
ER

PT J
AU Castro, MCR
   Panajotopoulos, N
   Araujo, LMP
   Rodrigues, H
   Maciel, R
   Ronda, C
   Viggiani, CS
   Nahas, W
   David-Neto, E
   Ianhez, LE
   Kalil, J
   Glotz, D
AF Castro, MCR
   Panajotopoulos, N
   Araujo, LMP
   Rodrigues, H
   Maciel, R
   Ronda, C
   Viggiani, CS
   Nahas, W
   David-Neto, E
   Ianhez, LE
   Kalil, J
   Glotz, D
TI Renal transplantation using living donors with a positive crossmatch:
   Can we predict efficacy of desensitization with IVIg by an "in vitro"
   test?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY MAY 14-19, 2004
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 Univ Sao Paulo, Renal Transplant Unit, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Immunol Lab, BR-05508 Sao Paulo, Brazil.
   Hop European George Pompidou, Renal Transplant Unit, Paris, France.
RI de castro, maria cristina ribeiro/B-6648-2009; Neto, Elias
   David/O-3866-2018; KALIL, JORGE/C-8029-2012; David-Neto,
   Elias/C-9112-2012
OI de castro, maria cristina ribeiro/0000-0002-6731-8369; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2004
VL 4
SU 8
MA 1425
BP 549
EP 549
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 819NT
UT WOS:000221322501421
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Kalil, J
   Saldiva, PH
   Latorre, MD
   Morato-Castro, FF
AF Graudenz, GS
   Kalil, J
   Saldiva, PH
   Latorre, MD
   Morato-Castro, FF
TI Decreased respiratory symptoms after intervention in artificially
   ventilated offices in Sao Paulo, Brazil
SO CHEST
LA English
DT Article
DE air conditioning; air pollution; indoor; intervention studies;
   occupational health
ID SICK BUILDING SYNDROME; AIR; EPIDEMIOLOGY; HEALTH
AB Background: The increase in work-related respiratory complaints in artificially ventilated buildings have multiple causes, and intervention studies are a valuable approach to understanding possible mechanisms.
   Study objectives: To analyze the effects of an intervention in a ventilation system with > 20 years of continuous use, and with a high rate of building-related respiratory complains.
   Design: An epidemiologic study was done among individuals working in places with ventilation machinery and ducts with > 20 years of use, before and after intervention. Analysis of symptoms and logistic regression were performed to check the associations between air-conditioning intervention and reported symptoms.
   Results: The air-conditioning intervention showed a protective effect on building-related worsening of respiratory symptoms (odds ratio, 0.132; 95% confidence interval, 0.030 to 0.575), naso-ocular symptoms (odds ratio, 0.231; 95% confidence interval, 0.058 to 0.915), and persistent cough (odds ratio, 0.071; 95% confidence interval, 0.014 to 0.356).
   Conclusion: Intervention in high-risk occupational locations can be effective in improving perceived indoor air quality.
C1 Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Rua Heitor Penteado 477, BR-05437000 Sao Paulo, Brazil.
EM gustavog@usp.br
RI Saldiva, Paulo HN/D-7385-2012; KALIL, JORGE/C-8029-2012; Latorre, Maria
   RDO/J-5780-2014
OI Saldiva, Paulo HN/0000-0003-2005-8253; KALIL, JORGE/0000-0001-8415-4274;
   Latorre, Maria RDO/0000-0002-5189-3457
CR ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483
   Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283, DOI 10.1016/S1081-1206(10)63017-7
   BARDANA EJ, 1988, CLIN REV ALLERG, V6, P61
   FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1
   Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729
   Kildeso J, 1999, SCAND J WORK ENV HEA, V25, P361, DOI 10.5271/sjweh.446
   Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107
   Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397
   Oliver LC, 1998, PUBLIC HEALTH REP, V113, P398
   Ooi PL, 1998, OCCUP ENVIRON MED, V55, P188, DOI 10.1136/oem.55.3.188
   POLINOSE ME, 1989, ALERGIA BRASIL, P67
   RAW GJ, 1993, INDOOR AIR, V3, P237
   Rouadi P, 1999, J APPL PHYSIOL, V87, P400
   TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113
NR 14
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD JAN
PY 2004
VL 125
IS 1
BP 326
EP 329
DI 10.1378/chest.125.1.326
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 764QN
UT WOS:000188217700054
PM 14718461
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Kalil, J
AF Guilherme, L
   Kalil, J
TI Rheumatic fever: From sore throat to autoimmune heart lesions
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
LA English
DT Review
DE autoimmunity; cytokines; heart tissue proteins; M protein; rheumatic
   heart disease; T cell receptor
ID STREPTOCOCCAL-M-PROTEIN; CLASS-II ANTIGENS; T-CELL-RECEPTOR; DISEASE
   PATIENTS; IMMUNE-RESPONSE; IMMUNOLOGICAL HOMUNCULUS; BRAZILIAN
   POPULATION; MONONUCLEAR-CELLS; CROSS-REACTIVITY; GENE USAGE
AB Molecular mimicry between streptococci and heart components has been proposed as the triggering factor leading to autoimmunity in rheumatic heart disease (RHD). In this review, we present data from cellular autoimmune responses, focusing on the interactions between HLA class II molecules, streptococcal peptides and heart tissue proteins and T-cell receptor (TCR) usage. HLA-DR7DR53 associated with DQ molecules seem to be related with the development of valvular lesions in severe RHD patients. DR7DR53 molecules were also involved in the recognition of an immunodominant M5 peptide in these patients. T cells infiltrating RHD hearts displayed several oligoclonal expansions. Intralesional T-cell clones presenting identical TCR-BVBJ AVAJ and -CDR3 sequences were able to recognize several antigens with little or low homology, showing an intramolecular degenerate pattern of antigen recognition. Peripheral blood mononuclear cells of rheumatic fever (RF) patients produced proinflammatory cytokines, and intralesional mononuclear cells from severe RHD patients produced predominantly Th1-type cytokines. These results illustrate the complex mechanisms leading to heart tissue damage in RF/RHD patients. Copyright (C) 2004 S. Karger AG, Basel.
C1 Univ Sao Paulo, Heart Inst Incor, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Invest Immunol, Millenium Inst, Sch Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Div Clin Immunol & Allergy, Dept Clin Med, Sch Med, Sao Paulo, Brazil.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas Carvalho Aguiar,44-9 Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273
   BENACERRAF B, 1967, COLD SPRING HARB SYM, V32, P569, DOI 10.1101/SQB.1967.032.01.069
   COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2
   COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9
   Cohen IR, 2001, J AUTOIMMUN, V16, P337, DOI 10.1006/jaut.2000.0481
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
   Degnan B, 1997, HUM IMMUNOL, V53, P206, DOI 10.1016/S0198-8859(97)00028-1
   ElDemellawy M, 1997, INFECT IMMUN, V65, P2197, DOI 10.1128/IAI.65.6.2197-2205.1997
   Fae K, 2004, MOL IMMUNOL, V40, P1129, DOI 10.1016/j.molimm.2003.11.007
   Figueroa F, 2002, J AUTOIMMUN, V19, P233, DOI 10.1006/jaut.2002.0620
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   FLEISCHER B, 1992, INFECT IMMUN, V60, P1767, DOI 10.1128/IAI.60.5.1767-1770.1992
   Fraser WJ, 1997, HISTOPATHOLOGY, V31, P460, DOI 10.1046/j.1365-2559.1997.2990883.x
   Galvin JE, 2000, J CLIN INVEST, V106, P217, DOI 10.1172/JCI7132
   GIBOFSKY A, 1991, J RHEUMATOL, V18, P1
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   Guilherme L, 2001, J AUTOIMMUN, V16, P363, DOI 10.1006/jaut.2000.0487
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOTB M, 1990, J IMMUNOL, V145, P1332
   Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   Mason D, 1998, IMMUNOLOGIST, V6, P220
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   MILLER L, 1988, J BIOL CHEM, V263, P5668
   MILLER LC, 1989, J RHEUMATOL, V16, P1436
   MORRIS K, 1993, CLIN EXP IMMUNOL, V91, P429
   NARIN N, 1995, CLIN IMMUNOL IMMUNOP, V77, P172, DOI 10.1006/clin.1995.1140
   OLMEZ U, 1993, SCAND J RHEUMATOL, V22, P49
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Roberts S, 2001, J INFECT DIS, V183, P507, DOI 10.1086/318076
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   SAMSONOV MY, 1995, CLIN IMMUNOL IMMUNOP, V74, P31, DOI 10.1006/clin.1995.1005
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   Stanevicha V, 2003, ARTHRITIS RES THER, V5, pR340, DOI 10.1186/ar1000
   STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P131, DOI 10.1016/S0090-1229(05)80019-4
   Stollerman GH, 1988, HEART DIS TXB CARDIO, P1706
   TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359
   TOMAI MA, 1991, J EXP MED, V174, P285, DOI 10.1084/jem.174.1.285
   TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992
   VIRMANI R, 1999, RHEUMATIC FEVER, P217
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WANG B, 1993, J IMMUNOL, V151, P1419
   WATANABEOHNISHI R, 1994, J IMMUNOL, V152, P2066
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   Yegin O, 1997, EUR J PEDIATR, V156, P25
NR 55
TC 35
Z9 39
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-2438
EI 1423-0097
J9 INT ARCH ALLERGY IMM
JI Int. Arch. Allergy Immunol.
PY 2004
VL 134
IS 1
BP 56
EP 64
DI 10.1159/000077915
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA 822YH
UT WOS:000221576300008
PM 15103230
DA 2020-11-26
ER

PT J
AU Fonseca, CT
   Cunha-Neto, E
   Kalil, J
   de Jesus, AR
   Correa-Oliveira, R
   Carvalho, E
   Oliveira, S
AF Fonseca, CT
   Cunha-Neto, E
   Kalil, J
   de Jesus, AR
   Correa-Oliveira, R
   Carvalho, E
   Oliveira, S
TI Identification of immunodominant epitopes of Schistosoma mansoni vaccine
   candidate antigens using human T cells
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT 9th international Symposium on Schistosomiasis
CY NOV 02-05, 2003
CL Salvador, BRAZIL
DE T cells; synthetic peptides; vaccines; Schistosoma mansoni; Sm14;
   paramyosin
ID ACID-BINDING PROTEIN; PROTECTIVE IMMUNITY; PARAMYOSIN; RESPONSES;
   INDIVIDUALS; ANTIBODY; GAMMA; ALPHA; MICE
AB Paramyosin and Sm14 are two of the six antigens selected by the World Health Organization as candidates to compose a subunit vaccine against schistosomiasis. Both antigens are recognized by individuals naturally resistant to Schistosoma mansoni infection and induced protective immunity in the murine model. Three Sm14 epitopes and eleven paramyosin epitopes were selected by their ability to bind to different HLA-DR molecules using the TEPITOPE computer program, and these peptides were synthetically produced. The cellular recognition of Sm14 and paramyosin epitopes by peripheral blood mononuclear cells of individuals living in endemic area for schistosomiasis was tested by T cell proliferation assay. Among all Sm14 and paramyosin epitopes studied, Sm14-3 was Preferentially recognized by individuals naturally resistant to S. mansoni infection while Para-5 was preferentially recognized by individuals resistant to reinfection. These two peptides represent promising antigens to be used in an experimental vaccine against schistosomiasis, since their preferential recognition by resistant individuals suggest their involvement in the induction of protective immunity.
C1 Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Invest Imunol, Inst Milenio, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Imunol, Sao Paulo, Brazil.
   Univ Fed Bahia, Hosp Professor Edgard Santos, Serv Immunol, Salvador, BA, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Immunol Lab, Belo Horizonte, MG, Brazil.
RP Oliveira, S (corresponding author), Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Invest Imunol, Inst Milenio, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM scozeus@icb.ufmg.br
RI Cunha-Neto, Edecio/B-4157-2009; Fonseca, Cristina/M-8511-2019; KALIL,
   JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Fonseca,
   Cristina/0000-0003-1527-5050; KALIL, JORGE/0000-0001-8415-4274
CR Agiro L., 2000, VACCINE, V18, P2033
   Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5
   BERGERSEN R, 1995, J BIOGEOGR, V22, P1, DOI 10.2307/2846068
   Bergquist NR, 2002, TRENDS PARASITOL, V18, P309, DOI 10.1016/S1471-4922(02)02301-2
   Bergquist NR, 1998, MEM I OSWALDO CRUZ, V93, P95, DOI 10.1590/S0074-02761998000700013
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brito CFA, 2000, SCAND J IMMUNOL, V51, P595
   Brito CFA, 2000, PARASITE IMMUNOL, V22, P41
   COLLEY DG, 1977, INT ARCH ALLER A IMM, V53, P420, DOI 10.1159/000231780
   CORREAOLIVEIRA R, 1989, T ROY SOC TROP MED H, V83, P798, DOI 10.1016/0035-9203(89)90334-9
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   Fonseca CT, 2004, VACCINE, V22, P503, DOI 10.1016/j.vaccine.2003.07.010
   Harder A, 2002, PARASITOL RES, V88, P395, DOI 10.1007/s00436-001-0588-x
   LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144
   MOSER D, 1991, J BIOL CHEM, V266, P8447
   Nara T, 1997, VACCINE, V15, P79, DOI 10.1016/S0264-410X(96)00100-4
   PEARCE EJ, 1988, P NATL ACAD SCI USA, V85, P5678, DOI 10.1073/pnas.85.15.5678
   Tallima H, 2003, VACCINE, V21, P3290, DOI 10.1016/S0264-410X(03)00180-4
   Tarrab-Hazdai R, 1998, INFECT IMMUN, V66, P4526
   Vilar MM, 2003, VACCINE, V22, P137, DOI 10.1016/S0264-410X(03)00300-1
NR 20
TC 19
Z9 20
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2004
VL 99
IS 5
SU S
BP 63
EP 66
DI 10.1590/S0074-02762004000900011
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 853VS
UT WOS:000223857600011
PM 15486637
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT B
AU Iwai, LK
   Yoshida, M
   Shikanai-Yasuda, MA
   Juliano, MA
   Hammer, J
   Julian, L
   Kalil, J
   Travassos, LR
   Cunha-Neto, E
AF Iwai, Leo Kei
   Yoshida, Marcia
   Shikanai-Yasuda, Maria A.
   Juliano, Maria A.
   Hammer, Jurgen
   Julian, Luiz
   Kalil, Jorge
   Travassos, Luiz R.
   Cunha-Neto, Edecio
BE Chorev, M
   Sawyer, TK
TI Identification of potential vaccine T cell epitopes based on computer
   selected sequences
SO Peptide Revolution: Genomics, Proteomics & Therapeutics
LA English
DT Proceedings Paper
CT 18th American Peptide Symposium
CY JUL 19-23, 2003
CL BOSTON, MA
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RP Iwai, LK (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RI Yasuda, Maria Aparecida Shikanai/AAX-7693-2020; Iwai, Leo/M-1734-2013
OI Yasuda, Maria Aparecida Shikanai/0000-0003-3864-041X; Iwai,
   Leo/0000-0002-1571-7763
CR Cunha-Neto E, 1999, BRAZ J MED BIOL RES, V32, P199, DOI 10.1590/S0100-879X1999000200008
   Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9
   HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353
   Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998
NR 4
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 USA
BN 0-9715560-1-6
PY 2004
BP 1005
EP 1006
PG 2
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA BEQ46
UT WOS:000238911100421
DA 2020-11-26
ER

PT J
AU Bilate, AMB
   Salemi, VMC
   Ramires, FJA
   de Brito, T
   Silva, AM
   Umezawa, ES
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Bilate, AMB
   Salemi, VMC
   Ramires, FJA
   de Brito, T
   Silva, AM
   Umezawa, ES
   Mady, C
   Kalil, J
   Cunha-Neto, E
TI The Syrian hamster as a model for the dilated cardiomyopathy of Chagas'
   disease: a quantitative echocardiographical and histopathological
   analysis
SO MICROBES AND INFECTION
LA English
DT Article
DE Trypanosoma cruzi; hamster; Chagas' disease cardiomyopathy; myocarditis;
   fibrosis; echocardiography
ID TRYPANOSOMA-CRUZI INFECTION; CONGESTIVE-HEART-FAILURE; VISCERAL
   LEISHMANIASIS; VIRUS MYOCARDITIS; GOLDEN-HAMSTERS; ANIMAL-MODELS;
   MICROSCOPY; MICE; PATHOGENESIS; AUTOIMMUNITY
AB Chronic Chagas' disease cardiomyopathy (CCC) is caused by the protozoan Trypanosoma cruzi, and it affects 30% of the 16-18 million people infected in Latin America. A good rodent model that develops a dilated cardiomyopathy closely resembling human CCC after T cruzi infection is still needed. We compared the cardiomyopathy developed by T cruzi-infected Syrian hamsters with human Chagas' disease cardiomyopathy using quantitative methods. Female hamsters were infected with 3.5 x 10(4) (G1, n = 10) or 10(5) (G2, n = 10) T. cruzi Y strain blood trypomastigotes. Control animals (C, n = 10) were injected with saline solution. Cardiac function was assessed by echocardiography at 4, 8 and 12 months post-infection. Heart sections were submitted to histopathological/morphometric analysis 12 months post-infection. At this time, ventricular dysfunction and diffuse or multi-focal myocarditis were observed in 91% and 100% of G1 and G2 infected groups, respectively. Median interstitial collagen volumes in groups C, G1 and G2 were 1.2%, 1.9% and 3.9%, respectively, and were significantly higher in group G2 than in group C. Among infected animals, myocarditis showed a positive correlation with interstitial fibrosis. Deaths in the chronic phase (8-12 months post-infection) were more frequent among G2 than G1, and were associated with macroscopic ventricular dilation, severe myocarditis and increased fibrosis values, along with an earlier onset of ventricular dysfunction. The T cruzi chronically infected Syrian hamster develops a cardiomyopathy which resembles human Chagas' disease cardiomyopathy, and might be an adequate tool to investigate pathogenic mechanisms of this disease and to search for novel therapeutic strategies. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Div Gen Cardiopathies, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Protozool, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, BR-0540300 Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Av Dr Eneas Carvalho Aguiar,44-Bloco 2-90 Andar, BR-0540300 Sao Paulo, Brazil.
RI Salemi, Vera/AAY-5024-2020; De Brito, Thales/L-2865-2017; Mady,
   Charles/C-8870-2012; Ramires, Felix JA/D-5996-2012; Salemi, Vera
   MC/C-9104-2013; da Silva, Ana Maria Goncalves/ABD-3920-2020; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI De Brito, Thales/0000-0003-1106-7254; Mady, Charles/0000-0002-8838-199X;
   Ramires, Felix JA/0000-0003-2437-2485; Salemi, Vera
   MC/0000-0002-7152-1810; Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Silva, Ana Maria/0000-0001-7554-0894
CR ACQUATELLA H, 1980, CIRCULATION, V62, P787, DOI 10.1161/01.CIR.62.4.787
   Andrade SG, 1997, INT J EXP PATHOL, V78, P391, DOI 10.1046/j.1365-2613.1997.390370.x
   ANDRADE ZA, 1987, AM J PATHOL, V127, P467
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   CAMARA EJN, 1993, ARQ BRAS CARDIOL, V60, P51
   Cavasin MA, 2000, J CARDIOVASC PHARM, V36, P472, DOI 10.1097/00005344-200010000-00009
   Chandra M, 2002, INT J PARASITOL, V32, P207, DOI 10.1016/S0020-7519(01)00320-4
   Chapadeiro E, 1988, Rev Soc Bras Med Trop, V21, P95, DOI 10.1590/S0037-86821988000300002
   Cunha-Neto E, 2000, MOLECULAR MIMICRY, MICROBES, AND AUTOIMMUNITY, P257
   FALASCA CA, 1990, REV I MED TROP, V32, P151, DOI 10.1590/S0036-46651990000300002
   Goineau S, 2002, J CARDIOVASC PHARM, V40, P189, DOI 10.1097/00005344-200208000-00004
   Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2
   Higuchi MD, 1999, HEART, V82, P279, DOI 10.1136/hrt.82.3.279
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Ikeda Y, 2000, CURR OPIN CARDIOL, V15, P197, DOI 10.1097/00001573-200005000-00013
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8
   Lemire I, 2001, AM J PHYSIOL-HEART C, V281, pH931
   Leon JS, 2001, INT J PARASITOL, V31, P555, DOI 10.1016/S0020-7519(01)00163-1
   Li YY, 2000, P NATL ACAD SCI USA, V97, P12746, DOI 10.1073/pnas.97.23.12746
   Lissaldo Ana Maria, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P163, DOI 10.1590/S0036-46651994000200012
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Mady C, 1999, AM J CARDIOL, V84, P354, DOI 10.1016/S0002-9149(99)00295-7
   MADY C, 1995, REV PAUL MED, V113, P791
   Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999
   Melby PC, 1998, INFECT IMMUN, V66, P2135, DOI 10.1128/IAI.66.5.2135-2142.1998
   Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912
   MENGEL JO, 1992, AM HEART J, V124, P1052, DOI 10.1016/0002-8703(92)90991-4
   MORITA H, 1981, JPN CIRC J, V45, P713, DOI 10.1253/jcj.45.713
   MORITA H, 1984, JPN CIRC J, V48, P1097, DOI 10.1253/jcj.48.1097
   NOGUEIRA EA, 1996, SOCESP CARDIOLOGIA A, P620
   OLIVEIRA JSM, 1981, BRIT HEART J, V46, P432, DOI 10.1136/hrt.46.4.432
   PEREIRABARRETO AC, 1986, AM HEART J, V111, P307
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   Ramirez L E, 1994, Rev Soc Bras Med Trop, V27, P163, DOI 10.1590/S0037-86821994000300007
   ROSSI MA, 1995, REV PAUL MED, V113, P750
   SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072
   Schwartz PJ, 1998, AM J CARDIOL, V81, p14D, DOI 10.1016/S0002-9149(98)00148-9
   Shulman IA, 1997, TRANSFUSION, V37, P727, DOI 10.1046/j.1537-2995.1997.37797369449.x
   Simoes MV, 2000, REV SOC CARDIOL EST, V10, P50
   Straub V, 1998, AM J PATHOL, V153, P1623, DOI 10.1016/S0002-9440(10)65751-3
   Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109
   TEIXEIRA ARL, 1983, AM J TROP MED HYG, V32, P258, DOI 10.4269/ajtmh.1983.32.258
   World Health Organization - WHO, 2002, WHO TECH REP SER, V905, p[i, 1]
NR 45
TC 35
Z9 35
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
J9 MICROBES INFECT
JI Microbes Infect.
PD OCT
PY 2003
VL 5
IS 12
BP 1116
EP 1124
DI 10.1016/j.micinf.2003.07.001
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 738UL
UT WOS:000186306200008
PM 14554253
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Farias, AQ
   Abrantes-Lemos, CP
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Farias, AQ
   Abrantes-Lemos, CP
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of major histocompatibility complex and CTLA-4 alleles in
   Brazilian patients with primary biliary cirrhosis
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE CTLA-4 gene polymorphisms; genetic susceptibility; HLA-DR antigens;
   primary biliary cirrhosis; tumor necrosis factor alpha; TNFA
   polymorphisms
ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA PROMOTER; GENE POLYMORPHISM;
   AUTOIMMUNE-DISEASES; HLA DRW8; PCR-SSP; SUSCEPTIBILITY; ASSOCIATION;
   TRANSPLANTATION; PROGRESSION
AB Background and Aims: Predisposition to primary biliary cirrhosis (PBC) has been classically linked to HLA-DRB1 locus. However, the presence of the HLA-DRB1*08 antigen has been reported in less than one-third of PBC patients from Northern Europe and Japan. Recently, polymorphisms in the tumor necrosis factor alpha (TNFA) gene promoter at position -308 and in exon 1 of the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene at position 49 have been associated with susceptibility to PBC in Caucasians. In addition, the presence of HLA-DRB1*08 and the TNFA*1 allele was also linked to progression to end-stage liver disease. The aims of the present study were to investigate the frequencies of HLA-DR and DQ antigens and TNFA and CTLA-4 alleles in PBC patients from a different genetic background, as well as to assess the role of TNFA alleles and HLA-DR antigens in disease progression.
   Methods: Determination of HLA-DRB1, DQB1, TNFA and CTLA-4 alleles was performed in patients with PBC and healthy controls using polymerase chain reaction-based techniques.
   Results: Frequencies of HLA-DR and DQ antigens were similar in PBC patients and healthy controls. Accordingly, no association between TNFA and CTLA-4 alleles was observed in PBC patients. The histological stage at admission of patients with PBC also showed no correlation with HLA antigens and TNFA and CTLA-4 alleles.
   Conclusions: Susceptibility to PBC in Brazil is not associated with HLA-DR and DQ antigens and CTLA-4 genotypes. TNFA alleles were not shown to influence disease progression. (C) 2003 Blackwell Publishing Asia Pty Ltd.
C1 Portuguese Hosp Salvador, Bahia Blanca, Argentina.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302 A,Rio Vermelho, BR-41940040 Salvador, BA, Brazil.
RI Farias, Alberto Q/H-7873-2013; Carrilho, Flair J/I-3046-2012; Farias,
   Alberto/ABB-1291-2020; KALIL, JORGE/C-8029-2012; Cancado,
   Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna
   Carla/H-8594-2014
OI Farias, Alberto/0000-0002-5572-663X; KALIL, JORGE/0000-0001-8415-4274;
   Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940
CR Agarwal K, 1999, EUR J GASTROEN HEPAT, V11, P603, DOI 10.1097/00042737-199906000-00004
   Agarwal K, 2000, J HEPATOL, V32, P538, DOI 10.1016/S0168-8278(00)80213-5
   Beutler BA, 1999, J RHEUMATOL, V26, P16
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3
   COPPEL RL, 1995, IMMUNOL REV, V144, P17, DOI 10.1111/j.1600-065X.1995.tb00064.x
   DONALDSON P, 1994, HEPATOLOGY, V20, P225, DOI 10.1002/hep.1840200133
   Donaldson P, 2001, GUT, V48, P397, DOI 10.1136/gut.48.3.397
   Donaldson PT, 1999, J HEPATOL, V31, P366, DOI 10.1016/S0168-8278(99)80238-4
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   Gordon MA, 1999, J HEPATOL, V31, P242, DOI 10.1016/S0168-8278(99)80220-7
   GREGORY WL, 1993, Q J MED, V86, P393
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Jones DEJ, 1999, J HEPATOL, V30, P232, DOI 10.1016/S0168-8278(99)80067-1
   Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107
   Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606
   Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   MAEDA T, 1992, GASTROENTEROLOGY, V103, P1118, DOI 10.1016/0016-5085(92)90069-B
   MANNS MP, 1991, GASTROENTEROLOGY, V101, P1367, DOI 10.1016/0016-5085(91)90090-8
   MEHAL WZ, 1994, HEPATOLOGY, V20, P1213, DOI 10.1002/hep.1840200517
   MELLA JG, 1995, HEPATOLOGY, V21, P398, DOI 10.1002/hep.1840210221
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   ONISHI S, 1994, J HEPATOL, V21, P1053, DOI 10.1016/S0168-8278(05)80617-8
   Parikh-Patel A, 1999, CLIN IMMUNOL, V91, P206, DOI 10.1006/clim.1999.4690
   SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205
   SEKI T, 1993, HEPATOLOGY, V18, P73
   STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147
   Stone J, 2002, J HEPATOL, V36, P8, DOI 10.1016/S0168-8278(01)00237-9
   Tanaka A, 1999, J HEPATOL, V30, P826, DOI 10.1016/S0168-8278(99)80135-4
   UNDERHILL J, 1992, HEPATOLOGY, V16, P1404, DOI 10.1002/hep.1840160616
   UNDERHILL JA, 1995, HEPATOLOGY, V21, P959, DOI 10.1016/0270-9139(95)90240-6
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
NR 36
TC 41
Z9 43
U1 0
U2 4
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 0815-9319
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD SEP
PY 2003
VL 18
IS 9
BP 1061
EP 1066
DI 10.1046/j.1440-1746.2003.03091.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 711CL
UT WOS:000184721300010
PM 12911663
DA 2020-11-26
ER

PT J
AU Iwai, LK
   Yoshida, M
   Sidney, J
   Shikanai-Yasuda, MA
   Goldberg, AC
   Juliano, MA
   Hammer, J
   Juliano, L
   Sette, A
   Kalil, J
   Travassos, LR
   Cunha-Neto, E
AF Iwai, LK
   Yoshida, M
   Sidney, J
   Shikanai-Yasuda, MA
   Goldberg, AC
   Juliano, MA
   Hammer, J
   Juliano, L
   Sette, A
   Kalil, J
   Travassos, LR
   Cunha-Neto, E
TI In silico prediction of peptides binding to multiple HLA-DR molecules
   accurately identifies immunodominant epitopes from gp43 of
   Paracoccidioides brasiliensis frequently recognized in primary
   peripheral blood mononuclear cell responses from sensitized individuals
SO MOLECULAR MEDICINE
LA English
DT Article
ID CLINICAL FORMS; MOUTH-DISEASE; MYCOBACTERIUM-TUBERCULOSIS; 43-KILODALTON
   GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY; SYNTHETIC
   PEPTIDE; T-CELLS; ANTIGEN; VACCINE
AB One of the major drawbacks limiting the use of synthetic peptide vaccines in genetically distinct populations is the fact that different epitopes are recognized by T cells from individuals displaying distinct major histocompatibility complex molecules. Immunization of mice with peptide (181-195) from the immunodominant 43 kDa glycoprotein of Paracoccidioides brasiliensis (gp43), the causative agent of Paracoccidioidomycosis (PCM), conferred protection against infectious challenge by the fungus. To identify immunodominant and potentially protective human T-cell epitopes in gp43, we used the TEPITOPE algorithm to select peptide sequences that would most likely bind multiple HLA-DR molecules and tested their recognition by T cells from sensitized individuals. The 5 most promiscuous peptides were selected from the gp43 sequence and the actual promiscuity of HLA binding was assessed by direct binding assays to 9 prevalent HLA-DR molecules. Synthetic peptides were tested in proliferation assays with peripheral blood mononuclear cells (PBMC) from PCM patients after chemotherapy and healthy controls. PBMC from 14 of 19 patients recognized at least one of the promiscuous peptides, whereas none of the healthy controls recognized the gp43 promiscuous peptides. Peptide gp43(180-194) was recognized by 53% of patients, whereas the other promiscuous gp43 peptides were recognized by 32% to 47% of patients. The frequency of peptide binding and peptide recognition correlated with the promiscuity of HLA-DR binding, as determined by TEPITOPE analysis. In silico prediction of promiscuous epitopes led to the identification of naturally immunodominant epitopes recognized by PBMC from a significant proportion of a genetically heterogeneous patient population exposed to P. brasiliensis. The combination of several such epitopes may increase the frequency of positive responses and allow the immunization of genetically distinct populations.
C1 Univ Sao Paulo, Sch Med, Immunol Lab,Dept Med, Inst Heart,Incor,Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Invest & Immunol, Millenium Inst, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05403000 Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
   Hoffmann La Roche Inc, Dept Genomic & Informat Sci, Nutley, NJ 07110 USA.
   Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Discipline Cell Biol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab,Dept Med, Inst Heart,Incor,Div Clin Immunol & Allergy, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunho@usp.br
RI Yasuda, Maria Aparecida Shikanai/AAX-7693-2020; Cunha-Neto,
   Edecio/B-4157-2009; Travassos, Luiz/V-2467-2019; Iwai, Leo
   K/M-1734-2013; ShikanaiYasuda, Maria A/A-9000-2013; Shikanai-Yasuda,
   Maria A/C-4268-2012; Goldberg, Anna Carla/H-8594-2014; Juliano,
   Luiz/D-7204-2012; KALIL, JORGE/C-8029-2012; Travassos, Luiz
   R/J-3631-2012
OI Yasuda, Maria Aparecida Shikanai/0000-0003-3864-041X; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Iwai, Leo K/0000-0002-1571-7763;
   ShikanaiYasuda, Maria A/0000-0003-3864-041X; Goldberg, Anna
   Carla/0000-0003-2600-7940; Juliano, Luiz/0000-0002-5589-2822; KALIL,
   JORGE/0000-0001-8415-4274; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI095362, N01AI095362, N01AI095362, N01AI095362] Funding Source: NIH
   RePORTER; AHRQ HHSUnited States Department of Health & Human
   ServicesAgency for Healthcare Research & Quality [HHSN266200400006C]
   Funding Source: Medline; NIAID NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [N01AI95362,
   N01-AI-95362] Funding Source: Medline
CR Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   Atherton E, 1989, SOLID PHASE PEPTIDE
   Benard G, 1997, J INFECT DIS, V175, P1263, DOI 10.1086/593694
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   BIAGIONI L, 1984, T ROY SOC TROP MED H, V78, P617, DOI 10.1016/0035-9203(84)90220-7
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   Bignon J. D., 1997, GENETIC DIVERSITY HL, P584
   BRUMMER E, 1993, CLIN MICROBIOL REV, V6, P89, DOI 10.1128/CMR.6.2.89-117.1993
   Calich VL, 1994, PARACOCCIDIOIDOMYCOS, P151
   CAMARGO ZP, 1989, J MED VET MYCOL, V27, P407
   Campi G, 2003, CANCER RES, V63, P8481
   CASAL JI, 1995, J VIROL, V69, P7274, DOI 10.1128/JVI.69.11.7274-7277.1995
   Cochlovius B, 2000, J IMMUNOL, V165, P4731, DOI 10.4049/jimmunol.165.8.4731
   Consogno G, 2003, BLOOD, V101, P1038, DOI 10.1182/blood-2002-03-0933
   CREVAT D, 1983, ANN INST PASTEUR IMM, VC134, P31, DOI 10.1016/S0769-2625(83)80151-2
   Cunha-Neto E, 1999, BRAZ J MED BIOL RES, V32, P199, DOI 10.1590/S0100-879X1999000200008
   de Lalla C, 1999, J IMMUNOL, V163, P1725
   DECAMARGO ZP, 1988, J CLIN MICROBIOL, V26, P2147, DOI 10.1128/JCM.26.10.2147-2151.1988
   Del Negro GMB, 2000, J MED MICROBIOL, V49, P37, DOI 10.1099/0022-1317-49-1-37
   DIMARCHI R, 1986, SCIENCE, V232, P639, DOI 10.1126/science.3008333
   Dong XN, 2002, VACCINE, V21, P167, DOI 10.1016/S0264-410X(02)00466-8
   Ertl HCJ, 1996, J IMMUNOL, V156, P3579
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   GOLDBERG AC, 1997, UCLA TISSUE TYPING L
   Guilherme L, 2001, INFECT IMMUN, V69, P5345, DOI 10.1128/IAI.69.9.5345-5351.2001
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   HAMMER J, 1995, CURR OPIN IMMUNOL, V7, P263, DOI 10.1016/0952-7915(95)80013-1
   Hunziker IP, 2001, MOL IMMUNOL, V38, P475, DOI 10.1016/S0161-5890(01)00083-9
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   Kruger S, 2003, J IMMUNOTHER, V26, P212, DOI 10.1097/00002371-200305000-00005
   Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871
   MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   MOTA NGS, 1985, T ROY SOC TROP MED H, V79, P765, DOI 10.1016/0035-9203(85)90112-9
   MULLER GM, 1982, P NATL ACAD SCI-BIOL, V79, P569, DOI 10.1073/pnas.79.2.569
   Nargi F, 1999, VACCINE, V17, P2888, DOI 10.1016/S0264-410X(99)00127-9
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   PUCCIA R, 1986, INFECT IMMUN, V53, P199, DOI 10.1128/IAI.53.1.199-206.1986
   PUCCIA R, 1991, J CLIN MICROBIOL, V29, P1610, DOI 10.1128/JCM.29.8.1610-1615.1991
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   Restrepo A, 2001, MED MYCOL, V39, P233, DOI 10.1080/714031028
   Saraiva ECO, 1996, J MED VET MYCOL, V34, P155
   Schroers R, 2003, CLIN CANCER RES, V9, P3260
   Schroers R, 2002, CANCER RES, V62, P2600
   SHEN L, 2003, CANC IMMUNOL IMMUNOT, V18
   SHIKANAIYASUDA MA, 1996, OXFORD TXB MED, P814
   SIDNEY J, 1998, CURR PROTOCOLS IMMUN
   SINIGAGLIA F, 1991, METHOD ENZYMOL, V203, P370
   Smith DJ, 2003, INFECT IMMUN, V71, P1179, DOI 10.1128/IAI.71.3.1179-1184.2003
   Smith JW, 2003, J CLIN ONCOL, V21, P1562, DOI 10.1200/JCO.2003.09.020
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Souza AR, 2000, CLIN DIAGN LAB IMMUN, V7, P175, DOI 10.1128/CDLI.7.2.175-181.2000
   Stassar MJJG, 2001, IMMUNOBIOLOGY, V203, P743, DOI 10.1016/S0171-2985(01)80003-6
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Taboga O, 1997, J VIROL, V71, P2606, DOI 10.1128/JVI.71.4.2606-2614.1997
   TABORDA CP, 1993, J MED VET MYCOL, V31, P155
   Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998
   Travassos LR, 2004, MYCOTA, V12, P279
   Tsuji M, 2001, MOL IMMUNOL, V38, P433, DOI 10.1016/S0161-5890(01)00079-7
   Van Regenmortel MHV, 1998, DEV BIOL STAND, V92, P139
NR 66
TC 57
Z9 58
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD SEP-DEC
PY 2003
VL 9
IS 9-12
BP 209
EP 219
DI 10.1007/BF03402131
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 833JP
UT WOS:000222333900004
PM 15208742
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Nakao, LS
   Iwai, LK
   Kalil, J
   Augusto, O
AF Nakao, LS
   Iwai, LK
   Kalil, J
   Augusto, O
TI Radical production from free and peptide-bound methionine sulfoxide
   oxidation by peroxynitrite and hydrogen peroxide/iron(II)
SO FEBS LETTERS
LA English
DT Article
DE methionine sulfoxide; methionine sulfoxide reductase; protein-derived
   radical; electron paramagnetic resonance; oxidative stress; aging
ID SPIN-TRAPPED RADICALS; ONE-ELECTRON; ANTIOXIDANT DEFENSE;
   AQUEOUS-SOLUTIONS; FENTON SYSTEMS; REDUCTASE; PROTEINS; CLEAVAGE; ESR
AB Methionine sulfoxide is a post-translational protein modification that has been receiving increasing attention in the literature. Here we used electron paramagnetic resonance spin trapping techniques to show that free and peptide-bound methionine sulfoxide is oxidized by hydrogen peroxide/iron(II)-EDTA and peroxynitrite through the intermediacy of the hydroxyl radical to produce both (CH3)-C-. and (CH2CH2CH)-C-. radicals. The results indicate that methionine sulfoxide residues are important targets of reactive oxygen- and nitrogen-derived species in proteins. Since the produced protein-derived radicals can propagate oxidative damage, the results add a new antioxidant route for the action of the enzyme peptide methionine sulfoxide reductase. (C) 2003 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil.
   Pontificia Univ Catolica Parana, Ctr Ciencias Biol & Saude, Parana, PR, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Imunol, BR-0540300 Sao Paulo, Brazil.
RP Augusto, O (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26077, BR-05513970 Sao Paulo, Brazil.
EM oaugusto@iq.usp.br
RI KALIL, JORGE/C-8029-2012; Iwai, Leo K/M-1734-2013; Nakao, Lia
   S/M-1507-2018; Augusto, Ohara/D-3839-2012
OI KALIL, JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763;
   Nakao, Lia S/0000-0001-9647-6350; Augusto, Ohara/0000-0002-7220-4286
CR Augusto O, 1996, METHOD ENZYMOL, V269, P346
   AUGUSTO O, 1993, FREE RADICAL BIO MED, V15, P329, DOI 10.1016/0891-5849(93)90079-A
   Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4
   Butterfield DA, 2002, PEPTIDES, V23, P1299, DOI 10.1016/S0196-9781(02)00066-9
   CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889
   DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060
   Davies M. J., 1997, RADICAL MEDIATED PRO
   de Menezes SL, 2001, J BIOL CHEM, V276, P39879, DOI 10.1074/jbc.M104012200
   DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062
   Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p
   HILLER KO, 1981, J AM CHEM SOC, V103, P2734, DOI 10.1021/ja00400a042
   Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u
   Hong JY, 2001, FREE RADICAL BIO MED, V31, P1432, DOI 10.1016/S0891-5849(01)00722-5
   Jensen JL, 1997, J AM CHEM SOC, V119, P4749, DOI 10.1021/ja964031z
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   KOHNO M, 1991, B CHEM SOC JPN, V64, P1447, DOI 10.1246/bcsj.64.1447
   Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056
   MAKINO K, 1979, J PHYS CHEM-US, V83, P2520, DOI 10.1021/j100482a020
   Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071
   Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998
   Nakao LS, 1999, CHEM RES TOXICOL, V12, P1010, DOI 10.1021/tx990055i
   Ostdal H, 2002, FREE RADICAL BIO MED, V33, P201, DOI 10.1016/S0891-5849(02)00785-2
   Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819
   PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173
   Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   RUSTGI S, 1977, INT J RADIAT BIOL, V31, P415, DOI 10.1080/09553007714550521
   Santos CXC, 2000, ARCH BIOCHEM BIOPHYS, V377, P146, DOI 10.1006/abbi.2000.1751
   Schoneich C, 2002, ARCH BIOCHEM BIOPHYS, V397, P370, DOI 10.1006/abbi.2001.2621
   Schoneich C, 1996, J CHEM SOC PERK T 2, P915, DOI 10.1039/p29960000915
   VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G
   Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664
NR 32
TC 36
Z9 40
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD JUL 17
PY 2003
VL 547
IS 1-3
BP 87
EP 91
DI 10.1016/S0014-5793(03)00674-4
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 702XT
UT WOS:000184250600016
PM 12860391
OA Bronze
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer
   susceptibility to autoimmune hepatitis types 1 and 2 in Brazil
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID HLA; CTLA-4; DIAGNOSIS; CLASSIFICATION; HETEROGENEITY; EXPRESSION;
   DISEASES
AB OBJECTIVES: Susceptibility to autoimmune hepatitis (AIH) has been linked to different HLA-DR antigens in distinct populations. Recently, an A-G polymorphism in exon 1 of the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene was associated with predisposition to AIH type 1 (AIH-1) in white individuals in North America. This polymorphism has been associated with several other autoimmune diseases, presumably because of its effect in the expression of CTLA-4, an adhesion molecule that downregulates peripheral T cell responses. The aims of this study were to assess the frequency of CTLA-4 genotypes in Brazilian patients with AIH-1 and AIH type 2 (AIH-1), as well as to investigate the influence of these genotypes in disease expression.
   METHODS: Determination of CTLA-4 genotypes was carried out in 106 patients with AIH-1, 26 subjects with AIH-2, and 67 healthy control subjects by polymerase chain reaction (PCR)-based techniques.
   RESULTS: No difference in the distribution of CTLA-4 genotypes was observed in subjects with AIH-1 and AIH-2 as compared to healthy controls. Patients with AIH-1 and AIH-2 with the GG genotype exhibited lower gamma-globulin and ALT levels, respectively.
   CONCLUSIONS: Susceptibility to AIH-1 and AIH-2 in Brazilian patients is not influenced by exon 1 CTLA-4 gene polymorphisms at position 49. (C) 2003 by Am. Coll. of Gastroenterology.
C1 Portuguese Hosp Salvador, Salvador, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit,Lab Immunol,Heart Inst, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, Salvador, BA, Brazil.
RI Cancado, Eduardo/K-1861-2016; Goldberg, Anna Carla/H-8594-2014;
   BITTENCOURT, PAULO l/I-5817-2014; KALIL, JORGE/C-8029-2012
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; BITTENCOURT, PAULO l/0000-0003-0883-4870;
   KALIL, JORGE/0000-0001-8415-4274
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
   Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
   Czaja AJ, 2000, IMMUNOL REV, V174, P250, DOI 10.1034/j.1600-0528.2002.017401.x
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   Djilali-Saiah I, 2001, HUM IMMUNOL, V62, P1356, DOI 10.1016/S0198-8859(01)00344-5
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655
   Ligers A, 2001, GENES IMMUN, V2, P145, DOI 10.1038/sj.gene.6363752
   Manns MP, 2001, GASTROENTEROLOGY, V120, P1502, DOI 10.1053/gast.2001.24227
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
NR 30
TC 43
Z9 50
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 2003
VL 98
IS 7
BP 1616
EP 1620
DI 10.1016/S0002-9270(03)00307-1
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 702GP
UT WOS:000184216400027
PM 12873588
DA 2020-11-26
ER

PT J
AU Yamamoto, JH
   Boletti, DI
   Nakashima, Y
   Hirata, CE
   Olivalves, E
   Shinzato, MM
   Okay, TS
   Santo, RM
   Duarte, MIS
   Kalil, J
AF Yamamoto, JH
   Boletti, DI
   Nakashima, Y
   Hirata, CE
   Olivalves, E
   Shinzato, MM
   Okay, TS
   Santo, RM
   Duarte, MIS
   Kalil, J
TI Severe bilateral necrotising retinitis caused by Toxoplasma gondii in a
   patient with systemic lupus erythematosus and diabetes mellitus
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCULAR TOXOPLASMOSIS; RETINAL NECROSIS; CLASSIFICATION; RETINOPATHY;
   CRITERIA; THERAPY
C1 Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Rheumatol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Allergy & Immunopathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Sao Paulo, Brazil.
RP Yamamoto, JH (corresponding author), Av Dr Eneas Carvalho Aguiar 500 3 Andar, BR-05403000 Sao Paulo, Brazil.
RI Santo, Ruth/B-6154-2015; KALIL, JORGE/C-8029-2012; Okay,
   Thelma/Q-6353-2019; shinzato, marcia/M-4079-2016; Yamamoto, Joyce
   H/B-6192-2015; Okay, Thelma S/G-2616-2012
OI Santo, Ruth/0000-0002-0247-6315; KALIL, JORGE/0000-0001-8415-4274;
   shinzato, marcia/0000-0002-0199-8189; Yamamoto,
   Joyce/0000-0001-6869-2988; Okay, Thelma/0000-0002-5985-388X
CR Girard P, 1984, Bull Soc Ophtalmol Fr, V84, P751
   Held R, 1990, Fortschr Ophthalmol, V87, P206
   HOLLAND GN, 1989, INT OPHTHALMOL, V13, P399, DOI 10.1007/BF02306488
   Johnson MW, 1997, OPHTHALMOLOGY, V104, P48, DOI 10.1016/S0161-6420(97)30362-5
   KLINKHOFF AV, 1986, ARTHRITIS RHEUM-US, V29, P1152, DOI 10.1002/art.1780290914
   MOUTSCHEN MP, 1992, DIABETES METAB, V18, P187
   NICHOLSON DH, 1976, ARCH OPHTHALMOL-CHIC, V94, P248, DOI 10.1001/archopht.1976.03910030120009
   Rappaport KD, 2000, RETINA-J RET VIT DIS, V20, P545, DOI 10.1097/00006982-200005000-00019
   SABATES R, 1981, AM J OPHTHALMOL, V92, P497, DOI 10.1016/0002-9394(81)90642-5
   STAFFORDBRADY FJ, 1988, ARTHRITIS RHEUM, V31, P1105, DOI 10.1002/art.1780310904
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Topilow HW, 1995, OPHTHALMOLOGY, V102, P1737, DOI 10.1016/S0161-6420(95)30801-9
   Toyoda M, 1997, TRANSPLANTATION, V63, P957, DOI 10.1097/00007890-199704150-00009
   Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
NR 14
TC 7
Z9 7
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2003
VL 87
IS 5
BP 651
EP 652
DI 10.1136/bjo.87.5.651
PG 2
WC Ophthalmology
SC Ophthalmology
GA 671MT
UT WOS:000182469100039
PM 12714420
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Caldas, C
   Coelho, V
   Kalil, J
   Moro, AM
   Maranhao, AQ
   Brigido, MM
AF Caldas, C
   Coelho, V
   Kalil, J
   Moro, AM
   Maranhao, AQ
   Brigido, MM
TI Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a
   framework residue in binding to antigen
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE humanization; framework; CDR-grafting; CD18
ID COMPLEMENTARITY-DETERMINING REGIONS; SINGLE-CHAIN FV;
   MONOCLONAL-ANTIBODY; IDENTIFICATION; SEQUENCES; DATABASE; CONFORMATION;
   EXPRESSION; REDUCTION; PROGRAM
AB Humanization of monoclonal antibodies by complementary determinant region (CDR)-grafting has become a standard procedure to improve the clinical usage of animal antibodies. However, antibody humanization may result in loss of activity that has been attributed to structural constraints in the framework structure. In this paper, we report the complete humanization of the 6.7 anti-human CD18 monoclonal antibody in a scFv form. We used a germline-based approach to design a humanized VL gene fragment and expressed it together with a previously described humanized VH. The designed humanized VL has only 14 mutations compared to the closest human germline sequence. The resulting humanized scFv maintained the binding capacity and specificity to human CD 18 expressed on the cell surface of peripheral blood mononuclear cells (PBMC), and showed the same pattern of staining T-lymphocytes sub-populations, in comparison to the original monoclonal antibody. We observed an unexpected effect of a conserved mouse-human framework position (L37) that hinders the binding of the humanized scFv to antigen. This paper reveals a new framework residue that interferes with paratope and antigen binding and also reinforces the germline approach as a successful strategy to humanize antibodies. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart InCor, BR-05403000 Sao Paulo, Brazil.
   Inst Butantan, BR-05503900 Sao Paulo, Brazil.
RP Brigido, MM (corresponding author), Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil.
EM brigido@unb.br
RI Brigido, Marcelo/N-9277-2019; Moro, Ana Maria/A-5134-2012;
   Maranh\\xc3\\xa3o, Andrea Queiroz/S-8696-2019; Maranhao,
   Andrea/AAC-3560-2019; Brigido, Marcelo/H-2718-2019; COELHO,
   VERONICA/D-1433-2013; Brigido, Marcelo/A-1972-2015; KALIL,
   JORGE/C-8029-2012; Maranhao, Andrea Q/L-4474-2013
OI Brigido, Marcelo/0000-0002-7136-7059; Moro, Ana
   Maria/0000-0002-0650-7764; Maranhao, Andrea/0000-0002-1946-7191; KALIL,
   JORGE/0000-0001-8415-4274; Maranhao, Andrea Q/0000-0002-1946-7191;
   Coelho, Veronica/0000-0002-0989-2581
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6
   BRIGIDO MM, 1993, J IMMUNOL, V150, P469
   Caldas C, 2000, PROTEIN ENG, V13, P353, DOI 10.1093/protein/13.5.353
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   Cascalho M, 1996, SCIENCE, V272, P1649, DOI 10.1126/science.272.5268.1649
   CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532
   Chothia C, 1998, J MOL BIOL, V278, P457, DOI 10.1006/jmbi.1998.1653
   CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8
   Co MS, 1996, CANCER RES, V56, P1118
   CREIGHTON TE, 1984, PROTEINS STRUCTURES, P133
   DAVID V, 1991, CELL IMMUNOL, V136, P519, DOI 10.1016/0008-8749(91)90372-I
   de Andrade EV, 2000, J BIOCHEM-TOKYO, V128, P891, DOI 10.1093/oxfordjournals.jbchem.a022838
   De Pascalis R, 2002, J IMMUNOL, V169, P3076, DOI 10.4049/jimmunol.169.6.3076
   Dove A, 2000, NAT BIOTECHNOL, V18, P817, DOI 10.1038/78412
   FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M
   Gao F, 2002, CARDIOVASC RES, V53, P414, DOI 10.1016/S0008-6363(01)00488-6
   Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8
   HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302
   Higgins DG, 1996, METHOD ENZYMOL, V266, P383
   Holmes MA, 1997, J IMMUNOL, V158, P2192
   Holmes MA, 1998, J EXP MED, V187, P479, DOI 10.1084/jem.187.4.479
   HSIAO KC, 1994, PROTEIN ENG, V7, P815, DOI 10.1093/protein/7.6.815
   ISAACS JD, 1992, J IMMUNOL, V148, P3062
   Isobe M, 1997, CIRCULATION, V96, P2247
   Iwahashi M, 1999, MOL IMMUNOL, V36, P1079, DOI 10.1016/S0161-5890(99)00094-2
   Johnson G, 2000, NUCLEIC ACIDS RES, V28, P214, DOI 10.1093/nar/28.1.214
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Kabat E, 1991, SEQUENCES PROTEINS I
   KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773
   KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6499, DOI 10.1093/nar/13.18.6499
   LAUTNERRIESKE A, 1992, EUR J IMMUNOL, V22, P1023, DOI 10.1002/eji.1830220422
   Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629
   Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339
   NAKATANI T, 1994, PROTEIN ENG, V7, P435, DOI 10.1093/protein/7.3.435
   PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9
   Pearson W R, 2000, Methods Mol Biol, V132, P185
   Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256
   RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8
   Rosok MJ, 1996, J BIOL CHEM, V271, P22611, DOI 10.1074/jbc.271.37.22611
   Saldanha JW, 1999, MOL IMMUNOL, V36, P709, DOI 10.1016/S0161-5890(99)00087-5
   SINGER II, 1993, J IMMUNOL, V150, P2844
   STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B
   STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805
   Tamura M, 2000, J IMMUNOL, V164, P1432, DOI 10.4049/jimmunol.164.3.1432
   Tan P, 2002, J IMMUNOL, V169, P1119, DOI 10.4049/jimmunol.169.2.1119
   TEMPEST PR, 1995, INT J BIOL MACROMOL, V17, P37, DOI 10.1016/0141-8130(95)93516-Z
   TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266
   TOMLINSON IM, 1995, EMBO J, V14, P4628, DOI 10.1002/j.1460-2075.1995.tb00142.x
   TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0
   Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061
   TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959
   WINTER G, 1993, IMMUNOL TODAY, V14, P243, DOI 10.1016/0167-5699(93)90039-N
   WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211
   ZHU ZP, 1995, J IMMUNOL, V155, P1903
NR 57
TC 17
Z9 23
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAY
PY 2003
VL 39
IS 15
BP 941
EP 952
DI 10.1016/S0161-5890(03)00022-1
PG 12
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 671CN
UT WOS:000182447800004
PM 12695120
DA 2020-11-26
ER

PT J
AU Ferreira, RC
   Ianni, BM
   Abel, LCJ
   Buck, P
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Ferreira, RC
   Ianni, BM
   Abel, LCJ
   Buck, P
   Mady, C
   Kalil, J
   Cunha-Neto, E
TI Increased plasma levels of tumor necrosis factor-alpha in
   asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Chagas disease cardiomyopathy; tumor necrosis factor-alpha; Trypanosoma
   cruzi
ID CONGESTIVE-HEART-FAILURE; FAILING HUMAN HEART; TRYPANOSOMA-CRUZI;
   DILATED CARDIOMYOPATHY; IFN-GAMMA; MYOCARDITIS; CYTOKINES; RECEPTORS;
   LESIONS
AB We compared plasma tumor necrosis factor-alpha (TNF-alpha) levels among asymptomatic/"indeterminate" Chagas disease patients (ASY) and patients across the clinical spectrum of chronic Chagas disease cardiomyopathy (CCC). Idiopathic dilated cardiomyopathy (DCM) patients and normal controls (NC) were included as controls. ASY Chagas disease patients had significantly higher plasma TNF-alpha levels than NC TNF-alpha levels among severe CCC patients with significant left ventricular (LV) dysfunction were similar to those of DCM patients, showing average 2-fold higher levels than CCC patients without LV dysfunction and ASY patients, and 8-fold higher levels than NC. In Chagas disease, chronic TNF-alpha production prior to heart failure may play a role in CCC progression.
C1 Univ Sao Paulo, Lab Imunol, BR-05403000 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Div Cardiopatias Gerais, Inst Coracao, BR-05403000 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Div Imunol Clin & Alergia, Dept Clin Med, Fac Med, BR-05403000 Sao Paulo, SP, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Lab Imunol, Av Dr Eneas Carvalho Aguiar,44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM edecunha@usp.br
RI KALIL, JORGE/C-8029-2012; Ianni, Barbara Maria/C-7689-2012; Mady,
   Charles/C-8870-2012; Buck, Paula C/F-8781-2012; Cunha-Neto,
   Edecio/B-4157-2009; Abel, Lucia Cristina Jamli/P-8816-2014
OI KALIL, JORGE/0000-0001-8415-4274; Ianni, Barbara
   Maria/0000-0002-1588-5492; Mady, Charles/0000-0002-8838-199X; Buck,
   Paula C/0000-0002-1411-4485; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Abel, Lucia Cristina Jamli/0000-0003-4915-4265
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476
   Bestetti RB, 1997, INT J CARDIOL, V60, P187, DOI 10.1016/S0167-5273(97)00083-1
   Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044
   BRITTO C, 1995, PARASITOLOGY, V110, P241, DOI 10.1017/S0031182000080823
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2
   FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   KIRCHHOFF LV, 1989, ANN INTERN MED, V111, P773, DOI 10.7326/0003-4819-111-10-773
   Kubota T, 2000, J HEART LUNG TRANSPL, V19, P819, DOI 10.1016/S1053-2498(00)00173-X
   LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405
   Mady, 1999, AM J CARDIOL, V84, P1456
   MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098
   Mady C, 1999, AM J CARDIOL, V84, P354, DOI 10.1016/S0002-9149(99)00295-7
   Muller-Werdan U, 1998, EUR CYTOKINE NETW, V9, P689
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Shulman IA, 1997, TRANSFUSION, V37, P727, DOI 10.1046/j.1537-2995.1997.37797369449.x
   Sliwa K, 1998, LANCET, V351, P1091, DOI 10.1016/S0140-6736(97)09338-0
   TARLETON RL, 1988, CLIN EXP IMMUNOL, V73, P186
   TorreAmione G, 1996, CIRCULATION, V93, P704
   Ward L S, 1999, Rev Soc Bras Med Trop, V32, P285, DOI 10.1590/S0037-86821999000300010
NR 25
TC 80
Z9 85
U1 0
U2 8
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2003
VL 98
IS 3
BP 407
EP 411
DI 10.1590/S0074-02762003000300021
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 691QV
UT WOS:000183617700021
PM 12886425
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Iwai, LK
   Yoshida, M
   Shikanai-Yasuda, MA
   Juliano, MA
   Hammer, J
   Juliano, L
   Kalil, J
   Travassos, LR
   Cunha-Neto, E
AF Iwai, LK
   Yoshida, M
   Shikanai-Yasuda, MA
   Juliano, MA
   Hammer, J
   Juliano, L
   Kalil, J
   Travassos, LR
   Cunha-Neto, E
TI Identification of potential vaccine T cell epitopes based on computer
   selected sequences
SO BIOPOLYMERS
LA English
DT Meeting Abstract
CT 18th American Peptide Symposium
CY JUL 19-23, 2003
CL BOSTON, MASSACHUSETTS
C1 Univ Sao Paulo, Sch Med, Heart Inst Incor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Infect Paras Dis, BR-05508 Sao Paulo, Brazil.
   UNIFESP, Dept Biophys, Sao Paulo, Brazil.
   UNIFESP, Dept Microb Immunol Parasitol, Sao Paulo, Brazil.
   Hoffmann La Roche Inc, Dept Gen Info Sci, Nutley, NJ 07110 USA.
RI Iwai, Leo K/M-1734-2013; Shikanai-Yasuda, Maria A/C-4268-2012;
   Cunha-Neto, Edecio/B-4157-2009; Juliano, Luiz/D-7204-2012; Travassos,
   Luiz/V-2467-2019; Yasuda, Maria Aparecida Shikanai/AAX-7693-2020;
   ShikanaiYasuda, Maria A/A-9000-2013; KALIL, JORGE/C-8029-2012;
   Travassos, Luiz R/J-3631-2012
OI Iwai, Leo K/0000-0002-1571-7763; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Juliano, Luiz/0000-0002-5589-2822; Yasuda, Maria Aparecida
   Shikanai/0000-0003-3864-041X; ShikanaiYasuda, Maria
   A/0000-0003-3864-041X; KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 2003
VL 71
IS 3
MA P038
BP 313
EP 313
PG 1
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 696GG
UT WOS:000183878800163
DA 2020-11-26
ER

PT J
AU Nakao, L
   Iway, L
   Kalil, J
   Augusto, O
AF Nakao, L
   Iway, L
   Kalil, J
   Augusto, O
TI Radical production from free and peptide-bound methionine sulfoxide
   oxidation by peroxynitrite and hydrogen peroxide-iron (II)
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicne
CY NOV 20-24, 2003
CL SEATTLE, WASHINGTON
SP Soc Free Rad Biol & Med
C1 Pontificia Univ Catolica Parana, Ctr Ciencias Biol & Saude, Curitiba, Parana, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Imunol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Quim, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Nakao, Lia S/M-1507-2018
OI KALIL, JORGE/0000-0001-8415-4274; Nakao, Lia S/0000-0001-9647-6350
NR 0
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PY 2003
VL 35
SU 1
MA 298
BP S96
EP S96
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 744XV
UT WOS:000186658900319
DA 2020-11-26
ER

PT J
AU da Silva, MER
   Porta, G
   Goldberg, AC
   Bittencourt, PL
   Fukui, RT
   Correia, MRS
   Miura, IK
   Pugliese, RS
   Baggio, VL
   Cancado, ELR
   Kalil, J
   Santos, RF
   Rochal, DM
   Wajchenberg, BL
   Ursich, MJM
   Rosenbloom, AL
AF da Silva, MER
   Porta, G
   Goldberg, AC
   Bittencourt, PL
   Fukui, RT
   Correia, MRS
   Miura, IK
   Pugliese, RS
   Baggio, VL
   Cancado, ELR
   Kalil, J
   Santos, RF
   Rochal, DM
   Wajchenberg, BL
   Ursich, MJM
   Rosenbloom, AL
TI Diabetes mellitus-related autoantibodies in childhood autoimmune
   hepatitis (vol 15, pg 831, 2002)
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Correction
RI BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna Carla/H-8594-2014;
   Silva, Maria E R/F-1081-2012
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940; 
CR da Silva MER, 2002, J PEDIATR ENDOCR MET, V15, P831
NR 1
TC 1
Z9 1
U1 0
U2 1
PU FREUND PUBLISHING HOUSE LTD
PI LONDON
PA STE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON W1R 5FA, ENGLAND
SN 0334-018X
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD NOV-DEC
PY 2002
VL 15
IS 9
BP 1574
EP 1574
PG 1
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 625NW
UT WOS:000179823400019
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Carrilho, FJ
   Porta, G
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Carrilho, FJ
   Porta, G
   Kalil, J
   Goldberg, AC
TI Susceptibility to primary sclerosing cholangitis in Brazil is associated
   with HLA-DRB1*13 but not with tumour necrosis factor alpha-308 promoter
   polymorphism
SO GUT
LA English
DT Letter
ID PRIMERS PCR-SSP; AUTOIMMUNE HEPATITIS; DISEASE
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Portuguese Hosp, Salvador, BA, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, Salvador, BA, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; KALIL,
   JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Cancado,
   Eduardo/K-1861-2016
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; Goldberg, Anna Carla/0000-0003-2600-7940;
   Cancado, Eduardo/0000-0002-9309-1524
CR Bernal W, 1999, J HEPATOL, V30, P237, DOI 10.1016/S0168-8278(99)80068-3
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bittencourt PL, 2001, J HEPATOL, V35, P24, DOI 10.1016/S0168-8278(01)00072-1
   BUNCE M, 1995, TISSUE ANTIGENS, V45, P81, DOI 10.1111/j.1399-0039.1995.tb02422.x
   CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870
   Czaja AJ, 2001, DIGEST DIS SCI, V46, P140, DOI 10.1023/A:1005670111068
   Donaldson PT, 1998, HEPATOLOGY, V28, p392A
   FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217
   MEHAL WZ, 1994, GASTROENTEROLOGY, V106, P160, DOI 10.1016/S0016-5085(94)95085-7
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1995, GASTROENTEROLOGY, V108, P937
   Spurkland A, 1999, TISSUE ANTIGENS, V53, P459, DOI 10.1034/j.1399-0039.1999.530502.x
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
NR 13
TC 13
Z9 14
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD OCT
PY 2002
VL 51
IS 4
BP 609
EP 610
DI 10.1136/gut.51.4.609
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 597WK
UT WOS:000178243600031
PM 12235090
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of major histocompatibility complex antigens and CTLA-4 alleles
   in patients with primary sclerosing chotangitis.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases
   (AASLD)
CY NOV 01-05, 2002
CL BOSTON, MASSACHUSETTS
SP Amer Assoc Study Liver Dis
C1 Portuguese Hosp Salvador, Salvador, BA, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; BITTENCOURT,
   PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; BITTENCOURT, PAULO l/0000-0003-0883-4870;
   Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2002
VL 36
IS 4
SU S
MA 1325
BP 494A
EP 494A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 598XK
UT WOS:000178301701306
DA 2020-11-26
ER

PT J
AU Machado, DJB
   Paula, FJ
   Monteiro, FAS
   Rodrigues, H
   Viggiani, CS
   Panajotopoulos, N
   Kalil, J
   Ianhez, LE
AF Machado, DJB
   Paula, FJ
   Monteiro, FAS
   Rodrigues, H
   Viggiani, CS
   Panajotopoulos, N
   Kalil, J
   Ianhez, LE
TI Anti-CD20 (rituximab) in highly sensitized patients: An attempt to
   reduce panel reactive antibody.
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Meeting Abstract
C1 USP, Hosp Clin, Renal Transplant Unit, BR-09500900 Sao Paulo, Brazil.
   Inst Heart, Lab Imunol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD SEP
PY 2002
VL 13
SU S
BP 560A
EP 560A
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 589KL
UT WOS:000177757502748
DA 2020-11-26
ER

PT J
AU Graudenz, GS
   Kalil, J
   Saldiva, PH
   Gambale, W
   Latorre, MDDO
   Morato-Castro, FF
AF Graudenz, GS
   Kalil, J
   Saldiva, PH
   Gambale, W
   Latorre, MDDO
   Morato-Castro, FF
TI Upper respiratory symptoms associated with aging of the ventilation
   system in artificially ventilated offices in Sao Paulo, Brazil
SO CHEST
LA English
DT Article
DE air conditioning; air pollution; indoor; environment exposure;
   occupational health
ID SICK-BUILDING SYNDROME; DAY-CARE-CENTERS; DOMESTIC ALLERGENS; INDOOR
   ALLERGENS; VARYING LEVELS; AIR; WORKERS; EXPOSURE; ASTHMA; ENVIRONMENT
AB Background: The increase of work-related respiratory complaints in artificially ventilated buildings has multiple causes, and the role of allergen exposure and symptoms is still controversial. Study objectives: To analyze the risk factors and the association of work-related symptoms with allergen exposure and different conditions of the same air conditioning system in SA Paulo, Brazil.
   Design: Workers were classified according to characteristics of the air conditioning system: the first group (group 1) with ventilation machinery, and ducts with > 20 years of use, the second group (group 2) with ventilation machinery with > 20 years of use and ventilation ducts with < 2 years of use, and the third group (group 3) with ventilation machinery and ducts with < 2 years of use. Logistic regression was performed to check the associations between air conditioning groups, allergen exposure (fungi, mites, animal dander, and cockroach), and symptoms.
   Results: There was a higher prevalence of building-related worsening of respiratory symptoms (p = 0.004; odds ratio [OR], 8.53) and symptoms of rhinoconjunctivitis (p = 0.01; OR, 8.49) in group 1. There was a lower relative humidity (p = 0.05) and nonsignificant lower temperature in group 1, when compared to the other groups. he viable mold spores totals were higher outdoors than in the indoor samples (n = 45, p = 0.017). There were higher levels of Der p 1 in group 2 (p = 0.032). All allergen levels were considered low.
   Conclusion: There was a strong association of building-related upper-airway symptoms with places having ventilation systems with > 20 years of use.
C1 Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Graudenz, GS (corresponding author), Rua Heitor Penteado 477, BR-05437000 Sao Paulo, Brazil.
EM gustavog@usp.br
RI KALIL, JORGE/C-8029-2012; Saldiva, Paulo HN/D-7385-2012; Latorre, Maria
   RDO/J-5780-2014
OI KALIL, JORGE/0000-0001-8415-4274; Saldiva, Paulo HN/0000-0003-2005-8253;
   Latorre, Maria RDO/0000-0002-5189-3457
CR Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7
   ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958
   APTER A, 1994, J ALLERGY CLIN IMMUN, V94, P277, DOI 10.1016/0091-6749(94)90087-6
   ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483
   Bjornsson E, 1998, INT J TUBERC LUNG D, V2, P1023
   Boquete M, 2000, J INVEST ALLERG CLIN, V10, P229
   Bourbeau J, 1996, OCCUP ENVIRON MED, V53, P204, DOI 10.1136/oem.53.3.204
   BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013
   BUTTNER MP, 1993, APPL ENVIRON MICROB, V59, P1694
   BUTTNER MP, 1993, APPL ENVIRON MICROB, V59, P219, DOI 10.1128/AEM.59.1.219-226.1993
   Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579, DOI 10.1136/oem.55.9.579
   Costa MDB, 2000, ARCH ENVIRON HEALTH, V55, P279, DOI 10.1080/00039890009603419
   ESTEVES AR, 1999, BRAZ PEDIAT NEWS, V1, P1
   ESTEVES PC, 1999, REV BRAS ALERG IMUNO, V22, P106
   FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1
   GAMBALE W, 1993, J INVEST ALLERG CLIN, V3, P45
   GAMBALE W, 1977, REV MICROBIOL, V8, P74
   INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5
   JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6
   Kildeso J, 1999, SCAND J WORK ENV HEA, V25, P361, DOI 10.5271/sjweh.446
   LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012
   Leung R, 1997, CLIN EXP ALLERGY, V27, P856
   Li CS, 1997, ARCH ENVIRON HEALTH, V52, P68, DOI 10.1080/00039899709603803
   Li CS, 1997, ARCH ENVIRON HEALTH, V52, P200, DOI 10.1080/00039899709602887
   LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193
   MENDES E, 1989, ALERGIA NO BRASIL, P67
   Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360, DOI 10.1080/00039899709602212
   Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629
   Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397
   Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5
   MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201
   NACLERIO RM, 1995, J APPL PHYSIOL, V79, P467
   Oliver LC, 1998, PUBLIC HEALTH REP, V113, P398
   Ooi PL, 1996, LANCET, V347, P841, DOI 10.1016/S0140-6736(96)90927-7
   Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9
   Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6
   PlattsMills TAE, 1997, CIBA F SYMP, V206, P173
   POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D
   RAW GJ, 1993, INDOOR AIR, V3, P237
   REINIKAINEN LM, 1991, ENVIRON INT, V17, P243, DOI 10.1016/0160-4120(91)90009-F
   Rouadi P, 1999, J APPL PHYSIOL, V87, P400
   SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286, DOI 10.5271/sjweh.1851
   SPAUL WA, 1994, J ALLERGY CLIN IMMUN, V94, P385
   TAMBLYN RM, 1992, J CLIN EPIDEMIOL, V45, P603, DOI 10.1016/0895-4356(92)90132-7
   TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339
   TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113
   WALLACE L, 1993, RISK ANAL, V13, P135, DOI 10.1111/j.1539-6924.1993.tb01059.x
   WYON DP, 1992, ENVIRON TECHNOL, V13, P313, DOI 10.1080/09593339209385159
NR 49
TC 20
Z9 20
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD AUG
PY 2002
VL 122
IS 2
BP 729
EP 735
DI 10.1378/chest.122.2.729
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 584CJ
UT WOS:000177449400057
PM 12171858
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Drigo, S
   Ferreira, R
   Fae, K
   Abel, L
   Ianni, B
   Buck, P
   MAdy, C
   Kalil, J
   Goldberg, AC
AF Cunha-Neto, E
   Drigo, S
   Ferreira, R
   Fae, K
   Abel, L
   Ianni, B
   Buck, P
   MAdy, C
   Kalil, J
   Goldberg, AC
TI The -308 TNF2 allele is associated to shorter survival among severe
   chronic Chagas' disease cardiomyopathy patients.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Inst Heart, Div Clin Cardiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Buck, Paula C/F-8781-2012; KALIL,
   JORGE/C-8029-2012; Ianni, Barbara Maria/C-7689-2012; Goldberg, Anna
   Carla/H-8594-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Buck, Paula
   C/0000-0002-1411-4485; KALIL, JORGE/0000-0001-8415-4274; Ianni, Barbara
   Maria/0000-0002-1588-5492; Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 430
BP S141
EP S141
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600429
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Fonseca, S
   Guilherme, L
   Coelho, V
   Bacal, F
   Monteiro, S
   Reis, M
   Benvenuti, L
   Ianni, B
   Mady, C
   Bocchi, E
   Kalil, J
AF Cunha-Neto, E
   Fonseca, S
   Guilherme, L
   Coelho, V
   Bacal, F
   Monteiro, S
   Reis, M
   Benvenuti, L
   Ianni, B
   Mady, C
   Bocchi, E
   Kalil, J
TI Locally produced IL-15 may underlie the predominance of CD8+IL2Ralpha-T
   cells at heart lesions of human Chagas' disease cardiomyopathy.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Heart Inst, InCor,Clin Div, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Heart Inst, InCor,Pathol Unit, BR-05508 Sao Paulo, Brazil.
RI COELHO, VERONICA/D-1433-2013; Benvenuti, Luiz/C-6614-2014; Guglielmi,
   Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Bacal,
   Fernando/H-7952-2012; Reis, Marcia/P-5850-2016; Cunha-Neto,
   Edecio/B-4157-2009; Ianni, Barbara Maria/C-7689-2012
OI KALIL, JORGE/0000-0001-8415-4274; Reis, Marcia/0000-0002-1020-757X;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Ianni, Barbara
   Maria/0000-0002-1588-5492
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 122
BP S39
EP S40
PN 2
PG 2
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600123
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Fonseca, S
   Clave, E
   Teisserrenc, T
   Guilherme, L
   Ianni, B
   Mady, C
   Goldberg, AC
   Coelho, V
   Umezawa, E
   Toubert, A
   Kalil, J
AF Cunha-Neto, E
   Fonseca, S
   Clave, E
   Teisserrenc, T
   Guilherme, L
   Ianni, B
   Mady, C
   Goldberg, AC
   Coelho, V
   Umezawa, E
   Toubert, A
   Kalil, J
TI Heart-infiltrating CD8+ T cells from Chagas' cardiomyopathy patients
   recognize epitopes from Trypanosoma cruzi proteins cruzipain and FL-160.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Heart Inst, InCor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
   Hop St Louis, F-75475 Paris, France.
   Univ Sao Paulo, Sch Med, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor,Div Clin Cardiol, BR-05508 Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Clave, Emmanuel/ABD-8112-2020; Clave,
   Emmanuel/ABD-8127-2020; Guglielmi, Luiza G/E-7676-2013; KALIL,
   JORGE/C-8029-2012; Ianni, Barbara Maria/C-7689-2012; Goldberg, Anna
   Carla/H-8594-2014; COELHO, VERONICA/D-1433-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Clave,
   Emmanuel/0000-0001-8217-5039; KALIL, JORGE/0000-0001-8415-4274; Ianni,
   Barbara Maria/0000-0002-1588-5492; Goldberg, Anna
   Carla/0000-0003-2600-7940; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 123
BP S40
EP S40
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600124
DA 2020-11-26
ER

PT J
AU Guerra, CV
   Benitez, JMC
   Kokron, CM
   Rizzo, LV
   Kalil, J
   Barros, MT
AF Guerra, CV
   Benitez, JMC
   Kokron, CM
   Rizzo, LV
   Kalil, J
   Barros, MT
TI Common variable immunodeficiency: Clinical characteristics of 51
   patients.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009; Kokron,
   Cristina M/D-3140-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 374
BP S123
EP S123
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600373
DA 2020-11-26
ER

PT J
AU Kalil, J
   Fae, K
   da Silva, DD
   Oshiro, SE
   Tanaka, AC
   Douay, C
   Toubert, A
   Guilherme, L
AF Kalil, J
   Fae, K
   da Silva, DD
   Oshiro, SE
   Tanaka, AC
   Douay, C
   Toubert, A
   Guilherme, L
TI Rheumatic heart disease: T cell plays a major role in the molecular
   mimicry.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
   INSERM, U396, Paris, France.
   Univ Paris, Inst Hematol, F-75252 Paris, France.
   Hop St Louis, Paris, France.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 218
BP S72
EP S72
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600219
DA 2020-11-26
ER

PT J
AU Spadafora-Ferreira, M
   Caldas, C
   Fonseca, JA
   Kalil, J
   Coelho, V
AF Spadafora-Ferreira, M
   Caldas, C
   Fonseca, JA
   Kalil, J
   Coelho, V
TI Indirect allorecognition may activate regulatory cells in renal
   transplantation.
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Renal Transplantat Unit, BR-05508 Sao Paulo, Brazil.
RI Spadafora-Ferreira, Monica/G-2635-2012; KALIL, JORGE/C-8029-2012;
   COELHO, VERONICA/D-1433-2013
OI Spadafora-Ferreira, Monica/0000-0001-8823-9929; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2002
VL 103
IS 3
SU S
MA 163
BP S54
EP S54
PN 2
PG 1
WC Immunology
SC Immunology
GA 566QK
UT WOS:000176439600164
DA 2020-11-26
ER

PT J
AU da Silva, MER
   Porta, G
   Golberg, AC
   Bittencourt, PL
   Fukui, RT
   Correia, MRS
   Miura, IK
   Pugliese, RS
   Baggio, VL
   Cancado, ELR
   Kalil, J
   Santos, RF
   Rochal, DM
   Wajchenberg, BL
   Ursich, MJM
   Rosenbloom, AL
AF da Silva, MER
   Porta, G
   Golberg, AC
   Bittencourt, PL
   Fukui, RT
   Correia, MRS
   Miura, IK
   Pugliese, RS
   Baggio, VL
   Cancado, ELR
   Kalil, J
   Santos, RF
   Rochal, DM
   Wajchenberg, BL
   Ursich, MJM
   Rosenbloom, AL
TI Diabetes mellitus-related autoantibodies in childhood autoimmune
   hepatitis
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE diabetes mellitus-related autoantibodies; autoimmune hepatitis;
   anti-islet cell antibodies (ICA); insulin autoantibodies (IAA);
   anti-glutamic acid decarboxylase (GAD65) antibodies; azathioprine;
   prednisone; immunosuppression; Graves' disease; HLA antigens
ID ISLET-CELL ANTIBODIES; CHRONIC ACTIVE HEPATITIS; RAT PANCREAS; PCR-SSP;
   TYPE-1; SUSCEPTIBILITY; RELATIVES; RISK; PROGRESSION; CRITERIA
AB Objective: To determine the frequency and significance of diabetes mellitus (DM)-related autoantibodies in children with autoimmune hepatitis (AIH).
   Research design and methods: Anti-islet cell antibodies (ICA), insulin autoantibodies (IAA), and anti-glutamic acid decarboxylase (GAD65) antibodies were assessed in 28 children (25 female) with AIH before and after 3-9 years of therapy with azathioprine and prednisone.
   Results: There was biochemical and clinical remission of AIH activity in 76% of the children after 1 year of immunosuppressive therapy. Positive ICA and IAA were found in 60.7% and 18.5% of the patients, decreasing to 38.5% and 12% after 3-9 years of therapy. Anti-GAD autoantibodies were present in only one patient who had Graves' disease, high ICA titer, and developed type 1 DM after 3 years. After 3-9 years of follow up, all had normal fasting glycemia, glycosylated hemoglobin (HbA(1c)), and, with a single exception, normal responses to oral glucose tolerance testing. No increase in the frequencies of HLA antigens was observed in ICA- and IAA-positive patients compared to antibody-negative patients or a control population. The majority of the patients with HLA-DRB1*03 or DRB1*04, however, were positive for ICA (7/10), and three of them had IAA. The frequency of high risk HLA DQB1*0302 or DQB1*02 alleles was low and similar to control frequencies, indicating low-risk for DM despite the presence of DM-related autoimmunity markers.
   Conclusions: AIII in childhood is associated with high frequency of ICA and IAA, with less than expected rates of progression to DM. Immunosuppression reduced ICA and IAA frequency and titers.
C1 Sao Paulo Med Sch, Lab Med Invest, Sao Paulo, Brazil.
   Sao Paulo Med Sch, Childrens Inst, Sao Paulo, Brazil.
   Sao Paulo Med Sch, Lab Transplantat Immunol, Sao Paulo, Brazil.
   Univ Florida, Coll Med, Dept Pediat, Gainesville, FL USA.
RP da Silva, MER (corresponding author), Rua Joao Moura 627 Conj 72, BR-05412911 Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Silva,
   Maria E R/F-1081-2012; KALIL, JORGE/C-8029-2012
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; KALIL, JORGE/0000-0001-8415-4274
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   BETTERLE C, 1994, DIABETOLOGIA, V37, P95
   Bingley PJ, 1996, DIABETES, V45, P1720, DOI 10.2337/diabetes.45.12.1720
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   BLECHER M, 1984, CLIN CHEM, V30, P1137
   BOSI E, 1991, DIABETES, V40, P977, DOI 10.2337/diabetes.40.8.977
   BROSNAN P, 1996, PEDIAT ENDOCRINOLOGY, P509
   Bylund DJ, 1997, CLIN LAB MED, V17, P483
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Christie MR, 1997, DIABETES CARE, V20, P965, DOI 10.2337/diacare.20.6.965
   COLMAN PG, 1988, DIABETES CARE, V11, P367, DOI 10.2337/diacare.11.4.367
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   Czaja AJ, 1997, HEPATOLOGY, V26, P567, DOI 10.1002/hep.510260306
   DIB SA, 1987, DIABETES, V36, P982, DOI 10.2337/diabetes.36.8.982
   DONALDSON PT, 1998, AUTOIMMUNE LIVER DIS, P141
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   Greenbaum CJ, 1994, DIABETES ANN, P21
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   LETIEXHE MR, 1993, J CLIN ENDOCR METAB, V77, P1263, DOI 10.1210/jc.77.5.1263
   LUHDER F, 1994, AUTOIMMUNITY, V19, P71, DOI 10.3109/08916939409009534
   MACKAY IR, 1993, HEPATOLOGY, V18, P1006, DOI 10.1002/hep.1840180436
   Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
   MARCOS Y, 1994, HEPATOLOGY, V19, P1371, DOI 10.1016/0270-9139(94)90230-5
   MCCULLOCH DK, 1990, DIABETES, V39, P549, DOI 10.2337/diabetes.39.5.549
   MICHELE TM, 1994, POSTGRAD MED J, V70, P128, DOI 10.1136/pgmj.70.820.128
   MIELIVERGANI G, 1998, AUTOIMMUNE LIVER DIS, P425
   Muratori L, 1998, GUT, V42, P721, DOI 10.1136/gut.42.5.721
   Nishioka M., 1998, AUTOIMMUNE LIVER DIS, P413
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   Pupo AA, 1970, REV ASSOC MED BRAS, V16, P153
   SCHATZ D, 1994, J CLIN INVEST, V93, P2403, DOI 10.1172/JCI117247
   SHMUELI E, 1993, HEPATOLOGY, V18, P86, DOI 10.1002/hep.1840180115
   Slover RH, 1997, ENDOCR REV, V18, P241, DOI 10.1210/er.18.2.241
   STECHEMESSER E, 1993, HEPATOLOGY, V18, P1
   Strettell MDJ, 1997, GASTROENTEROLOGY, V112, P2028, DOI 10.1053/gast.1997.v112.pm9178696
   Strettell MDJ, 1997, HEPATOLOGY, V26, P1023, DOI 10.1053/jhep.1997.v26.pm0009328330
   Tuomi T, 1996, J CLIN ENDOCR METAB, V81, P1488, DOI 10.1210/jc.81.4.1488
   VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286
   WAGNER R, 1994, DIABETOLOGIA, V37, P365, DOI 10.1007/s001250050118
NR 46
TC 7
Z9 8
U1 0
U2 1
PU FREUND PUBLISHING HOUSE LTD
PI LONDON
PA STE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON W1R 5FA, ENGLAND
SN 0334-018X
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD JUN
PY 2002
VL 15
IS 6
BP 831
EP 840
PG 10
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 568CY
UT WOS:000176525900010
PM 12099394
DA 2020-11-26
ER

PT J
AU Banic, DM
   Goldberg, AC
   Pratt-Riccio, LR
   De Oliveira-Ferreira, J
   Santos, F
   Gras-Masse, H
   Camus, D
   Kalil, J
   Daniel-Ribeiro, CT
AF Banic, DM
   Goldberg, AC
   Pratt-Riccio, LR
   De Oliveira-Ferreira, J
   Santos, F
   Gras-Masse, H
   Camus, D
   Kalil, J
   Daniel-Ribeiro, CT
TI Human leukocyte antigen class II control of the immune response to
   p126-derived amino terminal peptide from Plasmodium falciparum
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ERYTHROCYTE SURFACE-ANTIGEN; PRIMERS PCR-SSP; CIRCUMSPOROZOITE PROTEIN;
   ANTIBODY-RESPONSE; GENETIC-CONTROL; AOTUS MONKEYS; P126 ANTIGEN;
   MALARIA; HLA; VACCINE
AB We investigated the relationships between class II human leukocyte antigens (HLA) and the antibody response to Plasmodium falciparum p126 protein and to its amino-terminal portion (Nt47) in 2 malaria-endemic villages in Brazil, Colina and Ribeirinha. All people from the endemic areas had anti-p126 antibodies, and the frequencies of anti-Nt47 antibodies were similar in both communities (66% for Colina and 75% for Ribeirinha). Typing of HLA showed that Colina and Ribeirinha groups had no significant differences in HLA antigen frequencies. However, in both groups, significant associations between positive response to anti-Nt47 and presence of HLA-DR4, as well as between absence of response and presence of HLA-DR15, were observed. The predominance of positive responses to Nt47 among HLA-DR4 people was independent of the presence of any particular allele. There was no evidence for association between HLA-DQB1 alleles and antibody response to Nt47. Thus, naturally exposed people with different HLA class II antigens seem to respond differently to Nt47, indicating that the choice of relevant peptide sequences may have important consequences for subunit vaccine development.
C1 Fiocruz MS, Dept Imunol, IOC, Lab Pesquisas Malaria, BR-21045900 Rio De Janeiro, Brazil.
   Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol, Sao Paulo, Brazil.
   Minist Hlth, Fdn Nacl Saude, Rondonia, Brazil.
   Univ Lille, CNRS, Inst Pasteur, Inst Biol, Lille, France.
   Fac Med Lille, Serv Parasitol Mycol, F-59045 Lille, France.
   INSERM, Villeneuve Dascq, France.
RP Banic, DM (corresponding author), Fiocruz MS, Dept Imunol, IOC, Lab Pesquisas Malaria, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI Daniel-Ribeiro, Claudio Tadeu/G-2216-2015; Goldberg, Anna
   Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR ASSAADKHALIL SH, 1993, ANN BIOL CLIN-PARIS, V51, P619
   BANIC DM, 1992, MEM I OSWALDO CRUZ, V87, P159, DOI 10.1590/S0074-02761992000700025
   BANIC DM, 1994, CLIN EXP IMMUNOL, V95, P472, DOI 10.1111/j.1365-2249.1994.tb07021.x
   Banic DM, 1998, AM J TROP MED HYG, V58, P768, DOI 10.4269/ajtmh.1998.58.768
   BANYAL HS, 1985, AM J TROP MED HYG, V34, P1055, DOI 10.4269/ajtmh.1985.34.1055
   BAUR MP, 1980, HISTOCOMPATIBILITY T, P955
   BECK HP, 1995, INFECT IMMUN, V63, P596, DOI 10.1128/IAI.63.2.596-600.1995
   BHATIA A, 1987, AM J TROP MED HYG, V36, P15, DOI 10.4269/ajtmh.1987.36.15
   Bignon J. D., 1997, GENETIC DIVERSITY HL, P584
   Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   CalvoCalle JM, 1997, J IMMUNOL, V159, P1362
   Camargo LMA, 1996, AM J TROP MED HYG, V55, P32, DOI 10.4269/ajtmh.1996.55.32
   Chiarella JM, 1998, BRAZ J MED BIOL RES, V31, P665, DOI 10.1590/S0100-879X1998000500010
   DEBRABANT A, 1989, MOL BIOCHEM PARASIT, V33, P151, DOI 10.1016/0166-6851(89)90029-7
   DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H
   DELGIUDICE G, 1986, J IMMUNOL, V137, P2952
   DELPLACE P, 1988, BIOL CELL, V64, P215, DOI 10.1016/0248-4900(88)90080-9
   DELPLACE P, 1985, MOL BIOCHEM PARASIT, V17, P239, DOI 10.1016/0166-6851(85)90021-0
   ENDERS B, 1992, VACCINE, V10, P920, DOI 10.1016/0264-410X(92)90326-F
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6
   GILARDEAUTRUFFI.M, 1996, PEPTIDE RES, V2, P61
   Goldfeld AE, 1998, JAMA-J AM MED ASSOC, V279, P226, DOI 10.1001/jama.279.3.226
   GOOD MF, 1986, J EXP MED, V164, P655, DOI 10.1084/jem.164.2.655
   HILL AVS, 1994, PHILOS T R SOC B, V346, P379, DOI 10.1098/rstb.1994.0155
   INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993
   INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991
   JEPSON AP, 1995, J INFECT DIS, V172, P316, DOI 10.1093/infdis/172.1.316
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEW AM, 1989, J IMMUNOL, V142, P4012
   LI CC, 1961, HUMAN GENETICS PRINC
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   MIGOT F, 1995, AM J TROP MED HYG, V52, P252, DOI 10.4269/ajtmh.1995.52.252
   MOTTRAM JC, 1989, NATURE, V342, P132, DOI 10.1038/342132c0
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Pang XL, 1999, INFECT IMMUN, V67, P1821
   PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x
   PAVIA CS, 1983, AM J TROP MED HYG, V32, P675, DOI 10.4269/ajtmh.1983.32.675
   PERKINS ME, 1994, INFECT IMMUN, V62, P1207, DOI 10.1128/IAI.62.4.1207-1212.1994
   PERRIN LH, 1984, CLIN EXP IMMUNOL, V56, P67
   PETZLERLER ML, 1991, HUM IMMUNOL, V32, P254, DOI 10.1016/0198-8859(91)90088-Q
   Riley EM, 1996, PARASITOLOGY, V112, pS39, DOI 10.1017/S0031182000076654
   Shute G. T., 1988, Malaria: principles and practice of malariology. Volume 1., P781
   STEPHENS HAF, 1995, EUR J IMMUNOL, V25, P3142, DOI 10.1002/eji.1830251123
   Suzuki H, 1997, EXP ANIM TOKYO, V46, P17, DOI 10.1538/expanim.46.17
   TODD JR, 1990, REV INFECT DIS, V12, P63
   Udhayakumar V, 1998, VACCINE, V16, P982, DOI 10.1016/S0264-410X(97)00290-9
NR 48
TC 12
Z9 12
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2002
VL 66
IS 5
BP 509
EP 515
DI 10.4269/ajtmh.2002.66.509
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 585AM
UT WOS:000177501000014
PM 12201584
OA Bronze
DA 2020-11-26
ER

PT J
AU Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Kalil, J
   Yamamoto, JH
AF Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Kalil, J
   Yamamoto, JH
TI T cells from HLA-DRB1*0405 Vogt-Koyanagi-Harada patients recognize
   melanocyte epitopes with high avidity and a T-1-type cytokine profile
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
CT Annual Meeting of the
   Association-for-Research-in-Vision-and-Ophthalmology
CY MAY 05-10, 2002
CL FT LAUDERDALE, FLORIDA
SP Assoc Res Vis & Ophthalmol
C1 Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
RI Iwai, Leo K/M-1734-2013; Cunha-Neto, Edecio/B-4157-2009; Goldberg, Anna
   Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Yamamoto, Joyce
   H/B-6192-2015; Damico, Francisco Max/G-1175-2015
OI Iwai, Leo K/0000-0002-1571-7763; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Damico, Francisco Max/0000-0002-2594-0336
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2002
VL 43
SU 1
MA 1530
BP U341
EP U341
PG 1
WC Ophthalmology
SC Ophthalmology
GA 709CF
UT WOS:000184606601487
DA 2020-11-26
ER

PT J
AU Suarez, IM
   Benvenutti, LA
   Noronha, I
   Van Kaer, L
   Kalil, J
   Coelho, V
AF Suarez, IM
   Benvenutti, LA
   Noronha, I
   Van Kaer, L
   Kalil, J
   Coelho, V
TI Rejection of grafts with no H-2 disparity in TAP1 mutant mice: CD4 T
   cells are important effector cells and self H-2(b) class I molecules are
   target
SO TRANSPLANT IMMUNOLOGY
LA English
DT Review
DE CD4(+) T cells; H-2Kb peptides; TAP1 mutant mice; class I deficiency;
   graft rejection
ID MHC CLASS-I; ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM;
   ALLOGRAFT-REJECTION; POSITIVE SELECTION; VIRAL-ANTIGEN; TRANSPORTER;
   DEFICIENT; BETA(2)-MICROGLOBULIN; MECHANISMS
AB Our previous results showed that TAPI mutant mice rejected heart and skin grafts from donors with no H-2 disparity that express normal density of MHC class I molecules at the cell surface. During rejection, CD4 cells were predominant and essentially, no CD8 cells were found infiltrating the grafts. We hypothesized that TAPI mutant mice, which developed and matured in an MHC class I-deficient environment, may have selected a repertoire of T cells with distinct reactivity to self class I molecules. The rejection of grafts with no H-2 disparity could be mediated by CD4(+) T cells reactive to wild type H-2(b) class I molecules, or derived peptides, in the context of self-APC. Accordingly, we observed that transplanted TAPI mutant mice presented a significant amplification of the proliferative T cell response to H-2K(b) peptides, indicating that the stimulus with the graft was sufficient to induce peripheral expansion of these T cell repertoires. Therefore, the response to H-2k(b) molecules could be a relevant pathway of activating T cells and triggering rejection of grafts expressing normal levels of these class I molecules. To test our hypothesis, we investigate the effect of pre-transplantation H-2K(b) peptide-immunization on TAPI mutant, which were then transplanted with C57BL/6 skin grafts (H-2(b)). Mice were immunized with a pool of five peptides derived from the polymorphic region of K' a. chain, before tail skin grafting. To study the role of CD4(+) T cells in the rejection of C57BL/6 skin grafts, mice were in vivo depleted with an anti-CD4 monoclonal antibody GK1.5, and transplant evolution was observed. Sensitization of TAPI mutant mice with H-2K(b) peptides accelerated the rejection of skin grafts. Immunized mice rejected grafts with a MST of 13 days, compared to 16 days for the non-immunized mice (P=0.0089). The significant acceleration of graft rejection, induced by immunization with H-2K(b) peptides, indicates that these peptides are capable of mobilizing effector T-cells that participate in rejection. These results support our hypothesis that class I molecules may be a target in the rejection of grafts with no MHC disparity. Depletion of CD4 T-cells resulted in a significant delay in rejection compared with the untreated control group. The MST of skin grafts in the controls was 16 days, whereas CD4-depleted recipients rejected skin grafts with a MST of 41 days (P=0.025). Moreover, some animals did not show macroscopic signs of rejection up to > 100 days posttransplantation. The contribution of CD4(+) T cells to skin graft rejection, in our model, may reflect the occurrence of the presentation of H-2(b) peptides during graft rejection, in the context of self-APC. In conclusion, our results demonstrate an important role for H-2(b) molecules and CD4 T cells in the rejection of C57BL/6 grafts by TAPI mutant mice. The low expression of MHC-1 molecules on TAP1(-/-) mice may be determinant in the selection of a T cell repertoire strongly reactive to self MHC class I molecules which probably escapes the control of peripheral regulatory mechanisms. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, Dept Pathol, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Renal, BR-01246903 Sao Paulo, Brazil.
   Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
   Millennium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Dept Pathol, Av Dr Eneas de Carvalho Aguiar 44,9 Andar,Bloco 2, BR-0540300 Sao Paulo, Brazil.
EM vecoelho@usp.br
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013; Van Kaer,
   Luc/H-1033-2015
OI KALIL, JORGE/0000-0001-8415-4274; Van Kaer, Luc/0000-0001-5275-2309
CR ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525
   APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837
   ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T
   ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3
   Boisgerault F, 2001, J IMMUNOL, V167, P1891, DOI 10.4049/jimmunol.167.4.1891
   BRUSIC V, 1994, NUCLEIC ACIDS RES, V22, P3663, DOI 10.1093/nar/22.17.3663
   Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507
   Cobbold SP, 1996, IMMUNOL REV, V149, P5, DOI 10.1111/j.1600-065X.1996.tb00897.x
   Coelho V, 1999, TRANSPLANT P, V31, P900, DOI 10.1016/S0041-1345(98)01828-4
   Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x
   Dalloul AH, 1996, EUR J IMMUNOL, V26, P213, DOI 10.1002/eji.1830260133
   Day PM, 1997, P NATL ACAD SCI USA, V94, P8064, DOI 10.1073/pnas.94.15.8064
   Gil-Torregrosa BC, 1998, J EXP MED, V188, P1105, DOI 10.1084/jem.188.6.1105
   GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661
   Groux H, 1997, NATURE, V389, P737
   Han WR, 2000, TRANSPLANTATION, V70, P168
   Ito H, 1998, J HEART LUNG TRANSPL, V17, P460
   KAGEYAMA S, 1995, J IMMUNOL, V154, P567
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Lautscham G, 2001, J EXP MED, V194, P1053, DOI 10.1084/jem.194.8.1053
   Le Moine A, 1999, J CLIN INVEST, V103, P1659, DOI 10.1172/JCI5504
   LI L, 1994, J IMMUNOL, V153, P3967
   Li W, 1998, TRANSPLANTATION, V66, P1587, DOI 10.1097/00007890-199812270-00004
   LJUNGGREN HG, 1995, EUR J IMMUNOL, V25, P174, DOI 10.1002/eji.1830250129
   LJUNGGREN HG, 1995, IMMUNOLOGIST, V3, P136
   MacEachern MC, 1998, TRANSPLANTATION, V65, P1357, DOI 10.1097/00007890-199805270-00013
   MANNON RB, 1995, TRANSPLANTATION, V59, P746, DOI 10.1097/00007890-199503150-00019
   MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487
   MORTON AL, 1993, EUR J IMMUNOL, V23, P2078, DOI 10.1002/eji.1830230906
   Motoyama K, 2000, TRANSPLANTATION, V69, P285, DOI 10.1097/00007890-200001270-00015
   Mottram PL, 1998, J IMMUNOL, V161, P602
   MOTTRAM PL, 1995, TRANSPLANTATION, V59, P559
   Motyka B, 1998, J IMMUNOL, V160, P77
   NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042
   Owen BAL, 1999, J IMMUNOL, V162, P4677
   Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323
   Paulsson KM, 2001, INT IMMUNOL, V13, P1063, DOI 10.1093/intimm/13.8.1063
   PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1
   Qian SG, 1996, TRANSPLANTATION, V62, P1709, DOI 10.1097/00007890-199612270-00002
   RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403
   REYES AA, 1992, P NATL ACAD SCI USA, V79, P3270
   Ritz U, 2001, MOL MED, V7, P149, DOI 10.1007/BF03401948
   ROSEMBERG AS, 1991, CURRENT PROTOCOLS IM, V1
   Sawada T, 1997, TRANSPLANTATION, V64, P335, DOI 10.1097/00007890-199707270-00027
   Shenoy S, 1998, CLIN EXP IMMUNOL, V112, P188
   SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M
   Shi Y, 1998, J IMMUNOL, V160, P4305
   Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087
   Solheim JC, 1997, J IMMUNOL, V158, P2236
   Song R, 1996, J IMMUNOL, V156, P4182
   SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0
   VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6
   Vella JP, 1999, TRANSPLANTATION, V67, P1523, DOI 10.1097/00007890-199906270-00005
   Wise M, 1999, EUR J IMMUNOL, V29, P156, DOI 10.1002/(SICI)1521-4141(199901)29:01<156::AID-IMMU156>3.0.CO;2-K
   ZIJLSTRA M, 1992, J EXP MED, V175, P885, DOI 10.1084/jem.175.4.885
NR 55
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0966-3274
EI 1878-5492
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD MAY
PY 2002
VL 9
IS 2-4
BP 101
EP 110
AR PII S0966-3274(02)00032-1
DI 10.1016/S0966-3274(02)00032-1
PG 10
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 581WM
UT WOS:000177317300006
PM 12180815
DA 2020-11-26
ER

PT J
AU Bittencourt, P
   Palacios, S
   Cancado, E
   Porta, G
   Carrilho, F
   Laudanna, A
   Kalil, J
   Goldberg, AC
AF Bittencourt, P
   Palacios, S
   Cancado, E
   Porta, G
   Carrilho, F
   Laudanna, A
   Kalil, J
   Goldberg, AC
TI Lack of association of CTLA-4 polymorphisms with autoimmune hepatitis
   types 1 and 2 in Brazilian patients
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; KALIL, JORGE/C-8029-2012; Cancado,
   Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna
   Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2002
VL 36
SU 1
MA 943
BP 261
EP 262
DI 10.1016/S0168-8278(02)80944-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 553YG
UT WOS:000175704700940
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Couto, CA
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Gayotto, LCC
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Couto, CA
   Cancado, ELR
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Gayotto, LCC
   Goldberg, AC
TI Analysis of HLA-A antigens and C282Y and H63D mutations of the HFE gene
   in Brazilian patients with hemochromatosis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE hemochromatosis; HFE mutations; iron overload; HLA-A3 mutation; C282Y
   mutation; H63D mutation; chromosome 6
ID HEREDITARY HEMOCHROMATOSIS; JUVENILE HEMOCHROMATOSIS; CANDIDATE GENE;
   IRON OVERLOAD; POPULATION; EXPRESSION; FAMILIES; PREVALENCE; PROBANDS;
   DISEASE
AB The hemochromatosis gene, HFE, is located on chromosome 6 in close proximity to the HLA-A locus. Most Caucasian patients with hereditary hemochromatosis (HH) are homozygous for HLA-A3 and for the C282Y mutation of the HFE gene, while a minority are compound heterozygotes for C282Y and H63D. The prevalence of these mutations in non-Caucasian patients with HH is lower than expected. The objective of the present study was to evaluate the frequencies of HLA-A antigens and the C282Y and H63D mutations of the 14FE gene in Brazilian patients with HH and to compare clinical and laboratory profiles of C282Y-positive and -negative patients with HH. The frequencies of HLA-A and C282Y and H63D mutations were determined by PCR-based methods in 15 male patients (median age 44 (20-72) years) with HH. Eight patients (53%) were homozygous and one (7%) was heterozygous for the C282Y mutation. None had compound heterozygosity for C282Y and H63D mutations. All but three C282Y homozygotes were positive for HLA-A3 and three other patients without C282Y were shown to be either heterozygous (N = 2) or homozygous (N = 1) for HLA-A3. Patients homozygous for the C282Y mutation had higher ferritin levels and lower age at onset, but the difference was not significant. The presence of C282Y homozygosity in roughly half of the Brazilian patients with HH, together with the findings of HLA-A homozygosity in C282Y-negative subjects, suggest that other mutations in the HFE gene or in other genes involved in iron homeostasis might also be linked to HH in Brazil.
C1 Hosp Portugues Salvador, Salvador, BA, Brazil.
   Hosp Portugues Salvador, Salvador, BA, Brazil.
   Univ Sao Paulo, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Coracao, Lab Imunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Anat Patol, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A, BR-4190040 Salvador, BA, Brazil.
RI Cancado, Eduardo/K-1861-2016; Couto, Claudia Alves/H-7420-2013;
   Goldberg, Anna Carla/H-8594-2014; BITTENCOURT, PAULO l/I-5817-2014;
   KALIL, JORGE/C-8029-2012; Carrilho, Flair J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; Couto, Claudia
   Alves/0000-0002-9776-4757; Goldberg, Anna Carla/0000-0003-2600-7940;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; 
CR Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428
   Agostinho MF, 1999, BLOOD CELL MOL DIS, V25, P324, DOI 10.1006/bcmd.1999.0260
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913
   Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1
   BART BY, 1993, TERAPEVT ARKH, V65, P25
   Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129
   Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027
   Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211
   Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172
   Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534
   Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509
   Carella M, 1997, AM J HUM GENET, V60, P828
   Carvalho-Silva DR, 2001, AM J HUM GENET, V68, P281, DOI 10.1086/316931
   Datz C, 1997, J HEPATOL, V27, P773, DOI 10.1016/S0168-8278(97)80312-1
   FARIAS AQ, 2000, DOENCAS FIGADO VIAS
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025
   Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143
   GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249
   Jouanolle AM, 1997, HUM GENET, V100, P544, DOI 10.1007/s004390050549
   Kelly AL, 1998, QJM-INT J MED, V91, P607, DOI 10.1093/qjmed/91.9.607
   Marshall DS, 1999, INT J MOL MED, V4, P389
   McNamara L, 1998, BRIT J HAEMATOL, V102, P1176
   MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275
   Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U
   Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505
   Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534
   Pereira AC, 2001, HUM BIOL, V73, P145, DOI 10.1353/hub.2001.0009
   Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1
   Rivard SR, 2000, BLOOD CELL MOL DIS, V26, P10, DOI 10.1006/bcmd.2000.0271
   Robson KJH, 1997, GUT, V41, P841
   Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379
   Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434
   SIMON M, 1987, AM J HUM GENET, V41, P89
   SIMON M, 1977, CLIN GENET, V11, P327
   Wallace DF, 1999, GASTROENTEROLOGY, V116, P1409, DOI 10.1016/S0016-5085(99)70505-6
NR 40
TC 8
Z9 16
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAR
PY 2002
VL 35
IS 3
BP 329
EP 335
DI 10.1590/S0100-879X2002000300007
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 536GQ
UT WOS:000174692700007
PM 11887210
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Viggiani, C
   Rodrigues, H
   Massarolo, P
   Panajotopoulos, N
   Raia, S
   Kalil, J
   Mies, S
AF Monteiro, F
   Viggiani, C
   Rodrigues, H
   Massarolo, P
   Panajotopoulos, N
   Raia, S
   Kalil, J
   Mies, S
TI Monitoring of soluble HLA class I in liver transplant recipients:
   Correlation with transplant-related complications
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Congress of the Brazilian-Organ-Transplant-Association (ABTO)
CY MAR 28-31, 2001
CL VITORIA, BRAZIL
SP Brazilian Organ Transplant Assoc
C1 Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Liver Unity, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
RP Monteiro, F (corresponding author), Univ Fed Sao Paulo, Fac Med, Lab Imunol Transplantes, Rua Dr Eneas de Carvalho Aguiar 44,9 Andar, BR-05403001 Sao Carlos, SP, Brazil.
RI KALIL, JORGE/C-8029-2012; Massarollo, Paulo/I-2283-2013; Massarollo,
   Paulo/AAS-3567-2020
OI KALIL, JORGE/0000-0001-8415-4274; Massarollo, Paulo/0000-0001-6398-1027;
   Massarollo, Paulo/0000-0001-6398-1027
CR McDonald JC, 1998, HUM IMMUNOL, V59, P387, DOI 10.1016/S0198-8859(98)00033-0
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2002
VL 34
IS 2
BP 469
EP 470
AR PII S0041-1345(02)02598-8
DI 10.1016/S0041-1345(02)02598-8
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 553LB
UT WOS:000175675700014
PM 12009593
DA 2020-11-26
ER

PT J
AU Barros, MT
   Perini, A
   Garcia, MLB
   Acencio, M
   Soares, MFM
   Macedo, MS
   Ibanez, OM
   Kalil, J
   Martins, MA
AF Barros, MT
   Perini, A
   Garcia, MLB
   Acencio, M
   Soares, MFM
   Macedo, MS
   Ibanez, OM
   Kalil, J
   Martins, MA
TI Experimental S mansoni infection in genetically selected mice through
   high and low inflammatory response
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
   Inst Butantan, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Ibanez, Olga CM/B-9627-2015; Martins, Milton
   A/L-7541-2017; Bueno Garcia, Maria Lucia/G-5882-2013; Martins, Milton
   A/D-6658-2012
OI KALIL, JORGE/0000-0001-8415-4274; Ibanez, Olga CM/0000-0002-2672-4758; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2002
VL 109
IS 1
SU S
MA 321
BP S114
EP S114
DI 10.1016/S0091-6749(02)81457-9
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 519UX
UT WOS:000173744800320
DA 2020-11-26
ER

PT J
AU Geller, P
   Castro, FM
   Cunha-Neto, E
   Kalil, J
AF Geller, P
   Castro, FM
   Cunha-Neto, E
   Kalil, J
TI Antiinflammatory activity of fexofenadine in perennial allergic
   rhinitis: Soluble ICAM-1 analysis in nasal secretions
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Castro,
   Fabio/AAP-5433-2020; Castro, Fabio FM/C-1082-2017
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Castro, Fabio FM/0000-0002-6211-5773
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2002
VL 109
IS 1
SU S
MA 807
BP S264
EP S264
DI 10.1016/S0091-6749(02)81942-X
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 519UX
UT WOS:000173744800804
DA 2020-11-26
ER

PT J
AU Motta, AA
   Araujo, P
   Martinez, J
   Machado, L
   Kalil, J
   Barros, MT
AF Motta, AA
   Araujo, P
   Martinez, J
   Machado, L
   Kalil, J
   Barros, MT
TI Is atopic dermatitis associated with sensitization to house dust mites
   through skin and airways?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
   Univ Bilbao, Bilbao, Spain.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2002
VL 109
IS 1
SU S
MA 1082
BP S348
EP S348
DI 10.1016/S0091-6749(02)82217-5
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 519UX
UT WOS:000173744801079
DA 2020-11-26
ER

PT J
AU Marin, ML
   Savioli, CR
   Yamamoto, JH
   Kalil, J
   Goldberg, AC
AF Marin, ML
   Savioli, CR
   Yamamoto, JH
   Kalil, J
   Goldberg, AC
TI MIC-A haplotypes in a sample from Sao Paulo, Brazil
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Lab Histocompatibil & Cell Immun, Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RI Yamamoto, Joyce H/B-6192-2015; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 2002
VL 59
SU 2
BP 102
EP 102
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 564JM
UT WOS:000176311300332
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Carrilho, FJ
   Kalil, J
AF Goldberg, AC
   Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Carrilho, FJ
   Kalil, J
TI A study of 19 hemochromatosis (HH) patients in Sao Paulo, Brazil
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Millenium Inst, Inst Invest Immunol, Sao Paulo, Brazil.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; BITTENCOURT,
   PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; BITTENCOURT, PAULO l/0000-0003-0883-4870;
   Cancado, Eduardo/0000-0002-9309-1524
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 2002
VL 59
SU 2
BP 109
EP 109
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 564JM
UT WOS:000176311300355
DA 2020-11-26
ER

PT J
AU Spadafora-Ferreira, M
   Fonseca, JA
   Granja, C
   Malheiros, DMAC
   Kalil, J
   Coelho, V
AF Spadafora-Ferreira, M
   Fonseca, JA
   Granja, C
   Malheiros, DMAC
   Kalil, J
   Coelho, V
TI Predominant IL-10 production in indirect alloreactivity is not
   associated with rejection
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE indirect allorecognition; renal transplantation; rejection; HLA-DR
   peptides; IL-10; regulatory cells
ID T-CELL ALLORECOGNITION; ORGAN ALLOGRAFT-REJECTION; ANTIGEN-PRESENTING
   CELLS; HLA CLASS-I; INDIRECT RECOGNITION; GRAFT-REJECTION;
   TRANSPLANTATION TOLERANCE; KIDNEY ALLOGRAFTS; DENDRITIC CELLS; MHC
   PEPTIDES
AB In a prospective study of indirect alloresponse in renal transplantation, we detected proliferation and cytokine production to donor and third-party HLA-DR peptides unrelated to rejection. Twenty of 28 patients (71%) presented proliferation, 29% before and 71% after transplantation. Half of the patients also presented proliferation to third-party peptides. Indirect alloresponse was also detected in 75% of healthy individuals (HI). Variability of response was observed in patients and III for both proliferation and cytokine production. IL-10 predominance was observed in indirect alloresponses to donor peptides pre- and post-Tx, in contrast with more IFN-gamma and TGF-beta being detected in HI. IL-10 production was frequently detected without proliferation, in contrast with more frequent proliferation being found with IFN-gamma and TGF-beta production. The lack of association of either cytokine or proliferation with rejection, together with the predominance of IL-10 unrelated to proliferation, suggests that regulatory cells may be part of the T cell repertoire involved in indirect alloreactivity. (C) 2001 Elsevier Science.
C1 Univ Sao Paulo, Heart Inst InCor, Sch Med, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin, Div Rental Transplantat, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin, Dept Nephrol, BR-0540300 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Clin Med, BR-0540300 Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Heart Inst InCor, Sch Med, BR-0540300 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; COELHO, VERONICA/D-1433-2013;
   Spadafora-Ferreira, Monica/G-2635-2012; MALHEIROS, DENISE
   MAC/L-7382-2017
OI KALIL, JORGE/0000-0001-8415-4274; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929; MALHEIROS, DENISE MAC/0000-0002-0409-816X;
   Coelho, Veronica/0000-0002-0989-2581
CR Baudouin V, 1998, TRANSPLANTATION, V66, P376, DOI 10.1097/00007890-199808150-00016
   BENHAM AM, 1995, TRANSPLANTATION, V59, P1028, DOI 10.1097/00007890-199504150-00019
   BENICHOU G, 1992, J EXP MED, V175, P305, DOI 10.1084/jem.175.1.305
   Benichou G, 1997, IMMUNOL TODAY, V18, P67, DOI 10.1016/S0167-5699(97)01004-9
   Benichou G, 1999, J IMMUNOL, V162, P352
   Bignon JD, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P584
   BUELOW R, 1995, TRANSPLANTATION, V59, P649, DOI 10.1097/00007890-199503150-00001
   Chen WJ, 1996, TRANSPLANTATION, V62, P705, DOI 10.1097/00007890-199609270-00001
   Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117
   Coelho V, 1999, CLIN IMMUNOL, V90, P220, DOI 10.1006/clim.1998.4626
   Davies JD, 1996, J IMMUNOL, V157, P529
   FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521
   Gafter U, 1996, CLIN SCI, V91, P519, DOI 10.1042/cs0910519
   Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   Heeger PS, 1999, J IMMUNOL, V163, P2267
   HOPKINS KA, 1990, ASHI LABORATORY MANU, P195
   Hornick PI, 2000, CIRCULATION, V101, P2405, DOI 10.1161/01.CIR.101.20.2405
   Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213
   LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31
   Lederman S, 1999, HUM IMMUNOL, V60, P553, DOI 10.1016/S0198-8859(99)00045-2
   Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530
   Liang J, 2000, TRANSPLANTATION, V70, P1363, DOI 10.1097/00007890-200011150-00017
   Liu Z, 1996, CLIN IMMUNOL IMMUNOP, V78, P228, DOI 10.1006/clin.1996.0034
   LIU Z, 1993, J EXP MED, V177, P1648
   Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Molajoni ER, 1997, HUM IMMUNOL, V53, P57, DOI 10.1016/S0198-8859(97)00029-3
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Renna-Molajoni E, 1998, TRANSPLANT P, V30, P2140, DOI 10.1016/S0041-1345(98)00566-1
   Robinson J, 2000, TISSUE ANTIGENS, V55, P280, DOI 10.1034/j.1399-0039.2000.550314.x
   Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X
   Saleem M, 1996, IMMUNOL LETT, V54, P21, DOI 10.1016/S0165-2478(96)02636-3
   Sayegh M H, 1996, Int Rev Immunol, V13, P221, DOI 10.3109/08830189609061749
   SCHMITZ J, 1993, EUR J IMMUNOL, V23, P191, DOI 10.1002/eji.1830230130
   SCHULICK RD, 1993, TRANSPLANTATION, V56, P590
   Shirwan H, 1997, TRANSPLANTATION, V64, P1671, DOI 10.1097/00007890-199712270-00007
   SHOSKES DA, 1994, IMMUNOL TODAY, V15, P32, DOI 10.1016/0167-5699(94)90023-X
   SivaSai KSR, 1999, TRANSPLANTATION, V67, P1094, DOI 10.1097/00007890-199904270-00002
   Stegmann S, 2000, HUM IMMUNOL, V61, P1363, DOI 10.1016/S0198-8859(00)00215-9
   Suciu-Foca N, 1998, IMMUNOL REV, V164, P241, DOI 10.1111/j.1600-065X.1998.tb01224.x
   Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4
   VanBuskirk AM, 2000, J CLIN INVEST, V106, P145, DOI 10.1172/JCI9171
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
   Waaga AM, 1998, TRANSPLANTATION, V65, P876, DOI 10.1097/00007890-199804150-00004
   Wong W, 1997, TRANSPLANTATION, V63, P1490, DOI 10.1097/00007890-199705270-00020
   Zeller JC, 1999, J IMMUNOL, V163, P3684
   Zhai Y, 1999, CURR OPIN IMMUNOL, V11, P497, DOI 10.1016/S0952-7915(99)00007-2
NR 49
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD DEC
PY 2001
VL 101
IS 3
BP 315
EP 327
DI 10.1006/clim.2001.5127
PG 13
WC Immunology
SC Immunology
GA 502DM
UT WOS:000172728500009
PM 11726224
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Oshiro, SE
   Fae, KC
   Cunha-Neto, E
   Renesto, G
   Goldberg, AC
   Tanaka, AC
   Pomerantzeff, PMA
   Kiss, MH
   Silva, C
   Guzman, F
   Patarroyo, ME
   Southwood, S
   Sette, A
   Kalil, J
AF Guilherme, L
   Oshiro, SE
   Fae, KC
   Cunha-Neto, E
   Renesto, G
   Goldberg, AC
   Tanaka, AC
   Pomerantzeff, PMA
   Kiss, MH
   Silva, C
   Guzman, F
   Patarroyo, ME
   Southwood, S
   Sette, A
   Kalil, J
TI T-cell reactivity against streptococcal antigens in the periphery
   mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic
   heart disease patients
SO INFECTION AND IMMUNITY
LA English
DT Article
ID GROUP-A STREPTOCOCCI; CLASS-II ANTIGENS; CARDIAC MYOSIN; FEVER PATIENTS;
   M-PROTEINS; EPITOPES; ASSOCIATION; ANTIBODIES; IDENTIFICATION;
   RECOGNITION
AB T-cell molecular mimicry between streptococcal and heart proteins has been proposed as the triggering factor leading to autoimmunity in rheumatic heart disease (RHD). We searched for immunodominant T-cell M5 epitopes among RHD patients with defined clinical outcomes and compared the T-cell reactivities of peripheral blood and intralesional T cells from patients with severe RHD. The role of HLA class II molecules in the presentation of M5 peptides was also evaluated. We studied the T-cell reactivity against M5 peptides and heart proteins on peripheral blood mononuclear cells (PBMC) from 74 RHD patients grouped according to the severity of disease, along with intralesional and peripheral T-cell clones from RHD patients. Peptides encompassing residues 1 to 25, 81 to 103, 125 to 139, and 163 to 177 were more frequently recognized by PBMC from RHD patients than by those from controls. The M5 peptide encompassing residues 81 to 96 [M5(81-96) peptide] was most frequently recognized by PBMC from HLA-DR7(+) DR53(+) patients with severe RHD, and 46.9% (15 of 32) and 43% (3 of 7) of heart-infiltrating and PBMC-derived peptide-reactive T-cell clones, respectively, recognized the M5(81-103) region. Heart proteins were recognized more frequently by PBMC from patients with severe RHD than by those from patients with mild RHD. The similar pattern of T-cell reactivity found with both peripheral blood and heart-infiltrating T cells is consistent with the migration of M-protein-sensitized T cells to the heart tissue. Conversely, the presence of heart-reactive T cells in the PBMC of patients with severe RHD also suggests a spillover of sensitized T cells from the heart lesion.
C1 InCor, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med, Sao Paulo, Brazil.
   Univ Nacl Colombia, HSJD, Inst Inmunol, Bogota, Colombia.
   Epimmune Inc, San Diego, CA USA.
RP Guilherme, L (corresponding author), HC FMUSP, Lab Imunol, Inst Coracao, Av Dr Encas Carvalho Aguiar,500 3o Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Guglielmi, Luiza G/E-7676-2013; Cunha-Neto, Edecio/B-4157-2009;
   Pomerantzeff, Pablo M A/L-5525-2016; Guzman, Fanny fg/K-5592-2013;
   KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Patarroyo,
   Manuel-Elkin/S-1422-2017
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Pomerantzeff, Pablo M
   A/0000-0003-0566-1038; Guzman, Fanny fg/0000-0003-1537-0904; KALIL,
   JORGE/0000-0001-8415-4274; Goldberg, Anna Carla/0000-0003-2600-7940;
   Patarroyo, Manuel-Elkin/0000-0002-1119-6040
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Bromelow KV, 1997, J AUTOIMMUN, V10, P219, DOI 10.1006/jaut.1996.0119
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   DAJANI AS, 1993, CIRCULATION, V87, P302
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   ElDemellawy M, 1997, INFECT IMMUN, V65, P2197, DOI 10.1128/IAI.65.6.2197-2205.1997
   Fairchild PJ, 1996, IMMUNOL TODAY, V17, P80, DOI 10.1016/0167-5699(96)80584-6
   FENDERSON PG, 1989, J IMMUNOL, V142, P2475
   FROUDE J, 1989, CURR TOP MICROBIOL, V145, P5
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   GULIZIA JM, 1991, AM J PATHOL, V138, P285
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   Khanna AK, 1997, J AUTOIMMUN, V10, P99, DOI 10.1006/jaut.1996.0107
   KRIEGER JI, 1991, J IMMUNOL, V146, P2331
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   MCLAUGHLIN JF, 1972, ARTHRITIS RHEUM-US, V15, P600, DOI 10.1002/art.1780150606
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   READ SE, 1974, J CLIN INVEST, V54, P439, DOI 10.1172/JCI107780
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   Southwood S, 1998, J IMMUNOL, V160, P3363
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   YOSHINAGA M, 1995, J AUTOIMMUN, V8, P601, DOI 10.1016/0896-8411(95)90011-X
NR 30
TC 74
Z9 77
U1 0
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD SEP
PY 2001
VL 69
IS 9
BP 5345
EP 5351
DI 10.1128/IAI.69.9.5345-5351.2001
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 464PB
UT WOS:000170540000017
PM 11500404
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Vallochi, AL
   Yamamoto, JH
   Schlesinger, D
   Machado, MAC
   Silveira, C
   Martins, MC
   Belfort, R
   Kalil, J
   Rizzo, LV
AF Vallochi, AL
   Yamamoto, JH
   Schlesinger, D
   Machado, MAC
   Silveira, C
   Martins, MC
   Belfort, R
   Kalil, J
   Rizzo, LV
TI Lack of evidence for superantigen activity of Toxoplasma gondii towards
   human T cells
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Toxoplasma; tolerance; superantigen; T cell receptor
ID MAJOR HISTOCOMPATIBILITY COMPLEX; MAMMARY-TUMOR VIRUS; OCULAR
   TOXOPLASMOSIS; SELECTIVE EXPANSION; RECEPTOR; LYMPHOCYTES;
   IDENTIFICATION; EXPRESSION; DISEASE; ANTIGEN
AB Toxoplasma gondii is an obligatory intracellular parasite whose life cycle may include man as an intermediate host. More than 500 million people are infected with this parasite worldwide. It has been previously reported that T. gondii contains a superantigen activity. The purpose of the present study was to determine if the putative superantigen activity of T gondii would manifest towards human T cells. Peripheral blood mononuclear cells (PBMC) from individuals with no previous contact with the parasite were evaluated for proliferation as well as specific V beta expansion after exposure to Toxoplasma antigens. Likewise, PBMC from individuals with the congenital infection were evaluated for putative V beta family deletions in their T cell repertoire. We also evaluated, over a period of one year, the PBMC proliferation pattern in response to Toxoplasma antigens in patients with recently acquired infection. Some degree of proliferation in response to T. gondii was observed in the PBMC from individuals never exposed to the parasite. accompanied by specific V beta expansion, suggesting a superantigen effect. However, we found no specific deletion of V beta (or V alpha) families in the blood of congenitally infected individuals. Furthermore, PBMC from recently infected individuals followed up over a period of one year did not present a reduction of the V beta families that were originally expanded in response to the parasite antigens. Taken together, our data suggest that T. gondii does not have a strong superantigen activity on human T cells.
C1 Univ Sao Paulo, ICB, Dept Imunol, BR-05509800 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Div Oftalmol, BR-05509800 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Lab Invest Med LIM60, Div Alergia & Imunol Clin, Fac Med, BR-05509800 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Dept Oftalmol, BR-05509800 Sao Paulo, SP, Brazil.
   Fundacao EJ Zerbini, Sao Paulo, SP, Brazil.
RP Rizzo, LV (corresponding author), Univ Sao Paulo, ICB, Dept Imunol, Av Prof Lineu Prestes,1730, BR-05509800 Sao Paulo, SP, Brazil.
RI Belfort, Rubens/E-2252-2012; Vallochi, Adriana/W-6405-2018; KALIL,
   JORGE/C-8029-2012; Yamamoto, Joyce H/B-6192-2015; Rizzo, Luiz
   Vicente/B-4458-2009
OI Belfort, Rubens/0000-0002-8422-3898; KALIL, JORGE/0000-0001-8415-4274;
   Yamamoto, Joyce/0000-0001-6869-2988
CR ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066
   Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   BERTOLI F, 1995, ARCH PATHOL LAB MED, V119, P214
   BJERKAS I, 1994, CLIN DIAGN LAB IMMUN, V1, P214, DOI 10.1128/CDLI.1.2.214-221.1994
   BREZIN AP, 1994, RETINA-J RET VIT DIS, V14, P19, DOI 10.1097/00006982-199401000-00005
   COLE BC, 1989, J IMMUNOL, V142, P4131
   CORREASALES C, 1997, INT J IMMUNOPHARMACO, V19, P1177
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CURIEL TJ, 1993, J IMMUNOL, V151, P2024
   Denkers EY, 1996, J IMMUNOL, V156, P1089
   DENKERS EY, 1994, J EXP MED, V180, P985, DOI 10.1084/jem.180.3.985
   DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7
   DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0
   FISHBACK JL, 1991, SEMIN VET MED SURG, V6, P219
   FRENKEL JK, 1985, PEDIATR CLIN N AM, V32, P917
   Fuchs N, 1999, INT J PARASITOL, V29, P1597, DOI 10.1016/S0020-7519(99)00118-6
   GAZZINELLI RT, 1995, J IMMUNOL, V155, P1565
   GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5
   HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525
   HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954
   Huber B T, 1992, Semin Immunol, V4, P313
   KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8
   KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0
   LAFON M, 1994, J EXP MED, V180, P1207, DOI 10.1084/jem.180.4.1207
   Locksley RM, 1997, PARASITOLOGY, V115, pS5, DOI 10.1017/S0031182097001984
   MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0
   Mitchell W G, 1999, Semin Pediatr Neurol, V6, P267, DOI 10.1016/S1071-9091(99)80025-4
   NUSSENBLATT RB, 1994, JAMA-J AM MED ASSOC, V271, P304, DOI 10.1001/jama.271.4.304
   PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183
   Sher A, 1995, CIBA F SYMP, V195, P95
   SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0
   Smith JL, 1999, J FOOD PROTECT, V62, P818, DOI 10.4315/0362-028X-62.7.818
   STUART PM, 1992, J IMMUNOL, V148, P225
   Suzuki Y, 1996, J INFECT DIS, V173, P265, DOI 10.1093/infdis/173.1.265
   TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359
   Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8
   WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255
   Yamamoto JH, 2000, J INFECT DIS, V181, P2018, DOI 10.1086/315494
   Yao ZB, 1996, J IMMUNOL, V156, P3260
   ZUMLA A, 1992, PARASITOLOGY, V105, pS93, DOI 10.1017/S0031182000075405
NR 40
TC 7
Z9 7
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2001
VL 34
IS 8
BP 1023
EP 1031
DI 10.1590/S0100-879X2001000800008
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 467YR
UT WOS:000170731800008
PM 11471041
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Abel, LCJ
   Rizzo, LV
   Ianni, B
   Albuquerque, F
   Bacal, F
   Carrara, D
   Bocchi, EA
   Teixeira, HC
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Abel, LCJ
   Rizzo, LV
   Ianni, B
   Albuquerque, F
   Bacal, F
   Carrara, D
   Bocchi, EA
   Teixeira, HC
   Mady, C
   Kalil, J
   Cunha-Neto, E
TI Chronic Chagas' disease cardiomyopathy patients display an increased
   IFN-gamma response to Trypanosoma cruzi infection
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE infectious immunity-parasites; human-clinical studies; cytokines;
   Th1/Th2; T lymphocytes
ID TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE UVEITIS; T-CELL CLONES;
   HEART-FAILURE; FACTOR-ALPHA; NONEXPOSED DONORS; PERIPHERAL-BLOOD;
   IMMUNE-RESPONSE; SURFACE PROTEIN; MICE
AB One-third of all Trypanosoma cruzi-infected patients eventually develop chronic Chagas' disease cardiomyopathy (CCC), a particularly lethal inflammatory dilated cardiomyopathy, where parasites are scarce and heart-infiltrating mononuclear cells seem to be the effectors of tissue damage. Since T cruzi is a major inducer of interleukin-12 production, the role of inflammatory cytokines in the pathogenesis of CCC was investigated. We assayed cytokine production by peripheral blood mononuclear cells (PBMC) from CCC and asymptomatic T cruzi-infected (ASY) individuals, as well as by T cell lines from endomyocardial biopsies from CCC patients. PBMC from CCC and ASY patients produced higher IFN-gamma levels than normal (N) individuals in response to B13 protein and phytohaemagglutinin PHA; IFN-gamma high responders (greater than or equal to1 ng/ml) were 2-3 fold more frequent among CCC patients than ASY individuals. Conversely, IL-4 production in response to the same stimuli was suppressed among T. cruzi-infected patients. The frequency of PHA-induced IFN gamma -producing cells on PBMC was significantly higher among CCC than ASY and N individuals. IFN-gamma and TNF-a were produced by ten out of ten PHA-stimulated T cell lines from CCC patients; IL-2 and IL-10 were produced by four out of ten and one out of ten lines, respectively; IL-4, IL-1 alpha, IL-1 beta, IL-6 and IL-12 were undetectable. Our results suggest that CCC and ASY patients may respond differentially to the IFN-gamma -inducing stimulus provided by T. cruzi infection. Given the T-1-type cytokine profile of heart-infiltrating T cell lines from CCC patients, the ability to mount a vigorous IFN-gamma -response may play a role on the differential susceptibility to CCC development. (C) 2001 Academic Press.
C1 Univ Sao Paulo, Fac Med, Heart Inst InCor, Immunol Lab, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Heart Inst InCor, Div Surg, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Heart Inst InCor, Clin Div, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.
   Univ Fed Juiz de Fora, Immunol Lab, Juiz De Fora, Brazil.
   Howard Hughes Med Inst, Coconut Grove, FL 33133 USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Heart Inst InCor, Immunol Lab, Av Dr Eneas C Aguiar,500 3o Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunha@usp.br
RI Bacal, Fernando/H-7952-2012; Cunha-Neto, Edecio/B-4157-2009; Teixeira,
   Henrique C/R-2133-2019; Mady, Charles/C-8870-2012; Rizzo, Luiz
   Vicente/B-4458-2009; KALIL, JORGE/C-8029-2012; Ianni, Barbara
   Maria/C-7689-2012; Abel, Lucia Cristina Jamli/P-8816-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Teixeira, Henrique
   C/0000-0002-0172-9720; Mady, Charles/0000-0002-8838-199X; KALIL,
   JORGE/0000-0001-8415-4274; Ianni, Barbara Maria/0000-0002-1588-5492;
   Abel, Lucia Cristina Jamli/0000-0003-4915-4265
CR Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   Aliberti JCS, 1996, INFECT IMMUN, V64, P1961, DOI 10.1128/IAI.64.6.1961-1967.1996
   Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476
   ARNHOLDT ACV, 1993, J IMMUNOL, V151, P3171
   BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   Camargo MM, 1997, J IMMUNOL, V159, P6131
   Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996
   CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CURRIER J, 1992, INT IMMUNOL, V4, P985, DOI 10.1093/intimm/4.9.985
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   Dutra WO, 1997, SCAND J IMMUNOL, V45, P74, DOI 10.1046/j.1365-3083.1997.d01-362.x
   Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901
   Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2
   FERN J, 1992, J IMMUNOL, V148, P907
   FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479
   Frosch S, 1997, INFECT IMMUN, V65, P971, DOI 10.1128/IAI.65.3.971-977.1997
   GAMARGO MM, 1997, J IMMUNOL, V158, P5890
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   HEGEWISCH S, 1990, LANCET, V335, P294, DOI 10.1016/0140-6736(90)90115-L
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Hunter CA, 1996, INFECT IMMUN, V64, P2381, DOI 10.1128/IAI.64.7.2381-2386.1996
   Ianni B M, 1998, Arq Bras Cardiol, V71, P21, DOI 10.1590/S0066-782X1998000700005
   Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   KEMP M, 1992, INFECT IMMUN, V60, P2246, DOI 10.1128/IAI.60.6.2246-2251.1992
   LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405
   Mady, 1999, AM J CARDIOL, V84, P1456
   Mady C, 1999, AM J CARDIOL, V84, P354, DOI 10.1016/S0002-9149(99)00295-7
   MATTERN T, 1994, J IMMUNOL, V153, P2996
   MEYER ZB, 1997, CLIN EXP IMMUNOL, V110, P378
   Millar AE, 1999, J IMMUNOL, V162, P6092
   PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674
   PIUVEZAM MR, 1993, J IMMUNOL, V150, P916
   Quanquin NM, 1999, INFECT IMMUN, V67, P4603, DOI 10.1128/IAI.67.9.4603-4612.1999
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Revelli S, 1999, PARASITOL RES, V85, P147, DOI 10.1007/s004360050524
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   RIZZO LV, 1992, J IMMUNOL, V148, P3733
   Samudio M, 1998, ACTA TROP, V69, P89, DOI 10.1016/S0001-706X(97)00118-6
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   Shulman IA, 1997, TRANSFUSION, V37, P727, DOI 10.1046/j.1537-2995.1997.37797369449.x
   Sun B, 1997, J IMMUNOL, V159, P1004
   Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932
   TEIXEIRA HC, 1995, IMMUNOL LETT, V46, P15, DOI 10.1016/0165-2478(95)00009-T
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   TorreAmione G, 1996, CIRCULATION, V93, P704
   TORRICO F, 1991, J IMMUNOL, V146, P3626
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   Weiner HL, 1997, ANNU REV MED, V48, P341
   Xu H, 1997, CELL IMMUNOL, V178, P69, DOI 10.1006/cimm.1997.1121
NR 56
TC 122
Z9 125
U1 2
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD AUG
PY 2001
VL 17
IS 1
BP 99
EP 107
DI 10.1006/jaut.2001.0523
PG 9
WC Immunology
SC Immunology
GA 461RR
UT WOS:000170377700011
PM 11488642
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Drigo, S
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, ELR
   Porta, G
   Drigo, S
   Carrilho, FJ
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Autoimmune hepatitis in Brazilian patients is not linked to tumor
   necrosis factor alpha polymorphisms at position-308
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE tumor necrosis factor alpha gene polymorphisms; tumor necrosis factor
   alpha; autoimmune hepatitis; HLA-DR antigens; genetic susceptibility
ID MAJOR HISTOCOMPATIBILITY COMPLEX; PCR-SSP; TYPE-1; HLA; SUSCEPTIBILITY;
   PROMOTER; CLASSIFICATION; HETEROGENEITY; ASSOCIATION; DIAGNOSIS
AB Background/Aims: Susceptibility to autoimmune hepatitis (AIH) has been linked to different HLA-DR antigens, Recently, AIH type 1 was associated with polymorphisms in the tumor necrosis factor alpha gene promotes (TNFA) at position -308. In this respect, the frequency of the TNFA*2 allele, in linkage disequilibrium with HLA-DRB1*0301, was shown to be significantly increased in whites with AIH type 1. The aim of this study was to assess the role of TNFA alleles in conferring susceptibility to AIH, studying a population where the disease is not primarily associated with HLA-DRB1*03.
   Methods: The determination of HLA-DRB1 and TNFA alleles was performed in 92 patients with ALH type 1, 29 subjects with AIH type 2 and 53 healthy controls by polymerase chain reaction-based techniques.
   Results: The distribution of TNFA alleles was similar in patients with AIH types 1 and 2, when compared with controls. In addition, the TNFA*2 allele was identified in patients carrying HLA-DR antigens other than HLA-DRB1*03. Interestingly, higher gammaglobulin levels were observed in TNFA*2 positive patients.
   Conclusions: Our data indicate that susceptibility to AIH remains primarily linked to the HLA-DRB1 locus, and suggest that the association of AIH with TNFA*2 previously observed in whites might be secondary to a linkage disequilibrium with MLA-DRB1*0301, (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart, Sao Paulo, Brazil.
   Howard Hughes Med Inst, Bethesda, MD 20815 USA.
RP Bittencourt, PL (corresponding author), Rua Tamoios 314,Apto 302A,Rio Vermelho, BR-41940040 Salvador, BA, Brazil.
EM plbbr@uol.com.br
RI BITTENCOURT, PAULO l/I-5817-2014; Carrilho, Flair J/I-3046-2012; LINDE,
   SANDRA/S-3128-2019; Goldberg, Anna Carla/H-8594-2014; Drigo, Sandra
   A/I-6514-2012; KALIL, JORGE/C-8029-2012; Cancado, Eduardo/K-1861-2016
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; LINDE,
   SANDRA/0000-0001-6747-6642; Goldberg, Anna Carla/0000-0003-2600-7940;
   Drigo, Sandra A/0000-0001-6747-6642; KALIL, JORGE/0000-0001-8415-4274;
   Cancado, Eduardo/0000-0002-9309-1524
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Beutler BA, 1999, J RHEUMATOL, V26, P16
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   Cancado ELR, 2000, FALK SYMP, V114, P82
   Cookson S, 1999, HEPATOLOGY, V30, P851, DOI 10.1002/hep.510300412
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Goldman JM, 1998, BONE MARROW TRANSPL, V21, P1, DOI 10.1038/sj.bmt.1701089
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   Jurado A, 1997, J HEPATOL, V26, P983, DOI 10.1016/S0168-8278(97)80106-7
   KRAKAUER T, 2000, FUNDAMENTALS IMMUNOL, P775
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   LENZI M, 1997, HEPATOLOGY, V26, P443
   Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
   Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093
   McManus R, 1996, EUR J IMMUNOL, V26, P2113, DOI 10.1002/eji.1830260923
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   POCIOT F, 1993, EUR J IMMUNOL, V23, P3050, DOI 10.1002/eji.1830231148
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   WILSON AG, 1994, EUR J IMMUNOL, V24, P191, DOI 10.1002/eji.1830240130
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557
NR 36
TC 31
Z9 35
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JUL
PY 2001
VL 35
IS 1
BP 24
EP 28
DI 10.1016/S0168-8278(01)00072-1
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 455HN
UT WOS:000170021600006
PM 11495038
DA 2020-11-26
ER

PT J
AU Portugal, K
   Dozmorov, I
   Sidorov, I
   Marrero, I
   Fonseca, JA
   Spadafora-Ferreira, M
   Kalil, J
   Coelho, V
AF Portugal, K
   Dozmorov, I
   Sidorov, I
   Marrero, I
   Fonseca, JA
   Spadafora-Ferreira, M
   Kalil, J
   Coelho, V
TI Renal transplant patients show variations in their self-reactive
   repertoires: a serial study
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE autologous limiting dilution assay; autoreactivity; multi-hit limiting
   dilution assay; regulatory cells; renal transplantation
ID LIMITING DILUTION ANALYSIS; MIXED LYMPHOCYTE-REACTION; T-CELL RESPONSES;
   VERSUS-HOST DISEASE; AUTOIMMUNE-DISEASES; MULTIPLE-SCLEROSIS;
   IMMUNOLOGICAL SELF; PROTEIN; CLONES; MICE
AB We addressed the question of whether allo-transplantation (Tx) induces breakdown of tolerance to self-antigens or alteration of the autoreactive T cell repertoire in humans. The serial variation of T cell autoreactivity was studied in the peripheral blood of 12 renal transplant patients, by autologous limiting dilution assay and autologous mixed lymphocyte reaction. Ten of 12 patients presented a positive response in autologous peripheral blood mononuclear cells in the post-Tx period, in contrast to four of 12 patients before Tx (P = 0.038), Multi-hit kinetics was found in 57% of the assays analyzed, indicating frequent regulatory control of the autologous response. Quantitative analysis performed in eight patients showed an increase in precursor frequency at >1 year post-Tx in five patients. These data indicate that autoreactivity increases or develops following Tx, in humans. Post-Tx events such as alloreactivity, infections or immunosuppression could interfere with the balance of autoreactive and regulatory cells, leading to changes in the T cell repertoires to self-antigens and eventually breakdown of self-tolerance, Further investigation is needed to elucidate whether post-Tx autoreactivity contributes to rejection, plays a regulatory role over alloreactivity or both, at separate times.
C1 Univ Sao Paulo, Sch Med, Hosp Clin, Heart Inst InCor, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Hosp Clin, Div Renal Transplantat, BR-05403000 Sao Paulo, Brazil.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   NCI, NIH, Frederick, MD 21702 USA.
RP Coelho, V (corresponding author), Univ Sao Paulo, Sch Med, Hosp Clin, Heart Inst InCor, Av Dr Eneas de Carvalho Aguiar 500,3A, BR-05403000 Sao Paulo, Brazil.
RI Spadafora-Ferreira, Monica/G-2635-2012; COELHO, VERONICA/D-1433-2013;
   KALIL, JORGE/C-8029-2012
OI Spadafora-Ferreira, Monica/0000-0001-8823-9929; KALIL,
   JORGE/0000-0001-8415-4274; Sidorov, Igor/0000-0001-6519-4983; Coelho,
   Veronica/0000-0002-0989-2581
CR AGRAWAL B, 1991, J IMMUNOL, V147, P383
   ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3
   BARRAL AP, 1984, AM J TROP MED HYG, V33, P1078, DOI 10.4269/ajtmh.1984.33.1078
   BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094
   BURROWS SR, 1999, IMMUNOL TODAY, V5, P2083
   Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117
   CORLEY RB, 1978, J IMMUNOL, V121, P1082
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   DOSREIS GA, 1981, J IMMUNOL, V127, P2456
   DOZMOROV I, 1995, IMMUNOL LETT, V46, P43, DOI 10.1016/0165-2478(95)00016-X
   Dozmorov IM, 1996, J IMMUNOL METHODS, V189, P183, DOI 10.1016/0022-1759(95)00241-3
   Dozmorov IM, 1996, CELL IMMUNOL, V172, P141, DOI 10.1006/cimm.1996.0226
   DOZMOROV IM, 1995, J IMMUNOL, V154, P4283
   ELLIS TM, 1985, TRANSPLANTATION, V39, P127, DOI 10.1097/00007890-198502000-00004
   Fedoseyeva EV, 1999, J IMMUNOL, V162, P6836
   Fedoseyeva EV, 1996, TRANSPLANTATION, V61, P679, DOI 10.1097/00007890-199603150-00001
   FEY K, 1983, J EXP MED, V158, P40, DOI 10.1084/jem.158.1.40
   FISHERLINDAHL K, 1977, J EXP MED, V145, P508
   FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627
   FULLER L, 1983, J CLIN INVEST, V71, P1322, DOI 10.1172/JCI110883
   GLAZIER A, 1983, J EXP MED, V158, P1, DOI 10.1084/jem.158.1.1
   Groux H, 1997, NATURE, V389, P737
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   HAFLER DA, 1991, CLIN IMMUNOL IMMUNOP, V58, P115, DOI 10.1016/0090-1229(91)90153-2
   Hess AD, 1998, TRANSPLANTATION, V65, P785, DOI 10.1097/00007890-199803270-00004
   Jacquot S, 1997, CELL IMMUNOL, V179, P48, DOI 10.1006/cimm.1997.1150
   KAMINSKI ER, 1992, BRIT J HAEMATOL, V81, P23, DOI 10.1111/j.1365-2141.1992.tb08165.x
   Kumar V, 1999, LIFE SCI, V65, P1523, DOI 10.1016/S0024-3205(99)00198-8
   KUNTZ MM, 1979, J CLIN INVEST, V63, P151, DOI 10.1172/JCI109270
   LeDouarin N, 1996, IMMUNOL REV, V149, P35
   LEFKOVITS I, 1999, LIMITING DILUTION AN
   LIU ZR, 1992, J EXP MED, V175, P1663, DOI 10.1084/jem.175.6.1663
   LOMBARDI G, 1989, P NATL ACAD SCI USA, V86, P4190, DOI 10.1073/pnas.86.11.4190
   Lukey PT, 1998, CLIN EXP IMMUNOL, V111, P293
   MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6
   Medzhitov R, 1997, IMMUNOL REV, V159, P208, DOI 10.1111/j.1600-065X.1997.tb01018.x
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   MUNK ME, 1989, J IMMUNOL, V143, P2844
   NG KC, 1982, J IMMUNOL METHODS, V52, P115, DOI 10.1016/0022-1759(82)90357-X
   OPELZ G, 1975, J EXP MED, V142, P1327, DOI 10.1084/jem.142.5.1327
   OTA H, 1995, CLIN EXP IMMUNOL, V100, P99
   Sakaguchi S, 1996, J AUTOIMMUN, V9, P211, DOI 10.1006/jaut.1996.0026
   Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9
   Sercarz EE, 2000, J AUTOIMMUN, V14, P275, DOI 10.1006/jaut.2000.0380
   Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423
   Silverstein AM, 1997, IMMUNOL REV, V159, P197, DOI 10.1111/j.1600-065X.1997.tb01016.x
   SMITH JB, 1979, J IMMUNOL, V123, P419
   SMOLEN JS, 1982, J CLIN LAB IMMUNOL, V9, P185
   STROBER W, 1990, IMMUNOL REV, V116, P117, DOI 10.1111/j.1600-065X.1990.tb00807.x
   Tan KN, 1996, INT IMMUNOL, V8, P689, DOI 10.1093/intimm/8.5.689
   Trieb K, 1996, Transpl Immunol, V4, P43, DOI 10.1016/S0966-3274(96)80032-3
   Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331
   Udaka K, 1996, J IMMUNOL, V157, P670
   Van Parijs L, 1998, SCIENCE, V280, P243
   vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
   ZAUDERER M, 1989, ADV IMMUNOL, V45, P417, DOI 10.1016/S0065-2776(08)60698-7
   Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344
   ZOLLER M, 1985, IMMUNOLOGY, V55, P703
   Zucker K, 1996, J CLIN IMMUNOL, V16, P60, DOI 10.1007/BF01540974
NR 60
TC 8
Z9 8
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
EI 1460-2377
J9 INT IMMUNOL
JI Int. Immunol.
PD JUN
PY 2001
VL 13
IS 6
BP 747
EP 755
DI 10.1093/intimm/13.6.747
PG 9
WC Immunology
SC Immunology
GA 440PU
UT WOS:000169184100004
PM 11369701
OA Bronze
DA 2020-11-26
ER

PT J
AU Iwai, LK
   Duranti, MA
   Abel, LCJ
   Juliano, MA
   Kalil, J
   Juliano, L
   Cunha-Neto, E
AF Iwai, LK
   Duranti, MA
   Abel, LCJ
   Juliano, MA
   Kalil, J
   Juliano, L
   Cunha-Neto, E
TI Retro-inverso peptide analogues of Trypanosoma cruzi B13 protein
   epitopes fail to be recognized by human sera and peripheral blood
   mononuclear cells
SO PEPTIDES
LA English
DT Article
ID MOUTH-DISEASE VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   T-LYMPHOCYTE RESPONSES; MAJOR ANTIGENIC SITE; CROSS-REACTIVITY;
   CHAGAS-DISEASE; CARDIAC MYOSIN; PEPTIDOMIMETICS; ANTIBODIES; BINDING
AB Retro inverso (RI) analogues of antigenic synthetic peptides, which are made of D-amino acids with a reversed sequence, may mimic the side chain conformation of natural all-L peptides. RI analogues were cross-reactively recognized by antibodies and CD4+ T cells reactive against natural all-L synthetic peptides or native proteins in animal models. Since peptides containing D-amino acids are highly resistant to proteolytic digestion, cross-reactive RI analogues may be ideal for in vivo administration to humans as synthetic peptide vaccines or immunomodulators. B13 is an immunodominant tandemly repetitive protein from Trypanosoma cruzi, a protozoan parasite that is the causative antigen of Chagas' disease. In order to test whether RI peptides can be recognized by human antibody and T cells, we synthesized two all-L peptides containing the immunodominant B (S12) and T (S15.7) cell epitopes of B13 protein from T. cruzi and their retro (R, made of all-L amino acids with reversed sequence), inverse (I, made of all-D amino acids) and RI analogues. Recognition of peptides S12, S12-R, S12-I and S12-RI by anti-B13 antibodies in sera from T. cruzi-infected patients was tested in competitive ELISA assay with recombinant B13 protein as the solid phase antigen. Peptides S15.7 and its topological analogues were tested at the 10-50 muM range in proliferation assays on peripheral blood mononuclear cells (PBMC) from S15.7-responder individuals. The median percentage inhibition of B13 ELISA for peptide S12 was 94%. while those of the RI analogue or the other topological analogues were below 12%. While peptide S15.7 was recognized by PBMC from all subjects tested, none recognized the RI analogue of the S15.7 T cell epitope. Our results indicate that cross-reactivity with natural epitopes is not an universal property of RI analogues. This may limit the general applicability of the use of cross-reactive RI analogues as human vaccines and immunotherapeutic agents. (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Allergy & Immunopathol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Juliano, Luiz/D-7204-2012; Iwai, Leo
   K/M-1734-2013; Cunha-Neto, Edecio/B-4157-2009; Abel, Lucia Cristina
   Jamli/P-8816-2014
OI KALIL, JORGE/0000-0001-8415-4274; Juliano, Luiz/0000-0002-5589-2822;
   Iwai, Leo K/0000-0002-1571-7763; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Abel, Lucia Cristina Jamli/0000-0003-4915-4265
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   ABEL LCJ, 1999, THESIS U SAO PAULO B
   Atherton E, 1989, SOLID PHASE PEPTIDE
   Bartnes K, 1997, EUR J IMMUNOL, V27, P1387, DOI 10.1002/eji.1830270614
   BENKIRANE N, 1993, J BIOL CHEM, V268, P26279
   BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921
   Bignon JD, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P584
   Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545
   BRIAND JP, 1995, J BIOL CHEM, V270, P20686, DOI 10.1074/jbc.270.35.20686
   Carver JA, 1997, BIOPOLYMERS, V41, P569, DOI 10.1002/(SICI)1097-0282(19970415)41:5<569::AID-BIP8>3.0.CO;2-K
   CHOREV M, 1993, ACCOUNTS CHEM RES, V26, P266, DOI 10.1021/ar00029a007
   Cunha-Neto E, 1999, BRAZ J MED BIOL RES, V32, P199, DOI 10.1590/S0100-879X1999000200008
   Cunha-Neto Edecio, 1997, Memorias do Instituto Oswaldo Cruz, V92, P40
   Cunha-Neto Edecio, 1998, Memorias do Instituto Oswaldo Cruz, V93, P30
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   Duranti MA, 1999, EXP PARASITOL, V93, P38, DOI 10.1006/expr.1999.4428
   FAUCHERE JL, 1992, ADV DRUG RES, V23, P127
   Fu TM, 1997, J VIROL, V71, P2715, DOI 10.1128/JVI.71.4.2715-2721.1997
   Geluk A, 1998, J AUTOIMMUN, V11, P353, DOI 10.1006/jaut.1998.0207
   GOODMAN M, 1979, ACCOUNTS CHEM RES, V12, P1, DOI 10.1021/ar50133a001
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765
   GUPTASARMA P, 1992, FEBS LETT, V310, P205, DOI 10.1016/0014-5793(92)81333-H
   Guptasarma P, 1996, TRENDS BIOTECHNOL, V14, P42, DOI 10.1016/0167-7799(96)80917-6
   Herve M, 1997, MOL IMMUNOL, V34, P157, DOI 10.1016/S0161-5890(97)00004-7
   HIGGINS PJ, 1988, J IMMUNOL, V140, P440
   IWAI LK, 1999, THESIS SAO PAULO FED
   JANEWAY CA, 1968, IMMUNOLOGY, V14, P225
   JANEWAY CA, 1967, IMMUNOLOGY, V12, P29
   JASKIEWICZ E, 1994, BLOOD, V84, P2340
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   Marino M, 1999, EUR J IMMUNOL, V29, P2560, DOI 10.1002/(SICI)1521-4141(199908)29:08<2560::AID-IMMU2560>3.3.CO;2-O
   MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449
   MEZIERE C, 1997, EUR J IMMUNOL, V27, P1387
   MOZES E, 1974, IMMUNOLOGY, V27, P641
   MULLER GM, 1982, P NATL ACAD SCI-BIOL, V79, P569, DOI 10.1073/pnas.79.2.569
   MULLER S, 1995, PEPTIDE RES, V8, P138
   MURILLO LA, 1991, PARASITE IMMUNOL, V13, P201, DOI 10.1111/j.1365-3024.1991.tb00275.x
   Nargi F, 1999, VACCINE, V17, P2888, DOI 10.1016/S0264-410X(99)00127-9
   OLLERUP O, 1992, TISSUE ANTIGENS, V39, P223
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   Petit MC, 1999, J BIOL CHEM, V274, P3686, DOI 10.1074/jbc.274.6.3686
   Raddrizzani L, 1997, J IMMUNOL, V159, P703
   Rizzo LV, 1999, J IMMUNOL, V162, P2613
   Saito NG, 1997, MOL IMMUNOL, V34, P1133, DOI 10.1016/S0161-5890(97)00140-5
   Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3
   SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729
   SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296
   SIDNEY J, 1994, J IMMUNOL, V152, P4516
   Southwood S, 1998, J IMMUNOL, V160, P3363
   vanderMost RG, 1997, J VIROL, V71, P5110, DOI 10.1128/JVI.71.7.5110-5114.1997
   Verdoliva A, 1995, J BIOL CHEM, V270, P30422, DOI 10.1074/jbc.270.51.30422
   VERDOLIVA A, 1995, BBA-PROTEIN STRUCT M, V1253, P57, DOI 10.1016/0167-4838(95)00149-O
NR 54
TC 14
Z9 14
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD JUN
PY 2001
VL 22
IS 6
BP 853
EP 860
DI 10.1016/S0196-9781(01)00409-0
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA 440NT
UT WOS:000169181800001
PM 11390013
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Cunha-Neto, E
   Tanaka, AC
   Dulphy, N
   Toubert, A
   Kalil, J
AF Guilherme, L
   Cunha-Neto, E
   Tanaka, AC
   Dulphy, N
   Toubert, A
   Kalil, J
TI Heart-directed autoimmunity: the case of rheumatic fever
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article; Proceedings Paper
CT International Symposium on Autoimmunity Induced by Infection or
   Immunization
CY NOV 28-DEC 01, 2000
CL LES PENSIERES, FRANCE
SP Merieux Fdn
DE autoimmunity; cytokines; heart proteins; M protein; T cells; TCR
ID CLASS-II ANTIGENS; DISEASE; ASSOCIATION; LYMPHOCYTES; SPECIFICITY;
   FRAGMENT; ANTIBODY; CELLS
AB Molecular mimicry was proposed as a potential mechanism for streptococcal sequelae leading to rheumatic fever (RF) and rheumatic heart disease (RHD). CD4(+) infiltrating T cells are able to recognize streptococcal M peptides and heart tissue proteins. We analyzed the M5 peptide- and heart-specific responses, cytokine profile and T cell receptor (TCR) BV usage from peripheral and heart-infiltrating T cell lines and clones from patients across the clinical spectrum of ARF/RHD. The patient with ARF displayed a higher frequency of mitral valve infiltrating T cell clones reactive against M5: 1-25, 81-103 and 163-177 regions and several valve-derived proteins than the post-RF and chronic RHD patient (67%; 20% and 27%, respectively). The presence of oligoclonal BV families indicative of oligoclonal T cell expansion among mitral valve-derived T cell Lines was increased in the chronic RHD patient. Furthermore, mitral valve T cell lines from all patients produced significant amounts of inflammatory cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF alpha) in response to M5(81-96) peptide, with the highest production attained by the chronic RHD patient. These data are consistent with an important role for M5 peptide and host antigen-driven, T1-type CD4(+) T cells in the pathogenesis of RHD and heart lesion progression after recurrence of the streptococcal infection. (C) 2001 Academic Press.
C1 Univ Sao Paulo, Heart Inst InCor, Sch Med, BR-05508 Sao Paulo, Brazil.
   Howard Hughes Med Inst, Dept Clin Med, Sao Paulo, Brazil.
   Hop St Louis, Lab Immunol & Histocompatibil, INSERM, U396, Paris, France.
RP Guilherme, L (corresponding author), Inst Coracao HC FMUSP, Lab Imunol, Av Dr Eneas Carvalho Aguiar,500-3o Andar, BR-05403000 Sao Paulo, Brazil.
EM luizagui@usp.br
RI Toubert, Antoine/Q-3404-2017; Dulphy, Nicolas/J-5960-2017; KALIL,
   JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013; Cunha-Neto,
   Edecio/B-4157-2009
OI Toubert, Antoine/0000-0002-7308-7317; Dulphy,
   Nicolas/0000-0002-1243-6456; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   DAJANI AS, 1993, CIRCULATION, V87, P302
   DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113
   EVEN J, 1995, RES IMMUNOL, V146, P65, DOI 10.1016/0923-2494(96)80240-9
   FISCHETTI VA, 1991, SCI AM, V264, P58, DOI 10.1038/scientificamerican0691-58
   Garderet L, 1998, BLOOD, V91, P340, DOI 10.1182/blood.V91.1.340.340_340_346
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   Guilherme L, 2000, INT IMMUNOL, V12, P1063, DOI 10.1093/intimm/12.7.1063
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   KAPLAN MH, 1969, AM J CARDIOL, V24, P459, DOI 10.1016/0002-9149(69)90489-5
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOTB M, 1989, J IMMUNOL, V142, P966
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   PADULA SJ, 1985, J CLIN INVEST, V75, P788, DOI 10.1172/JCI111774
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Visentainer JEL, 2000, J RHEUMATOL, V27, P1518
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
NR 23
TC 33
Z9 36
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAY
PY 2001
VL 16
IS 3
SI SI
BP 363
EP 367
DI 10.1006/jaut.2000.0487
PG 5
WC Immunology
SC Immunology
GA 431XG
UT WOS:000168656600026
PM 11334505
DA 2020-11-26
ER

PT J
AU Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, IK
   Marin, ML
   Kalil, J
   Yamamoto, JH
AF Damico, FM
   Cunha-Neto, E
   Goldberg, AC
   Iwai, IK
   Marin, ML
   Kalil, J
   Yamamoto, JH
TI HLA-DRB1*0405-restricted T cell epitopes of melanocyte/melanoma proteins
   and induced IFN-gamma secretion in Vogt-Koyanagi-Harada syndrome.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
RI Yamamoto, Joyce H/B-6192-2015; KALIL, JORGE/C-8029-2012; Damico,
   Francisco Max/G-1175-2015; Goldberg, Anna Carla/H-8594-2014; Cunha-Neto,
   Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Damico, Francisco
   Max/0000-0002-2594-0336; Goldberg, Anna Carla/0000-0003-2600-7940;
   Cunha-Neto, Edecio/0000-0002-3699-3345
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 3058
BP S570
EP S570
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392103024
DA 2020-11-26
ER

PT J
AU Yamamoto, JH
   Okay, T
   Damico, FM
   Villela, FF
   Usuba, F
   Kanashiro, EHY
   Panutti, C
   Hirata, CE
   Olivalves, E
   Kalil, J
AF Yamamoto, JH
   Okay, T
   Damico, FM
   Villela, FF
   Usuba, F
   Kanashiro, EHY
   Panutti, C
   Hirata, CE
   Olivalves, E
   Kalil, J
TI Specific antibodies and PCR in intraocular fluids for the diagnosis of
   uveitis.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Trop Med, Sao Paulo, Brazil.
RI Okay, Thelma S/G-2616-2012; Okay, Thelma/Q-6353-2019; KALIL,
   JORGE/C-8029-2012; Yamamoto, Joyce H/B-6192-2015; Damico, Francisco
   Max/G-1175-2015
OI KALIL, JORGE/0000-0001-8415-4274; Damico, Francisco
   Max/0000-0002-2594-0336
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2001
VL 42
IS 4
SU S
MA 3069
BP S571
EP S571
PG 1
WC Ophthalmology
SC Ophthalmology
GA 427EP
UT WOS:000168392103034
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Bittencourt, PL
   Mougin, B
   Cancado, ELR
   Porta, G
   Carrilho, F
   Kalil, J
AF Goldberg, AC
   Bittencourt, PL
   Mougin, B
   Cancado, ELR
   Porta, G
   Carrilho, F
   Kalil, J
TI Analysis of HLA haplotypes in autoimmune hepatitis type 1: Identifying
   the major susceptibility locus
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE HLA genes; autoimmune hepatitis; genetic susceptibility; peptide
   presentation
ID ALLELES; GENES
AB Susceptibility to autoimmune hepatitis type I (AIH-1) has been associated with HLA-DR3, DR52, acid DR4 antigens in Caucasian and Oriental patients. However, in Brazil, disease susceptibility is primarily linked to DR13 and DR52. In this highly admired population, we find different DR13-associated haplotypes, presenting a unique opportunity to discriminate relevant genes within a tightly linked genomic region. To identify the primary susceptibility locus, we sequenced DR13 alleles of 39 patients with AIH-1 and 22 controls. Patients were almost exclusively DRB1*1301, bur half of controls typed DRB1*1302. HLA-DQ haplotypes were varied. Oligotyping of DRD3 locus of all patients and also within the HLA-DR13 positive group showed an allele distribution comparable to controls, confirming that the stronger association lies in the DRB1 locus. On the other hand, if DRB1*1301 is the major susceptibility factor in our sample, the only amino acid different from DRB1*1302 in position 86, corresponding to pocket 1 in the peptide-presenting groove, may be important. We Propose that peptide presentation leading to pathogenesis of AIH-1 may ie quite stringent, but will also be affected by other strong genetic or environmental susceptibility factors, which would explain the various HLA molecules associated to the disease in the different populations. (C) American Society for Histocompatibility and Immunogenetics, 2001. Published by Elsevier Science Inc.
C1 Univ Sao Paulo, Fac Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
   Biomerieux, Dept Sondes Nucl, Lyon, France.
   Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Goldberg, AC (corresponding author), HCFMUSP, Lab Imunol, Av Dr Eneas de Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI Carrilho, Flair J/I-3046-2012; Cancado, Eduardo/K-1861-2016; KALIL,
   JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; BITTENCOURT, PAULO
   l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274;
   Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870
CR BIGNON JD, 1995, HLA GENETIC DIVERSIT
   Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
   Bodmer JG, 1999, TISSUE ANTIGENS, V53, P407, DOI 10.1034/j.1399-0039.1999.530421.x
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CROS P, 1992, LANCET, V340, P873
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   DAVENPORT MP, 1995, P NATL ACAD SCI USA, V92, P6567, DOI 10.1073/pnas.92.14.6567
   DIELPOLDER HM, 1998, CLIN EXP IMMUNOL, V113, P244
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   FAINBOIM L, 1997, P 12 IHWC GEN DIV HL
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   GORSKI J, 1986, NATURE, V322, P6770
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V90, pS23
   MANNS M, 1991, HEPATOLOGY, V14, P60
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
   MCGINNIS MD, 1995, TISSUE ANTIGENS, V46, P173, DOI 10.1111/j.1399-0039.1995.tb03116.x
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
NR 23
TC 52
Z9 58
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD FEB
PY 2001
VL 62
IS 2
BP 165
EP 169
DI 10.1016/S0198-8859(00)00234-2
PG 5
WC Immunology
SC Immunology
GA 405CZ
UT WOS:000167141200010
PM 11182227
DA 2020-11-26
ER

PT J
AU Bezerra, R
   Geller, P
   Giavina-Bianchi, P
   Kalil, JE
AF Bezerra, R
   Geller, P
   Giavina-Bianchi, P
   Kalil, JE
TI Adverse-reaction to local anesthetics: IgE-mediated or pseudoallergic?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2001
VL 107
IS 2
SU S
MA 23
BP S7
EP S7
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 405RE
UT WOS:000167172300024
DA 2020-11-26
ER

PT J
AU Esher, SHG
   Castro, APB
   Croce, J
   Palma, MS
   Malaspina, O
   Kalil, JE
   Castro, FFM
AF Esher, SHG
   Castro, APB
   Croce, J
   Palma, MS
   Malaspina, O
   Kalil, JE
   Castro, FFM
TI Study of laboratorial methods for Hymenoptera allergy diagnosis: A
   critical analysis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RI Castro, Fabio FM/C-1082-2017; Castro, Fabio/AAP-5433-2020; Palma,
   Mario/N-3903-2019; Palma, Mario Sergio/E-7800-2012; Malaspina,
   Osmar/E-7338-2012; KALIL, JORGE/C-8029-2012
OI Castro, Fabio FM/0000-0002-6211-5773; Palma, Mario
   Sergio/0000-0002-7363-8211; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 2
Z9 2
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2001
VL 107
IS 2
SU S
MA 375
BP S113
EP S113
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 405RE
UT WOS:000167172300374
DA 2020-11-26
ER

PT J
AU Galvao, CE
   Kalil, JE
   Castro, FM
AF Galvao, CE
   Kalil, JE
   Castro, FM
TI Sensitization to aeroallergens: Urban/rural differences in Sao
   Paulo-Brazil
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
RI Castro, Fabio/AAP-5433-2020; Castro, Fabio FM/C-1082-2017; KALIL,
   JORGE/C-8029-2012
OI Castro, Fabio FM/0000-0002-6211-5773; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2001
VL 107
IS 2
SU S
MA 85
BP S25
EP S25
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 405RE
UT WOS:000167172300086
DA 2020-11-26
ER

PT J
AU Geller, P
   Guerra, CV
   Grecco, O
   Kalil, JE
   Barros, MT
AF Geller, P
   Guerra, CV
   Grecco, O
   Kalil, JE
   Barros, MT
TI Transient IgA-deficiency in adulthood and chronic hepatitis C: Cause or
   effect?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2001
VL 107
IS 2
SU S
MA 692
BP S210
EP S210
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 405RE
UT WOS:000167172300688
DA 2020-11-26
ER

PT J
AU Guerra, CV
   Kokron, CM
   Rizzo, LV
   Kalil, J
   Barros, MT
AF Guerra, CV
   Kokron, CM
   Rizzo, LV
   Kalil, J
   Barros, MT
TI Disorders of immunoglobulin synthesis: Clinical characteristics of 76
   patients
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Kokron, Cristina M/D-3140-2012; Rizzo, Luiz
   Vicente/B-4458-2009
OI KALIL, JORGE/0000-0001-8415-4274; Kokron, Cristina
   M/0000-0002-9080-0305; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2001
VL 107
IS 2
SU S
MA 700
BP S212
EP S213
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA 405RE
UT WOS:000167172300696
DA 2020-11-26
ER

PT J
AU Avila, SLM
   Goldberg, AC
   Arruk, VG
   Marin, ML
   Guilherme, L
   Kalil, J
   Ferreira, AW
AF Avila, SLM
   Goldberg, AC
   Arruk, VG
   Marin, ML
   Guilherme, L
   Kalil, J
   Ferreira, AW
TI Immune responses to multiple antigen peptides containing T and B
   epitopes from Plasmodium falciparum circumsporozoite protein of
   Brazilian individuals naturally exposed to malaria
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE malaria; T-cell epitope; B-cell epitope; multiple antigen peptides;
   circumsporozoite protein; HLA
ID CELL EPITOPES; SYNTHETIC PEPTIDES; IMMUNOGENICITY; VACCINE; INDUCTION;
   SEQUENCES; MAP
AB We have evaluated the immune responses of individuals living in a malaria endemic area of Brazil to the (T1B)(4), a multiple antigen peptide (MAP) from Plasmodium falciparum circumsporozoite (CS) protein and the related monoepitope MAPs, B-4 and (T1)(4), and the linear peptides, T1B and B. The highest antibody frequencies were against MAPs containing the B cell epitope sequence (T1B)(4) (42.2%) and B-4 (28.8%), while the highest lymphoproliferative response frequencies were against the MAPs containing the T cell epitope sequence (T1)(4) (47%) and (T1B)(4) (36.4%). We analysed individual responses considering lymphoproliferative response to (T1)(4) MAP and IgG antibody titre to (T1B)(4) as patterns of ideal cellular and humoral responses, respectively The frequency of responders, cellular and/or humoral was 66.6%, significantly higher than non responders (P = 0.003). We also determined the HLA class II haplotype of each individual bur no association between these and immune response patterns to the MAPs was observed. The results showed that individuals primed against P. falciparum in their natural habitat, present a very diverse array of responses against the same peptide antigens, varying from no response in one-third of the individuals to cognate B and T cell responses. Our study underlines the importance of previous studies of vaccine candidates to guarantee that the immunization will be capable of reverting inefficient or absent responses to malaria epitopes.
C1 Univ Sao Paulo, Sch Med, Inst Trop Med Sao Paulo, BR-05403140 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor, BR-05508 Sao Paulo, Brazil.
RP Avila, SLM (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med Sao Paulo, Ave Dr Eneas de Carvalho Aguiar 500, BR-05403140 Sao Paulo, Brazil.
RI Goldberg, Anna Carla/H-8594-2014; Guglielmi, Luiza G/E-7676-2013; KALIL,
   JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR AHLHORG N, 1998, VACCINE, V16, P38
   Avila Sandra L. M., 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P309, DOI 10.1590/S0036-46651998000500008
   Bharadwaj A, 1998, INFECT IMMUN, V66, P3232, DOI 10.1128/IAI.66.7.3232-3241.1998
   Bignon J.D., 1995, TECHN HDB 12 INT HIS
   CalvoCalle JM, 1997, J IMMUNOL, V159, P1362
   CALVOCALLE JM, 1993, J IMMUNOL, V150, P1403
   CHATTERJEE S, 1995, VACCINE, V13, P1474, DOI 10.1016/0264-410X(94)00052-O
   Le TP, 1998, VACCINE, V16, P305, DOI 10.1016/S0264-410X(97)00165-5
   Marussig M, 1997, INT IMMUNOL, V9, P1817, DOI 10.1093/intimm/9.12.1817
   Moreno CA, 1999, VACCINE, V18, P89, DOI 10.1016/S0264-410X(99)00184-X
   MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217
   Nardin EH, 1995, ADV IMMUNOL, V60, P105, DOI 10.1016/S0065-2776(08)60585-4
   NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642
   Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   OLIVEIRA GA, 1994, VACCINE, V12, P1012
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5470
   ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595
   ZEGERS ND, 1993, EUR J IMMUNOL, V23, P630, DOI 10.1002/eji.1830230308
NR 23
TC 13
Z9 14
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD FEB
PY 2001
VL 23
IS 2
BP 103
EP 108
DI 10.1046/j.1365-3024.2001.00363.x
PG 6
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 410FL
UT WOS:000167429300006
PM 11240901
DA 2020-11-26
ER

PT J
AU Spadafora-Ferreira, M
   Granja, C
   Fonseca, JA
   Marrero, I
   Kalil, J
   Coelho, V
AF Spadafora-Ferreira, M
   Granja, C
   Fonseca, JA
   Marrero, I
   Kalil, J
   Coelho, V
TI Indirect alloreactivity and cytokine production to HLA-DR peptides in
   human renal transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 18th World Congress of the Transplantation-Society
CY AUG 27-SEP 01, 2000
CL ROME, ITALY
SP Transplant Soc
ID ALLOGRAFT-REJECTION; CLASS-I; INDIRECT ALLORECOGNITION; INDIRECT
   RECOGNITION; ALLOPEPTIDES; PATHWAY
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin, Div Renal Transplantat, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Clin Med, Clin Immunol & Allergy, BR-05508900 Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Av Dr Eneas Carvalho,Aguiar 500,3 Andar, BR-0540300 Sao Paulo, Brazil.
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012;
   Spadafora-Ferreira, Monica/G-2635-2012
OI KALIL, JORGE/0000-0001-8415-4274; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929
CR Benichou G, 1997, IMMUNOL TODAY, V18, P67, DOI 10.1016/S0167-5699(97)01004-9
   Bignon JD, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P584
   BUELOW R, 1995, TRANSPLANTATION, V59, P649, DOI 10.1097/00007890-199503150-00001
   Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117
   Coelho V, 1999, CLIN IMMUNOL, V90, P220, DOI 10.1006/clim.1998.4626
   HOPKINS KA, 1990, ASHI LABORATORY MANU, P195
   LIU Z, 1993, J EXP MED, V177, P1648
   Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898
   Molajoni ER, 1997, HUM IMMUNOL, V53, P57, DOI 10.1016/S0198-8859(97)00029-3
   Nadeau K, 1997, TRANSPL P, V29, P1038, DOI 10.1016/S0041-1345(96)00359-4
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Shirwan H, 1997, TRANSPLANTATION, V64, P1671, DOI 10.1097/00007890-199712270-00007
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
   Wong W, 1997, TRANSPLANTATION, V63, P1490, DOI 10.1097/00007890-199705270-00020
NR 14
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB-MAR
PY 2001
VL 33
IS 1-2
BP 435
EP 436
DI 10.1016/S0041-1345(00)02081-9
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 413UK
UT WOS:000167629900204
PM 11266897
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Kalil, J
AF Cunha-Neto, E
   Kalil, J
TI Heart-infiltrating and peripheral T cells in the pathogenesis of human
   Chagas' disease cardiomyopathy
SO AUTOIMMUNITY
LA English
DT Article
DE Chagas' disease cardiomyopathy; molecular mimicry; cytokines;
   autoimmunity; T lymphocytes
ID TRYPANOSOMA-CRUZI ANTIGEN; CARDIAC MYOSIN; AUTOIMMUNITY; IDENTIFICATION
AB Heart tissue destruction in chronic Chagas' disease cardiomyopathy (CCC), occurring in 30% of individuals chronically infected by the protozoan parasite Trypanosoma cruzi, may be caused by autoimmune recognition of patients' heart tissue by a T cell rich inflammatory infiltrate. Recently, our group demonstrated that T cells infiltrating the heart of CCC patients crossreactively recognize cardiac myosin heavy chain and tandemly repetitive T cruzi antigen B13, and possess an inflammatory T-1-type cytokine profile. Susceptibility factors leading 30% of infected patients to develop CCC, while the rest of the patients remain largely asymptomatic (ASY), are still obscure. We compared immunological phenotypes of CCC and ASY patients, who have distinct clinical outcomes despite bearing a similar chronic T cruzi infection. Preliminary observations indicate that PBMC from CCC patients recognize a set of B13 and cardiac myosin epitopes distinct from that recognized by ASY patients. Moreover, the IFN-gamma response of CCC patients is more intense than that of ASY, both at qualitative and quantitative levels. Taken together, results suggest that heart damage in Chagas' disease cardiomyopathy may be secondary to inflammatory cytokines and a delayed-type hypersensitivity process started and/or maintained by heart-crossreactive T cells. Furthermore, the distinct recognition repertoire and the high frequency of IFN-gamma producing among CCC patients could be important factors leading to the differential development of CCC among T cruzi infected individuals.
C1 Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart InCor, BR-05403000 Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Immunol Lab, Inst Heart InCor, Av Dr Eneas Carvalho Aguiar,500 3o Andar, BR-05403000 Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Bahia-Oliveira LMG, 1998, BRAZ J MED BIOL RES, V31, P127, DOI 10.1590/S0100-879X1998000100017
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto E., 1998, MEM I O CRUZ S1, V93, P40
   Cunha-Neto Edecio, 1997, Memorias do Instituto Oswaldo Cruz, V92, P40
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   CUNHANETO E, 2000, MOL MIMICRY MICROBES, P245
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
NR 13
TC 34
Z9 35
U1 2
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0891-6934
J9 AUTOIMMUNITY
JI Autoimmunity
PY 2001
VL 34
IS 3
BP 187
EP 192
DI 10.3109/08916930109007383
PG 6
WC Immunology
SC Immunology
GA 524XB
UT WOS:000174037200006
PM 11908776
DA 2020-11-26
ER

PT B
AU Cunha-Neto, E
   Abel, LCJ
   Drigo, S
   Iwai, LK
   Fonseca, SG
   Bilate, AMB
   Ferreira, RC
   Fae, K
   Ianni, B
   Mady, C
   Goldberg, AC
   Kalil, J
AF Cunha-Neto, E
   Abel, LCJ
   Drigo, S
   Iwai, LK
   Fonseca, SG
   Bilate, AMB
   Ferreira, RC
   Fae, K
   Ianni, B
   Mady, C
   Goldberg, AC
   Kalil, J
BE Pinotti, HW
   Cecconello, I
   Felix, VN
   DeOliveira, MA
TI Understanding the immunopathogenesis of Chagas'disease: Perspectives for
   the new millenium
SO RECENT ADVANCES IN DISEASES OF THE ESOPHAGUS
LA English
DT Proceedings Paper
CT 8th World Congress of the
   International-Society-for-Diseases-of-the-Esophagus
CY SEP 05-08, 2001
CL SAO PAULO, BRAZIL
SP Int Soc Dis Esophagus
ID CHAGAS-DISEASE CARDIOMYOPATHY; AUTOIMMUNITY; MYOCARDITIS; CHAIN
AB The immunopathogenesis of chronic Chagas' disease cardiomyopathy and achalasia is under intense debate; they seem to be distinct clinical syndromes overlapping in a percentage of patients. We will review results from our group and recent evidence for the involvement of immunological/inflammatory mechanisms in the pathogenesis of Chagas' disease cardiomyopathy and achalasia.
C1 Univ Sao Paulo, Sch Med, Lab Immunol, BR-05508 Sao Paulo, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Lab Immunol, BR-05508 Sao Paulo, Brazil.
RI Iwai, Leo K/M-1734-2013; Cunha-Neto, Edecio/B-4157-2009; Goldberg, Anna
   Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Ianni, Barbara
   Maria/C-7689-2012
OI Iwai, Leo K/0000-0002-1571-7763; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Ianni, Barbara Maria/0000-0002-1588-5492
CR ABEL LCJ, 2001, IN PRESS J AUTOIMMUN
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   CUNHANETO E, 2000, MOL MIMICRY MICROBES
   Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224
   Dos Santos R. R., 1976, Transactions of the Royal Society of Tropical Medicine and Hygiene, V70, P167, DOI 10.1016/0035-9203(76)90195-4
   Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Lemos EM, 1998, CLIN IMMUNOL IMMUNOP, V88, P150, DOI 10.1006/clin.1998.4549
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   RIBEIRODOSSANTO.R, 1992, J EXP MED, V175, P29
   Vago AR, 2000, AM J PATHOL, V156, P1805, DOI 10.1016/S0002-9440(10)65052-3
   Weiner HL, 1997, ANNU REV MED, V48, P341
NR 15
TC 0
Z9 0
U1 0
U2 1
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 88-323-1905-5
PY 2001
BP 205
EP 209
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA BU06L
UT WOS:000174896000036
DA 2020-11-26
ER

PT J
AU Bilate, AMB
   Salemi, VMC
   Ramires, FJA
   Brito, T
   Mady, C
   Kalil, J
   Cunha-Neto, E
AF Bilate, AMB
   Salemi, VMC
   Ramires, FJA
   Brito, T
   Mady, C
   Kalil, J
   Cunha-Neto, E
TI Syrian hamsters (Mesocricetus auratus) develop chronic heart dysfunction
   upon infection with Trypanosoma cruzi. An animal model for Chagas'
   disease cardiomyopathy?
SO CIRCULATION
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Salemi, Vera/AAY-5024-2020; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012; Ramires, Felix JA/D-5996-2012; Salemi, Vera
   MC/C-9104-2013
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Ramires, Felix JA/0000-0003-2437-2485;
   Salemi, Vera MC/0000-0002-7152-1810
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 31
PY 2000
VL 102
IS 18
SU S
MA 3682
BP 762
EP 763
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 367QE
UT WOS:000090072303674
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Dulphy, N
   Douay, C
   Coelho, V
   Cunha-Neto, E
   Oshiro, SE
   Assis, RV
   Tanaka, AC
   Pomerantzeff, PMA
   Charron, D
   Toubert, A
   Kalil, J
AF Guilherme, L
   Dulphy, N
   Douay, C
   Coelho, V
   Cunha-Neto, E
   Oshiro, SE
   Assis, RV
   Tanaka, AC
   Pomerantzeff, PMA
   Charron, D
   Toubert, A
   Kalil, J
TI Molecular evidence for antigen-driven immune responses in cardiac
   lesions of rheumatic heart disease patients
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE autoimmunity; M protein; rheumatic heart disease; superantigens; TCR
ID STREPTOCOCCAL M-PROTEIN; T-CELL REPERTOIRES; CLASS-II ANTIGENS; HLA-DR;
   GENE USAGE; FEVER; SUPERANTIGEN; ASSOCIATION; MYOSIN; EXPANSIONS
AB Rheumatic heart disease (RHD) is a sequel of post-streptococcal throat infection. Molecular mimicry between streptococcal and heart components has been proposed as the triggering factor of the disease, and CD4(+) T cells have been found predominantly at pathological sites in the heart of RHD patients. These infiltrating T cells are able to recognize streptococcal M protein peptides, involving mainly 1-25, 81-103 and 163-177 N-terminal amino acids residues. In the present work we focused on the TCR beta chain family (TCR BV) usage and the degree of clonality assessed by beta chain complementarity-determining region (CDR)-3 length analysis. We have shown that in chronic RHD patients, TCR BV usage in peripheral blood mononuclear cells (PBMC) paired with heart-infiltrating T cell lines (HIL) is not suggestive of a superantigen effect. Oligoclonal T cell expansions were more frequently observed in HIL than in PBMC, Some major BV expansions were shared between the mitral valve (Miv) and left atrium (LA)T cell lines, but an in-depth analysis of BJ segments usage in these shared expansions as well as nucleotide sequencing of the CDR3 regions suggested that different antigenic peptides could be predominantly recognized in the Miv and the myocardium, Since different antigenic proteins probably are constitutively represented in myocardium and valvular tissue, these findings could suggest a differential epitope recognition at the two lesional heart sites after a common initial bacterial challenge.
C1 Univ Sao Paulo, Heart Inst InCor, Sch Med, Sao Paulo, Brazil.
   Dept Clin Med, Sao Paulo, Brazil.
   Int Scholar Howard Hughes Med Inst, Sao Paulo, Brazil.
   Univ Juiz Fora, Dept Pathol, Minas Gerais, Brazil.
   Univ Paris, Hop St Louis, Inst Hematol, INSERM U396,Lab Immunol & Histocompatibil, F-75252 Paris, France.
RP Guilherme, L (corresponding author), FMUSP, HC, Inst Coracao, Lab Imunol Transplantes, Av Dr Eneas Carvalho Agular,500-3, BR-05403000 Sao Paulo, SP, Brazil.
RI Dulphy, Nicolas/J-5960-2017; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009; Pomerantzeff, Pablo M A/L-5525-2016; COELHO,
   VERONICA/D-1433-2013; Toubert, Antoine/Q-3404-2017; Guglielmi, Luiza
   G/E-7676-2013
OI Dulphy, Nicolas/0000-0002-1243-6456; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Pomerantzeff, Pablo M
   A/0000-0003-0566-1038; Toubert, Antoine/0000-0002-7308-7317; 
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331
   ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   Bach JF, 1996, LANCET, V347, P644, DOI 10.1016/S0140-6736(96)91202-7
   BEHAR SM, 1995, ARTHRITIS RHEUM-US, V38, P458, DOI 10.1002/art.1780380403
   CHOPRA P, 1988, INT J CARDIOL, V20, P99, DOI 10.1016/0167-5273(88)90319-1
   CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0
   CUNHANETO E, 2000, IN PRESS PATHOGENIC
   Cunningham MW, 1997, INFECT IMMUN, V65, P3913, DOI 10.1128/IAI.65.9.3913-3923.1997
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   CUNNINGHAM MW, 1988, J IMMUNOL, V141, P2760
   Currier JR, 1996, J IMMUNOL, V157, P170
   Currier JR, 1996, HUM IMMUNOL, V48, P39, DOI 10.1016/0198-8859(96)00076-6
   DAJANI AS, 1993, CIRCULATION, V87, P302
   DALE JB, 1982, J EXP MED, V156, P1165, DOI 10.1084/jem.156.4.1165
   DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   Degnan B, 1997, HUM IMMUNOL, V53, P206, DOI 10.1016/S0198-8859(97)00028-1
   Dietrich PY, 1997, INT IMMUNOL, V9, P1073, DOI 10.1093/intimm/9.8.1073
   Dulphy N, 1999, J IMMUNOL, V162, P3830
   EVEN J, 1995, RES IMMUNOL, V146, P65, DOI 10.1016/0923-2494(96)80240-9
   FLEISCHER B, 1992, INFECT IMMUN, V60, P1767, DOI 10.1128/IAI.60.5.1767-1770.1992
   Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369
   Garderet L, 1998, BLOOD, V91, P340, DOI 10.1182/blood.V91.1.340.340_340_346
   GIBOFSKY A, 1991, J RHEUMATOL, V18, P1
   Gigliotti D, 1996, MOL MED, V2, P452, DOI 10.1007/BF03401904
   Guedez Y, 1999, CIRCULATION, V99, P2784, DOI 10.1161/01.CIR.99.21.2784
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   KAPLAN MH, 1964, J EXP MED, V119, P643, DOI 10.1084/jem.119.4.643
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOTO M, 1990, J IMMUNOL, V145, P1332
   Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375
   Lim A, 1996, HUM IMMUNOL, V48, P77, DOI 10.1016/0198-8859(96)00089-4
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MALKIEL S, 1996, MOL MED TODAY, V2, P337
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55
   MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544
   MASLANKA K, 1995, HUM IMMUNOL, V44, P28, DOI 10.1016/0198-8859(95)00056-A
   OKSENBERG JR, 1993, NATURE, V362, P69
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLMEZ U, 1992, RHEUMATOLOGY, V22, P49
   PADULA SJ, 1985, J CLIN INVEST, V75, P788, DOI 10.1172/JCI111774
   PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319
   PENNINGER JM, 1996, IMMUNOLOGIST, V4, P131
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   PUSIEUX I, 1994, J IMMUNOL, V153, P2807
   RAIZADA V, 1983, AM J MED, V74, P225
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   Schiffenbauer J, 1998, IMMUNOL TODAY, V19, P117, DOI 10.1016/S0167-5699(97)01199-7
   SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131
   STEINMAN L, 1992, IMMUNOL TODAY, V13, P49, DOI 10.1016/0167-5699(92)90133-R
   STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P113
   TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359
   TOMAI MA, 1991, J EXP MED, V174, P285, DOI 10.1084/jem.174.1.285
   TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992
   WANG B, 1993, J IMMUNOL, V151, P1419
   WATANABEOHNISHI R, 1994, J IMMUNOL, V152, P2066
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
   ZABRISKIE JB, 1986, CLIN EXP RHEUMATOL, V4, P65
NR 66
TC 49
Z9 51
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD JUL
PY 2000
VL 12
IS 7
BP 1063
EP 1074
DI 10.1093/intimm/12.7.1063
PG 12
WC Immunology
SC Immunology
GA 340UD
UT WOS:000088552600013
PM 10882418
OA Bronze
DA 2020-11-26
ER

PT J
AU Yamamoto, JH
   Vallochi, AL
   Silveira, C
   Kalil, J
   Nussenblatt, RB
   Cunha-Neto, E
   Gazzinelli, RT
   Belfort, R
   Rizzo, LV
AF Yamamoto, JH
   Vallochi, AL
   Silveira, C
   Kalil, J
   Nussenblatt, RB
   Cunha-Neto, E
   Gazzinelli, RT
   Belfort, R
   Rizzo, LV
TI Discrimination between patients with acquired toxoplasmosis and
   congenital toxoplasmosis on the basis of the immune response to parasite
   antigens
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID T-CELL RECEPTOR; POLYMERASE CHAIN-REACTION; OCULAR TOXOPLASMOSIS;
   IFN-GAMMA; DEFICIENCY SYNDROME; CD8+ LYMPHOCYTES; PROTECTIVE ROLE;
   IN-VIVO; GONDII; ALPHA
AB Many persons infected with Toxoplasma gondii develop ocular lesions, Immunologic parameters in the response to I gondii were evaluated in infected persons with and without ocular lesions and in noninfected controls. Subjects were divided into groups on the basis of presence of serum antibodies to I: gondii, presence of ocular lesions, and clinical history. Production of interleukin-2 and interferon-gamma by peripheral blood mononuclear cells from patients with probable congenital toxoplasmosis was decreased, compared with that in persons with presumed acquired infection. Cell proliferation and delayed-type skin reaction induced by soluble toxoplasma tachyzoite antigen followed the same pattern. Asymptomatic persons showed high levels of interleukin-12 and interferon-gamma, whereas persons with ocular lesions had high interleukin-1 and tumor necrosis factor-alpha responses toward soluble toxoplasma tachyzoite antigen. These data suggest that patients with ocular disease due to congenital infection show tolerance toward the parasite. Furthermore, susceptibility to ocular lesions after acquired toxoplasmosis is associated with high levels of interleukin-1 and tumor necrosis factor-alpha, whereas resistance is associated with high levels of interleukin-12 and interferon-gamma.
C1 Univ Sao Paulo, ICB, Dept Immunol, BR-05509890 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Heart, Lab Transplant Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Lab Med Invest, Sao Paulo, Brazil.
   Fundacao EJ Zerbini, Sao Paulo, Brazil.
   Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
   Fundacao Osvaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
RP Rizzo, LV (corresponding author), Univ Sao Paulo, ICB, Dept Immunol, Av Prof Lineu Prestes 1730, BR-05509890 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Belfort, Rubens/E-2252-2012; Cunha-Neto,
   Edecio/B-4157-2009; Rizzo, Luiz Vicente/B-4458-2009; Yamamoto, Joyce
   H/B-6192-2015; Vallochi, Adriana/W-6405-2018
OI KALIL, JORGE/0000-0001-8415-4274; Belfort, Rubens/0000-0002-8422-3898;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Gazzinelli,
   Ricardo/0000-0003-2427-7699; Yamamoto, Joyce/0000-0001-6869-2988
CR Amichay D, 1996, J IMMUNOL, V157, P4511
   BELFORT R, 1983, ARQ BRAS OFTALMOL, V46, P2
   BERTOLI F, 1995, ARCH PATHOL LAB MED, V119, P214
   BREZIN AP, 1990, AM J OPHTHALMOL, V110, P599, DOI 10.1016/S0002-9394(14)77055-2
   CHAN CC, 1994, AM J OPHTHALMOL, V117, P803, DOI 10.1016/S0002-9394(14)70327-7
   CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   DENKERS EY, 1993, RES IMMUNOL, V144, P51, DOI 10.1016/S0923-2494(05)80099-9
   Denkers EY, 1996, J IMMUNOL, V156, P1089
   DENKERS EY, 1994, J EXP MED, V180, P985, DOI 10.1084/jem.180.3.985
   GAZZINELLI RT, 1994, EXP PARASITOL, V78, P217, DOI 10.1006/expr.1994.1022
   GAZZINELLI RT, 1991, J IMMUNOL, V146, P286
   GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5
   Hayashi S, 1996, BRIT J OPHTHALMOL, V80, P644, DOI 10.1136/bjo.80.7.644
   LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913
   NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303
   NUSSENBLATT RB, 1994, JAMA-J AM MED ASSOC, V271, P304, DOI 10.1001/jama.271.4.304
   NUSSENBLATT RB, 1996, UVEITIS FUNDAMENTALS, V1
   Perkins E S, 1967, Bull Ophthalmol Soc Egypt, V60, P523
   PERKINS ES, 1972, BRIT MED J, V4, P46, DOI 10.1136/bmj.4.5831.46
   PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P1, DOI 10.1136/bjo.57.1.1
   SAARI M, 1976, ARCH OPHTHALMOL-CHIC, V94, P1485, DOI 10.1001/archopht.1976.03910040319005
   SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0
NR 23
TC 62
Z9 64
U1 0
U2 5
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN
PY 2000
VL 181
IS 6
BP 2018
EP 2022
DI 10.1086/315494
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 329TH
UT WOS:000087923900020
PM 10837184
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Fae, KC
   Drigo, SA
   Cunha-Neto, E
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
AF Fae, KC
   Drigo, SA
   Cunha-Neto, E
   Ianni, B
   Mady, C
   Kalil, J
   Goldberg, AC
TI HLA and beta-myosin heavy chain do not influence susceptibility to
   Chagas' disease cardiomyopathy
SO MICROBES AND INFECTION
LA English
DT Article
DE Chagas' cardiomyopathy; autoimmune disease; HLA genes; genetic
   susceptibility
ID TRYPANOSOMA-CRUZI; T-CELLS; IDENTIFICATION; AUTOIMMUNITY; ASSOCIATION;
   MYOCARDITIS; MHC; SCHISTOSOMIASIS; POLYMORPHISM; POPULATION
AB An inflammatory dilated cardiomyopathy occurs in 30% of Chagas' disease patients, chronically infected by Trypanosoma cruzi, while the remaining infected individuals are asymptomatic. Studies have indicated a role for genetic factors in the susceptibility to Chagas' disease cardiomyopathy. In an attempt to identify the genetic factors influencing the development and outcome of Chagas' cardiomyopathy, we compared the frequencies of alleles from two candidate gene loci, class II HLA and a microsatellite marker for the human cardiac beta-myosin heavy chain gene in different clinical groups. Patients were grouped as asymptomatic or with severe or mild cardiomyopathy. The results indicate that the HLA and myosin microsatellite allele profiles in all cardiomyopathy and in asymptomatic groups are similar. In conclusion, these results establish that polymorphism of HLA-DR and -DQ molecules, as well as beta-cardiac myosin, do not influence the susceptibility to different clinical forms of Chagas' disease or the progression to severe Chagas' cardiomyopathy. On the other hand, male sex was identified as a risk factor for progression to the more severe forms of cardiomyopathy (relative risk = 8.75). (C) 2000 Editions scientifiques et medicales Elsevier SAS.
C1 Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Transplant Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Heart Inst InCor, Dept Clin Cardiol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Howard Hughes Med Inst, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Transplant Immunol, Sao Paulo, Brazil.
RI Ianni, Barbara Maria/C-7689-2012; Mady, Charles/C-8870-2012; Drigo,
   Sandra A/I-6514-2012; Goldberg, Anna Carla/H-8594-2014; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; LINDE, SANDRA/S-3128-2019
OI Ianni, Barbara Maria/0000-0002-1588-5492; Mady,
   Charles/0000-0002-8838-199X; Drigo, Sandra A/0000-0001-6747-6642;
   Goldberg, Anna Carla/0000-0003-2600-7940; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274; LINDE,
   SANDRA/0000-0001-6747-6642
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   ASCURRA M, 1990, Memorias do Instituto Oswaldo Cruz, V85, P78
   Barretto A C, 1993, Arq Bras Cardiol, V60, P225
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Chiarella JM, 1998, BRAZ J MED BIOL RES, V31, P665, DOI 10.1590/S0100-879X1998000500010
   Cunha-Neto E, 1998, BRAZ J MED BIOL RES, V31, P133, DOI 10.1590/S0100-879X1998000100018
   Cunha-Neto Edecio, 1997, Memorias do Instituto Oswaldo Cruz, V92, P40
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   De Andrade ALSS, 1998, AM J TROP MED HYG, V59, P530, DOI 10.4269/ajtmh.1998.59.530
   Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197
   FUKUDA K, 1985, TISSUE ANTIGENS, V26, P81
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   Goldberg AC, 1998, HUM IMMUNOL, V59, P183, DOI 10.1016/S0198-8859(97)00265-6
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Hill AVS, 1996, PARASITOLOGY, V112, pS75, DOI 10.1017/S003118200007668X
   Ianni B M, 1998, Arq Bras Cardiol, V71, P21, DOI 10.1590/S0066-782X1998000700005
   Kay RA, 1996, EUR J IMMUNOGENET, V23, P161, DOI 10.1111/j.1744-313X.1996.tb00279.x
   LAYRISSE Z, 1988, HUM IMMUNOL, V23, P116, DOI 10.1016/0198-8859(88)90189-9
   LIAO L, 1993, J CLIN INVEST, V92, P2877, DOI 10.1172/JCI116909
   LLOP E, 1988, REV MED CHILE, V116, P211
   LLOP E, 1991, REV MED CHILE, V119, P633
   MACEDO V, 1982, TXB MED, P1728
   Marques SBD, 1998, BRAZ J MED BIOL RES, V31, P365, DOI 10.1590/S0100-879X1998000300005
   NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Prado Jose Clovis Do Jr., 1998, Parasitology Research, V84, P100
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   Secor WE, 1996, J INFECT DIS, V174, P1131, DOI 10.1093/infdis/174.5.1131
   TRICHSMAN TM, 1983, ADV EXP MED BIOL, V162, P365
   TRICHSMAN TM, 1982, INFECT IMMUN, V35, P546
   Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289
   Warlick C. A., 1992, Human Molecular Genetics, V1, P136, DOI 10.1093/hmg/1.2.136
   WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703
   WilliamsBlangero S, 1997, AM J TROP MED HYG, V57, P538, DOI 10.4269/ajtmh.1997.57.538
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
NR 39
TC 36
Z9 36
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUN
PY 2000
VL 2
IS 7
BP 745
EP 751
DI 10.1016/S1286-4579(00)00501-3
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 342TC
UT WOS:000088660400003
PM 10955954
DA 2020-11-26
ER

PT J
AU Lucchiari, N
   Panajotopoulos, N
   Xu, C
   Rodrigues, H
   Ianhez, LE
   Kalil, J
   Glotz, D
AF Lucchiari, N
   Panajotopoulos, N
   Xu, C
   Rodrigues, H
   Ianhez, LE
   Kalil, J
   Glotz, D
TI Antibodies fluted from acutely rejected renal allografts bind to and
   activate human endothelial cells
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE allograft rejection; acute rejection; endothelial cell; adhesion
   molecules
ID CELLULAR CYTO-TOXICITY; TRANSPLANTATION; INFLAMMATION; RECIPIENTS;
   CRITERIA; KIDNEYS
AB This study was designed co investigate how antiendothelial antibodies (EAbs) are involved in acute irreversible renal graft rejection. Eluates from 25 renal allografts, lost by irreversible rejection (n = 22) and by renal vein thrombosis (controls n = 3), were tested against a panel of cultured human umbilical vein endothelial cells (HUVEC). All patients were under immunosuppression at the time of nephrectomy. EAbs binding and membrane expression of adhesion molecules ELAM-1 and VCAM-1 were analyzed by flow cytometry (FACS) and by semiquantitative RT-PCR for mRNAs coding for those molecules. The absence of anti-HLA antibodies against the donor was ascertained at transplant, and before and after nephrectomy by the negativity of specific crossmatches performed using the most sensitive techniques. EAbs eluted from eight rejected kidneys bound to HUVEC. They did not induce any cytotoxicity, but their incubation with HUVEC (4 h at 37 degrees C; 2.5 mg/ml) led to upregulation of mRNAs coding for VCAM-1 (35- to 60-fold increases) and ICAM-1 (8- to 12-fold increases) as compared with control EAbs, Membrane expression of adhesion molecules was also strikingly increased, with 80% of the cells expressing VCAM-1 and 65% expressing ELAM-1 upon incubation. EAbs were detected in eight out of nine (88.8%) eluates from kidneys lost from acute vascular rejection, but in none of the 13 (0.0%) kidneys lost from other types of rejection (p < 0.0001). We conclude that EAbs, capable of activating human endothelial cells, can be recovered from acutely rejected kidneys and may play a direct role in the pathogenesis of acute rejection. Human Immunology 61, 518-527 (2000). (C) American Society for Histocompatibility and Immunogenetics, 2000. Published by Elsevier Science Inc.
C1 Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Unity Renal Transplantat, BR-05403000 Sao Paulo, Brazil.
   Hop Broussais, INSERM, U430, Unite Rech Immunopathol Humaine, F-75674 Paris, France.
RP Lucchiari, N (corresponding author), Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol Transplantes, Rua Dr Eneas de Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil.
RI Glotz, Denis/F-7881-2011; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Glotz, Denis/0000-0001-5258-4237
CR ANDRES GA, 1970, LAB INVEST, V22, P588
   BACH FH, 1993, XENO, V41, P8
   BALDWIN WM, 1981, TRANSPLANT P, V13, P1547
   BALDWIN WM, 1983, TISSUE ANTIGENS, V21, P254
   BALDWIN WM, 1995, TRANSPLANTATION, V59, P797, DOI 10.1097/00007890-199503270-00001
   BERGSTRAND A, 1985, CLIN NEPHROL, V24, P107
   BRASILE L, 1986, SURGERY, V99, P639
   CERILLI J, 1983, HUM IMMUNOL, V7, P45, DOI 10.1016/0198-8859(83)90006-X
   CERILLI J, 1985, TRANSPLANTATION, V39, P286, DOI 10.1097/00007890-198503000-00016
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P150
   DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S
   FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030
   FUGGLE SV, 1993, TRANSPLANTATION, V55, P117, DOI 10.1097/00007890-199301000-00022
   GARAVOY MR, 1978, NEPHRON, V22, P208
   HOPKINS KA, 1990, ASHI LABORATORY MANU, P195
   Iwaki Y, 1987, CLIN TRANSPLANT, V1, P125
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   JEANNET M, 1970, NEW ENGL J MED, V282, P111, DOI 10.1056/NEJM197001152820301
   Jutte N H, 1993, Transpl Immunol, V1, P39, DOI 10.1016/0966-3274(93)90057-F
   KALIL J, 1989, TRANSPLANT P, V21, P711
   KARUPPAN SS, 1992, TRANSPLANTATION, V54, P839, DOI 10.1097/00007890-199211000-00014
   KISSMEYE F, 1966, LANCET, V2, P662, DOI 10.1016/S0140-6736(66)92829-7
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MCPHAUL J J JR, 1970, Journal of Clinical Investigation, V49, P308, DOI 10.1172/JCI106240
   MILTENBURG AMM, 1989, TRANSPLANTATION, V48, P681
   MORAES JR, 1976, TISSUE ANTIGENS, V8, P272
   MULLER C, 1987, CLIN IMMUNOL IMMUNOP, V44, P12, DOI 10.1016/0090-1229(87)90047-X
   NOREEN HJ, 1990, ASHI LABORATORY MANU, P307
   PATEL R, 1969, NEW ENGL J MED, V280, P735, DOI 10.1056/NEJM196904032801401
   PAUL LC, 1979, TRANSPLANT P, V11, P427
   PAUL LC, 1985, TRANSPLANTATION, V40, P117, DOI 10.1097/00007890-198508000-00001
   POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259
   SOULILLOU JP, 1981, TRANSPLANT P, V13, P1551
   VONVILLEBRAND E, 1996, TRANSPL IMMUNOL, V4, P57
   WILLIAMS GM, 1968, NEW ENGL J MED, V279, P611, DOI 10.1056/NEJM196809192791201
   YARD B, 1993, TRANSPLANTATION, V55, P1287, DOI 10.1097/00007890-199306000-00015
NR 38
TC 43
Z9 44
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAY
PY 2000
VL 61
IS 5
BP 518
EP 527
DI 10.1016/S0198-8859(00)00109-9
PG 10
WC Immunology
SC Immunology
GA 310EU
UT WOS:000086814200012
PM 10773356
DA 2020-11-26
ER

PT J
AU Galbiatti, F
   Kalil, J
   Rizzo, L
AF Galbiatti, F
   Kalil, J
   Rizzo, L
TI The imbalance in the immune system causing X-linked lymphoproliferative
   syndrome (XLP) is corrected by cytokine treatment.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Lab Invest Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Lab Invest Med, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR 20
PY 2000
VL 14
IS 6
SU S
BP A932
EP A932
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 307FQ
UT WOS:000086643100116
DA 2020-11-26
ER

PT J
AU Damico, FM
   Neto, EC
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Kalil, J
   Yamamoto, JH
AF Damico, FM
   Neto, EC
   Goldberg, AC
   Iwai, LK
   Marin, ML
   Kalil, J
   Yamamoto, JH
TI HLA-DBR1*0405 and presentation of peptides derived from human
   melanocyte/melanoma proteins in Vogt-Koyanagi-Harada Syndrome.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Heart Inst, InCor, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.
RI Damico, Francisco Max/G-1175-2015; KALIL, JORGE/C-8029-2012; Iwai, Leo
   K/M-1734-2013; Goldberg, Anna Carla/H-8594-2014; Yamamoto, Joyce
   H/B-6192-2015
OI Damico, Francisco Max/0000-0002-2594-0336; KALIL,
   JORGE/0000-0001-8415-4274; Iwai, Leo K/0000-0002-1571-7763; Goldberg,
   Anna Carla/0000-0003-2600-7940; 
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 2000
VL 41
IS 4
SU S
MA 4121B68
BP S777
EP S777
PG 1
WC Ophthalmology
SC Ophthalmology
GA 300HF
UT WOS:000086246704190
DA 2020-11-26
ER

PT J
AU Spadafora-Ferreira, M
   Lopes, AAB
   Coelho, V
   Guilherme, L
   Kalil, J
AF Spadafora-Ferreira, M
   Lopes, AAB
   Coelho, V
   Guilherme, L
   Kalil, J
TI Two novel anti-von Willebrand Factor monoclonal antibodies
SO THROMBOSIS RESEARCH
LA English
DT Article
DE von Willebrand factor; endothelial cells; monoclonal antibodies;
   coagulation; platelet aggregation
ID HUMAN-ENDOTHELIAL-CELLS; FACTOR-VIII BINDING; VONWILLEBRAND-FACTOR;
   FACTOR VWF; PULMONARY-HYPERTENSION; GLYCOPROTEIN IB; IDENTIFICATION;
   DISEASE; LOCALIZATION; POLYPEPTIDE
AB Von Willebrand Factor is a multimer produced by endothelial cells and megakaryocytes, being stared in intracellular organelles, such as the Weibel-Palade bodies and or-granules in endothelial cells and platelets, respectively. This molecule acts as a carrier protein for factor VIIIc, involved in the intrinsic pathway of blood coagulation maintaining its stability in circulation. Von Willebrand Factor also plays an important role in platelet aggregation and adhesion to injured vessel wall. It interacts with platelets through two distinct glycoproteins, GPIb and GPIIb/IIIa. We raised two monoclonal antibodies, ECA-3 and ECA-4, against human umbilical vascular endothelial cells that recognize and immunoprecipitate van Willebrand Factor. Interestingly , ECA-4 monoclonal antibody is able to completely inhibit platelet agglutination induced by ristocetin, suggesting that it binds to von Willebrand Factor close to platelet GPIb binding site, The use of monoclonal antibodies to identify van Willebrand Factor binding regions to factor VIII or platelets has been reported by others. In pulmonary hypertension, abnormalities have been detected on the multimeric structure of the molecule as well as on its proteolytic fragments, by using monoclonal antibodies. Moreover, monoclonal antibodies raised against specific regions of von Willebrand Factor molecule may allow studies of functional abnormalities of this protein in inherited and acquired disorders like subtypes of van Willebrand's disease. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Heart Inst InCor, Sch Med, BR-05508 Sao Paulo, Brazil.
   Hemoctr Sao Paulo, Fdn Prosangue, BR-05403000 Sao Paulo, SP, Brazil.
RP Kalil, J (corresponding author), FMUSP, Lab Imunol Transplantes, Inst Coracao, Av Dr Encas Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, SP, Brazil.
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Lopes, Antonio
   Augusto/C-4408-2012; Guglielmi, Luiza G/E-7676-2013; Spadafora-Ferreira,
   Monica/G-2635-2012
OI KALIL, JORGE/0000-0001-8415-4274; Lopes, Antonio
   Augusto/0000-0002-8939-2252; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929
CR BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169
   Beacham DA, 1997, BLOOD, V89, P4071, DOI 10.1182/blood.V89.11.4071
   BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
   COLLER BS, 1983, BLOOD, V61, P99
   CREVAT D, 1983, ANN INST PASTEUR IMM, VC134, P31, DOI 10.1016/S0769-2625(83)80151-2
   Danilovs J, 1980, HISTOCOMPATIBILITY T, P287
   DATTA YH, 1995, CIRCULATION, V92, P3304, DOI 10.1161/01.CIR.92.11.3304
   DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306
   FEDERICI AB, 1993, BLOOD, V81, P720
   GIRMA JP, 1986, BLOOD, V67, P1356
   GIRMA JP, 1987, BLOOD, V70, P605
   GOODALL AH, 1985, THROMB HAEMOSTASIS, V54, P878
   HARLOW E, 1988, ANTIBODIES LAB MANUA, P283
   HATTORI R, 1989, J BIOL CHEM, V264, P7768
   Isobe T, 1997, J BIOL CHEM, V272, P8447, DOI 10.1074/jbc.272.13.8447
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   JAFFE EA, 1980, TRANSPL P, V12, P49
   JORIEUX S, 1994, BRIT J HAEMATOL, V87, P113, DOI 10.1111/j.1365-2141.1994.tb04879.x
   Kaartinen M, 1996, ATHEROSCLEROSIS, V123, P123, DOI 10.1016/0021-9150(95)05794-3
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kroner PA, 1996, BLOOD, V87, P1013, DOI 10.1182/blood.V87.3.1013.bloodjournal8731013
   Lattuada A, 1997, THROMB HAEMOSTASIS, V78, P813
   LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679
   LOPES AAB, 1995, EUR RESPIR J, V8, P530
   LOPES AAB, 1993, CHEST, V104, P1455, DOI 10.1378/chest.104.5.1455
   MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406
   MEYER D, 1984, BRIT J HAEMATOL, V57, P597, DOI 10.1111/j.1365-2141.1984.tb02937.x
   ROSE M, 1991, EUR HEART J, V12, P147, DOI 10.1093/eurheartj/12.suppl_D.147
   SAENKO EL, 1997, J BIOL CHEM, V272, P1807
   SULTAN Y, 1984, THROMB HAEMOSTASIS, V52, P250
   Tanigawa N, 1996, CANCER RES, V56, P2671
   TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013
   THORGEIRSSON G, 1978, American Journal of Pathology, V93, P803
   Tomisaki S, 1996, CANCER, V77, P1722, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1722::AID-CNCR22>3.0.CO;2-Z
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   VANDERPOLL T, 1992, THROMB HAEMOSTASIS, V67, P623
   VANE JR, 1990, NEW ENGL J MED, V323, P27
   VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184
   Vlot AJ, 1996, BLOOD, V87, P1809
   VONSON WJ, 1997, TRANSPLANT P, V29, P161
   WAGNER DD, 1983, J BIOL CHEM, V258, P2065
   Yokoyama K, 1997, BIOCHEM BIOPH RES CO, V234, P147, DOI 10.1006/bbrc.1997.6605
NR 43
TC 9
Z9 9
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD JAN 15
PY 2000
VL 97
IS 2
BP 3
EP 13
DI 10.1016/S0049-3848(99)00122-X
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 279CU
UT WOS:000085026400002
PM 10688330
DA 2020-11-26
ER

PT J
AU Giavina-Bianchi, PF
   Kalil, JE
   Rizzo, LV
AF Giavina-Bianchi, PF
   Kalil, JE
   Rizzo, LV
TI The development of an animal model for perennial allergic conjunctivitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI Rizzo, Luiz Vicente/B-4458-2009; Giavina-Bianchi, Pedro/I-3112-2014;
   KALIL, JORGE/C-8029-2012
OI Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2000
VL 105
IS 1
SU S
MA 140
BP S47
EP S47
DI 10.1016/S0091-6749(00)90571-2
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 287WR
UT WOS:000085530100139
DA 2020-11-26
ER

PT J
AU Guerra, C
   Kalil, J
   Barros, MT
AF Guerra, C
   Kalil, J
   Barros, MT
TI Prevalence of primary immunodeficiences in families of patients with IgA
   deficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Div Allegy & Immunopathol, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2000
VL 105
IS 1
SU S
MA 651
BP S219
EP S219
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 287WR
UT WOS:000085530100647
DA 2020-11-26
ER

PT J
AU Guerra, CV
   Kalil, J
   Barros, MT
AF Guerra, CV
   Kalil, J
   Barros, MT
TI Follow-up of serum immunoglobulin levels in IgA deficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Div Allergy & Immunopathol, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2000
VL 105
IS 1
SU S
MA 655
BP S221
EP S221
DI 10.1016/S0091-6749(00)91083-2
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 287WR
UT WOS:000085530100651
DA 2020-11-26
ER

PT J
AU Guerra, CV
   Kalil, J
   Barros, MT
AF Guerra, CV
   Kalil, J
   Barros, MT
TI Serum immunoglobulin levels in IgA deficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Div Allergy & Immunopathol, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2000
VL 105
IS 1
SU S
MA 650
BP S219
EP S219
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 287WR
UT WOS:000085530100646
DA 2020-11-26
ER

PT J
AU Motta, AA
   Araujo, P
   Martinez, J
   Machado, LM
   Kalil, J
   Barros, MT
AF Motta, AA
   Araujo, P
   Martinez, J
   Machado, LM
   Kalil, J
   Barros, MT
TI Interaction between IgE-mediated hypersensitivity and delayed T-cell
   responses to domiciliar mites in atopic dermatitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Div Allergy & Immunopathol, BR-05508 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2000
VL 105
IS 1
SU S
MA 135
BP S46
EP S46
DI 10.1016/S0091-6749(00)90566-9
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 287WR
UT WOS:000085530100134
DA 2020-11-26
ER

PT J
AU Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Farias, AQ
   Massarollo, PCB
   Mies, S
   Kalil, J
   Goldberg, AC
AF Palacios, SA
   Bittencourt, PL
   Cancado, ELR
   Farias, AQ
   Massarollo, PCB
   Mies, S
   Kalil, J
   Goldberg, AC
TI Familial amyloidotic polyneuropathy type 1 in Brazil is associated with
   the transthyretin Val30Met variant
SO AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION
LA English
DT Article
DE transthyretin; familial amyloidotic polyneuropathy; Brazil
ID LIVER-TRANSPLANTATION
AB Familial amyloidotic polyneuropathy type I (FAP1) is an inherited systemic amyloidosis that is secondary to the deposition of transthyretin (TTR) variants in peripheral nerves and in certain visceral organs. More than 50 distinct mutations have already been described in the TTR gene. Yet, the most common mutation found worldwide is a substitution of valine for methionine in position 30 (Val30Met). Currently, the variants of TTR in Brazilian FAP1 patients remain largely unknown and the aim of this study was to analyze the frequency of the TTR Val30Met mutation in such Brazilian subjects. Methods: Thirty-two FAP1 patients belonging to 24 different families were studied for the presence of Val30Met variant by PCR-RFLP. Results: All Brazilian FAP1 subjects studied were positive for the TTR Val30Met variant. As expected, all of them were heterozygous for the mutation. Conclusion: TTR Val30Met mutation was the sole TTR variant found in Brazilian FAP1 patients in this cohort, and it was present even in those subjects without a clear history of Portuguese ancestry.
C1 Univ Sao Paulo, Sch Med, Liver Unit, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Inst Heart, Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), 129 Rua Ouro Branco,Apt 105, BR-0142508 Sao Paulo, Brazil.
RI Massarollo, Paulo/AAS-3567-2020; Farias, Alberto/ABB-1291-2020; Cancado,
   Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Farias, Alberto
   Q/H-7873-2013; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014; Massarollo, Paulo/I-2283-2013
OI Massarollo, Paulo/0000-0001-6398-1027; Farias,
   Alberto/0000-0002-5572-663X; Cancado, Eduardo/0000-0002-9309-1524;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; Goldberg, Anna Carla/0000-0003-2600-7940;
   Massarollo, Paulo/0000-0001-6398-1027
CR BENSON MD, 1986, J RHEUMATOL, V13, P927
   Dubrey SW, 1997, TRANSPLANTATION, V64, P74, DOI 10.1097/00007890-199707150-00014
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   Monteiro E, 1998, HEPATO-GASTROENTEROL, V45, P1375
   MURAKAMI T, 1995, PATHOL INT, V45, P1, DOI 10.1111/j.1440-1827.1995.tb03373.x
   NAKAZATO M, 1992, INTERNAL MED, V31, P1335, DOI 10.2169/internalmedicine.31.1335
   NICHOLS WC, 1990, CLIN GENET, V37, P44
   Saraiva M J, 1991, Neuromuscul Disord, V1, P3, DOI 10.1016/0960-8966(91)90037-S
   Sousa A, 1995, AM J MED GENET, V60, P512, DOI 10.1002/ajmg.1320600606
   SOUSA A, 1993, HUM HERED, V43, P288, DOI 10.1159/000154146
NR 10
TC 14
Z9 14
U1 0
U2 1
PU PARTHENON PUBLISHING GROUP
PI CARNFORTH LANCASHIRE
PA CASTERTON HALL, CARNFORTH LANCASHIRE LA6 2LA, ENGLAND
SN 1350-6129
J9 AMYLOID
JI Amyloid-Int. J. Exp. Clin. Investig.
PD DEC
PY 1999
VL 6
IS 4
BP 289
EP 291
DI 10.3109/13506129909007342
PG 3
WC Biochemistry & Molecular Biology; Medicine, General & Internal;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; General & Internal Medicine; Research
   & Experimental Medicine
GA 263WK
UT WOS:000084148100009
PM 10611951
DA 2020-11-26
ER

PT J
AU Damiani, D
   Guedes, DR
   Fellous, M
   Barbaux, S
   McElreavey, K
   Kalil, J
   Goldberg, ACK
   Moreira, CA
   Barbosa, A
   Manna, TD
   Dichtchekenian, V
   Setian, N
AF Damiani, D
   Guedes, DR
   Fellous, M
   Barbaux, S
   McElreavey, K
   Kalil, J
   Goldberg, ACK
   Moreira, CA
   Barbosa, A
   Manna, TD
   Dichtchekenian, V
   Setian, N
TI Ullrich-Turner syndrome: Relevance of searching for Y chromosome
   fragments
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE Ullrich-Turner syndrome; Turner's syndrome; dysgenic gonads; Y
   chromosome; gonadoblastoma; FISH
ID GONADAL-DYSGENESIS; GONADOBLASTOMA; GENE; DELETIONS; MOSAICISM;
   SEQUENCES; REGION; MARKER; 45,X; SRY
AB Forty consecutive patients with Ullrich-Turner syndrome (UTS) were followed-up and investigated for the presence of Y chromosome fragments in their genomes, We used the polymerase chain reaction (PCR) to detect SRY (sex-determining region on the Y chromosome) and the sequence-tagged sites (STS) sY57, sY59, sY85, sY94, sY124 and sY157 - which correspond to regions 3C (sY57 and 59), 5C, 5G, 5P, and 6F, respectively, of the Y chromosome searching for Y fragments that could bear the putative locus (loci) for gonadoblastoma (GBY). It has been shown that the presence of GBY greatly increases the risk of dysgenic gonads to undergo malignant transformation. Among our 40 patients, we found Y-derived sequences - including SRY and the region spanning from sY57 to sY94 - in two. These two patients had a marker chromosome detected by conventional cytogenetic analysis (45,X/46,X + mar). Their gonads were excised and found to be streaks. In one of the patients, we found foci of primitive sex cords (amidst the gonadal stroma), oviducts and Wolffian remnants. Fluorescence in situ hybridization (FISH) did not show Y chromosome material in her gonad-derived fibroblasts, The other girl had hyperplastic Leydig cells in the gonadal stroma, oviducts and Wolffian remnants, with signs of epididymal differentiation. PCR assays performed on DNA extracted from paraffin-embedded gonadal tissue were negative for SRY sequences in both patients. These findings show that all UTS patients should be examined for Y chromosome material, and that positive cases should have their dysgenic gonads excised due to the high risk of malignancy.
C1 Univ Sao Paulo, Sch Med, Pediat Endocrinol Unit, Inst Crianca,Hosp Clin, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Transplant Immunol Lab, Inst Coracao, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Sao Paulo, Brazil.
RP Damiani, D (corresponding author), Rua Bela Cintra 2117,Apto 9,C Cesar, BR-01415002 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Barbaux,
   Sandrine C/B-2878-2019; moreira-filho, carlos alberto/J-2551-2014;
   Barbosa, Angela S/I-3518-2013
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; Barbaux, Sandrine C/0000-0002-8204-1855;
   moreira-filho, carlos alberto/0000-0003-3433-4714; Barbosa, Angela
   S/0000-0002-6458-9489
CR BARBAUX S, 1995, HUM MOL GENET, V4, P1565, DOI 10.1093/hmg/4.9.1565
   BARBOSA AS, 1995, HUM GENET, V95, P63
   BINDER G, 1995, J CLIN ENDOCR METAB, V80, P3532, DOI 10.1210/jc.80.12.3532
   COTO E, 1995, AM J MED GENET, V57, P393, DOI 10.1002/ajmg.1320570305
   DAMIANI D, 1990, HUM GENET, V85, P85
   HSU LYF, 1994, AM J MED GENET, V53, P108, DOI 10.1002/ajmg.1320530204
   KOCOVA M, 1993, LANCET, V342, P140, DOI 10.1016/0140-6736(93)91345-M
   KOEBERL DD, 1995, AM J HUM GENET, V57, P661
   KRASNA IH, 1992, J PEDIATR SURG, V27, P1376, DOI 10.1016/0022-3468(92)90180-F
   Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675
   LIPPE B, 1991, ENDOCRIN METAB CLIN, V20, P121, DOI 10.1016/S0889-8529(18)30284-6
   LIPPE BM, 1996, PEDIAT ENDOCRINOLOGY, P387
   MEDLEJ R, 1992, J CLIN ENDOCR METAB, V75, P1289, DOI 10.1210/jc.75.5.1289
   MULVIHILL JJ, 1975, LANCET, V1, P863
   NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097
   PETROVIC V, 1992, J MED GENET, V29, P542, DOI 10.1136/jmg.29.8.542
   Petrusevska R, 1996, CLIN GENET, V49, P261
   PIERGA JY, 1994, GYNECOL ONCOL, V55, P459, DOI 10.1006/gyno.1994.1323
   Rosenfeld RG, 1998, J PEDIATR-US, V132, P319, DOI 10.1016/S0022-3476(98)70452-4
   SCHELLHAS HF, 1974, OBSTET GYNECOL, V44, P289
   SULTANA R, 1995, GENE CHROMOSOME CANC, V13, P257, DOI 10.1002/gcc.2870130405
   TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400
   VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769
NR 23
TC 8
Z9 8
U1 0
U2 2
PU FREUND PUBLISHING HOUSE LTD
PI LONDON
PA STE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON W1R 5FA, ENGLAND
SN 0334-018X
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD NOV-DEC
PY 1999
VL 12
IS 6
BP 827
EP 831
PG 5
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 264MF
UT WOS:000084185500003
PM 10614539
DA 2020-11-26
ER

PT J
AU Panajotopoulos, N
   Silva, RA
   Rodrigues, H
   Oliveira, ZNP
   Fukumori, LMI
   Ianhez, LE
   Nahas, W
   Kalil, J
AF Panajotopoulos, N
   Silva, RA
   Rodrigues, H
   Oliveira, ZNP
   Fukumori, LMI
   Ianhez, LE
   Nahas, W
   Kalil, J
TI Clinical significance of skin crossmatch in kidney transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Latin-American-Transplantation-Society/5th Congress
   of the Pan-American-Dialysis-and-Transplantation-Society
CY MAR 10-13, 1999
CL CANELA, BRAZIL
SP Latin Amer Transplantat Soc, Pan Amer Dialysis & Transplantat Soc
ID REJECTION
C1 Univ Sao Paulo, Fac Med, Inst Heart, Transplantat Immunol Lab, BR-05403000 Sao Carlos, SP, Brazil.
   Univ Sao Paulo, Fac Med, Dept Dermatol, Renal Transplantat Unit Urol, BR-05403000 Sao Carlos, SP, Brazil.
RP Panajotopoulos, N (corresponding author), Univ Sao Paulo, Fac Med, Lab Immunol Transplantes, Inst Coracao, Rua Dr Eneas Carvalho Aguiar,500,3 Andar, BR-05403000 Sao Carlos, SP, Brazil.
RI KALIL, JORGE/C-8029-2012; Silva, Rosemeire A/B-8486-2012
OI KALIL, JORGE/0000-0001-8415-4274; Silva, Rosemeire/0000-0003-1901-5678
CR Iwaki Y, 1987, CLIN TRANSPLANT, V1, P125
   KALIL J, 1989, TRANSPLANT P, V21, P711
   MORAES J, 1991, TRANSPLANTATION, V50, P370
   MORAES JR, 1989, TRANSPLANTATION, V48, P951, DOI 10.1097/00007890-198912000-00010
   MORAES JR, 1991, TRANSPLANT P, V23, P471
   TERASAKI P, 1989, TRANSPLANT P, V21, P615
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 1999
VL 31
IS 7
BP 2982
EP 2983
DI 10.1016/S0041-1345(99)00634-X
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 255GL
UT WOS:000083661100107
PM 10578357
DA 2020-11-26
ER

PT J
AU Rodrigues, H
   Monteiro, F
   Massarolo, P
   Viggiani, C
   Preuhs, G
   Panajotopoulos, N
   Leitao, R
   Mies, S
   Raia, S
   Kalil, J
AF Rodrigues, H
   Monteiro, F
   Massarolo, P
   Viggiani, C
   Preuhs, G
   Panajotopoulos, N
   Leitao, R
   Mies, S
   Raia, S
   Kalil, J
TI Clinical significance of donor-specific alloantibodies in liver
   transplant recipients
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Latin-American-Transplantation-Society/5th Congress
   of the Pan-American-Dialysis-and-Transplantation-Society
CY MAR 10-13, 1999
CL CANELA, BRAZIL
SP Latin Amer Transplantat Soc, Pan Amer Dialysis & Transplantat Soc
C1 Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Clin Med & Liver Unity, Sao Paulo, Brazil.
RP Rodrigues, H (corresponding author), Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol Transplantes, Rua Dr Eneas Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI Massarollo, Paulo/AAS-3567-2020; Massarollo, Paulo/I-2283-2013; KALIL,
   JORGE/C-8029-2012
OI Massarollo, Paulo/0000-0001-6398-1027; Massarollo,
   Paulo/0000-0001-6398-1027; KALIL, JORGE/0000-0001-8415-4274
CR HANTO DW, 1987, CLIN TRANSPLANT, V1, P304
   KATZ SM, 1994, TRANSPLANTATION, V57, P4
   LOBO PI, 1993, TRANSPLANTATION, V53, P5
   MANEZ R, 1995, HEPATOLOGY, V21, P5
   TAKAYA S, 1992, TRANSPLANTATION, V53, P400, DOI 10.1097/00007890-199202010-00026
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 1999
VL 31
IS 7
BP 2986
EP 2987
DI 10.1016/S0041-1345(99)00636-3
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 255GL
UT WOS:000083661100109
PM 10578359
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Rodrigues, H
   Viggiani, C
   Fiorelli, A
   Stolf, N
   Kalil, J
AF Monteiro, F
   Rodrigues, H
   Viggiani, C
   Fiorelli, A
   Stolf, N
   Kalil, J
TI Influence of pretransplant allosensitization in cardiac transplant
   outcome
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Latin-American-Transplantation-Society/5th Congress
   of the Pan-American-Dialysis-and-Transplantation-Society
CY MAR 10-13, 1999
CL CANELA, BRAZIL
SP Latin Amer Transplantat Soc, Pan Amer Dialysis & Transplantat Soc
ID SURVIVAL
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor,Lab Transplantat Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor,Dept Clin Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Heart, InCor,Surg Div, Sao Paulo, Brazil.
RP Monteiro, F (corresponding author), Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol Transplantes, Rue Dr Eneas Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR Kobashigawa JA, 1996, CIRCULATION, V94, P294
   LOH E, 1994, J HEART LUNG TRANSPL, V13, P194
   MCCLOSKEY D, 1989, TRANSPLANT P, V21, P804
   OPELZ G, 1990, CARDIAC TRANSPLANTAT, P91
NR 4
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 1999
VL 31
IS 7
BP 2988
EP 2988
DI 10.1016/S0041-1345(99)00637-5
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 255GL
UT WOS:000083661100110
PM 10578360
DA 2020-11-26
ER

PT J
AU Panajotopoulos, N
   Rodrigues, H
   Viggiani, CS
   Rosales, C
   Ianhez, LE
   Kalil, J
AF Panajotopoulos, N
   Rodrigues, H
   Viggiani, CS
   Rosales, C
   Ianhez, LE
   Kalil, J
TI Relevance of positive B-cell crossmatch in renal transplantation with
   living donors
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Latin-American-Transplantation-Society/5th Congress
   of the Pan-American-Dialysis-and-Transplantation-Society
CY MAR 10-13, 1999
CL CANELA, BRAZIL
SP Latin Amer Transplantat Soc, Pan Amer Dialysis & Transplantat Soc
ID ANTIBODIES; ALLOGRAFT; KIDNEY
C1 Univ Sao Paulo, Fac Med, Transplantat Immunol Lab, Heart Inst,Renal Transplantat Unit Urol, BR-05403000 Sao Paulo, Brazil.
RP Panajotopoulos, N (corresponding author), Univ Sao Paulo, Fac Med, Inst Coracao, Lab Imunol Transplantes, Rua Dr Eneas Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR AYOUB G, 1980, TRANSPLANTATION, V29, P227, DOI 10.1097/00007890-198003000-00013
   DAPICE AJF, 1979, TRANSPLANTATION, V27, P324, DOI 10.1097/00007890-197905000-00007
   HART DNJ, 1981, TRANSPLANTATION, V31, P428, DOI 10.1097/00007890-198106000-00005
   JEANNET M, 1981, TRANSPLANTATION, V31, P160, DOI 10.1097/00007890-198103000-00003
   PANAJOTOPOULOS N, 1992, CLIN TRANSPLANT, V6, P196
   TAYLOR CJ, 1989, TRANSPLANTATION, V48, P953, DOI 10.1097/00007890-198912000-00011
   TAYLOR CJ, 1987, TISSUE ANTIGENS, V30, P104
   TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601
NR 8
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 1999
VL 31
IS 7
BP 2994
EP 2995
DI 10.1016/S0041-1345(99)00639-9
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 255GL
UT WOS:000083661100112
PM 10578362
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Farias, AQ
   Carrilho, FJ
   Marin, ML
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Farias, AQ
   Carrilho, FJ
   Marin, ML
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI HLA class II antigens and tumor necrosis factor (TNF) gene polymorphism
   in patients with autoimmune cholestatic liver diseases.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014; BITTENCOURT, PAULO l/I-5817-2014; Carrilho, Flair
   J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274;
   Goldberg, Anna Carla/0000-0003-2600-7940; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1999
VL 30
IS 4
SU S
MA 1608
BP 562A
EP 562A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 239XE
UT WOS:000082794701605
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Drigo, S
   Laudanna, AA
   Kalil, J
   Goldberg, AC
AF Bittencourt, PL
   Palacios, SA
   Cancado, EL
   Porta, G
   Carrilho, FJ
   Drigo, S
   Laudanna, AA
   Kalil, J
   Goldberg, AC
TI Analysis of -308 tumor necrosis factor (TNF) polymorphism in patients
   with autoimmune hepatitis types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sao Paulo, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; Cancado, Eduardo/K-1861-2016; KALIL,
   JORGE/C-8029-2012; Carrilho, Flair J/I-3046-2012; Goldberg, Anna
   Carla/H-8594-2014
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; Cancado,
   Eduardo/0000-0002-9309-1524; KALIL, JORGE/0000-0001-8415-4274; Goldberg,
   Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1999
VL 30
IS 4
SU S
MA 1634
BP 569A
EP 569A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 239XE
UT WOS:000082794701632
DA 2020-11-26
ER

PT J
AU Duranti, MA
   Franzoni, L
   Sartor, G
   Benedetti, A
   Iwai, LK
   Gruber, A
   Zingales, B
   Guzman, F
   Kalil, J
   Spisni, A
   Cunha-Neto, E
AF Duranti, MA
   Franzoni, L
   Sartor, G
   Benedetti, A
   Iwai, LK
   Gruber, A
   Zingales, B
   Guzman, F
   Kalil, J
   Spisni, A
   Cunha-Neto, E
TI Trypanosoma cruzi: Conformational preferences of antigenic peptides
   bearing the immunodominant epitope of the B13 antigen
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Trypanosoma cruzi; Chagas' disease; B13 antigen; repetitive epitope;
   antigenicity; immunodominance; peptide conformation
ID LINKED-IMMUNOSORBENT-ASSAY; CHAGAS-DISEASE; SYNTHETIC PEPTIDES;
   SECONDARY STRUCTURE; COMPLETE SEQUENCE; PROTEIN ANTIGENS;
   TRIFLUOROETHANOL; REACTIVITY; ANTIBODIES; PLASMODIUM
AB Duranti, M. A., Franzoni, L., Sartor, G., Benedetti, A., Iwai, L,. K., Gruber, A., Zingales, B., Guzman, F, Kalil, J., Spisni. A., and Cunha-Neto, E. 1999. Trypanosoma cruzi: Conformational preferences of antigenic peptides bearing the immunodominant epitope of the B13 antigen. Expermental Parasitology 93, 38-44. The Trypanosoma cruzi recombinant protein B13 contains tandemly repeated domains and shows high sensitivity in the serological diagnosis of Chagas' disease. it has been shown that the immunodominant epitope of B13 is contained in the GDKPSLFGQAAAGDKPSLF-NH2 sequence and that the hexapeptide AAAGDK seems to be the "core" of that epitope. Three peptides containing that "core" sequence, one corresponding to the entire repeat motif GDKPSLFGQAAAGDKPSLF-NH2, pB13, and two smaller fragments, FGQAAAGDK-NH2, S4, and QAAAGDKPS-NH2, S5, have been tested in competitive ELISA with recombinant protein B13 in the solid phase against 40 chagasic sera from Brazilian patients. The median percentage inhibition for pB13, S4, and S5 were, respectively, 91, 86, and 68%. The possibility that the distinct antigenic activity of those peptides correlates with the existence of preferential conformational properties has been investigated by CD and NMR spectroscopy. Results indicate their propensity to adopt a helical configuration. centered in the AAAGDK sequence, and whose extent and stability directly correlates with the peptides' antigenicity. The data are discussed in the light of the existence of conformational preferences involving immunodominant epitopes in tandemly repeated antigens. (C) 1999 Academic Press.
C1 Univ Sao Paulo, Fac Med, Inst Heart, Lab Transplantat Immunol, BR-05403 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Fac Vet Med & Zootechny, BR-05403 Sao Paulo, SP, Brazil.
   Univ Sao Paulo, Inst Chem, BR-05403 Sao Paulo, SP, Brazil.
   Univ Parma, Inst Biol Chem, I-43100 Parma, Italy.
   Univ Nacl Colombia, Hosp San Juan Dios, Inst Immunol, Bogota, Colombia.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Inst Heart, Lab Transplantat Immunol, BR-05403 Sao Paulo, SP, Brazil.
EM edecunha@usp.br
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Iwai, Leo
   K/M-1734-2013; Guzman, Fanny fg/K-5592-2013; Gruber, Arthur/B-4711-2011
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Iwai, Leo K/0000-0002-1571-7763; Guzman,
   Fanny fg/0000-0003-1537-0904; Gruber, Arthur/0000-0001-8093-2278
CR CAZZULO JJ, 1992, FASEB J, V6, P3259
   Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305
   DYSON HJ, 1985, NATURE, V318, P480
   DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V
   DYSON HJ, 1995, FASEB J, V9, P37
   DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U
   DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P7828, DOI 10.1021/bi00486a008
   FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568
   FRASCH ACC, 1991, PARASITOL TODAY, V7, P148, DOI 10.1016/0169-4758(91)90284-U
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989
   IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6
   JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020
   KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145
   LEDER L, 1995, BIOMEDICAL PEPTIDES, V1, P109
   LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025
   NUSSENZWEIG V, 1986, AM J TROP MED HYG, V35, P678, DOI 10.4269/ajtmh.1986.35.678
   OHERN PA, 1991, MOL IMMUNOL, V28, P1047, DOI 10.1016/0161-5890(91)90019-G
   PERALTA JM, 1994, J CLIN MICROBIOL, V32, P971, DOI 10.1128/JCM.32.4.971-974.1994
   SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L
   SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015
   STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7
   VERGARA U, 1992, AM J TROP MED HYG, V46, P39, DOI 10.4269/ajtmh.1992.46.39
   WHISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647
   Wutrich K, 1986, NMR PROTEINS NUCL AC
NR 27
TC 6
Z9 6
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD SEP
PY 1999
VL 93
IS 1
BP 38
EP 44
DI 10.1006/expr.1999.4428
PG 7
WC Parasitology
SC Parasitology
GA 321UR
UT WOS:000087473500005
PM 10464037
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Palacios, SA
   Chiarella, JM
   Abrantes-Lemos, CP
   Baggio, VL
   Laudanna, AA
   Kalil, J
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Palacios, SA
   Chiarella, JM
   Abrantes-Lemos, CP
   Baggio, VL
   Laudanna, AA
   Kalil, J
TI Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1
   and 2
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID CHRONIC ACTIVE HEPATITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMERS
   PCR-SSP; LIVER-DISEASE; C VIRUS; ANTIBODY TYPE-1; HLA; SEQUENCE;
   AUTOANTIBODIES; ASSOCIATION
AB OBJECTIVE: Susceptibility to autoimmune hepatitis (AIH) type 1 has been associated with DRB1*03, DRB1*04, and DRB3 alleles in European and North-American whites, with DRB1*04 in Japan, and with DRB1*04 and DRB1*13 in Latin America. Very few studies have been performed on AIH type 2. The aim of the present study was to evaluate the association of AIH types 1 and 2 with HLA-DR and DQ loci.
   METHODS: We performed HLA-DRB and -DQB1 typing by polymerase chain reaction amplification with sequence-specific primers (PCR-SSP) in 139 AIH patients. Most had AIH type 1 associated with circulating anti-smooth muscle antibody with F-actin specificity or antinuclear antibody. Twenty-eight patients presented AIH type 2 with anti-liver/kidney microsome type 1 or anti-liver cytosol type 1 antibodies.
   RESULTS: We observed a significant increase of DRB1*13 (70% vs 26% of controls, p < 0.00001) and DRB3 (93% vs 69% of controls, p < 0.00001) in AIH type 1 patients. Analysis of patients without DRB1*13 disclosed a secondary association with DRB1*03 (70% vs 30% of controls, p = 0.0001) and either the DRB1*13 or the DRB1*03 alleles were present in the majority of these patients (91% vs 48% of controls, p = 0.001). Comparison of DRB1*13- and DRB1*03-positive subjects revealed that the former alleles conferred susceptibility to younger patients with AIH type I. DQB1 typing showed a significant increase in DQB1*06 (68% vs 41% of controls, p = 0.00007) in strong linkage disequilibrium with DRB1*13,and a decrease in DQB1*0301 (8% vs 47% of controls, p(c) = 0.0003). On the other hand, HLA typing of patients with AIH type 2 disclosed a significant increase in the DRB1*07 (68% vs 20% of controls, p(c) < 0.00014), DRB4 (79% vs 43% of controls, p(c) = 0.004), and DQB1*02 (86% vs 42%, p = 0.00002) alleles. After exclusion of DRB1*07, a secondary association with HLA-DRB1*03 was further observed in these patients (78% vs 30%, p = 0.007) and most of them had either DRB1*07 or DRB1*03 (93% vs 44% of controls, p(c) < 0.0001).
   CONCLUSIONS: Our data indicate that predisposition to AIH types 1 and 2 is associated, respectively, with the DRB1*13 or DRB1*03 and DRB1*07 or DRB1*03 alleles, and suggest that protection against type 1 disease may be conferred by DQB1*0301. In addition, the cluster of DRB1*13 in children with AIH type 1 also supports the concept that different HLA alleles might influence the onset of the disease. (Am J Gastroenterol 1999;94:1906-1913. (C) 1999 by Am. Coll. of Gastroenterology).
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Lab Transplantat Immunol,Heart Inst, BR-01246000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, BR-01246000 Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Univ Sao Paulo, Fac Med, Unidade Figado, Av Dr Arnaldo 455,3 Andar, BR-01246000 Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; Farias, Alberto Q/H-7873-2013; Goldberg,
   Anna Carla/H-8594-2014; Farias, Alberto/ABB-1291-2020; BITTENCOURT,
   PAULO l/I-5817-2014; KALIL, JORGE/C-8029-2012; Carrilho, Flair
   J/I-3046-2012
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; Farias, Alberto/0000-0002-5572-663X;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; 
CR ABUAF N, 1992, HEPATOLOGY, V16, P892, DOI 10.1002/hep.1840160407
   ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
   Bittencourt PL, 1998, AM J GASTROENTEROL, V93, P1394, DOI 10.1111/j.1572-0241.1998.1394a.x
   Bittencourt PL, 1996, HEPATOLOGY, V24, P423
   BODMER JG, 1994, TISSUE ANTIGENS, V44, P1, DOI 10.1111/j.1399-0039.1994.tb02351.x
   BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R
   Cancado E. L. R., 1996, Hepatology, V24, p492A
   Cancado ELR, 1996, HEPATOLOGY, V23, P1098
   CORDONERFRANCH P, 1989, CLIN EXP IMMUNOL, V75, P354
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311
   DOHERTY DG, 1994, AUTOIMMUNITY, V18, P243, DOI 10.3109/08916939409009525
   DONALDSON P, 1994, HEPATOLOGY, V20, P225, DOI 10.1002/hep.1840200133
   DUCLOSVALLEE JC, 1995, GASTROENTEROLOGY, V108, P470, DOI 10.1016/0016-5085(95)90076-4
   Fainboim L, 1997, HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL I: WORKSHOP, P418
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   Goldberg A. C., 1996, Human Immunology, V47, P32, DOI 10.1016/0198-8859(96)84848-8
   Goldberg AC, 1998, GENET MOL BIOL, V21, P301, DOI 10.1590/S1415-47571998000300001
   GOLDBERG AC, 1997, HLA 1997, P330
   GORSKI J, 1986, NATURE, V322, P67, DOI 10.1038/322067a0
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   HEARD R, 1994, HLA DIS, P123
   HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Jurado A, 1997, J HEPATOL, V26, P983, DOI 10.1016/S0168-8278(97)80106-7
   Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406
   KRAWITT EL, 1994, AM J MED, V96, P23, DOI 10.1016/0002-9343(94)90186-4
   LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O
   Lenzi M., 1997, Hepatology, V26, p443A
   LENZI M, 1991, J HEPATOL, V16, P59
   LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266
   MANABE K, 1994, GASTROENTEROLOGY, V106, P1321, DOI 10.1016/0016-5085(94)90025-6
   MANNS M, 1991, HEPATOLOGY, V14, pA60
   MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949
   MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
   MARCOS Y, 1994, HEPATOLOGY, V19, P1371, DOI 10.1016/0270-9139(94)90230-5
   MURATORI L, 1995, GUT, V37, P406, DOI 10.1136/gut.37.3.406
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   REDDY KR, 1995, J VIRAL HEPATITIS, V2, P175, DOI 10.1111/j.1365-2893.1995.tb00026.x
   SCULLY LJ, 1993, GASTROENTEROLOGY, V104, P1478, DOI 10.1016/0016-5085(93)90359-K
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
   Strettell MDJ, 1997, HEPATOLOGY, V26, P1023, DOI 10.1053/jhep.1997.v26.pm0009328330
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   WHITTINGHAM S, 1981, CLIN EXP IMMUNOL, V43, P80
   WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597
NR 50
TC 112
Z9 124
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 1999
VL 94
IS 7
BP 1906
EP 1913
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 212NW
UT WOS:000081224000034
PM 10406258
DA 2020-11-26
ER

PT J
AU Kalil, J
   Abel, LCJ
   Rizzo, LV
   Fae, K
   Goldberg, AC
   Mady, C
   Ianni, B
   Hammer, J
   Sinigaglia, F
   Cunha-Neto, E
AF Kalil, J
   Abel, LCJ
   Rizzo, LV
   Fae, K
   Goldberg, AC
   Mady, C
   Ianni, B
   Hammer, J
   Sinigaglia, F
   Cunha-Neto, E
TI Autoimmunity in human Chagas' disease cardiomyopathy: T cell molecular
   mimicry and effector mechanisms
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Fac Med, Clin Immunol Allergy & Heart Inst, Sao Paulo, Brazil.
   Univ Sao Paulo, Dept Immunol, Sao Paulo, Brazil.
   Roche Milano Ric, Milan, Italy.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; Ianni, Barbara
   Maria/C-7689-2012; Rizzo, Luiz Vicente/B-4458-2009; Goldberg, Anna
   Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Ianni, Barbara Maria/0000-0002-1588-5492;
   Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 15
PY 1999
VL 13
IS 5
SU S
BP A976
EP A976
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 228JG
UT WOS:000082132901905
DA 2020-11-26
ER

PT J
AU Yamamoto, JH
   Goncalves, ACP
   Duranti, M
   Neto, EC
   Rizzo, LV
   Fujino, Y
   Kalil, J
AF Yamamoto, JH
   Goncalves, ACP
   Duranti, M
   Neto, EC
   Rizzo, LV
   Fujino, Y
   Kalil, J
TI Purification of human and bovine S-antigen by anion-exchange FPLC.
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
RI Goncalves, Allan C. Pieroni/W-2538-2019; Yamamoto, Joyce H/B-6192-2015;
   Rizzo, Luiz Vicente/B-4458-2009; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 1999
VL 40
IS 4
MA 1115B23
BP S212
EP S212
PG 1
WC Ophthalmology
SC Ophthalmology
GA 178MF
UT WOS:000079269201115
DA 2020-11-26
ER

PT J
AU Coelho, V
   Spadafora-Ferreira, M
   Marrero, I
   Fonseca, JA
   Portugal, K
   Kalil, J
AF Coelho, V
   Spadafora-Ferreira, M
   Marrero, I
   Fonseca, JA
   Portugal, K
   Kalil, J
TI Evidence of indirect allorecognition in long-term human renal
   transplantation
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE indirect; alloreactivity; renal; transplantation
ID T-CELL ALLORECOGNITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DONOR
   MHC PEPTIDES; CLASS-I PEPTIDES; INDIRECT RECOGNITION;
   ALLOGRAFT-REJECTION; GRAFT-REJECTION; ANTIGENS CONTRIBUTES; KIDNEY
   ALLOGRAFTS; MOLECULAR-BASIS
AB The purpose of this study was to investigate indirect alloreactivity in the peripheral blood of long-term renal transplanted patients. We evaluated the T cell proliferative response to a whole pool of donor cell-derived allopeptides, processed and presented by host antigen-presenting cells (APC), rather than to synthetic peptides. For the indirect pathway, proliferation assays were performed using APC-depleted donor cells. Indirect alloreactivity was detected in 57% (8/14) of the patients, 6 of whom presented no evidence of rejection, but 2 patients had a diagnosis of chronic rejection. In 4 of 8 positive cases (50%), proliferation was detected with 5 days of culture, and sometimes indirect alloresponse was the dominant route. We present evidence that the indirect alloproliferative response to a pool of naturally processed donor peptides is present in the peripheral blood of long-term renal transplanted patients irrespective of rejection. (C) 1999 Academic Press.
C1 Univ Sao Paulo, Inst Coracao, Lab Imunol Transplantes, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Unidade Transplante Renal, BR-05403000 Sao Paulo, Brazil.
RP Coelho, V (corresponding author), Univ Sao Paulo, Inst Coracao, Lab Imunol Transplantes, BR-05403000 Sao Paulo, Brazil.
RI COELHO, VERONICA/D-1433-2013; Spadafora-Ferreira, Monica/G-2635-2012;
   KALIL, JORGE/C-8029-2012
OI Spadafora-Ferreira, Monica/0000-0001-8823-9929; KALIL,
   JORGE/0000-0001-8415-4274
CR ANSARI AA, 1992, J HEART LUNG TRANSPL, V11, P467
   AUCHINCLOSS H, 1993, P NATL ACAD SCI USA, V90, P3373, DOI 10.1073/pnas.90.8.3373
   BENHAM AM, 1995, TRANSPLANTATION, V59, P1028, DOI 10.1097/00007890-199504150-00019
   BENHAM AM, 1995, TRANSPLANT P, V27, P547
   BENICHOU G, 1994, J IMMUNOL, V153, P938
   BENICHOU G, 1992, J EXP MED, V175, P305, DOI 10.1084/jem.175.1.305
   BESOUW NM, 1996, TRANSPLANTATION, V61, P165
   BRADLEY JA, 1992, IMMUNOL TODAY, V13, P434, DOI 10.1016/0167-5699(92)90069-J
   BRAUN MY, 1993, TRANSPLANTATION, V55, P177, DOI 10.1097/00007890-199301000-00033
   Chen WJ, 1996, TRANSPLANTATION, V62, P705, DOI 10.1097/00007890-199609270-00001
   Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117
   Colovai A I, 1996, Int Rev Immunol, V13, P161, DOI 10.3109/08830189609061745
   DALCHAU R, 1992, EUR J IMMUNOL, V22, P669, DOI 10.1002/eji.1830220309
   ECKELS DD, 1990, TISSUE ANTIGENS, V35, P49, DOI 10.1111/j.1399-0039.1990.tb01755.x
   FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521
   GALLON L, 1995, TRANSPLANTATION, V59, P612
   KALIL J, 1982, IA ANTIGENS, P55
   LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6
   LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31
   LECHLER RI, 1982, J EXP MED, V156, P1835, DOI 10.1084/jem.156.6.1835
   LEE RS, 1994, J EXP MED, V179, P865, DOI 10.1084/jem.179.3.865
   Liu Z, 1996, CLIN IMMUNOL IMMUNOP, V78, P228, DOI 10.1006/clin.1996.0034
   LIU Z, 1993, J EXP MED, V177, P1648
   Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898
   MASON DW, 1981, IMMUNOLOGY, V44, P75
   MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75
   MULUK SC, 1991, TRANSPLANTATION, V52, P284, DOI 10.1097/00007890-199108000-00019
   Popov IA, 1995, TRANSPLANTATION, V60, P1621
   Rose ML, 1996, J HEART LUNG TRANSPL, V15, P342
   Saleem M, 1996, IMMUNOL LETT, V54, P21, DOI 10.1016/S0165-2478(96)02636-3
   Sayegh MH, 1996, KIDNEY INT, V49, pS13
   SCHULICK RD, 1993, TRANSPLANTATION, V56, P590
   SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.iy.11.040193.002125
   SPANER D, 1993, P NATL ACAD SCI USA, V90, P8415, DOI 10.1073/pnas.90.18.8415
   Susskind B, 1996, HUM IMMUNOL, V46, P1, DOI 10.1016/0198-8859(95)00215-4
   Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331
   Vella JP, 1997, TRANSPLANTATION, V64, P1823, DOI 10.1097/00007890-199712270-00033
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
   Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777
NR 39
TC 7
Z9 7
U1 0
U2 5
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD FEB
PY 1999
VL 90
IS 2
BP 220
EP 229
DI 10.1006/clim.1998.4626
PG 10
WC Immunology
SC Immunology
GA 176WW
UT WOS:000079175900010
PM 10080834
DA 2020-11-26
ER

PT J
AU Coelho, V
   Marrero, I
   Noronha, I
   Benvenuti, LA
   Van Kaer, L
   Kalil, J
AF Coelho, V
   Marrero, I
   Noronha, I
   Benvenuti, LA
   Van Kaer, L
   Kalil, J
TI TAP1 mutant mice reject heart grafts from donors with no MHC disparity
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT XVIIth World Congress of the Transplantation-Society
CY JUL 12-17, 1998
CL MONTREAL, CANADA
SP Transplantat Soc
ID T-CELLS
C1 Incor HC FMUSP, Lab Imunol Transplantes, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Coracao, Transplantat Immunol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Coracao, Dept Pathol, Sao Paulo, Brazil.
   Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN USA.
RP Coelho, V (corresponding author), Incor HC FMUSP, Lab Imunol Transplantes, 3Andar,Av Dr Eneas Carvalho Agular 500, Sao Paulo, Brazil.
RI Van Kaer, Luc/H-1033-2015; KALIL, JORGE/C-8029-2012; COELHO,
   VERONICA/D-1433-2013; Benvenuti, Luiz/C-6614-2014
OI Van Kaer, Luc/0000-0001-5275-2309; KALIL, JORGE/0000-0001-8415-4274; 
CR ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525
   FULMER RI, 1963, AM J ANAT, V113, P273, DOI 10.1002/aja.1001130206
   LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975
   LJUNGGREN HG, 1995, IMMUNOLOGIST, V3, P136
   VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6
   ZIJLSTRA M, 1992, J EXP MED, V175, P885, DOI 10.1084/jem.175.4.885
NR 6
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB-MAR
PY 1999
VL 31
IS 1-2
BP 900
EP 901
DI 10.1016/S0041-1345(98)01828-4
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 173BG
UT WOS:000078960600406
PM 10083397
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Laudanna, A
   Kalil, J
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Carrilho, FJ
   Farias, AQ
   Laudanna, A
   Kalil, J
TI Different HLA profiles confer susceptibility to autoimmune hepatitis
   types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Transplantat Immunol, Inst Heart, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Childrens Inst, Liver Unit, Sao Paulo, Brazil.
RI BITTENCOURT, PAULO l/I-5817-2014; KALIL, JORGE/C-8029-2012; Cancado,
   Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; Goldberg, Anna
   Carla/H-8594-2014
OI BITTENCOURT, PAULO l/0000-0003-0883-4870; KALIL,
   JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1998
VL 28
IS 4
SU S
MA 303
BP 238A
EP 238A
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 125VQ
UT WOS:000076258100302
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Chiarella, JM
   Marin, MLC
   Rosales, C
   Banic, D
   Oliveira, MA
   Rodrigues, H
   Viggiani, CS
   Kalil, J
AF Goldberg, AC
   Chiarella, JM
   Marin, MLC
   Rosales, C
   Banic, D
   Oliveira, MA
   Rodrigues, H
   Viggiani, CS
   Kalil, J
TI Molecular typing of HLA class II antigens in a Sao Paulo population
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
ID BRAZILIAN POPULATIONS
AB In the present paper we show data obtained from a normal population with a racially mixed profile typical of the city of Sao Paulo, State of Sao Paulo. Data were generated with polymerase chain reaction using sequence specific primers (PCR-SSP) for HLA-DRB and polymerase chain reaction followed by hybridization with sequence specific oligonucleotide probes (PCR-SSO) for HLA-DQA1 and HLA-DQB1 loci. HLA-DRB, DQA1, DQB1 and haplotype frequencies as well as common linkage disequilibria were found. This population was also shown to be in genetic equilibrium according to the Hardy-Weinberg law. HLA-DR typing of a normal sample from the city of Porto Velho, State of Rondonia, highlighted the importance of different sets of HLA profiles found in other regions of the country. This database provides essential information for screening studies of disease associations, forensic analyses and transplants.
C1 Univ Sao Paulo, Fac Med, Lab Imunol Transplantes, InCor, BR-00540300 Sao Paulo, Brazil.
   Fiocruz Manguinhos, Dept Imunol, Rio De Janeiro, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Fac Med, Lab Imunol Transplantes, InCor, Av Eneas Carvalho Aguiar 500,3 Andar, BR-00540300 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR BAUR MP, 1980, HISTOCOMPATIBILITY T, P955
   BIGNON JD, 1995, 12 INT HIST WORKSH
   DAUSSET J, 1985, COMPLEXE MAJEUR HIST, P116
   FERNANDEZVINA M, 1991, TISSUE ANTIGENS, V38, P235, DOI 10.1111/j.1399-0039.1991.tb01904.x
   FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299, DOI 10.1007/BF00211994
   Goodman AH, 1997, SCIENCES, V37, P20, DOI 10.1002/j.2326-1951.1997.tb03296.x
   GORODEZKY C, 1992, HLA 1991, V1, P662
   HLA Colombani J, 1993, HLA FONCTIONS IMMUNI
   KERMAN R, 1994, CLIN TRANSPLANTS 199, P431
   MORAES JR, 1996, HEMATOLOGIA HEMOTERA, V1, P18
   MORAES ME, 1993, TISSUE ANTIGENS, V41, P238, DOI 10.1111/j.1399-0039.1993.tb02012.x
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   TRACHTENBERG A, 1988, ANN HUM BIOL, V15, P213, DOI 10.1080/03014468800009651
NR 13
TC 9
Z9 10
U1 0
U2 1
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PD SEP
PY 1998
VL 21
IS 3
BP 301
EP 305
DI 10.1590/S1415-47571998000300001
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 134NJ
UT WOS:000076749200001
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Laudanna, AA
   Kalil, J
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Laudanna, AA
   Kalil, J
TI Different HLA profiles confer susceptibility to autoimmune hepatitis
   type 1 and 2
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
C1 Univ Sao Paulo, Sch Med,Fac Med,Childrens Inst, Liver Unit,Lab Transplantat Immunol, Heart Inst,Dept Gastroenterol,Unidade Figado, BR-01246000 Sao Paulo, Brazil.
RP Bittencourt, PL (corresponding author), Univ Sao Paulo, Sch Med,Fac Med,Childrens Inst, Liver Unit,Lab Transplantat Immunol, Heart Inst,Dept Gastroenterol,Unidade Figado, Av Dr Arnaldo 455,3 Andar, BR-01246000 Sao Paulo, Brazil.
RI Cancado, Eduardo/K-1861-2016; Goldberg, Anna Carla/H-8594-2014; KALIL,
   JORGE/C-8029-2012; BITTENCOURT, PAULO l/I-5817-2014
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274;
   BITTENCOURT, PAULO l/0000-0003-0883-4870
CR Bittencourt P. L., 1996, Hepatology, V24, p232A
   Czaja AJ, 1997, AM J GASTROENTEROL, V92, P2197
   CZAJA AJ, 1995, AM J GASTROENTEROL, V90, P1206
   FAINBOIM L, 1994, HUM IMMUNOL, V41, P146, DOI 10.1016/0198-8859(94)90008-6
   Goldberg A. C., 1996, Human Immunology, V47, P32, DOI 10.1016/0198-8859(96)84848-8
   JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
   Jurado A, 1997, J HEPATOL, V26, P983, DOI 10.1016/S0168-8278(97)80106-7
   Lenzi M., 1997, Hepatology, V26, p443A
   LENZI M, 1991, J HEPATOL, V16, P59
   MANNS M, 1991, HEPATOLOGY, V14, P60
   MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8
NR 11
TC 18
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD AUG
PY 1998
VL 93
IS 8
BP 1394
EP 1395
DI 10.1111/j.1572-0241.1998.1394a.x
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 109PC
UT WOS:000075330800052
PM 9707090
DA 2020-11-26
ER

PT J
AU Chiarella, JM
   Goldberg, AC
   Abel, L
   Carvalho, EM
   Kalil, J
   Dessein, A
AF Chiarella, JM
   Goldberg, AC
   Abel, L
   Carvalho, EM
   Kalil, J
   Dessein, A
TI Absence of linkage between MHC and a gene involved in susceptibility to
   human schistosomiasis
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE HLA; linkage study; human schistosomiasis
ID PROTECTIVE IMMUNITY; MANSONI; INFECTION; RESISTANCE; MICE
AB Six hundred million people are at risk of infection by Schistosoma mansoni. MHC haplotypes have been reported to segregate with susceptibility to schistosomiasis in murine models. In humans, a major gene related to susceptibility/resistance to infection by S. mansoni (SM1) and displaying the mean fecal egg count as phenotype was detected by segregation analysis. This gene displayed a codominant mode of inheritance with an estimated frequency of 0.20-0.25 for the deleterious allele and accounted for more than 50% of the variance of infection levels. To determine if the SM1 gene segregates with the human MHC chromosomal region, we performed a linkage study by the lod score method. We typed for HLA-A, B, C, DR and DQ antigens in 11 informative families from an endemic area for schistosomiasis in Bahia, Brazil, by the microlymphocytotoxicity technique. HLA-DR typing by the polymerase chain reaction with sequence-specific primers (PCR-SSP) and HLA-DQ were confirmed by PCR-sequence-specific oligonucleotide probes (PCR-SSOP). The lod scores for the different theta values obtained clearly indicate that there is no physical linkage between HLA and SM1 genes. Thus, susceptibility or resistance to schistosomiasis, as defined by mean fecal egg count, is not primarily dependent on the host's HLA profile. However, if the HLA molecule plays an important role in specific immune responses to S. mansoni, this may involve the development of the different clinical aspects of the disease such as granuloma formation and development of hepatosplenomegaly.
C1 Univ Sao Paulo, FM, HC, Lab Imunol Transplantes, BR-05403000 Sao Paulo, Brazil.
   Hop La Pitie Salpetriere, Ctr Informat Med, INSERM U436, Paris, France.
   Hosp Clin, Lab Imunol, Salvador, BA, Brazil.
   Fac Med, INSERM U439, Ctr Immunol & Genet Malad Parasitaires, Marseille, France.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, FM, HC, Lab Imunol Transplantes, Av Dr Eneas C Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
EM goldberg@usp.br
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Abel,
   Laurent/H-8888-2017; Alain, Dessein/A-3142-2009; Abel, Lucia Cristina
   Jamli/P-8816-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; Abel, Laurent/0000-0001-7016-6493; Abel,
   Lucia Cristina Jamli/0000-0003-4915-4265
CR ABEL L, 1991, AM J HUM GENET, V48, P959
   AMOS DB, 1976, MANUAL CLIN IMMUNOLO
   BINA JC, 1978, HUM BIOL, V50, P41
   BODMER JG, 1995, HUM IMMUNOL, V43, P149, DOI 10.1016/0198-8859(95)00071-B
   BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235
   CAPRON A, 1992, ANNU REV MED, V43, P209, DOI 10.1146/annurev.me.43.020192.001233
   CORREAOLIVEIRA R, 1986, J IMMUNOL, V137, P2014
   COUISSINIERPARIS P, 1995, EUR J IMMUNOL, V25, P2295, DOI 10.1002/eji.1830250827
   DEVLAS SJ, 1992, PARASITOLOGY, V104, P451, DOI 10.1017/S003118200006371X
   ERLICH HA, 1990, PCR PROTOCOLS, P261
   JONES JT, 1983, PARASITOLOGY, V86, P19, DOI 10.1017/S0031182000057139
   MARQUET S, 1996, NAT GENET, V14, P1
   MORTON NE, 1956, AM J HUM GENET, V8, P80
   MORTON NE, 1955, AM J HUM GENET, V7, P277
   OHTA N, 1990, CLIN EXP IMMUNOL, V79, P403, DOI 10.1111/j.1365-2249.1990.tb08103.x
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OTT J, 1991, ANAL HUMAN GENETIC L
   PESSOA SB, 1986, PARASITOLOGIA MED
   SALAM EA, 1979, J IMMUNOL, V123, P1829
   Secor WE, 1996, J INFECT DIS, V174, P1131, DOI 10.1093/infdis/174.5.1131
   SHER A, 1984, PARASITE IMMUNOL, V6, P319, DOI 10.1111/j.1365-3024.1984.tb00804.x
   WHO, 1987, ATL GLOB DISTR SCHIS
NR 22
TC 6
Z9 8
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAY
PY 1998
VL 31
IS 5
BP 665
EP 670
DI 10.1590/S0100-879X1998000500010
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA ZP928
UT WOS:000073802500010
PM 9698772
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Yamamoto, JH
   Chiarella, JM
   Marin, MLC
   Sibinelli, M
   Neufeld, R
   Hirata, CE
   Olivalves, E
   Kalil, J
AF Goldberg, AC
   Yamamoto, JH
   Chiarella, JM
   Marin, MLC
   Sibinelli, M
   Neufeld, R
   Hirata, CE
   Olivalves, E
   Kalil, J
TI HLA-DRB1*0405 is the predominant Allele in Brazilian patients with
   Vogt-Koyanagi-Harada disease
SO HUMAN IMMUNOLOGY
LA English
DT Article
ID PRIMERS PCR-SSP; MAJOR HISTOCOMPATIBILITY COMPLEX; RHEUMATOID-ARTHRITIS;
   SUSCEPTIBILITY; HLA-DR4; ASSOCIATION; SPECIFICITY; PEPTIDES
AB Vogt-Koyanagi-Harada (VKH) disease is a rare disorder affecting pigmented structures especially the eye and is the main cause of autoimmune non-infectious uveitis in the Brazilian population. The autoimmune target is believed to be the melanocyte. A strong association of VKH disease with HLA-DR4 in the Japanese population is well known. The same association, albeit with lower relative risks has been found in other populations. A secondary association to HLA-DR1 involving a sequence linked with susceptibility to Rheumatoid Arthritis has also been described. VKH disease is more common in non-Caucasian populations. Brazilian patients of varying ethnic origins have been typed for HLA class II antigens. Several of the features found in other population samples are present. Over half of the patients typed HLA-DR4 (20/37) and typing with sequence-specific oligonucleotides disclosed predominance of the DRB1*0405 allele with a relative risk of 11.76 over the general population. In addition, HLA-DR1 and DQ4 were also present, in patients both positive and negative for HLA-DR4. These results suggest that, as in other autoimmune diseases, multiple overlapping susceptibility factors encoded by the MHC complex contribute to the overall susceptibility for the disease, the major factor however, being the presence of the DRB1*0405 allele. (C) American Society for Histocompatibility and Immunogenetics, 1998. Published by Elsevier Science Inc.
C1 Univ Sao Paulo, Inst Heart, Lab Transplant Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Clin Hosp, Dept Ophthalmol, Sao Paulo, Brazil.
   Santa Casa Misericordia Sao Paulo, Dept Ophthalmol, Sch Med, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), FMUSP, INCOR, Lab Imunol Transplantes, Av Eneas de Carvalho Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014; Yamamoto,
   Joyce H/B-6192-2015
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940; Yamamoto, Joyce/0000-0001-6869-2988
CR BIGNON JD, 1995, TECHNICAL HDB 12 INT
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R
   DAVIS JL, 1990, OPHTHALMOLOGY, V97, P1137
   de Abreu M. T., 1980, ARQ BRAS OFTALMOL, V43, P10
   DUNSTON GM, 1990, ARCH DERMATOL, V126, P56, DOI 10.1001/archderm.126.1.56
   GOMI CF, 1997, REV MED SAO PAULO, V76, P101
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847
   ISLAM SMM, 1994, INVEST OPHTH VIS SCI, V35, P3890
   Konno Yasuhiro, 1993, Japanese Journal of Clinical Ophthalmology, V47, P1243
   MATSUSHITA S, 1994, J EXP MED, V180, P873, DOI 10.1084/jem.180.3.873
   Norose K, 1996, BRIT J OPHTHALMOL, V80, P1002, DOI 10.1136/bjo.80.11.1002
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   RAGAWA Y, 1976, NEW ENGL J MED, V295, P173
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   SAKAMOTO T, 1991, ARCH OPHTHALMOL-CHIC, V109, P1270, DOI 10.1001/archopht.1991.01080090096030
   SNYDER DA, 1980, AM J OPHTHALMOL, V90, P69, DOI 10.1016/S0002-9394(14)75078-0
   Sugita S, 1996, INT IMMUNOL, V8, P799, DOI 10.1093/intimm/8.5.799
   SUGIURA S, 1978, JPN J OPHTHALMOL, V22, P9
   SUGIURA S, 1978, JPN J OPHTHALMOL, V22, P36
   WEISZ JM, 1995, OPHTHALMOLOGY, V102, P1012
   WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935
   ZHANG XY, 1992, AM J OPHTHALMOL, V113, P567, DOI 10.1016/S0002-9394(14)74731-2
NR 24
TC 54
Z9 56
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAR
PY 1998
VL 59
IS 3
BP 183
EP 188
DI 10.1016/S0198-8859(97)00265-6
PG 6
WC Immunology
SC Immunology
GA ZD325
UT WOS:000072673900006
PM 9548078
DA 2020-11-26
ER

PT J
AU Cunha-Neto, E
   Rizzo, LV
   Albuquerque, F
   Abel, L
   Guilherme, L
   Bocchi, E
   Bacal, F
   Carrara, D
   Ianni, B
   Mady, C
   Kalil, J
AF Cunha-Neto, E
   Rizzo, LV
   Albuquerque, F
   Abel, L
   Guilherme, L
   Bocchi, E
   Bacal, F
   Carrara, D
   Ianni, B
   Mady, C
   Kalil, J
TI Cytokine production profile of heart-infiltrating T cells in Chagas'
   disease cardiomyopathy
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Trypanosoma cruzi; Chagas' disease cardiomyopathy; immunology;
   cytokines; gamma-interferon
ID TRYPANOSOMA-CRUZI INFECTION; NECROSIS-FACTOR-ALPHA; GAMMA-INTERFERON;
   IFN-GAMMA; MICE; INTERLEUKIN-10; SUSCEPTIBILITY; LYMPHOCYTES;
   MYOCARDITIS; MACROPHAGES
AB The hallmark of chronic Chagas' disease cardiomyopathy (CCC) is the finding of a T cell-rich inflammatory mononuclear cell infiltrate in the presence of extremely few parasites in the heart lesions. The scarcity of parasites in affected heart tissue casts doubt on the direct participation of Trypanosoma cruzi in CCC heart tissue lesions, and suggests the possible involvement of autoimmunity. The cells in the infiltrate are presumably the ultimate effecters of tissue damage, and there is evidence that such cells recognize cardiac myosin in molecular mimicry with T. cruzi proteins rather than primary reactivity to T. cruzi antigens (Cunha-Neto et al. (1996) Journal of Clinical Investigation, 98: 1709-1712). Recently, we have studied heart-infiltrating T cells at the functional level. In this short review we summarize the studies about the role of cytokines in human and experimental T. cruzi infection, along with our data on heart-infiltrating T cells in human Chagas' cardiomyopathy. The bulk of evidence points to a significant production of IFN-gamma and TNF-alpha which may be linked to T. cruzi-induced IL-12 production.
C1 Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao,Lab Imunol Transplantes, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao,Div Clin, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao,Div Cirurg, BR-05403000 Sao Paulo, Brazil.
   NEI, NIH, Bethesda, MD 20892 USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao,Lab Imunol Transplantes, Av Eneas C Aguiar 500, BR-05403000 Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Ianni, Barbara Maria/C-7689-2012;
   Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Bacal,
   Fernando/H-7952-2012; Rizzo, Luiz Vicente/B-4458-2009; Mady,
   Charles/C-8870-2012; Abel, Lucia Cristina Jamli/P-8816-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Ianni, Barbara
   Maria/0000-0002-1588-5492; KALIL, JORGE/0000-0001-8415-4274; Mady,
   Charles/0000-0002-8838-199X; Abel, Lucia Cristina
   Jamli/0000-0003-4915-4265
CR Abel LCJ, 1997, BRAZ J MED BIOL RES, V30, P1305, DOI 10.1590/S0100-879X1997001100007
   Abrahamsohn IA, 1996, EXP PARASITOL, V84, P231, DOI 10.1006/expr.1996.0109
   ALIBERTI JC, 1996, INFECT IMMUN, V64, P2381
   Cardillo F, 1996, INFECT IMMUN, V64, P128, DOI 10.1128/IAI.64.1.128-134.1996
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   deOliveira LCB, 1996, CELL IMMUNOL, V170, P41, DOI 10.1006/cimm.1996.0132
   Dutra WO, 1997, SCAND J IMMUNOL, V45, P74, DOI 10.1046/j.1365-3083.1997.d01-362.x
   Frosch S, 1996, MED MICROBIOL IMMUN, V185, P189, DOI 10.1007/s004300050030
   Frosch S, 1997, INFECT IMMUN, V65, P971, DOI 10.1128/IAI.65.3.971-977.1997
   GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   HOFT DF, 1993, J IMMUNOL, V151, P7038
   HONTEBEYRIEJOSKOWICZ M, 1987, EUR J IMMUNOL, V17, P1027, DOI 10.1002/eji.1830170720
   HUNTER CA, 1996, INFECT IMMUN, V64, P1961
   MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203
   PLATA F, 1984, EUR J IMMUNOL, V14, P930, DOI 10.1002/eji.1830141013
   REED SG, 1994, J IMMUNOL, V153, P3135
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995
   SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169
   SPINELLA S, 1990, EUR J IMMUNOL, V20, P1045, DOI 10.1002/eji.1830200515
   TORRICO F, 1991, J IMMUNOL, V146, P3626
   VANVOORHIS WC, 1992, J IMMUNOL, V148, P239
   WIRTH JJ, 1989, IMMUNOLOGY, V66, P296
   Zhang L, 1996, EUR J IMMUNOL, V26, P102, DOI 10.1002/eji.1830260116
   Zhang L, 1996, EXP PARASITOL, V84, P203, DOI 10.1006/expr.1996.0106
NR 30
TC 47
Z9 51
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 1998
VL 31
IS 1
BP 133
EP 137
DI 10.1590/S0100-879X1998000100018
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA YR478
UT WOS:000071499300018
PM 9686190
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Abel, LCJ
   Kalil, J
   CunhaNeto, E
AF Abel, LCJ
   Kalil, J
   CunhaNeto, E
TI Molecular mimicry between cardiac myosin and Trypanosoma cruzi antigen
   B13: identification of a B13-driven human T cell clone that recognizes
   cardiac myosin
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT XII Annual Meeting of the
   Federacao-de-Sociedades-de-Biologia-Experimental
CY AUG 27-30, 1997
CL CAXAMBU, BRAZIL
SP Federacao Soc Biol Exptl
DE molecular mimicry; crossreactive T cells; cardiac myosin; Trypanosoma
   cruzi; Chagas' disease
ID CHAGAS-DISEASE; NONEXPOSED DONORS; AUTOIMMUNITY; CARDIOMYOPATHY;
   MALARIA; MICE; REACTIVITY; RESPONSES; LESIONS; PROTEIN
AB Previous reports from our group have demonstrated the association of molecular mimicry between cardiac myosin and the immunodominant Trypanosoma cruzi protein B13 with chronic Chagas' disease cardiomyopathy at both the antibody and heart-infiltrating T cell level. At the peripheral blood level, we observed no difference in primary proliferative responses to T. cruzi B13 protein between chronic Chagas' cardiopathy patients, asymptomatic chagasics and normal individuals. In the present study, we investigated whether T cells sensitized by T. cruzi B13 protein respond to cardiac myosin. T cell clones generated from a B13-stimulated T cell line obtained from peripheral blood of a B13-responsive normal donor were tested for proliferation against B13 protein and human cardiac myosin. The results showed that one clone responded to B13 protein alone and the clone FA46, displaying the highest stimulation index to B13 protein (SI = 25.7), also recognized cardiac myosin. These data show that B13 and cardiac myosin share epitopes at the T cell level and that sensitization of a T cell with B13 protein results in response to cardiac myosin, It can be hypothesized that this also occurs in vivo during T. cruzi infection which results in heart tissue damage in chronic Chagas' disease cardiomyopathy.
C1 UNIV SAO PAULO,FAC MED,HOSP CLIN,INST CORACAO,LAB IMUNOL TRANSPLANTES,BR-05403000 SAO PAULO,SP,BRAZIL.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Abel, Lucia
   Cristina Jamli/P-8816-2014
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Abel, Lucia Cristina
   Jamli/0000-0003-4915-4265
CR ALBUQUERQUE F, 1995, MEMORIAS I O CRUZ S1, V90, P150
   Aliberti JCS, 1996, INFECT IMMUN, V64, P1961, DOI 10.1128/IAI.64.6.1961-1967.1996
   Bellotti G, 1996, AM HEART J, V131, P301, DOI 10.1016/S0002-8703(96)90358-0
   BRNADARIZ S, 1996, LANCET, V346, P1370
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   CURRIER J, 1992, INT IMMUNOL, V4, P985, DOI 10.1093/intimm/4.9.985
   FERN J, 1992, J IMMUNOL, V148, P907
   Frosch S, 1997, INFECT IMMUN, V65, P971, DOI 10.1128/IAI.65.3.971-977.1997
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Klein J., 1990, IMMUNOLOGY
   MACEDO V, 1982, CECIL TXB MED, P1728
   PIUVEZAM MR, 1993, J IMMUNOL, V150, P916
   RIBEIRODOSSANTO.R, 1992, J EXP MED, V175, P29
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   SCHMUNIS G A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P287, DOI 10.1590/S0074-02761987000500011
   SINIGAGLIA F, 1992, METHOD ENZYMOL, V203, P370
   Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   VOGEL SN, 1983, J IMMUNOL, V130, P1774
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
   ZEVERING Y, 1992, EUR J IMMUNOL, V22, P689, DOI 10.1002/eji.1830220311
NR 26
TC 33
Z9 33
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 1997
VL 30
IS 11
BP 1305
EP 1308
DI 10.1590/S0100-879X1997001100007
PG 4
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA YF247
UT WOS:A1997YF24700007
PM 9532238
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Marin, MLC
   Carrilho, F
   daSilva, LC
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Marin, MLC
   Carrilho, F
   daSilva, LC
   Kalil, J
   Laudanna, AA
TI Association of primary sclerosing cholangitis with HLA-DR and -DQ
   antigens in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST HEART,LAB TRANSPLANTAT IMMUNOL,BR-05508 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Carrilho, Flair J/I-3046-2012; Cancado,
   Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014; Goldberg, Anna
   Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   BITTENCOURT, PAULO l/0000-0003-0883-4870; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 8
Z9 8
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1420
EP 1420
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401420
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Marin, MLC
   Carrilho, F
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Marin, MLC
   Carrilho, F
   Kalil, J
   Laudanna, AA
TI HLA-DQ association to autoimmune hepatitis types 1 and 2.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST HEART,LAB TRANSPLANTAT IMMUNOL,BR-05508 SAO PAULO,BRAZIL.
RI Cancado, Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; Goldberg,
   Anna Carla/H-8594-2014; BITTENCOURT, PAULO l/I-5817-2014; KALIL,
   JORGE/C-8029-2012
OI Cancado, Eduardo/0000-0002-9309-1524; Goldberg, Anna
   Carla/0000-0003-2600-7940; BITTENCOURT, PAULO l/0000-0003-0883-4870;
   KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1997
VL 26
IS 4
SU S
BP 1421
EP 1421
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA XY874
UT WOS:A1997XY87401421
DA 2020-11-26
ER

PT J
AU Kalil, J
   CunhaNeto, E
AF Kalil, J
   CunhaNeto, E
TI More on Chagas disease cardiomyopathy
SO PARASITOLOGY TODAY
LA English
DT Letter
ID T-CELL CLONES; HEART-DISEASE; AUTOIMMUNITY; PARASITE; LESIONS; PROTEIN;
   DNA
RP Kalil, J (corresponding author), UNIV SAO PAULO,HOSP CLIN,INST CORACAO,FAC MED,BR-05403000 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
CR Bestetti RB, 1996, LANCET, V347, P913, DOI 10.1016/S0140-6736(96)91403-8
   BOCCHI EA, 1993, TRANSPLANT P, V25, P1329
   BRANDARIZ S, 1995, LANCET, V346, P1370, DOI 10.1016/S0140-6736(95)92388-8
   Chocair P. R., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P43, DOI 10.1590/S0037-86821985000100009
   CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   Levin MJ, 1996, PARASITOL TODAY, V12, P415, DOI 10.1016/0169-4758(96)20051-1
   MORROT A, 1996, MEM I OSWALDO CRUS S, V91, P248
   SCHOOTEN W, 1991, IMMUNOL REV, V121, P171
   TEIXEIRA ARL, 1994, MUTAT RES, V305, P197, DOI 10.1016/0027-5107(94)90240-2
   Vianna Gaspar, 1911, Memorias do Instituto Oswaldo Cruz, V3
   WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8
NR 15
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0169-4758
J9 PARASITOL TODAY
JI Parasitol. Today
PD SEP
PY 1997
VL 13
IS 9
BP 362
EP 362
DI 10.1016/S0169-4758(97)87521-7
PG 1
WC Parasitology
SC Parasitology
GA XT472
UT WOS:A1997XT47200014
PM 15275052
DA 2020-11-26
ER

PT J
AU Kalil, J
   CunhaNeto, E
AF Kalil, J
   CunhaNeto, E
TI Autoimmunity in Chagas disease: The mouse model - Reply
SO PARASITOLOGY TODAY
LA English
DT Letter
ID HEART-CELLS
RP Kalil, J (corresponding author), UNIV SAO PAULO,FAC MED,HOSP CLIN,INST CORACAO,BR-05403000 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
CR CUNHANETO E, IN PRESS J CLIN INVE
   HONTEBEYRIEJOSKOWICZ M, 1987, EUR J IMMUNOL, V17, P1027, DOI 10.1002/eji.1830170720
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   RIZZO LV, 1989, INFECT IMMUN, V57, P2460
   SAID G, 1985, ANN NEUROL, V18, P676, DOI 10.1002/ana.410180609
   SANTOSBU.CA, 1974, J EXP MED, V140, P38, DOI 10.1084/jem.140.1.38
   TEIXEIRA ARL, 1978, AM J TROP MED HYG, V27, P1097, DOI 10.4269/ajtmh.1978.27.1097
NR 7
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0169-4758
J9 PARASITOL TODAY
JI Parasitol. Today
PD APR
PY 1997
VL 13
IS 4
BP 157
EP 157
DI 10.1016/S0169-4758(97)90000-4
PG 1
WC Parasitology
SC Parasitology
GA WN167
UT WOS:A1997WN16700013
DA 2020-11-26
ER

PT J
AU Rizzo, LV
   Yamamoto, JH
   Gazzinelli, RT
   Silveira, C
   Kalil, J
   Belfort, R
   Nussenblatt, RB
AF Rizzo, LV
   Yamamoto, JH
   Gazzinelli, RT
   Silveira, C
   Kalil, J
   Belfort, R
   Nussenblatt, RB
TI Low responsiveness towards T-gondii antigens in congenital toxoplasmosis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 NEI,IMMUNOL LAB,BETHESDA,MD 20892.
   USP,DEPT OPHTHALMOL,SAO PAULO,BRAZIL.
   UNIV FED MINAS GERAIS,DEPT BIOCHEM IMMUNOL,BELO HORIZONT,MG,BRAZIL.
   INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
   UNIV FED SAO PAULO,DEPT OPHTHALMOL,SAO PAULO,BRAZIL.
RI Belfort, Rubens/E-2252-2012; Yamamoto, Joyce H/B-6192-2015; Rizzo, Luiz
   Vicente/B-4458-2009; KALIL, JORGE/C-8029-2012
OI Belfort, Rubens/0000-0002-8422-3898; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR 15
PY 1997
VL 38
IS 4
BP 1005
EP 1005
PN 1
PG 1
WC Ophthalmology
SC Ophthalmology
GA WN186
UT WOS:A1997WN18601002
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Buelow, R
   Mineiro, C
   Rodrigues, H
   Kalil, J
AF Monteiro, F
   Buelow, R
   Mineiro, C
   Rodrigues, H
   Kalil, J
TI Identification of patients at high risk of graft loss by pre- and
   posttransplant monitoring of anti-HLA class I IgG antibodies by
   enzyme-linked immunosorbent assay
SO TRANSPLANTATION
LA English
DT Article
ID PANEL-REACTIVE ANTIBODY; HEART-TRANSPLANTATION; REJECTION EPISODES;
   HISTOCOMPATIBILITY; LYMPHOCYTOTOXICITY; IMMUNOADSORPTION; SURVIVAL
AB Identification of risk factors influencing graft survival may lead to the development of models to predict graft outcome, Such models may provide guidance for immunosuppressive therapy, measure posttransplantation outcome, and eventually improve graft survival in high-risk patients. A major risk factor influencing graft survival is allosensitization. However, due to the lack of standardization of lymphocytotoxicity assays, the detection of alloantibodies utilizing this current methodology may not correlate with posttransplant events. Recently, a novel standardized enzyme-linked immunosorbent assay (ELISA) for the detection of anti-HLA class I IgG antibodies was developed. To evaluate the predictive value of this diagnostic test, a retrospective analysis of 124 renal allograft recipients with an Is-month follow-up time was performed, A highly significant (P=0.01) correlation between pretransplant ELISA panel reactive antibody (PRA) results and graft loss was observed. Patients with pretransplant ELISA PRA of >10% had a three times higher risk of graft loss compared with patients who tested negative, No such correlation was observed with complement-dependent cytotoxicity results independent of the reduction of IgM antibodies with dithiothreitol. Similarly, a highly significant correlation of ELISA results with the occurrence of early graft dysfunction was observed, Almost all patients (88%) with a pretransplant ELISA PRA of >50% required posttransplant dialysis, compared with 45% of patients with a pretransplant ELISA PRA of 10-50% and 27% of patients with a pretransplant ELISA PRA of <10%. No such difference was observed with complement-dependent cytotoxicity %PRA values. Analysis of posttransplant specimens by ELISA demonstrated a strong correlation of assay results with graft rejection and graft dysfunction. In summary, these results suggest that detection of anti-HLA class I antibodies by ELISA identifies patients at high risk for graft loss, No other single risk factor of such magnitude has been identified so far.
C1 UNIV SAO PAULO,SCH MED,INST HEART,SAO PAULO,BRAZIL.
   SANGSTAT MED CORP,MENLO PK,CA.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ALARABI AA, 1993, ARTIF ORGANS, V17, P702
   ALBERT E, 1989, EUROTRANSPLANT NEWSL, V89, P11
   BALL PG, 1984, CLIN CHEM, V34, P257
   Bryan CF, 1995, TRANSPLANTATION, V60, P1588, DOI 10.1097/00007890-199560120-00036
   BUELOW R, 1995, HUM IMMUNOL, V44, P1, DOI 10.1016/0198-8859(95)00057-B
   BURLINGHAM WJ, 1984, TRANSPLANTATION, V5, P342
   Cecka J M, 1988, Clin Transpl, P365
   Cecka J M, 1994, Clin Transpl, P1
   Cook D J, 1988, Clin Transpl, P357
   *CTR TRASF IMM TRA, 1988, CIN TRANSPL, P131
   DOXIADIS IN, 1988, EUROTRANSPLANT NEWSL, V98, P11
   FRASCA GM, 1991, INT J ARTIF ORGANS, V14, P51
   Gjertson D W, 1994, Clin Transpl, P519
   GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013
   HOPKINS KA, 1992, HUM IMMUNOL, V33, P122, DOI 10.1016/0198-8859(92)90062-R
   HOPKINS KA, 1990, ASHI LABORATORY MANU, P195
   Kerman RH, 1996, TRANSPLANTATION, V62, P201, DOI 10.1097/00007890-199607270-00009
   KERMAN RH, 1983, TRANSPLANT P       S, V3, P534
   KOKA P, 1990, CLIN TRANSPLANT  198, P379
   LAVEE J, 1991, J HEART LUNG TRANSPL, V10, P921
   LOH E, 1994, J HEART LUNG TRANSPL, V13, P194
   MARRARI M, 1994, HUM IMMUNOL, V39, P87, DOI 10.1016/0198-8859(94)90106-6
   MARTIN S, 1987, TRANSPLANTATION, V44, P50, DOI 10.1097/00007890-198707000-00012
   NOREEN HJ, 1990, ASHI LABORATORY MANU, P307
   OLIVARI MT, 1994, CIRCULATION, V90, P70
   Opelz G, 1995, TRANSPLANTATION, V60, P1220
   Regan J, 1996, AM J KIDNEY DIS, V28, P92, DOI 10.1016/S0272-6386(96)90136-5
   SMITH JD, 1992, TRANSPLANTATION, V53, P1358, DOI 10.1097/00007890-199206000-00034
   SOLEZ K, 1993, KIDNEY INT, V44, P441
   TANABE M, 1992, J IMMUNOL, V148, P3202
   TERASAKI PI, 1988, ORGAN TRANSPLANTATIO, P197
   Zachary AA, 1995, TRANSPLANTATION, V60, P1600, DOI 10.1097/00007890-199560120-00038
   ZERBE TR, 1991, TRANSPLANTATION, V52, P485, DOI 10.1097/00007890-199109000-00019
   Zhou Y C, 1991, Clin Transpl, P313
   ZMIJEWSKI C, 1990, ASHI LAB MANUAL, P249
NR 35
TC 54
Z9 59
U1 0
U2 2
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD FEB 27
PY 1997
VL 63
IS 4
BP 542
EP 546
DI 10.1097/00007890-199702270-00010
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA WL855
UT WOS:A1997WL85500010
PM 9047148
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Mineiro, C
   Rodrigues, H
   dePaula, FJ
   Kalil, J
AF Monteiro, F
   Mineiro, C
   Rodrigues, H
   dePaula, FJ
   Kalil, J
TI Pretransplant and posttransplant monitoring of anti-HLA class I IgG1
   antibodies by ELISA identifies patients at high risk of graft loss
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT XVI International Congress of the Transplantation-Society
CY AUG 25-30, 1996
CL BARCELONA, SPAIN
SP Sandoz, Fujisawa, Congress Org Comm, Transplantat Soc
C1 UNIV SAO PAULO, SCH MED, DIV UROL, RENAL TRANSPLANT UNIT, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, SCH MED, INST HEART, LAB TRANSPLANTAT IMMUNOL, SAO PAULO, BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BUELOW R, 1995, HUM IMMUNOL, V44, P1, DOI 10.1016/0198-8859(95)00057-B
   REGAN J, 1996, AM J KIDNEY DIS, V28, P1
   Zachary AA, 1995, TRANSPLANTATION, V60, P1600, DOI 10.1097/00007890-199560120-00038
NR 3
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD FEB-MAR
PY 1997
VL 29
IS 1-2
BP 1433
EP 1434
DI 10.1016/S0041-1345(96)00541-6
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA WM127
UT WOS:A1997WM12700634
PM 9123368
DA 2020-11-26
ER

PT B
AU Bunce, M
   Vilches, C
   Marsh, SGE
   Van den Berg-Loonen, EM
   Pazderka, F
   Hammond, MG
   Alosco, S
   Bartova, A
   Brown, C
   Charoenwongse, P
   Ferraro, GB
   Fotju, H
   Hashemi, S
   Kalil, JE
   Kamoun, M
   Mayr, WR
   Park, MS
   Mariani, M
   Tait, B
   Taylor, CJ
   Abbal, M
   Westphal, E
   Yang, E
AF Bunce, M
   Vilches, C
   Marsh, SGE
   Van den Berg-Loonen, EM
   Pazderka, F
   Hammond, MG
   Alosco, S
   Bartova, A
   Brown, C
   Charoenwongse, P
   Ferraro, GB
   Fotju, H
   Hashemi, S
   Kalil, JE
   Kamoun, M
   Mayr, WR
   Park, MS
   Mariani, M
   Tait, B
   Taylor, CJ
   Abbal, M
   Westphal, E
   Yang, E
BE Charron, D
TI AHS9: all HLA-C alleles
SO HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION,
   PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND
   CONFERENCE (12TH IHWC), VOL I: WORKSHOP
LA English
DT Proceedings Paper
CT 12th International Histocompatibility Workshop - HLA
CY JUN, 1996
CL ST MALO, FRANCE
SP Agence Francaise Sang, European Community, Biomed, Ligue Natl Francaise Contre Canc, HLA & Med, Univ Rennes I, Conseil Reg Ille et Vilaine, European Sci Fdn, Etablissement Transfus Bretagne Est, Ligue Natl Contre Cancer, Comite Ille et Vilaine, INSERM, Reseau Rech Clin, Imperial Canc Res Fund, Ludwig Maximillians Univ, Soc Francophone Histocompatib & Immunogenet, CREG, COFECUB, Perkin Elmer, Pharmacia Biotech, Innogenet & Murex, ALK, Chugai Pharm, Coulter, France Biochem, Jouan, One Lambda, Ortho Diagnost Syst, Produits Roche Roche Diagnost, Sandoz, Sangstat, DNA Gency, CICT Toulouse
C1 Churchill Hosp, Nuffield Dept Surg, Oxford Transplant Ctr, Tissue Typing Lab, Oxford OX3 7LJ, England.
RP Bunce, M (corresponding author), Churchill Hosp, Nuffield Dept Surg, Oxford Transplant Ctr, Tissue Typing Lab, Oxford OX3 7LJ, England.
RI KALIL, JORGE/C-8029-2012; Vilches, Carlos/G-1471-2012
OI KALIL, JORGE/0000-0001-8415-4274; Vilches, Carlos/0000-0002-0300-9225
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EDITIONS EDK
PI SEVRES
PA 10, RUE CHAMPFLEURY, 92310 SEVRES, FRANCE
BN 2-84254-004-2
PY 1997
BP 83
EP 88
PG 6
WC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
SC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
GA BK29Y
UT WOS:000071716700016
DA 2020-11-26
ER

PT B
AU Goldberg, AC
   Kalil, J
   Gorodezky, C
   Kotb, M
   Mehra, N
   Saruhan-Direskeneli, G
   Barbalho, TP
   Chavez-Negrete, A
   Chiarella, JM
   Crowe, D
   Debaz, H
   El-Demellawy, M
   Eker-Omeroglu, R
   Guedez, Y
   Kiss, MH
   Marin, ML
   Meric, F
   Rajalingam, R
   Snitcowsky, R
   Tanaka, AC
AF Goldberg, AC
   Kalil, J
   Gorodezky, C
   Kotb, M
   Mehra, N
   Saruhan-Direskeneli, G
   Barbalho, TP
   Chavez-Negrete, A
   Chiarella, JM
   Crowe, D
   Debaz, H
   El-Demellawy, M
   Eker-Omeroglu, R
   Guedez, Y
   Kiss, MH
   Marin, ML
   Meric, F
   Rajalingam, R
   Snitcowsky, R
   Tanaka, AC
BE Charron, D
TI HLA and rheumatic fever: 12th International Histocompatibility Workshop
   study
SO HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION,
   PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND
   CONFERENCE (12TH IHWC), VOL I: WORKSHOP
LA English
DT Proceedings Paper
CT 12th International Histocompatibility Workshop - HLA
CY JUN, 1996
CL ST MALO, FRANCE
SP Agence Francaise Sang, European Community, Biomed, Ligue Natl Francaise Contre Canc, HLA & Med, Univ Rennes I, Conseil Reg Ille et Vilaine, European Sci Fdn, Etablissement Transfus Bretagne Est, Ligue Natl Contre Cancer, Comite Ille et Vilaine, INSERM, Reseau Rech Clin, Imperial Canc Res Fund, Ludwig Maximillians Univ, Soc Francophone Histocompatib & Immunogenet, CREG, COFECUB, Perkin Elmer, Pharmacia Biotech, Innogenet & Murex, ALK, Chugai Pharm, Coulter, France Biochem, Jouan, One Lambda, Ortho Diagnost Syst, Produits Roche Roche Diagnost, Sandoz, Sangstat, DNA Gency, CICT Toulouse
C1 Univ Sao Paulo, Inst Heart, Lab Transplant Immunol, Sao Paulo, Brazil.
RP Goldberg, AC (corresponding author), Univ Sao Paulo, Inst Heart, Lab Transplant Immunol, Ave Dr Arnaldo 455, Sao Paulo, Brazil.
RI Goldberg, Anna Carla/H-8594-2014; Gorodezky, Clara/AAB-7332-2020; KALIL,
   JORGE/C-8029-2012; Omeroglu, Rukiye Nurten/AAT-7658-2020
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; 
NR 0
TC 1
Z9 1
U1 0
U2 1
PU EDITIONS EDK
PI SEVRES
PA 10, RUE CHAMPFLEURY, 92310 SEVRES, FRANCE
BN 2-84254-004-2
PY 1997
BP 413
EP 418
PG 6
WC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
SC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
GA BK29Y
UT WOS:000071716700070
DA 2020-11-26
ER

PT B
AU Fainboim, L
   Pando, M
   Larriba, J
   Goldberg, AC
   Gorodezky, C
   Fainboim, H
   Ciocca, M
   Ramonet, M
   Badia, I
   Galoppo, C
   Fernandez, GC
   Lindel, N
   Capucchio, M
   Findor, J
   Daruich, J
   Vazquez, MN
   Alaez, C
   de la Rosa, G
   Bandera, J
   Kershenobich, D
   Borras, S
   Tanno, H
   Prigoshin, N
   Agostino, D
   Kalil, J
   Alvarez, F
   Salz, ML
AF Fainboim, L
   Pando, M
   Larriba, J
   Goldberg, AC
   Gorodezky, C
   Fainboim, H
   Ciocca, M
   Ramonet, M
   Badia, I
   Galoppo, C
   Fernandez, GC
   Lindel, N
   Capucchio, M
   Findor, J
   Daruich, J
   Vazquez, MN
   Alaez, C
   de la Rosa, G
   Bandera, J
   Kershenobich, D
   Borras, S
   Tanno, H
   Prigoshin, N
   Agostino, D
   Kalil, J
   Alvarez, F
   Salz, ML
BE Charron, D
TI HLA and autoimmune hepatitis: 12th International Histocompatibility
   Workshop study
SO HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION,
   PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND
   CONFERENCE (12TH IHWC), VOL I: WORKSHOP
LA English
DT Proceedings Paper
CT 12th International Histocompatibility Workshop - HLA
CY JUN, 1996
CL ST MALO, FRANCE
SP Agence Francaise Sang, European Community, Biomed, Ligue Natl Francaise Contre Canc, HLA & Med, Univ Rennes I, Conseil Reg Ille et Vilaine, European Sci Fdn, Etablissement Transfus Bretagne Est, Ligue Natl Contre Cancer, Comite Ille et Vilaine, INSERM, Reseau Rech Clin, Imperial Canc Res Fund, Ludwig Maximillians Univ, Soc Francophone Histocompatib & Immunogenet, CREG, COFECUB, Perkin Elmer, Pharmacia Biotech, Innogenet & Murex, ALK, Chugai Pharm, Coulter, France Biochem, Jouan, One Lambda, Ortho Diagnost Syst, Produits Roche Roche Diagnost, Sandoz, Sangstat, DNA Gency, CICT Toulouse
C1 Hosp Clin, Div Inmunogenet, RA-1120 Buenos Aires, DF, Argentina.
RP Fainboim, L (corresponding author), Hosp Clin, Div Inmunogenet, Ave Cordoba 2351, RA-1120 Buenos Aires, DF, Argentina.
RI Goldberg, Anna Carla/H-8594-2014; Gorodezky, Clara/AAB-7332-2020
OI Goldberg, Anna Carla/0000-0003-2600-7940; 
NR 0
TC 3
Z9 3
U1 0
U2 3
PU EDITIONS EDK
PI SEVRES
PA 10, RUE CHAMPFLEURY, 92310 SEVRES, FRANCE
BN 2-84254-004-2
PY 1997
BP 418
EP 423
PG 6
WC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
SC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
GA BK29Y
UT WOS:000071716700071
DA 2020-11-26
ER

PT B
AU Monteiro, F
   Rodrigues, H
   Viggiani, C
   Ianhez, LE
   Kalil, J
AF Monteiro, F
   Rodrigues, H
   Viggiani, C
   Ianhez, LE
   Kalil, J
BE Charron, D
TI Crossmatch testing of organ donors and recipients by Cross-Stat ELISA:
   clinical relevance of test results
SO HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION,
   PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND
   CONFERENCE (12TH IHWC), VOL II: CONFERENCE
LA English
DT Proceedings Paper
CT 12th International Histocompatibility Conference - HLA
CY JUN, 1996
CL ST MALO, FRANCE
SP Agence Francaise Sang, European Community, Biomed, Ligue Natl Francaise Contre Canc, HLA & Med, European Sci Fdn, Etablissement Francaise Greffes, Fdn St Louis, LNFCC, Comite Paris, Fac Med St Louis Lariboisiere, Inst Biomed Cordeliers, Inst Univ Hematol, Assoc France Transplant, Imperial Canc Res Fund, Soc Francophone Histocompatib & Immunogenet, CREG, Perkin Elmer, Pharmacia Biotech, IUnnogenet & Murex, ALK, Chugai Pharm, One Lambda, Prod Roche Roche Diagnost, Sandoz, France Biochem, Genset, Biotest AG
C1 Univ Sao Paulo, Sch Med, Inst Heart, Lab Transplantat Immunol, BR-05403000 Sao Paulo, Brazil.
RP Monteiro, F (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Lab Transplantat Immunol, R Dr Eneas C Aguiar 500,3 Andar, BR-05403000 Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EDITIONS EDK
PI SEVRES
PA 10, RUE CHAMPFLEURY, 92310 SEVRES, FRANCE
BN 2-84254-003-4
PY 1997
BP 551
EP 553
PG 3
WC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
SC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory
   Technology
GA BK29Z
UT WOS:000071717200161
DA 2020-11-26
ER

PT J
AU CunhaNeto, E
   Coelho, V
   Guilherme, L
   Fiorelli, A
   Stolf, N
   Kalil, J
AF CunhaNeto, E
   Coelho, V
   Guilherme, L
   Fiorelli, A
   Stolf, N
   Kalil, J
TI Autoimmunity in Chagas' disease - Identification of cardiac myosin-B13
   Trypanosoma cruzi protein crossreactive T cell clones in heart lesions
   of a chronic Chagas' cardiomyopathy patient
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE autoimmunity; immunology; immunopathology; Trypanosoma cruzi; Chagas'
   disease cardiomyopathy
ID RECOMBINANT ANTIGENS; MYOCARDITIS; MICE; RECOGNITION
AB Heart tissue destruction in chronic Chagas' disease cardiomyopathy (CCC) may be caused by autoimmune recognition of heart tissue by a mononuclear cell infiltrate decades after Trypanosoma cruzi infection. Indirect evidence suggests there is molecular mimicry between T. cruzi and heart tissue. In murine models of CCC, antibodies and CD4+ T cells recognize myosin, the major heart protein. We recently identified a heart-specific epitope of cardiac myosin heavy chain (residues 1442-1447, AAALDK) that is crossreactive with a homologous sequence (AAAGDK) of the immunodominant T. cruzi antigen B13. Furthermore, cardiac myosin-B13 crossreactive antibodies are present in 100% CCC patients vs 14% asymptomatic T. cruzi-seropositive individuals (P = 2.3 x 10(-6)), suggesting a role for molecular mimicry between cardiac myosin and B13 in CCC pathogenesis. In this paper, we obtained heart-infiltrating T cell clones from CCC patients to assess whether molecular mimicry between cardiac myosin and B13 is directly involved in the genesis of heart lesions. We identified T cell clones derived from CCC heart lesions simultaneously responsive to cardiac myosin heavy chain (but not skeletal myosin heavy chain) and B13 T. cruzi protein, but could not find T cell clones primarily reactive to any T. cruzi antigen. Together with the association of myosin-B13 crossreactive antibodies with CCC, the present data strongly suggest the relevance of molecular mimicry between cardiac myosin and the T. cruzi protein B13 in the pathogenesis of heart lesions in chronic Chagas' disease cardiomyopathy.
C1 UNIV SAO PAULO,FAC MED,INST CORACAO,LAB TRANSPLANTAT IMMUNOL,BR-05403000 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,INST CORACAO,DEPT SURG,BR-05403000 SAO PAULO,BRAZIL.
RI COELHO, VERONICA/D-1433-2013; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; 
CR ANDRADE ZA, 1958, REV GOIANA MED, V4, P103
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541
   DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785
   DAYAN CM, 1991, P NATL ACAD SCI USA, V88, P7415, DOI 10.1073/pnas.88.16.7415
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   Kalil J, 1996, PARASITOL TODAY, V12, P396, DOI 10.1016/0169-4758(96)10058-2
   KRIEGER MA, 1992, AM J TROP MED HYG, V46, P427, DOI 10.4269/ajtmh.1992.46.427
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAMB JR, 1988, J IMMUNOL METHODS, V110, P1, DOI 10.1016/0022-1759(88)90076-2
   LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530
   LIFE PF, 1991, IMMUNOL REV, V121, P113, DOI 10.1111/j.1600-065X.1991.tb00825.x
   LOHR H, 1991, CLIN EXP IMMUNOL, V84, P297
   MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818
   MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55
   NEU N, 1987, J IMMUNOL, V138, P2488
   NEU N, 1987, J IMMUNOL, V139, P3630
   PADULA SJ, 1985, J CLIN INVEST, V75, P788, DOI 10.1172/JCI111774
   RASSI A, 1982, DOENCAS INFECCIOSAS, P675
   RIBEIRODOSSANTO.R, 1992, J EXP MED, V175, P29
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131
   SMITH SC, 1991, J IMMUNOL, V147, P2141
   TEIXEIRA ARL, 1990, J INFECT DIS, V162, P1420, DOI 10.1093/infdis/162.6.1420
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   TORRES CM, 1930, AN 5 REUN SOC ARG PA, V2, P902
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   ZINGALES B, 1982, MOL BIOCHEM PARASIT, V6, P111, DOI 10.1016/0166-6851(82)90069-X
NR 34
TC 153
Z9 158
U1 2
U2 12
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 222 E 70TH STREET, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT 15
PY 1996
VL 98
IS 8
BP 1709
EP 1712
DI 10.1172/JCI118969
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA VN973
UT WOS:A1996VN97300005
PM 8878420
OA Green Published
DA 2020-11-26
ER

PT J
AU Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Silva, LC
   Carrilho, F
   Kalil, J
   Laudanna, AA
AF Bittencourt, PL
   Goldberg, AC
   Cancado, ELR
   Porta, G
   Farias, AQ
   Baggio, VL
   Silva, LC
   Carrilho, F
   Kalil, J
   Laudanna, AA
TI Association of autoimmune hepatitis (AIH) and primary sclerosing
   cholangitis (PSC) with HLA-DR antigens in Brazil.
SO HEPATOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,CHILDRENS INST,DEPT GASTROENTEROL,LIVER UNIT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,LAB TRANSPLANTAT IMMUNOL,INST HEART,SAO PAULO,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; Cancado,
   Eduardo/K-1861-2016; Carrilho, Flair J/I-3046-2012; BITTENCOURT, PAULO
   l/I-5817-2014
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274; Cancado, Eduardo/0000-0002-9309-1524;
   BITTENCOURT, PAULO l/0000-0003-0883-4870
NR 0
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 1996
VL 24
IS 4
SU S
BP 423
EP 423
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VL285
UT WOS:A1996VL28500422
DA 2020-11-26
ER

PT J
AU Marquet, S
   Abel, L
   Hillaire, D
   Dessein, H
   Kalil, J
   Feingold, J
   Weissenbach, J
   Dessein, AJ
AF Marquet, S
   Abel, L
   Hillaire, D
   Dessein, H
   Kalil, J
   Feingold, J
   Weissenbach, J
   Dessein, AJ
TI Genetic localization of a locus controlling the intensity of infection
   by Schistosoma mansoni on chromosome 5q31-q33
SO NATURE GENETICS
LA English
DT Letter
ID MULTILOCUS LINKAGE ANALYSIS; HUMAN RESISTANCE; MAJOR GENE;
   IMMUNE-RESPONSES; IGE LEVELS; REINFECTION; ASSOCIATION; SUSCEPTIBILITY;
   INTERLEUKIN-4; HAEMATOBIUM
C1 FAC MED MARSEILLE,LAB PARASITOL MYCOL,INSERM,U399,F-13385 MARSEILLE 5,FRANCE.
   HOSP PITIE SALPETRIERE,INSERM,U436,PARIS,FRANCE.
   UNIV SAO PAULO,INST HEART,IMMUNOL LAB,BR-05508 SAO PAULO,BRAZIL.
   INSERM,U155,PARIS,FRANCE.
   GENETHON,EVRY,FRANCE.
   CNRS,URA 1922,EVRY,FRANCE.
RI KALIL, JORGE/C-8029-2012; MARQUET, Sandrine/I-6566-2016; Abel,
   Laurent/H-8888-2017; MARQUET, Sandrine/B-2843-2008
OI KALIL, JORGE/0000-0001-8415-4274; MARQUET, Sandrine/0000-0001-7011-6496;
   Abel, Laurent/0000-0001-7016-6493; 
CR ABEL L, 1991, AM J HUM GENET, V48, P959
   BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420
   BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8
   CHANDRASEKHARAPPA SC, 1990, GENOMICS, V6, P94, DOI 10.1016/0888-7543(90)90452-Z
   CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059
   COULSSINIERPARI.P, 1995, EUR J IMMUNOL, V25, P2295
   DEMENAIS F, 1994, GENET EPIDEMIOL, V11, P291
   DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000
   DESSEIN AJ, 1992, IMMUNOL INVEST, V21, P423, DOI 10.3109/08820139209069383
   DESSEIN AJ, 1988, J IMMUNOL, V140, P2727
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622
   GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246
   HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0
   HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443
   MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175
   MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524
   MOUT R, 1991, NUCLEIC ACIDS RES, V19, P3763, DOI 10.1093/nar/19.13.3763
   OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402
   POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402
   RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106
   ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993
   SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254
   STANLEY ER, 1994, CYTOKINE HDB, P387
   *UNDP WORLD BANK W, 1990, TROP DIS PROGR RES, P41
   VANLIESHOUT L, 1995, J INFECT DIS, V172, P1336, DOI 10.1093/infdis/172.5.1336
   VIGNAL A, 1993, METHODS MOL GENETICS, V1, P211
   WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2
NR 30
TC 286
Z9 294
U1 2
U2 25
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 1996
VL 14
IS 2
BP 181
EP 184
DI 10.1038/ng1096-181
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA VL446
UT WOS:A1996VL44600024
PM 8841190
DA 2020-11-26
ER

PT J
AU Kalil, J
   CunhaNeto, E
AF Kalil, J
   CunhaNeto, E
TI Autoimmunity in Chagas disease cardiomyopathy: Fulfilling the criteria
   at last?
SO PARASITOLOGY TODAY
LA English
DT Article
ID TRYPANOSOMA-CRUZI; ANTIGENIC DETERMINANTS; MONOCLONAL-ANTIBODY;
   MOLECULAR MIMICRY; AUTOANTIBODIES; MYOCARDITIS; CELLS; EXPRESSION;
   PROTEINS; RECEPTOR
AB Here, Jorge Kalil and Edecio Cunha-Neto review the recent evidence for autoimmunity in chronic Chagas cardiomyopathy (CCC) involving molecularly defined antigens and immunopathological mechanisms. They also discuss the criteria for assignment of CCC as an organ-specific autoimmune disease.
RP Kalil, J (corresponding author), UNIV SAO PAULO,INST CORACAO FAC MED,TRANSPLANTAT IMMUNOL LAB,BR-05508 SAO PAULO,SP,BRAZIL.
RI Cunha-Neto, Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
CR BONFA E, 1993, J IMMUNOL, V150, P3917
   COSSIO PM, 1974, CIRCULATION, V50, P1252, DOI 10.1161/01.CIR.50.6.1252
   CUNHANETO E, 1994, PARASITE IMMUNOL, V16, P171, DOI 10.1111/j.1365-3024.1994.tb00337.x
   CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P2591
   CUNHANETO E, IN PRESS J CLIN INVE
   FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59
   HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   KERNER N, 1991, EXP PARASITOL, V73, P451, DOI 10.1016/0014-4894(91)90069-9
   KHOURY EL, 1983, CLIN IMMUNOL IMMUNOP, V27, P283, DOI 10.1016/0090-1229(83)90078-8
   Kierszenbaum F, 1985, Parasitol Today, V1, P4, DOI 10.1016/0169-4758(85)90098-5
   Klein J., 1990, IMMUNOLOGY
   LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530
   MACEDO V, 1982, CECIL TXB MED, P1728
   PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5
   REIS DD, 1993, AM J TROP MED HYG, V49, P192, DOI 10.4269/ajtmh.1993.49.192
   RIBEIRODOSSANTO.R, 1992, J EXP MED, V175, P29
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   SANTOSBUCH CA, 1985, CLIN IMMUNOL IMMUNOP, V37, P334, DOI 10.1016/0090-1229(85)90103-5
   SCHMUNIS G A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P287, DOI 10.1590/S0074-02761987000500011
   SENECAL JL, 1993, J RHEUMATOL, V20, P211
   SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131
   SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617
   TEIXEIRA ARL, 1975, AM J PATHOL, V80, P163
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   TRETHAM DE, 1993, SCIENCE, V261, P1727
   UNTERKIRCHER C, 1993, J CLIN LAB ANAL, V7, P60, DOI 10.1002/jcla.1860070111
   VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993
   WITEBSKY E, 1957, JAMA-J AM MED ASSOC, V164, P1439, DOI 10.1001/jama.1957.02980130015004
   WOOD JN, 1982, NATURE, V296, P34, DOI 10.1038/296034a0
NR 32
TC 114
Z9 116
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0169-4758
J9 PARASITOL TODAY
JI Parasitol. Today
PD OCT
PY 1996
VL 12
IS 10
BP 396
EP 399
DI 10.1016/0169-4758(96)10058-2
PG 4
WC Parasitology
SC Parasitology
GA VK020
UT WOS:A1996VK02000007
PM 15275290
DA 2020-11-26
ER

PT J
AU Regan, J
   Monteiro, F
   Speiser, D
   Kalil, J
   Pouletty, P
   Buelow, R
AF Regan, J
   Monteiro, F
   Speiser, D
   Kalil, J
   Pouletty, P
   Buelow, R
TI Pretransplant rejection risk assessment through enzyme-linked
   immunosorbent assay analysis of anti-HLA class I antibodies
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE HLA; antibody; enzyme-linked immunosorbent assay; transplantation
ID TRANSPLANTATION
AB Soluble HLA enzyme-linked immunosorbent assays (ELISAs) for the detection of anti-HLA class I immunoglobulin G (IgG), IgG1, IgG2, IgG3, IgG4, IgM, and IgA antibodies were developed and used to analyze retrospectively the correlation between pretransplant allosensitization and posttransplant rejection episodes in renal allograft recipients, Enzyme-linked immunosorbent assay plates were coated with 46 different soluble HLA preparations representing 40 different HLA class I antigens, After incubation with a serum specimen, bound antibodies were detected with a peroxidase-conjugated antibody. Serum specimens from 85 patients were analyzed, All patients tested positive by microlymphocytotoxicity (ie, >5% panel-reactive antibody [PRA]), Approximately half (56%) of the patients had experienced one or more rejection episodes within 12 months posttransplantation. Fifty-five patients tested positive by ELISA (total IgG %PRA >10%). A strong correlation between first-year rejection and ELISA-detected anti-HLA class I IgG1 was observed (P = 0.0004), The predictive value for IgG1 and first-year rejection was 77.5%, demonstrating that ELISA results identify patients at high risk of rejecting the transplanted kidney. Anti-HLA class I total IgG detected by ELISA also correlated with first-year rejection episodes (P = 0.04). The presence of anti-HLA class I IgG2, IgG3, IgG4, or IgM was not predictive of first-year rejection episodes. Anticlass I IgA antibodies were only found in combination with anti-class I IgG1 antibodies. (C) 1996 by the National Kidney Foundation, Inc.
C1 SANGSTAT MED CORP,MENLO PK,CA 94025.
   UNIV SAO PAULO,SCH MED,INST HEART,BR-05508 SAO PAULO,BRAZIL.
   HOP CANTONAL UNIV GENEVA,DIV IMMUNOL & ALLERGOL,SWISS NATL REFERENCE LAB HISTOCOMPATIBIL,GENEVA,SWITZERLAND.
RI KALIL, JORGE/C-8029-2012; Speiser, Daniel E./F-2173-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR ALBERT E, 1989, EUROTRANSPLANT NEWSL, V89, P11
   BUELOW R, 1995, HUM IMMUNOL, V44, P1, DOI 10.1016/0198-8859(95)00057-B
   DOXIADIS I, 1989, BLUT, V59, P449, DOI 10.1007/BF00349066
   DOXIADIS IN, 1988, EUROTRANSPLANT NEWSL, V98, P11
   Gjertson D W, 1992, Clin Transpl, P299
   GRUMET FC, 1994, HUM IMMUNOL, V40, P153, DOI 10.1016/0198-8859(94)90062-0
   HOPKINS KA, 1992, HUM IMMUNOL, V33, P122, DOI 10.1016/0198-8859(92)90062-R
   HOPKINS KA, 1990, ASHI LABORATORY MANU, P195
   KERMAN RH, 1988, TRANSPLANT P      S3, V3, P534
   KERMAN RH, IN PRESS TRANSPLANTA
   KOKA P, 1993, TRANSPLANTATION, V56, P207, DOI 10.1097/00007890-199307000-00038
   KOKA P, 1990, CLIN TRANSPLANT  198, P379
   LOH E, 1994, J HEART LUNG TRANSPL, V13, P194
   MARRARI M, 1994, HUM IMMUNOL, V39, P87, DOI 10.1016/0198-8859(94)90106-6
   NOREEN HJ, 1990, ASHI LABORATORY MANU, P307
   POULETTY C, 1994, HUM IMMUNOL, V40, P218, DOI 10.1016/0198-8859(94)90072-8
   POULETTY P, 1993, TISSUE ANTIGENS, V42, P14, DOI 10.1111/j.1399-0039.1993.tb02160.x
   POULETTY P, 1993, TISSUE ANTIGENS, V42, P45, DOI 10.1111/j.1399-0039.1993.tb02166.x
   SHIMIZU B, 1992, HUM IMMUNOL S1, V32, P289
   TERASAKI PI, 1988, ORGAN TRANSPLANTATIO, P197
   TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121
   ZMIJEWSKI C, 1990, ASHI LAB MANUAL, P249
NR 22
TC 21
Z9 22
U1 0
U2 3
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUL
PY 1996
VL 28
IS 1
BP 92
EP 98
DI 10.1016/S0272-6386(96)90136-5
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA UW523
UT WOS:A1996UW52300013
PM 8712228
DA 2020-11-26
ER

PT J
AU Copelli, SB
   Bergada, C
   Billerbeck, AEC
   Goldberg, AC
   Kalil, J
   Damiani, D
   Targovnik, HM
AF Copelli, SB
   Bergada, C
   Billerbeck, AEC
   Goldberg, AC
   Kalil, J
   Damiani, D
   Targovnik, HM
TI Molecular analysis of sex determination in sex-reversed and true
   hermaphroditism
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE sex-reversed hermaphroditism; true hermaphroditism; SRY gene;
   Y-heterochromatin region; amelogenin gene
ID DETERMINING REGION; SRY; POLYMERASE; PRIMER; DNA
AB The SRY (sex region of Y) gene determines testis formation but not all cases of sex reversal in humans can be explained by alterations in this gene. We studied one 46,XY female, four 46,XX males, and nine true hermaphrodites (TH): three with an XY and six with an XX chromosomal constitution. The SRY gene was identified in the XX males and the TH with a Y chromosome but was not demonstrated in the XY female and the six XX TH. The Y-heterochromatin region was also identified in one 46,XX male, indicating a low grade mosaicism undetected by cytogenetics. The amplification of the amelogenin gene showed the presence of a 977-bp band that belongs to the shea arm of chromosome X in all patients but the absence of a 780-bp band of the short arm of chromosome Y in three 46,XX males and in all the 46,XX TH. These studies demonstrate that the molecular study of sex-reversed patients and TH will help to understand the complex mechanisms of sex determination. The SRY gene is involved but other genes on the X chromosome and autosomes still remain to be studied.
C1 UNIV BUENOS AIRES,FAC FARM & BIOQUIM,CATEDRA GENET & BIOL MOLEC,RA-1113 BUENOS AIRES,DF,ARGENTINA.
   UNIV SAO PAULO,FAC MED,INST CRIANCA,UNIDADE ENDOCRINOL PEDIAT,BR-05043000 SAO PAULO,BRAZIL.
RP Copelli, SB (corresponding author), HOSP NINOS DR RICARDO GUTIERREZ,CTR INVEST ENDOCRINOL,DIV ENDOCRINOL,CEDIE,CONICET,GALLO 1330,RA-1425 BUENOS AIRES,DF,ARGENTINA.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497
   BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0
   DARRIANI D, 1990, HUM GENET, V85, P85
   HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684
   KOGAN S, 1987, NEW ENGL J MED, V117, P985
   KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0
   MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368
   MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016
   NAKAHORI Y, 1991, AM J MED GENET, V39, P472, DOI 10.1002/ajmg.1320390420
   OGATA T, 1994, J MED GENET, V31, P349, DOI 10.1136/jmg.31.4.349
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0
NR 12
TC 7
Z9 8
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 1996
VL 29
IS 6
BP 743
EP 748
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA UU922
UT WOS:A1996UU92200006
PM 9070386
DA 2020-11-26
ER

PT J
AU Chiarella, J
   Goldberg, AC
   Abel, L
   Kalil, J
   Dessein, A
AF Chiarella, J
   Goldberg, AC
   Abel, L
   Kalil, J
   Dessein, A
TI Linkage study between HLA antigens and a major gene involved in
   susceptibility/resistance to infection to Schistosoma mansoni.
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 FMUSP,INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
   HOP LA PITIE SALPETRIERE,CTR IMMUNOL MALAD PARASITAIRES,PARIS,FRANCE.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR 15
PY 1996
VL 47
IS 1-2
BP P679
EP P679
PG 1
WC Immunology
SC Immunology
GA UM455
UT WOS:A1996UM45500679
DA 2020-11-26
ER

PT J
AU Goldberg, AC
   Bittencourt, PL
   Porta, G
   Cancado, ER
   Laudanna, AA
   Kalil, J
AF Goldberg, AC
   Bittencourt, PL
   Porta, G
   Cancado, ER
   Laudanna, AA
   Kalil, J
TI Autoantibody profile in autoimmune hepatitis and HLA class II
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,INCOR,LAB TRANSPLANT IMMUNOL,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,DEPT GASTROENTEROL,BR-05508 SAO PAULO,BRAZIL.
RI Cancado, Eduardo/K-1861-2016; BITTENCOURT, PAULO l/I-5817-2014;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Cancado, Eduardo/0000-0002-9309-1524; BITTENCOURT, PAULO
   l/0000-0003-0883-4870; Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR 15
PY 1996
VL 47
IS 1-2
BP P153
EP P153
PG 1
WC Immunology
SC Immunology
GA UM455
UT WOS:A1996UM45500154
DA 2020-11-26
ER

PT J
AU Guilherme, L
   Neto, EC
   Renesto, G
   Goldberg, AC
   Chiarella, J
   Snitcowsky, R
   Kiss, MH
   Silva, C
   Kalil, J
AF Guilherme, L
   Neto, EC
   Renesto, G
   Goldberg, AC
   Chiarella, J
   Snitcowsky, R
   Kiss, MH
   Silva, C
   Kalil, J
TI Significance of PBMC response of rheumatic fever patients and control
   individuals to immunodominant streptococcal M5 protein epitopes
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
   ICR,HC,FMUSP,SAO PAULO,BRAZIL.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR 15
PY 1996
VL 47
IS 1-2
BP P92
EP P92
PG 1
WC Immunology
SC Immunology
GA UM455
UT WOS:A1996UM45500091
DA 2020-11-26
ER

PT J
AU Kalil, J
   Banic, D
   Goldberg, AC
   Riccio, LP
   Ferreira, JO
   Tartar, A
   Camus, D
   Ribeiro, CD
AF Kalil, J
   Banic, D
   Goldberg, AC
   Riccio, LP
   Ferreira, JO
   Tartar, A
   Camus, D
   Ribeiro, CD
TI Correlation of antibodies to p126 P-falciparum protein with HLA profile
   in individuals living in an endemic area in Brazil
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 FMUSP,INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR 15
PY 1996
VL 47
IS 1-2
BP P678
EP P678
PG 1
WC Immunology
SC Immunology
GA UM455
UT WOS:A1996UM45500681
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Mineiro, C
   Rodrigues, H
   Kalil, J
AF Monteiro, F
   Mineiro, C
   Rodrigues, H
   Kalil, J
TI Monitoring of IgG anti-HLA class I by PRA-STAT and graft outcome
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 FMUSP,INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD APR 15
PY 1996
VL 47
IS 1-2
BP P720
EP P720
PG 1
WC Immunology
SC Immunology
GA UM455
UT WOS:A1996UM45500721
DA 2020-11-26
ER

PT J
AU Yamamoto, JH
   Goldberg, AC
   Chiarella, JM
   Hirata, CE
   Olivalves, E
   Kalil, J
AF Yamamoto, JH
   Goldberg, AC
   Chiarella, JM
   Hirata, CE
   Olivalves, E
   Kalil, J
TI HLA-DR4 in Vogt-Koyanagi-Harada's disease in Brazilian patients
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,INST HEART,LIM 19,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,DEPT OPHTHALMOL,LIM 33,BR-05508 SAO PAULO,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; Yamamoto, Joyce H/B-6192-2015; KALIL,
   JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB 15
PY 1996
VL 37
IS 3
BP 1679
EP 1679
PG 1
WC Ophthalmology
SC Ophthalmology
GA TX397
UT WOS:A1996TX39701677
DA 2020-11-26
ER

PT J
AU Rizzo, LV
   Yamamoto, JH
   Gazzinelli, RT
   Silveira, C
   Kalil, J
   Belfort, R
AF Rizzo, LV
   Yamamoto, JH
   Gazzinelli, RT
   Silveira, C
   Kalil, J
   Belfort, R
TI Analysis of immunological parameters of patients with toxoplasmosis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Meeting Abstract
C1 NEI,IMMUNOL LAB,BETHESDA,MD 20892.
   USP,DEPT OPHTHALMOL,SAO PAULO,BRAZIL.
   UNIV FED MINAS GERAIS,DEPT BIOCHEM IMMUNOL,BELO HORIZONT,MG,BRAZIL.
   UFSP,DEPT OPHTHALMOL,SAO PAULO,BRAZIL.
RI Yamamoto, Joyce H/B-6192-2015; Belfort, Rubens/E-2252-2012; KALIL,
   JORGE/C-8029-2012; Rizzo, Luiz Vicente/B-4458-2009
OI Belfort, Rubens/0000-0002-8422-3898; KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB 15
PY 1996
VL 37
IS 3
BP 2083
EP 2083
PG 1
WC Ophthalmology
SC Ophthalmology
GA TX397
UT WOS:A1996TX39702081
DA 2020-11-26
ER

PT J
AU Monteiro, F
   Rodrigues, H
   Viggiani, C
   Kalil, J
AF Monteiro, F
   Rodrigues, H
   Viggiani, C
   Kalil, J
TI Clinical relevance of the detected anti-donor HLA class I antibodies
   detected by ELISA.
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
C1 FMUSP,INCOR,LAB TRANSPLANT IMMUNOL,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PY 1996
VL 49
SU 1
BP 68
EP 68
PG 1
WC Immunology
SC Immunology
GA VD912
UT WOS:A1996VD91200146
DA 2020-11-26
ER

PT B
AU Regan, J
   Monteiro, F
   Speiser, D
   Kalil, J
   Kerman, R
   Pouletty, P
   Buelow, R
AF Regan, J
   Monteiro, F
   Speiser, D
   Kalil, J
   Kerman, R
   Pouletty, P
   Buelow, R
BE Abraham, NG
   Asano, S
   Brittinger, G
   Maestroni, GJM
   Shadduck, RK
TI Correlation of ELISA-measured anti-HLA class I IgG and IgG1 antibodies
   and first-year rejection episodes
SO MOLECULAR BIOLOGY OF HEMATOPOIESIS 5
LA English
DT Proceedings Paper
CT 9th Symposium on Molecular Biology of Hematopoiesis and Treatment of
   Leukemias and Lymphomas
CY JUN 23-27, 1995
CL GENOA, ITALY
SP Menarini Int Fdn
AB Pretransprant screening of potential recipient patient sera to determine the level of allosensitization to class I HLA antigens has traditionally been done as an aid in the management of transplant waiting lists. A soluble HLA (sHLA) ELISA was developed as an alternative to lymphocytotoxicity for anti-HLA antibody screening. This ELISA was used for the detection of anti-HLA class I IgG, IgG1, IgG2, 1gG3, IgG4, and IgM antibodies and used to analyze the correlation of pretransplant allosensitization and post transplant rejection episodes in renal allograft recipients. ELISA plates were coated with 46 different sHLA preparations representing 40 different HLA class I antigens. After incubation with a serum specimen, bound antibodies were detected with a peroxidase conjugated antibody. Serum specimens from 158 microlymphocytotoxicity positive patients were analyzed. Eighty-four patients had experienced one or more rejection episodes within twelve months post transplantation. One hundred two patients were tested positive by ELISA (total IgG %PRA > 10%). A strong correlation between first year rejection and ELISA detected anti-HLA class I IgG (p = 0.0004) and IgG1 (p < 0.0001) was observed. The predictive value for IgG was 64%, and for IgG1, 73% demonstrating that ELISA results allow the identification of patients at high risk to reject the transplanted kidney. Presence of anti-HLA class I IgG2, 1gG3, IgG4 or IgM was not predictive of first year rejection episodes.
RP Regan, J (corresponding author), SANGSTAT MED CORP,MENLO PARK,CA 94025, USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
BN 0-306-45318-5
PY 1996
BP 107
EP 113
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Hematology;
   Transplantation
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Hematology;
   Transplantation
GA BG81N
UT WOS:A1996BG81N00014
DA 2020-11-26
ER

PT J
AU COELHO, V
   MOLITERNO, R
   HIGUCHI, MD
   GUILHERME, L
   CUNHANETO, E
   FIORELLI, AI
   KALIL, J
AF COELHO, V
   MOLITERNO, R
   HIGUCHI, MD
   GUILHERME, L
   CUNHANETO, E
   FIORELLI, AI
   KALIL, J
TI GAMMA-DELTA T-CELLS PLAY NO MAJOR ROLE IN HUMAN HEART
   ALLOGRAFT-REJECTION
SO TRANSPLANTATION
LA English
DT Article
ID LYMPHOCYTES-T; RHEUMATOID-ARTHRITIS; ANTIGEN RECEPTOR; SYNOVIAL-FLUID;
   RECOGNITION; SPECIFICITY; CLONES; BEARING; TRANSPLANTATION; HETERODIMER
AB To investigate the role of gamma delta T cells in human heart transplantation, Fee searched for this T cell population in endomyocardial biopsies as well as in T cell lines and clones derived from graft-infiltrating lymphocytes. The number of gamma delta T cells in endomyocardial biopsies from transplanted patients (n=55) was mostly low and did not differ significantly from nontransplanted patients (n=21). Moreover, there was no association of gamma delta T cell distribution with rejection status or with time posttransplantation. Graft-derived T cell lines were established in the presence of autologous feeder cells and recombinant interleukin-2 to favor the growth of in vivo-activated T cells. Twenty T cell lines analyzed by flow cytometry showed low percentages of gamma delta T cells, and we were unable to obtain gamma delta T cell clones for functional studies. These results show that gamma delta T cells are poorly expressed on human heart allograft infiltrates and indicate that, when present, they are not activated in the graft. Our data suggest that gamma delta T cells do not have a major role in human heart rejection.
C1 UNIV SAO PAULO,SCH MED,INST CORACAO,DIV PATHOL,TRANSPLANTAT IMMUNOL LAB,BR-05403000 SAO PAULO,SP,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST CORACAO,DIV SURG,BR-05403000 SAO PAULO,SP,BRAZIL.
RI Guglielmi, Luiza G/E-7676-2013; de Lourdes Higuchi, Maria/K-3886-2017;
   KALIL, JORGE/C-8029-2012; Cunha-Neto, Edecio/B-4157-2009; COELHO,
   VERONICA/D-1433-2013
OI de Lourdes Higuchi, Maria/0000-0002-1673-6456; KALIL,
   JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Coelho, Veronica/0000-0002-0989-2581
CR Billingham M E, 1990, J Heart Transplant, V9, P587
   BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899
   BOSNES V, 1990, EUR J IMMUNOL, V20, P1429, DOI 10.1002/eji.1830200704
   BRENNAN F, 1989, CLIN EXP IMMUNOL, V77, P175
   BRENNAN FM, 1988, J AUTOIMMUN, V1, P319, DOI 10.1016/0896-8411(88)90002-9
   CARBONE A, 1991, IMMUNOL REV, V120, P35
   CICCONE E, 1989, EUR J IMMUNOL, V19, P1267, DOI 10.1002/eji.1830190718
   CICCONE E, 1988, J EXP MED, V167, P1517, DOI 10.1084/jem.167.4.1517
   COELHO V, 1994, THESIS U SAO PAULO B
   CREVAT D, 1983, ANN INST PASTEUR IMM, VC134, P31, DOI 10.1016/S0769-2625(83)80151-2
   GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277
   GUILHERME L, 1995, CIRCULATION, V92, P415, DOI 10.1161/01.CIR.92.3.415
   HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637
   HOLOSHITZ J, 1992, J CLIN INVEST, V89, P308, DOI 10.1172/JCI115577
   HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0
   JUTTE NHPM, 1990, HUM IMMUNOL, V28, P170, DOI 10.1016/0198-8859(90)90015-H
   KABELITZ D, 1990, HUM IMMUNOL, V28, P167, DOI 10.1016/0198-8859(90)90014-G
   KABELITZ D, 1990, J IMMUNOL, V144, P1288
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   KAUFMAN C, 1991, TRANSPLANT P, V23, P1142
   KEYSTONE EC, 1991, CLIN EXP IMMUNOL, V84, P78
   KIRK AD, 1993, HUM IMMUNOL, V36, P11, DOI 10.1016/0198-8859(93)90003-J
   MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206
   MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0
   MOLITERNO R, 1995, TRANSPLANTATION, V59, P1
   OBRIEN RL, 1991, IMMUNOL REV, V121, P155, DOI 10.1111/j.1600-065X.1991.tb00827.x
   OROSZ CG, 1986, TRANSPLANTATION, V41, P75, DOI 10.1097/00007890-198601000-00016
   OUWEHAND AJ, 1991, HUM IMMUNOL, V30, P50, DOI 10.1016/0198-8859(91)90071-G
   RIVAS A, 1989, J IMMUNOL, V142, P1840
   ROUSSILHON C, 1990, J INFECT DIS, V162, P283, DOI 10.1093/infdis/162.1.283-a
   RUSSO DM, 1993, J IMMUNOL, V151, P3712
   SINCLAIR NRS, 1994, IMMUNOL CELL BIOL, V72, P508, DOI 10.1038/icb.1994.75
   SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728
   SPITS H, 1990, J IMMUNOL, V144, P4156
   STEPKOWSKI SM, 1990, TRANSPLANTATION, V50, P112, DOI 10.1097/00007890-199007000-00021
   SUITTERS AJ, 1990, TRANSPLANTATION, V49, P1105, DOI 10.1097/00007890-199006000-00015
   VAESSEN LMB, 1991, J IMMUNOL, V147, P846
   VANDEKERCKHOVE BAE, 1990, J IMMUNOL, V144, P1288
   VANKAER L, 1991, IMMUNOL REV, V120, P89, DOI 10.1111/j.1600-065X.1991.tb00589.x
   WEBER T, 1988, TRANSPLANT P, V20, P176
NR 40
TC 11
Z9 11
U1 0
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD NOV 15
PY 1995
VL 60
IS 9
BP 980
EP 984
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA TE946
UT WOS:A1995TE94600017
PM 7491704
DA 2020-11-26
ER

PT J
AU GUILHERME, L
   CUNHANETO, E
   COELHO, V
   SNITCOWSKY, R
   POMERANTZEFF, PMA
   ASSIS, RV
   PEDRA, F
   NEUMANN, J
   GOLDBERG, A
   PATARROYO, ME
   PILEGGI, F
   KALIL, J
AF GUILHERME, L
   CUNHANETO, E
   COELHO, V
   SNITCOWSKY, R
   POMERANTZEFF, PMA
   ASSIS, RV
   PEDRA, F
   NEUMANN, J
   GOLDBERG, A
   PATARROYO, ME
   PILEGGI, F
   KALIL, J
TI HUMAN HEART-INFILTRATING T-CELL CLONES FROM RHEUMATIC HEART-DISEASE
   PATIENTS RECOGNIZE BOTH STREPTOCOCCAL AND CARDIAC PROTEINS
SO CIRCULATION
LA English
DT Article
DE AUTOIMMUNITY; RHEUMATIC HEART DISEASE; T CELL CLONES; MOLECULAR MIMICRY;
   GROUP A BETA-HEMOLYTIC STREPTOCOCCI
ID COILED-COIL STRUCTURE; HUMAN-LYMPHOCYTES; HLA-DR; ANTIGENS; EPITOPES;
   FEVER; ANTIBODIES; SPECIFICITY; ASSOCIATION; PEPTIDES
AB Background beta-Hemolytic streptococcal infection in developing countries still causes thousands of cases of rheumatic heart disease, demanding surgical valve correction. Antigenic mimicry between self and streptococcal components has been proposed as the triggering factor leading to autoimmunity in individuals with genetic susceptibility. Although heart streptococcal-M protein cross-reactive antibodies have been demonstrated, heart tissue damage seems to be T lymphocyte-dependent. We studied the infiltrating T lymphocytes in rheumatic heart lesions with the aim of understanding the role of cellular immune response at the site of the lesions.
   Methods and Results We obtained 107 T-cell clones from surgical fragments of cardiac tissue from four rheumatic heart disease patients. We tested their capacity to recognize streptococcal M protein-derived synthetic peptides and heart proteins. We found eight infiltrating T-cell clones from all four patients that simultaneously recognize streptococcal M and heart proteins. Among the M-protein sequences tested, only synthetic peptides corresponding to regions 1 through 25, 81 through 103, and 163 through 177 were simultaneously recognized with heart protein fractions. Interestingly, regions 81 through 103 and 163 through 177 have been known to bear heart cross-reactive epitopes at the antibody level. Five of these clones are CD4(+), and one is CD8(+).
   Conclusions The presence of heart-M protein cross-reactive T-cell clones in rheumatic heart lesions suggests their direct involvement in the pathogenesis of this disease. The dissection of protective and pathogenic epitopes of streptococcal M protein is an important step in allowing the development of a safe anti-streptococcal synthetic vaccine.
C1 UNIV SAO PAULO, FAC MED,HOSP CLIN,INST CORACAO, IMUNOL TRANSPLANTES LAB, BR-05403000 SAO PAULO, BRAZIL.
   UNIV NATL COLOMBIA, HOSP SAN JUAN DE DIOS, INST IMMUNOL, BOGOTA, COLOMBIA.
RI Pomerantzeff, Pablo M A/L-5525-2016; Guglielmi, Luiza G/E-7676-2013;
   Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012; COELHO,
   VERONICA/D-1433-2013; Cunha-Neto, Edecio/B-4157-2009
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; Goldberg, Anna
   Carla/0000-0003-2600-7940; KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Coelho, Veronica/0000-0002-0989-2581
CR ABOUZEID C, 1987, J IMMUNOL METHODS, V98, P5, DOI 10.1016/0022-1759(87)90429-7
   ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106
   CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27
   CONCEICAOSILVA F, 1990, CLIN EXP IMMUNOL, V79, P221, DOI 10.1111/j.1365-2249.1990.tb05182.x
   CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677
   DALE JB, 1982, J EXP MED, V156, P1165, DOI 10.1084/jem.156.4.1165
   DALE JB, 1986, J EXP MED, V163, P1191, DOI 10.1084/jem.163.5.1191
   DALE JB, 1981, J IMMUNOL, V126, P1499
   DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583
   FENDERSON PG, 1989, J IMMUNOL, V142, P2475
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   GULIZIA JM, 1991, AM J PATHOL, V138, P285
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   KEMENY E, 1989, CLIN IMMUNOL IMMUNOP, V52, P225, DOI 10.1016/0090-1229(89)90174-8
   KOTB M, 1989, J IMMUNOL, V142, P966
   LIFE PF, 1991, IMMUNOL REV, V121, P113, DOI 10.1111/j.1600-065X.1991.tb00825.x
   MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MANJULA BN, 1984, J BIOL CHEM, V259, P3686
   MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064
   MOLANO A, 1992, PARASITE IMMUNOL, V14, P111, DOI 10.1111/j.1365-3024.1992.tb00010.x
   OSULLIVAN D, 1991, J IMMUNOL, V147, P2663
   PADULA SJ, 1985, J CLIN INVEST, V75, P788, DOI 10.1172/JCI111774
   PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   QUAILE A, 1989, SPRINGER SEMIN IMMUN, V11, P273
   RAIZADA V, 1983, AM J MED, V74, P90, DOI 10.1016/0002-9343(83)91124-5
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   READ SE, 1974, J CLIN INVEST, V54, P439, DOI 10.1172/JCI107780
   ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5
   ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991
   STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P131, DOI 10.1016/S0090-1229(05)80019-4
   TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359
   TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992
   WATANABEOHNISHI R, 1994, J IMMUNOL, V152, P2066
   WEBER T, 1989, J HEART TRANSPLANT, V8, P233
   WEIDEBACH W, 1994, HUM IMMUNOL, V40, P253, DOI 10.1016/0198-8859(94)90024-8
NR 40
TC 132
Z9 137
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 1
PY 1995
VL 92
IS 3
BP 415
EP 420
DI 10.1161/01.CIR.92.3.415
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA RL562
UT WOS:A1995RL56200024
PM 7634457
DA 2020-11-26
ER

PT J
AU CUNHANETO, E
   DURANTI, M
   GRUBER, A
   ZINGALES, B
   DEMESSIAS, I
   STOLF, N
   BELLOTTI, G
   PATARROYO, ME
   PILLEGGI, F
   KALIL, J
AF CUNHANETO, E
   DURANTI, M
   GRUBER, A
   ZINGALES, B
   DEMESSIAS, I
   STOLF, N
   BELLOTTI, G
   PATARROYO, ME
   PILLEGGI, F
   KALIL, J
TI AUTOIMMUNITY IN CHAGAS-DISEASE CARDIOPATHY - BIOLOGICAL RELEVANCE OF A
   CARDIAC MYOSIN-SPECIFIC EPITOPE CROSS-REACTIVE TO AN IMMUNODOMINANT
   TRYPANOSOMA-CRUZI ANTIGEN
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HEART-DISEASE; MYOCARDITIS; MICE; INFECTION; PROTEINS; ANTIBODY;
   LESIONS; RABBITS; PEPTIDE; REACTS
AB Heart tissue destruction in chronic Chagas disease cardiopathy (CCC) may be caused by autoimmune recognition of heart tissue by a mononuclear cell infiltrate decades after Trypanosoma cruzi infection. Indirect evidence suggests that there is antigenic crossreactivity between T. cruzi and heart tissue. As there is evidence for immune recognition of cardiac myosin in CCC, we searched for a putative myosin-crossreactive T. cruzi antigen. T. cruzi lysate immunoblots were probed with anti-cardiac myosin heavy chain. IgG antibodies (AMA) affinity-purified from CCC or asymptomatic Chagas disease patient-seropositive sera. A 140/116-kDa doublet was predominantly recognized by AMA from CCC sera. Further, recombinant T. cruzi protein B13-whose native protein is also a 140- and 116-kDa double band-was identified by crossreactive AMA. Among 28 sera tested in a dot-blot assay, AMA from 100% of CCC sera but only 14% of the asymptomatic Chagas disease sera recognized B13 protein (P = 2.3 x 10(-6)). Sequence homology to B13 protein was found at positions 8-13 and 1442-1447 of human cardiac myosin heavy chain. Competitive ELISA assays that used the correspondent myosin synthetic peptides to inhibit serum antibody binding to B13 protein identified the heart-specific AAALDK (1442-1447) sequence of human cardiac myosin heavy chain and the homologous AAAGDK B13 sequence as the respective crossreactive epitopes. The recognition of a heart-specific T. cruzi crossreactive epitope, in strong association with the presence of chronic heart lesions, suggests the involvement of crossreactivity between cardiac myosin and B13 in the pathogenesis of CCC.
C1 SAO PAULO UNIV HOSP,FAC MED,INST CORACAO,TRANSPLANTAT IMMUNOL LAB,BR-05403000 SAO PAULO,BRAZIL.
   SAO PAULO UNIV HOSP,FAC MED,INST CORACAO,DIV SURG CARDIOL,BR-05403000 SAO PAULO,BRAZIL.
   SAO PAULO UNIV HOSP,FAC MED,INST CORACAO,DIV CLIN CARDIOL,BR-05403000 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,INST QUIM,BR-05403000 SAO PAULO,BRAZIL.
   FED UNIV PARANA,HOSP CINICAS,IMMUNOPATHOL LAB,CURITIBA,PARANA,BRAZIL.
   UNIV NACL COLOMBIA,HOSP SAN JUAN DE DIOS,INST IMMUNOL,BOGOTA,COLOMBIA.
RI Gruber, Arthur/B-4711-2011; Cunha-Neto, Edecio/B-4157-2009; KALIL,
   JORGE/C-8029-2012
OI Gruber, Arthur/0000-0001-8093-2278; Cunha-Neto,
   Edecio/0000-0002-3699-3345; KALIL, JORGE/0000-0001-8415-4274
CR ANDRADE ZA, 1958, REV GOIANA MED, V4, P103
   ASCURRA M, 1990, Memorias do Instituto Oswaldo Cruz, V85, P78
   BERNEMAN A, 1992, EUR J IMMUNOL, V22, P625, DOI 10.1002/eji.1830220303
   COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13
   CUNNINGHAM MW, 1988, J IMMUNOL, V14, P2760
   DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8
   GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694
   GRUBER A, 1993, EXP PARASITOL, V76, P1, DOI 10.1006/expr.1993.1001
   HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   KABAT EA, 1970, ANN NY ACAD SCI, V169, P43
   KERNER N, 1991, EXP PARASITOL, V73, P451, DOI 10.1016/0014-4894(91)90069-9
   KHOURY EL, 1983, CLIN IMMUNOL IMMUNOP, V27, P283, DOI 10.1016/0090-1229(83)90078-8
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAYRISSE Z, 1988, HUM IMMUNOL, V23, P116, DOI 10.1016/0198-8859(88)90189-9
   LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530
   MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55
   NEU N, 1987, J IMMUNOL, V138, P2488
   NEU N, 1987, J IMMUNOL, V139, P3630
   RASSI A, 1982, DOENCAS INFECCIOSAS, P675
   RIBEIRODOSSANTO.R, 1992, J EXP MED, V175, P29
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304
   SMITH SC, 1991, J IMMUNOL, V147, P2141
   TEIXEIRA ARL, 1975, AM J PATHOL, V80, P163
   TEIXEIRA ARL, 1990, J INFECT DIS, V162, P1420, DOI 10.1093/infdis/162.6.1420
   TIBBETTS RS, 1994, J IMMUNOL, V152, P1493
   TORRES CM, 1930, 5A AN REUN SOC ARG P, V2, P902
   TOVEY ER, 1989, PROTEIN BLOTTING MET, P43
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993
   ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498
   ZINGALES B, 1982, MOL BIOCHEM PARASIT, V6, P111, DOI 10.1016/0166-6851(82)90069-X
   1990, MEM I O CRUZ, V85, P487
NR 36
TC 162
Z9 166
U1 2
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 11
PY 1995
VL 92
IS 8
BP 3541
EP 3545
DI 10.1073/pnas.92.8.3541
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA QR968
UT WOS:A1995QR96800097
PM 7536937
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU MACAUBAS, C
   HALLMAYER, J
   KALIL, J
   KIMURA, A
   YASUNAGA, S
   GRUMET, FC
   MIGNOT, E
AF MACAUBAS, C
   HALLMAYER, J
   KALIL, J
   KIMURA, A
   YASUNAGA, S
   GRUMET, FC
   MIGNOT, E
TI EXTENSIVE POLYMORPHISM OF A (CA)(N) MICROSATELLITE LOCATED IN THE
   HLA-DQA1/DQB1 CLASS-II REGION
SO HUMAN IMMUNOLOGY
LA English
DT Article
ID DEPENDENT DIABETES-MELLITUS; DQ-BETA-GENES; EVOLUTIONARY IMPLICATIONS;
   LINKAGE DISEQUILIBRIUM; HLA; HAPLOTYPE; RECOMBINATION; ALPHA; MHC;
   SUSCEPTIBILITY
AB A highly polymorphic (CA)n microsatellite marker (DQCAR), located between the DQA1 and the DQB1 genes, was characterized in four ethnic groups. Based on length polymorphism, 12 alleles could be defined. The marker is located 1- to 2-kb telomeric to the DQB1 gene and 10 kb centromeric to the DQA1 gene and was shown to be in tight linkage disequilibrium with HLA-DQ. Analysis of the linkage disequilibrium pattern revealed little additional diversity in DQ1-associated haplotypes. Almost all DQ1 subjects examined were DQCAR 103 or DQCAR 107 (13 and 15 CA repeats, respectively). In contrast, significant haplotypic diversity was observed for most DQ2-, DQ3-, and DQ4-associated haplotypes. These haplotypes often had longer allele sizes (DQCAR > 111, more than 17 CA repeats) and more DQCAR alleles per haplotype. These haplotypes also carried DQCAR alleles of different sizes, even though they bore the same DQA1 and DQB1 alleles, and sometimes the same DRB1 allele as well. These results indicate that DQCAR could be a useful marker to better define disease associations with HLA. Our results are also consistent with the hypothesis that CAR alleles with higher numbers of repeats have higher mutation rates and that recombination within the HLA-DR/DQ region is haplotype dependent.
C1 CTR NARCOLEPSY RES,DEPT PSYCHIAT,PALO ALTO,CA.
   STANFORD UNIV,SCH MED,DEPT GENET,PALO ALTO,CA 94304.
   UNIV SAO PAULO,TRANSPLANTAT IMMUNOL LAB,SAO PAULO,BRAZIL.
   KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,FUKUOKA 812,JAPAN.
   STANFORD UNIV,CTR BLOOD,PALO ALTO,CA 94304.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P01NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P01NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724] Funding Source: NIH RePORTER;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 11383] Funding Source: Medline; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS 23724] Funding Source: Medline
CR ALDENER A, 1993, TISSUE ANTIGENS, V42, P536, DOI 10.1111/j.1399-0039.1993.tb02201.x
   BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z
   BEGOVICH AB, 1992, J IMMUNOL, V148, P249
   BLANCK G, 1988, J IMMUNOL, V141, P1734
   DONG RP, 1992, IMMUNOGENETICS, V36, P130, DOI 10.1007/BF00215291
   ERLICH HA, 1991, IMMUNOL TODAY, V12, P411, DOI 10.1016/0167-5699(91)90143-H
   Falconer D. S., 1989, INTRO QUANTITATIVE G
   FENSKE TS, 1992, TISSUE ANTIGENS, V40, P49, DOI 10.1111/j.1399-0039.1992.tb01958.x
   FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299, DOI 10.1007/BF00211994
   GERNANDEZVINA MA, 1994, HUM IMMUNOL, V39, P290
   GREGERSEN PK, 1988, J IMMUNOL, V141, P1365
   GUIGNIER F, 1993, TISSUE ANTIGENS, V42, P42, DOI 10.1111/j.1399-0039.1993.tb02165.x
   GYLLENSTEN UB, 1989, P NATL ACAD SCI USA, V86, P9986, DOI 10.1073/pnas.86.24.9986
   GYLLENSTEN UB, 1993, HUM IMMUNOL, V36, P1, DOI 10.1016/0198-8859(93)90002-I
   H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67
   HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D
   HURLEY CK, 1988, J IMMUNOL, V140, P885
   IMANISHI T, 1992, HLA 1991 11TH P INT
   KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x
   KWOK WW, 1993, J IMMUNOL, V150, P2263
   LEE KW, 1990, J IMMUNOL, V145, P3119
   LEE KW, 1991, TISSUE ANTIGENS, V38, P231, DOI 10.1111/j.1399-0039.1991.tb01903.x
   LIU CP, 1988, J IMMUNOL, V140, P3631
   MERRYMAN P, 1989, J IMMUNOL, V143, P2068
   MIGNOT E, 1993, SLEEP, V16, P764
   NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493
   NISHIMURA Y, 1992, HLA 1991 11TH INT HI
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1991, P NATL ACAD SCI USA, V88, P8480, DOI 10.1073/pnas.88.19.8480
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x
   PLOSKI R, 1993, TISSUE ANTIGENS, V41, P173, DOI 10.1111/j.1399-0039.1993.tb01998.x
   RONNINGEN KS, 1991, TISSUE ANTIGENS, V37, P165
   SANJEEVI CB, 1993, TISSUE ANTIGENS, V42, P72, DOI 10.1111/j.1399-0039.1993.tb02170.x
   SARYANARAYANA K, 1992, IMMUNOGENETICS, V35, P235
   SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211
   SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595
   SONG QL, 1987, J IMMUNOL, V139, P2993
   STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S
   TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0
   VALDES AM, 1993, GENETICS, V133, P737
   WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z
   YANG SY, 1987, IMMUNOBIOLOGY HLA, V1
NR 42
TC 38
Z9 39
U1 0
U2 1
PU ELSEVIER SCIENCE PUBL CO INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAR
PY 1995
VL 42
IS 3
BP 209
EP 220
DI 10.1016/0198-8859(94)00101-U
PG 12
WC Immunology
SC Immunology
GA QL393
UT WOS:A1995QL39300004
PM 7759308
DA 2020-11-26
ER

PT J
AU MORO, AM
   RODRIGUES, MTA
   GOUVEA, MN
   SILVESTRI, MLZ
   KALIL, JE
   RAW, I
AF MORO, AM
   RODRIGUES, MTA
   GOUVEA, MN
   SILVESTRI, MLZ
   KALIL, JE
   RAW, I
TI MULTIPARAMETRIC ANALYSES OF HYBRIDOMA GROWTH ON GLASS CYLINDERS IN A
   PACKED-BED BIOREACTOR SYSTEM WITH INTERNAL AERATION - SERUM-SUPPLEMENTED
   AND SERUM-FREE MEDIA COMPARISON FOR MAB PRODUCTION
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE HYBRIDOMA; MONOCLONAL ANTIBODY; PACKED-BED BIOREACTOR; DOWNSTREAM
   PROCESSING; SERUM-FREE MEDIUM; PERFUSION SYSTEM
ID PROTEIN-FREE MEDIUM; ANTIBODY PRODUCTIVITY; CELLS; IMMOBILIZATION;
   REACTORS; CULTURE
AB Monoclonal antibodies are one of the most important products of biotechnology and laboratories and companies all over the world are pursuing their large-scale production. Herein we report a protocol for hybridoma cell cultivation over small glass cylinders inside a 3 liter bioreactor vessel which leads to the production and purification - in order of grams - of one MAb intended for human therapeutic use. This protocol proved to be simple, reproducible and cost effective. Three trials are reported: the first two using conventionally serum-supplemented medium culture and producing 3.15 and 2.1 g of purified MAb in 30 and 21 days respectively, and the third one using serum-free medium culture and producing 6 g of purified MAb in 36 days. We have ascertained the stability of the hybridoma by its cloning directly in serum-free medium. The downstream processing of the serum-free trial was done in a single step, concentrating large volumes of supernatant while simultaneously purifying the antibody.
C1 UNIV SAO PAULO, FAC MED, IMUNOL TRANSPLANTES LAB, BR-05508 SAO PAULO, BRAZIL.
RP MORO, AM (corresponding author), INST BUTANTAN, CTR BIOTECHNOL, AV DR VITAL BRAZIL, BR-05503900 SAO PAULO, SP, BRAZIL.
RI Moro, Ana Maria/A-5134-2012; GOUVEA, MIRIAN/F-3332-2019; KALIL,
   JORGE/C-8029-2012; Rodrigues, Maria Teresa Alves/G-8072-2014
OI Moro, Ana Maria/0000-0002-0650-7764; GOUVEA, MIRIAN/0000-0003-0785-2401;
   KALIL, JORGE/0000-0001-8415-4274; 
CR ABUREESH I, 1989, J BIOTECHNOL, V9, P167, DOI 10.1016/0168-1656(89)90106-5
   BLIEM R, 1990, CYTOTECHNOLOGY, V4, P279, DOI 10.1007/BF00563788
   FAMILLETTI PC, 1988, BIO-TECHNOL, V6, P41, DOI 10.1038/nbt0188-41
   FAMILLETTI PC, 1987, TECHNICAL NOTE B NOV
   FEDER J, 1985, LARGE SCALE MAMMALIA
   FRAME KK, 1990, BIOTECHNOL BIOENG, V35, P469, DOI 10.1002/bit.260350504
   GOKA AKJ, 1987, J IMMUNOASSAY, V8, P29, DOI 10.1080/01971528708063053
   HANDACORRIGAN A, 1990, ANIMAL CELL BIOTECHN, V4, P123
   MERTEN OW, 1987, TRENDS BIOTECHNOL, V5, P230, DOI 10.1016/0167-7799(87)90053-9
   OZTURK SS, 1990, HYBRIDOMA, V9, P167, DOI 10.1089/hyb.1990.9.167
   RACHER AJ, 1993, J BIOTECHNOL, V29, P145, DOI 10.1016/0168-1656(93)90047-Q
   RAMIREZ OT, 1989, BIOTECHNOL BIOENG, V33, P1072, DOI 10.1002/bit.260330816
   REUVENY S, 1986, J IMMUNOL METHODS, V86, P53, DOI 10.1016/0022-1759(86)90264-4
   REUVENY S, 1986, J IMMUNOL METHODS, V86, P61, DOI 10.1016/0022-1759(86)90265-6
   REUVENY S, 1989, ADV BIOTECHNOL PROCE, V11, P47
   RIGHETTI PG, 1976, J CHROMATOGR, V127, P1, DOI 10.1016/S0021-9673(00)98537-6
   SAMOILOVICH SR, 1987, J IMMUNOL METHODS, V101, P153, DOI 10.1016/0022-1759(87)90147-5
   SEAVER SS, 1987, COMMERCIAL PRODUCTIO
   SPIER RE, 1984, DEV BIOL STAND, V55, P81
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   TARLETON RL, 1991, BIOTECHNIQUES, V11, P590
   YAMAJI H, 1989, APPL MICROBIOL BIOT, V30, P609
   1969, WHO B TECHNICAL REPO, V413, P49
   1990, US PHARMACOPEIAL CON, P1493
NR 24
TC 10
Z9 11
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD NOV 10
PY 1994
VL 176
IS 1
BP 67
EP 77
DI 10.1016/0022-1759(94)90351-4
PG 11
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA PR818
UT WOS:A1994PR81800007
PM 7963595
DA 2020-11-26
ER

PT J
AU BEHAR, E
   BRYANT, P
   TAIDILASKOWSKI, B
   KALIL, J
   GRUMET, FC
AF BEHAR, E
   BRYANT, P
   TAIDILASKOWSKI, B
   KALIL, J
   GRUMET, FC
TI CELL-SURFACE ANTIGEN STABILITY OF CULTURED HUMAN UMBILICAL VEIN VASCULAR
   ENDOTHELIAL (VEC) CELLS
SO TISSUE ANTIGENS
LA English
DT Note
DE VEC; ANTIGEN STABILITY
ID CARDIAC TRANSPLANTATION; ANTIBODIES; IDENTIFICATION; REJECTION; HLA
C1 STANFORD MED SCH,CTR BLOOD,PALO ALTO,CA 94304.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811] Funding Source: NIH RePORTER; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL33811] Funding Source: Medline
CR BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   BRASILE L, 1985, TRANSPLANTATION, V40, P672, DOI 10.1097/00007890-198512000-00020
   CERILLI J, 1985, TRANSPLANT P, V1, P567
   CERILLI J, 1987, TRANSPLANT P, V6, P4468
   DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   KALIL J, 1989, TRANSPLANT P, V21, P711
   LIZAK GE, 1983, HUM IMMUNOL, V8, P265, DOI 10.1016/0198-8859(83)90053-8
   MORAES JR, 1989, TRANSPLANTATION, V48, P951, DOI 10.1097/00007890-198912000-00010
   NEUMANN J, 1989, TRANSPLANT P, V21, P700
   RODEY GE, 1973, TISSUE ANTIGENS, V3, P63
   STASTNY P, 1981, TRANSPLANT CLIN IMM, P32
   1991, LANCET, V337, P649
NR 13
TC 2
Z9 2
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD NOV
PY 1994
VL 44
IS 5
BP 332
EP 334
DI 10.1111/j.1399-0039.1994.tb02406.x
PG 3
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA PR817
UT WOS:A1994PR81700011
PM 7878662
DA 2020-11-26
ER

PT J
AU BILLERBECK, AEC
   CAVALIERE, H
   GOLDBERG, AC
   KALIL, J
   MEDEIROSNETO, G
AF BILLERBECK, AEC
   CAVALIERE, H
   GOLDBERG, AC
   KALIL, J
   MEDEIROSNETO, G
TI CLINICAL AND MOLECULAR-GENETICS STUDIES IN PENDREDS-SYNDROME
SO THYROID
LA English
DT Article
ID HUMAN THYROID PEROXIDASE; SEQUENCE; IDENTIFICATION; DEFICIENCY; CDNA
AB A large and highly inbred kindred including patients with incomplete and complete forms of Pendred's syndrome was studied. Blood samples were collected from 42 individuals (23 affected and 19 normal), and serum thyroid hormones, TSH, Tg, and anti-TPO autoantibodies were assayed. Thyroid function studies have indicated euthyroidism in all 42 individuals. The affected subjects, however, had significantly elevated serum Tg levels (19.4 +/- 6.8 ng/dL) as compared with normals (9.6 +/- 2.9 ng/dL). Nineteen subjects had clinical and or ultrasonographic evidence of a multinodular goiter. In addition, 13 individuals had impaired hearing with or without goiter. Computer axial tomography scan studies in six patients confirmed the presence of a defective cochlea (Mondini's cochlear defect) in three of these subjects. It has been suggested that thyroperoxidase (TPO) in patients with Pendred's syndrome might be defective for coupling but could be partially effective for iodide organification. We have investigated possible abnormalities in the TPO gene by Southern blot analysis. Genomic DNA was obtained from peripheral blood leukocytes of 40 subjects (22 affected and 18 normal). DNA samples were digested with five restriction enzymes and hybridized with the pM5 probe (831 bp). Polymorphic fragment patterns obtained with three of the five enzymes employed were equally distributed in normal and affected subjects of this kindred, Lod score analysis did not disclose any linkage of TPO gene polymorphisms with the phenotypic characteristics observed in this family. Our findings may be explained in two different ways. First one might have hitherto undetected mutations in the TPO gene, and, second, the pathology may in fact be due to a genetic defect lying elsewhere.
C1 UNIV SAO PAULO,SCH MED,INCOR,THYROID LAB,DIV ENDOCRINOL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INCOR,TRANSPLANT IMMUNOL LAB,SAO PAULO,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR ABDELMOUMENE N, 1978, J MOL MED-NETH, V3, P305
   ABRAMOWICZ MJ, 1992, J CLIN INVEST, V90, P1200, DOI 10.1172/JCI115981
   ALMEIDA F, 1974, Pan American Health Organization Scientific Publication, V292, P167
   BASCHIERI L, 1963, J CLIN ENDOCR METAB, V23, P786, DOI 10.1210/jcem-23-8-786
   BURROW GN, 1973, J CLIN ENDOCR METAB, V36, P522, DOI 10.1210/jcem-36-3-522
   CAVE WT, 1975, J CLIN ENDOCR METAB, V41, P590, DOI 10.1210/jcem-41-3-590
   DAMIANI D, 1990, HUM GENET, V85, P85
   FRIIS J, 1988, J ENDOCRINOL INVEST, V11, P97, DOI 10.1007/BF03350112
   ILLUM P, 1972, ARCHIV OTOLARYNGOL, V96, P297
   JOHNSEN T, 1989, CLIN OTOLARYNGOL, V14, P389, DOI 10.1111/j.1365-2273.1989.tb00391.x
   JOHNSEN T, 1989, CLIN OTOLARYNGOL, V14, P395, DOI 10.1111/j.1365-2273.1989.tb00392.x
   KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555
   LIBERT F, 1987, NUCLEIC ACIDS RES, V15, P6735, DOI 10.1093/nar/15.16.6735
   LJUNGGREN JG, 1973, ACTA ENDOCRINOL-COP, V72, P171
   MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856
   MANGKLABRUKS A, 1991, J CLIN ENDOCR METAB, V72, P471, DOI 10.1210/jcem-72-2-471
   MEDEIROSNETO GA, 1988, B WORLD HEALTH ORGAN, V66, P637
   MEDEIROSNETO GA, 1993, THYROID, V3, P143, DOI 10.1089/thy.1993.3.143
   Mondini C, 1791, BONONIAE, V7, P419
   MORGANS ME, 1958, LANCET, V1, P607
   NIEPOMNISZCZE H, 1978, ACTA ENDOCRINOL-COP, V89, P70, DOI 10.1530/acta.0.0890070
   OTT J, 1976, AM J HUM GENET, V28, P528
   PENDRED V, 1896, LANCET, V2, P523
   SACREZ R, 1967, ANN PEDIATR, V1, P1
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
NR 25
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 1050-7256
J9 THYROID
JI Thyroid
PD FAL
PY 1994
VL 4
IS 3
BP 279
EP 284
DI 10.1089/thy.1994.4.279
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PH851
UT WOS:A1994PH85100009
PM 7833664
DA 2020-11-26
ER

PT J
AU WEIDEBACH, W
   GOLDBERG, AC
   CHIARELLA, JM
   GUILHERME, L
   SNITCOWSKY, R
   PILEGGI, F
   KALIL, J
AF WEIDEBACH, W
   GOLDBERG, AC
   CHIARELLA, JM
   GUILHERME, L
   SNITCOWSKY, R
   PILEGGI, F
   KALIL, J
TI HLA CLASS-II ANTIGENS IN RHEUMATIC-FEVER - ANALYSIS OF THE DR LOCUS BY
   RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND OLIGOTYPING
SO HUMAN IMMUNOLOGY
LA English
DT Article
ID DR BETA-CHAINS; HEART-DISEASE; CDNA CLONE; ASSOCIATION; POPULATION;
   SEQUENCES
AB We recently described an association of serologically defined HLA class II antigens DR7 and DR53 with RF. This study aimed at determining more precisely the class II gene associated with the disease. We studied patients and age- and race-matched controls. Genomic DNA was digested with four different enzymes and hybridized with HLA cDNA probes for DR beta, DQ beta, DQ alpha, and DP beta genes. RFLP analysis disclosed a fragment of 13,81 kb on Tag I DR beta blots, which correlates with HLA-DR53 and HLA-DR16, according to data from the Tenth International Histocompatibility Workshop. Of 24 patients, 20 (83.3%), were positive for the 13.81-kb/Taq I/DR beta allogenotope, compared with 16 (34%) of 47 healthy individuals (P = 0.000079, Fisher's exact test). Search for specific nucleotide sequences was performed using polymerase chain reaction technique. Oligonucleotides corresponding either to allele-specific DR7 and DR53 sequences, or shared by DRB1 and DRB3, DRB4, or DRB5 sequences were screened. Differences were tested throughout the second exon up to codon 100. Results were as expected by simple comparison with the published sequences of individual alleles. Although a clear association with DRB loci is shown, a susceptibility associated either with an allele or with a unique sequence was not found. A promiscuous presentation of the putative cross-reacting peptide or a heterogeneity of the causative agent might be the origin of these results. Genetic complementarity may be an additional factor defining inherited susceptibility to this disease.
C1 UNIV SAO PAULO,FAC MED,HOSP CLIN,INST HEART,SAO PAULO,BRAZIL.
RI Guglielmi, Luiza G/E-7676-2013; KALIL, JORGE/C-8029-2012; Goldberg, Anna
   Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   [Anonymous], 1965, Circulation, V32, P664
   AUFFRAY C, 1982, P NATL ACAD SCI-BIOL, V79, P6337, DOI 10.1073/pnas.79.20.6337
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   CHEADLE WB, 1889, LANCET, V1, P821
   DUPONT B, 1989, HISTOCOMPATIBILITY T
   ERLICH HA, 1990, PCR PROTOCOLS, P261
   GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P9149, DOI 10.1073/pnas.83.23.9149
   GUILHERME L, 1991, CIRCULATION, V83, P1995, DOI 10.1161/01.CIR.83.6.1995
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   LARHAMMAR D, 1982, P NATL ACAD SCI-BIOL, V79, P3687, DOI 10.1073/pnas.79.12.3687
   LONG EO, 1982, P NATL ACAD SCI-BIOL, V79, P7465, DOI 10.1073/pnas.79.23.7465
   MANIATIS T, 1982, MOL CLONING LABORATO, P1273
   MARSH SGE, 1992, HUM IMMUNOL, V35, P1, DOI 10.1016/0198-8859(92)90090-A
   MORAES ME, 1991, HUM IMMUNOL, V31, P139, DOI 10.1016/0198-8859(91)90017-4
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   ROSALES T, 1992, BRAZ J MED BIOL RES, V25, P39
   ROUXDOSSETO M, 1983, P NATL ACAD SCI-BIOL, V80, P6036, DOI 10.1073/pnas.80.19.6036
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   STOLLERMAN GH, 1975, RHEUMATIC FEVCER STR
   WILLIAMS RC, 1985, CLIN RHEUM DIS, V11, P573
   WILLIAMS RC, 1982, HOSP PRACT, V8, P125
   ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077
NR 23
TC 36
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD AUG
PY 1994
VL 40
IS 4
BP 253
EP 258
DI 10.1016/0198-8859(94)90024-8
PG 6
WC Immunology
SC Immunology
GA PG065
UT WOS:A1994PG06500001
PM 8002374
DA 2020-11-26
ER

PT J
AU SAMPAIO, SO
   GOLDBERG, AC
   KALIL, J
AF SAMPAIO, SO
   GOLDBERG, AC
   KALIL, J
TI HIGH-FREQUENCY OF SPECIFIC T-CELL RECEPTOR REARRANGEMENTS IN
   RHEUMATOID-ARTHRITIS - ANALYSIS OF SYNOVIAL-FLUID T-LYMPHOCYTES
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE RHEUMATOID ARTHRITIS; SYNOVIAL FLUID T-LYMPHOCYTES; T-CELL RECEPTOR
   GENES; SOUTHERN BLOT; BAMH-I; HIND-III
ID BETA-CHAIN; TISSUE
AB 1. We have searched for rearrangements in the beta chain T cell receptor genes to identify clonal T lymphocyte populations in the synovial fluid of 10 patients with well established rheumatoid arthritis, using a T cell population unbiased by preselection.
   2. Analysis of the restriction fragments with the beta chain constant region probe CBETA2 disclosed a rearranged band in 50% of cases (5/10). No significant differences in age, duration of the disease, treatment employed and presence of articular deformities or erosion upon X-ray examination were observed when patients with or without rearrangements were compared.
   3. The rearranged band observed after BamH I digestion was of the same size in the 5 patients (14 kb). In addition, two patients presented a 10-kb rearranged band upon restriction with Hind III.
   3. These data indicate that a significant number of rheumatoid arthritis patients probably present oligoclonal T cell proliferation of their synovial fluid lymphocytes.
C1 UNIV SAO PAULO,FAC MED,INST CORACAO,IMUNOL TRANSPLANTES LAB,AV DR ARNALDO 455,3 ANDAR SALA 33,BR-01246903 SAO PAULO,SP,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR CHATILA MK, 1990, HUM IMMUNOL, V28, P252, DOI 10.1016/0198-8859(90)90026-L
   COHEN IR, 1985, ARTHRITIS RHEUM, V28, P841, DOI 10.1002/art.1780280802
   FLUG F, 1985, P NATL ACAD SCI USA, V82, P3460, DOI 10.1073/pnas.82.10.3460
   GOLDBERG AC, 1989, BRAZ J MED BIOL RES, V22, P870
   KALIL J, 1982, 1ST INT WORKSH HUM L
   KEYSTONE EC, 1988, ARTHRITIS RHEUM, V31, P1555, DOI 10.1002/art.1780311213
   KLARESKOG L, 1982, SCAND J IMMUNOL, V15, P501, DOI 10.1111/j.1365-3083.1982.tb00676.x
   LAY WH, 1971, NATURE, V230, P531, DOI 10.1038/230531a0
   MANTEGAZZA R, 1993, J CLIN INVEST, V91, P2880, DOI 10.1172/JCI116533
   OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0
   PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971
   PEARSON CM, 1964, J EXP MED, V120, P547, DOI 10.1084/jem.120.4.547
   RAMOS F, 1989, European Journal of Clinical Investigation, V19, pA53
   SAVILL CM, 1987, SCAND J IMMUNOL, V25, P629, DOI 10.1111/j.1365-3083.1987.tb01089.x
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   STAMENKOVIC I, 1988, P NATL ACAD SCI USA, V85, P1179, DOI 10.1073/pnas.85.4.1179
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD MAY
PY 1994
VL 27
IS 5
BP 1207
EP 1213
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA NN037
UT WOS:A1994NN03700014
PM 8000342
DA 2020-11-26
ER

PT J
AU CUNHANETO, E
   MOLITERNO, R
   COELHO, V
   GUILHERME, L
   BOCCHI, E
   HIGUCHI, MD
   STOLF, N
   PILEGGI, F
   STEINMAN, L
   KALIL, J
AF CUNHANETO, E
   MOLITERNO, R
   COELHO, V
   GUILHERME, L
   BOCCHI, E
   HIGUCHI, MD
   STOLF, N
   PILEGGI, F
   STEINMAN, L
   KALIL, J
TI RESTRICTED HETEROGENEITY OF T-CELL RECEPTOR VARIABLE ALPHA-CHAIN
   TRANSCRIPTS IN HEARTS OF CHAGAS-DISEASE CARDIOMYOPATHY PATIENTS
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE TRYPANOSOMA CRUZI; CHAGAS CARDIOMYOPATHY; AUTOIMMUNITY; T CELL RECEPTOR;
   PCR
ID BETA-GENE USAGE; CHRONIC ACTIVE HEPATITIS; LYMPHOCYTES-T; PREDOMINANT
   EXPRESSION; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; CLONES;
   REARRANGEMENTS; LIVER
AB The role of autoimmunity in the pathogenesis and progression of heart lesions in the chronic phase of Chagas' disease is controversial. In the absence of parasites in situ, the T cell infiltrate seen in heart lesions may be the primary determinant of tissue damage ultimately lending to heart failure and death. We used the polymerase chain reaction to amplify each known T cell receptor (TCR) V alpha and V beta subfamily-specific sequence in transcripts derived from heart samples obtained from Chagas' cardiomyopathy patients. The average number of TCR V alpha subfamilies (7.1 per tissue sample) was significantly lower than that for TCR V beta subfamilies (15.1 per sample). The average percentage of tissue samples positive pet TCR V alpha and Y beta subfamily was respectively 39.6% vs. 73.5%. These data suggest that, in Chagas' heart lesions, the detectable TCR V alpha repertoile is significantly narrower than TCR V beta repertoire. On the other hand, in normal heart tissue, diversity of V alpha and V beta TCR is similar among the scarce circulating T cell population. Such evidence of restricted TCR V region repertoire has been described in experimental and human autoimmune diseases. Our results ave consistent with the possibility that T cells responsible for heart damage in chronic Chagas' cardiomyopathy may be recognizing a few heart-specific antigenic tal gets.
C1 UNIV SAO PAULO, FAC MED, SAO PAULO HEART INST, TRANSPLANTAT IMMUNOL LAB, BR-01246903 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, SAO PAULO HEART INST, DIV MED, BR-01246903 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, SAO PAULO HEART INST, DIV PATHOL, BR-01246903 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, SAO PAULO HEART INST, DIV SURG, BR-01246903 SAO PAULO, BRAZIL.
   STANFORD UNIV, MED CTR, DEPT NEUROL, STANFORD, CA 94305 USA.
   STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA.
   STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA.
   STANFORD UNIV, MED CTR, DEPT PATHOL, STANFORD, CA 94305 USA.
RI COELHO, VERONICA/D-1433-2013; de Lourdes Higuchi, Maria/K-3886-2017;
   KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013; Cunha-Neto,
   Edecio/B-4157-2009
OI de Lourdes Higuchi, Maria/0000-0002-1673-6456; KALIL,
   JORGE/0000-0001-8415-4274; Cunha-Neto, Edecio/0000-0002-3699-3345
CR BEALL SS, 1987, J IMMUNOL, V139, P1320
   BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466
   BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765
   BRENER Z, 1987, MEMORIAS I O CRUZ S1, V82, P152
   CONCEICAOSILVA F, 1990, CLIN EXP IMMUNOL, V79, P221, DOI 10.1111/j.1365-2249.1990.tb05182.x
   CUNHANETO E, 1992, IMUNOLOGIA INFECCOE, P67
   DAVIES TF, 1991, NEW ENGL J MED, V325, P238, DOI 10.1056/NEJM199107253250404
   DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29
   GAZZINELLI RT, 1990, INFECT IMMUN, V58, P1437, DOI 10.1128/IAI.58.5.1437-1444.1990
   GREGERSON DS, 1991, CLIN IMMUNOL IMMUNOP, V58, P154, DOI 10.1016/0090-1229(91)90157-6
   GRUNEWALD J, 1992, EUR J IMMUNOL, V22, P129, DOI 10.1002/eji.1830220120
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, VIRCHOWS ARCH A, V423, P157, DOI 10.1007/BF01614765
   LEVENSON C, 1990, PCR PROTOCOLS GUIDE, P99
   LOHR H, 1991, CLIN EXP IMMUNOL, V84, P297
   MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818
   MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544
   MINOPRIO P, 1989, IMMUNOL REV, V112, P183, DOI 10.1111/j.1600-065X.1989.tb00558.x
   MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426
   NAJARIAN JS, 1963, J EXP MED, V117, P775, DOI 10.1084/jem.117.5.775
   NAOR D, 1991, ANN NY ACAD SCI, V636, P135, DOI 10.1111/j.1749-6632.1991.tb33444.x
   NITTA T, 1990, SCIENCE, V249, P672, DOI 10.1126/science.2382141
   OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0
   PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971
   PIUVEZAM MR, 1993, J IMMUNOL, V150, P916
   POBER JS, 1991, ADV IMMUNOL, V50, P261
   REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   SANTOSBU.CA, 1974, J EXP MED, V140, P38, DOI 10.1084/jem.140.1.38
   SCHMUNIS G A, 1987, Memorias do Instituto Oswaldo Cruz, V82, P287, DOI 10.1590/S0074-02761987000500011
   SOTTINI A, 1991, EUR J IMMUNOL, V21, P461, DOI 10.1002/eji.1830210231
   STEINMAN L, 1991, IR GENES BIOL MED
   TEIXEIRA ARL, 1978, AM J TROP MED HYG, V27, P1097, DOI 10.4269/ajtmh.1978.27.1097
   WILLIAMS WV, 1992, J CLIN INVEST, V90, P326, DOI 10.1172/JCI115866
   ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586
NR 35
TC 23
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD APR
PY 1994
VL 16
IS 4
BP 171
EP 179
DI 10.1111/j.1365-3024.1994.tb00337.x
PG 9
WC Immunology; Parasitology
SC Immunology; Parasitology
GA NG784
UT WOS:A1994NG78400001
PM 7914690
DA 2020-11-26
ER

PT J
AU TUDER, RM
   WEINBERG, A
   PANAJOTOPOULOS, N
   KALIL, J
AF TUDER, RM
   WEINBERG, A
   PANAJOTOPOULOS, N
   KALIL, J
TI CYTOMEGALOVIRUS-INFECTION AMPLIFIES CLASS-I MAJOR HISTOCOMPATIBILITY
   COMPLEX EXPRESSION ON CULTURED HUMAN ENDOTHELIAL-CELLS
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
AB Cytomegalovirus infection, a common complication in immunosuppressed graft recipients, bears an adverse impact on graft survival. Cytomegalovirus enhances the expression of the monotypic determinants of the class I major histocompatibility complex molecule by the endothelium, possibly rendering the endothelial cells more immunogenic and prone to attack by the allogeneic lymphocytes. In the present study, we focused on the effect of cytomegalovirus on the endothelial cell expression of different class I genes, on the relation between the extent of endothelial cell infection and the class I effect, and on the time course of the class I changes induced by the cytomegalovirus infection. Cytomegalovirus infection of primary cultures of human umbilical vein endothelial cells augmented the expression of the A2, A3, and B7 class I major histocompatibility complex genes when compared with uninfected cells. beta2 microglobulin upregulation by the infected cells paralleled the changes in specific class I expression; this effect was significant only after 7 days after infection. Double immunocytochemical staining and fluorescence-activated cell sorter analysis revealed that the class I enhancement was uniform throughout the umbilical vein endothelial cell monolayer and not restricted to the cells that expressed cytomegalovirus early or late antigens. Ultraviolet-inactivated supernatants from infected umbilical vein endothelial cell did not increase class I expression on uninfected cells. In conclusion, cytomegalovirus might affect graft survival by amplifying the changes in class I expression beyond the sites of viral replication.
RP TUDER, RM (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,CAMPUS BOX B216,4200 E 9TH AVE,DENVER,CO 80262, USA.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 16
Z9 16
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JAN-FEB
PY 1994
VL 13
IS 1
BP 129
EP 138
PN 1
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA MX227
UT WOS:A1994MX22700019
PM 8167118
DA 2020-11-26
ER

PT J
AU HIGUCHI, MD
   GUTIERREZ, PS
   AIELLO, VD
   PALOMINO, S
   BOCCHI, E
   KALIL, J
   BELLOTTI, G
   PILEGGI, F
AF HIGUCHI, MD
   GUTIERREZ, PS
   AIELLO, VD
   PALOMINO, S
   BOCCHI, E
   KALIL, J
   BELLOTTI, G
   PILEGGI, F
TI IMMUNOHISTOCHEMICAL CHARACTERIZATION OF INFILTRATING CELLS IN HUMAN
   CHRONIC CHAGASIC MYOCARDITIS - COMPARISON WITH MYOCARDIAL REJECTION
   PROCESS
SO VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY
LA English
DT Article
DE CHAGAS DISEASE; MYOCARDITIS; LYMPHOCYTES; IMMUNOHISTOCHEMISTRY; HEART
   TRANSPLANTATION
ID HUMAN CARDIAC ALLOGRAFTS; ENDOMYOCARDIAL BIOPSIES;
   HEART-TRANSPLANTATION; MONOCLONAL-ANTIBODIES; CRUZI INFECTION; DISEASE;
   EXPRESSION; CARDIOMYOPATHY; INTERLEUKIN-2; LYMPHOCYTES
AB Cellular subpopulations that infiltrate the heart in human chronic chagasic myocarditis were defined immunohistochemically in endomyocardial biopsy (EMB) specimens. T cells formed 96.3% of the inflammatory infiltrate, predominantly CD8 + (cytotoxic/suppressor) T cells. The mean numbers of CD8 + and CD4 + (helper) T cells in the myocarditis were compared to those present in the myocardial rejection process. Mean numbers of CD8 + T cells were similar in both groups of EMB specimens while CD4+ T cell counts, CD4 +/CD8 + ratios and CD4 + antigen expression were significantly lower in the chagasic group compared to the myocardial rejection group (P < 0.002). The persistent lower number and diminished expression of CD4 + T cells suggest an immunological imbalance in patients with chronic chagasic myocarditis. A possible participation of Trypanosoma cruzi parasites in the development of such immunological abnormalities is also discussed.
RP HIGUCHI, MD (corresponding author), HOSP CLIN FMUSP, INST CORACAO, AV DR ENEAS C AGUIAR, CEP 05403000, SAO PAULO, SP, BRAZIL.
RI KALIL, JORGE/C-8029-2012; Gutierrez, Paulo S/E-6783-2012; Palomino,
   Suely/P-5845-2016; Aiello, Vera/A-9495-2008; de Lourdes Higuchi,
   Maria/K-3886-2017
OI KALIL, JORGE/0000-0001-8415-4274; Gutierrez, Paulo
   S/0000-0002-9544-2359; Palomino, Suely/0000-0001-5286-9072; Aiello,
   Vera/0000-0002-4185-9423; de Lourdes Higuchi, Maria/0000-0002-1673-6456
CR BARRETTO ACP, 1986, AM HEART J, V111, P307, DOI 10.1016/0002-8703(86)90144-4
   BILLINGHAM ME, 1990, J HEART TRANSPLANT, V9, P587
   CHOW LH, 1989, ARCH PATHOL LAB MED, V113, P1357
   DEGUCHI H, 1987, JPN CIRC J, V51, P1365, DOI 10.1253/jcj.51.1365
   HARELBELLAN A, 1985, EUR J IMMUNOL, V15, P438, DOI 10.1002/eji.1830150505
   HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   HIGUCHI MD, 1991, J HEART LUNG TRANSPL, V10, P235
   KIERSZENBAUM F, 1989, IMMUNOL TODAY, V10, P129, DOI 10.1016/0167-5699(89)90246-6
   MILEI J, 1990, CARDIOLOGY, V77, P77, DOI 10.1159/000174587
   MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900
   PELLETIER LC, 1988, ANN THORAC SURG, V45, P11, DOI 10.1016/S0003-4975(10)62385-5
   REED SG, 1984, J IMMUNOL, V133, P1558
   REED SG, 1989, J IMMUNOL, V142, P2067
   ROSE ML, 1984, TRANSPLANTATION, V38, P230, DOI 10.1097/00007890-198409000-00007
   ROWLAND EC, 1978, INFECT IMMUN, V20, P393, DOI 10.1128/IAI.20.2.393-397.1978
   SADIGURSKY M, 1989, CIRCULATION, V80, P1269, DOI 10.1161/01.CIR.80.5.1269
   SANTOSBU.CA, 1974, J EXP MED, V140, P38, DOI 10.1084/jem.140.1.38
   SZTEIN MB, 1990, J IMMUNOL, V144, P3558
   TEIXEIRA ARL, 1975, AM J PATHOL, V80, P163
   Torres CM, 1941, MEMORIAS I O CRUZ, V36, P391, DOI 10.1590/S0074-02761941000300015
NR 21
TC 99
Z9 103
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-7398
J9 VIRCHOWS ARCH A
JI Virchows Arch. A-Pathol. Anat. Histopathol.
PD SEP
PY 1993
VL 423
IS 3
BP 157
EP 160
DI 10.1007/BF01614765
PG 4
WC Anatomy & Morphology; Pathology
SC Anatomy & Morphology; Pathology
GA MC618
UT WOS:A1993MC61800003
PM 7901937
DA 2020-11-26
ER

PT J
AU POULETTY, P
   CHANG, C
   KALIL, J
   ATWOOD, E
   FERRONE, S
   SHIMIZU, B
   HOWSON, W
   MAZAHERI, R
   DELVILLANO, B
   GRUMET, C
AF POULETTY, P
   CHANG, C
   KALIL, J
   ATWOOD, E
   FERRONE, S
   SHIMIZU, B
   HOWSON, W
   MAZAHERI, R
   DELVILLANO, B
   GRUMET, C
TI TYPING OF SERUM-SOLUBLE HLA-B27 ANTIGEN BY ELISA
SO TISSUE ANTIGENS
LA English
DT Article
DE SOLUBLE HLA; HLA-B27; ELISA; TYPING
ID LINKED-IMMUNOSORBENT-ASSAY; CLASS-I MOLECULES; HLA-A;
   MONOCLONAL-ANTIBODIES; GENE-PRODUCTS; PLASMA
AB An ELISA using serum as soluble HLA antigen source was developed for HLA-B27 typing. Two sandwich assays were run in parallel. The first assay utilized a monoclonal antibody (mAb) reacting with a determinant expressed by both HLA-B7 and B27 antigens; the other assay utilized a mAb reactive with HLA-B7 antigens but not with HLA-B27 antigens. After incubation with serum samples, bound HLA antigen was detected using an anti-beta2m antibody conjugated to peroxidase and a chromogenic substrate. Absorbance of each well was measured at 490 nm. Based on analysis of absorbances obtained with panels of specimens of known HLA phenotypes, a mathematical algorithm was developed to derive the specimen HLA-B27 phenotype from its ELISA absorbance values. Despite the lack of monospecific mAb, an accurate HLA-B27 typing was possible. 362 specimens (including 151 HLA-B27-positive) were tested. Agreement between microlymphocytotoxicity and ELISA was 99.2%. No correlation between the level of HLA-B27 antigen reactivity and the amount of total HLA class I antigen in serum was observed. This report demonstrates the possibility of using serum-soluble HLA antigen and ELISA technology for histocompatibility testing. The assay offers several significant advantages over microlymphocytotoxicity: no need for cell preparation, batch testing capabilities and objective, reproducible interpretation of results.
C1 STANFORD UNIV,HISTOCOMPATIBIL LAB,STANFORD,CA 94305.
   NEW YORK MED COLL,VALHALLA,NY 10595.
   UNIV WESTERN ONTARIO,UNIV HOSP,LONDON N6A 5A5,ONTARIO,CANADA.
   ID LABS INC,LONDON,ON,CANADA.
RP POULETTY, P (corresponding author), SANGSTAT MED CORP,1505 B ADAMS DR,MENLO PK,CA 94025, USA.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ALLISON JP, 1977, J IMMUNOL, V118, P1004
   CHARLTON RK, 1970, SCIENCE, V170, P636, DOI 10.1126/science.170.3958.636
   DOBBE LME, 1988, IMMUNOGENETICS, V27, P203, DOI 10.1007/BF00346587
   DOXIADIS I, 1989, BLUT, V59, P449, DOI 10.1007/BF00349066
   DOXIADIS I, 1989, VOX SANG, V56, P196, DOI 10.1111/j.1423-0410.1989.tb02026.x
   DUQUESNOY RJ, 1987, ARCH PATHOL LAB MED, V111, P1101
   HAGA JA, 1991, HUM IMMUNOL, V32, P79, DOI 10.1016/0198-8859(91)90103-G
   HOPKINS KA, 1992, HUM IMMUNOL, V33, P122, DOI 10.1016/0198-8859(92)90062-R
   Hors J, 1986, Adv Nephrol Necker Hosp, V15, P329
   KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173
   PARHAM P, 1984, J BIOL CHEM, V259, P3077
   PELLEGRINO MA, 1974, EUR J IMMUNOL, V4, P250, DOI 10.1002/eji.1830040405
   PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4
   RUSSO C, 1983, TRANSPLANT P, V15, P66
   SAKAGUCHI K, 1988, HUM IMMUNOL, V21, P193, DOI 10.1016/0198-8859(88)90071-7
   SHIMIZU B, 1991, HUM IMMUNOL, V32, P289
   VANROOD JJ, 1970, NATURE, V226, P366, DOI 10.1038/226366a0
   WESTHOFF U, 1991, VOX SANG, V61, P106, DOI 10.1111/j.1423-0410.1991.tb00255.x
NR 18
TC 22
Z9 22
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD JUL
PY 1993
VL 42
IS 1
BP 14
EP 19
DI 10.1111/j.1399-0039.1993.tb02160.x
PG 6
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA LX640
UT WOS:A1993LX64000004
PM 8248889
DA 2020-11-26
ER

PT J
AU PASSOSBUENO, MR
   RICHARD, I
   VAINZOF, M
   FOUGEROUSSE, F
   WEISSENBACH, J
   BROUX, O
   COHEN, D
   AKIYAMA, J
   MARIE, SKN
   CARVALHO, AA
   GUILHERME, L
   KALIL, J
   TSANACLIS, AM
   ZATZ, M
   BECKMANN, JS
AF PASSOSBUENO, MR
   RICHARD, I
   VAINZOF, M
   FOUGEROUSSE, F
   WEISSENBACH, J
   BROUX, O
   COHEN, D
   AKIYAMA, J
   MARIE, SKN
   CARVALHO, AA
   GUILHERME, L
   KALIL, J
   TSANACLIS, AM
   ZATZ, M
   BECKMANN, JS
TI EVIDENCE OF GENETIC-HETEROGENEITY IN THE AUTOSOMAL RECESSIVE ADULT FORMS
   OF LIMB-GIRDLE MUSCULAR-DYSTROPHY FOLLOWING LINKAGE ANALYSIS WITH 15Q
   PROBES IN BRAZILIAN FAMILIES
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MUSCLE
AB The autosomal recessive limb-girdle muscular dystrophies (LGMD) represent a heterogeneous group of diseases which may be characterised by one or more autosomal loci. A gene at 15q has recently been found to be responsible for a mild form of LGMD in a group of families from the isolated island of Reunion, now classified as LGMD2. Based on results of eight out of 11 large Brazilian LGMD families of different racial background (which were informative for the closest available probe to the LGMD2 gene), we confirmed linkage to the LGMD2 gene at 15q in two of these families and exclusion in six others. These data provide the first evidence of genetic heterogeneity for the autosomal recessive limb-girdle muscular dystrophies.
C1 GENETHON, PARIS, FRANCE.
   CEPH, PARIS, FRANCE.
   UNIV SAO PAULO, FAC MED, DOENCAS NEUROMUSCULARES GRP, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, SAO PAULO, BRAZIL.
RP PASSOSBUENO, MR (corresponding author), UNIV SAO PAULO, CTR MIOPATIAS, DEPT BIOL, CAIXA POSTAL 11461, BR-05422-970 SAO PAULO, BRAZIL.
RI Beckmann, Jacques S/A-9772-2008; Richard, isabelle/J-8298-2013; Zatz,
   Mayana/M-5338-2015; KALIL, JORGE/C-8029-2012; Passos-Bueno, Maria
   Rita/I-6796-2016; Vainzof, Mariz/J-7150-2012; Marie, Suely Kazue
   Nagahashi/D-1870-2012; Guglielmi, Luiza G/E-7676-2013; Vainzof,
   Mariz/Q-4787-2019
OI Beckmann, Jacques S/0000-0002-9741-1900; Zatz,
   Mayana/0000-0003-3970-8025; KALIL, JORGE/0000-0001-8415-4274;
   Passos-Bueno, Maria Rita/0000-0002-9248-3008; Vainzof,
   Mariz/0000-0002-2797-0782; Marie, Suely Kazue
   Nagahashi/0000-0003-4419-7928; Vainzof, Mariz/0000-0002-2797-0782
CR BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141
   BUENO MRP, 1991, AM J MED GENET, V103, P65
   DONLON TA, 1991, CYTOGENET CELL GENET, V58, P624, DOI 10.1159/000133175
   EMERY AEH, 1987, DUCHENNE MUSCULAR DY
   FOUGEROUSSE F, 1992, GENOMICS, V13, P903, DOI 10.1016/0888-7543(92)90184-T
   FREZAL J, 1991, CYTOGENET CELL GENET, V58, P986, DOI 10.1159/000133716
   HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702
   KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245
   LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443
   LITT M, 1989, AM J HUM GENET, V44, P397
   LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0
   PASSOSBUENO MR, 1991, AM J MED GENET, V38, P140, DOI 10.1002/ajmg.1320380130
   SHIELDS RW, 1986, MYOLOGY, V2
   VAINZOF M, 1990, J NEUROL SCI, V98, P221, DOI 10.1016/0022-510X(90)90263-M
   Walton J, 1988, DISORDERS VOLUNTARY
   YOUNG K, 1991, HGM11, P26966
   ZATZ M, 1989, AM J MED GENET, V32, P407, DOI 10.1002/ajmg.1320320328
NR 17
TC 43
Z9 43
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD MAY
PY 1993
VL 30
IS 5
BP 385
EP 387
DI 10.1136/jmg.30.5.385
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA LB008
UT WOS:A1993LB00800006
PM 8320700
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU TUDER, R
   WEINBERG, A
   ZHANG, L
   KALIL, J
AF TUDER, R
   WEINBERG, A
   ZHANG, L
   KALIL, J
TI INTERFERON-PRODUCTION AND ITS ROLE IN CLASS-I MHC UP-REGULATION BY
   CYTOMEGALOVIRUS INFECTED HUMAN ENDOTHELIAL-CELLS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL & PEDIAT,DENVER,CO 80262.
   FMUSP,INCOR,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A713
EP A713
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501117
DA 2020-11-26
ER

PT J
AU BOCCHI, EA
   BELLOTTI, G
   UIP, D
   KALIL, J
   HIGUCHI, MD
   FIORELLI, A
   STOLF, N
   JATENE, A
   PILLEGGI, F
AF BOCCHI, EA
   BELLOTTI, G
   UIP, D
   KALIL, J
   HIGUCHI, MD
   FIORELLI, A
   STOLF, N
   JATENE, A
   PILLEGGI, F
TI LONG-TERM FOLLOW-UP AFTER HEART-TRANSPLANTATION IN CHAGAS-DISEASE
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT JEAN HAMBURGER MEMORIAL CONGRESS / 14TH INTERNATIONAL CONGRESS OF THE
   TRANSPLANTATION SOC
CY AUG 16-21, 1992
CL PARIS, FRANCE
SP TRANSPLANTAT SOC
ID TRYPANOSOMA-CRUZI; CELLS
C1 UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,HOSP CLIN,DIV CLIN,INST CORACAO,BR-14100 RIBEIRAO PRE,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012; de Lourdes Higuchi, Maria/K-3886-2017
OI KALIL, JORGE/0000-0001-8415-4274; de Lourdes Higuchi,
   Maria/0000-0002-1673-6456
CR ACQUATELLA H, 1987, CIRCULATION, V76, P556, DOI 10.1161/01.CIR.76.3.556
   Billingham M E, 1990, J Heart Transplant, V9, P587
   BILLINGHAM ME, 1990, PROG CARDIOVASC DIS, V33, P11, DOI 10.1016/0033-0620(90)90036-2
   BOCCHI EA, 1987, REV SOC BRAS MED S2, V20, P39
   CAPRON A, 1989, IMMUNOL REV, V112, P27, DOI 10.1111/j.1600-065X.1989.tb00551.x
   ESPINOSA R, 1985, INT J CARDIOL, V8, P45, DOI 10.1016/0167-5273(85)90262-1
   GRIES W, 1992, J HEART LUNG TRANSPL, V11, P370
   Griffith BP, 1983, HEART TRANSPLANTATIO, V2, P251
   HANTO DW, 1982, NEW ENGL J MED, V306, P913, DOI 10.1056/NEJM198204153061506
   RIZZO LV, 1989, INFECT IMMUN, V57, P2640, DOI 10.1128/IAI.57.9.2640-2644.1989
   SMITHERS DW, 1969, LANCET, V1, P672
   TEIXEIRA ARL, 1978, AM J TROP MED HYG, V27, P1097, DOI 10.4269/ajtmh.1978.27.1097
NR 12
TC 57
Z9 61
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1993
VL 25
IS 1
BP 1329
EP 1330
PN 2
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA KN622
UT WOS:A1993KN62200200
PM 8442131
DA 2020-11-26
ER

PT J
AU BRYANT, PC
   VAYNTRUB, TA
   SCHRANDT, HA
   KALIL, JE
   GRUMET, FC
AF BRYANT, PC
   VAYNTRUB, TA
   SCHRANDT, HA
   KALIL, JE
   GRUMET, FC
TI HLA ANTIBODY ENHANCEMENT BY DOUBLE ADDITION OF SERUM - USE IN PLATELET
   DONOR SELECTION
SO TRANSFUSION
LA English
DT Article
ID ALLOGRAFT SURVIVAL; TRANSFUSION
AB The identification of HLA class I alloantibodies is important for organ transplantation and platelet transfusion in alloimmunized patients. Because microcytotoxicity testing against frozen trays of lymphocyte panels is rapid and efficient for determining specificities of unknown antibodies, a simple method was devised to increase test sensitivity to weak antibodies. Standard anti-human globulin (AHG)-facilitated microcytotoxicity was modified by the insertion of a double addition-of-serum (DAS) step, and reagent and patient's sera were evaluated by both methods. DAS modification increased antibody titers and, more significantly, made the identification of weak specificities easier because of the twofold to threefold increase in reactivity rates (29-42% for AHG vs. 75-82% for DAS) of panel cells that were expected to be positive, while low (approx. 1%) "extra" reaction rates were maintained for cells that were expected to be negative. DAS was relatively unaffected by variations in serum volumes or target cell preparation, and its use did not significantly increase test time or costs. In a program of platelet donor selection driven by donor antibody rather than donor-recipient antigen matching, DAS greatly facilitated platelet transfusion support for alloimmunized patients.
C1 STANFORD UNIV,MED CTR,DEPT PATHOL,HISTOCOMPATIBIL LAB,800 WELCH RD,PALO ALTO,CA 94304.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811, P50HL033811, P50HL033811, P50HL033811,
   P50HL033811, P50HL033811] Funding Source: NIH RePORTER; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL33811] Funding Source: Medline
CR BOUHABIB JC, 1991, TRANSPLANTATION, V51, P543
   BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235
   FULLER TC, 1978, TRANSPL P, V10, P463
   GALEL S, 1990, 1990 JOINT C INT SOC, P197
   GALEL SA, 1991, PRINCIPLES TRANSFUSI, P271
   HEAL JM, 1987, BLOOD, V70, P23
   LIZAK GE, 1983, HUM IMMUNOL, V8, P265, DOI 10.1016/0198-8859(83)90053-8
   MCFARLAND JG, 1991, PRINCIPLES TRANSFUSI, P193
   Mueller-Eckhardt C, 1990, Transfus Med Rev, V4, P98, DOI 10.1016/S0887-7963(90)70254-4
   OLDFATHER JW, 1984, BLOOD S, V64, pA229
   RACHEL JM, 1988, AM J CLIN PATHOL, V90, P63, DOI 10.1093/ajcp/90.1.63
   RODEY G, 1987, TRANSPLANT P, V19, P778
   RUDER H, 1984, CRYOBIOLOGY, V21, P480, DOI 10.1016/0011-2240(84)90045-2
   SCHIFFER CA, 1987, PROG HEMATOL, V15, P91
   Terasaki P.I., 1965, HISTOCOMPATIBILITY T, P83
   TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103
   WEIL R, 1981, HYPERACUTE REJECTION, V32, P71
   YANG SY, 1989, IMMUNOBIOLOGY HLA, V1, P332
   YANKEE RA, 1969, NEW ENGL J MED, V281, P1208, DOI 10.1056/NEJM196911272812202
NR 19
TC 6
Z9 6
U1 0
U2 1
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD NOV-DEC
PY 1992
VL 32
IS 9
BP 839
EP 844
DI 10.1046/j.1537-2995.1992.32993110756.x
PG 6
WC Hematology
SC Hematology
GA KC094
UT WOS:A1992KC09400012
PM 1471248
DA 2020-11-26
ER

PT J
AU MIGNOT, E
   LIN, X
   KALIL, J
   GEORGE, C
   SINGH, S
   BILLIARD, M
   MONTPLAISIR, J
   ARRIGONI, J
   GUILLEMINAULT, C
   DEMENT, WC
   GRUMET, FC
AF MIGNOT, E
   LIN, X
   KALIL, J
   GEORGE, C
   SINGH, S
   BILLIARD, M
   MONTPLAISIR, J
   ARRIGONI, J
   GUILLEMINAULT, C
   DEMENT, WC
   GRUMET, FC
TI DQB1-0602 (DQW1) IS NOT PRESENT IN MOST NONDR2 CAUCASIAN NARCOLEPTICS
SO SLEEP
LA English
DT Article
DE NARCOLEPSY; CATAPLEXY; HLA DR; HLA DQ; REM SLEEP
ID MONOZYGOTIC TWINS; AMPLIFIED DNA; HLA-DR2; ASSOCIATION; ALLELES; MHC
AB Human narcolepsy is a genetically determined disorder of sleep strongly associated with the human leucocyte antigens (HLA) DR2 and DQw1. In black narcoleptic patients, susceptibility for narcolepsy is more closely related to a specific gene subtype of DQw1, DQB1-0602, than to DR2. About 30% of black narcoleptic patients are nonDR2, but all carry the HLA DQB1-0602 gene. In the present study, we have tested caucasian nonDR2 cataplectic patients (6 sporadic cases and 7 familial cases from 3 multiplex families) for the presence of the HLA DQB1-0602 and DQA1-0102 (DQw1) using a specific polymerase chain reaction (PCR)-oligotyping technique. None of the patients was DQB1-0602 or DQA1-0102 positive, thus proving that, in caucasians, DQB1-0602 and DQA1-0102 (DQw1) are not prerequisites for the diagnosis of narcolepsy. Further studies with more patients are warranted to exclude the possibility that a few caucasian patients carry rare haplotypes with DQB1-0602 independently of DR2.
C1 STANFORD UNIV,CTR BLOOD,PALO ALTO,CA 94304.
   VICTORIA HOSP,DEPT MED,LONDON N6A 4G5,ONTARIO,CANADA.
   HOP GUI DE CHAULIAC,SERV NEUROL B,F-34059 MONTPELLIER,FRANCE.
   CTR ETUD SACRE COEUR,MONTREAL,QUEBEC,CANADA.
RP MIGNOT, E (corresponding author), STANFORD UNIV,SCH MED,CTR SLEEP DISORDERS,701 WELCH RD,SUITE 2226,PALO ALTO,CA 94304, USA.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P01NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P01NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724, P50NS023724, P50NS023724,
   P50NS023724, P50NS023724, P50NS023724] Funding Source: NIH RePORTER;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL11383] Funding Source: Medline; NINDS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [NS 23724] Funding Source: Medline
CR ALDRICH MS, 1990, NEW ENGL J MED, V323, P388
   BILLIARD M, 1985, LANCET, V1, P226
   BRUHOVA SN, 1972, ARCH SUISSE NEUROL N, V110, P45
   BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235
   CHARON D, 1990, ADV IMMUNOL, V18, P107
   DALY DD, 1959, P STAFF M MAYO CLIN, V34, P313
   DEMENT WC, 1973, SLEEP RES, V2, P147
   DITTA SD, 1992, SLEEP, V15, P48
   DOUGLASS AB, 1989, NEUROLOGY, V39, P140, DOI 10.1212/WNL.39.1.140
   ERLICH HA, 1990, PCR PROTOCOLS, P261
   FERNANDEZVINA M, 1991, TISSUE ANTIGENS, V38, P235, DOI 10.1111/j.1399-0039.1991.tb01904.x
   FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299, DOI 10.1007/BF00211994
   FREDRIKSON S, 1990, ACTA NEUROL SCAND, V81, P253
   GUILLEMINAULT C, 1989, LANCET, V2, P1376
   GUILLEMINAULT C, 1986, HUM IMMUNOL, V17, P1, DOI 10.1016/0198-8859(86)90068-6
   GUILLEMINAULT C, 1976, NARCOLEPSY
   HONDA Y, 1983, SLEEP RES, V12, P254
   HONDA Y, 1979, SLEEP RES, V8, P191
   IMLAH NW, 1961, J NEUROL NEUROSUR PS, V24, P158, DOI 10.1136/jnnp.24.2.158
   KESSLER S, 1974, ACTA NEUROL SCAND, V50, P503
   KESSLER S, 1976, ADV SLEEP RES, V3, P285
   Krabbe E, 1942, ACTA PSYCH NEUROL, V17, P149, DOI 10.1111/j.1600-0447.1942.tb06773.x
   KRAMER RE, 1987, ARCH NEUROL-CHICAGO, V44, P853, DOI 10.1001/archneur.1987.00520200055019
   LANGDON N, 1984, LANCET, V2, P1178
   LOCK CB, 1988, IMMUNOGENETICS, V27, P449, DOI 10.1007/BF00364432
   MAEDA M, 1989, TISSUE ANTIGENS, V34, P290, DOI 10.1111/j.1399-0039.1989.tb01745.x
   MAMELAK M, 1979, BIOL PSYCHIAT, V14, P821
   MATSUKI K, 1992, LANCET, V339, P1052, DOI 10.1016/0140-6736(92)90571-J
   MATSUKI K, 1989, IMMUNOBIOLOGY HLA IM, V2, P438
   MATSUKI K, 1988, HLA NARCOLEPSY, P58
   MIGNOT E, 1991, P NATL ACAD SCI USA, V88, P3475, DOI 10.1073/pnas.88.8.3475
   MIGNOT E, 1991, IN PRESS 3RD P MIL I
   MOLKENTIN J, 1991, HUM IMMUNOL, V31, P114, DOI 10.1016/0198-8859(91)90014-Z
   MONTPLAISIR J, 1987, NEUROLOGY, V37, P1089, DOI 10.1212/WNL.37.6.1089
   Montplaisir J., 1988, HLA NARCOLEPSY, P97
   NEELY S, 1987, NEUROLOGY, V37, P1858, DOI 10.1212/WNL.37.12.1858
   NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493
   ORR WC, 1991, SLEEP, V14, P270, DOI 10.1093/sleep/14.3.270
   PARKES JD, 1986, BRIT MED J, V292, P359, DOI 10.1136/bmj.292.6517.359
   POLLMACHER T, 1990, SLEEP, V10, P336
   RUBIN RL, 1988, CLIN IMMUNOL IMMUNOP, V49, P149, DOI 10.1016/0090-1229(88)90104-3
   SINGH SM, 1990, LANCET, V335, P726, DOI 10.1016/0140-6736(90)90842-S
   SINGHA AA, 1990, SCIENCE, V248, P1380
   Solomon P, 1945, DIS NERV SYST, V6, P179
   TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N
   TSUJI T, 1992, HLA 1991
   URYU N, 1989, HUM IMMUNOL, V24, P175, DOI 10.1016/0198-8859(89)90058-X
NR 47
TC 35
Z9 35
U1 0
U2 2
PU AMER SLEEP DISORDERS ASSOC
PI ROCHESTER
PA 1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806
SN 0161-8105
J9 SLEEP
JI Sleep
PD OCT
PY 1992
VL 15
IS 5
BP 415
EP 422
DI 10.1093/sleep/15.5.415
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA JT084
UT WOS:A1992JT08400005
PM 1455124
OA Bronze
DA 2020-11-26
ER

PT J
AU PAULA, FJ
   PANAJOTOPOULOS, N
   RODRIGUES, H
   KALIL, JE
   SABBAGA, E
   ARAP, S
AF PAULA, FJ
   PANAJOTOPOULOS, N
   RODRIGUES, H
   KALIL, JE
   SABBAGA, E
   ARAP, S
TI HYPERREACTIVITY AGAINST PANEL - A RISK FACTOR FOR RENAL-TRANSPLANT
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID ALLOGRAFT
C1 UNIV SAO PAULO,SCH MED,RENAL TRANSPLANT UNIT,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ALARIF L, 1987, TRANSPLANT P, V19, P771
   FERGUSON RM, 1986, CLIN TRANSPLANT, P195
   SAUBE DH, 1984, TRANSPLANTATION, V37, P254
   SEORNICK JC, 1984, TRANSPLANTATION, V37, P249
   TURKA LA, 1989, TRANSPLANT P, V21, P696
   1988, SCANDIATRANSPLANT 19
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD OCT
PY 1992
VL 24
IS 5
BP 1745
EP 1745
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA JU180
UT WOS:A1992JU18000044
PM 1412821
DA 2020-11-26
ER

PT J
AU PAULA, FJ
   CAVALCANTI, FCB
   KALIL, JE
   SABBAGA, E
   ARAP, S
AF PAULA, FJ
   CAVALCANTI, FCB
   KALIL, JE
   SABBAGA, E
   ARAP, S
TI ORGAN HARVESTING PROGRAM IMPROVES CADAVER RENAL-TRANSPLANT AT
   SAO-PAULO-UNIVERSITY, BRAZIL
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
C1 UNIV SAO PAULO,SCH MED,RENAL TRANSPLANT UNIT,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR RIBEIRO DS, 1989, 25TH C EUR DYAL TRAN, P140
   SAUBE DH, 1984, TRANSPLANTATION, V37, P254
   SCORNIK JC, 1984, TRANSPLANTATION, V37, P249, DOI 10.1097/00007890-198403000-00006
   1987, SCANDIATRANSPLANT
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD OCT
PY 1992
VL 24
IS 5
BP 1807
EP 1807
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA JU180
UT WOS:A1992JU18000077
PM 1412854
DA 2020-11-26
ER

PT J
AU PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   ROSALES, C
   SABBAGA, E
   KALIL, J
AF PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   ROSALES, C
   SABBAGA, E
   KALIL, J
TI A SUCCESSFUL 2ND RENAL-ALLOGRAFT ACROSS POSITIVE B-CELL CROSS-MATCH DUE
   TO IGG ANTI-HLA DR5 ANTIBODY
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE KIDNEY TRANSPLANT; CROSS-MATCH; HLA-DR; ANTI-HLA ANTIBODIES;
   LYMPHOCYTES-B
AB The role of antibodies specific to donor B-cell antigens in renal transplantation remains to be firmly established. We have used, in a sensitized patient awaiting his second transplant, reduction with dithiothreitol (DTT), platelet absortion and panel reactivity analysis to identify imunoglobulin class and specificity of the antibody causing positive B-cell crossmatch. The results show that the antibody was an IgG anti-HLA DR5. The transplant was performed using the recipient's mother, specifically mismatched for DR5, as donor. The graft bas excellent function 18 months after transplantation. The experience with this patient raises questions about the clinical significance of anti-DR antibodies, and of anti-B cells antibodies in general, in kidney transplantation.
C1 UNIV SAO PAULO,FAC MED,TRANSPLANTAT IMMUNOL LAB,AV DR ARNALDO 455 3 ANDAR SALA 33,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 4
Z9 4
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JUN
PY 1992
VL 6
IS 3
BP 196
EP 198
PN 1
PG 3
WC Surgery; Transplantation
SC Surgery; Transplantation
GA JB849
UT WOS:A1992JB84900011
DA 2020-11-26
ER

PT J
AU ROSALES, T
   GUILHERME, L
   CHIARELLA, J
   MARIN, ML
   ROSALES, C
   MELO, CP
   GOLDBERG, AC
   KALIL, J
AF ROSALES, T
   GUILHERME, L
   CHIARELLA, J
   MARIN, ML
   ROSALES, C
   MELO, CP
   GOLDBERG, AC
   KALIL, J
TI HUMAN LEUKOCYTE-A AND LEUKOCYTE-B ANTIGEN, GENE AND HAPLOTYPE
   FREQUENCIES IN THE POPULATION OF THE CITY OF SAO-PAULO IN BRAZIL
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE HLA; POPULATION GENETICS; GENE FREQUENCY; ANTIGEN FREQUENCY; HAPLOTYPE
   FREQUENCY
AB 1. Antigen, gene and haplotype frequencies are important data for population analysis, paternity exclusion testing, genetic studies, and for organ transplantation selection.
   2. We have studied the Class I histocompatibility antigens of 617 unrelated individuals from the city of Sao Paulo, Brazil, to determine antigen and gene frequencies of 16 HLA-A and 28 HLA-B antigens. Estimated haplotype frequencies were also determined, as well as the genetic distances of this population from European Caucasian and Negro populations.
   3. A previously unknown linkage disequilibrium was detected for A23-B49 and a clear trend towards antigen frequencies intermediate between Caucasoid and Negro populations was observed.
C1 UNIV SAO PAULO,FAC MED,HOSP CLIN,INST CORACAO,IMUNOL TRANSPLANTES LAB,AV DR ARNALDO 455 3-33,BR-01246 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,HOSP CLIN,INST CORACAO,DIV INFORMAT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,INVEST MED & REUMATOL LAB,BR-01246 SAO PAULO,BRAZIL.
   BANCO SANGUE SAO PAULO,BR-04038 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Guilherme, Luiz Roberto Guimaraes/V-6163-2019;
   Guglielmi, Luiza G/E-7676-2013; Guilherme, Luiz Roberto G/B-3998-2009;
   Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Guilherme, Luiz Roberto
   Guimaraes/0000-0002-5387-6028; Guilherme, Luiz Roberto
   G/0000-0002-5387-6028; Goldberg, Anna Carla/0000-0003-2600-7940
CR AMOS DB, 1976, MANUAL CLIN IMMUNOLO, P978
   BAUR MP, 1984, HISTOCOMPATIBILITY T, P677
   BAUR MP, 1980, HISTOCOMPATIBILITY T, P994
   BAUR MP, 1980, HISTOCOMPATIBILITY T, P955
   BOYUM A, 1968, SCAND J CLIN LAB S97, V21, P1
   DAUSSET J, 1989, HLA COMPLEXE MAJEUR, P298
   DAUSSET J, 1989, HLA COMPLOEXE MAJEUR, P215
   MICKEY MR, 1980, HISTOCOMPATIBILITY T, P21
   TRACHTENBERG A, 1988, ANN HUM BIOL, V15, P213, DOI 10.1080/03014468800009651
   YANG SY, 1987, HISTOCOMPATIBILITY T, V1, P116
NR 10
TC 10
Z9 10
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1992
VL 25
IS 1
BP 39
EP 47
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA HG231
UT WOS:A1992HG23100006
PM 1304942
DA 2020-11-26
ER

PT J
AU MURILLO, LA
   TENJO, FA
   CLAVIJO, OP
   OROZCO, MA
   SAMPAIO, S
   KALIL, J
   PATARROYO, ME
AF MURILLO, LA
   TENJO, FA
   CLAVIJO, OP
   OROZCO, MA
   SAMPAIO, S
   KALIL, J
   PATARROYO, ME
TI A SPECIFIC T-CELL RECEPTOR GENOTYPE PREFERENCE IN THE IMMUNE-RESPONSE TO
   A SYNTHETIC PLASMODIUM-FALCIPARUM MALARIA VACCINE
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE TCR; PLASMODIUM-FALCIPARUM MALARIA; IMMUNE RESPONSE; MALARIA VACCINE
ID BETA-CHAIN GENE; MOLECULAR-GENETICS; RECOGNITION; GENERATION;
   REPERTOIRE; ANTIGEN; CLONES
AB In recent studies with 63 and 122 volunteers vaccinated with the SPf66 synthetic malaria vaccine, specific antibody patterns were classified as high or low responders. Using the Polymerase Chain Reaction (PCR), a specific and selective preference was shown for the V-beta arrangement of the T-cell receptor in the high responder group involving the V-beta-8 gene. The low responder group showed the rearrangement of a different set of genes, and a particular association with V-beta-10.
C1 UNIV NACL COLOMBIA, HOSP SAN JUAN DIOS, INST INMUNOL, BOGOTA, COLOMBIA.
   UNIV SAO PAULO, ESCUELA MED, SAO PAULO, BRAZIL.
RI KALIL, JORGE/C-8029-2012; Patarroyo, Manuel-Elkin/S-1422-2017
OI KALIL, JORGE/0000-0001-8415-4274; Patarroyo,
   Manuel-Elkin/0000-0002-1119-6040
CR ERLICH HA, 1989, PCR TECHNOLOGY, pCH15
   GAIT MJ, 1984, OLIGONUCLEOTIDE SYNT
   Hedrick S. M., 1989, Fundamental immunology., P291
   HEWITT CRA, 1989, J IMMUNOL, V142, P1429
   HOCHGESCHWENDER U, 1986, NATURE, V322, P376, DOI 10.1038/322376a0
   KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876
   KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8
   KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525
   MURILLO LA, 1991, PARASITE IMMUNOL, V13, P201, DOI 10.1111/j.1365-3024.1991.tb00275.x
   PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x
   PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0
   PATARROYO ME, 1988, NATURE, V332, P358
   RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135
   SAITO T, 1988, IMMUNOL REV, V101, P81, DOI 10.1111/j.1600-065X.1988.tb00733.x
   SALCEDO M, 1991, CLIN EXP IMMUNOL, V84, P122, DOI 10.1111/j.1365-2249.1991.tb08134.x
   SORGER SB, 1987, J EXP MED, V165, P279, DOI 10.1084/jem.165.2.279
   TERASAKI PL, 1978, AM J CLIN PATHOL, V68, P103
   WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x
   WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015
   ZANVIL SS, 1988, J EXP MED, V167, P1586
NR 20
TC 21
Z9 21
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JAN
PY 1992
VL 14
IS 1
BP 87
EP 94
DI 10.1111/j.1365-3024.1992.tb00008.x
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA HA211
UT WOS:A1992HA21100008
PM 1532634
DA 2020-11-26
ER

PT J
AU DEPAIVA, TM
   TAKIMOTO, S
   ISHIDA, MA
   DESOUZA, MCO
   ISHIMARU, T
   NEUMANN, J
   KALIL, J
AF DEPAIVA, TM
   TAKIMOTO, S
   ISHIDA, MA
   DESOUZA, MCO
   ISHIMARU, T
   NEUMANN, J
   KALIL, J
TI COMPARATIVE-STUDY OF ADENOVIRUSES WITH MONOCLONAL-ANTIBODIES
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE ADENOVIRUS; SPECIES SPECIFIC; MONOCLONAL ANTIBODIES; ADENOVIRUS-4;
   ANTIGENIC RELATIONSHIP
ID SEROTYPES; HEXON; DNA
AB The obtainment of monoclonal antibodies for adenovirus species 4(Ad4) is described. The specificities of selected monoclonal antibodies were determined by means of viral neutralization test in cell culture, immunofluorescence and Enzyme-Linked Immunosorbent Assay (ELISA), in the presence of the following species of human adenovirus: 1, 2, 5 (subgenus C), 4 (subgenus E), 7 and 16 (subgenus B) and 9 (subgenus D).
   Two monoclonal antibodies species specific to adenovirus 4 (1CIII and 3DIII) and one monoclonal antibody that cross reacted with adenovirus species 4 and 7 (2HIII) were obtained.
C1 UNIV SAO PAULO,FAC MED,IMUNOL TRANSPLANTES LAB,SAO PAULO,BRAZIL.
RP DEPAIVA, TM (corresponding author), INST ADOLFO LUTZ REGISTRO,VIRUS RESP LAB,AV DR ARNALDO 355,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ADAM E, 1988, ACTA VIROL, V32, P393
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   DUDDING BA, 1972, NEW ENGL J MED, V286, P1289, DOI 10.1056/NEJM197206152862403
   GARON CF, 1973, VIROLOGY, V54, P414, DOI 10.1016/0042-6822(73)90153-0
   GREEN M, 1970, ANNU REV BIOCHEM, V39, P701, DOI 10.1146/annurev.bi.39.070170.003413
   GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4
   HERRMANN JE, 1987, ARCH VIROL, V94, P3
   HIERHOLZER JC, 1988, J INFECT DIS, V158, P804, DOI 10.1093/infdis/158.4.804
   HIERHOLZER JC, 1973, J INFECT DIS, V128, P541, DOI 10.1093/infdis/128.4.541
   HUEBNER RJ, 1967, PERSPECT VIROL, V5, P147
   LU JR, 1989, CHINESE MED J-PEKING, V102, P650
   MCALLISTER RM, 1969, JNCI-J NATL CANCER I, V43, P917
   NORRBY E, 1969, J VIROL, V4, P663, DOI 10.1128/JVI.4.5.663-670.1969
   PETTERSSON U, 1971, VIROLOGY, V43, P123, DOI 10.1016/0042-6822(71)90230-3
   Philipson L, 1975, Virol Monogr, V14, P1
   PINA M, 1965, P NATL ACAD SCI USA, V54, P547, DOI 10.1073/pnas.54.2.547
   PRICE JP, 1985, ADV CELL CULT, V4, P157
   ROSEN L, 1960, AM J HYG, V71, P120, DOI 10.1093/oxfordjournals.aje.a120085
   ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714
   TOKUNAGA O, 1986, VIROLOGY, V155, P418, DOI 10.1016/0042-6822(86)90204-7
   VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55
   WADELL G, 1969, J VIROL, V4, P671, DOI 10.1128/JVI.4.5.671-680.1969
   WADELL G, 1979, INTERVIROLOGY, V11, P47, DOI 10.1159/000149011
   WIGAND R, 1982, INTERVIROLOGY, V18, P169, DOI 10.1159/000149322
   WILCOX N, 1976, J IMMUNOL, V116, P25
NR 25
TC 2
Z9 2
U1 0
U2 1
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD JAN-FEB
PY 1992
VL 34
IS 1
BP 19
EP 26
DI 10.1590/S0036-46651992000100004
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA HU082
UT WOS:A1992HU08200004
PM 1284894
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU NEUMANN, J
   SPADAFORAFERREIRA, M
   GOLDBERG, AC
   TUDER, R
   MACAUBAS, C
   SABBAGA, E
   KALIL, J
AF NEUMANN, J
   SPADAFORAFERREIRA, M
   GOLDBERG, AC
   TUDER, R
   MACAUBAS, C
   SABBAGA, E
   KALIL, J
TI REACTIVITY OF RENAL-TRANSPLANT SERA AGAINST A 17 KD MONONUCLEAR CELL
   ANTIGEN
SO TRANSPLANT INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT 5TH CONGRESS OF THE EUROPEAN SOC FOR ORGAN TRANSPLANTATION
CY OCT 07-10, 1991
CL MAASTRICHT, NETHERLANDS
SP EUROPEAN SOC ORGAN TRANSPLANTAT
DE MONONUCLEAR CELL ANTIGEN; RENAL TRANSPLANT SERA
AB In recent years, studies have shown that non-HLA antigens can be involved in renal graft rejection [1]. The so called minor antigens have been found to be expressed on a variety of cells, including endothelial cells [2]. With the aim of understanding better the role of minor antigens in graft rejection, we undertook a Western blot screening of sera from patients waiting for or having received grafts from living-related or cadaveric donors. In this study we described the reactivity of these sera against a 17 kD antigen with expression in many different cell types.
RP NEUMANN, J (corresponding author), UNIV SAO PAULO,FAC MED,TRANSPLANTAT IMMUNOL LAB,AV DR ARNALDO 455,3 ANDAR SALA 33,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Spadafora-Ferreira, Monica/G-2635-2012;
   Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Spadafora-Ferreira,
   Monica/0000-0001-8823-9929; Goldberg, Anna Carla/0000-0003-2600-7940
NR 0
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0934-0874
J9 TRANSPLANT INT
JI Transpl. Int.
PY 1992
VL 5
SU 1
BP S617
EP S620
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA JV189
UT WOS:A1992JV18900181
PM 14621891
DA 2020-11-26
ER

PT J
AU PATARROYO, ME
   VINASCO, J
   AMADOR, R
   ESPEJO, F
   SILVA, Y
   MORENO, A
   ROJAS, M
   MORA, AL
   SALCEDO, M
   VALERO, V
   GOLDBERG, AK
   KALIL, J
AF PATARROYO, ME
   VINASCO, J
   AMADOR, R
   ESPEJO, F
   SILVA, Y
   MORENO, A
   ROJAS, M
   MORA, AL
   SALCEDO, M
   VALERO, V
   GOLDBERG, AK
   KALIL, J
TI GENETIC-CONTROL OF THE IMMUNE-RESPONSE TO A SYNTHETIC VACCINE AGAINST
   PLASMODIUM-FALCIPARUM
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE SYNTHETIC MALARIA VACCINE; IMMUNE RESPONSE; HLA CLASS-II ANTIGENS;
   PLASMODIUM-FALCIPARUM
ID SPOROZOITE VACCINE; PEPTIDES; ANTIGENS; MALARIA; HLA
AB Two independent vaccination trials using a hybrid synthetic polypeptide containing epitopes from four proteins of Plasmodium falciparum were performed. In the first trial 63 and in the second 122 volunteers were vaccinated, using different immunization schedules. The analysis of the humoral response to the vaccine, measured by IgG antibody titres to the polypeptide showed a bimodal distribution in both cases suggesting genetic control of the immune response to this protein. There was a small group of low or non-responders and a large group of good responders. HLA phenotyping of the two groups disclosed an association of the low responders to HLA-DR4 antigens with chi-square P value of 0.00039 when compared with the good responders group. These findings provide evidence for the genetic control of the immune response to the synthetic vaccine by the association of this response with particular alleles of the HLA class II antigens; such findings may lead to an explanation of the mechanism involved in disease susceptibility and need to be used in the design of a totally effective vaccine.
C1 UNIV SAO PAULO, FAC MED, INST CORACAO, IMMUNOL TRANSPLANTES LAB, SAO PAULO, BRAZIL.
RP PATARROYO, ME (corresponding author), UNIV NACL COLOMBIA, HOSP SAN JUAN DE DIOS, INST IMMUNOL, SANTA FE DE BOGOTA, COLOMBIA.
RI KALIL, JORGE/C-8029-2012; Patarroyo, Manuel-Elkin/S-1422-2017
OI KALIL, JORGE/0000-0001-8415-4274; Moreno, Alberto/0000-0002-3031-7194;
   Patarroyo, Manuel-Elkin/0000-0002-1119-6040; Valero-Bernal, Maria
   Victoria/0000-0002-7926-8944
CR ALBERT ED, 1984, HISTOCOMPATIBILITY T
   ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103
   BALLOU WR, 1987, LANCET, V1, P1277
   BATCHELOR JR, 1987, BRIT MED BULL, V43, P156, DOI 10.1093/oxfordjournals.bmb.a072169
   CAMPBELL GH, 1987, AM J TROP MED HYG, V37, P428, DOI 10.4269/ajtmh.1987.37.428
   COLLINS WE, 1988, AM J TROP MED HYG, V38, P268, DOI 10.4269/ajtmh.1988.38.268
   GOOD MF, 1986, J EXP MED, V164, P655, DOI 10.1084/jem.164.2.655
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131
   JENDOUBI M, 1987, AM J TROP MED HYG, V37, P9, DOI 10.4269/ajtmh.1987.37.9
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   NUSSENZWEIG RS, 1984, PHILOS T ROY SOC B, V307, P117, DOI 10.1098/rstb.1984.0113
   PATARROYO ME, 1988, NATURE, V332, P358
   SALCEDO M, 1991, CLIN EXP IMMUNOL, V84, P122, DOI 10.1111/j.1365-2249.1991.tb08134.x
   STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9
   TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103
   WASSOM DL, 1990, CRIT REV IMMUNOL, V10, P31
   WAYNE WD, 1980, BIOSTATISTICS, P325
NR 17
TC 52
Z9 52
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD SEP
PY 1991
VL 13
IS 5
BP 509
EP 516
DI 10.1111/j.1365-3024.1991.tb00547.x
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA GG347
UT WOS:A1991GG34700004
PM 1956698
DA 2020-11-26
ER

PT J
AU GUILHERME, L
   WEIDEBACH, W
   KISS, MH
   SNITCOWSKY, R
   KALIL, J
AF GUILHERME, L
   WEIDEBACH, W
   KISS, MH
   SNITCOWSKY, R
   KALIL, J
TI ASSOCIATION OF HUMAN-LEUKOCYTE CLASS-II ANTIGENS WITH RHEUMATIC-FEVER OR
   RHEUMATIC HEART-DISEASE IN A BRAZILIAN POPULATION
SO CIRCULATION
LA English
DT Article
DE HUMAN LEUKOCYTE ANTIGENS; GENETICS; SURFACE MARKERS; RHEUMATIC FEVER;
   RHEUMATIC HEART DISEASE
ID B-CELL ALLOANTIGEN; HLA ANTIGENS
AB Background. The incidence of rheumatic heart disease is great in Brazil. We analyzed the distribution of human leukocyte (HLA) antigens in a Brazilian population sample with rheumatic fever or rheumatic heart disease, with the aim of better understanding the mechanisms involved.
   Methods and Results. HLA class I (A, B, and C) and class II (DR and DQ) antigen distribution was studied in 40 patients with diagnosis of rheumatic fever or rheumatic heart disease and compared with a control group of 617 healthy individuals for class I typing, from which 118 were drawn for class II typing. A strong correlation between rheumatic fever and rheumatic heart disease and HLA-DRw53 (72.9% in the disease group versus 39% in the control group: p = 0.00061, relative risk, 4.2; etiologic fraction, 0.43) was found. We also found an increase in the frequency of HLA-DR7 (57.5% in the disease group versus 26.3% in control group: p = 0.00715; relative risk, 3.8; etiologic fraction, 0.56). HLA class I and HLA-DQ typing did not point to any association with these diseases.
   Conclusions. HLA-DR7 and HLA-DRw53 are markers for susceptibility to rheumatic fever and rheumatic heart disease in Brazil. These results could be explained by genetic differences resulting from racial or geographical diversity.
C1 UNIV SAO PAULO, FAC MED, INST HEART, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, INST CHILDREN, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, FAC MED, RHEUMATOL LAB, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, HOSP CLIN, SAO PAULO, BRAZIL.
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR AMOS DB, 1976, MANUAL CLIN IMMUNOLO, P797
   ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X
   [Anonymous], 1965, Circulation, V32, P664
   AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531
   BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9
   CAUGHEY DE, 1975, J RHEUMATOL, V2, P319
   CHEADLE WB, 1889, LANCET, V1, P821
   Danilovs J, 1980, HISTOCOMPATIBILITY T, P287
   FALK JA, 1973, TISSUE ANTIGENS, V3, P173
   GLYNN LE, 1961, ARTHRITIS RHEUM, V4, P203, DOI 10.1002/art.1780040210
   GORODEZKY C, 1977, J RHEUMATOL, V4, P112
   GREENBERG LJ, 1975, J EXP MED, V141, P935, DOI 10.1084/jem.141.5.935
   JHINGHAN B, 1986, TISSUE ANTIGENS, V27, P172, DOI 10.1111/j.1399-0039.1986.tb01517.x
   JOYSEY VC, 1977, J RHEUMATOL, V4, P84
   KHANNA AK, 1989, J CLIN INVEST, V83, P1710, DOI 10.1172/JCI114071
   LEIRISALO M, 1977, J RHEUMATOL, V4, P78
   MAHARAJ B, 1987, CIRCULATION, V76, P259, DOI 10.1161/01.CIR.76.2.259
   MURRAY GC, 1978, ARTHRITIS RHEUM, V21, P652, DOI 10.1002/art.1780210607
   PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0
   RAJAPAKSE CNA, 1987, BRIT HEART J, V58, P659
   READ SE, 1977, TRANSPL P, V9, P543
   ROSALES T, IN PRESS BRAZIL J ME
   RYDER LP, 1981, ANNU REV GENET, V15, P169, DOI 10.1146/annurev.ge.15.120181.001125
   SVEJGAARRD A, 1975, TRANSPLANT REV, V22, P1
   TANEJA V, 1989, CIRCULATION, V80, P335, DOI 10.1161/01.CIR.80.2.335
   TARANTA A, 1959, CIRCULATION, V20, P778
   UCHIDA IA, 1953, AM J HUM GENET, V5, P61
   WARD C, 1976, BRIT MED J, V1, P1499, DOI 10.1136/bmj.1.6024.1499
   WILSON MG, 1954, CIRCULATION, V10, P699, DOI 10.1161/01.CIR.10.5.699
   YOSHINOYA S, 1980, J CLIN INVEST, V65, P136, DOI 10.1172/JCI109643
   ZABRISKIE JB, 1985, ARTHRITIS RHEUM, V28, P1047, DOI 10.1002/art.1780280912
NR 32
TC 86
Z9 89
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JUN
PY 1991
VL 83
IS 6
BP 1995
EP 1998
DI 10.1161/01.CIR.83.6.1995
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FP800
UT WOS:A1991FP80000016
PM 2040052
OA Bronze
DA 2020-11-26
ER

PT J
AU PAULA, FJ
   SABBAGA, E
   KALIL, J
AF PAULA, FJ
   SABBAGA, E
   KALIL, J
TI A MONOCLONAL-ANTIBODY (PK1) AGAINST DIGOXIN REGONIZES AND INHIBITS A
   DIGOXIN-LIKE SUBSTANCE IN UREMIC SERA
SO HYPERTENSION
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,FAC MED,HC,UTR,BR-01246 SAO PAULO,BRAZIL.
   LIT INCOR,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAR
PY 1991
VL 17
IS 3
BP 408
EP 408
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FA882
UT WOS:A1991FA88200036
DA 2020-11-26
ER

PT J
AU KALIL, J
   SHIMIZU, MHM
   ALVES, VAF
   TIMOIARIA, C
   SABBAGA, E
   PAULA, FJ
AF KALIL, J
   SHIMIZU, MHM
   ALVES, VAF
   TIMOIARIA, C
   SABBAGA, E
   PAULA, FJ
TI IMMUNO-LOCALIZATION OF THE DIGOXIN-LIKE SUBSTANCE IN THE DIENCEPHALON OF
   VOLUME-EXPANDED RATS
SO HYPERTENSION
LA English
DT Meeting Abstract
C1 LIT INCOR,BR-01246 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,HC,UTR,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAR
PY 1991
VL 17
IS 3
BP 409
EP 409
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FA882
UT WOS:A1991FA88200037
DA 2020-11-26
ER

PT J
AU SEQUEIRA, DMC
   HEIMANN, J
   KALIL, JE
   SABBAGA, E
   MARCONDES, M
   PAULA, FJ
AF SEQUEIRA, DMC
   HEIMANN, J
   KALIL, JE
   SABBAGA, E
   MARCONDES, M
   PAULA, FJ
TI EFFECT OF A SERUM FRACTION (F) FROM UREMIC PATIENTS WITH DIGOXIN-LIKE
   AND ATPASE INHIBITORY ACTIVITIES ON THE RENAL-FUNCTION OF CONSCIOUS DOGS
SO HYPERTENSION
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,NEPHROL UNIT,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAR
PY 1991
VL 17
IS 3
BP 409
EP 409
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FA882
UT WOS:A1991FA88200038
DA 2020-11-26
ER

PT J
AU HIGUCHI, MD
   DEASSIS, RVC
   SAMBIASE, NV
   REIS, MM
   KALIL, J
   BOCCHI, E
   FIORELLI, A
   STOLF, N
   BELLOTTI, G
   PILEGGI, F
   JATENE, A
AF HIGUCHI, MD
   DEASSIS, RVC
   SAMBIASE, NV
   REIS, MM
   KALIL, J
   BOCCHI, E
   FIORELLI, A
   STOLF, N
   BELLOTTI, G
   PILEGGI, F
   JATENE, A
TI USEFULNESS OF T-CELL PHENOTYPE CHARACTERIZATION IN ENDOMYOCARDIAL BIOPSY
   FRAGMENTS FROM HUMAN CARDIAC ALLOGRAFTS
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
AB The mean numbers of cytotoxic/suppressor (CD8+) and helper/inducer (CD4+) T cells were determined in 111 successive endomyocardial biopsy fragments from eight cardiac allograft patients in an attempt to define their significance in the rejection process.  Endomyocardial fragments from autopsy or donor hearts without myocarditis were evaluated as controls.  The mean numbers of CD8+ and CD4+ T cells in the control group were 0.8 and 0.5 cells/field at x 400 magnification, respectively.  The mean numbers of CD8+ T cells per field in the cardiac allograft biopsies were 2.4, no rejection group; 5.4, mild rejection group; 11.1, moderate rejection group; and 4.9, resolving rejection group.  The mean numbers of CD4+ T cells per field for the same groups were slightly lower than those of the CD8+ T cells.  The number of CD8+ T cells per field reliably indicated the severity of rejection.  Patients with normal numbers of CD8+ T cells and no evidence of rejection had better long-term outcomes (two or fewer moderate rejection episodes) than those with higher numbers.  Analysis of the data suggests that the presence of two or fewer CD8+ T cells/field may be considered normal in the myocardial interstitium.  The diagnosis of no evidence of rejection should be coupled to the presence of a normal number of CD8+ T cells.  High numbers (> 10) of CD8+ T cells, even in absence of myocytolysis, should be treated more assertively, including the use of high doses of prednisone, because all our cases with high numbers showed a worse histologic picture at the subsequent biopsy.  The presence of from three to 10 CD8+ T cells/field indicates the necessity of modification of the basal immunosuppressive regimen to avoid more severe rejection.  Thus the characterization and quantification of T-cell subsets appear to be useful in evaluating the degree of acute heart rejection and the response to immunosuppressive therapy.
RP HIGUCHI, MD (corresponding author), INST CORACAO HCFMUSP,SERV ANAT PATOL,AV DR ENEAS C AGUIAR 44,BR-05403 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; de Lourdes Higuchi, Maria/K-3886-2017; Reis,
   Marcia/P-5850-2016
OI KALIL, JORGE/0000-0001-8415-4274; de Lourdes Higuchi,
   Maria/0000-0002-1673-6456; Reis, Marcia/0000-0002-1020-757X
NR 0
TC 10
Z9 11
U1 0
U2 2
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD MAR-APR
PY 1991
VL 10
IS 2
BP 235
EP 242
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA FE166
UT WOS:A1991FE16600005
PM 1674430
DA 2020-11-26
ER

PT J
AU MURILLO, LA
   ROCHA, CL
   MORA, AL
   KALIL, J
   GOLDENBERG, AK
   PATARROYO, ME
AF MURILLO, LA
   ROCHA, CL
   MORA, AL
   KALIL, J
   GOLDENBERG, AK
   PATARROYO, ME
TI MOLECULAR ANALYSIS OF HLA DR4-BETA-1 GENE IN MALARIA VACCINEES - TYPING
   AND SUBTYPING BY PCR TECHNIQUE AND OLIGONUCLEOTIDES
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE HLA DR4 HAPLOTYPE; SUBTYPE(DW); PROTEIN SPF 66; HLA DR4-BETA-1 GENE;
   PCR; OLIGOTYPING; TCR
ID DQ; SUSCEPTIBILITY; POLYMERASE; ALLELES; PROBES; DNA
AB The combination of the PCR technique and the synthetic oligonucleotides has proved to be a useful tool in the molecular analysis of HLA class II genes, allowing recognition of as little as a single nucleotide modification in the sequence of the gene. The molecules encoded by these genes have been associated with genetic control of the immune response and with susceptibility to certain diseases. Studies carried out in our laboratory have shown three patterns of humoral immune response in the human volunteers vaccinated with the synthetic protein SPf 66; high, intermediate and low responders. Approximately 73.3% of the low responders were serologically typed as HLA DR4 and 42% as DQw6. These results moved us to look for a subtype (Dw) correlation between the DR4 positive individuals and the different humoral immune response patterns. Using oligo-typing methods after previous amplification of the DR4 B1 exon, we subtyped 20 DR4 volunteers, classified as high, intermediate and low responders. We did not find any direct association between the HLA DR4 Dw special subtype in the high or low responders immunized with the SPf 66 vaccine.
C1 UNIV SAO PAULO, ESCUELA MED, SAO PAULO, BRAZIL.
RP MURILLO, LA (corresponding author), UNIV NACL COLOMBIA, HOSP SAN JUAN DE DIOS, INST IMMUNOL, SANTA FE DE BOGOTA, COLOMBIA.
RI KALIL, JORGE/C-8029-2012; Patarroyo, Manuel-Elkin/S-1422-2017
OI KALIL, JORGE/0000-0001-8415-4274; Patarroyo,
   Manuel-Elkin/0000-0002-1119-6040
CR ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103
   Anderson M. L. M., 1985, NUCLEIC ACID HYBRIDI, P73
   ERLICH HA, 1989, PCR TECHNOLOGY PRINC, P193
   FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629
   FREEMAN SM, 1987, HUM IMMUNOL, V20, P1, DOI 10.1016/0198-8859(87)90002-4
   GREGERSEN PK, 1989, LAB INVEST, V61, P5
   GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642
   HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0
   HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012
   HURD CM, 1989, BIOTEST B, V4, P35
   MANIATIS T, 1989, MOL CLONING LABORATO, P31
   PATARROYO ME, 1988, NATURE, V332, P358
   RONCHESE F, 1987, NATURE, V329, P256
   ROTHBARD J, 1987, NATURE, V330, P107
   SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0
   SALCEDO M, 1990, IN PRESS CLIN EXPT I
   SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2
   SINGAGLIA F, 1988, NATURE, V336, P778
   TIERCY JM, 1988, P NATL ACAD SCI USA, V85, P198, DOI 10.1073/pnas.85.1.198
NR 19
TC 27
Z9 27
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD MAR
PY 1991
VL 13
IS 2
BP 201
EP 210
DI 10.1111/j.1365-3024.1991.tb00275.x
PG 10
WC Immunology; Parasitology
SC Immunology; Parasitology
GA FF102
UT WOS:A1991FF10200008
PM 2052406
DA 2020-11-26
ER

PT J
AU BECKMANN, JS
   RICHARD, I
   HILLAIRE, D
   BROUX, O
   ANTIGNAC, C
   BOIS, E
   CANN, H
   COTTINGHAM, RW
   FEINGOLD, N
   FEINGOLD, J
   KALIL, J
   LATHROP, GM
   MARCADET, A
   MASSET, M
   MIGNARD, C
   PASSOSBUENO, MR
   PELLERAIN, N
   ZATZ, M
   DAUSSET, J
   FARDEAU, M
   COHEN, D
AF BECKMANN, JS
   RICHARD, I
   HILLAIRE, D
   BROUX, O
   ANTIGNAC, C
   BOIS, E
   CANN, H
   COTTINGHAM, RW
   FEINGOLD, N
   FEINGOLD, J
   KALIL, J
   LATHROP, GM
   MARCADET, A
   MASSET, M
   MIGNARD, C
   PASSOSBUENO, MR
   PELLERAIN, N
   ZATZ, M
   DAUSSET, J
   FARDEAU, M
   COHEN, D
TI A GENE FOR LIMB-GIRDLE MUSCULAR-DYSTROPHY MAPS TO CHROMOSOME-15 BY
   LINKAGE
SO COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA
   VIE-LIFE SCIENCES
LA French
DT Article
ID DNA; FRAGMENTS
AB Limb-girdle muscular dystrophy (LGMD) is inherited as a monogenic, autosomal recessive trait. A genetically homogeneous group of families from the Isle of La Reunion, comprising individuals at high risk for this disorder, was systematically analysed using a panel of 85 polymorphic markers spanning approximately 30% of the human genome. Linkage was detected between the LGMD gene and the marker D15S25, uncovered with the probe pTHH114 and restriction enzyme RsaI (lod score = 5.52 at a theta = 0.0), localising this gene onto chromosome 15. Such a lod score corresponds to odds of 3.3 x 10(5) in favor of linkage versus absence of linkage.
   Additional families from other populations will need to be examined before the role of this newly identified locus can be understood.
C1 INSERM, CTR TRANSFUS SANGUINE, LA REUNION, FRANCE.
   UNIV PARIS 07, UNITE RECH, INSERM, U155, F-75221 PARIS 05, FRANCE.
   UNIV SAO PAULO, FAC MED, SAO PAULO, BRAZIL.
   CTR HOSP ST PIERRE LE TAMPON, LA REUNION, FRANCE.
   UNIV SAO PAULO, INST BIOCIENCIAS, DEPT BIOL, SAO PAULO, BRAZIL.
   INSERM, UNITE RECH, U153, F-75005 PARIS, FRANCE.
   CNRS, UA 614, F-75005 PARIS, FRANCE.
RP BECKMANN, JS (corresponding author), CTR ETUDE POLYMORPHISME HUMAIN, 27 RUE JULIETTE DODU, F-75010 PARIS, FRANCE.
RI Beckmann, Jacques S/A-9772-2008; Passos-Bueno, Maria Rita/I-6796-2016;
   Zatz, Mayana/M-5338-2015; Richard, isabelle/J-8298-2013; KALIL,
   JORGE/C-8029-2012; ANTIGNAC, Corinne/H-8945-2017; Cottingham,
   Robert/D-2628-2014
OI Beckmann, Jacques S/0000-0002-9741-1900; Passos-Bueno, Maria
   Rita/0000-0002-9248-3008; Zatz, Mayana/0000-0003-3970-8025; KALIL,
   JORGE/0000-0001-8415-4274; ANTIGNAC, Corinne/0000-0002-9934-4940;
   Cottingham, Robert/0000-0002-2775-3905
CR DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C
   ERB W, 1884, DTSCH ARCH KLIN MED, V34, P467
   FARDEAU M, 1988, 14 P WORLD C NEUR S, V37
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   GARDNERMEDWIN D, 1980, BRIT MED BULL, V36, P109, DOI 10.1093/oxfordjournals.bmb.a071623
   HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702
   KUMLINWOLFF E, 1988, NUCLEIC ACIDS RES, V16, P1224, DOI 10.1093/nar/16.3.1224
   LATHROP GM, 1985, AM J HUM GENET, V37, P482
   LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0
   NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5
   PASSOSBUENO MR, 1990, IN PRESS AM J MED GE
   RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740
   Sambrook J, 1989, MOL CLONING LABORATO
   SHIELDS RW, 1986, MYOLOGY BASIC CLIN, P1349
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169
   ZATZ M, 1989, AM J MED GENET, V32, P407, DOI 10.1002/ajmg.1320320328
NR 17
TC 188
Z9 189
U1 2
U2 12
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0764-4469
J9 CR ACAD SCI III-VIE
JI Comptes Rendus Acad. Sci. Ser. III-Sci. Vie-Life Sci.
PD FEB 14
PY 1991
VL 312
IS 4
BP 141
EP 148
PG 8
WC Biology; Multidisciplinary Sciences
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA EZ275
UT WOS:A1991EZ27500002
PM 1901754
DA 2020-11-26
ER

PT J
AU TUDER, RM
   WEINBERG, A
   PANAJOTOPOULOS, N
   KALIL, J
AF TUDER, RM
   WEINBERG, A
   PANAJOTOPOULOS, N
   KALIL, J
TI CYTOMEGALOVIRUS ENHANCES PBMC BINDING AND HLA CLASS-I EXPRESSION ON
   CULTURED ENDOTHELIAL-CELLS
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13TH INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOC
CY AUG 19-24, 1990
CL SAN FRANCISCO, CA
SP TRANSPLANTAT SOC
ID VIRUS-INFECTION
C1 UNIV SAO PAULO,HOSP CLIN,SCH MED,INST CORACAO,TRANSPLANTAT IMMUNOL LAB,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,HOSP CLIN,SCH MED,DIV ANAT PATHOL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST TROP MED,VIROL LAB,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR GRUNDY JE, 1988, J MED VIROL, V25, P483, DOI 10.1002/jmv.1890250412
   KALIL J, 1982, TISSUE ANTIGENS, V20, P47
   PARHAM P, 1989, NATURE, V340, P426, DOI 10.1038/340426a0
   TUDER RM, 1990, J CELL PHYSL, V142, P278
   VANDORP WT, 1989, TRANSPLANTATION, V48, P469, DOI 10.1097/00007890-198909000-00024
NR 5
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1991
VL 23
IS 1
BP 91
EP 92
PN 1
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA EV390
UT WOS:A1991EV39000032
PM 1846720
DA 2020-11-26
ER

PT J
AU PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   GUILHERME, L
   MARIN, ML
   ROSALES, C
   SABBAGA, E
   KALIL, J
AF PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   GUILHERME, L
   MARIN, ML
   ROSALES, C
   SABBAGA, E
   KALIL, J
TI IMMUNOLOGICAL-TOLERANCE IN HUMAN TRANSPLANTATION - DOES A MATERNAL
   EFFECT EXIST
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID HLA ANTIGENS
C1 UNIV SAO PAULO,FAC MED,DIV UROL,RENAL TRANSPLANTAT UNIT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,MED INVEST RHEUMATOL LAB,SAO PAULO,BRAZIL.
RP PANAJOTOPOULOS, N (corresponding author), UNIV SAO PAULO,FAC MED,INST HEART,TRANSPLANTAT IMMUNOL LAB,AV DR ARNALDO 455,3 ANDAR SALA 33,BR-01246 SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377
   CLAAS FHJ, 1989, TRANSPL P, V21, P665
   CLAAS FHJ, 1988, TRANSPLANT INT, V1, P53, DOI 10.1007/BF00353819
   FLUIT L, 1989, TRANSPLANT P, V21, P689
NR 4
TC 3
Z9 3
U1 0
U2 1
PU APPLETON & LANGE
PI E NORWALK
PA 25 VAN ZANT ST, E NORWALK, CT 06855
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1991
VL 23
IS 1
BP 1291
EP 1292
PN 2
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA EV391
UT WOS:A1991EV39100153
PM 1989216
DA 2020-11-26
ER

PT J
AU BECKMANN, JS
   RICHARD, I
   HILLAIRE, D
   BROUX, O
   FOUGEROUSSE, F
   ANTIGNAC, C
   BOIS, E
   CANN, H
   COTTINGHAM, RW
   FEINGOLD, N
   KALIL, J
   LATHROP, GM
   MARCADET, A
   MASSET, M
   MIGNARD, C
   PASSOSBUENO, MR
   PELLERAIN, N
   ZATZ, M
   DAUSSET, J
   FARDEAU, M
   COHEN, D
AF BECKMANN, JS
   RICHARD, I
   HILLAIRE, D
   BROUX, O
   FOUGEROUSSE, F
   ANTIGNAC, C
   BOIS, E
   CANN, H
   COTTINGHAM, RW
   FEINGOLD, N
   KALIL, J
   LATHROP, GM
   MARCADET, A
   MASSET, M
   MIGNARD, C
   PASSOSBUENO, MR
   PELLERAIN, N
   ZATZ, M
   DAUSSET, J
   FARDEAU, M
   COHEN, D
TI LOCALIZATION OF A GENE FOR LIMB-GIRDLE MUSCULAR-DYSTROPHY TO
   CHROMOSOME-15
SO CYTOGENETICS AND CELL GENETICS
LA English
DT Meeting Abstract
C1 CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE.
   UNIV PARIS 07, INSERM, CTR TRANSFUS SANGUINE, F-75221 PARIS 05, FRANCE.
   UNIV SAO PAULO, FAC MED, SAO PAULO, BRAZIL.
   CTR HOSP ST PIERRE, LE TAMPON, Reunion, FRANCE.
   UNIV SAO PAULO, INST BIOCIENCIAS, DEPT BIOL, SAO PAULO, BRAZIL.
   CNRS, UA 614, INSERM, U153, F-75005 PARIS, FRANCE.
RI Zatz, Mayana/M-5338-2015; KALIL, JORGE/C-8029-2012; Richard,
   isabelle/J-8298-2013
OI Zatz, Mayana/0000-0003-3970-8025; KALIL, JORGE/0000-0001-8415-4274; 
CR BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141
   FOUGEROUSSE F, 1991, HGM11 C
   YOUNG K, 1991, HGM11 C
NR 3
TC 0
Z9 0
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0301-0171
J9 CYTOGENET CELL GENET
JI Cytogenet. Cell Genet.
PY 1991
VL 58
IS 3-4
BP 1990
EP 1990
PG 1
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA HE949
UT WOS:A1991HE94900363
DA 2020-11-26
ER

PT J
AU PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   SABBAGA, E
   KALIL, J
AF PANAJOTOPOULOS, N
   IANHEZ, LE
   NEUMANN, J
   SABBAGA, E
   KALIL, J
TI IMMUNOLOGICAL-TOLERANCE IN HUMAN TRANSPLANTATION - THE POSSIBLE
   EXISTENCE OF A MATERNAL EFFECT
SO TRANSPLANTATION
LA English
DT Article
C1 UNIV SAO PAULO,DIV UROL,RENAL TRANSPLANT UNIT,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,FAC MED,MED INVEST RHEUMATOL LAB,SAO PAULO,BRAZIL.
RP PANAJOTOPOULOS, N (corresponding author), UNIV SAO PAULO,INST HEART,TRANSPLANTAT IMMUNOL LAB,SAO PAULO,BRAZIL.
RI Neumann, Jorge/L-4790-2018; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR AMOS DB, 1979, NIH80545 PUBL, P42
   Cicciarelli J, 1988, Clin Transpl, P293
   CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377
   CLAAS FHJ, 1989, TRANSPL P, V21, P665
   CLAAS FHJ, 1988, TRANSPLANT INT, V1, P53, DOI 10.1007/BF00353819
   FLUIT L, 1989, TRANSPLANT P, V21, P689
   OPELZ G, 1989, CTS NEWSLETTER   JUL
NR 7
TC 29
Z9 30
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD SEP
PY 1990
VL 50
IS 3
BP 443
EP 445
DI 10.1097/00007890-199009000-00016
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DY855
UT WOS:A1990DY85500016
PM 2402794
DA 2020-11-26
ER

PT J
AU DAMIANI, D
   BILLERBECK, AEC
   GOLDBERG, ACK
   SETIAN, N
   FELLOUS, M
   KALIL, J
AF DAMIANI, D
   BILLERBECK, AEC
   GOLDBERG, ACK
   SETIAN, N
   FELLOUS, M
   KALIL, J
TI INVESTIGATION OF THE ZFY GENE IN XX TRUE HERMAPHRODITISM AND SWYER
   SYNDROME
SO HUMAN GENETICS
LA English
DT Article
C1 UNIV SAO PAULO,INST CURACAO,IMUNOL TRANSPLANTES LAB,BR-01246 SAO PAULO,SP,BRAZIL.
   UNIV SAO PAULO,FAC MED,INVEST REUMATOL LAB,BR-01246 SAO PAULO,SP,BRAZIL.
   INST PASTEUR,IMMUNOGENET HUMAINE LAB,F-75724 PARIS,FRANCE.
RP DAMIANI, D (corresponding author), UNIV SAO PAULO,FAC MED,INST CRIANCA,UNIDADE ENDOCRINOL PEDIAT,AVE DR ENEAS DECARVALHO AGUIAR 647,BR-05403 SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR BERNSTEIN R, 1980, SCIENCE, V207, P768, DOI 10.1126/science.7352285
   BISHOP CE, 1983, NATURE, V303, P831, DOI 10.1038/303831a0
   BRIONNETMETZGER S, 1988, SEM HOP PARIS, V64, P1561
   COOKE H, 1976, NATURE, V262, P182, DOI 10.1038/262182a0
   DELACHAPELLE A, 1986, COLD SPRING HARB SYM, V51, P249, DOI 10.1101/SQB.1986.051.01.030
   DELACHAPELLE A, 1987, DEVELOPMENT, V101, P33
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   FORD CE, 1959, LANCET, V1, P711
   GUELLAEN G, 1984, NATURE, V307, P172, DOI 10.1038/307172a0
   JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0
   KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245
   LAU Y-F, 1986, American Journal of Human Genetics, V39, pA142
   MANIATIS T, 1982, MOL CLONING LABORATO, P383
   Manouvrier S, 1987, J Genet Hum, V35, P131
   MARDON G, 1989, CELL, V56, P765, DOI 10.1016/0092-8674(89)90680-6
   NAGAI Y, 1979, DIFFERENTIATION, V13, P155, DOI 10.1111/j.1432-0436.1979.tb01578.x
   PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2
   PETIT C, 1987, CELL, V49, P595, DOI 10.1016/0092-8674(87)90535-6
   SCHERER G, 1989, HUM GENET, V81, P291
   SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   URBAN E, 1981, DIFFERENTIATION, V18, P161, DOI 10.1111/j.1432-0436.1981.tb01117.x
   VERGNAUD G, 1986, AM J HUM GENET, V38, P109
   WACHTEL SS, 1980, HUM GENET, V54, P25, DOI 10.1007/BF00279045
   WAIBEL F, 1987, HUM GENET, V76, P332, DOI 10.1007/BF00272440
   WOLF U, 1979, HUM GENET, V47, P269, DOI 10.1007/BF00321019
NR 26
TC 22
Z9 23
U1 0
U2 1
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD JUN
PY 1990
VL 85
IS 1
BP 85
EP 88
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA DJ093
UT WOS:A1990DJ09300014
PM 2358305
DA 2020-11-26
ER

PT J
AU GOLDBERG, AC
   KALIL, J
AF GOLDBERG, AC
   KALIL, J
TI BGLII AND ECORV RFLPS ON THE HUMAN DQB LOCUS
SO NUCLEIC ACIDS RESEARCH
LA English
DT Note
C1 UNIV SAO PAULO,FAC MED,RHEUMATOL LAB,SAO PAULO,SP,BRAZIL.
RP GOLDBERG, AC (corresponding author), UNIV SAO PAULO,INST CORACAO,TRANSPLANTAT IMMUNOL LAB,SAO PAULO,SP,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x
NR 1
TC 3
Z9 3
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAY 25
PY 1990
VL 18
IS 10
BP 3106
EP 3106
DI 10.1093/nar/18.10.3106
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DG797
UT WOS:A1990DG79700083
PM 1971931
OA Green Published
DA 2020-11-26
ER

PT J
AU NEUMANN, J
   KALIL, J
   BRASILE, L
   CERILLI, J
AF NEUMANN, J
   KALIL, J
   BRASILE, L
   CERILLI, J
TI IMMUNOBLOT ANALYSIS OF SERA SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
C1 UNION UNIV ALBANY MED COLL,DEPT SURG,ALBANY,NY 12208.
RP NEUMANN, J (corresponding author), UNIV SAO PAULO,HEART INST,FAC MED,TRANSPLANTAT IMMUNOL LAB,AV DR ARNALDO 455 3 & S33,BR-02146 SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BRASILE L, 1985, TRANSPLANTATION, V40, P672, DOI 10.1097/00007890-198512000-00020
   CERILLI J, 1985, TRANSPLANTATION, V39, P286, DOI 10.1097/00007890-198503000-00016
   MORAES JR, 1977, J CLIN INVEST, V60, P449, DOI 10.1172/JCI108795
   WOOD NL, 1988, TRANSPLANTATION, V45, P787, DOI 10.1097/00007890-198804000-00024
NR 4
TC 7
Z9 7
U1 0
U2 1
PU APPLETON & LANGE
PI E NORWALK
PA 25 VAN ZANT ST, E NORWALK, CT 06855
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1989
VL 21
IS 1
BP 700
EP 701
PN 1
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA U1523
UT WOS:A1989U152300293
PM 2650230
DA 2020-11-26
ER

PT J
AU KALIL, J
   GUILHERME, L
   NEUMANN, J
   ROSALES, C
   MARIN, M
   SALDANHA, L
   CHOCAIR, PR
   IANHEZ, LE
   SABBAGA, E
AF KALIL, J
   GUILHERME, L
   NEUMANN, J
   ROSALES, C
   MARIN, M
   SALDANHA, L
   CHOCAIR, PR
   IANHEZ, LE
   SABBAGA, E
TI HUMORAL REJECTION IN 2 HLA IDENTICAL LIVING RELATED DONOR
   KIDNEY-TRANSPLANTS
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
C1 UNIV SAO PAULO,INST HEART,SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR AHERN AT, 1982, TRANSPLANTATION, V33, P103, DOI 10.1097/00007890-198201000-00023
   AMOS DB, 1979, NIH80545 PUBL, P42
   CERILLI J, 1985, TRANSPLANTATION, V39, P286, DOI 10.1097/00007890-198503000-00016
   COXEGILLILAND R, 1981, TRANSPLANT P, V13, P945
   DANILOUS J, 1980, HISTOCOMPATIBILITY T
   ETTENGER RB, 1979, TRANSPLANTATION, V27, P315, DOI 10.1097/00007890-197905000-00005
   HAYRY P, 1980, SCAND J IMMUNOL, V11, P303, DOI 10.1111/j.1365-3083.1980.tb00238.x
   KALIL J, 1987, IN PRESS HISTOCOMPAT
   SIEGLER H, 1977, SURGERY, V81, P274
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
NR 10
TC 33
Z9 34
U1 0
U2 1
PU APPLETON & LANGE
PI E NORWALK
PA 25 VAN ZANT ST, E NORWALK, CT 06855
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1989
VL 21
IS 1
BP 711
EP 713
PN 1
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA U1523
UT WOS:A1989U152300299
PM 2650236
DA 2020-11-26
ER

PT J
AU IANHEZ, L
   SALDANHA, LB
   PAULA, FJ
   NETO, ED
   SABBAGA, E
   ARAP, S
   MARIN, ML
   ROSALES, C
   GUILHERME, L
   RODRIGUES, H
   KALIL, J
AF IANHEZ, L
   SALDANHA, LB
   PAULA, FJ
   NETO, ED
   SABBAGA, E
   ARAP, S
   MARIN, ML
   ROSALES, C
   GUILHERME, L
   RODRIGUES, H
   KALIL, J
TI HUMORAL REJECTION WITH NEGATIVE CROSSMATCHES
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
RP IANHEZ, L (corresponding author), UNIV SAO PAULO,HOSP CLIN,FAC MED,DIV CLIN UROL,UNIDAD TRANSPLANTE RENAL,BR-05403 SAO PAULO,BRAZIL.
RI Neto, Elias David/O-3866-2018; David-Neto, Elias/C-9112-2012; KALIL,
   JORGE/C-8029-2012; Guglielmi, Luiza G/E-7676-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
CR AMOS DB, 1979, NIH80545 PUBL, P42
   CERILLI J, 1985, TRANSPLANTATION, V39, P286, DOI 10.1097/00007890-198503000-00016
   Danilovs J, 1980, HISTOCOMPATIBILITY T, P287
   Iwaki Y, 1987, CLIN TRANSPLANT, V1, P125
   JOHNSON AH, 1980, MANUAL IMMUNOLOGY, P1000
   KALIL J, 1989, TRANSPLAN P, V21
   MORAES JR, 1977, J CLIN INVEST, V60, P449, DOI 10.1172/JCI108795
NR 7
TC 7
Z9 7
U1 0
U2 2
PU APPLETON & LANGE
PI E NORWALK
PA 25 VAN ZANT ST, E NORWALK, CT 06855
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 1989
VL 21
IS 1
BP 720
EP 721
PN 1
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA U1523
UT WOS:A1989U152300304
PM 2650241
DA 2020-11-26
ER

PT J
AU GOLDBERG, AC
   KALIL, J
AF GOLDBERG, AC
   KALIL, J
TI DNA ANALYSIS OF HISTOCOMPATIBILITY ANTIGENS - FRAGMENTS FROM THE
   RECENTLY IDENTIFIED DR LOCI
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
C1 UNIV SAO PAULO,FAC MED,INVEST REUMATOL LAB,BR-01246 SAO PAULO,SP,BRAZIL.
RP GOLDBERG, AC (corresponding author), UNIV SAO PAULO,FAC MED,INST CORACAO,IMUNOL TRANSPLANTES LAB,AV DR ARNALDO 455,30 ANDAR,SALA 33,BR-01246 SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR BELL JI, 1986, COLD SPRING HARB SYM, V51, P75, DOI 10.1101/SQB.1986.051.01.010
   BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5
   BODMER WF, 1986, COLD SPRING HARB SYM, V51, P1
   BOHME J, 1985, J IMMUNOL, V135, P2149
   BONTROP R, 1986, IMMUNOGENETICS, V23, P401, DOI 10.1007/BF00372674
   BOSCH ML, 1987, HUM IMMUNOL, V19, P91, DOI 10.1016/0198-8859(87)90097-8
   COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P7870, DOI 10.1073/pnas.81.24.7870
   COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P1774, DOI 10.1073/pnas.81.6.1774
   DUNHAM I, 1987, P NATL ACAD SCI USA, V84, P7237, DOI 10.1073/pnas.84.20.7237
   DUPONT B, 1989, IN PRESS HISTOCOMPAT
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   FONT MP, 1986, P NATL ACAD SCI USA, V83, P3361, DOI 10.1073/pnas.83.10.3361
   GORSKI J, 1987, IMMUNOGENETICS, V25, P397, DOI 10.1007/BF00396106
   HORS J, 1985, HLA COMPLEXE MAJEUR, P227
   KALIL J, 1988, IMUNOLOGIA BASICA, P293
   KARR RW, 1986, J IMMUNOL, V136, P999
   LEE JS, 1982, P NATL ACAD SCI-BIOL, V79, P545, DOI 10.1073/pnas.79.2.545
   LIMA GMC, 1988, IMUNOLOGIA BASICA, P189
   LONG EO, 1982, P NATL ACAD SCI-BIOL, V79, P7465, DOI 10.1073/pnas.79.23.7465
   MANIATIS T, 1982, MOL CLONING LABORATO, P383
   OWERBACH D, 1983, P NATL ACAD SCI-BIOL, V80, P3758, DOI 10.1073/pnas.80.12.3758
   SHEEHY MJ, 1988, HUM IMMUNOL, V21, P49, DOI 10.1016/0198-8859(88)90080-8
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   TERASAKI PI, 1987, CLIN TRANSPLANTS, P303
   TIERCY JM, 1988, P NATL ACAD SCI USA, V85, P198, DOI 10.1073/pnas.85.1.198
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1989
VL 22
IS 7
BP 849
EP 857
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA AH143
UT WOS:A1989AH14300007
PM 2483529
DA 2020-11-26
ER

PT J
AU GOLDBERG, AC
   KALIL, J
AF GOLDBERG, AC
   KALIL, J
TI DNA ANALYSIS OF HISTOCOMPATIBILITY ANTIGENS - IDENTIFICATION OF NEW DQW
   SPECIFICITIES AND OF DPW PATTERNS
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
C1 UNIV SAO PAULO,FAC MED,INVEST REUMATOL LAB,BR-01246 SAO PAULO,SP,BRAZIL.
RP GOLDBERG, AC (corresponding author), UNIV SAO PAULO,FAC MED,INST CORACAO,IMUNOL TRANSPLANTES LAB,AV DR ARNALDO 455,30 ANDAR,SALA 33,BR-01246 SAO PAULO,SP,BRAZIL.
RI Goldberg, Anna Carla/H-8594-2014; KALIL, JORGE/C-8029-2012
OI Goldberg, Anna Carla/0000-0003-2600-7940; KALIL,
   JORGE/0000-0001-8415-4274
CR BALL EJ, 1987, XIHWS NEWSLETTER, V5, P8
   BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5
   CARROLL MC, 1987, P NATL ACAD SCI USA, V84, P8535, DOI 10.1073/pnas.84.23.8535
   Cecka J M, 1986, Clin Transpl, P141
   DECORDOBA SR, 1987, HUM IMMUNOL, V20, P71
   DUNHAM I, 1987, P NATL ACAD SCI USA, V84, P7237, DOI 10.1073/pnas.84.20.7237
   DUPONT B, 1989, HISTOCOMPATIBILITY T
   ENDO T, 1987, HUM IMMUNOL, V20, P209, DOI 10.1016/0198-8859(87)90104-2
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   GOLDBERG AC, 1989, BRAZ J MED BIOL RES, V22, P849
   HYLDIGNIELSEN JJ, 1987, P NATL ACAD SCI USA, V84, P1644, DOI 10.1073/pnas.84.6.1644
   LARHAMMAR D, 1982, P NATL ACAD SCI-BIOL, V79, P3687, DOI 10.1073/pnas.79.12.3687
   MANIATIS T, 1982, MOL CLONING LABORATO, P383
   MONOS DS, 1987, IMMUNOGENETICS, V26, P299, DOI 10.1007/BF00346526
   OKADA K, 1985, P NATL ACAD SCI USA, V82, P3410, DOI 10.1073/pnas.82.10.3410
   RADKA SF, 1987, HUM IMMUNOL, V18, P287, DOI 10.1016/0198-8859(87)90076-0
   ROUXDOSSETO M, 1983, P NATL ACAD SCI-BIOL, V80, P6036, DOI 10.1073/pnas.80.19.6036
   SANSOM DM, 1987, HUM IMMUNOL, V19, P269, DOI 10.1016/0198-8859(87)90044-9
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   THORSBY E, 1982, IMMUNOL REV, V66, P39, DOI 10.1111/j.1600-065X.1982.tb00433.x
   TONELLE C, 1985, EMBO J, V4, P2839
   TOSI R, 1978, J EXP MED, V148, P1592, DOI 10.1084/jem.148.6.1592
   TRUCCO M, 1986, IMMUNOL TODAY, V7, P297, DOI 10.1016/0167-5699(86)90065-4
   TRUCCO M, 1987, TRANSPLANT P, V19, P848
   ZEEVI A, 1987, HUM IMMUNOL, V18, P225, DOI 10.1016/0198-8859(87)90087-5
   ZIER KS, 1981, HUM IMMUNOL, V3, P57, DOI 10.1016/0198-8859(81)90043-4
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1989
VL 22
IS 7
BP 859
EP 867
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA AH143
UT WOS:A1989AH14300008
PM 2483530
DA 2020-11-26
ER

PT J
AU GOLDBERG, AC
   KALIL, J
AF GOLDBERG, AC
   KALIL, J
TI DNA ANALYSIS OF HISTOCOMPATIBILITY ANTIGENS OF A SAMPLE OF THE SAO-PAULO
   POPULATION
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
C1 UNIV SAO PAULO,FAC MED,INVEST REUMATOL LAB,BR-01246 SAO PAULO,SP,BRAZIL.
RP GOLDBERG, AC (corresponding author), UNIV SAO PAULO,FAC MED,INST CORACAO,IMUNOL TRANSPLANTES LAB,AV DR ARNALDO 455,30 ANDAR,SALA 33,BR-01246 SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012; Goldberg, Anna Carla/H-8594-2014
OI KALIL, JORGE/0000-0001-8415-4274; Goldberg, Anna
   Carla/0000-0003-2600-7940
CR AUFFRAY C, 1982, P NATL ACAD SCI-BIOL, V79, P6337, DOI 10.1073/pnas.79.20.6337
   DECORDOBA SR, 1987, HUM IMMUNOL, V20, P71
   DUPONT B, 1989, HISTOCOMPATIBILITY T
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P9149, DOI 10.1073/pnas.83.23.9149
   Grumet F C, 1983, Mol Biol Med, V1, P501
   HORS J, 1985, HLA COMPLEXE MAJEUR, P227
   KALIL J, 1989, IN PRESS HISTOCOMPAT
   KALIL J, 1988, IMUNOLOGIA BASICA, P293
   KOLLER BH, 1985, J IMMUNOL, V135, P4229
   LARHAMMAR D, 1982, P NATL ACAD SCI-BIOL, V79, P3687, DOI 10.1073/pnas.79.12.3687
   LONG EO, 1982, P NATL ACAD SCI-BIOL, V79, P7465, DOI 10.1073/pnas.79.23.7465
   MALISSEN M, 1982, P NATL ACAD SCI-BIOL, V79, P893, DOI 10.1073/pnas.79.3.893
   MANIATIS T, 1982, MOL CLONING, P373
   MARCADET A, 1988, IN PRESS HISTOCOMPAT
   NEPOM BS, 1986, J EXP MED, V164, P345, DOI 10.1084/jem.164.1.345
   OPELZ G, 1988, KIDNEY TRANSPLANT DA
   OWERBACH D, 1983, P NATL ACAD SCI-BIOL, V80, P3758, DOI 10.1073/pnas.80.12.3758
   RADKA SF, 1987, HUM IMMUNOL, V18, P287, DOI 10.1016/0198-8859(87)90076-0
   SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   WILNER A, 1988, HUM IMMUNOL, V21, P15, DOI 10.1016/0198-8859(88)90077-8
NR 22
TC 0
Z9 0
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1989
VL 22
IS 7
BP 869
EP 875
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA AH143
UT WOS:A1989AH14300009
PM 2576523
DA 2020-11-26
ER

PT J
AU CHOCAIR, PR
   IANHEZ, LE
   RODRIGUES, H
   KALIL, JE
   NEUMAN, J
   XAVIER, MA
   SABBAGA, E
AF CHOCAIR, PR
   IANHEZ, LE
   RODRIGUES, H
   KALIL, JE
   NEUMAN, J
   XAVIER, MA
   SABBAGA, E
TI HOW DOES THE PANEL OF HYPERSENSITIZED PATIENTS BEHAVE AFTER
   RENAL-TRANSPLANTATION
SO KIDNEY INTERNATIONAL
LA English
DT Meeting Abstract
C1 HOSP CLIN,UNIDADE TRANSPLANTE RENAL,SAO PAULO,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JAN
PY 1987
VL 31
IS 1
BP 455
EP 455
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA F4838
UT WOS:A1987F483801210
DA 2020-11-26
ER

PT J
AU VIANA, VST
   OLIVEIRA, RM
   MARCHIORI, PE
   KALIL, JE
   NEUMANN, J
   ASSIS, JL
   COSSERMELLI, W
AF VIANA, VST
   OLIVEIRA, RM
   MARCHIORI, PE
   KALIL, JE
   NEUMANN, J
   ASSIS, JL
   COSSERMELLI, W
TI MUSCULAR ANTIGEN ANTIBODIES IN MYASTHENIA-GRAVIS - CHARACTERIZATION OF
   THE ANTIGEN FRACTION OF MUSCLE EXTRACTS
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,FAC MED,HOSP CLIN,DEPT REUMATOL & NEUROL,SAO PAULO,SP,BRAZIL.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR AARLI JA, 1981, EUR NEUROL, V20, P380, DOI 10.1159/000115265
   AARLI JA, 1972, CLIN EXP IMMUNOL, V10, P453
   ESPINOSA E, 1968, J IMMUNOL, V100, P1020
   VIANA, IN PRESS ACTA NEUROL
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1986
VL 19
IS 4-5
BP A645
EP A645
PG 1
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA H2829
UT WOS:A1986H282900329
DA 2020-11-26
ER

PT J
AU BENSUSSAN, A
   KALIL, JE
   ALVAREZLOPEZ, MR
   BOUCHARD, B
   FRIDMAN, WH
   FELLOUS, M
   SASPORTES, M
AF BENSUSSAN, A
   KALIL, JE
   ALVAREZLOPEZ, MR
   BOUCHARD, B
   FRIDMAN, WH
   FELLOUS, M
   SASPORTES, M
TI HUMAN-CELLS ALLOSENSITIZED INVITRO RELEASE SOLUBLE SUPPRESSOR FACTORS -
   PRESENCE OF AT LEAST 2 DISTINCT FACTORS
SO ANNALES DE L INSTITUT PASTEUR-IMMUNOLOGY
LA English
DT Article
C1 CTR BIOTECNOL,BR-90000 PORTO ALEGRE,BRAZIL.
   INST CURIE,INSERM,U255,UNITE RECH IMMUNOL CELLULAIRE & CLIN,F-75231 PARIS 05,FRANCE.
   INST PASTEUR,F-75724 PARIS 15,FRANCE.
RP BENSUSSAN, A (corresponding author), HOP ST LOUIS,INSERM,U93,UNITE RECH IMMUNOGENET TRANSPLANTAT,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012; Bensussan, Armand/E-5434-2017
OI KALIL, JORGE/0000-0001-8415-4274; fridman, wolf
   herman/0000-0002-1332-0973; Bensussan, Armand/0000-0002-0409-2497
CR BECKWITH M, 1982, J IMMUNOL, V128, P791
   BENSUSSAN A, 1982, TRANSPLANT P, V14, P584
   CAROSELLA E, 1981, IMMUNOGENET, V14, P105
   CHAOUAT G, 1982, J IMMUNOL, V129, P502
   CHAOUAT G, 1979, J IMMUNOL, V122, P1983
   ENGLEMAN EG, 1978, J EXP MED, V147, P1037, DOI 10.1084/jem.147.4.1037
   ENGLEMAN EG, 1980, J EXP MED, V152, pS114
   ENGLEMAN EG, 1978, J CLIN INVEST, V61, P828, DOI 10.1172/JCI108997
   FRIDMAN WH, 1981, IMMUNOL REV, V56, P51, DOI 10.1111/j.1600-065X.1981.tb01047.x
   GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235
   KADISH AS, 1980, J EXP MED, V151, P637, DOI 10.1084/jem.151.3.637
   KALIL JE, 1982, IA ANTIGENS, V2, P55
   LETHI BT, 1982, J IMMUNOL, V129, P150
   LETHIBICHTHUY, 1980, EUR J IMMUNOL, V10, P894, DOI 10.1002/eji.1830101116
   PIERCE CW, 1979, J EXP MED, V134, P391
   RABOURDINCOMBE C, 1979, EUR J IMMUNOL, V9, P237, DOI 10.1002/eji.1830090313
   RICH SS, 1979, J EXP MED, V149, P114, DOI 10.1084/jem.149.1.114
   RICH SS, 1975, J EXP MED, V142, P1391, DOI 10.1084/jem.142.6.1391
   SASPORTES M, 1980, J EXP MED, V152, pS270
   SASPORTES M, 1981, IMMUNOGENETICS, V14, P117, DOI 10.1007/BF00344305
   SASPORTES M, 1978, NATURE, V276, P502, DOI 10.1038/276502a0
NR 21
TC 1
Z9 1
U1 0
U2 1
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0300-4910
J9 ANN INST PASTEUR IMM
PY 1985
VL C136
IS 2
BP 211
EP 223
DI 10.1016/S0769-2625(85)80051-9
PG 13
WC Immunology
SC Immunology
GA AHV01
UT WOS:A1985AHV0100004
PM 3159333
DA 2020-11-26
ER

PT J
AU RIBEIRO, CD
   KALIL, J
   MONJOUR, L
   ALFRED, C
   PLOTON, I
   GENTILINI, M
AF RIBEIRO, CD
   KALIL, J
   MONJOUR, L
   ALFRED, C
   PLOTON, I
   GENTILINI, M
TI CROSS REACTIONS BETWEEN PLASMODIUM-FALCIPARUM AND MAMMALIAN TISSUE
   ANTIGENS DETECTED BY MONOCLONAL-ANTIBODIES
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Note
C1 CHU PITIE SALPETRIERE,DEPT PARASITOL & MED TROP,F-75013 PARIS,FRANCE.
   HOP ST LOUIS,INSERM,U93,IMMUNOGENET TRANSPLANTAT HUMAINE LAB,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR DANFORTH HD, 1982, J PARASITOL, V68, P1029, DOI 10.2307/3281086
   FIZET D, 1980, PATHOL BIOL, V28, P581
   FREEMAN RR, 1980, NATURE, V284, P366, DOI 10.1038/284366a0
   GREENWOOD BM, 1970, CLIN EXPT IMMUNOLOGY, V32, P41
   Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0
   JARRA W, 1983, CIBA F SYMP, V94, P137
   KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713
   MONJOUR L, 1982, NOUV PRESSE MED, V11, P3138
   PERRIN LH, 1981, NATURE, V289, P301, DOI 10.1038/289301a0
   REKVIG OP, 1979, SCAND J IMMUNOL, V9, P325, DOI 10.1111/j.1365-3083.1979.tb03170.x
   RIBEIRO CD, 1983, T ROY SOC TROP MED H, V77, P185
   SIDDIQUI WA, 1980, MALARIA, V3
   YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745
NR 13
TC 5
Z9 5
U1 0
U2 1
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PY 1984
VL 78
IS 1
BP 75
EP 76
PG 2
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA SF028
UT WOS:A1984SF02800011
PM 6202251
DA 2020-11-26
ER

PT J
AU REYNIER, M
   LEBEC, S
   ROHNER, C
   KALIL, J
   AUBERT, C
AF REYNIER, M
   LEBEC, S
   ROHNER, C
   KALIL, J
   AUBERT, C
TI IA-LIKE ANTIGEN EXPRESSION ON BIOLOGICALLY DIFFERENT HUMAN-MELANOMA
   CELL-LINES
SO EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY
LA English
DT Article
C1 INSERM,CNRS MARSEILLE,CTR IMMUNOL,LUMINY,FRANCE.
   INSERM,U93,F-75005 PARIS,FRANCE.
RP REYNIER, M (corresponding author), INSERM,U119,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ACCOLA RS, HUM IMMUNOL
   ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764
   AUBERT C, 1980, J NATL CANCER I, V64, P1029
   BERGHOLTZ BO, 1978, SCAND J IMMUNOL, V8, P63, DOI 10.1111/j.1365-3083.1978.tb00496.x
   BURCHIEL SW, 1982, CANCER RES, V42, P4110
   CURRY RA, 1981, CANCER RES, V41, P463
   Ferrone S, 1978, Contemp Top Mol Immunol, V7, P239
   FITCHEN JH, 1980, J IMMUNOL, V125, P2004
   GOYERT SM, 1982, J EXP MED, V156, P550, DOI 10.1084/jem.156.2.550
   HERLYN M, 1980, CANCER RES, V40, P3602
   HIRN M, 1981, BRAIN RES BULL, V7, P441, DOI 10.1016/0361-9230(81)90044-7
   HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755
   HURLEY CK, 1983, HUM IMMUNOL, V6, P199
   KALIL J, 1982, IA ANTIGENS, P55
   KARR RW, 1982, J IMMUNOL, V128, P1809
   LIAO SK, 1982, TISSUE ANTIGENS, V20, P147
   MITCHELL KF, 1980, P NATL ACAD SCI-BIOL, V77, P7287, DOI 10.1073/pnas.77.12.7287
   NATALI PG, 1981, CLIN IMMUNOL IMMUNOP, V19, P250, DOI 10.1016/0090-1229(81)90067-2
   NATALI PG, 1981, IMMUNOGENETICS, V12, P409, DOI 10.1007/BF01561680
   PELLEGRINO MA, 1977, CANCER-AM CANCER SOC, V40, P36, DOI 10.1002/1097-0142(197707)40:1<36::AID-CNCR2820400108>3.0.CO;2-7
   PIERRES M, 1982, TISSUE ANTIGENS, V19, P289, DOI 10.1111/j.1399-0039.1982.tb01452.x
   PIERRES M, 1982, TISSUE ANTIGENS, V20, P208
   POLLACK MS, 1981, J NATL CANCER I, V66, P1003, DOI 10.1093/jnci/66.6.1003
   REBAI N, 1983, EUR J IMMUNOL, V13, P106, DOI 10.1002/eji.1830130205
   SARKAR S, 1980, P NATL ACAD SCI-BIOL, V77, P7297, DOI 10.1073/pnas.77.12.7297
   SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288
   SHACKELFORD DA, 1981, P NATL ACAD SCI-BIOL, V78, P4566, DOI 10.1073/pnas.78.7.4566
   SHAW S, 1981, NATURE, V293, P745, DOI 10.1038/293745a0
   SORG C, 1978, CANCER IMMUNOL IMMUN, V3, P259
   THOMPSON JJ, 1982, HYBRIDOMA, V1, P161, DOI 10.1089/hyb.1.1982.1.161
   WILSON BS, 1979, J EXP MED, V149, P658, DOI 10.1084/jem.149.3.658
   WINCHESTER RJ, 1977, P NATL ACAD SCI USA, V74, P4012, DOI 10.1073/pnas.74.9.4012
   WINCHESTER RJ, 1978, P NATL ACAD SCI USA, V75, P6235, DOI 10.1073/pnas.75.12.6235
   WOLF P, 1982, LAB INVEST, V46, pA91
NR 34
TC 4
Z9 4
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0277-5379
J9 EUR J CANCER CLIN ON
PY 1984
VL 20
IS 5
BP 659
EP 665
DI 10.1016/0277-5379(84)90013-0
PG 7
WC Oncology
SC Oncology
GA ST268
UT WOS:A1984ST26800013
PM 6376131
DA 2020-11-26
ER

PT J
AU MOSSALAYI, MD
   KALIL, J
   LEMAIRE, M
   FELLOUS, M
   TANZER, J
   CHEVALIER, S
   AUCOUTURIER, P
   DELAFOREST, PG
AF MOSSALAYI, MD
   KALIL, J
   LEMAIRE, M
   FELLOUS, M
   TANZER, J
   CHEVALIER, S
   AUCOUTURIER, P
   DELAFOREST, PG
TI OBTAINING OF MONOCYTES AND LYMPHOCYTES-T AND LYMPHOCYTES-B WHICH ARE NOT
   HIGHLY PURIFIED BY IMPROVEMENT OF DIFFERENTIAL CENTRIFUGATION, ADHERENCE
   AND PANNING TECHNIQUES, AIDED BY MONOCLONAL-ANTIBODIES
SO NOUVELLE REVUE FRANCAISE D HEMATOLOGIE
LA French
DT Meeting Abstract
C1 CTR RECH MALAD SANG,F-86021 POITIERS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0029-4810
J9 NOUV REV FR HEMATOL
JI Nouv. Rev. Fr. Hematol.
PY 1984
VL 26
IS 2
BP 86
EP 86
PG 1
WC Hematology
SC Hematology
GA SN285
UT WOS:A1984SN28500025
DA 2020-11-26
ER

PT J
AU CREVAT, D
   KALIL, J
   ROSA, F
   FELLOUS, M
AF CREVAT, D
   KALIL, J
   ROSA, F
   FELLOUS, M
TI 2 DISTINCT EPITOPES ON BETA-2M DEFINED BY MONOCLONAL-ANTIBODIES
SO ANNALES D IMMUNOLOGIE
LA French
DT Article
C1 INST PASTEUR,IMMUNOGENET HUMAINE LAB,F-75724 PARIS 15,FRANCE.
RP CREVAT, D (corresponding author), HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI Rosa, Frederic/L-5990-2017; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BERGGARD B, 1980, SCAND J CLIN LAB INV, V40, P154
   BERGGARD I, 1968, J BIOL CHEM, V243, P4095
   BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709
   FELLOUS M, 1978, J EXP MED, V148, P58, DOI 10.1084/jem.148.1.58
   FELLOUS M, 1977, IMMUNOGENETICS, V5, P423, DOI 10.1007/BF01570501
   GELTER ML, 1977, SOMAT CELL GENET, V3, P231
   KESSLER SW, 1976, J IMMUNOL, V117, P1482
   KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713
   LAMPSON LA, 1980, MONOCLONAL ANTIBODIE
   LERNHARDT W, 1978, EXP CELL RES, V111, P309, DOI 10.1016/0014-4827(78)90175-1
   MICHAELSON J, 1977, J EXP MED, V145, P1066, DOI 10.1084/jem.145.4.1066
   MITTAL KK, 1978, VOX SANG, V34, P58, DOI 10.1111/j.1423-0410.1978.tb02882.x
   PETERSON PA, 1974, P NATL ACAD SCI USA, V71, P35, DOI 10.1073/pnas.71.1.35
   PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697
   TEILLAUD JL, 1982, IMMUNOGENETICS, V15, P377, DOI 10.1007/BF00364261
   Williams A F, 1977, Contemp Top Mol Immunol, V6, P83
   ZIEGLER A, 1979, NATURE, V279, P243, DOI 10.1038/279243a0
NR 17
TC 9
Z9 9
U1 0
U2 1
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 0300-4910
J9 ANN INST PASTEUR IMM
PY 1983
VL C134
IS 1
BP 31
EP &
DI 10.1016/S0769-2625(83)80151-2
PG 0
WC Immunology
SC Immunology
GA QJ926
UT WOS:A1983QJ92600003
PM 6190430
DA 2020-11-26
ER

PT J
AU KALIL, J
   WOLLMAN, EE
AF KALIL, J
   WOLLMAN, EE
TI ROLE OF CLASS-I AND CLASS-II ANTIGENS IN THE ALLOGENIC STIMULATION -
   CLASS-I AND CLASS-II RECOGNITION IN ALLOGENIC STIMULATION - BLOCKING OF
   MLR BY MONOCLONAL-ANTIBODIES AND F(AB')2 FRAGMENTS
SO CELLULAR IMMUNOLOGY
LA English
DT Article
RP KALIL, J (corresponding author), HOP ST LOUIS,INSERM,UNITE 93,IMMUNOGENET LAB,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BRIGHT S, 1981, TISSUE ANTIGENS, V18, P217, DOI 10.1111/j.1399-0039.1981.tb01385.x
   BRODER, 1980, J EXP MED, V151, P257
   BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x
   CEPPELLINI R, 1981, TISSUE ANTIGENS, V17, P28
   CREVAT D, ANN IMMUNOL I PASTEU
   ECKELS DD, 1981, HUM IMMUNOL, V3, P133, DOI 10.1016/0198-8859(81)90050-1
   GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235
   JONKER M, 1978, TISSUE ANTIGENS, V11, P251, DOI 10.1111/j.1399-0039.1978.tb01256.x
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   KLEIN J, 1981, NATURE, V291, P455, DOI 10.1038/291455a0
   LARHAMMAR D, 1981, SCAND J IMMUNOL, V14, P617, DOI 10.1111/j.1365-3083.1981.tb00603.x
   MCCALMON RT, 1975, SCAND J IMMUNOL, V4, P613, DOI 10.1111/j.1365-3083.1975.tb02668.x
   MITCHISON NA, 1980, IMMUNOL TODAY, V1, P91, DOI 10.1016/0167-5699(80)90039-0
   MITCHISON NA, 1981, CELL IMMUNOL, V62, P258, DOI 10.1016/0008-8749(81)90324-5
   OKSENBERG JR, 1982, HUM IMMUNOL, V4, P47, DOI 10.1016/0198-8859(82)90049-0
   SCHACKELFORD DA, 1982, IMMUNOL REV, V66, P133
   SHAW S, 1981, NATURE, V293, P745, DOI 10.1038/293745a0
   TERMIJTELEN A, 1981, SCAND J IMMUNOL, V14, P459
NR 18
TC 33
Z9 33
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 1983
VL 79
IS 2
BP 367
EP 373
DI 10.1016/0008-8749(83)90078-3
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA RB591
UT WOS:A1983RB59100015
PM 6223710
DA 2020-11-26
ER

PT J
AU ROSA, F
   LEBOUTEILLER, PP
   ABADIE, A
   MISHAL, Z
   LEMONNIER, FA
   BOURREL, D
   LAMOTTE, M
   KALIL, J
   JORDAN, B
   FELLOUS, M
AF ROSA, F
   LEBOUTEILLER, PP
   ABADIE, A
   MISHAL, Z
   LEMONNIER, FA
   BOURREL, D
   LAMOTTE, M
   KALIL, J
   JORDAN, B
   FELLOUS, M
TI HLA CLASS I GENES INTEGRATED INTO MURINE CELLS ARE INDUCIBLE BY
   INTERFERON
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
C1 UNIV PARIS 07,INST PASTEUR,F-75724 PARIS 15,FRANCE.
   CTR IMMUNOL MARSEILLE LUMINY,MARSEILLE,FRANCE.
   CTR REG TRANSFUS SANGUINE,RENNES,FRANCE.
RI KALIL, JORGE/C-8029-2012; Rosa, Frederic/L-5990-2017
OI KALIL, JORGE/0000-0001-8415-4274; 
CR AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0
   BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   BOURREL D, IMMUNOL LETT
   BREGEGERE F, 1981, NATURE, V292, P78, DOI 10.1038/292078a0
   BURRONE OR, 1982, EMBO J, V1, P345, DOI 10.1002/j.1460-2075.1982.tb01172.x
   FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082
   KALIL J, 1982, B I PASTEUR, V80, P97
   KORMAN AJ, 1980, J EXP MED, V152, P65
   LEBOUTEILLER PP, J IMMUNOL METHODS
   LEMONNIER FA, 1982, IMMUNOGENETICS, V16, P355, DOI 10.1007/BF00372307
   LESERMAN LD, 1980, NATURE, V288, P602, DOI 10.1038/288602a0
   MALISSEN B, 1982, EUR J IMMUNOL, V12, P739, DOI 10.1002/eji.1830120908
   Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115
   PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253
   PLOEGH HL, 1981, J IMMUNOL, V126, P270
   REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0
   SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616
   WALLACH M, 1982, NATURE, V299, P650, DOI 10.1038/299650a0
   WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6
NR 19
TC 45
Z9 45
U1 0
U2 0
PU VCH PUBLISHERS INC
PI DEERFIELD BEACH
PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PY 1983
VL 13
IS 6
BP 495
EP 499
DI 10.1002/eji.1830130612
PG 5
WC Immunology
SC Immunology
GA QZ194
UT WOS:A1983QZ19400011
PM 6190661
DA 2020-11-26
ER

PT J
AU PLATA, F
   KALIL, J
   ZILBER, MT
   FELLOUS, M
   LEVY, D
AF PLATA, F
   KALIL, J
   ZILBER, MT
   FELLOUS, M
   LEVY, D
TI IDENTIFICATION OF A VIRAL-ANTIGEN RECOGNIZED BY H-2-RESTRICTED CYTOLYTIC
   LYMPHOCYTES-T ON A MURINE LEUKEMIA VIRUS-INDUCED TUMOR
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
C1 HOP COCHIN,IMMUNOL & VIROL TUMEURS LAB,F-75674 PARIS 14,FRANCE.
   HOP ST LOUIS,IMMUNOGENET TRANSPLANTAT HUMAINE LAB,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BLANK KJ, 1976, NATURE, V260, P250, DOI 10.1038/260250a0
   BUETTI E, 1980, J VIROL, V33, P936, DOI 10.1128/JVI.33.3.936-944.1980
   CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X
   COLLINS JK, 1980, J IMMUNOL, V125, P1318
   EFFROS RB, 1979, J IMMUNOL, V123, P1343
   ENJUANES L, 1979, J IMMUNOL, V122, P665
   FINBERG R, 1982, J IMMUNOL, V129, P2235
   FINBERG R, 1981, INFECT IMMUN, V31, P646, DOI 10.1128/IAI.31.2.646-649.1981
   FREEDMAN HA, 1975, J EXP MED, V142, P212, DOI 10.1084/jem.142.1.212
   GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818
   GLYNN JP, 1968, CANCER RES, V28, P434
   GOMARD E, 1977, J EXP MED, V146, P909, DOI 10.1084/jem.146.4.909
   GOMARD E, 1978, EUR J IMMUNOL, V8, P228, DOI 10.1002/eji.1830080403
   GREEN WR, 1980, J IMMUNOL, V125, P647
   HALE AH, 1978, P NATL ACAD SCI USA, V75, P970, DOI 10.1073/pnas.75.2.970
   HERBERMAN RB, 1974, JNCI-J NATL CANCER I, V53, P1103, DOI 10.1093/jnci/53.4.1103
   JONES PP, 1980, SELECTED METHODS CEL, P398
   KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KOSZINOWSKI U, 1975, EUR J IMMUNOL, V5, P245, DOI 10.1002/eji.1830050405
   LEDBETTER J, 1977, J VIROL, V23, P315, DOI 10.1128/JVI.23.2.315-322.1977
   LEVY D, 1980, INT J CANCER, V25, P147, DOI 10.1002/ijc.2910250120
   MARQUARDT H, 1977, BIOCHEMISTRY-US, V16, P710, DOI 10.1021/bi00623a024
   OLD LJ, 1964, NATURE, V201, P777, DOI 10.1038/201777a0
   OLD LJ, 1965, CANCER RES, V25, P813
   PLATA F, 1981, J EXP MED, V154, P1795, DOI 10.1084/jem.154.6.1795
   PLATA F, 1979, J EXP MED, V150, P1174, DOI 10.1084/jem.150.5.1174
   PLATA F, 1980, J EXP MED, V151, P726, DOI 10.1084/jem.151.3.726
   PLATA F, 1982, J EXP MED, V155, P1050, DOI 10.1084/jem.155.4.1050
   PLATA F, 1979, CURRENT TREND TUMOR, P155
   SNYDER HW, 1977, J VIROL, V23, P302, DOI 10.1128/JVI.23.2.302-314.1977
   Stephenson J R, 1978, Adv Cancer Res, V27, P1
   TUNG JS, 1976, CELL, V9, P573, DOI 10.1016/0092-8674(76)90039-8
   WEISS A, 1980, J EXP MED, V152, P1210, DOI 10.1084/jem.152.5.1210
NR 34
TC 23
Z9 23
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PY 1983
VL 131
IS 5
BP 2551
EP 2556
PG 6
WC Immunology
SC Immunology
GA RN219
UT WOS:A1983RN21900077
PM 6605389
DA 2020-11-26
ER

PT J
AU STERKERS, G
   HENIN, Y
   KALIL, J
   BAGOT, M
   LEVY, JP
AF STERKERS, G
   HENIN, Y
   KALIL, J
   BAGOT, M
   LEVY, JP
TI INFLUENCE OF HLA CLASS I-SPECIFIC AND CLASS II-SPECIFIC
   MONOCLONAL-ANTIBODIES ON DR-RESTRICTED LYMPHOPROLIFERATIVE RESPONSES .1.
   UNSEPARATED POPULATIONS OF EFFECTOR-CELLS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
C1 HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RP STERKERS, G (corresponding author), HOP COCHIN,CNRS,ERA 781,INSERM,U152,IMMUNOL & VIROL TUMEURS LAB,F-75674 PARIS 14,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BERGHOLTZ BO, 1978, SCAND J IMMUNOL, V8, P63, DOI 10.1111/j.1365-3083.1978.tb00496.x
   BRIGHT S, 1981, TISSUE ANTIGENS, V18, P217, DOI 10.1111/j.1399-0039.1981.tb01385.x
   CREVAT D, 1983, ANN IMMUNOL
   DUBREUIL PC, 1982, J IMMUNOGENET, V9, P11
   EVANS RL, 1978, J IMMUNOL, V120, P1423
   GILLIS S, 1978, J IMMUNOL, V120, P2027
   KALIL J, 1981, ANN INST PASTEUR IMM, VC132, P319, DOI 10.1016/0769-2625(81)90080-5
   LAMB JR, 1982, J IMMUNOL, V129, P1085
   LAMB JR, 1982, J IMMUNOL, V128, P233
   LEMONNIER FA, 1982, IMMUNOGENETICS, V16, P355, DOI 10.1007/BF00372307
   LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085
   MACMICHAEL AJ, 1977, NATURE, V270, P524
   MORETTA A, 1982, J EXP MED, V155, P599, DOI 10.1084/jem.155.2.599
   NEPOM JT, 1981, J IMMUNOL, V127, P31
   NG AK, 1982, CELL IMMUNOL, V66, P78, DOI 10.1016/0008-8749(82)90159-9
   PALACIOS R, 1982, IMMUNOGENETICS, V15, P341, DOI 10.1007/BF00364258
   PAWELEC GP, 1982, J IMMUNOL, V129, P1070
   RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528
   RODEY GE, 1979, J IMMUNOL, V123, P2250
   SHACKELFORD DA, 1982, IMMUNOL REV, V66, P133, DOI 10.1111/j.1600-065X.1982.tb00437.x
   SHACKELFORD DA, 1981, J IMMUNOL, V130, P289
   Shreffler D C, 1975, Adv Immunol, V20, P125, DOI 10.1016/S0065-2776(08)60208-4
   STEEL CM, 1982, IMMUNOLOGY, V47, P597
   STERKERS G, 1983, IMMUNOGENETICS, V17, P271, DOI 10.1007/BF00364411
   THOMAS DW, 1977, J IMMUNOL, V119, P223
   THORSBY E, 1982, IMMUNOL REV, V66, P39, DOI 10.1111/j.1600-065X.1982.tb00433.x
   ZIEGLER K, 1979, J EXP MED, V150, P1143, DOI 10.1084/jem.150.5.1143
   ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0
NR 28
TC 50
Z9 50
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PY 1983
VL 131
IS 6
BP 2735
EP 2740
PG 6
WC Immunology
SC Immunology
GA RT385
UT WOS:A1983RT38500023
PM 6227663
DA 2020-11-26
ER

PT J
AU MEZIOU, W
   CHARDON, P
   FLECHON, JE
   KALIL, J
   VAIMAN, M
AF MEZIOU, W
   CHARDON, P
   FLECHON, JE
   KALIL, J
   VAIMAN, M
TI EXPRESSION OF BETA-2-MICROGLOBULIN ON PRE-IMPLANTATION PIG EMBRYOS
SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
C1 INRA,RADIOBIOL APPL LAB,F-78350 JOUY EN JOSAS,FRANCE.
   CEA,IPSN,DEPT PROTECT,RADIOBIOL APPL LAB,F-78350 JOUY EN JOSAS,FRANCE.
   HOP ST LOUIS,INSERM,U95,F-75475 PARIS 10,FRANCE.
RP MEZIOU, W (corresponding author), INRA,CENT PHYSIOL ANIM LAB,F-78350 JOUY EN JOSAS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ACKERMAN GA, 1979, J HISTOCHEM CYTOCHEM, V27, P1413, DOI 10.1177/27.11.512328
   BERGGARD B, 1980, SCAND J CLIN LAB INV, V40, P13
   CHARDON P, 1978, TRANSPLANTATION, V26, P107, DOI 10.1097/00007890-197808000-00010
   DAUSSET J, 1981, SCIENCE, V213, P1469, DOI 10.1126/science.6792704
   DUBOIS P, 1976, TRANSPLANTATION, V22, P467, DOI 10.1097/00007890-197611000-00009
   EPSTEIN CJ, 1980, TISSUE ANTIGENS, V15, P63, DOI 10.1111/j.1399-0039.1980.tb00886.x
   FELLOUS M, 1978, J EXP MED, V148, P50
   GOODMAN SL, 1981, J MICROSC-OXFORD, V123, P201, DOI 10.1111/j.1365-2818.1981.tb01295.x
   GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291
   HEYNER S, 1969, NATURE, V222, P783, DOI 10.1038/222783a0
   JOHNSON PM, 1980, OXFORD REV REPRODUCT, V2, P40
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KRCO CJ, 1977, TRANSPLANT P, V9, P1367
   KRCO CJ, 1976, SCIENCE, V193, P1134, DOI 10.1126/science.959826
   MATZINGER P, 1981, NATURE, V292, P497, DOI 10.1038/292497a0
   MICHAELSON J, 1977, J EXP MED, V145, P1066, DOI 10.1084/jem.145.4.1066
   MUGGLETONHARRIS AL, 1976, J EMBRYOL EXP MORPH, V35, P59
   PALM J, 1971, J EXP MED, V133, P1282, DOI 10.1084/jem.133.6.1282
   SAWICKI JA, 1981, NATURE, V294, P450, DOI 10.1038/294450a0
   SEARLE RF, 1974, TRANSPLANTATION, V18, P136, DOI 10.1097/00007890-197408000-00006
   SEARLE RF, 1976, J EXP MED, V143, P348, DOI 10.1084/jem.143.2.348
   TEILLAUD JL, 1982, IMMUNOGENETICS, V15, P377, DOI 10.1007/BF00364261
   VAIMAN M, 1979, IMMUNOGENETICS, V9, P353, DOI 10.1007/BF01570430
   VAIMAN M, 1978, J IMMUNOGENET, V5, P59
   VITETTA ES, 1975, J IMMUNOL, V114, P252
   WILEY LM, 1980, DEV BIOL, V14, P167
NR 26
TC 16
Z9 17
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0165-0378
J9 J REPROD IMMUNOL
JI J. Reprod. Immunol.
PY 1983
VL 5
IS 2
BP 73
EP 80
DI 10.1016/0165-0378(83)90002-5
PG 8
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA QK041
UT WOS:A1983QK04100002
PM 6188827
DA 2020-11-26
ER

PT J
AU MOSSALAYI, MD
   KALIL, J
   LEMAIRE, M
   NTYAME, E
   FELLOUS, M
   TANZER, J
   DELAFOREST, PG
AF MOSSALAYI, MD
   KALIL, J
   LEMAIRE, M
   NTYAME, E
   FELLOUS, M
   TANZER, J
   DELAFOREST, PG
TI DIVIDING OF LYMPHOCYTE SUB-POPULATIONS AND THE PURIFICATION OF
   LYMPHOCYTES-B BY PANNING AS A CONTRIBUTION TO A MONOCLONAL ANTI-HLA-DR
   ANTIBODY
SO NOUVELLE REVUE FRANCAISE D HEMATOLOGIE
LA French
DT Meeting Abstract
C1 CTR RECH MALAD SANG,F-86021 POITIERS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0029-4810
J9 NOUV REV FR HEMATOL
JI Nouv. Rev. Fr. Hematol.
PY 1983
VL 25
IS 3
BP 212
EP 212
PG 1
WC Hematology
SC Hematology
GA QW305
UT WOS:A1983QW30500232
DA 2020-11-26
ER

PT J
AU THOMAS, P
   ALCALAY, D
   KALILFILHO, JE
   ALCALAY, M
   BONTOUX, D
AF THOMAS, P
   ALCALAY, D
   KALILFILHO, JE
   ALCALAY, M
   BONTOUX, D
TI STUDY OF THE SUB-POPULATION OF LYMPHOCYTES-T WITH THE HLA-DR MOLECULE IN
   RHEUMATOID-ARTHRITIS
SO REVUE DU RHUMATISME
LA French
DT Article
C1 CTR HOSP REG UNIV POITIER,HOP JEAN BERNARD,SERV RHUMATOL,F-86021 POITIERS,FRANCE.
   HOTEL DIEU,CTR TRANSFUS SANGUINE,POITIERS,FRANCE.
   HOP ST LOUIS,INST RECH MALAD SANG,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR CLOT J, 1979, INSERM, V80, P341
   FAGIOLO U, 1982, ADV INFLAMMATION RES, V3, P147
   FU SM, 1978, J EXP MED, V148, P1423, DOI 10.1084/jem.148.5.1423
   KALIL JE, IA ANTIGENS, pCH4
   MERCIER P, 1981, REV RHUM, V48, P713
   PELLEGRINO MA, 1975, CLIN IMMUNOL IMMUNOP, V3, P324, DOI 10.1016/0090-1229(75)90019-7
   REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472
   SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288
   THOMAS P, 1980, DEC SOC FRANC RHUM
   WINCHESTER RJ, 1975, J EXP MED, V141, P924
   YU DTY, 1980, J EXP MED, V151, P91, DOI 10.1084/jem.151.1.91
   YU DTY, 1980, J EXP MED, V152, P89
NR 12
TC 2
Z9 2
U1 0
U2 0
PU EXPANSION SCI FRANCAISE
PI PARIS
PA 31 BLVD LATOUR MAUBOURG, 75007 PARIS, FRANCE
SN 1169-8446
J9 REV RHUM
JI Rev. Rhum.
PY 1983
VL 50
IS 2
BP 111
EP 114
PG 4
WC Rheumatology
SC Rheumatology
GA QG888
UT WOS:A1983QG88800005
PM 6602364
DA 2020-11-26
ER

PT J
AU WOLLMAN, EE
   KALIL, J
AF WOLLMAN, EE
   KALIL, J
TI EXPRESSION OF CELL-SURFACE ANTIGENS DURING ALLOGENEIC RESPONSE STUDIES
   WITH MONOCLONAL-ANTIBODIES TO A POLYMORPHIC MARKER OF ACTIVATED
   LYMPHOCYTES AND HLA CLASS-I AND CLASS-II ANTIGENS
SO TISSUE ANTIGENS
LA English
DT Article
RP WOLLMAN, EE (corresponding author), HOP ST LOUIS,INSERM,U93,UNITE RECH IMMUNOGENET TRANSPLANTAT HUMAINE,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR CORTE G, 1981, EUR J IMMUNOL, V11, P162, DOI 10.1002/eji.1830110220
   CREVAT D, 1982, ANN IMMUNOL
   FU SM, 1978, J EXP MED, V148, P1423, DOI 10.1084/jem.148.5.1423
   GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235
   GUILHERME L, 1983, UNPUB MONOCLONAL ANT
   HERCEND T, 1981, HUM IMMUNOL, V3, P247, DOI 10.1016/0198-8859(81)90021-5
   KALIL J, 1982, IA ANTIGEN, V5
   Williams A F, 1977, Contemp Top Mol Immunol, V6, P83
NR 8
TC 1
Z9 1
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 1983
VL 22
IS 1
BP 37
EP 41
PG 5
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA QX816
UT WOS:A1983QX81600007
PM 6225221
DA 2020-11-26
ER

PT J
AU CHARDON, P
   KALIL, J
   LEVEZIEL, H
   COLOMBANI, J
   VAIMAN, M
AF CHARDON, P
   KALIL, J
   LEVEZIEL, H
   COLOMBANI, J
   VAIMAN, M
TI MONOCLONAL-ANTIBODIES TO HLA RECOGNIZE MONOMORPHIC AND POLYMORPHIC
   EPITOPES ON BOLA
SO TISSUE ANTIGENS
LA English
DT Article
C1 HOP ST LOUIS,IMMUNOGENET TRANSPLANTAT HUMAINE LAB,F-75475 PARIS 10,FRANCE.
   DEPT PROTECT,LAB RADIOBIOL APPL,JOUY EN JOSAS,FRANCE.
   LAB GENET BIOCHIM,JOUY EN JOSAS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR AMORENA B, 1978, SCIENCE, V201, P159, DOI 10.1126/science.663645
   BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   BRODSKY FM, 1981, HUM IMMUNOL, V3, P143, DOI 10.1016/0198-8859(81)90051-3
   BRODSKY FM, 1982, IMMUNOGENETICS, V15, P151, DOI 10.1007/BF00621948
   BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709
   CALDWELL J, 1977, ANIM BLOOD GROUPS BI, V8, P197
   CHARDON P, 1981, ANIM BLOOD GROUPS BI, V12, P59
   CREVAT D, 1983, ANN INST PASTEUR IMM, VC134, P31, DOI 10.1016/S0769-2625(83)80151-2
   CULLEN SE, 1976, J IMMUNOL, V117, P136
   GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235
   GROVES ML, 1982, J BIOL CHEM, V257, P2619
   HOANGXUAN M, 1982, IMMUNOGENETICS, V15, P621
   HOANGXUAN M, 1982, IMMUNOGENETICS, V15, P207, DOI 10.1007/BF00621952
   IHA TH, 1973, TISSUE ANTIGENS, V3, P291
   KALIL J, 1983, TRANSPLANT P
   KALIL JE, 1982, IA ANTIGENS, V2, P55
   LIABEUF A, 1981, J IMMUNOL, V127, P1542
   MALISSEN B, 1982, MECHANISMS CELL MEDI, P563
   SINGER DS, 1982, P NATL ACAD SCI-BIOL, V79, P1403, DOI 10.1073/pnas.79.5.1403
   SPOONER RL, 1978, J IMMUNOGENET, V5, P335
   TEILLAUD JL, 1982, IMMUNOGENETICS, V15, P377, DOI 10.1007/BF00364261
   1982, ANIM BLOOD GROUPS BI, V13, P33
NR 22
TC 16
Z9 16
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 1983
VL 22
IS 1
BP 62
EP 71
PG 10
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA QX816
UT WOS:A1983QX81600011
PM 6193607
DA 2020-11-26
ER

PT J
AU COLOMBANI, J
   LEPAGE, V
   KALIL, J
AF COLOMBANI, J
   LEPAGE, V
   KALIL, J
TI HLA MONOCLONAL-ANTIBODY REGISTRY 2ND LISTING
SO TISSUE ANTIGENS
LA English
DT Article
RP COLOMBANI, J (corresponding author), HOP ST LOUIS,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ACCOLLA, 1982, EUR J IMM, V12, P166
   ACCOLLA RS, 1981, P NATL ACAD SCI-BIOL, V78, P4549, DOI 10.1073/pnas.78.7.4549
   BECKMAN, 1982, COMMUNICATION
   BILLING, 1982, HUM IM, V4, P351
   BIRNBAUM, 1982, MOL IM, V19, P755
   BOUREL, 1982, COMMUNICATION
   BOUREL, 1983, IM LETT
   BROCHIER, 1982, COMMUNICATION
   BRODSKY FM, 1981, HUM IMMUNOL, V3, P143, DOI 10.1016/0198-8859(81)90051-3
   BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x
   BROOKS, 1982, COMMUNICATION
   DEKRETSER, 1982, EUR J IM, V12, P214
   DEKRETSER, 1982, EUR J IM, V12, P600
   ELLIS, 1982, HUM IM, V5, P49
   FAUCHET, 1982, COMMUNICATION
   FINN, 1982, PNAS, V79, P2658
   GONY, 1982, COMMUNICATION
   GOYERT, 1982, J EXP MED, V156, P550
   GRUMET, 1982, HUM IM, V5, P61
   HAYNES, 1982, HUM IM, V4, P273
   HEINRICH, 1979, IMMUNOBIOL, V156, P225
   HILDRETH, CITED INDIRECTLY
   IKEDA, 1982, 2D P AS OC HIST WORK
   JOHNSON, 1982, J EXP MED, V156, P104
   KASAHARA, 1983, IMMUNOGENETICS
   KASAHARA, 1983, TIS ANT
   KAUFMAN, 1982, J IM METH, V54, P1
   KOIDE, 1982, J IM, V129, P1061
   KORMAN, 1982, PNAS, V79, P1844
   LECLAIR K, 1981, J IMMUNOL METHODS, V41, P137, DOI 10.1016/0022-1759(81)90237-4
   LEMONIER, 1982, J IM METH, V54, P9
   LETARTE, 1982, AACHT
   LLOYD KO, 1981, J IMMUNOL, V126, P2408
   LONG, 1982, EMBO J, V1, P649
   MALAVASI, 1982, 30 C PROT BIOL FLUID
   MALAVASI, 1982, INT S MONOCL AB VENI
   MALISSEN, 1982, COMMUNICATION
   MAYER, 1982, COMMUNICATION
   MITCHEL, 1982, HUM IM, V4, P15
   MITCHELL KF, 1980, P NATL ACAD SCI-BIOL, V77, P7287, DOI 10.1073/pnas.77.12.7287
   MULLER, 1981, IMMUNOBIOLOGY, V160, P76
   NG, 1982, CELL IMM, V66, P78
   PARHAM, 1981, MONOCLONAL ANTIBODIE, P67
   PARHAM P, 1981, IMMUNOGENETICS, V13, P509, DOI 10.1007/BF00343719
   PAWELEC, 1982, J IM, V129, P1070
   PELLEGRINO, 1982, TRANSPL, V34, P18
   PIERRES, 1982, TIS ANT, V19, P289
   PIERRES M, 1981, J IMMUNOL, V126, P2424
   RADKA, 1982, J IM, V128, P2804
   RICHIARDI, 1983, HUM IM
   SHAW, 1982, J EXP MED, V156, P731
   TANIGAKI, 1983, COMMUNICATION
   THOMPSON, 1982, HYBRIDOMA, V1, P161
   TRUCCO MM, 1979, IMMUNOL REV, V47, P219, DOI 10.1111/j.1600-065X.1979.tb00295.x
   VILELLA, 1983, HUM IM
   VILELLA, 1982, COMMUNICATION
   YAMAMOTO, 1983, IMMUNOGENETICS
   YANG, 1982, AACHT
   YU, 1982, HYBRIDOMA, V1, P91
   1982, HUMAN IMMUNOLOGY, V5, P139
   1982, TISSUE ANTIGENS, V20, P161
NR 61
TC 46
Z9 46
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 1983
VL 22
IS 2
BP 97
EP 106
PG 10
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA RE121
UT WOS:A1983RE12100001
PM 6194572
DA 2020-11-26
ER

PT J
AU AZOGUI, O
   KALIL, J
   ANDERSEN, E
   GUILLET, J
   FELLOUS, M
   GLUCKMAN, E
AF AZOGUI, O
   KALIL, J
   ANDERSEN, E
   GUILLET, J
   FELLOUS, M
   GLUCKMAN, E
TI PERIPHERAL-BLOOD LYMPHOCYTES-T BEARING DR ANTIGEN AFTER BONE-MARROW
   TRANSPLANTATION
SO TRANSPLANTATION
LA English
DT Note
C1 HOP ST LOUIS,BONE MARROW TRANSPLANTAT UNIT,F-75475 PARIS 10,FRANCE.
   HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ATKINSON F, 1981, EXP HEMATOL S9, V9, P188
   BOUMSELL L, 1980, J EXP MED, V152, P229, DOI 10.1084/jem.152.1.229
   BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
   CHARRON DJ, 1980, J EXP MED, V153, P127
   DEBRUIN HG, 1981, J IMMUNOL, V127, P244
   DELOVITCH TL, 1982, J EXP MED, V155, P61, DOI 10.1084/jem.155.1.61
   DONEY KC, 1981, AM J HEMATOL, V11, P1, DOI 10.1002/ajh.2830110102
   FRIEDRICH W, 1981, EXP HEMATOL S9, P188
   GLUCKMAN E, 1981, Experimental Hematology (Charlottesville), V9, P126
   KALIL JE, 1982, IA ANTIGENS, V2, P55
   LUM LG, 1981, TRANSPL P, V13, P1231
   MITTAL KK, 1968, TRANSPLANTATION, V6, P913, DOI 10.1097/00007890-196811000-00006
   POWLES PL, 1978, LANCET, V2, P1327
   REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472
   REINHERZ EL, 1979, NEW ENGL J MED, V300, P1061, DOI 10.1056/NEJM197905103001901
   SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0
   SPRENT J, 1981, IMMUNOL TODAY, V2, P189, DOI 10.1016/0167-5699(81)90070-0
   THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605
   TOSATO G, 1979, NEW ENGL J MED, V301, P1133, DOI 10.1056/NEJM197911223012101
   TSOI MS, 1981, NATURE, V292, P355, DOI 10.1038/292355a0
   WASON DW, 1981, NATURE, V293, P150
   WITHERSPOON R, 1978, TRANSPLANT P, V10, P233
   YU DTY, 1980, J EXP MED, V151, P91, DOI 10.1084/jem.151.1.91
NR 23
TC 12
Z9 12
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PY 1983
VL 35
IS 5
BP 513
EP 515
DI 10.1097/00007890-198305000-00030
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA QR007
UT WOS:A1983QR00700030
PM 6342235
DA 2020-11-26
ER

PT J
AU KALIL, J
   LEPAGE, V
   FELLOUS, M
   REBOUL, M
   DASTOT, H
   GIRAUD, MC
   COLOMBANI, J
AF KALIL, J
   LEPAGE, V
   FELLOUS, M
   REBOUL, M
   DASTOT, H
   GIRAUD, MC
   COLOMBANI, J
TI 3 ANTI-HLA POLYMORPHIC MONOCLONAL-ANTIBODIES (MCAB)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
C1 INST PASTEUR,IMMUNOGENET HUMAINE LAB,F-75724 PARIS 15,FRANCE.
RP KALIL, J (corresponding author), HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87
   COLOMBANI J, 1982, TISSUE ANTIGENS, V20, P161
   GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818
   KALIL J, 1982, B I PASTEUR, V80, P97
   KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411
NR 5
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PY 1983
VL 15
IS 1
BP 63
EP 65
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA QH347
UT WOS:A1983QH34700015
DA 2020-11-26
ER

PT J
AU KALIL, J
   ABITA, JP
   DRESCH, C
   POIRIER, O
   BESLUAU, D
   DASTOT, H
   REBOUL, M
   COLOMBANI, J
   FELLOUS, M
AF KALIL, J
   ABITA, JP
   DRESCH, C
   POIRIER, O
   BESLUAU, D
   DASTOT, H
   REBOUL, M
   COLOMBANI, J
   FELLOUS, M
TI A DIFFERENTIATION ANTIGEN OF HUMAN-GRANULOCYTES RECOGNIZED BY A
   MONOCLONAL-ANTIBODY
SO BIOLOGY OF THE CELL
LA English
DT Meeting Abstract
C1 HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
   HOP ST LOUIS,INSERM,U204,F-75475 PARIS 10,FRANCE.
   INST PASTEUR,F-75724 PARIS 15,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0248-4900
J9 BIOL CELL
JI Biol. Cell
PY 1982
VL 45
SI SI
BP 83
EP 83
PG 1
WC Cell Biology
SC Cell Biology
GA PP325
UT WOS:A1982PP32500114
DA 2020-11-26
ER

PT J
AU BENSUSSAN, A
   KALIL, J
   BOUCHARD, B
   SASPORTES, M
AF BENSUSSAN, A
   KALIL, J
   BOUCHARD, B
   SASPORTES, M
TI MODULATION OF THE CELLULAR ALLOGENIC RESPONSE INVITRO IN MAN BY SOLUBLE
   MEDIATORS
SO BIOLOGY OF THE CELL
LA French
DT Meeting Abstract
C1 HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI Bensussan, Armand/E-5434-2017; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0248-4900
J9 BIOL CELL
JI Biol. Cell
PY 1982
VL 45
SI SI
BP 131
EP 131
PG 1
WC Cell Biology
SC Cell Biology
GA PP325
UT WOS:A1982PP32500255
DA 2020-11-26
ER

PT J
AU KALIL, J
   LEPAGE, V
   FELLOUS, M
   COLOMBANI, J
AF KALIL, J
   LEPAGE, V
   FELLOUS, M
   COLOMBANI, J
TI ANTI-HLA MONOCLONAL-ANTIBODIES
SO BULLETIN DE L INSTITUT PASTEUR
LA French
DT Review
C1 INST PASTEUR,UNITE IMMUNOGENET HUMAINE,F-75724 PARIS 15,FRANCE.
RP KALIL, J (corresponding author), HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   BECKMAN IGR, 1981, TISSUE ANTIGENS, V18, P341, DOI 10.1111/j.1399-0039.1981.tb01402.x
   BECKMAN IGR, 1980, CLIN EXP IMMUNOL, V40, P593
   BENSUSSAN A, 1982, BIORENCONTRE MERIEUX
   BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87
   BILLING R, 1982, TISSUE ANTIGENS, V19, P121, DOI 10.1111/j.1399-0039.1982.tb01427.x
   BIRNBAUM D, 1981, EUR J IMMUNOL, V11, P734, DOI 10.1002/eji.1830110912
   BONO R, 1979, TRANSPLANTATION CLIN, V2, P109
   BOYD HC, 1981, IMMUNOGENETICS, V12, P313, DOI 10.1007/BF01561673
   BRODSKY FM, 1981, HUM IMMUNOL, V3, P143, DOI 10.1016/0198-8859(81)90051-3
   BRODSKY FM, 1982, IMMUNOGENETICS, V15, P151, DOI 10.1007/BF00621948
   BRODSKY FM, 1982, J IMMUNOL, V128, P129
   BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x
   BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709
   BRODSKY FM, 1980, TISSUE ANTIGENS, V16, P30
   CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4
   CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567
   CHARRON DJ, 1980, J EXP MED, V152, pS127
   CLAAS F, 1982, TISSUE ANTIGENS
   CORTE G, 1981, P NATL ACAD SCI-BIOL, V78, P534, DOI 10.1073/pnas.78.1.534
   CORTE G, 1981, NATURE, V292, P357, DOI 10.1038/292357a0
   COTNER T, 1981, P NATL ACAD SCI-BIOL, V78, P3858, DOI 10.1073/pnas.78.6.3858
   CREVAT D, 1982, TISSUE ANTIGENS
   DAMLE NK, 1981, P NAT ACAD SCI WASH, V78, P5094
   DAUSSET J, 1981, FLAMMARION PARIS
   ECKELS DD, 1981, HUM IMMUNOL, V3, P133, DOI 10.1016/0198-8859(81)90050-1
   ELLIS SA, UNPUB EUROP J IMMUNO
   FITCHEN JH, 1980, J IMMUNOL, V125, P2004
   GALFRE G, 1981, IMMUNOCHEMICAL TECHN, V73, P3
   GASSER DL, 1979, P NATL ACAD SCI USA, V76, P4636, DOI 10.1073/pnas.76.9.4636
   GLADSTONE P, 1980, SOMAT CELL GENET, V6, P285, DOI 10.1007/BF01538802
   GODING JW, 1980, J IMMUNOL METHODS, V39, P285, DOI 10.1016/0022-1759(80)90230-6
   GOYERT SM, 1981, NATURE, V294, P266, DOI 10.1038/294266a0
   GOYERT SM, 1980, HUM IMMUNOL, V1, P161, DOI 10.1016/0198-8859(80)90103-2
   GRUMET FC, 1981, LANCET, V2, P174
   GRUMET FC, 1980, J IMMUNOL, V125, P2785
   GRUMET FC, 1982, UNPUB HUMAN IMMUNOL
   HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454
   HANSEN JA, 1981, HUM IMMUNOL, V2, P103, DOI 10.1016/0198-8859(81)90057-4
   HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573
   HART DNJ, 1981, TRANSPLANTATION, V31, P428, DOI 10.1097/00007890-198106000-00005
   HAYNES BF, 1980, P NATL ACAD SCI-BIOL, V77, P2914, DOI 10.1073/pnas.77.5.2914
   HAYNES BF, 1982, HUM IMMUNOL
   INDIVERI F, 1980, J IMMUNOL, V125, P2673
   KALIL J, 1982, MONOCLONAL ANTIBODIE
   KLEIN J, 1979, IMMUNOGENETICS, V8, P419, DOI 10.1007/BF01561453
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KOSTYU DD, 1980, IMMUNOGENETICS, V10, P433, DOI 10.1007/BF01572579
   LAMPSON LA, 1980, J IMMUNOL, V125, P293
   LANDSTEINER K, 1945, SPECIFICITY SEROLOGI
   LEGRAND L, 1975, TRANSPLANTATION, V19, P177, DOI 10.1097/00007890-197502000-00011
   LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0
   LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552
   LIABEUF A, 1981, J IMMUNOL, V127, P1542
   MALISSEN B, 1982, INHIBITION HUMAN T C
   MASON DW, 1980, BIOCHEM J, V187, P1
   MCKEARN TJ, 1979, IMMUNOL REV, V47, P91, DOI 10.1111/j.1600-065X.1979.tb00290.x
   MCMASTER WR, 1979, TISSUE ANTIGENS, V14, P453
   MCMASTER WR, 1979, IMMUNOL REV, V47, P117, DOI 10.1111/j.1600-065X.1979.tb00291.x
   MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603
   MCMICHAEL AJ, 1980, J EXP MED, V152, pS195
   MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307
   MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3
   MITCHELL KF, 1980, P NATL ACAD SCI-BIOL, V77, P7287, DOI 10.1073/pnas.77.12.7287
   NADLER LM, 1981, NATURE, V290, P591, DOI 10.1038/290591a0
   NADLER LM, 1981, HUM IMMUNOL, V1, P77
   NERI TM, 1981, MONOCLONAL ANTIBODIE, P79
   PARHAM P, 1980, HUM IMMUNOL, V1, P131, DOI 10.1016/0198-8859(80)90100-7
   PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3
   PARHAM P, 1980, IMMUNOGENETICS, V11, P131, DOI 10.1007/BF01567779
   PARHAM P, 1979, J IMMUNOL, V123, P342
   PARHAM P, 1981, IMMUNOGENETICS, V13, P509, DOI 10.1007/BF00343719
   PARHAM P, 1979, NATURE, V279, P639, DOI 10.1038/279639a0
   PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0
   PARHAM P, 1981, MONOCLONAL ANTIBODIE, P67
   PELLEGRINO MA, 1981, IMMUNOGENETICS, V14, P141, DOI 10.1007/BF00344307
   PIERRES M, 1981, J IMMUNOL, V126, P2424
   PIERRES M, 1980, EUR J IMMUNOL, V10, P950, DOI 10.1002/eji.1830101211
   QUARANTA V, 1981, IMMUNOGENETICS, V13, P285, DOI 10.1007/BF00364494
   QUARANTA V, 1981, IMMUNOGENETICS, V14, P403, DOI 10.1007/BF00373320
   QUARANTA V, 1980, J IMMUNOL, V125, P1421
   QUARANTA V, 1981, J IMMUNOL, V126, P548
   QUARANTA V, 1981, MONOCLONAL ANTIBODIE, P84
   QUARANTA V, 1980, HUM IMMUNOL, V3, P211
   REINHERZ EL, 1979, J IMMUNOL, V123, P1312
   REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472
   RICHIARDI P, 1981, IMMUNOGENETICS, V12, P615, DOI 10.1007/BF01561701
   RUSSO C, 1980, IMMUNOGENETICS, V11, P413, DOI 10.1007/BF01567808
   RUSSO C, 1981, IMMUNOGENETICS, V12, P267, DOI 10.1007/BF01561669
   SARKAR S, 1980, P NATL ACAD SCI-BIOL, V77, P7297, DOI 10.1073/pnas.77.12.7297
   SCALAMOGNA M, 1976, TISSUE ANTIGENS, V7, P125
   SCHACKELFORD DA, 1981, P NATL ACAD SCI USA, V78, P4566
   SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403
   SHALEV A, 1982, UNPUB TISSUE ANTIGEN
   SMILEK DE, 1980, J EXP MED, V151, P1139, DOI 10.1084/jem.151.5.1139
   STASHENKO P, 1980, J IMMUNOL, V125, P1678
   STOCKER JW, 1979, TISSUE ANTIGENS, V13, P212
   TEILLAUD JL, 1982, IMMUNOGENETICS, V15, P377, DOI 10.1007/BF00364261
   THOMPSON JJ, 1982, HYBRIDOMA, V1, P161, DOI 10.1089/hyb.1.1982.1.161
   TOSI R, 1981, EUR J IMMUNOL, V11, P721, DOI 10.1002/eji.1830110910
   TRUCCO M, 1980, HUM IMMUNOL, V1, P233, DOI 10.1016/0198-8859(80)90018-X
   TRUCCO MM, 1979, IMMUNOL REV, V47, P219, DOI 10.1111/j.1600-065X.1979.tb00295.x
   TRUCCO MM, 1978, NATURE, V273, P666, DOI 10.1038/273666a0
   VOLLMERS HP, 1979, IMMUNOGENETICS, V8, P447, DOI 10.1007/BF01561455
   WILSON BS, 1981, SCAND J IMMUNOL, V14, P201, DOI 10.1111/j.1365-3083.1981.tb00200.x
   WILSON BS, 1981, CURRENT TRENDS HISTO, P307
   ZIEGLER A, 1979, NATURE, V279, P243, DOI 10.1038/279243a0
   ZOLA H, 1980, TRANSPLANTATION, V29, P72
NR 108
TC 10
Z9 10
U1 0
U2 2
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0020-2452
J9 B I PASTEUR
JI Bull. Inst. Pasteur
PY 1982
VL 80
IS 2
BP 97
EP 126
PG 30
WC Immunology; Microbiology; Virology
SC Immunology; Microbiology; Virology
GA NZ725
UT WOS:A1982NZ72500001
DA 2020-11-26
ER

PT J
AU KADOUCHE, J
   DARNE, C
   KETELS, F
   POULETTY, P
   CREVAT, D
   KALIL, J
   NAJEAN, Y
AF KADOUCHE, J
   DARNE, C
   KETELS, F
   POULETTY, P
   CREVAT, D
   KALIL, J
   NAJEAN, Y
TI ANALYSIS OF VARIOUS ISOFERRITINS WITH MONOCLONAL-ANTIBODIES
SO COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA
   VIE-LIFE SCIENCES
LA French
DT Article
C1 UNIV PARIS 07,HOP ST LOUIS,SERV MED NUCL,F-75010 PARIS,FRANCE.
RP KADOUCHE, J (corresponding author), INSERM,U204,PL DR A FOURNIER,F-75010 PARIS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR BROXMEYER HE, 1981, J EXP MED, V153, P1426, DOI 10.1084/jem.153.6.1426
   CRICHTON RR, 1973, BIOCHEM J, V131, P51, DOI 10.1042/bj1310051
   CRICHTON RR, 1973, STRUCTURE BANDING FE, V17, P134
   DRYSDALE JW, 1974, BIOCHEM J, V141, P627, DOI 10.1042/bj1410627
   DRYSDALE JW, 1980, RADIOIMMUNOASSAY HOR, P213
   FELDMAN H, 1971, PRINCIPLES COMPETITI, P158
   Granick S, 1942, J BIOL CHEM, V146, P0451
   HALLIDAY JW, 1977, BRIT J HAEMATOL, V36, P395, DOI 10.1111/j.1365-2141.1977.tb00663.x
   HAZARD JT, 1977, NATURE, V265, P755, DOI 10.1038/265755a0
   HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7
   JONES BM, 1980, CLIN CHIM ACTA, V106, P203, DOI 10.1016/0009-8981(80)90173-4
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   LAVOIE DJ, 1977, PROTEINS IRON METABO, P71
   Oi V. T., 1980, SELECTED METHODS CEL, P351
   POWELL LW, 1975, BRIT J HAEMATOL, V30, P47, DOI 10.1111/j.1365-2141.1975.tb00516.x
   TAETLE R, 1981, BLOOD, V58, P653
   WORWOOD M, 1977, PROTEINS IRON METABO, V79, P88
NR 17
TC 7
Z9 7
U1 0
U2 1
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0764-4469
J9 CR ACAD SCI III-VIE
JI Comptes Rendus Acad. Sci. Ser. III-Sci. Vie-Life Sci.
PY 1982
VL 295
IS 6
BP 443
EP &
PG 0
WC Biology; Multidisciplinary Sciences
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA PT917
UT WOS:A1982PT91700005
PM 6817879
DA 2020-11-26
ER

PT J
AU KADOUCHE, J
   POULETTY, P
   KETELS, F
   KALIL, J
   NAJEAN, Y
AF KADOUCHE, J
   POULETTY, P
   KETELS, F
   KALIL, J
   NAJEAN, Y
TI ANALYSIS OF VARIOUS ISOFERRITINS WITH MONOCLONAL-ANTIBODIES
SO HYBRIDOMA
LA English
DT Meeting Abstract
C1 HOP ST LOUIS,SERV MED NUCL,F-75475 PARIS 10,FRANCE.
   HOP ST LOUIS,INSERM,U204,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0272-457X
J9 HYBRIDOMA
JI Hybridoma
PY 1982
VL 1
IS 3
BP 346
EP 346
PG 1
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Immunology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology
GA PA053
UT WOS:A1982PA05300018
DA 2020-11-26
ER

PT J
AU BENSUSSAN, A
   KALIL, J
   BOUCHARD, B
   SASPORTES, M
AF BENSUSSAN, A
   KALIL, J
   BOUCHARD, B
   SASPORTES, M
TI SUPPRESSOR REGULATORY MOLECULES OF THE HUMAN ALLOGENEIC INVITRO RESPONSE
SO IMMUNOBIOLOGY
LA English
DT Meeting Abstract
C1 HOP ST LOUIS,CTR HAYEM,INSERM,U93,UNITE RECH IMMUNOGENET TRANSPLANTAT HUMAINE,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012; Bensussan, Armand/E-5434-2017
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PY 1982
VL 163
IS 2-4
BP 154
EP 154
PG 1
WC Immunology
SC Immunology
GA PR608
UT WOS:A1982PR60800073
DA 2020-11-26
ER

PT J
AU BOUMSELL, L
   GELIN, C
   COPPIN, H
   PHAN, D
   KALIL, J
   GOSSE, C
   RAYNAL, B
   BERNARD, A
AF BOUMSELL, L
   GELIN, C
   COPPIN, H
   PHAN, D
   KALIL, J
   GOSSE, C
   RAYNAL, B
   BERNARD, A
TI VARIANTS OF CLASS-I MOLECULES HEAVY AND LIGHT-CHAINS ON HUMAN
   THYMUS-CELLS
SO IMMUNOBIOLOGY
LA English
DT Meeting Abstract
C1 HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
   INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE.
RI KALIL, JORGE/C-8029-2012; Coppin, Helene/G-4326-2013
OI KALIL, JORGE/0000-0001-8415-4274; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PY 1982
VL 163
IS 2-4
BP 319
EP 319
PG 1
WC Immunology
SC Immunology
GA PR608
UT WOS:A1982PR60800337
DA 2020-11-26
ER

PT J
AU TEILLAUD, JL
   CREVAT, D
   CHARDON, P
   KALIL, J
   GOUJETZALC, C
   MAHOUY, G
   VAIMAN, M
   PIOUS, D
   FELLOUS, M
AF TEILLAUD, JL
   CREVAT, D
   CHARDON, P
   KALIL, J
   GOUJETZALC, C
   MAHOUY, G
   VAIMAN, M
   PIOUS, D
   FELLOUS, M
TI PHYLOGENETIC STUDIES USING MONOCLONAL-ANTIBODIES AGAINST HUMAN MAJOR
   HISTOCOMPATIBILITY COMPLEX AND BETA-2-MICROGLOBULIN ANTIGENS
SO IMMUNOBIOLOGY
LA English
DT Meeting Abstract
C1 HOP ST LOUIS,INTERACT LYMPHOCYTAIRES LAB,F-75475 PARIS 10,FRANCE.
   HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
   LAB RADIOBIOL APPL,F-78350 JOUY JOSAS,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PY 1982
VL 162
IS 4-5
BP 429
EP 430
PG 2
WC Immunology
SC Immunology
GA PJ945
UT WOS:A1982PJ94500164
DA 2020-11-26
ER

PT J
AU TEILLAUD, JL
   CREVAT, D
   CHARDON, P
   KALIL, J
   GOUJETZALC, C
   MAHOUY, G
   VAIMAN, M
   FELLOUS, M
   PIOUS, D
AF TEILLAUD, JL
   CREVAT, D
   CHARDON, P
   KALIL, J
   GOUJETZALC, C
   MAHOUY, G
   VAIMAN, M
   FELLOUS, M
   PIOUS, D
TI MONOCLONAL-ANTIBODIES AS A TOOL FOR PHYLOGENETIC STUDIES OF MAJOR
   HISTOCOMPATIBILITY ANTIGENS AND BETA-2-MICROGLOBULIN
SO IMMUNOGENETICS
LA English
DT Article
C1 HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
   INRA,CTR NATL RECH ZOOTECH,RADIOBIOL APPL LAB,F-78350 JOUY EN JOSAS,FRANCE.
   IPSN,CEA,DEPT PROTECT,RADIOBIOL APPL LAB,F-78350 JOUY EN JOSAS,FRANCE.
   UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195.
RP TEILLAUD, JL (corresponding author), HOP ST LOUIS,CTR HAYEM,INTERACT LYMPHOCYTAIRES LAB,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ARMERDING D, 1974, J EXP MED, V140, P1717, DOI 10.1084/jem.140.6.1717
   Balner H, 1971, Tissue Antigens, V1, P229
   BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709
   COLOMBANI J, 1977, TISSUE ANTIGENS, V9, P111
   DORF ME, 1972, TISSUE ANTIGENS, V2, P461
   FRIDMAN WH, 1981, IMMUNOL REV, V56, P51, DOI 10.1111/j.1600-065X.1981.tb01047.x
   GATES FT, 1979, BIOCHEMISTRY-US, V18, P2267, DOI 10.1021/bi00578a021
   GORDON SM, 1976, SCAND J IMMUNOL, V5, P505, DOI 10.1111/j.1365-3083.1976.tb00305.x
   KAPP JA, 1978, J EXP MED, V147, P997, DOI 10.1084/jem.147.4.997
   LIPINSKI M, 1979, J EXP MED, V150, P1310, DOI 10.1084/jem.150.6.1310
   MCMICHAEL AJ, 1980, J EXP MED, V152, pS195
   MICHAELSON J, 1980, IMMUNOGENETICS, V11, P93, DOI 10.1007/BF01567773
   PARHAM P, 1979, NATURE, V279, P63
   RABOURDINCOMBE C, 1979, EUR J IMMUNOL, V9, P237, DOI 10.1002/eji.1830090313
   WALTENBAUGH C, 1977, J IMMUNOL, V118, P2073
NR 15
TC 52
Z9 52
U1 0
U2 2
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0093-7711
J9 IMMUNOGENETICS
JI Immunogenetics
PY 1982
VL 15
IS 4
BP 377
EP 384
DI 10.1007/BF00364261
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA NL539
UT WOS:A1982NL53900005
PM 6176537
DA 2020-11-26
ER

PT J
AU MONJOUR, L
   KALIL, J
   ALFRED, C
   RIBEIRO, CD
   GENTILINI, M
AF MONJOUR, L
   KALIL, J
   ALFRED, C
   RIBEIRO, CD
   GENTILINI, M
TI ASEXUAL INTRA-ERYTHOCYTIC MULTIPLICATION OF PLASMODIUM-FALCIPARUM -
   PRODUCTION OF MONOCLONAL-ANTIBODIES
SO NOUVELLE PRESSE MEDICALE
LA French
DT Letter
C1 HOP ST LOUIS,INSERM,U93,IMMUNO GENET TRANSPLANTAT HUMAINE LAB,F-75475 PARIS 10,FRANCE.
RP MONJOUR, L (corresponding author), GRP HOSP PITIE SALPETRIERE,SERV PARASITOL & MED TROPICALE,F-75634 PARIS 13,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713
   PERRIN LH, 1981, NATURE, V289, P301, DOI 10.1038/289301a0
   VOLLER A, 1971, T ROY SOC TROP MED H, V65, P2
NR 3
TC 1
Z9 1
U1 0
U2 1
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 0301-1518
J9 NOUV PRESSE MED
PY 1982
VL 11
IS 42
BP 3138
EP &
PG 0
WC Medicine, General & Internal
SC General & Internal Medicine
GA PM899
UT WOS:A1982PM89900016
PM 27483553
DA 2020-11-26
ER

PT J
AU KALIL, J
   FELLOUS, M
   TANIGAKI, N
   ROSA, F
   PAGNIEZ, C
   HERZOG, C
   DASTOT, H
   LENOIR, G
AF KALIL, J
   FELLOUS, M
   TANIGAKI, N
   ROSA, F
   PAGNIEZ, C
   HERZOG, C
   DASTOT, H
   LENOIR, G
TI A NEW EPSTEIN-BARR VIRUS NEGATIVE BURKITTS-LYMPHOMA DERIVED CELL-LINE
   .1. ANALYSIS OF CELL-SURFACE MARKERS AND ABNORMAL EXPRESSION OF HLA
   ANTIGENS
SO TISSUE ANTIGENS
LA English
DT Article
C1 HOP ST LOUIS,CTR HAYEM,INSERM,U93,UNITE RECH IMMUNOGENET TRANSPLANT HUMAINE,F-75475 PARIS 10,FRANCE.
   INT AGCY RES CANC,F-69372 LYON 2,FRANCE.
   NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT IMMUNOL RES,BUFFALO,NY 14263.
RI Rosa, Frederic/L-5990-2017; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x
   ARTZT K, 1974, TRANSPLANTATION, V17, P632, DOI 10.1097/00007890-197406000-00015
   BALLET JJ, 1980, SCAND J IMMUNOL, V11, P555, DOI 10.1111/j.1365-3083.1980.tb00024.x
   BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   BERGER R, 1979, J NATL CANCER I, V62, P1187
   BETUEL H, 1978, TISSUE ANTIGENS, V11, P62
   BIANCO C, 1970, J EXP MED, V132, P702, DOI 10.1084/jem.132.4.702
   BONO R, 1979, 11 P INT COURS TRANS, P109
   BORNKAMM GW, 1976, INT J CANCER, V17, P177, DOI 10.1002/ijc.2910170205
   BROUET JC, 1976, BRIT J HAEMATOL, V33, P319, DOI 10.1111/j.1365-2141.1976.tb03547.x
   BROWN G, 1979, EUR J IMMUNOL, V9, P272, DOI 10.1002/eji.1830090405
   CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347
   DETHE G, 1975, INT J CANCER, V16, P713, DOI 10.1002/ijc.2910160503
   DETHE G, 1976, J NATL CANCER I, V57, P1101, DOI 10.1093/jnci/57.5.1101
   DOHERTY PC, 1976, TRANSPLANT REV, V29, P89
   DOHERTY PC, 1977, NATURE, V255, P361
   FELLOUS M, 1977, IMMUNOGENETICS, V5, P423, DOI 10.1007/BF01570501
   FERRONE S, 1971, J IMMUNOL, V107, P613
   FRIBERG S, 1973, NATURE-NEW BIOL, V241, P112
   GOODFELLOW PN, 1976, TRANSPLANTATION, V22, P595, DOI 10.1097/00007890-197612000-00009
   HAYWOOD GR, 1971, J EXP MED, V133, P1171, DOI 10.1084/jem.133.6.1171
   HIRAI T, 1980, J IMMUNOL, V124, P2766
   HOGAN B, 1977, NATURE, V270, P515, DOI 10.1038/270515a0
   JONDAL M, 1976, SCAND J IMMUNOL, V5, P410
   KLEIN E, 1967, LANCET, V2, P1068
   KLEIN G, 1977, INT J CANCER, V19, P66, DOI 10.1002/ijc.2910190110
   KLEIN G, 1976, INT J CANCER, V18, P639, DOI 10.1002/ijc.2910180513
   KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283
   LIPINSKI M, 1979, J EXP MED, V150, P1310, DOI 10.1084/jem.150.6.1310
   MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184
   PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273
   PREUDHOMME JL, 1976, IN VITRO METHODS CEL, P155
   REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302
   RICKINSON AB, 1980, NATURE, V283, P865, DOI 10.1038/283865a0
   SCHUURMAN RKB, 1979, CLIN IMMUNOL IMMUNOP, V14, P418, DOI 10.1016/0090-1229(79)90094-1
   SHULMAN NR, 1964, PROG HEMATOL, V4, P222
   SINGAL DP, 1973, J CLIN INVEST, V52, P2259, DOI 10.1172/JCI107412
   SVEDMYR E, 1975, P NATL ACAD SCI USA, V72, P1622, DOI 10.1073/pnas.72.4.1622
   TANIGAKI N, 1980, IMMUNOGENETICS, V10, P151, DOI 10.1007/BF01561564
   TING LL, 1970, NATURE NEW BIOL, V232, P118
   TOSI R, 1978, J EXP MED, V148, P1592, DOI 10.1084/jem.148.6.1592
   TSAKRAKL.E, 1974, J NATL CANCER I, V52, P1499, DOI 10.1093/jnci/52.5.1499
   TURSZ T, 1977, NATURE, V269, P806, DOI 10.1038/269806a0
   YEFENOF E, 1976, INT J CANCER, V17, P693, DOI 10.1002/ijc.2910170602
NR 44
TC 4
Z9 4
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 1982
VL 20
IS 1
BP 47
EP 62
PG 16
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA NY593
UT WOS:A1982NY59300005
PM 6289490
DA 2020-11-26
ER

PT J
AU COLOMBANI, J
   DAUSSET, J
   LEPAGE, V
   DEGOS, L
   KALIL, J
   FELLOUS, M
AF COLOMBANI, J
   DAUSSET, J
   LEPAGE, V
   DEGOS, L
   KALIL, J
   FELLOUS, M
TI HLA MONOCLONAL-ANTIBODY REGISTRY - A PROPOSAL
SO TISSUE ANTIGENS
LA English
DT Article
C1 INST PASTEUR,F-75724 PARIS 15,FRANCE.
RP COLOMBANI, J (corresponding author), HOP ST LOUIS,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 62
Z9 62
U1 0
U2 2
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PY 1982
VL 20
IS 3
BP 161
EP 171
PG 11
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA PH504
UT WOS:A1982PH50400001
PM 6982543
DA 2020-11-26
ER

PT J
AU BENSUSSAN, A
   KLATZMANN, D
   GLUCKMAN, JC
   KALIL, J
   DAUSSET, J
   SASPORTES, M
AF BENSUSSAN, A
   KLATZMANN, D
   GLUCKMAN, JC
   KALIL, J
   DAUSSET, J
   SASPORTES, M
TI PROBABLE ROLE OF SUPPRESSOR CELLS AND FACTORS IN KIDNEY GRAFT-SURVIVAL
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
C1 HOP PITIE SALPETRIERE,IMMUNOL LAB,PARIS,FRANCE.
RP BENSUSSAN, A (corresponding author), HOP ST LOUIS,INSERM,U93,F-75475 PARIS 10,FRANCE.
RI Bensussan, Armand/E-5434-2017; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Klatzmann, David/0000-0002-0054-3422;
   Bensussan, Armand/0000-0002-0409-2497
CR CAROSELLA E, 1981, IMMUNOGENETICS, V14, P107, DOI 10.1007/BF00344304
   COMOYTOURNESAC A, 1981, COMPTES RENDU ACAD 3, V292, P785
   FISCHER E, 1980, HUM IMMUNOL, V3, P187
   KALIL J, MONOCLONAL ANTIBODIE
   SASPORTES M, 1981, IMMUNOGENETICS, V14, P117, DOI 10.1007/BF00344305
   SASPORTES M, 1978, NATURE, V267, P502
   SASPORTES M, 1980, J EXP MED, V152, P2705
NR 7
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PY 1982
VL 14
IS 3
BP 584
EP 587
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA PL767
UT WOS:A1982PL76700027
PM 6217608
DA 2020-11-26
ER

PT J
AU KALIL, J
   CREVAT, D
   FELLOUS, M
   DROUET, J
   COUROUCE, AM
   ROPARS, C
AF KALIL, J
   CREVAT, D
   FELLOUS, M
   DROUET, J
   COUROUCE, AM
   ROPARS, C
TI PRODUCTION OF MONOCLONAL-ANTIBODIES AGAINST HBS
SO ANNALES D IMMUNOLOGIE
LA French
DT Article
C1 CTR NATL TRANSFUS SANGUINE,F-75739 PARIS 15,FRANCE.
RP KALIL, J (corresponding author), HOP ST LOUIS,IMMUNOCHEM LAB,F-75475 PARIS 10,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
CR CATT K J, 1970, Clinica Chimica Acta, V27, P267, DOI 10.1016/0009-8981(70)90344-X
   COUROUCE AM, 1976, HAEMATOLOGIA
   GERHARD W, 1978, J EXP MED, V148, P383, DOI 10.1084/jem.148.2.383
   GERIN JL, 1969, J VIROL, V4, P763, DOI 10.1128/JVI.4.5.763-768.1969
   GERIN JL, 1979, VIRAL HEPATITIS, P147
   HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0
   KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713
   KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   LERNHARDT W, 1978, EXP CELL RES, V111, P309, DOI 10.1016/0014-4827(78)90175-1
   LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709
   PETERSON DL, 1979, VIRAL HEPATITIS, P569
   ROPARS C, 1980, 4TH INT C IMM PAR
   SHIH WK, 1980, J VIROL METH, V1, P257
   WIKTOR TJ, 1980, J EXP MED, V152, P99, DOI 10.1084/jem.152.1.99
NR 15
TC 10
Z9 10
U1 0
U2 3
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 0300-4910
J9 ANN INST PASTEUR IMM
PY 1981
VL C132
IS 3
BP 319
EP 326
DI 10.1016/0769-2625(81)90080-5
PG 8
WC Immunology
SC Immunology
GA MT525
UT WOS:A1981MT52500006
PM 6800300
DA 2020-11-26
ER

PT J
AU KALIL, J
   CREVAT, D
   FELLOUS, M
   DROUET, J
   COUROUCE, AM
   SOULIER, JP
AF KALIL, J
   CREVAT, D
   FELLOUS, M
   DROUET, J
   COUROUCE, AM
   SOULIER, JP
TI ANTI-HEMOGLOBIN HYBRIDOMAS
SO REVUE FRANCAISE DE TRANSFUSION ET IMMUNO-HEMATOLOGIE
LA French
DT Meeting Abstract
C1 HOP ST LOUIS,F-75475 PARIS 10,FRANCE.
   CTR NATL TRANSFUS SANGUINE,F-75739 PARIS 15,FRANCE.
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIBRAIRIE ARNETTE
PI PARIS
PA 2 RUE CASIMIR-DELAVIGNE, 6E PARIS, FRANCE
SN 0338-4535
J9 REV FR TRANSFUS IMMU
PY 1980
VL 23
IS 4
BP 496
EP 497
PG 2
WC Hematology; Immunology
SC Hematology; Immunology
GA KN817
UT WOS:A1980KN81700007
DA 2020-11-26
ER

EF